data_2czn_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2czn _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.56 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.78 158.58 44.05 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.473 -1.016 . . . . 0.0 109.699 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.532 ' CD1' ' HG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -153.02 123.89 7.38 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.08 -1.012 . . . . 0.0 110.749 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.473 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 3.3 mt-10 -122.05 113.72 19.93 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.476 ' CG1' ' O ' ' A' ' 281' ' ' ASP . 47.5 t -108.11 145.8 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.957 -1.089 . . . . 0.0 111.734 -178.513 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.421 ' C ' HG23 ' A' ' 271' ' ' VAL . 5.5 mttp -130.16 156.91 43.8 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.003 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.534 HG21 ' CD2' ' A' ' 280' ' ' TYR . 75.4 t -144.75 139.44 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.407 -1.433 . . . . 0.0 111.647 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.529 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -134.52 110.89 9.66 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.174 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.507 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.9 m-20 -98.72 135.42 40.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.939 -1.101 . . . . 0.0 111.71 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.541 ' CZ2' ' C ' ' A' ' 277' ' ' GLY . 33.6 p90 -119.75 20.15 12.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.507 -0.746 . . . . 0.0 109.209 178.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . 0.405 ' O ' ' NZ ' ' A' ' 345' ' ' LYS . . . 87.06 -77.97 1.93 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 32.0 m -51.22 -24.63 4.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.366 -1.079 . . . . 0.0 110.465 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.541 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -165.62 174.28 41.35 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.298 -1.429 . . . . 0.0 110.311 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.567 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -133.58 141.77 47.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.46 -1.024 . . . . 0.0 110.028 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.53 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 5.3 mt-10 -97.66 146.65 25.12 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.325 -0.859 . . . . 0.0 109.915 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 94.4 m-85 -141.84 85.24 1.93 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.442 -0.786 . . . . 0.0 110.405 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.476 ' O ' ' CG1' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -69.6 154.21 42.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.864 . . . . 0.0 109.997 179.498 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.602 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 4.2 t -145.03 89.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 O-C-N 121.629 -0.669 . . . . 0.0 109.506 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 10.5 m -86.08 117.48 24.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.126 -0.984 . . . . 0.0 109.626 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.572 HD13 ' CE3' ' A' ' 292' ' ' TRP . 0.9 OUTLIER -106.25 144.08 33.45 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.202 -0.936 . . . . 0.0 110.766 -179.07 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.56 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.5 OUTLIER -126.65 115.9 20.18 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.604 -0.685 . . . . 0.0 109.825 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.58 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 11.0 mt -124.9 155.21 39.9 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.633 -1.292 . . . . 0.0 110.262 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -89.8 34.87 0.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.195 -0.94 . . . . 0.0 110.105 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 161.57 -157.44 29.12 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.492 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -96.42 93.62 6.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -1.118 . . . . 0.0 110.706 -179.663 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.58 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.9 m-30 -116.36 143.09 45.99 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.218 -0.926 . . . . 0.0 110.109 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.564 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 1.6 m-20 -77.89 98.71 5.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.083 -1.011 . . . . 0.0 109.201 179.032 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.582 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 54.8 p-90 -98.31 113.32 25.23 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.286 -0.884 . . . . 0.0 110.785 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.534 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 10.5 m -105.71 115.58 30.48 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 109.526 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.467 HG23 HD23 ' A' ' 351' ' ' LEU . 3.3 t -97.19 113.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.101 -0.999 . . . . 0.0 110.49 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.477 ' HA ' HD12 ' A' ' 320' ' ' ILE . 9.2 ttpt -92.5 135.09 34.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.333 -0.854 . . . . 0.0 109.599 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.547 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 95.0 t -132.26 108.05 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.064 -1.023 . . . . 0.0 110.691 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.456 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtt -70.0 134.55 48.43 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.086 -1.009 . . . . 0.0 109.178 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.589 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 61.5 mt -88.51 162.48 16.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.181 -0.95 . . . . 0.0 111.723 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -64.37 176.77 0.65 Allowed Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.779 -0.576 . . . . 0.0 109.877 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.501 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.82 77.28 0.57 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.657 1.346 . . . . 0.0 109.903 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.43 19.73 5.71 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.541 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -103.65 150.18 24.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.415 -1.05 . . . . 0.0 110.248 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.553 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 27.0 p -149.92 144.36 25.85 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.267 -0.895 . . . . 0.0 110.642 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.508 ' CG1' ' HD2' ' A' ' 312' ' ' LYS . 29.5 t -67.45 136.54 26.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.356 -0.84 . . . . 0.0 109.975 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.8 -41.98 0.54 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.464 ' O ' HD11 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -128.94 129.96 46.14 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.134 -1.215 . . . . 0.0 110.756 -179.659 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.593 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.1 p90 -146.39 169.09 19.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.398 -0.814 . . . . 0.0 109.463 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.482 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.96 160.98 22.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.878 -1.139 . . . . 0.0 111.23 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.85 20.99 12.55 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.485 -0.759 . . . . 0.0 111.003 179.433 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -174.98 144.33 0.76 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.355 -0.841 . . . . 0.0 110.05 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.527 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -78.51 124.44 28.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.023 -1.048 . . . . 0.0 109.166 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.51 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 1.1 ttpt -91.92 138.34 31.62 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.775 0.797 . . . . 0.0 110.916 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.505 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -121.41 173.7 7.21 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.003 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -136.35 106.48 6.34 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.392 -0.817 . . . . 0.0 110.487 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.45 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -94.04 40.82 2.69 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.45 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 25.1 m120 57.43 82.33 0.13 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.249 -1.148 . . . . 0.0 110.195 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.623 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.84 0.87 57.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.623 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.9 m-85 -145.77 -169.62 3.27 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.333 -1.098 . . . . 0.0 109.279 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.508 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 4.7 t -162.55 157.84 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.216 -0.928 . . . . 0.0 109.8 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.534 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.3 mm -126.65 145.91 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.156 -0.965 . . . . 0.0 111.086 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.637 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.3 m-85 -123.16 128.5 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.125 -0.984 . . . . 0.0 110.195 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.527 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 25.0 p -129.58 166.37 26.33 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 120.802 -1.187 . . . . 0.0 109.394 179.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.512 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.8 Cg_endo -65.22 121.17 8.55 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.698 1.367 . . . . 0.0 111.132 -179.138 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.534 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 28.5 m -64.39 -125.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.626 -0.672 . . . . 0.0 110.182 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 1.4 m -100.69 -13.12 18.64 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.832 -1.168 . . . . 0.0 110.658 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 15.9 p-90 -136.35 6.57 3.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.139 -0.975 . . . . 0.0 110.6 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.534 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.7 OUTLIER -108.4 38.14 2.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.136 -0.977 . . . . 0.0 110.41 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.483 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.7 OUTLIER -118.72 -7.69 10.48 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.283 -0.886 . . . . 0.0 110.184 179.76 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.45 -153.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.4 Cg_endo -76.64 8.34 3.08 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.938 1.494 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.423 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.5 m -163.77 128.08 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.926 -1.109 . . . . 0.0 110.089 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.507 ' CB ' ' CZ2' ' A' ' 292' ' ' TRP . . . -146.39 111.33 5.31 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.159 -0.963 . . . . 0.0 110.579 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.479 ' O ' ' HB3' ' A' ' 309' ' ' SER . 50.2 m -104.41 126.75 51.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.925 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.603 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 11.8 p90 -137.08 175.38 9.67 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.497 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -154.98 163.3 31.32 Favored Glycine 0 N--CA 1.486 1.982 0 C-N-CA 118.831 -1.652 . . . . 0.0 109.953 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.676 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.2 p90 -147.04 148.34 31.57 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.566 -0.961 . . . . 0.0 109.631 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.539 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.7 mp -121.12 121.05 63.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.968 -1.083 . . . . 0.0 109.311 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.589 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.0 t -97.09 159.61 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.683 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -128.03 129.57 46.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.463 -0.773 . . . . 0.0 110.161 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.451 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.492 2.39 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.55 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.2 mtmt . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 121.237 0.541 . . . . 0.0 110.475 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.589 HG12 ' CE2' ' A' ' 280' ' ' TYR . 11.1 p -133.3 120.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.233 -0.917 . . . . 0.0 110.189 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.436 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -52.5 -45.39 66.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.293 -0.88 . . . . 0.0 110.346 -179.652 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.402 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 5.4 pt-20 -177.09 158.4 1.52 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.049 -1.032 . . . . 0.0 110.905 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.533 HG12 ' CG1' ' A' ' 296' ' ' VAL . 72.1 mt -120.57 109.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.333 -0.854 . . . . 0.0 110.093 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.05 150.97 26.47 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.319 -0.863 . . . . 0.0 110.384 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.536 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.73 126.31 52.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.35 -0.844 . . . . 0.0 109.995 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -138.2 110.17 7.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.163 -0.961 . . . . 0.0 109.935 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.533 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.27 111.26 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.564 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 39.17 32.35 0.07 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.762 -0.586 . . . . 0.0 110.918 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 114.91 -17.75 17.27 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.351 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.499 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 56.3 mm-40 -89.49 115.64 27.07 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.019 -1.283 . . . . 0.0 110.366 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 12.3 p -79.11 130.07 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.294 -0.879 . . . . 0.0 110.224 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . . . . . . . . . 18.6 mm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.24 179.999 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.54 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -126.84 164.83 20.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.347 -1.09 . . . . 0.0 109.497 179.59 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.595 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.8 tm? -161.19 140.52 10.33 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.008 -1.077 . . . . 0.0 111.068 -179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -140.07 134.33 31.2 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 109.182 -0.674 . . . . 0.0 109.182 179.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 60.1 t -125.41 136.86 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.807 -1.183 . . . . 0.0 111.648 -178.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.481 ' HG3' ' CB ' ' A' ' 281' ' ' ASP . 0.0 OUTLIER -122.96 157.06 33.48 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.55 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.576 HG21 ' CD2' ' A' ' 280' ' ' TYR . 88.7 t -142.77 146.9 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.295 -1.503 . . . . 0.0 112.378 -178.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.523 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.49 113.16 8.5 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.986 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.9 p-10 -96.21 147.22 23.99 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.069 -1.02 . . . . 0.0 111.425 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.555 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 33.7 p90 -132.08 20.86 4.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.489 -0.757 . . . . 0.0 110.056 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.92 -59.52 4.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.04 -24.63 64.21 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.295 -1.121 . . . . 0.0 110.488 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.535 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -173.26 178.6 45.15 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.588 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -133.75 145.18 49.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -1.166 . . . . 0.0 110.528 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.552 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 7.3 mt-10 -95.83 147.31 23.79 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.612 -0.68 . . . . 0.0 110.04 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.649 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 94.8 m-85 -140.43 86.1 2.05 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.353 -0.842 . . . . 0.0 110.417 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.481 ' CB ' ' HG3' ' A' ' 270' ' ' LYS . 2.7 t70 -68.88 152.9 44.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.294 -0.879 . . . . 0.0 109.846 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.595 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 4.6 t -145.21 90.4 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.579 -0.701 . . . . 0.0 109.938 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.465 ' O ' HD21 ' A' ' 267' ' ' LEU . 85.1 m -86.72 126.36 34.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.007 . . . . 0.0 109.865 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.606 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.74 151.13 32.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.264 -0.897 . . . . 0.0 110.905 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.54 ' ND2' ' HB2' ' A' ' 266' ' ' SER . 0.4 OUTLIER -132.43 128.05 36.65 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.825 . . . . 0.0 110.543 -179.42 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.61 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 5.6 mt -140.41 156.32 46.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.533 -1.355 . . . . 0.0 109.596 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -89.04 39.13 0.92 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.79 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 157.23 -142.8 8.93 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 119.397 -1.382 . . . . 0.0 109.739 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.78 120.96 43.3 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.945 -1.327 . . . . 0.0 110.814 -179.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.61 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 10.8 m-85 -142.77 146.81 34.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.283 -0.886 . . . . 0.0 109.909 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.517 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 2.3 m-20 -75.9 97.33 3.93 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.156 -0.965 . . . . 0.0 109.421 179.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.576 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 52.3 p-90 -98.21 111.59 23.87 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.203 -0.936 . . . . 0.0 110.485 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.598 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 6.4 m -104.7 115.98 31.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.642 -0.661 . . . . 0.0 109.894 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.463 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 2.8 t -97.01 110.89 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.06 -1.025 . . . . 0.0 110.42 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.484 ' HA ' HD11 ' A' ' 320' ' ' ILE . 6.5 ttpt -85.69 144.86 27.58 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.27 -0.893 . . . . 0.0 109.016 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.553 HG11 ' CG2' ' A' ' 346' ' ' VAL . 30.9 t -141.94 109.72 2.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.779 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.51 ' O ' ' N ' ' A' ' 347' ' ' GLU . 22.4 mmtp -72.57 132.01 43.23 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.212 -0.93 . . . . 0.0 109.476 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.569 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 67.4 mt -87.31 152.95 21.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.108 -0.995 . . . . 0.0 111.695 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.486 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -60.46 173.76 0.58 Allowed Pre-proline 0 N--CA 1.488 1.439 0 O-C-N 121.62 -0.675 . . . . 0.0 109.364 178.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.486 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -68.73 84.59 0.5 Allowed 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.696 1.366 . . . . 0.0 110.038 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.37 26.44 3.71 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.472 ' HB2' ' CG1' ' A' ' 338' ' ' VAL . . . -120.5 145.98 46.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -1.148 . . . . 0.0 110.601 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.554 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 18.5 p -147.63 145.99 29.18 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.294 -0.879 . . . . 0.0 110.399 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.525 HG21 ' CB ' ' A' ' 319' ' ' VAL . 70.4 t -74.46 142.41 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.214 -0.929 . . . . 0.0 110.45 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.55 -32.96 0.41 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 3.3 m -128.87 127.94 42.84 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 111.092 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.471 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.8 p90 -146.59 160.81 41.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.433 -0.792 . . . . 0.0 109.239 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.505 ' CH2' HD13 ' A' ' 337' ' ' ILE . 1.3 p90 -150.9 157.42 42.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.946 -1.096 . . . . 0.0 110.975 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.48 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.6 OUTLIER 58.6 23.6 11.1 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.765 179.708 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.529 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 140.68 0.71 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.369 -0.832 . . . . 0.0 110.088 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.514 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -78.62 122.4 25.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.07 -1.019 . . . . 0.0 109.735 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.516 ' CD ' HG11 ' A' ' 304' ' ' VAL . 11.1 ttpt -88.85 144.33 26.29 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.766 0.793 . . . . 0.0 110.847 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.511 ' CB ' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -129.7 173.7 10.38 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.39 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.454 ' HA ' HG21 ' A' ' 319' ' ' VAL . 5.3 mt-10 -135.3 103.09 5.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 110.588 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -89.85 39.09 3.13 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.461 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 5.9 m120 58.5 89.42 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.304 -1.115 . . . . 0.0 110.075 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.39 -0.76 75.26 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.611 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.8 m-85 -144.56 -167.89 2.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.446 -1.032 . . . . 0.0 109.095 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.525 ' CB ' HG21 ' A' ' 304' ' ' VAL . 2.7 t -163.4 161.64 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 109.713 179.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.598 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 25.2 mm -129.28 151.93 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.074 -1.016 . . . . 0.0 110.997 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.641 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 73.4 m-85 -128.36 130.67 48.08 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.225 -0.922 . . . . 0.0 109.963 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.514 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 2.2 p -132.96 168.87 15.78 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.727 -1.233 . . . . 0.0 109.991 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.497 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.7 Cg_endo -65.55 121.5 8.91 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.813 1.428 . . . . 0.0 110.981 -179.237 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.44 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 19.1 m -66.8 -117.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.47 -0.769 . . . . 0.0 110.087 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 57.7 m -108.98 -16.46 14.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.814 -1.179 . . . . 0.0 110.339 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.452 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 10.6 p-90 -125.96 -18.53 5.05 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.237 -0.915 . . . . 0.0 110.617 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.44 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.4 t30 -87.43 33.21 0.69 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.96 12.07 22.16 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.319 -0.863 . . . . 0.0 109.656 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -84.99 -152.13 16.4 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.548 ' O ' ' N ' ' A' ' 286' ' ' LEU . 41.4 Cg_endo -68.86 -55.57 0.2 Allowed 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.938 1.494 . . . . 0.0 110.021 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.26 115.22 30.1 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.418 -0.802 . . . . 0.0 110.415 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.526 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -134.49 107.83 7.78 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.251 -0.906 . . . . 0.0 110.101 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 309' ' ' SER . 97.6 m -103.82 147.64 27.05 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.148 -0.97 . . . . 0.0 110.733 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.595 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 13.8 p90 -152.35 175.06 13.07 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.493 -0.754 . . . . 0.0 109.102 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.7 160.77 28.95 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.401 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.649 ' CE2' ' CB ' ' A' ' 280' ' ' TYR . 1.1 p90 -147.46 147.4 30.15 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.388 -1.066 . . . . 0.0 110.041 179.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.545 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.6 mp -121.71 123.31 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.013 -1.054 . . . . 0.0 109.958 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.569 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.6 t -97.12 154.26 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.199 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.32 133.38 53.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.221 -0.924 . . . . 0.0 110.557 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.434 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.491 2.351 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.488 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 121.136 0.493 . . . . 0.0 111.119 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.591 ' CG1' ' CE2' ' A' ' 280' ' ' TYR . 9.0 p -127.53 123.87 62.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.224 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.51 ' N ' ' O ' ' A' ' 297' ' ' LYS . 6.8 mt-10 -55.47 -43.64 75.71 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 110.223 -179.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -177.09 159.02 1.6 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 110.513 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.497 ' CG2' HG21 ' A' ' 296' ' ' VAL . 45.7 mt -123.13 109.58 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 110.218 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.78 140.66 43.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.32 -0.863 . . . . 0.0 110.143 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.606 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -101.05 130.86 47.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.247 -0.908 . . . . 0.0 110.271 179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -138.86 111.78 7.84 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 110.115 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.487 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.5 mt -91.7 107.82 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.079 -1.013 . . . . 0.0 110.3 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.517 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.94 37.56 0.22 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.585 -0.697 . . . . 0.0 111.56 179.611 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 106.77 11.12 27.28 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.582 -1.294 . . . . 0.0 110.664 178.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.473 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 26.4 mm-40 -121.57 101.48 7.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.013 -1.286 . . . . 0.0 110.034 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.487 ' O ' ' CD1' ' A' ' 358' ' ' ILE . 9.9 p -66.56 135.66 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.234 -0.916 . . . . 0.0 110.4 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' A' ' 357' ' ' VAL . 12.3 mm . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.187 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.41 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.575 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.61 153.6 51.54 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.504 -0.998 . . . . 0.0 109.473 179.904 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.526 HD21 ' CG1' ' A' ' 282' ' ' VAL . 0.0 OUTLIER -147.99 123.56 10.43 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 120.932 -1.105 . . . . 0.0 111.03 -179.451 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.8 OUTLIER -122.36 111.04 16.4 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 178.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 45.4 t -104.99 124.62 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.893 -1.129 . . . . 0.0 111.953 -178.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -111.89 156.74 21.57 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 56.9 t -144.84 143.66 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.341 -1.475 . . . . 0.0 112.148 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.544 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -134.52 108.76 8.28 Favored 'General case' 0 N--CA 1.486 1.37 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.08 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 21.0 p30 -96.18 146.78 24.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 111.083 -178.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.581 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 31.7 p90 -130.38 17.98 5.38 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.412 -0.805 . . . . 0.0 109.958 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.27 -58.77 3.86 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -73.18 -19.32 61.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 110.458 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.581 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.98 179.44 41.72 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.635 -1.269 . . . . 0.0 109.983 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.534 ' HB3' ' CZ ' ' A' ' 280' ' ' TYR . . . -138.09 136.6 36.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.442 -1.034 . . . . 0.0 109.97 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.575 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.7 mt-10 -93.84 147.15 23.34 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.378 -0.826 . . . . 0.0 110.478 -179.462 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.701 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 92.8 m-85 -139.05 94.96 2.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 110.674 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.493 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -83.5 106.41 15.22 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.538 -0.726 . . . . 0.0 110.271 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.632 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.5 t -97.28 94.28 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.493 -0.754 . . . . 0.0 110.17 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 3.8 m -86.95 113.47 22.75 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.172 -0.955 . . . . 0.0 109.815 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.563 HD12 ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -102.18 147.94 26.03 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.096 -1.003 . . . . 0.0 110.507 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.575 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.36 106.7 7.66 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.516 -0.74 . . . . 0.0 109.636 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.574 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.8 mt -113.83 160.75 18.39 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.622 -1.299 . . . . 0.0 110.763 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -89.79 36.64 0.86 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 110.03 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 155.3 -135.25 4.54 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.476 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.2 mm-40 -120.67 113.41 20.18 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.05 -1.265 . . . . 0.0 110.911 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.574 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.1 m-85 -138.74 148.92 44.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.36 -0.838 . . . . 0.0 109.641 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.502 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 5.4 m-20 -75.53 97.9 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.205 -0.935 . . . . 0.0 109.512 179.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.59 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 51.5 p-90 -97.07 110.17 22.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.583 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.523 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 4.2 m -102.34 115.21 30.09 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.331 -0.856 . . . . 0.0 109.44 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.484 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.8 t -97.0 111.09 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 110.54 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.515 ' HG3' HD12 ' A' ' 320' ' ' ILE . 4.5 ttpt -83.15 149.17 27.02 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 108.966 178.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.573 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 53.7 t -145.75 104.73 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.971 -1.081 . . . . 0.0 110.761 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 347' ' ' GLU . 7.6 mmtt -70.88 131.28 43.53 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.208 -0.933 . . . . 0.0 109.391 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.55 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 70.3 mt -87.12 152.49 22.3 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 111.507 -179.056 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.506 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -56.47 176.0 0.21 Allowed Pre-proline 0 C--N 1.301 -1.504 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.081 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.506 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -68.99 79.87 0.69 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 123.554 1.292 . . . . 0.0 109.891 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.19 20.9 5.42 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -106.73 149.0 27.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.395 -1.062 . . . . 0.0 109.936 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.55 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 37.5 p -150.03 144.2 25.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.106 -0.997 . . . . 0.0 111.152 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.51 HG22 ' CG1' ' A' ' 319' ' ' VAL . 87.4 t -69.59 129.79 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -0.862 . . . . 0.0 109.928 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.25 -28.18 2.91 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.4 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 6.8 t -144.66 141.4 29.32 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.007 -1.29 . . . . 0.0 110.744 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.3 p90 -155.54 168.81 25.93 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.403 -0.811 . . . . 0.0 110.053 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.499 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -158.53 163.72 36.8 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.057 -1.027 . . . . 0.0 110.645 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.468 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.5 OUTLIER 58.41 21.31 8.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.5 -0.75 . . . . 0.0 110.757 179.739 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.521 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 148.84 1.21 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.442 -0.786 . . . . 0.0 110.328 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.503 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -86.78 120.12 27.74 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.225 -0.922 . . . . 0.0 109.379 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 3.6 ttpt -87.63 140.03 29.93 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.892 0.853 . . . . 0.0 110.601 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.5 175.22 7.28 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.418 ' HG2' HG21 ' A' ' 319' ' ' VAL . 4.5 mt-10 -134.84 116.55 14.92 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.316 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.448 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -109.93 39.25 2.97 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 1.4 t30 66.23 90.92 0.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.29 -1.123 . . . . 0.0 110.286 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 81.53 3.31 90.66 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.597 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.9 m-85 -141.52 -172.67 3.58 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -1.135 . . . . 0.0 109.544 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.511 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 3.5 t -163.38 157.85 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.212 -0.93 . . . . 0.0 109.775 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.523 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 17.4 mm -125.98 144.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.012 -1.055 . . . . 0.0 111.474 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 56.9 m-85 -121.18 129.33 53.18 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.005 -1.059 . . . . 0.0 109.93 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.503 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 2.9 p -129.94 168.52 16.29 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 120.864 -1.148 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.531 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.2 Cg_endo -65.95 117.09 4.36 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.76 1.4 . . . . 0.0 111.029 -179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.487 HG11 ' ND2' ' A' ' 311' ' ' ASN . 25.4 m -64.29 -120.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 110.041 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.453 ' O ' ' HE2' ' A' ' 328' ' ' LYS . 0.6 OUTLIER -104.44 -15.88 15.26 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.776 -1.202 . . . . 0.0 110.665 -179.849 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.468 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 5.3 p-90 -131.11 -6.85 3.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.132 -0.98 . . . . 0.0 110.822 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.471 ' O ' ' HB1' ' A' ' 332' ' ' ALA . 1.6 t-20 -90.96 38.67 0.96 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.063 -1.023 . . . . 0.0 110.115 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 5.5 pttt -121.26 4.99 10.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.06 -1.025 . . . . 0.0 110.332 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -69.16 -156.38 1.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 50.5 Cg_endo -76.72 7.16 3.66 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.77 1.405 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.429 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 19.5 m -164.2 128.25 2.64 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.288 -0.882 . . . . 0.0 109.725 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.575 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -143.89 108.63 4.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 110.319 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 283' ' ' THR . 89.8 m -100.77 117.54 35.07 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.309 -0.87 . . . . 0.0 109.953 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.632 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 7.9 p90 -124.49 171.96 9.56 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.485 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.34 158.04 27.5 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.945 -1.597 . . . . 0.0 109.951 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.701 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.2 p90 -145.89 146.13 30.98 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.633 -0.922 . . . . 0.0 109.186 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.539 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.7 mp -119.23 120.23 63.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.684 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.537 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.8 t -95.78 147.84 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.195 -0.941 . . . . 0.0 109.576 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -118.6 134.69 54.91 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.384 -0.822 . . . . 0.0 110.617 -179.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.413 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.172 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.537 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.191 0.52 . . . . 0.0 110.685 . . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.586 HG13 ' CE2' ' A' ' 280' ' ' TYR . 4.2 p -132.78 116.5 27.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.028 -1.045 . . . . 0.0 110.831 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -44.67 -50.08 10.06 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.912 -1.117 . . . . 0.0 109.533 179.787 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -177.48 158.06 1.36 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.382 -0.824 . . . . 0.0 110.482 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.435 HG12 HG12 ' A' ' 296' ' ' VAL . 14.4 mt -117.15 111.62 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.255 -0.903 . . . . 0.0 110.076 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.69 151.65 24.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.285 -0.885 . . . . 0.0 110.376 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.534 HD12 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -110.27 125.71 53.41 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.321 -0.862 . . . . 0.0 109.812 179.604 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 11.5 tt0 -137.26 111.41 8.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.184 -0.948 . . . . 0.0 109.832 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.476 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.4 mt -92.02 109.97 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 110.521 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.502 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 38.36 31.22 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.546 -0.721 . . . . 0.0 111.061 179.457 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.48 -10.04 16.9 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.427 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.0 mp0 -97.16 108.4 21.12 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.061 -1.258 . . . . 0.0 110.214 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 7.3 p -76.58 110.42 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.335 -0.853 . . . . 0.0 110.249 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . . . . . . . . . 24.2 mm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.146 -179.956 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.569 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -136.88 157.11 47.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.477 -1.013 . . . . 0.0 109.535 179.863 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.514 ' CD1' ' HG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.56 124.38 10.57 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.943 -1.098 . . . . 0.0 110.989 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.482 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 1.4 mm-40 -121.38 113.32 19.73 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 38.4 t -109.44 139.67 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 111.668 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.2 mmtm -123.83 156.58 35.92 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.591 HG12 ' CE1' ' A' ' 280' ' ' TYR . 92.3 t -145.19 144.7 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.462 -1.399 . . . . 0.0 112.092 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.14 112.21 6.61 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 179.315 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.502 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.7 p-10 -97.03 144.82 26.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.047 -1.033 . . . . 0.0 111.297 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.575 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 34.5 p90 -129.82 18.62 5.63 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.399 -0.813 . . . . 0.0 109.786 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.58 -61.92 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.67 -23.79 67.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -1.158 . . . . 0.0 110.224 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.82 177.68 46.02 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.562 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -130.58 146.6 52.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.329 -1.101 . . . . 0.0 110.201 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.575 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 6.2 mt-10 -98.0 147.32 24.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.514 -0.741 . . . . 0.0 109.942 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 95.2 m-85 -144.28 86.37 1.83 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.233 -0.917 . . . . 0.0 110.999 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.471 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.1 OUTLIER -71.17 153.5 42.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.403 -0.811 . . . . 0.0 109.88 179.376 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.58 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.5 t -144.82 88.09 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 109.615 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.442 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.5 m -86.03 114.92 23.29 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.683 -179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.568 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -101.73 145.57 28.94 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.259 -0.901 . . . . 0.0 110.736 -179.16 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.569 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -129.67 106.86 9.0 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.391 -0.818 . . . . 0.0 110.093 -179.458 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.545 ' N ' ' O ' ' A' ' 330' ' ' PRO . 7.6 mt -116.62 164.34 14.75 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.648 -1.283 . . . . 0.0 110.299 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -94.04 34.59 1.23 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.402 -0.811 . . . . 0.0 110.458 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.449 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 157.11 -137.52 5.44 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.876 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mm-40 -113.84 108.26 16.83 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.184 -1.186 . . . . 0.0 111.391 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.541 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.26 135.27 40.77 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.301 -0.874 . . . . 0.0 109.67 178.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.53 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 4.5 m-20 -64.88 97.02 0.2 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.05 -1.032 . . . . 0.0 109.402 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.602 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 53.3 p-90 -95.07 108.07 20.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.279 -0.888 . . . . 0.0 110.494 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.596 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 32.4 m -101.67 115.48 30.61 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.475 HG21 ' CE2' ' A' ' 334' ' ' PHE . 3.3 t -96.72 111.54 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.092 -1.005 . . . . 0.0 110.925 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.491 ' HG3' HD11 ' A' ' 320' ' ' ILE . 7.9 ttpt -82.01 149.84 27.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.264 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.533 HG12 ' CG2' ' A' ' 346' ' ' VAL . 88.7 t -149.02 104.77 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.951 -1.093 . . . . 0.0 110.719 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.499 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 18.9 mmtp -70.35 128.54 36.56 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.223 -0.923 . . . . 0.0 109.658 179.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.589 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 85.5 mt -84.06 165.81 18.24 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.763 0.792 . . . . 0.0 111.377 -179.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.545 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -74.33 175.81 3.47 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.623 -0.673 . . . . 0.0 109.726 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.491 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.5 Cg_endo -67.24 83.2 0.36 Allowed 'Trans proline' 0 C--N 1.304 -1.786 0 O-C-N 123.598 1.315 . . . . 0.0 109.84 179.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 110.99 22.72 6.12 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.474 ' O ' HD12 ' A' ' 298' ' ' LEU . . . -112.14 144.17 41.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -1.085 . . . . 0.0 110.13 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.52 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 13.0 p -147.06 145.18 29.58 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.879 . . . . 0.0 110.332 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.539 HG21 ' CG2' ' A' ' 319' ' ' VAL . 71.4 t -64.97 120.94 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.38 -0.825 . . . . 0.0 110.11 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.29 -38.6 3.48 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 24.9 m -139.03 144.25 38.77 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.144 -1.209 . . . . 0.0 110.781 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 5.6 p90 -155.02 160.34 40.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.466 -0.771 . . . . 0.0 109.463 179.553 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.432 ' C ' ' OG ' ' A' ' 309' ' ' SER . 1.0 OUTLIER -151.04 152.87 34.08 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.923 -1.111 . . . . 0.0 111.491 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.537 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.9 OUTLIER 67.24 24.19 9.2 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.663 -0.648 . . . . 0.0 111.054 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.515 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.27 143.41 0.87 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.276 -0.89 . . . . 0.0 110.138 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.531 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -82.37 122.9 28.58 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.15 -0.969 . . . . 0.0 109.182 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.527 ' HG2' ' N ' ' A' ' 313' ' ' GLN . 3.1 ttmt -88.7 148.09 24.17 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.861 0.839 . . . . 0.0 111.05 -178.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.527 ' N ' ' HG2' ' A' ' 312' ' ' LYS . 0.0 OUTLIER -131.74 171.85 13.0 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.36 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.419 ' HA ' HG21 ' A' ' 319' ' ' VAL . 32.4 mt-10 -132.96 109.7 9.75 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.179 -0.95 . . . . 0.0 110.345 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.73 39.81 2.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 8.4 t-20 60.86 92.25 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.346 -1.091 . . . . 0.0 110.474 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.3 2.27 87.76 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.61 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.1 m-85 -145.81 -169.48 3.24 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.339 -1.095 . . . . 0.0 109.27 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.539 ' CG2' HG21 ' A' ' 304' ' ' VAL . 2.8 t -163.44 161.92 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 179.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.596 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 5.5 mm -130.19 143.57 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.174 -0.954 . . . . 0.0 111.084 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.652 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 98.6 m-85 -118.61 136.79 53.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.938 . . . . 0.0 109.515 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.531 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.5 p -135.3 168.88 15.47 Favored Pre-proline 0 C--N 1.301 -1.527 0 O-C-N 120.844 -1.16 . . . . 0.0 110.303 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.535 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 40.5 Cg_endo -67.03 121.09 8.21 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 124.127 1.593 . . . . 0.0 110.85 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.523 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 27.0 m -73.22 -129.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.845 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.402 ' C ' ' HD2' ' A' ' 328' ' ' LYS . 18.1 p -100.17 -19.15 16.57 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.904 -1.122 . . . . 0.0 110.346 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.537 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 23.7 p-90 -125.96 11.08 7.68 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.108 -0.995 . . . . 0.0 110.507 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.523 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.5 OUTLIER -117.63 49.58 1.21 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.073 -1.017 . . . . 0.0 110.254 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.535 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -125.57 -12.47 6.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -0.865 . . . . 0.0 110.134 -179.902 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.09 -160.95 0.02 OUTLIER Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.9 Cg_endo -73.4 3.53 4.66 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.905 1.477 . . . . 0.0 110.872 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.97 117.67 3.28 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.171 -0.955 . . . . 0.0 110.088 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.499 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -140.03 108.6 5.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.253 -0.904 . . . . 0.0 110.077 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.494 ' O ' ' HB2' ' A' ' 309' ' ' SER . 60.7 m -99.81 138.63 36.62 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.287 -0.883 . . . . 0.0 110.449 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.652 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 10.9 p90 -145.92 157.36 43.9 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -134.33 164.27 24.57 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.088 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.68 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.1 p90 -149.74 143.4 25.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.483 -1.01 . . . . 0.0 109.469 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.557 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -117.16 120.55 65.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.115 -0.991 . . . . 0.0 109.689 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.589 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.6 t -96.79 149.93 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.203 -0.936 . . . . 0.0 109.817 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.418 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -121.77 131.54 54.12 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.16 -0.963 . . . . 0.0 111.061 -179.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.742 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.545 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.488 1.442 0 CA-C-O 121.448 0.642 . . . . 0.0 110.24 . . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.6 HG12 ' CE1' ' A' ' 280' ' ' TYR . 10.7 p -133.84 116.73 24.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.399 -0.813 . . . . 0.0 110.002 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 1.5 mt-10 -47.16 -47.1 23.91 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.174 -0.954 . . . . 0.0 110.164 -179.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -177.01 158.92 1.61 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.401 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.515 HG21 HD12 ' A' ' 349' ' ' ILE . 26.4 mt -118.2 119.42 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.23 -0.919 . . . . 0.0 110.101 179.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.49 151.33 33.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.301 -0.874 . . . . 0.0 110.267 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.558 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -108.96 126.83 53.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.252 -0.905 . . . . 0.0 109.725 179.661 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.474 ' N ' HD23 ' A' ' 351' ' ' LEU . 2.5 tp10 -138.19 113.11 9.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.077 -1.014 . . . . 0.0 110.373 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.455 HG22 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -93.07 103.66 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.183 -0.948 . . . . 0.0 110.003 179.725 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.53 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 43.55 30.55 0.35 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.459 -0.775 . . . . 0.0 110.46 -179.85 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 117.63 -22.65 9.95 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.426 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 1.0 OUTLIER -82.41 99.58 9.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 110.127 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.48 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 13.4 p -69.96 113.76 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.246 -0.909 . . . . 0.0 110.173 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.44 HG21 ' OXT' ' A' ' 358' ' ' ILE . 25.9 mm . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.119 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.583 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -130.81 150.54 51.94 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.4 -1.059 . . . . 0.0 109.978 179.924 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.518 HD22 ' CG1' ' A' ' 282' ' ' VAL . 0.0 OUTLIER -145.2 125.87 14.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.036 -1.04 . . . . 0.0 110.781 -179.676 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.488 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 15.0 mm-40 -124.51 110.99 15.17 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.491 -0.756 . . . . 0.0 108.996 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.504 ' CG1' ' O ' ' A' ' 281' ' ' ASP . 85.6 t -110.53 145.19 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 120.942 -1.098 . . . . 0.0 111.827 -178.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.444 ' N ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -130.86 157.74 42.07 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.136 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.589 HG11 ' CE2' ' A' ' 280' ' ' TYR . 97.5 t -141.69 146.75 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 120.237 -1.539 . . . . 0.0 112.454 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.02 110.28 6.91 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.11 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 43.8 p-10 -95.68 145.36 25.34 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.062 -1.024 . . . . 0.0 111.379 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.575 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 35.4 p90 -130.95 22.77 4.93 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.36 -0.837 . . . . 0.0 109.858 179.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.81 -68.82 3.32 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.22 -27.41 68.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.253 -1.145 . . . . 0.0 110.685 -179.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.533 ' C ' ' CE2' ' A' ' 274' ' ' TRP . . . -166.3 178.52 40.8 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.574 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -134.72 145.28 48.33 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.275 -1.132 . . . . 0.0 110.512 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.575 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 5.4 mt-10 -97.22 147.17 24.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 109.973 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.657 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 88.5 m-85 -142.08 83.77 1.85 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.274 -0.891 . . . . 0.0 110.523 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.504 ' O ' ' CG1' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.14 153.19 44.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.289 -0.882 . . . . 0.0 110.123 179.551 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.585 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 5.4 t -144.87 90.36 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.531 -0.73 . . . . 0.0 109.667 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.458 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.5 m -86.28 123.66 31.79 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.134 -0.979 . . . . 0.0 109.362 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.551 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -109.71 148.26 31.71 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.072 -1.017 . . . . 0.0 111.28 -178.85 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.583 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.33 107.37 7.59 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.607 -0.683 . . . . 0.0 109.975 -179.45 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.586 HD13 ' CD1' ' A' ' 292' ' ' TRP . 9.7 mt -115.53 163.27 16.0 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.897 -1.127 . . . . 0.0 109.805 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . 0.469 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 2.1 t0 -91.64 31.28 1.21 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.552 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.532 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 163.76 -164.33 36.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.545 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -93.76 94.87 8.79 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.176 -1.19 . . . . 0.0 110.599 -179.738 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 1.9 m-85 -120.96 171.44 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.181 -0.95 . . . . 0.0 109.793 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.505 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 0.2 OUTLIER -95.78 99.34 11.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.655 179.392 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.589 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 53.1 p-90 -97.29 113.99 25.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.309 -0.869 . . . . 0.0 110.624 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.576 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 99.1 m -106.75 113.38 26.84 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.464 -0.773 . . . . 0.0 109.176 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.507 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.6 t -96.37 110.81 25.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.184 -0.948 . . . . 0.0 110.137 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.524 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 6.4 ttmt -84.77 149.07 26.0 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.208 -0.933 . . . . 0.0 109.197 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.564 HG11 ' CG2' ' A' ' 346' ' ' VAL . 45.9 t -144.63 106.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 O-C-N 121.403 -0.811 . . . . 0.0 109.93 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.471 ' O ' ' CG2' ' A' ' 346' ' ' VAL . 34.9 mmtt -71.1 134.69 47.21 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.114 -0.991 . . . . 0.0 109.704 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.559 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 92.7 mt -87.59 162.57 17.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 111.569 -179.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.496 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -75.65 171.57 11.59 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.469 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.4 84.61 0.47 Allowed 'Trans proline' 0 C--N 1.301 -1.945 0 O-C-N 123.684 1.36 . . . . 0.0 109.798 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . 0.414 ' O ' ' HA3' ' A' ' 340' ' ' GLY . . . 116.26 26.02 3.33 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.541 ' CB ' ' CG1' ' A' ' 338' ' ' VAL . . . -126.51 138.26 53.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -1.139 . . . . 0.0 110.257 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.516 ' N ' HG12 ' A' ' 338' ' ' VAL . 7.2 p -141.43 145.83 35.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 110.419 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.513 ' CG2' HG21 ' A' ' 319' ' ' VAL . 98.2 t -71.82 124.28 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.366 -0.834 . . . . 0.0 110.225 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.4 -34.84 1.26 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.411 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 2.7 m -122.45 110.15 15.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.025 -1.28 . . . . 0.0 110.716 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.578 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 11.9 p90 -134.23 153.92 51.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.856 . . . . 0.0 109.788 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.472 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -149.19 161.37 42.13 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.05 -1.031 . . . . 0.0 111.155 -179.35 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.545 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.23 28.71 15.54 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.542 -0.723 . . . . 0.0 111.224 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -175.9 145.44 0.66 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.038 -1.039 . . . . 0.0 110.553 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.474 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -78.13 118.74 20.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -0.998 . . . . 0.0 109.238 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.578 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 19.9 ttpt -92.2 115.7 28.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.546 -0.721 . . . . 0.0 111.083 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.566 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.4 OUTLIER -102.97 176.31 5.19 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.327 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.413 ' OE1' ' HE3' ' A' ' 312' ' ' LYS . 0.6 OUTLIER -139.02 105.95 5.42 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -0.981 . . . . 0.0 110.773 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -95.26 43.79 2.2 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 58.52 91.06 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.321 -1.105 . . . . 0.0 110.126 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.629 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 84.33 5.12 87.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.629 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 7.0 m-85 -141.93 -178.53 5.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.413 -1.051 . . . . 0.0 109.078 179.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.587 HG12 ' CZ ' ' A' ' 321' ' ' PHE . 39.9 t -159.4 148.98 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.149 -0.969 . . . . 0.0 109.986 179.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.576 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 1.7 mm -114.9 151.56 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.112 -0.992 . . . . 0.0 110.497 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.659 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 76.5 m-85 -130.69 112.78 13.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.101 -0.999 . . . . 0.0 109.866 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.546 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 3.7 p -116.49 171.07 5.09 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 120.627 -1.296 . . . . 0.0 109.786 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.546 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.9 Cg_endo -69.2 120.96 7.77 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 O-C-N 123.652 1.343 . . . . 0.0 110.727 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.532 ' N ' ' OD1' ' A' ' 327' ' ' ASN . 16.0 m -64.12 -113.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.482 -0.761 . . . . 0.0 110.224 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 14.1 p -120.17 -12.47 9.06 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.753 -1.217 . . . . 0.0 110.688 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.476 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 24.8 p-90 -128.9 17.01 6.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 0.0 110.921 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.545 ' ND2' ' O ' ' A' ' 309' ' ' SER . 28.8 p-10 -135.56 45.07 2.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.079 . . . . 0.0 110.921 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -116.05 7.96 14.41 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.097 -1.002 . . . . 0.0 109.847 179.774 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . . . . . . . . . . . -74.67 -153.72 3.54 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.124 -1.191 . . . . 0.0 110.124 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.534 ' O ' ' N ' ' A' ' 286' ' ' LEU . 50.5 Cg_endo -75.61 4.66 4.85 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 124.182 1.622 . . . . 0.0 110.925 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.458 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.6 m -165.25 123.54 1.64 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.158 -0.964 . . . . 0.0 110.253 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.584 ' HB3' ' CZ2' ' A' ' 292' ' ' TRP . . . -150.72 120.28 6.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.848 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.483 ' O ' ' HB2' ' A' ' 309' ' ' SER . 34.0 m -104.32 144.66 31.33 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.229 -0.92 . . . . 0.0 110.441 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.659 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 10.0 p90 -149.78 168.82 22.62 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.37 159.84 28.16 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 118.744 -1.693 . . . . 0.0 110.535 -179.209 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.657 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.6 p90 -144.2 145.02 31.81 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.648 -0.913 . . . . 0.0 109.679 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.544 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -118.98 120.99 65.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.626 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.559 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 19.8 t -97.71 142.65 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 110.399 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.451 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.6 m-80 -115.55 130.09 56.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 110.133 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 301' ' ' GLY . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.532 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 2.3 mtmt . . . . . 0 N--CA 1.488 1.472 0 CA-C-O 121.274 0.559 . . . . 0.0 110.463 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.586 HG12 ' CE2' ' A' ' 280' ' ' TYR . 11.8 p -130.58 118.21 41.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.311 -0.868 . . . . 0.0 110.22 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.432 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -48.33 -45.9 35.8 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.378 -0.826 . . . . 0.0 110.575 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.418 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 2.5 pt-20 -177.02 159.39 1.67 Allowed 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.847 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.449 HG12 HG13 ' A' ' 296' ' ' VAL . 14.2 mt -119.6 114.6 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.254 -0.904 . . . . 0.0 110.439 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -113.91 158.2 21.41 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.148 -0.97 . . . . 0.0 109.855 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.549 ' CD1' HD22 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.42 126.63 51.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.253 -0.905 . . . . 0.0 110.633 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.486 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.0 OUTLIER -139.25 119.76 13.99 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.864 179.45 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.491 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -90.81 93.01 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.924 -1.11 . . . . 0.0 110.22 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.505 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 46.94 31.96 1.68 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.817 -0.552 . . . . 0.0 111.249 179.496 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 132.13 -33.86 2.63 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.651 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.41 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 66.0 mm-40 -89.92 117.61 28.87 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.987 -1.302 . . . . 0.0 110.745 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 4.0 p -78.93 124.07 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.298 -0.876 . . . . 0.0 110.135 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.447 ' O ' HD12 ' A' ' 351' ' ' LEU . 21.5 mm . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.092 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.403 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.552 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.58 162.67 33.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.371 -1.076 . . . . 0.0 109.87 179.837 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.56 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.0 tm? -159.92 138.27 10.33 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.143 -1.023 . . . . 0.0 111.15 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.426 ' N ' HD21 ' A' ' 267' ' ' LEU . 18.8 mt-10 -141.15 136.57 31.98 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -128.11 144.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.618 -1.301 . . . . 0.0 112.306 -178.509 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.403 ' N ' HG12 ' A' ' 269' ' ' VAL . 63.3 mttt -128.65 157.74 40.49 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.566 HG13 ' CE1' ' A' ' 280' ' ' TYR . 98.7 t -144.36 147.38 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 120.346 -1.472 . . . . 0.0 112.319 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.525 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.12 110.63 6.38 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.737 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.551 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -96.13 149.08 22.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.988 -1.07 . . . . 0.0 111.503 -178.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.561 ' CZ2' HG22 ' A' ' 337' ' ' ILE . 28.1 p90 -129.46 18.42 5.84 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-O 121.447 0.641 . . . . 0.0 109.691 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.42 -61.63 3.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.67 -25.26 65.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 110.383 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.522 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -167.56 178.93 41.31 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.449 -1.358 . . . . 0.0 109.95 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.3 144.63 48.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -1.103 . . . . 0.0 110.345 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.525 ' HG2' ' CG1' ' A' ' 337' ' ' ILE . 4.7 mt-10 -97.47 145.92 25.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.396 -0.815 . . . . 0.0 109.828 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.9 m-85 -137.9 87.72 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.827 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.458 ' O ' HG12 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -70.88 140.91 51.21 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.483 179.13 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.602 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.8 t -133.89 91.7 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.568 -0.708 . . . . 0.0 109.803 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.465 ' O ' HD23 ' A' ' 267' ' ' LEU . 9.0 m -86.49 124.2 32.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 109.977 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.607 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.82 148.41 38.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 110.832 -179.427 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.553 ' O ' ' CD2' ' A' ' 286' ' ' LEU . 0.4 OUTLIER -128.66 137.43 51.64 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.434 -0.791 . . . . 0.0 109.823 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.577 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 14.5 mt -142.42 159.7 41.71 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.794 -1.191 . . . . 0.0 109.759 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.94 36.02 0.97 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.361 -0.837 . . . . 0.0 110.31 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.478 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 152.07 -100.94 0.21 Allowed Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.139 -1.505 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.554 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 15.9 mm-40 -141.8 111.93 6.88 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.024 -1.28 . . . . 0.0 110.881 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.639 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 5.5 m-85 -135.51 138.36 43.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.687 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.504 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 5.5 m-20 -74.17 96.87 2.82 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.002 -1.061 . . . . 0.0 108.905 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.586 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 55.1 p-90 -97.45 114.87 26.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 0.0 110.568 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.579 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 28.7 m -109.45 116.09 31.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.489 HG22 ' CD2' ' A' ' 351' ' ' LEU . 2.8 t -96.83 111.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 0.0 110.528 -179.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.464 ' HG3' HD13 ' A' ' 320' ' ' ILE . 28.9 ttpt -91.64 130.19 37.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.659 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.54 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 80.2 t -126.58 115.87 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.185 -0.947 . . . . 0.0 111.103 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.571 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 55.7 mmtt -73.21 134.23 44.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.149 -0.97 . . . . 0.0 109.269 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.576 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 80.1 mt -88.15 159.38 18.22 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.324 -0.86 . . . . 0.0 111.466 -178.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.574 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -65.18 178.09 0.56 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.68 -0.638 . . . . 0.0 110.025 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.531 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.24 79.06 0.6 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.718 1.378 . . . . 0.0 109.662 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.89 21.15 6.11 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.543 ' CB ' ' HB2' ' A' ' 299' ' ' ALA . . . -106.05 144.37 32.85 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.417 -1.049 . . . . 0.0 110.241 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.534 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 10.8 p -145.75 145.95 31.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.3 -0.875 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.551 ' CG1' ' CD ' ' A' ' 312' ' ' LYS . 76.1 t -70.99 134.83 29.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.329 -0.857 . . . . 0.0 109.88 179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.45 -37.29 0.8 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.081 -179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 67.6 m -131.55 128.15 38.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.06 -1.259 . . . . 0.0 110.919 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.564 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.7 p90 -144.78 157.73 44.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.377 -0.827 . . . . 0.0 109.794 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.483 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -150.55 159.52 44.44 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.007 -1.058 . . . . 0.0 111.236 -179.329 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.554 ' OG ' ' CZ3' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 59.45 24.81 13.49 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.562 -0.712 . . . . 0.0 110.679 179.735 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.521 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 142.56 0.77 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 110.213 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.523 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -81.09 113.97 19.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.084 -1.01 . . . . 0.0 109.383 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.564 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 18.6 ttpt -82.56 149.71 27.33 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-O 121.762 0.792 . . . . 0.0 110.459 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.722 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -134.13 170.63 15.39 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -142.41 95.17 2.75 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.595 -0.69 . . . . 0.0 110.165 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.14 -80.28 0.44 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -160.93 77.5 0.58 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.433 -1.04 . . . . 0.0 108.812 179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.617 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.34 11.25 54.64 Favored Glycine 0 N--CA 1.487 2.082 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.617 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.3 m-85 -143.06 -166.97 2.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.736 -0.861 . . . . 0.0 108.709 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.5 HG13 ' N ' ' A' ' 320' ' ' ILE . 2.5 t -163.52 160.19 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.01 -1.056 . . . . 0.0 109.454 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.722 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.3 mm -128.98 145.22 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.891 -1.131 . . . . 0.0 111.136 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.0 m-85 -123.04 129.33 51.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.156 -0.965 . . . . 0.0 110.378 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.523 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 3.0 p -131.01 167.73 20.32 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 120.72 -1.237 . . . . 0.0 110.014 179.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.513 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.0 Cg_endo -66.1 128.68 20.07 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.861 1.453 . . . . 0.0 110.915 -179.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.429 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 34.6 m -78.01 -122.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.51 -0.744 . . . . 0.0 110.114 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -101.83 -21.43 14.58 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.757 -1.214 . . . . 0.0 110.631 -179.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.554 ' CZ3' ' OG ' ' A' ' 309' ' ' SER . 14.9 p-90 -126.46 5.55 6.91 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.173 -0.955 . . . . 0.0 110.578 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.429 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.8 OUTLIER -108.39 49.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.156 -0.965 . . . . 0.0 110.125 -179.8 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.453 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -133.84 -4.83 2.82 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.107 -0.996 . . . . 0.0 110.404 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.466 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.56 -155.72 0.05 OUTLIER Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.426 ' C ' ' OG1' ' A' ' 331' ' ' THR . 46.9 Cg_endo -73.65 3.06 5.18 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.915 1.482 . . . . 0.0 110.749 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.426 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.8 m -163.03 120.52 1.94 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 110.061 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -141.0 112.71 7.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.261 -0.899 . . . . 0.0 110.277 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 309' ' ' SER . 38.1 m -104.49 138.92 40.16 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 110.049 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.602 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 13.6 p90 -142.85 172.37 12.79 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.89 160.29 28.44 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 118.755 -1.688 . . . . 0.0 110.333 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.679 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -147.32 145.24 29.28 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.481 -1.011 . . . . 0.0 110.048 179.485 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.561 HG22 ' CZ2' ' A' ' 274' ' ' TRP . 1.6 mp -119.81 119.86 61.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.094 -1.004 . . . . 0.0 109.783 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.576 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.8 t -96.96 145.83 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -112.68 126.51 55.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 110.014 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.967 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.574 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.3 mtmt . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 121.204 0.526 . . . . 0.0 111.076 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.583 HG12 ' CE1' ' A' ' 280' ' ' TYR . 4.3 p -133.59 120.08 36.38 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.203 -0.935 . . . . 0.0 110.402 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.5 mm-40 -50.2 -47.02 54.91 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.979 -1.076 . . . . 0.0 109.643 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.456 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 1.2 pt-20 -177.88 158.99 1.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.616 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.52 HG12 ' CG1' ' A' ' 296' ' ' VAL . 62.9 mt -118.67 121.77 67.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.268 -0.895 . . . . 0.0 110.22 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.76 139.75 53.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.193 -0.942 . . . . 0.0 110.215 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.607 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.41 130.61 45.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.177 -0.952 . . . . 0.0 110.284 179.818 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.8 OUTLIER -138.0 110.64 7.57 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.354 -0.842 . . . . 0.0 109.572 179.784 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.474 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 110.01 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.973 . . . . 0.0 110.464 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.504 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 39.12 31.21 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.661 -0.649 . . . . 0.0 110.52 179.758 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.54 -19.3 12.83 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.4 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.8 OUTLIER -85.82 104.39 15.45 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.2 -1.176 . . . . 0.0 110.437 -179.868 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 12.0 p -72.03 128.66 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.09 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.436 HD12 ' O ' ' A' ' 357' ' ' VAL . 12.1 mm . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.156 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.549 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -133.74 163.24 29.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.397 -1.061 . . . . 0.0 109.865 179.862 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.538 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.6 tm? -161.59 133.34 5.58 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.055 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.485 ' N ' HD23 ' A' ' 267' ' ' LEU . 7.9 mt-10 -132.92 128.1 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 61.9 t -120.28 137.28 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 120.894 -1.129 . . . . 0.0 111.569 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.406 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.4 OUTLIER -122.51 156.93 33.13 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.808 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.573 HG12 ' CE2' ' A' ' 280' ' ' TYR . 78.1 t -142.56 145.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.325 -1.484 . . . . 0.0 112.288 -179.305 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.547 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -138.57 111.38 7.72 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.0 147.04 23.83 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.209 -0.932 . . . . 0.0 111.304 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.589 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 32.2 p90 -131.92 16.16 4.72 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.455 -0.778 . . . . 0.0 109.818 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.62 -60.27 3.24 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.49 -23.3 66.23 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.124 . . . . 0.0 110.302 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.579 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.14 -178.53 45.06 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.574 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -134.31 142.9 47.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 110.554 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.589 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.6 mt-10 -93.93 147.21 23.31 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.53 -0.731 . . . . 0.0 109.653 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.661 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 96.9 m-85 -141.53 83.93 1.88 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.38 -0.825 . . . . 0.0 110.45 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.12 151.74 47.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.377 -0.827 . . . . 0.0 109.943 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.636 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -143.96 88.56 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.436 -0.79 . . . . 0.0 109.691 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 24.3 m -86.09 117.25 24.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 109.628 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.605 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -105.52 150.4 25.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.242 -0.912 . . . . 0.0 110.575 -179.263 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.549 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -131.15 134.95 47.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.451 -0.78 . . . . 0.0 110.016 -179.804 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.588 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 14.3 mt -142.32 152.07 42.59 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.811 -1.181 . . . . 0.0 109.535 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.89 38.49 0.92 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.31 -0.869 . . . . 0.0 109.3 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.98 -139.12 5.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.541 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.6 mt-30 -118.09 96.05 5.17 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.059 -1.26 . . . . 0.0 110.959 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.588 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -121.29 133.58 55.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.362 -0.836 . . . . 0.0 110.025 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.444 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 67.6 m-20 -65.35 109.92 2.45 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.122 -0.986 . . . . 0.0 109.624 179.438 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.578 ' CE3' HD11 ' A' ' 284' ' ' LEU . 55.0 p-90 -107.99 116.15 31.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.105 -0.997 . . . . 0.0 110.835 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.53 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 54.8 m -110.25 115.92 30.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.426 -0.797 . . . . 0.0 109.902 179.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.509 HG22 ' CD2' ' A' ' 351' ' ' LEU . 3.7 t -96.8 111.3 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.16 -0.963 . . . . 0.0 110.608 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.479 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.3 ttpt -90.07 130.11 36.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.254 -0.904 . . . . 0.0 109.404 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.568 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 76.3 t -127.86 108.1 17.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.254 -0.903 . . . . 0.0 110.513 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.518 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 24.9 mmtt -70.08 138.3 51.91 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.148 -0.97 . . . . 0.0 109.09 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.579 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 91.7 mt -90.61 156.58 18.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.495 -0.753 . . . . 0.0 111.609 -178.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -60.72 175.33 0.44 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.629 -0.669 . . . . 0.0 109.381 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.494 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.57 80.53 0.6 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.547 1.288 . . . . 0.0 110.009 179.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.76 21.27 5.77 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.526 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -107.34 152.89 23.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -1.045 . . . . 0.0 110.064 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.542 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.8 p -153.16 146.51 24.85 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.077 -1.014 . . . . 0.0 111.312 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.478 HG22 HG12 ' A' ' 319' ' ' VAL . 63.7 t -63.88 142.16 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.372 -0.83 . . . . 0.0 109.97 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -121.77 -39.63 0.56 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -142.01 120.17 12.18 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.045 -1.268 . . . . 0.0 110.713 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.488 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.7 p90 -132.88 166.41 22.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.905 . . . . 0.0 110.021 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.484 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -157.68 160.6 38.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.161 -0.962 . . . . 0.0 111.197 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 60.25 23.17 12.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 110.881 179.502 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.473 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -174.99 144.88 0.78 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.352 -0.843 . . . . 0.0 109.854 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.529 ' ND2' ' HA ' ' A' ' 324' ' ' VAL . 2.2 m-80 -83.43 122.48 28.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.028 -1.045 . . . . 0.0 109.43 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.494 ' HG3' HG12 ' A' ' 319' ' ' VAL . 4.2 ttpt -89.7 140.29 29.72 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.877 0.846 . . . . 0.0 110.609 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.41 176.11 7.03 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -137.63 107.15 6.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.409 -0.807 . . . . 0.0 110.247 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.47 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -98.06 37.4 3.49 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.47 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.6 OUTLIER 68.43 88.17 0.11 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.226 -1.161 . . . . 0.0 110.448 179.852 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.37 6.95 83.34 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.614 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.0 m-85 -146.35 -170.81 3.59 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.305 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.539 HG13 ' N ' ' A' ' 320' ' ' ILE . 6.5 t -162.28 156.25 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.894 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.539 ' N ' HG13 ' A' ' 319' ' ' VAL . 7.2 mm -125.79 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.888 -1.133 . . . . 0.0 111.476 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 36.9 m-85 -114.37 131.18 56.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.273 -0.892 . . . . 0.0 109.532 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.522 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 1.8 p -132.06 169.94 12.59 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 120.624 -1.297 . . . . 0.0 110.317 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -64.92 109.37 1.27 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.883 1.465 . . . . 0.0 110.923 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.54 HG23 ' ND2' ' A' ' 327' ' ' ASN . 6.2 m -48.18 -59.0 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.427 -0.796 . . . . 0.0 110.63 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 324' ' ' VAL . 14.6 t 177.89 -25.91 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.991 -1.068 . . . . 0.0 111.133 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.407 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 7.1 p-90 -113.85 -22.87 9.93 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.958 -1.089 . . . . 0.0 110.912 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.54 ' ND2' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -83.36 12.18 5.79 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.991 -1.068 . . . . 0.0 110.929 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 12.1 mtmt -74.12 -11.07 60.2 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.46 -0.775 . . . . 0.0 109.329 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.21 -158.13 0.01 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.542 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -73.06 7.14 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 124.069 1.562 . . . . 0.0 111.388 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 4.4 m -162.32 131.23 4.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.123 -0.986 . . . . 0.0 109.841 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -144.23 104.37 4.1 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.231 -0.918 . . . . 0.0 110.355 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.473 ' O ' ' HB3' ' A' ' 309' ' ' SER . 48.2 m -100.98 135.16 42.87 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.058 -1.027 . . . . 0.0 110.312 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 6.6 p90 -144.39 173.14 12.04 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.67 157.54 27.24 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.478 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.661 ' CE2' ' CB ' ' A' ' 280' ' ' TYR . 0.4 OUTLIER -144.35 144.81 31.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.598 -0.943 . . . . 0.0 110.01 179.512 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.541 HG23 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -119.31 118.65 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.099 -1.001 . . . . 0.0 109.589 179.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.579 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.2 t -96.67 150.06 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.241 -0.912 . . . . 0.0 109.855 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -122.57 133.8 54.55 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.437 -0.789 . . . . 0.0 110.333 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.153 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.897 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.55 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 2.2 mtmt . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 121.196 0.522 . . . . 0.0 110.812 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.54 ' CG2' HG11 ' A' ' 296' ' ' VAL . 7.5 p -132.08 118.17 35.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 110.46 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.476 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -46.76 -46.61 20.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.457 -0.777 . . . . 0.0 110.504 -179.845 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.428 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 9.2 pt-20 -177.27 158.93 1.53 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.041 -1.037 . . . . 0.0 110.803 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.46 HG12 HG11 ' A' ' 296' ' ' VAL . 44.9 mt -120.46 106.69 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.131 -0.98 . . . . 0.0 110.392 179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.49 136.48 51.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.225 -0.922 . . . . 0.0 110.228 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.605 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -95.71 134.35 38.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.238 -0.914 . . . . 0.0 110.332 179.83 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.481 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 6.2 tt0 -138.94 112.43 8.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.361 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.442 ' O ' ' C ' ' A' ' 354' ' ' ASN . 1.2 mt -91.71 105.2 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.066 -1.021 . . . . 0.0 109.942 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.444 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 40.15 31.51 0.1 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.591 -0.693 . . . . 0.0 110.625 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 119.14 -22.08 9.15 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -85.35 105.29 15.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.255 -1.144 . . . . 0.0 110.096 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.481 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 4.1 p -75.73 130.52 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.458 HG21 HD12 ' A' ' 358' ' ' ILE . 27.0 mm . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.276 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.55 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.7 OUTLIER -133.62 165.85 23.96 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -1.079 . . . . 0.0 109.883 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.55 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.7 tm? -161.31 137.2 8.02 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.412 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.472 ' N ' HD21 ' A' ' 267' ' ' LEU . 1.3 mm-40 -132.94 154.09 50.78 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 46.2 t -145.41 139.74 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.62 -1.3 . . . . 0.0 111.739 -179.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.08 154.84 45.24 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.537 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 70.8 t -140.67 141.43 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.466 -1.396 . . . . 0.0 111.984 -179.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -134.41 110.25 9.3 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 179.205 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.2 m-20 -96.77 142.19 29.08 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.071 -1.018 . . . . 0.0 110.926 -178.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.58 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 26.0 p90 -123.16 15.31 9.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.312 -0.867 . . . . 0.0 110.223 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.14 -53.62 3.22 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -76.9 -16.6 59.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -1.136 . . . . 0.0 110.066 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.559 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.74 -178.68 43.87 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.851 -1.299 . . . . 0.0 109.851 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.546 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.88 138.63 39.27 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -1.111 . . . . 0.0 110.053 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.58 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.0 mt-10 -95.22 147.14 23.79 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.351 -0.843 . . . . 0.0 110.017 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.686 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.0 m-85 -140.17 89.27 2.28 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 110.814 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.462 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -71.34 148.48 47.01 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.324 -0.86 . . . . 0.0 109.639 179.239 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.616 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.6 t -142.69 92.29 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.413 -0.805 . . . . 0.0 109.968 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.465 ' O ' HD23 ' A' ' 267' ' ' LEU . 15.4 m -86.45 126.46 34.42 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.032 -1.043 . . . . 0.0 109.77 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.606 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -115.19 149.6 37.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.969 -1.082 . . . . 0.0 110.987 -179.081 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.55 ' ND2' ' HB2' ' A' ' 266' ' ' SER . 0.4 OUTLIER -129.67 133.78 47.29 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.334 -0.854 . . . . 0.0 110.071 -179.691 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.547 ' CD1' ' HB2' ' A' ' 290' ' ' TYR . 17.8 mt -142.1 162.94 34.2 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.65 -1.281 . . . . 0.0 110.055 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -87.65 29.71 0.87 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.921 . . . . 0.0 110.473 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.506 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.09 -136.82 6.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.46 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 32.4 mm-40 -90.11 104.74 17.28 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.276 -1.132 . . . . 0.0 110.873 -179.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.547 ' HB2' ' CD1' ' A' ' 286' ' ' LEU . 8.4 m-85 -128.43 129.61 46.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.398 -0.814 . . . . 0.0 109.265 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.533 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 58.9 m-20 -74.6 96.31 2.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.742 -1.224 . . . . 0.0 109.369 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.586 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 60.3 p-90 -98.01 115.43 28.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 110.689 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.528 HG22 ' CG2' ' A' ' 322' ' ' THR . 4.6 m -109.51 115.78 30.56 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.52 -0.738 . . . . 0.0 109.425 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.493 HG23 ' CD2' ' A' ' 351' ' ' LEU . 4.6 t -96.89 111.27 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.106 -0.996 . . . . 0.0 110.394 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.495 ' HA ' HD11 ' A' ' 320' ' ' ILE . 21.2 ttpt -91.29 136.5 33.05 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.594 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 69.9 t -135.46 109.2 10.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.136 -0.978 . . . . 0.0 110.634 -179.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.517 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 53.8 mmtt -69.97 132.77 46.46 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.243 -0.911 . . . . 0.0 109.32 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.591 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 60.1 mt -86.68 165.45 16.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.304 -0.872 . . . . 0.0 111.198 -179.062 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.507 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -75.69 176.43 3.21 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.752 -0.593 . . . . 0.0 109.43 179.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.507 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 41.0 Cg_endo -67.6 84.94 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.527 1.278 . . . . 0.0 109.955 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.87 20.95 6.57 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.482 ' HB3' ' HG2' ' A' ' 345' ' ' LYS . . . -111.2 142.37 43.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.274 -1.133 . . . . 0.0 110.23 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.493 ' N ' HG13 ' A' ' 338' ' ' VAL . 17.0 p -150.28 144.36 25.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -0.941 . . . . 0.0 110.834 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.521 HG13 ' CD ' ' A' ' 312' ' ' LYS . 14.7 t -63.75 137.37 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.388 -0.82 . . . . 0.0 110.193 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -120.69 -33.15 1.03 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.43 ' O ' HD12 ' A' ' 337' ' ' ILE . 24.7 m -138.86 117.14 11.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.223 -1.163 . . . . 0.0 110.441 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.486 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.4 p90 -133.91 148.38 51.22 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.288 -0.883 . . . . 0.0 109.908 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -141.23 164.53 30.01 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.14 -0.975 . . . . 0.0 111.173 -179.433 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.519 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 54.33 25.13 5.64 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.728 -0.607 . . . . 0.0 111.173 179.499 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -173.88 138.65 0.64 Allowed 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.099 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.527 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -76.89 120.08 21.53 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.074 -1.017 . . . . 0.0 108.711 179.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.521 ' CD ' HG13 ' A' ' 304' ' ' VAL . 4.3 ttpt -88.43 128.05 35.52 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.824 0.821 . . . . 0.0 110.799 -178.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -113.31 175.73 5.32 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -135.5 110.56 8.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.292 -0.88 . . . . 0.0 110.731 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.574 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -95.35 40.56 2.64 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.0 77.65 0.26 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.233 -1.157 . . . . 0.0 109.962 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.616 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.96 3.56 54.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.616 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.8 m-85 -145.12 -170.76 3.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.486 -1.008 . . . . 0.0 109.003 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 18.2 t -161.39 157.74 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.199 -0.938 . . . . 0.0 109.691 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.511 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 13.0 mm -127.03 146.79 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -0.922 . . . . 0.0 110.885 -179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 91.0 m-85 -124.12 119.19 28.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.321 -0.862 . . . . 0.0 109.814 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.528 ' CG2' HG22 ' A' ' 293' ' ' THR . 12.6 p -121.11 168.0 11.92 Favored Pre-proline 0 C--N 1.301 -1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.641 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.501 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.5 Cg_endo -66.28 117.97 5.13 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.692 1.364 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.539 HG23 ' CD1' ' A' ' 326' ' ' TRP . 23.9 m -65.72 -130.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.507 -0.746 . . . . 0.0 110.332 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.409 ' O ' ' HE2' ' A' ' 328' ' ' LYS . 1.9 t -96.94 -12.84 22.89 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.08 -1.013 . . . . 0.0 110.554 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.539 ' CD1' HG23 ' A' ' 324' ' ' VAL . 34.0 p-90 -133.46 5.53 3.75 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.07 -1.019 . . . . 0.0 110.946 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.459 ' O ' ' HB3' ' A' ' 323' ' ' PRO . 1.3 t-20 -112.45 42.89 1.73 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.998 -1.064 . . . . 0.0 110.768 -179.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.495 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.8 OUTLIER -122.97 0.95 9.23 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.338 -0.851 . . . . 0.0 109.71 179.064 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -63.69 -158.79 0.23 Allowed Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.506 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 47.8 Cg_endo -75.36 3.88 5.41 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.999 1.526 . . . . 0.0 110.767 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.6 m -165.02 117.6 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.16 -0.963 . . . . 0.0 109.814 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.547 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -140.18 123.7 17.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.274 -0.891 . . . . 0.0 110.373 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.476 ' O ' ' HB2' ' A' ' 309' ' ' SER . 40.9 m -111.58 142.07 44.36 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 109.99 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.616 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 14.0 p90 -143.95 174.82 10.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.515 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.04 158.05 27.49 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.288 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.686 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -144.97 147.44 32.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.476 -1.014 . . . . 0.0 110.041 179.627 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.549 HG21 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -120.6 118.93 58.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.005 -1.059 . . . . 0.0 109.704 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.591 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.5 t -96.73 147.27 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.113 -0.992 . . . . 0.0 110.095 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.434 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.15 137.85 53.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.339 -0.85 . . . . 0.0 110.332 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.422 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.508 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.461 0 CA-C-O 121.369 0.604 . . . . 0.0 110.29 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.594 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 7.5 p -130.22 117.84 41.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -0.839 . . . . 0.0 110.568 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.0 mt-10 -47.08 -46.98 23.03 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 110.141 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.443 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.74 158.34 1.66 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.291 -0.88 . . . . 0.0 110.59 -179.843 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.468 HG21 HD11 ' A' ' 349' ' ' ILE . 33.1 mt -118.26 105.99 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.336 -0.852 . . . . 0.0 110.289 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.86 143.02 38.62 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.959 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.606 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.37 130.91 54.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.115 -0.991 . . . . 0.0 110.442 -179.867 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.439 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 15.0 tt0 -139.13 114.69 9.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.875 . . . . 0.0 109.823 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.523 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -91.38 111.52 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.014 -1.054 . . . . 0.0 109.744 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.533 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 39.86 30.28 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.793 -0.567 . . . . 0.0 110.44 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 115.88 -15.02 16.69 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 0.0 OUTLIER -89.54 108.06 19.44 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.128 -1.219 . . . . 0.0 110.412 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 9.8 p -73.09 123.99 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.165 -0.959 . . . . 0.0 110.125 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.413 HG21 ' O ' ' A' ' 358' ' ' ILE . 20.6 mm . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.423 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.553 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.79 167.89 21.0 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.64 -0.918 . . . . 0.0 109.533 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.562 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.8 tm? -161.47 133.96 5.98 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.0 -1.08 . . . . 0.0 111.266 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.516 ' N ' HD21 ' A' ' 267' ' ' LEU . 14.3 mm-40 -134.33 129.62 35.77 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.44 HG12 ' O ' ' A' ' 281' ' ' ASP . 89.5 t -125.9 139.54 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.853 -1.154 . . . . 0.0 111.625 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.1 mtmt -124.9 157.56 35.67 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.59 HG12 ' CE1' ' A' ' 280' ' ' TYR . 74.5 t -141.62 146.73 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.43 -1.418 . . . . 0.0 112.068 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.557 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -136.28 107.9 6.99 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.309 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.2 m-20 -94.74 142.44 27.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.997 -1.064 . . . . 0.0 111.1 -179.03 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.592 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 25.6 p90 -123.97 17.06 9.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.44 -0.787 . . . . 0.0 109.831 179.173 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.43 -55.54 3.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.31 -18.94 58.7 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.227 -1.161 . . . . 0.0 110.286 -179.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.24 -179.37 40.63 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.551 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -139.06 137.13 35.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -1.111 . . . . 0.0 110.173 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.592 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 5.6 mt-10 -92.7 146.84 23.35 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.264 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.2 m-85 -139.98 90.34 2.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.201 -0.937 . . . . 0.0 111.265 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.44 ' O ' HG12 ' A' ' 269' ' ' VAL . 4.7 t70 -72.62 146.92 46.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.51 -0.744 . . . . 0.0 109.408 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.604 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 4.4 t -140.77 86.94 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.184 -0.947 . . . . 0.0 110.094 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.47 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 13.2 m -86.74 122.88 31.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.069 -1.019 . . . . 0.0 110.04 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.591 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.56 154.05 22.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 0.0 110.226 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.553 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -133.69 113.75 12.7 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.106 -0.996 . . . . 0.0 110.89 -179.071 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.549 ' O ' ' CB ' ' A' ' 330' ' ' PRO . 13.3 mt -123.83 158.59 31.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.549 -1.345 . . . . 0.0 109.884 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.1 35.22 0.85 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.292 -0.88 . . . . 0.0 109.807 179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 154.92 -134.25 4.15 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.515 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 47.5 mm-40 -106.84 111.63 24.24 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.177 -1.19 . . . . 0.0 111.026 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.569 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 6.9 m-85 -132.06 136.96 47.59 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.336 -0.852 . . . . 0.0 109.301 179.175 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.513 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 31.1 m-20 -75.37 96.42 3.4 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.756 -1.215 . . . . 0.0 108.617 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.589 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 61.3 p-90 -99.6 114.1 26.93 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.449 -0.782 . . . . 0.0 110.904 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.584 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 27.3 m -111.43 118.09 34.84 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.155 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.493 HG21 HD22 ' A' ' 351' ' ' LEU . 3.1 t -96.75 111.0 25.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.183 -0.948 . . . . 0.0 110.737 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.493 ' HA ' HD11 ' A' ' 320' ' ' ILE . 7.0 ttpp -83.34 148.6 27.24 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.441 -0.787 . . . . 0.0 109.012 178.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.529 HG13 ' CG2' ' A' ' 346' ' ' VAL . 44.5 t -147.3 104.99 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.096 -1.003 . . . . 0.0 110.707 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.581 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.7 mmtp -70.63 133.14 46.42 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 179.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.559 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 91.0 mt -86.37 150.28 24.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 111.474 -179.071 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.504 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -61.0 171.89 1.01 Allowed Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.686 -0.634 . . . . 0.0 109.681 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.491 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.2 Cg_endo -67.53 82.58 0.41 Allowed 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.785 1.413 . . . . 0.0 109.642 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.11 28.27 2.68 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -122.32 146.36 47.38 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.373 -1.075 . . . . 0.0 110.557 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.559 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 19.3 p -149.57 143.59 25.68 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.185 -0.947 . . . . 0.0 110.748 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.578 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 66.8 t -68.48 130.76 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 110.246 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -114.04 -39.33 1.06 Allowed Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.46 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 18.1 m -132.64 141.67 48.75 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.188 -1.184 . . . . 0.0 110.913 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.578 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 28.5 p90 -153.75 167.96 27.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.363 -0.836 . . . . 0.0 109.656 179.465 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.497 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -160.67 158.43 28.82 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.995 -1.066 . . . . 0.0 111.253 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.555 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.61 31.96 21.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.631 -0.668 . . . . 0.0 111.245 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.534 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -175.91 150.85 1.04 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.049 -1.032 . . . . 0.0 110.457 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.493 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 1.9 m-80 -81.22 109.7 16.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.088 -1.007 . . . . 0.0 109.439 179.012 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.578 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 27.6 ttpt -84.97 132.52 34.34 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.46 -0.775 . . . . 0.0 110.603 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.519 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.07 174.73 7.83 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.53 -0.731 . . . . 0.0 109.465 179.329 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -138.2 104.68 5.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.523 -0.736 . . . . 0.0 110.064 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -92.0 37.93 3.29 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.12 81.24 0.21 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.048 -1.266 . . . . 0.0 110.253 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.25 -0.04 57.12 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.614 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.3 m-85 -146.33 -171.33 3.71 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.347 -1.09 . . . . 0.0 109.359 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.578 ' CG2' ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -159.46 157.91 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.117 -0.989 . . . . 0.0 109.844 178.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.584 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 8.7 mm -125.87 150.32 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.073 -1.017 . . . . 0.0 111.376 -179.176 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.638 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 89.3 m-85 -130.98 112.49 12.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.301 -0.874 . . . . 0.0 110.285 179.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.566 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.8 p -115.02 174.23 2.48 Favored Pre-proline 0 N--CA 1.498 1.973 0 O-C-N 120.512 -1.367 . . . . 0.0 109.54 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.566 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 43.1 Cg_endo -71.13 125.07 11.07 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.607 1.319 . . . . 0.0 111.283 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.514 ' N ' ' OD1' ' A' ' 327' ' ' ASN . 14.9 m -70.06 -110.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.518 -0.739 . . . . 0.0 110.438 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.42 -16.95 8.88 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.715 -1.241 . . . . 0.0 111.299 -179.277 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.53 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 3.1 p-90 -125.93 -18.9 4.97 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.914 -1.116 . . . . 0.0 111.077 -179.507 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.555 ' ND2' ' O ' ' A' ' 309' ' ' SER . 34.0 p-10 -89.7 47.28 1.45 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.928 -1.108 . . . . 0.0 110.046 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.491 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 13.5 mtmt -118.26 -10.09 10.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.493 -0.754 . . . . 0.0 109.426 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.24 -157.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.549 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -74.73 5.69 3.71 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.03 1.542 . . . . 0.0 111.077 -179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 3.6 m -161.93 120.03 2.25 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.874 179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.41 117.78 14.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.222 -0.924 . . . . 0.0 110.361 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.47 ' OG1' ' CG2' ' A' ' 283' ' ' THR . 26.2 m -109.68 135.28 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 110.434 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.608 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 13.4 p90 -142.82 174.44 10.65 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.09 162.94 29.35 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.582 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.68 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.3 p90 -150.84 145.05 25.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.567 -0.961 . . . . 0.0 109.558 179.352 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.555 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.5 mp -118.89 122.4 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.058 -1.026 . . . . 0.0 110.069 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.534 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 3.4 t -98.36 146.06 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.22 -0.925 . . . . 0.0 109.695 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -119.39 137.22 53.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 110.729 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.446 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.492 2.397 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.534 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.322 0.582 . . . . 0.0 110.742 . . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.592 HG12 ' CE1' ' A' ' 280' ' ' TYR . 7.1 p -131.46 111.22 18.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.1 mm-40 -43.14 -46.83 6.03 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.202 -0.936 . . . . 0.0 110.425 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -175.95 157.78 1.95 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 110.357 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . . . . . . . . . 13.5 mt -118.43 104.36 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.243 -0.911 . . . . 0.0 109.945 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.03 126.83 52.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 110.499 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.591 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -91.11 130.17 37.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.03 -1.044 . . . . 0.0 110.025 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.527 ' N ' HD23 ' A' ' 351' ' ' LEU . 15.9 tt0 -138.55 117.59 12.54 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.31 -0.869 . . . . 0.0 109.549 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.506 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.11 98.19 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.921 -1.112 . . . . 0.0 110.118 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.513 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 38.57 28.24 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.296 179.634 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 134.94 -19.47 3.92 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.889 179.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.474 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 11.1 mm100 -102.78 113.15 26.33 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.871 -1.37 . . . . 0.0 110.905 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.416 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.7 p -76.89 121.17 28.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.485 -0.759 . . . . 0.0 110.354 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.412 HG22 HD12 ' A' ' 358' ' ' ILE . 26.7 mm . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.165 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.535 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.41 166.08 25.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.334 -1.098 . . . . 0.0 110.043 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.569 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.7 tm? -161.65 139.77 9.22 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.025 -1.047 . . . . 0.0 111.409 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.435 ' N ' HD23 ' A' ' 267' ' ' LEU . 3.7 mt-10 -136.12 153.78 51.19 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 54.0 t -145.27 135.67 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.697 -1.252 . . . . 0.0 111.567 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.445 ' O ' HG21 ' A' ' 271' ' ' VAL . 7.7 mtpt -122.88 157.05 33.38 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.523 HG11 ' CE1' ' A' ' 280' ' ' TYR . 92.5 t -144.81 147.2 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.478 -1.389 . . . . 0.0 112.167 -179.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.64 112.64 7.35 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.791 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 p-10 -97.53 141.76 30.19 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.948 -1.095 . . . . 0.0 111.402 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.553 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 32.3 p90 -124.5 19.99 8.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.502 -0.748 . . . . 0.0 109.8 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.74 -59.58 4.75 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.99 -20.07 66.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -1.159 . . . . 0.0 110.11 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.48 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.12 -175.03 44.93 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.4 143.94 42.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -1.138 . . . . 0.0 110.225 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.512 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 3.9 mt-10 -96.97 145.83 25.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.385 -0.822 . . . . 0.0 109.789 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.681 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 96.1 m-85 -138.93 86.73 2.16 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.452 -0.78 . . . . 0.0 110.92 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.449 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.59 146.83 49.84 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.316 -0.865 . . . . 0.0 109.442 179.105 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.639 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.6 t -140.22 90.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 121.336 -0.853 . . . . 0.0 109.932 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.452 ' O ' HD22 ' A' ' 267' ' ' LEU . 53.9 m -86.58 127.92 34.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.058 -1.026 . . . . 0.0 109.681 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.607 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.89 152.1 32.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.127 -0.983 . . . . 0.0 110.687 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.54 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.4 OUTLIER -130.56 134.54 47.1 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.282 -0.886 . . . . 0.0 110.263 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.565 ' N ' ' O ' ' A' ' 330' ' ' PRO . 12.7 mt -143.72 155.55 44.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.938 -1.101 . . . . 0.0 109.491 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -88.6 40.02 0.95 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 109.723 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 150.3 -116.69 0.79 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.991 -1.576 . . . . 0.0 110.242 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.559 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.6 mt-30 -128.62 116.31 19.4 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.022 -1.281 . . . . 0.0 110.926 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.599 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 8.8 m-85 -138.23 137.03 37.15 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.191 -0.943 . . . . 0.0 109.664 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.523 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 23.2 m-20 -71.02 96.81 1.36 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.815 -1.178 . . . . 0.0 108.981 179.043 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.585 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 59.2 p-90 -98.08 113.1 24.89 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.221 -0.924 . . . . 0.0 110.833 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.602 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 10.3 m -106.23 111.75 24.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.417 -0.802 . . . . 0.0 109.243 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.529 HG23 ' CD2' ' A' ' 351' ' ' LEU . 3.1 t -96.21 111.24 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.167 -0.958 . . . . 0.0 110.371 -179.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.543 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 5.1 ttmt -89.19 149.51 23.09 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.438 -0.788 . . . . 0.0 109.51 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.568 HG12 ' CG2' ' A' ' 346' ' ' VAL . 56.1 t -142.34 107.87 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.288 -0.882 . . . . 0.0 110.31 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.555 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 11.5 mmtt -70.2 131.34 44.07 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.179 -0.95 . . . . 0.0 109.645 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.592 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 94.8 mt -85.25 160.89 19.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.81 . . . . 0.0 111.312 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.521 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -71.43 174.32 4.01 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 121.571 -0.705 . . . . 0.0 109.212 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.502 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.43 84.08 0.37 Allowed 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 123.492 1.259 . . . . 0.0 110.096 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.97 24.66 4.79 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.508 ' HB1' ' HB1' ' A' ' 299' ' ' ALA . . . -115.9 148.32 40.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -1.104 . . . . 0.0 110.225 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.53 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.8 p -149.84 143.6 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.104 -0.998 . . . . 0.0 110.718 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.525 HG21 ' CG2' ' A' ' 319' ' ' VAL . 85.2 t -65.63 121.94 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.418 -0.801 . . . . 0.0 109.906 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -103.16 -30.25 5.46 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.412 ' O ' ' N ' ' A' ' 337' ' ' ILE . 3.3 t -145.85 142.32 28.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.004 -1.292 . . . . 0.0 110.911 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.509 ' CD1' ' C ' ' A' ' 307' ' ' PHE . 15.0 p90 -152.6 174.65 13.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.544 -0.722 . . . . 0.0 109.38 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.474 ' NE1' ' N ' ' A' ' 335' ' ' GLY . 1.3 p90 -163.84 159.55 21.26 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.848 -1.158 . . . . 0.0 111.486 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.482 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.7 OUTLIER 55.68 26.41 9.3 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.564 -0.71 . . . . 0.0 111.116 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.536 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -173.68 139.25 0.7 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.195 -0.941 . . . . 0.0 109.897 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.521 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.3 m-80 -77.42 121.24 23.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.062 -1.024 . . . . 0.0 109.488 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.3 ttpt -88.33 142.81 27.44 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.844 0.83 . . . . 0.0 110.552 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.586 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.6 mt-30 -130.25 176.48 8.07 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.454 ' OE1' ' O ' ' A' ' 318' ' ' TYR . 5.3 mm-40 -135.79 113.32 10.8 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.115 -0.99 . . . . 0.0 110.545 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.6 42.13 2.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.465 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 20.6 t-20 57.41 81.49 0.14 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.335 -1.097 . . . . 0.0 110.269 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.82 3.74 58.08 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.597 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 0.8 OUTLIER -147.08 -167.72 2.85 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.353 -1.087 . . . . 0.0 109.055 179.532 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.535 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.7 t -163.28 147.73 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.195 -0.94 . . . . 0.0 109.733 178.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.602 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.6 mm -112.35 152.06 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.005 -1.06 . . . . 0.0 110.998 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 58.4 m-85 -129.24 125.86 37.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.812 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.521 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 7.2 p -129.04 167.7 18.71 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 120.488 -1.382 . . . . 0.0 109.965 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.538 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.7 Cg_endo -65.74 119.36 6.37 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.78 1.411 . . . . 0.0 111.087 -179.233 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.497 HG11 ' ND2' ' A' ' 311' ' ' ASN . 31.3 m -64.73 -121.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.485 -0.759 . . . . 0.0 110.297 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.437 ' C ' ' HD2' ' A' ' 328' ' ' LYS . 0.6 OUTLIER -106.18 -19.9 13.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.809 -1.182 . . . . 0.0 110.666 -179.649 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.453 ' CE2' HG23 ' A' ' 324' ' ' VAL . 21.6 p-90 -126.2 3.17 7.13 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.08 -1.012 . . . . 0.0 110.653 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.532 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 1.9 t-20 -108.08 31.72 5.32 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.093 -1.005 . . . . 0.0 110.576 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -110.46 -2.6 16.47 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.102 -0.999 . . . . 0.0 109.547 179.433 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.05 -153.33 0.02 OUTLIER Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.565 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.6 Cg_endo -69.8 -48.89 0.62 Allowed 'Trans proline' 0 C--N 1.301 -1.935 0 O-C-N 123.987 1.52 . . . . 0.0 109.474 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.437 HG23 ' O ' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -109.08 125.58 52.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.527 -0.733 . . . . 0.0 110.327 179.643 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.74 108.09 6.86 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.36 -0.838 . . . . 0.0 109.993 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.449 ' OG1' HG22 ' A' ' 283' ' ' THR . 3.3 m -103.17 138.92 39.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 110.227 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.639 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 14.0 p90 -144.74 174.63 10.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.374 -0.829 . . . . 0.0 109.138 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.04 158.26 27.59 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 118.984 -1.579 . . . . 0.0 110.336 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.681 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -147.93 143.87 27.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.57 -0.959 . . . . 0.0 109.553 179.321 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.56 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.5 mp -118.01 129.67 74.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.073 -1.017 . . . . 0.0 110.107 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.592 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.3 t -104.92 148.48 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.027 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -120.7 135.47 55.12 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 110.181 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.416 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.537 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 2.1 mtmt . . . . . 0 N--CA 1.488 1.467 0 CA-C-O 121.25 0.548 . . . . 0.0 110.335 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.595 HG13 ' CE1' ' A' ' 280' ' ' TYR . 6.8 p -128.91 117.4 44.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.309 -0.869 . . . . 0.0 110.107 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.2 OUTLIER -47.57 -47.88 28.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.046 -1.034 . . . . 0.0 110.068 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.419 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.7 OUTLIER -177.2 158.33 1.47 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.289 -0.882 . . . . 0.0 110.35 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.491 HD11 HG21 ' A' ' 349' ' ' ILE . 17.0 mt -117.34 110.37 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 110.215 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.67 144.03 41.59 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.271 -0.893 . . . . 0.0 110.2 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.607 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.66 132.77 50.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.18 -0.95 . . . . 0.0 110.249 179.869 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.409 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 5.4 tt0 -139.07 113.13 8.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.945 179.674 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.47 HD12 ' HB3' ' A' ' 292' ' ' TRP . 2.8 mt -91.64 112.53 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.913 -1.117 . . . . 0.0 110.088 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.523 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.84 29.72 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.782 -0.574 . . . . 0.0 111.295 -179.961 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.26 -10.24 14.98 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.667 -1.254 . . . . 0.0 110.6 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . . . . . . . . . 43.1 mm-40 -101.45 115.06 29.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.878 -1.366 . . . . 0.0 110.364 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.1 p -75.13 139.09 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.279 -0.888 . . . . 0.0 110.493 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.456 HD11 ' O ' ' A' ' 357' ' ' VAL . 26.6 mm . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.196 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.421 ' HA3' HD21 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.3 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.541 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.8 OUTLIER -136.0 167.06 21.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.447 -1.031 . . . . 0.0 109.495 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.562 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.9 tm? -161.06 136.84 8.05 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.515 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.457 ' N ' HD21 ' A' ' 267' ' ' LEU . 8.0 mm-40 -135.69 156.12 49.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 59.9 t -146.96 146.29 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.648 -1.283 . . . . 0.0 111.617 -179.249 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.446 ' N ' HG12 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -132.4 157.6 44.14 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.186 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.546 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 86.7 t -144.88 147.2 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 120.262 -1.524 . . . . 0.0 112.401 -179.258 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.522 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.46 114.58 8.66 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.906 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.0 p-10 -97.81 148.73 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.087 -1.008 . . . . 0.0 111.366 -178.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.54 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 37.1 p90 -134.85 17.42 3.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.608 -0.682 . . . . 0.0 109.96 179.381 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 92.46 -66.28 2.05 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.48 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 57.4 m -64.3 -18.77 64.92 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.322 -1.105 . . . . 0.0 110.581 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.532 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -179.24 178.65 48.82 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.164 -1.493 . . . . 0.0 110.246 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.54 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.66 145.99 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.505 -0.997 . . . . 0.0 110.019 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.546 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 11.4 mt-10 -96.36 146.86 24.38 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.433 -0.792 . . . . 0.0 109.425 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.2 m-85 -138.33 89.17 2.36 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.31 -0.869 . . . . 0.0 110.584 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 71.4 m-20 -69.64 147.49 50.57 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.679 -0.638 . . . . 0.0 109.828 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.595 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -142.76 89.96 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.355 -0.84 . . . . 0.0 109.543 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.418 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 27.3 m -86.49 120.51 27.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.106 -0.996 . . . . 0.0 109.857 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.571 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.34 149.37 28.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.602 -179.478 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.541 ' ND2' ' HB2' ' A' ' 266' ' ' SER . 0.5 OUTLIER -128.04 136.21 50.93 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.395 -0.816 . . . . 0.0 110.084 -179.799 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.605 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 14.2 mt -142.17 154.52 44.9 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.721 -1.237 . . . . 0.0 109.854 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -85.77 36.27 0.65 Allowed 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.381 -0.825 . . . . 0.0 110.311 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.481 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 150.56 -104.12 0.26 Allowed Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.082 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.5 mm-40 -139.87 113.67 8.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.015 -1.285 . . . . 0.0 111.429 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.639 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 4.8 m-85 -138.75 129.93 26.95 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.503 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 90.0 m-20 -65.16 99.69 0.39 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.817 -1.177 . . . . 0.0 109.266 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.581 ' CZ2' ' HB2' ' A' ' 332' ' ' ALA . 52.4 p-90 -98.77 115.86 29.72 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.335 -0.853 . . . . 0.0 110.868 -179.27 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.594 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 9.8 m -105.98 116.26 31.63 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.66 -0.65 . . . . 0.0 109.299 179.538 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.459 HG21 ' CE2' ' A' ' 334' ' ' PHE . 3.9 t -96.75 111.44 26.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.02 -1.05 . . . . 0.0 110.662 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.526 ' HG3' ' CD1' ' A' ' 320' ' ' ILE . 2.8 ttpt -85.44 144.03 28.22 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.431 -0.793 . . . . 0.0 109.156 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 99.0 t -144.34 106.84 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.028 -1.045 . . . . 0.0 110.662 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.539 ' HD3' ' CG ' ' A' ' 318' ' ' TYR . 35.7 mmtt -70.57 130.38 41.67 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.27 -0.894 . . . . 0.0 109.804 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.596 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 77.2 mt -85.38 155.08 21.45 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.516 -0.74 . . . . 0.0 111.398 -178.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.546 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -59.7 176.23 0.33 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.54 -0.725 . . . . 0.0 109.409 179.106 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.494 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.5 Cg_endo -69.19 81.07 0.69 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.612 1.322 . . . . 0.0 109.895 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.2 4.9 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.493 ' HB3' ' HB2' ' A' ' 299' ' ' ALA . . . -110.24 149.7 29.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.417 -1.049 . . . . 0.0 110.188 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.532 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 9.5 p -150.15 145.08 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 110.573 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.473 HG23 HG22 ' A' ' 338' ' ' VAL . 77.5 t -71.25 122.6 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.527 -0.733 . . . . 0.0 109.865 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -103.5 -37.99 2.91 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.411 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -132.29 136.4 46.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.076 -1.249 . . . . 0.0 111.035 -179.559 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.583 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 50.3 p90 -147.67 159.91 43.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.458 -0.776 . . . . 0.0 109.468 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.517 ' CH2' HD13 ' A' ' 337' ' ' ILE . 1.2 p90 -154.65 158.13 39.19 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.976 -1.077 . . . . 0.0 111.239 -179.46 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.503 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.2 OUTLIER 63.98 20.39 12.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.553 -0.717 . . . . 0.0 110.532 179.63 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.482 ' HA ' HG12 ' A' ' 324' ' ' VAL . . . -174.76 147.44 1.03 Allowed 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.564 -0.71 . . . . 0.0 110.022 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.524 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -82.07 123.81 29.27 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.109 -0.994 . . . . 0.0 108.982 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.583 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 11.6 ttpt -89.42 137.96 31.87 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.63 0.729 . . . . 0.0 111.217 -178.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.5 ' CB ' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -123.15 172.36 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.776 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -139.28 104.49 5.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.201 -0.937 . . . . 0.0 110.506 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.464 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -92.31 40.37 2.89 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.464 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 0.8 OUTLIER 58.08 86.13 0.08 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.352 -1.087 . . . . 0.0 110.418 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.596 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.51 -4.54 58.25 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.596 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.0 OUTLIER -144.94 -172.05 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.4 -1.059 . . . . 0.0 109.243 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.3 t -159.08 161.45 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.211 -0.931 . . . . 0.0 109.739 178.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.594 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 42.4 mm -129.26 151.13 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.275 -0.89 . . . . 0.0 111.184 -179.66 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.628 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 97.4 m-85 -128.9 125.2 37.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.315 -0.866 . . . . 0.0 109.915 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.524 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 10.7 p -124.82 168.36 13.51 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 120.799 -1.188 . . . . 0.0 109.715 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.52 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.7 Cg_endo -66.73 121.71 8.97 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.692 1.364 . . . . 0.0 110.808 -179.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.502 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 31.2 m -69.5 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.554 -0.716 . . . . 0.0 110.083 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.417 ' C ' ' HD2' ' A' ' 328' ' ' LYS . 0.9 OUTLIER -100.44 -20.89 15.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 110.606 -179.76 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.503 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 8.4 p-90 -127.15 5.89 6.45 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.126 -0.984 . . . . 0.0 110.564 -179.728 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.502 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.9 OUTLIER -103.39 37.53 1.98 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.125 -0.984 . . . . 0.0 110.473 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -117.47 -9.0 10.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.282 -0.886 . . . . 0.0 109.619 179.689 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.463 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -56.31 -162.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.451 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 47.6 Cg_endo -74.14 5.16 3.72 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.228 1.646 . . . . 0.0 110.953 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.1 m -164.81 115.7 1.17 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.254 -0.904 . . . . 0.0 109.987 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.581 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -134.14 117.93 17.11 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.143 -0.973 . . . . 0.0 110.319 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.481 ' O ' ' HB3' ' A' ' 309' ' ' SER . 87.6 m -108.78 136.61 48.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.407 -0.808 . . . . 0.0 109.995 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.595 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 14.3 p90 -140.63 172.09 13.19 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.21 158.51 27.71 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.935 -1.602 . . . . 0.0 110.075 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.676 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.0 OUTLIER -146.22 147.28 31.28 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.437 -1.037 . . . . 0.0 109.906 179.614 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.546 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -120.58 119.58 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.056 -1.028 . . . . 0.0 109.809 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.596 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.8 t -97.17 149.1 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.194 -0.941 . . . . 0.0 110.37 -179.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.21 134.07 55.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.473 -0.767 . . . . 0.0 109.807 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.481 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.923 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.546 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.488 1.435 0 CA-C-O 121.385 0.612 . . . . 0.0 110.722 . . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.582 HG12 ' CE1' ' A' ' 280' ' ' TYR . 11.0 p -133.41 112.64 17.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.224 -0.922 . . . . 0.0 109.79 179.168 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.471 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.07 5.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.465 -0.772 . . . . 0.0 110.587 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.456 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 25.7 pt-20 -177.14 158.94 1.57 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.224 -0.923 . . . . 0.0 110.86 -179.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.475 HG12 ' CG1' ' A' ' 296' ' ' VAL . 19.0 mt -119.4 108.65 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.249 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.24 146.24 33.12 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.249 -0.907 . . . . 0.0 109.797 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.571 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.38 133.1 49.83 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.99 -1.068 . . . . 0.0 110.465 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.509 ' N ' HD23 ' A' ' 351' ' ' LEU . 47.8 tt0 -138.98 110.2 6.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.795 . . . . 0.0 109.79 179.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.491 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.5 mt -91.06 109.27 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.047 -1.033 . . . . 0.0 109.863 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.503 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 41.12 32.76 0.2 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.596 -0.69 . . . . 0.0 110.328 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.69 -21.4 16.52 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.466 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 1.1 mp0 -80.17 104.22 10.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.225 -1.162 . . . . 0.0 110.292 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.453 HG12 ' O ' ' A' ' 357' ' ' VAL . 14.6 p -75.62 135.29 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 110.081 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.435 HD12 ' O ' ' A' ' 357' ' ' VAL . 13.0 mm . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.154 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.37 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.536 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.48 167.79 21.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.376 -1.073 . . . . 0.0 110.038 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.566 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -161.76 135.43 6.52 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.139 -0.976 . . . . 0.0 111.044 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -134.96 126.95 29.63 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.08 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 64.6 t -117.76 138.61 47.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 C-N-CA 118.828 -1.149 . . . . 0.0 112.137 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.4 ' C ' HG21 ' A' ' 271' ' ' VAL . 0.3 OUTLIER -122.83 157.55 32.2 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.802 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 99.3 t -144.56 146.28 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.35 -1.469 . . . . 0.0 112.232 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.569 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -134.34 110.64 9.6 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.771 -0.58 . . . . 0.0 109.528 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 13.9 m-20 -97.85 127.55 43.88 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.336 -0.853 . . . . 0.0 111.456 -178.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.58 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 30.5 p90 -113.04 18.76 17.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.372 -0.83 . . . . 0.0 109.723 178.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.33 -64.33 3.81 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.412 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 1.5 m -63.66 -23.4 67.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.238 -1.154 . . . . 0.0 110.418 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.561 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -167.25 -179.46 40.19 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.543 -1.313 . . . . 0.0 109.941 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.556 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -135.28 141.57 45.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.33 -1.1 . . . . 0.0 109.986 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.58 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 2.6 mt-10 -96.34 147.32 23.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -0.778 . . . . 0.0 110.32 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.691 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 97.0 m-85 -139.04 85.14 2.05 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 110.753 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.544 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.4 t0 -74.53 119.81 19.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.566 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.605 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 15.6 t -111.6 92.78 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.594 -0.691 . . . . 0.0 109.871 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.45 ' O ' HD23 ' A' ' 267' ' ' LEU . 17.3 m -86.48 124.31 32.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.987 . . . . 0.0 109.367 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.603 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.69 152.27 27.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.091 -1.005 . . . . 0.0 110.718 -179.115 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.536 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -130.62 128.55 41.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.33 -0.856 . . . . 0.0 110.408 -179.563 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.613 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 10.1 mt -138.62 149.55 45.33 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.823 -1.173 . . . . 0.0 109.31 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.02 38.92 0.78 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.305 -0.872 . . . . 0.0 110.003 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 159.23 -110.31 0.44 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.095 -1.526 . . . . 0.0 109.95 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.521 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 4.8 mt-30 -145.27 118.17 8.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.248 . . . . 0.0 110.359 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.62 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 5.6 m-85 -141.06 147.82 39.21 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.276 -0.89 . . . . 0.0 110.103 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.491 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 34.6 m-20 -75.2 96.8 3.37 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.102 -0.999 . . . . 0.0 109.15 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.588 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 59.8 p-90 -98.73 114.38 26.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.38 -0.825 . . . . 0.0 110.241 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 321' ' ' PHE . 4.3 m -109.15 112.1 24.07 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.423 -0.798 . . . . 0.0 109.403 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.478 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 2.8 t -96.33 110.73 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -0.931 . . . . 0.0 110.402 -179.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.524 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 30.7 ttmt -88.65 147.15 24.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.214 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.554 HG11 ' CG2' ' A' ' 346' ' ' VAL . 79.5 t -140.64 107.73 2.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.163 -0.961 . . . . 0.0 110.367 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.595 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 23.0 mmtt -69.96 133.82 47.7 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.129 -0.982 . . . . 0.0 109.362 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.581 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 70.7 mt -88.23 156.98 18.93 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.217 -0.927 . . . . 0.0 111.505 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.555 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.54 173.49 2.36 Favored Pre-proline 0 C--N 1.302 -1.471 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.497 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -66.84 82.75 0.32 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.438 1.231 . . . . 0.0 109.806 179.583 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.23 22.56 5.17 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -111.82 143.34 42.93 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.405 -1.056 . . . . 0.0 110.125 -179.702 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.499 ' O ' ' HA ' ' A' ' 338' ' ' VAL . 15.3 p -147.36 144.07 28.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 110.688 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.531 HG21 ' CG2' ' A' ' 319' ' ' VAL . 43.8 t -67.4 135.72 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.478 -0.764 . . . . 0.0 109.985 179.619 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.35 -44.52 0.56 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.454 ' O ' HD12 ' A' ' 337' ' ' ILE . 8.8 m -131.27 128.7 40.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.06 -1.259 . . . . 0.0 110.811 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.637 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 4.9 p90 -140.74 168.8 18.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.414 -0.804 . . . . 0.0 109.423 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.452 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -159.92 154.19 23.6 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.875 -1.141 . . . . 0.0 111.366 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 65.22 24.28 12.27 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.546 -0.721 . . . . 0.0 110.716 179.594 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.518 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 146.74 0.9 Allowed 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.232 -0.918 . . . . 0.0 110.347 179.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.51 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -81.8 125.06 30.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.091 -1.006 . . . . 0.0 108.895 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 2.4 ttpt -96.58 137.11 36.16 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 121.819 0.818 . . . . 0.0 111.018 -178.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.706 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -124.16 179.37 4.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.618 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 313' ' ' GLN . 2.5 mt-10 -139.98 102.05 4.31 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.138 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.518 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.55 46.9 3.65 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.41 82.05 0.12 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -1.126 . . . . 0.0 110.113 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.618 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.87 2.77 62.57 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.618 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.0 m-85 -143.28 -168.41 2.8 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.443 -1.034 . . . . 0.0 109.221 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.573 HG13 ' CZ ' ' A' ' 321' ' ' PHE . 3.5 t -163.37 153.29 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.176 -0.952 . . . . 0.0 109.727 179.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.706 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 17.3 mm -119.77 150.75 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.992 -1.067 . . . . 0.0 110.711 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.4 m-85 -128.91 125.26 37.19 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.387 -0.821 . . . . 0.0 110.164 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.51 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 35.9 p -131.05 166.44 27.65 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.676 -1.265 . . . . 0.0 109.91 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.512 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.6 Cg_endo -65.56 119.55 6.59 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.695 1.366 . . . . 0.0 110.882 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.48 HG13 ' ND2' ' A' ' 311' ' ' ASN . 24.9 m -64.57 -121.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.532 -0.73 . . . . 0.0 110.197 -179.737 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.451 ' O ' ' CE ' ' A' ' 328' ' ' LYS . 5.9 m -100.55 -23.5 14.68 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.746 -1.222 . . . . 0.0 110.57 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.431 ' CH2' ' OG ' ' A' ' 309' ' ' SER . 9.4 p-90 -124.4 -7.75 7.53 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.128 -0.983 . . . . 0.0 110.447 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.467 ' OD1' ' O ' ' A' ' 309' ' ' SER . 2.3 t-20 -89.13 31.83 0.86 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.221 -0.924 . . . . 0.0 110.598 -179.528 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.451 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -117.48 7.24 12.68 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.17 -0.956 . . . . 0.0 110.045 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -67.62 -150.09 0.19 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.559 ' N ' ' O ' ' A' ' 288' ' ' GLY . 46.1 Cg_endo -73.09 -51.61 0.16 Allowed 'Trans proline' 0 C--N 1.3 -2.024 0 O-C-N 123.835 1.439 . . . . 0.0 109.246 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -108.09 124.23 49.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.617 -0.677 . . . . 0.0 110.184 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -135.44 110.97 9.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.472 ' O ' ' HB3' ' A' ' 309' ' ' SER . 54.1 m -105.58 129.57 53.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 110.286 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.605 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 12.7 p90 -135.33 175.06 9.93 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.237 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.9 162.46 29.73 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 118.684 -1.722 . . . . 0.0 110.308 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.691 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.0 OUTLIER -149.52 145.37 26.82 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 109.483 179.308 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.545 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -118.73 119.25 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.005 -1.059 . . . . 0.0 110.017 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.581 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.4 t -98.32 144.18 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.201 -0.937 . . . . 0.0 110.105 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.91 137.38 52.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.415 -0.803 . . . . 0.0 110.213 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 179.999 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.555 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.5 mtmt . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 121.435 0.636 . . . . 0.0 110.659 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.581 HG11 ' CE2' ' A' ' 280' ' ' TYR . 2.7 p -127.67 113.87 33.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.095 -1.003 . . . . 0.0 110.244 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.86 5.96 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.27 -0.894 . . . . 0.0 109.713 179.916 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.451 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.4 OUTLIER -177.59 158.34 1.35 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.238 -0.914 . . . . 0.0 110.947 179.461 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.47 HG12 HG13 ' A' ' 296' ' ' VAL . 27.7 mt -115.34 104.81 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.5 132.13 53.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.204 -0.935 . . . . 0.0 110.266 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.603 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -94.6 130.42 41.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 110.284 179.897 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 7.5 tt0 -138.91 114.19 9.58 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.241 -0.912 . . . . 0.0 110.12 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.473 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 1.5 mt -91.32 105.45 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.047 -1.033 . . . . 0.0 109.801 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.491 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 40.31 29.21 0.05 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.735 -0.603 . . . . 0.0 110.887 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 126.02 -26.73 5.26 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.525 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.476 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 6.5 mm100 -84.98 118.13 24.37 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.953 -1.322 . . . . 0.0 110.485 -179.53 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 11.4 p -81.91 126.86 39.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.276 -0.89 . . . . 0.0 110.108 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.414 HD12 ' O ' ' A' ' 357' ' ' VAL . 13.0 mm . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.21 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.561 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.64 169.77 17.16 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.446 -1.032 . . . . 0.0 109.841 179.809 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.552 ' CD1' ' HG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -161.09 125.41 3.49 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.229 -0.92 . . . . 0.0 110.665 -179.733 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.468 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 40.4 mt-10 -121.31 111.34 17.23 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.494 -0.754 . . . . 0.0 108.986 179.279 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 40.5 t -109.21 137.39 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.99 -1.068 . . . . 0.0 111.798 -178.74 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.453 ' C ' HG23 ' A' ' 271' ' ' VAL . 11.9 tttp -127.55 155.98 42.94 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 178.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.546 HG21 ' CD2' ' A' ' 280' ' ' TYR . 69.8 t -142.68 147.17 21.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.25 -1.531 . . . . 0.0 112.097 -178.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.518 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.21 114.23 8.98 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.056 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.2 m-20 -96.51 147.89 23.38 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.165 -0.959 . . . . 0.0 111.525 -178.601 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.587 ' CD1' ' HB2' ' A' ' 276' ' ' SER . 39.4 p90 -135.34 18.88 3.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.486 -0.759 . . . . 0.0 109.969 179.206 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.39 -62.78 4.25 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.587 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 3.1 m -62.44 -20.15 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -1.136 . . . . 0.0 110.156 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.92 179.42 48.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.556 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -132.34 143.62 49.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -1.145 . . . . 0.0 110.305 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.54 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 5.1 mt-10 -95.06 146.24 24.41 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.377 -0.827 . . . . 0.0 109.949 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.689 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 85.1 m-85 -139.6 83.6 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.402 -0.811 . . . . 0.0 110.252 -179.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.465 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.89 150.49 48.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.44 -0.787 . . . . 0.0 109.935 179.62 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.589 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.3 t -142.78 87.76 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.613 -0.679 . . . . 0.0 109.402 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.507 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 20.6 m -85.9 111.63 20.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.25 -0.906 . . . . 0.0 109.556 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.555 HD11 ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -96.62 150.55 20.53 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.223 -0.923 . . . . 0.0 111.059 -179.053 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.561 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.23 106.02 7.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.575 -0.703 . . . . 0.0 110.056 -179.496 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.578 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 9.6 mt -115.96 152.37 33.62 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.793 -1.192 . . . . 0.0 109.715 179.478 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.67 38.19 0.78 Allowed 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.091 -1.006 . . . . 0.0 110.003 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 161.23 -134.02 3.4 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.368 -1.396 . . . . 0.0 109.751 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.448 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 8.8 mm-40 -124.31 116.65 22.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.136 -1.214 . . . . 0.0 110.531 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.578 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 0.9 OUTLIER -146.67 129.41 16.17 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.317 -0.865 . . . . 0.0 109.741 179.558 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.52 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 10.2 t70 -57.45 102.56 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.961 -1.087 . . . . 0.0 109.431 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.599 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 45.7 p-90 -99.77 110.28 22.67 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.38 -0.825 . . . . 0.0 110.183 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.56 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 29.7 m -102.3 114.95 29.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.327 -0.858 . . . . 0.0 109.798 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.492 HG21 HD21 ' A' ' 351' ' ' LEU . 3.9 t -96.82 111.09 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.188 -0.945 . . . . 0.0 110.258 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.483 ' HA ' HD11 ' A' ' 320' ' ' ILE . 30.4 ttpt -87.33 149.82 24.26 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.314 -0.866 . . . . 0.0 109.591 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.581 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 94.3 t -148.24 106.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.17 -0.957 . . . . 0.0 110.417 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.561 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtm -70.04 134.35 48.17 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.269 179.709 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.54 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 94.4 mt -87.26 160.53 18.41 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.393 -0.817 . . . . 0.0 111.369 -178.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.545 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.57 175.8 1.25 Allowed Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.672 -0.642 . . . . 0.0 109.78 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.474 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.3 Cg_endo -68.65 80.57 0.61 Allowed 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.752 1.396 . . . . 0.0 109.6 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.78 20.79 5.94 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.515 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -107.79 143.47 36.31 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.583 -0.951 . . . . 0.0 110.125 -179.649 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.52 ' N ' HG13 ' A' ' 338' ' ' VAL . 56.0 p -145.1 143.16 30.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 110.635 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.591 ' CG1' ' CD ' ' A' ' 312' ' ' LYS . 31.7 t -69.98 129.0 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.319 -0.863 . . . . 0.0 109.957 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.61 -32.72 1.54 Allowed Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.097 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.454 ' O ' HD13 ' A' ' 337' ' ' ILE . 4.8 m -132.88 121.06 22.33 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.999 -1.295 . . . . 0.0 110.951 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.522 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 45.4 p90 -140.12 154.31 46.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.398 -0.814 . . . . 0.0 109.593 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.532 ' CH2' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -147.55 158.3 43.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.954 -1.091 . . . . 0.0 111.332 -179.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.491 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 61.36 24.72 14.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.473 -0.767 . . . . 0.0 110.973 179.481 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.523 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.82 140.01 0.54 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 110.13 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.506 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -77.14 121.25 23.35 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.042 -1.036 . . . . 0.0 109.159 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.591 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 20.2 ttpt -88.44 138.58 31.3 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.826 0.822 . . . . 0.0 111.048 -178.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.512 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.57 174.45 7.41 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.065 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -138.46 109.26 6.67 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.368 -0.833 . . . . 0.0 110.419 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.57 39.9 2.7 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.21 80.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -1.152 . . . . 0.0 110.23 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.619 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.87 3.1 57.11 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.619 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.8 m-85 -147.46 -173.84 4.37 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.431 -1.041 . . . . 0.0 109.065 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.527 ' CG2' HG22 ' A' ' 304' ' ' VAL . 4.6 t -159.13 159.85 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.103 -0.998 . . . . 0.0 109.526 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.56 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.2 mm -129.38 151.2 35.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.074 -179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.66 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 39.5 m-85 -127.49 130.02 48.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.248 -0.907 . . . . 0.0 110.287 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.52 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -130.1 169.36 13.61 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.826 -1.171 . . . . 0.0 110.117 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.52 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.3 Cg_endo -65.04 123.82 12.15 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.859 1.452 . . . . 0.0 110.809 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.53 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 20.3 m -73.22 -116.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.537 -0.727 . . . . 0.0 110.211 -179.529 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -108.16 -23.98 11.73 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.699 -1.251 . . . . 0.0 110.668 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.421 ' CH2' ' OG ' ' A' ' 309' ' ' SER . 4.4 p-90 -124.0 5.61 8.63 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.181 -0.949 . . . . 0.0 110.306 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.53 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.9 t30 -108.57 49.95 0.79 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 110.37 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.464 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -124.29 -11.35 7.46 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.317 -0.864 . . . . 0.0 109.882 179.732 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.8 -158.28 0.02 OUTLIER Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.831 -1.307 . . . . 0.0 109.831 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -75.59 6.83 3.4 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.115 1.587 . . . . 0.0 110.738 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -161.26 124.39 3.21 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 120.964 -1.085 . . . . 0.0 109.68 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.568 ' HB3' ' CZ2' ' A' ' 292' ' ' TRP . . . -142.65 106.04 4.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.227 -0.92 . . . . 0.0 109.887 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.507 ' OG1' ' CG2' ' A' ' 283' ' ' THR . 54.1 m -98.76 131.74 44.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.283 -0.886 . . . . 0.0 110.291 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.589 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 10.1 p90 -139.34 175.14 9.81 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.69 158.42 27.75 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.852 -1.642 . . . . 0.0 110.015 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.689 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.7 OUTLIER -143.27 145.18 32.51 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.556 -0.967 . . . . 0.0 109.709 179.371 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.534 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.7 mp -121.51 120.32 61.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.54 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 9.9 t -96.24 160.61 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 109.858 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -130.66 129.62 42.87 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.2 -0.937 . . . . 0.0 110.722 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.887 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.545 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.5 mtmt . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 121.237 0.542 . . . . 0.0 110.791 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.594 HG13 ' CE2' ' A' ' 280' ' ' TYR . 14.6 p -140.28 118.04 10.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 110.475 179.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.458 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -50.08 -44.43 51.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.478 -0.764 . . . . 0.0 110.607 -179.734 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.7 pt-20 -176.73 158.66 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.076 -1.015 . . . . 0.0 110.9 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.484 HG12 ' CG2' ' A' ' 296' ' ' VAL . 54.1 mt -121.79 114.79 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.44 -0.787 . . . . 0.0 109.823 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.68 150.35 36.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.331 -0.856 . . . . 0.0 110.55 -179.504 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.552 ' CD1' HD22 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -105.44 127.6 53.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.3 -0.875 . . . . 0.0 109.773 179.597 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.451 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -138.52 112.85 8.73 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.137 -0.977 . . . . 0.0 110.447 -179.919 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.487 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.4 mt -92.1 109.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.945 . . . . 0.0 109.981 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.52 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 46.08 32.85 1.51 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.52 -0.737 . . . . 0.0 110.433 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.39 -21.26 26.68 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.419 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 69.0 mm-40 -83.23 109.41 17.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.271 -1.135 . . . . 0.0 110.29 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 4.5 p -70.38 131.03 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -0.882 . . . . 0.0 110.09 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.464 HG21 ' O ' ' A' ' 358' ' ' ILE . 29.8 mm . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.152 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.563 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.74 163.05 31.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -1.126 . . . . 0.0 109.948 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.547 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -161.22 132.68 5.53 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.197 -179.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -133.49 132.38 40.95 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 179.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 21.9 t -123.75 134.14 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.71 -1.244 . . . . 0.0 111.976 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.437 ' C ' HG21 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -119.94 151.84 38.32 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 178.657 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.566 HG22 ' CD2' ' A' ' 280' ' ' TYR . 77.9 t -140.8 146.16 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 120.368 -1.458 . . . . 0.0 112.018 -179.004 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.533 ' N ' HG13 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -139.0 113.83 9.23 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.707 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.8 m-20 -101.29 140.87 34.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.893 -1.129 . . . . 0.0 111.395 -178.481 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.573 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 34.0 p90 -123.87 19.76 9.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.654 -0.654 . . . . 0.0 109.375 179.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.53 -62.21 4.62 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.503 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 0.5 OUTLIER -60.62 -18.15 51.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.259 -1.142 . . . . 0.0 109.951 179.655 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.58 177.23 48.39 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.566 ' HB3' ' CZ ' ' A' ' 280' ' ' TYR . . . -133.31 137.8 46.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -1.115 . . . . 0.0 110.124 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.534 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 5.5 mt-10 -93.99 145.54 24.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.251 -0.906 . . . . 0.0 110.163 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.682 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.1 m-85 -139.99 85.02 2.0 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.448 -0.782 . . . . 0.0 110.746 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.477 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 3.7 t0 -69.54 141.46 53.83 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.334 -0.853 . . . . 0.0 109.555 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.63 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 4.0 t -132.85 91.71 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.486 -0.759 . . . . 0.0 109.506 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.445 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 2.7 m -86.67 122.31 30.4 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.32 -0.862 . . . . 0.0 109.982 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.603 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.67 149.04 32.13 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.296 -0.877 . . . . 0.0 110.149 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.563 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -134.03 109.4 8.95 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.316 -0.865 . . . . 0.0 110.637 -178.758 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.605 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.1 mt -119.59 157.47 28.35 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.722 -1.236 . . . . 0.0 110.251 179.731 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 287' ' ' ASP . 15.3 p-10 -91.43 36.61 0.94 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.125 -0.984 . . . . 0.0 109.544 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.5 -136.1 4.18 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.463 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -121.81 116.31 24.21 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.201 -1.176 . . . . 0.0 110.847 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.605 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.3 m-85 -142.39 138.28 31.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.313 -0.867 . . . . 0.0 109.435 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.535 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 14.5 t0 -67.7 97.46 0.63 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.841 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.599 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 46.3 p-90 -96.17 109.86 22.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.037 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.592 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 3.1 m -102.06 115.33 30.31 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.846 . . . . 0.0 109.592 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.456 HG22 HD23 ' A' ' 351' ' ' LEU . 3.9 t -96.46 110.99 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 110.461 -179.535 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.464 ' HA ' HD12 ' A' ' 320' ' ' ILE . 28.5 ttpt -86.37 149.59 24.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.364 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.562 HG11 ' CG2' ' A' ' 346' ' ' VAL . 70.8 t -148.14 108.17 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.123 -0.985 . . . . 0.0 110.706 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.556 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.0 mmtp -70.81 131.79 44.34 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.132 -0.98 . . . . 0.0 109.675 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.537 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 98.5 mt -85.52 156.05 20.94 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.259 -0.901 . . . . 0.0 111.599 -179.095 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.52 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.66 171.04 4.79 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 39.7 Cg_endo -66.87 81.86 0.34 Allowed 'Trans proline' 0 C--N 1.305 -1.757 0 O-C-N 123.518 1.273 . . . . 0.0 109.727 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.76 18.06 5.76 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -108.65 149.19 29.3 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.385 -1.068 . . . . 0.0 110.105 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.537 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 24.8 p -154.56 144.21 21.53 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.122 -0.987 . . . . 0.0 110.897 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.502 HG13 ' CD ' ' A' ' 312' ' ' LYS . 24.7 t -68.9 124.06 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -106.39 -33.71 3.32 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -142.0 131.21 23.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.005 -1.291 . . . . 0.0 110.868 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.547 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 39.2 p90 -141.78 162.89 34.36 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.29 -0.881 . . . . 0.0 109.855 179.485 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.494 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -152.31 159.51 43.47 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.928 -1.107 . . . . 0.0 110.946 -179.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.458 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 59.84 23.91 12.9 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.472 -0.767 . . . . 0.0 111.091 179.471 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.523 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.09 145.46 0.8 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.325 -0.86 . . . . 0.0 110.179 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.497 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -83.81 120.03 25.55 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.202 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.547 ' HD3' ' CE2' ' A' ' 307' ' ' PHE . 1.8 ttpt -87.03 145.38 26.5 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.946 0.879 . . . . 0.0 111.044 -178.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.713 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -130.41 179.03 6.16 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.013 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.45 ' HG2' HG21 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -140.0 101.76 4.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.702 -0.624 . . . . 0.0 110.108 179.546 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.481 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -87.51 40.4 3.08 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.481 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 9.5 t30 63.65 79.71 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.304 -1.115 . . . . 0.0 110.084 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.591 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 95.0 3.81 61.78 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.774 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.591 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.7 m-85 -143.3 -170.66 3.32 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.996 . . . . 0.0 108.784 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.524 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.3 t -161.68 154.29 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 120.976 -1.077 . . . . 0.0 110.019 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.713 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 22.0 mm -125.17 142.85 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.756 -179.583 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.0 m-85 -119.6 127.05 52.59 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.435 -0.791 . . . . 0.0 109.637 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.523 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -126.65 169.15 12.52 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 120.877 -1.14 . . . . 0.0 110.5 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.524 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.5 Cg_endo -65.04 112.23 1.98 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 O-C-N 124.049 1.552 . . . . 0.0 111.044 -179.5 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.532 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 16.5 m -56.96 -114.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.634 -0.666 . . . . 0.0 109.918 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.17 -20.26 9.32 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.7 -1.25 . . . . 0.0 110.417 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.49 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 5.1 p-90 -120.78 -20.65 6.92 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.204 -0.935 . . . . 0.0 110.408 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.532 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.9 OUTLIER -84.23 46.14 1.18 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.081 -1.012 . . . . 0.0 109.989 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.487 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 10.7 mtmt -119.84 -9.63 9.66 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.359 -0.838 . . . . 0.0 109.675 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.5 -157.45 0.01 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.535 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.68 5.32 4.39 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.065 1.561 . . . . 0.0 110.682 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.408 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 4.2 m -162.83 119.88 1.94 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.998 -1.064 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.472 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -140.08 112.0 7.52 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.299 -0.875 . . . . 0.0 110.247 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.458 ' O ' ' HB3' ' A' ' 309' ' ' SER . 35.1 m -103.72 132.26 50.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 110.049 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.63 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 11.4 p90 -135.17 173.93 11.17 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.46 151.76 23.65 Favored Glycine 0 N--CA 1.486 1.977 0 C-N-CA 118.827 -1.654 . . . . 0.0 110.242 -179.357 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.682 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -139.0 147.93 42.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.684 -0.892 . . . . 0.0 109.476 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.544 HD13 ' N ' ' A' ' 337' ' ' ILE . 1.7 mp -120.6 119.46 59.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.006 -1.059 . . . . 0.0 110.025 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.522 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.4 t -96.84 145.2 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.94 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.483 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 2.0 m-80 -115.63 133.23 56.24 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.391 -0.818 . . . . 0.0 110.341 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.521 ' N ' ' HE3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.487 2.06 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.525 ' O ' ' CB ' ' A' ' 302' ' ' ALA . 3.1 mtpt . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 121.467 0.651 . . . . 0.0 110.13 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.572 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.1 p -126.03 113.71 35.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.448 -0.783 . . . . 0.0 109.779 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.501 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.4 mm-40 -41.97 -47.33 4.34 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.995 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.457 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 18.1 pt-20 -177.28 158.52 1.48 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.872 . . . . 0.0 110.524 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.46 HD12 HG11 ' A' ' 269' ' ' VAL . 11.9 mt -118.14 122.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.237 -0.914 . . . . 0.0 110.068 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.11 132.19 50.66 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.219 -0.926 . . . . 0.0 110.175 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.603 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -92.66 131.22 37.94 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.174 -0.954 . . . . 0.0 110.22 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.454 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.4 tt0 -139.68 114.53 9.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.168 -0.957 . . . . 0.0 110.358 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.469 HG12 ' HA ' ' A' ' 292' ' ' TRP . 2.1 mt -92.05 110.9 23.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.976 -1.077 . . . . 0.0 110.28 179.665 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.535 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.47 32.1 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.716 -0.615 . . . . 0.0 111.115 179.587 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 112.26 8.86 21.01 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.462 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.5 mp0 -116.4 111.46 20.06 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.11 -1.229 . . . . 0.0 110.058 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -75.3 135.67 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.227 -0.92 . . . . 0.0 110.433 -179.662 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.439 HD11 ' O ' ' A' ' 357' ' ' VAL . 31.9 mm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.223 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.408 ' HA3' HD21 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.546 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.78 168.31 19.79 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.523 -0.986 . . . . 0.0 109.631 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.576 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.3 tm? -160.24 136.86 8.96 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.996 -1.065 . . . . 0.0 111.165 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -136.19 123.36 21.71 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.553 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.473 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 50.2 t -116.97 134.69 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.969 -1.082 . . . . 0.0 111.738 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.428 ' C ' HG21 ' A' ' 271' ' ' VAL . 37.0 mttm -118.29 157.35 27.23 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.519 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.58 142.2 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.256 -1.528 . . . . 0.0 112.115 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -138.04 113.04 9.14 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.102 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 80.2 m-20 -98.78 146.21 26.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.958 -1.089 . . . . 0.0 111.444 -178.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.563 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 37.6 p90 -131.71 23.16 4.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.608 -0.682 . . . . 0.0 109.474 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 80.55 -64.23 4.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.505 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -59.13 -22.6 61.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.293 -1.122 . . . . 0.0 110.226 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.516 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.44 -171.88 38.4 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.549 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -142.87 142.05 31.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -1.072 . . . . 0.0 110.009 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.563 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.7 mt-10 -97.98 146.14 25.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.414 -0.804 . . . . 0.0 110.329 -179.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.692 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 81.6 m-85 -141.15 82.99 1.86 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.398 -0.814 . . . . 0.0 110.653 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.473 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 9.3 t0 -64.91 151.53 45.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.769 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.625 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.9 t -145.05 89.34 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.55 -0.719 . . . . 0.0 109.964 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.471 ' O ' HD22 ' A' ' 267' ' ' LEU . 72.2 m -86.75 126.36 34.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.131 -0.981 . . . . 0.0 109.717 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.639 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -114.96 148.24 39.01 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.04 -1.038 . . . . 0.0 110.902 -179.172 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.546 ' ND2' ' HB3' ' A' ' 266' ' ' SER . 0.5 OUTLIER -128.4 134.82 48.89 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.484 -0.76 . . . . 0.0 109.949 -179.696 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.624 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 10.2 mt -143.7 149.97 37.99 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.62 -1.3 . . . . 0.0 110.158 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -88.41 38.49 0.87 Allowed 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.278 -0.889 . . . . 0.0 109.398 179.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.97 -145.47 11.05 Favored Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.787 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.498 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 5.1 mt-30 -112.36 98.43 7.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -1.167 . . . . 0.0 110.665 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.624 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -120.21 154.97 34.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.257 -0.902 . . . . 0.0 110.295 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.526 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 23.0 t0 -85.76 97.46 10.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 109.242 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.639 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 51.9 p-90 -95.38 108.03 20.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.169 -0.957 . . . . 0.0 110.819 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.41 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 2.8 m -100.11 115.13 29.09 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.543 -0.723 . . . . 0.0 109.304 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.461 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.1 t -96.71 111.38 26.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 121.187 -0.946 . . . . 0.0 110.162 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.525 ' HG3' ' CD1' ' A' ' 320' ' ' ILE . 3.3 ttpp -87.74 149.37 24.24 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.404 -0.81 . . . . 0.0 109.247 179.461 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.536 HG13 ' CE2' ' A' ' 336' ' ' PHE . 84.4 t -148.23 107.71 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.079 -1.013 . . . . 0.0 110.225 -179.603 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.582 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 21.0 mmtp -69.95 132.37 45.84 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.344 -0.848 . . . . 0.0 109.587 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.548 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 87.8 mt -87.37 158.71 18.96 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.646 -0.659 . . . . 0.0 110.943 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.543 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.32 173.86 2.06 Favored Pre-proline 0 C--N 1.303 -1.426 0 O-C-N 121.459 -0.775 . . . . 0.0 109.285 179.07 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.452 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.34 79.7 0.59 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 123.619 1.326 . . . . 0.0 109.637 179.576 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.26 17.02 5.87 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.531 ' CB ' ' HB2' ' A' ' 299' ' ' ALA . . . -104.26 147.09 27.88 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.467 -1.019 . . . . 0.0 110.12 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.548 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 37.6 p -148.68 143.86 26.76 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.873 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.445 HG23 HG13 ' A' ' 319' ' ' VAL . 92.1 t -71.55 121.74 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.317 -0.864 . . . . 0.0 109.951 179.623 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.48 -21.34 6.92 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.5 OUTLIER -139.51 124.14 18.37 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.029 -1.277 . . . . 0.0 111.216 -179.464 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.501 ' CE1' ' HD3' ' A' ' 312' ' ' LYS . 29.0 p90 -145.23 164.57 30.96 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.311 -0.868 . . . . 0.0 109.884 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.491 ' CH2' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -158.34 161.29 37.6 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.948 -1.095 . . . . 0.0 110.995 -179.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.547 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.1 OUTLIER 54.47 29.03 10.44 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.471 -0.768 . . . . 0.0 110.843 179.517 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 334' ' ' PHE . . . -175.33 144.43 0.71 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.285 -0.885 . . . . 0.0 109.872 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.498 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.3 m-80 -82.23 115.81 21.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.092 -1.005 . . . . 0.0 109.355 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.501 ' HD3' ' CE1' ' A' ' 307' ' ' PHE . 8.7 ttpt -83.27 142.13 31.34 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.803 0.811 . . . . 0.0 110.757 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -129.38 173.81 10.2 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.437 ' HG2' HG23 ' A' ' 319' ' ' VAL . 4.4 mt-10 -139.49 101.36 4.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.309 -0.869 . . . . 0.0 110.497 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.12 42.84 2.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 4.5 m120 53.8 86.16 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.311 -1.111 . . . . 0.0 110.174 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.33 -0.27 55.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.607 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 0.5 OUTLIER -150.26 -172.79 4.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.371 -1.076 . . . . 0.0 109.642 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 6.1 t -156.89 156.37 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.425 -0.797 . . . . 0.0 109.337 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.525 ' CD1' ' HG3' ' A' ' 295' ' ' LYS . 45.6 mm -126.56 147.83 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.08 -1.012 . . . . 0.0 111.22 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 83.3 m-85 -125.29 125.1 43.0 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.399 -0.813 . . . . 0.0 109.661 179.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.531 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.6 p -127.7 169.86 11.52 Favored Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 120.82 -1.175 . . . . 0.0 110.232 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.531 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.7 Cg_endo -64.26 115.76 3.35 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.898 1.473 . . . . 0.0 111.52 -179.088 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.525 ' N ' ' OD1' ' A' ' 327' ' ' ASN . 17.3 m -64.16 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.66 -0.65 . . . . 0.0 110.192 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 19.9 m -116.78 -12.57 10.8 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.696 -1.253 . . . . 0.0 111.198 -179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.464 ' CH2' ' OG ' ' A' ' 309' ' ' SER . 13.3 p-90 -133.72 1.37 3.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.811 -1.18 . . . . 0.0 111.133 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.547 ' ND2' ' O ' ' A' ' 309' ' ' SER . 28.3 p-10 -110.38 50.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.987 -1.071 . . . . 0.0 110.508 -179.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -129.09 10.51 5.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.267 -0.896 . . . . 0.0 109.664 179.466 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.418 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -73.89 -151.58 2.13 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.517 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -74.09 2.26 6.3 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.094 1.576 . . . . 0.0 110.838 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.481 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 27.5 m -167.28 122.74 1.08 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.35 -0.843 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.537 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -142.56 118.17 10.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.134 -0.979 . . . . 0.0 110.321 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 309' ' ' SER . 18.0 m -104.36 148.55 26.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 110.214 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.625 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 5.9 p90 -153.88 175.22 13.59 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -156.44 157.91 28.29 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.838 -1.649 . . . . 0.0 110.548 -179.418 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.692 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -141.52 147.6 38.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.411 -1.052 . . . . 0.0 110.308 179.594 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.536 ' HA ' ' O ' ' A' ' 278' ' ' ALA . 1.7 mp -121.96 122.69 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.078 -1.014 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.546 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 6.3 t -100.45 156.23 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.132 -0.98 . . . . 0.0 110.782 -179.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -123.97 132.72 53.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.506 -0.746 . . . . 0.0 110.337 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.412 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.492 2.384 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.546 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.394 0 CA-C-O 121.201 0.524 . . . . 0.0 111.077 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.582 HG13 ' CE2' ' A' ' 280' ' ' TYR . 11.7 p -135.13 117.72 22.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.163 -0.961 . . . . 0.0 110.11 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.459 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -50.34 -45.15 54.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.343 -0.848 . . . . 0.0 110.425 -179.534 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.413 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -176.61 154.19 1.2 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -0.994 . . . . 0.0 110.703 -179.876 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.431 HD13 HG13 ' A' ' 269' ' ' VAL . 23.3 mt -113.97 124.8 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.175 -0.953 . . . . 0.0 110.133 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.21 154.39 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.389 -0.82 . . . . 0.0 109.974 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.591 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -120.65 124.51 45.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.188 -0.945 . . . . 0.0 109.659 179.478 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 34.6 tt0 -138.63 117.11 12.05 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.221 -0.925 . . . . 0.0 110.181 -179.796 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.526 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.4 107.68 19.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.165 -0.959 . . . . 0.0 109.76 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.51 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 43.66 26.74 0.13 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 110.381 -179.647 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 123.41 -31.92 4.48 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.461 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 12.2 mm100 -75.99 114.56 14.76 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.084 -1.244 . . . . 0.0 110.47 -179.65 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 8.5 p -79.09 133.34 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.146 -0.972 . . . . 0.0 110.226 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.454 HD11 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.068 -0.967 . . . . 0.0 110.299 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.573 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.33 163.79 31.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.366 -1.079 . . . . 0.0 110.049 -179.774 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.544 ' CD1' ' HG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -156.73 122.8 4.9 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.106 -0.996 . . . . 0.0 110.737 -179.868 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.3 mt-10 -123.31 114.29 20.01 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 57.6 t -110.05 124.51 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.971 -1.081 . . . . 0.0 112.347 -178.105 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.425 ' C ' HG22 ' A' ' 271' ' ' VAL . 3.9 mmtt -111.61 156.79 21.26 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 83.0 t -144.61 147.92 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.426 -1.421 . . . . 0.0 112.238 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -136.8 110.05 7.83 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.928 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.4 p30 -95.34 146.35 24.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.074 -1.016 . . . . 0.0 111.247 -178.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.573 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 29.4 p90 -129.0 16.86 6.21 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.517 -0.739 . . . . 0.0 109.963 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.4 -54.57 3.52 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.507 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 2.8 m -74.63 -19.35 60.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.226 -1.161 . . . . 0.0 110.256 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.19 -175.85 42.98 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.543 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -140.6 140.1 35.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -1.15 . . . . 0.0 110.238 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.538 ' CG ' HG13 ' A' ' 337' ' ' ILE . 10.7 mt-10 -92.88 146.12 23.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.402 -0.811 . . . . 0.0 110.077 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.699 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 96.5 m-85 -133.33 89.96 2.67 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.44 -0.788 . . . . 0.0 110.64 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.544 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -77.21 105.03 8.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 109.821 179.525 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.608 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 6.6 t -97.72 92.53 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.466 -0.772 . . . . 0.0 110.368 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.463 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 24.3 m -86.87 112.77 22.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.022 -1.049 . . . . 0.0 109.931 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.566 HD12 ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -100.41 149.73 23.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.124 -0.985 . . . . 0.0 110.497 -179.504 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.573 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.49 106.71 7.6 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.347 -0.846 . . . . 0.0 110.541 -179.252 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.573 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 8.9 mt -113.63 164.88 13.11 Favored 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.778 -1.201 . . . . 0.0 110.302 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -97.97 35.63 1.69 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.269 -0.894 . . . . 0.0 110.11 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.45 -116.01 0.69 Allowed Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.277 -1.44 . . . . 0.0 109.887 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.441 ' HG2' ' O ' ' A' ' 288' ' ' GLY . 11.8 mm-40 -139.81 107.14 5.52 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.175 -1.191 . . . . 0.0 110.55 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.573 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.2 m-85 -137.08 129.17 29.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.2 -0.937 . . . . 0.0 109.723 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.527 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 0.4 OUTLIER -57.81 101.59 0.08 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.458 179.565 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.611 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 45.6 p-90 -98.4 107.72 20.24 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.373 -0.829 . . . . 0.0 109.968 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.587 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 2.0 m -98.87 115.07 28.01 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.328 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.47 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.3 t -96.27 111.67 26.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.114 -0.991 . . . . 0.0 110.548 -179.202 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.509 ' HG3' HD12 ' A' ' 320' ' ' ILE . 8.4 ttpt -85.71 148.03 26.06 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.365 -0.834 . . . . 0.0 109.541 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.525 HG12 ' CG2' ' A' ' 346' ' ' VAL . 54.0 t -148.41 110.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 120.965 -1.084 . . . . 0.0 110.762 -179.314 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.523 ' CB ' ' HB2' ' A' ' 347' ' ' GLU . 47.2 mmtt -74.36 131.82 41.46 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.292 -0.88 . . . . 0.0 109.628 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.549 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 83.5 mt -83.95 151.65 24.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.261 -0.899 . . . . 0.0 111.445 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.531 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -55.55 173.69 0.25 Allowed Pre-proline 0 N--CA 1.487 1.401 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.481 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -68.76 78.27 0.71 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.592 1.312 . . . . 0.0 109.516 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.86 22.95 3.78 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 -179.279 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.529 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -109.03 154.79 21.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.307 -1.114 . . . . 0.0 110.337 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.549 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 41.0 p -152.33 144.36 23.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.179 -0.951 . . . . 0.0 110.716 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.5 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 49.0 t -72.22 117.74 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.462 -0.774 . . . . 0.0 109.89 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.94 -36.44 3.69 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 3.5 m -134.64 145.7 48.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.05 -1.265 . . . . 0.0 111.026 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.574 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 33.8 p90 -160.23 165.08 32.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.525 -0.734 . . . . 0.0 109.565 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.5 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -154.3 165.13 37.28 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 120.901 -1.124 . . . . 0.0 111.356 -179.408 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.486 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 51.58 28.55 4.75 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.54 -0.725 . . . . 0.0 111.488 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.547 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 138.83 0.47 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.083 -1.01 . . . . 0.0 110.302 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.53 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.64 115.39 17.36 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 109.112 179.326 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.574 ' HD3' ' CE2' ' A' ' 307' ' ' PHE . 1.1 ttpt -84.28 140.22 31.8 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.805 0.812 . . . . 0.0 110.738 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.66 174.95 7.13 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 179.204 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -137.61 109.42 7.11 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.331 -0.856 . . . . 0.0 110.276 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.426 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -99.85 46.87 1.35 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 58.47 85.72 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 110.5 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.552 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 89.86 -0.09 78.98 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.552 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.5 m-85 -138.78 -170.04 2.76 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.235 -1.156 . . . . 0.0 109.281 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.3 t -163.08 157.31 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.81 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.587 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.1 mm -127.58 151.8 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.227 -0.921 . . . . 0.0 110.929 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.627 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 99.4 m-85 -128.72 125.56 38.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.928 -1.108 . . . . 0.0 110.144 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.53 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 11.9 p -124.75 167.83 14.9 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 120.876 -1.14 . . . . 0.0 109.596 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.526 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.48 123.84 12.01 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 O-C-N 123.737 1.388 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.505 HG11 ' ND2' ' A' ' 311' ' ' ASN . 18.5 m -70.61 -114.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.497 -0.752 . . . . 0.0 109.855 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 2.6 m -110.46 -13.36 14.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.743 -1.223 . . . . 0.0 110.547 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.473 ' CE2' HG23 ' A' ' 324' ' ' VAL . 7.3 p-90 -132.86 -6.17 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.155 -0.965 . . . . 0.0 110.928 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.462 ' OD1' ' HB2' ' A' ' 332' ' ' ALA . 0.5 OUTLIER -97.49 46.68 1.02 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.046 -1.034 . . . . 0.0 110.216 -179.785 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -124.43 -8.05 7.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.099 -1.0 . . . . 0.0 109.92 -179.966 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.22 -157.87 0.02 OUTLIER Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.534 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -75.88 8.16 2.87 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.804 1.423 . . . . 0.0 111.0 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.1 m -165.17 115.53 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.473 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -132.83 109.04 9.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.237 -0.915 . . . . 0.0 110.27 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.463 ' HA ' ' HA ' ' A' ' 283' ' ' THR . 54.2 m -100.03 122.26 42.65 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.308 -0.87 . . . . 0.0 110.111 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.608 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 10.7 p90 -128.9 175.17 8.86 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.628 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.44 157.8 27.48 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.823 -1.656 . . . . 0.0 110.268 -179.368 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.699 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -145.28 148.98 34.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.7 -0.882 . . . . 0.0 109.265 179.449 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.538 HG13 ' CG ' ' A' ' 279' ' ' GLU . 1.7 mp -121.24 118.25 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.023 -1.048 . . . . 0.0 109.679 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.54 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.1 t -96.23 152.22 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.206 -0.934 . . . . 0.0 109.801 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -124.76 133.26 53.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.199 -0.938 . . . . 0.0 110.756 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.859 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.531 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 CA-C-O 121.097 0.475 . . . . 0.0 110.955 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.584 HG13 ' CE2' ' A' ' 280' ' ' TYR . 3.3 p -130.55 113.55 25.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.223 -0.923 . . . . 0.0 109.7 179.212 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.523 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 35.2 mt-10 -41.55 -45.93 3.43 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.247 -0.908 . . . . 0.0 110.304 -179.488 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.454 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.59 158.55 1.76 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.135 -0.978 . . . . 0.0 110.64 179.847 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.467 HG21 HG23 ' A' ' 296' ' ' VAL . 12.1 mt -119.74 129.05 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 110.193 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -131.2 151.74 51.17 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.266 -0.896 . . . . 0.0 110.297 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.554 ' CD1' HD22 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.43 130.5 54.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.232 -0.917 . . . . 0.0 109.914 179.815 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 48.1 tt0 -138.37 113.38 9.23 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.189 -0.945 . . . . 0.0 110.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.466 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.4 mt -96.31 108.76 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.985 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.527 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 39.42 34.6 0.14 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.544 -0.722 . . . . 0.0 110.629 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 112.59 -19.05 22.1 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.451 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.1 OUTLIER -85.18 100.54 11.82 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.27 -1.135 . . . . 0.0 110.317 -179.823 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.507 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 5.3 p -71.15 121.65 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.463 HD12 ' O ' ' A' ' 357' ' ' VAL . 35.7 mm . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.279 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 110.17 -1.172 . . . . 0.0 110.17 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.578 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.87 157.24 46.47 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.485 -1.009 . . . . 0.0 109.791 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.509 ' HG ' HD13 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -149.33 124.66 10.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 110.615 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.506 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 2.1 mp0 -124.47 111.34 15.6 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.089 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 41.0 t -105.07 129.57 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.024 -1.047 . . . . 0.0 111.959 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.452 ' O ' HG21 ' A' ' 271' ' ' VAL . 7.7 ttmt -117.38 156.89 27.11 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.574 HG22 ' CD2' ' A' ' 280' ' ' TYR . 78.5 t -144.86 146.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.424 -1.422 . . . . 0.0 112.399 -179.094 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -138.22 109.39 6.84 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.15 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.7 p-10 -95.75 147.95 23.08 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.127 -0.983 . . . . 0.0 111.111 -178.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.574 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 35.9 p90 -133.66 16.97 3.94 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.515 -0.741 . . . . 0.0 110.019 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.05 -58.48 3.96 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.561 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 6.0 t -68.8 -20.31 64.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -1.141 . . . . 0.0 110.103 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -177.7 179.09 48.41 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.538 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -132.55 141.84 48.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -1.125 . . . . 0.0 110.121 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.574 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 6.3 mt-10 -95.62 147.45 23.58 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.47 -0.769 . . . . 0.0 110.209 -179.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.694 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 93.5 m-85 -138.6 95.08 2.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 110.709 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.52 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.71 108.49 16.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.526 -0.734 . . . . 0.0 110.091 179.657 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.623 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 6.7 t -100.11 92.72 2.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.6 -0.688 . . . . 0.0 109.85 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.508 ' CB ' HG23 ' A' ' 333' ' ' THR . 3.6 m -86.57 113.89 22.84 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.932 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.545 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -100.98 149.74 23.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.096 -1.003 . . . . 0.0 110.806 -179.322 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.578 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.56 106.37 6.97 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -179.61 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.577 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 8.1 mt -116.91 162.54 17.59 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.688 -1.257 . . . . 0.0 109.94 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.86 36.24 1.2 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.974 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.447 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.4 -135.5 3.9 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.325 -1.417 . . . . 0.0 110.039 -179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.478 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.5 mt-30 -121.43 104.65 9.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.152 -1.205 . . . . 0.0 110.978 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.577 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -132.6 129.24 38.69 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.3 -0.875 . . . . 0.0 109.702 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.513 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 39.1 m-20 -58.58 99.57 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.4 179.435 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.6 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 53.0 p-90 -97.94 113.07 24.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 110.418 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.501 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 23.5 m -105.17 113.8 27.61 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.336 -0.853 . . . . 0.0 109.478 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.499 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.1 t -96.08 110.54 24.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.799 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.429 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 31.9 ttmt -83.44 146.77 28.23 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.301 -0.875 . . . . 0.0 109.217 179.378 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.559 HG12 ' CG2' ' A' ' 346' ' ' VAL . 42.4 t -140.93 105.13 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.518 ' O ' ' N ' ' A' ' 347' ' ' GLU . 10.6 mmtp -70.18 132.33 45.62 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.189 -0.945 . . . . 0.0 109.136 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.548 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 95.9 mt -87.41 152.13 22.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.441 -0.787 . . . . 0.0 111.376 -178.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -61.71 174.74 0.61 Allowed Pre-proline 0 C--N 1.301 -1.505 0 O-C-N 121.63 -0.668 . . . . 0.0 109.293 179.002 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.483 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.9 Cg_endo -68.48 82.87 0.51 Allowed 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.703 1.37 . . . . 0.0 110.041 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.1 24.48 4.82 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.498 ' HB1' ' HB1' ' A' ' 299' ' ' ALA . . . -114.41 148.89 37.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -1.09 . . . . 0.0 110.155 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.548 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 21.0 p -151.76 144.35 24.24 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 110.614 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.521 HG11 ' CD ' ' A' ' 312' ' ' LYS . 61.3 t -64.65 129.7 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.458 -0.776 . . . . 0.0 110.357 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.74 -34.41 2.05 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.459 ' O ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -142.21 131.72 23.83 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.194 -1.18 . . . . 0.0 110.59 -179.827 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 13.6 p90 -145.96 163.92 33.65 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.263 -0.898 . . . . 0.0 109.817 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.511 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.7 OUTLIER -154.33 166.75 32.21 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.99 -1.068 . . . . 0.0 110.982 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.446 ' CB ' ' HA ' ' A' ' 334' ' ' PHE . 0.5 OUTLIER 54.99 23.07 4.8 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.561 -0.712 . . . . 0.0 111.03 179.772 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.516 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.92 149.39 1.13 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.423 179.635 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.525 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -87.77 124.65 33.82 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.163 -0.961 . . . . 0.0 109.263 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.521 ' CD ' HG11 ' A' ' 304' ' ' VAL . 7.8 ttpt -92.29 139.77 30.27 Favored 'General case' 0 N--CA 1.489 1.486 0 CA-C-O 121.697 0.76 . . . . 0.0 110.976 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.96 175.18 7.49 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 178.808 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.467 ' HA ' HG21 ' A' ' 319' ' ' VAL . 4.6 mt-10 -136.34 109.69 7.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.083 -1.01 . . . . 0.0 110.629 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -98.59 39.58 2.71 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 61.26 90.22 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 0.0 110.095 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.09 0.87 82.65 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.622 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 4.0 m-85 -143.83 -171.31 3.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.466 -1.02 . . . . 0.0 109.567 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 2.9 t -163.43 156.73 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -0.854 . . . . 0.0 109.467 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.509 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 15.2 mm -122.43 147.52 26.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.92 -1.112 . . . . 0.0 110.715 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.661 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.0 m-85 -124.28 129.6 51.04 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.212 -0.93 . . . . 0.0 109.855 179.389 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.525 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 16.1 p -132.41 167.22 23.6 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 120.575 -1.328 . . . . 0.0 110.178 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.527 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.5 Cg_endo -65.99 115.95 3.72 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.839 1.442 . . . . 0.0 111.01 -179.698 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.517 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 9.2 m -58.36 -111.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.427 -0.795 . . . . 0.0 110.006 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 2.2 p -117.78 -18.43 9.6 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.742 -1.224 . . . . 0.0 110.379 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.421 ' CE2' HG23 ' A' ' 324' ' ' VAL . 6.9 p-90 -125.93 -4.13 6.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.244 -0.91 . . . . 0.0 110.401 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.517 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 2.3 t30 -97.73 50.29 1.04 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.288 -0.882 . . . . 0.0 109.977 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.487 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 4.2 mtmt -124.72 -9.82 7.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.344 -0.847 . . . . 0.0 109.894 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.53 -160.57 0.02 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.23 6.08 3.71 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.059 1.557 . . . . 0.0 110.744 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.433 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.7 m -163.07 116.55 1.62 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.066 -1.022 . . . . 0.0 109.943 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.403 ' HB3' ' CG ' ' A' ' 327' ' ' ASN . . . -137.53 105.79 5.75 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.22 -0.925 . . . . 0.0 110.324 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.508 HG23 ' CB ' ' A' ' 283' ' ' THR . 13.9 m -96.0 123.23 39.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.623 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 9.8 p90 -127.48 172.67 10.49 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.366 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.475 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.89 160.29 28.34 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.653 -1.736 . . . . 0.0 110.397 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.694 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.1 p90 -147.08 143.75 28.55 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.717 -0.873 . . . . 0.0 109.348 179.379 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.572 HG22 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -117.65 117.25 54.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.797 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.537 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 3.2 t -96.9 152.03 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.997 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.79 134.72 54.41 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 110.353 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.935 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.55 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.1 mtmt . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 121.299 0.571 . . . . 0.0 110.728 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.59 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.4 p -136.12 114.74 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.474 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.518 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.1 mm-40 -44.07 -47.2 8.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.879 . . . . 0.0 110.045 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -176.8 153.46 1.06 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.124 -0.985 . . . . 0.0 110.733 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.478 HG12 HG12 ' A' ' 296' ' ' VAL . 18.5 mt -115.38 104.23 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.153 -0.967 . . . . 0.0 110.033 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.78 154.03 20.04 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.228 -0.92 . . . . 0.0 110.448 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.534 HD13 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.38 127.56 55.7 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.296 -0.877 . . . . 0.0 110.261 179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 27.3 tt0 -138.21 112.65 8.77 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.083 -1.011 . . . . 0.0 109.895 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.475 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.5 mt -91.74 108.03 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 110.669 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.513 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 37.76 35.84 0.08 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.674 -0.641 . . . . 0.0 111.139 179.563 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.1 -0.07 28.4 Favored Glycine 0 N--CA 1.493 2.433 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.468 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -108.68 104.5 13.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.126 -1.22 . . . . 0.0 110.134 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.3 p -71.9 114.11 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.332 -0.855 . . . . 0.0 110.283 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.473 HG21 ' OXT' ' A' ' 358' ' ' ILE . 41.6 mm . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.112 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.143 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.546 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.22 166.39 24.67 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.486 -1.008 . . . . 0.0 109.488 179.759 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.57 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -161.69 140.2 9.44 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.001 -1.062 . . . . 0.0 111.11 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.426 ' N ' HD12 ' A' ' 267' ' ' LEU . 9.5 mt-10 -141.94 123.89 15.33 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 179.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.45 HG11 ' O ' ' A' ' 281' ' ' ASP . 71.8 t -117.14 141.61 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 120.845 -1.16 . . . . 0.0 111.607 -178.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.438 ' C ' HG23 ' A' ' 271' ' ' VAL . 4.7 tttt -126.88 157.55 39.05 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.587 HG11 ' CE2' ' A' ' 280' ' ' TYR . 74.1 t -144.73 146.95 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.416 -1.427 . . . . 0.0 112.085 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.516 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -144.5 114.9 7.58 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.643 -0.661 . . . . 0.0 109.288 179.056 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.5 p30 -96.04 148.01 23.12 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.2 -0.938 . . . . 0.0 111.291 -178.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.572 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 34.2 p90 -132.78 19.17 4.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.489 -0.757 . . . . 0.0 109.949 179.23 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.61 -62.43 3.4 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.519 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 22.0 m -66.37 -21.14 66.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -1.149 . . . . 0.0 110.481 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.486 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -176.4 -179.55 46.91 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.43 -1.366 . . . . 0.0 109.776 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.55 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.99 143.94 48.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.258 -1.142 . . . . 0.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.572 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 9.0 mt-10 -96.37 147.35 23.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.439 -0.788 . . . . 0.0 110.332 -179.546 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.675 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.0 m-85 -141.2 86.63 2.04 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.474 -0.766 . . . . 0.0 110.372 -179.52 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.45 ' O ' HG11 ' A' ' 269' ' ' VAL . 3.9 t0 -71.09 152.19 43.73 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.367 -0.833 . . . . 0.0 110.092 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.629 ' CG1' ' CZ ' ' A' ' 334' ' ' PHE . 4.8 t -144.83 89.84 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.601 -0.687 . . . . 0.0 109.812 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.48 ' O ' HD23 ' A' ' 267' ' ' LEU . 13.5 m -86.29 127.9 34.84 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.951 -1.093 . . . . 0.0 109.596 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.61 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.3 OUTLIER -116.53 151.16 36.71 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.02 -1.05 . . . . 0.0 110.862 -179.35 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.55 ' O ' ' CD2' ' A' ' 286' ' ' LEU . 0.5 OUTLIER -131.62 136.0 47.4 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.402 -0.811 . . . . 0.0 109.88 -179.853 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.563 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 17.9 mt -140.67 172.69 12.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.773 -1.204 . . . . 0.0 109.965 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -94.55 29.16 2.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.22 -0.925 . . . . 0.0 110.967 -179.157 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.517 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 149.91 -82.84 0.18 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.484 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.2 tt0 -151.59 107.94 3.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.092 -1.24 . . . . 0.0 110.737 -179.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.61 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 6.4 m-85 -133.27 140.89 47.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.299 -0.876 . . . . 0.0 109.829 179.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.523 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 18.3 m-20 -74.01 97.09 2.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.05 -1.031 . . . . 0.0 109.001 179.022 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.61 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 56.8 p-90 -98.63 115.27 28.29 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.206 -0.934 . . . . 0.0 110.64 -179.193 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.468 HG21 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -108.09 113.9 27.4 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.506 -0.746 . . . . 0.0 109.547 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.529 HG21 ' CD2' ' A' ' 351' ' ' LEU . 3.7 t -96.75 110.88 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 109.948 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.53 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 26.7 ttmt -84.84 148.24 26.39 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.344 -0.847 . . . . 0.0 109.768 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.535 HG12 ' CG2' ' A' ' 346' ' ' VAL . 46.3 t -144.58 108.51 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.256 -0.902 . . . . 0.0 110.398 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.566 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 2.6 mmtp -73.25 141.59 47.25 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.291 -0.88 . . . . 0.0 109.054 179.444 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.556 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 97.9 mt -93.45 156.7 16.61 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.164 -0.96 . . . . 0.0 111.708 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.486 ' HB3' ' HD2' ' A' ' 300' ' ' PRO . . . -69.65 172.45 5.42 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.629 -0.67 . . . . 0.0 109.49 179.073 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.486 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 40.0 Cg_endo -67.61 84.34 0.39 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.73 1.384 . . . . 0.0 109.704 179.199 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.29 28.05 3.19 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 -179.244 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.511 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -123.42 145.25 48.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.331 -1.099 . . . . 0.0 110.623 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.556 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 42.0 p -145.68 144.4 30.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.254 -0.904 . . . . 0.0 110.367 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.57 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 19.6 t -78.62 136.86 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 110.179 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -136.67 -34.01 0.22 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.448 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -114.22 113.08 24.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.142 -1.21 . . . . 0.0 110.712 -179.632 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.477 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 28.9 p90 -144.4 164.37 31.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.297 -0.877 . . . . 0.0 109.844 179.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.482 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -157.64 161.56 38.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.076 -1.015 . . . . 0.0 111.102 -179.297 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 57.91 23.66 10.06 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.797 . . . . 0.0 111.22 179.31 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.525 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.46 141.85 0.72 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.185 -0.947 . . . . 0.0 110.057 179.469 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.3 m-80 -77.24 119.46 20.94 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.135 -0.978 . . . . 0.0 109.399 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.464 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.4 ttpt -90.33 141.45 28.71 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.658 0.742 . . . . 0.0 110.404 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.765 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -128.99 178.47 6.38 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.447 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.446 ' HA ' HG21 ' A' ' 319' ' ' VAL . 2.5 mt-10 -141.48 104.69 4.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.686 -0.634 . . . . 0.0 110.024 179.511 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.38 42.05 2.93 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.59 78.78 0.27 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.225 -1.162 . . . . 0.0 110.436 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.613 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 102.7 -1.64 48.94 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.613 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.2 m-85 -144.38 -165.67 2.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.337 -1.096 . . . . 0.0 109.42 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.57 ' CG2' ' CG2' ' A' ' 304' ' ' VAL . 2.8 t -163.48 154.25 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.331 -0.856 . . . . 0.0 109.7 179.341 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.765 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 13.4 mm -121.11 148.02 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.027 -1.046 . . . . 0.0 110.693 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.651 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.8 m-85 -126.27 124.53 40.57 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.357 -0.839 . . . . 0.0 109.815 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.519 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 8.7 p -128.9 166.51 24.45 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.935 -1.103 . . . . 0.0 109.576 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.43 120.43 7.64 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.853 1.449 . . . . 0.0 110.912 -179.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.48 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 31.1 m -64.48 -123.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.576 -0.702 . . . . 0.0 110.205 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.35 -17.7 15.75 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.815 -1.178 . . . . 0.0 110.669 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.409 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 20.4 p-90 -126.74 -8.78 6.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.018 -1.051 . . . . 0.0 110.505 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.48 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.4 t-20 -89.82 38.98 0.94 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.416 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -118.47 -6.35 10.74 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.137 -0.977 . . . . 0.0 109.715 179.75 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.26 -164.69 0.06 OUTLIER Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.517 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.6 Cg_endo -72.35 1.05 6.54 Favored 'Trans proline' 0 C--N 1.307 -1.633 0 O-C-N 124.236 1.65 . . . . 0.0 110.793 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -160.04 114.74 2.29 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.421 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.485 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -136.43 120.92 18.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -0.89 . . . . 0.0 110.499 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.495 ' O ' ' HB2' ' A' ' 309' ' ' SER . 97.4 m -110.37 142.38 42.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -0.872 . . . . 0.0 110.099 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.629 ' CZ ' ' CG1' ' A' ' 282' ' ' VAL . 16.4 p90 -145.22 174.39 11.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.419 -0.801 . . . . 0.0 108.918 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.14 164.62 30.12 Favored Glycine 0 N--CA 1.488 2.148 0 C-N-CA 118.913 -1.613 . . . . 0.0 110.146 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.675 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.3 p90 -151.54 143.4 23.78 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.512 -0.993 . . . . 0.0 109.642 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.562 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.5 mp -119.42 123.16 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.07 -1.019 . . . . 0.0 109.569 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 13.3 t -96.26 154.91 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.098 -1.002 . . . . 0.0 110.353 -179.522 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.58 135.03 52.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.368 -0.832 . . . . 0.0 110.582 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.439 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.49 2.246 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.539 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.434 0 CA-C-O 121.312 0.577 . . . . 0.0 110.526 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.559 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.5 p -129.21 123.13 57.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.302 -0.874 . . . . 0.0 110.103 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.509 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 8.8 mt-10 -56.11 -41.38 75.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.314 -0.866 . . . . 0.0 110.907 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.413 ' CD ' ' N ' ' A' ' 349' ' ' ILE . 2.4 tp10 -177.14 156.13 1.23 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.93 -1.106 . . . . 0.0 110.623 -179.352 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.462 HG21 HG22 ' A' ' 296' ' ' VAL . 38.6 mt -123.98 104.02 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.121 -0.987 . . . . 0.0 110.063 179.283 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.73 148.46 30.45 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.211 -0.931 . . . . 0.0 110.129 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.604 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -109.84 129.51 55.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.946 . . . . 0.0 110.347 179.844 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 24.2 tp10 -138.46 114.37 10.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.895 . . . . 0.0 109.779 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.459 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.4 mt -91.54 104.86 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.101 -0.999 . . . . 0.0 110.462 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.523 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 38.94 36.1 0.14 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.831 -0.543 . . . . 0.0 110.794 179.752 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.41 12.72 16.54 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.454 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 1.4 mp0 -120.88 105.45 10.71 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.979 -1.307 . . . . 0.0 110.358 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 9.8 p -72.22 128.02 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.275 -0.891 . . . . 0.0 110.324 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.433 HG12 ' O ' ' A' ' 356' ' ' GLN . 10.7 mm . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.097 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.52 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.53 166.29 24.97 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.722 -0.87 . . . . 0.0 109.495 179.908 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.547 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.5 tm? -161.59 137.58 7.94 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.497 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.502 ' N ' HD23 ' A' ' 267' ' ' LEU . 0.8 OUTLIER -137.27 151.0 48.21 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.032 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 66.1 t -138.93 138.83 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.683 -1.261 . . . . 0.0 111.431 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.425 ' C ' HG21 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -120.69 157.77 28.9 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.215 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 99.4 t -144.9 146.76 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.287 -1.508 . . . . 0.0 112.169 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.7 113.5 7.13 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.451 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 4.8 m-20 -98.1 143.72 28.34 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.209 -0.932 . . . . 0.0 111.016 -178.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.564 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 34.8 p90 -128.99 17.75 6.14 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 110.079 179.56 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.76 -58.3 4.36 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.414 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 0.7 OUTLIER -68.94 -18.31 64.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.229 -1.16 . . . . 0.0 110.093 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.551 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.72 178.14 48.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.554 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -132.14 143.49 50.02 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -1.111 . . . . 0.0 110.111 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.564 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 4.7 mt-10 -97.52 147.13 24.57 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.459 -0.776 . . . . 0.0 110.031 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 94.3 m-85 -142.41 84.52 1.87 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.336 -0.853 . . . . 0.0 110.749 -179.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.447 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -66.41 152.12 45.75 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.408 -0.808 . . . . 0.0 110.03 179.288 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.587 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 10.6 t -144.41 90.33 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.66 -0.65 . . . . 0.0 109.572 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 81.9 m -86.43 124.56 32.9 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.146 -0.971 . . . . 0.0 109.465 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.596 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.07 147.51 37.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.308 -0.87 . . . . 0.0 110.531 -179.243 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.531 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.5 OUTLIER -126.33 134.17 51.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.382 -0.824 . . . . 0.0 109.804 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.544 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 16.5 mt -141.63 150.42 41.95 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.607 -1.308 . . . . 0.0 110.208 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.51 35.59 0.77 Allowed 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.484 -0.76 . . . . 0.0 109.374 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.59 -128.94 2.04 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.256 -1.45 . . . . 0.0 109.91 -179.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.498 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -124.59 96.07 4.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -1.195 . . . . 0.0 110.714 -179.531 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.544 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.7 m-85 -118.53 129.44 55.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.33 -0.857 . . . . 0.0 109.74 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.519 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 0.3 OUTLIER -63.49 100.57 0.27 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.948 -1.095 . . . . 0.0 109.224 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.589 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 54.7 p-90 -99.85 112.98 25.21 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.213 -0.929 . . . . 0.0 111.065 -179.257 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.584 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 14.8 m -106.01 115.81 30.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.648 -0.658 . . . . 0.0 109.271 179.256 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.463 ' HA ' HD22 ' A' ' 351' ' ' LEU . 3.2 t -96.27 110.95 25.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.035 -1.04 . . . . 0.0 110.388 -179.424 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.473 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.9 ttpt -86.0 145.95 26.88 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.469 -0.769 . . . . 0.0 109.223 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.54 HG11 ' CG2' ' A' ' 346' ' ' VAL . 55.1 t -146.3 108.04 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 110.448 -179.501 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.496 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 30.8 mmtp -70.38 139.88 52.0 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.186 -0.946 . . . . 0.0 109.324 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.549 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 81.8 mt -94.71 158.45 15.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.454 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.489 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -66.65 177.12 0.88 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.684 -0.635 . . . . 0.0 109.748 179.33 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.489 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 41.4 Cg_endo -68.47 87.38 0.42 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.758 1.399 . . . . 0.0 109.838 179.501 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 107.32 22.28 7.55 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.479 ' O ' ' HB3' ' A' ' 298' ' ' LEU . . . -112.9 139.15 48.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.262 -1.14 . . . . 0.0 110.161 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.549 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 19.3 p -143.68 145.65 32.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 110.524 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.585 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 22.7 t -76.04 129.63 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.214 -0.929 . . . . 0.0 109.939 179.756 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.29 -17.98 3.51 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.148 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.404 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -143.78 129.76 19.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.046 -1.267 . . . . 0.0 111.245 -179.588 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.553 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.8 p90 -150.04 -178.14 6.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.545 -0.722 . . . . 0.0 109.636 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.518 ' CH2' HD13 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -166.06 151.15 8.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.534 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.6 OUTLIER 61.67 30.82 18.65 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.471 -0.768 . . . . 0.0 110.819 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.531 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.68 141.66 0.51 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.237 -0.915 . . . . 0.0 110.045 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.489 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.3 m-80 -81.17 112.4 18.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.074 -1.016 . . . . 0.0 109.317 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.553 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 2.3 ttpt -84.93 142.72 29.47 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.957 0.884 . . . . 0.0 110.981 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.705 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -129.34 179.08 5.99 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.099 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.449 ' HG2' ' O ' ' A' ' 313' ' ' GLN . 2.4 mt-10 -142.04 100.04 3.65 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.091 -0.644 . . . . 0.0 110.189 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -86.13 42.46 3.15 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.447 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 19.6 m120 59.69 80.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.239 -1.154 . . . . 0.0 110.328 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.605 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.86 2.61 56.14 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.605 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.1 m-85 -147.29 -166.87 2.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.396 -1.061 . . . . 0.0 109.382 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.585 ' CG2' ' CG2' ' A' ' 304' ' ' VAL . 4.0 t -163.16 154.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.283 -0.885 . . . . 0.0 109.975 178.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.705 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 5.2 mm -125.86 138.69 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.174 -0.953 . . . . 0.0 111.545 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.655 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.9 m-85 -117.4 122.61 44.28 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.326 -0.859 . . . . 0.0 109.515 178.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.522 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.3 p -124.4 168.75 12.2 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 120.61 -1.306 . . . . 0.0 110.554 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -64.66 112.2 1.9 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 124.04 1.548 . . . . 0.0 110.908 -179.362 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.516 ' N ' ' OD1' ' A' ' 327' ' ' ASN . 33.8 m -58.69 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.687 -0.633 . . . . 0.0 109.961 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.409 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 3.1 p -112.39 -12.72 13.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.636 -1.29 . . . . 0.0 111.01 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.445 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 14.8 p-90 -129.85 -12.31 4.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.984 -1.073 . . . . 0.0 111.226 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.538 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 23.1 p-10 -96.28 40.83 1.12 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.047 -1.033 . . . . 0.0 110.985 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.461 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -114.14 -3.0 13.29 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.162 -0.961 . . . . 0.0 109.51 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.81 -157.74 0.02 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.524 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -74.66 6.97 2.93 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.052 1.553 . . . . 0.0 110.956 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 5.6 m -165.35 122.11 1.46 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.099 -1.001 . . . . 0.0 110.088 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.538 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -138.91 116.25 11.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.933 . . . . 0.0 110.617 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.453 ' O ' ' HB2' ' A' ' 309' ' ' SER . 13.3 m -108.36 134.16 51.56 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.243 -0.91 . . . . 0.0 110.046 179.737 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.587 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 11.0 p90 -142.65 174.89 10.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.058 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.61 156.96 27.01 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.014 -1.565 . . . . 0.0 110.272 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.68 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.4 p90 -141.7 147.74 37.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.496 -1.002 . . . . 0.0 110.04 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.553 HG21 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -121.75 122.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.179 -0.951 . . . . 0.0 109.623 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.528 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 18.3 t -97.29 153.28 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.934 . . . . 0.0 110.554 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -121.02 132.76 55.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.561 -0.712 . . . . 0.0 109.867 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.437 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.528 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 121.231 0.539 . . . . 0.0 111.06 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.588 HG11 ' CE1' ' A' ' 280' ' ' TYR . 14.7 p -132.87 119.03 35.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.282 -0.886 . . . . 0.0 110.187 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -51.26 -46.96 62.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.444 -0.785 . . . . 0.0 110.268 -179.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.476 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 6.8 pt-20 -177.05 158.66 1.56 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.267 -0.896 . . . . 0.0 110.627 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.477 ' CG2' HG23 ' A' ' 296' ' ' VAL . 77.2 mt -121.29 112.41 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 110.245 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -116.54 137.47 52.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.238 -0.913 . . . . 0.0 110.177 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.596 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -93.04 135.3 34.35 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.12 -0.988 . . . . 0.0 110.523 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.47 108.26 5.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.402 -0.811 . . . . 0.0 110.012 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.459 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.8 mt -91.67 108.85 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.992 -1.067 . . . . 0.0 110.068 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.519 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 38.88 31.51 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.746 -0.596 . . . . 0.0 110.796 -179.855 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.13 -12.14 22.07 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 358' ' ' ILE . 2.2 mp0 -95.03 105.55 17.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.1 -1.236 . . . . 0.0 110.487 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.9 p -68.83 133.97 30.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.882 . . . . 0.0 110.185 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.425 HG12 ' O ' ' A' ' 356' ' ' GLN . 22.1 mm . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.289 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.523 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.69 164.59 27.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.378 -1.072 . . . . 0.0 110.049 179.992 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.549 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.3 tm? -161.34 131.93 5.15 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.226 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.522 ' N ' HD23 ' A' ' 267' ' ' LEU . 1.6 mt-10 -128.91 151.34 49.76 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.28 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 268' ' ' GLU . 96.5 t -142.71 138.83 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.712 -1.242 . . . . 0.0 111.509 -179.26 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.425 ' C ' HG23 ' A' ' 271' ' ' VAL . 17.2 mtpt -122.19 157.46 31.52 Favored 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.278 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.537 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 92.9 t -143.2 146.98 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.324 -1.485 . . . . 0.0 111.957 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.5 112.22 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 179.485 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.504 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.9 m-20 -96.49 143.95 27.04 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.014 -1.054 . . . . 0.0 111.125 -179.214 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.583 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 32.7 p90 -128.38 16.79 6.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 109.847 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.27 -63.17 2.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.6 -20.42 64.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -1.133 . . . . 0.0 110.306 -179.751 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.554 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.88 177.98 42.44 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.15 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.543 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -134.13 142.65 47.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.339 -1.094 . . . . 0.0 109.704 179.599 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.583 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 7.8 mt-10 -98.91 147.11 25.3 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.281 -0.887 . . . . 0.0 110.429 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.668 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.9 m-85 -143.09 84.2 1.82 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.511 -0.743 . . . . 0.0 110.649 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.44 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.87 151.69 46.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.347 -0.846 . . . . 0.0 109.967 179.407 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.595 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 14.0 t -143.93 91.38 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.459 -0.776 . . . . 0.0 110.131 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 88.4 m -86.74 123.89 32.4 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.39 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.6 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -111.27 147.49 34.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.017 -1.052 . . . . 0.0 110.976 -179.037 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.535 ' O ' ' CD2' ' A' ' 286' ' ' LEU . 0.5 OUTLIER -126.5 132.32 51.42 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.462 -0.774 . . . . 0.0 110.163 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.607 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 18.1 mt -142.77 157.52 44.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.43 36.86 1.06 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.194 -0.941 . . . . 0.0 109.671 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 160.68 -144.31 9.82 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.401 -1.381 . . . . 0.0 109.896 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.53 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -108.76 94.22 4.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -1.126 . . . . 0.0 110.711 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.607 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.7 m-30 -114.65 143.67 44.66 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 109.901 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.464 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 2.6 m-20 -76.97 97.21 4.57 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.198 -0.939 . . . . 0.0 109.078 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.588 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 57.4 p-90 -96.75 112.37 24.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.378 -0.826 . . . . 0.0 110.596 -179.185 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.605 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 1.5 m -105.44 113.78 27.56 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.416 -0.802 . . . . 0.0 109.515 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.496 HG22 ' CD2' ' A' ' 351' ' ' LEU . 5.4 t -96.07 110.67 24.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.076 -1.015 . . . . 0.0 109.829 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.46 ' HE2' HD11 ' A' ' 320' ' ' ILE . 8.4 ttmt -87.78 149.54 24.11 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.234 -0.916 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.598 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 98.6 t -144.89 108.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.419 -0.801 . . . . 0.0 110.352 -179.604 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 347' ' ' GLU . 14.5 mmtt -71.95 132.53 44.45 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.242 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.501 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 84.5 mt -88.0 156.05 19.51 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.233 -0.917 . . . . 0.0 111.594 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.517 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -68.29 173.08 3.57 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.581 -0.699 . . . . 0.0 109.318 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.497 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 39.6 Cg_endo -66.95 81.49 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.436 1.23 . . . . 0.0 110.067 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.79 23.09 4.09 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -115.03 144.94 42.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.366 -1.079 . . . . 0.0 110.085 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.504 ' N ' HG11 ' A' ' 338' ' ' VAL . 17.9 p -150.35 145.88 26.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.104 -0.998 . . . . 0.0 110.782 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.465 HG12 ' HG3' ' A' ' 312' ' ' LYS . 37.6 t -66.42 126.3 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.383 -0.823 . . . . 0.0 110.071 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.51 -16.19 6.11 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 337' ' ' ILE . 14.7 t -152.04 113.33 4.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.064 -1.257 . . . . 0.0 111.009 -179.624 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 18.7 p90 -134.39 163.64 29.22 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.396 -0.815 . . . . 0.0 109.43 179.135 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.497 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -153.91 160.92 42.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.995 -1.066 . . . . 0.0 111.246 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.484 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 54.13 29.08 9.79 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.694 . . . . 0.0 110.95 179.774 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.536 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.32 139.56 0.61 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.256 -0.903 . . . . 0.0 110.112 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.501 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -79.17 118.8 21.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.308 179.616 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.465 ' HG3' HG12 ' A' ' 304' ' ' VAL . 8.1 ttpt -87.53 134.92 33.54 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.688 0.756 . . . . 0.0 111.235 -179.126 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.95 172.68 7.1 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.409 ' HA ' HG22 ' A' ' 319' ' ' VAL . 3.8 mt-10 -131.71 112.62 12.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.343 -0.848 . . . . 0.0 110.082 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.567 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.58 47.81 1.15 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 8.0 t30 49.49 77.04 0.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.287 -1.125 . . . . 0.0 110.142 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.615 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.01 2.12 54.92 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.615 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.8 m-85 -143.67 -170.78 3.38 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.998 . . . . 0.0 109.13 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.537 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.9 t -163.95 154.5 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.254 -0.904 . . . . 0.0 109.11 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.605 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 17.6 mt -131.75 135.83 58.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 120.711 -1.243 . . . . 0.0 111.298 -179.591 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.665 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 52.9 m-85 -106.36 138.76 41.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.301 -0.874 . . . . 0.0 110.537 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.501 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.0 OUTLIER -136.41 169.92 12.24 Favored Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.934 -1.104 . . . . 0.0 110.023 179.427 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 41.0 Cg_endo -67.86 116.39 4.27 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 O-C-N 123.797 1.42 . . . . 0.0 110.816 -179.175 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.466 HG12 ' ND2' ' A' ' 311' ' ' ASN . 19.9 m -65.69 -129.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.578 -0.701 . . . . 0.0 110.098 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.416 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 0.4 OUTLIER -98.33 -12.82 21.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.912 -1.117 . . . . 0.0 110.712 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.447 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 36.2 p-90 -135.41 7.57 3.34 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.033 -1.042 . . . . 0.0 110.676 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.434 ' OD1' ' HB2' ' A' ' 332' ' ' ALA . 2.1 t-20 -111.32 42.62 1.63 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.18 -0.95 . . . . 0.0 110.119 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -122.79 -5.87 8.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 0.0 110.092 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.22 -160.35 0.02 OUTLIER Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.736 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 286' ' ' LEU . 45.9 Cg_endo -74.63 4.13 4.81 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 124.056 1.556 . . . . 0.0 110.592 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 3.7 m -164.61 116.1 1.24 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.925 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.505 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -137.18 119.15 15.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.189 -0.945 . . . . 0.0 110.325 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.484 ' O ' ' HB2' ' A' ' 309' ' ' SER . 3.3 m -105.03 142.26 35.14 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.948 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.595 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 11.2 p90 -148.6 174.89 11.67 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.94 159.87 29.02 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.61 -1.757 . . . . 0.0 110.447 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.668 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 0.5 OUTLIER -143.55 147.61 34.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.506 -0.996 . . . . 0.0 110.034 179.572 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.517 ' N ' HD12 ' A' ' 337' ' ' ILE . 1.7 mp -123.29 119.18 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.922 . . . . 0.0 109.188 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 5.9 t -96.55 146.2 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.143 -0.973 . . . . 0.0 110.352 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.437 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.08 137.04 52.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.497 -0.752 . . . . 0.0 110.088 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.441 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.527 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.067 0.461 . . . . 0.0 110.814 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.573 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.1 p -127.64 116.92 45.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.927 . . . . 0.0 110.081 179.418 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -47.84 -46.82 31.48 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.363 -0.835 . . . . 0.0 110.482 -179.69 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.404 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -177.18 158.78 1.54 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.103 -0.998 . . . . 0.0 110.861 -179.928 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.433 HG12 ' CG1' ' A' ' 296' ' ' VAL . 69.1 mt -120.39 122.97 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.026 -1.046 . . . . 0.0 110.278 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.42 137.58 52.76 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.193 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.6 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -96.34 130.57 43.42 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.059 -1.026 . . . . 0.0 110.367 179.975 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -139.06 110.06 6.8 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.841 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.468 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.5 mt -91.69 110.22 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.081 -1.012 . . . . 0.0 110.231 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.412 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 43.31 30.6 0.32 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.645 -0.659 . . . . 0.0 110.969 179.917 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.09 -3.8 28.55 Favored Glycine 0 N--CA 1.492 2.39 0 C-N-CA 119.811 -1.185 . . . . 0.0 110.295 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.401 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 37.2 mm-40 -102.39 114.5 28.73 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.093 -1.239 . . . . 0.0 110.518 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.482 ' O ' ' CD1' ' A' ' 358' ' ' ILE . 4.5 p -73.69 136.22 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.251 -0.905 . . . . 0.0 110.363 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.482 ' CD1' ' O ' ' A' ' 357' ' ' VAL . 20.6 mm . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.051 -0.976 . . . . 0.0 110.267 -179.769 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.42 ' O ' ' CG2' ' A' ' 358' ' ' ILE . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.572 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -119.3 163.39 17.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.424 -1.045 . . . . 0.0 109.932 179.733 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.508 ' C ' ' CD2' ' A' ' 267' ' ' LEU . 0.0 OUTLIER -152.06 122.11 7.12 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.09 -1.006 . . . . 0.0 110.817 -179.822 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.443 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.9 mt-10 -118.72 111.15 18.13 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.696 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 71.4 t -113.23 141.2 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.011 -1.056 . . . . 0.0 111.861 -178.479 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.466 ' O ' HG23 ' A' ' 271' ' ' VAL . 0.1 OUTLIER -130.1 157.63 41.88 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.858 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.563 HG21 ' CD1' ' A' ' 280' ' ' TYR . 88.5 t -142.41 147.03 21.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.312 -1.492 . . . . 0.0 112.141 -179.064 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.562 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -135.83 107.5 6.99 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.958 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.517 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.4 p30 -93.66 146.03 24.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.031 . . . . 0.0 111.572 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.562 ' CZ3' ' O ' ' A' ' 272' ' ' ASN . 39.5 p90 -134.84 23.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.563 -0.71 . . . . 0.0 109.694 179.293 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.4 -69.23 3.38 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.875 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -27.67 48.16 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 110.425 179.888 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.537 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.83 -173.57 38.74 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.817 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.562 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -141.39 143.77 34.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -1.162 . . . . 0.0 110.379 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.554 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 4.7 mt-10 -93.67 145.61 24.43 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.475 -0.766 . . . . 0.0 109.578 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.1 m-85 -137.9 82.66 1.93 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.332 -0.855 . . . . 0.0 110.422 -179.543 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -67.91 144.11 55.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.485 -0.76 . . . . 0.0 109.676 179.433 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.594 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 6.7 t -137.71 88.4 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.484 -0.76 . . . . 0.0 109.772 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.412 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 60.6 m -86.25 120.47 27.64 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 109.245 179.808 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -104.32 149.02 25.72 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.076 -1.015 . . . . 0.0 111.106 -178.69 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.572 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -131.57 107.19 8.69 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.505 -0.747 . . . . 0.0 110.224 -179.298 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 330' ' ' PRO . 4.8 mt -122.24 172.78 8.04 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.525 -1.359 . . . . 0.0 110.177 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -101.1 28.19 5.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.355 -0.841 . . . . 0.0 110.926 -179.603 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.637 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 161.92 -179.43 37.29 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 119.177 -1.487 . . . . 0.0 110.6 179.739 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.46 ' O ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -71.41 109.0 5.12 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.426 -1.044 . . . . 0.0 111.039 -179.417 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.637 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 10.2 m-85 -137.08 151.55 49.03 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.251 -0.906 . . . . 0.0 109.786 178.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.518 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 57.8 m-20 -80.42 97.09 6.92 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.273 179.074 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.59 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 53.4 p-90 -97.18 110.67 23.17 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.406 -179.605 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.571 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 4.0 m -103.02 116.76 33.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.5 -0.75 . . . . 0.0 109.485 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.456 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.7 t -96.91 111.19 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.131 -0.981 . . . . 0.0 110.432 -179.465 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.51 ' HG3' ' CD1' ' A' ' 320' ' ' ILE . 17.5 ttpt -82.96 147.85 27.97 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.219 -0.925 . . . . 0.0 109.47 179.433 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.524 HG13 ' CG2' ' A' ' 346' ' ' VAL . 77.3 t -146.61 105.01 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.135 -0.978 . . . . 0.0 110.629 -179.323 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.534 ' O ' ' CG2' ' A' ' 346' ' ' VAL . 19.2 mmtt -71.26 130.51 41.6 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.259 -0.9 . . . . 0.0 109.393 179.404 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.601 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 95.2 mt -83.8 161.42 20.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.46 -0.775 . . . . 0.0 111.6 -178.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.581 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -63.56 179.12 0.35 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.675 -0.641 . . . . 0.0 109.674 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.514 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 43.5 Cg_endo -69.24 76.46 0.93 Allowed 'Trans proline' 0 C--N 1.305 -1.745 0 O-C-N 123.742 1.391 . . . . 0.0 109.825 179.369 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.73 19.68 6.0 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.24 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.539 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -101.08 152.69 20.31 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.399 -1.059 . . . . 0.0 110.271 -179.596 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.556 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.8 p -150.6 144.62 25.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 110.588 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.525 HG21 ' CG2' ' A' ' 319' ' ' VAL . 55.2 t -68.07 140.95 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.35 -0.844 . . . . 0.0 109.734 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.79 -39.04 0.51 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.665 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.406 ' O ' HD12 ' A' ' 337' ' ' ILE . 19.5 m -137.05 129.36 29.75 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.007 -1.29 . . . . 0.0 111.117 -179.678 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 30.1 p90 -141.2 167.09 23.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.387 -0.821 . . . . 0.0 109.434 179.27 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.461 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.06 157.15 37.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.877 -1.14 . . . . 0.0 111.083 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.48 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.5 OUTLIER 58.79 25.23 13.25 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.477 -0.764 . . . . 0.0 111.106 179.797 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.54 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.18 140.03 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.242 -0.911 . . . . 0.0 109.997 179.465 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.496 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -79.47 121.96 25.84 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.104 -0.998 . . . . 0.0 109.312 179.569 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.505 ' HG2' ' N ' ' A' ' 313' ' ' GLN . 0.6 OUTLIER -88.75 145.75 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.771 0.796 . . . . 0.0 110.991 -179.119 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.17 175.23 9.28 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.458 ' HA ' HG21 ' A' ' 319' ' ' VAL . 3.4 mm-40 -138.68 112.99 8.74 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.228 -0.92 . . . . 0.0 110.457 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -99.76 40.63 2.38 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.79 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 59.27 82.27 0.15 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.29 -1.123 . . . . 0.0 110.179 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.56 -1.56 57.07 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.614 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.2 m-85 -146.37 -172.72 4.01 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.499 -1.0 . . . . 0.0 109.317 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.525 ' CG2' HG21 ' A' ' 304' ' ' VAL . 2.5 t -158.67 160.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.137 -0.977 . . . . 0.0 109.743 179.355 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.571 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 35.8 mm -127.93 146.82 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.163 -0.961 . . . . 0.0 111.304 -179.25 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 51.8 m-85 -123.67 132.68 53.9 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 110.003 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.515 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -131.54 169.69 13.17 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.924 -1.11 . . . . 0.0 110.135 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.553 ' HA ' ' CZ2' ' A' ' 292' ' ' TRP . 39.3 Cg_endo -65.76 116.49 3.99 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.065 -179.482 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.453 ' O ' ' HD3' ' A' ' 328' ' ' LYS . 12.1 m -57.62 -111.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.479 -0.763 . . . . 0.0 109.951 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 1.1 t -119.6 -14.25 9.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.785 -1.197 . . . . 0.0 110.376 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.439 ' CE2' HG21 ' A' ' 324' ' ' VAL . 6.5 p-90 -126.66 -24.75 3.51 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.229 -0.919 . . . . 0.0 110.614 -179.846 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.463 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 0.3 OUTLIER -86.92 40.8 0.93 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.236 -0.915 . . . . 0.0 110.137 -179.898 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.453 ' HD3' ' O ' ' A' ' 324' ' ' VAL . 0.0 OUTLIER -112.33 -6.22 14.07 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.292 -0.88 . . . . 0.0 109.995 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.69 -143.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.801 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 47.5 Cg_endo -74.85 -49.52 0.15 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.05 1.553 . . . . 0.0 110.395 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 19.0 m -111.08 134.48 52.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.247 -0.908 . . . . 0.0 110.511 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.463 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -148.72 123.26 9.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.349 -0.845 . . . . 0.0 109.863 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.455 ' O ' ' HB2' ' A' ' 309' ' ' SER . 45.5 m -111.48 137.22 49.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 110.504 -179.826 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.594 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 13.2 p90 -145.45 174.59 11.01 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.483 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.21 159.14 28.05 Favored Glycine 0 N--CA 1.488 2.144 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.358 -179.397 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.688 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -144.98 146.24 31.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.572 -0.958 . . . . 0.0 109.781 179.686 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.546 ' N ' HD12 ' A' ' 337' ' ' ILE . 1.7 mp -121.03 125.66 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.175 -0.953 . . . . 0.0 110.091 -179.669 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.601 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.0 t -102.13 153.87 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.23 -0.918 . . . . 0.0 110.007 179.818 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.83 126.77 46.11 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.434 -0.791 . . . . 0.0 109.848 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.884 . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.581 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.7 mtmt . . . . . 0 N--CA 1.488 1.432 0 CA-C-O 121.105 0.479 . . . . 0.0 111.418 . . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.584 HG13 ' CE1' ' A' ' 280' ' ' TYR . 11.2 p -136.66 119.17 20.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.065 -1.022 . . . . 0.0 110.316 179.238 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.32 -46.46 46.74 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.286 -0.884 . . . . 0.0 110.38 -179.653 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -177.02 158.37 1.54 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.242 -0.911 . . . . 0.0 110.479 -179.756 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.464 HG12 HG12 ' A' ' 296' ' ' VAL . 23.6 mt -121.08 118.81 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.842 -1.161 . . . . 0.0 110.523 179.939 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.57 156.24 25.03 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.336 -0.852 . . . . 0.0 110.121 179.819 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.551 ' CD1' HD23 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -115.49 125.7 53.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.289 -0.882 . . . . 0.0 110.033 179.909 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.5 tt0 -139.06 118.4 12.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.966 -1.084 . . . . 0.0 110.618 179.869 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.481 ' O ' ' N ' ' A' ' 356' ' ' GLN . 2.4 mt -94.58 115.8 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.077 -1.015 . . . . 0.0 110.376 179.502 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 37.34 31.47 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.597 -0.689 . . . . 0.0 111.159 179.741 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 110.53 4.53 28.47 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.535 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 353' ' ' ILE . 2.6 mp0 -108.05 105.93 15.92 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.149 -1.207 . . . . 0.0 110.087 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.42 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 14.5 p -70.83 120.31 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.347 -0.845 . . . . 0.0 110.589 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.469 HG12 ' O ' ' A' ' 356' ' ' GLN . 17.1 mm . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 117.978 -1.011 . . . . 0.0 110.172 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.562 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.1 159.68 38.16 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.497 -1.002 . . . . 0.0 109.985 179.843 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.506 ' C ' ' CD2' ' A' ' 267' ' ' LEU . 0.0 OUTLIER -147.99 122.59 9.82 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 110.586 -179.626 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.461 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 14.7 mt-10 -123.59 114.26 19.79 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.509 ' CG1' ' O ' ' A' ' 281' ' ' ASP . 62.1 t -111.84 146.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.984 -1.072 . . . . 0.0 112.164 -178.417 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.426 ' C ' HG23 ' A' ' 271' ' ' VAL . 2.9 tptt -130.68 157.21 43.4 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.844 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.523 HG11 ' CE2' ' A' ' 280' ' ' TYR . 89.6 t -142.66 147.02 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.317 -1.489 . . . . 0.0 112.112 -179.203 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.537 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -141.12 111.13 6.61 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.216 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.514 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -97.48 148.43 23.23 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.906 -1.121 . . . . 0.0 111.459 -178.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.579 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 37.7 p90 -134.52 20.21 3.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.59 -0.694 . . . . 0.0 109.903 179.459 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.91 -68.42 3.38 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.6 t -58.33 -24.02 58.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -1.206 . . . . 0.0 110.455 -179.838 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.9 179.73 43.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.917 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.564 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -134.5 143.49 47.49 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.309 -1.112 . . . . 0.0 110.245 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.579 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 5.4 mt-10 -96.82 146.55 24.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.332 -0.855 . . . . 0.0 110.178 -179.644 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.683 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 87.4 m-85 -143.32 81.53 1.71 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.414 -0.804 . . . . 0.0 110.539 -179.553 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.509 ' O ' ' CG1' ' A' ' 269' ' ' VAL . 2.0 t0 -66.28 154.03 41.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 110.124 179.57 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.6 HG12 ' CZ ' ' A' ' 334' ' ' PHE . 4.0 t -143.2 88.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.493 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.424 HG21 ' OG1' ' A' ' 333' ' ' THR . 8.8 m -85.93 115.38 23.51 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.294 -0.878 . . . . 0.0 109.376 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.552 HD23 ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.14 148.55 24.47 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.327 -0.858 . . . . 0.0 110.818 -178.921 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.562 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -131.15 106.34 8.28 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.492 -0.755 . . . . 0.0 110.316 -179.521 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.509 ' N ' ' O ' ' A' ' 330' ' ' PRO . 4.6 mt -121.03 169.25 10.67 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.648 -1.282 . . . . 0.0 109.801 179.447 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . 0.403 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -103.15 32.8 3.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 110.253 -179.856 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.552 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 163.79 -165.17 36.8 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.384 -1.389 . . . . 0.0 110.281 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.464 ' HG2' ' HA2' ' A' ' 329' ' ' GLY . 5.0 mm-40 -89.28 110.58 21.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.268 -1.137 . . . . 0.0 111.046 -179.447 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.552 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 7.9 m-85 -137.8 142.07 40.86 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.179 -0.951 . . . . 0.0 109.706 179.169 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.52 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 10.0 t70 -72.6 97.89 2.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.34 179.215 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.59 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 55.5 p-90 -97.32 112.32 24.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.272 -0.893 . . . . 0.0 110.383 -179.357 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.542 HG22 ' CG2' ' A' ' 322' ' ' THR . 4.1 m -105.78 113.87 27.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.359 -0.838 . . . . 0.0 110.043 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.481 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.6 t -96.61 111.1 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 110.047 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.488 ' HG3' HD13 ' A' ' 320' ' ' ILE . 23.1 ttpt -87.87 149.29 24.2 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.28 -0.888 . . . . 0.0 109.319 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.58 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 98.8 t -146.2 108.93 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 121.077 -1.014 . . . . 0.0 110.543 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.504 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 9.3 mmtm -70.13 135.41 49.14 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.112 -0.992 . . . . 0.0 109.228 179.585 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.585 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 88.4 mt -89.63 162.52 15.58 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.455 -0.778 . . . . 0.0 111.572 -178.879 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.549 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -69.48 177.47 1.23 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.756 -0.59 . . . . 0.0 109.759 179.358 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.499 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 42.7 Cg_endo -69.32 81.97 0.68 Allowed 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.735 1.387 . . . . 0.0 109.786 179.351 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.26 22.58 5.8 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.357 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.482 ' HB3' ' HB3' ' A' ' 299' ' ' ALA . . . -111.47 146.2 37.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.379 -1.071 . . . . 0.0 110.388 -179.623 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.529 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 5.4 p -149.86 145.74 26.73 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.274 -0.891 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.532 HG22 ' CG2' ' A' ' 319' ' ' VAL . 92.2 t -68.09 131.31 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.263 -0.898 . . . . 0.0 109.852 179.744 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.12 -28.83 2.11 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.475 ' O ' HD12 ' A' ' 337' ' ' ILE . 1.7 t -142.33 115.99 9.16 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.103 -1.233 . . . . 0.0 111.116 -179.635 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.1 p90 -131.52 178.33 6.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.376 -0.828 . . . . 0.0 109.365 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.55 ' CH2' HD11 ' A' ' 337' ' ' ILE . 1.2 p90 -167.91 160.7 12.47 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.872 -1.143 . . . . 0.0 111.073 -179.643 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.484 ' HB3' ' HA ' ' A' ' 334' ' ' PHE . 0.1 OUTLIER 57.81 23.61 9.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.496 -0.752 . . . . 0.0 110.881 179.789 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.491 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 146.79 1.0 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.301 -0.874 . . . . 0.0 110.074 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.532 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -82.48 119.74 24.59 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.168 -0.958 . . . . 0.0 109.283 179.46 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.518 ' CD ' HG12 ' A' ' 304' ' ' VAL . 1.6 ttpt -88.78 146.15 25.18 Favored 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.813 0.816 . . . . 0.0 110.657 -179.486 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -130.74 172.71 11.67 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.52 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.48 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 53.2 mt-10 -138.79 104.95 5.22 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.32 -0.863 . . . . 0.0 110.486 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.455 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -93.7 38.7 3.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.455 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 11.3 t-20 59.97 83.48 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.277 -1.131 . . . . 0.0 110.344 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.627 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.09 -2.71 55.13 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 179.709 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.627 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.1 m-85 -145.76 -167.58 2.75 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.349 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.54 HG12 ' CZ ' ' A' ' 321' ' ' PHE . 2.9 t -163.3 157.45 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.178 -0.952 . . . . 0.0 109.428 178.974 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.527 ' N ' HG11 ' A' ' 319' ' ' VAL . 11.1 mm -127.38 142.99 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.021 -179.641 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 47.8 m-85 -119.31 136.21 54.35 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.146 -0.971 . . . . 0.0 109.808 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.542 ' CG2' HG22 ' A' ' 293' ' ' THR . 1.3 p -138.48 169.98 11.4 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.792 -1.193 . . . . 0.0 110.122 -179.928 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.504 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.79 123.97 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.926 1.487 . . . . 0.0 111.09 -179.292 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.502 HG11 ' ND2' ' A' ' 311' ' ' ASN . 18.6 m -74.35 -116.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.499 -0.751 . . . . 0.0 110.135 -179.938 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.68 -32.55 8.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.709 -1.245 . . . . 0.0 110.808 -179.588 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 4.1 p-90 -116.34 -1.77 12.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.12 -0.987 . . . . 0.0 110.502 -179.778 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.493 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.27 50.01 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.107 -0.995 . . . . 0.0 109.79 179.796 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.475 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.1 OUTLIER -125.68 -2.6 7.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.376 -0.828 . . . . 0.0 109.716 -179.804 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.464 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -72.34 -143.91 0.48 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.735 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.509 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.2 Cg_endo -73.58 -53.73 0.12 Allowed 'Trans proline' 0 C--N 1.303 -1.838 0 O-C-N 124.166 1.614 . . . . 0.0 110.473 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.25 130.61 50.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.259 -0.901 . . . . 0.0 110.467 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.463 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -145.03 104.48 3.98 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.435 -0.791 . . . . 0.0 109.749 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.465 ' O ' ' HB3' ' A' ' 309' ' ' SER . 27.8 m -100.68 133.73 44.71 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.084 -1.01 . . . . 0.0 110.604 -179.61 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.6 ' CZ ' HG12 ' A' ' 282' ' ' VAL . 8.8 p90 -141.85 174.73 10.31 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.336 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.71 153.65 25.06 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.905 -1.617 . . . . 0.0 110.226 -179.542 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.683 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -138.72 146.73 41.85 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.468 -1.019 . . . . 0.0 109.794 179.354 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.55 HD11 ' CH2' ' A' ' 308' ' ' TRP . 1.7 mp -121.88 122.09 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.238 -0.914 . . . . 0.0 109.798 -179.891 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.585 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 10.0 t -99.89 154.08 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.1 -1.0 . . . . 0.0 110.644 -179.398 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -124.91 130.65 52.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.464 -0.772 . . . . 0.0 110.065 -179.96 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.833 . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.549 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 121.114 0.483 . . . . 0.0 111.281 . . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.594 HG13 ' CE2' ' A' ' 280' ' ' TYR . 12.2 p -138.74 118.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.152 -0.968 . . . . 0.0 110.303 179.391 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.504 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 5.7 mt-10 -49.26 -48.45 45.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.415 -0.803 . . . . 0.0 110.368 -179.728 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.463 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.8 pt-20 -177.21 158.74 1.52 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.188 -0.945 . . . . 0.0 111.008 -179.852 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.506 HG12 ' CG1' ' A' ' 296' ' ' VAL . 57.0 mt -117.46 121.44 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.324 -0.86 . . . . 0.0 109.993 179.509 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.56 136.97 54.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.246 -0.909 . . . . 0.0 110.291 -179.792 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.552 ' CD1' HD23 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -95.98 127.85 42.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.196 -0.94 . . . . 0.0 110.378 179.966 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -139.39 113.02 8.43 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.16 -0.963 . . . . 0.0 110.399 179.746 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.472 HG12 ' HA ' ' A' ' 292' ' ' TRP . 2.3 mt -91.78 112.26 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.003 -1.061 . . . . 0.0 110.0 179.473 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.52 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 41.19 29.02 0.07 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.501 -0.749 . . . . 0.0 110.393 -179.69 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 113.15 -13.03 23.99 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.69 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.448 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 0.2 OUTLIER -88.6 110.86 21.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.306 -1.114 . . . . 0.0 110.431 -179.842 . . . . . . . . 3 3 . 1 . 022 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.518 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 5.3 p -68.66 119.33 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.172 -0.955 . . . . 0.0 110.171 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.476 ' CG2' ' O ' ' A' ' 358' ' ' ILE . 42.9 mm . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.268 -179.88 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.555 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.1 158.41 44.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.535 -0.98 . . . . 0.0 109.431 179.754 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.55 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -157.32 141.34 16.13 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.943 -1.098 . . . . 0.0 110.93 -179.488 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -140.34 122.02 15.31 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.797 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.499 HG22 ' CD1' ' A' ' 267' ' ' LEU . 50.9 t -115.39 133.14 62.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.01 -1.056 . . . . 0.0 111.559 -178.934 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.432 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.3 OUTLIER -122.16 157.19 32.08 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.734 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.567 HG21 ' CD2' ' A' ' 280' ' ' TYR . 71.6 t -143.12 147.04 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.286 -1.509 . . . . 0.0 112.251 -178.879 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.24 113.93 8.75 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.706 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 17.6 p-10 -98.81 148.21 24.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.039 -1.038 . . . . 0.0 111.718 -178.098 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.531 ' CZ2' HG23 ' A' ' 337' ' ' ILE . 39.1 p90 -134.11 19.07 3.74 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.652 -0.655 . . . . 0.0 109.453 179.14 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.43 -65.83 3.91 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -58.48 -21.43 51.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -1.133 . . . . 0.0 110.255 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.531 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.35 -179.08 46.61 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.938 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.587 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -136.76 140.73 42.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.42 -1.047 . . . . 0.0 109.983 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.52 ' HG2' ' CG1' ' A' ' 337' ' ' ILE . 3.0 mt-10 -93.66 146.58 23.72 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.466 -0.771 . . . . 0.0 110.37 -179.534 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 91.0 m-85 -140.81 84.47 1.94 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.524 -0.735 . . . . 0.0 110.405 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.8 OUTLIER -67.24 151.75 46.95 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.418 -0.801 . . . . 0.0 109.487 179.208 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.598 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 5.6 t -145.72 88.6 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.564 -0.71 . . . . 0.0 109.615 -179.537 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 267' ' ' LEU . 88.6 m -87.01 123.83 32.54 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.081 -1.012 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.585 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.85 150.51 30.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 110.408 -179.76 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.555 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -134.1 115.86 14.76 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.376 -0.827 . . . . 0.0 110.103 -179.377 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.605 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 13.2 mt -124.09 154.88 39.32 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 120.759 -1.213 . . . . 0.0 110.454 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -89.9 37.22 0.88 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.248 -0.908 . . . . 0.0 109.786 179.627 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.61 -141.86 7.71 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.512 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 1.6 tp60 -111.67 92.62 4.1 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.162 -1.199 . . . . 0.0 110.489 -179.758 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.605 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.1 m-30 -116.93 129.99 56.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.268 -0.895 . . . . 0.0 110.074 179.396 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.515 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 1.5 m-20 -64.16 103.67 0.64 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.146 -0.972 . . . . 0.0 109.557 179.549 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.581 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 55.0 p-90 -101.95 109.32 21.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.189 -0.944 . . . . 0.0 110.391 -179.756 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.58 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 3.1 m -101.04 116.18 32.23 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.463 -0.773 . . . . 0.0 109.526 179.641 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.495 HG22 ' CD2' ' A' ' 351' ' ' LEU . 20.6 t -96.67 111.1 26.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 110.487 -179.378 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.476 ' HA ' HG12 ' A' ' 320' ' ' ILE . 22.8 ttpt -87.36 147.25 25.55 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.496 -0.752 . . . . 0.0 109.024 179.0 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.555 HG11 ' CG2' ' A' ' 346' ' ' VAL . 55.6 t -146.67 105.45 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 110.702 -178.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.48 ' O ' ' N ' ' A' ' 347' ' ' GLU . 26.4 mmtt -70.93 133.51 46.47 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.15 -0.969 . . . . 0.0 109.732 179.628 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.529 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 90.7 mt -86.31 162.44 18.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.323 -0.861 . . . . 0.0 111.573 -178.93 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.542 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -71.28 173.48 4.96 Favored Pre-proline 0 N--CA 1.488 1.441 0 O-C-N 121.582 -0.699 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.501 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -67.92 82.4 0.46 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 O-C-N 123.508 1.267 . . . . 0.0 109.932 179.531 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.63 25.71 3.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.424 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.484 ' HB3' ' HB1' ' A' ' 299' ' ' ALA . . . -117.79 148.45 42.05 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -1.113 . . . . 0.0 110.144 -179.748 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.529 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.4 p -149.82 144.52 26.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 110.239 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.599 ' CG1' ' CD ' ' A' ' 312' ' ' LYS . 38.2 t -63.99 119.9 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.232 -0.918 . . . . 0.0 109.886 179.767 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -105.95 -20.35 9.41 Favored Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.818 -1.182 . . . . 0.0 110.339 -179.392 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.489 ' O ' ' N ' ' A' ' 337' ' ' ILE . 42.2 t -154.8 134.28 12.64 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.983 -1.304 . . . . 0.0 110.889 -179.695 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.493 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -149.43 176.42 10.6 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.354 -0.841 . . . . 0.0 109.773 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.467 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -166.72 158.84 13.38 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.794 -1.191 . . . . 0.0 111.719 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.483 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.8 OUTLIER 59.4 26.08 14.92 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.667 -0.646 . . . . 0.0 111.407 179.363 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.524 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 140.89 0.65 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.17 -0.956 . . . . 0.0 109.936 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.5 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.34 114.14 15.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.078 -1.014 . . . . 0.0 109.586 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.599 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 1.9 ttpp -83.01 144.6 29.84 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.695 0.76 . . . . 0.0 110.691 -179.444 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.544 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -126.85 173.84 9.27 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.412 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -137.93 105.13 5.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.448 -0.782 . . . . 0.0 110.344 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -97.17 35.78 4.27 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.442 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.4 OUTLIER 65.65 91.96 0.08 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -1.182 . . . . 0.0 110.135 -179.962 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.58 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 87.47 0.69 84.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.857 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.58 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.9 m-85 -143.28 -172.75 3.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.339 -1.095 . . . . 0.0 109.654 179.629 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.7 t -163.46 152.52 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.575 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.58 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 68.8 mt -131.99 132.17 61.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.648 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 70.8 m-85 -104.76 141.47 36.42 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.374 -0.829 . . . . 0.0 110.748 -179.725 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.503 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 0.9 OUTLIER -137.05 171.02 9.3 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 120.969 -1.082 . . . . 0.0 110.143 179.762 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.532 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.3 Cg_endo -67.29 114.68 3.33 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 O-C-N 123.822 1.433 . . . . 0.0 110.986 -179.461 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.53 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 7.3 m -65.44 -134.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.464 -0.773 . . . . 0.0 109.894 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.479 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 0.7 OUTLIER -92.09 -14.73 28.78 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.021 -1.049 . . . . 0.0 110.602 -179.697 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.463 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 26.4 p-90 -136.06 15.97 3.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.241 -0.912 . . . . 0.0 110.444 -179.841 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.53 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.5 OUTLIER -116.24 31.17 6.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.097 -1.002 . . . . 0.0 110.8 -179.481 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -114.6 -6.47 12.78 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.244 -0.91 . . . . 0.0 109.801 179.539 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.1 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.869 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.529 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 50.2 Cg_endo -75.42 5.75 4.0 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.04 1.547 . . . . 0.0 110.987 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.7 m -165.36 121.64 1.41 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 120.96 -1.087 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -143.44 112.74 6.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.139 -0.975 . . . . 0.0 110.446 -179.894 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.483 ' O ' ' HB2' ' A' ' 309' ' ' SER . 87.9 m -103.04 139.05 39.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.407 -0.808 . . . . 0.0 110.009 179.864 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.598 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 17.7 p90 -144.72 172.77 12.54 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.403 -0.81 . . . . 0.0 108.834 179.566 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.37 160.01 28.37 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 118.954 -1.594 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.679 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.0 OUTLIER -145.33 146.4 31.59 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.582 -0.952 . . . . 0.0 109.63 179.237 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.535 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.7 mp -120.85 120.25 61.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.836 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.534 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 6.0 t -96.74 146.3 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.13 -0.981 . . . . 0.0 110.621 -179.519 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -120.02 131.9 55.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.49 -0.756 . . . . 0.0 110.219 -179.935 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.912 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.542 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 2.0 mtmt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.024 0.44 . . . . 0.0 111.1 . . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.592 HG13 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -130.77 122.45 52.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.126 -0.984 . . . . 0.0 110.18 179.22 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.48 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -51.83 -45.45 63.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -0.941 . . . . 0.0 110.16 -179.703 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.456 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 6.9 pt-20 -177.03 158.27 1.52 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.253 -0.904 . . . . 0.0 110.324 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.411 HG23 HG21 ' A' ' 269' ' ' VAL . 11.5 mt -118.11 110.31 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.318 -0.864 . . . . 0.0 110.055 179.904 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.45 149.47 29.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.585 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -113.6 127.25 56.0 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.228 -0.92 . . . . 0.0 109.509 179.252 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.421 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 15.4 pt-20 -138.31 118.78 13.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.135 -0.978 . . . . 0.0 110.086 -179.797 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.515 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -97.73 104.7 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.197 -0.939 . . . . 0.0 110.351 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.488 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 1.5 m-80 35.16 30.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.057 0.455 . . . . 0.0 111.073 179.805 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 133.61 -43.41 1.27 Allowed Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.276 179.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.488 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 35.2 mm-40 -73.97 120.71 19.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.124 -1.221 . . . . 0.0 110.627 -179.505 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.499 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 12.9 p -91.3 111.51 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.066 -1.022 . . . . 0.0 110.08 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.456 HD13 HG22 ' A' ' 358' ' ' ILE . 9.4 mm . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.187 -179.837 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . 0.441 ' HA3' HD21 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 . . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.493 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.92 169.28 18.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.53 -0.983 . . . . 0.0 109.729 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.582 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.7 tm? -161.77 133.34 5.44 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.039 -1.038 . . . . 0.0 111.396 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.528 ' N ' HD21 ' A' ' 267' ' ' LEU . 0.3 OUTLIER -129.76 138.38 51.05 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.404 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 49.0 t -131.54 134.04 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.869 -1.145 . . . . 0.0 111.653 -179.3 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.24 157.08 29.89 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.705 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.574 HG22 ' CD1' ' A' ' 280' ' ' TYR . 75.7 t -141.26 145.34 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.494 -1.378 . . . . 0.0 111.879 -179.392 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.57 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.15 110.17 8.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.666 -0.646 . . . . 0.0 109.825 179.631 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.436 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.8 m-20 -96.39 128.41 43.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.167 -0.958 . . . . 0.0 111.102 -179.412 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.585 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 29.0 p90 -113.17 16.59 19.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.879 . . . . 0.0 109.762 178.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.06 -59.0 3.93 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.45 -22.01 63.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -1.143 . . . . 0.0 110.18 179.858 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.583 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.78 -178.39 40.29 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.821 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -136.56 139.37 42.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.339 -1.095 . . . . 0.0 110.167 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.585 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 3.6 mt-10 -93.58 147.53 22.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.508 -0.745 . . . . 0.0 110.11 -179.511 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.3 m-85 -141.75 82.16 1.8 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.279 -0.888 . . . . 0.0 110.432 -179.661 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.468 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.6 m-20 -67.38 146.01 54.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.509 -0.745 . . . . 0.0 109.695 179.557 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.61 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 4.8 t -139.12 88.78 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 109.931 -179.738 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 25.9 m -86.04 125.35 33.36 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.058 -1.026 . . . . 0.0 109.218 179.746 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.602 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -112.06 153.7 26.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.109 -0.994 . . . . 0.0 110.882 -179.072 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.539 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.4 OUTLIER -131.63 128.37 38.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.474 -0.766 . . . . 0.0 110.162 -179.582 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.8 mt -143.69 157.09 44.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.771 -1.206 . . . . 0.0 109.938 179.862 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -94.38 35.7 1.19 Allowed 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.401 -0.812 . . . . 0.0 109.732 179.526 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 162.21 -174.61 38.66 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.908 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mt-30 -83.93 96.3 8.78 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.308 -1.113 . . . . 0.0 110.406 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.584 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.74 153.38 32.51 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.227 -0.92 . . . . 0.0 109.749 179.586 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.543 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 53.9 m-20 -82.85 95.74 8.03 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.328 179.327 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.593 ' CZ2' ' HB2' ' A' ' 332' ' ' ALA . 55.5 p-90 -97.13 116.42 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 110.226 -179.737 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.517 ' CG2' HG22 ' A' ' 322' ' ' THR . 1.9 m -111.03 114.07 27.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.541 -0.724 . . . . 0.0 109.93 -179.83 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.529 HG22 ' CD2' ' A' ' 351' ' ' LEU . 3.4 t -96.2 111.33 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.097 -1.002 . . . . 0.0 110.205 -179.689 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.44 ' C ' HG21 ' A' ' 296' ' ' VAL . 27.3 ttmt -86.63 149.81 24.65 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.368 -0.833 . . . . 0.0 109.622 179.361 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.568 HG12 ' CG2' ' A' ' 346' ' ' VAL . 54.5 t -147.69 109.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.117 -0.99 . . . . 0.0 110.599 -179.575 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.548 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 51.9 mmtt -72.6 141.42 48.37 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.107 -0.996 . . . . 0.0 109.591 179.441 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.565 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 81.2 mt -94.03 156.2 16.72 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.26 -0.9 . . . . 0.0 111.481 -179.059 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.52 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -65.27 174.45 1.4 Allowed Pre-proline 0 C--N 1.303 -1.442 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.52 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 42.8 Cg_endo -68.74 83.42 0.53 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.531 1.28 . . . . 0.0 109.848 179.65 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.37 4.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 -179.468 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.507 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -114.69 149.41 36.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.298 -1.119 . . . . 0.0 109.753 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.538 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 18.6 p -150.69 143.46 24.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.062 . . . . 0.0 111.214 -179.796 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.535 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 58.6 t -70.89 116.46 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.56 -0.713 . . . . 0.0 110.013 179.515 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.43 -38.49 3.48 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.82 -1.181 . . . . 0.0 110.359 -179.264 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.414 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -129.94 140.33 50.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.004 -1.292 . . . . 0.0 111.139 -179.457 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.575 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 13.1 p90 -152.88 160.96 43.1 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 109.577 179.334 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -155.38 155.18 33.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.902 -1.124 . . . . 0.0 111.394 -179.48 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.466 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.9 OUTLIER 63.11 26.8 15.5 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 111.337 179.373 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.509 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.29 148.6 1.29 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.049 -1.032 . . . . 0.0 110.805 179.573 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 2.1 m-80 -77.59 114.02 16.01 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 179.259 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.575 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 23.3 ttpt -89.51 122.45 32.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.435 -0.791 . . . . 0.0 110.831 -179.57 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.568 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.9 OUTLIER -111.87 177.54 4.61 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.518 -0.739 . . . . 0.0 109.284 179.008 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -137.26 105.14 5.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.278 -0.889 . . . . 0.0 110.286 179.593 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.57 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -92.22 47.19 2.63 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.755 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 55.21 78.97 0.16 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.126 -1.22 . . . . 0.0 110.376 179.818 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.621 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.86 3.68 58.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 179.697 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.621 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.9 m-85 -144.85 -172.63 3.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.42 -1.047 . . . . 0.0 109.061 179.545 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.535 ' CG2' ' CG2' ' A' ' 304' ' ' VAL . 12.1 t -158.89 150.08 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.988 -1.07 . . . . 0.0 110.286 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.568 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 6.4 mm -114.96 151.85 16.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.104 -0.998 . . . . 0.0 110.687 -179.656 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 35.0 m-85 -131.74 112.2 12.32 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.199 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.54 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 1.7 p -113.22 -176.46 0.38 Allowed Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 120.374 -1.454 . . . . 0.0 109.591 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.54 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 45.6 Cg_endo -77.63 117.44 4.28 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.446 1.235 . . . . 0.0 111.458 -178.502 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.507 HG11 ' CA ' ' A' ' 310' ' ' ALA . 3.7 m -53.58 -105.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.424 -0.797 . . . . 0.0 110.592 179.905 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.448 ' O ' ' HE3' ' A' ' 328' ' ' LYS . 14.5 m -133.79 -12.37 2.61 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.691 -1.256 . . . . 0.0 111.428 -179.448 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.609 ' CE3' ' HB3' ' A' ' 327' ' ' ASN . 2.0 p-90 -126.47 -25.6 3.43 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.776 -1.202 . . . . 0.0 111.228 -179.586 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.609 ' HB3' ' CE3' ' A' ' 326' ' ' TRP . 0.0 OUTLIER -96.0 36.66 1.29 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.762 -1.211 . . . . 0.0 110.963 -179.697 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -99.71 -6.23 27.46 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.157 -0.964 . . . . 0.0 108.736 178.179 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.469 ' HA2' ' HA ' ' A' ' 289' ' ' GLN . . . -61.55 -138.38 0.01 OUTLIER Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.474 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.541 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.0 Cg_endo -73.01 -54.62 0.11 Allowed 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 124.205 1.634 . . . . 0.0 111.054 -179.721 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -102.61 140.25 37.13 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.156 -0.965 . . . . 0.0 110.77 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.593 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -152.26 107.77 3.31 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 53.8 m -105.41 135.9 45.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.907 -1.121 . . . . 0.0 110.166 179.67 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.61 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 13.0 p90 -145.32 174.6 10.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.631 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.509 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.26 158.08 27.75 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.659 -1.734 . . . . 0.0 110.435 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.684 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -143.42 146.5 33.51 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.669 -0.901 . . . . 0.0 109.33 179.252 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.539 HG23 ' CZ2' ' A' ' 274' ' ' TRP . 1.6 mp -119.74 121.31 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.968 -1.083 . . . . 0.0 109.831 179.904 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.565 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.5 t -96.6 145.92 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.184 -0.947 . . . . 0.0 109.634 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -121.33 135.43 55.09 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 110.905 -179.234 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.265 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.735 . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.531 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.092 0.473 . . . . 0.0 111.187 . . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.58 HG11 ' CE1' ' A' ' 280' ' ' TYR . 7.4 p -126.53 119.05 52.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.911 -1.118 . . . . 0.0 110.241 179.378 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.474 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 4.1 mm-40 -49.67 -44.56 47.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -0.91 . . . . 0.0 110.523 -179.533 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.456 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.1 pt-20 -176.68 158.85 1.76 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.09 -1.006 . . . . 0.0 110.718 -179.713 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.478 ' CG2' HG22 ' A' ' 296' ' ' VAL . 29.6 mt -124.42 110.17 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.095 -1.003 . . . . 0.0 110.228 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.67 160.05 19.8 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.415 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.602 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.52 129.72 54.83 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.906 . . . . 0.0 110.554 -179.903 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.9 tt0 -139.32 118.35 12.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.824 . . . . 0.0 109.456 179.405 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.543 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.08 100.66 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.892 -1.13 . . . . 0.0 110.399 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' A' ' 353' ' ' ILE . 0.9 OUTLIER 38.27 40.08 0.32 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.949 -0.47 . . . . 0.0 111.396 179.492 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.44 ' O ' ' CD ' ' A' ' 356' ' ' GLN . . . 113.06 23.37 5.27 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.793 179.056 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.477 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 6.2 mm100 -141.46 101.47 4.0 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.015 -1.285 . . . . 0.0 110.238 179.661 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 8.5 p -65.7 136.35 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.252 -0.905 . . . . 0.0 110.552 -179.827 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.465 HD11 ' O ' ' A' ' 357' ' ' VAL . 22.9 mm . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.215 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.247 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.564 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -138.6 165.86 25.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.602 -0.94 . . . . 0.0 109.593 179.908 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.555 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -161.63 141.35 10.25 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.94 -1.104 . . . . 0.0 111.436 -179.554 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.49 ' CG ' ' HB ' ' A' ' 283' ' ' THR . 0.2 OUTLIER -139.48 149.5 44.06 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.853 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 39.8 t -138.19 137.9 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.694 -1.254 . . . . 0.0 111.654 -179.337 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.439 ' C ' HG22 ' A' ' 271' ' ' VAL . 3.2 mmtp -125.27 156.93 37.81 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.111 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.558 HG23 ' CD2' ' A' ' 280' ' ' TYR . 69.1 t -145.07 145.84 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 120.374 -1.454 . . . . 0.0 112.15 -179.193 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.533 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.8 112.56 7.59 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.796 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.52 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.1 p-10 -97.37 144.84 26.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.955 -1.091 . . . . 0.0 111.602 -178.338 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.535 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 36.1 p90 -129.9 21.54 5.41 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.472 0.654 . . . . 0.0 109.681 179.281 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.24 -68.53 3.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.495 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 8.1 t -56.93 -23.73 47.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.144 -1.209 . . . . 0.0 110.35 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . . . . . . . . . . . -174.46 -170.02 37.19 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.387 -1.387 . . . . 0.0 109.987 179.918 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.585 ' HB3' ' CZ ' ' A' ' 280' ' ' TYR . . . -141.88 143.78 33.5 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.337 -1.096 . . . . 0.0 110.514 -179.905 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.541 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 4.4 mt-10 -94.87 147.34 23.47 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.412 -0.805 . . . . 0.0 109.904 -179.853 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.658 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 88.1 m-85 -142.91 90.27 2.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.396 -0.815 . . . . 0.0 110.514 -179.63 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.464 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -74.16 153.02 39.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.365 -0.835 . . . . 0.0 110.117 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.6 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.3 t -145.12 90.61 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.83 -179.665 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.503 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 7.5 m -87.04 122.61 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 0.0 110.457 -179.746 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.609 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -108.14 151.09 26.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 110.122 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.564 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -134.58 106.57 7.06 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.211 -0.93 . . . . 0.0 110.646 -179.036 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.605 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.6 mt -113.07 173.9 6.16 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.666 -1.272 . . . . 0.0 110.006 179.671 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -109.5 30.19 6.87 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.434 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 170.19 -102.79 0.18 Allowed Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.357 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.471 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.1 OUTLIER -150.7 105.38 3.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -1.181 . . . . 0.0 110.463 -179.395 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.605 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -136.33 132.74 36.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 110.025 179.596 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.46 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 0.2 OUTLIER -61.04 100.25 0.11 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.289 -0.882 . . . . 0.0 109.366 179.337 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.607 ' CZ2' ' CB ' ' A' ' 332' ' ' ALA . 56.4 p-90 -98.34 111.07 23.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.345 -0.847 . . . . 0.0 110.447 -179.637 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.546 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 4.4 m -105.37 114.58 28.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.46 HG21 ' CE2' ' A' ' 334' ' ' PHE . 3.5 t -96.92 110.74 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.145 -0.972 . . . . 0.0 110.085 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.482 ' HG3' HD12 ' A' ' 320' ' ' ILE . 18.8 ttpt -87.41 149.01 24.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.227 -0.92 . . . . 0.0 109.362 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.576 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 71.0 t -145.78 110.53 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.193 -0.942 . . . . 0.0 110.745 -179.325 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.515 ' O ' ' CG2' ' A' ' 346' ' ' VAL . 29.3 mmtp -71.51 132.71 45.1 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.246 -0.909 . . . . 0.0 109.73 179.343 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.569 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 83.0 mt -85.42 159.06 20.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.375 -0.828 . . . . 0.0 111.445 -179.036 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.548 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -62.94 174.77 0.77 Allowed Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.699 -0.626 . . . . 0.0 109.454 179.08 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.488 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -69.4 78.88 0.86 Allowed 'Trans proline' 0 C--N 1.304 -1.812 0 O-C-N 123.575 1.303 . . . . 0.0 109.754 179.451 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.19 24.58 3.81 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.166 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.522 ' CB ' ' HB2' ' A' ' 299' ' ' ALA . . . -112.22 152.93 27.84 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -1.152 . . . . 0.0 110.338 -179.479 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.521 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 21.5 p -153.31 143.61 22.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.235 -0.915 . . . . 0.0 110.502 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.529 ' CG1' ' HD2' ' A' ' 312' ' ' LYS . 76.4 t -64.72 139.75 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.463 -0.773 . . . . 0.0 110.215 179.881 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -123.28 -33.69 0.81 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.47 ' O ' HD13 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -138.23 124.42 20.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -1.19 . . . . 0.0 110.98 -179.667 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.552 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 52.9 p90 -141.08 156.37 46.0 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.323 -0.861 . . . . 0.0 109.714 179.362 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -150.0 157.31 43.02 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.955 -1.091 . . . . 0.0 111.368 -179.288 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.494 ' HB3' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 64.57 21.66 12.48 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.609 -0.682 . . . . 0.0 110.906 179.803 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.514 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 150.2 1.35 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.272 -0.893 . . . . 0.0 110.394 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -83.84 125.34 31.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.119 -0.988 . . . . 0.0 109.586 179.485 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.552 ' HD3' ' CD2' ' A' ' 307' ' ' PHE . 3.7 ttpt -92.85 135.91 33.72 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.838 0.828 . . . . 0.0 110.751 -179.582 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.683 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.3 OUTLIER -122.37 179.46 4.56 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.63 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.413 ' HG2' HG21 ' A' ' 319' ' ' VAL . 3.5 mt-10 -142.49 113.07 7.31 Favored 'General case' 0 N--CA 1.492 1.634 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.444 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.09 49.71 1.05 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.83 79.37 0.2 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -1.167 . . . . 0.0 110.093 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.595 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.95 5.34 66.24 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.778 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.595 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 5.4 m-85 -138.88 -174.31 3.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.401 -1.058 . . . . 0.0 109.167 179.449 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 5.7 t -163.14 156.96 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.287 -0.883 . . . . 0.0 109.767 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.683 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 12.8 mm -127.08 148.91 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.074 -1.016 . . . . 0.0 111.361 -179.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.675 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 86.0 m-85 -124.85 122.01 36.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.446 -0.784 . . . . 0.0 109.703 179.01 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.521 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 5.5 p -124.52 169.01 11.59 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 120.738 -1.226 . . . . 0.0 109.953 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.533 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 37.3 Cg_endo -63.89 112.38 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.769 1.405 . . . . 0.0 111.415 -179.319 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.534 HG22 ' ND2' ' A' ' 327' ' ' ASN . 3.6 m -50.4 -58.24 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.545 -0.722 . . . . 0.0 110.746 179.74 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 178.65 -26.11 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.081 -1.012 . . . . 0.0 110.947 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.505 ' NE1' HG21 ' A' ' 324' ' ' VAL . 6.3 p-90 -110.43 -27.03 9.22 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.853 -1.154 . . . . 0.0 110.98 -179.79 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.551 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 0.0 OUTLIER -83.34 14.56 3.52 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 120.979 -1.076 . . . . 0.0 111.06 179.934 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 11.4 mtmt -77.12 -8.58 57.74 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.174 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.18 -153.14 0.01 OUTLIER Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 -179.322 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -76.12 9.61 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 124.267 1.667 . . . . 0.0 111.153 -179.581 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.47 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.5 m -164.87 135.15 3.86 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.607 ' CB ' ' CZ2' ' A' ' 292' ' ' TRP . . . -147.87 104.19 3.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.171 -0.956 . . . . 0.0 110.378 -179.463 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.503 ' OG1' ' CG2' ' A' ' 283' ' ' THR . 4.8 m -101.12 133.22 45.98 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.287 -0.883 . . . . 0.0 110.313 179.883 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.601 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 24.2 p90 -144.2 168.21 20.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 108.957 179.553 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -141.65 165.3 26.5 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.078 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.675 ' CB ' ' CZ ' ' A' ' 321' ' ' PHE . 0.5 OUTLIER -150.52 143.88 24.98 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.689 -0.889 . . . . 0.0 109.379 179.191 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.543 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.7 mp -119.51 118.79 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.028 -1.045 . . . . 0.0 110.223 -179.67 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.569 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.7 t -97.64 153.18 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.163 -0.96 . . . . 0.0 110.153 -179.795 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.56 131.65 53.93 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 110.212 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.403 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -179.98 . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.548 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 121.475 0.655 . . . . 0.0 110.275 . . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.595 HG13 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -134.7 117.09 22.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.406 -0.809 . . . . 0.0 110.13 179.739 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.466 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -45.66 -45.84 14.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 110.455 -179.61 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.468 ' OE2' ' HG3' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -176.79 158.71 1.68 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.072 -1.017 . . . . 0.0 110.673 -179.713 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.475 HG12 ' CG1' ' A' ' 296' ' ' VAL . 65.1 mt -120.76 119.39 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.118 -0.989 . . . . 0.0 110.304 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.33 159.89 24.12 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.341 -0.85 . . . . 0.0 110.173 179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.609 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -120.99 129.7 53.52 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.887 . . . . 0.0 110.361 -179.852 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.461 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -139.29 122.87 17.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.13 -0.981 . . . . 0.0 110.103 179.58 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.473 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 1.2 mt -97.15 106.16 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.031 -1.043 . . . . 0.0 109.742 179.474 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.46 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 41.06 29.25 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.565 -0.71 . . . . 0.0 110.649 -179.752 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.81 -22.83 7.17 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.363 179.379 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.473 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 40.5 mm-40 -87.96 110.95 20.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.004 -1.292 . . . . 0.0 110.552 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.469 ' O ' HD11 ' A' ' 358' ' ' ILE . 6.2 p -76.81 142.02 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.284 -0.885 . . . . 0.0 110.527 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.469 HD11 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.494 1.729 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.139 179.801 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.574 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.3 OUTLIER -139.53 164.4 30.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.401 -1.058 . . . . 0.0 109.765 179.848 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.538 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.0 tm? -161.31 133.76 6.0 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.047 -1.033 . . . . 0.0 111.003 -179.044 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -136.77 131.45 33.4 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.532 -0.73 . . . . 0.0 109.242 179.476 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.46 ' CG1' ' O ' ' A' ' 281' ' ' ASP . 89.4 t -126.38 143.11 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.79 -1.194 . . . . 0.0 111.653 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.451 ' N ' HG13 ' A' ' 269' ' ' VAL . 1.7 ttpt -126.98 157.38 39.69 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.996 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.583 ' CG2' ' CD1' ' A' ' 280' ' ' TYR . 91.7 t -139.74 146.97 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.298 -1.501 . . . . 0.0 112.375 -179.171 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.542 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.2 109.43 6.46 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.127 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 p30 -96.14 146.75 24.41 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.008 -1.057 . . . . 0.0 111.189 -178.863 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.588 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 35.4 p90 -132.02 17.85 4.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.777 179.32 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.5 -62.78 4.0 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.947 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.439 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.4 t -63.68 -21.24 66.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.383 -1.069 . . . . 0.0 110.239 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -174.31 179.92 45.34 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.543 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.22 141.19 47.93 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.352 -1.087 . . . . 0.0 110.245 179.941 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.588 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 9.3 mt-10 -96.84 147.65 23.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.346 -0.846 . . . . 0.0 110.159 -179.683 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.655 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 98.1 m-85 -143.51 90.2 2.14 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.214 -0.929 . . . . 0.0 110.84 -179.776 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.46 ' O ' ' CG1' ' A' ' 269' ' ' VAL . 6.6 t0 -70.87 152.75 43.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.384 -0.823 . . . . 0.0 109.555 179.237 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.644 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 2.9 t -147.26 89.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 110.205 -179.535 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.448 HG23 ' OG1' ' A' ' 333' ' ' THR . 93.1 m -86.97 121.96 30.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.08 -1.013 . . . . 0.0 109.615 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.594 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -109.7 150.89 27.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 110.754 -179.323 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.574 ' ND2' ' HB3' ' A' ' 266' ' ' SER . 0.4 OUTLIER -131.25 137.06 48.72 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.468 -0.77 . . . . 0.0 109.934 -179.767 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.585 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 16.8 mt -142.32 159.87 41.37 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.926 -1.109 . . . . 0.0 109.513 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.61 34.66 0.82 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.296 -0.877 . . . . 0.0 110.458 -179.538 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.474 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 153.3 -97.47 0.17 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.052 -1.546 . . . . 0.0 110.358 179.902 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.474 ' HG2' ' O ' ' A' ' 288' ' ' GLY . 11.7 mm-40 -144.3 105.26 4.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.25 -1.147 . . . . 0.0 110.561 -179.577 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.616 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 4.4 m-85 -128.9 130.29 46.63 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.338 -0.851 . . . . 0.0 109.671 179.645 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.464 ' O ' HG23 ' A' ' 353' ' ' ILE . 42.5 m-20 -65.61 100.11 0.49 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.782 -1.199 . . . . 0.0 109.084 179.19 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.593 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 57.4 p-90 -100.12 109.67 21.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 111.127 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.556 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 2.0 m -103.78 114.83 29.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.466 -0.772 . . . . 0.0 109.108 179.003 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.483 HG21 ' CD2' ' A' ' 351' ' ' LEU . 3.3 t -95.95 111.31 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 110.568 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.453 ' O ' HG23 ' A' ' 296' ' ' VAL . 5.7 ttpt -85.71 145.16 27.41 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.471 -0.768 . . . . 0.0 109.327 179.17 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.563 HG11 ' CG2' ' A' ' 346' ' ' VAL . 79.7 t -144.36 106.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 110.177 -179.49 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 347' ' ' GLU . 43.4 mmtt -70.02 133.9 47.71 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.108 -0.995 . . . . 0.0 109.168 179.537 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.555 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 66.8 mt -90.32 157.24 17.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 111.392 -178.826 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.497 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.22 173.25 2.35 Favored Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.806 -0.558 . . . . 0.0 109.533 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.489 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.15 83.52 0.35 Allowed 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.621 1.327 . . . . 0.0 109.826 179.627 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.6 21.14 5.87 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -179.359 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -113.29 140.89 47.61 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.33 -1.1 . . . . 0.0 109.951 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.476 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 22.2 p -145.2 146.11 31.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.958 . . . . 0.0 110.628 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.519 HG21 ' CB ' ' A' ' 319' ' ' VAL . 53.3 t -70.11 122.82 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.148 -0.97 . . . . 0.0 109.958 179.695 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.08 -28.32 4.19 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.034 -1.226 . . . . 0.0 110.034 -179.592 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.45 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 49.4 m -137.46 130.26 30.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.973 -1.31 . . . . 0.0 110.85 -179.637 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.533 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 50.2 p90 -150.38 160.09 43.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.491 -0.756 . . . . 0.0 109.512 179.369 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.466 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -151.85 159.46 43.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.89 -1.131 . . . . 0.0 111.284 -179.333 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.487 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.9 OUTLIER 56.91 28.34 14.46 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.617 -0.677 . . . . 0.0 110.683 179.855 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.53 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.11 138.23 0.58 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.161 -0.962 . . . . 0.0 110.22 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.503 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.9 112.91 15.27 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.454 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.533 ' HD3' ' CD2' ' A' ' 307' ' ' PHE . 4.0 ttpt -83.16 137.65 33.97 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.658 0.742 . . . . 0.0 110.8 -179.25 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.1 OUTLIER -120.64 170.61 9.26 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.135 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.436 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 15.8 mt-10 -143.24 95.97 2.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.531 -0.731 . . . . 0.0 109.688 179.588 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.97 -82.9 0.36 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.804 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.442 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 5.4 t-20 -154.38 81.15 1.12 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.467 -1.019 . . . . 0.0 108.59 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.608 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.42 17.87 56.29 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 107.993 -2.043 . . . . 0.0 107.993 -178.009 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.608 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.7 m-85 -144.45 -171.84 3.68 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 4.0 t -163.26 153.72 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.231 -0.918 . . . . 0.0 109.322 178.502 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.556 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 42.1 mt -132.45 133.81 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.78 -1.2 . . . . 0.0 111.639 -179.313 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.645 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 82.6 m-85 -105.9 139.09 41.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.459 -0.775 . . . . 0.0 110.651 -179.791 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.553 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 1.1 p -134.62 169.06 14.83 Favored Pre-proline 0 C--N 1.3 -1.578 0 O-C-N 120.912 -1.117 . . . . 0.0 110.324 179.154 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.533 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 39.7 Cg_endo -65.67 112.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.061 1.559 . . . . 0.0 111.045 -179.259 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.517 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 32.9 m -60.83 -127.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.422 -0.799 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 18.9 m -101.9 -17.02 16.35 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.739 -1.226 . . . . 0.0 111.167 -179.361 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 22.5 p-90 -129.86 -3.85 4.62 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.943 -1.098 . . . . 0.0 110.649 -179.688 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.517 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 2.6 t30 -98.64 45.04 1.01 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.233 -0.917 . . . . 0.0 110.473 -179.476 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.32 -4.48 8.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.345 -0.847 . . . . 0.0 109.77 179.829 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.81 -159.92 0.08 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.406 ' C ' ' OG1' ' A' ' 331' ' ' THR . 46.8 Cg_endo -72.9 2.64 5.18 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 124.191 1.627 . . . . 0.0 110.829 -179.852 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.406 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.8 m -162.56 114.87 1.63 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -136.53 115.65 12.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 110.069 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 309' ' ' SER . 99.9 m -105.78 147.5 28.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 110.395 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.644 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 6.4 p90 -150.76 174.45 13.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.415 -0.803 . . . . 0.0 109.188 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.2 162.24 28.94 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.209 -179.564 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.655 ' CE2' ' CB ' ' A' ' 280' ' ' TYR . 0.4 OUTLIER -151.37 143.8 24.19 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -1.077 . . . . 0.0 109.994 179.554 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.543 HD13 ' N ' ' A' ' 337' ' ' ILE . 1.7 mp -119.06 119.73 61.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.171 -0.956 . . . . 0.0 109.744 179.437 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.555 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.6 t -96.23 139.79 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.136 -0.978 . . . . 0.0 110.111 -179.661 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -111.1 142.2 43.58 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.384 -0.822 . . . . 0.0 110.422 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.906 . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.531 ' O ' ' CB ' ' A' ' 302' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 121.142 0.496 . . . . 0.0 111.114 . . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.573 HG11 ' CE1' ' A' ' 280' ' ' TYR . 7.1 p -126.71 113.84 34.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 121.056 -1.027 . . . . 0.0 110.136 179.375 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -45.36 -47.07 13.4 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 110.47 -179.564 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.55 158.76 1.81 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.209 -0.932 . . . . 0.0 110.263 -179.838 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.465 HG12 ' CG2' ' A' ' 296' ' ' VAL . 28.2 mt -121.93 113.22 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.116 -0.99 . . . . 0.0 110.13 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -117.76 133.71 55.66 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.25 -0.907 . . . . 0.0 110.077 -179.934 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.594 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -90.85 132.46 35.88 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.168 -0.958 . . . . 0.0 109.774 179.529 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 3.7 tt0 -138.01 111.72 8.24 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.38 -0.825 . . . . 0.0 109.956 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.483 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 2.1 mt -94.91 114.0 30.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.21 -0.931 . . . . 0.0 110.42 -179.851 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.44 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.85 31.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.758 -0.589 . . . . 0.0 111.136 179.75 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.78 -15.62 19.16 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.736 -1.221 . . . . 0.0 110.306 179.415 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.483 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 20.9 mm-40 -93.17 112.03 23.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.084 -1.245 . . . . 0.0 110.424 -179.758 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.485 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 1.2 t -76.35 125.63 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.236 -0.915 . . . . 0.0 109.961 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.415 ' N ' ' O ' ' A' ' 351' ' ' LEU . 10.2 mm . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.098 179.802 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.549 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.6 161.64 37.03 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -1.156 . . . . 0.0 110.006 179.823 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.546 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.5 tm? -161.32 137.17 7.98 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.613 -179.546 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.515 ' N ' HD21 ' A' ' 267' ' ' LEU . 1.3 mm-40 -134.03 147.14 50.92 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.799 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.412 HG13 ' N ' ' A' ' 270' ' ' LYS . 59.9 t -138.55 144.43 30.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.66 -1.275 . . . . 0.0 111.769 -179.091 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.412 ' N ' HG13 ' A' ' 269' ' ' VAL . 0.0 OUTLIER -128.88 157.38 41.71 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.902 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 92.7 t -144.17 146.13 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.28 -1.512 . . . . 0.0 112.199 -179.492 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.576 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.63 108.76 7.21 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.182 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.445 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.0 m-20 -95.26 140.38 30.24 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.278 -0.889 . . . . 0.0 111.277 -179.003 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.576 ' CZ3' ' O ' ' A' ' 272' ' ' ASN . 40.9 p90 -131.94 20.42 4.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.431 -0.793 . . . . 0.0 109.868 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.59 -60.4 4.87 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.899 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -65.8 -18.94 65.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.369 -1.077 . . . . 0.0 110.293 -179.86 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.568 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -179.38 175.85 47.35 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.513 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -131.26 140.98 49.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -1.186 . . . . 0.0 110.119 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.568 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 5.4 mt-10 -93.28 147.1 23.21 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.424 -0.798 . . . . 0.0 109.99 -179.969 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.7 m-85 -142.11 86.39 1.97 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.929 -179.412 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.441 ' C ' ' CG2' ' A' ' 282' ' ' VAL . 12.1 t70 -69.67 152.6 44.5 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.86 . . . . 0.0 109.464 179.206 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.562 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 2.7 t -148.39 90.17 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.283 -0.885 . . . . 0.0 110.177 -179.51 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 56.6 m -86.99 122.31 30.65 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.1 -1.0 . . . . 0.0 109.692 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.602 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.3 OUTLIER -110.75 150.78 28.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.952 . . . . 0.0 110.8 -179.357 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.554 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.3 OUTLIER -131.43 138.42 49.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.469 -0.769 . . . . 0.0 109.446 179.949 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.613 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 18.8 mt -140.46 163.4 32.93 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.77 -1.206 . . . . 0.0 109.824 -179.816 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.12 30.61 0.59 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.228 -0.92 . . . . 0.0 111.086 -178.95 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.504 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 147.26 -75.39 0.28 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 118.952 -1.594 . . . . 0.0 110.479 179.616 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.558 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.7 tt0 -160.26 106.88 1.56 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.07 -1.253 . . . . 0.0 110.85 -179.371 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.619 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 5.0 m-85 -135.38 135.35 40.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 179.384 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.558 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 1.0 OUTLIER -66.84 102.77 1.0 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.987 -1.071 . . . . 0.0 109.515 179.425 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.602 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 53.9 p-90 -101.18 111.32 23.51 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 110.645 -179.53 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.588 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 6.6 m -104.48 115.66 30.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.532 -0.73 . . . . 0.0 109.726 179.692 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.492 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.9 t -97.05 111.41 26.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.864 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.511 ' HA ' ' CD1' ' A' ' 320' ' ' ILE . 27.1 ttpt -84.99 144.1 28.52 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.387 -0.821 . . . . 0.0 109.511 179.464 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.548 HG12 ' CZ ' ' A' ' 336' ' ' PHE . 99.8 t -141.32 104.98 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.249 -0.907 . . . . 0.0 110.823 -179.179 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 38.0 mmtt -69.8 131.11 44.0 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.078 -1.014 . . . . 0.0 109.066 179.226 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.555 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 93.6 mt -87.85 148.77 24.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.371 -0.831 . . . . 0.0 111.166 -178.895 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.531 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -58.66 172.22 0.54 Allowed Pre-proline 0 C--N 1.303 -1.432 0 O-C-N 121.624 -0.672 . . . . 0.0 109.306 179.093 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.489 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -67.32 80.57 0.41 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.575 1.303 . . . . 0.0 110.111 179.777 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.64 23.29 4.08 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 -179.546 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.508 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -113.58 148.54 35.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.365 -1.08 . . . . 0.0 110.376 -179.534 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.555 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 37.4 p -150.7 144.61 25.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.195 -0.94 . . . . 0.0 110.399 179.789 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.548 HG22 ' CG2' ' A' ' 319' ' ' VAL . 21.3 t -64.02 116.04 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.066 -1.021 . . . . 0.0 110.04 179.723 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -102.35 -20.51 12.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.486 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -147.36 154.44 40.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.26 -1.141 . . . . 0.0 110.317 -179.784 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.507 ' CG ' ' NZ ' ' A' ' 312' ' ' LYS . 25.1 p90 -178.54 175.52 1.11 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.594 -0.691 . . . . 0.0 109.738 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.459 ' O ' ' CB ' ' A' ' 309' ' ' SER . 1.1 p90 -170.0 151.11 3.95 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.991 -1.068 . . . . 0.0 111.637 -179.437 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.503 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 67.93 30.22 6.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.684 -0.635 . . . . 0.0 111.45 179.173 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.514 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 137.48 0.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.144 -0.972 . . . . 0.0 110.168 179.57 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.52 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.19 129.09 35.49 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.073 -1.017 . . . . 0.0 109.353 179.621 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.56 ' CE ' HG13 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -92.07 149.15 21.67 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.907 0.861 . . . . 0.0 111.642 -178.622 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.519 ' N ' ' HG3' ' A' ' 312' ' ' LYS . 0.0 OUTLIER -133.34 171.39 14.11 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.306 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.441 ' HA ' HG23 ' A' ' 319' ' ' VAL . 35.9 mt-10 -137.09 114.85 11.28 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.046 -1.034 . . . . 0.0 110.858 -179.473 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -103.96 42.76 1.81 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.454 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.45 83.48 0.07 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -1.113 . . . . 0.0 110.066 -179.788 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.34 -0.55 57.1 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.89 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.61 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.5 m-85 -145.6 -170.9 3.56 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.463 -1.022 . . . . 0.0 109.157 179.365 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.56 HG13 ' CE ' ' A' ' 312' ' ' LYS . 2.6 t -163.82 161.99 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.366 -0.834 . . . . 0.0 109.347 179.427 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.588 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 28.5 mm -131.02 150.17 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.876 -1.14 . . . . 0.0 111.468 -179.514 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.601 ' CE2' ' HB3' ' A' ' 336' ' ' PHE . 96.5 m-85 -120.42 139.12 53.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.549 -0.719 . . . . 0.0 109.38 178.908 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.52 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.0 OUTLIER -140.66 170.74 8.89 Favored Pre-proline 0 C--N 1.302 -1.461 0 O-C-N 120.79 -1.194 . . . . 0.0 110.244 -179.998 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.504 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.1 Cg_endo -65.72 122.01 9.53 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 123.98 1.516 . . . . 0.0 110.692 -179.505 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.459 ' HA ' ' ND2' ' A' ' 311' ' ' ASN . 12.8 m -76.16 -136.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.384 -0.823 . . . . 0.0 110.363 -179.752 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.411 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 0.4 OUTLIER -88.45 -12.63 42.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.209 -0.932 . . . . 0.0 110.886 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 20.9 p-90 -140.17 13.39 2.41 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.95 -1.094 . . . . 0.0 111.118 -179.475 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.443 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.1 t30 -119.99 50.59 1.27 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.886 -1.134 . . . . 0.0 110.776 -179.651 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.481 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.1 OUTLIER -130.46 -0.95 4.44 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.257 -0.902 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -66.58 -153.72 0.25 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.791 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.504 ' N ' ' O ' ' A' ' 288' ' ' GLY . 46.5 Cg_endo -73.97 3.08 5.35 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 124.12 1.59 . . . . 0.0 110.653 -179.858 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.432 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.9 m -163.93 117.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.197 -0.94 . . . . 0.0 110.244 179.944 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -139.43 111.93 7.71 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.878 . . . . 0.0 110.12 179.943 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.512 HG23 ' N ' ' A' ' 334' ' ' PHE . 7.0 m -101.09 151.78 21.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.181 -0.949 . . . . 0.0 110.275 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.562 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 8.7 p90 -159.03 155.19 27.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.519 -0.738 . . . . 0.0 109.156 179.712 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -133.24 165.96 23.89 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.264 -1.446 . . . . 0.0 110.035 -179.634 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.688 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.4 OUTLIER -152.44 147.04 25.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -1.171 . . . . 0.0 110.288 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.538 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.7 mp -121.74 119.56 59.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.049 -1.032 . . . . 0.0 109.88 179.687 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.6 t -96.43 147.94 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.163 -0.961 . . . . 0.0 110.13 -179.907 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.14 132.93 56.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.375 -0.828 . . . . 0.0 110.142 -179.867 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.445 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.493 2.453 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 179.943 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.531 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 2.3 mtmt . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 121.522 0.677 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.532 ' CG2' HG13 ' A' ' 296' ' ' VAL . 4.5 p -127.17 113.28 31.65 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.497 -0.752 . . . . 0.0 109.566 179.429 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.18 -48.33 4.81 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.269 -0.894 . . . . 0.0 110.129 -179.44 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -177.63 149.9 0.64 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.31 -0.869 . . . . 0.0 110.468 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.454 HG12 HG13 ' A' ' 296' ' ' VAL . 12.9 mt -113.62 127.92 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.111 -0.993 . . . . 0.0 110.207 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -132.21 140.51 48.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.959 -179.81 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.599 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -99.44 130.75 45.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.055 -1.028 . . . . 0.0 110.395 -179.93 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.454 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.8 tt0 -138.28 113.87 9.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.308 -0.87 . . . . 0.0 109.788 179.645 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.489 ' O ' ' N ' ' A' ' 355' ' ' GLY . 2.2 mt -91.77 110.51 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.121 -0.987 . . . . 0.0 110.249 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.558 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 37.84 28.51 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.802 -0.561 . . . . 0.0 110.952 179.885 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 123.22 -20.94 7.43 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.739 -1.219 . . . . 0.0 110.298 179.451 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 1.4 mp0 -86.53 112.66 21.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.03 -1.276 . . . . 0.0 110.58 -179.756 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.501 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 7.3 p -79.0 118.13 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.323 -0.861 . . . . 0.0 110.169 179.797 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.411 HD12 HG21 ' A' ' 358' ' ' ILE . 12.7 mm . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.214 -179.942 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.577 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.02 152.19 51.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.221 -1.164 . . . . 0.0 109.908 179.866 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.497 HD21 ' CG1' ' A' ' 282' ' ' VAL . 0.0 OUTLIER -148.59 117.71 6.81 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.198 -0.939 . . . . 0.0 110.962 -179.592 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -118.36 116.63 27.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.649 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 52.0 t -109.37 144.52 17.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.863 -1.148 . . . . 0.0 112.154 -178.305 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 9.1 mtmt -128.59 156.42 43.38 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.618 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.569 HG12 ' CE1' ' A' ' 280' ' ' TYR . 99.9 t -145.29 147.03 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.288 -1.508 . . . . 0.0 112.29 -179.068 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.537 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -137.9 111.08 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.757 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.9 p-10 -100.5 140.02 35.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.882 -1.136 . . . . 0.0 111.407 -178.437 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.544 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 32.4 p90 -123.98 20.64 9.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.82 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.72 -68.01 3.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 7.8 m -61.06 -22.02 64.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.261 -1.141 . . . . 0.0 110.485 -179.833 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -168.32 176.74 42.67 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.641 -1.266 . . . . 0.0 110.016 -179.936 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.572 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -135.06 143.54 46.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.381 -1.07 . . . . 0.0 109.864 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.519 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 4.1 mt-10 -100.71 145.63 28.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.271 -0.893 . . . . 0.0 110.042 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.695 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -139.12 90.96 2.47 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.362 -0.836 . . . . 0.0 110.545 -179.701 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.563 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -79.58 118.64 21.61 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.534 -0.729 . . . . 0.0 110.136 179.657 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.602 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 8.8 t -107.41 95.82 4.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.63 -0.669 . . . . 0.0 110.041 179.747 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.422 ' O ' HD22 ' A' ' 267' ' ' LEU . 5.2 m -86.5 120.17 27.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.131 -0.98 . . . . 0.0 109.437 179.551 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.581 HD13 ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -109.1 148.9 30.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 110.991 -179.042 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.577 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.04 107.13 7.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.618 -0.676 . . . . 0.0 109.679 -179.659 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.54 ' N ' ' O ' ' A' ' 330' ' ' PRO . 11.8 mt -114.67 156.57 24.51 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.837 -1.164 . . . . 0.0 110.243 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . 0.432 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 20.1 m-20 -86.7 33.86 0.65 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.513 -0.742 . . . . 0.0 110.413 -179.811 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.514 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.87 -154.04 25.07 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 119.499 -1.334 . . . . 0.0 109.79 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.523 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -101.89 93.85 5.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.173 -1.192 . . . . 0.0 110.608 -179.708 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.523 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 2.3 m-85 -118.12 163.49 16.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.79 179.627 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.519 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 15.2 m-20 -90.26 98.97 12.08 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.249 -0.907 . . . . 0.0 109.43 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.581 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.0 p-90 -99.82 117.26 33.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.192 -0.943 . . . . 0.0 110.749 -179.369 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.564 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 89.2 m -110.86 114.65 28.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.482 -0.761 . . . . 0.0 109.589 179.665 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.484 HG23 HD21 ' A' ' 351' ' ' LEU . 3.2 t -97.18 111.46 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.16 -0.963 . . . . 0.0 110.633 -179.284 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.537 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 18.3 ttmt -86.51 149.89 24.65 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.617 179.299 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.602 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 90.4 t -143.95 108.36 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.054 -1.029 . . . . 0.0 110.672 -179.459 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.551 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 14.5 mmtp -70.5 133.86 47.19 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.27 -0.894 . . . . 0.0 109.318 179.411 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.59 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 85.0 mt -89.71 158.13 17.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -0.788 . . . . 0.0 111.717 -178.727 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.557 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -64.78 173.32 1.69 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.637 -0.665 . . . . 0.0 109.44 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.64 78.6 0.51 Allowed 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.555 1.292 . . . . 0.0 109.913 179.738 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.74 23.27 4.05 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 -179.393 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.519 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -113.08 146.68 38.74 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.361 -1.082 . . . . 0.0 110.141 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.513 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 8.8 p -147.93 145.08 28.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.225 -0.922 . . . . 0.0 110.505 179.766 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.473 HG21 ' CG2' ' A' ' 319' ' ' VAL . 71.4 t -65.62 132.18 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.911 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.21 -36.97 1.71 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.476 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.433 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -140.97 139.49 34.23 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -1.209 . . . . 0.0 110.819 -179.735 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.491 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 23.1 p90 -150.63 167.01 28.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.471 -0.768 . . . . 0.0 109.599 179.56 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.501 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -154.98 155.2 33.79 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.946 -1.096 . . . . 0.0 111.585 -179.558 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.555 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 62.71 25.49 15.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.527 -0.733 . . . . 0.0 110.854 179.742 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.526 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 141.22 0.65 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.891 . . . . 0.0 110.365 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -78.65 117.54 19.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.136 -0.977 . . . . 0.0 109.17 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.511 ' HG2' ' N ' ' A' ' 313' ' ' GLN . 2.0 ttpt -87.84 145.67 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.791 0.805 . . . . 0.0 110.824 -179.274 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.729 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -133.19 178.6 6.78 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.35 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.476 ' HA ' HG22 ' A' ' 319' ' ' VAL . 30.7 mt-10 -141.45 106.57 4.97 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.533 -0.729 . . . . 0.0 110.539 179.509 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.93 51.83 2.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 51.51 80.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.277 -1.131 . . . . 0.0 110.317 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.602 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.47 -0.12 58.22 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.602 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.6 m-85 -141.23 -166.96 2.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -1.115 . . . . 0.0 109.435 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.536 HG11 ' N ' ' A' ' 320' ' ' ILE . 2.7 t -163.61 157.84 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.21 -0.931 . . . . 0.0 109.839 179.286 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.729 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 9.2 mm -127.1 146.61 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 120.915 -1.116 . . . . 0.0 110.685 179.486 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 74.8 m-85 -125.42 124.83 42.31 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.364 -0.835 . . . . 0.0 109.729 179.263 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.52 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 8.3 p -126.96 168.04 15.85 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.491 -1.381 . . . . 0.0 110.39 179.857 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.539 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.4 Cg_endo -65.92 119.07 6.04 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.868 1.457 . . . . 0.0 111.13 -179.306 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.5 HG22 ' NE1' ' A' ' 326' ' ' TRP . 34.2 m -67.29 -124.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.527 -0.733 . . . . 0.0 109.895 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 32.1 t -107.15 -12.92 15.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.763 -1.211 . . . . 0.0 110.693 -179.877 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.555 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 19.6 p-90 -130.34 4.32 4.74 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.069 -1.02 . . . . 0.0 110.526 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.45 ' HB2' HG21 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -113.85 40.91 2.33 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.247 -0.908 . . . . 0.0 110.351 -179.546 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -115.97 -11.17 11.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 179.821 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.498 ' HA2' ' NE2' ' A' ' 289' ' ' GLN . . . -57.08 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.424 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.54 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.8 Cg_endo -75.41 7.05 3.2 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 124.143 1.602 . . . . 0.0 111.119 -179.663 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.424 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 1.5 m -162.41 124.15 2.69 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.021 -1.049 . . . . 0.0 109.957 179.992 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.567 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -145.93 110.81 5.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 110.311 -179.821 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.406 HG23 ' HA ' ' A' ' 283' ' ' THR . 24.9 m -102.68 123.13 45.81 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.153 -0.967 . . . . 0.0 110.235 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.602 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 13.2 p90 -128.67 175.48 8.55 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.191 -0.943 . . . . 0.0 108.952 179.456 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.473 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.41 162.58 29.07 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.074 -1.536 . . . . 0.0 109.967 -179.222 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.695 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.7 OUTLIER -152.0 144.81 24.36 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.487 -1.008 . . . . 0.0 109.256 179.378 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.545 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -119.77 121.25 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.97 -1.081 . . . . 0.0 109.935 -179.743 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.59 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.5 t -96.88 151.7 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.107 -0.996 . . . . 0.0 109.835 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.461 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -123.36 132.3 53.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.277 -0.889 . . . . 0.0 110.307 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.246 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.768 . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.557 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 121.443 0.639 . . . . 0.0 110.547 . . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.582 HG12 ' CE1' ' A' ' 280' ' ' TYR . 11.4 p -132.39 117.4 31.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.319 -0.863 . . . . 0.0 109.927 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.449 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -49.64 -45.43 48.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.851 . . . . 0.0 110.784 -179.243 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.404 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 11.4 pt-20 -176.95 158.83 1.63 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.942 -1.099 . . . . 0.0 110.916 -179.737 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.496 HG12 ' CG2' ' A' ' 296' ' ' VAL . 42.5 mt -121.06 109.82 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.187 -0.946 . . . . 0.0 110.088 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.64 158.19 16.88 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.537 HD13 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.29 125.83 50.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.357 -0.839 . . . . 0.0 110.056 179.807 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.471 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.9 tt0 -137.96 116.26 11.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.14 -0.975 . . . . 0.0 110.248 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.529 ' CD1' ' HB3' ' A' ' 292' ' ' TRP . 0.9 OUTLIER -91.31 95.87 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 110.162 179.903 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.519 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 49.51 32.3 4.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.641 -0.662 . . . . 0.0 110.742 179.834 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.18 -31.31 4.94 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.471 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 79.3 mm-40 -81.77 119.75 24.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.148 -1.207 . . . . 0.0 110.519 -179.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.503 ' O ' ' CD1' ' A' ' 358' ' ' ILE . 12.0 p -79.04 135.64 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.176 -0.952 . . . . 0.0 110.087 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.503 ' CD1' ' O ' ' A' ' 357' ' ' VAL . 27.5 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.201 -179.778 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.575 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.15 158.06 44.84 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.364 -1.08 . . . . 0.0 109.9 -179.955 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.495 ' C ' ' CD2' ' A' ' 267' ' ' LEU . 0.0 OUTLIER -146.94 113.47 5.98 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.177 -0.952 . . . . 0.0 110.532 180.0 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -114.69 114.76 26.07 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.067 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.53 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 61.4 t -112.62 133.3 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.894 -1.129 . . . . 0.0 112.588 -178.233 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.423 ' C ' HG23 ' A' ' 271' ' ' VAL . 1.7 mptm? -116.73 156.66 26.78 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 177.959 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.543 HG21 ' CD1' ' A' ' 280' ' ' TYR . 87.1 t -144.64 147.05 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.231 -1.543 . . . . 0.0 112.235 -179.201 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.559 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -133.7 106.95 7.64 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.096 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.495 ' N ' ' OD1' ' A' ' 273' ' ' ASP . 20.8 p-10 -93.09 145.92 24.03 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.087 -1.008 . . . . 0.0 111.254 -178.884 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.585 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 38.1 p90 -134.04 16.98 3.82 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.421 -0.799 . . . . 0.0 109.902 179.423 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.52 -59.26 4.38 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.14 -17.64 64.85 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.357 -1.084 . . . . 0.0 110.09 179.822 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.585 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.38 -178.7 48.66 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.776 -1.329 . . . . 0.0 109.776 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.501 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -135.1 138.54 43.89 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.378 -1.072 . . . . 0.0 110.229 -179.965 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.578 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.2 mt-10 -92.28 146.18 23.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.434 -0.791 . . . . 0.0 110.093 -179.812 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.707 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.5 m-85 -136.0 95.28 3.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 110.726 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.53 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.4 103.78 12.21 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.496 -0.752 . . . . 0.0 109.94 179.562 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.598 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.2 t -93.93 91.79 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.402 -0.811 . . . . 0.0 110.42 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.485 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 8.9 m -86.54 112.47 21.59 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.158 179.337 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.546 HD13 ' CE3' ' A' ' 292' ' ' TRP . 0.3 OUTLIER -97.55 153.0 18.46 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.098 -1.001 . . . . 0.0 111.096 -178.913 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.575 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.1 OUTLIER -135.51 106.43 6.63 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.452 -0.78 . . . . 0.0 109.978 -179.699 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 330' ' ' PRO . 2.3 mt -117.05 169.51 9.36 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.689 -1.257 . . . . 0.0 110.026 179.799 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . 0.421 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 10.7 m-20 -100.85 32.29 3.23 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.268 -0.895 . . . . 0.0 110.455 -179.705 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.498 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 162.87 -145.54 10.73 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.272 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -106.87 105.86 16.1 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.362 -1.081 . . . . 0.0 110.871 -179.442 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.498 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 3.7 m-85 -135.67 150.47 49.6 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.233 -0.917 . . . . 0.0 109.756 179.356 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.527 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 86.8 m-20 -78.97 96.91 5.87 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 108.97 179.098 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.603 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 52.3 p-90 -94.19 112.11 23.89 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.35 -0.844 . . . . 0.0 110.474 -179.46 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.562 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 15.2 m -106.5 116.52 32.07 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.411 -0.806 . . . . 0.0 109.261 179.641 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.473 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.3 t -96.29 110.79 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 110.667 -179.103 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.47 ' HA ' HD11 ' A' ' 320' ' ' ILE . 9.0 ttpt -83.07 148.85 27.28 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.379 -0.826 . . . . 0.0 108.792 178.696 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.592 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 76.2 t -148.55 108.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.005 -1.059 . . . . 0.0 111.11 -178.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.568 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 56.3 mmtt -70.69 141.56 51.58 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.233 -0.917 . . . . 0.0 109.302 179.167 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.553 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 95.3 mt -94.07 157.97 15.84 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.273 -0.892 . . . . 0.0 111.854 -178.608 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.504 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -68.06 173.12 3.41 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.709 -0.62 . . . . 0.0 109.734 179.404 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.5 Cg_endo -68.25 83.66 0.47 Allowed 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.715 1.376 . . . . 0.0 109.76 179.58 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.72 24.45 5.25 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.353 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.512 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . . . -118.44 142.67 47.33 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.423 -1.046 . . . . 0.0 110.11 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.553 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 9.6 p -143.6 144.45 31.92 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.202 -0.936 . . . . 0.0 110.764 179.753 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.514 ' CG2' HG22 ' A' ' 319' ' ' VAL . 36.2 t -69.87 134.1 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 179.456 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.5 -46.76 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.332 -179.329 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.488 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 31.0 t -119.63 140.27 50.88 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.063 -1.257 . . . . 0.0 110.91 -179.432 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.628 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.3 p90 -157.99 170.7 21.71 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.54 -0.725 . . . . 0.0 109.695 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.511 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -160.46 162.68 33.23 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.09 -1.006 . . . . 0.0 111.044 -179.585 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.8 OUTLIER 54.77 24.8 5.95 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.585 -0.697 . . . . 0.0 110.774 179.816 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.547 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -173.86 144.45 1.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.404 -0.81 . . . . 0.0 109.882 179.455 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.505 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -86.4 122.2 30.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.031 -1.043 . . . . 0.0 109.754 179.747 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.504 ' CD ' HG13 ' A' ' 304' ' ' VAL . 1.7 ttpt -87.5 141.42 28.63 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 121.888 0.851 . . . . 0.0 110.374 -179.749 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.505 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -128.02 175.7 8.19 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.688 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -134.46 117.71 16.55 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.111 -0.993 . . . . 0.0 110.382 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.498 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -108.0 33.65 6.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.2 OUTLIER 70.08 85.57 0.13 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.295 -1.121 . . . . 0.0 110.37 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.56 5.11 75.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.6 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.0 OUTLIER -146.16 -168.24 2.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.362 -1.081 . . . . 0.0 109.173 179.513 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 4.2 t -163.45 161.54 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.235 -0.916 . . . . 0.0 109.765 179.369 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.562 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.4 mm -128.2 143.38 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.122 -0.986 . . . . 0.0 111.271 -179.84 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.664 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 65.4 m-85 -120.05 127.29 52.43 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 178.997 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.52 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.3 p -128.25 169.92 11.64 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.693 -1.254 . . . . 0.0 110.213 -179.498 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.52 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -65.31 112.74 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 123.944 1.497 . . . . 0.0 111.15 -179.354 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.55 HG23 ' ND2' ' A' ' 327' ' ' ASN . 3.6 m -53.3 -59.03 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.435 -0.79 . . . . 0.0 110.994 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.498 ' O ' ' CE ' ' A' ' 328' ' ' LYS . 0.0 OUTLIER -179.29 -24.72 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.959 -1.088 . . . . 0.0 111.307 -179.67 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.495 ' CE2' HG22 ' A' ' 324' ' ' VAL . 5.3 p-90 -115.78 -24.84 8.02 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.92 -1.112 . . . . 0.0 110.718 -179.72 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.55 ' ND2' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -85.22 29.36 0.66 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.144 -0.972 . . . . 0.0 111.303 -179.817 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.498 ' CE ' ' O ' ' A' ' 325' ' ' SER . 0.0 OUTLIER -90.87 -6.27 54.42 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.207 -0.933 . . . . 0.0 109.45 179.599 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.58 -157.69 0.01 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.492 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.519 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -75.86 6.54 3.69 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 124.14 1.6 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.446 HG22 ' O ' ' A' ' 284' ' ' LEU . 0.9 OUTLIER -159.02 131.64 6.87 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.734 -179.932 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -144.99 109.08 4.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.185 -0.947 . . . . 0.0 110.385 -179.691 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.485 ' HA ' ' HA ' ' A' ' 283' ' ' THR . 51.8 m -104.12 118.38 36.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.163 -0.961 . . . . 0.0 110.558 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.598 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 9.7 p90 -128.56 174.67 9.18 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.463 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.1 162.37 28.76 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 118.801 -1.666 . . . . 0.0 110.477 -179.247 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.707 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.1 p90 -151.39 143.85 24.2 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.685 -0.891 . . . . 0.0 109.32 179.25 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.556 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.7 mp -117.95 119.34 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.959 -1.088 . . . . 0.0 110.283 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.564 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.4 t -97.01 142.8 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 109.71 179.768 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.7 m-80 -111.23 136.1 50.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.188 -0.945 . . . . 0.0 110.215 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.344 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.927 . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.564 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 121.173 0.511 . . . . 0.0 110.903 . . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.592 HG13 ' CE1' ' A' ' 280' ' ' TYR . 12.8 p -128.31 115.01 36.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.077 179.525 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.48 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 6.9 mt-10 -43.45 -46.93 6.96 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.244 -0.91 . . . . 0.0 110.102 -179.641 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -177.19 158.54 1.51 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.105 -0.997 . . . . 0.0 110.833 -179.968 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.403 HD11 HG22 ' A' ' 349' ' ' ILE . 16.6 mt -117.75 105.63 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.877 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.81 141.96 35.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.327 -0.858 . . . . 0.0 110.005 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.543 ' CD1' HD22 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -100.88 131.42 46.77 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.064 -1.023 . . . . 0.0 110.177 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.424 ' N ' HD23 ' A' ' 351' ' ' LEU . 1.4 tp10 -139.03 110.48 7.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 110.019 179.677 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.467 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.3 mt -91.45 105.21 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.045 -1.034 . . . . 0.0 109.894 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.527 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 45.19 40.56 5.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.48 -0.762 . . . . 0.0 110.619 -179.887 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 105.05 -22.47 33.23 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.448 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.455 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 76.1 mm-40 -84.03 110.3 18.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.093 -1.24 . . . . 0.0 110.27 -179.87 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 357' ' ' VAL . 8.5 p -72.41 130.24 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.458 ' OXT' HD11 ' A' ' 351' ' ' LEU . 17.0 mm . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.241 179.893 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.578 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.14 155.39 49.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.277 -1.131 . . . . 0.0 109.832 179.968 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.513 ' C ' ' CD2' ' A' ' 267' ' ' LEU . 0.0 OUTLIER -148.48 121.53 8.85 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.124 -0.985 . . . . 0.0 110.884 -179.353 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.447 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 23.9 mt-10 -121.61 127.35 50.77 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.875 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.55 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 48.1 t -121.33 138.45 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 120.634 -1.291 . . . . 0.0 112.428 -178.402 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 6.6 mtpp -125.3 157.82 35.71 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.968 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 84.4 t -144.62 144.93 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.379 -1.45 . . . . 0.0 112.021 -179.577 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.539 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -132.99 108.14 8.71 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.974 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 19.2 m-20 -96.4 144.83 26.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.999 -1.063 . . . . 0.0 111.077 -178.793 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.582 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 37.1 p90 -131.51 20.03 4.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.496 -0.752 . . . . 0.0 110.025 179.551 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.48 -61.49 4.59 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.816 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -67.53 -18.98 65.23 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -1.171 . . . . 0.0 110.465 -179.735 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.582 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.99 177.75 45.31 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.909 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.529 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -135.2 137.53 42.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.313 -1.11 . . . . 0.0 109.989 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.579 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 7.4 mt-10 -94.33 146.4 24.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.276 -0.89 . . . . 0.0 110.205 -179.68 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.694 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 90.3 m-85 -137.68 88.81 2.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.268 -0.895 . . . . 0.0 110.624 -179.747 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.55 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -75.97 117.78 18.06 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 110.325 179.734 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.607 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 11.1 t -109.83 94.37 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.436 -0.79 . . . . 0.0 110.131 179.626 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.461 ' OG1' HG22 ' A' ' 333' ' ' THR . 19.8 m -86.97 120.42 28.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.182 -0.949 . . . . 0.0 109.778 179.546 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.545 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -107.25 149.94 27.2 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.195 -0.941 . . . . 0.0 110.828 -179.346 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.578 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.72 106.94 7.63 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.401 -0.812 . . . . 0.0 110.147 -179.33 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.556 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 12.2 mt -114.99 155.6 26.65 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.568 -1.332 . . . . 0.0 110.638 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . 0.429 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -88.09 37.76 0.82 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.488 -0.758 . . . . 0.0 109.746 179.572 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 160.33 -147.29 14.05 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.55 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -111.56 95.02 5.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.151 -1.205 . . . . 0.0 110.633 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.556 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -122.43 141.34 51.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.262 -0.899 . . . . 0.0 110.05 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.536 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 13.2 t70 -71.94 108.73 5.35 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.149 -0.97 . . . . 0.0 109.72 179.564 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.592 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 42.9 p-90 -105.22 114.89 29.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 110.544 -179.651 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.58 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 3.2 m -102.27 113.96 27.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.418 -0.801 . . . . 0.0 109.534 179.751 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.477 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 5.1 t -96.67 113.33 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 110.448 -179.516 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.492 ' HA ' ' CD1' ' A' ' 320' ' ' ILE . 4.1 ttpt -87.9 149.6 23.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.7 179.535 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.552 HG12 ' CZ ' ' A' ' 336' ' ' PHE . 71.5 t -149.35 110.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.079 -1.013 . . . . 0.0 110.273 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.52 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 52.1 mmtt -72.18 138.68 47.79 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.197 -0.939 . . . . 0.0 109.58 179.575 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.516 ' HG ' ' HA ' ' A' ' 318' ' ' TYR . 91.8 mt -91.93 158.36 16.32 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.262 -0.899 . . . . 0.0 111.696 -178.779 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.566 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -65.5 175.24 1.17 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 121.792 -0.567 . . . . 0.0 109.586 179.216 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.518 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -66.36 81.27 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 O-C-N 123.581 1.306 . . . . 0.0 109.902 179.42 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.69 6.3 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.364 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.522 ' CB ' ' HB3' ' A' ' 299' ' ' ALA . . . -104.86 153.32 21.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.337 -1.096 . . . . 0.0 110.213 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.518 ' CG2' ' O ' ' A' ' 302' ' ' ALA . 64.8 p -156.51 145.42 20.23 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.074 -1.016 . . . . 0.0 110.719 -179.864 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.515 HG21 ' CG2' ' A' ' 319' ' ' VAL . 61.6 t -74.21 131.56 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.395 -0.816 . . . . 0.0 109.908 179.562 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.55 -25.14 2.01 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.458 ' O ' HD12 ' A' ' 337' ' ' ILE . 0.3 OUTLIER -139.68 112.71 8.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.039 -1.271 . . . . 0.0 110.95 -179.698 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -132.97 163.75 28.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.323 -0.861 . . . . 0.0 109.782 179.361 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.501 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.95 162.8 40.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.033 -1.042 . . . . 0.0 110.843 -179.612 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.493 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.5 OUTLIER 57.49 22.6 8.22 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.583 -0.698 . . . . 0.0 111.025 179.55 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.534 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -175.06 143.28 0.69 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.295 -0.878 . . . . 0.0 110.401 179.514 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.501 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -80.71 120.79 25.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.271 -0.893 . . . . 0.0 109.117 179.255 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 0.6 OUTLIER -87.92 127.7 35.36 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.733 0.778 . . . . 0.0 111.1 -178.982 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.487 ' CB ' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -108.54 174.5 5.85 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.323 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -134.29 114.58 13.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.131 -0.98 . . . . 0.0 110.784 -179.637 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.59 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -103.76 57.43 0.55 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.53 ' ND2' ' O ' ' A' ' 316' ' ' ASN . 2.3 p-10 37.75 75.7 0.06 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.951 . . . . 0.0 110.754 -179.687 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.584 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 108.39 -2.17 32.77 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.778 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.59 ' CD2' ' O ' ' A' ' 315' ' ' GLY . 1.9 m-85 -142.24 -169.69 3.0 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.288 -1.125 . . . . 0.0 109.299 179.673 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.515 ' CG2' HG21 ' A' ' 304' ' ' VAL . 6.7 t -162.45 158.39 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 179.165 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.58 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 32.3 mm -128.9 148.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.001 -1.062 . . . . 0.0 111.338 -179.394 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.4 m-85 -124.58 122.8 38.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.988 -1.07 . . . . 0.0 110.164 179.284 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.501 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 5.9 p -121.21 168.09 11.79 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.924 -1.11 . . . . 0.0 110.002 179.756 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.521 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.7 Cg_endo -66.78 119.47 6.5 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 O-C-N 123.805 1.424 . . . . 0.0 110.963 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.446 HG11 ' ND2' ' A' ' 311' ' ' ASN . 35.4 m -67.88 -128.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.364 -179.889 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.35 -13.03 22.14 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.836 -1.165 . . . . 0.0 110.878 -179.473 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.487 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 10.0 p-90 -135.35 5.34 3.22 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.054 -1.029 . . . . 0.0 110.63 -179.918 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 309' ' ' SER . 11.6 t30 -108.67 42.62 1.37 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.109 -0.994 . . . . 0.0 110.722 -179.701 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -123.43 -2.81 8.44 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.118 -0.989 . . . . 0.0 110.09 179.689 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.97 -157.11 0.08 OUTLIER Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.537 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.8 Cg_endo -75.96 5.3 4.55 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 124.006 1.53 . . . . 0.0 110.574 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.455 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.1 m -165.09 118.57 1.24 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.126 -0.984 . . . . 0.0 110.195 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.543 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -140.41 118.78 12.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -0.972 . . . . 0.0 110.225 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.465 ' O ' ' HB3' ' A' ' 309' ' ' SER . 91.2 m -107.21 126.9 53.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.398 -0.814 . . . . 0.0 110.32 -179.957 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.607 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 10.8 p90 -131.37 175.35 9.21 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.364 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.485 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -155.37 156.63 27.11 Favored Glycine 0 N--CA 1.487 2.073 0 C-N-CA 118.861 -1.638 . . . . 0.0 110.076 -179.44 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.694 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.5 p90 -142.09 151.85 42.73 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.548 -0.972 . . . . 0.0 109.687 179.519 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.527 ' N ' HD12 ' A' ' 337' ' ' ILE . 1.7 mp -123.02 119.14 56.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.125 -0.984 . . . . 0.0 109.38 179.377 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.513 HG23 ' CD2' ' A' ' 298' ' ' LEU . 3.4 t -96.27 147.27 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 110.291 -179.398 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -118.17 131.29 56.41 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 109.987 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.893 . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.566 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 121.557 0.694 . . . . 0.0 110.383 . . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.599 HG13 ' CE2' ' A' ' 280' ' ' TYR . 7.1 p -127.27 123.74 62.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.094 -1.004 . . . . 0.0 109.709 179.199 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.52 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -55.06 -43.88 74.27 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.218 -179.258 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.475 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.9 pt-20 -177.31 159.23 1.55 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.113 -0.992 . . . . 0.0 111.119 -179.896 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.432 HD11 HG13 ' A' ' 269' ' ' VAL . 36.2 mt -121.34 122.33 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 110.104 179.517 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 350' ' ' THR . . . . . 0.412 ' O ' HG12 ' A' ' 294' ' ' VAL . 0.0 OUTLIER -123.39 160.05 27.63 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.892 . . . . 0.0 110.046 -179.858 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.537 ' CD1' HD23 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.18 126.95 52.78 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.234 -0.916 . . . . 0.0 110.278 -179.922 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.3 tt0 -138.59 113.31 9.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.185 -0.947 . . . . 0.0 109.942 179.665 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.536 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.6 113.22 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.108 -0.995 . . . . 0.0 110.144 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.521 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 40.08 40.56 0.78 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.537 -0.727 . . . . 0.0 111.031 179.879 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.86 -20.84 37.73 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.83 -1.176 . . . . 0.0 110.342 179.185 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.472 ' O ' ' N ' ' A' ' 353' ' ' ILE . 39.1 mm-40 -87.0 111.3 20.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.045 -1.268 . . . . 0.0 110.5 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 9.8 p -73.44 141.88 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.299 -0.876 . . . . 0.0 110.222 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.43 HG12 ' C ' ' A' ' 357' ' ' VAL . 28.8 mm . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.199 179.975 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.531 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -140.12 166.52 24.45 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.61 -0.936 . . . . 0.0 109.597 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.548 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.6 tm? -161.02 130.83 4.92 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.944 -1.097 . . . . 0.0 110.952 -179.8 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.447 ' N ' HD23 ' A' ' 267' ' ' LEU . 25.7 mt-10 -131.86 122.92 26.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.64 -0.662 . . . . 0.0 109.414 179.879 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 96.5 t -117.1 137.29 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 111.478 -179.058 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -120.25 157.42 29.17 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.91 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.56 HG11 ' CE2' ' A' ' 280' ' ' TYR . 96.2 t -143.67 146.72 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.269 -1.519 . . . . 0.0 112.265 -179.266 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -147.89 117.5 7.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.639 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.521 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.0 OUTLIER -100.13 147.59 25.51 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.205 -0.934 . . . . 0.0 111.195 -178.663 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.557 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 32.9 p90 -130.14 18.61 5.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.541 -0.724 . . . . 0.0 109.864 179.398 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.19 -57.23 4.57 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.735 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.65 -14.91 62.19 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -1.162 . . . . 0.0 110.264 -179.895 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.548 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . 179.6 175.08 46.14 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.892 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.557 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -130.39 147.34 52.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.315 -1.109 . . . . 0.0 109.999 179.851 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.542 ' CG ' HG13 ' A' ' 337' ' ' ILE . 5.8 mt-10 -103.12 147.64 26.74 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.264 -0.897 . . . . 0.0 110.519 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 84.2 m-85 -142.59 81.09 1.72 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.556 -0.715 . . . . 0.0 110.625 -179.816 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.459 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -62.63 153.97 30.61 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.384 -0.822 . . . . 0.0 109.825 179.335 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.611 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.7 t -147.62 86.77 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.571 -0.705 . . . . 0.0 109.982 -179.473 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.436 HG22 ' OG1' ' A' ' 333' ' ' THR . 24.9 m -86.21 118.72 25.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.092 -1.005 . . . . 0.0 109.387 179.656 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.65 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -106.04 147.24 29.12 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.196 -0.94 . . . . 0.0 110.374 -179.341 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.531 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.5 OUTLIER -127.07 133.07 50.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.175 -0.953 . . . . 0.0 110.458 -179.432 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.631 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 9.2 mt -142.1 158.54 43.63 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.896 -1.128 . . . . 0.0 108.992 179.332 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.66 35.56 0.96 Allowed 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.531 -179.588 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 158.21 -110.14 0.43 Allowed Glycine 0 N--CA 1.493 2.468 0 C-N-CA 118.758 -1.687 . . . . 0.0 110.982 179.779 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.505 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -135.07 122.37 21.68 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.061 -1.258 . . . . 0.0 111.051 -178.594 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.631 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 8.6 m-85 -150.88 147.02 26.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.245 -0.91 . . . . 0.0 109.998 179.172 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.532 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 18.8 m-20 -80.58 96.79 6.94 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.371 179.316 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.65 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 57.9 p-90 -96.82 115.64 27.78 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.365 -0.835 . . . . 0.0 110.424 -179.589 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.466 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 3.3 m -109.31 113.72 26.79 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.465 -0.772 . . . . 0.0 109.753 179.927 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.507 HG21 ' CD2' ' A' ' 351' ' ' LEU . 2.5 t -97.07 113.06 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.287 -0.883 . . . . 0.0 110.339 -179.463 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.534 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 31.3 ttmt -94.55 135.58 35.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.598 179.362 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.59 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 81.1 t -130.25 112.34 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.187 -0.946 . . . . 0.0 110.579 -179.548 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.51 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 53.3 mmtt -70.32 136.08 49.46 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.063 -1.023 . . . . 0.0 109.472 179.421 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.593 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 88.3 mt -90.49 163.12 14.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.296 -0.878 . . . . 0.0 111.838 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.551 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -68.78 178.06 0.97 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.82 -0.55 . . . . 0.0 109.846 179.583 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.2 77.39 0.87 Allowed 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.757 1.398 . . . . 0.0 109.811 179.449 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.7 18.69 5.97 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 -179.275 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.526 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -105.04 141.68 36.18 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.417 -1.049 . . . . 0.0 109.677 -179.856 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.538 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 82.2 p -143.99 143.95 31.45 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.84 -1.162 . . . . 0.0 111.058 179.859 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.537 ' CG2' HG22 ' A' ' 319' ' ' VAL . 88.5 t -67.13 116.86 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.658 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.74 -31.6 5.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.341 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.465 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.3 OUTLIER -140.63 132.03 26.81 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.927 -1.337 . . . . 0.0 111.136 -179.414 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.571 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 16.4 p90 -146.42 168.93 19.94 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.411 -0.805 . . . . 0.0 109.496 179.287 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.9 OUTLIER -159.56 157.07 29.2 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.881 -1.137 . . . . 0.0 111.546 -179.558 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.578 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.4 OUTLIER 60.76 27.09 16.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.749 -0.595 . . . . 0.0 111.186 179.47 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.428 ' N ' HG12 ' A' ' 324' ' ' VAL . . . -174.08 142.7 0.86 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 110.102 179.627 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.478 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -76.3 114.49 15.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.171 -0.956 . . . . 0.0 109.421 179.628 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.571 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 1.1 ttpp -87.08 132.95 33.67 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.76 0.79 . . . . 0.0 110.782 -179.579 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.526 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -120.03 174.52 6.42 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.991 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -137.71 103.14 4.93 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.195 -0.94 . . . . 0.0 110.242 179.764 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.499 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -90.44 30.44 6.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.893 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.499 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.1 OUTLIER 69.89 89.03 0.1 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.224 -1.162 . . . . 0.0 110.378 -179.992 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.632 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.55 1.32 71.54 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.861 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.632 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.2 m-85 -146.72 -168.6 3.07 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.463 -1.022 . . . . 0.0 108.921 179.396 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.537 HG22 ' CG2' ' A' ' 304' ' ' VAL . 6.4 t -162.18 158.15 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.973 -1.08 . . . . 0.0 110.123 179.116 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 312' ' ' LYS . 6.5 mm -122.41 152.38 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.896 -1.128 . . . . 0.0 110.747 -179.677 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 76.2 m-85 -132.54 115.12 15.07 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.167 -0.958 . . . . 0.0 110.026 179.224 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.542 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 5.6 p -118.03 169.47 7.64 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 120.65 -1.281 . . . . 0.0 109.676 179.456 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.542 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.7 Cg_endo -67.57 121.28 8.35 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.619 1.326 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.535 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 2.7 m -75.75 -141.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -0.769 . . . . 0.0 110.458 -179.563 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.522 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 3.2 m -76.24 -37.25 57.9 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 110.775 -179.626 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.578 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 42.0 p-90 -117.77 22.24 12.44 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.16 -0.962 . . . . 0.0 110.803 -179.57 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.535 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.3 OUTLIER -122.73 32.62 5.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.096 -1.003 . . . . 0.0 110.897 -179.172 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.475 ' CB ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -120.64 9.86 10.9 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.085 -1.009 . . . . 0.0 110.061 179.785 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -72.05 -149.5 0.87 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 179.895 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.556 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.3 Cg_endo -73.32 -52.46 0.14 Allowed 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.934 1.492 . . . . 0.0 109.64 179.811 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.435 HG21 ' O ' ' A' ' 284' ' ' LEU . 2.0 m -111.89 115.73 29.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 179.593 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.471 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -125.52 117.45 23.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.379 -0.825 . . . . 0.0 109.958 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.486 ' O ' ' HB2' ' A' ' 309' ' ' SER . 53.2 m -107.6 142.87 36.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.287 -0.883 . . . . 0.0 110.32 -179.859 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.611 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 8.4 p90 -151.7 173.06 15.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.766 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.89 153.73 25.02 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.021 -1.562 . . . . 0.0 110.1 -179.465 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.684 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.3 p90 -137.98 145.96 42.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.531 -0.982 . . . . 0.0 109.876 179.662 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.542 HG13 ' CG ' ' A' ' 279' ' ' GLU . 1.6 mp -120.05 125.4 74.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.133 -0.979 . . . . 0.0 109.593 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.593 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.5 t -99.49 161.42 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.175 -0.953 . . . . 0.0 110.726 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.438 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.9 m-80 -128.47 137.06 51.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.447 -0.783 . . . . 0.0 110.205 179.869 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.494 2.517 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.951 . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.551 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.322 0 CA-C-O 121.362 0.601 . . . . 0.0 111.044 . . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.59 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 14.9 p -138.44 119.18 16.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 110.064 179.062 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.416 ' O ' ' HB3' ' A' ' 348' ' ' GLU . 4.2 mt-10 -54.34 -42.22 69.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.412 -0.805 . . . . 0.0 110.928 -179.152 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.416 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.6 OUTLIER -176.66 158.77 1.76 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.94 -1.1 . . . . 0.0 110.867 -179.666 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.404 HG21 HG22 ' A' ' 296' ' ' VAL . 14.6 mt -119.28 120.22 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.144 -0.973 . . . . 0.0 110.36 179.858 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.11 141.9 51.66 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.113 -0.992 . . . . 0.0 110.16 179.825 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.598 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.89 130.11 54.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.193 -0.942 . . . . 0.0 110.386 179.803 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.8 tt0 -139.47 116.62 11.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.239 -0.913 . . . . 0.0 109.582 179.642 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.532 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -90.52 102.86 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.792 -1.193 . . . . 0.0 110.45 -179.704 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.448 ' C ' ' O ' ' A' ' 353' ' ' ILE . 1.0 OUTLIER 35.72 44.89 0.24 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.433 179.647 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.45 8.4 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.408 179.106 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.5 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 78.2 mm-40 -137.2 101.31 4.5 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.062 -1.258 . . . . 0.0 110.042 179.765 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.1 p -66.91 138.22 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.278 -0.889 . . . . 0.0 110.732 -179.672 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.45 ' HB ' ' HB3' ' A' ' 351' ' ' LEU . 19.6 mm . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.171 179.596 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.561 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.39 162.82 34.11 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.371 -1.076 . . . . 0.0 109.736 179.762 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.577 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.4 tm? -155.23 131.39 10.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.048 -1.032 . . . . 0.0 110.565 -179.148 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 18.0 mt-10 -133.28 124.02 26.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.542 -0.724 . . . . 0.0 109.285 179.455 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.504 HG21 ' CD1' ' A' ' 267' ' ' LEU . 32.0 t -115.54 139.08 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.924 -1.11 . . . . 0.0 111.809 -178.714 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -123.21 156.65 34.72 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.492 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.538 HG13 ' CE1' ' A' ' 280' ' ' TYR . 91.4 t -145.08 144.94 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.276 -1.515 . . . . 0.0 112.152 -179.275 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.549 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.27 109.05 6.27 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.175 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.497 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -94.62 146.17 24.32 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.208 -0.932 . . . . 0.0 111.36 -178.763 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.558 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 39.6 p90 -134.63 22.94 3.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.589 -0.694 . . . . 0.0 109.897 179.275 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.69 -66.81 3.84 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.827 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.41 -24.85 65.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.28 -1.129 . . . . 0.0 110.431 -179.668 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.535 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.92 -177.8 41.76 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.533 -1.318 . . . . 0.0 109.84 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.576 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -136.5 144.8 44.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -1.1 . . . . 0.0 110.247 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.534 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 4.1 mt-10 -97.01 147.05 24.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.421 -0.8 . . . . 0.0 109.816 -179.629 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.7 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -143.74 86.79 1.89 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.204 -0.935 . . . . 0.0 110.894 -179.619 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.455 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 4.6 t0 -71.06 151.58 44.39 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.641 179.11 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.646 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -143.52 91.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.46 -0.775 . . . . 0.0 109.717 -179.689 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.439 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 5.6 m -85.82 123.14 30.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.104 179.66 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.631 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -113.89 145.18 41.85 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.148 -0.97 . . . . 0.0 110.467 -179.034 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.561 ' ND2' ' HB3' ' A' ' 266' ' ' SER . 0.6 OUTLIER -127.15 134.26 50.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -179.642 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.604 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 15.9 mt -142.94 148.66 37.24 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.808 -1.183 . . . . 0.0 109.83 179.638 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -85.68 38.7 0.76 Allowed 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.593 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 159.53 -136.42 4.61 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.301 -1.428 . . . . 0.0 109.752 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.491 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -117.82 94.25 4.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.192 -1.181 . . . . 0.0 110.815 -179.49 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.604 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.05 137.14 52.38 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.192 -0.943 . . . . 0.0 109.918 179.311 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.452 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 2.1 m-20 -71.85 97.6 1.84 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.104 -0.998 . . . . 0.0 109.287 179.248 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.631 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 56.9 p-90 -97.1 113.74 25.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 110.663 -179.376 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.459 ' HA ' ' O ' ' A' ' 321' ' ' PHE . 2.0 m -107.11 117.05 33.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.523 -0.735 . . . . 0.0 109.258 179.527 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.482 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.1 t -97.14 111.0 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.121 -0.987 . . . . 0.0 110.655 -179.247 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.528 ' HG3' ' CD1' ' A' ' 320' ' ' ILE . 18.7 ttpt -84.68 138.97 32.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.258 -0.901 . . . . 0.0 108.933 178.923 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.557 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 85.1 t -136.22 107.11 6.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 110.906 -179.116 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.57 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 8.2 mmtm -69.96 130.72 42.96 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 121.075 -1.016 . . . . 0.0 108.881 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.599 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 66.2 mt -87.02 157.9 19.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.336 -0.853 . . . . 0.0 111.304 -178.816 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.563 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -59.14 177.89 0.24 Allowed Pre-proline 0 C--N 1.303 -1.438 0 O-C-N 121.764 -0.585 . . . . 0.0 109.803 179.503 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.507 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.06 81.0 0.66 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.717 1.377 . . . . 0.0 109.449 179.294 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.05 21.98 6.1 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 -179.102 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.476 ' CB ' ' HB2' ' A' ' 299' ' ' ALA . . . -104.91 149.77 25.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.313 -1.11 . . . . 0.0 110.397 -179.661 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.552 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 4.7 p -148.9 145.63 27.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.294 -0.879 . . . . 0.0 110.424 179.729 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.522 HG11 ' CD ' ' A' ' 312' ' ' LYS . 55.5 t -71.64 117.66 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 110.044 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -97.38 -45.26 2.58 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 68.1 m -126.15 148.76 49.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -1.161 . . . . 0.0 110.843 -179.77 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.477 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.0 p90 -162.95 160.03 24.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.462 -0.773 . . . . 0.0 109.479 179.473 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.489 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -153.35 162.46 41.26 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.835 -1.166 . . . . 0.0 111.172 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.499 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 58.19 21.83 8.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.963 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.532 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -173.84 137.76 0.6 Allowed 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.426 -0.796 . . . . 0.0 110.057 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.514 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.31 124.96 28.57 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.117 -0.989 . . . . 0.0 109.538 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.522 ' CD ' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -92.2 139.83 30.23 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.719 0.771 . . . . 0.0 110.882 -179.25 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.504 ' CB ' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -122.61 170.5 9.96 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.135 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.418 ' HG3' ' HE3' ' A' ' 312' ' ' LYS . 46.3 mt-10 -141.55 100.98 3.89 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.137 -0.977 . . . . 0.0 110.518 -179.767 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -81.41 -76.68 1.05 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.209 -1.557 . . . . 0.0 109.209 179.595 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.57 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 2.8 m120 -163.85 86.79 0.5 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.423 -1.045 . . . . 0.0 109.001 179.553 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 86.63 14.4 65.6 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -178.57 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.622 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.4 m-85 -146.79 -168.76 3.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.836 -0.803 . . . . 0.0 109.096 179.642 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.52 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 3.8 t -163.85 161.59 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.177 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.528 ' CD1' ' HG3' ' A' ' 295' ' ' LYS . 40.6 mm -127.24 144.97 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 111.184 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 49.2 m-85 -120.55 133.59 55.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.212 -0.93 . . . . 0.0 109.912 179.56 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.514 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 2.3 p -134.53 167.81 20.95 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 120.852 -1.155 . . . . 0.0 109.881 179.64 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.479 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 42.2 Cg_endo -67.72 115.51 3.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.858 1.451 . . . . 0.0 110.725 -179.384 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.526 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 23.0 m -61.18 -135.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.334 -0.854 . . . . 0.0 110.245 -179.88 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 2.0 m -90.47 -18.68 24.92 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.059 -1.026 . . . . 0.0 110.763 -179.475 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.573 ' CZ3' ' OD1' ' A' ' 327' ' ' ASN . 27.7 p-90 -132.97 21.56 4.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.182 -0.949 . . . . 0.0 110.404 -179.742 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.573 ' OD1' ' CZ3' ' A' ' 326' ' ' TRP . 1.7 m120 -120.25 38.25 4.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.073 -1.017 . . . . 0.0 110.614 -179.365 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -120.06 -4.95 10.04 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.184 -0.948 . . . . 0.0 109.889 179.565 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.99 -160.64 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -74.52 4.09 4.79 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.998 1.526 . . . . 0.0 110.72 -179.868 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.429 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.4 m -163.66 117.05 1.51 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.19 -0.944 . . . . 0.0 110.048 -179.853 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.461 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -140.12 114.61 9.31 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.961 . . . . 0.0 110.357 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.499 ' O ' ' HB3' ' A' ' 309' ' ' SER . 21.7 m -105.15 139.17 40.22 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.23 -0.919 . . . . 0.0 110.022 179.793 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 8.5 p90 -141.57 174.5 10.51 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.349 -0.844 . . . . 0.0 109.019 179.891 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.23 156.33 26.61 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.162 -1.494 . . . . 0.0 110.015 -179.525 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.7 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.1 p90 -146.25 144.65 30.0 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.385 -1.068 . . . . 0.0 110.328 179.752 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.551 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -118.71 123.06 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.184 -0.948 . . . . 0.0 109.215 179.321 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.599 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.1 t -96.59 162.11 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 110.699 -179.144 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 0.7 OUTLIER -126.07 127.38 45.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.568 -0.707 . . . . 0.0 109.56 -179.967 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 C-N-CA 119.494 -1.336 . . . . 0.0 110.042 179.977 . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.563 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 2.5 mtmt . . . . . 0 N--CA 1.488 1.471 0 CA-C-O 121.298 0.571 . . . . 0.0 110.492 . . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.584 HG13 ' CE1' ' A' ' 280' ' ' TYR . 11.8 p -136.85 118.35 18.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.415 -0.803 . . . . 0.0 110.026 179.272 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.466 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -50.96 -45.84 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.348 -0.845 . . . . 0.0 110.38 -179.513 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.438 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.0 pt-20 -176.61 157.84 1.65 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.272 -0.892 . . . . 0.0 110.426 -179.695 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.497 HG12 ' CG1' ' A' ' 296' ' ' VAL . 64.5 mt -120.59 106.54 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.157 -0.964 . . . . 0.0 110.232 179.644 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.82 130.91 53.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 110.286 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.589 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -91.3 129.37 37.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.101 -0.999 . . . . 0.0 110.241 179.782 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.0 tt0 -138.83 112.69 8.46 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.183 -0.948 . . . . 0.0 109.934 179.81 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.471 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.9 mt -91.4 110.7 22.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.065 -1.022 . . . . 0.0 110.165 179.961 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.421 ' C ' ' O ' ' A' ' 353' ' ' ILE . 0.8 OUTLIER 38.89 29.25 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.774 -0.578 . . . . 0.0 110.639 179.922 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 118.59 -21.68 9.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -86.2 112.53 21.43 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.055 -1.262 . . . . 0.0 110.392 -179.755 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 14.8 p -74.84 141.63 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.138 -0.976 . . . . 0.0 110.407 179.842 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.472 ' HB ' ' HB3' ' A' ' 351' ' ' LEU . 30.8 mm . . . . . 0 N--CA 1.494 1.755 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.309 179.837 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.579 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -128.52 165.94 19.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.617 -0.931 . . . . 0.0 109.664 179.665 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.532 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -159.43 126.21 4.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.977 -1.077 . . . . 0.0 111.17 -179.555 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.52 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.4 OUTLIER -123.78 118.05 26.3 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.681 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 55.2 t -117.15 142.15 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.851 -1.156 . . . . 0.0 112.14 -178.428 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 7.9 tttm -128.5 157.28 41.59 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.969 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.575 HG12 ' CE1' ' A' ' 280' ' ' TYR . 86.5 t -144.2 145.42 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.367 -1.458 . . . . 0.0 111.947 -179.445 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.65 113.23 7.71 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.483 179.534 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.525 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.86 145.76 25.11 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.151 -0.968 . . . . 0.0 110.942 -179.016 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.561 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 27.9 p90 -127.83 16.04 6.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.305 179.377 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 95.01 -56.11 1.82 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.483 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.6 m -78.53 -17.86 55.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -1.151 . . . . 0.0 110.453 -179.678 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -174.1 177.71 46.24 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.35 -1.405 . . . . 0.0 109.922 -179.952 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.561 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.65 144.84 48.07 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.329 -1.1 . . . . 0.0 110.066 179.862 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.56 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 4.2 mt-10 -96.88 147.48 23.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.365 -0.835 . . . . 0.0 109.878 -179.441 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 92.8 m-85 -139.38 86.43 2.12 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.302 -0.874 . . . . 0.0 110.69 -179.294 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.465 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.6 OUTLIER -69.77 145.65 52.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.431 -0.793 . . . . 0.0 109.809 179.317 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.608 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.8 t -139.06 87.55 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.577 -0.702 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.464 HG23 ' OG1' ' A' ' 333' ' ' THR . 19.2 m -86.12 117.12 24.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.102 -0.999 . . . . 0.0 109.645 -179.886 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.59 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -103.05 150.43 23.6 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.109 -0.994 . . . . 0.0 110.769 -179.279 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.579 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.62 106.63 7.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.576 -0.702 . . . . 0.0 110.098 -179.324 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.583 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.1 mt -113.98 157.16 22.83 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.824 -1.172 . . . . 0.0 109.987 179.772 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.47 35.16 0.76 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.356 -0.84 . . . . 0.0 110.501 -179.432 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.48 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.15 -103.39 0.23 Allowed Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.878 -1.63 . . . . 0.0 110.423 179.855 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.447 ' HG3' ' O ' ' A' ' 328' ' ' LYS . 3.0 tt0 -149.95 111.06 4.37 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.053 -1.263 . . . . 0.0 110.705 -179.252 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.583 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 2.4 m-85 -140.14 138.54 35.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.405 -0.809 . . . . 0.0 109.866 179.542 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.506 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 29.5 m-20 -64.92 97.09 0.21 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.102 -0.999 . . . . 0.0 109.294 179.349 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.59 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 56.5 p-90 -96.41 110.71 23.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.262 -0.899 . . . . 0.0 110.67 -179.502 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.576 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 5.5 m -102.81 114.94 29.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.518 -0.739 . . . . 0.0 109.314 179.459 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.493 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.5 t -96.18 113.08 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.102 -0.999 . . . . 0.0 110.007 -179.547 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.472 ' HA ' HD13 ' A' ' 320' ' ' ILE . 12.9 ttpt -89.73 149.47 22.73 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.527 -0.733 . . . . 0.0 109.184 179.657 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.588 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 77.4 t -148.16 109.33 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.005 -1.059 . . . . 0.0 110.763 -179.327 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.522 ' CB ' ' HB2' ' A' ' 347' ' ' GLU . 9.0 mmtt -71.81 135.03 46.51 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.102 -0.999 . . . . 0.0 109.324 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.599 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 89.6 mt -86.11 167.13 15.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.28 -0.888 . . . . 0.0 111.755 -178.75 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.559 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -72.18 176.17 2.56 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.672 -0.643 . . . . 0.0 109.353 179.068 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.507 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.9 Cg_endo -69.3 80.3 0.76 Allowed 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.554 1.291 . . . . 0.0 109.918 179.564 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.41 23.45 4.79 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.985 -1.646 . . . . 0.0 108.985 -179.446 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.483 ' HB3' ' HB2' ' A' ' 299' ' ' ALA . . . -111.7 150.4 30.26 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.373 -1.075 . . . . 0.0 110.401 -179.558 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.516 ' N ' HG13 ' A' ' 338' ' ' VAL . 77.3 p -150.43 144.14 25.23 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.286 -0.884 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.525 ' CG1' ' HD2' ' A' ' 312' ' ' LYS . 55.2 t -64.81 133.32 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 110.16 179.69 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.2 -37.6 1.48 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.843 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.41 138.22 32.8 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.182 -1.187 . . . . 0.0 110.768 -179.681 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.501 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 48.1 p90 -147.11 163.78 35.2 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.326 -0.858 . . . . 0.0 109.776 179.486 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.461 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.47 158.2 38.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.941 -1.099 . . . . 0.0 111.554 -179.434 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.504 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.52 21.6 12.74 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.719 -0.613 . . . . 0.0 110.818 179.479 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.516 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.7 143.6 0.78 Allowed 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.465 -0.772 . . . . 0.0 109.956 179.538 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.518 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -79.33 119.71 22.76 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.035 . . . . 0.0 109.351 179.579 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.525 ' HD2' ' CG1' ' A' ' 304' ' ' VAL . 4.9 ttpt -86.2 140.33 30.25 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.767 0.794 . . . . 0.0 110.59 -179.612 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.518 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.13 173.2 8.9 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.423 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -136.7 112.7 9.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 110.167 179.926 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -102.73 43.56 1.66 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 57.75 80.15 0.18 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.354 -1.086 . . . . 0.0 110.395 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.39 -1.02 57.12 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.64 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.592 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.1 m-85 -142.55 -170.1 3.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.377 -1.072 . . . . 0.0 109.472 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.532 HG13 ' N ' ' A' ' 320' ' ' ILE . 3.9 t -162.81 156.12 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.177 -0.952 . . . . 0.0 109.922 179.2 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.576 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 37.2 mm -125.65 151.78 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.114 -0.991 . . . . 0.0 111.294 -179.462 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 78.5 m-85 -129.54 126.49 38.7 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.166 -0.959 . . . . 0.0 110.408 179.421 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.518 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 6.4 p -126.5 167.56 16.91 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 120.919 -1.113 . . . . 0.0 109.579 179.195 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.503 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.4 Cg_endo -65.15 119.93 7.05 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.225 -179.164 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.53 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 12.4 m -63.74 -111.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.439 -0.788 . . . . 0.0 110.166 179.987 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -111.67 -23.32 10.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.697 -1.252 . . . . 0.0 110.534 -179.811 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 3.9 p-90 -125.73 1.49 7.47 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 -179.874 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.53 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.2 OUTLIER -99.91 40.97 1.19 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.233 -0.917 . . . . 0.0 110.38 -179.69 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -120.05 -8.4 9.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.25 -0.907 . . . . 0.0 109.532 179.736 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.89 -159.06 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.939 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.1 Cg_endo -74.76 5.75 3.69 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.978 1.515 . . . . 0.0 110.821 -179.899 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.1 m -163.14 121.23 1.98 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.959 -1.088 . . . . 0.0 109.897 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.61 113.75 8.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.957 . . . . 0.0 110.26 -179.776 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.504 ' O ' ' HB3' ' A' ' 309' ' ' SER . 11.8 m -103.04 133.42 48.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.392 -0.817 . . . . 0.0 110.364 -179.739 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.628 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 15.0 p90 -141.77 164.6 29.75 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.379 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -144.24 158.27 27.41 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.843 -1.646 . . . . 0.0 110.32 -179.397 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.693 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.4 p90 -144.01 147.65 34.17 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.556 -0.967 . . . . 0.0 109.882 179.417 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.543 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.7 mp -120.74 122.81 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.992 -1.068 . . . . 0.0 110.048 -179.969 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.599 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.9 t -97.07 157.28 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.884 . . . . 0.0 109.999 179.712 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -125.85 131.32 52.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.84 . . . . 0.0 110.396 -179.575 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.851 . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.559 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.3 mtmt . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 121.113 0.482 . . . . 0.0 111.234 . . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.587 HG11 ' CE1' ' A' ' 280' ' ' TYR . 9.0 p -132.2 125.51 54.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.022 -1.049 . . . . 0.0 110.412 179.231 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.522 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 3.8 mt-10 -53.08 -45.74 68.29 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.313 -0.867 . . . . 0.0 110.149 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.445 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 1.8 pt-20 -177.55 158.63 1.4 Allowed 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.185 -179.704 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.452 HG23 HG23 ' A' ' 296' ' ' VAL . 3.5 mm -109.13 122.58 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.603 -0.686 . . . . 0.0 109.709 179.419 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.42 141.76 51.67 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.33 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.537 HD12 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.68 126.84 52.62 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 109.952 179.633 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 11.5 tt0 -138.99 113.8 9.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.643 179.92 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.476 HG12 ' HA ' ' A' ' 292' ' ' TRP . 2.0 mt -92.97 112.14 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.154 -0.966 . . . . 0.0 109.913 179.522 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.506 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 41.74 34.11 0.38 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.492 -0.755 . . . . 0.0 110.113 -179.579 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 108.9 -25.12 19.89 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.933 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.471 ' N ' ' CD ' ' A' ' 356' ' ' GLN . 3.2 mp0 -77.41 106.07 8.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.223 -1.163 . . . . 0.0 110.523 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.465 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 13.5 p -70.92 120.93 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.259 -0.901 . . . . 0.0 110.184 179.719 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.457 HG22 ' O ' ' A' ' 358' ' ' ILE . 35.5 mm . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.009 179.777 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.531 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.79 169.35 17.87 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.585 -0.95 . . . . 0.0 109.33 179.909 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.578 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.0 tm? -161.38 134.49 6.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.36 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.489 ' N ' HD21 ' A' ' 267' ' ' LEU . 8.4 mm-40 -133.96 138.46 45.47 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.294 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.472 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 59.4 t -131.35 142.0 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 120.858 -1.151 . . . . 0.0 111.753 -178.846 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.439 ' C ' HG21 ' A' ' 271' ' ' VAL . 0.1 OUTLIER -127.17 156.99 40.93 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.771 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.588 HG22 ' CD2' ' A' ' 280' ' ' TYR . 69.3 t -144.81 147.07 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 120.401 -1.437 . . . . 0.0 112.344 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -143.18 113.91 7.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.669 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.507 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.6 m-20 -100.07 142.87 30.96 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.872 -1.142 . . . . 0.0 111.205 -178.538 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.553 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 26.8 p90 -122.77 20.1 10.17 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.576 -0.703 . . . . 0.0 109.475 179.451 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 84.44 -58.32 5.0 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.744 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.502 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -66.87 -19.34 65.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.25 -1.147 . . . . 0.0 110.216 179.793 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.553 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.93 -172.69 38.79 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.556 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -143.69 136.89 27.77 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -1.122 . . . . 0.0 109.894 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.541 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 7.2 mt-10 -95.93 146.4 24.62 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 110.446 -179.447 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.662 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.1 m-85 -140.01 86.36 2.08 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 110.766 -179.699 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.8 OUTLIER -66.54 143.64 56.93 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 179.155 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.646 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.4 t -138.35 89.36 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.191 -0.943 . . . . 0.0 110.014 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.464 ' HA ' HG22 ' A' ' 333' ' ' THR . 87.4 m -86.76 126.96 34.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.181 -0.949 . . . . 0.0 109.568 179.799 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.605 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.81 147.08 40.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 110.77 -179.204 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.535 ' O ' ' CD2' ' A' ' 286' ' ' LEU . 0.6 OUTLIER -125.3 135.21 52.25 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.35 -0.844 . . . . 0.0 110.467 -179.453 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.545 ' N ' ' O ' ' A' ' 330' ' ' PRO . 10.3 mt -144.77 161.69 38.61 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.731 -1.23 . . . . 0.0 109.595 179.8 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.09 37.47 1.16 Allowed 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.776 179.733 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 148.55 -129.89 3.25 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.33 -1.414 . . . . 0.0 109.973 -179.68 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.546 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.1 mm-40 -108.3 114.06 27.62 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.891 -1.358 . . . . 0.0 111.132 -179.326 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.564 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 6.3 m-85 -134.43 133.09 40.12 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.444 -0.785 . . . . 0.0 109.234 179.205 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.54 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 1.1 m-20 -73.5 96.26 2.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.808 -1.183 . . . . 0.0 108.857 179.236 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.569 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 64.2 p-90 -98.98 117.47 33.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.893 . . . . 0.0 110.996 -179.038 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.586 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 17.3 m -112.68 113.98 26.37 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.425 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.529 HG23 ' CD2' ' A' ' 351' ' ' LEU . 3.2 t -96.68 110.92 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.058 -1.026 . . . . 0.0 110.265 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.541 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 17.6 ttmt -89.51 148.21 23.54 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.381 -0.825 . . . . 0.0 109.187 179.144 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.582 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 71.3 t -144.26 111.66 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.126 -0.984 . . . . 0.0 110.204 -179.666 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 72.6 mmtt -70.24 135.44 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.219 -0.926 . . . . 0.0 109.154 179.653 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.594 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 93.9 mt -89.84 155.59 19.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.316 -0.865 . . . . 0.0 111.447 -178.851 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.518 ' HB1' ' CB ' ' A' ' 302' ' ' ALA . . . -59.4 173.86 0.46 Allowed Pre-proline 0 N--CA 1.487 1.378 0 O-C-N 121.493 -0.755 . . . . 0.0 109.086 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -69.23 79.33 0.78 Allowed 'Trans proline' 0 C--N 1.302 -1.913 0 O-C-N 123.608 1.32 . . . . 0.0 109.874 179.747 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.93 20.15 4.99 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.425 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.522 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -109.99 148.39 31.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.407 -1.055 . . . . 0.0 109.859 -179.884 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.552 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 19.8 p -147.52 146.15 29.36 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.953 -1.092 . . . . 0.0 111.247 -179.747 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.489 ' CG1' ' HD2' ' A' ' 312' ' ' LYS . 53.7 t -69.28 129.02 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.287 -0.883 . . . . 0.0 109.821 179.542 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.66 -40.22 1.13 Allowed Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.73 -1.224 . . . . 0.0 110.201 -179.466 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -126.96 129.65 48.55 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 0.0 110.686 -179.463 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.531 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.6 p90 -145.44 162.02 38.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.36 -0.837 . . . . 0.0 109.823 179.59 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -158.16 156.09 30.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.927 -1.108 . . . . 0.0 111.171 -179.579 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.576 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 63.5 24.31 14.02 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.575 -0.703 . . . . 0.0 110.941 179.598 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.495 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -174.18 146.1 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.908 . . . . 0.0 110.497 179.474 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.488 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.0 m-80 -77.31 123.46 26.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.375 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.531 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 12.0 ttpt -93.03 121.94 34.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.5 -0.75 . . . . 0.0 111.025 -179.448 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.545 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.6 tt0 -109.86 175.13 5.56 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.324 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -138.17 101.99 4.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.347 -0.846 . . . . 0.0 110.12 179.773 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.466 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -90.11 37.05 3.41 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.868 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . 0.488 ' ND2' ' N ' ' A' ' 316' ' ' ASN . 2.2 m120 63.78 88.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -1.168 . . . . 0.0 110.266 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.08 3.07 70.47 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.729 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.611 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.3 m-85 -146.34 -169.38 3.25 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.376 -1.073 . . . . 0.0 109.338 179.491 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 22.6 t -160.8 161.08 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.119 -0.988 . . . . 0.0 109.97 178.964 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.586 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 4.4 mm -126.55 152.33 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.133 -0.98 . . . . 0.0 110.93 -179.378 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.65 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 79.2 m-85 -131.76 112.48 12.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.232 -0.918 . . . . 0.0 109.888 178.791 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.548 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 6.5 p -115.67 170.28 5.86 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 120.725 -1.234 . . . . 0.0 109.529 179.561 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.548 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.0 Cg_endo -67.24 120.62 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.495 1.261 . . . . 0.0 110.943 -179.199 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.504 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 30.7 m -68.24 -123.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.488 -0.757 . . . . 0.0 110.143 -179.922 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 325' ' ' SER . . . . . 0.431 ' C ' ' HD2' ' A' ' 328' ' ' LYS . 0.0 OUTLIER -104.74 -18.1 14.39 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.776 -1.202 . . . . 0.0 110.67 -179.734 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.576 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 19.7 p-90 -126.73 3.53 6.73 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.93 -1.106 . . . . 0.0 110.539 -179.994 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.504 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.6 t30 -110.92 34.76 3.83 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.141 -0.975 . . . . 0.0 110.646 -179.429 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.519 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -114.22 2.8 14.94 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.158 -0.964 . . . . 0.0 109.636 179.54 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -68.85 -153.4 0.58 Allowed Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 179.888 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.9 Cg_endo -69.24 -50.45 0.52 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.906 1.477 . . . . 0.0 109.863 179.974 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.56 116.66 31.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -0.839 . . . . 0.0 110.34 179.779 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.471 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -130.34 113.62 14.6 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.271 -0.893 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.464 HG22 ' HA ' ' A' ' 283' ' ' THR . 57.2 m -105.73 149.84 26.05 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.175 -0.953 . . . . 0.0 110.37 -179.966 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 8.3 p90 -154.73 170.74 20.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.408 -0.808 . . . . 0.0 108.905 179.67 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.71 149.73 21.62 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.057 -179.3 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.662 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -136.15 147.98 47.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.496 -1.002 . . . . 0.0 110.019 179.573 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.556 ' HA ' ' O ' ' A' ' 278' ' ' ALA . 1.6 mp -120.65 122.49 68.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 120.997 -1.065 . . . . 0.0 109.925 179.501 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.594 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.1 t -96.55 150.23 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.082 -1.011 . . . . 0.0 110.003 -179.968 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -119.1 132.36 56.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.437 -0.789 . . . . 0.0 109.946 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.437 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.177 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.997 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.536 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.433 0 CA-C-O 121.291 0.567 . . . . 0.0 110.575 . . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.582 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 14.5 p -130.02 126.74 62.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.386 -0.821 . . . . 0.0 109.667 179.106 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.1 mt-10 -62.85 -38.43 90.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 111.106 -179.072 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.466 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.7 pt-20 -176.86 158.9 1.68 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 110.897 -179.479 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.509 HG12 ' CG1' ' A' ' 296' ' ' VAL . 14.7 mt -123.42 103.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.143 -0.973 . . . . 0.0 110.03 179.627 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.0 145.58 31.18 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.306 -0.871 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.605 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.07 128.36 55.85 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.308 179.693 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 13.9 tt0 -138.61 120.86 15.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.875 179.689 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.54 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -90.81 93.82 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.092 -1.005 . . . . 0.0 110.026 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.529 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 46.34 26.38 0.47 Allowed 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.909 -0.495 . . . . 0.0 110.797 179.923 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 135.66 -29.66 2.85 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.658 179.398 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.472 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 58.7 mm-40 -89.06 110.18 20.93 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.911 -1.347 . . . . 0.0 110.65 -179.442 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 13.9 p -74.13 140.36 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.255 -0.903 . . . . 0.0 109.917 179.408 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.474 HD13 HG22 ' A' ' 358' ' ' ILE . 9.7 mm . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.114 -0.991 . . . . 0.0 110.234 -179.752 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.54 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.43 164.69 29.19 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.402 -1.057 . . . . 0.0 109.841 179.933 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.556 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.6 tm? -161.04 135.37 7.13 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.124 -179.436 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.528 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -132.31 144.25 50.44 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.175 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 49.9 t -135.58 140.95 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.689 -1.257 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.491 ' O ' HG22 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -127.47 156.7 41.72 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.734 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.565 HG23 ' CD2' ' A' ' 280' ' ' TYR . 94.4 t -143.31 146.93 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.391 -1.443 . . . . 0.0 112.162 -179.338 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.534 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.94 113.8 8.79 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.084 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 m-20 -97.52 148.84 22.83 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.002 -1.061 . . . . 0.0 111.339 -178.818 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.589 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 34.1 p90 -133.74 17.68 3.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.487 -0.758 . . . . 0.0 109.942 179.417 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.37 -57.04 3.9 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.711 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -72.78 -17.12 61.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -1.164 . . . . 0.0 110.226 -179.827 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.543 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.14 -178.04 47.31 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.49 -1.338 . . . . 0.0 109.981 179.876 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.545 ' HB3' ' CZ ' ' A' ' 280' ' ' TYR . . . -138.35 141.23 39.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.388 -1.066 . . . . 0.0 110.125 -179.898 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.589 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 7.8 mt-10 -93.01 147.21 23.03 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.294 -0.879 . . . . 0.0 110.0 -179.838 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.6 m-85 -139.13 84.54 2.01 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.406 -0.809 . . . . 0.0 110.444 -179.581 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.431 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -66.26 150.68 48.44 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.525 -0.734 . . . . 0.0 109.736 179.419 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.59 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.2 t -146.47 89.37 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.392 -0.818 . . . . 0.0 110.019 -179.555 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.407 ' O ' HD21 ' A' ' 267' ' ' LEU . 26.2 m -86.04 126.15 33.95 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 109.342 179.601 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.597 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.12 152.18 29.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.119 -0.988 . . . . 0.0 110.929 -178.894 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.544 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.5 OUTLIER -131.39 134.73 46.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.731 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.531 ' CD2' ' O ' ' A' ' 285' ' ' ASN . 17.2 mt -142.72 162.04 36.51 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.871 -1.143 . . . . 0.0 110.332 -179.846 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.68 34.94 0.71 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.29 -0.881 . . . . 0.0 109.984 179.731 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 144.98 -128.08 3.08 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.825 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.473 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.6 mm-40 -106.25 108.0 19.28 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.033 -1.275 . . . . 0.0 110.969 -179.621 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 8.4 m-85 -127.02 134.76 50.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.336 -0.853 . . . . 0.0 109.493 179.523 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.544 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 2.0 t70 -73.85 96.37 2.58 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.808 -1.183 . . . . 0.0 108.785 179.02 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.583 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 56.0 p-90 -98.66 109.26 22.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 111.36 -178.853 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.597 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 2.8 m -100.82 115.65 30.83 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.769 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 320' ' ' ILE . 6.6 t -96.59 111.01 25.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.132 -0.98 . . . . 0.0 110.83 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.443 ' HA ' HG12 ' A' ' 320' ' ' ILE . 2.9 ttpp -87.87 145.32 26.12 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.459 -0.776 . . . . 0.0 109.346 179.118 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.56 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 84.6 t -145.4 107.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.153 -0.967 . . . . 0.0 110.452 -179.439 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.561 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.1 mmtt -70.33 133.06 46.58 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.194 -0.941 . . . . 0.0 109.773 179.806 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.541 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 72.4 mt -87.43 157.83 19.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.441 -0.787 . . . . 0.0 111.731 -178.735 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.533 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -64.95 176.95 0.68 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.6 -0.688 . . . . 0.0 109.571 179.237 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.508 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.6 Cg_endo -68.1 82.47 0.48 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.62 1.327 . . . . 0.0 110.001 179.628 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.7 22.62 5.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.38 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.501 ' HB3' ' HB2' ' A' ' 299' ' ' ALA . . . -110.48 144.7 38.89 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.357 -1.084 . . . . 0.0 110.227 -179.747 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.52 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.5 p -147.57 146.12 29.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 110.391 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.447 HG22 HD22 ' A' ' 298' ' ' LEU . 77.8 t -73.11 125.73 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.374 -0.829 . . . . 0.0 110.101 179.896 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.63 -15.8 5.72 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.429 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.3 OUTLIER -144.73 126.99 15.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.207 -1.173 . . . . 0.0 110.837 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.503 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -149.69 173.46 13.66 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.361 -0.837 . . . . 0.0 109.835 179.531 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.417 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -163.54 158.06 20.33 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.797 -1.189 . . . . 0.0 111.713 -179.761 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.525 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 1.2 m 58.87 26.32 14.73 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.292 0.568 . . . . 0.0 111.052 179.575 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.546 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.87 141.47 0.61 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 110.089 179.405 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.514 ' ND2' HG11 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.09 117.76 18.96 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.017 -1.052 . . . . 0.0 109.35 179.61 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.449 ' HG3' HG11 ' A' ' 319' ' ' VAL . 4.2 ttpt -86.21 133.16 33.86 Favored 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.719 0.771 . . . . 0.0 110.877 -179.355 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.528 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -115.17 172.3 7.15 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.903 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -134.75 103.12 5.5 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 110.177 -179.868 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.496 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.21 49.82 3.01 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 47.92 80.85 0.05 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.146 -1.208 . . . . 0.0 109.971 -179.947 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.79 -1.26 58.05 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.6 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.3 m-85 -141.71 179.48 6.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.464 -1.021 . . . . 0.0 109.256 179.502 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.564 HG13 ' CZ ' ' A' ' 321' ' ' PHE . 5.2 t -154.22 153.8 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.932 . . . . 0.0 109.286 178.721 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.597 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 78.3 mt -132.19 138.69 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.996 -1.065 . . . . 0.0 111.337 -179.536 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.5 m-85 -113.42 133.61 55.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.084 -1.01 . . . . 0.0 111.066 -179.629 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.503 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.3 p -127.74 169.19 12.99 Favored Pre-proline 0 C--N 1.3 -1.546 0 O-C-N 121.072 -1.017 . . . . 0.0 109.672 179.011 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.52 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.5 Cg_endo -66.34 117.23 4.54 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.812 1.428 . . . . 0.0 111.1 -179.22 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.514 HG11 ' ND2' ' A' ' 311' ' ' ASN . 13.3 m -62.12 -112.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.455 -0.778 . . . . 0.0 110.059 179.872 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.46 -19.38 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 179.873 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.43 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 7.9 p-90 -122.48 -17.96 6.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.232 -0.917 . . . . 0.0 110.287 -179.904 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.484 ' ND2' ' HB1' ' A' ' 332' ' ' ALA . 4.5 t30 -83.9 46.47 1.19 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 0.0 110.066 -179.885 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.493 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.61 -11.95 7.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.393 -0.817 . . . . 0.0 109.783 -179.933 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.49 -163.77 0.02 OUTLIER Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.735 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.13 2.24 5.75 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 124.07 1.563 . . . . 0.0 110.625 179.9 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.8 m -159.61 114.98 2.43 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.619 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.484 ' HB1' ' ND2' ' A' ' 327' ' ' ASN . . . -137.76 128.23 26.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.136 -0.978 . . . . 0.0 110.13 -179.767 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 87.0 m -117.27 148.9 41.26 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.151 -0.968 . . . . 0.0 110.496 -179.785 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.59 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 11.8 p90 -150.4 169.2 22.0 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.448 -0.782 . . . . 0.0 108.952 179.796 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.503 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -145.48 158.66 27.73 Favored Glycine 0 N--CA 1.489 2.21 0 C-N-CA 118.737 -1.697 . . . . 0.0 110.128 -179.704 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.693 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.1 p90 -145.03 148.18 33.43 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.521 -0.988 . . . . 0.0 109.876 179.397 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.54 HG21 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -121.48 120.19 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.839 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.541 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.7 t -97.89 149.37 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.264 -0.897 . . . . 0.0 110.266 -179.749 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -118.96 131.36 56.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.398 -0.814 . . . . 0.0 110.396 -179.776 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 179.869 . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.533 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 121.177 0.513 . . . . 0.0 110.757 . . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.586 HG12 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -132.46 119.66 39.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.305 -0.872 . . . . 0.0 110.148 179.335 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.501 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.87 -44.71 50.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.874 . . . . 0.0 110.151 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.45 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.83 158.49 1.64 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.287 -0.883 . . . . 0.0 110.524 -179.967 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.479 HG12 ' CG1' ' A' ' 296' ' ' VAL . 35.5 mt -118.89 104.85 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.198 -0.939 . . . . 0.0 110.04 179.521 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.03 138.76 43.74 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -0.873 . . . . 0.0 110.325 -179.921 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.597 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.33 133.43 42.74 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.229 179.832 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.415 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 28.6 tt0 -139.24 108.83 6.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.192 -0.942 . . . . 0.0 110.262 179.985 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.544 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.64 108.62 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.932 -1.105 . . . . 0.0 109.816 179.447 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.523 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 40.45 33.14 0.16 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.688 -0.633 . . . . 0.0 110.474 -179.724 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 115.29 -22.33 12.25 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.842 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.419 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 0.1 OUTLIER -79.77 104.41 10.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.148 -1.207 . . . . 0.0 110.139 179.988 . . . . . . . . 3 3 . 1 . 035 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 5.2 p -74.5 109.9 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 110.358 -179.775 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 351' ' ' LEU . 23.0 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.199 179.86 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 . . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.531 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -138.76 164.86 28.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -1.075 . . . . 0.0 110.234 179.958 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.566 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.7 tm? -160.59 133.9 6.7 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.066 -179.703 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.533 ' N ' HD21 ' A' ' 267' ' ' LEU . 3.0 mp0 -131.35 146.72 52.4 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.175 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.419 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -139.99 145.66 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.587 -1.321 . . . . 0.0 111.551 -178.966 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . 0.426 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -132.97 157.59 44.8 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.203 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.575 HG21 ' CD2' ' A' ' 280' ' ' TYR . 76.5 t -143.77 147.06 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.413 -1.429 . . . . 0.0 112.18 -179.175 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.541 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.63 111.12 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.594 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -96.29 147.87 23.34 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.982 -1.074 . . . . 0.0 111.179 -179.101 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.591 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 33.8 p90 -133.05 16.68 4.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.497 -0.752 . . . . 0.0 110.096 179.388 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 92.0 -60.28 2.72 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.694 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.48 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 22.9 t -71.03 -17.73 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -1.178 . . . . 0.0 110.293 -179.864 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.541 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.45 179.4 47.51 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.315 -1.422 . . . . 0.0 110.148 179.926 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.82 140.38 44.18 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.39 -1.065 . . . . 0.0 110.168 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.591 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 9.5 mt-10 -93.11 147.06 23.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.734 -179.936 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 93.7 m-85 -140.64 87.77 2.15 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.202 -0.937 . . . . 0.0 110.383 -179.615 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.419 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.16 150.05 46.91 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.436 -0.79 . . . . 0.0 109.854 179.573 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.645 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.6 t -143.21 90.35 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.409 -0.807 . . . . 0.0 109.87 -179.61 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.415 ' HA ' HG22 ' A' ' 333' ' ' THR . 10.6 m -86.49 122.45 30.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.995 . . . . 0.0 109.6 179.745 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.602 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.3 OUTLIER -110.22 149.95 29.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.205 -0.934 . . . . 0.0 110.801 -179.166 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.533 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.4 OUTLIER -129.67 132.4 46.67 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.281 -0.887 . . . . 0.0 110.324 -179.557 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.532 ' CD2' ' O ' ' A' ' 285' ' ' ASN . 16.4 mt -142.7 159.88 41.37 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.107 . . . . 0.0 109.859 179.458 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -87.86 32.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 110.154 -179.952 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.493 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 150.97 -134.11 4.56 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.467 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 8.7 mm-40 -101.52 106.95 18.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.253 -1.145 . . . . 0.0 110.476 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.518 ' HB2' ' CD1' ' A' ' 286' ' ' LEU . 7.2 m-85 -126.17 130.4 50.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.372 -0.83 . . . . 0.0 109.185 179.588 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.535 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 24.7 m-20 -68.67 96.93 0.76 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.718 -1.239 . . . . 0.0 109.291 179.576 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.602 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 60.7 p-90 -100.51 114.26 27.73 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.139 -0.976 . . . . 0.0 110.776 -179.424 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.488 HG22 ' CG2' ' A' ' 320' ' ' ILE . 4.9 m -109.34 114.57 28.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.528 -0.732 . . . . 0.0 109.325 179.495 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.509 HG21 ' CD2' ' A' ' 351' ' ' LEU . 3.9 t -96.78 111.6 27.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.075 -1.016 . . . . 0.0 110.752 -179.198 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.491 ' HA ' HD12 ' A' ' 320' ' ' ILE . 32.7 ttpt -91.41 141.03 29.19 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.328 -0.857 . . . . 0.0 109.362 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.56 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 71.8 t -137.54 112.27 9.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.262 -0.899 . . . . 0.0 110.564 -179.311 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.573 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 10.4 mmtp -71.72 131.53 43.25 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.183 -0.948 . . . . 0.0 109.308 179.454 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.569 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 91.1 mt -83.53 161.45 21.22 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.282 -0.886 . . . . 0.0 111.889 -178.658 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.568 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.16 176.99 0.84 Allowed Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.686 -0.634 . . . . 0.0 109.77 179.354 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.54 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.9 Cg_endo -67.43 80.2 0.43 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.615 1.324 . . . . 0.0 109.79 179.288 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.2 19.88 6.95 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.377 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.523 ' CB ' ' HB3' ' A' ' 299' ' ' ALA . . . -101.33 156.37 17.49 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.365 -1.079 . . . . 0.0 110.351 -179.759 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.537 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 74.3 p -156.85 144.19 18.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.92 . . . . 0.0 110.474 179.93 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.587 ' CG1' ' CD ' ' A' ' 312' ' ' LYS . 30.1 t -71.1 133.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.353 -0.842 . . . . 0.0 110.123 179.784 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.17 -42.11 0.78 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.706 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.61 136.41 46.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.108 -1.231 . . . . 0.0 110.998 -179.554 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.9 p90 -149.08 174.99 11.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.413 -0.805 . . . . 0.0 109.693 179.469 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.494 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.57 159.29 21.71 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.041 -1.037 . . . . 0.0 111.136 -179.751 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.574 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 58.57 23.81 11.28 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.561 -0.712 . . . . 0.0 111.077 179.668 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.519 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 140.92 0.61 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 110.262 179.494 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.521 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -79.45 124.64 28.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.022 -1.049 . . . . 0.0 109.053 179.387 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.587 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 6.2 ttpt -91.85 133.18 35.88 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.796 0.808 . . . . 0.0 111.199 -179.148 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.51 175.43 5.57 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.61 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -135.77 103.6 5.47 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.251 -0.906 . . . . 0.0 110.286 -179.975 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -90.07 47.57 3.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.828 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 m120 51.9 82.62 0.06 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.343 -1.093 . . . . 0.0 110.416 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.29 1.43 60.91 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.607 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.2 m-85 -143.32 -168.37 2.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -1.027 . . . . 0.0 109.102 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 6.8 t -162.52 158.21 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.325 -0.859 . . . . 0.0 109.832 178.964 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.507 ' O ' ' HA ' ' A' ' 312' ' ' LYS . 21.6 mm -127.88 148.44 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.096 -1.003 . . . . 0.0 111.114 -179.717 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.632 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 84.8 m-85 -124.85 127.02 46.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.235 -0.916 . . . . 0.0 109.836 179.116 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.521 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 3.2 p -126.76 168.77 13.56 Favored Pre-proline 0 C--N 1.301 -1.533 0 C-N-CA 119.068 -1.053 . . . . 0.0 110.307 179.984 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.521 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.8 Cg_endo -66.05 116.09 3.81 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.84 1.442 . . . . 0.0 111.056 -179.448 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.515 HG23 ' CE2' ' A' ' 326' ' ' TRP . 16.0 m -63.18 -115.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.335 -0.853 . . . . 0.0 109.839 179.865 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 73.6 m -118.18 -13.31 9.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.797 -1.189 . . . . 0.0 110.295 179.933 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.574 ' CZ2' ' HA ' ' A' ' 309' ' ' SER . 18.6 p-90 -127.76 -3.36 5.93 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 0.0 110.411 -179.932 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.497 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 1.0 OUTLIER -104.99 41.59 1.32 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.269 -0.894 . . . . 0.0 110.31 -179.72 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.486 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -115.91 -9.26 11.83 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 179.825 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.81 -161.73 0.02 OUTLIER Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.607 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.493 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.5 Cg_endo -74.37 4.77 4.12 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 O-C-N 123.992 1.522 . . . . 0.0 111.097 -179.837 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.437 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 6.6 m -163.96 114.99 1.33 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.842 179.741 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.0 127.45 28.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.185 -0.947 . . . . 0.0 110.267 -179.774 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.472 ' O ' ' HB2' ' A' ' 309' ' ' SER . 91.3 m -115.3 137.51 51.96 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.915 . . . . 0.0 110.308 -179.95 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.645 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 14.9 p90 -138.87 174.95 9.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.303 -0.873 . . . . 0.0 109.014 179.568 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.31 156.87 26.94 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 119.034 -1.555 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.679 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.2 p90 -144.37 149.09 35.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.594 -0.945 . . . . 0.0 109.689 179.445 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.535 ' N ' HD12 ' A' ' 337' ' ' ILE . 1.7 mp -120.47 117.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.078 -1.014 . . . . 0.0 109.833 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.569 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.4 t -96.77 152.05 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -0.871 . . . . 0.0 110.204 -179.598 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.453 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -122.78 134.59 54.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.409 -0.807 . . . . 0.0 109.88 179.866 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.453 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 179.951 . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.568 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 121.427 0.632 . . . . 0.0 110.8 . . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.585 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.9 p -132.55 116.94 29.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.231 -0.918 . . . . 0.0 109.938 179.561 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -45.3 -46.1 12.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.021 -1.049 . . . . 0.0 110.116 -179.604 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.429 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.3 pt-20 -177.12 158.5 1.52 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 110.473 179.979 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.492 HG21 HG22 ' A' ' 296' ' ' VAL . 27.3 mt -116.32 117.86 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.24 -0.912 . . . . 0.0 110.216 179.677 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.88 145.42 47.67 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.162 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.592 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.63 133.67 51.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.015 -1.053 . . . . 0.0 110.679 179.903 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.48 ' N ' HD23 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -138.82 112.88 8.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.371 -0.83 . . . . 0.0 109.901 179.617 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.535 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.55 94.04 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.979 -1.075 . . . . 0.0 110.051 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.427 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 50.68 31.23 5.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.699 -0.626 . . . . 0.0 110.704 179.981 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.65 -26.06 6.36 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.683 -1.246 . . . . 0.0 110.45 179.351 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 41.7 mm-40 -85.92 103.66 14.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.045 -1.267 . . . . 0.0 110.499 -179.576 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.482 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.3 p -73.6 116.47 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.265 -0.897 . . . . 0.0 110.162 179.891 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.495 HG23 HD13 ' A' ' 358' ' ' ILE . 36.9 mm . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.24 -179.992 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.548 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.28 163.61 28.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.428 -1.042 . . . . 0.0 109.511 179.628 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.56 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.8 tm? -161.28 134.73 6.54 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 111.736 -179.611 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . 0.52 ' N ' HD23 ' A' ' 267' ' ' LEU . 2.0 mt-10 -130.38 149.61 51.99 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.975 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 58.6 t -141.3 141.23 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.628 -1.295 . . . . 0.0 111.684 -179.306 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -126.81 157.99 37.78 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.908 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.571 HG12 ' CE2' ' A' ' 280' ' ' TYR . 89.0 t -144.02 146.39 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.333 -1.479 . . . . 0.0 112.193 -179.325 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.517 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.16 110.87 6.47 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.005 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 46.1 p30 -96.15 147.82 23.35 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.163 -0.961 . . . . 0.0 111.378 -178.493 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.562 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 39.4 p90 -134.95 23.65 3.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.586 -0.696 . . . . 0.0 109.884 179.42 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.97 -66.96 3.84 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 276' ' ' SER . . . . . 0.543 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 9.2 m -59.85 -26.35 65.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.197 -1.178 . . . . 0.0 110.615 -179.881 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.562 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -170.96 -177.8 41.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.972 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.563 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -137.22 144.07 42.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.244 -1.15 . . . . 0.0 110.18 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.53 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 6.3 mt-10 -97.41 147.43 24.22 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.385 -0.822 . . . . 0.0 109.967 -179.523 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.691 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 91.1 m-85 -141.43 83.89 1.89 Allowed 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.341 -0.849 . . . . 0.0 110.787 -179.344 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.456 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.8 t70 -64.52 146.98 53.74 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.434 -0.791 . . . . 0.0 109.623 179.144 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.618 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 6.7 t -142.58 89.08 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 -179.647 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 283' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 97.8 m -86.46 123.5 31.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.203 -0.935 . . . . 0.0 109.756 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.599 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.48 150.47 28.84 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.168 -0.957 . . . . 0.0 110.517 -179.525 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.548 ' ND2' ' HB3' ' A' ' 266' ' ' SER . 0.4 OUTLIER -129.12 135.77 49.32 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 109.958 -179.687 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.601 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 11.6 mt -143.18 160.68 39.98 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.075 -1.016 . . . . 0.0 109.481 179.564 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.76 31.76 1.76 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 110.528 -179.598 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.0 -94.6 0.13 Allowed Glycine 0 N--CA 1.491 2.312 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.425 179.876 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.47 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.5 tt0 -152.48 106.51 3.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.055 -1.262 . . . . 0.0 110.695 -179.322 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.644 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 5.0 m-85 -128.38 134.85 48.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 179.585 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.579 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 96.7 m-20 -67.34 96.92 0.52 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.846 -1.159 . . . . 0.0 108.754 178.859 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.58 ' CE3' HD11 ' A' ' 284' ' ' LEU . 59.5 p-90 -97.68 108.89 21.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.146 -0.971 . . . . 0.0 111.166 -178.862 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.589 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 8.6 m -102.18 114.85 29.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.643 -0.661 . . . . 0.0 109.233 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.468 HG23 ' CD2' ' A' ' 351' ' ' LEU . 5.5 t -96.71 111.88 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.1 -1.0 . . . . 0.0 111.076 -178.964 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . 0.414 ' O ' HG21 ' A' ' 296' ' ' VAL . 6.3 ttpt -86.63 149.39 24.95 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.476 -0.765 . . . . 0.0 109.351 179.008 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.6 HG12 ' CZ ' ' A' ' 336' ' ' PHE . 43.4 t -148.67 108.0 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.033 -1.042 . . . . 0.0 110.585 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.544 ' HD2' ' CE1' ' A' ' 318' ' ' TYR . 9.1 mmtm -71.01 134.3 47.02 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.131 -0.981 . . . . 0.0 110.044 179.781 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.533 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 74.9 mt -87.5 165.56 15.42 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.331 -0.855 . . . . 0.0 111.131 -179.37 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.514 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -79.73 173.98 6.85 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 178.883 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.514 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.4 Cg_endo -66.09 84.52 0.26 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.496 1.261 . . . . 0.0 110.125 179.816 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.11 24.15 4.62 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.62 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.472 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -115.73 149.29 38.68 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -1.127 . . . . 0.0 110.202 -179.761 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.493 ' N ' HG13 ' A' ' 338' ' ' VAL . 14.1 p -153.96 144.57 22.43 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.664 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.507 HG23 ' CB ' ' A' ' 319' ' ' VAL . 75.0 t -75.09 135.04 28.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 110.09 179.803 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -128.81 -31.33 0.65 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.707 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.5 m -126.56 109.54 12.25 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.033 -1.275 . . . . 0.0 110.92 -179.555 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.578 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 55.4 p90 -133.44 156.54 47.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.631 179.213 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.486 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -149.32 158.42 44.16 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.966 -1.084 . . . . 0.0 111.201 -179.411 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.55 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 65.46 21.12 11.82 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.741 -0.599 . . . . 0.0 111.279 179.55 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.524 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.97 150.49 1.23 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.231 -0.918 . . . . 0.0 110.516 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.499 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -83.62 119.25 24.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.148 -0.97 . . . . 0.0 108.979 179.134 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.578 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 6.7 ttpt -90.44 131.22 36.33 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.916 0.865 . . . . 0.0 111.407 -178.891 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.529 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 4.7 mt-30 -112.18 178.69 4.22 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.61 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . 0.402 ' HA ' ' O ' ' A' ' 318' ' ' TYR . 7.5 mm-40 -143.78 108.13 4.8 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.458 -0.776 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.44 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -96.53 50.65 1.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 52.48 84.7 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.315 -1.109 . . . . 0.0 110.003 -179.948 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 93.97 -2.28 68.98 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.892 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.545 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.2 m-85 -137.19 -179.59 5.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -1.109 . . . . 0.0 109.683 179.665 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.507 ' CB ' HG23 ' A' ' 304' ' ' VAL . 3.8 t -157.63 155.69 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.444 -0.785 . . . . 0.0 109.421 178.771 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.589 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 1.9 mt -131.99 140.31 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 111.674 -179.147 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 67.5 m-85 -115.74 130.17 56.75 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 110.384 179.548 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.505 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.4 p -127.97 169.96 11.41 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 120.963 -1.086 . . . . 0.0 109.57 179.657 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.505 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -66.16 126.6 16.03 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.594 1.313 . . . . 0.0 110.915 -179.301 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.497 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 35.4 m -77.79 -123.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.826 -179.985 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 19.8 m -100.32 -12.98 19.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.766 -1.209 . . . . 0.0 110.586 -179.911 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . 0.55 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 15.3 p-90 -137.25 5.33 2.74 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.144 -0.972 . . . . 0.0 110.679 -179.887 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.497 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.4 t30 -107.09 43.14 1.2 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.068 -1.02 . . . . 0.0 110.381 -179.639 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.479 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 1.2 pttt -126.82 -5.71 6.28 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.38 -0.825 . . . . 0.0 109.969 179.704 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.0 -156.13 0.03 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 -179.882 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.456 ' O ' ' OG1' ' A' ' 331' ' ' THR . 47.8 Cg_endo -72.23 2.5 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 124.134 1.597 . . . . 0.0 110.964 -179.89 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.9 m -165.4 121.67 1.4 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.257 -0.902 . . . . 0.0 109.946 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.558 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -136.93 107.94 6.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.188 -0.945 . . . . 0.0 110.45 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.458 ' O ' ' HB3' ' A' ' 309' ' ' SER . 25.6 m -98.41 142.04 30.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.192 -0.943 . . . . 0.0 109.96 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.618 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 7.2 p90 -149.14 169.82 19.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.771 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.45 151.68 23.84 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.141 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.691 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.0 OUTLIER -136.44 149.46 48.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.563 -0.963 . . . . 0.0 109.83 179.569 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.542 HD13 ' N ' ' A' ' 337' ' ' ILE . 1.7 mp -122.86 119.34 57.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.144 -0.973 . . . . 0.0 109.529 179.356 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.54 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 3.4 t -95.95 143.74 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.077 -1.014 . . . . 0.0 109.239 179.702 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -120.07 140.48 50.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.176 -0.953 . . . . 0.0 110.86 -179.255 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.234 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.817 . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.54 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.289 0.566 . . . . 0.0 110.436 . . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.604 ' CG1' ' CE2' ' A' ' 280' ' ' TYR . 6.2 p -127.61 120.18 53.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.168 -0.957 . . . . 0.0 110.133 179.614 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.527 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 0.8 OUTLIER -48.43 -46.38 37.53 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.074 -1.016 . . . . 0.0 109.717 -179.825 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.411 ' OE1' ' HB3' ' A' ' 347' ' ' GLU . 1.6 pt-20 -176.99 158.59 1.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.351 -0.843 . . . . 0.0 110.429 179.679 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.477 HG12 HG13 ' A' ' 296' ' ' VAL . 11.3 mt -117.07 103.53 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.887 . . . . 0.0 109.793 179.675 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.61 146.45 28.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.292 -0.88 . . . . 0.0 110.306 -179.737 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.599 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -106.62 132.95 52.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.161 -0.962 . . . . 0.0 110.135 179.576 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.4 tt0 -138.53 112.69 8.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.948 179.86 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.488 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 2.7 mt -91.61 113.17 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.104 -0.997 . . . . 0.0 110.099 179.963 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.579 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.54 29.54 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.752 -0.592 . . . . 0.0 110.918 -179.809 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.84 -13.85 12.91 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.523 179.23 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.488 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 72.7 mm-40 -93.8 113.98 26.14 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.885 -1.362 . . . . 0.0 110.368 -179.836 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.519 ' O ' ' CD1' ' A' ' 358' ' ' ILE . 2.2 p -74.23 138.35 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.183 179.998 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.519 ' CD1' ' O ' ' A' ' 357' ' ' VAL . 19.1 mm . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.277 -179.909 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 038 nuclear orig core ' A' A ' 266' ' ' SER . . . . . 0.574 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -134.62 165.95 24.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.532 -0.981 . . . . 0.0 109.69 179.866 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 267' ' ' LEU . . . . . 0.576 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.0 tm? -161.37 139.17 9.19 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.193 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -138.02 130.38 29.16 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.542 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 269' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 94.9 t -124.32 138.13 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.804 -1.185 . . . . 0.0 111.681 -178.854 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -121.19 157.64 29.78 Favored 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.131 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 271' ' ' VAL . . . . . 0.585 ' CG2' ' CD1' ' A' ' 280' ' ' TYR . 86.7 t -144.15 147.07 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 120.404 -1.435 . . . . 0.0 112.531 -179.049 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 272' ' ' ASN . . . . . 0.528 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -141.35 109.98 6.04 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.864 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 273' ' ' ASP . . . . . 0.53 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 m-20 -94.82 146.71 24.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.114 -0.991 . . . . 0.0 111.535 -178.718 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 274' ' ' TRP . . . . . 0.583 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 39.0 p90 -134.67 23.52 3.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.616 -0.678 . . . . 0.0 109.667 179.062 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.39 -65.33 4.11 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.932 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.0 -23.99 65.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -1.186 . . . . 0.0 110.354 -179.929 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 277' ' ' GLY . . . . . 0.557 ' O ' ' CD2' ' A' ' 274' ' ' TRP . . . -176.57 176.43 47.87 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 278' ' ' ALA . . . . . 0.582 ' HB1' ' CE2' ' A' ' 280' ' ' TYR . . . -131.36 148.55 52.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.359 -1.083 . . . . 0.0 110.259 -179.879 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 279' ' ' GLU . . . . . 0.583 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 16.3 mt-10 -97.63 147.07 24.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.513 -0.742 . . . . 0.0 109.683 -179.81 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 80.1 m-85 -141.7 85.98 1.97 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.362 -0.836 . . . . 0.0 111.045 -179.242 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 281' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -69.22 150.22 47.7 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.389 -0.82 . . . . 0.0 109.54 179.115 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 282' ' ' VAL . . . . . 0.593 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 4.9 t -143.86 87.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.353 -0.842 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 98.0 m -86.68 123.44 31.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.093 -1.005 . . . . 0.0 109.885 179.927 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 284' ' ' LEU . . . . . 0.602 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.4 148.25 30.41 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.201 -0.937 . . . . 0.0 110.062 -179.66 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 285' ' ' ASN . . . . . 0.574 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -129.6 111.98 13.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.221 -0.924 . . . . 0.0 111.134 -178.742 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 286' ' ' LEU . . . . . 0.614 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 10.2 mt -121.47 158.66 27.92 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.809 -1.182 . . . . 0.0 109.407 178.982 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.97 35.62 1.25 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.201 -0.937 . . . . 0.0 110.38 -179.69 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 288' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 163.79 -103.14 0.21 Allowed Glycine 0 N--CA 1.492 2.379 0 C-N-CA 118.879 -1.629 . . . . 0.0 110.561 179.983 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 289' ' ' GLN . . . . . 0.52 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 1.7 mt-30 -148.27 120.45 8.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -1.132 . . . . 0.0 110.411 -179.343 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 290' ' ' TYR . . . . . 0.614 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -151.27 131.29 13.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.826 179.553 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 291' ' ' ASP . . . . . 0.518 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 4.9 t70 -62.1 103.81 0.41 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.096 -1.002 . . . . 0.0 109.568 179.59 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 292' ' ' TRP . . . . . 0.586 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 53.9 p-90 -103.0 111.07 23.23 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.291 -0.881 . . . . 0.0 110.49 -179.758 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 293' ' ' THR . . . . . 0.562 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 25.3 m -105.08 114.71 29.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.776 179.639 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 294' ' ' VAL . . . . . 0.517 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.1 t -97.07 110.86 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 110.077 -179.732 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 21.2 ttmt -86.32 149.4 25.07 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.189 -0.945 . . . . 0.0 109.42 179.148 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 296' ' ' VAL . . . . . 0.575 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 86.3 t -145.6 107.04 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.275 -0.891 . . . . 0.0 110.749 -179.161 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 297' ' ' LYS . . . . . 0.576 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 4.4 mmtt -70.47 136.95 49.88 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.13 -0.981 . . . . 0.0 109.157 179.188 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 298' ' ' LEU . . . . . 0.543 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 95.8 mt -90.47 157.43 17.57 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.23 -0.919 . . . . 0.0 111.673 -178.573 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 299' ' ' ALA . . . . . 0.521 ' HB3' ' CB ' ' A' ' 302' ' ' ALA . . . -65.02 175.43 1.01 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.574 -0.704 . . . . 0.0 109.771 179.443 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 300' ' ' PRO . . . . . 0.493 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -67.25 81.81 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 123.707 1.372 . . . . 0.0 110.049 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.76 19.14 7.5 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.54 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 302' ' ' ALA . . . . . 0.521 ' CB ' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 144.2 34.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.414 -1.051 . . . . 0.0 110.026 -179.812 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 303' ' ' THR . . . . . 0.543 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 18.4 p -145.09 145.04 31.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.137 -0.977 . . . . 0.0 110.886 -179.985 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 304' ' ' VAL . . . . . 0.519 ' CG2' HG22 ' A' ' 319' ' ' VAL . 75.4 t -70.39 142.41 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.46 -0.775 . . . . 0.0 109.96 179.697 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.65 -40.68 0.2 Allowed Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.663 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 306' ' ' SER . . . . . 0.428 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -120.76 118.69 30.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.051 -1.264 . . . . 0.0 110.631 -179.599 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 307' ' ' PHE . . . . . 0.538 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.7 p90 -141.86 156.78 45.52 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.255 -0.903 . . . . 0.0 109.641 179.671 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 308' ' ' TRP . . . . . 0.478 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.83 158.72 42.62 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.087 -1.008 . . . . 0.0 111.188 -179.206 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 309' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 60.47 25.43 15.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.592 -0.692 . . . . 0.0 110.926 179.611 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 310' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -174.61 142.24 0.71 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.183 -0.948 . . . . 0.0 110.282 179.679 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 311' ' ' ASN . . . . . 0.522 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -77.21 123.74 26.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.115 -0.991 . . . . 0.0 109.296 179.355 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 312' ' ' LYS . . . . . 0.538 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 1.7 ttpt -94.5 123.4 37.9 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.555 0.693 . . . . 0.0 110.95 -179.341 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 313' ' ' GLN . . . . . 0.617 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 2.1 mt-30 -109.65 177.21 4.8 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.549 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -136.28 99.69 4.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.468 -0.77 . . . . 0.0 110.129 179.939 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.58 41.3 3.08 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.777 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 58.31 83.98 0.11 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.155 -1.203 . . . . 0.0 110.158 179.981 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 317' ' ' GLY . . . . . 0.612 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.14 3.99 63.22 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 318' ' ' TYR . . . . . 0.612 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.3 m-85 -146.47 -169.87 3.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.398 -1.06 . . . . 0.0 108.988 179.54 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 319' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 12.8 t -161.44 149.98 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 0.0 109.843 179.147 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 320' ' ' ILE . . . . . 0.617 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 8.7 mm -114.76 151.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 120.937 -1.102 . . . . 0.0 110.836 -179.946 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.8 m-85 -130.06 115.68 17.45 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.166 -0.959 . . . . 0.0 109.963 178.977 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 322' ' ' THR . . . . . 0.522 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 24.7 p -122.23 167.0 15.02 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 120.728 -1.232 . . . . 0.0 109.654 179.551 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 323' ' ' PRO . . . . . 0.525 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.1 Cg_endo -64.81 120.05 7.22 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.803 1.423 . . . . 0.0 110.893 -179.362 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 324' ' ' VAL . . . . . 0.452 HG11 ' ND2' ' A' ' 311' ' ' ASN . 28.9 m -63.31 -126.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.498 -0.751 . . . . 0.0 110.149 -179.873 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.09 -20.78 15.2 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.847 -1.158 . . . . 0.0 110.869 -179.585 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 23.9 p-90 -124.57 -1.68 7.99 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.998 -1.063 . . . . 0.0 110.699 -179.753 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 327' ' ' ASN . . . . . 0.44 ' O ' ' HB3' ' A' ' 323' ' ' PRO . 2.7 t30 -104.7 44.52 1.02 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.107 -0.996 . . . . 0.0 110.614 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 328' ' ' LYS . . . . . 0.443 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -126.13 10.86 7.55 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.055 -1.028 . . . . 0.0 109.961 179.704 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 329' ' ' GLY . . . . . 0.455 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -73.89 -143.37 0.73 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.615 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 330' ' ' PRO . . . . . 0.554 ' O ' ' N ' ' A' ' 286' ' ' LEU . 43.7 Cg_endo -72.75 -56.15 0.09 OUTLIER 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.463 . . . . 0.0 109.756 179.602 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 7.2 m -107.94 126.43 52.69 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.177 -0.952 . . . . 0.0 110.204 179.76 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 332' ' ' ALA . . . . . 0.563 ' HB3' ' CZ2' ' A' ' 292' ' ' TRP . . . -138.66 109.48 6.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.379 -0.826 . . . . 0.0 109.945 179.902 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 333' ' ' THR . . . . . 0.463 ' O ' ' HB2' ' A' ' 309' ' ' SER . 8.8 m -100.81 145.33 28.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.432 -179.715 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 334' ' ' PHE . . . . . 0.593 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 10.1 p90 -151.54 174.92 12.85 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.552 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 335' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.9 165.45 31.13 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 118.838 -1.648 . . . . 0.0 110.518 -179.319 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 336' ' ' PHE . . . . . 0.676 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -152.27 143.58 23.3 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.525 -0.986 . . . . 0.0 109.9 179.634 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 337' ' ' ILE . . . . . 0.552 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.5 mp -117.76 125.27 74.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.064 -1.022 . . . . 0.0 109.886 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 338' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.7 t -101.9 145.47 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.276 -0.89 . . . . 0.0 109.945 179.835 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 339' ' ' ASN . . . . . 0.466 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 1.9 m-80 -113.84 126.76 55.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.344 -0.847 . . . . 0.0 110.098 179.873 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 340' ' ' GLY . . . . . 0.406 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.994 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 345' ' ' LYS . . . . . 0.533 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.126 0.489 . . . . 0.0 110.809 . . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 346' ' ' VAL . . . . . 0.605 HG12 ' CE1' ' A' ' 280' ' ' TYR . 12.6 p -132.5 116.93 29.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.195 -0.941 . . . . 0.0 110.245 179.632 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 347' ' ' GLU . . . . . 0.455 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -46.65 -45.39 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.895 . . . . 0.0 110.319 -179.937 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 348' ' ' GLU . . . . . 0.415 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 13.9 pt-20 -176.67 158.34 1.69 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.125 -0.984 . . . . 0.0 110.686 -179.781 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 349' ' ' ILE . . . . . 0.522 HG12 ' CG1' ' A' ' 296' ' ' VAL . 39.8 mt -122.31 105.94 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.121 -0.987 . . . . 0.0 109.918 179.516 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.78 143.92 35.66 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.085 -1.009 . . . . 0.0 110.283 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 351' ' ' LEU . . . . . 0.602 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.6 128.59 53.7 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.194 -0.941 . . . . 0.0 109.953 179.694 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 352' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.3 OUTLIER -138.62 119.26 14.01 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.974 . . . . 0.0 110.123 179.814 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 353' ' ' ILE . . . . . 0.482 HG12 ' HA ' ' A' ' 292' ' ' TRP . 2.0 mt -92.8 109.7 21.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.16 -0.963 . . . . 0.0 110.271 179.934 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.27 46.36 0.88 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.592 . . . . 0.0 111.202 -179.979 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.37 -36.24 4.38 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.385 179.246 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 356' ' ' GLN . . . . . 0.476 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 38.3 mm-40 -66.88 176.07 2.2 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.012 -1.287 . . . . 0.0 110.311 -179.587 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 357' ' ' VAL . . . . . 0.461 ' O ' HD11 ' A' ' 358' ' ' ILE . 5.6 p -140.65 129.82 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.305 -0.872 . . . . 0.0 109.969 -179.955 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 358' ' ' ILE . . . . . 0.461 HD11 ' O ' ' A' ' 357' ' ' VAL . 8.3 mm . . . . . 0 N--CA 1.494 1.726 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.303 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -73.19 -178.62 3.71 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 124.017 1.535 . . . . 0.0 110.668 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.522 ' CG2' ' O ' ' A' ' 258' ' ' THR . 9.1 t -60.23 120.21 9.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.349 -0.844 . . . . 0.0 110.206 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 259' ' ' THR . . . . . 0.444 HG23 ' HD2' ' A' ' 260' ' ' PRO . 89.0 m -112.57 134.03 21.72 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.923 . . . . 0.0 110.179 179.944 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . 0.444 ' HD2' HG23 ' A' ' 259' ' ' THR . 47.5 Cg_endo -72.93 160.21 46.43 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.928 1.488 . . . . 0.0 110.491 -179.856 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.42 HG22 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -105.82 142.83 25.62 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.291 -0.881 . . . . 0.0 110.472 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.45 ' HB3' HG22 ' A' ' 358' ' ' ILE . 46.8 Cg_endo -72.67 146.14 42.83 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 O-C-N 124.122 1.591 . . . . 0.0 110.449 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.461 ' O ' ' OG ' ' A' ' 264' ' ' SER . 40.8 t -139.88 29.82 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.238 -0.914 . . . . 0.0 110.01 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.461 ' OG ' ' O ' ' A' ' 263' ' ' VAL . 1.4 m 179.32 74.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.298 -0.876 . . . . 0.0 110.477 -179.904 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 128.8 174.97 13.88 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.77 -1.205 . . . . 0.0 110.122 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.56 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.78 158.58 44.05 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.473 -1.016 . . . . 0.0 109.699 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.532 ' CD1' ' HG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -153.02 123.89 7.38 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.08 -1.012 . . . . 0.0 110.749 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.473 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 3.3 mt-10 -122.05 113.72 19.93 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.476 ' CG1' ' O ' ' A' ' 281' ' ' ASP . 47.5 t -108.11 145.8 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.957 -1.089 . . . . 0.0 111.734 -178.513 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.421 ' C ' HG23 ' A' ' 271' ' ' VAL . 5.5 mttp -130.16 156.91 43.8 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.003 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.534 HG21 ' CD2' ' A' ' 280' ' ' TYR . 75.4 t -144.75 139.44 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.407 -1.433 . . . . 0.0 111.647 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.529 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -134.52 110.89 9.66 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.174 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.507 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.9 m-20 -98.72 135.42 40.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.939 -1.101 . . . . 0.0 111.71 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.541 ' CZ2' ' C ' ' A' ' 277' ' ' GLY . 33.6 p90 -119.75 20.15 12.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.507 -0.746 . . . . 0.0 109.209 178.919 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.47 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 87.06 -77.97 1.93 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 32.0 m -51.22 -24.63 4.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.366 -1.079 . . . . 0.0 110.465 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.541 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -165.62 174.28 41.35 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.298 -1.429 . . . . 0.0 110.311 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.567 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -133.58 141.77 47.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.46 -1.024 . . . . 0.0 110.028 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.53 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 5.3 mt-10 -97.66 146.65 25.12 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.325 -0.859 . . . . 0.0 109.915 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 94.4 m-85 -141.84 85.24 1.93 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.442 -0.786 . . . . 0.0 110.405 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.476 ' O ' ' CG1' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -69.6 154.21 42.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.864 . . . . 0.0 109.997 179.498 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.602 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 4.2 t -145.03 89.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 O-C-N 121.629 -0.669 . . . . 0.0 109.506 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 10.5 m -86.08 117.48 24.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.126 -0.984 . . . . 0.0 109.626 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.572 HD13 ' CE3' ' A' ' 292' ' ' TRP . 0.9 OUTLIER -106.25 144.08 33.45 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.202 -0.936 . . . . 0.0 110.766 -179.07 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.56 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.5 OUTLIER -126.65 115.9 20.18 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.604 -0.685 . . . . 0.0 109.825 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.58 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 11.0 mt -124.9 155.21 39.9 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.633 -1.292 . . . . 0.0 110.262 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -89.8 34.87 0.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.195 -0.94 . . . . 0.0 110.105 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 161.57 -157.44 29.12 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.492 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -96.42 93.62 6.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -1.118 . . . . 0.0 110.706 -179.663 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.58 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.9 m-30 -116.36 143.09 45.99 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.218 -0.926 . . . . 0.0 110.109 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.564 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 1.6 m-20 -77.89 98.71 5.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.083 -1.011 . . . . 0.0 109.201 179.032 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.582 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 54.8 p-90 -98.31 113.32 25.23 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.286 -0.884 . . . . 0.0 110.785 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.534 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 10.5 m -105.71 115.58 30.48 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 109.526 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.467 HG23 HD23 ' A' ' 351' ' ' LEU . 3.3 t -97.19 113.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.101 -0.999 . . . . 0.0 110.49 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.477 ' HA ' HD12 ' A' ' 320' ' ' ILE . 9.2 ttpt -92.5 135.09 34.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.333 -0.854 . . . . 0.0 109.599 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.547 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 95.0 t -132.26 108.05 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.064 -1.023 . . . . 0.0 110.691 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.456 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtt -70.0 134.55 48.43 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.086 -1.009 . . . . 0.0 109.178 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.589 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 61.5 mt -88.51 162.48 16.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.181 -0.95 . . . . 0.0 111.723 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -64.37 176.77 0.65 Allowed Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.779 -0.576 . . . . 0.0 109.877 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.501 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.82 77.28 0.57 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.657 1.346 . . . . 0.0 109.903 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.43 19.73 5.71 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.541 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -103.65 150.18 24.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.415 -1.05 . . . . 0.0 110.248 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.553 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 27.0 p -149.92 144.36 25.85 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.267 -0.895 . . . . 0.0 110.642 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.508 ' CG1' ' HD2' ' A' ' 312' ' ' LYS . 29.5 t -67.45 136.54 26.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.356 -0.84 . . . . 0.0 109.975 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.8 -41.98 0.54 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.464 ' O ' HD11 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -128.94 129.96 46.14 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.134 -1.215 . . . . 0.0 110.756 -179.659 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.593 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.1 p90 -146.39 169.09 19.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.398 -0.814 . . . . 0.0 109.463 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.482 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.96 160.98 22.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.878 -1.139 . . . . 0.0 111.23 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.479 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.85 20.99 12.55 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.485 -0.759 . . . . 0.0 111.003 179.433 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.49 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -174.98 144.33 0.76 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.355 -0.841 . . . . 0.0 110.05 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.527 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -78.51 124.44 28.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.023 -1.048 . . . . 0.0 109.166 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.51 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 1.1 ttpt -91.92 138.34 31.62 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.775 0.797 . . . . 0.0 110.916 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.505 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -121.41 173.7 7.21 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.003 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -136.35 106.48 6.34 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.392 -0.817 . . . . 0.0 110.487 -179.806 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.45 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -94.04 40.82 2.69 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.45 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 25.1 m120 57.43 82.33 0.13 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.249 -1.148 . . . . 0.0 110.195 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.623 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.84 0.87 57.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.623 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.9 m-85 -145.77 -169.62 3.27 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.333 -1.098 . . . . 0.0 109.279 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.508 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 4.7 t -162.55 157.84 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.216 -0.928 . . . . 0.0 109.8 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.534 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.3 mm -126.65 145.91 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.156 -0.965 . . . . 0.0 111.086 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.637 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.3 m-85 -123.16 128.5 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.125 -0.984 . . . . 0.0 110.195 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.527 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 25.0 p -129.58 166.37 26.33 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 120.802 -1.187 . . . . 0.0 109.394 179.442 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.512 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.8 Cg_endo -65.22 121.17 8.55 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.698 1.367 . . . . 0.0 111.132 -179.138 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.534 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 28.5 m -64.39 -125.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.626 -0.672 . . . . 0.0 110.182 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 1.4 m -100.69 -13.12 18.64 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.832 -1.168 . . . . 0.0 110.658 -179.701 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 15.9 p-90 -136.35 6.57 3.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.139 -0.975 . . . . 0.0 110.6 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.534 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.7 OUTLIER -108.4 38.14 2.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.136 -0.977 . . . . 0.0 110.41 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.483 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.7 OUTLIER -118.72 -7.69 10.48 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.283 -0.886 . . . . 0.0 110.184 179.76 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.45 -153.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.4 Cg_endo -76.64 8.34 3.08 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.938 1.494 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.423 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.5 m -163.77 128.08 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.926 -1.109 . . . . 0.0 110.089 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.507 ' CB ' ' CZ2' ' A' ' 292' ' ' TRP . . . -146.39 111.33 5.31 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.159 -0.963 . . . . 0.0 110.579 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.479 ' O ' ' HB3' ' A' ' 309' ' ' SER . 50.2 m -104.41 126.75 51.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.925 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.603 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 11.8 p90 -137.08 175.38 9.67 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.497 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -154.98 163.3 31.32 Favored Glycine 0 N--CA 1.486 1.982 0 C-N-CA 118.831 -1.652 . . . . 0.0 109.953 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.676 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.2 p90 -147.04 148.34 31.57 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.566 -0.961 . . . . 0.0 109.631 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.539 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.7 mp -121.12 121.05 63.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.968 -1.083 . . . . 0.0 109.311 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.589 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.0 t -97.09 159.61 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.683 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -128.03 129.57 46.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.463 -0.773 . . . . 0.0 110.161 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.451 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . 179.26 -129.64 1.4 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.523 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 43.5 Cg_endo -69.61 171.6 14.01 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.891 1.469 . . . . 0.0 110.486 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.487 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 16.2 mm-40 -94.56 131.47 40.27 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.236 -0.915 . . . . 0.0 110.854 -179.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 115.93 -87.47 0.44 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 344' ' ' ASP . 21.8 p-10 -115.62 131.38 56.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.447 -1.031 . . . . 0.0 109.168 179.254 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.55 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.2 mtmt -129.21 10.54 5.82 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.959 -1.088 . . . . 0.0 110.475 -179.564 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.589 HG12 ' CE2' ' A' ' 280' ' ' TYR . 11.1 p -133.3 120.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.233 -0.917 . . . . 0.0 110.189 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.436 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -52.5 -45.39 66.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.293 -0.88 . . . . 0.0 110.346 -179.652 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.402 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 5.4 pt-20 -177.09 158.4 1.52 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.049 -1.032 . . . . 0.0 110.905 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.533 HG12 ' CG1' ' A' ' 296' ' ' VAL . 72.1 mt -120.57 109.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.333 -0.854 . . . . 0.0 110.093 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.05 150.97 26.47 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.319 -0.863 . . . . 0.0 110.384 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.536 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.73 126.31 52.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.35 -0.844 . . . . 0.0 109.995 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 2.2 tp10 -138.2 110.17 7.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.163 -0.961 . . . . 0.0 109.935 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.533 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.27 111.26 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.564 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 39.17 32.35 0.07 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.762 -0.586 . . . . 0.0 110.918 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 114.91 -17.75 17.27 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.351 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.499 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 56.3 mm-40 -89.49 115.64 27.07 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.019 -1.283 . . . . 0.0 110.366 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.413 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 12.3 p -79.11 130.07 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.294 -0.879 . . . . 0.0 110.224 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.45 HG22 ' HB3' ' A' ' 262' ' ' PRO . 18.6 mm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.24 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.72 -177.74 2.68 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.002 1.528 . . . . 0.0 110.762 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.468 ' O ' HG23 ' A' ' 258' ' ' THR . 13.3 t -56.9 147.4 23.72 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.489 -0.757 . . . . 0.0 110.693 -179.574 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 259' ' ' THR . . . . . 0.418 ' O ' HG23 ' A' ' 259' ' ' THR . 1.8 t -126.14 115.69 23.8 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.34 -0.85 . . . . 0.0 109.82 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.65 149.32 48.75 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.902 1.474 . . . . 0.0 110.732 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.472 HG22 ' N ' ' A' ' 262' ' ' PRO . 3.0 p -79.42 142.67 58.57 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.357 -0.84 . . . . 0.0 110.271 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.472 ' N ' HG22 ' A' ' 261' ' ' VAL . 47.3 Cg_endo -73.13 125.48 10.35 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 O-C-N 124.125 1.592 . . . . 0.0 110.514 179.763 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.455 HG11 ' O ' ' A' ' 263' ' ' VAL . 64.4 t -117.39 28.98 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.264 -0.897 . . . . 0.0 110.185 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.4 96.18 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.34 -0.85 . . . . 0.0 110.264 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 102.22 166.3 26.73 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.54 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -126.84 164.83 20.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.347 -1.09 . . . . 0.0 109.497 179.59 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.595 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.8 tm? -161.19 140.52 10.33 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.008 -1.077 . . . . 0.0 111.068 -179.561 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 5.2 mt-10 -140.07 134.33 31.2 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 109.182 -0.674 . . . . 0.0 109.182 179.7 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 60.1 t -125.41 136.86 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.807 -1.183 . . . . 0.0 111.648 -178.892 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.481 ' HG3' ' CB ' ' A' ' 281' ' ' ASP . 0.0 OUTLIER -122.96 157.06 33.48 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.55 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.576 HG21 ' CD2' ' A' ' 280' ' ' TYR . 88.7 t -142.77 146.9 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.295 -1.503 . . . . 0.0 112.378 -178.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.523 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.49 113.16 8.5 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.986 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.493 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.9 p-10 -96.21 147.22 23.99 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.069 -1.02 . . . . 0.0 111.425 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.555 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 33.7 p90 -132.08 20.86 4.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.489 -0.757 . . . . 0.0 110.056 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.92 -59.52 4.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.04 -24.63 64.21 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.295 -1.121 . . . . 0.0 110.488 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.535 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -173.26 178.6 45.15 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.588 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -133.75 145.18 49.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -1.166 . . . . 0.0 110.528 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.552 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 7.3 mt-10 -95.83 147.31 23.79 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.612 -0.68 . . . . 0.0 110.04 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.649 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 94.8 m-85 -140.43 86.1 2.05 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.353 -0.842 . . . . 0.0 110.417 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.481 ' CB ' ' HG3' ' A' ' 270' ' ' LYS . 2.7 t70 -68.88 152.9 44.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.294 -0.879 . . . . 0.0 109.846 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.595 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 4.6 t -145.21 90.4 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.579 -0.701 . . . . 0.0 109.938 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.465 ' O ' HD21 ' A' ' 267' ' ' LEU . 85.1 m -86.72 126.36 34.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.007 . . . . 0.0 109.865 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.606 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.74 151.13 32.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.264 -0.897 . . . . 0.0 110.905 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.54 ' ND2' ' HB2' ' A' ' 266' ' ' SER . 0.4 OUTLIER -132.43 128.05 36.65 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.825 . . . . 0.0 110.543 -179.42 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.61 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 5.6 mt -140.41 156.32 46.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.533 -1.355 . . . . 0.0 109.596 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -89.04 39.13 0.92 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.79 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 157.23 -142.8 8.93 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 119.397 -1.382 . . . . 0.0 109.739 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.78 120.96 43.3 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.945 -1.327 . . . . 0.0 110.814 -179.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.61 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 10.8 m-85 -142.77 146.81 34.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.283 -0.886 . . . . 0.0 109.909 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.517 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 2.3 m-20 -75.9 97.33 3.93 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.156 -0.965 . . . . 0.0 109.421 179.287 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.576 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 52.3 p-90 -98.21 111.59 23.87 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.203 -0.936 . . . . 0.0 110.485 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.598 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 6.4 m -104.7 115.98 31.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.642 -0.661 . . . . 0.0 109.894 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.463 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 2.8 t -97.01 110.89 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.06 -1.025 . . . . 0.0 110.42 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.484 ' HA ' HD11 ' A' ' 320' ' ' ILE . 6.5 ttpt -85.69 144.86 27.58 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.27 -0.893 . . . . 0.0 109.016 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.553 HG11 ' CG2' ' A' ' 346' ' ' VAL . 30.9 t -141.94 109.72 2.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.779 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.51 ' O ' ' N ' ' A' ' 347' ' ' GLU . 22.4 mmtp -72.57 132.01 43.23 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.212 -0.93 . . . . 0.0 109.476 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.569 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 67.4 mt -87.31 152.95 21.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.108 -0.995 . . . . 0.0 111.695 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.486 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -60.46 173.76 0.58 Allowed Pre-proline 0 N--CA 1.488 1.439 0 O-C-N 121.62 -0.675 . . . . 0.0 109.364 178.989 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.486 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -68.73 84.59 0.5 Allowed 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.696 1.366 . . . . 0.0 110.038 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.37 26.44 3.71 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.472 ' HB2' ' CG1' ' A' ' 338' ' ' VAL . . . -120.5 145.98 46.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -1.148 . . . . 0.0 110.601 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.554 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 18.5 p -147.63 145.99 29.18 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.294 -0.879 . . . . 0.0 110.399 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.525 HG21 ' CB ' ' A' ' 319' ' ' VAL . 70.4 t -74.46 142.41 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.214 -0.929 . . . . 0.0 110.45 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.55 -32.96 0.41 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 3.3 m -128.87 127.94 42.84 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 111.092 -179.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.471 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.8 p90 -146.59 160.81 41.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.433 -0.792 . . . . 0.0 109.239 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.505 ' CH2' HD13 ' A' ' 337' ' ' ILE . 1.3 p90 -150.9 157.42 42.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.946 -1.096 . . . . 0.0 110.975 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.48 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.6 OUTLIER 58.6 23.6 11.1 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.765 179.708 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.529 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 140.68 0.71 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.369 -0.832 . . . . 0.0 110.088 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.514 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -78.62 122.4 25.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.07 -1.019 . . . . 0.0 109.735 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.516 ' CD ' HG11 ' A' ' 304' ' ' VAL . 11.1 ttpt -88.85 144.33 26.29 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.766 0.793 . . . . 0.0 110.847 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.511 ' CB ' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -129.7 173.7 10.38 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.39 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.454 ' HA ' HG21 ' A' ' 319' ' ' VAL . 5.3 mt-10 -135.3 103.09 5.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 110.588 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -89.85 39.09 3.13 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.461 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 5.9 m120 58.5 89.42 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.304 -1.115 . . . . 0.0 110.075 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.39 -0.76 75.26 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.611 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.8 m-85 -144.56 -167.89 2.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.446 -1.032 . . . . 0.0 109.095 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.525 ' CB ' HG21 ' A' ' 304' ' ' VAL . 2.7 t -163.4 161.64 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 109.713 179.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.598 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 25.2 mm -129.28 151.93 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.074 -1.016 . . . . 0.0 110.997 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.641 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 73.4 m-85 -128.36 130.67 48.08 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.225 -0.922 . . . . 0.0 109.963 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.514 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 2.2 p -132.96 168.87 15.78 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.727 -1.233 . . . . 0.0 109.991 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.497 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.7 Cg_endo -65.55 121.5 8.91 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.813 1.428 . . . . 0.0 110.981 -179.237 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.44 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 19.1 m -66.8 -117.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.47 -0.769 . . . . 0.0 110.087 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 57.7 m -108.98 -16.46 14.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.814 -1.179 . . . . 0.0 110.339 -179.764 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.452 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 10.6 p-90 -125.96 -18.53 5.05 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.237 -0.915 . . . . 0.0 110.617 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.44 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.4 t30 -87.43 33.21 0.69 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.96 12.07 22.16 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.319 -0.863 . . . . 0.0 109.656 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -84.99 -152.13 16.4 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.548 ' O ' ' N ' ' A' ' 286' ' ' LEU . 41.4 Cg_endo -68.86 -55.57 0.2 Allowed 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.938 1.494 . . . . 0.0 110.021 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.26 115.22 30.1 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.418 -0.802 . . . . 0.0 110.415 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.526 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -134.49 107.83 7.78 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.251 -0.906 . . . . 0.0 110.101 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.468 ' O ' ' HB2' ' A' ' 309' ' ' SER . 97.6 m -103.82 147.64 27.05 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.148 -0.97 . . . . 0.0 110.733 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.595 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 13.8 p90 -152.35 175.06 13.07 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.493 -0.754 . . . . 0.0 109.102 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.471 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.7 160.77 28.95 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.401 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.649 ' CE2' ' CB ' ' A' ' 280' ' ' TYR . 1.1 p90 -147.46 147.4 30.15 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.388 -1.066 . . . . 0.0 110.041 179.633 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.545 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.6 mp -121.71 123.31 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.013 -1.054 . . . . 0.0 109.958 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.569 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.6 t -97.12 154.26 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.199 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.32 133.38 53.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.221 -0.924 . . . . 0.0 110.557 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.434 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.18 -132.07 1.87 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.483 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 42.8 Cg_endo -68.86 -158.75 0.05 OUTLIER 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 123.824 1.434 . . . . 0.0 110.298 179.551 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.592 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -122.58 144.72 48.93 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.122 -0.987 . . . . 0.0 110.557 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.487 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 97.14 68.25 0.95 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.487 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 3.7 m-20 66.85 140.45 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.41 -1.053 . . . . 0.0 108.966 -179.142 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.488 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.3 OUTLIER -137.92 21.89 2.85 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.911 -1.118 . . . . 0.0 111.119 -179.226 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.591 ' CG1' ' CE2' ' A' ' 280' ' ' TYR . 9.0 p -127.53 123.87 62.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.224 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.51 ' N ' ' O ' ' A' ' 297' ' ' LYS . 6.8 mt-10 -55.47 -43.64 75.71 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 110.223 -179.528 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -177.09 159.02 1.6 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 110.513 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.497 ' CG2' HG21 ' A' ' 296' ' ' VAL . 45.7 mt -123.13 109.58 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 110.218 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.78 140.66 43.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.32 -0.863 . . . . 0.0 110.143 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.606 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -101.05 130.86 47.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.247 -0.908 . . . . 0.0 110.271 179.995 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -138.86 111.78 7.84 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 110.115 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.487 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.5 mt -91.7 107.82 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.079 -1.013 . . . . 0.0 110.3 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.517 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.94 37.56 0.22 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.585 -0.697 . . . . 0.0 111.56 179.611 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 106.77 11.12 27.28 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.582 -1.294 . . . . 0.0 110.664 178.866 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.473 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 26.4 mm-40 -121.57 101.48 7.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.013 -1.286 . . . . 0.0 110.034 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.487 ' O ' ' CD1' ' A' ' 358' ' ' ILE . 9.9 p -66.56 135.66 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.234 -0.916 . . . . 0.0 110.4 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.487 ' CD1' ' O ' ' A' ' 357' ' ' VAL . 12.3 mm . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.187 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -73.8 -178.26 3.67 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 124.047 1.551 . . . . 0.0 110.505 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.463 ' CG2' ' O ' ' A' ' 258' ' ' THR . 7.0 t -60.01 125.29 23.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.407 -0.808 . . . . 0.0 110.295 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 259' ' ' THR . . . . . 0.46 HG22 ' O ' ' A' ' 259' ' ' THR . 8.0 t -62.76 146.3 94.87 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.311 -0.868 . . . . 0.0 110.35 -179.893 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.23 154.63 56.72 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.046 1.551 . . . . 0.0 110.32 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.473 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.8 p -108.76 139.64 21.06 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.224 -0.922 . . . . 0.0 110.613 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.473 ' HD2' HG23 ' A' ' 261' ' ' VAL . 49.6 Cg_endo -77.33 146.36 24.8 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 124.167 1.614 . . . . 0.0 109.968 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.472 ' O ' ' HB2' ' A' ' 264' ' ' SER . 46.3 t -140.31 29.51 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.169 -0.957 . . . . 0.0 110.433 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.472 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 29.0 t 178.96 76.94 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.202 -0.936 . . . . 0.0 110.7 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 122.84 176.97 15.06 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.575 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.61 153.6 51.54 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.504 -0.998 . . . . 0.0 109.473 179.904 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.526 HD21 ' CG1' ' A' ' 282' ' ' VAL . 0.0 OUTLIER -147.99 123.56 10.43 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 120.932 -1.105 . . . . 0.0 111.03 -179.451 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.8 OUTLIER -122.36 111.04 16.4 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 178.902 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 45.4 t -104.99 124.62 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.893 -1.129 . . . . 0.0 111.953 -178.722 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -111.89 156.74 21.57 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 56.9 t -144.84 143.66 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.341 -1.475 . . . . 0.0 112.148 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.544 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -134.52 108.76 8.28 Favored 'General case' 0 N--CA 1.486 1.37 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.08 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 21.0 p30 -96.18 146.78 24.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 111.083 -178.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.581 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 31.7 p90 -130.38 17.98 5.38 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.412 -0.805 . . . . 0.0 109.958 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.27 -58.77 3.86 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -73.18 -19.32 61.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 110.458 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.581 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.98 179.44 41.72 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.635 -1.269 . . . . 0.0 109.983 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.534 ' HB3' ' CZ ' ' A' ' 280' ' ' TYR . . . -138.09 136.6 36.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.442 -1.034 . . . . 0.0 109.97 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.575 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.7 mt-10 -93.84 147.15 23.34 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.378 -0.826 . . . . 0.0 110.478 -179.462 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.701 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 92.8 m-85 -139.05 94.96 2.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 110.674 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.493 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -83.5 106.41 15.22 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.538 -0.726 . . . . 0.0 110.271 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.632 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.5 t -97.28 94.28 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.493 -0.754 . . . . 0.0 110.17 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 3.8 m -86.95 113.47 22.75 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.172 -0.955 . . . . 0.0 109.815 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.563 HD12 ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -102.18 147.94 26.03 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.096 -1.003 . . . . 0.0 110.507 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.575 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.36 106.7 7.66 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.516 -0.74 . . . . 0.0 109.636 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.574 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.8 mt -113.83 160.75 18.39 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.622 -1.299 . . . . 0.0 110.763 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -89.79 36.64 0.86 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 110.03 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 155.3 -135.25 4.54 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.476 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.2 mm-40 -120.67 113.41 20.18 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.05 -1.265 . . . . 0.0 110.911 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.574 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.1 m-85 -138.74 148.92 44.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.36 -0.838 . . . . 0.0 109.641 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.502 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 5.4 m-20 -75.53 97.9 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.205 -0.935 . . . . 0.0 109.512 179.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.59 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 51.5 p-90 -97.07 110.17 22.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.583 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.523 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 4.2 m -102.34 115.21 30.09 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.331 -0.856 . . . . 0.0 109.44 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.484 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.8 t -97.0 111.09 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 110.54 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.515 ' HG3' HD12 ' A' ' 320' ' ' ILE . 4.5 ttpt -83.15 149.17 27.02 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 108.966 178.968 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.573 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 53.7 t -145.75 104.73 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.971 -1.081 . . . . 0.0 110.761 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.502 ' O ' ' N ' ' A' ' 347' ' ' GLU . 7.6 mmtt -70.88 131.28 43.53 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.208 -0.933 . . . . 0.0 109.391 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.55 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 70.3 mt -87.12 152.49 22.3 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 111.507 -179.056 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.506 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -56.47 176.0 0.21 Allowed Pre-proline 0 C--N 1.301 -1.504 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.081 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.506 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -68.99 79.87 0.69 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 123.554 1.292 . . . . 0.0 109.891 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.19 20.9 5.42 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.482 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.526 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -106.73 149.0 27.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.395 -1.062 . . . . 0.0 109.936 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.55 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 37.5 p -150.03 144.2 25.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.106 -0.997 . . . . 0.0 111.152 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.51 HG22 ' CG1' ' A' ' 319' ' ' VAL . 87.4 t -69.59 129.79 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -0.862 . . . . 0.0 109.928 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.25 -28.18 2.91 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.4 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 6.8 t -144.66 141.4 29.32 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.007 -1.29 . . . . 0.0 110.744 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.3 p90 -155.54 168.81 25.93 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.403 -0.811 . . . . 0.0 110.053 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.499 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -158.53 163.72 36.8 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.057 -1.027 . . . . 0.0 110.645 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.468 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.5 OUTLIER 58.41 21.31 8.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.5 -0.75 . . . . 0.0 110.757 179.739 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.521 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 148.84 1.21 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.442 -0.786 . . . . 0.0 110.328 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.503 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -86.78 120.12 27.74 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.225 -0.922 . . . . 0.0 109.379 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.494 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 3.6 ttpt -87.63 140.03 29.93 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.892 0.853 . . . . 0.0 110.601 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.5 175.22 7.28 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.418 ' HG2' HG21 ' A' ' 319' ' ' VAL . 4.5 mt-10 -134.84 116.55 14.92 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.316 179.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.448 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -109.93 39.25 2.97 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 1.4 t30 66.23 90.92 0.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.29 -1.123 . . . . 0.0 110.286 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 81.53 3.31 90.66 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.597 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.9 m-85 -141.52 -172.67 3.58 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -1.135 . . . . 0.0 109.544 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.511 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 3.5 t -163.38 157.85 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.212 -0.93 . . . . 0.0 109.775 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.523 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 17.4 mm -125.98 144.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.012 -1.055 . . . . 0.0 111.474 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 56.9 m-85 -121.18 129.33 53.18 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.005 -1.059 . . . . 0.0 109.93 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.503 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 2.9 p -129.94 168.52 16.29 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 120.864 -1.148 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.531 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.2 Cg_endo -65.95 117.09 4.36 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.76 1.4 . . . . 0.0 111.029 -179.54 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.487 HG11 ' ND2' ' A' ' 311' ' ' ASN . 25.4 m -64.29 -120.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 110.041 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.453 ' O ' ' HE2' ' A' ' 328' ' ' LYS . 0.6 OUTLIER -104.44 -15.88 15.26 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.776 -1.202 . . . . 0.0 110.665 -179.849 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.468 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 5.3 p-90 -131.11 -6.85 3.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.132 -0.98 . . . . 0.0 110.822 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.471 ' O ' ' HB1' ' A' ' 332' ' ' ALA . 1.6 t-20 -90.96 38.67 0.96 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.063 -1.023 . . . . 0.0 110.115 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.476 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 5.5 pttt -121.26 4.99 10.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.06 -1.025 . . . . 0.0 110.332 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -69.16 -156.38 1.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 50.5 Cg_endo -76.72 7.16 3.66 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.77 1.405 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.429 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 19.5 m -164.2 128.25 2.64 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.288 -0.882 . . . . 0.0 109.725 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.575 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -143.89 108.63 4.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 110.319 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 283' ' ' THR . 89.8 m -100.77 117.54 35.07 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.309 -0.87 . . . . 0.0 109.953 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.632 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 7.9 p90 -124.49 171.96 9.56 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.485 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.34 158.04 27.5 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.945 -1.597 . . . . 0.0 109.951 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.701 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.2 p90 -145.89 146.13 30.98 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.633 -0.922 . . . . 0.0 109.186 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.539 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.7 mp -119.23 120.23 63.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.684 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.537 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.8 t -95.78 147.84 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.195 -0.941 . . . . 0.0 109.576 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -118.6 134.69 54.91 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.384 -0.822 . . . . 0.0 110.617 -179.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.413 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -179.53 -137.91 3.13 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.517 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 44.4 Cg_endo -71.44 -158.28 0.06 OUTLIER 'Trans proline' 0 C--N 1.304 -1.788 0 O-C-N 123.982 1.517 . . . . 0.0 110.142 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.403 ' NE2' ' HA ' ' A' ' 341' ' ' PRO . 10.7 mp0 -118.92 144.55 46.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.034 -1.041 . . . . 0.0 110.456 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.439 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 100.31 65.76 0.81 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.439 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 10.5 t70 65.77 134.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.282 -1.128 . . . . 0.0 109.593 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.537 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.6 OUTLIER -133.05 25.17 4.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.23 -0.919 . . . . 0.0 110.685 -179.516 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.586 HG13 ' CE2' ' A' ' 280' ' ' TYR . 4.2 p -132.78 116.5 27.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.028 -1.045 . . . . 0.0 110.831 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.502 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -44.67 -50.08 10.06 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.912 -1.117 . . . . 0.0 109.533 179.787 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -177.48 158.06 1.36 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.382 -0.824 . . . . 0.0 110.482 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.435 HG12 HG12 ' A' ' 296' ' ' VAL . 14.4 mt -117.15 111.62 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.255 -0.903 . . . . 0.0 110.076 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.69 151.65 24.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.285 -0.885 . . . . 0.0 110.376 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.534 HD12 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -110.27 125.71 53.41 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.321 -0.862 . . . . 0.0 109.812 179.604 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.41 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 11.5 tt0 -137.26 111.41 8.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.184 -0.948 . . . . 0.0 109.832 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.476 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.4 mt -92.02 109.97 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 110.521 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.502 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 38.36 31.22 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.546 -0.721 . . . . 0.0 111.061 179.457 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.48 -10.04 16.9 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.563 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.427 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.0 mp0 -97.16 108.4 21.12 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.061 -1.258 . . . . 0.0 110.214 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 7.3 p -76.58 110.42 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.335 -0.853 . . . . 0.0 110.249 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.433 HG22 ' HB3' ' A' ' 262' ' ' PRO . 24.2 mm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.146 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.77 -177.57 3.22 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.989 1.52 . . . . 0.0 110.859 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.518 ' CG2' ' O ' ' A' ' 258' ' ' THR . 2.0 t -83.6 123.27 29.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.511 -0.743 . . . . 0.0 110.502 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 21.6 p -119.94 101.59 47.53 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.227 -0.921 . . . . 0.0 110.068 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.99 143.03 35.66 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.918 1.483 . . . . 0.0 110.512 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.449 HG22 ' HD2' ' A' ' 262' ' ' PRO . 6.7 p -66.03 143.84 98.57 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.18 -0.95 . . . . 0.0 110.226 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.449 ' HD2' HG22 ' A' ' 261' ' ' VAL . 50.9 Cg_endo -79.01 149.4 22.56 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 124.153 1.607 . . . . 0.0 110.398 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 3.5 t -115.74 28.38 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.226 -0.921 . . . . 0.0 109.992 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.44 97.69 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.268 -0.895 . . . . 0.0 110.465 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 103.5 173.89 25.98 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.569 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -136.88 157.11 47.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.477 -1.013 . . . . 0.0 109.535 179.863 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.514 ' CD1' ' HG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.56 124.38 10.57 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.943 -1.098 . . . . 0.0 110.989 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.482 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 1.4 mm-40 -121.38 113.32 19.73 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.471 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 38.4 t -109.44 139.67 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 111.668 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.2 mmtm -123.83 156.58 35.92 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.717 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.591 HG12 ' CE1' ' A' ' 280' ' ' TYR . 92.3 t -145.19 144.7 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.462 -1.399 . . . . 0.0 112.092 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.14 112.21 6.61 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 179.315 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.502 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.7 p-10 -97.03 144.82 26.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.047 -1.033 . . . . 0.0 111.297 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.575 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 34.5 p90 -129.82 18.62 5.63 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.399 -0.813 . . . . 0.0 109.786 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.475 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 87.58 -61.92 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.67 -23.79 67.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -1.158 . . . . 0.0 110.224 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.82 177.68 46.02 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.562 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -130.58 146.6 52.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.329 -1.101 . . . . 0.0 110.201 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.575 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 6.2 mt-10 -98.0 147.32 24.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.514 -0.741 . . . . 0.0 109.942 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 95.2 m-85 -144.28 86.37 1.83 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.233 -0.917 . . . . 0.0 110.999 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.471 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.1 OUTLIER -71.17 153.5 42.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.403 -0.811 . . . . 0.0 109.88 179.376 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.58 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.5 t -144.82 88.09 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 109.615 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.442 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.5 m -86.03 114.92 23.29 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.683 -179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.568 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -101.73 145.57 28.94 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.259 -0.901 . . . . 0.0 110.736 -179.16 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.569 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -129.67 106.86 9.0 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.391 -0.818 . . . . 0.0 110.093 -179.458 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.545 ' N ' ' O ' ' A' ' 330' ' ' PRO . 7.6 mt -116.62 164.34 14.75 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.648 -1.283 . . . . 0.0 110.299 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -94.04 34.59 1.23 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.402 -0.811 . . . . 0.0 110.458 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.449 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 157.11 -137.52 5.44 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.876 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mm-40 -113.84 108.26 16.83 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.184 -1.186 . . . . 0.0 111.391 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.541 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.26 135.27 40.77 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.301 -0.874 . . . . 0.0 109.67 178.538 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.53 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 4.5 m-20 -64.88 97.02 0.2 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.05 -1.032 . . . . 0.0 109.402 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.602 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 53.3 p-90 -95.07 108.07 20.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.279 -0.888 . . . . 0.0 110.494 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.596 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 32.4 m -101.67 115.48 30.61 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.475 HG21 ' CE2' ' A' ' 334' ' ' PHE . 3.3 t -96.72 111.54 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.092 -1.005 . . . . 0.0 110.925 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.491 ' HG3' HD11 ' A' ' 320' ' ' ILE . 7.9 ttpt -82.01 149.84 27.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.264 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.533 HG12 ' CG2' ' A' ' 346' ' ' VAL . 88.7 t -149.02 104.77 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.951 -1.093 . . . . 0.0 110.719 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.499 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 18.9 mmtp -70.35 128.54 36.56 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.223 -0.923 . . . . 0.0 109.658 179.511 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.589 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 85.5 mt -84.06 165.81 18.24 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.763 0.792 . . . . 0.0 111.377 -179.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.545 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -74.33 175.81 3.47 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.623 -0.673 . . . . 0.0 109.726 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.491 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.5 Cg_endo -67.24 83.2 0.36 Allowed 'Trans proline' 0 C--N 1.304 -1.786 0 O-C-N 123.598 1.315 . . . . 0.0 109.84 179.421 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 110.99 22.72 6.12 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.474 ' O ' HD12 ' A' ' 298' ' ' LEU . . . -112.14 144.17 41.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -1.085 . . . . 0.0 110.13 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.52 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 13.0 p -147.06 145.18 29.58 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.879 . . . . 0.0 110.332 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.539 HG21 ' CG2' ' A' ' 319' ' ' VAL . 71.4 t -64.97 120.94 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.38 -0.825 . . . . 0.0 110.11 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.29 -38.6 3.48 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 24.9 m -139.03 144.25 38.77 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.144 -1.209 . . . . 0.0 110.781 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 5.6 p90 -155.02 160.34 40.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.466 -0.771 . . . . 0.0 109.463 179.553 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.432 ' C ' ' OG ' ' A' ' 309' ' ' SER . 1.0 OUTLIER -151.04 152.87 34.08 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.923 -1.111 . . . . 0.0 111.491 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.537 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.9 OUTLIER 67.24 24.19 9.2 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.663 -0.648 . . . . 0.0 111.054 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.515 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.27 143.41 0.87 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.276 -0.89 . . . . 0.0 110.138 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.531 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -82.37 122.9 28.58 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.15 -0.969 . . . . 0.0 109.182 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.527 ' HG2' ' N ' ' A' ' 313' ' ' GLN . 3.1 ttmt -88.7 148.09 24.17 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.861 0.839 . . . . 0.0 111.05 -178.957 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.527 ' N ' ' HG2' ' A' ' 312' ' ' LYS . 0.0 OUTLIER -131.74 171.85 13.0 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.36 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.419 ' HA ' HG21 ' A' ' 319' ' ' VAL . 32.4 mt-10 -132.96 109.7 9.75 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.179 -0.95 . . . . 0.0 110.345 -179.89 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.73 39.81 2.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 8.4 t-20 60.86 92.25 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.346 -1.091 . . . . 0.0 110.474 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.3 2.27 87.76 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.61 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.1 m-85 -145.81 -169.48 3.24 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.339 -1.095 . . . . 0.0 109.27 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.539 ' CG2' HG21 ' A' ' 304' ' ' VAL . 2.8 t -163.44 161.92 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 179.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.596 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 5.5 mm -130.19 143.57 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.174 -0.954 . . . . 0.0 111.084 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.652 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 98.6 m-85 -118.61 136.79 53.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.938 . . . . 0.0 109.515 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.531 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.5 p -135.3 168.88 15.47 Favored Pre-proline 0 C--N 1.301 -1.527 0 O-C-N 120.844 -1.16 . . . . 0.0 110.303 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.535 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 40.5 Cg_endo -67.03 121.09 8.21 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 124.127 1.593 . . . . 0.0 110.85 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.523 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 27.0 m -73.22 -129.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.845 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.402 ' C ' ' HD2' ' A' ' 328' ' ' LYS . 18.1 p -100.17 -19.15 16.57 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.904 -1.122 . . . . 0.0 110.346 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.537 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 23.7 p-90 -125.96 11.08 7.68 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.108 -0.995 . . . . 0.0 110.507 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.523 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.5 OUTLIER -117.63 49.58 1.21 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.073 -1.017 . . . . 0.0 110.254 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.535 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -125.57 -12.47 6.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -0.865 . . . . 0.0 110.134 -179.902 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.09 -160.95 0.02 OUTLIER Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.9 Cg_endo -73.4 3.53 4.66 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.905 1.477 . . . . 0.0 110.872 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.97 117.67 3.28 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.171 -0.955 . . . . 0.0 110.088 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.499 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -140.03 108.6 5.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.253 -0.904 . . . . 0.0 110.077 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.494 ' O ' ' HB2' ' A' ' 309' ' ' SER . 60.7 m -99.81 138.63 36.62 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.287 -0.883 . . . . 0.0 110.449 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.652 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 10.9 p90 -145.92 157.36 43.9 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -134.33 164.27 24.57 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.088 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.68 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.1 p90 -149.74 143.4 25.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.483 -1.01 . . . . 0.0 109.469 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.557 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -117.16 120.55 65.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.115 -0.991 . . . . 0.0 109.689 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.589 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.6 t -96.79 149.93 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.203 -0.936 . . . . 0.0 109.817 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.418 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -121.77 131.54 54.12 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.16 -0.963 . . . . 0.0 111.061 -179.167 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.54 -120.79 0.73 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.537 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 41.4 Cg_endo -68.01 -151.7 0.03 OUTLIER 'Trans proline' 0 C--N 1.306 -1.71 0 O-C-N 123.819 1.431 . . . . 0.0 109.61 178.792 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.475 ' HB3' ' HA2' ' A' ' 275' ' ' GLY . 0.0 OUTLIER -134.17 139.99 46.23 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.737 -1.227 . . . . 0.0 110.731 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 100.78 -79.73 0.44 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -115.81 119.85 37.35 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.476 -1.014 . . . . 0.0 109.118 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.545 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.4 OUTLIER -124.03 10.99 8.86 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.084 -1.01 . . . . 0.0 110.24 -179.49 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.6 HG12 ' CE1' ' A' ' 280' ' ' TYR . 10.7 p -133.84 116.73 24.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.399 -0.813 . . . . 0.0 110.002 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 1.5 mt-10 -47.16 -47.1 23.91 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.174 -0.954 . . . . 0.0 110.164 -179.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -177.01 158.92 1.61 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.401 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.515 HG21 HD12 ' A' ' 349' ' ' ILE . 26.4 mt -118.2 119.42 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.23 -0.919 . . . . 0.0 110.101 179.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.49 151.33 33.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.301 -0.874 . . . . 0.0 110.267 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.558 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -108.96 126.83 53.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.252 -0.905 . . . . 0.0 109.725 179.661 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.474 ' N ' HD23 ' A' ' 351' ' ' LEU . 2.5 tp10 -138.19 113.11 9.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.077 -1.014 . . . . 0.0 110.373 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.455 HG22 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -93.07 103.66 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.183 -0.948 . . . . 0.0 110.003 179.725 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.53 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 43.55 30.55 0.35 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.459 -0.775 . . . . 0.0 110.46 -179.85 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 117.63 -22.65 9.95 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.426 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 1.0 OUTLIER -82.41 99.58 9.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 110.127 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.48 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 13.4 p -69.96 113.76 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.246 -0.909 . . . . 0.0 110.173 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.44 HG21 ' OXT' ' A' ' 358' ' ' ILE . 25.9 mm . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.119 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.74 179.37 5.3 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 124.035 1.545 . . . . 0.0 110.629 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 5.4 t -58.71 146.39 36.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -0.897 . . . . 0.0 110.191 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -88.37 168.7 15.5 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.244 -0.91 . . . . 0.0 110.13 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.88 133.9 20.79 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.993 1.523 . . . . 0.0 110.371 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.461 HG23 ' N ' ' A' ' 262' ' ' PRO . 4.5 p -79.16 144.85 63.64 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.285 -0.885 . . . . 0.0 110.337 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.513 ' CB ' HG23 ' A' ' 358' ' ' ILE . 49.4 Cg_endo -76.11 151.04 34.24 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 124.094 1.576 . . . . 0.0 110.671 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.531 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 68.7 t -130.54 25.43 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.341 -0.849 . . . . 0.0 109.884 179.618 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.498 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.4 OUTLIER 168.49 55.43 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.184 -0.947 . . . . 0.0 110.449 179.922 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 158.94 165.28 15.7 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.583 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -130.81 150.54 51.94 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.4 -1.059 . . . . 0.0 109.978 179.924 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.518 HD22 ' CG1' ' A' ' 282' ' ' VAL . 0.0 OUTLIER -145.2 125.87 14.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.036 -1.04 . . . . 0.0 110.781 -179.676 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.488 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 15.0 mm-40 -124.51 110.99 15.17 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.491 -0.756 . . . . 0.0 108.996 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.504 ' CG1' ' O ' ' A' ' 281' ' ' ASP . 85.6 t -110.53 145.19 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 120.942 -1.098 . . . . 0.0 111.827 -178.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.444 ' N ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -130.86 157.74 42.07 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.136 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.589 HG11 ' CE2' ' A' ' 280' ' ' TYR . 97.5 t -141.69 146.75 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 120.237 -1.539 . . . . 0.0 112.454 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.02 110.28 6.91 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.11 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 43.8 p-10 -95.68 145.36 25.34 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.062 -1.024 . . . . 0.0 111.379 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.575 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 35.4 p90 -130.95 22.77 4.93 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.36 -0.837 . . . . 0.0 109.858 179.088 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.456 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 85.81 -68.82 3.32 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -61.22 -27.41 68.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.253 -1.145 . . . . 0.0 110.685 -179.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.533 ' C ' ' CE2' ' A' ' 274' ' ' TRP . . . -166.3 178.52 40.8 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.574 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -134.72 145.28 48.33 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.275 -1.132 . . . . 0.0 110.512 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.575 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 5.4 mt-10 -97.22 147.17 24.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 109.973 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.657 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 88.5 m-85 -142.08 83.77 1.85 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.274 -0.891 . . . . 0.0 110.523 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.504 ' O ' ' CG1' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.14 153.19 44.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.289 -0.882 . . . . 0.0 110.123 179.551 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.585 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 5.4 t -144.87 90.36 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.531 -0.73 . . . . 0.0 109.667 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.458 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.5 m -86.28 123.66 31.79 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.134 -0.979 . . . . 0.0 109.362 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.551 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -109.71 148.26 31.71 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.072 -1.017 . . . . 0.0 111.28 -178.85 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.583 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.33 107.37 7.59 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.607 -0.683 . . . . 0.0 109.975 -179.45 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.586 HD13 ' CD1' ' A' ' 292' ' ' TRP . 9.7 mt -115.53 163.27 16.0 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.897 -1.127 . . . . 0.0 109.805 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . 0.469 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 2.1 t0 -91.64 31.28 1.21 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.552 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.532 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 163.76 -164.33 36.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.545 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -93.76 94.87 8.79 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.176 -1.19 . . . . 0.0 110.599 -179.738 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 1.9 m-85 -120.96 171.44 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.181 -0.95 . . . . 0.0 109.793 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.505 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 0.2 OUTLIER -95.78 99.34 11.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.655 179.392 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.589 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 53.1 p-90 -97.29 113.99 25.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.309 -0.869 . . . . 0.0 110.624 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.576 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 99.1 m -106.75 113.38 26.84 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.464 -0.773 . . . . 0.0 109.176 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.507 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.6 t -96.37 110.81 25.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.184 -0.948 . . . . 0.0 110.137 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.524 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 6.4 ttmt -84.77 149.07 26.0 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.208 -0.933 . . . . 0.0 109.197 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.564 HG11 ' CG2' ' A' ' 346' ' ' VAL . 45.9 t -144.63 106.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 O-C-N 121.403 -0.811 . . . . 0.0 109.93 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.471 ' O ' ' CG2' ' A' ' 346' ' ' VAL . 34.9 mmtt -71.1 134.69 47.21 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.114 -0.991 . . . . 0.0 109.704 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.559 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 92.7 mt -87.59 162.57 17.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 111.569 -179.083 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.496 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -75.65 171.57 11.59 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.469 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.4 84.61 0.47 Allowed 'Trans proline' 0 C--N 1.301 -1.945 0 O-C-N 123.684 1.36 . . . . 0.0 109.798 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . 0.414 ' O ' ' HA3' ' A' ' 340' ' ' GLY . . . 116.26 26.02 3.33 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.541 ' CB ' ' CG1' ' A' ' 338' ' ' VAL . . . -126.51 138.26 53.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -1.139 . . . . 0.0 110.257 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.516 ' N ' HG12 ' A' ' 338' ' ' VAL . 7.2 p -141.43 145.83 35.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 110.419 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.513 ' CG2' HG21 ' A' ' 319' ' ' VAL . 98.2 t -71.82 124.28 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.366 -0.834 . . . . 0.0 110.225 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.4 -34.84 1.26 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.411 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 2.7 m -122.45 110.15 15.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.025 -1.28 . . . . 0.0 110.716 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.578 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 11.9 p90 -134.23 153.92 51.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.856 . . . . 0.0 109.788 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.472 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -149.19 161.37 42.13 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.05 -1.031 . . . . 0.0 111.155 -179.35 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.545 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.23 28.71 15.54 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.542 -0.723 . . . . 0.0 111.224 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -175.9 145.44 0.66 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.038 -1.039 . . . . 0.0 110.553 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.474 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -78.13 118.74 20.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -0.998 . . . . 0.0 109.238 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.578 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 19.9 ttpt -92.2 115.7 28.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.546 -0.721 . . . . 0.0 111.083 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.566 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.4 OUTLIER -102.97 176.31 5.19 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.327 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.413 ' OE1' ' HE3' ' A' ' 312' ' ' LYS . 0.6 OUTLIER -139.02 105.95 5.42 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -0.981 . . . . 0.0 110.773 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -95.26 43.79 2.2 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 58.52 91.06 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.321 -1.105 . . . . 0.0 110.126 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.629 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 84.33 5.12 87.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.629 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 7.0 m-85 -141.93 -178.53 5.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.413 -1.051 . . . . 0.0 109.078 179.404 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.587 HG12 ' CZ ' ' A' ' 321' ' ' PHE . 39.9 t -159.4 148.98 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.149 -0.969 . . . . 0.0 109.986 179.126 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.576 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 1.7 mm -114.9 151.56 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.112 -0.992 . . . . 0.0 110.497 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.659 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 76.5 m-85 -130.69 112.78 13.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.101 -0.999 . . . . 0.0 109.866 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.546 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 3.7 p -116.49 171.07 5.09 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 120.627 -1.296 . . . . 0.0 109.786 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.546 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.9 Cg_endo -69.2 120.96 7.77 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 O-C-N 123.652 1.343 . . . . 0.0 110.727 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.532 ' N ' ' OD1' ' A' ' 327' ' ' ASN . 16.0 m -64.12 -113.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.482 -0.761 . . . . 0.0 110.224 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 14.1 p -120.17 -12.47 9.06 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.753 -1.217 . . . . 0.0 110.688 -179.665 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.476 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 24.8 p-90 -128.9 17.01 6.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 0.0 110.921 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.545 ' ND2' ' O ' ' A' ' 309' ' ' SER . 28.8 p-10 -135.56 45.07 2.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.079 . . . . 0.0 110.921 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.495 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -116.05 7.96 14.41 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.097 -1.002 . . . . 0.0 109.847 179.774 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . . . . . . . . . . . -74.67 -153.72 3.54 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.124 -1.191 . . . . 0.0 110.124 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.534 ' O ' ' N ' ' A' ' 286' ' ' LEU . 50.5 Cg_endo -75.61 4.66 4.85 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 124.182 1.622 . . . . 0.0 110.925 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.458 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.6 m -165.25 123.54 1.64 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.158 -0.964 . . . . 0.0 110.253 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.584 ' HB3' ' CZ2' ' A' ' 292' ' ' TRP . . . -150.72 120.28 6.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.848 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.483 ' O ' ' HB2' ' A' ' 309' ' ' SER . 34.0 m -104.32 144.66 31.33 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.229 -0.92 . . . . 0.0 110.441 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.659 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 10.0 p90 -149.78 168.82 22.62 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.37 159.84 28.16 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 118.744 -1.693 . . . . 0.0 110.535 -179.209 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.657 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.6 p90 -144.2 145.02 31.81 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.648 -0.913 . . . . 0.0 109.679 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.544 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -118.98 120.99 65.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.626 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.559 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 19.8 t -97.71 142.65 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 110.399 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.451 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.6 m-80 -115.55 130.09 56.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 110.133 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.414 ' HA3' ' O ' ' A' ' 301' ' ' GLY . . . -175.93 -136.38 2.33 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.505 ' C ' ' NE2' ' A' ' 342' ' ' GLN . 47.0 Cg_endo -72.14 -169.42 0.45 Allowed 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 124.078 1.567 . . . . 0.0 110.579 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.505 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 12.6 mm-40 -107.43 145.38 33.06 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.235 -0.915 . . . . 0.0 110.087 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 97.9 72.16 1.06 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.473 ' O ' ' O ' ' A' ' 343' ' ' GLY . 1.2 t70 61.1 140.81 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.328 -1.101 . . . . 0.0 109.171 -179.24 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.532 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 2.3 mtmt -134.65 18.09 3.59 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.006 -1.059 . . . . 0.0 110.463 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.586 HG12 ' CE2' ' A' ' 280' ' ' TYR . 11.8 p -130.58 118.21 41.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.311 -0.868 . . . . 0.0 110.22 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.432 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -48.33 -45.9 35.8 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.378 -0.826 . . . . 0.0 110.575 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.418 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 2.5 pt-20 -177.02 159.39 1.67 Allowed 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.847 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.449 HG12 HG13 ' A' ' 296' ' ' VAL . 14.2 mt -119.6 114.6 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.254 -0.904 . . . . 0.0 110.439 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -113.91 158.2 21.41 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.148 -0.97 . . . . 0.0 109.855 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.549 ' CD1' HD22 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.42 126.63 51.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.253 -0.905 . . . . 0.0 110.633 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.486 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.0 OUTLIER -139.25 119.76 13.99 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.864 179.45 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.491 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -90.81 93.01 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.924 -1.11 . . . . 0.0 110.22 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.505 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 46.94 31.96 1.68 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.817 -0.552 . . . . 0.0 111.249 179.496 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 132.13 -33.86 2.63 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.651 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.41 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 66.0 mm-40 -89.92 117.61 28.87 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.987 -1.302 . . . . 0.0 110.745 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.486 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 4.0 p -78.93 124.07 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.298 -0.876 . . . . 0.0 110.135 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.513 HG23 ' CB ' ' A' ' 262' ' ' PRO . 21.5 mm . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.092 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.37 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . 0.417 ' O ' HG21 ' A' ' 259' ' ' THR . 44.9 Cg_endo -72.26 -177.75 2.87 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 O-C-N 123.935 1.492 . . . . 0.0 110.575 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.455 ' O ' HG21 ' A' ' 258' ' ' THR . 14.4 t -57.13 122.8 13.26 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -0.82 . . . . 0.0 110.598 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 259' ' ' THR . . . . . 0.417 HG21 ' O ' ' A' ' 257' ' ' PRO . 19.7 p -133.82 94.43 18.87 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.344 -0.848 . . . . 0.0 109.858 179.705 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . 0.428 ' HG2' HG21 ' A' ' 357' ' ' VAL . 45.3 Cg_endo -72.29 130.14 15.91 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.059 1.557 . . . . 0.0 110.606 -179.67 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.434 HG21 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -66.59 143.56 98.21 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.281 -0.887 . . . . 0.0 110.025 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.444 ' HB3' ' O ' ' A' ' 358' ' ' ILE . 46.7 Cg_endo -73.53 125.67 10.29 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 O-C-N 124.044 1.549 . . . . 0.0 110.542 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.458 HG13 ' O ' ' A' ' 263' ' ' VAL . 19.8 t -124.13 30.42 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.212 -0.93 . . . . 0.0 110.07 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -163.24 102.85 0.97 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.237 -0.914 . . . . 0.0 110.442 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 84.28 -169.88 46.22 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.552 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.58 162.67 33.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.371 -1.076 . . . . 0.0 109.87 179.837 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.56 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.0 tm? -159.92 138.27 10.33 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.143 -1.023 . . . . 0.0 111.15 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.426 ' N ' HD21 ' A' ' 267' ' ' LEU . 18.8 mt-10 -141.15 136.57 31.98 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.458 HG12 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -128.11 144.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.618 -1.301 . . . . 0.0 112.306 -178.509 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.403 ' N ' HG12 ' A' ' 269' ' ' VAL . 63.3 mttt -128.65 157.74 40.49 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.566 HG13 ' CE1' ' A' ' 280' ' ' TYR . 98.7 t -144.36 147.38 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 120.346 -1.472 . . . . 0.0 112.319 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.525 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.12 110.63 6.38 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.737 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.551 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -96.13 149.08 22.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.988 -1.07 . . . . 0.0 111.503 -178.465 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.561 ' CZ2' HG22 ' A' ' 337' ' ' ILE . 28.1 p90 -129.46 18.42 5.84 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-O 121.447 0.641 . . . . 0.0 109.691 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.42 -61.63 3.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.67 -25.26 65.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 110.383 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.522 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -167.56 178.93 41.31 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.449 -1.358 . . . . 0.0 109.95 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.3 144.63 48.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -1.103 . . . . 0.0 110.345 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.525 ' HG2' ' CG1' ' A' ' 337' ' ' ILE . 4.7 mt-10 -97.47 145.92 25.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.396 -0.815 . . . . 0.0 109.828 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.9 m-85 -137.9 87.72 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.827 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.458 ' O ' HG12 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -70.88 140.91 51.21 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.483 179.13 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.602 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.8 t -133.89 91.7 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.568 -0.708 . . . . 0.0 109.803 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.465 ' O ' HD23 ' A' ' 267' ' ' LEU . 9.0 m -86.49 124.2 32.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 109.977 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.607 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.82 148.41 38.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 110.832 -179.427 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.553 ' O ' ' CD2' ' A' ' 286' ' ' LEU . 0.4 OUTLIER -128.66 137.43 51.64 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.434 -0.791 . . . . 0.0 109.823 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.577 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 14.5 mt -142.42 159.7 41.71 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.794 -1.191 . . . . 0.0 109.759 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.94 36.02 0.97 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.361 -0.837 . . . . 0.0 110.31 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.478 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 152.07 -100.94 0.21 Allowed Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.139 -1.505 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.554 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 15.9 mm-40 -141.8 111.93 6.88 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.024 -1.28 . . . . 0.0 110.881 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.639 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 5.5 m-85 -135.51 138.36 43.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.687 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.504 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 5.5 m-20 -74.17 96.87 2.82 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.002 -1.061 . . . . 0.0 108.905 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.586 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 55.1 p-90 -97.45 114.87 26.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 0.0 110.568 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.579 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 28.7 m -109.45 116.09 31.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.489 HG22 ' CD2' ' A' ' 351' ' ' LEU . 2.8 t -96.83 111.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 0.0 110.528 -179.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.464 ' HG3' HD13 ' A' ' 320' ' ' ILE . 28.9 ttpt -91.64 130.19 37.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.659 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.54 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 80.2 t -126.58 115.87 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.185 -0.947 . . . . 0.0 111.103 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.571 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 55.7 mmtt -73.21 134.23 44.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.149 -0.97 . . . . 0.0 109.269 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.576 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 80.1 mt -88.15 159.38 18.22 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.324 -0.86 . . . . 0.0 111.466 -178.833 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.574 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -65.18 178.09 0.56 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.68 -0.638 . . . . 0.0 110.025 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.531 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.24 79.06 0.6 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.718 1.378 . . . . 0.0 109.662 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.89 21.15 6.11 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.543 ' CB ' ' HB2' ' A' ' 299' ' ' ALA . . . -106.05 144.37 32.85 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.417 -1.049 . . . . 0.0 110.241 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.534 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 10.8 p -145.75 145.95 31.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.3 -0.875 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.551 ' CG1' ' CD ' ' A' ' 312' ' ' LYS . 76.1 t -70.99 134.83 29.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.329 -0.857 . . . . 0.0 109.88 179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.45 -37.29 0.8 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.081 -179.507 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 67.6 m -131.55 128.15 38.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.06 -1.259 . . . . 0.0 110.919 -179.563 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.564 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.7 p90 -144.78 157.73 44.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.377 -0.827 . . . . 0.0 109.794 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.483 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -150.55 159.52 44.44 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.007 -1.058 . . . . 0.0 111.236 -179.329 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.554 ' OG ' ' CZ3' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 59.45 24.81 13.49 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.562 -0.712 . . . . 0.0 110.679 179.735 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.521 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 142.56 0.77 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 110.213 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.523 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -81.09 113.97 19.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.084 -1.01 . . . . 0.0 109.383 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.564 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 18.6 ttpt -82.56 149.71 27.33 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-O 121.762 0.792 . . . . 0.0 110.459 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.722 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -134.13 170.63 15.39 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -142.41 95.17 2.75 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.595 -0.69 . . . . 0.0 110.165 179.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.14 -80.28 0.44 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -160.93 77.5 0.58 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.433 -1.04 . . . . 0.0 108.812 179.687 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.617 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.34 11.25 54.64 Favored Glycine 0 N--CA 1.487 2.082 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.617 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.3 m-85 -143.06 -166.97 2.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.736 -0.861 . . . . 0.0 108.709 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.5 HG13 ' N ' ' A' ' 320' ' ' ILE . 2.5 t -163.52 160.19 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.01 -1.056 . . . . 0.0 109.454 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.722 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.3 mm -128.98 145.22 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.891 -1.131 . . . . 0.0 111.136 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.0 m-85 -123.04 129.33 51.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.156 -0.965 . . . . 0.0 110.378 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.523 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 3.0 p -131.01 167.73 20.32 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 120.72 -1.237 . . . . 0.0 110.014 179.33 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.513 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.0 Cg_endo -66.1 128.68 20.07 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.861 1.453 . . . . 0.0 110.915 -179.293 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.429 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 34.6 m -78.01 -122.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.51 -0.744 . . . . 0.0 110.114 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -101.83 -21.43 14.58 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.757 -1.214 . . . . 0.0 110.631 -179.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.554 ' CZ3' ' OG ' ' A' ' 309' ' ' SER . 14.9 p-90 -126.46 5.55 6.91 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.173 -0.955 . . . . 0.0 110.578 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.429 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.8 OUTLIER -108.39 49.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.156 -0.965 . . . . 0.0 110.125 -179.8 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.453 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -133.84 -4.83 2.82 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.107 -0.996 . . . . 0.0 110.404 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.466 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.56 -155.72 0.05 OUTLIER Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.426 ' C ' ' OG1' ' A' ' 331' ' ' THR . 46.9 Cg_endo -73.65 3.06 5.18 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.915 1.482 . . . . 0.0 110.749 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.426 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.8 m -163.03 120.52 1.94 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 110.061 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -141.0 112.71 7.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.261 -0.899 . . . . 0.0 110.277 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.468 ' O ' ' HB3' ' A' ' 309' ' ' SER . 38.1 m -104.49 138.92 40.16 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 110.049 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.602 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 13.6 p90 -142.85 172.37 12.79 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.89 160.29 28.44 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 118.755 -1.688 . . . . 0.0 110.333 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.679 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -147.32 145.24 29.28 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.481 -1.011 . . . . 0.0 110.048 179.485 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.561 HG22 ' CZ2' ' A' ' 274' ' ' TRP . 1.6 mp -119.81 119.86 61.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.094 -1.004 . . . . 0.0 109.783 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.576 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.8 t -96.96 145.83 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -112.68 126.51 55.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 110.014 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -172.42 -132.35 1.49 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.551 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 43.6 Cg_endo -69.15 -163.14 0.09 OUTLIER 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 123.807 1.425 . . . . 0.0 110.754 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.579 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -126.53 126.53 43.84 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.187 -0.946 . . . . 0.0 110.845 -179.362 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.415 ' O ' ' HB3' ' A' ' 344' ' ' ASP . . . 118.08 -21.28 10.27 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.415 ' HB3' ' O ' ' A' ' 343' ' ' GLY . 2.6 p-10 176.79 124.54 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.686 -0.891 . . . . 0.0 108.803 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.574 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.3 mtmt -127.48 11.18 6.8 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 118.773 -1.171 . . . . 0.0 111.076 -179.148 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.583 HG12 ' CE1' ' A' ' 280' ' ' TYR . 4.3 p -133.59 120.08 36.38 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.203 -0.935 . . . . 0.0 110.402 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.5 mm-40 -50.2 -47.02 54.91 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.979 -1.076 . . . . 0.0 109.643 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.456 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 1.2 pt-20 -177.88 158.99 1.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.616 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.52 HG12 ' CG1' ' A' ' 296' ' ' VAL . 62.9 mt -118.67 121.77 67.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.268 -0.895 . . . . 0.0 110.22 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.76 139.75 53.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.193 -0.942 . . . . 0.0 110.215 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.607 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.41 130.61 45.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.177 -0.952 . . . . 0.0 110.284 179.818 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.8 OUTLIER -138.0 110.64 7.57 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.354 -0.842 . . . . 0.0 109.572 179.784 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.474 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 110.01 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.973 . . . . 0.0 110.464 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.504 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 39.12 31.21 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.661 -0.649 . . . . 0.0 110.52 179.758 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.54 -19.3 12.83 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.4 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.8 OUTLIER -85.82 104.39 15.45 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.2 -1.176 . . . . 0.0 110.437 -179.868 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.457 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 12.0 p -72.03 128.66 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.09 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.444 ' O ' ' HB3' ' A' ' 262' ' ' PRO . 12.1 mm . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.156 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -74.24 -178.82 4.18 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.102 1.58 . . . . 0.0 110.535 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.407 ' O ' ' CG2' ' A' ' 258' ' ' THR . 6.0 t -59.21 130.65 47.98 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 110.081 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 9.4 t -135.83 145.03 51.14 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.206 -0.934 . . . . 0.0 110.476 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.83 162.03 42.19 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.098 1.578 . . . . 0.0 110.185 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.426 ' CG2' ' HD2' ' A' ' 262' ' ' PRO . 4.0 p -113.64 144.53 31.56 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.15 -0.968 . . . . 0.0 110.359 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.501 ' CB ' HG21 ' A' ' 358' ' ' ILE . 48.1 Cg_endo -76.75 127.55 9.58 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.07 1.563 . . . . 0.0 110.627 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.476 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 86.7 t -117.18 30.44 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.227 -0.921 . . . . 0.0 110.325 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.431 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 4.3 t 174.21 129.26 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.24 -0.913 . . . . 0.0 110.563 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 74.61 179.27 41.71 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.56 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.549 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -133.74 163.24 29.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.397 -1.061 . . . . 0.0 109.865 179.862 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.538 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.6 tm? -161.59 133.34 5.58 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.055 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.485 ' N ' HD23 ' A' ' 267' ' ' LEU . 7.9 mt-10 -132.92 128.1 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 61.9 t -120.28 137.28 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 120.894 -1.129 . . . . 0.0 111.569 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.406 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.4 OUTLIER -122.51 156.93 33.13 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.808 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.573 HG12 ' CE2' ' A' ' 280' ' ' TYR . 78.1 t -142.56 145.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.325 -1.484 . . . . 0.0 112.288 -179.305 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.547 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -138.57 111.38 7.72 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.473 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.0 147.04 23.83 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.209 -0.932 . . . . 0.0 111.304 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.589 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 32.2 p90 -131.92 16.16 4.72 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.455 -0.778 . . . . 0.0 109.818 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.62 -60.27 3.24 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.49 -23.3 66.23 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.124 . . . . 0.0 110.302 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.579 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.14 -178.53 45.06 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.574 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -134.31 142.9 47.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 110.554 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.589 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.6 mt-10 -93.93 147.21 23.31 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.53 -0.731 . . . . 0.0 109.653 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.661 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 96.9 m-85 -141.53 83.93 1.88 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.38 -0.825 . . . . 0.0 110.45 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.469 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.12 151.74 47.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.377 -0.827 . . . . 0.0 109.943 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.636 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -143.96 88.56 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.436 -0.79 . . . . 0.0 109.691 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 24.3 m -86.09 117.25 24.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 109.628 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.605 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -105.52 150.4 25.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.242 -0.912 . . . . 0.0 110.575 -179.263 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.549 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -131.15 134.95 47.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.451 -0.78 . . . . 0.0 110.016 -179.804 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.588 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 14.3 mt -142.32 152.07 42.59 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.811 -1.181 . . . . 0.0 109.535 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.89 38.49 0.92 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.31 -0.869 . . . . 0.0 109.3 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.98 -139.12 5.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.541 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.6 mt-30 -118.09 96.05 5.17 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.059 -1.26 . . . . 0.0 110.959 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.588 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -121.29 133.58 55.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.362 -0.836 . . . . 0.0 110.025 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.444 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 67.6 m-20 -65.35 109.92 2.45 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.122 -0.986 . . . . 0.0 109.624 179.438 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.578 ' CE3' HD11 ' A' ' 284' ' ' LEU . 55.0 p-90 -107.99 116.15 31.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.105 -0.997 . . . . 0.0 110.835 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.53 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 54.8 m -110.25 115.92 30.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.426 -0.797 . . . . 0.0 109.902 179.835 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.509 HG22 ' CD2' ' A' ' 351' ' ' LEU . 3.7 t -96.8 111.3 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.16 -0.963 . . . . 0.0 110.608 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.479 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.3 ttpt -90.07 130.11 36.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.254 -0.904 . . . . 0.0 109.404 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.568 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 76.3 t -127.86 108.1 17.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.254 -0.903 . . . . 0.0 110.513 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.518 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 24.9 mmtt -70.08 138.3 51.91 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.148 -0.97 . . . . 0.0 109.09 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.579 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 91.7 mt -90.61 156.58 18.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.495 -0.753 . . . . 0.0 111.609 -178.553 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -60.72 175.33 0.44 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.629 -0.669 . . . . 0.0 109.381 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.494 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.57 80.53 0.6 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.547 1.288 . . . . 0.0 110.009 179.755 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.76 21.27 5.77 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.526 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -107.34 152.89 23.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -1.045 . . . . 0.0 110.064 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.542 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.8 p -153.16 146.51 24.85 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.077 -1.014 . . . . 0.0 111.312 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.478 HG22 HG12 ' A' ' 319' ' ' VAL . 63.7 t -63.88 142.16 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.372 -0.83 . . . . 0.0 109.97 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -121.77 -39.63 0.56 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -142.01 120.17 12.18 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.045 -1.268 . . . . 0.0 110.713 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.488 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.7 p90 -132.88 166.41 22.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.905 . . . . 0.0 110.021 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.484 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -157.68 160.6 38.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.161 -0.962 . . . . 0.0 111.197 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.473 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 60.25 23.17 12.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 110.881 179.502 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.473 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -174.99 144.88 0.78 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.352 -0.843 . . . . 0.0 109.854 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.529 ' ND2' ' HA ' ' A' ' 324' ' ' VAL . 2.2 m-80 -83.43 122.48 28.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.028 -1.045 . . . . 0.0 109.43 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.494 ' HG3' HG12 ' A' ' 319' ' ' VAL . 4.2 ttpt -89.7 140.29 29.72 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.877 0.846 . . . . 0.0 110.609 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.41 176.11 7.03 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -137.63 107.15 6.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.409 -0.807 . . . . 0.0 110.247 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.47 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -98.06 37.4 3.49 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.47 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.6 OUTLIER 68.43 88.17 0.11 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.226 -1.161 . . . . 0.0 110.448 179.852 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.37 6.95 83.34 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.614 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.0 m-85 -146.35 -170.81 3.59 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.305 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.539 HG13 ' N ' ' A' ' 320' ' ' ILE . 6.5 t -162.28 156.25 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.894 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.539 ' N ' HG13 ' A' ' 319' ' ' VAL . 7.2 mm -125.79 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.888 -1.133 . . . . 0.0 111.476 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 36.9 m-85 -114.37 131.18 56.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.273 -0.892 . . . . 0.0 109.532 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.522 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 1.8 p -132.06 169.94 12.59 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 120.624 -1.297 . . . . 0.0 110.317 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -64.92 109.37 1.27 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.883 1.465 . . . . 0.0 110.923 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.54 HG23 ' ND2' ' A' ' 327' ' ' ASN . 6.2 m -48.18 -59.0 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.427 -0.796 . . . . 0.0 110.63 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.453 ' HB2' ' O ' ' A' ' 324' ' ' VAL . 14.6 t 177.89 -25.91 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.991 -1.068 . . . . 0.0 111.133 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.407 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 7.1 p-90 -113.85 -22.87 9.93 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.958 -1.089 . . . . 0.0 110.912 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.54 ' ND2' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -83.36 12.18 5.79 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.991 -1.068 . . . . 0.0 110.929 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.536 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 12.1 mtmt -74.12 -11.07 60.2 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.46 -0.775 . . . . 0.0 109.329 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.21 -158.13 0.01 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.542 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -73.06 7.14 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 124.069 1.562 . . . . 0.0 111.388 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 4.4 m -162.32 131.23 4.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.123 -0.986 . . . . 0.0 109.841 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.539 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -144.23 104.37 4.1 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.231 -0.918 . . . . 0.0 110.355 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.473 ' O ' ' HB3' ' A' ' 309' ' ' SER . 48.2 m -100.98 135.16 42.87 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.058 -1.027 . . . . 0.0 110.312 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 6.6 p90 -144.39 173.14 12.04 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.439 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.67 157.54 27.24 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.478 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.661 ' CE2' ' CB ' ' A' ' 280' ' ' TYR . 0.4 OUTLIER -144.35 144.81 31.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.598 -0.943 . . . . 0.0 110.01 179.512 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.541 HG23 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -119.31 118.65 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.099 -1.001 . . . . 0.0 109.589 179.614 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.579 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.2 t -96.67 150.06 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.241 -0.912 . . . . 0.0 109.855 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -122.57 133.8 54.55 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.437 -0.789 . . . . 0.0 110.333 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -176.97 -140.03 3.46 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.516 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 47.6 Cg_endo -75.28 -170.42 0.8 Allowed 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 124.035 1.545 . . . . 0.0 110.382 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.444 ' CD ' ' N ' ' A' ' 342' ' ' GLN . 5.9 mp0 -101.19 153.36 19.67 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.128 -0.983 . . . . 0.0 110.295 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.474 ' O ' ' HB3' ' A' ' 344' ' ' ASP . . . 91.81 71.6 1.2 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.474 ' HB3' ' O ' ' A' ' 343' ' ' GLY . 16.5 t70 59.87 147.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.4 -1.059 . . . . 0.0 109.626 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.55 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 2.2 mtmt -140.9 19.72 2.31 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.998 -1.064 . . . . 0.0 110.812 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.54 ' CG2' HG11 ' A' ' 296' ' ' VAL . 7.5 p -132.08 118.17 35.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 110.46 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.476 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -46.76 -46.61 20.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.457 -0.777 . . . . 0.0 110.504 -179.845 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.428 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 9.2 pt-20 -177.27 158.93 1.53 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.041 -1.037 . . . . 0.0 110.803 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.46 HG12 HG11 ' A' ' 296' ' ' VAL . 44.9 mt -120.46 106.69 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.131 -0.98 . . . . 0.0 110.392 179.7 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.49 136.48 51.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.225 -0.922 . . . . 0.0 110.228 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.605 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -95.71 134.35 38.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.238 -0.914 . . . . 0.0 110.332 179.83 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.481 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 6.2 tt0 -138.94 112.43 8.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.361 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.442 ' O ' ' C ' ' A' ' 354' ' ' ASN . 1.2 mt -91.71 105.2 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.066 -1.021 . . . . 0.0 109.942 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.444 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 40.15 31.51 0.1 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.591 -0.693 . . . . 0.0 110.625 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 119.14 -22.08 9.15 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -85.35 105.29 15.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.255 -1.144 . . . . 0.0 110.096 179.974 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.481 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 4.1 p -75.73 130.52 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.501 HG21 ' CB ' ' A' ' 262' ' ' PRO . 27.0 mm . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.276 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.86 -177.93 3.18 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.995 1.524 . . . . 0.0 110.545 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.466 HG22 ' O ' ' A' ' 258' ' ' THR . 13.5 t -57.1 125.03 20.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.305 -0.872 . . . . 0.0 110.537 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 12.4 m -117.37 121.84 31.7 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.258 -0.901 . . . . 0.0 110.195 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -74.99 125.63 9.45 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 O-C-N 123.945 1.497 . . . . 0.0 110.568 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.466 HG22 ' HD2' ' A' ' 262' ' ' PRO . 2.4 p -109.04 143.28 27.32 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.139 -0.975 . . . . 0.0 110.114 179.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.478 ' HA ' ' HA ' ' A' ' 358' ' ' ILE . 44.0 Cg_endo -71.55 137.78 31.08 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 124.02 1.537 . . . . 0.0 110.725 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 9.6 t -130.97 28.9 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.34 -0.85 . . . . 0.0 110.293 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.41 ' OG ' HD13 ' A' ' 358' ' ' ILE . 0.3 OUTLIER -179.52 97.61 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 110.446 179.926 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 98.06 -177.94 31.66 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.55 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.7 OUTLIER -133.62 165.85 23.96 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -1.079 . . . . 0.0 109.883 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.55 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.7 tm? -161.31 137.2 8.02 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.412 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.472 ' N ' HD21 ' A' ' 267' ' ' LEU . 1.3 mm-40 -132.94 154.09 50.78 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.462 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 46.2 t -145.41 139.74 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.62 -1.3 . . . . 0.0 111.739 -179.307 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.08 154.84 45.24 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.746 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.537 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 70.8 t -140.67 141.43 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.466 -1.396 . . . . 0.0 111.984 -179.294 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -134.41 110.25 9.3 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 179.205 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.516 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.2 m-20 -96.77 142.19 29.08 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.071 -1.018 . . . . 0.0 110.926 -178.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.58 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 26.0 p90 -123.16 15.31 9.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.312 -0.867 . . . . 0.0 110.223 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.14 -53.62 3.22 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -76.9 -16.6 59.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -1.136 . . . . 0.0 110.066 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.559 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.74 -178.68 43.87 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.851 -1.299 . . . . 0.0 109.851 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.546 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.88 138.63 39.27 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -1.111 . . . . 0.0 110.053 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.58 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.0 mt-10 -95.22 147.14 23.79 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.351 -0.843 . . . . 0.0 110.017 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.686 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.0 m-85 -140.17 89.27 2.28 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 110.814 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.462 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -71.34 148.48 47.01 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.324 -0.86 . . . . 0.0 109.639 179.239 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.616 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.6 t -142.69 92.29 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.413 -0.805 . . . . 0.0 109.968 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.465 ' O ' HD23 ' A' ' 267' ' ' LEU . 15.4 m -86.45 126.46 34.42 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.032 -1.043 . . . . 0.0 109.77 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.606 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -115.19 149.6 37.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.969 -1.082 . . . . 0.0 110.987 -179.081 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.55 ' ND2' ' HB2' ' A' ' 266' ' ' SER . 0.4 OUTLIER -129.67 133.78 47.29 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.334 -0.854 . . . . 0.0 110.071 -179.691 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.547 ' CD1' ' HB2' ' A' ' 290' ' ' TYR . 17.8 mt -142.1 162.94 34.2 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.65 -1.281 . . . . 0.0 110.055 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -87.65 29.71 0.87 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.921 . . . . 0.0 110.473 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.506 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.09 -136.82 6.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.46 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 32.4 mm-40 -90.11 104.74 17.28 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.276 -1.132 . . . . 0.0 110.873 -179.561 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.547 ' HB2' ' CD1' ' A' ' 286' ' ' LEU . 8.4 m-85 -128.43 129.61 46.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.398 -0.814 . . . . 0.0 109.265 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.533 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 58.9 m-20 -74.6 96.31 2.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.742 -1.224 . . . . 0.0 109.369 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.586 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 60.3 p-90 -98.01 115.43 28.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 110.689 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.528 HG22 ' CG2' ' A' ' 322' ' ' THR . 4.6 m -109.51 115.78 30.56 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.52 -0.738 . . . . 0.0 109.425 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.493 HG23 ' CD2' ' A' ' 351' ' ' LEU . 4.6 t -96.89 111.27 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.106 -0.996 . . . . 0.0 110.394 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.495 ' HA ' HD11 ' A' ' 320' ' ' ILE . 21.2 ttpt -91.29 136.5 33.05 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.594 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 69.9 t -135.46 109.2 10.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.136 -0.978 . . . . 0.0 110.634 -179.152 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.517 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 53.8 mmtt -69.97 132.77 46.46 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.243 -0.911 . . . . 0.0 109.32 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.591 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 60.1 mt -86.68 165.45 16.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.304 -0.872 . . . . 0.0 111.198 -179.062 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.507 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -75.69 176.43 3.21 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.752 -0.593 . . . . 0.0 109.43 179.208 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.507 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 41.0 Cg_endo -67.6 84.94 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.527 1.278 . . . . 0.0 109.955 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.87 20.95 6.57 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.482 ' HB3' ' HG2' ' A' ' 345' ' ' LYS . . . -111.2 142.37 43.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.274 -1.133 . . . . 0.0 110.23 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.493 ' N ' HG13 ' A' ' 338' ' ' VAL . 17.0 p -150.28 144.36 25.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -0.941 . . . . 0.0 110.834 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.521 HG13 ' CD ' ' A' ' 312' ' ' LYS . 14.7 t -63.75 137.37 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.388 -0.82 . . . . 0.0 110.193 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -120.69 -33.15 1.03 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.43 ' O ' HD12 ' A' ' 337' ' ' ILE . 24.7 m -138.86 117.14 11.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.223 -1.163 . . . . 0.0 110.441 179.961 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.486 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.4 p90 -133.91 148.38 51.22 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.288 -0.883 . . . . 0.0 109.908 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -141.23 164.53 30.01 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.14 -0.975 . . . . 0.0 111.173 -179.433 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.519 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 54.33 25.13 5.64 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.728 -0.607 . . . . 0.0 111.173 179.499 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.474 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -173.88 138.65 0.64 Allowed 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.099 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.527 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -76.89 120.08 21.53 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.074 -1.017 . . . . 0.0 108.711 179.337 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.521 ' CD ' HG13 ' A' ' 304' ' ' VAL . 4.3 ttpt -88.43 128.05 35.52 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.824 0.821 . . . . 0.0 110.799 -178.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -113.31 175.73 5.32 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -135.5 110.56 8.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.292 -0.88 . . . . 0.0 110.731 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.574 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -95.35 40.56 2.64 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.0 77.65 0.26 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.233 -1.157 . . . . 0.0 109.962 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.616 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.96 3.56 54.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.616 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.8 m-85 -145.12 -170.76 3.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.486 -1.008 . . . . 0.0 109.003 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.532 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 18.2 t -161.39 157.74 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.199 -0.938 . . . . 0.0 109.691 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.511 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 13.0 mm -127.03 146.79 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -0.922 . . . . 0.0 110.885 -179.563 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 91.0 m-85 -124.12 119.19 28.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.321 -0.862 . . . . 0.0 109.814 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.528 ' CG2' HG22 ' A' ' 293' ' ' THR . 12.6 p -121.11 168.0 11.92 Favored Pre-proline 0 C--N 1.301 -1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.641 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.501 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.5 Cg_endo -66.28 117.97 5.13 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.692 1.364 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.539 HG23 ' CD1' ' A' ' 326' ' ' TRP . 23.9 m -65.72 -130.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.507 -0.746 . . . . 0.0 110.332 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.409 ' O ' ' HE2' ' A' ' 328' ' ' LYS . 1.9 t -96.94 -12.84 22.89 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.08 -1.013 . . . . 0.0 110.554 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.539 ' CD1' HG23 ' A' ' 324' ' ' VAL . 34.0 p-90 -133.46 5.53 3.75 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.07 -1.019 . . . . 0.0 110.946 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.459 ' O ' ' HB3' ' A' ' 323' ' ' PRO . 1.3 t-20 -112.45 42.89 1.73 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.998 -1.064 . . . . 0.0 110.768 -179.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.495 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.8 OUTLIER -122.97 0.95 9.23 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.338 -0.851 . . . . 0.0 109.71 179.064 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -63.69 -158.79 0.23 Allowed Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.506 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 47.8 Cg_endo -75.36 3.88 5.41 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.999 1.526 . . . . 0.0 110.767 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.6 m -165.02 117.6 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.16 -0.963 . . . . 0.0 109.814 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.547 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -140.18 123.7 17.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.274 -0.891 . . . . 0.0 110.373 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.476 ' O ' ' HB2' ' A' ' 309' ' ' SER . 40.9 m -111.58 142.07 44.36 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 109.99 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.616 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 14.0 p90 -143.95 174.82 10.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.515 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.486 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.04 158.05 27.49 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.288 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.686 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -144.97 147.44 32.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.476 -1.014 . . . . 0.0 110.041 179.627 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.549 HG21 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -120.6 118.93 58.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.005 -1.059 . . . . 0.0 109.704 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.591 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.5 t -96.73 147.27 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.113 -0.992 . . . . 0.0 110.095 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.434 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.15 137.85 53.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.339 -0.85 . . . . 0.0 110.332 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.422 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 176.66 -134.53 2.58 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.502 ' O ' ' NZ ' ' A' ' 345' ' ' LYS . 43.9 Cg_endo -71.48 -158.82 0.06 OUTLIER 'Trans proline' 0 C--N 1.303 -1.844 0 O-C-N 124.019 1.537 . . . . 0.0 110.326 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.579 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -122.97 141.31 52.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.094 -1.004 . . . . 0.0 110.121 -179.818 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.484 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 101.45 66.86 0.79 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 108.811 -1.716 . . . . 0.0 108.811 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.7 OUTLIER 68.39 128.72 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.291 -1.123 . . . . 0.0 109.279 -179.165 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.508 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.7 OUTLIER -127.45 19.61 6.81 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.096 -1.003 . . . . 0.0 110.29 -179.461 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.594 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 7.5 p -130.22 117.84 41.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -0.839 . . . . 0.0 110.568 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.0 mt-10 -47.08 -46.98 23.03 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 110.141 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.443 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.74 158.34 1.66 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.291 -0.88 . . . . 0.0 110.59 -179.843 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.468 HG21 HD11 ' A' ' 349' ' ' ILE . 33.1 mt -118.26 105.99 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.336 -0.852 . . . . 0.0 110.289 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.86 143.02 38.62 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.959 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.606 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.37 130.91 54.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.115 -0.991 . . . . 0.0 110.442 -179.867 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.439 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 15.0 tt0 -139.13 114.69 9.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.875 . . . . 0.0 109.823 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.523 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -91.38 111.52 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.014 -1.054 . . . . 0.0 109.744 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.533 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 39.86 30.28 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.793 -0.567 . . . . 0.0 110.44 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 115.88 -15.02 16.69 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.4 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 0.0 OUTLIER -89.54 108.06 19.44 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.128 -1.219 . . . . 0.0 110.412 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.487 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 9.8 p -73.09 123.99 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.165 -0.959 . . . . 0.0 110.125 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 262' ' ' PRO . 20.6 mm . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.423 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.701 -1.359 . . . . 0.0 109.701 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.13 -178.56 3.97 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 123.975 1.513 . . . . 0.0 109.988 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 6.1 t -58.21 141.32 51.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 110.025 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 14.4 t -132.76 138.67 32.48 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.279 -0.888 . . . . 0.0 110.052 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.95 155.58 52.93 Favored 'Trans proline' 0 C--N 1.304 -1.815 0 O-C-N 123.966 1.508 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.441 HG22 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -83.09 141.62 43.52 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.936 . . . . 0.0 110.581 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.441 ' HD2' HG22 ' A' ' 261' ' ' VAL . 47.4 Cg_endo -74.53 139.43 25.59 Favored 'Trans proline' 0 C--N 1.304 -1.815 0 O-C-N 124.213 1.639 . . . . 0.0 110.005 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.488 ' O ' ' CB ' ' A' ' 264' ' ' SER . 24.5 t -117.53 30.62 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.182 -0.949 . . . . 0.0 110.496 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.488 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 170.18 105.35 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.191 -0.943 . . . . 0.0 110.9 179.881 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 89.28 -170.82 37.78 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 120.064 -1.065 . . . . 0.0 110.505 179.07 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.553 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.79 167.89 21.0 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.64 -0.918 . . . . 0.0 109.533 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.562 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.8 tm? -161.47 133.96 5.98 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.0 -1.08 . . . . 0.0 111.266 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.516 ' N ' HD21 ' A' ' 267' ' ' LEU . 14.3 mm-40 -134.33 129.62 35.77 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.44 HG12 ' O ' ' A' ' 281' ' ' ASP . 89.5 t -125.9 139.54 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.853 -1.154 . . . . 0.0 111.625 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.1 mtmt -124.9 157.56 35.67 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.59 HG12 ' CE1' ' A' ' 280' ' ' TYR . 74.5 t -141.62 146.73 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.43 -1.418 . . . . 0.0 112.068 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.557 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -136.28 107.9 6.99 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.309 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.508 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.2 m-20 -94.74 142.44 27.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.997 -1.064 . . . . 0.0 111.1 -179.03 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.592 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 25.6 p90 -123.97 17.06 9.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.44 -0.787 . . . . 0.0 109.831 179.173 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.43 -55.54 3.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.31 -18.94 58.7 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.227 -1.161 . . . . 0.0 110.286 -179.785 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.24 -179.37 40.63 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.551 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -139.06 137.13 35.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -1.111 . . . . 0.0 110.173 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.592 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 5.6 mt-10 -92.7 146.84 23.35 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.264 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.2 m-85 -139.98 90.34 2.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.201 -0.937 . . . . 0.0 111.265 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.44 ' O ' HG12 ' A' ' 269' ' ' VAL . 4.7 t70 -72.62 146.92 46.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.51 -0.744 . . . . 0.0 109.408 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.604 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 4.4 t -140.77 86.94 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.184 -0.947 . . . . 0.0 110.094 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.47 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 13.2 m -86.74 122.88 31.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.069 -1.019 . . . . 0.0 110.04 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.591 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.56 154.05 22.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 0.0 110.226 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.553 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -133.69 113.75 12.7 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.106 -0.996 . . . . 0.0 110.89 -179.071 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.549 ' O ' ' CB ' ' A' ' 330' ' ' PRO . 13.3 mt -123.83 158.59 31.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.549 -1.345 . . . . 0.0 109.884 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.1 35.22 0.85 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.292 -0.88 . . . . 0.0 109.807 179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 154.92 -134.25 4.15 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.515 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 47.5 mm-40 -106.84 111.63 24.24 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.177 -1.19 . . . . 0.0 111.026 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.569 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 6.9 m-85 -132.06 136.96 47.59 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.336 -0.852 . . . . 0.0 109.301 179.175 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.513 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 31.1 m-20 -75.37 96.42 3.4 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.756 -1.215 . . . . 0.0 108.617 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.589 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 61.3 p-90 -99.6 114.1 26.93 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.449 -0.782 . . . . 0.0 110.904 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.584 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 27.3 m -111.43 118.09 34.84 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.155 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.493 HG21 HD22 ' A' ' 351' ' ' LEU . 3.1 t -96.75 111.0 25.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.183 -0.948 . . . . 0.0 110.737 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.493 ' HA ' HD11 ' A' ' 320' ' ' ILE . 7.0 ttpp -83.34 148.6 27.24 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.441 -0.787 . . . . 0.0 109.012 178.778 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.529 HG13 ' CG2' ' A' ' 346' ' ' VAL . 44.5 t -147.3 104.99 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.096 -1.003 . . . . 0.0 110.707 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.581 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.7 mmtp -70.63 133.14 46.42 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 179.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.559 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 91.0 mt -86.37 150.28 24.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 111.474 -179.071 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.504 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -61.0 171.89 1.01 Allowed Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.686 -0.634 . . . . 0.0 109.681 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.491 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.2 Cg_endo -67.53 82.58 0.41 Allowed 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.785 1.413 . . . . 0.0 109.642 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.11 28.27 2.68 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -122.32 146.36 47.38 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.373 -1.075 . . . . 0.0 110.557 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.559 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 19.3 p -149.57 143.59 25.68 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.185 -0.947 . . . . 0.0 110.748 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.578 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 66.8 t -68.48 130.76 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 110.246 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -114.04 -39.33 1.06 Allowed Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.46 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 18.1 m -132.64 141.67 48.75 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.188 -1.184 . . . . 0.0 110.913 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.578 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 28.5 p90 -153.75 167.96 27.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.363 -0.836 . . . . 0.0 109.656 179.465 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.497 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -160.67 158.43 28.82 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.995 -1.066 . . . . 0.0 111.253 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.555 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.61 31.96 21.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.631 -0.668 . . . . 0.0 111.245 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.534 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -175.91 150.85 1.04 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.049 -1.032 . . . . 0.0 110.457 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.493 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 1.9 m-80 -81.22 109.7 16.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.088 -1.007 . . . . 0.0 109.439 179.012 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.578 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 27.6 ttpt -84.97 132.52 34.34 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.46 -0.775 . . . . 0.0 110.603 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.519 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.07 174.73 7.83 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.53 -0.731 . . . . 0.0 109.465 179.329 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -138.2 104.68 5.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.523 -0.736 . . . . 0.0 110.064 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -92.0 37.93 3.29 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.12 81.24 0.21 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.048 -1.266 . . . . 0.0 110.253 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.25 -0.04 57.12 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.614 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.3 m-85 -146.33 -171.33 3.71 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.347 -1.09 . . . . 0.0 109.359 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.578 ' CG2' ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -159.46 157.91 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.117 -0.989 . . . . 0.0 109.844 178.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.584 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 8.7 mm -125.87 150.32 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.073 -1.017 . . . . 0.0 111.376 -179.176 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.638 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 89.3 m-85 -130.98 112.49 12.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.301 -0.874 . . . . 0.0 110.285 179.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.566 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.8 p -115.02 174.23 2.48 Favored Pre-proline 0 N--CA 1.498 1.973 0 O-C-N 120.512 -1.367 . . . . 0.0 109.54 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.566 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 43.1 Cg_endo -71.13 125.07 11.07 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.607 1.319 . . . . 0.0 111.283 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.514 ' N ' ' OD1' ' A' ' 327' ' ' ASN . 14.9 m -70.06 -110.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.518 -0.739 . . . . 0.0 110.438 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -119.42 -16.95 8.88 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.715 -1.241 . . . . 0.0 111.299 -179.277 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.53 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 3.1 p-90 -125.93 -18.9 4.97 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.914 -1.116 . . . . 0.0 111.077 -179.507 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.555 ' ND2' ' O ' ' A' ' 309' ' ' SER . 34.0 p-10 -89.7 47.28 1.45 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.928 -1.108 . . . . 0.0 110.046 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.491 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 13.5 mtmt -118.26 -10.09 10.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.493 -0.754 . . . . 0.0 109.426 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.24 -157.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.549 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -74.73 5.69 3.71 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.03 1.542 . . . . 0.0 111.077 -179.741 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 3.6 m -161.93 120.03 2.25 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.874 179.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.41 117.78 14.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.222 -0.924 . . . . 0.0 110.361 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.47 ' OG1' ' CG2' ' A' ' 283' ' ' THR . 26.2 m -109.68 135.28 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 110.434 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.608 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 13.4 p90 -142.82 174.44 10.65 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.476 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.09 162.94 29.35 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.582 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.68 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.3 p90 -150.84 145.05 25.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.567 -0.961 . . . . 0.0 109.558 179.352 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.555 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.5 mp -118.89 122.4 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.058 -1.026 . . . . 0.0 110.069 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.534 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 3.4 t -98.36 146.06 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.22 -0.925 . . . . 0.0 109.695 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -119.39 137.22 53.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 110.729 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.446 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.49 -136.59 2.98 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.725 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.493 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 45.3 Cg_endo -72.01 -156.83 0.05 OUTLIER 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.836 1.44 . . . . 0.0 109.697 179.159 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.563 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -120.41 144.18 48.07 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.007 -1.058 . . . . 0.0 110.119 -179.936 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.473 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 103.08 66.59 0.74 Allowed Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.473 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 16.3 m-20 61.51 134.61 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.296 -1.12 . . . . 0.0 109.782 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.534 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.8 OUTLIER -133.12 28.71 4.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.193 -0.942 . . . . 0.0 110.742 -179.506 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.592 HG12 ' CE1' ' A' ' 280' ' ' TYR . 7.1 p -131.46 111.22 18.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.1 mm-40 -43.14 -46.83 6.03 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.202 -0.936 . . . . 0.0 110.425 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -175.95 157.78 1.95 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 110.357 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . . . . . . . . . 13.5 mt -118.43 104.36 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.243 -0.911 . . . . 0.0 109.945 179.906 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.03 126.83 52.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 110.499 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.591 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -91.11 130.17 37.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.03 -1.044 . . . . 0.0 110.025 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.527 ' N ' HD23 ' A' ' 351' ' ' LEU . 15.9 tt0 -138.55 117.59 12.54 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.31 -0.869 . . . . 0.0 109.549 179.907 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.506 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.11 98.19 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.921 -1.112 . . . . 0.0 110.118 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.513 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 38.57 28.24 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.296 179.634 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 134.94 -19.47 3.92 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.889 179.201 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.474 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 11.1 mm100 -102.78 113.15 26.33 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.871 -1.37 . . . . 0.0 110.905 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.416 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.7 p -76.89 121.17 28.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.485 -0.759 . . . . 0.0 110.354 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.416 HG22 ' HB2' ' A' ' 262' ' ' PRO . 26.7 mm . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.165 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -73.17 -178.27 3.49 Favored 'Trans proline' 0 C--N 1.303 -1.834 0 O-C-N 124.048 1.551 . . . . 0.0 110.505 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.514 ' CG2' ' O ' ' A' ' 258' ' ' THR . 5.2 t -65.79 122.77 18.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.328 -0.858 . . . . 0.0 110.349 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 17.0 p -112.0 125.44 30.22 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.88 142.15 31.23 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.884 1.465 . . . . 0.0 110.25 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.454 HG22 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -110.39 145.65 32.66 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.23 -0.919 . . . . 0.0 110.423 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.521 ' CB ' HG21 ' A' ' 358' ' ' ILE . 44.5 Cg_endo -71.21 157.67 56.66 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 124.113 1.586 . . . . 0.0 110.441 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.428 ' O ' ' OG ' ' A' ' 264' ' ' SER . 23.5 t -144.61 29.41 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.165 -0.959 . . . . 0.0 110.536 -179.846 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.428 ' OG ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 176.05 104.04 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.285 -0.885 . . . . 0.0 110.424 179.878 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 92.59 -172.78 34.7 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.535 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.41 166.08 25.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.334 -1.098 . . . . 0.0 110.043 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.569 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.7 tm? -161.65 139.77 9.22 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.025 -1.047 . . . . 0.0 111.409 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.435 ' N ' HD23 ' A' ' 267' ' ' LEU . 3.7 mt-10 -136.12 153.78 51.19 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.449 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 54.0 t -145.27 135.67 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.697 -1.252 . . . . 0.0 111.567 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.445 ' O ' HG21 ' A' ' 271' ' ' VAL . 7.7 mtpt -122.88 157.05 33.38 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.523 HG11 ' CE1' ' A' ' 280' ' ' TYR . 92.5 t -144.81 147.2 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.478 -1.389 . . . . 0.0 112.167 -179.144 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.64 112.64 7.35 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.791 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.518 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 p-10 -97.53 141.76 30.19 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.948 -1.095 . . . . 0.0 111.402 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.553 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 32.3 p90 -124.5 19.99 8.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.502 -0.748 . . . . 0.0 109.8 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.464 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 85.74 -59.58 4.75 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.99 -20.07 66.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -1.159 . . . . 0.0 110.11 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.48 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.12 -175.03 44.93 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.4 143.94 42.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -1.138 . . . . 0.0 110.225 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.512 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 3.9 mt-10 -96.97 145.83 25.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.385 -0.822 . . . . 0.0 109.789 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.681 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 96.1 m-85 -138.93 86.73 2.16 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.452 -0.78 . . . . 0.0 110.92 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.449 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.59 146.83 49.84 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.316 -0.865 . . . . 0.0 109.442 179.105 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.639 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.6 t -140.22 90.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 121.336 -0.853 . . . . 0.0 109.932 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.452 ' O ' HD22 ' A' ' 267' ' ' LEU . 53.9 m -86.58 127.92 34.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.058 -1.026 . . . . 0.0 109.681 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.607 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.89 152.1 32.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.127 -0.983 . . . . 0.0 110.687 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.54 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.4 OUTLIER -130.56 134.54 47.1 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.282 -0.886 . . . . 0.0 110.263 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.565 ' N ' ' O ' ' A' ' 330' ' ' PRO . 12.7 mt -143.72 155.55 44.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.938 -1.101 . . . . 0.0 109.491 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -88.6 40.02 0.95 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 109.723 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 150.3 -116.69 0.79 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.991 -1.576 . . . . 0.0 110.242 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.559 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.6 mt-30 -128.62 116.31 19.4 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.022 -1.281 . . . . 0.0 110.926 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.599 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 8.8 m-85 -138.23 137.03 37.15 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.191 -0.943 . . . . 0.0 109.664 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.523 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 23.2 m-20 -71.02 96.81 1.36 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.815 -1.178 . . . . 0.0 108.981 179.043 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.585 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 59.2 p-90 -98.08 113.1 24.89 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.221 -0.924 . . . . 0.0 110.833 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.602 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 10.3 m -106.23 111.75 24.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.417 -0.802 . . . . 0.0 109.243 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.529 HG23 ' CD2' ' A' ' 351' ' ' LEU . 3.1 t -96.21 111.24 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.167 -0.958 . . . . 0.0 110.371 -179.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.543 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 5.1 ttmt -89.19 149.51 23.09 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.438 -0.788 . . . . 0.0 109.51 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.568 HG12 ' CG2' ' A' ' 346' ' ' VAL . 56.1 t -142.34 107.87 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.288 -0.882 . . . . 0.0 110.31 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.555 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 11.5 mmtt -70.2 131.34 44.07 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.179 -0.95 . . . . 0.0 109.645 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.592 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 94.8 mt -85.25 160.89 19.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.81 . . . . 0.0 111.312 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.521 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -71.43 174.32 4.01 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 121.571 -0.705 . . . . 0.0 109.212 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.502 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.43 84.08 0.37 Allowed 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 123.492 1.259 . . . . 0.0 110.096 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.97 24.66 4.79 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.508 ' HB1' ' HB1' ' A' ' 299' ' ' ALA . . . -115.9 148.32 40.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -1.104 . . . . 0.0 110.225 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.53 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.8 p -149.84 143.6 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.104 -0.998 . . . . 0.0 110.718 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.525 HG21 ' CG2' ' A' ' 319' ' ' VAL . 85.2 t -65.63 121.94 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.418 -0.801 . . . . 0.0 109.906 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -103.16 -30.25 5.46 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.483 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.412 ' O ' ' N ' ' A' ' 337' ' ' ILE . 3.3 t -145.85 142.32 28.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.004 -1.292 . . . . 0.0 110.911 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.509 ' CD1' ' C ' ' A' ' 307' ' ' PHE . 15.0 p90 -152.6 174.65 13.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.544 -0.722 . . . . 0.0 109.38 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.474 ' NE1' ' N ' ' A' ' 335' ' ' GLY . 1.3 p90 -163.84 159.55 21.26 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.848 -1.158 . . . . 0.0 111.486 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.482 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.7 OUTLIER 55.68 26.41 9.3 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.564 -0.71 . . . . 0.0 111.116 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.536 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -173.68 139.25 0.7 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.195 -0.941 . . . . 0.0 109.897 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.521 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.3 m-80 -77.42 121.24 23.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.062 -1.024 . . . . 0.0 109.488 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.482 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.3 ttpt -88.33 142.81 27.44 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.844 0.83 . . . . 0.0 110.552 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.586 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.6 mt-30 -130.25 176.48 8.07 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.255 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.454 ' OE1' ' O ' ' A' ' 318' ' ' TYR . 5.3 mm-40 -135.79 113.32 10.8 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.115 -0.99 . . . . 0.0 110.545 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.6 42.13 2.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.465 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 20.6 t-20 57.41 81.49 0.14 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.335 -1.097 . . . . 0.0 110.269 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.82 3.74 58.08 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.597 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 0.8 OUTLIER -147.08 -167.72 2.85 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.353 -1.087 . . . . 0.0 109.055 179.532 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.535 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.7 t -163.28 147.73 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.195 -0.94 . . . . 0.0 109.733 178.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.602 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.6 mm -112.35 152.06 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.005 -1.06 . . . . 0.0 110.998 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 58.4 m-85 -129.24 125.86 37.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.812 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.521 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 7.2 p -129.04 167.7 18.71 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 120.488 -1.382 . . . . 0.0 109.965 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.538 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.7 Cg_endo -65.74 119.36 6.37 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.78 1.411 . . . . 0.0 111.087 -179.233 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.497 HG11 ' ND2' ' A' ' 311' ' ' ASN . 31.3 m -64.73 -121.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.485 -0.759 . . . . 0.0 110.297 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.437 ' C ' ' HD2' ' A' ' 328' ' ' LYS . 0.6 OUTLIER -106.18 -19.9 13.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.809 -1.182 . . . . 0.0 110.666 -179.649 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.453 ' CE2' HG23 ' A' ' 324' ' ' VAL . 21.6 p-90 -126.2 3.17 7.13 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.08 -1.012 . . . . 0.0 110.653 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.532 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 1.9 t-20 -108.08 31.72 5.32 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.093 -1.005 . . . . 0.0 110.576 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -110.46 -2.6 16.47 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.102 -0.999 . . . . 0.0 109.547 179.433 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.05 -153.33 0.02 OUTLIER Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.565 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.6 Cg_endo -69.8 -48.89 0.62 Allowed 'Trans proline' 0 C--N 1.301 -1.935 0 O-C-N 123.987 1.52 . . . . 0.0 109.474 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.437 HG23 ' O ' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -109.08 125.58 52.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.527 -0.733 . . . . 0.0 110.327 179.643 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.74 108.09 6.86 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.36 -0.838 . . . . 0.0 109.993 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.449 ' OG1' HG22 ' A' ' 283' ' ' THR . 3.3 m -103.17 138.92 39.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 110.227 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.639 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 14.0 p90 -144.74 174.63 10.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.374 -0.829 . . . . 0.0 109.138 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.482 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.04 158.26 27.59 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 118.984 -1.579 . . . . 0.0 110.336 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.681 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -147.93 143.87 27.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.57 -0.959 . . . . 0.0 109.553 179.321 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.56 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.5 mp -118.01 129.67 74.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.073 -1.017 . . . . 0.0 110.107 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.592 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.3 t -104.92 148.48 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.027 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -120.7 135.47 55.12 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 110.181 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.416 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -179.73 -138.63 3.41 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.503 ' C ' ' NE2' ' A' ' 342' ' ' GLN . 50.0 Cg_endo -74.91 -166.14 0.33 Allowed 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 124.0 1.526 . . . . 0.0 110.479 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.503 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 21.3 mm-40 -110.29 143.27 40.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.201 -0.937 . . . . 0.0 110.284 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 103.52 69.37 0.8 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.467 ' O ' ' O ' ' A' ' 343' ' ' GLY . 15.3 m-20 61.52 134.76 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.337 -1.096 . . . . 0.0 109.466 -179.27 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.537 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 2.1 mtmt -129.13 15.7 6.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.035 -1.04 . . . . 0.0 110.335 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.595 HG13 ' CE1' ' A' ' 280' ' ' TYR . 6.8 p -128.91 117.4 44.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.309 -0.869 . . . . 0.0 110.107 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.2 OUTLIER -47.57 -47.88 28.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.046 -1.034 . . . . 0.0 110.068 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.419 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.7 OUTLIER -177.2 158.33 1.47 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.289 -0.882 . . . . 0.0 110.35 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.491 HD11 HG21 ' A' ' 349' ' ' ILE . 17.0 mt -117.34 110.37 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 110.215 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.67 144.03 41.59 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.271 -0.893 . . . . 0.0 110.2 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.607 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.66 132.77 50.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.18 -0.95 . . . . 0.0 110.249 179.869 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.409 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 5.4 tt0 -139.07 113.13 8.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.945 179.674 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.47 HD12 ' HB3' ' A' ' 292' ' ' TRP . 2.8 mt -91.64 112.53 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.913 -1.117 . . . . 0.0 110.088 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.523 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.84 29.72 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.782 -0.574 . . . . 0.0 111.295 -179.961 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.26 -10.24 14.98 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.667 -1.254 . . . . 0.0 110.6 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . . . . . . . . . 43.1 mm-40 -101.45 115.06 29.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.878 -1.366 . . . . 0.0 110.364 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.487 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.1 p -75.13 139.09 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.279 -0.888 . . . . 0.0 110.493 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.521 HG21 ' CB ' ' A' ' 262' ' ' PRO . 26.6 mm . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.196 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.82 -178.24 3.35 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 O-C-N 124.149 1.605 . . . . 0.0 110.619 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 11.1 t -57.6 145.51 33.55 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.358 -0.838 . . . . 0.0 110.39 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -110.52 95.67 23.94 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.344 -0.848 . . . . 0.0 110.245 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.86 158.12 50.56 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.984 1.518 . . . . 0.0 110.638 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.485 ' CG2' ' HD2' ' A' ' 262' ' ' PRO . 3.8 p -85.06 145.72 43.9 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.179 -0.95 . . . . 0.0 110.269 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.507 ' CB ' HG23 ' A' ' 358' ' ' ILE . 50.2 Cg_endo -74.62 125.9 9.84 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 O-C-N 124.08 1.568 . . . . 0.0 110.577 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.474 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 96.3 t -114.28 28.71 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.305 -0.872 . . . . 0.0 109.781 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.526 ' CB ' HD13 ' A' ' 358' ' ' ILE . 3.1 t -141.22 -139.84 0.13 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.385 -0.822 . . . . 0.0 110.408 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 264' ' ' SER . . . -59.78 -139.4 0.01 OUTLIER Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.541 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.8 OUTLIER -136.0 167.06 21.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.447 -1.031 . . . . 0.0 109.495 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.562 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.9 tm? -161.06 136.84 8.05 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.515 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.457 ' N ' HD21 ' A' ' 267' ' ' LEU . 8.0 mm-40 -135.69 156.12 49.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 59.9 t -146.96 146.29 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.648 -1.283 . . . . 0.0 111.617 -179.249 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.446 ' N ' HG12 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -132.4 157.6 44.14 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.186 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.546 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 86.7 t -144.88 147.2 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 120.262 -1.524 . . . . 0.0 112.401 -179.258 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.522 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.46 114.58 8.66 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.906 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.0 p-10 -97.81 148.73 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.087 -1.008 . . . . 0.0 111.366 -178.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.54 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 37.1 p90 -134.85 17.42 3.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.608 -0.682 . . . . 0.0 109.96 179.381 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.42 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 92.46 -66.28 2.05 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.48 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 57.4 m -64.3 -18.77 64.92 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.322 -1.105 . . . . 0.0 110.581 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.532 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -179.24 178.65 48.82 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.164 -1.493 . . . . 0.0 110.246 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.54 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.66 145.99 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.505 -0.997 . . . . 0.0 110.019 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.546 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 11.4 mt-10 -96.36 146.86 24.38 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.433 -0.792 . . . . 0.0 109.425 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.2 m-85 -138.33 89.17 2.36 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.31 -0.869 . . . . 0.0 110.584 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 71.4 m-20 -69.64 147.49 50.57 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.679 -0.638 . . . . 0.0 109.828 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.595 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -142.76 89.96 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.355 -0.84 . . . . 0.0 109.543 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.418 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 27.3 m -86.49 120.51 27.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.106 -0.996 . . . . 0.0 109.857 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.571 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.34 149.37 28.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.602 -179.478 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.541 ' ND2' ' HB2' ' A' ' 266' ' ' SER . 0.5 OUTLIER -128.04 136.21 50.93 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.395 -0.816 . . . . 0.0 110.084 -179.799 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.605 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 14.2 mt -142.17 154.52 44.9 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.721 -1.237 . . . . 0.0 109.854 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -85.77 36.27 0.65 Allowed 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.381 -0.825 . . . . 0.0 110.311 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.481 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 150.56 -104.12 0.26 Allowed Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.082 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.5 mm-40 -139.87 113.67 8.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.015 -1.285 . . . . 0.0 111.429 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.639 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 4.8 m-85 -138.75 129.93 26.95 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.503 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 90.0 m-20 -65.16 99.69 0.39 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.817 -1.177 . . . . 0.0 109.266 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.581 ' CZ2' ' HB2' ' A' ' 332' ' ' ALA . 52.4 p-90 -98.77 115.86 29.72 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.335 -0.853 . . . . 0.0 110.868 -179.27 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.594 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 9.8 m -105.98 116.26 31.63 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.66 -0.65 . . . . 0.0 109.299 179.538 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.459 HG21 ' CE2' ' A' ' 334' ' ' PHE . 3.9 t -96.75 111.44 26.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.02 -1.05 . . . . 0.0 110.662 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.526 ' HG3' ' CD1' ' A' ' 320' ' ' ILE . 2.8 ttpt -85.44 144.03 28.22 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.431 -0.793 . . . . 0.0 109.156 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.542 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 99.0 t -144.34 106.84 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.028 -1.045 . . . . 0.0 110.662 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.539 ' HD3' ' CG ' ' A' ' 318' ' ' TYR . 35.7 mmtt -70.57 130.38 41.67 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.27 -0.894 . . . . 0.0 109.804 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.596 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 77.2 mt -85.38 155.08 21.45 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.516 -0.74 . . . . 0.0 111.398 -178.972 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.546 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -59.7 176.23 0.33 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.54 -0.725 . . . . 0.0 109.409 179.106 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.494 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.5 Cg_endo -69.19 81.07 0.69 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.612 1.322 . . . . 0.0 109.895 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.2 4.9 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.303 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.493 ' HB3' ' HB2' ' A' ' 299' ' ' ALA . . . -110.24 149.7 29.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.417 -1.049 . . . . 0.0 110.188 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.532 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 9.5 p -150.15 145.08 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 110.573 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.473 HG23 HG22 ' A' ' 338' ' ' VAL . 77.5 t -71.25 122.6 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.527 -0.733 . . . . 0.0 109.865 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -103.5 -37.99 2.91 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.411 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -132.29 136.4 46.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.076 -1.249 . . . . 0.0 111.035 -179.559 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.583 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 50.3 p90 -147.67 159.91 43.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.458 -0.776 . . . . 0.0 109.468 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.517 ' CH2' HD13 ' A' ' 337' ' ' ILE . 1.2 p90 -154.65 158.13 39.19 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.976 -1.077 . . . . 0.0 111.239 -179.46 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.503 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.2 OUTLIER 63.98 20.39 12.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.553 -0.717 . . . . 0.0 110.532 179.63 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.482 ' HA ' HG12 ' A' ' 324' ' ' VAL . . . -174.76 147.44 1.03 Allowed 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.564 -0.71 . . . . 0.0 110.022 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.524 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -82.07 123.81 29.27 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.109 -0.994 . . . . 0.0 108.982 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.583 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 11.6 ttpt -89.42 137.96 31.87 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.63 0.729 . . . . 0.0 111.217 -178.967 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.5 ' CB ' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -123.15 172.36 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.776 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -139.28 104.49 5.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.201 -0.937 . . . . 0.0 110.506 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.464 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -92.31 40.37 2.89 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.464 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 0.8 OUTLIER 58.08 86.13 0.08 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.352 -1.087 . . . . 0.0 110.418 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.596 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.51 -4.54 58.25 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.596 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.0 OUTLIER -144.94 -172.05 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.4 -1.059 . . . . 0.0 109.243 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.496 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.3 t -159.08 161.45 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.211 -0.931 . . . . 0.0 109.739 178.978 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.594 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 42.4 mm -129.26 151.13 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.275 -0.89 . . . . 0.0 111.184 -179.66 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.628 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 97.4 m-85 -128.9 125.2 37.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.315 -0.866 . . . . 0.0 109.915 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.524 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 10.7 p -124.82 168.36 13.51 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 120.799 -1.188 . . . . 0.0 109.715 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.52 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.7 Cg_endo -66.73 121.71 8.97 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.692 1.364 . . . . 0.0 110.808 -179.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.502 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 31.2 m -69.5 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.554 -0.716 . . . . 0.0 110.083 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.417 ' C ' ' HD2' ' A' ' 328' ' ' LYS . 0.9 OUTLIER -100.44 -20.89 15.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 110.606 -179.76 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.503 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 8.4 p-90 -127.15 5.89 6.45 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.126 -0.984 . . . . 0.0 110.564 -179.728 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.502 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.9 OUTLIER -103.39 37.53 1.98 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.125 -0.984 . . . . 0.0 110.473 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.469 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -117.47 -9.0 10.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.282 -0.886 . . . . 0.0 109.619 179.689 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.463 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -56.31 -162.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.451 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 47.6 Cg_endo -74.14 5.16 3.72 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.228 1.646 . . . . 0.0 110.953 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.1 m -164.81 115.7 1.17 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.254 -0.904 . . . . 0.0 109.987 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.581 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -134.14 117.93 17.11 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.143 -0.973 . . . . 0.0 110.319 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.481 ' O ' ' HB3' ' A' ' 309' ' ' SER . 87.6 m -108.78 136.61 48.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.407 -0.808 . . . . 0.0 109.995 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.595 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 14.3 p90 -140.63 172.09 13.19 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.692 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.21 158.51 27.71 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.935 -1.602 . . . . 0.0 110.075 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.676 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.0 OUTLIER -146.22 147.28 31.28 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.437 -1.037 . . . . 0.0 109.906 179.614 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.546 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -120.58 119.58 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.056 -1.028 . . . . 0.0 109.809 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.596 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.8 t -97.17 149.1 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.194 -0.941 . . . . 0.0 110.37 -179.713 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.21 134.07 55.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.473 -0.767 . . . . 0.0 109.807 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.94 -124.98 0.95 Allowed Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.549 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 41.6 Cg_endo -66.4 -159.36 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.82 1.431 . . . . 0.0 110.565 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.484 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 0.9 OUTLIER -119.35 132.2 55.83 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.15 -0.969 . . . . 0.0 111.041 -179.192 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 102.35 -87.91 0.64 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -103.07 133.7 47.75 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.424 -1.045 . . . . 0.0 109.234 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.549 ' CG ' ' HD2' ' A' ' 341' ' ' PRO . 0.4 OUTLIER -135.57 7.51 3.3 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.962 -1.086 . . . . 0.0 110.722 -179.559 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.582 HG12 ' CE1' ' A' ' 280' ' ' TYR . 11.0 p -133.41 112.64 17.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.224 -0.922 . . . . 0.0 109.79 179.168 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.471 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.07 5.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.465 -0.772 . . . . 0.0 110.587 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.456 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 25.7 pt-20 -177.14 158.94 1.57 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.224 -0.923 . . . . 0.0 110.86 -179.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.475 HG12 ' CG1' ' A' ' 296' ' ' VAL . 19.0 mt -119.4 108.65 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.249 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.24 146.24 33.12 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.249 -0.907 . . . . 0.0 109.797 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.571 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.38 133.1 49.83 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.99 -1.068 . . . . 0.0 110.465 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.509 ' N ' HD23 ' A' ' 351' ' ' LEU . 47.8 tt0 -138.98 110.2 6.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.795 . . . . 0.0 109.79 179.473 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.491 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.5 mt -91.06 109.27 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.047 -1.033 . . . . 0.0 109.863 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.503 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 41.12 32.76 0.2 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.596 -0.69 . . . . 0.0 110.328 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.69 -21.4 16.52 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.466 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 1.1 mp0 -80.17 104.22 10.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.225 -1.162 . . . . 0.0 110.292 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.453 HG12 ' O ' ' A' ' 357' ' ' VAL . 14.6 p -75.62 135.29 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 110.081 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.526 HD13 ' CB ' ' A' ' 264' ' ' SER . 13.0 mm . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.154 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.15 -178.93 4.23 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 124.011 1.532 . . . . 0.0 110.549 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.433 HG22 ' O ' ' A' ' 258' ' ' THR . 6.1 t -58.83 146.07 38.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.138 -0.976 . . . . 0.0 110.122 179.958 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 45.7 p -104.89 122.53 42.99 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 110.406 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -74.17 161.04 41.55 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.847 1.446 . . . . 0.0 110.225 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.47 HG22 ' HD2' ' A' ' 262' ' ' PRO . 2.4 p -94.28 137.95 22.63 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.146 -0.971 . . . . 0.0 110.067 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.476 ' CB ' HG23 ' A' ' 358' ' ' ILE . 50.0 Cg_endo -75.18 153.79 41.16 Favored 'Trans proline' 0 C--N 1.303 -1.866 0 O-C-N 124.081 1.569 . . . . 0.0 110.592 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.504 ' O ' ' CB ' ' A' ' 264' ' ' SER . 49.0 t -127.2 26.55 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.273 -0.892 . . . . 0.0 109.932 179.676 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 1.5 p 166.38 142.05 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.446 -0.783 . . . . 0.0 110.327 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 64.21 -173.53 14.8 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.536 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.48 167.79 21.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.376 -1.073 . . . . 0.0 110.038 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.566 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -161.76 135.43 6.52 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.139 -0.976 . . . . 0.0 111.044 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 96.4 mt-10 -134.96 126.95 29.63 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.08 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 64.6 t -117.76 138.61 47.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 C-N-CA 118.828 -1.149 . . . . 0.0 112.137 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.4 ' C ' HG21 ' A' ' 271' ' ' VAL . 0.3 OUTLIER -122.83 157.55 32.2 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.802 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.534 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 99.3 t -144.56 146.28 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.35 -1.469 . . . . 0.0 112.232 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.569 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -134.34 110.64 9.6 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.771 -0.58 . . . . 0.0 109.528 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.448 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 13.9 m-20 -97.85 127.55 43.88 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.336 -0.853 . . . . 0.0 111.456 -178.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.58 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 30.5 p90 -113.04 18.76 17.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.372 -0.83 . . . . 0.0 109.723 178.957 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.473 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 87.33 -64.33 3.81 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.412 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 1.5 m -63.66 -23.4 67.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.238 -1.154 . . . . 0.0 110.418 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.561 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -167.25 -179.46 40.19 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.543 -1.313 . . . . 0.0 109.941 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.556 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -135.28 141.57 45.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.33 -1.1 . . . . 0.0 109.986 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.58 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 2.6 mt-10 -96.34 147.32 23.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -0.778 . . . . 0.0 110.32 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.691 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 97.0 m-85 -139.04 85.14 2.05 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 110.753 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.544 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.4 t0 -74.53 119.81 19.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.566 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.605 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 15.6 t -111.6 92.78 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.594 -0.691 . . . . 0.0 109.871 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.45 ' O ' HD23 ' A' ' 267' ' ' LEU . 17.3 m -86.48 124.31 32.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.987 . . . . 0.0 109.367 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.603 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.69 152.27 27.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.091 -1.005 . . . . 0.0 110.718 -179.115 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.536 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -130.62 128.55 41.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.33 -0.856 . . . . 0.0 110.408 -179.563 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.613 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 10.1 mt -138.62 149.55 45.33 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.823 -1.173 . . . . 0.0 109.31 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.02 38.92 0.78 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.305 -0.872 . . . . 0.0 110.003 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 159.23 -110.31 0.44 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.095 -1.526 . . . . 0.0 109.95 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.521 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 4.8 mt-30 -145.27 118.17 8.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.248 . . . . 0.0 110.359 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.62 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 5.6 m-85 -141.06 147.82 39.21 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.276 -0.89 . . . . 0.0 110.103 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.491 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 34.6 m-20 -75.2 96.8 3.37 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.102 -0.999 . . . . 0.0 109.15 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.588 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 59.8 p-90 -98.73 114.38 26.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.38 -0.825 . . . . 0.0 110.241 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.462 ' HA ' ' O ' ' A' ' 321' ' ' PHE . 4.3 m -109.15 112.1 24.07 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.423 -0.798 . . . . 0.0 109.403 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.478 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 2.8 t -96.33 110.73 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -0.931 . . . . 0.0 110.402 -179.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.524 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 30.7 ttmt -88.65 147.15 24.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.214 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.554 HG11 ' CG2' ' A' ' 346' ' ' VAL . 79.5 t -140.64 107.73 2.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.163 -0.961 . . . . 0.0 110.367 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.595 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 23.0 mmtt -69.96 133.82 47.7 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.129 -0.982 . . . . 0.0 109.362 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.581 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 70.7 mt -88.23 156.98 18.93 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.217 -0.927 . . . . 0.0 111.505 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.555 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.54 173.49 2.36 Favored Pre-proline 0 C--N 1.302 -1.471 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.065 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.497 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -66.84 82.75 0.32 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.438 1.231 . . . . 0.0 109.806 179.583 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.23 22.56 5.17 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.544 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -111.82 143.34 42.93 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.405 -1.056 . . . . 0.0 110.125 -179.702 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.499 ' O ' ' HA ' ' A' ' 338' ' ' VAL . 15.3 p -147.36 144.07 28.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 110.688 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.531 HG21 ' CG2' ' A' ' 319' ' ' VAL . 43.8 t -67.4 135.72 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.478 -0.764 . . . . 0.0 109.985 179.619 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.35 -44.52 0.56 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.454 ' O ' HD12 ' A' ' 337' ' ' ILE . 8.8 m -131.27 128.7 40.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.06 -1.259 . . . . 0.0 110.811 -179.609 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.637 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 4.9 p90 -140.74 168.8 18.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.414 -0.804 . . . . 0.0 109.423 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.452 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -159.92 154.19 23.6 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.875 -1.141 . . . . 0.0 111.366 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.472 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 65.22 24.28 12.27 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.546 -0.721 . . . . 0.0 110.716 179.594 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.518 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 146.74 0.9 Allowed 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.232 -0.918 . . . . 0.0 110.347 179.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.51 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -81.8 125.06 30.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.091 -1.006 . . . . 0.0 108.895 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 2.4 ttpt -96.58 137.11 36.16 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 121.819 0.818 . . . . 0.0 111.018 -178.816 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.706 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -124.16 179.37 4.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.618 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.465 ' HG2' ' O ' ' A' ' 313' ' ' GLN . 2.5 mt-10 -139.98 102.05 4.31 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.138 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.518 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.55 46.9 3.65 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.41 82.05 0.12 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -1.126 . . . . 0.0 110.113 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.618 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.87 2.77 62.57 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.618 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.0 m-85 -143.28 -168.41 2.8 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.443 -1.034 . . . . 0.0 109.221 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.573 HG13 ' CZ ' ' A' ' 321' ' ' PHE . 3.5 t -163.37 153.29 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.176 -0.952 . . . . 0.0 109.727 179.341 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.706 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 17.3 mm -119.77 150.75 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.992 -1.067 . . . . 0.0 110.711 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.4 m-85 -128.91 125.26 37.19 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.387 -0.821 . . . . 0.0 110.164 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.51 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 35.9 p -131.05 166.44 27.65 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.676 -1.265 . . . . 0.0 109.91 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.512 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.6 Cg_endo -65.56 119.55 6.59 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.695 1.366 . . . . 0.0 110.882 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.48 HG13 ' ND2' ' A' ' 311' ' ' ASN . 24.9 m -64.57 -121.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.532 -0.73 . . . . 0.0 110.197 -179.737 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.451 ' O ' ' CE ' ' A' ' 328' ' ' LYS . 5.9 m -100.55 -23.5 14.68 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.746 -1.222 . . . . 0.0 110.57 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.431 ' CH2' ' OG ' ' A' ' 309' ' ' SER . 9.4 p-90 -124.4 -7.75 7.53 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.128 -0.983 . . . . 0.0 110.447 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.467 ' OD1' ' O ' ' A' ' 309' ' ' SER . 2.3 t-20 -89.13 31.83 0.86 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.221 -0.924 . . . . 0.0 110.598 -179.528 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.451 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -117.48 7.24 12.68 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.17 -0.956 . . . . 0.0 110.045 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -67.62 -150.09 0.19 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.559 ' N ' ' O ' ' A' ' 288' ' ' GLY . 46.1 Cg_endo -73.09 -51.61 0.16 Allowed 'Trans proline' 0 C--N 1.3 -2.024 0 O-C-N 123.835 1.439 . . . . 0.0 109.246 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -108.09 124.23 49.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.617 -0.677 . . . . 0.0 110.184 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -135.44 110.97 9.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.472 ' O ' ' HB3' ' A' ' 309' ' ' SER . 54.1 m -105.58 129.57 53.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 110.286 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.605 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 12.7 p90 -135.33 175.06 9.93 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.237 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.48 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.9 162.46 29.73 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 118.684 -1.722 . . . . 0.0 110.308 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.691 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.0 OUTLIER -149.52 145.37 26.82 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 109.483 179.308 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.545 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -118.73 119.25 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.005 -1.059 . . . . 0.0 110.017 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.581 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.4 t -98.32 144.18 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.201 -0.937 . . . . 0.0 110.105 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.457 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.91 137.38 52.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.415 -0.803 . . . . 0.0 110.213 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 177.93 -128.42 1.29 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.546 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.1 Cg_endo -66.67 -157.95 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.822 1.433 . . . . 0.0 110.532 179.625 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.473 ' HG3' ' HA2' ' A' ' 275' ' ' GLY . 1.4 mp0 -121.01 131.83 54.53 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.033 -1.042 . . . . 0.0 111.099 -179.273 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 107.37 -87.49 0.5 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.535 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.77 126.0 52.54 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.384 -1.068 . . . . 0.0 109.401 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.555 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.5 mtmt -128.27 4.47 5.76 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.041 -1.037 . . . . 0.0 110.659 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.581 HG11 ' CE2' ' A' ' 280' ' ' TYR . 2.7 p -127.67 113.87 33.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.095 -1.003 . . . . 0.0 110.244 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.86 5.96 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.27 -0.894 . . . . 0.0 109.713 179.916 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.451 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.4 OUTLIER -177.59 158.34 1.35 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.238 -0.914 . . . . 0.0 110.947 179.461 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.47 HG12 HG13 ' A' ' 296' ' ' VAL . 27.7 mt -115.34 104.81 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.5 132.13 53.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.204 -0.935 . . . . 0.0 110.266 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.603 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -94.6 130.42 41.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 110.284 179.897 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 7.5 tt0 -138.91 114.19 9.58 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.241 -0.912 . . . . 0.0 110.12 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.473 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 1.5 mt -91.32 105.45 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.047 -1.033 . . . . 0.0 109.801 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.491 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 40.31 29.21 0.05 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.735 -0.603 . . . . 0.0 110.887 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 126.02 -26.73 5.26 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.525 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.476 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 6.5 mm100 -84.98 118.13 24.37 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.953 -1.322 . . . . 0.0 110.485 -179.53 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.451 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 11.4 p -81.91 126.86 39.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.276 -0.89 . . . . 0.0 110.108 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.476 HG23 ' CB ' ' A' ' 262' ' ' PRO . 13.0 mm . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.21 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.51 -178.32 3.29 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.918 1.483 . . . . 0.0 110.354 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.452 ' O ' ' CG2' ' A' ' 258' ' ' THR . 6.1 t -58.09 128.74 38.64 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.272 -0.892 . . . . 0.0 110.055 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 3.0 m -132.16 138.82 33.16 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.187 -0.946 . . . . 0.0 110.466 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -77.23 135.17 14.91 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 O-C-N 124.091 1.574 . . . . 0.0 110.581 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.466 HG22 ' HD2' ' A' ' 262' ' ' PRO . 2.5 p -106.25 141.77 23.47 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.375 -0.828 . . . . 0.0 110.215 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.466 ' HD2' HG22 ' A' ' 261' ' ' VAL . 45.2 Cg_endo -71.61 126.48 12.15 Favored 'Trans proline' 0 C--N 1.304 -1.801 0 O-C-N 124.124 1.592 . . . . 0.0 110.481 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 39.7 t -122.83 31.15 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.224 -0.923 . . . . 0.0 110.342 -179.869 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -173.86 60.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.116 -0.99 . . . . 0.0 110.815 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 133.75 -177.89 18.72 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.561 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.64 169.77 17.16 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.446 -1.032 . . . . 0.0 109.841 179.809 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.552 ' CD1' ' HG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -161.09 125.41 3.49 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.229 -0.92 . . . . 0.0 110.665 -179.733 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.468 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 40.4 mt-10 -121.31 111.34 17.23 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.494 -0.754 . . . . 0.0 108.986 179.279 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 40.5 t -109.21 137.39 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.99 -1.068 . . . . 0.0 111.798 -178.74 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.453 ' C ' HG23 ' A' ' 271' ' ' VAL . 11.9 tttp -127.55 155.98 42.94 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 178.813 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.546 HG21 ' CD2' ' A' ' 280' ' ' TYR . 69.8 t -142.68 147.17 21.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.25 -1.531 . . . . 0.0 112.097 -178.971 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.518 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.21 114.23 8.98 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.056 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.2 m-20 -96.51 147.89 23.38 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.165 -0.959 . . . . 0.0 111.525 -178.601 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.587 ' CD1' ' HB2' ' A' ' 276' ' ' SER . 39.4 p90 -135.34 18.88 3.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.486 -0.759 . . . . 0.0 109.969 179.206 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.39 -62.78 4.25 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.587 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 3.1 m -62.44 -20.15 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -1.136 . . . . 0.0 110.156 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.92 179.42 48.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.556 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -132.34 143.62 49.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -1.145 . . . . 0.0 110.305 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.54 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 5.1 mt-10 -95.06 146.24 24.41 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.377 -0.827 . . . . 0.0 109.949 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.689 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 85.1 m-85 -139.6 83.6 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.402 -0.811 . . . . 0.0 110.252 -179.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.465 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.89 150.49 48.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.44 -0.787 . . . . 0.0 109.935 179.62 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.589 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.3 t -142.78 87.76 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.613 -0.679 . . . . 0.0 109.402 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.507 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 20.6 m -85.9 111.63 20.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.25 -0.906 . . . . 0.0 109.556 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.555 HD11 ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -96.62 150.55 20.53 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.223 -0.923 . . . . 0.0 111.059 -179.053 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.561 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.23 106.02 7.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.575 -0.703 . . . . 0.0 110.056 -179.496 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.578 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 9.6 mt -115.96 152.37 33.62 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.793 -1.192 . . . . 0.0 109.715 179.478 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.67 38.19 0.78 Allowed 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.091 -1.006 . . . . 0.0 110.003 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.461 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 161.23 -134.02 3.4 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.368 -1.396 . . . . 0.0 109.751 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.448 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 8.8 mm-40 -124.31 116.65 22.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.136 -1.214 . . . . 0.0 110.531 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.578 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 0.9 OUTLIER -146.67 129.41 16.17 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.317 -0.865 . . . . 0.0 109.741 179.558 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.52 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 10.2 t70 -57.45 102.56 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.961 -1.087 . . . . 0.0 109.431 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.599 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 45.7 p-90 -99.77 110.28 22.67 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.38 -0.825 . . . . 0.0 110.183 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.56 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 29.7 m -102.3 114.95 29.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.327 -0.858 . . . . 0.0 109.798 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.492 HG21 HD21 ' A' ' 351' ' ' LEU . 3.9 t -96.82 111.09 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.188 -0.945 . . . . 0.0 110.258 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.483 ' HA ' HD11 ' A' ' 320' ' ' ILE . 30.4 ttpt -87.33 149.82 24.26 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.314 -0.866 . . . . 0.0 109.591 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.581 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 94.3 t -148.24 106.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.17 -0.957 . . . . 0.0 110.417 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.561 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtm -70.04 134.35 48.17 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.269 179.709 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.54 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 94.4 mt -87.26 160.53 18.41 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.393 -0.817 . . . . 0.0 111.369 -178.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.545 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.57 175.8 1.25 Allowed Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.672 -0.642 . . . . 0.0 109.78 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.474 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.3 Cg_endo -68.65 80.57 0.61 Allowed 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.752 1.396 . . . . 0.0 109.6 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.78 20.79 5.94 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.515 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -107.79 143.47 36.31 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.583 -0.951 . . . . 0.0 110.125 -179.649 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.52 ' N ' HG13 ' A' ' 338' ' ' VAL . 56.0 p -145.1 143.16 30.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 110.635 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.591 ' CG1' ' CD ' ' A' ' 312' ' ' LYS . 31.7 t -69.98 129.0 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.319 -0.863 . . . . 0.0 109.957 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.61 -32.72 1.54 Allowed Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.097 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.454 ' O ' HD13 ' A' ' 337' ' ' ILE . 4.8 m -132.88 121.06 22.33 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.999 -1.295 . . . . 0.0 110.951 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.522 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 45.4 p90 -140.12 154.31 46.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.398 -0.814 . . . . 0.0 109.593 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.532 ' CH2' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -147.55 158.3 43.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.954 -1.091 . . . . 0.0 111.332 -179.132 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.491 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 61.36 24.72 14.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.473 -0.767 . . . . 0.0 110.973 179.481 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.523 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.82 140.01 0.54 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 110.13 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.506 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -77.14 121.25 23.35 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.042 -1.036 . . . . 0.0 109.159 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.591 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 20.2 ttpt -88.44 138.58 31.3 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.826 0.822 . . . . 0.0 111.048 -178.927 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.512 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.57 174.45 7.41 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.065 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -138.46 109.26 6.67 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.368 -0.833 . . . . 0.0 110.419 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.57 39.9 2.7 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.21 80.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -1.152 . . . . 0.0 110.23 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.619 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.87 3.1 57.11 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.619 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.8 m-85 -147.46 -173.84 4.37 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.431 -1.041 . . . . 0.0 109.065 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.527 ' CG2' HG22 ' A' ' 304' ' ' VAL . 4.6 t -159.13 159.85 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.103 -0.998 . . . . 0.0 109.526 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.56 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.2 mm -129.38 151.2 35.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.074 -179.494 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.66 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 39.5 m-85 -127.49 130.02 48.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.248 -0.907 . . . . 0.0 110.287 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.52 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -130.1 169.36 13.61 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.826 -1.171 . . . . 0.0 110.117 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.52 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.3 Cg_endo -65.04 123.82 12.15 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.859 1.452 . . . . 0.0 110.809 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.53 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 20.3 m -73.22 -116.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.537 -0.727 . . . . 0.0 110.211 -179.529 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -108.16 -23.98 11.73 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.699 -1.251 . . . . 0.0 110.668 -179.544 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.421 ' CH2' ' OG ' ' A' ' 309' ' ' SER . 4.4 p-90 -124.0 5.61 8.63 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.181 -0.949 . . . . 0.0 110.306 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.53 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.9 t30 -108.57 49.95 0.79 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 110.37 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.464 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -124.29 -11.35 7.46 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.317 -0.864 . . . . 0.0 109.882 179.732 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.8 -158.28 0.02 OUTLIER Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.831 -1.307 . . . . 0.0 109.831 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -75.59 6.83 3.4 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.115 1.587 . . . . 0.0 110.738 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -161.26 124.39 3.21 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 120.964 -1.085 . . . . 0.0 109.68 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.568 ' HB3' ' CZ2' ' A' ' 292' ' ' TRP . . . -142.65 106.04 4.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.227 -0.92 . . . . 0.0 109.887 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.507 ' OG1' ' CG2' ' A' ' 283' ' ' THR . 54.1 m -98.76 131.74 44.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.283 -0.886 . . . . 0.0 110.291 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.589 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 10.1 p90 -139.34 175.14 9.81 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.69 158.42 27.75 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.852 -1.642 . . . . 0.0 110.015 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.689 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.7 OUTLIER -143.27 145.18 32.51 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.556 -0.967 . . . . 0.0 109.709 179.371 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.534 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.7 mp -121.51 120.32 61.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.54 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 9.9 t -96.24 160.61 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 109.858 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -130.66 129.62 42.87 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.2 -0.937 . . . . 0.0 110.722 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -177.58 -125.11 0.89 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.542 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.8 Cg_endo -67.44 -161.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 123.87 1.458 . . . . 0.0 110.256 179.415 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . . . . . . . . . 6.0 mp0 -118.16 124.28 47.58 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.024 -1.048 . . . . 0.0 111.032 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 118.6 -85.58 0.39 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.596 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -113.64 136.86 52.37 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.276 -1.132 . . . . 0.0 109.758 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.545 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.5 mtmt -137.97 18.52 2.82 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.074 -1.017 . . . . 0.0 110.791 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.594 HG13 ' CE2' ' A' ' 280' ' ' TYR . 14.6 p -140.28 118.04 10.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 110.475 179.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.458 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -50.08 -44.43 51.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.478 -0.764 . . . . 0.0 110.607 -179.734 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.7 pt-20 -176.73 158.66 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.076 -1.015 . . . . 0.0 110.9 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.484 HG12 ' CG2' ' A' ' 296' ' ' VAL . 54.1 mt -121.79 114.79 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.44 -0.787 . . . . 0.0 109.823 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.68 150.35 36.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.331 -0.856 . . . . 0.0 110.55 -179.504 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.552 ' CD1' HD22 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -105.44 127.6 53.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.3 -0.875 . . . . 0.0 109.773 179.597 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.451 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -138.52 112.85 8.73 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.137 -0.977 . . . . 0.0 110.447 -179.919 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.487 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.4 mt -92.1 109.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.945 . . . . 0.0 109.981 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.52 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 46.08 32.85 1.51 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.52 -0.737 . . . . 0.0 110.433 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.39 -21.26 26.68 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.419 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 69.0 mm-40 -83.23 109.41 17.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.271 -1.135 . . . . 0.0 110.29 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 4.5 p -70.38 131.03 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -0.882 . . . . 0.0 110.09 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.465 HG23 ' CB ' ' A' ' 262' ' ' PRO . 29.8 mm . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.152 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -73.2 -178.24 3.48 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 123.999 1.526 . . . . 0.0 110.137 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.522 ' CG2' ' O ' ' A' ' 258' ' ' THR . 6.6 t -57.56 119.32 6.36 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.2 -0.938 . . . . 0.0 109.859 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 7.3 p -112.84 128.95 24.95 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.106 -0.996 . . . . 0.0 110.343 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.65 139.65 31.33 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 124.041 1.548 . . . . 0.0 110.254 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.453 ' O ' HG11 ' A' ' 261' ' ' VAL . 7.4 p -78.04 143.34 65.65 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.258 -0.901 . . . . 0.0 110.565 -179.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.53 ' HA ' ' HA ' ' A' ' 358' ' ' ILE . 50.2 Cg_endo -81.57 124.63 4.71 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 O-C-N 124.117 1.588 . . . . 0.0 110.528 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.449 ' O ' ' CB ' ' A' ' 264' ' ' SER . 4.1 t -112.71 25.2 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.171 -0.956 . . . . 0.0 109.508 179.38 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.475 ' CB ' HD13 ' A' ' 358' ' ' ILE . 0.5 OUTLIER 172.8 75.49 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.367 -0.833 . . . . 0.0 110.492 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 111.45 -164.27 12.15 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.563 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.74 163.05 31.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -1.126 . . . . 0.0 109.948 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.547 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -161.22 132.68 5.53 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.197 -179.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.3 mt-10 -133.49 132.38 40.95 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 179.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.477 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 21.9 t -123.75 134.14 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.71 -1.244 . . . . 0.0 111.976 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.437 ' C ' HG21 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -119.94 151.84 38.32 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 178.657 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.566 HG22 ' CD2' ' A' ' 280' ' ' TYR . 77.9 t -140.8 146.16 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 120.368 -1.458 . . . . 0.0 112.018 -179.004 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.533 ' N ' HG13 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -139.0 113.83 9.23 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.707 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.511 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.8 m-20 -101.29 140.87 34.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.893 -1.129 . . . . 0.0 111.395 -178.481 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.573 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 34.0 p90 -123.87 19.76 9.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.654 -0.654 . . . . 0.0 109.375 179.506 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.512 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 82.53 -62.21 4.62 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.474 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.503 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 0.5 OUTLIER -60.62 -18.15 51.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.259 -1.142 . . . . 0.0 109.951 179.655 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.58 177.23 48.39 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.566 ' HB3' ' CZ ' ' A' ' 280' ' ' TYR . . . -133.31 137.8 46.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -1.115 . . . . 0.0 110.124 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.534 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 5.5 mt-10 -93.99 145.54 24.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.251 -0.906 . . . . 0.0 110.163 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.682 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.1 m-85 -139.99 85.02 2.0 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.448 -0.782 . . . . 0.0 110.746 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.477 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 3.7 t0 -69.54 141.46 53.83 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.334 -0.853 . . . . 0.0 109.555 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.63 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 4.0 t -132.85 91.71 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.486 -0.759 . . . . 0.0 109.506 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.445 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 2.7 m -86.67 122.31 30.4 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.32 -0.862 . . . . 0.0 109.982 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.603 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.67 149.04 32.13 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.296 -0.877 . . . . 0.0 110.149 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.563 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -134.03 109.4 8.95 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.316 -0.865 . . . . 0.0 110.637 -178.758 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.605 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.1 mt -119.59 157.47 28.35 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.722 -1.236 . . . . 0.0 110.251 179.731 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 287' ' ' ASP . 15.3 p-10 -91.43 36.61 0.94 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.125 -0.984 . . . . 0.0 109.544 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.5 -136.1 4.18 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.463 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -121.81 116.31 24.21 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.201 -1.176 . . . . 0.0 110.847 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.605 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.3 m-85 -142.39 138.28 31.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.313 -0.867 . . . . 0.0 109.435 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.535 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 14.5 t0 -67.7 97.46 0.63 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.841 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.599 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 46.3 p-90 -96.17 109.86 22.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.037 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.592 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 3.1 m -102.06 115.33 30.31 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.846 . . . . 0.0 109.592 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.456 HG22 HD23 ' A' ' 351' ' ' LEU . 3.9 t -96.46 110.99 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 110.461 -179.535 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.464 ' HA ' HD12 ' A' ' 320' ' ' ILE . 28.5 ttpt -86.37 149.59 24.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.364 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.562 HG11 ' CG2' ' A' ' 346' ' ' VAL . 70.8 t -148.14 108.17 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.123 -0.985 . . . . 0.0 110.706 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.556 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.0 mmtp -70.81 131.79 44.34 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.132 -0.98 . . . . 0.0 109.675 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.537 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 98.5 mt -85.52 156.05 20.94 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.259 -0.901 . . . . 0.0 111.599 -179.095 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.52 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.66 171.04 4.79 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.488 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 39.7 Cg_endo -66.87 81.86 0.34 Allowed 'Trans proline' 0 C--N 1.305 -1.757 0 O-C-N 123.518 1.273 . . . . 0.0 109.727 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.76 18.06 5.76 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.525 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -108.65 149.19 29.3 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.385 -1.068 . . . . 0.0 110.105 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.537 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 24.8 p -154.56 144.21 21.53 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.122 -0.987 . . . . 0.0 110.897 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.502 HG13 ' CD ' ' A' ' 312' ' ' LYS . 24.7 t -68.9 124.06 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -106.39 -33.71 3.32 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -142.0 131.21 23.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.005 -1.291 . . . . 0.0 110.868 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.547 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 39.2 p90 -141.78 162.89 34.36 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.29 -0.881 . . . . 0.0 109.855 179.485 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.494 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -152.31 159.51 43.47 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.928 -1.107 . . . . 0.0 110.946 -179.524 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.458 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 59.84 23.91 12.9 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.472 -0.767 . . . . 0.0 111.091 179.471 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.523 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.09 145.46 0.8 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.325 -0.86 . . . . 0.0 110.179 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.497 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -83.81 120.03 25.55 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.202 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.547 ' HD3' ' CE2' ' A' ' 307' ' ' PHE . 1.8 ttpt -87.03 145.38 26.5 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.946 0.879 . . . . 0.0 111.044 -178.981 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.713 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -130.41 179.03 6.16 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.013 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.45 ' HG2' HG21 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -140.0 101.76 4.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.702 -0.624 . . . . 0.0 110.108 179.546 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.481 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -87.51 40.4 3.08 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.481 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 9.5 t30 63.65 79.71 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.304 -1.115 . . . . 0.0 110.084 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.591 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 95.0 3.81 61.78 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.774 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.591 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.7 m-85 -143.3 -170.66 3.32 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.996 . . . . 0.0 108.784 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.524 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.3 t -161.68 154.29 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 120.976 -1.077 . . . . 0.0 110.019 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.713 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 22.0 mm -125.17 142.85 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.756 -179.583 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.0 m-85 -119.6 127.05 52.59 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.435 -0.791 . . . . 0.0 109.637 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.523 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -126.65 169.15 12.52 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 120.877 -1.14 . . . . 0.0 110.5 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.524 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.5 Cg_endo -65.04 112.23 1.98 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 O-C-N 124.049 1.552 . . . . 0.0 111.044 -179.5 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.532 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 16.5 m -56.96 -114.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.634 -0.666 . . . . 0.0 109.918 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -117.17 -20.26 9.32 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.7 -1.25 . . . . 0.0 110.417 179.914 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.49 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 5.1 p-90 -120.78 -20.65 6.92 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.204 -0.935 . . . . 0.0 110.408 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.532 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.9 OUTLIER -84.23 46.14 1.18 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.081 -1.012 . . . . 0.0 109.989 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.487 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 10.7 mtmt -119.84 -9.63 9.66 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.359 -0.838 . . . . 0.0 109.675 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.5 -157.45 0.01 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.535 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.68 5.32 4.39 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.065 1.561 . . . . 0.0 110.682 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.408 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 4.2 m -162.83 119.88 1.94 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.998 -1.064 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.472 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -140.08 112.0 7.52 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.299 -0.875 . . . . 0.0 110.247 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.458 ' O ' ' HB3' ' A' ' 309' ' ' SER . 35.1 m -103.72 132.26 50.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 110.049 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.63 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 11.4 p90 -135.17 173.93 11.17 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.436 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.46 151.76 23.65 Favored Glycine 0 N--CA 1.486 1.977 0 C-N-CA 118.827 -1.654 . . . . 0.0 110.242 -179.357 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.682 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -139.0 147.93 42.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.684 -0.892 . . . . 0.0 109.476 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.544 HD13 ' N ' ' A' ' 337' ' ' ILE . 1.7 mp -120.6 119.46 59.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.006 -1.059 . . . . 0.0 110.025 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.522 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.4 t -96.84 145.2 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.94 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.483 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 2.0 m-80 -115.63 133.23 56.24 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.391 -0.818 . . . . 0.0 110.341 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.521 ' N ' ' HE3' ' A' ' 345' ' ' LYS . . . 179.33 -140.31 4.29 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.49 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 50.3 Cg_endo -82.63 116.15 2.55 Favored 'Trans proline' 0 C--N 1.302 -1.896 0 O-C-N 124.065 1.561 . . . . 0.0 110.903 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.531 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -41.09 153.34 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.295 -0.878 . . . . 0.0 110.568 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 96.45 66.42 0.94 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.439 ' O ' ' O ' ' A' ' 343' ' ' GLY . 0.7 OUTLIER 61.23 118.86 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.324 -1.103 . . . . 0.0 109.373 -179.479 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.525 ' O ' ' CB ' ' A' ' 302' ' ' ALA . 3.1 mtpt -123.61 16.09 9.55 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.004 -1.06 . . . . 0.0 110.13 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.572 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.1 p -126.03 113.71 35.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.448 -0.783 . . . . 0.0 109.779 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.501 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.4 mm-40 -41.97 -47.33 4.34 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.995 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.457 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 18.1 pt-20 -177.28 158.52 1.48 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.872 . . . . 0.0 110.524 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.46 HD12 HG11 ' A' ' 269' ' ' VAL . 11.9 mt -118.14 122.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.237 -0.914 . . . . 0.0 110.068 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.11 132.19 50.66 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.219 -0.926 . . . . 0.0 110.175 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.603 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -92.66 131.22 37.94 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.174 -0.954 . . . . 0.0 110.22 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.454 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.4 tt0 -139.68 114.53 9.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.168 -0.957 . . . . 0.0 110.358 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.469 HG12 ' HA ' ' A' ' 292' ' ' TRP . 2.1 mt -92.05 110.9 23.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.976 -1.077 . . . . 0.0 110.28 179.665 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.535 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.47 32.1 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.716 -0.615 . . . . 0.0 111.115 179.587 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 112.26 8.86 21.01 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.462 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.5 mp0 -116.4 111.46 20.06 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.11 -1.229 . . . . 0.0 110.058 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.49 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -75.3 135.67 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.227 -0.92 . . . . 0.0 110.433 -179.662 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.53 ' HA ' ' HA ' ' A' ' 262' ' ' PRO . 31.9 mm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.223 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -78.12 179.99 5.98 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.955 1.503 . . . . 0.0 110.582 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.428 ' CG2' ' O ' ' A' ' 258' ' ' THR . 4.3 t -63.48 130.46 44.5 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.352 -0.842 . . . . 0.0 110.046 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.3 p -98.92 162.33 21.89 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.221 -0.924 . . . . 0.0 110.204 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.07 131.06 17.45 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.981 1.517 . . . . 0.0 110.503 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . . . . . . . . . 3.6 p -93.13 143.67 27.13 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.267 -0.896 . . . . 0.0 110.237 179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.415 ' HB3' ' HA ' ' A' ' 358' ' ' ILE . 48.0 Cg_endo -75.54 155.36 40.44 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 O-C-N 124.122 1.59 . . . . 0.0 110.019 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 18.5 t -145.88 30.14 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.195 -0.941 . . . . 0.0 110.064 179.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -177.52 78.1 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.249 -0.907 . . . . 0.0 110.749 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.408 ' HA3' HD21 ' A' ' 286' ' ' LEU . . . 106.46 -169.27 15.26 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.3 179.289 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.546 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.78 168.31 19.79 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.523 -0.986 . . . . 0.0 109.631 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.576 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.3 tm? -160.24 136.86 8.96 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.996 -1.065 . . . . 0.0 111.165 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -136.19 123.36 21.71 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.553 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.473 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 50.2 t -116.97 134.69 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.969 -1.082 . . . . 0.0 111.738 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.428 ' C ' HG21 ' A' ' 271' ' ' VAL . 37.0 mttm -118.29 157.35 27.23 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.519 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.58 142.2 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.256 -1.528 . . . . 0.0 112.115 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -138.04 113.04 9.14 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.102 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 80.2 m-20 -98.78 146.21 26.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.958 -1.089 . . . . 0.0 111.444 -178.766 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.563 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 37.6 p90 -131.71 23.16 4.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.608 -0.682 . . . . 0.0 109.474 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.47 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 80.55 -64.23 4.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.505 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -59.13 -22.6 61.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.293 -1.122 . . . . 0.0 110.226 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.516 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.44 -171.88 38.4 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.549 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -142.87 142.05 31.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -1.072 . . . . 0.0 110.009 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.563 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.7 mt-10 -97.98 146.14 25.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.414 -0.804 . . . . 0.0 110.329 -179.508 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.692 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 81.6 m-85 -141.15 82.99 1.86 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.398 -0.814 . . . . 0.0 110.653 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.473 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 9.3 t0 -64.91 151.53 45.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.769 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.625 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.9 t -145.05 89.34 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.55 -0.719 . . . . 0.0 109.964 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.471 ' O ' HD22 ' A' ' 267' ' ' LEU . 72.2 m -86.75 126.36 34.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.131 -0.981 . . . . 0.0 109.717 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.639 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -114.96 148.24 39.01 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.04 -1.038 . . . . 0.0 110.902 -179.172 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.546 ' ND2' ' HB3' ' A' ' 266' ' ' SER . 0.5 OUTLIER -128.4 134.82 48.89 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.484 -0.76 . . . . 0.0 109.949 -179.696 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.624 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 10.2 mt -143.7 149.97 37.99 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.62 -1.3 . . . . 0.0 110.158 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -88.41 38.49 0.87 Allowed 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.278 -0.889 . . . . 0.0 109.398 179.222 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.97 -145.47 11.05 Favored Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.787 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.498 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 5.1 mt-30 -112.36 98.43 7.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -1.167 . . . . 0.0 110.665 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.624 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -120.21 154.97 34.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.257 -0.902 . . . . 0.0 110.295 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.526 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 23.0 t0 -85.76 97.46 10.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 109.242 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.639 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 51.9 p-90 -95.38 108.03 20.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.169 -0.957 . . . . 0.0 110.819 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.41 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 2.8 m -100.11 115.13 29.09 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.543 -0.723 . . . . 0.0 109.304 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.461 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.1 t -96.71 111.38 26.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 121.187 -0.946 . . . . 0.0 110.162 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.525 ' HG3' ' CD1' ' A' ' 320' ' ' ILE . 3.3 ttpp -87.74 149.37 24.24 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.404 -0.81 . . . . 0.0 109.247 179.461 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.536 HG13 ' CE2' ' A' ' 336' ' ' PHE . 84.4 t -148.23 107.71 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.079 -1.013 . . . . 0.0 110.225 -179.603 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.582 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 21.0 mmtp -69.95 132.37 45.84 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.344 -0.848 . . . . 0.0 109.587 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.548 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 87.8 mt -87.37 158.71 18.96 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.646 -0.659 . . . . 0.0 110.943 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.543 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.32 173.86 2.06 Favored Pre-proline 0 C--N 1.303 -1.426 0 O-C-N 121.459 -0.775 . . . . 0.0 109.285 179.07 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.452 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.34 79.7 0.59 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 123.619 1.326 . . . . 0.0 109.637 179.576 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.26 17.02 5.87 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.531 ' CB ' ' HB2' ' A' ' 299' ' ' ALA . . . -104.26 147.09 27.88 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.467 -1.019 . . . . 0.0 110.12 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.548 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 37.6 p -148.68 143.86 26.76 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.873 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.445 HG23 HG13 ' A' ' 319' ' ' VAL . 92.1 t -71.55 121.74 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.317 -0.864 . . . . 0.0 109.951 179.623 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.48 -21.34 6.92 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.5 OUTLIER -139.51 124.14 18.37 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.029 -1.277 . . . . 0.0 111.216 -179.464 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.501 ' CE1' ' HD3' ' A' ' 312' ' ' LYS . 29.0 p90 -145.23 164.57 30.96 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.311 -0.868 . . . . 0.0 109.884 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.491 ' CH2' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -158.34 161.29 37.6 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.948 -1.095 . . . . 0.0 110.995 -179.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.547 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.1 OUTLIER 54.47 29.03 10.44 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.471 -0.768 . . . . 0.0 110.843 179.517 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.46 ' HB2' ' HB2' ' A' ' 334' ' ' PHE . . . -175.33 144.43 0.71 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.285 -0.885 . . . . 0.0 109.872 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.498 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.3 m-80 -82.23 115.81 21.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.092 -1.005 . . . . 0.0 109.355 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.501 ' HD3' ' CE1' ' A' ' 307' ' ' PHE . 8.7 ttpt -83.27 142.13 31.34 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.803 0.811 . . . . 0.0 110.757 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -129.38 173.81 10.2 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.437 ' HG2' HG23 ' A' ' 319' ' ' VAL . 4.4 mt-10 -139.49 101.36 4.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.309 -0.869 . . . . 0.0 110.497 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.12 42.84 2.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 4.5 m120 53.8 86.16 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.311 -1.111 . . . . 0.0 110.174 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.33 -0.27 55.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.607 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 0.5 OUTLIER -150.26 -172.79 4.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.371 -1.076 . . . . 0.0 109.642 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 6.1 t -156.89 156.37 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.425 -0.797 . . . . 0.0 109.337 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.525 ' CD1' ' HG3' ' A' ' 295' ' ' LYS . 45.6 mm -126.56 147.83 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.08 -1.012 . . . . 0.0 111.22 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 83.3 m-85 -125.29 125.1 43.0 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.399 -0.813 . . . . 0.0 109.661 179.055 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.531 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.6 p -127.7 169.86 11.52 Favored Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 120.82 -1.175 . . . . 0.0 110.232 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.531 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.7 Cg_endo -64.26 115.76 3.35 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.898 1.473 . . . . 0.0 111.52 -179.088 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.525 ' N ' ' OD1' ' A' ' 327' ' ' ASN . 17.3 m -64.16 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.66 -0.65 . . . . 0.0 110.192 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 19.9 m -116.78 -12.57 10.8 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.696 -1.253 . . . . 0.0 111.198 -179.539 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.464 ' CH2' ' OG ' ' A' ' 309' ' ' SER . 13.3 p-90 -133.72 1.37 3.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.811 -1.18 . . . . 0.0 111.133 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.547 ' ND2' ' O ' ' A' ' 309' ' ' SER . 28.3 p-10 -110.38 50.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.987 -1.071 . . . . 0.0 110.508 -179.589 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -129.09 10.51 5.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.267 -0.896 . . . . 0.0 109.664 179.466 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.418 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -73.89 -151.58 2.13 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.517 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -74.09 2.26 6.3 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.094 1.576 . . . . 0.0 110.838 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.481 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 27.5 m -167.28 122.74 1.08 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.35 -0.843 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.537 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -142.56 118.17 10.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.134 -0.979 . . . . 0.0 110.321 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.467 ' O ' ' HB3' ' A' ' 309' ' ' SER . 18.0 m -104.36 148.55 26.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 110.214 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.625 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 5.9 p90 -153.88 175.22 13.59 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -156.44 157.91 28.29 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.838 -1.649 . . . . 0.0 110.548 -179.418 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.692 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -141.52 147.6 38.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.411 -1.052 . . . . 0.0 110.308 179.594 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.536 ' HA ' ' O ' ' A' ' 278' ' ' ALA . 1.7 mp -121.96 122.69 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.078 -1.014 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.546 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 6.3 t -100.45 156.23 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.132 -0.98 . . . . 0.0 110.782 -179.29 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -123.97 132.72 53.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.506 -0.746 . . . . 0.0 110.337 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.412 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -176.67 -132.52 1.65 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.548 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.1 Cg_endo -67.29 -165.63 0.11 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 123.885 1.466 . . . . 0.0 110.691 179.744 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.583 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 2.6 mp0 -115.59 21.32 14.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.117 -0.989 . . . . 0.0 110.633 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.498 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . -134.97 76.86 0.38 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.498 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.7 OUTLIER 68.17 141.93 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.371 -1.076 . . . . 0.0 108.726 -178.844 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.548 ' CG ' ' HD2' ' A' ' 341' ' ' PRO . 0.2 OUTLIER -135.42 15.92 3.43 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.8 -1.188 . . . . 0.0 111.077 -179.163 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.582 HG13 ' CE2' ' A' ' 280' ' ' TYR . 11.7 p -135.13 117.72 22.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.163 -0.961 . . . . 0.0 110.11 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.459 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -50.34 -45.15 54.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.343 -0.848 . . . . 0.0 110.425 -179.534 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.413 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -176.61 154.19 1.2 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -0.994 . . . . 0.0 110.703 -179.876 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.431 HD13 HG13 ' A' ' 269' ' ' VAL . 23.3 mt -113.97 124.8 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.175 -0.953 . . . . 0.0 110.133 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.21 154.39 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.389 -0.82 . . . . 0.0 109.974 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.591 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -120.65 124.51 45.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.188 -0.945 . . . . 0.0 109.659 179.478 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 34.6 tt0 -138.63 117.11 12.05 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.221 -0.925 . . . . 0.0 110.181 -179.796 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.526 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.4 107.68 19.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.165 -0.959 . . . . 0.0 109.76 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.51 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 43.66 26.74 0.13 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 110.381 -179.647 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 123.41 -31.92 4.48 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.461 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 12.2 mm100 -75.99 114.56 14.76 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.084 -1.244 . . . . 0.0 110.47 -179.65 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 8.5 p -79.09 133.34 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.146 -0.972 . . . . 0.0 110.226 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.454 HD11 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.068 -0.967 . . . . 0.0 110.299 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.52 -178.3 3.28 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.119 1.589 . . . . 0.0 110.66 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.435 ' CG2' ' O ' ' A' ' 258' ' ' THR . 7.4 t -59.15 128.55 37.74 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.422 -0.799 . . . . 0.0 110.423 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 5.3 m -141.57 112.32 6.47 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.201 -0.937 . . . . 0.0 110.192 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -76.37 144.53 26.02 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 123.917 1.483 . . . . 0.0 110.503 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.423 ' O ' HG13 ' A' ' 261' ' ' VAL . 3.5 p -108.65 140.75 22.12 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.199 -0.938 . . . . 0.0 110.445 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.456 ' CB ' HG23 ' A' ' 358' ' ' ILE . 51.0 Cg_endo -78.64 151.55 25.28 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 124.128 1.594 . . . . 0.0 110.531 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.464 ' O ' ' OG ' ' A' ' 264' ' ' SER . 4.8 t -143.03 26.82 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.366 -0.833 . . . . 0.0 109.95 179.703 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.464 ' OG ' ' O ' ' A' ' 263' ' ' VAL . 2.6 m -177.46 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.341 -0.849 . . . . 0.0 110.308 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.38 -174.04 25.67 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.696 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.573 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.33 163.79 31.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.366 -1.079 . . . . 0.0 110.049 -179.774 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.544 ' CD1' ' HG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -156.73 122.8 4.9 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.106 -0.996 . . . . 0.0 110.737 -179.868 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.3 mt-10 -123.31 114.29 20.01 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 57.6 t -110.05 124.51 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.971 -1.081 . . . . 0.0 112.347 -178.105 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.425 ' C ' HG22 ' A' ' 271' ' ' VAL . 3.9 mmtt -111.61 156.79 21.26 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.528 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 83.0 t -144.61 147.92 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.426 -1.421 . . . . 0.0 112.238 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -136.8 110.05 7.83 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.928 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.4 p30 -95.34 146.35 24.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.074 -1.016 . . . . 0.0 111.247 -178.746 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.573 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 29.4 p90 -129.0 16.86 6.21 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.517 -0.739 . . . . 0.0 109.963 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.4 -54.57 3.52 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.507 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 2.8 m -74.63 -19.35 60.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.226 -1.161 . . . . 0.0 110.256 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.19 -175.85 42.98 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.543 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -140.6 140.1 35.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -1.15 . . . . 0.0 110.238 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.538 ' CG ' HG13 ' A' ' 337' ' ' ILE . 10.7 mt-10 -92.88 146.12 23.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.402 -0.811 . . . . 0.0 110.077 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.699 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 96.5 m-85 -133.33 89.96 2.67 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.44 -0.788 . . . . 0.0 110.64 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.544 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -77.21 105.03 8.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 109.821 179.525 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.608 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 6.6 t -97.72 92.53 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.466 -0.772 . . . . 0.0 110.368 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.463 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 24.3 m -86.87 112.77 22.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.022 -1.049 . . . . 0.0 109.931 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.566 HD12 ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -100.41 149.73 23.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.124 -0.985 . . . . 0.0 110.497 -179.504 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.573 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.49 106.71 7.6 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.347 -0.846 . . . . 0.0 110.541 -179.252 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.573 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 8.9 mt -113.63 164.88 13.11 Favored 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.778 -1.201 . . . . 0.0 110.302 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -97.97 35.63 1.69 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.269 -0.894 . . . . 0.0 110.11 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.45 -116.01 0.69 Allowed Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.277 -1.44 . . . . 0.0 109.887 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.441 ' HG2' ' O ' ' A' ' 288' ' ' GLY . 11.8 mm-40 -139.81 107.14 5.52 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.175 -1.191 . . . . 0.0 110.55 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.573 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.2 m-85 -137.08 129.17 29.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.2 -0.937 . . . . 0.0 109.723 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.527 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 0.4 OUTLIER -57.81 101.59 0.08 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.458 179.565 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.611 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 45.6 p-90 -98.4 107.72 20.24 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.373 -0.829 . . . . 0.0 109.968 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.587 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 2.0 m -98.87 115.07 28.01 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.328 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.47 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.3 t -96.27 111.67 26.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.114 -0.991 . . . . 0.0 110.548 -179.202 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.509 ' HG3' HD12 ' A' ' 320' ' ' ILE . 8.4 ttpt -85.71 148.03 26.06 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.365 -0.834 . . . . 0.0 109.541 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.525 HG12 ' CG2' ' A' ' 346' ' ' VAL . 54.0 t -148.41 110.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 120.965 -1.084 . . . . 0.0 110.762 -179.314 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.523 ' CB ' ' HB2' ' A' ' 347' ' ' GLU . 47.2 mmtt -74.36 131.82 41.46 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.292 -0.88 . . . . 0.0 109.628 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.549 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 83.5 mt -83.95 151.65 24.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.261 -0.899 . . . . 0.0 111.445 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.531 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -55.55 173.69 0.25 Allowed Pre-proline 0 N--CA 1.487 1.401 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.158 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.481 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -68.76 78.27 0.71 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.592 1.312 . . . . 0.0 109.516 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.86 22.95 3.78 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 -179.279 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.529 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -109.03 154.79 21.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.307 -1.114 . . . . 0.0 110.337 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.549 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 41.0 p -152.33 144.36 23.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.179 -0.951 . . . . 0.0 110.716 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.5 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 49.0 t -72.22 117.74 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.462 -0.774 . . . . 0.0 109.89 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.94 -36.44 3.69 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 3.5 m -134.64 145.7 48.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.05 -1.265 . . . . 0.0 111.026 -179.442 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.574 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 33.8 p90 -160.23 165.08 32.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.525 -0.734 . . . . 0.0 109.565 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.5 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -154.3 165.13 37.28 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 120.901 -1.124 . . . . 0.0 111.356 -179.408 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.486 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 51.58 28.55 4.75 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.54 -0.725 . . . . 0.0 111.488 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.547 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 138.83 0.47 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.083 -1.01 . . . . 0.0 110.302 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.53 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.64 115.39 17.36 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 109.112 179.326 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.574 ' HD3' ' CE2' ' A' ' 307' ' ' PHE . 1.1 ttpt -84.28 140.22 31.8 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.805 0.812 . . . . 0.0 110.738 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.509 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.66 174.95 7.13 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 179.204 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -137.61 109.42 7.11 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.331 -0.856 . . . . 0.0 110.276 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.426 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -99.85 46.87 1.35 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 58.47 85.72 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 110.5 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.552 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 89.86 -0.09 78.98 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.552 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.5 m-85 -138.78 -170.04 2.76 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.235 -1.156 . . . . 0.0 109.281 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.509 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.3 t -163.08 157.31 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.81 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.587 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.1 mm -127.58 151.8 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.227 -0.921 . . . . 0.0 110.929 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.627 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 99.4 m-85 -128.72 125.56 38.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.928 -1.108 . . . . 0.0 110.144 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.53 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 11.9 p -124.75 167.83 14.9 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 120.876 -1.14 . . . . 0.0 109.596 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.526 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.48 123.84 12.01 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 O-C-N 123.737 1.388 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.505 HG11 ' ND2' ' A' ' 311' ' ' ASN . 18.5 m -70.61 -114.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.497 -0.752 . . . . 0.0 109.855 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 2.6 m -110.46 -13.36 14.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.743 -1.223 . . . . 0.0 110.547 -179.789 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.473 ' CE2' HG23 ' A' ' 324' ' ' VAL . 7.3 p-90 -132.86 -6.17 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.155 -0.965 . . . . 0.0 110.928 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.462 ' OD1' ' HB2' ' A' ' 332' ' ' ALA . 0.5 OUTLIER -97.49 46.68 1.02 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.046 -1.034 . . . . 0.0 110.216 -179.785 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -124.43 -8.05 7.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.099 -1.0 . . . . 0.0 109.92 -179.966 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.22 -157.87 0.02 OUTLIER Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.534 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -75.88 8.16 2.87 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.804 1.423 . . . . 0.0 111.0 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.1 m -165.17 115.53 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.473 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -132.83 109.04 9.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.237 -0.915 . . . . 0.0 110.27 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.463 ' HA ' ' HA ' ' A' ' 283' ' ' THR . 54.2 m -100.03 122.26 42.65 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.308 -0.87 . . . . 0.0 110.111 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.608 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 10.7 p90 -128.9 175.17 8.86 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.628 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.44 157.8 27.48 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.823 -1.656 . . . . 0.0 110.268 -179.368 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.699 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -145.28 148.98 34.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.7 -0.882 . . . . 0.0 109.265 179.449 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.538 HG13 ' CG ' ' A' ' 279' ' ' GLU . 1.7 mp -121.24 118.25 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.023 -1.048 . . . . 0.0 109.679 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.54 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.1 t -96.23 152.22 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.206 -0.934 . . . . 0.0 109.801 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.424 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -124.76 133.26 53.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.199 -0.938 . . . . 0.0 110.756 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.33 -120.3 0.69 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.522 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.1 Cg_endo -67.19 -157.39 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.836 1.44 . . . . 0.0 110.417 179.433 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.587 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -120.91 132.02 54.71 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.021 -1.05 . . . . 0.0 110.549 -179.498 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 95.33 -86.98 1.01 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -94.92 128.9 42.05 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.267 -1.137 . . . . 0.0 109.516 179.591 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.531 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.4 OUTLIER -136.38 5.41 2.97 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.965 -1.084 . . . . 0.0 110.955 -179.619 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.584 HG13 ' CE2' ' A' ' 280' ' ' TYR . 3.3 p -130.55 113.55 25.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.223 -0.923 . . . . 0.0 109.7 179.212 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.523 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 35.2 mt-10 -41.55 -45.93 3.43 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.247 -0.908 . . . . 0.0 110.304 -179.488 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.454 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.59 158.55 1.76 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.135 -0.978 . . . . 0.0 110.64 179.847 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.467 HG21 HG23 ' A' ' 296' ' ' VAL . 12.1 mt -119.74 129.05 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 110.193 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -131.2 151.74 51.17 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.266 -0.896 . . . . 0.0 110.297 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.554 ' CD1' HD22 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.43 130.5 54.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.232 -0.917 . . . . 0.0 109.914 179.815 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.467 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 48.1 tt0 -138.37 113.38 9.23 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.189 -0.945 . . . . 0.0 110.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.466 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.4 mt -96.31 108.76 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.985 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.527 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 39.42 34.6 0.14 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.544 -0.722 . . . . 0.0 110.629 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 112.59 -19.05 22.1 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.451 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.1 OUTLIER -85.18 100.54 11.82 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.27 -1.135 . . . . 0.0 110.317 -179.823 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.507 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 5.3 p -71.15 121.65 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.463 HD12 ' O ' ' A' ' 357' ' ' VAL . 35.7 mm . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.279 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.338 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.1 -178.54 3.64 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 124.016 1.535 . . . . 0.0 110.295 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 6.6 t -57.76 143.06 43.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.157 -0.964 . . . . 0.0 110.098 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.1 p -112.3 150.0 41.86 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.181 -0.949 . . . . 0.0 110.23 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.67 142.12 35.4 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 124.056 1.556 . . . . 0.0 110.37 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . . . . . . . . . 3.0 p -74.42 140.97 76.21 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 110.514 -179.759 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.478 ' HB2' HG23 ' A' ' 358' ' ' ILE . 46.5 Cg_endo -74.16 149.25 40.63 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 124.192 1.628 . . . . 0.0 110.324 179.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.526 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 76.5 t -137.72 29.69 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.293 -0.88 . . . . 0.0 110.083 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.3 t -166.49 45.66 0.07 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 0.0 110.79 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 142.35 -178.1 21.14 Favored Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.17 179.493 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.578 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.87 157.24 46.47 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.485 -1.009 . . . . 0.0 109.791 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.509 ' HG ' HD13 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -149.33 124.66 10.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 110.615 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.506 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 2.1 mp0 -124.47 111.34 15.6 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.089 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 41.0 t -105.07 129.57 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.024 -1.047 . . . . 0.0 111.959 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.452 ' O ' HG21 ' A' ' 271' ' ' VAL . 7.7 ttmt -117.38 156.89 27.11 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.507 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.574 HG22 ' CD2' ' A' ' 280' ' ' TYR . 78.5 t -144.86 146.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.424 -1.422 . . . . 0.0 112.399 -179.094 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -138.22 109.39 6.84 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.15 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.505 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.7 p-10 -95.75 147.95 23.08 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.127 -0.983 . . . . 0.0 111.111 -178.783 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.574 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 35.9 p90 -133.66 16.97 3.94 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.515 -0.741 . . . . 0.0 110.019 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.05 -58.48 3.96 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.561 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 6.0 t -68.8 -20.31 64.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -1.141 . . . . 0.0 110.103 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -177.7 179.09 48.41 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.538 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -132.55 141.84 48.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -1.125 . . . . 0.0 110.121 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.574 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 6.3 mt-10 -95.62 147.45 23.58 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.47 -0.769 . . . . 0.0 110.209 -179.546 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.694 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 93.5 m-85 -138.6 95.08 2.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 110.709 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.52 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.71 108.49 16.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.526 -0.734 . . . . 0.0 110.091 179.657 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.623 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 6.7 t -100.11 92.72 2.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.6 -0.688 . . . . 0.0 109.85 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.508 ' CB ' HG23 ' A' ' 333' ' ' THR . 3.6 m -86.57 113.89 22.84 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.932 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.545 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -100.98 149.74 23.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.096 -1.003 . . . . 0.0 110.806 -179.322 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.578 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.56 106.37 6.97 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -179.61 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.577 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 8.1 mt -116.91 162.54 17.59 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.688 -1.257 . . . . 0.0 109.94 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.86 36.24 1.2 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.974 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.447 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.4 -135.5 3.9 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.325 -1.417 . . . . 0.0 110.039 -179.853 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.478 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.5 mt-30 -121.43 104.65 9.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.152 -1.205 . . . . 0.0 110.978 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.577 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -132.6 129.24 38.69 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.3 -0.875 . . . . 0.0 109.702 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.513 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 39.1 m-20 -58.58 99.57 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.4 179.435 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.6 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 53.0 p-90 -97.94 113.07 24.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 110.418 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.501 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 23.5 m -105.17 113.8 27.61 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.336 -0.853 . . . . 0.0 109.478 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.499 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.1 t -96.08 110.54 24.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.799 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.429 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 31.9 ttmt -83.44 146.77 28.23 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.301 -0.875 . . . . 0.0 109.217 179.378 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.559 HG12 ' CG2' ' A' ' 346' ' ' VAL . 42.4 t -140.93 105.13 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.518 ' O ' ' N ' ' A' ' 347' ' ' GLU . 10.6 mmtp -70.18 132.33 45.62 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.189 -0.945 . . . . 0.0 109.136 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.548 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 95.9 mt -87.41 152.13 22.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.441 -0.787 . . . . 0.0 111.376 -178.875 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.55 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -61.71 174.74 0.61 Allowed Pre-proline 0 C--N 1.301 -1.505 0 O-C-N 121.63 -0.668 . . . . 0.0 109.293 179.002 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.483 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.9 Cg_endo -68.48 82.87 0.51 Allowed 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.703 1.37 . . . . 0.0 110.041 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.1 24.48 4.82 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.498 ' HB1' ' HB1' ' A' ' 299' ' ' ALA . . . -114.41 148.89 37.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -1.09 . . . . 0.0 110.155 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.548 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 21.0 p -151.76 144.35 24.24 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 110.614 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.521 HG11 ' CD ' ' A' ' 312' ' ' LYS . 61.3 t -64.65 129.7 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.458 -0.776 . . . . 0.0 110.357 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.74 -34.41 2.05 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.459 ' O ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -142.21 131.72 23.83 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.194 -1.18 . . . . 0.0 110.59 -179.827 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 13.6 p90 -145.96 163.92 33.65 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.263 -0.898 . . . . 0.0 109.817 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.511 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.7 OUTLIER -154.33 166.75 32.21 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.99 -1.068 . . . . 0.0 110.982 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.446 ' CB ' ' HA ' ' A' ' 334' ' ' PHE . 0.5 OUTLIER 54.99 23.07 4.8 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.561 -0.712 . . . . 0.0 111.03 179.772 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.516 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.92 149.39 1.13 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.423 179.635 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.525 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -87.77 124.65 33.82 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.163 -0.961 . . . . 0.0 109.263 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.521 ' CD ' HG11 ' A' ' 304' ' ' VAL . 7.8 ttpt -92.29 139.77 30.27 Favored 'General case' 0 N--CA 1.489 1.486 0 CA-C-O 121.697 0.76 . . . . 0.0 110.976 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.96 175.18 7.49 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 178.808 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.467 ' HA ' HG21 ' A' ' 319' ' ' VAL . 4.6 mt-10 -136.34 109.69 7.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.083 -1.01 . . . . 0.0 110.629 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -98.59 39.58 2.71 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 61.26 90.22 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 0.0 110.095 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.09 0.87 82.65 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.622 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 4.0 m-85 -143.83 -171.31 3.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.466 -1.02 . . . . 0.0 109.567 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 2.9 t -163.43 156.73 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -0.854 . . . . 0.0 109.467 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.509 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 15.2 mm -122.43 147.52 26.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.92 -1.112 . . . . 0.0 110.715 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.661 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.0 m-85 -124.28 129.6 51.04 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.212 -0.93 . . . . 0.0 109.855 179.389 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.525 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 16.1 p -132.41 167.22 23.6 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 120.575 -1.328 . . . . 0.0 110.178 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.527 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.5 Cg_endo -65.99 115.95 3.72 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.839 1.442 . . . . 0.0 111.01 -179.698 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.517 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 9.2 m -58.36 -111.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.427 -0.795 . . . . 0.0 110.006 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 2.2 p -117.78 -18.43 9.6 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.742 -1.224 . . . . 0.0 110.379 -179.878 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.421 ' CE2' HG23 ' A' ' 324' ' ' VAL . 6.9 p-90 -125.93 -4.13 6.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.244 -0.91 . . . . 0.0 110.401 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.517 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 2.3 t30 -97.73 50.29 1.04 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.288 -0.882 . . . . 0.0 109.977 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.487 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 4.2 mtmt -124.72 -9.82 7.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.344 -0.847 . . . . 0.0 109.894 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.53 -160.57 0.02 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.23 6.08 3.71 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.059 1.557 . . . . 0.0 110.744 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.433 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.7 m -163.07 116.55 1.62 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.066 -1.022 . . . . 0.0 109.943 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.403 ' HB3' ' CG ' ' A' ' 327' ' ' ASN . . . -137.53 105.79 5.75 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.22 -0.925 . . . . 0.0 110.324 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.508 HG23 ' CB ' ' A' ' 283' ' ' THR . 13.9 m -96.0 123.23 39.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.623 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 9.8 p90 -127.48 172.67 10.49 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.366 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.475 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.89 160.29 28.34 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.653 -1.736 . . . . 0.0 110.397 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.694 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.1 p90 -147.08 143.75 28.55 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.717 -0.873 . . . . 0.0 109.348 179.379 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.572 HG22 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -117.65 117.25 54.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.797 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.537 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 3.2 t -96.9 152.03 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.997 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.45 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.79 134.72 54.41 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 110.353 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.2 -127.45 1.14 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.539 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.1 Cg_endo -67.11 -157.75 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.815 1.429 . . . . 0.0 110.468 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.458 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 10.4 mp0 -122.9 128.93 50.97 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.173 -0.955 . . . . 0.0 110.543 -179.728 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 116.09 -87.89 0.45 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -115.33 131.0 57.07 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.426 -1.044 . . . . 0.0 109.041 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.55 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.1 mtmt -127.38 15.46 7.16 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.944 -1.098 . . . . 0.0 110.728 -179.329 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.59 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.4 p -136.12 114.74 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.474 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.518 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.1 mm-40 -44.07 -47.2 8.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.879 . . . . 0.0 110.045 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -176.8 153.46 1.06 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.124 -0.985 . . . . 0.0 110.733 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.478 HG12 HG12 ' A' ' 296' ' ' VAL . 18.5 mt -115.38 104.23 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.153 -0.967 . . . . 0.0 110.033 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.78 154.03 20.04 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.228 -0.92 . . . . 0.0 110.448 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.534 HD13 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.38 127.56 55.7 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.296 -0.877 . . . . 0.0 110.261 179.996 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.434 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 27.3 tt0 -138.21 112.65 8.77 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.083 -1.011 . . . . 0.0 109.895 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.475 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.5 mt -91.74 108.03 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 110.669 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.513 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 37.76 35.84 0.08 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.674 -0.641 . . . . 0.0 111.139 179.563 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.1 -0.07 28.4 Favored Glycine 0 N--CA 1.493 2.433 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.468 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -108.68 104.5 13.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.126 -1.22 . . . . 0.0 110.134 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.3 p -71.9 114.11 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.332 -0.855 . . . . 0.0 110.283 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.478 HG23 ' HB2' ' A' ' 262' ' ' PRO . 41.6 mm . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.112 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.244 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.2 -178.7 4.09 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.969 1.51 . . . . 0.0 110.782 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.48 ' CG2' ' O ' ' A' ' 258' ' ' THR . 5.0 t -66.64 124.53 23.1 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.323 -0.861 . . . . 0.0 110.171 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 7.2 t -129.87 145.22 56.22 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.178 -0.951 . . . . 0.0 110.372 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.28 138.65 30.7 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.131 1.595 . . . . 0.0 110.063 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . . . . . . . . . 3.2 p -65.78 138.85 96.69 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.074 -1.016 . . . . 0.0 110.517 -179.503 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.447 ' CB ' HG23 ' A' ' 358' ' ' ILE . 51.1 Cg_endo -79.99 126.49 6.45 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 O-C-N 124.105 1.581 . . . . 0.0 110.264 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.473 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 94.1 t -114.26 30.28 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.248 -0.908 . . . . 0.0 110.237 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 4.2 t 178.8 97.52 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.205 -0.934 . . . . 0.0 110.671 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.25 -177.27 34.9 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.546 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.22 166.39 24.67 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.486 -1.008 . . . . 0.0 109.488 179.759 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.57 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -161.69 140.2 9.44 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.001 -1.062 . . . . 0.0 111.11 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.426 ' N ' HD12 ' A' ' 267' ' ' LEU . 9.5 mt-10 -141.94 123.89 15.33 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 179.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.45 HG11 ' O ' ' A' ' 281' ' ' ASP . 71.8 t -117.14 141.61 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 120.845 -1.16 . . . . 0.0 111.607 -178.973 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.438 ' C ' HG23 ' A' ' 271' ' ' VAL . 4.7 tttt -126.88 157.55 39.05 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.923 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.587 HG11 ' CE2' ' A' ' 280' ' ' TYR . 74.1 t -144.73 146.95 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.416 -1.427 . . . . 0.0 112.085 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.516 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -144.5 114.9 7.58 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.643 -0.661 . . . . 0.0 109.288 179.056 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.5 p30 -96.04 148.01 23.12 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.2 -0.938 . . . . 0.0 111.291 -178.798 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.572 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 34.2 p90 -132.78 19.17 4.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.489 -0.757 . . . . 0.0 109.949 179.23 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.61 -62.43 3.4 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.519 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 22.0 m -66.37 -21.14 66.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -1.149 . . . . 0.0 110.481 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.486 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -176.4 -179.55 46.91 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.43 -1.366 . . . . 0.0 109.776 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.55 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.99 143.94 48.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.258 -1.142 . . . . 0.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.572 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 9.0 mt-10 -96.37 147.35 23.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.439 -0.788 . . . . 0.0 110.332 -179.546 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.675 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.0 m-85 -141.2 86.63 2.04 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.474 -0.766 . . . . 0.0 110.372 -179.52 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.45 ' O ' HG11 ' A' ' 269' ' ' VAL . 3.9 t0 -71.09 152.19 43.73 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.367 -0.833 . . . . 0.0 110.092 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.629 ' CG1' ' CZ ' ' A' ' 334' ' ' PHE . 4.8 t -144.83 89.84 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.601 -0.687 . . . . 0.0 109.812 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.48 ' O ' HD23 ' A' ' 267' ' ' LEU . 13.5 m -86.29 127.9 34.84 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.951 -1.093 . . . . 0.0 109.596 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.61 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.3 OUTLIER -116.53 151.16 36.71 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.02 -1.05 . . . . 0.0 110.862 -179.35 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.55 ' O ' ' CD2' ' A' ' 286' ' ' LEU . 0.5 OUTLIER -131.62 136.0 47.4 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.402 -0.811 . . . . 0.0 109.88 -179.853 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.563 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 17.9 mt -140.67 172.69 12.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.773 -1.204 . . . . 0.0 109.965 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -94.55 29.16 2.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.22 -0.925 . . . . 0.0 110.967 -179.157 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.517 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 149.91 -82.84 0.18 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.484 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.2 tt0 -151.59 107.94 3.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.092 -1.24 . . . . 0.0 110.737 -179.343 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.61 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 6.4 m-85 -133.27 140.89 47.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.299 -0.876 . . . . 0.0 109.829 179.51 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.523 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 18.3 m-20 -74.01 97.09 2.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.05 -1.031 . . . . 0.0 109.001 179.022 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.61 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 56.8 p-90 -98.63 115.27 28.29 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.206 -0.934 . . . . 0.0 110.64 -179.193 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.468 HG21 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -108.09 113.9 27.4 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.506 -0.746 . . . . 0.0 109.547 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.529 HG21 ' CD2' ' A' ' 351' ' ' LEU . 3.7 t -96.75 110.88 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 109.948 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.53 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 26.7 ttmt -84.84 148.24 26.39 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.344 -0.847 . . . . 0.0 109.768 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.535 HG12 ' CG2' ' A' ' 346' ' ' VAL . 46.3 t -144.58 108.51 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.256 -0.902 . . . . 0.0 110.398 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.566 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 2.6 mmtp -73.25 141.59 47.25 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.291 -0.88 . . . . 0.0 109.054 179.444 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.556 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 97.9 mt -93.45 156.7 16.61 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.164 -0.96 . . . . 0.0 111.708 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.486 ' HB3' ' HD2' ' A' ' 300' ' ' PRO . . . -69.65 172.45 5.42 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.629 -0.67 . . . . 0.0 109.49 179.073 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.486 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 40.0 Cg_endo -67.61 84.34 0.39 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.73 1.384 . . . . 0.0 109.704 179.199 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.29 28.05 3.19 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 -179.244 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.511 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -123.42 145.25 48.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.331 -1.099 . . . . 0.0 110.623 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.556 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 42.0 p -145.68 144.4 30.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.254 -0.904 . . . . 0.0 110.367 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.57 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 19.6 t -78.62 136.86 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 110.179 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -136.67 -34.01 0.22 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.448 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -114.22 113.08 24.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.142 -1.21 . . . . 0.0 110.712 -179.632 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.477 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 28.9 p90 -144.4 164.37 31.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.297 -0.877 . . . . 0.0 109.844 179.503 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.482 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -157.64 161.56 38.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.076 -1.015 . . . . 0.0 111.102 -179.297 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 57.91 23.66 10.06 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.797 . . . . 0.0 111.22 179.31 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.525 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.46 141.85 0.72 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.185 -0.947 . . . . 0.0 110.057 179.469 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.3 m-80 -77.24 119.46 20.94 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.135 -0.978 . . . . 0.0 109.399 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.464 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.4 ttpt -90.33 141.45 28.71 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.658 0.742 . . . . 0.0 110.404 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.765 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -128.99 178.47 6.38 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.447 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.446 ' HA ' HG21 ' A' ' 319' ' ' VAL . 2.5 mt-10 -141.48 104.69 4.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.686 -0.634 . . . . 0.0 110.024 179.511 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.38 42.05 2.93 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.59 78.78 0.27 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.225 -1.162 . . . . 0.0 110.436 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.613 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 102.7 -1.64 48.94 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.613 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.2 m-85 -144.38 -165.67 2.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.337 -1.096 . . . . 0.0 109.42 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.57 ' CG2' ' CG2' ' A' ' 304' ' ' VAL . 2.8 t -163.48 154.25 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.331 -0.856 . . . . 0.0 109.7 179.341 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.765 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 13.4 mm -121.11 148.02 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.027 -1.046 . . . . 0.0 110.693 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.651 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.8 m-85 -126.27 124.53 40.57 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.357 -0.839 . . . . 0.0 109.815 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.519 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 8.7 p -128.9 166.51 24.45 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.935 -1.103 . . . . 0.0 109.576 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.43 120.43 7.64 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.853 1.449 . . . . 0.0 110.912 -179.076 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.48 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 31.1 m -64.48 -123.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.576 -0.702 . . . . 0.0 110.205 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -102.35 -17.7 15.75 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.815 -1.178 . . . . 0.0 110.669 -179.673 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.409 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 20.4 p-90 -126.74 -8.78 6.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.018 -1.051 . . . . 0.0 110.505 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.48 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.4 t-20 -89.82 38.98 0.94 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.416 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.466 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -118.47 -6.35 10.74 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.137 -0.977 . . . . 0.0 109.715 179.75 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.26 -164.69 0.06 OUTLIER Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.517 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.6 Cg_endo -72.35 1.05 6.54 Favored 'Trans proline' 0 C--N 1.307 -1.633 0 O-C-N 124.236 1.65 . . . . 0.0 110.793 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -160.04 114.74 2.29 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.421 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.485 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -136.43 120.92 18.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -0.89 . . . . 0.0 110.499 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.495 ' O ' ' HB2' ' A' ' 309' ' ' SER . 97.4 m -110.37 142.38 42.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -0.872 . . . . 0.0 110.099 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.629 ' CZ ' ' CG1' ' A' ' 282' ' ' VAL . 16.4 p90 -145.22 174.39 11.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.419 -0.801 . . . . 0.0 108.918 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.14 164.62 30.12 Favored Glycine 0 N--CA 1.488 2.148 0 C-N-CA 118.913 -1.613 . . . . 0.0 110.146 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.675 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.3 p90 -151.54 143.4 23.78 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.512 -0.993 . . . . 0.0 109.642 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.562 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.5 mp -119.42 123.16 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.07 -1.019 . . . . 0.0 109.569 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.539 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 13.3 t -96.26 154.91 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.098 -1.002 . . . . 0.0 110.353 -179.522 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.58 135.03 52.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.368 -0.832 . . . . 0.0 110.582 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.439 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 176.3 -133.34 2.3 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 179.765 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.466 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 44.8 Cg_endo -72.54 -158.13 0.06 OUTLIER 'Trans proline' 0 C--N 1.306 -1.696 0 O-C-N 123.86 1.453 . . . . 0.0 109.965 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.581 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -121.76 144.56 48.73 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.114 -0.991 . . . . 0.0 110.446 -179.642 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.471 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 100.61 66.04 0.81 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.5 OUTLIER 67.15 130.98 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.282 -1.128 . . . . 0.0 109.288 -179.545 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.539 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER -130.48 23.77 5.12 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.101 -0.999 . . . . 0.0 110.526 -179.292 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.559 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.5 p -129.21 123.13 57.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.302 -0.874 . . . . 0.0 110.103 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.509 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 8.8 mt-10 -56.11 -41.38 75.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.314 -0.866 . . . . 0.0 110.907 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.413 ' CD ' ' N ' ' A' ' 349' ' ' ILE . 2.4 tp10 -177.14 156.13 1.23 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.93 -1.106 . . . . 0.0 110.623 -179.352 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.462 HG21 HG22 ' A' ' 296' ' ' VAL . 38.6 mt -123.98 104.02 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.121 -0.987 . . . . 0.0 110.063 179.283 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.73 148.46 30.45 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.211 -0.931 . . . . 0.0 110.129 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.604 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -109.84 129.51 55.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.946 . . . . 0.0 110.347 179.844 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 24.2 tp10 -138.46 114.37 10.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.895 . . . . 0.0 109.779 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.459 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.4 mt -91.54 104.86 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.101 -0.999 . . . . 0.0 110.462 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.523 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 38.94 36.1 0.14 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.831 -0.543 . . . . 0.0 110.794 179.752 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.41 12.72 16.54 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.454 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 1.4 mp0 -120.88 105.45 10.71 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.979 -1.307 . . . . 0.0 110.358 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.475 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 9.8 p -72.22 128.02 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.275 -0.891 . . . . 0.0 110.324 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.447 HG23 ' CB ' ' A' ' 262' ' ' PRO . 10.7 mm . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.097 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.21 -178.02 3.35 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.059 1.557 . . . . 0.0 110.482 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 8.2 t -57.16 142.18 43.62 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.211 -0.931 . . . . 0.0 110.162 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 259' ' ' THR . . . . . 0.463 ' O ' HG23 ' A' ' 259' ' ' THR . 5.2 t -115.85 112.31 42.75 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.145 -0.972 . . . . 0.0 110.558 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.37 139.51 26.15 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 O-C-N 123.946 1.498 . . . . 0.0 110.055 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.434 HG21 ' N ' ' A' ' 262' ' ' PRO . 4.1 p -69.58 144.04 93.58 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.165 -0.959 . . . . 0.0 110.383 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.453 ' HB3' ' HA ' ' A' ' 358' ' ' ILE . 49.3 Cg_endo -76.36 138.07 19.48 Favored 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 124.082 1.569 . . . . 0.0 110.509 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 21.2 t -103.69 30.92 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.241 -0.912 . . . . 0.0 110.132 179.926 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.413 ' O ' ' O ' ' A' ' 265' ' ' GLY . 0.1 OUTLIER -175.24 145.47 0.78 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.241 -0.912 . . . . 0.0 110.62 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' A' ' 264' ' ' SER . . . 45.34 -169.7 0.02 OUTLIER Glycine 0 N--CA 1.491 2.314 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.501 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.52 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.53 166.29 24.97 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.722 -0.87 . . . . 0.0 109.495 179.908 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.547 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.5 tm? -161.59 137.58 7.94 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.497 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.502 ' N ' HD23 ' A' ' 267' ' ' LEU . 0.8 OUTLIER -137.27 151.0 48.21 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.032 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.447 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 66.1 t -138.93 138.83 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.683 -1.261 . . . . 0.0 111.431 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.425 ' C ' HG21 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -120.69 157.77 28.9 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.215 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 99.4 t -144.9 146.76 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.287 -1.508 . . . . 0.0 112.169 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.7 113.5 7.13 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.451 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 4.8 m-20 -98.1 143.72 28.34 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.209 -0.932 . . . . 0.0 111.016 -178.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.564 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 34.8 p90 -128.99 17.75 6.14 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 110.079 179.56 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.475 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 87.76 -58.3 4.36 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.414 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 0.7 OUTLIER -68.94 -18.31 64.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.229 -1.16 . . . . 0.0 110.093 179.828 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.551 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.72 178.14 48.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.554 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -132.14 143.49 50.02 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -1.111 . . . . 0.0 110.111 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.564 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 4.7 mt-10 -97.52 147.13 24.57 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.459 -0.776 . . . . 0.0 110.031 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 94.3 m-85 -142.41 84.52 1.87 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.336 -0.853 . . . . 0.0 110.749 -179.598 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.447 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -66.41 152.12 45.75 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.408 -0.808 . . . . 0.0 110.03 179.288 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.587 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 10.6 t -144.41 90.33 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.66 -0.65 . . . . 0.0 109.572 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.42 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 81.9 m -86.43 124.56 32.9 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.146 -0.971 . . . . 0.0 109.465 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.596 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.07 147.51 37.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.308 -0.87 . . . . 0.0 110.531 -179.243 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.531 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.5 OUTLIER -126.33 134.17 51.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.382 -0.824 . . . . 0.0 109.804 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.544 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 16.5 mt -141.63 150.42 41.95 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.607 -1.308 . . . . 0.0 110.208 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.51 35.59 0.77 Allowed 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.484 -0.76 . . . . 0.0 109.374 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.59 -128.94 2.04 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.256 -1.45 . . . . 0.0 109.91 -179.7 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.498 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -124.59 96.07 4.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -1.195 . . . . 0.0 110.714 -179.531 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.544 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.7 m-85 -118.53 129.44 55.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.33 -0.857 . . . . 0.0 109.74 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.519 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 0.3 OUTLIER -63.49 100.57 0.27 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.948 -1.095 . . . . 0.0 109.224 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.589 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 54.7 p-90 -99.85 112.98 25.21 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.213 -0.929 . . . . 0.0 111.065 -179.257 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.584 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 14.8 m -106.01 115.81 30.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.648 -0.658 . . . . 0.0 109.271 179.256 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.463 ' HA ' HD22 ' A' ' 351' ' ' LEU . 3.2 t -96.27 110.95 25.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.035 -1.04 . . . . 0.0 110.388 -179.424 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.473 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.9 ttpt -86.0 145.95 26.88 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.469 -0.769 . . . . 0.0 109.223 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.54 HG11 ' CG2' ' A' ' 346' ' ' VAL . 55.1 t -146.3 108.04 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 110.448 -179.501 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.496 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 30.8 mmtp -70.38 139.88 52.0 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.186 -0.946 . . . . 0.0 109.324 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.549 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 81.8 mt -94.71 158.45 15.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.454 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.489 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -66.65 177.12 0.88 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.684 -0.635 . . . . 0.0 109.748 179.33 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.489 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 41.4 Cg_endo -68.47 87.38 0.42 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.758 1.399 . . . . 0.0 109.838 179.501 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 107.32 22.28 7.55 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.479 ' O ' ' HB3' ' A' ' 298' ' ' LEU . . . -112.9 139.15 48.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.262 -1.14 . . . . 0.0 110.161 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.549 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 19.3 p -143.68 145.65 32.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 110.524 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.585 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 22.7 t -76.04 129.63 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.214 -0.929 . . . . 0.0 109.939 179.756 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.29 -17.98 3.51 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.148 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.404 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -143.78 129.76 19.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.046 -1.267 . . . . 0.0 111.245 -179.588 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.553 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.8 p90 -150.04 -178.14 6.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.545 -0.722 . . . . 0.0 109.636 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.518 ' CH2' HD13 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -166.06 151.15 8.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.534 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.6 OUTLIER 61.67 30.82 18.65 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.471 -0.768 . . . . 0.0 110.819 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.531 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.68 141.66 0.51 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.237 -0.915 . . . . 0.0 110.045 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.489 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.3 m-80 -81.17 112.4 18.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.074 -1.016 . . . . 0.0 109.317 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.553 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 2.3 ttpt -84.93 142.72 29.47 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.957 0.884 . . . . 0.0 110.981 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.705 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -129.34 179.08 5.99 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.099 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.449 ' HG2' ' O ' ' A' ' 313' ' ' GLN . 2.4 mt-10 -142.04 100.04 3.65 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.091 -0.644 . . . . 0.0 110.189 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.447 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -86.13 42.46 3.15 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.447 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 19.6 m120 59.69 80.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.239 -1.154 . . . . 0.0 110.328 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.605 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.86 2.61 56.14 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.605 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.1 m-85 -147.29 -166.87 2.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.396 -1.061 . . . . 0.0 109.382 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.585 ' CG2' ' CG2' ' A' ' 304' ' ' VAL . 4.0 t -163.16 154.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.283 -0.885 . . . . 0.0 109.975 178.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.705 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 5.2 mm -125.86 138.69 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.174 -0.953 . . . . 0.0 111.545 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.655 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.9 m-85 -117.4 122.61 44.28 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.326 -0.859 . . . . 0.0 109.515 178.911 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.522 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.3 p -124.4 168.75 12.2 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 120.61 -1.306 . . . . 0.0 110.554 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -64.66 112.2 1.9 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 124.04 1.548 . . . . 0.0 110.908 -179.362 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.516 ' N ' ' OD1' ' A' ' 327' ' ' ASN . 33.8 m -58.69 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.687 -0.633 . . . . 0.0 109.961 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.409 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 3.1 p -112.39 -12.72 13.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.636 -1.29 . . . . 0.0 111.01 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.445 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 14.8 p-90 -129.85 -12.31 4.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.984 -1.073 . . . . 0.0 111.226 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.538 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 23.1 p-10 -96.28 40.83 1.12 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.047 -1.033 . . . . 0.0 110.985 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.461 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -114.14 -3.0 13.29 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.162 -0.961 . . . . 0.0 109.51 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.81 -157.74 0.02 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.524 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -74.66 6.97 2.93 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.052 1.553 . . . . 0.0 110.956 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.472 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 5.6 m -165.35 122.11 1.46 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.099 -1.001 . . . . 0.0 110.088 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.538 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -138.91 116.25 11.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.933 . . . . 0.0 110.617 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.453 ' O ' ' HB2' ' A' ' 309' ' ' SER . 13.3 m -108.36 134.16 51.56 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.243 -0.91 . . . . 0.0 110.046 179.737 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.587 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 11.0 p90 -142.65 174.89 10.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.058 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.484 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.61 156.96 27.01 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.014 -1.565 . . . . 0.0 110.272 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.68 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.4 p90 -141.7 147.74 37.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.496 -1.002 . . . . 0.0 110.04 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.553 HG21 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -121.75 122.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.179 -0.951 . . . . 0.0 109.623 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.528 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 18.3 t -97.29 153.28 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.934 . . . . 0.0 110.554 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -121.02 132.76 55.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.561 -0.712 . . . . 0.0 109.867 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.437 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -178.24 -138.03 2.99 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.478 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 45.8 Cg_endo -73.19 -159.28 0.08 OUTLIER 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 124.085 1.571 . . . . 0.0 110.684 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.523 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 2.5 mp0 -115.34 135.59 53.97 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.189 -0.944 . . . . 0.0 110.445 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.477 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 111.53 60.1 0.46 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.2 OUTLIER 66.5 142.07 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.397 -1.06 . . . . 0.0 108.66 -179.052 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.528 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER -135.11 28.4 3.46 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.981 -1.074 . . . . 0.0 111.06 -178.88 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.588 HG11 ' CE1' ' A' ' 280' ' ' TYR . 14.7 p -132.87 119.03 35.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.282 -0.886 . . . . 0.0 110.187 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -51.26 -46.96 62.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.444 -0.785 . . . . 0.0 110.268 -179.743 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.476 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 6.8 pt-20 -177.05 158.66 1.56 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.267 -0.896 . . . . 0.0 110.627 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.477 ' CG2' HG23 ' A' ' 296' ' ' VAL . 77.2 mt -121.29 112.41 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 110.245 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -116.54 137.47 52.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.238 -0.913 . . . . 0.0 110.177 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.596 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -93.04 135.3 34.35 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.12 -0.988 . . . . 0.0 110.523 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.47 108.26 5.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.402 -0.811 . . . . 0.0 110.012 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.459 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.8 mt -91.67 108.85 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.992 -1.067 . . . . 0.0 110.068 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.519 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 38.88 31.51 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.746 -0.596 . . . . 0.0 110.796 -179.855 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.13 -12.14 22.07 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.425 ' O ' HG12 ' A' ' 358' ' ' ILE . 2.2 mp0 -95.03 105.55 17.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.1 -1.236 . . . . 0.0 110.487 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.47 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.9 p -68.83 133.97 30.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.882 . . . . 0.0 110.185 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.453 ' HA ' ' HB3' ' A' ' 262' ' ' PRO . 22.1 mm . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.289 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -75.18 -178.28 4.1 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 124.026 1.54 . . . . 0.0 110.509 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.422 ' O ' ' CG2' ' A' ' 258' ' ' THR . 6.7 t -64.11 132.08 49.42 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.334 -0.854 . . . . 0.0 110.136 179.739 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 259' ' ' THR . . . . . 0.406 HG23 ' HD2' ' A' ' 260' ' ' PRO . 0.0 OUTLIER -141.15 146.51 43.38 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.146 -0.971 . . . . 0.0 110.302 179.809 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . 0.406 ' HD2' HG23 ' A' ' 259' ' ' THR . 49.0 Cg_endo -75.55 135.9 18.66 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 124.034 1.544 . . . . 0.0 110.292 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . . . . . . . . . 3.8 p -67.8 143.1 96.29 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.19 -0.944 . . . . 0.0 110.419 179.992 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.51 ' HB3' ' CG2' ' A' ' 358' ' ' ILE . 46.4 Cg_endo -75.3 157.0 41.74 Favored 'Trans proline' 0 C--N 1.303 -1.819 0 O-C-N 124.126 1.593 . . . . 0.0 110.692 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.517 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 69.8 t -137.75 26.12 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.583 179.445 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -164.78 63.63 0.13 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.361 -0.837 . . . . 0.0 110.117 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 117.13 -169.19 13.03 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.523 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.69 164.59 27.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.378 -1.072 . . . . 0.0 110.049 179.992 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.549 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.3 tm? -161.34 131.93 5.15 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.226 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.522 ' N ' HD23 ' A' ' 267' ' ' LEU . 1.6 mt-10 -128.91 151.34 49.76 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.28 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.454 HG23 ' O ' ' A' ' 268' ' ' GLU . 96.5 t -142.71 138.83 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.712 -1.242 . . . . 0.0 111.509 -179.26 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.425 ' C ' HG23 ' A' ' 271' ' ' VAL . 17.2 mtpt -122.19 157.46 31.52 Favored 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.278 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.537 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 92.9 t -143.2 146.98 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.324 -1.485 . . . . 0.0 111.957 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.5 112.22 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 179.485 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.504 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.9 m-20 -96.49 143.95 27.04 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.014 -1.054 . . . . 0.0 111.125 -179.214 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.583 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 32.7 p90 -128.38 16.79 6.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 109.847 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.27 -63.17 2.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.6 -20.42 64.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -1.133 . . . . 0.0 110.306 -179.751 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.554 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.88 177.98 42.44 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.15 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.543 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -134.13 142.65 47.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.339 -1.094 . . . . 0.0 109.704 179.599 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.583 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 7.8 mt-10 -98.91 147.11 25.3 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.281 -0.887 . . . . 0.0 110.429 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.668 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.9 m-85 -143.09 84.2 1.82 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.511 -0.743 . . . . 0.0 110.649 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.44 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.87 151.69 46.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.347 -0.846 . . . . 0.0 109.967 179.407 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.595 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 14.0 t -143.93 91.38 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.459 -0.776 . . . . 0.0 110.131 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 88.4 m -86.74 123.89 32.4 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.39 179.504 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.6 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -111.27 147.49 34.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.017 -1.052 . . . . 0.0 110.976 -179.037 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.535 ' O ' ' CD2' ' A' ' 286' ' ' LEU . 0.5 OUTLIER -126.5 132.32 51.42 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.462 -0.774 . . . . 0.0 110.163 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.607 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 18.1 mt -142.77 157.52 44.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.43 36.86 1.06 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.194 -0.941 . . . . 0.0 109.671 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 160.68 -144.31 9.82 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.401 -1.381 . . . . 0.0 109.896 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.53 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -108.76 94.22 4.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -1.126 . . . . 0.0 110.711 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.607 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.7 m-30 -114.65 143.67 44.66 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 109.901 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.464 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 2.6 m-20 -76.97 97.21 4.57 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.198 -0.939 . . . . 0.0 109.078 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.588 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 57.4 p-90 -96.75 112.37 24.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.378 -0.826 . . . . 0.0 110.596 -179.185 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.605 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 1.5 m -105.44 113.78 27.56 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.416 -0.802 . . . . 0.0 109.515 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.496 HG22 ' CD2' ' A' ' 351' ' ' LEU . 5.4 t -96.07 110.67 24.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.076 -1.015 . . . . 0.0 109.829 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.46 ' HE2' HD11 ' A' ' 320' ' ' ILE . 8.4 ttmt -87.78 149.54 24.11 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.234 -0.916 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.598 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 98.6 t -144.89 108.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.419 -0.801 . . . . 0.0 110.352 -179.604 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.511 ' O ' ' N ' ' A' ' 347' ' ' GLU . 14.5 mmtt -71.95 132.53 44.45 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.242 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.501 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 84.5 mt -88.0 156.05 19.51 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.233 -0.917 . . . . 0.0 111.594 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.517 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -68.29 173.08 3.57 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.581 -0.699 . . . . 0.0 109.318 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.497 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 39.6 Cg_endo -66.95 81.49 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.436 1.23 . . . . 0.0 110.067 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.79 23.09 4.09 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.518 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -115.03 144.94 42.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.366 -1.079 . . . . 0.0 110.085 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.504 ' N ' HG11 ' A' ' 338' ' ' VAL . 17.9 p -150.35 145.88 26.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.104 -0.998 . . . . 0.0 110.782 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.465 HG12 ' HG3' ' A' ' 312' ' ' LYS . 37.6 t -66.42 126.3 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.383 -0.823 . . . . 0.0 110.071 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.51 -16.19 6.11 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 337' ' ' ILE . 14.7 t -152.04 113.33 4.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.064 -1.257 . . . . 0.0 111.009 -179.624 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 18.7 p90 -134.39 163.64 29.22 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.396 -0.815 . . . . 0.0 109.43 179.135 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.497 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -153.91 160.92 42.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.995 -1.066 . . . . 0.0 111.246 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.484 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 54.13 29.08 9.79 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.694 . . . . 0.0 110.95 179.774 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.536 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.32 139.56 0.61 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.256 -0.903 . . . . 0.0 110.112 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.501 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -79.17 118.8 21.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.308 179.616 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.465 ' HG3' HG12 ' A' ' 304' ' ' VAL . 8.1 ttpt -87.53 134.92 33.54 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.688 0.756 . . . . 0.0 111.235 -179.126 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.95 172.68 7.1 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.409 ' HA ' HG22 ' A' ' 319' ' ' VAL . 3.8 mt-10 -131.71 112.62 12.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.343 -0.848 . . . . 0.0 110.082 179.928 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.567 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.58 47.81 1.15 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 8.0 t30 49.49 77.04 0.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.287 -1.125 . . . . 0.0 110.142 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.615 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.01 2.12 54.92 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.615 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.8 m-85 -143.67 -170.78 3.38 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.998 . . . . 0.0 109.13 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.537 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.9 t -163.95 154.5 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.254 -0.904 . . . . 0.0 109.11 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.605 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 17.6 mt -131.75 135.83 58.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 120.711 -1.243 . . . . 0.0 111.298 -179.591 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.665 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 52.9 m-85 -106.36 138.76 41.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.301 -0.874 . . . . 0.0 110.537 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.501 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.0 OUTLIER -136.41 169.92 12.24 Favored Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.934 -1.104 . . . . 0.0 110.023 179.427 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 41.0 Cg_endo -67.86 116.39 4.27 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 O-C-N 123.797 1.42 . . . . 0.0 110.816 -179.175 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.466 HG12 ' ND2' ' A' ' 311' ' ' ASN . 19.9 m -65.69 -129.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.578 -0.701 . . . . 0.0 110.098 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.416 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 0.4 OUTLIER -98.33 -12.82 21.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.912 -1.117 . . . . 0.0 110.712 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.447 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 36.2 p-90 -135.41 7.57 3.34 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.033 -1.042 . . . . 0.0 110.676 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.434 ' OD1' ' HB2' ' A' ' 332' ' ' ALA . 2.1 t-20 -111.32 42.62 1.63 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.18 -0.95 . . . . 0.0 110.119 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.53 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -122.79 -5.87 8.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 0.0 110.092 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.22 -160.35 0.02 OUTLIER Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.736 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 286' ' ' LEU . 45.9 Cg_endo -74.63 4.13 4.81 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 124.056 1.556 . . . . 0.0 110.592 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.43 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 3.7 m -164.61 116.1 1.24 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.925 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.505 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -137.18 119.15 15.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.189 -0.945 . . . . 0.0 110.325 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.484 ' O ' ' HB2' ' A' ' 309' ' ' SER . 3.3 m -105.03 142.26 35.14 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.948 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.595 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 11.2 p90 -148.6 174.89 11.67 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.94 159.87 29.02 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.61 -1.757 . . . . 0.0 110.447 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.668 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 0.5 OUTLIER -143.55 147.61 34.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.506 -0.996 . . . . 0.0 110.034 179.572 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.517 ' N ' HD12 ' A' ' 337' ' ' ILE . 1.7 mp -123.29 119.18 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.922 . . . . 0.0 109.188 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.527 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 5.9 t -96.55 146.2 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.143 -0.973 . . . . 0.0 110.352 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.437 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.08 137.04 52.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.497 -0.752 . . . . 0.0 110.088 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.441 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 177.18 -138.62 4.0 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.512 ' O ' ' NZ ' ' A' ' 345' ' ' LYS . 47.0 Cg_endo -76.56 165.5 28.88 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 O-C-N 124.074 1.565 . . . . 0.0 110.231 179.856 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.57 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 2.8 mp0 -85.28 142.57 29.27 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.15 -0.968 . . . . 0.0 110.435 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.44 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 105.83 65.4 0.65 Allowed Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.44 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 0.2 OUTLIER 64.25 140.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -1.149 . . . . 0.0 109.377 -179.196 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.527 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.7 OUTLIER -137.3 15.41 3.0 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.994 -1.066 . . . . 0.0 110.814 -179.534 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.573 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.1 p -127.64 116.92 45.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.927 . . . . 0.0 110.081 179.418 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -47.84 -46.82 31.48 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.363 -0.835 . . . . 0.0 110.482 -179.69 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.404 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -177.18 158.78 1.54 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.103 -0.998 . . . . 0.0 110.861 -179.928 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.433 HG12 ' CG1' ' A' ' 296' ' ' VAL . 69.1 mt -120.39 122.97 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.026 -1.046 . . . . 0.0 110.278 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.42 137.58 52.76 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.193 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.6 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -96.34 130.57 43.42 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.059 -1.026 . . . . 0.0 110.367 179.975 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 30.4 tt0 -139.06 110.06 6.8 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.841 179.683 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.468 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.5 mt -91.69 110.22 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.081 -1.012 . . . . 0.0 110.231 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.412 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 43.31 30.6 0.32 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.645 -0.659 . . . . 0.0 110.969 179.917 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.09 -3.8 28.55 Favored Glycine 0 N--CA 1.492 2.39 0 C-N-CA 119.811 -1.185 . . . . 0.0 110.295 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.401 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 37.2 mm-40 -102.39 114.5 28.73 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.093 -1.239 . . . . 0.0 110.518 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.482 ' O ' ' CD1' ' A' ' 358' ' ' ILE . 4.5 p -73.69 136.22 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.251 -0.905 . . . . 0.0 110.363 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.51 ' CG2' ' HB3' ' A' ' 262' ' ' PRO . 20.6 mm . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.051 -0.976 . . . . 0.0 110.267 -179.769 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -73.1 -179.47 4.37 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 124.025 1.539 . . . . 0.0 110.552 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.421 ' O ' ' CG2' ' A' ' 258' ' ' THR . 3.7 t -57.75 131.03 49.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.186 -0.946 . . . . 0.0 110.469 -179.908 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 19.1 m -68.21 122.34 83.78 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.159 -0.963 . . . . 0.0 110.338 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -72.92 144.96 39.4 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 O-C-N 123.961 1.506 . . . . 0.0 110.213 179.824 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.511 ' CG2' ' HD2' ' A' ' 262' ' ' PRO . 5.3 p -74.82 146.44 82.94 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.076 -1.015 . . . . 0.0 110.551 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.511 ' HD2' ' CG2' ' A' ' 261' ' ' VAL . 46.7 Cg_endo -75.68 149.94 34.67 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 124.051 1.553 . . . . 0.0 110.252 179.742 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 4.1 t -131.87 30.94 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -0.944 . . . . 0.0 110.3 -179.928 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 177.96 35.8 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.194 -0.941 . . . . 0.0 110.514 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.42 ' O ' ' CG2' ' A' ' 358' ' ' ILE . . . 163.64 154.34 7.7 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.667 -1.254 . . . . 0.0 110.24 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.572 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -119.3 163.39 17.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.424 -1.045 . . . . 0.0 109.932 179.733 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.508 ' C ' ' CD2' ' A' ' 267' ' ' LEU . 0.0 OUTLIER -152.06 122.11 7.12 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.09 -1.006 . . . . 0.0 110.817 -179.822 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.443 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.9 mt-10 -118.72 111.15 18.13 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.696 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 71.4 t -113.23 141.2 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.011 -1.056 . . . . 0.0 111.861 -178.479 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.466 ' O ' HG23 ' A' ' 271' ' ' VAL . 0.1 OUTLIER -130.1 157.63 41.88 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.858 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.563 HG21 ' CD1' ' A' ' 280' ' ' TYR . 88.5 t -142.41 147.03 21.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.312 -1.492 . . . . 0.0 112.141 -179.064 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.562 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -135.83 107.5 6.99 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.958 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.517 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.4 p30 -93.66 146.03 24.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.031 . . . . 0.0 111.572 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.562 ' CZ3' ' O ' ' A' ' 272' ' ' ASN . 39.5 p90 -134.84 23.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.563 -0.71 . . . . 0.0 109.694 179.293 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.407 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 82.4 -69.23 3.38 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -27.67 48.16 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 110.425 179.888 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.537 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.83 -173.57 38.74 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.817 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.562 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -141.39 143.77 34.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -1.162 . . . . 0.0 110.379 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.554 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 4.7 mt-10 -93.67 145.61 24.43 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.475 -0.766 . . . . 0.0 109.578 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.1 m-85 -137.9 82.66 1.93 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.332 -0.855 . . . . 0.0 110.422 -179.543 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.466 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -67.91 144.11 55.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.485 -0.76 . . . . 0.0 109.676 179.433 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.594 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 6.7 t -137.71 88.4 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.484 -0.76 . . . . 0.0 109.772 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.412 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 60.6 m -86.25 120.47 27.64 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 109.245 179.808 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.553 HD13 ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -104.32 149.02 25.72 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.076 -1.015 . . . . 0.0 111.106 -178.69 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.572 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -131.57 107.19 8.69 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.505 -0.747 . . . . 0.0 110.224 -179.298 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 330' ' ' PRO . 4.8 mt -122.24 172.78 8.04 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.525 -1.359 . . . . 0.0 110.177 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -101.1 28.19 5.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.355 -0.841 . . . . 0.0 110.926 -179.603 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.637 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 161.92 -179.43 37.29 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 119.177 -1.487 . . . . 0.0 110.6 179.739 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.46 ' O ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -71.41 109.0 5.12 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.426 -1.044 . . . . 0.0 111.039 -179.417 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.637 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 10.2 m-85 -137.08 151.55 49.03 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.251 -0.906 . . . . 0.0 109.786 178.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.518 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 57.8 m-20 -80.42 97.09 6.92 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.273 179.074 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.59 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 53.4 p-90 -97.18 110.67 23.17 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.406 -179.605 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.571 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 4.0 m -103.02 116.76 33.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.5 -0.75 . . . . 0.0 109.485 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.456 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.7 t -96.91 111.19 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.131 -0.981 . . . . 0.0 110.432 -179.465 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.51 ' HG3' ' CD1' ' A' ' 320' ' ' ILE . 17.5 ttpt -82.96 147.85 27.97 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.219 -0.925 . . . . 0.0 109.47 179.433 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.524 HG13 ' CG2' ' A' ' 346' ' ' VAL . 77.3 t -146.61 105.01 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.135 -0.978 . . . . 0.0 110.629 -179.323 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.534 ' O ' ' CG2' ' A' ' 346' ' ' VAL . 19.2 mmtt -71.26 130.51 41.6 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.259 -0.9 . . . . 0.0 109.393 179.404 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.601 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 95.2 mt -83.8 161.42 20.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.46 -0.775 . . . . 0.0 111.6 -178.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.581 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -63.56 179.12 0.35 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.675 -0.641 . . . . 0.0 109.674 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.514 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 43.5 Cg_endo -69.24 76.46 0.93 Allowed 'Trans proline' 0 C--N 1.305 -1.745 0 O-C-N 123.742 1.391 . . . . 0.0 109.825 179.369 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.73 19.68 6.0 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.24 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.539 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -101.08 152.69 20.31 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.399 -1.059 . . . . 0.0 110.271 -179.596 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.556 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.8 p -150.6 144.62 25.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 110.588 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.525 HG21 ' CG2' ' A' ' 319' ' ' VAL . 55.2 t -68.07 140.95 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.35 -0.844 . . . . 0.0 109.734 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.79 -39.04 0.51 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.665 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.406 ' O ' HD12 ' A' ' 337' ' ' ILE . 19.5 m -137.05 129.36 29.75 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.007 -1.29 . . . . 0.0 111.117 -179.678 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.483 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 30.1 p90 -141.2 167.09 23.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.387 -0.821 . . . . 0.0 109.434 179.27 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.461 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.06 157.15 37.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.877 -1.14 . . . . 0.0 111.083 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.48 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.5 OUTLIER 58.79 25.23 13.25 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.477 -0.764 . . . . 0.0 111.106 179.797 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.54 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.18 140.03 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.242 -0.911 . . . . 0.0 109.997 179.465 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.496 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -79.47 121.96 25.84 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.104 -0.998 . . . . 0.0 109.312 179.569 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.505 ' HG2' ' N ' ' A' ' 313' ' ' GLN . 0.6 OUTLIER -88.75 145.75 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.771 0.796 . . . . 0.0 110.991 -179.119 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.17 175.23 9.28 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.458 ' HA ' HG21 ' A' ' 319' ' ' VAL . 3.4 mm-40 -138.68 112.99 8.74 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.228 -0.92 . . . . 0.0 110.457 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -99.76 40.63 2.38 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.79 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 59.27 82.27 0.15 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.29 -1.123 . . . . 0.0 110.179 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.56 -1.56 57.07 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.614 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.2 m-85 -146.37 -172.72 4.01 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.499 -1.0 . . . . 0.0 109.317 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.525 ' CG2' HG21 ' A' ' 304' ' ' VAL . 2.5 t -158.67 160.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.137 -0.977 . . . . 0.0 109.743 179.355 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.571 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 35.8 mm -127.93 146.82 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.163 -0.961 . . . . 0.0 111.304 -179.25 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 51.8 m-85 -123.67 132.68 53.9 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 110.003 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.515 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -131.54 169.69 13.17 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.924 -1.11 . . . . 0.0 110.135 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.553 ' HA ' ' CZ2' ' A' ' 292' ' ' TRP . 39.3 Cg_endo -65.76 116.49 3.99 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.065 -179.482 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.453 ' O ' ' HD3' ' A' ' 328' ' ' LYS . 12.1 m -57.62 -111.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.479 -0.763 . . . . 0.0 109.951 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 1.1 t -119.6 -14.25 9.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.785 -1.197 . . . . 0.0 110.376 179.945 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.439 ' CE2' HG21 ' A' ' 324' ' ' VAL . 6.5 p-90 -126.66 -24.75 3.51 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.229 -0.919 . . . . 0.0 110.614 -179.846 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.463 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 0.3 OUTLIER -86.92 40.8 0.93 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.236 -0.915 . . . . 0.0 110.137 -179.898 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.453 ' HD3' ' O ' ' A' ' 324' ' ' VAL . 0.0 OUTLIER -112.33 -6.22 14.07 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.292 -0.88 . . . . 0.0 109.995 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.69 -143.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.801 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 47.5 Cg_endo -74.85 -49.52 0.15 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.05 1.553 . . . . 0.0 110.395 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 19.0 m -111.08 134.48 52.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.247 -0.908 . . . . 0.0 110.511 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.463 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -148.72 123.26 9.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.349 -0.845 . . . . 0.0 109.863 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.455 ' O ' ' HB2' ' A' ' 309' ' ' SER . 45.5 m -111.48 137.22 49.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 110.504 -179.826 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.594 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 13.2 p90 -145.45 174.59 11.01 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.483 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.21 159.14 28.05 Favored Glycine 0 N--CA 1.488 2.144 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.358 -179.397 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.688 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -144.98 146.24 31.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.572 -0.958 . . . . 0.0 109.781 179.686 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.546 ' N ' HD12 ' A' ' 337' ' ' ILE . 1.7 mp -121.03 125.66 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.175 -0.953 . . . . 0.0 110.091 -179.669 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.601 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.0 t -102.13 153.87 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.23 -0.918 . . . . 0.0 110.007 179.818 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.83 126.77 46.11 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.434 -0.791 . . . . 0.0 109.848 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -168.8 -125.57 0.8 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.442 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.2 Cg_endo -71.13 -158.38 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.864 1.455 . . . . 0.0 110.552 -179.899 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.548 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 3.0 mp0 -117.14 132.5 56.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.272 -0.892 . . . . 0.0 110.52 -179.707 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 113.87 -88.33 0.48 Allowed Glycine 0 N--CA 1.493 2.433 0 N-CA-C 108.986 -1.645 . . . . 0.0 108.986 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -114.6 151.27 33.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.374 -1.074 . . . . 0.0 108.817 179.057 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.581 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.7 mtmt -142.45 13.53 1.97 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.733 -1.229 . . . . 0.0 111.418 -179.577 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.584 HG13 ' CE1' ' A' ' 280' ' ' TYR . 11.2 p -136.66 119.17 20.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.065 -1.022 . . . . 0.0 110.316 179.238 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.32 -46.46 46.74 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.286 -0.884 . . . . 0.0 110.38 -179.653 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -177.02 158.37 1.54 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.242 -0.911 . . . . 0.0 110.479 -179.756 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.464 HG12 HG12 ' A' ' 296' ' ' VAL . 23.6 mt -121.08 118.81 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.842 -1.161 . . . . 0.0 110.523 179.939 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.57 156.24 25.03 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.336 -0.852 . . . . 0.0 110.121 179.819 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.551 ' CD1' HD23 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -115.49 125.7 53.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.289 -0.882 . . . . 0.0 110.033 179.909 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.479 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.5 tt0 -139.06 118.4 12.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.966 -1.084 . . . . 0.0 110.618 179.869 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.481 ' O ' ' N ' ' A' ' 356' ' ' GLN . 2.4 mt -94.58 115.8 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.077 -1.015 . . . . 0.0 110.376 179.502 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 37.34 31.47 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.597 -0.689 . . . . 0.0 111.159 179.741 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 110.53 4.53 28.47 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.535 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.481 ' N ' ' O ' ' A' ' 353' ' ' ILE . 2.6 mp0 -108.05 105.93 15.92 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.149 -1.207 . . . . 0.0 110.087 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.42 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 14.5 p -70.83 120.31 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.347 -0.845 . . . . 0.0 110.589 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.48 ' CG2' ' HB3' ' A' ' 262' ' ' PRO . 17.1 mm . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 117.978 -1.011 . . . . 0.0 110.172 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -73.3 175.85 10.01 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 O-C-N 123.985 1.519 . . . . 0.0 110.528 -179.974 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.51 ' CG2' ' O ' ' A' ' 258' ' ' THR . 1.2 t -67.12 124.49 23.21 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.311 -0.868 . . . . 0.0 110.135 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -133.71 104.37 11.94 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.213 -0.93 . . . . 0.0 110.319 -179.889 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.86 156.51 48.16 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 O-C-N 124.086 1.572 . . . . 0.0 110.431 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.412 HG21 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -72.79 141.78 82.56 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.151 -0.968 . . . . 0.0 110.35 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.429 ' CB ' HG21 ' A' ' 358' ' ' ILE . 46.9 Cg_endo -73.88 146.64 37.96 Favored 'Trans proline' 0 C--N 1.304 -1.803 0 O-C-N 124.08 1.569 . . . . 0.0 110.357 179.781 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.484 ' O ' ' CB ' ' A' ' 264' ' ' SER . 2.9 t -113.62 27.64 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.139 -0.976 . . . . 0.0 110.221 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.484 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.6 OUTLIER 171.04 79.76 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.26 -0.9 . . . . 0.0 110.668 179.925 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 119.08 175.81 16.21 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.262 179.456 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.562 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.1 159.68 38.16 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.497 -1.002 . . . . 0.0 109.985 179.843 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.506 ' C ' ' CD2' ' A' ' 267' ' ' LEU . 0.0 OUTLIER -147.99 122.59 9.82 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 110.586 -179.626 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.461 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 14.7 mt-10 -123.59 114.26 19.79 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.509 ' CG1' ' O ' ' A' ' 281' ' ' ASP . 62.1 t -111.84 146.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.984 -1.072 . . . . 0.0 112.164 -178.417 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.426 ' C ' HG23 ' A' ' 271' ' ' VAL . 2.9 tptt -130.68 157.21 43.4 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.844 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.523 HG11 ' CE2' ' A' ' 280' ' ' TYR . 89.6 t -142.66 147.02 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.317 -1.489 . . . . 0.0 112.112 -179.203 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.537 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -141.12 111.13 6.61 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.216 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.514 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -97.48 148.43 23.23 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.906 -1.121 . . . . 0.0 111.459 -178.526 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.579 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 37.7 p90 -134.52 20.21 3.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.59 -0.694 . . . . 0.0 109.903 179.459 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.471 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 85.91 -68.42 3.38 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.6 t -58.33 -24.02 58.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -1.206 . . . . 0.0 110.455 -179.838 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.9 179.73 43.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.917 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.564 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -134.5 143.49 47.49 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.309 -1.112 . . . . 0.0 110.245 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.579 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 5.4 mt-10 -96.82 146.55 24.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.332 -0.855 . . . . 0.0 110.178 -179.644 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.683 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 87.4 m-85 -143.32 81.53 1.71 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.414 -0.804 . . . . 0.0 110.539 -179.553 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.509 ' O ' ' CG1' ' A' ' 269' ' ' VAL . 2.0 t0 -66.28 154.03 41.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 110.124 179.57 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.6 HG12 ' CZ ' ' A' ' 334' ' ' PHE . 4.0 t -143.2 88.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.493 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.424 HG21 ' OG1' ' A' ' 333' ' ' THR . 8.8 m -85.93 115.38 23.51 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.294 -0.878 . . . . 0.0 109.376 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.552 HD23 ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.14 148.55 24.47 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.327 -0.858 . . . . 0.0 110.818 -178.921 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.562 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -131.15 106.34 8.28 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.492 -0.755 . . . . 0.0 110.316 -179.521 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.509 ' N ' ' O ' ' A' ' 330' ' ' PRO . 4.6 mt -121.03 169.25 10.67 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.648 -1.282 . . . . 0.0 109.801 179.447 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . 0.403 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -103.15 32.8 3.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 110.253 -179.856 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.552 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 163.79 -165.17 36.8 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.384 -1.389 . . . . 0.0 110.281 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.464 ' HG2' ' HA2' ' A' ' 329' ' ' GLY . 5.0 mm-40 -89.28 110.58 21.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.268 -1.137 . . . . 0.0 111.046 -179.447 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.552 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 7.9 m-85 -137.8 142.07 40.86 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.179 -0.951 . . . . 0.0 109.706 179.169 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.52 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 10.0 t70 -72.6 97.89 2.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.34 179.215 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.59 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 55.5 p-90 -97.32 112.32 24.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.272 -0.893 . . . . 0.0 110.383 -179.357 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.542 HG22 ' CG2' ' A' ' 322' ' ' THR . 4.1 m -105.78 113.87 27.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.359 -0.838 . . . . 0.0 110.043 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.481 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.6 t -96.61 111.1 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 110.047 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.488 ' HG3' HD13 ' A' ' 320' ' ' ILE . 23.1 ttpt -87.87 149.29 24.2 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.28 -0.888 . . . . 0.0 109.319 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.58 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 98.8 t -146.2 108.93 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 121.077 -1.014 . . . . 0.0 110.543 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.504 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 9.3 mmtm -70.13 135.41 49.14 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.112 -0.992 . . . . 0.0 109.228 179.585 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.585 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 88.4 mt -89.63 162.52 15.58 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.455 -0.778 . . . . 0.0 111.572 -178.879 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.549 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -69.48 177.47 1.23 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.756 -0.59 . . . . 0.0 109.759 179.358 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.499 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 42.7 Cg_endo -69.32 81.97 0.68 Allowed 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.735 1.387 . . . . 0.0 109.786 179.351 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.26 22.58 5.8 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.357 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.482 ' HB3' ' HB3' ' A' ' 299' ' ' ALA . . . -111.47 146.2 37.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.379 -1.071 . . . . 0.0 110.388 -179.623 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.529 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 5.4 p -149.86 145.74 26.73 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.274 -0.891 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.532 HG22 ' CG2' ' A' ' 319' ' ' VAL . 92.2 t -68.09 131.31 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.263 -0.898 . . . . 0.0 109.852 179.744 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.12 -28.83 2.11 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.475 ' O ' HD12 ' A' ' 337' ' ' ILE . 1.7 t -142.33 115.99 9.16 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.103 -1.233 . . . . 0.0 111.116 -179.635 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.491 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.1 p90 -131.52 178.33 6.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.376 -0.828 . . . . 0.0 109.365 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.55 ' CH2' HD11 ' A' ' 337' ' ' ILE . 1.2 p90 -167.91 160.7 12.47 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.872 -1.143 . . . . 0.0 111.073 -179.643 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.484 ' HB3' ' HA ' ' A' ' 334' ' ' PHE . 0.1 OUTLIER 57.81 23.61 9.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.496 -0.752 . . . . 0.0 110.881 179.789 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.491 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 146.79 1.0 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.301 -0.874 . . . . 0.0 110.074 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.532 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -82.48 119.74 24.59 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.168 -0.958 . . . . 0.0 109.283 179.46 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.518 ' CD ' HG12 ' A' ' 304' ' ' VAL . 1.6 ttpt -88.78 146.15 25.18 Favored 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.813 0.816 . . . . 0.0 110.657 -179.486 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.516 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -130.74 172.71 11.67 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.52 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.48 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 53.2 mt-10 -138.79 104.95 5.22 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.32 -0.863 . . . . 0.0 110.486 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.455 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -93.7 38.7 3.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.455 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 11.3 t-20 59.97 83.48 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.277 -1.131 . . . . 0.0 110.344 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.627 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.09 -2.71 55.13 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 179.709 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.627 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.1 m-85 -145.76 -167.58 2.75 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.349 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.54 HG12 ' CZ ' ' A' ' 321' ' ' PHE . 2.9 t -163.3 157.45 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.178 -0.952 . . . . 0.0 109.428 178.974 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.527 ' N ' HG11 ' A' ' 319' ' ' VAL . 11.1 mm -127.38 142.99 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.021 -179.641 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 47.8 m-85 -119.31 136.21 54.35 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.146 -0.971 . . . . 0.0 109.808 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.542 ' CG2' HG22 ' A' ' 293' ' ' THR . 1.3 p -138.48 169.98 11.4 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.792 -1.193 . . . . 0.0 110.122 -179.928 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.504 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.79 123.97 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.926 1.487 . . . . 0.0 111.09 -179.292 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.502 HG11 ' ND2' ' A' ' 311' ' ' ASN . 18.6 m -74.35 -116.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.499 -0.751 . . . . 0.0 110.135 -179.938 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -105.68 -32.55 8.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.709 -1.245 . . . . 0.0 110.808 -179.588 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 4.1 p-90 -116.34 -1.77 12.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.12 -0.987 . . . . 0.0 110.502 -179.778 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.493 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.27 50.01 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.107 -0.995 . . . . 0.0 109.79 179.796 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.475 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.1 OUTLIER -125.68 -2.6 7.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.376 -0.828 . . . . 0.0 109.716 -179.804 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.464 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -72.34 -143.91 0.48 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.735 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.509 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.2 Cg_endo -73.58 -53.73 0.12 Allowed 'Trans proline' 0 C--N 1.303 -1.838 0 O-C-N 124.166 1.614 . . . . 0.0 110.473 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.25 130.61 50.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.259 -0.901 . . . . 0.0 110.467 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.463 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -145.03 104.48 3.98 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.435 -0.791 . . . . 0.0 109.749 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.465 ' O ' ' HB3' ' A' ' 309' ' ' SER . 27.8 m -100.68 133.73 44.71 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.084 -1.01 . . . . 0.0 110.604 -179.61 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.6 ' CZ ' HG12 ' A' ' 282' ' ' VAL . 8.8 p90 -141.85 174.73 10.31 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.336 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.491 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.71 153.65 25.06 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.905 -1.617 . . . . 0.0 110.226 -179.542 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.683 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -138.72 146.73 41.85 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.468 -1.019 . . . . 0.0 109.794 179.354 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.55 HD11 ' CH2' ' A' ' 308' ' ' TRP . 1.7 mp -121.88 122.09 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.238 -0.914 . . . . 0.0 109.798 -179.891 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.585 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 10.0 t -99.89 154.08 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.1 -1.0 . . . . 0.0 110.644 -179.398 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -124.91 130.65 52.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.464 -0.772 . . . . 0.0 110.065 -179.96 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.74 -123.22 0.83 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.833 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.53 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.7 Cg_endo -68.62 174.99 7.66 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 123.856 1.451 . . . . 0.0 110.438 -179.944 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.498 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 21.4 mm-40 -99.2 127.29 45.15 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.176 -0.953 . . . . 0.0 110.532 -179.295 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.453 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 115.82 -87.09 0.43 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.24 140.72 44.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -1.118 . . . . 0.0 109.097 179.345 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.549 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER -139.03 13.27 2.65 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.822 -1.174 . . . . 0.0 111.281 -179.563 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.594 HG13 ' CE2' ' A' ' 280' ' ' TYR . 12.2 p -138.74 118.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.152 -0.968 . . . . 0.0 110.303 179.391 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.504 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 5.7 mt-10 -49.26 -48.45 45.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.415 -0.803 . . . . 0.0 110.368 -179.728 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.463 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.8 pt-20 -177.21 158.74 1.52 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.188 -0.945 . . . . 0.0 111.008 -179.852 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.506 HG12 ' CG1' ' A' ' 296' ' ' VAL . 57.0 mt -117.46 121.44 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.324 -0.86 . . . . 0.0 109.993 179.509 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.56 136.97 54.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.246 -0.909 . . . . 0.0 110.291 -179.792 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.552 ' CD1' HD23 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -95.98 127.85 42.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.196 -0.94 . . . . 0.0 110.378 179.966 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -139.39 113.02 8.43 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.16 -0.963 . . . . 0.0 110.399 179.746 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.472 HG12 ' HA ' ' A' ' 292' ' ' TRP . 2.3 mt -91.78 112.26 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.003 -1.061 . . . . 0.0 110.0 179.473 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.52 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 41.19 29.02 0.07 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.501 -0.749 . . . . 0.0 110.393 -179.69 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 113.15 -13.03 23.99 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.69 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.448 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 0.2 OUTLIER -88.6 110.86 21.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.306 -1.114 . . . . 0.0 110.431 -179.842 . . . . . . . . 3 3 . 1 . 022 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.518 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 5.3 p -68.66 119.33 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.172 -0.955 . . . . 0.0 110.171 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.476 ' CG2' ' O ' ' A' ' 358' ' ' ILE . 42.9 mm . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.268 -179.88 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -74.1 -178.65 4.03 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.98 1.516 . . . . 0.0 110.377 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.517 ' CG2' ' O ' ' A' ' 258' ' ' THR . 3.1 t -67.99 123.39 20.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -0.896 . . . . 0.0 109.988 179.83 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 259' ' ' THR . . . . . 0.406 ' O ' HG23 ' A' ' 259' ' ' THR . 5.4 t -131.16 144.15 52.31 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.163 -0.961 . . . . 0.0 110.497 -179.748 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -78.09 151.0 26.75 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.929 1.489 . . . . 0.0 110.479 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.45 ' CG2' ' HD2' ' A' ' 262' ' ' PRO . 3.5 p -103.85 145.14 30.07 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.265 -0.897 . . . . 0.0 110.071 179.764 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.53 ' HB3' ' CG2' ' A' ' 358' ' ' ILE . 50.3 Cg_endo -74.39 140.66 27.56 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.056 1.556 . . . . 0.0 110.399 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.535 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 63.6 t -110.06 23.96 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.148 -0.97 . . . . 0.0 110.011 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.524 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.4 OUTLIER 167.12 139.81 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.438 -0.789 . . . . 0.0 110.33 179.873 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 75.47 -179.46 46.15 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 179.716 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.555 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.1 158.41 44.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.535 -0.98 . . . . 0.0 109.431 179.754 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.55 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -157.32 141.34 16.13 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.943 -1.098 . . . . 0.0 110.93 -179.488 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -140.34 122.02 15.31 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.797 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.499 HG22 ' CD1' ' A' ' 267' ' ' LEU . 50.9 t -115.39 133.14 62.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.01 -1.056 . . . . 0.0 111.559 -178.934 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.432 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.3 OUTLIER -122.16 157.19 32.08 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.734 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.567 HG21 ' CD2' ' A' ' 280' ' ' TYR . 71.6 t -143.12 147.04 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.286 -1.509 . . . . 0.0 112.251 -178.879 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.24 113.93 8.75 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.706 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 17.6 p-10 -98.81 148.21 24.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.039 -1.038 . . . . 0.0 111.718 -178.098 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.531 ' CZ2' HG23 ' A' ' 337' ' ' ILE . 39.1 p90 -134.11 19.07 3.74 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.652 -0.655 . . . . 0.0 109.453 179.14 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.43 -65.83 3.91 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -58.48 -21.43 51.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -1.133 . . . . 0.0 110.255 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.531 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.35 -179.08 46.61 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.938 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.587 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -136.76 140.73 42.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.42 -1.047 . . . . 0.0 109.983 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.52 ' HG2' ' CG1' ' A' ' 337' ' ' ILE . 3.0 mt-10 -93.66 146.58 23.72 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.466 -0.771 . . . . 0.0 110.37 -179.534 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 91.0 m-85 -140.81 84.47 1.94 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.524 -0.735 . . . . 0.0 110.405 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.481 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.8 OUTLIER -67.24 151.75 46.95 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.418 -0.801 . . . . 0.0 109.487 179.208 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.598 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 5.6 t -145.72 88.6 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.564 -0.71 . . . . 0.0 109.615 -179.537 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.479 ' O ' ' HA ' ' A' ' 267' ' ' LEU . 88.6 m -87.01 123.83 32.54 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.081 -1.012 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.585 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.85 150.51 30.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 110.408 -179.76 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.555 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -134.1 115.86 14.76 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.376 -0.827 . . . . 0.0 110.103 -179.377 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.605 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 13.2 mt -124.09 154.88 39.32 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 120.759 -1.213 . . . . 0.0 110.454 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -89.9 37.22 0.88 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.248 -0.908 . . . . 0.0 109.786 179.627 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.61 -141.86 7.71 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.512 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 1.6 tp60 -111.67 92.62 4.1 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.162 -1.199 . . . . 0.0 110.489 -179.758 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.605 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.1 m-30 -116.93 129.99 56.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.268 -0.895 . . . . 0.0 110.074 179.396 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.515 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 1.5 m-20 -64.16 103.67 0.64 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.146 -0.972 . . . . 0.0 109.557 179.549 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.581 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 55.0 p-90 -101.95 109.32 21.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.189 -0.944 . . . . 0.0 110.391 -179.756 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.58 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 3.1 m -101.04 116.18 32.23 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.463 -0.773 . . . . 0.0 109.526 179.641 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.495 HG22 ' CD2' ' A' ' 351' ' ' LEU . 20.6 t -96.67 111.1 26.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 110.487 -179.378 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.476 ' HA ' HG12 ' A' ' 320' ' ' ILE . 22.8 ttpt -87.36 147.25 25.55 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.496 -0.752 . . . . 0.0 109.024 179.0 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.555 HG11 ' CG2' ' A' ' 346' ' ' VAL . 55.6 t -146.67 105.45 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 110.702 -178.981 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.48 ' O ' ' N ' ' A' ' 347' ' ' GLU . 26.4 mmtt -70.93 133.51 46.47 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.15 -0.969 . . . . 0.0 109.732 179.628 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.529 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 90.7 mt -86.31 162.44 18.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.323 -0.861 . . . . 0.0 111.573 -178.93 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.542 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -71.28 173.48 4.96 Favored Pre-proline 0 N--CA 1.488 1.441 0 O-C-N 121.582 -0.699 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.501 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -67.92 82.4 0.46 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 O-C-N 123.508 1.267 . . . . 0.0 109.932 179.531 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.63 25.71 3.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.424 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.484 ' HB3' ' HB1' ' A' ' 299' ' ' ALA . . . -117.79 148.45 42.05 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -1.113 . . . . 0.0 110.144 -179.748 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.529 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.4 p -149.82 144.52 26.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 110.239 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.599 ' CG1' ' CD ' ' A' ' 312' ' ' LYS . 38.2 t -63.99 119.9 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.232 -0.918 . . . . 0.0 109.886 179.767 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -105.95 -20.35 9.41 Favored Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.818 -1.182 . . . . 0.0 110.339 -179.392 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.489 ' O ' ' N ' ' A' ' 337' ' ' ILE . 42.2 t -154.8 134.28 12.64 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.983 -1.304 . . . . 0.0 110.889 -179.695 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.493 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -149.43 176.42 10.6 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.354 -0.841 . . . . 0.0 109.773 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.467 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -166.72 158.84 13.38 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.794 -1.191 . . . . 0.0 111.719 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.483 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.8 OUTLIER 59.4 26.08 14.92 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.667 -0.646 . . . . 0.0 111.407 179.363 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.524 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 140.89 0.65 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.17 -0.956 . . . . 0.0 109.936 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.5 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.34 114.14 15.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.078 -1.014 . . . . 0.0 109.586 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.599 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 1.9 ttpp -83.01 144.6 29.84 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.695 0.76 . . . . 0.0 110.691 -179.444 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.544 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -126.85 173.84 9.27 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.412 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.1 mm-40 -137.93 105.13 5.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.448 -0.782 . . . . 0.0 110.344 -179.931 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -97.17 35.78 4.27 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.442 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.4 OUTLIER 65.65 91.96 0.08 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -1.182 . . . . 0.0 110.135 -179.962 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.58 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 87.47 0.69 84.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.857 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.58 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.9 m-85 -143.28 -172.75 3.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.339 -1.095 . . . . 0.0 109.654 179.629 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.544 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 3.7 t -163.46 152.52 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.575 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.58 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 68.8 mt -131.99 132.17 61.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.648 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 70.8 m-85 -104.76 141.47 36.42 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.374 -0.829 . . . . 0.0 110.748 -179.725 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.503 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 0.9 OUTLIER -137.05 171.02 9.3 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 120.969 -1.082 . . . . 0.0 110.143 179.762 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.532 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.3 Cg_endo -67.29 114.68 3.33 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 O-C-N 123.822 1.433 . . . . 0.0 110.986 -179.461 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.53 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 7.3 m -65.44 -134.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.464 -0.773 . . . . 0.0 109.894 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.479 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 0.7 OUTLIER -92.09 -14.73 28.78 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.021 -1.049 . . . . 0.0 110.602 -179.697 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.463 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 26.4 p-90 -136.06 15.97 3.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.241 -0.912 . . . . 0.0 110.444 -179.841 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.53 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.5 OUTLIER -116.24 31.17 6.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.097 -1.002 . . . . 0.0 110.8 -179.481 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.497 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -114.6 -6.47 12.78 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.244 -0.91 . . . . 0.0 109.801 179.539 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.1 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.869 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.529 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 50.2 Cg_endo -75.42 5.75 4.0 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.04 1.547 . . . . 0.0 110.987 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.474 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.7 m -165.36 121.64 1.41 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 120.96 -1.087 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -143.44 112.74 6.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.139 -0.975 . . . . 0.0 110.446 -179.894 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.483 ' O ' ' HB2' ' A' ' 309' ' ' SER . 87.9 m -103.04 139.05 39.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.407 -0.808 . . . . 0.0 110.009 179.864 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.598 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 17.7 p90 -144.72 172.77 12.54 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.403 -0.81 . . . . 0.0 108.834 179.566 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.37 160.01 28.37 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 118.954 -1.594 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.679 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.0 OUTLIER -145.33 146.4 31.59 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.582 -0.952 . . . . 0.0 109.63 179.237 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.535 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.7 mp -120.85 120.25 61.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.836 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.534 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 6.0 t -96.74 146.3 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.13 -0.981 . . . . 0.0 110.621 -179.519 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -120.02 131.9 55.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.49 -0.756 . . . . 0.0 110.219 -179.935 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.18 -134.09 2.01 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.912 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.496 ' C ' ' NE2' ' A' ' 342' ' ' GLN . 45.9 Cg_endo -71.08 -170.31 0.47 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 123.926 1.487 . . . . 0.0 110.287 -179.723 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.496 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 20.8 mm-40 -107.62 149.08 28.49 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.144 -0.973 . . . . 0.0 110.255 -179.595 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.425 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 92.51 72.85 1.22 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 -179.863 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.425 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 1.0 OUTLIER 64.04 147.55 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.249 -1.148 . . . . 0.0 109.369 -179.48 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.542 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 2.0 mtmt -142.01 18.23 2.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.904 -1.123 . . . . 0.0 111.1 -179.762 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.592 HG13 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -130.77 122.45 52.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.126 -0.984 . . . . 0.0 110.18 179.22 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.48 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -51.83 -45.45 63.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -0.941 . . . . 0.0 110.16 -179.703 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.456 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 6.9 pt-20 -177.03 158.27 1.52 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.253 -0.904 . . . . 0.0 110.324 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.411 HG23 HG21 ' A' ' 269' ' ' VAL . 11.5 mt -118.11 110.31 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.318 -0.864 . . . . 0.0 110.055 179.904 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.45 149.47 29.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.949 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.585 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -113.6 127.25 56.0 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.228 -0.92 . . . . 0.0 109.509 179.252 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.421 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 15.4 pt-20 -138.31 118.78 13.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.135 -0.978 . . . . 0.0 110.086 -179.797 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.515 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -97.73 104.7 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.197 -0.939 . . . . 0.0 110.351 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.488 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 1.5 m-80 35.16 30.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.057 0.455 . . . . 0.0 111.073 179.805 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 133.61 -43.41 1.27 Allowed Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.276 179.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.488 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 35.2 mm-40 -73.97 120.71 19.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.124 -1.221 . . . . 0.0 110.627 -179.505 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.499 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 12.9 p -91.3 111.51 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.066 -1.022 . . . . 0.0 110.08 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.53 ' CG2' ' HB3' ' A' ' 262' ' ' PRO . 9.4 mm . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.187 -179.837 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -74.06 -178.31 3.79 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.999 1.526 . . . . 0.0 110.656 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.445 ' O ' HG22 ' A' ' 258' ' ' THR . 5.0 t -70.44 134.97 48.3 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.477 -0.764 . . . . 0.0 110.378 -179.9 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 34.1 p -85.12 129.88 54.24 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.206 -0.934 . . . . 0.0 110.124 179.892 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -71.94 133.76 22.26 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.899 1.473 . . . . 0.0 110.398 179.946 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.423 HG21 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -73.66 138.31 77.2 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.343 -0.848 . . . . 0.0 110.44 -179.812 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.458 ' HA ' ' HA ' ' A' ' 358' ' ' ILE . 50.7 Cg_endo -78.46 143.82 19.67 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 124.172 1.617 . . . . 0.0 110.493 -179.993 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 3.6 t -139.07 29.7 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.252 -0.905 . . . . 0.0 110.107 179.676 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.402 ' HB3' ' CD1' ' A' ' 358' ' ' ILE . 12.3 t -163.27 69.07 0.21 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 110.68 179.915 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . 0.441 ' HA3' HD21 ' A' ' 286' ' ' LEU . . . 108.09 -163.51 12.9 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 179.425 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.493 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.92 169.28 18.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.53 -0.983 . . . . 0.0 109.729 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.582 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.7 tm? -161.77 133.34 5.44 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.039 -1.038 . . . . 0.0 111.396 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.528 ' N ' HD21 ' A' ' 267' ' ' LEU . 0.3 OUTLIER -129.76 138.38 51.05 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.404 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.468 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 49.0 t -131.54 134.04 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.869 -1.145 . . . . 0.0 111.653 -179.3 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.24 157.08 29.89 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.705 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.574 HG22 ' CD1' ' A' ' 280' ' ' TYR . 75.7 t -141.26 145.34 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.494 -1.378 . . . . 0.0 111.879 -179.392 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.57 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.15 110.17 8.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.666 -0.646 . . . . 0.0 109.825 179.631 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.436 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.8 m-20 -96.39 128.41 43.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.167 -0.958 . . . . 0.0 111.102 -179.412 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.585 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 29.0 p90 -113.17 16.59 19.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.879 . . . . 0.0 109.762 178.995 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.06 -59.0 3.93 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.45 -22.01 63.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -1.143 . . . . 0.0 110.18 179.858 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.583 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.78 -178.39 40.29 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.821 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -136.56 139.37 42.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.339 -1.095 . . . . 0.0 110.167 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.585 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 3.6 mt-10 -93.58 147.53 22.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.508 -0.745 . . . . 0.0 110.11 -179.511 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.3 m-85 -141.75 82.16 1.8 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.279 -0.888 . . . . 0.0 110.432 -179.661 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.468 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.6 m-20 -67.38 146.01 54.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.509 -0.745 . . . . 0.0 109.695 179.557 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.61 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 4.8 t -139.12 88.78 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 109.931 -179.738 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 25.9 m -86.04 125.35 33.36 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.058 -1.026 . . . . 0.0 109.218 179.746 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.602 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -112.06 153.7 26.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.109 -0.994 . . . . 0.0 110.882 -179.072 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.539 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.4 OUTLIER -131.63 128.37 38.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.474 -0.766 . . . . 0.0 110.162 -179.582 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.584 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.8 mt -143.69 157.09 44.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.771 -1.206 . . . . 0.0 109.938 179.862 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -94.38 35.7 1.19 Allowed 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.401 -0.812 . . . . 0.0 109.732 179.526 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.487 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 162.21 -174.61 38.66 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.908 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.49 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mt-30 -83.93 96.3 8.78 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.308 -1.113 . . . . 0.0 110.406 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.584 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.74 153.38 32.51 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.227 -0.92 . . . . 0.0 109.749 179.586 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.543 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 53.9 m-20 -82.85 95.74 8.03 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.328 179.327 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.593 ' CZ2' ' HB2' ' A' ' 332' ' ' ALA . 55.5 p-90 -97.13 116.42 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 110.226 -179.737 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.517 ' CG2' HG22 ' A' ' 322' ' ' THR . 1.9 m -111.03 114.07 27.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.541 -0.724 . . . . 0.0 109.93 -179.83 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.529 HG22 ' CD2' ' A' ' 351' ' ' LEU . 3.4 t -96.2 111.33 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.097 -1.002 . . . . 0.0 110.205 -179.689 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.44 ' C ' HG21 ' A' ' 296' ' ' VAL . 27.3 ttmt -86.63 149.81 24.65 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.368 -0.833 . . . . 0.0 109.622 179.361 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.568 HG12 ' CG2' ' A' ' 346' ' ' VAL . 54.5 t -147.69 109.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.117 -0.99 . . . . 0.0 110.599 -179.575 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.548 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 51.9 mmtt -72.6 141.42 48.37 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.107 -0.996 . . . . 0.0 109.591 179.441 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.565 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 81.2 mt -94.03 156.2 16.72 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.26 -0.9 . . . . 0.0 111.481 -179.059 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.52 ' HB2' ' HD2' ' A' ' 300' ' ' PRO . . . -65.27 174.45 1.4 Allowed Pre-proline 0 C--N 1.303 -1.442 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.961 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.52 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 42.8 Cg_endo -68.74 83.42 0.53 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.531 1.28 . . . . 0.0 109.848 179.65 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.37 4.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 -179.468 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.507 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -114.69 149.41 36.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.298 -1.119 . . . . 0.0 109.753 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.538 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 18.6 p -150.69 143.46 24.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.062 . . . . 0.0 111.214 -179.796 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.535 ' CG2' ' CG2' ' A' ' 319' ' ' VAL . 58.6 t -70.89 116.46 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.56 -0.713 . . . . 0.0 110.013 179.515 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.43 -38.49 3.48 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.82 -1.181 . . . . 0.0 110.359 -179.264 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.414 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -129.94 140.33 50.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.004 -1.292 . . . . 0.0 111.139 -179.457 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.575 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 13.1 p90 -152.88 160.96 43.1 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 109.577 179.334 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -155.38 155.18 33.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.902 -1.124 . . . . 0.0 111.394 -179.48 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.466 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.9 OUTLIER 63.11 26.8 15.5 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 111.337 179.373 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.509 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.29 148.6 1.29 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.049 -1.032 . . . . 0.0 110.805 179.573 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 2.1 m-80 -77.59 114.02 16.01 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 179.259 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.575 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 23.3 ttpt -89.51 122.45 32.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.435 -0.791 . . . . 0.0 110.831 -179.57 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.568 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.9 OUTLIER -111.87 177.54 4.61 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.518 -0.739 . . . . 0.0 109.284 179.008 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 4.9 mt-10 -137.26 105.14 5.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.278 -0.889 . . . . 0.0 110.286 179.593 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.57 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -92.22 47.19 2.63 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.755 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 55.21 78.97 0.16 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.126 -1.22 . . . . 0.0 110.376 179.818 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.621 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.86 3.68 58.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 179.697 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.621 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.9 m-85 -144.85 -172.63 3.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.42 -1.047 . . . . 0.0 109.061 179.545 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.535 ' CG2' ' CG2' ' A' ' 304' ' ' VAL . 12.1 t -158.89 150.08 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.988 -1.07 . . . . 0.0 110.286 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.568 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 6.4 mm -114.96 151.85 16.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.104 -0.998 . . . . 0.0 110.687 -179.656 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 35.0 m-85 -131.74 112.2 12.32 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.199 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.54 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 1.7 p -113.22 -176.46 0.38 Allowed Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 120.374 -1.454 . . . . 0.0 109.591 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.54 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 45.6 Cg_endo -77.63 117.44 4.28 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.446 1.235 . . . . 0.0 111.458 -178.502 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.507 HG11 ' CA ' ' A' ' 310' ' ' ALA . 3.7 m -53.58 -105.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.424 -0.797 . . . . 0.0 110.592 179.905 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.448 ' O ' ' HE3' ' A' ' 328' ' ' LYS . 14.5 m -133.79 -12.37 2.61 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.691 -1.256 . . . . 0.0 111.428 -179.448 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.609 ' CE3' ' HB3' ' A' ' 327' ' ' ASN . 2.0 p-90 -126.47 -25.6 3.43 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.776 -1.202 . . . . 0.0 111.228 -179.586 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.609 ' HB3' ' CE3' ' A' ' 326' ' ' TRP . 0.0 OUTLIER -96.0 36.66 1.29 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.762 -1.211 . . . . 0.0 110.963 -179.697 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.49 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -99.71 -6.23 27.46 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.157 -0.964 . . . . 0.0 108.736 178.179 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.469 ' HA2' ' HA ' ' A' ' 289' ' ' GLN . . . -61.55 -138.38 0.01 OUTLIER Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.474 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.541 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.0 Cg_endo -73.01 -54.62 0.11 Allowed 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 124.205 1.634 . . . . 0.0 111.054 -179.721 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -102.61 140.25 37.13 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.156 -0.965 . . . . 0.0 110.77 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.593 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -152.26 107.77 3.31 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 53.8 m -105.41 135.9 45.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.907 -1.121 . . . . 0.0 110.166 179.67 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.61 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 13.0 p90 -145.32 174.6 10.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.631 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.509 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.26 158.08 27.75 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.659 -1.734 . . . . 0.0 110.435 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.684 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.9 OUTLIER -143.42 146.5 33.51 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.669 -0.901 . . . . 0.0 109.33 179.252 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.539 HG23 ' CZ2' ' A' ' 274' ' ' TRP . 1.6 mp -119.74 121.31 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.968 -1.083 . . . . 0.0 109.831 179.904 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.565 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.5 t -96.6 145.92 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.184 -0.947 . . . . 0.0 109.634 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -121.33 135.43 55.09 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 110.905 -179.234 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.26 -134.33 2.06 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.735 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.508 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.4 Cg_endo -71.33 -155.82 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.877 1.461 . . . . 0.0 110.275 179.728 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.565 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -126.13 128.44 47.32 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.965 -1.085 . . . . 0.0 110.202 -179.852 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 117.69 61.95 0.3 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 -179.825 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 10.4 t0 70.24 132.74 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.38 -1.071 . . . . 0.0 108.966 -179.066 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.531 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER -135.06 19.82 3.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.836 -1.165 . . . . 0.0 111.187 -179.098 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.58 HG11 ' CE1' ' A' ' 280' ' ' TYR . 7.4 p -126.53 119.05 52.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.911 -1.118 . . . . 0.0 110.241 179.378 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.474 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 4.1 mm-40 -49.67 -44.56 47.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -0.91 . . . . 0.0 110.523 -179.533 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.456 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.1 pt-20 -176.68 158.85 1.76 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.09 -1.006 . . . . 0.0 110.718 -179.713 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.478 ' CG2' HG22 ' A' ' 296' ' ' VAL . 29.6 mt -124.42 110.17 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.095 -1.003 . . . . 0.0 110.228 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.67 160.05 19.8 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.415 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.602 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.52 129.72 54.83 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.906 . . . . 0.0 110.554 -179.903 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.461 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.9 tt0 -139.32 118.35 12.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.824 . . . . 0.0 109.456 179.405 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.543 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.08 100.66 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.892 -1.13 . . . . 0.0 110.399 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.432 ' C ' ' O ' ' A' ' 353' ' ' ILE . 0.9 OUTLIER 38.27 40.08 0.32 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.949 -0.47 . . . . 0.0 111.396 179.492 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.44 ' O ' ' CD ' ' A' ' 356' ' ' GLN . . . 113.06 23.37 5.27 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.793 179.056 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.477 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 6.2 mm100 -141.46 101.47 4.0 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.015 -1.285 . . . . 0.0 110.238 179.661 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.498 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 8.5 p -65.7 136.35 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.252 -0.905 . . . . 0.0 110.552 -179.827 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.465 HD11 ' O ' ' A' ' 357' ' ' VAL . 22.9 mm . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.215 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.8 179.45 5.65 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.967 1.509 . . . . 0.0 110.432 -179.846 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 5.0 t -59.42 134.72 57.26 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.299 -0.876 . . . . 0.0 110.043 -179.903 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.4 t -119.12 101.61 49.59 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.139 -0.976 . . . . 0.0 110.586 -179.704 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.6 142.52 26.19 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.892 1.469 . . . . 0.0 109.969 179.716 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.417 ' CG2' ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -68.91 144.51 95.85 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.047 -1.033 . . . . 0.0 110.319 -179.806 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.539 ' CB ' HG22 ' A' ' 358' ' ' ILE . 46.0 Cg_endo -73.87 154.8 48.55 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.128 1.594 . . . . 0.0 110.417 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.507 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 90.9 t -139.49 28.91 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.308 -0.87 . . . . 0.0 110.105 179.799 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -179.83 91.1 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.24 -0.912 . . . . 0.0 110.72 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.32 -170.07 22.12 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.254 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.564 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -138.6 165.86 25.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.602 -0.94 . . . . 0.0 109.593 179.908 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.555 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.1 tm? -161.63 141.35 10.25 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.94 -1.104 . . . . 0.0 111.436 -179.554 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.49 ' CG ' ' HB ' ' A' ' 283' ' ' THR . 0.2 OUTLIER -139.48 149.5 44.06 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.853 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 39.8 t -138.19 137.9 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.694 -1.254 . . . . 0.0 111.654 -179.337 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.439 ' C ' HG22 ' A' ' 271' ' ' VAL . 3.2 mmtp -125.27 156.93 37.81 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.111 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.558 HG23 ' CD2' ' A' ' 280' ' ' TYR . 69.1 t -145.07 145.84 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 120.374 -1.454 . . . . 0.0 112.15 -179.193 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.533 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.8 112.56 7.59 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.796 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.52 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.1 p-10 -97.37 144.84 26.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.955 -1.091 . . . . 0.0 111.602 -178.338 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.535 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 36.1 p90 -129.9 21.54 5.41 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.472 0.654 . . . . 0.0 109.681 179.281 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.503 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 87.24 -68.53 3.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.495 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 8.1 t -56.93 -23.73 47.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.144 -1.209 . . . . 0.0 110.35 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . . . . . . . . . . . -174.46 -170.02 37.19 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.387 -1.387 . . . . 0.0 109.987 179.918 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.585 ' HB3' ' CZ ' ' A' ' 280' ' ' TYR . . . -141.88 143.78 33.5 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.337 -1.096 . . . . 0.0 110.514 -179.905 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.541 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 4.4 mt-10 -94.87 147.34 23.47 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.412 -0.805 . . . . 0.0 109.904 -179.853 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.658 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 88.1 m-85 -142.91 90.27 2.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.396 -0.815 . . . . 0.0 110.514 -179.63 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.464 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -74.16 153.02 39.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.365 -0.835 . . . . 0.0 110.117 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.6 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.3 t -145.12 90.61 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.83 -179.665 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.503 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 7.5 m -87.04 122.61 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 0.0 110.457 -179.746 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.609 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.4 OUTLIER -108.14 151.09 26.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 110.122 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.564 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -134.58 106.57 7.06 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.211 -0.93 . . . . 0.0 110.646 -179.036 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.605 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.6 mt -113.07 173.9 6.16 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.666 -1.272 . . . . 0.0 110.006 179.671 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -109.5 30.19 6.87 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.434 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 170.19 -102.79 0.18 Allowed Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.357 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.471 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.1 OUTLIER -150.7 105.38 3.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -1.181 . . . . 0.0 110.463 -179.395 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.605 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -136.33 132.74 36.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 110.025 179.596 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.46 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 0.2 OUTLIER -61.04 100.25 0.11 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.289 -0.882 . . . . 0.0 109.366 179.337 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.607 ' CZ2' ' CB ' ' A' ' 332' ' ' ALA . 56.4 p-90 -98.34 111.07 23.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.345 -0.847 . . . . 0.0 110.447 -179.637 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.546 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 4.4 m -105.37 114.58 28.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.46 HG21 ' CE2' ' A' ' 334' ' ' PHE . 3.5 t -96.92 110.74 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.145 -0.972 . . . . 0.0 110.085 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.482 ' HG3' HD12 ' A' ' 320' ' ' ILE . 18.8 ttpt -87.41 149.01 24.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.227 -0.92 . . . . 0.0 109.362 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.576 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 71.0 t -145.78 110.53 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.193 -0.942 . . . . 0.0 110.745 -179.325 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.515 ' O ' ' CG2' ' A' ' 346' ' ' VAL . 29.3 mmtp -71.51 132.71 45.1 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.246 -0.909 . . . . 0.0 109.73 179.343 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.569 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 83.0 mt -85.42 159.06 20.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.375 -0.828 . . . . 0.0 111.445 -179.036 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.548 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -62.94 174.77 0.77 Allowed Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.699 -0.626 . . . . 0.0 109.454 179.08 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.488 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -69.4 78.88 0.86 Allowed 'Trans proline' 0 C--N 1.304 -1.812 0 O-C-N 123.575 1.303 . . . . 0.0 109.754 179.451 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.19 24.58 3.81 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.166 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.522 ' CB ' ' HB2' ' A' ' 299' ' ' ALA . . . -112.22 152.93 27.84 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -1.152 . . . . 0.0 110.338 -179.479 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.521 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 21.5 p -153.31 143.61 22.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.235 -0.915 . . . . 0.0 110.502 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.529 ' CG1' ' HD2' ' A' ' 312' ' ' LYS . 76.4 t -64.72 139.75 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.463 -0.773 . . . . 0.0 110.215 179.881 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . 0.467 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -123.28 -33.69 0.81 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.47 ' O ' HD13 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -138.23 124.42 20.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -1.19 . . . . 0.0 110.98 -179.667 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.552 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 52.9 p90 -141.08 156.37 46.0 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.323 -0.861 . . . . 0.0 109.714 179.362 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -150.0 157.31 43.02 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.955 -1.091 . . . . 0.0 111.368 -179.288 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.494 ' HB3' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 64.57 21.66 12.48 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.609 -0.682 . . . . 0.0 110.906 179.803 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.514 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 150.2 1.35 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.272 -0.893 . . . . 0.0 110.394 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -83.84 125.34 31.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.119 -0.988 . . . . 0.0 109.586 179.485 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.552 ' HD3' ' CD2' ' A' ' 307' ' ' PHE . 3.7 ttpt -92.85 135.91 33.72 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.838 0.828 . . . . 0.0 110.751 -179.582 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.683 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.3 OUTLIER -122.37 179.46 4.56 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.63 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.413 ' HG2' HG21 ' A' ' 319' ' ' VAL . 3.5 mt-10 -142.49 113.07 7.31 Favored 'General case' 0 N--CA 1.492 1.634 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.444 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.09 49.71 1.05 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.83 79.37 0.2 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -1.167 . . . . 0.0 110.093 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.595 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.95 5.34 66.24 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.778 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.595 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 5.4 m-85 -138.88 -174.31 3.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.401 -1.058 . . . . 0.0 109.167 179.449 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 5.7 t -163.14 156.96 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.287 -0.883 . . . . 0.0 109.767 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.683 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 12.8 mm -127.08 148.91 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.074 -1.016 . . . . 0.0 111.361 -179.946 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.675 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 86.0 m-85 -124.85 122.01 36.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.446 -0.784 . . . . 0.0 109.703 179.01 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.521 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 5.5 p -124.52 169.01 11.59 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 120.738 -1.226 . . . . 0.0 109.953 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.533 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 37.3 Cg_endo -63.89 112.38 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.769 1.405 . . . . 0.0 111.415 -179.319 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.534 HG22 ' ND2' ' A' ' 327' ' ' ASN . 3.6 m -50.4 -58.24 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.545 -0.722 . . . . 0.0 110.746 179.74 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 178.65 -26.11 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.081 -1.012 . . . . 0.0 110.947 179.97 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.505 ' NE1' HG21 ' A' ' 324' ' ' VAL . 6.3 p-90 -110.43 -27.03 9.22 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.853 -1.154 . . . . 0.0 110.98 -179.79 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.551 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 0.0 OUTLIER -83.34 14.56 3.52 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 120.979 -1.076 . . . . 0.0 111.06 179.934 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.471 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 11.4 mtmt -77.12 -8.58 57.74 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.174 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.18 -153.14 0.01 OUTLIER Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 -179.322 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -76.12 9.61 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 124.267 1.667 . . . . 0.0 111.153 -179.581 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.47 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.5 m -164.87 135.15 3.86 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.607 ' CB ' ' CZ2' ' A' ' 292' ' ' TRP . . . -147.87 104.19 3.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.171 -0.956 . . . . 0.0 110.378 -179.463 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.503 ' OG1' ' CG2' ' A' ' 283' ' ' THR . 4.8 m -101.12 133.22 45.98 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.287 -0.883 . . . . 0.0 110.313 179.883 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.601 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 24.2 p90 -144.2 168.21 20.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 108.957 179.553 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -141.65 165.3 26.5 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.078 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.675 ' CB ' ' CZ ' ' A' ' 321' ' ' PHE . 0.5 OUTLIER -150.52 143.88 24.98 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.689 -0.889 . . . . 0.0 109.379 179.191 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.543 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.7 mp -119.51 118.79 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.028 -1.045 . . . . 0.0 110.223 -179.67 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.569 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.7 t -97.64 153.18 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.163 -0.96 . . . . 0.0 110.153 -179.795 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.428 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.56 131.65 53.93 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 110.212 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.89 -125.35 0.95 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.54 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.9 Cg_endo -66.58 -158.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.532 0 O-C-N 123.821 1.432 . . . . 0.0 111.117 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.516 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 1.2 mp0 -117.8 131.37 56.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.23 -0.919 . . . . 0.0 111.23 -179.055 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 98.18 -86.4 0.78 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.189 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -101.74 124.24 47.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.299 -1.118 . . . . 0.0 109.828 -179.882 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.548 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -127.64 10.26 6.6 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.119 -0.988 . . . . 0.0 110.275 -179.987 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.595 HG13 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -134.7 117.09 22.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.406 -0.809 . . . . 0.0 110.13 179.739 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.466 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -45.66 -45.84 14.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 110.455 -179.61 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.468 ' OE2' ' HG3' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -176.79 158.71 1.68 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.072 -1.017 . . . . 0.0 110.673 -179.713 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.475 HG12 ' CG1' ' A' ' 296' ' ' VAL . 65.1 mt -120.76 119.39 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.118 -0.989 . . . . 0.0 110.304 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.33 159.89 24.12 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.341 -0.85 . . . . 0.0 110.173 179.99 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.609 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -120.99 129.7 53.52 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.887 . . . . 0.0 110.361 -179.852 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.461 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -139.29 122.87 17.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.13 -0.981 . . . . 0.0 110.103 179.58 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.473 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 1.2 mt -97.15 106.16 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.031 -1.043 . . . . 0.0 109.742 179.474 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.46 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 41.06 29.25 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.565 -0.71 . . . . 0.0 110.649 -179.752 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.81 -22.83 7.17 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.363 179.379 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.473 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 40.5 mm-40 -87.96 110.95 20.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.004 -1.292 . . . . 0.0 110.552 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.469 ' O ' HD11 ' A' ' 358' ' ' ILE . 6.2 p -76.81 142.02 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.284 -0.885 . . . . 0.0 110.527 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.539 HG22 ' CB ' ' A' ' 262' ' ' PRO . 11.5 mm . . . . . 0 N--CA 1.494 1.729 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.139 179.801 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -73.81 -178.71 3.97 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 123.995 1.523 . . . . 0.0 110.454 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.532 ' CG2' ' O ' ' A' ' 258' ' ' THR . 6.5 t -58.81 119.02 6.39 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.252 -0.905 . . . . 0.0 110.107 179.9 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -102.0 154.6 37.24 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.173 -0.954 . . . . 0.0 110.268 -179.847 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.9 Cg_endo -74.0 148.27 39.93 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.101 1.579 . . . . 0.0 110.16 179.886 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.467 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.2 p -81.24 140.66 49.19 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.08 -1.012 . . . . 0.0 110.394 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.486 ' CB ' HG23 ' A' ' 358' ' ' ILE . 45.9 Cg_endo -76.17 146.36 28.53 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 124.06 1.558 . . . . 0.0 109.981 179.582 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 12.4 t -141.64 30.19 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.292 -0.88 . . . . 0.0 110.067 -179.88 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 26.4 t -163.63 83.02 0.46 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.315 -0.865 . . . . 0.0 110.637 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 104.29 -167.93 16.19 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.517 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.574 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.3 OUTLIER -139.53 164.4 30.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.401 -1.058 . . . . 0.0 109.765 179.848 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.538 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.0 tm? -161.31 133.76 6.0 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.047 -1.033 . . . . 0.0 111.003 -179.044 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -136.77 131.45 33.4 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.532 -0.73 . . . . 0.0 109.242 179.476 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.46 ' CG1' ' O ' ' A' ' 281' ' ' ASP . 89.4 t -126.38 143.11 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.79 -1.194 . . . . 0.0 111.653 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.451 ' N ' HG13 ' A' ' 269' ' ' VAL . 1.7 ttpt -126.98 157.38 39.69 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.996 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.583 ' CG2' ' CD1' ' A' ' 280' ' ' TYR . 91.7 t -139.74 146.97 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.298 -1.501 . . . . 0.0 112.375 -179.171 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.542 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.2 109.43 6.46 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.127 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 p30 -96.14 146.75 24.41 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.008 -1.057 . . . . 0.0 111.189 -178.863 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.588 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 35.4 p90 -132.02 17.85 4.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.777 179.32 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.5 -62.78 4.0 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.947 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.439 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.4 t -63.68 -21.24 66.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.383 -1.069 . . . . 0.0 110.239 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -174.31 179.92 45.34 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.543 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.22 141.19 47.93 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.352 -1.087 . . . . 0.0 110.245 179.941 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.588 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 9.3 mt-10 -96.84 147.65 23.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.346 -0.846 . . . . 0.0 110.159 -179.683 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.655 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 98.1 m-85 -143.51 90.2 2.14 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.214 -0.929 . . . . 0.0 110.84 -179.776 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.46 ' O ' ' CG1' ' A' ' 269' ' ' VAL . 6.6 t0 -70.87 152.75 43.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.384 -0.823 . . . . 0.0 109.555 179.237 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.644 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 2.9 t -147.26 89.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 110.205 -179.535 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.448 HG23 ' OG1' ' A' ' 333' ' ' THR . 93.1 m -86.97 121.96 30.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.08 -1.013 . . . . 0.0 109.615 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.594 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -109.7 150.89 27.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 110.754 -179.323 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.574 ' ND2' ' HB3' ' A' ' 266' ' ' SER . 0.4 OUTLIER -131.25 137.06 48.72 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.468 -0.77 . . . . 0.0 109.934 -179.767 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.585 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 16.8 mt -142.32 159.87 41.37 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.926 -1.109 . . . . 0.0 109.513 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.61 34.66 0.82 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.296 -0.877 . . . . 0.0 110.458 -179.538 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.474 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 153.3 -97.47 0.17 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.052 -1.546 . . . . 0.0 110.358 179.902 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.474 ' HG2' ' O ' ' A' ' 288' ' ' GLY . 11.7 mm-40 -144.3 105.26 4.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.25 -1.147 . . . . 0.0 110.561 -179.577 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.616 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 4.4 m-85 -128.9 130.29 46.63 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.338 -0.851 . . . . 0.0 109.671 179.645 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.464 ' O ' HG23 ' A' ' 353' ' ' ILE . 42.5 m-20 -65.61 100.11 0.49 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.782 -1.199 . . . . 0.0 109.084 179.19 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.593 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 57.4 p-90 -100.12 109.67 21.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 111.127 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.556 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 2.0 m -103.78 114.83 29.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.466 -0.772 . . . . 0.0 109.108 179.003 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.483 HG21 ' CD2' ' A' ' 351' ' ' LEU . 3.3 t -95.95 111.31 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 110.568 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.453 ' O ' HG23 ' A' ' 296' ' ' VAL . 5.7 ttpt -85.71 145.16 27.41 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.471 -0.768 . . . . 0.0 109.327 179.17 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.563 HG11 ' CG2' ' A' ' 346' ' ' VAL . 79.7 t -144.36 106.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 110.177 -179.49 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 347' ' ' GLU . 43.4 mmtt -70.02 133.9 47.71 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.108 -0.995 . . . . 0.0 109.168 179.537 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.555 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 66.8 mt -90.32 157.24 17.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 111.392 -178.826 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.497 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.22 173.25 2.35 Favored Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.806 -0.558 . . . . 0.0 109.533 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.489 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.15 83.52 0.35 Allowed 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.621 1.327 . . . . 0.0 109.826 179.627 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.6 21.14 5.87 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -179.359 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.531 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -113.29 140.89 47.61 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.33 -1.1 . . . . 0.0 109.951 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.476 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 22.2 p -145.2 146.11 31.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.958 . . . . 0.0 110.628 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.519 HG21 ' CB ' ' A' ' 319' ' ' VAL . 53.3 t -70.11 122.82 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.148 -0.97 . . . . 0.0 109.958 179.695 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.08 -28.32 4.19 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.034 -1.226 . . . . 0.0 110.034 -179.592 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.45 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 49.4 m -137.46 130.26 30.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.973 -1.31 . . . . 0.0 110.85 -179.637 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.533 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 50.2 p90 -150.38 160.09 43.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.491 -0.756 . . . . 0.0 109.512 179.369 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.466 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -151.85 159.46 43.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.89 -1.131 . . . . 0.0 111.284 -179.333 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.487 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.9 OUTLIER 56.91 28.34 14.46 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.617 -0.677 . . . . 0.0 110.683 179.855 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.53 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.11 138.23 0.58 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.161 -0.962 . . . . 0.0 110.22 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.503 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.9 112.91 15.27 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.454 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.533 ' HD3' ' CD2' ' A' ' 307' ' ' PHE . 4.0 ttpt -83.16 137.65 33.97 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.658 0.742 . . . . 0.0 110.8 -179.25 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.1 OUTLIER -120.64 170.61 9.26 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.135 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.436 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 15.8 mt-10 -143.24 95.97 2.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.531 -0.731 . . . . 0.0 109.688 179.588 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.97 -82.9 0.36 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.804 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.442 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 5.4 t-20 -154.38 81.15 1.12 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.467 -1.019 . . . . 0.0 108.59 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.608 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.42 17.87 56.29 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 107.993 -2.043 . . . . 0.0 107.993 -178.009 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.608 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.7 m-85 -144.45 -171.84 3.68 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.529 ' HA ' ' O ' ' A' ' 313' ' ' GLN . 4.0 t -163.26 153.72 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.231 -0.918 . . . . 0.0 109.322 178.502 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.556 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 42.1 mt -132.45 133.81 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.78 -1.2 . . . . 0.0 111.639 -179.313 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.645 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 82.6 m-85 -105.9 139.09 41.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.459 -0.775 . . . . 0.0 110.651 -179.791 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.553 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 1.1 p -134.62 169.06 14.83 Favored Pre-proline 0 C--N 1.3 -1.578 0 O-C-N 120.912 -1.117 . . . . 0.0 110.324 179.154 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.533 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 39.7 Cg_endo -65.67 112.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.061 1.559 . . . . 0.0 111.045 -179.259 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.517 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 32.9 m -60.83 -127.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.422 -0.799 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 18.9 m -101.9 -17.02 16.35 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.739 -1.226 . . . . 0.0 111.167 -179.361 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 22.5 p-90 -129.86 -3.85 4.62 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.943 -1.098 . . . . 0.0 110.649 -179.688 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.517 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 2.6 t30 -98.64 45.04 1.01 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.233 -0.917 . . . . 0.0 110.473 -179.476 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.32 -4.48 8.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.345 -0.847 . . . . 0.0 109.77 179.829 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.81 -159.92 0.08 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.406 ' C ' ' OG1' ' A' ' 331' ' ' THR . 46.8 Cg_endo -72.9 2.64 5.18 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 124.191 1.627 . . . . 0.0 110.829 -179.852 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.406 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.8 m -162.56 114.87 1.63 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -136.53 115.65 12.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 110.069 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.451 ' O ' ' HB2' ' A' ' 309' ' ' SER . 99.9 m -105.78 147.5 28.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 110.395 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.644 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 6.4 p90 -150.76 174.45 13.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.415 -0.803 . . . . 0.0 109.188 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.478 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.2 162.24 28.94 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.209 -179.564 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.655 ' CE2' ' CB ' ' A' ' 280' ' ' TYR . 0.4 OUTLIER -151.37 143.8 24.19 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -1.077 . . . . 0.0 109.994 179.554 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.543 HD13 ' N ' ' A' ' 337' ' ' ILE . 1.7 mp -119.06 119.73 61.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.171 -0.956 . . . . 0.0 109.744 179.437 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.555 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.6 t -96.23 139.79 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.136 -0.978 . . . . 0.0 110.111 -179.661 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -111.1 142.2 43.58 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.384 -0.822 . . . . 0.0 110.422 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 176.37 -137.49 3.66 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.906 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.522 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.9 Cg_endo -71.75 -156.65 0.05 OUTLIER 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.984 1.518 . . . . 0.0 110.083 179.695 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.581 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -120.86 134.36 55.29 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.027 -1.045 . . . . 0.0 110.432 -179.96 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.484 ' O ' ' HB3' ' A' ' 344' ' ' ASP . . . 109.34 64.41 0.55 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.819 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.484 ' HB3' ' O ' ' A' ' 343' ' ' GLY . 33.4 t0 67.14 143.19 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.482 -1.011 . . . . 0.0 109.251 -179.164 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.531 ' O ' ' CB ' ' A' ' 302' ' ' ALA . 0.1 OUTLIER -142.18 22.55 2.05 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.979 -1.076 . . . . 0.0 111.114 -179.49 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.573 HG11 ' CE1' ' A' ' 280' ' ' TYR . 7.1 p -126.71 113.84 34.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 121.056 -1.027 . . . . 0.0 110.136 179.375 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -45.36 -47.07 13.4 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 110.47 -179.564 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.55 158.76 1.81 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.209 -0.932 . . . . 0.0 110.263 -179.838 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.465 HG12 ' CG2' ' A' ' 296' ' ' VAL . 28.2 mt -121.93 113.22 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.116 -0.99 . . . . 0.0 110.13 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -117.76 133.71 55.66 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.25 -0.907 . . . . 0.0 110.077 -179.934 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.594 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -90.85 132.46 35.88 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.168 -0.958 . . . . 0.0 109.774 179.529 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.471 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 3.7 tt0 -138.01 111.72 8.24 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.38 -0.825 . . . . 0.0 109.956 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.483 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 2.1 mt -94.91 114.0 30.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.21 -0.931 . . . . 0.0 110.42 -179.851 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.44 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.85 31.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.758 -0.589 . . . . 0.0 111.136 179.75 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.78 -15.62 19.16 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.736 -1.221 . . . . 0.0 110.306 179.415 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.483 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 20.9 mm-40 -93.17 112.03 23.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.084 -1.245 . . . . 0.0 110.424 -179.758 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.485 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 1.2 t -76.35 125.63 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.236 -0.915 . . . . 0.0 109.961 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.486 HG23 ' CB ' ' A' ' 262' ' ' PRO . 10.2 mm . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.098 179.802 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.86 -179.32 4.83 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 124.06 1.558 . . . . 0.0 110.425 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.529 ' CG2' ' O ' ' A' ' 258' ' ' THR . 5.2 t -61.98 121.5 13.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.901 179.814 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 2.3 p -116.15 133.66 22.88 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.186 -0.946 . . . . 0.0 110.239 -179.816 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . 0.443 ' CG ' HG22 ' A' ' 357' ' ' VAL . 43.7 Cg_endo -71.76 126.51 12.08 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 O-C-N 124.031 1.542 . . . . 0.0 110.009 179.677 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.408 HG12 ' O ' ' A' ' 261' ' ' VAL . 3.9 p -65.91 141.91 97.82 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.19 -0.944 . . . . 0.0 110.451 -179.497 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.504 ' HB3' ' CG2' ' A' ' 358' ' ' ILE . 50.2 Cg_endo -78.28 126.4 7.66 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 124.118 1.588 . . . . 0.0 110.387 179.781 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.451 HG11 ' O ' ' A' ' 263' ' ' VAL . 35.4 t -114.73 28.79 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -0.866 . . . . 0.0 110.063 179.852 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 179.72 131.9 0.09 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 110.299 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 71.89 -177.37 38.41 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.549 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.6 161.64 37.03 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -1.156 . . . . 0.0 110.006 179.823 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.546 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.5 tm? -161.32 137.17 7.98 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.613 -179.546 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.515 ' N ' HD21 ' A' ' 267' ' ' LEU . 1.3 mm-40 -134.03 147.14 50.92 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.799 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.412 HG13 ' N ' ' A' ' 270' ' ' LYS . 59.9 t -138.55 144.43 30.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.66 -1.275 . . . . 0.0 111.769 -179.091 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.412 ' N ' HG13 ' A' ' 269' ' ' VAL . 0.0 OUTLIER -128.88 157.38 41.71 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.902 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 92.7 t -144.17 146.13 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.28 -1.512 . . . . 0.0 112.199 -179.492 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.576 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.63 108.76 7.21 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.182 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.445 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.0 m-20 -95.26 140.38 30.24 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.278 -0.889 . . . . 0.0 111.277 -179.003 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.576 ' CZ3' ' O ' ' A' ' 272' ' ' ASN . 40.9 p90 -131.94 20.42 4.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.431 -0.793 . . . . 0.0 109.868 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.59 -60.4 4.87 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.899 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -65.8 -18.94 65.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.369 -1.077 . . . . 0.0 110.293 -179.86 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.568 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -179.38 175.85 47.35 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.513 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -131.26 140.98 49.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -1.186 . . . . 0.0 110.119 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.568 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 5.4 mt-10 -93.28 147.1 23.21 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.424 -0.798 . . . . 0.0 109.99 -179.969 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.7 m-85 -142.11 86.39 1.97 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.929 -179.412 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.441 ' C ' ' CG2' ' A' ' 282' ' ' VAL . 12.1 t70 -69.67 152.6 44.5 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.86 . . . . 0.0 109.464 179.206 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.562 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 2.7 t -148.39 90.17 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.283 -0.885 . . . . 0.0 110.177 -179.51 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 56.6 m -86.99 122.31 30.65 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.1 -1.0 . . . . 0.0 109.692 179.515 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.602 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.3 OUTLIER -110.75 150.78 28.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.952 . . . . 0.0 110.8 -179.357 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.554 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.3 OUTLIER -131.43 138.42 49.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.469 -0.769 . . . . 0.0 109.446 179.949 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.613 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 18.8 mt -140.46 163.4 32.93 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.77 -1.206 . . . . 0.0 109.824 -179.816 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.12 30.61 0.59 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.228 -0.92 . . . . 0.0 111.086 -178.95 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.504 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 147.26 -75.39 0.28 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 118.952 -1.594 . . . . 0.0 110.479 179.616 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.558 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.7 tt0 -160.26 106.88 1.56 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.07 -1.253 . . . . 0.0 110.85 -179.371 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.619 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 5.0 m-85 -135.38 135.35 40.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 179.384 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.558 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 1.0 OUTLIER -66.84 102.77 1.0 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.987 -1.071 . . . . 0.0 109.515 179.425 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.602 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 53.9 p-90 -101.18 111.32 23.51 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 110.645 -179.53 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.588 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 6.6 m -104.48 115.66 30.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.532 -0.73 . . . . 0.0 109.726 179.692 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.492 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.9 t -97.05 111.41 26.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.864 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.511 ' HA ' ' CD1' ' A' ' 320' ' ' ILE . 27.1 ttpt -84.99 144.1 28.52 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.387 -0.821 . . . . 0.0 109.511 179.464 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.548 HG12 ' CZ ' ' A' ' 336' ' ' PHE . 99.8 t -141.32 104.98 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.249 -0.907 . . . . 0.0 110.823 -179.179 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 38.0 mmtt -69.8 131.11 44.0 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.078 -1.014 . . . . 0.0 109.066 179.226 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.555 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 93.6 mt -87.85 148.77 24.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.371 -0.831 . . . . 0.0 111.166 -178.895 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.531 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -58.66 172.22 0.54 Allowed Pre-proline 0 C--N 1.303 -1.432 0 O-C-N 121.624 -0.672 . . . . 0.0 109.306 179.093 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.489 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -67.32 80.57 0.41 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.575 1.303 . . . . 0.0 110.111 179.777 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.64 23.29 4.08 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 -179.546 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.508 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -113.58 148.54 35.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.365 -1.08 . . . . 0.0 110.376 -179.534 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.555 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 37.4 p -150.7 144.61 25.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.195 -0.94 . . . . 0.0 110.399 179.789 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.548 HG22 ' CG2' ' A' ' 319' ' ' VAL . 21.3 t -64.02 116.04 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.066 -1.021 . . . . 0.0 110.04 179.723 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -102.35 -20.51 12.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.486 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -147.36 154.44 40.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.26 -1.141 . . . . 0.0 110.317 -179.784 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.507 ' CG ' ' NZ ' ' A' ' 312' ' ' LYS . 25.1 p90 -178.54 175.52 1.11 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.594 -0.691 . . . . 0.0 109.738 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.459 ' O ' ' CB ' ' A' ' 309' ' ' SER . 1.1 p90 -170.0 151.11 3.95 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.991 -1.068 . . . . 0.0 111.637 -179.437 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.503 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 67.93 30.22 6.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.684 -0.635 . . . . 0.0 111.45 179.173 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.514 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 137.48 0.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.144 -0.972 . . . . 0.0 110.168 179.57 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.52 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.19 129.09 35.49 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.073 -1.017 . . . . 0.0 109.353 179.621 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.56 ' CE ' HG13 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -92.07 149.15 21.67 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.907 0.861 . . . . 0.0 111.642 -178.622 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.519 ' N ' ' HG3' ' A' ' 312' ' ' LYS . 0.0 OUTLIER -133.34 171.39 14.11 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.306 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.441 ' HA ' HG23 ' A' ' 319' ' ' VAL . 35.9 mt-10 -137.09 114.85 11.28 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.046 -1.034 . . . . 0.0 110.858 -179.473 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -103.96 42.76 1.81 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.454 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.45 83.48 0.07 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -1.113 . . . . 0.0 110.066 -179.788 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.34 -0.55 57.1 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.89 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.61 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.5 m-85 -145.6 -170.9 3.56 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.463 -1.022 . . . . 0.0 109.157 179.365 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.56 HG13 ' CE ' ' A' ' 312' ' ' LYS . 2.6 t -163.82 161.99 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.366 -0.834 . . . . 0.0 109.347 179.427 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.588 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 28.5 mm -131.02 150.17 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.876 -1.14 . . . . 0.0 111.468 -179.514 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.601 ' CE2' ' HB3' ' A' ' 336' ' ' PHE . 96.5 m-85 -120.42 139.12 53.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.549 -0.719 . . . . 0.0 109.38 178.908 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.52 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.0 OUTLIER -140.66 170.74 8.89 Favored Pre-proline 0 C--N 1.302 -1.461 0 O-C-N 120.79 -1.194 . . . . 0.0 110.244 -179.998 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.504 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.1 Cg_endo -65.72 122.01 9.53 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 123.98 1.516 . . . . 0.0 110.692 -179.505 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.459 ' HA ' ' ND2' ' A' ' 311' ' ' ASN . 12.8 m -76.16 -136.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.384 -0.823 . . . . 0.0 110.363 -179.752 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.411 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 0.4 OUTLIER -88.45 -12.63 42.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.209 -0.932 . . . . 0.0 110.886 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 20.9 p-90 -140.17 13.39 2.41 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.95 -1.094 . . . . 0.0 111.118 -179.475 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.443 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.1 t30 -119.99 50.59 1.27 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.886 -1.134 . . . . 0.0 110.776 -179.651 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.481 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.1 OUTLIER -130.46 -0.95 4.44 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.257 -0.902 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -66.58 -153.72 0.25 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.791 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.504 ' N ' ' O ' ' A' ' 288' ' ' GLY . 46.5 Cg_endo -73.97 3.08 5.35 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 124.12 1.59 . . . . 0.0 110.653 -179.858 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.432 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.9 m -163.93 117.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.197 -0.94 . . . . 0.0 110.244 179.944 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -139.43 111.93 7.71 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.878 . . . . 0.0 110.12 179.943 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.512 HG23 ' N ' ' A' ' 334' ' ' PHE . 7.0 m -101.09 151.78 21.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.181 -0.949 . . . . 0.0 110.275 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.562 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 8.7 p90 -159.03 155.19 27.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.519 -0.738 . . . . 0.0 109.156 179.712 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.468 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -133.24 165.96 23.89 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.264 -1.446 . . . . 0.0 110.035 -179.634 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.688 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.4 OUTLIER -152.44 147.04 25.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -1.171 . . . . 0.0 110.288 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.538 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.7 mp -121.74 119.56 59.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.049 -1.032 . . . . 0.0 109.88 179.687 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.525 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.6 t -96.43 147.94 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.163 -0.961 . . . . 0.0 110.13 -179.907 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.14 132.93 56.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.375 -0.828 . . . . 0.0 110.142 -179.867 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.445 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.88 -138.64 3.66 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 179.943 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.479 ' O ' ' CD ' ' A' ' 345' ' ' LYS . 46.3 Cg_endo -72.68 177.07 8.0 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 124.01 1.531 . . . . 0.0 110.548 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.433 ' CD ' ' N ' ' A' ' 342' ' ' GLN . 5.8 mp0 -98.07 146.79 25.19 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.212 -0.93 . . . . 0.0 110.286 -179.911 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.509 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 95.19 67.78 1.01 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 -179.834 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.509 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 7.5 t0 69.6 128.73 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.351 -1.088 . . . . 0.0 109.445 -179.415 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.531 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 2.3 mtmt -126.84 13.92 7.41 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.135 -0.978 . . . . 0.0 110.164 -179.791 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.532 ' CG2' HG13 ' A' ' 296' ' ' VAL . 4.5 p -127.17 113.28 31.65 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.497 -0.752 . . . . 0.0 109.566 179.429 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.18 -48.33 4.81 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.269 -0.894 . . . . 0.0 110.129 -179.44 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -177.63 149.9 0.64 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.31 -0.869 . . . . 0.0 110.468 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.454 HG12 HG13 ' A' ' 296' ' ' VAL . 12.9 mt -113.62 127.92 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.111 -0.993 . . . . 0.0 110.207 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -132.21 140.51 48.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.959 -179.81 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.599 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -99.44 130.75 45.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.055 -1.028 . . . . 0.0 110.395 -179.93 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.454 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.8 tt0 -138.28 113.87 9.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.308 -0.87 . . . . 0.0 109.788 179.645 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.489 ' O ' ' N ' ' A' ' 355' ' ' GLY . 2.2 mt -91.77 110.51 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.121 -0.987 . . . . 0.0 110.249 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.558 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 37.84 28.51 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.802 -0.561 . . . . 0.0 110.952 179.885 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 123.22 -20.94 7.43 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.739 -1.219 . . . . 0.0 110.298 179.451 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 1.4 mp0 -86.53 112.66 21.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.03 -1.276 . . . . 0.0 110.58 -179.756 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.501 ' O ' ' CG1' ' A' ' 357' ' ' VAL . 7.3 p -79.0 118.13 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.323 -0.861 . . . . 0.0 110.169 179.797 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.504 ' CG2' ' HB3' ' A' ' 262' ' ' PRO . 12.7 mm . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.214 -179.942 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.333 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -74.48 179.84 5.51 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 124.064 1.56 . . . . 0.0 110.541 -179.881 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.458 ' O ' ' CG2' ' A' ' 258' ' ' THR . 5.3 t -61.04 127.4 31.34 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.348 -0.845 . . . . 0.0 110.168 179.986 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.3 p -141.12 143.2 30.13 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.107 -0.996 . . . . 0.0 110.598 -179.844 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -73.81 162.1 40.16 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.084 1.571 . . . . 0.0 110.102 179.687 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.424 ' O ' HG13 ' A' ' 261' ' ' VAL . 3.6 p -109.47 139.88 21.56 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.126 -0.984 . . . . 0.0 110.39 179.944 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.464 ' HB3' HG23 ' A' ' 358' ' ' ILE . 49.6 Cg_endo -79.48 137.0 12.79 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.142 1.601 . . . . 0.0 110.338 179.875 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.467 ' O ' ' HB2' ' A' ' 264' ' ' SER . 3.1 t -122.84 28.04 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.207 -0.933 . . . . 0.0 110.007 179.857 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.467 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 0.2 OUTLIER 175.31 80.12 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.408 -0.808 . . . . 0.0 110.027 179.993 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 122.5 176.38 14.98 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.868 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.577 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.02 152.19 51.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.221 -1.164 . . . . 0.0 109.908 179.866 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.497 HD21 ' CG1' ' A' ' 282' ' ' VAL . 0.0 OUTLIER -148.59 117.71 6.81 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.198 -0.939 . . . . 0.0 110.962 -179.592 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -118.36 116.63 27.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.649 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 52.0 t -109.37 144.52 17.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.863 -1.148 . . . . 0.0 112.154 -178.305 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 9.1 mtmt -128.59 156.42 43.38 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.618 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.569 HG12 ' CE1' ' A' ' 280' ' ' TYR . 99.9 t -145.29 147.03 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.288 -1.508 . . . . 0.0 112.29 -179.068 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.537 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -137.9 111.08 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.757 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.9 p-10 -100.5 140.02 35.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.882 -1.136 . . . . 0.0 111.407 -178.437 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.544 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 32.4 p90 -123.98 20.64 9.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.82 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.72 -68.01 3.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 7.8 m -61.06 -22.02 64.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.261 -1.141 . . . . 0.0 110.485 -179.833 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -168.32 176.74 42.67 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.641 -1.266 . . . . 0.0 110.016 -179.936 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.572 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -135.06 143.54 46.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.381 -1.07 . . . . 0.0 109.864 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.519 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 4.1 mt-10 -100.71 145.63 28.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.271 -0.893 . . . . 0.0 110.042 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.695 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -139.12 90.96 2.47 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.362 -0.836 . . . . 0.0 110.545 -179.701 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.563 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -79.58 118.64 21.61 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.534 -0.729 . . . . 0.0 110.136 179.657 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.602 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 8.8 t -107.41 95.82 4.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.63 -0.669 . . . . 0.0 110.041 179.747 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.422 ' O ' HD22 ' A' ' 267' ' ' LEU . 5.2 m -86.5 120.17 27.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.131 -0.98 . . . . 0.0 109.437 179.551 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.581 HD13 ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -109.1 148.9 30.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 110.991 -179.042 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.577 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.04 107.13 7.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.618 -0.676 . . . . 0.0 109.679 -179.659 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.54 ' N ' ' O ' ' A' ' 330' ' ' PRO . 11.8 mt -114.67 156.57 24.51 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.837 -1.164 . . . . 0.0 110.243 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . 0.432 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 20.1 m-20 -86.7 33.86 0.65 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.513 -0.742 . . . . 0.0 110.413 -179.811 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.514 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.87 -154.04 25.07 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 119.499 -1.334 . . . . 0.0 109.79 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.523 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -101.89 93.85 5.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.173 -1.192 . . . . 0.0 110.608 -179.708 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.523 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 2.3 m-85 -118.12 163.49 16.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.79 179.627 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.519 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 15.2 m-20 -90.26 98.97 12.08 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.249 -0.907 . . . . 0.0 109.43 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.581 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.0 p-90 -99.82 117.26 33.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.192 -0.943 . . . . 0.0 110.749 -179.369 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.564 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 89.2 m -110.86 114.65 28.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.482 -0.761 . . . . 0.0 109.589 179.665 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.484 HG23 HD21 ' A' ' 351' ' ' LEU . 3.2 t -97.18 111.46 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.16 -0.963 . . . . 0.0 110.633 -179.284 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.537 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 18.3 ttmt -86.51 149.89 24.65 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.617 179.299 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.602 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 90.4 t -143.95 108.36 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.054 -1.029 . . . . 0.0 110.672 -179.459 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.551 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 14.5 mmtp -70.5 133.86 47.19 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.27 -0.894 . . . . 0.0 109.318 179.411 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.59 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 85.0 mt -89.71 158.13 17.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -0.788 . . . . 0.0 111.717 -178.727 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.557 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -64.78 173.32 1.69 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.637 -0.665 . . . . 0.0 109.44 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.64 78.6 0.51 Allowed 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.555 1.292 . . . . 0.0 109.913 179.738 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.74 23.27 4.05 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 -179.393 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.519 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -113.08 146.68 38.74 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.361 -1.082 . . . . 0.0 110.141 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.513 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 8.8 p -147.93 145.08 28.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.225 -0.922 . . . . 0.0 110.505 179.766 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.473 HG21 ' CG2' ' A' ' 319' ' ' VAL . 71.4 t -65.62 132.18 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.911 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.21 -36.97 1.71 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.476 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.433 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -140.97 139.49 34.23 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -1.209 . . . . 0.0 110.819 -179.735 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.491 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 23.1 p90 -150.63 167.01 28.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.471 -0.768 . . . . 0.0 109.599 179.56 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.501 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -154.98 155.2 33.79 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.946 -1.096 . . . . 0.0 111.585 -179.558 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.555 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 62.71 25.49 15.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.527 -0.733 . . . . 0.0 110.854 179.742 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.526 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 141.22 0.65 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.891 . . . . 0.0 110.365 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -78.65 117.54 19.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.136 -0.977 . . . . 0.0 109.17 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.511 ' HG2' ' N ' ' A' ' 313' ' ' GLN . 2.0 ttpt -87.84 145.67 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.791 0.805 . . . . 0.0 110.824 -179.274 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.729 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -133.19 178.6 6.78 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.35 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.476 ' HA ' HG22 ' A' ' 319' ' ' VAL . 30.7 mt-10 -141.45 106.57 4.97 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.533 -0.729 . . . . 0.0 110.539 179.509 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.93 51.83 2.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 51.51 80.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.277 -1.131 . . . . 0.0 110.317 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.602 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.47 -0.12 58.22 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.602 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.6 m-85 -141.23 -166.96 2.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -1.115 . . . . 0.0 109.435 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.536 HG11 ' N ' ' A' ' 320' ' ' ILE . 2.7 t -163.61 157.84 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.21 -0.931 . . . . 0.0 109.839 179.286 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.729 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 9.2 mm -127.1 146.61 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 120.915 -1.116 . . . . 0.0 110.685 179.486 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 74.8 m-85 -125.42 124.83 42.31 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.364 -0.835 . . . . 0.0 109.729 179.263 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.52 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 8.3 p -126.96 168.04 15.85 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.491 -1.381 . . . . 0.0 110.39 179.857 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.539 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.4 Cg_endo -65.92 119.07 6.04 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.868 1.457 . . . . 0.0 111.13 -179.306 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.5 HG22 ' NE1' ' A' ' 326' ' ' TRP . 34.2 m -67.29 -124.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.527 -0.733 . . . . 0.0 109.895 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 32.1 t -107.15 -12.92 15.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.763 -1.211 . . . . 0.0 110.693 -179.877 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.555 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 19.6 p-90 -130.34 4.32 4.74 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.069 -1.02 . . . . 0.0 110.526 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.45 ' HB2' HG21 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -113.85 40.91 2.33 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.247 -0.908 . . . . 0.0 110.351 -179.546 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.506 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -115.97 -11.17 11.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 179.821 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.498 ' HA2' ' NE2' ' A' ' 289' ' ' GLN . . . -57.08 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.424 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.54 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.8 Cg_endo -75.41 7.05 3.2 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 124.143 1.602 . . . . 0.0 111.119 -179.663 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.424 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 1.5 m -162.41 124.15 2.69 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.021 -1.049 . . . . 0.0 109.957 179.992 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.567 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -145.93 110.81 5.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 110.311 -179.821 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.406 HG23 ' HA ' ' A' ' 283' ' ' THR . 24.9 m -102.68 123.13 45.81 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.153 -0.967 . . . . 0.0 110.235 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.602 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 13.2 p90 -128.67 175.48 8.55 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.191 -0.943 . . . . 0.0 108.952 179.456 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.473 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.41 162.58 29.07 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.074 -1.536 . . . . 0.0 109.967 -179.222 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.695 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.7 OUTLIER -152.0 144.81 24.36 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.487 -1.008 . . . . 0.0 109.256 179.378 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.545 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -119.77 121.25 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.97 -1.081 . . . . 0.0 109.935 -179.743 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.59 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.5 t -96.88 151.7 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.107 -0.996 . . . . 0.0 109.835 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.461 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -123.36 132.3 53.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.277 -0.889 . . . . 0.0 110.307 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.43 -124.05 0.88 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.768 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.548 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.3 Cg_endo -66.67 -158.61 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.753 0 O-C-N 123.761 1.401 . . . . 0.0 110.139 179.28 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.568 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -123.68 131.69 53.67 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.078 -1.014 . . . . 0.0 110.49 -179.538 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 101.72 -75.29 0.35 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.799 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -111.29 126.01 54.45 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.415 -1.05 . . . . 0.0 109.477 179.503 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.557 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -135.06 2.87 3.12 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.169 -0.957 . . . . 0.0 110.547 -179.679 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.582 HG12 ' CE1' ' A' ' 280' ' ' TYR . 11.4 p -132.39 117.4 31.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.319 -0.863 . . . . 0.0 109.927 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.449 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -49.64 -45.43 48.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.851 . . . . 0.0 110.784 -179.243 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.404 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 11.4 pt-20 -176.95 158.83 1.63 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.942 -1.099 . . . . 0.0 110.916 -179.737 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.496 HG12 ' CG2' ' A' ' 296' ' ' VAL . 42.5 mt -121.06 109.82 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.187 -0.946 . . . . 0.0 110.088 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.64 158.19 16.88 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.537 HD13 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.29 125.83 50.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.357 -0.839 . . . . 0.0 110.056 179.807 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.471 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.9 tt0 -137.96 116.26 11.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.14 -0.975 . . . . 0.0 110.248 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.529 ' CD1' ' HB3' ' A' ' 292' ' ' TRP . 0.9 OUTLIER -91.31 95.87 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 110.162 179.903 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.519 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 49.51 32.3 4.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.641 -0.662 . . . . 0.0 110.742 179.834 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.18 -31.31 4.94 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.471 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 79.3 mm-40 -81.77 119.75 24.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.148 -1.207 . . . . 0.0 110.519 -179.596 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.503 ' O ' ' CD1' ' A' ' 358' ' ' ILE . 12.0 p -79.04 135.64 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.176 -0.952 . . . . 0.0 110.087 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.503 ' CD1' ' O ' ' A' ' 357' ' ' VAL . 27.5 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.201 -179.778 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.17 -178.04 3.34 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 123.997 1.525 . . . . 0.0 110.492 -179.995 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 14.4 t -56.77 145.62 28.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.871 . . . . 0.0 110.062 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.26 159.79 31.54 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.235 -0.916 . . . . 0.0 110.192 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.45 133.85 19.72 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.957 1.503 . . . . 0.0 110.22 179.84 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . . . . . . . . . 3.8 p -93.69 143.04 25.93 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.243 -0.911 . . . . 0.0 110.553 -179.7 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.45 ' CB ' HG23 ' A' ' 358' ' ' ILE . 48.3 Cg_endo -75.53 149.02 34.05 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.179 1.621 . . . . 0.0 110.282 179.557 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.517 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 83.2 t -133.87 29.03 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.237 -0.915 . . . . 0.0 110.501 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 170.76 83.51 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -0.927 . . . . 0.0 110.283 -179.994 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 123.31 176.52 14.83 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.813 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.575 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.15 158.06 44.84 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.364 -1.08 . . . . 0.0 109.9 -179.955 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.495 ' C ' ' CD2' ' A' ' 267' ' ' LEU . 0.0 OUTLIER -146.94 113.47 5.98 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.177 -0.952 . . . . 0.0 110.532 180.0 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -114.69 114.76 26.07 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.067 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.53 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 61.4 t -112.62 133.3 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.894 -1.129 . . . . 0.0 112.588 -178.233 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.423 ' C ' HG23 ' A' ' 271' ' ' VAL . 1.7 mptm? -116.73 156.66 26.78 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 177.959 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.543 HG21 ' CD1' ' A' ' 280' ' ' TYR . 87.1 t -144.64 147.05 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.231 -1.543 . . . . 0.0 112.235 -179.201 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.559 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -133.7 106.95 7.64 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.096 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.495 ' N ' ' OD1' ' A' ' 273' ' ' ASP . 20.8 p-10 -93.09 145.92 24.03 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.087 -1.008 . . . . 0.0 111.254 -178.884 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.585 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 38.1 p90 -134.04 16.98 3.82 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.421 -0.799 . . . . 0.0 109.902 179.423 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.52 -59.26 4.38 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.14 -17.64 64.85 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.357 -1.084 . . . . 0.0 110.09 179.822 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.585 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.38 -178.7 48.66 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.776 -1.329 . . . . 0.0 109.776 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.501 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -135.1 138.54 43.89 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.378 -1.072 . . . . 0.0 110.229 -179.965 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.578 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 8.2 mt-10 -92.28 146.18 23.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.434 -0.791 . . . . 0.0 110.093 -179.812 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.707 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.5 m-85 -136.0 95.28 3.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 110.726 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.53 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.4 103.78 12.21 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.496 -0.752 . . . . 0.0 109.94 179.562 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.598 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.2 t -93.93 91.79 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.402 -0.811 . . . . 0.0 110.42 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.485 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 8.9 m -86.54 112.47 21.59 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.158 179.337 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.546 HD13 ' CE3' ' A' ' 292' ' ' TRP . 0.3 OUTLIER -97.55 153.0 18.46 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.098 -1.001 . . . . 0.0 111.096 -178.913 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.575 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.1 OUTLIER -135.51 106.43 6.63 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.452 -0.78 . . . . 0.0 109.978 -179.699 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.519 ' N ' ' O ' ' A' ' 330' ' ' PRO . 2.3 mt -117.05 169.51 9.36 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.689 -1.257 . . . . 0.0 110.026 179.799 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . 0.421 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 10.7 m-20 -100.85 32.29 3.23 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.268 -0.895 . . . . 0.0 110.455 -179.705 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.498 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 162.87 -145.54 10.73 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.272 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.477 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -106.87 105.86 16.1 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.362 -1.081 . . . . 0.0 110.871 -179.442 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.498 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 3.7 m-85 -135.67 150.47 49.6 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.233 -0.917 . . . . 0.0 109.756 179.356 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.527 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 86.8 m-20 -78.97 96.91 5.87 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 108.97 179.098 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.603 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 52.3 p-90 -94.19 112.11 23.89 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.35 -0.844 . . . . 0.0 110.474 -179.46 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.562 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 15.2 m -106.5 116.52 32.07 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.411 -0.806 . . . . 0.0 109.261 179.641 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.473 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.3 t -96.29 110.79 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 110.667 -179.103 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.47 ' HA ' HD11 ' A' ' 320' ' ' ILE . 9.0 ttpt -83.07 148.85 27.28 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.379 -0.826 . . . . 0.0 108.792 178.696 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.592 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 76.2 t -148.55 108.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.005 -1.059 . . . . 0.0 111.11 -178.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.568 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 56.3 mmtt -70.69 141.56 51.58 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.233 -0.917 . . . . 0.0 109.302 179.167 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.553 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 95.3 mt -94.07 157.97 15.84 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.273 -0.892 . . . . 0.0 111.854 -178.608 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.504 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -68.06 173.12 3.41 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.709 -0.62 . . . . 0.0 109.734 179.404 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.5 Cg_endo -68.25 83.66 0.47 Allowed 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.715 1.376 . . . . 0.0 109.76 179.58 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.72 24.45 5.25 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.353 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.512 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . . . -118.44 142.67 47.33 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.423 -1.046 . . . . 0.0 110.11 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.553 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 9.6 p -143.6 144.45 31.92 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.202 -0.936 . . . . 0.0 110.764 179.753 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.514 ' CG2' HG22 ' A' ' 319' ' ' VAL . 36.2 t -69.87 134.1 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 179.456 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.5 -46.76 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.332 -179.329 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.488 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 31.0 t -119.63 140.27 50.88 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.063 -1.257 . . . . 0.0 110.91 -179.432 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.628 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.3 p90 -157.99 170.7 21.71 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.54 -0.725 . . . . 0.0 109.695 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.511 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -160.46 162.68 33.23 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.09 -1.006 . . . . 0.0 111.044 -179.585 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.8 OUTLIER 54.77 24.8 5.95 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.585 -0.697 . . . . 0.0 110.774 179.816 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.547 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -173.86 144.45 1.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.404 -0.81 . . . . 0.0 109.882 179.455 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.505 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -86.4 122.2 30.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.031 -1.043 . . . . 0.0 109.754 179.747 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.504 ' CD ' HG13 ' A' ' 304' ' ' VAL . 1.7 ttpt -87.5 141.42 28.63 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 121.888 0.851 . . . . 0.0 110.374 -179.749 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.505 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -128.02 175.7 8.19 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.688 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -134.46 117.71 16.55 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.111 -0.993 . . . . 0.0 110.382 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.498 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -108.0 33.65 6.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.2 OUTLIER 70.08 85.57 0.13 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.295 -1.121 . . . . 0.0 110.37 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.56 5.11 75.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.6 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.0 OUTLIER -146.16 -168.24 2.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.362 -1.081 . . . . 0.0 109.173 179.513 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 4.2 t -163.45 161.54 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.235 -0.916 . . . . 0.0 109.765 179.369 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.562 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.4 mm -128.2 143.38 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.122 -0.986 . . . . 0.0 111.271 -179.84 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.664 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 65.4 m-85 -120.05 127.29 52.43 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 178.997 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.52 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.3 p -128.25 169.92 11.64 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.693 -1.254 . . . . 0.0 110.213 -179.498 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.52 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -65.31 112.74 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 123.944 1.497 . . . . 0.0 111.15 -179.354 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.55 HG23 ' ND2' ' A' ' 327' ' ' ASN . 3.6 m -53.3 -59.03 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.435 -0.79 . . . . 0.0 110.994 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.498 ' O ' ' CE ' ' A' ' 328' ' ' LYS . 0.0 OUTLIER -179.29 -24.72 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.959 -1.088 . . . . 0.0 111.307 -179.67 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.495 ' CE2' HG22 ' A' ' 324' ' ' VAL . 5.3 p-90 -115.78 -24.84 8.02 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.92 -1.112 . . . . 0.0 110.718 -179.72 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.55 ' ND2' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -85.22 29.36 0.66 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.144 -0.972 . . . . 0.0 111.303 -179.817 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.498 ' CE ' ' O ' ' A' ' 325' ' ' SER . 0.0 OUTLIER -90.87 -6.27 54.42 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.207 -0.933 . . . . 0.0 109.45 179.599 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.58 -157.69 0.01 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.492 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.519 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -75.86 6.54 3.69 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 124.14 1.6 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.446 HG22 ' O ' ' A' ' 284' ' ' LEU . 0.9 OUTLIER -159.02 131.64 6.87 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.734 -179.932 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -144.99 109.08 4.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.185 -0.947 . . . . 0.0 110.385 -179.691 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.485 ' HA ' ' HA ' ' A' ' 283' ' ' THR . 51.8 m -104.12 118.38 36.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.163 -0.961 . . . . 0.0 110.558 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.598 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 9.7 p90 -128.56 174.67 9.18 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.463 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.474 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.1 162.37 28.76 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 118.801 -1.666 . . . . 0.0 110.477 -179.247 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.707 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.1 p90 -151.39 143.85 24.2 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.685 -0.891 . . . . 0.0 109.32 179.25 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.556 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.7 mp -117.95 119.34 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.959 -1.088 . . . . 0.0 110.283 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.564 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.4 t -97.01 142.8 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 109.71 179.768 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.7 m-80 -111.23 136.1 50.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.188 -0.945 . . . . 0.0 110.215 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.47 -141.76 4.45 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.927 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.52 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 43.9 Cg_endo -71.58 -158.61 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.757 0 O-C-N 123.983 1.518 . . . . 0.0 110.476 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . . . . . . . . . 10.9 mp0 -113.6 143.51 44.44 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.217 -0.927 . . . . 0.0 110.421 -179.792 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.445 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 99.63 64.53 0.82 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 -179.793 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.445 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 8.2 t0 65.18 147.96 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.373 -1.075 . . . . 0.0 109.384 -179.335 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.564 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER -140.83 21.49 2.31 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.016 -1.053 . . . . 0.0 110.903 -179.471 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.592 HG13 ' CE1' ' A' ' 280' ' ' TYR . 12.8 p -128.31 115.01 36.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.077 179.525 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.48 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 6.9 mt-10 -43.45 -46.93 6.96 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.244 -0.91 . . . . 0.0 110.102 -179.641 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -177.19 158.54 1.51 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.105 -0.997 . . . . 0.0 110.833 -179.968 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.403 HD11 HG22 ' A' ' 349' ' ' ILE . 16.6 mt -117.75 105.63 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.877 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.81 141.96 35.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.327 -0.858 . . . . 0.0 110.005 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.543 ' CD1' HD22 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -100.88 131.42 46.77 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.064 -1.023 . . . . 0.0 110.177 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.424 ' N ' HD23 ' A' ' 351' ' ' LEU . 1.4 tp10 -139.03 110.48 7.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 110.019 179.677 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.467 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.3 mt -91.45 105.21 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.045 -1.034 . . . . 0.0 109.894 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.527 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 45.19 40.56 5.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.48 -0.762 . . . . 0.0 110.619 -179.887 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 105.05 -22.47 33.23 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.448 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.455 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 76.1 mm-40 -84.03 110.3 18.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.093 -1.24 . . . . 0.0 110.27 -179.87 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.444 HG12 ' O ' ' A' ' 357' ' ' VAL . 8.5 p -72.41 130.24 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.458 ' OXT' HD11 ' A' ' 351' ' ' LEU . 17.0 mm . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.241 179.893 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -74.36 -178.72 4.16 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 O-C-N 124.029 1.542 . . . . 0.0 110.45 179.992 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.449 ' CG2' ' O ' ' A' ' 258' ' ' THR . 7.4 t -59.81 127.69 33.19 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.437 -0.79 . . . . 0.0 110.291 179.901 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.8 154.63 37.19 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.141 -0.974 . . . . 0.0 110.124 179.951 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.63 154.13 54.6 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.945 1.497 . . . . 0.0 110.2 179.867 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . . . . . . . . . 4.0 p -79.82 141.26 55.18 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.158 -0.964 . . . . 0.0 110.495 -179.646 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.428 ' CB ' HG21 ' A' ' 358' ' ' ILE . 48.5 Cg_endo -80.13 128.6 7.39 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 124.175 1.618 . . . . 0.0 110.598 -179.889 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.456 ' O ' ' CB ' ' A' ' 264' ' ' SER . 5.1 t -115.93 22.7 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -0.889 . . . . 0.0 109.824 179.525 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.3 OUTLIER 169.34 104.33 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.499 -0.751 . . . . 0.0 110.222 179.819 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 106.64 175.49 23.14 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 179.922 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.578 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.14 155.39 49.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.277 -1.131 . . . . 0.0 109.832 179.968 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.513 ' C ' ' CD2' ' A' ' 267' ' ' LEU . 0.0 OUTLIER -148.48 121.53 8.85 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.124 -0.985 . . . . 0.0 110.884 -179.353 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.447 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 23.9 mt-10 -121.61 127.35 50.77 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.875 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.55 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 48.1 t -121.33 138.45 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 120.634 -1.291 . . . . 0.0 112.428 -178.402 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 6.6 mtpp -125.3 157.82 35.71 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.968 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.503 ' HA ' ' O ' ' A' ' 279' ' ' GLU . 84.4 t -144.62 144.93 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.379 -1.45 . . . . 0.0 112.021 -179.577 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.539 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -132.99 108.14 8.71 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.974 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.494 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 19.2 m-20 -96.4 144.83 26.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.999 -1.063 . . . . 0.0 111.077 -178.793 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.582 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 37.1 p90 -131.51 20.03 4.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.496 -0.752 . . . . 0.0 110.025 179.551 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.48 -61.49 4.59 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.816 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -67.53 -18.98 65.23 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -1.171 . . . . 0.0 110.465 -179.735 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.582 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.99 177.75 45.31 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.909 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.529 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -135.2 137.53 42.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.313 -1.11 . . . . 0.0 109.989 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.579 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 7.4 mt-10 -94.33 146.4 24.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.276 -0.89 . . . . 0.0 110.205 -179.68 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.694 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 90.3 m-85 -137.68 88.81 2.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.268 -0.895 . . . . 0.0 110.624 -179.747 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.55 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -75.97 117.78 18.06 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 110.325 179.734 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.607 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 11.1 t -109.83 94.37 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.436 -0.79 . . . . 0.0 110.131 179.626 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.461 ' OG1' HG22 ' A' ' 333' ' ' THR . 19.8 m -86.97 120.42 28.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.182 -0.949 . . . . 0.0 109.778 179.546 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.545 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -107.25 149.94 27.2 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.195 -0.941 . . . . 0.0 110.828 -179.346 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.578 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.72 106.94 7.63 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.401 -0.812 . . . . 0.0 110.147 -179.33 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.556 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 12.2 mt -114.99 155.6 26.65 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.568 -1.332 . . . . 0.0 110.638 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . 0.429 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -88.09 37.76 0.82 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.488 -0.758 . . . . 0.0 109.746 179.572 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.454 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 160.33 -147.29 14.05 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.55 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -111.56 95.02 5.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.151 -1.205 . . . . 0.0 110.633 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.556 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -122.43 141.34 51.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.262 -0.899 . . . . 0.0 110.05 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.536 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 13.2 t70 -71.94 108.73 5.35 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.149 -0.97 . . . . 0.0 109.72 179.564 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.592 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 42.9 p-90 -105.22 114.89 29.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 110.544 -179.651 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.58 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 3.2 m -102.27 113.96 27.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.418 -0.801 . . . . 0.0 109.534 179.751 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.477 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 5.1 t -96.67 113.33 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 110.448 -179.516 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.492 ' HA ' ' CD1' ' A' ' 320' ' ' ILE . 4.1 ttpt -87.9 149.6 23.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.7 179.535 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.552 HG12 ' CZ ' ' A' ' 336' ' ' PHE . 71.5 t -149.35 110.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.079 -1.013 . . . . 0.0 110.273 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.52 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 52.1 mmtt -72.18 138.68 47.79 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.197 -0.939 . . . . 0.0 109.58 179.575 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.516 ' HG ' ' HA ' ' A' ' 318' ' ' TYR . 91.8 mt -91.93 158.36 16.32 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.262 -0.899 . . . . 0.0 111.696 -178.779 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.566 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -65.5 175.24 1.17 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 121.792 -0.567 . . . . 0.0 109.586 179.216 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.518 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -66.36 81.27 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 O-C-N 123.581 1.306 . . . . 0.0 109.902 179.42 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.69 6.3 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.364 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.522 ' CB ' ' HB3' ' A' ' 299' ' ' ALA . . . -104.86 153.32 21.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.337 -1.096 . . . . 0.0 110.213 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.518 ' CG2' ' O ' ' A' ' 302' ' ' ALA . 64.8 p -156.51 145.42 20.23 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.074 -1.016 . . . . 0.0 110.719 -179.864 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.515 HG21 ' CG2' ' A' ' 319' ' ' VAL . 61.6 t -74.21 131.56 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.395 -0.816 . . . . 0.0 109.908 179.562 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.55 -25.14 2.01 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.458 ' O ' HD12 ' A' ' 337' ' ' ILE . 0.3 OUTLIER -139.68 112.71 8.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.039 -1.271 . . . . 0.0 110.95 -179.698 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.485 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -132.97 163.75 28.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.323 -0.861 . . . . 0.0 109.782 179.361 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.501 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.95 162.8 40.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.033 -1.042 . . . . 0.0 110.843 -179.612 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.493 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.5 OUTLIER 57.49 22.6 8.22 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.583 -0.698 . . . . 0.0 111.025 179.55 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.534 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -175.06 143.28 0.69 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.295 -0.878 . . . . 0.0 110.401 179.514 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.501 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -80.71 120.79 25.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.271 -0.893 . . . . 0.0 109.117 179.255 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 0.6 OUTLIER -87.92 127.7 35.36 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.733 0.778 . . . . 0.0 111.1 -178.982 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.487 ' CB ' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -108.54 174.5 5.85 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.323 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -134.29 114.58 13.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.131 -0.98 . . . . 0.0 110.784 -179.637 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.59 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -103.76 57.43 0.55 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.53 ' ND2' ' O ' ' A' ' 316' ' ' ASN . 2.3 p-10 37.75 75.7 0.06 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.951 . . . . 0.0 110.754 -179.687 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.584 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 108.39 -2.17 32.77 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.778 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.59 ' CD2' ' O ' ' A' ' 315' ' ' GLY . 1.9 m-85 -142.24 -169.69 3.0 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.288 -1.125 . . . . 0.0 109.299 179.673 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.515 ' CG2' HG21 ' A' ' 304' ' ' VAL . 6.7 t -162.45 158.39 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 179.165 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.58 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 32.3 mm -128.9 148.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.001 -1.062 . . . . 0.0 111.338 -179.394 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.4 m-85 -124.58 122.8 38.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.988 -1.07 . . . . 0.0 110.164 179.284 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.501 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 5.9 p -121.21 168.09 11.79 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.924 -1.11 . . . . 0.0 110.002 179.756 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.521 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.7 Cg_endo -66.78 119.47 6.5 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 O-C-N 123.805 1.424 . . . . 0.0 110.963 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.446 HG11 ' ND2' ' A' ' 311' ' ' ASN . 35.4 m -67.88 -128.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.364 -179.889 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -97.35 -13.03 22.14 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.836 -1.165 . . . . 0.0 110.878 -179.473 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.487 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 10.0 p-90 -135.35 5.34 3.22 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.054 -1.029 . . . . 0.0 110.63 -179.918 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.493 ' ND2' ' O ' ' A' ' 309' ' ' SER . 11.6 t30 -108.67 42.62 1.37 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.109 -0.994 . . . . 0.0 110.722 -179.701 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.513 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -123.43 -2.81 8.44 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.118 -0.989 . . . . 0.0 110.09 179.689 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.97 -157.11 0.08 OUTLIER Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.537 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.8 Cg_endo -75.96 5.3 4.55 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 124.006 1.53 . . . . 0.0 110.574 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.455 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.1 m -165.09 118.57 1.24 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.126 -0.984 . . . . 0.0 110.195 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.543 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -140.41 118.78 12.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -0.972 . . . . 0.0 110.225 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.465 ' O ' ' HB3' ' A' ' 309' ' ' SER . 91.2 m -107.21 126.9 53.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.398 -0.814 . . . . 0.0 110.32 -179.957 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.607 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 10.8 p90 -131.37 175.35 9.21 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.364 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.485 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -155.37 156.63 27.11 Favored Glycine 0 N--CA 1.487 2.073 0 C-N-CA 118.861 -1.638 . . . . 0.0 110.076 -179.44 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.694 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 1.5 p90 -142.09 151.85 42.73 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.548 -0.972 . . . . 0.0 109.687 179.519 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.527 ' N ' HD12 ' A' ' 337' ' ' ILE . 1.7 mp -123.02 119.14 56.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.125 -0.984 . . . . 0.0 109.38 179.377 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.513 HG23 ' CD2' ' A' ' 298' ' ' LEU . 3.4 t -96.27 147.27 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 110.291 -179.398 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.473 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -118.17 131.29 56.41 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 109.987 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -179.27 -125.53 0.95 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.893 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.525 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.4 Cg_endo -69.28 -167.09 0.19 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.819 1.431 . . . . 0.0 110.675 -179.816 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.503 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 3.5 mp0 -111.2 132.16 54.55 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.288 -0.883 . . . . 0.0 110.954 -179.281 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 103.5 -86.71 0.54 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.604 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -104.32 128.97 52.21 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.322 -1.105 . . . . 0.0 109.356 179.597 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.566 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER -129.62 1.5 4.97 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.845 -1.159 . . . . 0.0 110.383 -179.869 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.599 HG13 ' CE2' ' A' ' 280' ' ' TYR . 7.1 p -127.27 123.74 62.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.094 -1.004 . . . . 0.0 109.709 179.199 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.52 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -55.06 -43.88 74.27 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.218 -179.258 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.475 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.9 pt-20 -177.31 159.23 1.55 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.113 -0.992 . . . . 0.0 111.119 -179.896 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.432 HD11 HG13 ' A' ' 269' ' ' VAL . 36.2 mt -121.34 122.33 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 110.104 179.517 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 350' ' ' THR . . . . . 0.412 ' O ' HG12 ' A' ' 294' ' ' VAL . 0.0 OUTLIER -123.39 160.05 27.63 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.892 . . . . 0.0 110.046 -179.858 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.537 ' CD1' HD23 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.18 126.95 52.78 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.234 -0.916 . . . . 0.0 110.278 -179.922 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.469 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.3 tt0 -138.59 113.31 9.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.185 -0.947 . . . . 0.0 109.942 179.665 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.536 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.6 113.22 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.108 -0.995 . . . . 0.0 110.144 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.521 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 40.08 40.56 0.78 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.537 -0.727 . . . . 0.0 111.031 179.879 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.86 -20.84 37.73 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.83 -1.176 . . . . 0.0 110.342 179.185 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.472 ' O ' ' N ' ' A' ' 353' ' ' ILE . 39.1 mm-40 -87.0 111.3 20.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.045 -1.268 . . . . 0.0 110.5 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.469 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 9.8 p -73.44 141.88 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.299 -0.876 . . . . 0.0 110.222 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.43 HG12 ' C ' ' A' ' 357' ' ' VAL . 28.8 mm . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.199 179.975 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -73.12 -178.19 3.42 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 123.886 1.467 . . . . 0.0 110.798 -179.912 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 1.4 t -84.36 146.23 27.81 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.442 -0.786 . . . . 0.0 110.391 -179.826 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.13 117.88 59.31 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.324 -0.86 . . . . 0.0 110.149 179.995 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -74.09 150.03 42.27 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 O-C-N 123.925 1.487 . . . . 0.0 110.432 -179.931 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.445 ' CG2' ' HD2' ' A' ' 262' ' ' PRO . 3.1 p -100.31 145.21 29.87 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.25 -0.906 . . . . 0.0 110.094 179.788 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.487 ' HA ' ' HA ' ' A' ' 358' ' ' ILE . 46.2 Cg_endo -73.33 146.81 40.75 Favored 'Trans proline' 0 C--N 1.302 -1.876 0 O-C-N 123.973 1.512 . . . . 0.0 110.106 179.729 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.426 HG21 ' C ' ' A' ' 262' ' ' PRO . 3.7 t -133.92 28.76 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.946 . . . . 0.0 110.325 -179.742 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.4 t -174.22 103.22 0.1 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.085 -1.009 . . . . 0.0 110.917 179.987 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 87.17 -165.47 35.94 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.95 -1.119 . . . . 0.0 110.305 179.284 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.531 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -140.12 166.52 24.45 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.61 -0.936 . . . . 0.0 109.597 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.548 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.6 tm? -161.02 130.83 4.92 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.944 -1.097 . . . . 0.0 110.952 -179.8 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.447 ' N ' HD23 ' A' ' 267' ' ' LEU . 25.7 mt-10 -131.86 122.92 26.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.64 -0.662 . . . . 0.0 109.414 179.879 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.459 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 96.5 t -117.1 137.29 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 111.478 -179.058 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -120.25 157.42 29.17 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.91 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.56 HG11 ' CE2' ' A' ' 280' ' ' TYR . 96.2 t -143.67 146.72 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.269 -1.519 . . . . 0.0 112.265 -179.266 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -147.89 117.5 7.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.639 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.521 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.0 OUTLIER -100.13 147.59 25.51 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.205 -0.934 . . . . 0.0 111.195 -178.663 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.557 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 32.9 p90 -130.14 18.61 5.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.541 -0.724 . . . . 0.0 109.864 179.398 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.19 -57.23 4.57 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.735 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.65 -14.91 62.19 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -1.162 . . . . 0.0 110.264 -179.895 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.548 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . 179.6 175.08 46.14 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.892 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.557 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -130.39 147.34 52.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.315 -1.109 . . . . 0.0 109.999 179.851 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.542 ' CG ' HG13 ' A' ' 337' ' ' ILE . 5.8 mt-10 -103.12 147.64 26.74 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.264 -0.897 . . . . 0.0 110.519 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 84.2 m-85 -142.59 81.09 1.72 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.556 -0.715 . . . . 0.0 110.625 -179.816 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.459 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -62.63 153.97 30.61 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.384 -0.822 . . . . 0.0 109.825 179.335 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.611 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.7 t -147.62 86.77 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.571 -0.705 . . . . 0.0 109.982 -179.473 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.436 HG22 ' OG1' ' A' ' 333' ' ' THR . 24.9 m -86.21 118.72 25.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.092 -1.005 . . . . 0.0 109.387 179.656 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.65 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -106.04 147.24 29.12 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.196 -0.94 . . . . 0.0 110.374 -179.341 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.531 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.5 OUTLIER -127.07 133.07 50.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.175 -0.953 . . . . 0.0 110.458 -179.432 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.631 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 9.2 mt -142.1 158.54 43.63 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.896 -1.128 . . . . 0.0 108.992 179.332 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.66 35.56 0.96 Allowed 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.531 -179.588 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 158.21 -110.14 0.43 Allowed Glycine 0 N--CA 1.493 2.468 0 C-N-CA 118.758 -1.687 . . . . 0.0 110.982 179.779 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.505 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -135.07 122.37 21.68 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.061 -1.258 . . . . 0.0 111.051 -178.594 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.631 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 8.6 m-85 -150.88 147.02 26.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.245 -0.91 . . . . 0.0 109.998 179.172 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.532 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 18.8 m-20 -80.58 96.79 6.94 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.371 179.316 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.65 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 57.9 p-90 -96.82 115.64 27.78 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.365 -0.835 . . . . 0.0 110.424 -179.589 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.466 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 3.3 m -109.31 113.72 26.79 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.465 -0.772 . . . . 0.0 109.753 179.927 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.507 HG21 ' CD2' ' A' ' 351' ' ' LEU . 2.5 t -97.07 113.06 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.287 -0.883 . . . . 0.0 110.339 -179.463 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.534 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 31.3 ttmt -94.55 135.58 35.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.598 179.362 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.59 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 81.1 t -130.25 112.34 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.187 -0.946 . . . . 0.0 110.579 -179.548 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.51 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 53.3 mmtt -70.32 136.08 49.46 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.063 -1.023 . . . . 0.0 109.472 179.421 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.593 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 88.3 mt -90.49 163.12 14.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.296 -0.878 . . . . 0.0 111.838 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.551 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -68.78 178.06 0.97 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.82 -0.55 . . . . 0.0 109.846 179.583 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.2 77.39 0.87 Allowed 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.757 1.398 . . . . 0.0 109.811 179.449 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.7 18.69 5.97 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 -179.275 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.526 ' CB ' ' HB1' ' A' ' 299' ' ' ALA . . . -105.04 141.68 36.18 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.417 -1.049 . . . . 0.0 109.677 -179.856 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.538 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 82.2 p -143.99 143.95 31.45 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.84 -1.162 . . . . 0.0 111.058 179.859 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.537 ' CG2' HG22 ' A' ' 319' ' ' VAL . 88.5 t -67.13 116.86 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.658 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.74 -31.6 5.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.341 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.465 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.3 OUTLIER -140.63 132.03 26.81 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.927 -1.337 . . . . 0.0 111.136 -179.414 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.571 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 16.4 p90 -146.42 168.93 19.94 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.411 -0.805 . . . . 0.0 109.496 179.287 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.9 OUTLIER -159.56 157.07 29.2 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.881 -1.137 . . . . 0.0 111.546 -179.558 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.578 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.4 OUTLIER 60.76 27.09 16.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.749 -0.595 . . . . 0.0 111.186 179.47 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.428 ' N ' HG12 ' A' ' 324' ' ' VAL . . . -174.08 142.7 0.86 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 110.102 179.627 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.478 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -76.3 114.49 15.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.171 -0.956 . . . . 0.0 109.421 179.628 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.571 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 1.1 ttpp -87.08 132.95 33.67 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.76 0.79 . . . . 0.0 110.782 -179.579 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.526 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -120.03 174.52 6.42 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.991 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -137.71 103.14 4.93 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.195 -0.94 . . . . 0.0 110.242 179.764 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.499 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -90.44 30.44 6.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.893 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.499 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.1 OUTLIER 69.89 89.03 0.1 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.224 -1.162 . . . . 0.0 110.378 -179.992 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.632 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.55 1.32 71.54 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.861 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.632 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.2 m-85 -146.72 -168.6 3.07 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.463 -1.022 . . . . 0.0 108.921 179.396 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.537 HG22 ' CG2' ' A' ' 304' ' ' VAL . 6.4 t -162.18 158.15 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.973 -1.08 . . . . 0.0 110.123 179.116 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.537 ' O ' ' HA ' ' A' ' 312' ' ' LYS . 6.5 mm -122.41 152.38 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.896 -1.128 . . . . 0.0 110.747 -179.677 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 76.2 m-85 -132.54 115.12 15.07 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.167 -0.958 . . . . 0.0 110.026 179.224 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.542 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 5.6 p -118.03 169.47 7.64 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 120.65 -1.281 . . . . 0.0 109.676 179.456 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.542 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.7 Cg_endo -67.57 121.28 8.35 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.619 1.326 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.535 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 2.7 m -75.75 -141.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -0.769 . . . . 0.0 110.458 -179.563 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.522 ' N ' ' CG2' ' A' ' 324' ' ' VAL . 3.2 m -76.24 -37.25 57.9 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 110.775 -179.626 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.578 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 42.0 p-90 -117.77 22.24 12.44 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.16 -0.962 . . . . 0.0 110.803 -179.57 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.535 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.3 OUTLIER -122.73 32.62 5.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.096 -1.003 . . . . 0.0 110.897 -179.172 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.475 ' CB ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -120.64 9.86 10.9 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.085 -1.009 . . . . 0.0 110.061 179.785 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -72.05 -149.5 0.87 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 179.895 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.556 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.3 Cg_endo -73.32 -52.46 0.14 Allowed 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.934 1.492 . . . . 0.0 109.64 179.811 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.435 HG21 ' O ' ' A' ' 284' ' ' LEU . 2.0 m -111.89 115.73 29.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 179.593 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.471 ' HB2' ' CZ2' ' A' ' 292' ' ' TRP . . . -125.52 117.45 23.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.379 -0.825 . . . . 0.0 109.958 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.486 ' O ' ' HB2' ' A' ' 309' ' ' SER . 53.2 m -107.6 142.87 36.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.287 -0.883 . . . . 0.0 110.32 -179.859 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.611 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 8.4 p90 -151.7 173.06 15.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.766 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.89 153.73 25.02 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.021 -1.562 . . . . 0.0 110.1 -179.465 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.684 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.3 p90 -137.98 145.96 42.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.531 -0.982 . . . . 0.0 109.876 179.662 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.542 HG13 ' CG ' ' A' ' 279' ' ' GLU . 1.6 mp -120.05 125.4 74.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.133 -0.979 . . . . 0.0 109.593 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.593 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.5 t -99.49 161.42 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.175 -0.953 . . . . 0.0 110.726 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.438 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.9 m-80 -128.47 137.06 51.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.447 -0.783 . . . . 0.0 110.205 179.869 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 172.9 -128.99 1.62 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.951 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.551 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 39.2 Cg_endo -65.53 -158.68 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.645 0 O-C-N 123.859 1.452 . . . . 0.0 110.223 179.467 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.564 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -125.22 130.25 51.71 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.028 -1.045 . . . . 0.0 111.342 -179.098 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 117.22 -75.33 0.28 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 179.464 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -130.14 133.65 46.78 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.533 -0.98 . . . . 0.0 108.776 179.149 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.551 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.0 OUTLIER -133.67 25.35 4.04 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.899 -1.126 . . . . 0.0 111.044 -179.35 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.59 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 14.9 p -138.44 119.18 16.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 110.064 179.062 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.416 ' O ' ' HB3' ' A' ' 348' ' ' GLU . 4.2 mt-10 -54.34 -42.22 69.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.412 -0.805 . . . . 0.0 110.928 -179.152 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.416 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.6 OUTLIER -176.66 158.77 1.76 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.94 -1.1 . . . . 0.0 110.867 -179.666 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.404 HG21 HG22 ' A' ' 296' ' ' VAL . 14.6 mt -119.28 120.22 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.144 -0.973 . . . . 0.0 110.36 179.858 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.11 141.9 51.66 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.113 -0.992 . . . . 0.0 110.16 179.825 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.598 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.89 130.11 54.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.193 -0.942 . . . . 0.0 110.386 179.803 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.8 tt0 -139.47 116.62 11.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.239 -0.913 . . . . 0.0 109.582 179.642 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.532 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -90.52 102.86 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.792 -1.193 . . . . 0.0 110.45 -179.704 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.448 ' C ' ' O ' ' A' ' 353' ' ' ILE . 1.0 OUTLIER 35.72 44.89 0.24 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.433 179.647 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.45 8.4 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.408 179.106 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.5 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 78.2 mm-40 -137.2 101.31 4.5 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.062 -1.258 . . . . 0.0 110.042 179.765 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.445 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.1 p -66.91 138.22 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.278 -0.889 . . . . 0.0 110.732 -179.672 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.487 ' HA ' ' HA ' ' A' ' 262' ' ' PRO . 19.6 mm . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.171 179.596 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -73.6 -178.34 3.67 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.002 1.528 . . . . 0.0 110.553 -179.951 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.468 HG22 ' O ' ' A' ' 258' ' ' THR . 5.8 t -66.27 135.37 54.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.358 -0.839 . . . . 0.0 110.159 179.826 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 259' ' ' THR . . . . . 0.42 ' O ' HG23 ' A' ' 259' ' ' THR . 1.5 t -141.69 92.74 7.89 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.154 -0.966 . . . . 0.0 110.471 -179.981 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.9 141.68 30.5 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.853 1.449 . . . . 0.0 110.102 179.759 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.461 HG21 ' HD2' ' A' ' 262' ' ' PRO . 2.4 p -102.65 138.04 19.51 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.116 -0.99 . . . . 0.0 110.554 -179.906 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.471 ' HB3' ' CA ' ' A' ' 358' ' ' ILE . 49.2 Cg_endo -75.29 158.1 41.24 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 124.081 1.569 . . . . 0.0 110.626 179.916 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.529 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 75.6 t -127.46 26.61 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.28 -0.888 . . . . 0.0 109.979 179.688 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.47 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 1.4 t 169.87 143.49 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.277 -0.89 . . . . 0.0 110.45 179.929 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 61.9 -169.89 11.8 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.621 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.561 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.39 162.82 34.11 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.371 -1.076 . . . . 0.0 109.736 179.762 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.577 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.4 tm? -155.23 131.39 10.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.048 -1.032 . . . . 0.0 110.565 -179.148 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 18.0 mt-10 -133.28 124.02 26.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.542 -0.724 . . . . 0.0 109.285 179.455 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.504 HG21 ' CD1' ' A' ' 267' ' ' LEU . 32.0 t -115.54 139.08 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.924 -1.11 . . . . 0.0 111.809 -178.714 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 7.6 mttt -123.21 156.65 34.72 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.492 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.538 HG13 ' CE1' ' A' ' 280' ' ' TYR . 91.4 t -145.08 144.94 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.276 -1.515 . . . . 0.0 112.152 -179.275 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.549 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.27 109.05 6.27 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.175 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.497 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -94.62 146.17 24.32 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.208 -0.932 . . . . 0.0 111.36 -178.763 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.558 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 39.6 p90 -134.63 22.94 3.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.589 -0.694 . . . . 0.0 109.897 179.275 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.69 -66.81 3.84 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.827 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.41 -24.85 65.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.28 -1.129 . . . . 0.0 110.431 -179.668 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.535 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.92 -177.8 41.76 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.533 -1.318 . . . . 0.0 109.84 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.576 ' HB1' ' CZ ' ' A' ' 280' ' ' TYR . . . -136.5 144.8 44.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -1.1 . . . . 0.0 110.247 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.534 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 4.1 mt-10 -97.01 147.05 24.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.421 -0.8 . . . . 0.0 109.816 -179.629 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.7 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -143.74 86.79 1.89 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.204 -0.935 . . . . 0.0 110.894 -179.619 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.455 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 4.6 t0 -71.06 151.58 44.39 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.641 179.11 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.646 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -143.52 91.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.46 -0.775 . . . . 0.0 109.717 -179.689 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.439 ' CG2' ' OG1' ' A' ' 333' ' ' THR . 5.6 m -85.82 123.14 30.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.104 179.66 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.631 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.5 OUTLIER -113.89 145.18 41.85 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.148 -0.97 . . . . 0.0 110.467 -179.034 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.561 ' ND2' ' HB3' ' A' ' 266' ' ' SER . 0.6 OUTLIER -127.15 134.26 50.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -179.642 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.604 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 15.9 mt -142.94 148.66 37.24 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.808 -1.183 . . . . 0.0 109.83 179.638 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -85.68 38.7 0.76 Allowed 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.593 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 159.53 -136.42 4.61 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.301 -1.428 . . . . 0.0 109.752 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.491 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -117.82 94.25 4.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.192 -1.181 . . . . 0.0 110.815 -179.49 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.604 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.05 137.14 52.38 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.192 -0.943 . . . . 0.0 109.918 179.311 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.452 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 2.1 m-20 -71.85 97.6 1.84 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.104 -0.998 . . . . 0.0 109.287 179.248 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.631 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 56.9 p-90 -97.1 113.74 25.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 110.663 -179.376 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.459 ' HA ' ' O ' ' A' ' 321' ' ' PHE . 2.0 m -107.11 117.05 33.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.523 -0.735 . . . . 0.0 109.258 179.527 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.482 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.1 t -97.14 111.0 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.121 -0.987 . . . . 0.0 110.655 -179.247 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.528 ' HG3' ' CD1' ' A' ' 320' ' ' ILE . 18.7 ttpt -84.68 138.97 32.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.258 -0.901 . . . . 0.0 108.933 178.923 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.557 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 85.1 t -136.22 107.11 6.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 110.906 -179.116 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.57 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 8.2 mmtm -69.96 130.72 42.96 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 121.075 -1.016 . . . . 0.0 108.881 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.599 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 66.2 mt -87.02 157.9 19.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.336 -0.853 . . . . 0.0 111.304 -178.816 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.563 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -59.14 177.89 0.24 Allowed Pre-proline 0 C--N 1.303 -1.438 0 O-C-N 121.764 -0.585 . . . . 0.0 109.803 179.503 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.507 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.06 81.0 0.66 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.717 1.377 . . . . 0.0 109.449 179.294 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.05 21.98 6.1 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 -179.102 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.476 ' CB ' ' HB2' ' A' ' 299' ' ' ALA . . . -104.91 149.77 25.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.313 -1.11 . . . . 0.0 110.397 -179.661 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.552 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 4.7 p -148.9 145.63 27.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.294 -0.879 . . . . 0.0 110.424 179.729 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.522 HG11 ' CD ' ' A' ' 312' ' ' LYS . 55.5 t -71.64 117.66 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 110.044 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -97.38 -45.26 2.58 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 68.1 m -126.15 148.76 49.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -1.161 . . . . 0.0 110.843 -179.77 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.477 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.0 p90 -162.95 160.03 24.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.462 -0.773 . . . . 0.0 109.479 179.473 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.489 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -153.35 162.46 41.26 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.835 -1.166 . . . . 0.0 111.172 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.499 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 58.19 21.83 8.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.963 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.532 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -173.84 137.76 0.6 Allowed 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.426 -0.796 . . . . 0.0 110.057 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.514 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.31 124.96 28.57 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.117 -0.989 . . . . 0.0 109.538 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.522 ' CD ' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -92.2 139.83 30.23 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.719 0.771 . . . . 0.0 110.882 -179.25 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.504 ' CB ' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -122.61 170.5 9.96 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.135 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.418 ' HG3' ' HE3' ' A' ' 312' ' ' LYS . 46.3 mt-10 -141.55 100.98 3.89 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.137 -0.977 . . . . 0.0 110.518 -179.767 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -81.41 -76.68 1.05 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.209 -1.557 . . . . 0.0 109.209 179.595 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.57 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 2.8 m120 -163.85 86.79 0.5 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.423 -1.045 . . . . 0.0 109.001 179.553 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 86.63 14.4 65.6 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -178.57 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.622 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.4 m-85 -146.79 -168.76 3.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.836 -0.803 . . . . 0.0 109.096 179.642 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.52 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 3.8 t -163.85 161.59 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.177 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.528 ' CD1' ' HG3' ' A' ' 295' ' ' LYS . 40.6 mm -127.24 144.97 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 111.184 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 49.2 m-85 -120.55 133.59 55.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.212 -0.93 . . . . 0.0 109.912 179.56 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.514 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 2.3 p -134.53 167.81 20.95 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 120.852 -1.155 . . . . 0.0 109.881 179.64 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.479 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 42.2 Cg_endo -67.72 115.51 3.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.858 1.451 . . . . 0.0 110.725 -179.384 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.526 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 23.0 m -61.18 -135.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.334 -0.854 . . . . 0.0 110.245 -179.88 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 2.0 m -90.47 -18.68 24.92 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.059 -1.026 . . . . 0.0 110.763 -179.475 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.573 ' CZ3' ' OD1' ' A' ' 327' ' ' ASN . 27.7 p-90 -132.97 21.56 4.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.182 -0.949 . . . . 0.0 110.404 -179.742 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.573 ' OD1' ' CZ3' ' A' ' 326' ' ' TRP . 1.7 m120 -120.25 38.25 4.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.073 -1.017 . . . . 0.0 110.614 -179.365 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.491 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -120.06 -4.95 10.04 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.184 -0.948 . . . . 0.0 109.889 179.565 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.99 -160.64 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -74.52 4.09 4.79 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.998 1.526 . . . . 0.0 110.72 -179.868 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.429 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.4 m -163.66 117.05 1.51 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.19 -0.944 . . . . 0.0 110.048 -179.853 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.461 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -140.12 114.61 9.31 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.961 . . . . 0.0 110.357 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.499 ' O ' ' HB3' ' A' ' 309' ' ' SER . 21.7 m -105.15 139.17 40.22 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.23 -0.919 . . . . 0.0 110.022 179.793 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 8.5 p90 -141.57 174.5 10.51 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.349 -0.844 . . . . 0.0 109.019 179.891 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.477 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.23 156.33 26.61 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.162 -1.494 . . . . 0.0 110.015 -179.525 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.7 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.1 p90 -146.25 144.65 30.0 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.385 -1.068 . . . . 0.0 110.328 179.752 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.551 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.6 mp -118.71 123.06 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.184 -0.948 . . . . 0.0 109.215 179.321 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.599 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.1 t -96.59 162.11 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 110.699 -179.144 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 0.7 OUTLIER -126.07 127.38 45.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.568 -0.707 . . . . 0.0 109.56 -179.967 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.52 -126.94 1.03 Allowed Glycine 0 N--CA 1.49 2.288 0 C-N-CA 119.494 -1.336 . . . . 0.0 110.042 179.977 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.524 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 43.5 Cg_endo -70.75 -174.79 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 O-C-N 123.921 1.484 . . . . 0.0 110.647 -179.676 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.475 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 6.5 mp0 -104.65 135.34 46.24 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.237 -0.914 . . . . 0.0 110.655 -179.623 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.452 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 109.64 -88.94 0.53 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.728 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -113.64 137.5 51.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.458 -1.025 . . . . 0.0 108.757 178.948 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.563 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 2.5 mtmt -129.32 14.43 6.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.834 -1.166 . . . . 0.0 110.492 -179.461 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.584 HG13 ' CE1' ' A' ' 280' ' ' TYR . 11.8 p -136.85 118.35 18.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.415 -0.803 . . . . 0.0 110.026 179.272 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.466 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -50.96 -45.84 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.348 -0.845 . . . . 0.0 110.38 -179.513 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.438 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.0 pt-20 -176.61 157.84 1.65 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.272 -0.892 . . . . 0.0 110.426 -179.695 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.497 HG12 ' CG1' ' A' ' 296' ' ' VAL . 64.5 mt -120.59 106.54 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.157 -0.964 . . . . 0.0 110.232 179.644 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.82 130.91 53.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 110.286 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.589 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -91.3 129.37 37.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.101 -0.999 . . . . 0.0 110.241 179.782 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.425 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.0 tt0 -138.83 112.69 8.46 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.183 -0.948 . . . . 0.0 109.934 179.81 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.471 HG12 ' HA ' ' A' ' 292' ' ' TRP . 1.9 mt -91.4 110.7 22.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.065 -1.022 . . . . 0.0 110.165 179.961 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.421 ' C ' ' O ' ' A' ' 353' ' ' ILE . 0.8 OUTLIER 38.89 29.25 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.774 -0.578 . . . . 0.0 110.639 179.922 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 118.59 -21.68 9.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . . . . . . . . . 1.2 mp0 -86.2 112.53 21.43 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.055 -1.262 . . . . 0.0 110.392 -179.755 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.425 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 14.8 p -74.84 141.63 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.138 -0.976 . . . . 0.0 110.407 179.842 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.472 ' HB ' ' HB3' ' A' ' 351' ' ' LEU . 30.8 mm . . . . . 0 N--CA 1.494 1.755 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.309 179.837 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -76.73 178.8 7.14 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.995 1.523 . . . . 0.0 110.611 -179.931 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.451 ' CG2' ' O ' ' A' ' 258' ' ' THR . 4.3 t -60.73 128.91 38.87 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.291 -0.881 . . . . 0.0 109.938 179.798 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 25.0 m -61.55 137.24 94.78 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.151 -0.968 . . . . 0.0 110.177 -179.853 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.61 142.0 35.43 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 123.967 1.509 . . . . 0.0 110.365 -179.779 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.529 ' CG2' ' HD2' ' A' ' 262' ' ' PRO . 3.5 p -81.88 147.13 57.52 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.362 -0.836 . . . . 0.0 110.266 -179.883 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.529 ' HD2' ' CG2' ' A' ' 261' ' ' VAL . 44.7 Cg_endo -71.11 138.18 33.06 Favored 'Trans proline' 0 C--N 1.303 -1.824 0 O-C-N 124.061 1.559 . . . . 0.0 110.035 179.582 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.511 ' O ' ' CB ' ' A' ' 264' ' ' SER . 12.1 t -125.12 28.79 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 110.418 -179.696 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.511 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 3.0 t 169.13 64.64 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.273 -0.892 . . . . 0.0 110.638 179.866 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 136.86 171.25 12.15 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.245 179.442 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.579 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -128.52 165.94 19.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.617 -0.931 . . . . 0.0 109.664 179.665 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.532 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -159.43 126.21 4.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.977 -1.077 . . . . 0.0 111.17 -179.555 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.52 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.4 OUTLIER -123.78 118.05 26.3 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.681 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.465 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 55.2 t -117.15 142.15 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.851 -1.156 . . . . 0.0 112.14 -178.428 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 7.9 tttm -128.5 157.28 41.59 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.969 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.575 HG12 ' CE1' ' A' ' 280' ' ' TYR . 86.5 t -144.2 145.42 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.367 -1.458 . . . . 0.0 111.947 -179.445 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.65 113.23 7.71 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.483 179.534 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.525 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.86 145.76 25.11 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.151 -0.968 . . . . 0.0 110.942 -179.016 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.561 ' CH2' ' C ' ' A' ' 278' ' ' ALA . 27.9 p90 -127.83 16.04 6.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.305 179.377 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 95.01 -56.11 1.82 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.483 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.6 m -78.53 -17.86 55.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -1.151 . . . . 0.0 110.453 -179.678 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -174.1 177.71 46.24 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.35 -1.405 . . . . 0.0 109.922 -179.952 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.561 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.65 144.84 48.07 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.329 -1.1 . . . . 0.0 110.066 179.862 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.56 ' O ' ' HA ' ' A' ' 271' ' ' VAL . 4.2 mt-10 -96.88 147.48 23.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.365 -0.835 . . . . 0.0 109.878 -179.441 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 92.8 m-85 -139.38 86.43 2.12 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.302 -0.874 . . . . 0.0 110.69 -179.294 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.465 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.6 OUTLIER -69.77 145.65 52.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.431 -0.793 . . . . 0.0 109.809 179.317 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.608 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 3.8 t -139.06 87.55 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.577 -0.702 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.464 HG23 ' OG1' ' A' ' 333' ' ' THR . 19.2 m -86.12 117.12 24.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.102 -0.999 . . . . 0.0 109.645 -179.886 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.59 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.4 OUTLIER -103.05 150.43 23.6 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.109 -0.994 . . . . 0.0 110.769 -179.279 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.579 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.62 106.63 7.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.576 -0.702 . . . . 0.0 110.098 -179.324 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.583 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.1 mt -113.98 157.16 22.83 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.824 -1.172 . . . . 0.0 109.987 179.772 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.47 35.16 0.76 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.356 -0.84 . . . . 0.0 110.501 -179.432 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.48 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.15 -103.39 0.23 Allowed Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.878 -1.63 . . . . 0.0 110.423 179.855 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.447 ' HG3' ' O ' ' A' ' 328' ' ' LYS . 3.0 tt0 -149.95 111.06 4.37 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.053 -1.263 . . . . 0.0 110.705 -179.252 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.583 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 2.4 m-85 -140.14 138.54 35.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.405 -0.809 . . . . 0.0 109.866 179.542 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.506 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 29.5 m-20 -64.92 97.09 0.21 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.102 -0.999 . . . . 0.0 109.294 179.349 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.59 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 56.5 p-90 -96.41 110.71 23.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.262 -0.899 . . . . 0.0 110.67 -179.502 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.576 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 5.5 m -102.81 114.94 29.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.518 -0.739 . . . . 0.0 109.314 179.459 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.493 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 4.5 t -96.18 113.08 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.102 -0.999 . . . . 0.0 110.007 -179.547 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.472 ' HA ' HD13 ' A' ' 320' ' ' ILE . 12.9 ttpt -89.73 149.47 22.73 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.527 -0.733 . . . . 0.0 109.184 179.657 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.588 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 77.4 t -148.16 109.33 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.005 -1.059 . . . . 0.0 110.763 -179.327 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.522 ' CB ' ' HB2' ' A' ' 347' ' ' GLU . 9.0 mmtt -71.81 135.03 46.51 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.102 -0.999 . . . . 0.0 109.324 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.599 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 89.6 mt -86.11 167.13 15.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.28 -0.888 . . . . 0.0 111.755 -178.75 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.559 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -72.18 176.17 2.56 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.672 -0.643 . . . . 0.0 109.353 179.068 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.507 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.9 Cg_endo -69.3 80.3 0.76 Allowed 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.554 1.291 . . . . 0.0 109.918 179.564 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.41 23.45 4.79 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.985 -1.646 . . . . 0.0 108.985 -179.446 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.483 ' HB3' ' HB2' ' A' ' 299' ' ' ALA . . . -111.7 150.4 30.26 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.373 -1.075 . . . . 0.0 110.401 -179.558 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.516 ' N ' HG13 ' A' ' 338' ' ' VAL . 77.3 p -150.43 144.14 25.23 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.286 -0.884 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.525 ' CG1' ' HD2' ' A' ' 312' ' ' LYS . 55.2 t -64.81 133.32 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 110.16 179.69 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.2 -37.6 1.48 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.843 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.41 138.22 32.8 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.182 -1.187 . . . . 0.0 110.768 -179.681 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.501 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 48.1 p90 -147.11 163.78 35.2 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.326 -0.858 . . . . 0.0 109.776 179.486 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.461 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.47 158.2 38.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.941 -1.099 . . . . 0.0 111.554 -179.434 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.504 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.52 21.6 12.74 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.719 -0.613 . . . . 0.0 110.818 179.479 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.516 ' HB1' ' CB ' ' A' ' 334' ' ' PHE . . . -174.7 143.6 0.78 Allowed 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.465 -0.772 . . . . 0.0 109.956 179.538 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.518 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -79.33 119.71 22.76 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.035 . . . . 0.0 109.351 179.579 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.525 ' HD2' ' CG1' ' A' ' 304' ' ' VAL . 4.9 ttpt -86.2 140.33 30.25 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.767 0.794 . . . . 0.0 110.59 -179.612 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.518 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.13 173.2 8.9 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.423 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -136.7 112.7 9.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 110.167 179.926 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -102.73 43.56 1.66 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 57.75 80.15 0.18 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.354 -1.086 . . . . 0.0 110.395 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.39 -1.02 57.12 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.64 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.592 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 2.1 m-85 -142.55 -170.1 3.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.377 -1.072 . . . . 0.0 109.472 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.532 HG13 ' N ' ' A' ' 320' ' ' ILE . 3.9 t -162.81 156.12 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.177 -0.952 . . . . 0.0 109.922 179.2 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.576 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 37.2 mm -125.65 151.78 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.114 -0.991 . . . . 0.0 111.294 -179.462 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 78.5 m-85 -129.54 126.49 38.7 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.166 -0.959 . . . . 0.0 110.408 179.421 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.518 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 6.4 p -126.5 167.56 16.91 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 120.919 -1.113 . . . . 0.0 109.579 179.195 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.503 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.4 Cg_endo -65.15 119.93 7.05 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.225 -179.164 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.53 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 12.4 m -63.74 -111.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.439 -0.788 . . . . 0.0 110.166 179.987 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -111.67 -23.32 10.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.697 -1.252 . . . . 0.0 110.534 -179.811 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 3.9 p-90 -125.73 1.49 7.47 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 -179.874 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.53 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 0.2 OUTLIER -99.91 40.97 1.19 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.233 -0.917 . . . . 0.0 110.38 -179.69 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -120.05 -8.4 9.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.25 -0.907 . . . . 0.0 109.532 179.736 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.89 -159.06 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.939 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.1 Cg_endo -74.76 5.75 3.69 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.978 1.515 . . . . 0.0 110.821 -179.899 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.1 m -163.14 121.23 1.98 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.959 -1.088 . . . . 0.0 109.897 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.61 113.75 8.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.957 . . . . 0.0 110.26 -179.776 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.504 ' O ' ' HB3' ' A' ' 309' ' ' SER . 11.8 m -103.04 133.42 48.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.392 -0.817 . . . . 0.0 110.364 -179.739 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.628 ' CE1' ' CG ' ' A' ' 321' ' ' PHE . 15.0 p90 -141.77 164.6 29.75 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.379 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -144.24 158.27 27.41 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.843 -1.646 . . . . 0.0 110.32 -179.397 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.693 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 1.4 p90 -144.01 147.65 34.17 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.556 -0.967 . . . . 0.0 109.882 179.417 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.543 ' N ' HD11 ' A' ' 337' ' ' ILE . 1.7 mp -120.74 122.81 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.992 -1.068 . . . . 0.0 110.048 -179.969 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.599 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 3.9 t -97.07 157.28 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.884 . . . . 0.0 109.999 179.712 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.463 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -125.85 131.32 52.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.84 . . . . 0.0 110.396 -179.575 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -179.84 -122.09 0.76 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.851 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.561 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 41.2 Cg_endo -67.59 -158.28 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.864 1.455 . . . . 0.0 110.625 179.632 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.557 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -125.39 126.58 45.23 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.11 -0.994 . . . . 0.0 110.628 -179.467 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 113.81 -71.61 0.23 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.941 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -123.62 141.44 52.01 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.329 -1.101 . . . . 0.0 109.045 179.306 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.561 ' CG ' ' HD2' ' A' ' 341' ' ' PRO . 1.3 mtmt -141.68 10.25 2.02 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.83 -1.169 . . . . 0.0 111.234 -179.369 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.587 HG11 ' CE1' ' A' ' 280' ' ' TYR . 9.0 p -132.2 125.51 54.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.022 -1.049 . . . . 0.0 110.412 179.231 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.522 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 3.8 mt-10 -53.08 -45.74 68.29 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.313 -0.867 . . . . 0.0 110.149 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.445 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 1.8 pt-20 -177.55 158.63 1.4 Allowed 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.185 -179.704 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.452 HG23 HG23 ' A' ' 296' ' ' VAL . 3.5 mm -109.13 122.58 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.603 -0.686 . . . . 0.0 109.709 179.419 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.42 141.76 51.67 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.33 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.537 HD12 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.68 126.84 52.62 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 109.952 179.633 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.465 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 11.5 tt0 -138.99 113.8 9.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.643 179.92 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.476 HG12 ' HA ' ' A' ' 292' ' ' TRP . 2.0 mt -92.97 112.14 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.154 -0.966 . . . . 0.0 109.913 179.522 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.506 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 41.74 34.11 0.38 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.492 -0.755 . . . . 0.0 110.113 -179.579 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 108.9 -25.12 19.89 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.933 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.471 ' N ' ' CD ' ' A' ' 356' ' ' GLN . 3.2 mp0 -77.41 106.07 8.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.223 -1.163 . . . . 0.0 110.523 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.465 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 13.5 p -70.92 120.93 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.259 -0.901 . . . . 0.0 110.184 179.719 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.51 HG21 ' CB ' ' A' ' 262' ' ' PRO . 35.5 mm . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.009 179.777 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.426 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.87 -178.38 3.46 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 O-C-N 123.879 1.463 . . . . 0.0 110.545 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.406 ' O ' ' CG2' ' A' ' 258' ' ' THR . 5.1 t -68.26 131.85 46.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.426 -0.797 . . . . 0.0 110.61 -179.805 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 10.1 p -133.44 111.1 12.66 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.223 -0.923 . . . . 0.0 110.141 179.813 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -71.83 154.31 58.69 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.998 1.526 . . . . 0.0 110.254 179.672 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . . . . . . . . . 3.0 p -89.7 141.59 28.59 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.228 -0.92 . . . . 0.0 110.496 -179.833 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -75.39 133.57 16.16 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.094 1.576 . . . . 0.0 110.14 179.785 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 2.8 t -115.64 29.06 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.108 -0.995 . . . . 0.0 110.222 -179.721 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -176.11 118.1 0.14 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.168 -0.958 . . . . 0.0 110.799 179.923 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 73.29 -173.42 48.86 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.365 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.531 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.79 169.35 17.87 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.585 -0.95 . . . . 0.0 109.33 179.909 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.578 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.0 tm? -161.38 134.49 6.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.36 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.489 ' N ' HD21 ' A' ' 267' ' ' LEU . 8.4 mm-40 -133.96 138.46 45.47 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.294 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.472 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 59.4 t -131.35 142.0 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 120.858 -1.151 . . . . 0.0 111.753 -178.846 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.439 ' C ' HG21 ' A' ' 271' ' ' VAL . 0.1 OUTLIER -127.17 156.99 40.93 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.771 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.588 HG22 ' CD2' ' A' ' 280' ' ' TYR . 69.3 t -144.81 147.07 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 120.401 -1.437 . . . . 0.0 112.344 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -143.18 113.91 7.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.669 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.507 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.6 m-20 -100.07 142.87 30.96 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.872 -1.142 . . . . 0.0 111.205 -178.538 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.553 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 26.8 p90 -122.77 20.1 10.17 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.576 -0.703 . . . . 0.0 109.475 179.451 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.494 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 84.44 -58.32 5.0 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.744 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.502 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -66.87 -19.34 65.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.25 -1.147 . . . . 0.0 110.216 179.793 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.553 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.93 -172.69 38.79 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.556 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -143.69 136.89 27.77 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -1.122 . . . . 0.0 109.894 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.541 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 7.2 mt-10 -95.93 146.4 24.62 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 110.446 -179.447 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.662 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.1 m-85 -140.01 86.36 2.08 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 110.766 -179.699 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.472 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.8 OUTLIER -66.54 143.64 56.93 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 179.155 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.646 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 5.4 t -138.35 89.36 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.191 -0.943 . . . . 0.0 110.014 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.464 ' HA ' HG22 ' A' ' 333' ' ' THR . 87.4 m -86.76 126.96 34.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.181 -0.949 . . . . 0.0 109.568 179.799 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.605 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.81 147.08 40.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 110.77 -179.204 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.535 ' O ' ' CD2' ' A' ' 286' ' ' LEU . 0.6 OUTLIER -125.3 135.21 52.25 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.35 -0.844 . . . . 0.0 110.467 -179.453 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.545 ' N ' ' O ' ' A' ' 330' ' ' PRO . 10.3 mt -144.77 161.69 38.61 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.731 -1.23 . . . . 0.0 109.595 179.8 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.09 37.47 1.16 Allowed 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.776 179.733 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.498 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 148.55 -129.89 3.25 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.33 -1.414 . . . . 0.0 109.973 -179.68 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.546 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.1 mm-40 -108.3 114.06 27.62 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.891 -1.358 . . . . 0.0 111.132 -179.326 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.564 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 6.3 m-85 -134.43 133.09 40.12 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.444 -0.785 . . . . 0.0 109.234 179.205 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.54 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 1.1 m-20 -73.5 96.26 2.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.808 -1.183 . . . . 0.0 108.857 179.236 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.569 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 64.2 p-90 -98.98 117.47 33.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.893 . . . . 0.0 110.996 -179.038 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.586 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 17.3 m -112.68 113.98 26.37 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.425 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.529 HG23 ' CD2' ' A' ' 351' ' ' LEU . 3.2 t -96.68 110.92 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.058 -1.026 . . . . 0.0 110.265 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.541 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 17.6 ttmt -89.51 148.21 23.54 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.381 -0.825 . . . . 0.0 109.187 179.144 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.582 ' CG1' ' CG2' ' A' ' 346' ' ' VAL . 71.3 t -144.26 111.66 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.126 -0.984 . . . . 0.0 110.204 -179.666 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 72.6 mmtt -70.24 135.44 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.219 -0.926 . . . . 0.0 109.154 179.653 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.594 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 93.9 mt -89.84 155.59 19.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.316 -0.865 . . . . 0.0 111.447 -178.851 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.518 ' HB1' ' CB ' ' A' ' 302' ' ' ALA . . . -59.4 173.86 0.46 Allowed Pre-proline 0 N--CA 1.487 1.378 0 O-C-N 121.493 -0.755 . . . . 0.0 109.086 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -69.23 79.33 0.78 Allowed 'Trans proline' 0 C--N 1.302 -1.913 0 O-C-N 123.608 1.32 . . . . 0.0 109.874 179.747 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.93 20.15 4.99 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.425 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.522 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -109.99 148.39 31.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.407 -1.055 . . . . 0.0 109.859 -179.884 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.552 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 19.8 p -147.52 146.15 29.36 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.953 -1.092 . . . . 0.0 111.247 -179.747 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.489 ' CG1' ' HD2' ' A' ' 312' ' ' LYS . 53.7 t -69.28 129.02 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.287 -0.883 . . . . 0.0 109.821 179.542 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.66 -40.22 1.13 Allowed Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.73 -1.224 . . . . 0.0 110.201 -179.466 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -126.96 129.65 48.55 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 0.0 110.686 -179.463 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.531 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.6 p90 -145.44 162.02 38.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.36 -0.837 . . . . 0.0 109.823 179.59 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -158.16 156.09 30.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.927 -1.108 . . . . 0.0 111.171 -179.579 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.576 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 63.5 24.31 14.02 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.575 -0.703 . . . . 0.0 110.941 179.598 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.495 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -174.18 146.1 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.908 . . . . 0.0 110.497 179.474 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.488 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.0 m-80 -77.31 123.46 26.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.375 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.531 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 12.0 ttpt -93.03 121.94 34.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.5 -0.75 . . . . 0.0 111.025 -179.448 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.545 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.6 tt0 -109.86 175.13 5.56 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.324 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -138.17 101.99 4.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.347 -0.846 . . . . 0.0 110.12 179.773 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.466 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -90.11 37.05 3.41 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.868 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . 0.488 ' ND2' ' N ' ' A' ' 316' ' ' ASN . 2.2 m120 63.78 88.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -1.168 . . . . 0.0 110.266 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.08 3.07 70.47 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.729 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.611 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.3 m-85 -146.34 -169.38 3.25 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.376 -1.073 . . . . 0.0 109.338 179.491 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.524 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 22.6 t -160.8 161.08 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.119 -0.988 . . . . 0.0 109.97 178.964 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.586 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 4.4 mm -126.55 152.33 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.133 -0.98 . . . . 0.0 110.93 -179.378 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.65 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 79.2 m-85 -131.76 112.48 12.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.232 -0.918 . . . . 0.0 109.888 178.791 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.548 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 6.5 p -115.67 170.28 5.86 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 120.725 -1.234 . . . . 0.0 109.529 179.561 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.548 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.0 Cg_endo -67.24 120.62 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.495 1.261 . . . . 0.0 110.943 -179.199 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.504 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 30.7 m -68.24 -123.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.488 -0.757 . . . . 0.0 110.143 -179.922 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 325' ' ' SER . . . . . 0.431 ' C ' ' HD2' ' A' ' 328' ' ' LYS . 0.0 OUTLIER -104.74 -18.1 14.39 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.776 -1.202 . . . . 0.0 110.67 -179.734 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.576 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 19.7 p-90 -126.73 3.53 6.73 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.93 -1.106 . . . . 0.0 110.539 -179.994 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.504 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.6 t30 -110.92 34.76 3.83 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.141 -0.975 . . . . 0.0 110.646 -179.429 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.519 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -114.22 2.8 14.94 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.158 -0.964 . . . . 0.0 109.636 179.54 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -68.85 -153.4 0.58 Allowed Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 179.888 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.9 Cg_endo -69.24 -50.45 0.52 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.906 1.477 . . . . 0.0 109.863 179.974 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.56 116.66 31.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -0.839 . . . . 0.0 110.34 179.779 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.471 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -130.34 113.62 14.6 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.271 -0.893 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.464 HG22 ' HA ' ' A' ' 283' ' ' THR . 57.2 m -105.73 149.84 26.05 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.175 -0.953 . . . . 0.0 110.37 -179.966 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 8.3 p90 -154.73 170.74 20.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.408 -0.808 . . . . 0.0 108.905 179.67 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.71 149.73 21.62 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.057 -179.3 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.662 ' CZ ' ' CG ' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -136.15 147.98 47.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.496 -1.002 . . . . 0.0 110.019 179.573 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.556 ' HA ' ' O ' ' A' ' 278' ' ' ALA . 1.6 mp -120.65 122.49 68.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 120.997 -1.065 . . . . 0.0 109.925 179.501 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.594 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.1 t -96.55 150.23 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.082 -1.011 . . . . 0.0 110.003 -179.968 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -119.1 132.36 56.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.437 -0.789 . . . . 0.0 109.946 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.437 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.57 -149.38 8.94 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.479 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 47.3 Cg_endo -76.52 116.77 4.38 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 124.071 1.564 . . . . 0.0 110.735 179.894 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.501 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.1 OUTLIER -37.41 158.49 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.502 -0.748 . . . . 0.0 110.99 -179.887 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 94.86 60.55 1.07 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 -179.89 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.489 ' O ' ' O ' ' A' ' 343' ' ' GLY . 39.2 m-20 59.27 127.61 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.567 -0.961 . . . . 0.0 109.629 -179.406 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.536 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.5 OUTLIER -128.3 24.15 5.92 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.767 -1.208 . . . . 0.0 110.575 -179.681 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.582 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 14.5 p -130.02 126.74 62.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.386 -0.821 . . . . 0.0 109.667 179.106 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.1 mt-10 -62.85 -38.43 90.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 111.106 -179.072 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.466 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.7 pt-20 -176.86 158.9 1.68 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 110.897 -179.479 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.509 HG12 ' CG1' ' A' ' 296' ' ' VAL . 14.7 mt -123.42 103.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.143 -0.973 . . . . 0.0 110.03 179.627 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.0 145.58 31.18 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.306 -0.871 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.605 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.07 128.36 55.85 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.308 179.693 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 13.9 tt0 -138.61 120.86 15.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.875 179.689 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.54 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -90.81 93.82 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.092 -1.005 . . . . 0.0 110.026 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.529 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 46.34 26.38 0.47 Allowed 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.909 -0.495 . . . . 0.0 110.797 179.923 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 135.66 -29.66 2.85 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.658 179.398 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.472 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 58.7 mm-40 -89.06 110.18 20.93 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.911 -1.347 . . . . 0.0 110.65 -179.442 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 13.9 p -74.13 140.36 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.255 -0.903 . . . . 0.0 109.917 179.408 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.474 HD13 HG22 ' A' ' 358' ' ' ILE . 9.7 mm . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.114 -0.991 . . . . 0.0 110.234 -179.752 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -74.57 -178.42 4.02 Favored 'Trans proline' 0 C--N 1.306 -1.706 0 O-C-N 124.073 1.565 . . . . 0.0 110.48 179.993 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 11.9 t -60.04 142.03 54.7 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.394 -0.816 . . . . 0.0 110.309 179.836 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 96.6 m -121.99 133.29 24.26 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.229 -0.919 . . . . 0.0 110.22 179.88 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.33 145.52 38.58 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.968 1.51 . . . . 0.0 110.364 179.83 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.521 ' CG2' ' HD2' ' A' ' 262' ' ' PRO . 4.1 p -86.58 146.83 42.5 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.279 -0.888 . . . . 0.0 110.125 -179.985 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.521 ' HD2' ' CG2' ' A' ' 261' ' ' VAL . 46.6 Cg_endo -73.57 150.23 45.32 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 O-C-N 124.153 1.607 . . . . 0.0 110.065 179.681 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.478 ' O ' ' CG1' ' A' ' 263' ' ' VAL . 90.3 t -122.51 30.03 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.262 -0.899 . . . . 0.0 110.301 -179.863 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.423 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 0.4 OUTLIER 179.83 139.73 0.12 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.268 -0.895 . . . . 0.0 110.558 -179.99 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 59.9 -172.56 5.31 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.635 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.54 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.43 164.69 29.19 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.402 -1.057 . . . . 0.0 109.841 179.933 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.556 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.6 tm? -161.04 135.37 7.13 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.124 -179.436 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.528 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -132.31 144.25 50.44 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.175 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.431 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 49.9 t -135.58 140.95 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.689 -1.257 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.491 ' O ' HG22 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -127.47 156.7 41.72 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.734 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.565 HG23 ' CD2' ' A' ' 280' ' ' TYR . 94.4 t -143.31 146.93 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.391 -1.443 . . . . 0.0 112.162 -179.338 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.534 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.94 113.8 8.79 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.084 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.477 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 m-20 -97.52 148.84 22.83 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.002 -1.061 . . . . 0.0 111.339 -178.818 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.589 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 34.1 p90 -133.74 17.68 3.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.487 -0.758 . . . . 0.0 109.942 179.417 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.37 -57.04 3.9 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.711 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -72.78 -17.12 61.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -1.164 . . . . 0.0 110.226 -179.827 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.543 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.14 -178.04 47.31 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.49 -1.338 . . . . 0.0 109.981 179.876 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.545 ' HB3' ' CZ ' ' A' ' 280' ' ' TYR . . . -138.35 141.23 39.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.388 -1.066 . . . . 0.0 110.125 -179.898 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.589 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 7.8 mt-10 -93.01 147.21 23.03 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.294 -0.879 . . . . 0.0 110.0 -179.838 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.6 m-85 -139.13 84.54 2.01 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.406 -0.809 . . . . 0.0 110.444 -179.581 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.431 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -66.26 150.68 48.44 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.525 -0.734 . . . . 0.0 109.736 179.419 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.59 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.2 t -146.47 89.37 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.392 -0.818 . . . . 0.0 110.019 -179.555 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.407 ' O ' HD21 ' A' ' 267' ' ' LEU . 26.2 m -86.04 126.15 33.95 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 109.342 179.601 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.597 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.12 152.18 29.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.119 -0.988 . . . . 0.0 110.929 -178.894 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.544 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.5 OUTLIER -131.39 134.73 46.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.731 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.531 ' CD2' ' O ' ' A' ' 285' ' ' ASN . 17.2 mt -142.72 162.04 36.51 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.871 -1.143 . . . . 0.0 110.332 -179.846 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.68 34.94 0.71 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.29 -0.881 . . . . 0.0 109.984 179.731 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 144.98 -128.08 3.08 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.825 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.473 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.6 mm-40 -106.25 108.0 19.28 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.033 -1.275 . . . . 0.0 110.969 -179.621 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.542 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 8.4 m-85 -127.02 134.76 50.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.336 -0.853 . . . . 0.0 109.493 179.523 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.544 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 2.0 t70 -73.85 96.37 2.58 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.808 -1.183 . . . . 0.0 108.785 179.02 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.583 ' CE3' ' O ' ' A' ' 292' ' ' TRP . 56.0 p-90 -98.66 109.26 22.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 111.36 -178.853 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.597 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 2.8 m -100.82 115.65 30.83 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.769 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 320' ' ' ILE . 6.6 t -96.59 111.01 25.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.132 -0.98 . . . . 0.0 110.83 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.443 ' HA ' HG12 ' A' ' 320' ' ' ILE . 2.9 ttpp -87.87 145.32 26.12 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.459 -0.776 . . . . 0.0 109.346 179.118 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.56 HG13 ' CZ ' ' A' ' 336' ' ' PHE . 84.6 t -145.4 107.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.153 -0.967 . . . . 0.0 110.452 -179.439 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.561 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.1 mmtt -70.33 133.06 46.58 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.194 -0.941 . . . . 0.0 109.773 179.806 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.541 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 72.4 mt -87.43 157.83 19.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.441 -0.787 . . . . 0.0 111.731 -178.735 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.533 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -64.95 176.95 0.68 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.6 -0.688 . . . . 0.0 109.571 179.237 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.508 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.6 Cg_endo -68.1 82.47 0.48 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.62 1.327 . . . . 0.0 110.001 179.628 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.7 22.62 5.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.38 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.501 ' HB3' ' HB2' ' A' ' 299' ' ' ALA . . . -110.48 144.7 38.89 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.357 -1.084 . . . . 0.0 110.227 -179.747 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.52 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 17.5 p -147.57 146.12 29.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 110.391 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.447 HG22 HD22 ' A' ' 298' ' ' LEU . 77.8 t -73.11 125.73 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.374 -0.829 . . . . 0.0 110.101 179.896 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.63 -15.8 5.72 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.429 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.3 OUTLIER -144.73 126.99 15.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.207 -1.173 . . . . 0.0 110.837 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.503 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -149.69 173.46 13.66 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.361 -0.837 . . . . 0.0 109.835 179.531 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.417 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -163.54 158.06 20.33 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.797 -1.189 . . . . 0.0 111.713 -179.761 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.525 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 1.2 m 58.87 26.32 14.73 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.292 0.568 . . . . 0.0 111.052 179.575 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.546 ' HB3' ' CB ' ' A' ' 334' ' ' PHE . . . -174.87 141.47 0.61 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 110.089 179.405 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.514 ' ND2' HG11 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.09 117.76 18.96 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.017 -1.052 . . . . 0.0 109.35 179.61 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.449 ' HG3' HG11 ' A' ' 319' ' ' VAL . 4.2 ttpt -86.21 133.16 33.86 Favored 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.719 0.771 . . . . 0.0 110.877 -179.355 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.528 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -115.17 172.3 7.15 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.903 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -134.75 103.12 5.5 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 110.177 -179.868 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.496 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.21 49.82 3.01 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 47.92 80.85 0.05 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.146 -1.208 . . . . 0.0 109.971 -179.947 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.79 -1.26 58.05 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.6 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.3 m-85 -141.71 179.48 6.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.464 -1.021 . . . . 0.0 109.256 179.502 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.564 HG13 ' CZ ' ' A' ' 321' ' ' PHE . 5.2 t -154.22 153.8 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.932 . . . . 0.0 109.286 178.721 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.597 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 78.3 mt -132.19 138.69 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.996 -1.065 . . . . 0.0 111.337 -179.536 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.5 m-85 -113.42 133.61 55.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.084 -1.01 . . . . 0.0 111.066 -179.629 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.503 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.3 p -127.74 169.19 12.99 Favored Pre-proline 0 C--N 1.3 -1.546 0 O-C-N 121.072 -1.017 . . . . 0.0 109.672 179.011 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.52 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.5 Cg_endo -66.34 117.23 4.54 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.812 1.428 . . . . 0.0 111.1 -179.22 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.514 HG11 ' ND2' ' A' ' 311' ' ' ASN . 13.3 m -62.12 -112.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.455 -0.778 . . . . 0.0 110.059 179.872 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -114.46 -19.38 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 179.873 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.43 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 7.9 p-90 -122.48 -17.96 6.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.232 -0.917 . . . . 0.0 110.287 -179.904 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.484 ' ND2' ' HB1' ' A' ' 332' ' ' ALA . 4.5 t30 -83.9 46.47 1.19 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 0.0 110.066 -179.885 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.493 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.61 -11.95 7.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.393 -0.817 . . . . 0.0 109.783 -179.933 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.49 -163.77 0.02 OUTLIER Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.735 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.13 2.24 5.75 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 124.07 1.563 . . . . 0.0 110.625 179.9 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.8 m -159.61 114.98 2.43 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.619 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.484 ' HB1' ' ND2' ' A' ' 327' ' ' ASN . . . -137.76 128.23 26.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.136 -0.978 . . . . 0.0 110.13 -179.767 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 333' ' ' THR . . . . . . . . . . . . . 87.0 m -117.27 148.9 41.26 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.151 -0.968 . . . . 0.0 110.496 -179.785 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.59 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 11.8 p90 -150.4 169.2 22.0 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.448 -0.782 . . . . 0.0 108.952 179.796 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.503 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -145.48 158.66 27.73 Favored Glycine 0 N--CA 1.489 2.21 0 C-N-CA 118.737 -1.697 . . . . 0.0 110.128 -179.704 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.693 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.1 p90 -145.03 148.18 33.43 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.521 -0.988 . . . . 0.0 109.876 179.397 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.54 HG21 ' CZ2' ' A' ' 274' ' ' TRP . 1.7 mp -121.48 120.19 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.839 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.541 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 4.7 t -97.89 149.37 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.264 -0.897 . . . . 0.0 110.266 -179.749 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -118.96 131.36 56.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.398 -0.814 . . . . 0.0 110.396 -179.776 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.38 -124.33 0.92 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 179.869 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.551 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 39.9 Cg_endo -65.71 -162.19 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.601 0 O-C-N 123.754 1.397 . . . . 0.0 110.448 179.702 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.589 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -123.78 127.9 48.77 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.236 -0.915 . . . . 0.0 110.642 -179.199 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.471 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 111.35 -75.17 0.21 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.867 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -119.56 127.99 53.5 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.311 -1.111 . . . . 0.0 108.943 179.13 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.551 ' CG ' ' HD2' ' A' ' 341' ' ' PRO . 0.7 OUTLIER -129.22 9.67 5.7 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.821 -1.174 . . . . 0.0 110.757 -179.353 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.586 HG12 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -132.46 119.66 39.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.305 -0.872 . . . . 0.0 110.148 179.335 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.501 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.87 -44.71 50.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.874 . . . . 0.0 110.151 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.45 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.83 158.49 1.64 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.287 -0.883 . . . . 0.0 110.524 -179.967 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.479 HG12 ' CG1' ' A' ' 296' ' ' VAL . 35.5 mt -118.89 104.85 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.198 -0.939 . . . . 0.0 110.04 179.521 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.03 138.76 43.74 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -0.873 . . . . 0.0 110.325 -179.921 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.597 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.33 133.43 42.74 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.229 179.832 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.415 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 28.6 tt0 -139.24 108.83 6.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.192 -0.942 . . . . 0.0 110.262 179.985 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.544 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.64 108.62 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.932 -1.105 . . . . 0.0 109.816 179.447 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.523 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 40.45 33.14 0.16 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.688 -0.633 . . . . 0.0 110.474 -179.724 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 115.29 -22.33 12.25 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.842 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.419 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 0.1 OUTLIER -79.77 104.41 10.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.148 -1.207 . . . . 0.0 110.139 179.988 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 5.2 p -74.5 109.9 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 110.358 -179.775 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.505 ' N ' ' O ' ' A' ' 351' ' ' LEU . 23.0 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.199 179.86 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 036 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -74.57 -178.32 3.95 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.078 1.567 . . . . 0.0 110.597 -179.833 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.464 ' O ' HG21 ' A' ' 258' ' ' THR . 14.1 t -58.83 145.41 40.96 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.473 -0.767 . . . . 0.0 110.33 179.977 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.9 m -102.39 125.14 37.12 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.187 -0.946 . . . . 0.0 110.041 179.892 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.57 150.37 51.09 Favored 'Trans proline' 0 C--N 1.307 -1.627 0 O-C-N 123.792 1.417 . . . . 0.0 110.408 -179.919 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.49 ' CG2' ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -66.04 147.07 98.99 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 110.081 -179.986 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.49 ' HD2' ' CG2' ' A' ' 261' ' ' VAL . 44.4 Cg_endo -71.45 157.2 56.99 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.996 1.524 . . . . 0.0 110.469 -179.994 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.51 ' O ' ' CB ' ' A' ' 264' ' ' SER . 15.5 t -119.03 22.75 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.884 . . . . 0.0 110.45 -179.794 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.51 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 167.49 159.39 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.278 -0.889 . . . . 0.0 110.498 179.923 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 53.25 -177.94 0.15 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 179.554 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.531 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -138.76 164.86 28.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -1.075 . . . . 0.0 110.234 179.958 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.566 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.7 tm? -160.59 133.9 6.7 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.066 -179.703 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.533 ' N ' HD21 ' A' ' 267' ' ' LEU . 3.0 mp0 -131.35 146.72 52.4 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.175 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.419 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -139.99 145.66 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.587 -1.321 . . . . 0.0 111.551 -178.966 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . 0.426 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -132.97 157.59 44.8 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.203 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.575 HG21 ' CD2' ' A' ' 280' ' ' TYR . 76.5 t -143.77 147.06 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.413 -1.429 . . . . 0.0 112.18 -179.175 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.541 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.63 111.12 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.594 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -96.29 147.87 23.34 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.982 -1.074 . . . . 0.0 111.179 -179.101 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.591 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 33.8 p90 -133.05 16.68 4.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.497 -0.752 . . . . 0.0 110.096 179.388 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.417 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 92.0 -60.28 2.72 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.694 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.48 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 22.9 t -71.03 -17.73 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -1.178 . . . . 0.0 110.293 -179.864 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.541 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.45 179.4 47.51 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.315 -1.422 . . . . 0.0 110.148 179.926 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.514 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.82 140.38 44.18 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.39 -1.065 . . . . 0.0 110.168 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.591 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 9.5 mt-10 -93.11 147.06 23.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.734 -179.936 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 93.7 m-85 -140.64 87.77 2.15 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.202 -0.937 . . . . 0.0 110.383 -179.615 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.419 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.16 150.05 46.91 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.436 -0.79 . . . . 0.0 109.854 179.573 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.645 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 3.6 t -143.21 90.35 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.409 -0.807 . . . . 0.0 109.87 -179.61 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.415 ' HA ' HG22 ' A' ' 333' ' ' THR . 10.6 m -86.49 122.45 30.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.995 . . . . 0.0 109.6 179.745 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.602 ' CD1' ' CE3' ' A' ' 292' ' ' TRP . 0.3 OUTLIER -110.22 149.95 29.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.205 -0.934 . . . . 0.0 110.801 -179.166 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.533 ' N ' ' ND2' ' A' ' 285' ' ' ASN . 0.4 OUTLIER -129.67 132.4 46.67 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.281 -0.887 . . . . 0.0 110.324 -179.557 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.532 ' CD2' ' O ' ' A' ' 285' ' ' ASN . 16.4 mt -142.7 159.88 41.37 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.107 . . . . 0.0 109.859 179.458 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -87.86 32.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 110.154 -179.952 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.493 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 150.97 -134.11 4.56 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.467 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 8.7 mm-40 -101.52 106.95 18.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.253 -1.145 . . . . 0.0 110.476 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.518 ' HB2' ' CD1' ' A' ' 286' ' ' LEU . 7.2 m-85 -126.17 130.4 50.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.372 -0.83 . . . . 0.0 109.185 179.588 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.535 ' O ' ' CG2' ' A' ' 353' ' ' ILE . 24.7 m-20 -68.67 96.93 0.76 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.718 -1.239 . . . . 0.0 109.291 179.576 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.602 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 60.7 p-90 -100.51 114.26 27.73 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.139 -0.976 . . . . 0.0 110.776 -179.424 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.488 HG22 ' CG2' ' A' ' 320' ' ' ILE . 4.9 m -109.34 114.57 28.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.528 -0.732 . . . . 0.0 109.325 179.495 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.509 HG21 ' CD2' ' A' ' 351' ' ' LEU . 3.9 t -96.78 111.6 27.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.075 -1.016 . . . . 0.0 110.752 -179.198 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.491 ' HA ' HD12 ' A' ' 320' ' ' ILE . 32.7 ttpt -91.41 141.03 29.19 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.328 -0.857 . . . . 0.0 109.362 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.56 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 71.8 t -137.54 112.27 9.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.262 -0.899 . . . . 0.0 110.564 -179.311 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.573 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 10.4 mmtp -71.72 131.53 43.25 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.183 -0.948 . . . . 0.0 109.308 179.454 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.569 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 91.1 mt -83.53 161.45 21.22 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.282 -0.886 . . . . 0.0 111.889 -178.658 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.568 ' CB ' ' HA ' ' A' ' 345' ' ' LYS . . . -66.16 176.99 0.84 Allowed Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.686 -0.634 . . . . 0.0 109.77 179.354 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.54 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.9 Cg_endo -67.43 80.2 0.43 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.615 1.324 . . . . 0.0 109.79 179.288 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.2 19.88 6.95 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.377 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.523 ' CB ' ' HB3' ' A' ' 299' ' ' ALA . . . -101.33 156.37 17.49 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.365 -1.079 . . . . 0.0 110.351 -179.759 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.537 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 74.3 p -156.85 144.19 18.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.92 . . . . 0.0 110.474 179.93 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.587 ' CG1' ' CD ' ' A' ' 312' ' ' LYS . 30.1 t -71.1 133.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.353 -0.842 . . . . 0.0 110.123 179.784 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.17 -42.11 0.78 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.706 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.61 136.41 46.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.108 -1.231 . . . . 0.0 110.998 -179.554 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.496 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.9 p90 -149.08 174.99 11.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.413 -0.805 . . . . 0.0 109.693 179.469 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.494 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.57 159.29 21.71 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.041 -1.037 . . . . 0.0 111.136 -179.751 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.574 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 58.57 23.81 11.28 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.561 -0.712 . . . . 0.0 111.077 179.668 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.519 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 140.92 0.61 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 110.262 179.494 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.521 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -79.45 124.64 28.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.022 -1.049 . . . . 0.0 109.053 179.387 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.587 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 6.2 ttpt -91.85 133.18 35.88 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.796 0.808 . . . . 0.0 111.199 -179.148 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.506 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.51 175.43 5.57 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.61 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 1.2 mm-40 -135.77 103.6 5.47 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.251 -0.906 . . . . 0.0 110.286 -179.975 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -90.07 47.57 3.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.828 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 m120 51.9 82.62 0.06 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.343 -1.093 . . . . 0.0 110.416 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.29 1.43 60.91 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.607 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.2 m-85 -143.32 -168.37 2.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -1.027 . . . . 0.0 109.102 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.526 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 6.8 t -162.52 158.21 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.325 -0.859 . . . . 0.0 109.832 178.964 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.507 ' O ' ' HA ' ' A' ' 312' ' ' LYS . 21.6 mm -127.88 148.44 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.096 -1.003 . . . . 0.0 111.114 -179.717 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.632 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 84.8 m-85 -124.85 127.02 46.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.235 -0.916 . . . . 0.0 109.836 179.116 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.521 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 3.2 p -126.76 168.77 13.56 Favored Pre-proline 0 C--N 1.301 -1.533 0 C-N-CA 119.068 -1.053 . . . . 0.0 110.307 179.984 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.521 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.8 Cg_endo -66.05 116.09 3.81 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.84 1.442 . . . . 0.0 111.056 -179.448 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.515 HG23 ' CE2' ' A' ' 326' ' ' TRP . 16.0 m -63.18 -115.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.335 -0.853 . . . . 0.0 109.839 179.865 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 73.6 m -118.18 -13.31 9.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.797 -1.189 . . . . 0.0 110.295 179.933 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.574 ' CZ2' ' HA ' ' A' ' 309' ' ' SER . 18.6 p-90 -127.76 -3.36 5.93 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 0.0 110.411 -179.932 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.497 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 1.0 OUTLIER -104.99 41.59 1.32 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.269 -0.894 . . . . 0.0 110.31 -179.72 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.486 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -115.91 -9.26 11.83 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 179.825 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.81 -161.73 0.02 OUTLIER Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.607 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.493 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.5 Cg_endo -74.37 4.77 4.12 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 O-C-N 123.992 1.522 . . . . 0.0 111.097 -179.837 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.437 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 6.6 m -163.96 114.99 1.33 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.842 179.741 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.0 127.45 28.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.185 -0.947 . . . . 0.0 110.267 -179.774 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.472 ' O ' ' HB2' ' A' ' 309' ' ' SER . 91.3 m -115.3 137.51 51.96 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.915 . . . . 0.0 110.308 -179.95 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.645 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 14.9 p90 -138.87 174.95 9.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.303 -0.873 . . . . 0.0 109.014 179.568 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.31 156.87 26.94 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 119.034 -1.555 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.679 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.2 p90 -144.37 149.09 35.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.594 -0.945 . . . . 0.0 109.689 179.445 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.535 ' N ' HD12 ' A' ' 337' ' ' ILE . 1.7 mp -120.47 117.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.078 -1.014 . . . . 0.0 109.833 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.569 ' CG2' ' CD2' ' A' ' 298' ' ' LEU . 2.4 t -96.77 152.05 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -0.871 . . . . 0.0 110.204 -179.598 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.453 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -122.78 134.59 54.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.409 -0.807 . . . . 0.0 109.88 179.866 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.21 -122.72 0.83 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 179.951 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.53 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.3 Cg_endo -69.74 -166.83 0.2 Allowed 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.837 1.44 . . . . 0.0 110.477 -179.806 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.57 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 1.8 mp0 -112.68 134.76 54.04 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.318 -0.864 . . . . 0.0 110.366 -179.696 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.43 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 101.59 -88.66 0.72 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 -179.92 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -104.28 132.79 50.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.319 -1.106 . . . . 0.0 109.308 179.376 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.568 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER -130.49 7.14 4.87 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 120.916 -1.115 . . . . 0.0 110.8 -179.558 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.585 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.9 p -132.55 116.94 29.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.231 -0.918 . . . . 0.0 109.938 179.561 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -45.3 -46.1 12.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.021 -1.049 . . . . 0.0 110.116 -179.604 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.429 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.3 pt-20 -177.12 158.5 1.52 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 110.473 179.979 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.492 HG21 HG22 ' A' ' 296' ' ' VAL . 27.3 mt -116.32 117.86 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.24 -0.912 . . . . 0.0 110.216 179.677 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.88 145.42 47.67 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.162 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.592 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.63 133.67 51.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.015 -1.053 . . . . 0.0 110.679 179.903 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.48 ' N ' HD23 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -138.82 112.88 8.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.371 -0.83 . . . . 0.0 109.901 179.617 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.535 ' CG2' ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.55 94.04 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.979 -1.075 . . . . 0.0 110.051 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.427 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 50.68 31.23 5.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.699 -0.626 . . . . 0.0 110.704 179.981 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.65 -26.06 6.36 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.683 -1.246 . . . . 0.0 110.45 179.351 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 41.7 mm-40 -85.92 103.66 14.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.045 -1.267 . . . . 0.0 110.499 -179.576 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.482 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.3 p -73.6 116.47 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.265 -0.897 . . . . 0.0 110.162 179.891 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.495 HG23 HD13 ' A' ' 358' ' ' ILE . 36.9 mm . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.24 -179.992 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -75.69 -178.16 4.11 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.978 1.514 . . . . 0.0 110.569 179.976 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 2.1 t -78.17 146.38 35.07 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.406 -0.809 . . . . 0.0 110.279 179.989 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 2.4 m -134.77 93.84 17.45 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.121 -0.987 . . . . 0.0 110.483 179.986 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -74.85 161.18 39.58 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.13 1.595 . . . . 0.0 110.111 179.787 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . 0.422 HG23 ' N ' ' A' ' 262' ' ' PRO . 3.0 p -106.8 143.53 27.25 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.159 -0.963 . . . . 0.0 110.307 -179.985 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.439 ' HB3' HG23 ' A' ' 358' ' ' ILE . 45.8 Cg_endo -74.79 133.64 17.19 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 O-C-N 124.106 1.582 . . . . 0.0 110.352 179.911 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.445 ' O ' ' HB2' ' A' ' 264' ' ' SER . 41.5 t -120.11 29.35 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.258 -0.901 . . . . 0.0 110.201 179.899 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 264' ' ' SER . . . . . 0.445 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 1.4 t -178.69 132.24 0.13 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.197 -0.939 . . . . 0.0 110.492 -179.975 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 64.19 179.0 6.0 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 179.807 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.548 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.28 163.61 28.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.428 -1.042 . . . . 0.0 109.511 179.628 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.56 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 1.8 tm? -161.28 134.73 6.54 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 111.736 -179.611 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . 0.52 ' N ' HD23 ' A' ' 267' ' ' LEU . 2.0 mt-10 -130.38 149.61 51.99 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.975 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.456 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 58.6 t -141.3 141.23 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.628 -1.295 . . . . 0.0 111.684 -179.306 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -126.81 157.99 37.78 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.908 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.571 HG12 ' CE2' ' A' ' 280' ' ' TYR . 89.0 t -144.02 146.39 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.333 -1.479 . . . . 0.0 112.193 -179.325 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.517 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.16 110.87 6.47 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.005 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 46.1 p30 -96.15 147.82 23.35 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.163 -0.961 . . . . 0.0 111.378 -178.493 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.562 ' NE1' ' N ' ' A' ' 277' ' ' GLY . 39.4 p90 -134.95 23.65 3.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.586 -0.696 . . . . 0.0 109.884 179.42 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.448 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 82.97 -66.96 3.84 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 276' ' ' SER . . . . . 0.543 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 9.2 m -59.85 -26.35 65.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.197 -1.178 . . . . 0.0 110.615 -179.881 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.562 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -170.96 -177.8 41.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.972 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.563 ' HB2' ' CZ ' ' A' ' 280' ' ' TYR . . . -137.22 144.07 42.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.244 -1.15 . . . . 0.0 110.18 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.53 ' N ' ' CZ3' ' A' ' 274' ' ' TRP . 6.3 mt-10 -97.41 147.43 24.22 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.385 -0.822 . . . . 0.0 109.967 -179.523 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.691 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 91.1 m-85 -141.43 83.89 1.89 Allowed 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.341 -0.849 . . . . 0.0 110.787 -179.344 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.456 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.8 t70 -64.52 146.98 53.74 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.434 -0.791 . . . . 0.0 109.623 179.144 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.618 ' CB ' ' CZ ' ' A' ' 334' ' ' PHE . 6.7 t -142.58 89.08 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 -179.647 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 283' ' ' THR . . . . . 0.414 ' HA ' ' HA ' ' A' ' 333' ' ' THR . 97.8 m -86.46 123.5 31.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.203 -0.935 . . . . 0.0 109.756 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.599 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.48 150.47 28.84 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.168 -0.957 . . . . 0.0 110.517 -179.525 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.548 ' ND2' ' HB3' ' A' ' 266' ' ' SER . 0.4 OUTLIER -129.12 135.77 49.32 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 109.958 -179.687 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.601 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 11.6 mt -143.18 160.68 39.98 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.075 -1.016 . . . . 0.0 109.481 179.564 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.76 31.76 1.76 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 110.528 -179.598 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.0 -94.6 0.13 Allowed Glycine 0 N--CA 1.491 2.312 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.425 179.876 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.47 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.5 tt0 -152.48 106.51 3.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.055 -1.262 . . . . 0.0 110.695 -179.322 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.644 ' N ' ' CD1' ' A' ' 290' ' ' TYR . 5.0 m-85 -128.38 134.85 48.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 179.585 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.579 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 96.7 m-20 -67.34 96.92 0.52 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.846 -1.159 . . . . 0.0 108.754 178.859 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.58 ' CE3' HD11 ' A' ' 284' ' ' LEU . 59.5 p-90 -97.68 108.89 21.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.146 -0.971 . . . . 0.0 111.166 -178.862 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.589 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 8.6 m -102.18 114.85 29.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.643 -0.661 . . . . 0.0 109.233 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.468 HG23 ' CD2' ' A' ' 351' ' ' LEU . 5.5 t -96.71 111.88 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.1 -1.0 . . . . 0.0 111.076 -178.964 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . 0.414 ' O ' HG21 ' A' ' 296' ' ' VAL . 6.3 ttpt -86.63 149.39 24.95 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.476 -0.765 . . . . 0.0 109.351 179.008 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.6 HG12 ' CZ ' ' A' ' 336' ' ' PHE . 43.4 t -148.67 108.0 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.033 -1.042 . . . . 0.0 110.585 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.544 ' HD2' ' CE1' ' A' ' 318' ' ' TYR . 9.1 mmtm -71.01 134.3 47.02 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.131 -0.981 . . . . 0.0 110.044 179.781 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.533 ' CD2' ' CG2' ' A' ' 338' ' ' VAL . 74.9 mt -87.5 165.56 15.42 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.331 -0.855 . . . . 0.0 111.131 -179.37 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.514 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -79.73 173.98 6.85 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 178.883 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.514 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.4 Cg_endo -66.09 84.52 0.26 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.496 1.261 . . . . 0.0 110.125 179.816 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.11 24.15 4.62 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.62 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.472 ' CB ' ' O ' ' A' ' 345' ' ' LYS . . . -115.73 149.29 38.68 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -1.127 . . . . 0.0 110.202 -179.761 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.493 ' N ' HG13 ' A' ' 338' ' ' VAL . 14.1 p -153.96 144.57 22.43 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.664 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.507 HG23 ' CB ' ' A' ' 319' ' ' VAL . 75.0 t -75.09 135.04 28.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 110.09 179.803 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -128.81 -31.33 0.65 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.707 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.5 m -126.56 109.54 12.25 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.033 -1.275 . . . . 0.0 110.92 -179.555 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.578 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 55.4 p90 -133.44 156.54 47.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.631 179.213 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.486 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -149.32 158.42 44.16 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.966 -1.084 . . . . 0.0 111.201 -179.411 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.55 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 65.46 21.12 11.82 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.741 -0.599 . . . . 0.0 111.279 179.55 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.524 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.97 150.49 1.23 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.231 -0.918 . . . . 0.0 110.516 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.499 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -83.62 119.25 24.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.148 -0.97 . . . . 0.0 108.979 179.134 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.578 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 6.7 ttpt -90.44 131.22 36.33 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.916 0.865 . . . . 0.0 111.407 -178.891 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.529 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 4.7 mt-30 -112.18 178.69 4.22 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.61 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . 0.402 ' HA ' ' O ' ' A' ' 318' ' ' TYR . 7.5 mm-40 -143.78 108.13 4.8 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.458 -0.776 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.44 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -96.53 50.65 1.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 52.48 84.7 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.315 -1.109 . . . . 0.0 110.003 -179.948 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 93.97 -2.28 68.98 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.892 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.545 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.2 m-85 -137.19 -179.59 5.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -1.109 . . . . 0.0 109.683 179.665 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.507 ' CB ' HG23 ' A' ' 304' ' ' VAL . 3.8 t -157.63 155.69 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.444 -0.785 . . . . 0.0 109.421 178.771 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.589 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 1.9 mt -131.99 140.31 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 111.674 -179.147 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 67.5 m-85 -115.74 130.17 56.75 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 110.384 179.548 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.505 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.4 p -127.97 169.96 11.41 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 120.963 -1.086 . . . . 0.0 109.57 179.657 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.505 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -66.16 126.6 16.03 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.594 1.313 . . . . 0.0 110.915 -179.301 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.497 ' CG2' ' HB2' ' A' ' 327' ' ' ASN . 35.4 m -77.79 -123.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.826 -179.985 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 19.8 m -100.32 -12.98 19.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.766 -1.209 . . . . 0.0 110.586 -179.911 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . 0.55 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 15.3 p-90 -137.25 5.33 2.74 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.144 -0.972 . . . . 0.0 110.679 -179.887 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.497 ' HB2' ' CG2' ' A' ' 324' ' ' VAL . 1.4 t30 -107.09 43.14 1.2 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.068 -1.02 . . . . 0.0 110.381 -179.639 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.479 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 1.2 pttt -126.82 -5.71 6.28 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.38 -0.825 . . . . 0.0 109.969 179.704 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.0 -156.13 0.03 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 -179.882 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.456 ' O ' ' OG1' ' A' ' 331' ' ' THR . 47.8 Cg_endo -72.23 2.5 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 124.134 1.597 . . . . 0.0 110.964 -179.89 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.9 m -165.4 121.67 1.4 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.257 -0.902 . . . . 0.0 109.946 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.558 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -136.93 107.94 6.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.188 -0.945 . . . . 0.0 110.45 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.458 ' O ' ' HB3' ' A' ' 309' ' ' SER . 25.6 m -98.41 142.04 30.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.192 -0.943 . . . . 0.0 109.96 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.618 ' CZ ' ' CB ' ' A' ' 282' ' ' VAL . 7.2 p90 -149.14 169.82 19.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.771 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.45 151.68 23.84 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.141 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.691 ' CE1' ' CD1' ' A' ' 280' ' ' TYR . 1.0 OUTLIER -136.44 149.46 48.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.563 -0.963 . . . . 0.0 109.83 179.569 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.542 HD13 ' N ' ' A' ' 337' ' ' ILE . 1.7 mp -122.86 119.34 57.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.144 -0.973 . . . . 0.0 109.529 179.356 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.54 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 3.4 t -95.95 143.74 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.077 -1.014 . . . . 0.0 109.239 179.702 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -120.07 140.48 50.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.176 -0.953 . . . . 0.0 110.86 -179.255 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 175.78 -128.82 1.43 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.817 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.489 ' O ' ' HD3' ' A' ' 345' ' ' LYS . 44.3 Cg_endo -70.68 -153.42 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 123.739 1.389 . . . . 0.0 109.493 179.2 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.448 ' HB3' ' HA2' ' A' ' 275' ' ' GLY . 0.0 OUTLIER -130.27 143.67 50.92 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.759 -1.213 . . . . 0.0 110.021 179.357 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.476 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 98.88 71.28 1.0 Allowed Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.632 -1.787 . . . . 0.0 108.632 -179.315 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.476 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 3.3 m-20 65.76 127.97 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.482 -1.011 . . . . 0.0 109.31 -178.99 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.54 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.1 OUTLIER -129.62 15.83 5.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.056 -1.027 . . . . 0.0 110.436 -179.61 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.604 ' CG1' ' CE2' ' A' ' 280' ' ' TYR . 6.2 p -127.61 120.18 53.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.168 -0.957 . . . . 0.0 110.133 179.614 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.527 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 0.8 OUTLIER -48.43 -46.38 37.53 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.074 -1.016 . . . . 0.0 109.717 -179.825 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.411 ' OE1' ' HB3' ' A' ' 347' ' ' GLU . 1.6 pt-20 -176.99 158.59 1.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.351 -0.843 . . . . 0.0 110.429 179.679 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.477 HG12 HG13 ' A' ' 296' ' ' VAL . 11.3 mt -117.07 103.53 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.887 . . . . 0.0 109.793 179.675 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.61 146.45 28.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.292 -0.88 . . . . 0.0 110.306 -179.737 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.599 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -106.62 132.95 52.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.161 -0.962 . . . . 0.0 110.135 179.576 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.463 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.4 tt0 -138.53 112.69 8.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.948 179.86 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.488 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 2.7 mt -91.61 113.17 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.104 -0.997 . . . . 0.0 110.099 179.963 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.579 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.54 29.54 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.752 -0.592 . . . . 0.0 110.918 -179.809 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.84 -13.85 12.91 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.523 179.23 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.488 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 72.7 mm-40 -93.8 113.98 26.14 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.885 -1.362 . . . . 0.0 110.368 -179.836 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.519 ' O ' ' CD1' ' A' ' 358' ' ' ILE . 2.2 p -74.23 138.35 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.183 179.998 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.519 ' CD1' ' O ' ' A' ' 357' ' ' VAL . 19.1 mm . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.277 -179.909 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -73.23 -178.93 3.92 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 O-C-N 124.051 1.553 . . . . 0.0 110.395 179.966 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 258' ' ' THR . . . . . 0.471 ' CG2' ' O ' ' A' ' 258' ' ' THR . 6.1 t -58.79 125.15 22.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.205 -0.935 . . . . 0.0 110.242 -179.849 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 57.6 m -124.68 112.15 27.45 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 0.0 110.362 -179.882 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.67 155.41 54.31 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 124.025 1.54 . . . . 0.0 110.339 179.781 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 261' ' ' VAL . . . . . . . . . . . . . 2.9 p -74.89 141.99 75.94 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.345 -0.847 . . . . 0.0 110.388 -179.806 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 262' ' ' PRO . . . . . 0.428 ' HB3' ' HA ' ' A' ' 358' ' ' ILE . 47.9 Cg_endo -75.97 152.75 36.71 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.078 1.567 . . . . 0.0 110.131 179.705 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 263' ' ' VAL . . . . . 0.401 ' CG2' ' C ' ' A' ' 262' ' ' PRO . 18.0 t -147.4 30.39 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 110.288 179.955 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 45.3 t -174.29 89.32 0.06 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.209 -0.932 . . . . 0.0 110.637 -179.949 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 98.88 -177.1 30.13 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 179.568 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 266' ' ' SER . . . . . 0.574 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -134.62 165.95 24.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.532 -0.981 . . . . 0.0 109.69 179.866 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 267' ' ' LEU . . . . . 0.576 ' HB2' ' CD1' ' A' ' 351' ' ' LEU . 2.0 tm? -161.37 139.17 9.19 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.193 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 -138.02 130.38 29.16 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.542 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 269' ' ' VAL . . . . . 0.484 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 94.9 t -124.32 138.13 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.804 -1.185 . . . . 0.0 111.681 -178.854 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 20.1 tttt -121.19 157.64 29.78 Favored 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.131 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 271' ' ' VAL . . . . . 0.585 ' CG2' ' CD1' ' A' ' 280' ' ' TYR . 86.7 t -144.15 147.07 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 120.404 -1.435 . . . . 0.0 112.531 -179.049 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 272' ' ' ASN . . . . . 0.528 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -141.35 109.98 6.04 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.864 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 273' ' ' ASP . . . . . 0.53 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 m-20 -94.82 146.71 24.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.114 -0.991 . . . . 0.0 111.535 -178.718 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 274' ' ' TRP . . . . . 0.583 ' CZ3' ' HG3' ' A' ' 279' ' ' GLU . 39.0 p90 -134.67 23.52 3.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.616 -0.678 . . . . 0.0 109.667 179.062 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 275' ' ' GLY . . . . . 0.525 ' HA2' ' CB ' ' A' ' 342' ' ' GLN . . . 82.39 -65.33 4.11 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.932 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.0 -23.99 65.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -1.186 . . . . 0.0 110.354 -179.929 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 277' ' ' GLY . . . . . 0.557 ' O ' ' CD2' ' A' ' 274' ' ' TRP . . . -176.57 176.43 47.87 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 278' ' ' ALA . . . . . 0.582 ' HB1' ' CE2' ' A' ' 280' ' ' TYR . . . -131.36 148.55 52.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.359 -1.083 . . . . 0.0 110.259 -179.879 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 279' ' ' GLU . . . . . 0.583 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 16.3 mt-10 -97.63 147.07 24.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.513 -0.742 . . . . 0.0 109.683 -179.81 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 80.1 m-85 -141.7 85.98 1.97 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.362 -0.836 . . . . 0.0 111.045 -179.242 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 281' ' ' ASP . . . . . 0.484 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -69.22 150.22 47.7 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.389 -0.82 . . . . 0.0 109.54 179.115 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 282' ' ' VAL . . . . . 0.593 ' HB ' ' CE2' ' A' ' 334' ' ' PHE . 4.9 t -143.86 87.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.353 -0.842 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 283' ' ' THR . . . . . . . . . . . . . 98.0 m -86.68 123.44 31.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.093 -1.005 . . . . 0.0 109.885 179.927 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 284' ' ' LEU . . . . . 0.602 ' CD2' ' CD1' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.4 148.25 30.41 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.201 -0.937 . . . . 0.0 110.062 -179.66 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 285' ' ' ASN . . . . . 0.574 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -129.6 111.98 13.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.221 -0.924 . . . . 0.0 111.134 -178.742 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 286' ' ' LEU . . . . . 0.614 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 10.2 mt -121.47 158.66 27.92 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.809 -1.182 . . . . 0.0 109.407 178.982 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.97 35.62 1.25 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.201 -0.937 . . . . 0.0 110.38 -179.69 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 288' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 163.79 -103.14 0.21 Allowed Glycine 0 N--CA 1.492 2.379 0 C-N-CA 118.879 -1.629 . . . . 0.0 110.561 179.983 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 289' ' ' GLN . . . . . 0.52 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 1.7 mt-30 -148.27 120.45 8.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -1.132 . . . . 0.0 110.411 -179.343 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 290' ' ' TYR . . . . . 0.614 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -151.27 131.29 13.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.826 179.553 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 291' ' ' ASP . . . . . 0.518 ' HB3' ' ND2' ' A' ' 354' ' ' ASN . 4.9 t70 -62.1 103.81 0.41 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.096 -1.002 . . . . 0.0 109.568 179.59 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 292' ' ' TRP . . . . . 0.586 ' CE3' ' CD1' ' A' ' 284' ' ' LEU . 53.9 p-90 -103.0 111.07 23.23 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.291 -0.881 . . . . 0.0 110.49 -179.758 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 293' ' ' THR . . . . . 0.562 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 25.3 m -105.08 114.71 29.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.776 179.639 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 294' ' ' VAL . . . . . 0.517 ' HB ' ' HB2' ' A' ' 321' ' ' PHE . 3.1 t -97.07 110.86 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 110.077 -179.732 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 21.2 ttmt -86.32 149.4 25.07 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.189 -0.945 . . . . 0.0 109.42 179.148 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 296' ' ' VAL . . . . . 0.575 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 86.3 t -145.6 107.04 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.275 -0.891 . . . . 0.0 110.749 -179.161 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 297' ' ' LYS . . . . . 0.576 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 4.4 mmtt -70.47 136.95 49.88 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.13 -0.981 . . . . 0.0 109.157 179.188 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 298' ' ' LEU . . . . . 0.543 ' CD1' ' HA ' ' A' ' 303' ' ' THR . 95.8 mt -90.47 157.43 17.57 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.23 -0.919 . . . . 0.0 111.673 -178.573 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 299' ' ' ALA . . . . . 0.521 ' HB3' ' CB ' ' A' ' 302' ' ' ALA . . . -65.02 175.43 1.01 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.574 -0.704 . . . . 0.0 109.771 179.443 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 300' ' ' PRO . . . . . 0.493 ' HD2' ' HB2' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -67.25 81.81 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 123.707 1.372 . . . . 0.0 110.049 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.76 19.14 7.5 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.54 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 302' ' ' ALA . . . . . 0.521 ' CB ' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 144.2 34.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.414 -1.051 . . . . 0.0 110.026 -179.812 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 303' ' ' THR . . . . . 0.543 ' HA ' ' CD1' ' A' ' 298' ' ' LEU . 18.4 p -145.09 145.04 31.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.137 -0.977 . . . . 0.0 110.886 -179.985 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 304' ' ' VAL . . . . . 0.519 ' CG2' HG22 ' A' ' 319' ' ' VAL . 75.4 t -70.39 142.41 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.46 -0.775 . . . . 0.0 109.96 179.697 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.65 -40.68 0.2 Allowed Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.663 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 306' ' ' SER . . . . . 0.428 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -120.76 118.69 30.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.051 -1.264 . . . . 0.0 110.631 -179.599 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 307' ' ' PHE . . . . . 0.538 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.7 p90 -141.86 156.78 45.52 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.255 -0.903 . . . . 0.0 109.641 179.671 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 308' ' ' TRP . . . . . 0.478 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.83 158.72 42.62 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.087 -1.008 . . . . 0.0 111.188 -179.206 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 309' ' ' SER . . . . . 0.463 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 60.47 25.43 15.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.592 -0.692 . . . . 0.0 110.926 179.611 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 310' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 322' ' ' THR . . . -174.61 142.24 0.71 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.183 -0.948 . . . . 0.0 110.282 179.679 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 311' ' ' ASN . . . . . 0.522 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -77.21 123.74 26.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.115 -0.991 . . . . 0.0 109.296 179.355 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 312' ' ' LYS . . . . . 0.538 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 1.7 ttpt -94.5 123.4 37.9 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.555 0.693 . . . . 0.0 110.95 -179.341 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 313' ' ' GLN . . . . . 0.617 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 2.1 mt-30 -109.65 177.21 4.8 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.549 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -136.28 99.69 4.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.468 -0.77 . . . . 0.0 110.129 179.939 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.58 41.3 3.08 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.777 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 58.31 83.98 0.11 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.155 -1.203 . . . . 0.0 110.158 179.981 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 317' ' ' GLY . . . . . 0.612 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.14 3.99 63.22 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 318' ' ' TYR . . . . . 0.612 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 1.3 m-85 -146.47 -169.87 3.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.398 -1.06 . . . . 0.0 108.988 179.54 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 319' ' ' VAL . . . . . 0.531 ' CG2' ' O ' ' A' ' 318' ' ' TYR . 12.8 t -161.44 149.98 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 0.0 109.843 179.147 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 320' ' ' ILE . . . . . 0.617 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 8.7 mm -114.76 151.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 120.937 -1.102 . . . . 0.0 110.836 -179.946 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.8 m-85 -130.06 115.68 17.45 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.166 -0.959 . . . . 0.0 109.963 178.977 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 322' ' ' THR . . . . . 0.522 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 24.7 p -122.23 167.0 15.02 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 120.728 -1.232 . . . . 0.0 109.654 179.551 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 323' ' ' PRO . . . . . 0.525 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.1 Cg_endo -64.81 120.05 7.22 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.803 1.423 . . . . 0.0 110.893 -179.362 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 324' ' ' VAL . . . . . 0.452 HG11 ' ND2' ' A' ' 311' ' ' ASN . 28.9 m -63.31 -126.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.498 -0.751 . . . . 0.0 110.149 -179.873 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 325' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -101.09 -20.78 15.2 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.847 -1.158 . . . . 0.0 110.869 -179.585 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 23.9 p-90 -124.57 -1.68 7.99 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.998 -1.063 . . . . 0.0 110.699 -179.753 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 327' ' ' ASN . . . . . 0.44 ' O ' ' HB3' ' A' ' 323' ' ' PRO . 2.7 t30 -104.7 44.52 1.02 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.107 -0.996 . . . . 0.0 110.614 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 328' ' ' LYS . . . . . 0.443 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -126.13 10.86 7.55 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.055 -1.028 . . . . 0.0 109.961 179.704 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 329' ' ' GLY . . . . . 0.455 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -73.89 -143.37 0.73 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.615 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 330' ' ' PRO . . . . . 0.554 ' O ' ' N ' ' A' ' 286' ' ' LEU . 43.7 Cg_endo -72.75 -56.15 0.09 OUTLIER 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.463 . . . . 0.0 109.756 179.602 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 7.2 m -107.94 126.43 52.69 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.177 -0.952 . . . . 0.0 110.204 179.76 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 332' ' ' ALA . . . . . 0.563 ' HB3' ' CZ2' ' A' ' 292' ' ' TRP . . . -138.66 109.48 6.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.379 -0.826 . . . . 0.0 109.945 179.902 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 333' ' ' THR . . . . . 0.463 ' O ' ' HB2' ' A' ' 309' ' ' SER . 8.8 m -100.81 145.33 28.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.432 -179.715 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 334' ' ' PHE . . . . . 0.593 ' CE2' ' HB ' ' A' ' 282' ' ' VAL . 10.1 p90 -151.54 174.92 12.85 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.552 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 335' ' ' GLY . . . . . 0.472 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.9 165.45 31.13 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 118.838 -1.648 . . . . 0.0 110.518 -179.319 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 336' ' ' PHE . . . . . 0.676 ' CE1' ' CD2' ' A' ' 280' ' ' TYR . 0.8 OUTLIER -152.27 143.58 23.3 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.525 -0.986 . . . . 0.0 109.9 179.634 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 337' ' ' ILE . . . . . 0.552 ' N ' ' CD1' ' A' ' 337' ' ' ILE . 1.5 mp -117.76 125.27 74.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.064 -1.022 . . . . 0.0 109.886 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 338' ' ' VAL . . . . . 0.533 ' CG1' ' HB3' ' A' ' 345' ' ' LYS . 2.7 t -101.9 145.47 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.276 -0.89 . . . . 0.0 109.945 179.835 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 339' ' ' ASN . . . . . 0.466 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 1.9 m-80 -113.84 126.76 55.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.344 -0.847 . . . . 0.0 110.098 179.873 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 340' ' ' GLY . . . . . 0.406 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -176.4 -147.37 6.45 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.994 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 341' ' ' PRO . . . . . 0.49 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 46.2 Cg_endo -71.33 118.38 5.64 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 124.055 1.555 . . . . 0.0 110.658 -179.732 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 342' ' ' GLN . . . . . 0.525 ' CB ' ' HA2' ' A' ' 275' ' ' GLY . 0.0 OUTLIER -39.91 155.78 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.389 -0.819 . . . . 0.0 110.851 -179.997 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 343' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 92.32 63.17 1.14 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.665 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 344' ' ' ASP . . . . . 0.475 ' O ' ' O ' ' A' ' 343' ' ' GLY . 16.0 t0 60.97 134.41 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.333 -1.098 . . . . 0.0 109.566 -179.751 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 345' ' ' LYS . . . . . 0.533 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.2 OUTLIER -135.05 28.92 3.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.996 -1.065 . . . . 0.0 110.809 -179.518 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 346' ' ' VAL . . . . . 0.605 HG12 ' CE1' ' A' ' 280' ' ' TYR . 12.6 p -132.5 116.93 29.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.195 -0.941 . . . . 0.0 110.245 179.632 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 347' ' ' GLU . . . . . 0.455 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -46.65 -45.39 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.895 . . . . 0.0 110.319 -179.937 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 348' ' ' GLU . . . . . 0.415 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 13.9 pt-20 -176.67 158.34 1.69 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.125 -0.984 . . . . 0.0 110.686 -179.781 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 349' ' ' ILE . . . . . 0.522 HG12 ' CG1' ' A' ' 296' ' ' VAL . 39.8 mt -122.31 105.94 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.121 -0.987 . . . . 0.0 109.918 179.516 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.78 143.92 35.66 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.085 -1.009 . . . . 0.0 110.283 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 351' ' ' LEU . . . . . 0.602 ' CD1' ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.6 128.59 53.7 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.194 -0.941 . . . . 0.0 109.953 179.694 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 352' ' ' GLU . . . . . 0.476 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.3 OUTLIER -138.62 119.26 14.01 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.974 . . . . 0.0 110.123 179.814 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 353' ' ' ILE . . . . . 0.482 HG12 ' HA ' ' A' ' 292' ' ' TRP . 2.0 mt -92.8 109.7 21.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.16 -0.963 . . . . 0.0 110.271 179.934 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.27 46.36 0.88 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.592 . . . . 0.0 111.202 -179.979 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.37 -36.24 4.38 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.385 179.246 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 356' ' ' GLN . . . . . 0.476 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 38.3 mm-40 -66.88 176.07 2.2 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.012 -1.287 . . . . 0.0 110.311 -179.587 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 357' ' ' VAL . . . . . 0.461 ' O ' HD11 ' A' ' 358' ' ' ILE . 5.6 p -140.65 129.82 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.305 -0.872 . . . . 0.0 109.969 -179.955 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 358' ' ' ILE . . . . . 0.461 HD11 ' O ' ' A' ' 357' ' ' VAL . 8.3 mm . . . . . 0 N--CA 1.494 1.726 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.303 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.559 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.78 158.58 44.05 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.473 -1.016 . . . . 0.0 109.699 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.575 HD12 ' CG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -153.02 123.89 7.38 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.08 -1.012 . . . . 0.0 110.749 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.473 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 3.3 mt-10 -122.05 113.72 19.93 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.903 HG13 ' O ' ' A' ' 281' ' ' ASP . 47.5 t -108.11 145.8 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.957 -1.089 . . . . 0.0 111.734 -178.513 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 5.5 mttp -130.16 156.91 43.8 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.003 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.646 HG13 ' O ' ' A' ' 279' ' ' GLU . 75.4 t -144.75 139.44 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.407 -1.433 . . . . 0.0 111.647 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.529 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -134.52 110.89 9.66 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.174 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.9 m-20 -98.72 135.42 40.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.939 -1.101 . . . . 0.0 111.71 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.812 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.6 p90 -119.75 20.15 12.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.507 -0.746 . . . . 0.0 109.209 178.919 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 275' ' ' GLY . . . . . 0.405 ' O ' ' NZ ' ' A' ' 345' ' ' LYS . . . 87.06 -77.97 1.93 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 32.0 m -51.22 -24.63 4.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.366 -1.079 . . . . 0.0 110.465 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.541 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -165.62 174.28 41.35 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.298 -1.429 . . . . 0.0 110.311 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.558 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -133.58 141.77 47.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.46 -1.024 . . . . 0.0 110.028 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.646 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.3 mt-10 -97.66 146.65 25.12 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.325 -0.859 . . . . 0.0 109.915 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 94.4 m-85 -141.84 85.24 1.93 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.442 -0.786 . . . . 0.0 110.405 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.903 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -69.6 154.21 42.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.864 . . . . 0.0 109.997 179.498 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.613 HG11 HG11 ' A' ' 294' ' ' VAL . 4.2 t -145.03 89.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 O-C-N 121.629 -0.669 . . . . 0.0 109.506 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.898 HG23 ' OG1' ' A' ' 333' ' ' THR . 10.5 m -86.08 117.48 24.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.126 -0.984 . . . . 0.0 109.626 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.023 HD21 HD11 ' A' ' 351' ' ' LEU . 0.9 OUTLIER -106.25 144.08 33.45 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.202 -0.936 . . . . 0.0 110.766 -179.07 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.559 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 2.2 m120 -126.65 115.9 20.18 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.604 -0.685 . . . . 0.0 109.825 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.599 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 11.0 mt -124.9 155.21 39.9 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.633 -1.292 . . . . 0.0 110.262 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -89.8 34.87 0.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.195 -0.94 . . . . 0.0 110.105 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 161.57 -157.44 29.12 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.518 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.2 OUTLIER -96.42 93.62 6.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -1.118 . . . . 0.0 110.706 -179.663 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.599 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.9 m-30 -116.36 143.09 45.99 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.218 -0.926 . . . . 0.0 110.109 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.825 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.6 m-20 -77.89 98.71 5.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.083 -1.011 . . . . 0.0 109.201 179.032 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.844 ' CE3' HD13 ' A' ' 284' ' ' LEU . 54.8 p-90 -98.31 113.32 25.23 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.286 -0.884 . . . . 0.0 110.785 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.623 HG23 ' CG2' ' A' ' 322' ' ' THR . 10.5 m -105.71 115.58 30.48 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 109.526 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.755 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -97.19 113.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.101 -0.999 . . . . 0.0 110.49 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.585 ' HA ' HD13 ' A' ' 320' ' ' ILE . 9.2 ttpt -92.5 135.09 34.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.333 -0.854 . . . . 0.0 109.599 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.758 HG13 HG12 ' A' ' 349' ' ' ILE . 95.0 t -132.26 108.05 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.064 -1.023 . . . . 0.0 110.691 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.477 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtt -70.0 134.55 48.43 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.086 -1.009 . . . . 0.0 109.178 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.967 HD13 ' HA ' ' A' ' 303' ' ' THR . 61.5 mt -88.51 162.48 16.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.181 -0.95 . . . . 0.0 111.723 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.87 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -64.37 176.77 0.65 Allowed Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.779 -0.576 . . . . 0.0 109.877 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.809 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.82 77.28 0.57 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.657 1.346 . . . . 0.0 109.903 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.43 19.73 5.71 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.87 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -103.65 150.18 24.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.415 -1.05 . . . . 0.0 110.248 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.967 ' HA ' HD13 ' A' ' 298' ' ' LEU . 27.0 p -149.92 144.36 25.85 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.267 -0.895 . . . . 0.0 110.642 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.71 HG21 HG11 ' A' ' 319' ' ' VAL . 29.5 t -67.45 136.54 26.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.356 -0.84 . . . . 0.0 109.975 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.8 -41.98 0.54 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.437 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 1.0 OUTLIER -128.94 129.96 46.14 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.134 -1.215 . . . . 0.0 110.756 -179.659 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.593 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.1 p90 -146.39 169.09 19.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.398 -0.814 . . . . 0.0 109.463 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.96 160.98 22.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.878 -1.139 . . . . 0.0 111.23 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.85 20.99 12.55 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.485 -0.759 . . . . 0.0 111.003 179.433 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.573 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 144.33 0.76 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.355 -0.841 . . . . 0.0 110.05 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.542 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.6 m120 -78.51 124.44 28.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.023 -1.048 . . . . 0.0 109.166 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 1.1 ttpt -91.92 138.34 31.62 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.775 0.797 . . . . 0.0 110.916 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.589 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -121.41 173.7 7.21 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.003 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.441 ' HG3' ' HE3' ' A' ' 312' ' ' LYS . 2.5 mt-10 -136.35 106.48 6.34 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.392 -0.817 . . . . 0.0 110.487 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -94.04 40.82 2.69 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 25.1 m120 57.43 82.33 0.13 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.249 -1.148 . . . . 0.0 110.195 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.623 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.84 0.87 57.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.809 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -145.77 -169.62 3.27 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.333 -1.098 . . . . 0.0 109.279 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.809 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.7 t -162.55 157.84 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.216 -0.928 . . . . 0.0 109.8 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.585 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.3 mm -126.65 145.91 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.156 -0.965 . . . . 0.0 111.086 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.637 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.3 m-85 -123.16 128.5 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.125 -0.984 . . . . 0.0 110.195 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.623 ' CG2' HG23 ' A' ' 293' ' ' THR . 25.0 p -129.58 166.37 26.33 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 120.802 -1.187 . . . . 0.0 109.394 179.442 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.509 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.8 Cg_endo -65.22 121.17 8.55 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.698 1.367 . . . . 0.0 111.132 -179.138 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.812 HG22 ' HB2' ' A' ' 327' ' ' ASN . 28.5 m -64.39 -125.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.626 -0.672 . . . . 0.0 110.182 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.482 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.4 m -100.69 -13.12 18.64 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.832 -1.168 . . . . 0.0 110.658 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.688 ' H ' HG23 ' A' ' 324' ' ' VAL . 15.9 p-90 -136.35 6.57 3.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.139 -0.975 . . . . 0.0 110.6 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.812 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.7 OUTLIER -108.4 38.14 2.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.136 -0.977 . . . . 0.0 110.41 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.7 OUTLIER -118.72 -7.69 10.48 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.283 -0.886 . . . . 0.0 110.184 179.76 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.45 -153.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.503 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.4 Cg_endo -76.64 8.34 3.08 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.938 1.494 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.423 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.5 m -163.77 128.08 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.926 -1.109 . . . . 0.0 110.089 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.625 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -146.39 111.33 5.31 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.159 -0.963 . . . . 0.0 110.579 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.898 ' OG1' HG23 ' A' ' 283' ' ' THR . 50.2 m -104.41 126.75 51.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.925 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.755 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.8 p90 -137.08 175.38 9.67 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -154.98 163.3 31.32 Favored Glycine 0 N--CA 1.486 1.982 0 C-N-CA 118.831 -1.652 . . . . 0.0 109.953 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.933 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -147.04 148.34 31.57 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.566 -0.961 . . . . 0.0 109.631 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.933 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.12 121.05 63.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.968 -1.083 . . . . 0.0 109.311 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.706 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.0 t -97.09 159.61 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.683 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -128.03 129.57 46.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.463 -0.773 . . . . 0.0 110.161 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.478 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.492 2.39 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.715 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.2 mtmt . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 121.237 0.541 . . . . 0.0 110.475 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.1 p -133.3 120.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.233 -0.917 . . . . 0.0 110.189 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.436 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -52.5 -45.39 66.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.293 -0.88 . . . . 0.0 110.346 -179.652 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.422 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 5.4 pt-20 -177.09 158.4 1.52 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.049 -1.032 . . . . 0.0 110.905 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.758 HG12 HG13 ' A' ' 296' ' ' VAL . 72.1 mt -120.57 109.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.333 -0.854 . . . . 0.0 110.093 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.05 150.97 26.47 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.319 -0.863 . . . . 0.0 110.384 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.023 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.73 126.31 52.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.35 -0.844 . . . . 0.0 109.995 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.2 tp10 -138.2 110.17 7.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.163 -0.961 . . . . 0.0 109.935 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.825 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.27 111.26 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.469 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 2.1 m-20 39.17 32.35 0.07 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.762 -0.586 . . . . 0.0 110.918 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 114.91 -17.75 17.27 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.351 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.512 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 56.3 mm-40 -89.49 115.64 27.07 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.019 -1.283 . . . . 0.0 110.366 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.837 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.3 p -79.11 130.07 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.294 -0.879 . . . . 0.0 110.224 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.837 HD13 ' O ' ' A' ' 357' ' ' VAL . 18.6 mm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.24 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.508 ' HB2' ' HB2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -126.84 164.83 20.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.347 -1.09 . . . . 0.0 109.497 179.59 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.929 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.19 140.52 10.33 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.008 -1.077 . . . . 0.0 111.068 -179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.765 ' H ' HD22 ' A' ' 267' ' ' LEU . 5.2 mt-10 -140.07 134.33 31.2 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 109.182 -0.674 . . . . 0.0 109.182 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.741 HG13 ' O ' ' A' ' 281' ' ' ASP . 60.1 t -125.41 136.86 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.807 -1.183 . . . . 0.0 111.648 -178.892 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.51 ' HG3' ' CB ' ' A' ' 281' ' ' ASP . 0.0 OUTLIER -122.96 157.06 33.48 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.55 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.746 HG13 ' O ' ' A' ' 279' ' ' GLU . 88.7 t -142.77 146.9 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.295 -1.503 . . . . 0.0 112.378 -178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.523 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.49 113.16 8.5 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.986 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.9 p-10 -96.21 147.22 23.99 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.069 -1.02 . . . . 0.0 111.425 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.796 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.7 p90 -132.08 20.86 4.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.489 -0.757 . . . . 0.0 110.056 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.92 -59.52 4.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.04 -24.63 64.21 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.295 -1.121 . . . . 0.0 110.488 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.535 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -173.26 178.6 45.15 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.555 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.75 145.18 49.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -1.166 . . . . 0.0 110.528 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.746 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.3 mt-10 -95.83 147.31 23.79 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.612 -0.68 . . . . 0.0 110.04 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.649 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 94.8 m-85 -140.43 86.1 2.05 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.353 -0.842 . . . . 0.0 110.417 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.741 ' O ' HG13 ' A' ' 269' ' ' VAL . 2.7 t70 -68.88 152.9 44.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.294 -0.879 . . . . 0.0 109.846 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.658 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.6 t -145.21 90.4 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.579 -0.701 . . . . 0.0 109.938 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.691 HG23 ' OG1' ' A' ' 333' ' ' THR . 85.1 m -86.72 126.36 34.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.007 . . . . 0.0 109.865 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.056 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.74 151.13 32.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.264 -0.897 . . . . 0.0 110.905 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.527 ' O ' HD23 ' A' ' 286' ' ' LEU . 1.9 m120 -132.43 128.05 36.65 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.825 . . . . 0.0 110.543 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.643 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 5.6 mt -140.41 156.32 46.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.533 -1.355 . . . . 0.0 109.596 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -89.04 39.13 0.92 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.79 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 157.23 -142.8 8.93 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 119.397 -1.382 . . . . 0.0 109.739 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.78 120.96 43.3 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.945 -1.327 . . . . 0.0 110.814 -179.547 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.643 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 10.8 m-85 -142.77 146.81 34.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.283 -0.886 . . . . 0.0 109.909 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.633 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.3 m-20 -75.9 97.33 3.93 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.156 -0.965 . . . . 0.0 109.421 179.287 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.822 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.3 p-90 -98.21 111.59 23.87 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.203 -0.936 . . . . 0.0 110.485 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.662 HG22 ' CG2' ' A' ' 320' ' ' ILE . 6.4 m -104.7 115.98 31.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.642 -0.661 . . . . 0.0 109.894 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.7 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.8 t -97.01 110.89 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.06 -1.025 . . . . 0.0 110.42 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.735 ' HA ' HD13 ' A' ' 320' ' ' ILE . 6.5 ttpt -85.69 144.86 27.58 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.27 -0.893 . . . . 0.0 109.016 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.9 HG22 HG23 ' A' ' 349' ' ' ILE . 30.9 t -141.94 109.72 2.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.779 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.51 ' O ' ' N ' ' A' ' 347' ' ' GLU . 22.4 mmtp -72.57 132.01 43.23 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.212 -0.93 . . . . 0.0 109.476 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.989 HD13 ' HA ' ' A' ' 303' ' ' THR . 67.4 mt -87.31 152.95 21.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.108 -0.995 . . . . 0.0 111.695 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.709 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -60.46 173.76 0.58 Allowed Pre-proline 0 N--CA 1.488 1.439 0 O-C-N 121.62 -0.675 . . . . 0.0 109.364 178.989 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.709 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -68.73 84.59 0.5 Allowed 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.696 1.366 . . . . 0.0 110.038 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.37 26.44 3.71 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.863 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -120.5 145.98 46.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -1.148 . . . . 0.0 110.601 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.989 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.5 p -147.63 145.99 29.18 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.294 -0.879 . . . . 0.0 110.399 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.667 HG21 HG11 ' A' ' 319' ' ' VAL . 70.4 t -74.46 142.41 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.214 -0.929 . . . . 0.0 110.45 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.55 -32.96 0.41 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.3 m -128.87 127.94 42.84 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 111.092 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.501 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.8 p90 -146.59 160.81 41.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.433 -0.792 . . . . 0.0 109.239 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -150.9 157.42 42.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.946 -1.096 . . . . 0.0 110.975 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.498 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.6 OUTLIER 58.6 23.6 11.1 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.765 179.708 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.698 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 140.68 0.71 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.369 -0.832 . . . . 0.0 110.088 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.534 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -78.62 122.4 25.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.07 -1.019 . . . . 0.0 109.735 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.63 ' HG3' HG11 ' A' ' 304' ' ' VAL . 11.1 ttpt -88.85 144.33 26.29 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.766 0.793 . . . . 0.0 110.847 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.772 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -129.7 173.7 10.38 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.39 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.466 ' HG2' HG22 ' A' ' 319' ' ' VAL . 5.3 mt-10 -135.3 103.09 5.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 110.588 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.463 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -89.85 39.09 3.13 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.463 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 5.9 m120 58.5 89.42 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.304 -1.115 . . . . 0.0 110.075 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.39 -0.76 75.26 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.833 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -144.56 -167.89 2.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.446 -1.032 . . . . 0.0 109.095 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.833 HG23 ' O ' ' A' ' 318' ' ' TYR . 2.7 t -163.4 161.64 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 109.713 179.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.735 HD13 ' HA ' ' A' ' 295' ' ' LYS . 25.2 mm -129.28 151.93 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.074 -1.016 . . . . 0.0 110.997 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.641 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 73.4 m-85 -128.36 130.67 48.08 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.225 -0.922 . . . . 0.0 109.963 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.618 HG23 HG23 ' A' ' 293' ' ' THR . 2.2 p -132.96 168.87 15.78 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.727 -1.233 . . . . 0.0 109.991 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.51 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.7 Cg_endo -65.55 121.5 8.91 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.813 1.428 . . . . 0.0 110.981 -179.237 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.684 HG22 ' HB2' ' A' ' 327' ' ' ASN . 19.1 m -66.8 -117.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.47 -0.769 . . . . 0.0 110.087 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.507 ' N ' HG23 ' A' ' 324' ' ' VAL . 57.7 m -108.98 -16.46 14.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.814 -1.179 . . . . 0.0 110.339 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.578 ' H ' HG23 ' A' ' 324' ' ' VAL . 10.6 p-90 -125.96 -18.53 5.05 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.237 -0.915 . . . . 0.0 110.617 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.684 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t30 -87.43 33.21 0.69 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.96 12.07 22.16 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.319 -0.863 . . . . 0.0 109.656 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -84.99 -152.13 16.4 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.564 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 41.4 Cg_endo -68.86 -55.57 0.2 Allowed 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.938 1.494 . . . . 0.0 110.021 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.26 115.22 30.1 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.418 -0.802 . . . . 0.0 110.415 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.494 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -134.49 107.83 7.78 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.251 -0.906 . . . . 0.0 110.101 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.691 ' OG1' HG23 ' A' ' 283' ' ' THR . 97.6 m -103.82 147.64 27.05 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.148 -0.97 . . . . 0.0 110.733 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.7 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.8 p90 -152.35 175.06 13.07 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.493 -0.754 . . . . 0.0 109.102 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.7 160.77 28.95 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.401 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.941 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -147.46 147.4 30.15 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.388 -1.066 . . . . 0.0 110.041 179.633 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.941 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -121.71 123.31 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.013 -1.054 . . . . 0.0 109.958 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.863 HG11 ' HB1' ' A' ' 302' ' ' ALA . 4.6 t -97.12 154.26 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.199 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.32 133.38 53.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.221 -0.924 . . . . 0.0 110.557 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.452 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.491 2.351 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.574 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 121.136 0.493 . . . . 0.0 111.119 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.62 HG21 HG13 ' A' ' 296' ' ' VAL . 9.0 p -127.53 123.87 62.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.224 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.51 ' N ' ' O ' ' A' ' 297' ' ' LYS . 6.8 mt-10 -55.47 -43.64 75.71 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 110.223 -179.528 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -177.09 159.02 1.6 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 110.513 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 296' ' ' VAL . 45.7 mt -123.13 109.58 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 110.218 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.78 140.66 43.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.32 -0.863 . . . . 0.0 110.143 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.056 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -101.05 130.86 47.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.247 -0.908 . . . . 0.0 110.271 179.995 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -138.86 111.78 7.84 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 110.115 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.633 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 107.82 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.079 -1.013 . . . . 0.0 110.3 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.439 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 4.7 m-20 38.94 37.56 0.22 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.585 -0.697 . . . . 0.0 111.56 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 106.77 11.12 27.28 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.582 -1.294 . . . . 0.0 110.664 178.866 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 26.4 mm-40 -121.57 101.48 7.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.013 -1.286 . . . . 0.0 110.034 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 1.04 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.9 p -66.56 135.66 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.234 -0.916 . . . . 0.0 110.4 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 1.04 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.3 mm . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.187 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.41 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.575 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.61 153.6 51.54 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.504 -0.998 . . . . 0.0 109.473 179.904 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.764 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -147.99 123.56 10.43 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 120.932 -1.105 . . . . 0.0 111.03 -179.451 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.8 OUTLIER -122.36 111.04 16.4 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 178.902 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.575 HG11 HD12 ' A' ' 349' ' ' ILE . 45.4 t -104.99 124.62 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.893 -1.129 . . . . 0.0 111.953 -178.722 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -111.89 156.74 21.57 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.644 HG22 ' CD2' ' A' ' 280' ' ' TYR . 56.9 t -144.84 143.66 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.341 -1.475 . . . . 0.0 112.148 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.544 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -134.52 108.76 8.28 Favored 'General case' 0 N--CA 1.486 1.37 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.08 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 21.0 p30 -96.18 146.78 24.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 111.083 -178.866 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.856 ' CH2' HG23 ' A' ' 337' ' ' ILE . 31.7 p90 -130.38 17.98 5.38 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.412 -0.805 . . . . 0.0 109.958 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.27 -58.77 3.86 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -73.18 -19.32 61.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 110.458 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.581 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.98 179.44 41.72 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.635 -1.269 . . . . 0.0 109.983 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -138.09 136.6 36.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.442 -1.034 . . . . 0.0 109.97 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.574 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.7 mt-10 -93.84 147.15 23.34 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.378 -0.826 . . . . 0.0 110.478 -179.462 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.832 ' CE2' HG11 ' A' ' 346' ' ' VAL . 92.8 m-85 -139.05 94.96 2.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 110.674 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.543 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -83.5 106.41 15.22 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.538 -0.726 . . . . 0.0 110.271 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.684 HG11 HG11 ' A' ' 294' ' ' VAL . 5.5 t -97.28 94.28 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.493 -0.754 . . . . 0.0 110.17 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.84 HG23 ' OG1' ' A' ' 333' ' ' THR . 3.8 m -86.95 113.47 22.75 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.172 -0.955 . . . . 0.0 109.815 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 0.998 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -102.18 147.94 26.03 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.096 -1.003 . . . . 0.0 110.507 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.575 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -133.36 106.7 7.66 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.516 -0.74 . . . . 0.0 109.636 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.603 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.8 mt -113.83 160.75 18.39 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.622 -1.299 . . . . 0.0 110.763 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -89.79 36.64 0.86 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 110.03 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 155.3 -135.25 4.54 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.473 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.2 mm-40 -120.67 113.41 20.18 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.05 -1.265 . . . . 0.0 110.911 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.603 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.1 m-85 -138.74 148.92 44.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.36 -0.838 . . . . 0.0 109.641 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.635 ' O ' HG23 ' A' ' 353' ' ' ILE . 5.4 m-20 -75.53 97.9 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.205 -0.935 . . . . 0.0 109.512 179.488 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.832 ' CE3' HD13 ' A' ' 284' ' ' LEU . 51.5 p-90 -97.07 110.17 22.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.583 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.682 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.2 m -102.34 115.21 30.09 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.331 -0.856 . . . . 0.0 109.44 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.778 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.8 t -97.0 111.09 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 110.54 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.633 ' HA ' HD13 ' A' ' 320' ' ' ILE . 4.5 ttpt -83.15 149.17 27.02 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 108.966 178.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.688 HG22 HG23 ' A' ' 349' ' ' ILE . 53.7 t -145.75 104.73 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.971 -1.081 . . . . 0.0 110.761 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.502 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 7.6 mmtt -70.88 131.28 43.53 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.208 -0.933 . . . . 0.0 109.391 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.994 HD13 ' HA ' ' A' ' 303' ' ' THR . 70.3 mt -87.12 152.49 22.3 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 111.507 -179.056 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.765 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -56.47 176.0 0.21 Allowed Pre-proline 0 C--N 1.301 -1.504 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.081 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.76 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -68.99 79.87 0.69 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 123.554 1.292 . . . . 0.0 109.891 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.19 20.9 5.42 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.482 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.765 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -106.73 149.0 27.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.395 -1.062 . . . . 0.0 109.936 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.994 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.5 p -150.03 144.2 25.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.106 -0.997 . . . . 0.0 111.152 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.771 HG21 HG11 ' A' ' 319' ' ' VAL . 87.4 t -69.59 129.79 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -0.862 . . . . 0.0 109.928 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.25 -28.18 2.91 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 6.8 t -144.66 141.4 29.32 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.007 -1.29 . . . . 0.0 110.744 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.517 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.3 p90 -155.54 168.81 25.93 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.403 -0.811 . . . . 0.0 110.053 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.502 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -158.53 163.72 36.8 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.057 -1.027 . . . . 0.0 110.645 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.521 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.5 OUTLIER 58.41 21.31 8.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.5 -0.75 . . . . 0.0 110.757 179.739 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.683 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 148.84 1.21 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.442 -0.786 . . . . 0.0 110.328 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.683 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.3 m120 -86.78 120.12 27.74 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.225 -0.922 . . . . 0.0 109.379 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.689 ' HG3' HG11 ' A' ' 304' ' ' VAL . 3.6 ttpt -87.63 140.03 29.93 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.892 0.853 . . . . 0.0 110.601 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.648 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.5 175.22 7.28 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -134.84 116.55 14.92 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.316 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.448 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -109.93 39.25 2.97 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 1.4 t30 66.23 90.92 0.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.29 -1.123 . . . . 0.0 110.286 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 81.53 3.31 90.66 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.836 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.9 m-85 -141.52 -172.67 3.58 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -1.135 . . . . 0.0 109.544 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.836 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.5 t -163.38 157.85 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.212 -0.93 . . . . 0.0 109.775 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.648 ' CG2' HG22 ' A' ' 293' ' ' THR . 17.4 mm -125.98 144.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.012 -1.055 . . . . 0.0 111.474 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 56.9 m-85 -121.18 129.33 53.18 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.005 -1.059 . . . . 0.0 109.93 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.682 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.9 p -129.94 168.52 16.29 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 120.864 -1.148 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.53 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.2 Cg_endo -65.95 117.09 4.36 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.76 1.4 . . . . 0.0 111.029 -179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.683 HG12 ' OD1' ' A' ' 311' ' ' ASN . 25.4 m -64.29 -120.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 110.041 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.501 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -104.44 -15.88 15.26 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.776 -1.202 . . . . 0.0 110.665 -179.849 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.599 ' H ' HG23 ' A' ' 324' ' ' VAL . 5.3 p-90 -131.11 -6.85 3.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.132 -0.98 . . . . 0.0 110.822 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.936 ' ND2' ' HB1' ' A' ' 332' ' ' ALA . 12.0 t30 -90.96 38.67 0.96 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.063 -1.023 . . . . 0.0 110.115 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.483 ' HE2' ' O ' ' A' ' 325' ' ' SER . 5.5 pttt -121.26 4.99 10.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.06 -1.025 . . . . 0.0 110.332 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -69.16 -156.38 1.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 50.5 Cg_endo -76.72 7.16 3.66 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.77 1.405 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 19.5 m -164.2 128.25 2.64 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.288 -0.882 . . . . 0.0 109.725 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.936 ' HB1' ' ND2' ' A' ' 327' ' ' ASN . . . -143.89 108.63 4.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 110.319 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.84 ' OG1' HG23 ' A' ' 283' ' ' THR . 89.8 m -100.77 117.54 35.07 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.309 -0.87 . . . . 0.0 109.953 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.778 ' HE2' HG21 ' A' ' 294' ' ' VAL . 7.9 p90 -124.49 171.96 9.56 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.34 158.04 27.5 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.945 -1.597 . . . . 0.0 109.951 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -145.89 146.13 30.98 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.633 -0.922 . . . . 0.0 109.186 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.23 120.23 63.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.684 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.725 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.8 t -95.78 147.84 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.195 -0.941 . . . . 0.0 109.576 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -118.6 134.69 54.91 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.384 -0.822 . . . . 0.0 110.617 -179.37 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.426 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.172 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.65 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.191 0.52 . . . . 0.0 110.685 . . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.832 HG11 ' CE2' ' A' ' 280' ' ' TYR . 4.2 p -132.78 116.5 27.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.028 -1.045 . . . . 0.0 110.831 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.502 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -44.67 -50.08 10.06 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.912 -1.117 . . . . 0.0 109.533 179.787 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -177.48 158.06 1.36 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.382 -0.824 . . . . 0.0 110.482 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.688 HG23 HG22 ' A' ' 296' ' ' VAL . 14.4 mt -117.15 111.62 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.255 -0.903 . . . . 0.0 110.076 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.69 151.65 24.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.285 -0.885 . . . . 0.0 110.376 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 0.998 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -110.27 125.71 53.41 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.321 -0.862 . . . . 0.0 109.812 179.604 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.5 tt0 -137.26 111.41 8.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.184 -0.948 . . . . 0.0 109.832 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.635 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -92.02 109.97 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 110.521 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.443 ' C ' ' O ' ' A' ' 353' ' ' ILE . 5.0 m-20 38.36 31.22 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.546 -0.721 . . . . 0.0 111.061 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.48 -10.04 16.9 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.563 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.444 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.0 mp0 -97.16 108.4 21.12 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.061 -1.258 . . . . 0.0 110.214 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 357' ' ' VAL . 7.3 p -76.58 110.42 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.335 -0.853 . . . . 0.0 110.249 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.736 ' HB ' HD13 ' A' ' 351' ' ' LEU . 24.2 mm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.146 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.57 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -136.88 157.11 47.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.477 -1.013 . . . . 0.0 109.535 179.863 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.813 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.56 124.38 10.57 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.943 -1.098 . . . . 0.0 110.989 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.482 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 1.4 mm-40 -121.38 113.32 19.73 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.736 HG13 ' O ' ' A' ' 281' ' ' ASP . 38.4 t -109.44 139.67 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 111.668 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.421 ' C ' HG23 ' A' ' 271' ' ' VAL . 4.2 mmtm -123.83 156.58 35.92 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.3 t -145.19 144.7 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.462 -1.399 . . . . 0.0 112.092 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -143.14 112.21 6.61 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 179.315 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.7 p-10 -97.03 144.82 26.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.047 -1.033 . . . . 0.0 111.297 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.5 p90 -129.82 18.62 5.63 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.399 -0.813 . . . . 0.0 109.786 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.58 -61.92 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.67 -23.79 67.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -1.158 . . . . 0.0 110.224 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.82 177.68 46.02 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.603 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -130.58 146.6 52.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.329 -1.101 . . . . 0.0 110.201 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.595 ' O ' HG13 ' A' ' 271' ' ' VAL . 6.2 mt-10 -98.0 147.32 24.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.514 -0.741 . . . . 0.0 109.942 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 95.2 m-85 -144.28 86.37 1.83 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.233 -0.917 . . . . 0.0 110.999 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.736 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.1 OUTLIER -71.17 153.5 42.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.403 -0.811 . . . . 0.0 109.88 179.376 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.646 HG11 HG11 ' A' ' 294' ' ' VAL . 3.5 t -144.82 88.09 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 109.615 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.79 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.5 m -86.03 114.92 23.29 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.683 -179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.018 HD21 HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -101.73 145.57 28.94 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.259 -0.901 . . . . 0.0 110.736 -179.16 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.57 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.8 m120 -129.67 106.86 9.0 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.391 -0.818 . . . . 0.0 110.093 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.572 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 7.6 mt -116.62 164.34 14.75 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.648 -1.283 . . . . 0.0 110.299 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -94.04 34.59 1.23 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.402 -0.811 . . . . 0.0 110.458 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.449 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 157.11 -137.52 5.44 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.876 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.484 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mm-40 -113.84 108.26 16.83 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.184 -1.186 . . . . 0.0 111.391 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.572 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.26 135.27 40.77 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.301 -0.874 . . . . 0.0 109.67 178.538 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.537 ' O ' HG23 ' A' ' 353' ' ' ILE . 4.5 m-20 -64.88 97.02 0.2 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.05 -1.032 . . . . 0.0 109.402 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.862 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.3 p-90 -95.07 108.07 20.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.279 -0.888 . . . . 0.0 110.494 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.596 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 32.4 m -101.67 115.48 30.61 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.782 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -96.72 111.54 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.092 -1.005 . . . . 0.0 110.925 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.644 ' HA ' HD13 ' A' ' 320' ' ' ILE . 7.9 ttpt -82.01 149.84 27.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.264 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.822 HG13 HG12 ' A' ' 349' ' ' ILE . 88.7 t -149.02 104.77 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.951 -1.093 . . . . 0.0 110.719 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.521 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 18.9 mmtp -70.35 128.54 36.56 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.223 -0.923 . . . . 0.0 109.658 179.511 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.956 HD13 ' HA ' ' A' ' 303' ' ' THR . 85.5 mt -84.06 165.81 18.24 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.763 0.792 . . . . 0.0 111.377 -179.065 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.788 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -74.33 175.81 3.47 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.623 -0.673 . . . . 0.0 109.726 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.788 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.5 Cg_endo -67.24 83.2 0.36 Allowed 'Trans proline' 0 C--N 1.304 -1.786 0 O-C-N 123.598 1.315 . . . . 0.0 109.84 179.421 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 110.99 22.72 6.12 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.879 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -112.14 144.17 41.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -1.085 . . . . 0.0 110.13 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.956 ' HA ' HD13 ' A' ' 298' ' ' LEU . 13.0 p -147.06 145.18 29.58 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.879 . . . . 0.0 110.332 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.855 HG21 HG11 ' A' ' 319' ' ' VAL . 71.4 t -64.97 120.94 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.38 -0.825 . . . . 0.0 110.11 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.29 -38.6 3.48 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.509 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 24.9 m -139.03 144.25 38.77 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.144 -1.209 . . . . 0.0 110.781 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 5.6 p90 -155.02 160.34 40.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.466 -0.771 . . . . 0.0 109.463 179.553 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.432 ' C ' ' OG ' ' A' ' 309' ' ' SER . 1.0 OUTLIER -151.04 152.87 34.08 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.923 -1.111 . . . . 0.0 111.491 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.522 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.9 OUTLIER 67.24 24.19 9.2 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.663 -0.648 . . . . 0.0 111.054 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.673 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.27 143.41 0.87 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.276 -0.89 . . . . 0.0 110.138 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.669 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.6 m120 -82.37 122.9 28.58 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.15 -0.969 . . . . 0.0 109.182 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.602 ' HG3' HG11 ' A' ' 304' ' ' VAL . 3.1 ttmt -88.7 148.09 24.17 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.861 0.839 . . . . 0.0 111.05 -178.957 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.733 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.74 171.85 13.0 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.36 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -132.96 109.7 9.75 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.179 -0.95 . . . . 0.0 110.345 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.73 39.81 2.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.405 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 8.4 t-20 60.86 92.25 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.346 -1.091 . . . . 0.0 110.474 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.3 2.27 87.76 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.823 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.1 m-85 -145.81 -169.48 3.24 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.339 -1.095 . . . . 0.0 109.27 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.855 HG11 HG21 ' A' ' 304' ' ' VAL . 2.8 t -163.44 161.92 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 179.129 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.644 HD13 ' HA ' ' A' ' 295' ' ' LYS . 5.5 mm -130.19 143.57 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.174 -0.954 . . . . 0.0 111.084 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.652 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 98.6 m-85 -118.61 136.79 53.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.938 . . . . 0.0 109.515 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.549 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.5 p -135.3 168.88 15.47 Favored Pre-proline 0 C--N 1.301 -1.527 0 O-C-N 120.844 -1.16 . . . . 0.0 110.303 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.557 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 40.5 Cg_endo -67.03 121.09 8.21 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 124.127 1.593 . . . . 0.0 110.85 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.877 HG22 ' HB2' ' A' ' 327' ' ' ASN . 27.0 m -73.22 -129.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.845 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.606 ' N ' HG23 ' A' ' 324' ' ' VAL . 18.1 p -100.17 -19.15 16.57 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.904 -1.122 . . . . 0.0 110.346 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.758 ' H ' HG23 ' A' ' 324' ' ' VAL . 23.7 p-90 -125.96 11.08 7.68 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.108 -0.995 . . . . 0.0 110.507 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.877 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -117.63 49.58 1.21 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.073 -1.017 . . . . 0.0 110.254 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.557 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -125.57 -12.47 6.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -0.865 . . . . 0.0 110.134 -179.902 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.09 -160.95 0.02 OUTLIER Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.9 Cg_endo -73.4 3.53 4.66 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.905 1.477 . . . . 0.0 110.872 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.97 117.67 3.28 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.171 -0.955 . . . . 0.0 110.088 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.565 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.03 108.6 5.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.253 -0.904 . . . . 0.0 110.077 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.79 ' OG1' HG23 ' A' ' 283' ' ' THR . 60.7 m -99.81 138.63 36.62 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.287 -0.883 . . . . 0.0 110.449 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.782 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.9 p90 -145.92 157.36 43.9 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -134.33 164.27 24.57 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.088 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.878 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -149.74 143.4 25.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.483 -1.01 . . . . 0.0 109.469 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.878 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -117.16 120.55 65.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.115 -0.991 . . . . 0.0 109.689 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.879 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.6 t -96.79 149.93 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.203 -0.936 . . . . 0.0 109.817 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.2 m120 -121.77 131.54 54.12 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.16 -0.963 . . . . 0.0 111.061 -179.167 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.742 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.69 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.488 1.442 0 CA-C-O 121.448 0.642 . . . . 0.0 110.24 . . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.58 HG13 ' O ' ' A' ' 346' ' ' VAL . 10.7 p -133.84 116.73 24.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.399 -0.813 . . . . 0.0 110.002 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 1.5 mt-10 -47.16 -47.1 23.91 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.174 -0.954 . . . . 0.0 110.164 -179.549 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -177.01 158.92 1.61 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.401 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.822 HG12 HG13 ' A' ' 296' ' ' VAL . 26.4 mt -118.2 119.42 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.23 -0.919 . . . . 0.0 110.101 179.788 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.49 151.33 33.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.301 -0.874 . . . . 0.0 110.267 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.018 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -108.96 126.83 53.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.252 -0.905 . . . . 0.0 109.725 179.661 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.444 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.5 tp10 -138.19 113.11 9.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.077 -1.014 . . . . 0.0 110.373 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.537 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -93.07 103.66 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.183 -0.948 . . . . 0.0 110.003 179.725 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 291' ' ' ASP . 4.1 m-20 43.55 30.55 0.35 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.459 -0.775 . . . . 0.0 110.46 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 117.63 -22.65 9.95 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.445 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 3.3 mp0 -82.41 99.58 9.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 110.127 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.686 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.4 p -69.96 113.76 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.246 -0.909 . . . . 0.0 110.173 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.653 ' HB ' HD13 ' A' ' 351' ' ' LEU . 25.9 mm . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.119 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.585 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -130.81 150.54 51.94 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.4 -1.059 . . . . 0.0 109.978 179.924 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.873 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -145.2 125.87 14.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.036 -1.04 . . . . 0.0 110.781 -179.676 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.488 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 15.0 mm-40 -124.51 110.99 15.17 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.491 -0.756 . . . . 0.0 108.996 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.936 HG13 ' O ' ' A' ' 281' ' ' ASP . 85.6 t -110.53 145.19 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 120.942 -1.098 . . . . 0.0 111.827 -178.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -130.86 157.74 42.07 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.136 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.81 HG13 ' O ' ' A' ' 279' ' ' GLU . 97.5 t -141.69 146.75 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 120.237 -1.539 . . . . 0.0 112.454 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.02 110.28 6.91 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.11 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 43.8 p-10 -95.68 145.36 25.34 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.062 -1.024 . . . . 0.0 111.379 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.835 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.4 p90 -130.95 22.77 4.93 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.36 -0.837 . . . . 0.0 109.858 179.088 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.81 -68.82 3.32 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.482 ' HG ' ' HE1' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -61.22 -27.41 68.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.253 -1.145 . . . . 0.0 110.685 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.533 ' C ' ' CE2' ' A' ' 274' ' ' TRP . . . -166.3 178.52 40.8 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.568 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.72 145.28 48.33 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.275 -1.132 . . . . 0.0 110.512 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.81 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -97.22 147.17 24.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 109.973 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.657 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 88.5 m-85 -142.08 83.77 1.85 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.274 -0.891 . . . . 0.0 110.523 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.936 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.14 153.19 44.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.289 -0.882 . . . . 0.0 110.123 179.551 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 294' ' ' VAL . 5.4 t -144.87 90.36 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.531 -0.73 . . . . 0.0 109.667 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.832 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.5 m -86.28 123.66 31.79 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.134 -0.979 . . . . 0.0 109.362 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.082 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -109.71 148.26 31.71 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.072 -1.017 . . . . 0.0 111.28 -178.85 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.585 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -134.33 107.37 7.59 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.607 -0.683 . . . . 0.0 109.975 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.534 ' N ' ' O ' ' A' ' 330' ' ' PRO . 9.7 mt -115.53 163.27 16.0 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.897 -1.127 . . . . 0.0 109.805 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 287' ' ' ASP . . . . . 0.469 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 2.1 t0 -91.64 31.28 1.21 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.552 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.54 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 163.76 -164.33 36.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.545 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -93.76 94.87 8.79 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.176 -1.19 . . . . 0.0 110.599 -179.738 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 1.9 m-85 -120.96 171.44 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.181 -0.95 . . . . 0.0 109.793 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.834 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.2 OUTLIER -95.78 99.34 11.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.655 179.392 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.905 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.1 p-90 -97.29 113.99 25.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.309 -0.869 . . . . 0.0 110.624 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.576 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 99.1 m -106.75 113.38 26.84 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.464 -0.773 . . . . 0.0 109.176 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 282' ' ' VAL . 4.6 t -96.37 110.81 25.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.184 -0.948 . . . . 0.0 110.137 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.517 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 6.4 ttmt -84.77 149.07 26.0 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.208 -0.933 . . . . 0.0 109.197 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.857 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 45.9 t -144.63 106.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 O-C-N 121.403 -0.811 . . . . 0.0 109.93 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.513 ' O ' HG23 ' A' ' 346' ' ' VAL . 34.9 mmtt -71.1 134.69 47.21 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.114 -0.991 . . . . 0.0 109.704 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.906 HD13 ' HA ' ' A' ' 303' ' ' THR . 92.7 mt -87.59 162.57 17.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 111.569 -179.083 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.661 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -75.65 171.57 11.59 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.661 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.4 84.61 0.47 Allowed 'Trans proline' 0 C--N 1.301 -1.945 0 O-C-N 123.684 1.36 . . . . 0.0 109.798 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 301' ' ' GLY . . . . . 0.442 ' O ' ' HA3' ' A' ' 340' ' ' GLY . . . 116.26 26.02 3.33 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 1.024 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -126.51 138.26 53.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -1.139 . . . . 0.0 110.257 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.906 ' HA ' HD13 ' A' ' 298' ' ' LEU . 7.2 p -141.43 145.83 35.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 110.419 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.749 ' CG2' HG21 ' A' ' 319' ' ' VAL . 98.2 t -71.82 124.28 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.366 -0.834 . . . . 0.0 110.225 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.4 -34.84 1.26 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.433 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 2.7 m -122.45 110.15 15.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.025 -1.28 . . . . 0.0 110.716 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.602 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 11.9 p90 -134.23 153.92 51.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.856 . . . . 0.0 109.788 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.475 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -149.19 161.37 42.13 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.05 -1.031 . . . . 0.0 111.155 -179.35 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.545 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.23 28.71 15.54 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.542 -0.723 . . . . 0.0 111.224 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.711 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.9 145.44 0.66 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.038 -1.039 . . . . 0.0 110.553 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 3.7 m120 -78.13 118.74 20.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -0.998 . . . . 0.0 109.238 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.602 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 19.9 ttpt -92.2 115.7 28.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.546 -0.721 . . . . 0.0 111.083 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.616 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.6 tt0 -102.97 176.31 5.19 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.327 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.447 ' HG3' HG22 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -139.02 105.95 5.42 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -0.981 . . . . 0.0 110.773 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -95.26 43.79 2.2 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 58.52 91.06 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.321 -1.105 . . . . 0.0 110.126 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.629 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 84.33 5.12 87.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.707 ' O ' HG23 ' A' ' 319' ' ' VAL . 7.0 m-85 -141.93 -178.53 5.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.413 -1.051 . . . . 0.0 109.078 179.404 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.749 HG21 ' CG2' ' A' ' 304' ' ' VAL . 39.9 t -159.4 148.98 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.149 -0.969 . . . . 0.0 109.986 179.126 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.616 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 1.7 mm -114.9 151.56 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.112 -0.992 . . . . 0.0 110.497 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.659 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 76.5 m-85 -130.69 112.78 13.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.101 -0.999 . . . . 0.0 109.866 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.584 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 3.7 p -116.49 171.07 5.09 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 120.627 -1.296 . . . . 0.0 109.786 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.584 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.9 Cg_endo -69.2 120.96 7.77 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 O-C-N 123.652 1.343 . . . . 0.0 110.727 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.656 HG22 ' CG ' ' A' ' 327' ' ' ASN . 16.0 m -64.12 -113.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.482 -0.761 . . . . 0.0 110.224 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.531 ' HG ' ' HD1' ' A' ' 326' ' ' TRP . 14.1 p -120.17 -12.47 9.06 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.753 -1.217 . . . . 0.0 110.688 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.531 ' HD1' ' HG ' ' A' ' 325' ' ' SER . 24.8 p-90 -128.9 17.01 6.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 0.0 110.921 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.656 ' CG ' HG22 ' A' ' 324' ' ' VAL . 28.8 p-10 -135.56 45.07 2.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.079 . . . . 0.0 110.921 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.539 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -116.05 7.96 14.41 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.097 -1.002 . . . . 0.0 109.847 179.774 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 329' ' ' GLY . . . . . . . . . . . . . . . -74.67 -153.72 3.54 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.124 -1.191 . . . . 0.0 110.124 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.54 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 50.5 Cg_endo -75.61 4.66 4.85 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 124.182 1.622 . . . . 0.0 110.925 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.6 m -165.25 123.54 1.64 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.158 -0.964 . . . . 0.0 110.253 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.627 ' HB1' ' HB2' ' A' ' 327' ' ' ASN . . . -150.72 120.28 6.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.848 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.832 ' OG1' HG23 ' A' ' 283' ' ' THR . 34.0 m -104.32 144.66 31.33 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.229 -0.92 . . . . 0.0 110.441 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.779 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.0 p90 -149.78 168.82 22.62 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.37 159.84 28.16 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 118.744 -1.693 . . . . 0.0 110.535 -179.209 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.882 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.6 p90 -144.2 145.02 31.81 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.648 -0.913 . . . . 0.0 109.679 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.882 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.98 120.99 65.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.626 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 1.024 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 19.8 t -97.71 142.65 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 110.399 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.6 m120 -115.55 130.09 56.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 110.133 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 301' ' ' GLY . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.628 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.3 mtmt . . . . . 0 N--CA 1.488 1.472 0 CA-C-O 121.274 0.559 . . . . 0.0 110.463 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.582 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.8 p -130.58 118.21 41.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.311 -0.868 . . . . 0.0 110.22 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.432 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -48.33 -45.9 35.8 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.378 -0.826 . . . . 0.0 110.575 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.42 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 2.5 pt-20 -177.02 159.39 1.67 Allowed 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.847 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.549 HG12 HG13 ' A' ' 296' ' ' VAL . 14.2 mt -119.6 114.6 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.254 -0.904 . . . . 0.0 110.439 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -113.91 158.2 21.41 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.148 -0.97 . . . . 0.0 109.855 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.082 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.42 126.63 51.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.253 -0.905 . . . . 0.0 110.633 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.0 OUTLIER -139.25 119.76 13.99 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.864 179.45 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.834 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -90.81 93.01 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.924 -1.11 . . . . 0.0 110.22 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.448 ' CG ' ' HB3' ' A' ' 291' ' ' ASP . 5.1 m-20 46.94 31.96 1.68 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.817 -0.552 . . . . 0.0 111.249 179.496 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 132.13 -33.86 2.63 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.651 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 66.0 mm-40 -89.92 117.61 28.87 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.987 -1.302 . . . . 0.0 110.745 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 4.0 p -78.93 124.07 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.298 -0.876 . . . . 0.0 110.135 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.683 ' HB ' HD13 ' A' ' 351' ' ' LEU . 21.5 mm . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.092 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.403 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.554 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.58 162.67 33.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.371 -1.076 . . . . 0.0 109.87 179.837 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.947 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -159.92 138.27 10.33 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.143 -1.023 . . . . 0.0 111.15 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.74 ' N ' HD22 ' A' ' 267' ' ' LEU . 18.8 mt-10 -141.15 136.57 31.98 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.819 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -128.11 144.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.618 -1.301 . . . . 0.0 112.306 -178.509 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.405 ' C ' HG23 ' A' ' 271' ' ' VAL . 63.3 mttt -128.65 157.74 40.49 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.844 HG13 ' O ' ' A' ' 279' ' ' GLU . 98.7 t -144.36 147.38 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 120.346 -1.472 . . . . 0.0 112.319 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.525 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.12 110.63 6.38 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.737 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -96.13 149.08 22.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.988 -1.07 . . . . 0.0 111.503 -178.465 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.82 ' CH2' HG23 ' A' ' 337' ' ' ILE . 28.1 p90 -129.46 18.42 5.84 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-O 121.447 0.641 . . . . 0.0 109.691 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.42 -61.63 3.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.67 -25.26 65.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 110.383 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.522 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -167.56 178.93 41.31 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.449 -1.358 . . . . 0.0 109.95 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.3 144.63 48.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -1.103 . . . . 0.0 110.345 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.844 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -97.47 145.92 25.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.396 -0.815 . . . . 0.0 109.828 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.731 ' CE1' HG11 ' A' ' 346' ' ' VAL . 98.9 m-85 -137.9 87.72 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.827 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.819 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -70.88 140.91 51.21 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.483 179.13 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.675 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.8 t -133.89 91.7 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.568 -0.708 . . . . 0.0 109.803 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.861 HG23 ' OG1' ' A' ' 333' ' ' THR . 9.0 m -86.49 124.2 32.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 109.977 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.82 148.41 38.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 110.832 -179.427 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -128.66 137.43 51.64 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.434 -0.791 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.5 mt -142.42 159.7 41.71 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.794 -1.191 . . . . 0.0 109.759 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.94 36.02 0.97 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.361 -0.837 . . . . 0.0 110.31 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.479 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 152.07 -100.94 0.21 Allowed Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.139 -1.505 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.554 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 15.9 mm-40 -141.8 111.93 6.88 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.024 -1.28 . . . . 0.0 110.881 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.639 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 5.5 m-85 -135.51 138.36 43.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.687 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.801 ' O ' HG23 ' A' ' 353' ' ' ILE . 5.5 m-20 -74.17 96.87 2.82 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.002 -1.061 . . . . 0.0 108.905 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.938 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.1 p-90 -97.45 114.87 26.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 0.0 110.568 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.707 HG23 HG23 ' A' ' 322' ' ' THR . 28.7 m -109.45 116.09 31.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.694 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.8 t -96.83 111.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 0.0 110.528 -179.486 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.577 ' HA ' HD13 ' A' ' 320' ' ' ILE . 28.9 ttpt -91.64 130.19 37.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.659 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.745 HG13 HG12 ' A' ' 349' ' ' ILE . 80.2 t -126.58 115.87 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.185 -0.947 . . . . 0.0 111.103 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.571 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 55.7 mmtt -73.21 134.23 44.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.149 -0.97 . . . . 0.0 109.269 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.974 HD13 ' HA ' ' A' ' 303' ' ' THR . 80.1 mt -88.15 159.38 18.22 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.324 -0.86 . . . . 0.0 111.466 -178.833 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.881 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.18 178.09 0.56 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.68 -0.638 . . . . 0.0 110.025 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.864 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.24 79.06 0.6 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.718 1.378 . . . . 0.0 109.662 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.89 21.15 6.11 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.881 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -106.05 144.37 32.85 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.417 -1.049 . . . . 0.0 110.241 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.974 ' HA ' HD13 ' A' ' 298' ' ' LEU . 10.8 p -145.75 145.95 31.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.3 -0.875 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.822 HG21 HG11 ' A' ' 319' ' ' VAL . 76.1 t -70.99 134.83 29.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.329 -0.857 . . . . 0.0 109.88 179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.45 -37.29 0.8 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.081 -179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 67.6 m -131.55 128.15 38.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.06 -1.259 . . . . 0.0 110.919 -179.563 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.7 p90 -144.78 157.73 44.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.377 -0.827 . . . . 0.0 109.794 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.487 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -150.55 159.52 44.44 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.007 -1.058 . . . . 0.0 111.236 -179.329 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.53 ' OG ' ' CZ3' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 59.45 24.81 13.49 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.562 -0.712 . . . . 0.0 110.679 179.735 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.72 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 142.56 0.77 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 110.213 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.706 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.6 m120 -81.09 113.97 19.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.084 -1.01 . . . . 0.0 109.383 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.559 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 18.6 ttpt -82.56 149.71 27.33 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-O 121.762 0.792 . . . . 0.0 110.459 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.823 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -134.13 170.63 15.39 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.481 ' HG2' HG22 ' A' ' 319' ' ' VAL . 15.8 mt-10 -142.41 95.17 2.75 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.595 -0.69 . . . . 0.0 110.165 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.14 -80.28 0.44 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -160.93 77.5 0.58 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.433 -1.04 . . . . 0.0 108.812 179.687 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.617 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.34 11.25 54.64 Favored Glycine 0 N--CA 1.487 2.082 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.812 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.3 m-85 -143.06 -166.97 2.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.736 -0.861 . . . . 0.0 108.709 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.823 HG22 ' O ' ' A' ' 313' ' ' GLN . 2.5 t -163.52 160.19 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.01 -1.056 . . . . 0.0 109.454 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.773 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.3 mm -128.98 145.22 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.891 -1.131 . . . . 0.0 111.136 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.0 m-85 -123.04 129.33 51.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.156 -0.965 . . . . 0.0 110.378 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.707 HG23 HG23 ' A' ' 293' ' ' THR . 3.0 p -131.01 167.73 20.32 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 120.72 -1.237 . . . . 0.0 110.014 179.33 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.512 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.0 Cg_endo -66.1 128.68 20.07 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.861 1.453 . . . . 0.0 110.915 -179.293 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.772 HG22 ' HB2' ' A' ' 327' ' ' ASN . 34.6 m -78.01 -122.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.51 -0.744 . . . . 0.0 110.114 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.598 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -101.83 -21.43 14.58 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.757 -1.214 . . . . 0.0 110.631 -179.651 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.61 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.9 p-90 -126.46 5.55 6.91 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.173 -0.955 . . . . 0.0 110.578 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.772 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.8 OUTLIER -108.39 49.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.156 -0.965 . . . . 0.0 110.125 -179.8 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.478 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -133.84 -4.83 2.82 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.107 -0.996 . . . . 0.0 110.404 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.466 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.56 -155.72 0.05 OUTLIER Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.426 ' C ' ' OG1' ' A' ' 331' ' ' THR . 46.9 Cg_endo -73.65 3.06 5.18 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.915 1.482 . . . . 0.0 110.749 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.426 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.8 m -163.03 120.52 1.94 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 110.061 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.561 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -141.0 112.71 7.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.261 -0.899 . . . . 0.0 110.277 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.861 ' OG1' HG23 ' A' ' 283' ' ' THR . 38.1 m -104.49 138.92 40.16 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 110.049 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.72 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 13.6 p90 -142.85 172.37 12.79 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.89 160.29 28.44 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 118.755 -1.688 . . . . 0.0 110.333 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.919 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -147.32 145.24 29.28 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.481 -1.011 . . . . 0.0 110.048 179.485 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.919 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.81 119.86 61.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.094 -1.004 . . . . 0.0 109.783 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.799 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.8 t -96.96 145.83 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -112.68 126.51 55.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 110.014 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.967 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.698 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.3 mtmt . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 121.204 0.526 . . . . 0.0 111.076 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.731 HG11 ' CE1' ' A' ' 280' ' ' TYR . 4.3 p -133.59 120.08 36.38 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.203 -0.935 . . . . 0.0 110.402 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.5 mm-40 -50.2 -47.02 54.91 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.979 -1.076 . . . . 0.0 109.643 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.444 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 1.2 pt-20 -177.88 158.99 1.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.616 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.745 HG12 HG13 ' A' ' 296' ' ' VAL . 62.9 mt -118.67 121.77 67.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.268 -0.895 . . . . 0.0 110.22 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.76 139.75 53.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.193 -0.942 . . . . 0.0 110.215 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.41 130.61 45.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.177 -0.952 . . . . 0.0 110.284 179.818 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.442 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.8 OUTLIER -138.0 110.64 7.57 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.354 -0.842 . . . . 0.0 109.572 179.784 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.801 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 110.01 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.973 . . . . 0.0 110.464 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.463 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 5.9 m-20 39.12 31.21 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.661 -0.649 . . . . 0.0 110.52 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.54 -19.3 12.83 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.411 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.8 OUTLIER -85.82 104.39 15.45 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.2 -1.176 . . . . 0.0 110.437 -179.868 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.848 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.0 p -72.03 128.66 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.09 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.848 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.1 mm . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.156 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.553 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -133.74 163.24 29.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.397 -1.061 . . . . 0.0 109.865 179.862 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.87 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.6 tm? -161.59 133.34 5.58 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.055 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.794 ' N ' HD22 ' A' ' 267' ' ' LEU . 7.9 mt-10 -132.92 128.1 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 281' ' ' ASP . 61.9 t -120.28 137.28 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 120.894 -1.129 . . . . 0.0 111.569 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.51 156.93 33.13 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.703 HG13 ' O ' ' A' ' 279' ' ' GLU . 78.1 t -142.56 145.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.325 -1.484 . . . . 0.0 112.288 -179.305 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.547 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -138.57 111.38 7.72 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.443 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.0 147.04 23.83 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.209 -0.932 . . . . 0.0 111.304 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.843 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.2 p90 -131.92 16.16 4.72 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.455 -0.778 . . . . 0.0 109.818 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.62 -60.27 3.24 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.49 -23.3 66.23 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.124 . . . . 0.0 110.302 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.579 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.14 -178.53 45.06 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.618 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.31 142.9 47.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 110.554 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.703 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.6 mt-10 -93.93 147.21 23.31 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.53 -0.731 . . . . 0.0 109.653 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.661 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 96.9 m-85 -141.53 83.93 1.88 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.38 -0.825 . . . . 0.0 110.45 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.772 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.12 151.74 47.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.377 -0.827 . . . . 0.0 109.943 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.699 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -143.96 88.56 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.436 -0.79 . . . . 0.0 109.691 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.602 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.3 m -86.09 117.25 24.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 109.628 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.063 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -105.52 150.4 25.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.242 -0.912 . . . . 0.0 110.575 -179.263 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.897 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -131.15 134.95 47.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.451 -0.78 . . . . 0.0 110.016 -179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.3 mt -142.32 152.07 42.59 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.811 -1.181 . . . . 0.0 109.535 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.89 38.49 0.92 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.31 -0.869 . . . . 0.0 109.3 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.98 -139.12 5.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.558 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 3.6 mt-30 -118.09 96.05 5.17 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.059 -1.26 . . . . 0.0 110.959 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.6 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -121.29 133.58 55.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.362 -0.836 . . . . 0.0 110.025 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.789 ' O ' HG23 ' A' ' 353' ' ' ILE . 67.6 m-20 -65.35 109.92 2.45 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.122 -0.986 . . . . 0.0 109.624 179.438 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.88 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.0 p-90 -107.99 116.15 31.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.105 -0.997 . . . . 0.0 110.835 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.604 HG23 HG23 ' A' ' 322' ' ' THR . 54.8 m -110.25 115.92 30.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.426 -0.797 . . . . 0.0 109.902 179.835 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.771 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.7 t -96.8 111.3 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.16 -0.963 . . . . 0.0 110.608 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.507 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.3 ttpt -90.07 130.11 36.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.254 -0.904 . . . . 0.0 109.404 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.82 HG22 HG23 ' A' ' 349' ' ' ILE . 76.3 t -127.86 108.1 17.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.254 -0.903 . . . . 0.0 110.513 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.662 ' O ' HG23 ' A' ' 346' ' ' VAL . 24.9 mmtt -70.08 138.3 51.91 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.148 -0.97 . . . . 0.0 109.09 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.968 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.7 mt -90.61 156.58 18.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.495 -0.753 . . . . 0.0 111.609 -178.553 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.801 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -60.72 175.33 0.44 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.629 -0.669 . . . . 0.0 109.381 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.57 80.53 0.6 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.547 1.288 . . . . 0.0 110.009 179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.76 21.27 5.77 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.801 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 152.89 23.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -1.045 . . . . 0.0 110.064 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.968 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -153.16 146.51 24.85 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.077 -1.014 . . . . 0.0 111.312 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.879 HG21 HG11 ' A' ' 319' ' ' VAL . 63.7 t -63.88 142.16 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.372 -0.83 . . . . 0.0 109.97 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 305' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -121.77 -39.63 0.56 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -142.01 120.17 12.18 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.045 -1.268 . . . . 0.0 110.713 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.511 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.7 p90 -132.88 166.41 22.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.905 . . . . 0.0 110.021 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -157.68 160.6 38.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.161 -0.962 . . . . 0.0 111.197 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 60.25 23.17 12.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 110.881 179.502 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.591 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.99 144.88 0.78 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.352 -0.843 . . . . 0.0 109.854 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.517 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.3 m120 -83.43 122.48 28.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.028 -1.045 . . . . 0.0 109.43 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.508 ' HG2' HG13 ' A' ' 319' ' ' VAL . 4.2 ttpt -89.7 140.29 29.72 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.877 0.846 . . . . 0.0 110.609 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.561 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.41 176.11 7.03 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -137.63 107.15 6.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.409 -0.807 . . . . 0.0 110.247 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.47 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -98.06 37.4 3.49 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.47 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.6 OUTLIER 68.43 88.17 0.11 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.226 -1.161 . . . . 0.0 110.448 179.852 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.37 6.95 83.34 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.801 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.0 m-85 -146.35 -170.81 3.59 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.305 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.879 HG11 HG21 ' A' ' 304' ' ' VAL . 6.5 t -162.28 156.25 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.894 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.53 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.2 mm -125.79 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.888 -1.133 . . . . 0.0 111.476 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 36.9 m-85 -114.37 131.18 56.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.273 -0.892 . . . . 0.0 109.532 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.604 HG23 HG23 ' A' ' 293' ' ' THR . 1.8 p -132.06 169.94 12.59 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 120.624 -1.297 . . . . 0.0 110.317 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -64.92 109.37 1.27 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.883 1.465 . . . . 0.0 110.923 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.735 HG23 ' H ' ' A' ' 325' ' ' SER . 6.2 m -48.18 -59.0 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.427 -0.796 . . . . 0.0 110.63 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.735 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.6 t 177.89 -25.91 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.991 -1.068 . . . . 0.0 111.133 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.428 ' CE2' HG21 ' A' ' 324' ' ' VAL . 7.1 p-90 -113.85 -22.87 9.93 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.958 -1.089 . . . . 0.0 110.912 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.985 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 46.0 p-10 -83.36 12.18 5.79 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.991 -1.068 . . . . 0.0 110.929 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 12.1 mtmt -74.12 -11.07 60.2 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.46 -0.775 . . . . 0.0 109.329 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.21 -158.13 0.01 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.542 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -73.06 7.14 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 124.069 1.562 . . . . 0.0 111.388 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 4.4 m -162.32 131.23 4.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.123 -0.986 . . . . 0.0 109.841 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.985 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -144.23 104.37 4.1 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.231 -0.918 . . . . 0.0 110.355 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.602 ' OG1' HG23 ' A' ' 283' ' ' THR . 48.2 m -100.98 135.16 42.87 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.058 -1.027 . . . . 0.0 110.312 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.771 ' HE2' HG21 ' A' ' 294' ' ' VAL . 6.6 p90 -144.39 173.14 12.04 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.439 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.67 157.54 27.24 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.478 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.911 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -144.35 144.81 31.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.598 -0.943 . . . . 0.0 110.01 179.512 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.911 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.31 118.65 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.099 -1.001 . . . . 0.0 109.589 179.614 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.732 HG21 ' CD2' ' A' ' 298' ' ' LEU . 2.2 t -96.67 150.06 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.241 -0.912 . . . . 0.0 109.855 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -122.57 133.8 54.55 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.437 -0.789 . . . . 0.0 110.333 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.153 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.897 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.778 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.2 mtmt . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 121.196 0.522 . . . . 0.0 110.812 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 297' ' ' LYS . 7.5 p -132.08 118.17 35.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 110.46 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.498 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -46.76 -46.61 20.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.457 -0.777 . . . . 0.0 110.504 -179.845 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.417 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 9.2 pt-20 -177.27 158.93 1.53 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.041 -1.037 . . . . 0.0 110.803 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.82 HG23 HG22 ' A' ' 296' ' ' VAL . 44.9 mt -120.46 106.69 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.131 -0.98 . . . . 0.0 110.392 179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.49 136.48 51.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.225 -0.922 . . . . 0.0 110.228 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.063 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -95.71 134.35 38.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.238 -0.914 . . . . 0.0 110.332 179.83 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 6.2 tt0 -138.94 112.43 8.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.361 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.789 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.71 105.2 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.066 -1.021 . . . . 0.0 109.942 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 353' ' ' ILE . 4.5 m-20 40.15 31.51 0.1 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.591 -0.693 . . . . 0.0 110.625 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 119.14 -22.08 9.15 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.403 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -85.35 105.29 15.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.255 -1.144 . . . . 0.0 110.096 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.58 ' O ' HD13 ' A' ' 358' ' ' ILE . 4.1 p -75.73 130.52 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.58 HD13 ' O ' ' A' ' 357' ' ' VAL . 27.0 mm . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.276 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.485 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.7 OUTLIER -133.62 165.85 23.96 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -1.079 . . . . 0.0 109.883 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.926 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.31 137.2 8.02 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.412 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.798 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mm-40 -132.94 154.09 50.78 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.225 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.702 HG13 ' O ' ' A' ' 281' ' ' ASP . 46.2 t -145.41 139.74 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.62 -1.3 . . . . 0.0 111.739 -179.307 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.08 154.84 45.24 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.746 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.609 HG13 ' O ' ' A' ' 279' ' ' GLU . 70.8 t -140.67 141.43 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.466 -1.396 . . . . 0.0 111.984 -179.294 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -134.41 110.25 9.3 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 179.205 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.483 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.2 m-20 -96.77 142.19 29.08 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.071 -1.018 . . . . 0.0 110.926 -178.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.838 ' CH2' HG23 ' A' ' 337' ' ' ILE . 26.0 p90 -123.16 15.31 9.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.312 -0.867 . . . . 0.0 110.223 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.14 -53.62 3.22 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -76.9 -16.6 59.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -1.136 . . . . 0.0 110.066 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.559 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.74 -178.68 43.87 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.851 -1.299 . . . . 0.0 109.851 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.546 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.88 138.63 39.27 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -1.111 . . . . 0.0 110.053 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.609 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.0 mt-10 -95.22 147.14 23.79 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.351 -0.843 . . . . 0.0 110.017 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.686 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.0 m-85 -140.17 89.27 2.28 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 110.814 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.702 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -71.34 148.48 47.01 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.324 -0.86 . . . . 0.0 109.639 179.239 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.694 HG11 HG11 ' A' ' 294' ' ' VAL . 3.6 t -142.69 92.29 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.413 -0.805 . . . . 0.0 109.968 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.934 HG23 ' OG1' ' A' ' 333' ' ' THR . 15.4 m -86.45 126.46 34.42 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.032 -1.043 . . . . 0.0 109.77 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.113 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -115.19 149.6 37.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.969 -1.082 . . . . 0.0 110.987 -179.081 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.892 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.2 m120 -129.67 133.78 47.29 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.334 -0.854 . . . . 0.0 110.071 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 1.059 HD13 ' HB2' ' A' ' 290' ' ' TYR . 17.8 mt -142.1 162.94 34.2 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.65 -1.281 . . . . 0.0 110.055 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -87.65 29.71 0.87 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.921 . . . . 0.0 110.473 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.514 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.09 -136.82 6.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.47 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 32.4 mm-40 -90.11 104.74 17.28 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.276 -1.132 . . . . 0.0 110.873 -179.561 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 1.059 ' HB2' HD13 ' A' ' 286' ' ' LEU . 8.4 m-85 -128.43 129.61 46.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.398 -0.814 . . . . 0.0 109.265 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.781 ' O ' HG23 ' A' ' 353' ' ' ILE . 58.9 m-20 -74.6 96.31 2.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.742 -1.224 . . . . 0.0 109.369 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.935 ' CE3' HD13 ' A' ' 284' ' ' LEU . 60.3 p-90 -98.01 115.43 28.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 110.689 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.872 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.6 m -109.51 115.78 30.56 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.52 -0.738 . . . . 0.0 109.425 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.781 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.6 t -96.89 111.27 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.106 -0.996 . . . . 0.0 110.394 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.593 ' HA ' HD13 ' A' ' 320' ' ' ILE . 21.2 ttpt -91.29 136.5 33.05 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.804 HG22 HG23 ' A' ' 349' ' ' ILE . 69.9 t -135.46 109.2 10.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.136 -0.978 . . . . 0.0 110.634 -179.152 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.54 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 53.8 mmtt -69.97 132.77 46.46 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.243 -0.911 . . . . 0.0 109.32 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.899 HD13 ' HA ' ' A' ' 303' ' ' THR . 60.1 mt -86.68 165.45 16.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.304 -0.872 . . . . 0.0 111.198 -179.062 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.773 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -75.69 176.43 3.21 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.752 -0.593 . . . . 0.0 109.43 179.208 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.773 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.0 Cg_endo -67.6 84.94 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.527 1.278 . . . . 0.0 109.955 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.87 20.95 6.57 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.2 142.37 43.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.274 -1.133 . . . . 0.0 110.23 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.899 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.0 p -150.28 144.36 25.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -0.941 . . . . 0.0 110.834 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.803 HG21 HG11 ' A' ' 319' ' ' VAL . 14.7 t -63.75 137.37 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.388 -0.82 . . . . 0.0 110.193 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -120.69 -33.15 1.03 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 24.7 m -138.86 117.14 11.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.223 -1.163 . . . . 0.0 110.441 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.518 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.4 p90 -133.91 148.38 51.22 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.288 -0.883 . . . . 0.0 109.908 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.5 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -141.23 164.53 30.01 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.14 -0.975 . . . . 0.0 111.173 -179.433 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.501 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 54.33 25.13 5.64 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.728 -0.607 . . . . 0.0 111.173 179.499 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.679 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 138.65 0.64 Allowed 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.099 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.544 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -76.89 120.08 21.53 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.074 -1.017 . . . . 0.0 108.711 179.337 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.672 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.3 ttpt -88.43 128.05 35.52 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.824 0.821 . . . . 0.0 110.799 -178.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.557 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -113.31 175.73 5.32 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -135.5 110.56 8.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.292 -0.88 . . . . 0.0 110.731 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.574 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -95.35 40.56 2.64 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.0 77.65 0.26 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.233 -1.157 . . . . 0.0 109.962 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.616 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.96 3.56 54.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.772 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -145.12 -170.76 3.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.486 -1.008 . . . . 0.0 109.003 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.803 HG11 HG21 ' A' ' 304' ' ' VAL . 18.2 t -161.39 157.74 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.199 -0.938 . . . . 0.0 109.691 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.624 ' CG2' HG22 ' A' ' 293' ' ' THR . 13.0 mm -127.03 146.79 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -0.922 . . . . 0.0 110.885 -179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 91.0 m-85 -124.12 119.19 28.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.321 -0.862 . . . . 0.0 109.814 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.872 ' CG2' HG23 ' A' ' 293' ' ' THR . 12.6 p -121.11 168.0 11.92 Favored Pre-proline 0 C--N 1.301 -1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.641 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.524 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.5 Cg_endo -66.28 117.97 5.13 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.692 1.364 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.797 HG23 ' H ' ' A' ' 326' ' ' TRP . 23.9 m -65.72 -130.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.507 -0.746 . . . . 0.0 110.332 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.613 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.9 t -96.94 -12.84 22.89 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.08 -1.013 . . . . 0.0 110.554 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.797 ' H ' HG23 ' A' ' 324' ' ' VAL . 34.0 p-90 -133.46 5.53 3.75 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.07 -1.019 . . . . 0.0 110.946 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.783 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.3 t-20 -112.45 42.89 1.73 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.998 -1.064 . . . . 0.0 110.768 -179.479 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.504 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.8 OUTLIER -122.97 0.95 9.23 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.338 -0.851 . . . . 0.0 109.71 179.064 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -63.69 -158.79 0.23 Allowed Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.514 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 47.8 Cg_endo -75.36 3.88 5.41 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.999 1.526 . . . . 0.0 110.767 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.6 m -165.02 117.6 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.16 -0.963 . . . . 0.0 109.814 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.561 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.18 123.7 17.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.274 -0.891 . . . . 0.0 110.373 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.934 ' OG1' HG23 ' A' ' 283' ' ' THR . 40.9 m -111.58 142.07 44.36 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 109.99 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.781 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.0 p90 -143.95 174.82 10.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.515 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.04 158.05 27.49 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.288 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.943 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -144.97 147.44 32.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.476 -1.014 . . . . 0.0 110.041 179.627 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.943 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.6 118.93 58.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.005 -1.059 . . . . 0.0 109.704 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.5 t -96.73 147.27 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.113 -0.992 . . . . 0.0 110.095 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.475 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -120.15 137.85 53.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.339 -0.85 . . . . 0.0 110.332 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.435 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.534 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.461 0 CA-C-O 121.369 0.604 . . . . 0.0 110.29 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.594 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 7.5 p -130.22 117.84 41.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -0.839 . . . . 0.0 110.568 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.0 mt-10 -47.08 -46.98 23.03 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 110.141 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.437 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.74 158.34 1.66 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.291 -0.88 . . . . 0.0 110.59 -179.843 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.804 HG23 HG22 ' A' ' 296' ' ' VAL . 33.1 mt -118.26 105.99 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.336 -0.852 . . . . 0.0 110.289 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.86 143.02 38.62 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.959 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.113 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.37 130.91 54.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.115 -0.991 . . . . 0.0 110.442 -179.867 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 15.0 tt0 -139.13 114.69 9.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.875 . . . . 0.0 109.823 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.781 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -91.38 111.52 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.014 -1.054 . . . . 0.0 109.744 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.447 ' C ' ' O ' ' A' ' 353' ' ' ILE . 3.2 m-20 39.86 30.28 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.793 -0.567 . . . . 0.0 110.44 -179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 115.88 -15.02 16.69 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.473 ' O ' ' N ' ' A' ' 353' ' ' ILE . 0.0 OUTLIER -89.54 108.06 19.44 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.128 -1.219 . . . . 0.0 110.412 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.677 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -73.09 123.99 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.165 -0.959 . . . . 0.0 110.125 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.677 HD13 ' O ' ' A' ' 357' ' ' VAL . 20.6 mm . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.423 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.558 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.79 167.89 21.0 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.64 -0.918 . . . . 0.0 109.533 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.862 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.47 133.96 5.98 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.0 -1.08 . . . . 0.0 111.266 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.828 ' N ' HD22 ' A' ' 267' ' ' LEU . 14.3 mm-40 -134.33 129.62 35.77 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 281' ' ' ASP . 89.5 t -125.9 139.54 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.853 -1.154 . . . . 0.0 111.625 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.1 mtmt -124.9 157.56 35.67 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.745 HG13 ' O ' ' A' ' 279' ' ' GLU . 74.5 t -141.62 146.73 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.43 -1.418 . . . . 0.0 112.068 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.557 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.28 107.9 6.99 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.309 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.2 m-20 -94.74 142.44 27.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.997 -1.064 . . . . 0.0 111.1 -179.03 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.811 ' CH2' HG23 ' A' ' 337' ' ' ILE . 25.6 p90 -123.97 17.06 9.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.44 -0.787 . . . . 0.0 109.831 179.173 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.43 -55.54 3.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.31 -18.94 58.7 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.227 -1.161 . . . . 0.0 110.286 -179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.24 -179.37 40.63 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.551 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -139.06 137.13 35.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -1.111 . . . . 0.0 110.173 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.745 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.6 mt-10 -92.7 146.84 23.35 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.264 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.2 m-85 -139.98 90.34 2.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.201 -0.937 . . . . 0.0 111.265 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.796 ' O ' HG13 ' A' ' 269' ' ' VAL . 4.7 t70 -72.62 146.92 46.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.51 -0.744 . . . . 0.0 109.408 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.71 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.4 t -140.77 86.94 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.184 -0.947 . . . . 0.0 110.094 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 283' ' ' THR . . . . . 1.003 HG23 ' OG1' ' A' ' 333' ' ' THR . 13.2 m -86.74 122.88 31.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.069 -1.019 . . . . 0.0 110.04 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.09 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.56 154.05 22.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 0.0 110.226 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.558 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.7 m120 -133.69 113.75 12.7 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.106 -0.996 . . . . 0.0 110.89 -179.071 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.988 HD13 ' HB2' ' A' ' 290' ' ' TYR . 13.3 mt -123.83 158.59 31.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.549 -1.345 . . . . 0.0 109.884 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.1 35.22 0.85 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.292 -0.88 . . . . 0.0 109.807 179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 154.92 -134.25 4.15 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.515 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 47.5 mm-40 -106.84 111.63 24.24 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.177 -1.19 . . . . 0.0 111.026 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.988 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.9 m-85 -132.06 136.96 47.59 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.336 -0.852 . . . . 0.0 109.301 179.175 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.778 ' O ' HG23 ' A' ' 353' ' ' ILE . 31.1 m-20 -75.37 96.42 3.4 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.756 -1.215 . . . . 0.0 108.617 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.932 ' CE3' HD13 ' A' ' 284' ' ' LEU . 61.3 p-90 -99.6 114.1 26.93 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.449 -0.782 . . . . 0.0 110.904 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 293' ' ' THR . . . . . 1.011 HG23 HG22 ' A' ' 322' ' ' THR . 27.3 m -111.43 118.09 34.84 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.155 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.755 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.1 t -96.75 111.0 25.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.183 -0.948 . . . . 0.0 110.737 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.585 ' HA ' HD13 ' A' ' 320' ' ' ILE . 7.0 ttpp -83.34 148.6 27.24 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.441 -0.787 . . . . 0.0 109.012 178.778 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.594 HG13 ' CG2' ' A' ' 346' ' ' VAL . 44.5 t -147.3 104.99 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.096 -1.003 . . . . 0.0 110.707 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.604 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.7 mmtp -70.63 133.14 46.42 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 179.517 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 1.038 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.0 mt -86.37 150.28 24.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 111.474 -179.071 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.675 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -61.0 171.89 1.01 Allowed Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.686 -0.634 . . . . 0.0 109.681 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.675 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.2 Cg_endo -67.53 82.58 0.41 Allowed 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.785 1.413 . . . . 0.0 109.642 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.11 28.27 2.68 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.72 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -122.32 146.36 47.38 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.373 -1.075 . . . . 0.0 110.557 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 303' ' ' THR . . . . . 1.038 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.3 p -149.57 143.59 25.68 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.185 -0.947 . . . . 0.0 110.748 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.988 ' CG2' HG21 ' A' ' 319' ' ' VAL . 66.8 t -68.48 130.76 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 110.246 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -114.04 -39.33 1.06 Allowed Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 18.1 m -132.64 141.67 48.75 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.188 -1.184 . . . . 0.0 110.913 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.569 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 28.5 p90 -153.75 167.96 27.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.363 -0.836 . . . . 0.0 109.656 179.465 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.505 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -160.67 158.43 28.82 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.995 -1.066 . . . . 0.0 111.253 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.555 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.61 31.96 21.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.631 -0.668 . . . . 0.0 111.245 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.785 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.91 150.85 1.04 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.049 -1.032 . . . . 0.0 110.457 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.51 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 3.4 m120 -81.22 109.7 16.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.088 -1.007 . . . . 0.0 109.439 179.012 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.569 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 27.6 ttpt -84.97 132.52 34.34 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.46 -0.775 . . . . 0.0 110.603 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.695 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.07 174.73 7.83 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.53 -0.731 . . . . 0.0 109.465 179.329 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -138.2 104.68 5.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.523 -0.736 . . . . 0.0 110.064 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -92.0 37.93 3.29 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.12 81.24 0.21 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.048 -1.266 . . . . 0.0 110.253 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.25 -0.04 57.12 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.716 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.33 -171.33 3.71 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.347 -1.09 . . . . 0.0 109.359 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.988 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -159.46 157.91 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.117 -0.989 . . . . 0.0 109.844 178.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.585 HD13 ' HA ' ' A' ' 295' ' ' LYS . 8.7 mm -125.87 150.32 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.073 -1.017 . . . . 0.0 111.376 -179.176 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.638 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 89.3 m-85 -130.98 112.49 12.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.301 -0.874 . . . . 0.0 110.285 179.436 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 322' ' ' THR . . . . . 1.011 HG22 HG23 ' A' ' 293' ' ' THR . 2.8 p -115.02 174.23 2.48 Favored Pre-proline 0 N--CA 1.498 1.973 0 O-C-N 120.512 -1.367 . . . . 0.0 109.54 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.601 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 43.1 Cg_endo -71.13 125.07 11.07 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.607 1.319 . . . . 0.0 111.283 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.764 HG22 ' CG ' ' A' ' 327' ' ' ASN . 14.9 m -70.06 -110.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.518 -0.739 . . . . 0.0 110.438 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.522 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.1 OUTLIER -119.42 -16.95 8.88 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.715 -1.241 . . . . 0.0 111.299 -179.277 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.499 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 3.1 p-90 -125.93 -18.9 4.97 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.914 -1.116 . . . . 0.0 111.077 -179.507 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.764 ' CG ' HG22 ' A' ' 324' ' ' VAL . 34.0 p-10 -89.7 47.28 1.45 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.928 -1.108 . . . . 0.0 110.046 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.501 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 13.5 mtmt -118.26 -10.09 10.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.493 -0.754 . . . . 0.0 109.426 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.24 -157.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.549 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -74.73 5.69 3.71 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.03 1.542 . . . . 0.0 111.077 -179.741 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 3.6 m -161.93 120.03 2.25 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.874 179.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.41 117.78 14.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.222 -0.924 . . . . 0.0 110.361 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 333' ' ' THR . . . . . 1.003 ' OG1' HG23 ' A' ' 283' ' ' THR . 26.2 m -109.68 135.28 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 110.434 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.785 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 13.4 p90 -142.82 174.44 10.65 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.09 162.94 29.35 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.582 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.899 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -150.84 145.05 25.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.567 -0.961 . . . . 0.0 109.558 179.352 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.899 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -118.89 122.4 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.058 -1.026 . . . . 0.0 110.069 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.72 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -98.36 146.06 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.22 -0.925 . . . . 0.0 109.695 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -119.39 137.22 53.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 110.729 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.469 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.492 2.397 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.576 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.322 0.582 . . . . 0.0 110.742 . . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 346' ' ' VAL . 7.1 p -131.46 111.22 18.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.1 mm-40 -43.14 -46.83 6.03 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.202 -0.936 . . . . 0.0 110.425 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -175.95 157.78 1.95 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 110.357 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.586 HG12 HG22 ' A' ' 296' ' ' VAL . 13.5 mt -118.43 104.36 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.243 -0.911 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.03 126.83 52.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 110.499 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.09 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -91.11 130.17 37.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.03 -1.044 . . . . 0.0 110.025 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -138.55 117.59 12.54 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.31 -0.869 . . . . 0.0 109.549 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.778 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.11 98.19 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.921 -1.112 . . . . 0.0 110.118 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.542 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 38.57 28.24 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.296 179.634 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 134.94 -19.47 3.92 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.889 179.201 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 11.1 mm100 -102.78 113.15 26.33 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.871 -1.37 . . . . 0.0 110.905 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.587 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.7 p -76.89 121.17 28.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.485 -0.759 . . . . 0.0 110.354 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.511 ' HB ' HD13 ' A' ' 351' ' ' LEU . 26.7 mm . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.165 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.536 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.41 166.08 25.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.334 -1.098 . . . . 0.0 110.043 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.927 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.65 139.77 9.22 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.025 -1.047 . . . . 0.0 111.409 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.793 ' N ' HD22 ' A' ' 267' ' ' LEU . 3.7 mt-10 -136.12 153.78 51.19 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.704 HG13 ' O ' ' A' ' 281' ' ' ASP . 54.0 t -145.27 135.67 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.697 -1.252 . . . . 0.0 111.567 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.411 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.7 mtpt -122.88 157.05 33.38 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.844 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.822 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.5 t -144.81 147.2 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.478 -1.389 . . . . 0.0 112.167 -179.144 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.64 112.64 7.35 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.791 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 p-10 -97.53 141.76 30.19 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.948 -1.095 . . . . 0.0 111.402 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.779 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.3 p90 -124.5 19.99 8.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.502 -0.748 . . . . 0.0 109.8 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.74 -59.58 4.75 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.99 -20.07 66.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -1.159 . . . . 0.0 110.11 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.48 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.12 -175.03 44.93 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.4 143.94 42.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -1.138 . . . . 0.0 110.225 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.822 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.9 mt-10 -96.97 145.83 25.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.385 -0.822 . . . . 0.0 109.789 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.681 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 96.1 m-85 -138.93 86.73 2.16 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.452 -0.78 . . . . 0.0 110.92 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.704 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.59 146.83 49.84 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.316 -0.865 . . . . 0.0 109.442 179.105 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.825 HG11 HG11 ' A' ' 294' ' ' VAL . 5.6 t -140.22 90.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 121.336 -0.853 . . . . 0.0 109.932 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.891 HG23 ' OG1' ' A' ' 333' ' ' THR . 53.9 m -86.58 127.92 34.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.058 -1.026 . . . . 0.0 109.681 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.89 152.1 32.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.127 -0.983 . . . . 0.0 110.687 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.902 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -130.56 134.54 47.1 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.282 -0.886 . . . . 0.0 110.263 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.902 HD23 ' O ' ' A' ' 285' ' ' ASN . 12.7 mt -143.72 155.55 44.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.938 -1.101 . . . . 0.0 109.491 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -88.6 40.02 0.95 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 109.723 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 150.3 -116.69 0.79 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.991 -1.576 . . . . 0.0 110.242 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.559 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.6 mt-30 -128.62 116.31 19.4 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.022 -1.281 . . . . 0.0 110.926 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.599 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 8.8 m-85 -138.23 137.03 37.15 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.191 -0.943 . . . . 0.0 109.664 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.717 ' O ' HG23 ' A' ' 353' ' ' ILE . 23.2 m-20 -71.02 96.81 1.36 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.815 -1.178 . . . . 0.0 108.981 179.043 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.867 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.2 p-90 -98.08 113.1 24.89 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.221 -0.924 . . . . 0.0 110.833 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.663 HG23 ' CG2' ' A' ' 322' ' ' THR . 10.3 m -106.23 111.75 24.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.417 -0.802 . . . . 0.0 109.243 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.825 HG11 HG11 ' A' ' 282' ' ' VAL . 3.1 t -96.21 111.24 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.167 -0.958 . . . . 0.0 110.371 -179.328 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.53 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 5.1 ttmt -89.19 149.51 23.09 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.438 -0.788 . . . . 0.0 109.51 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.914 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 56.1 t -142.34 107.87 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.288 -0.882 . . . . 0.0 110.31 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.555 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 11.5 mmtt -70.2 131.34 44.07 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.179 -0.95 . . . . 0.0 109.645 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.941 HD13 ' HA ' ' A' ' 303' ' ' THR . 94.8 mt -85.25 160.89 19.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.81 . . . . 0.0 111.312 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.714 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -71.43 174.32 4.01 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 121.571 -0.705 . . . . 0.0 109.212 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.43 84.08 0.37 Allowed 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 123.492 1.259 . . . . 0.0 110.096 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.97 24.66 4.79 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.8 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.9 148.32 40.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -1.104 . . . . 0.0 110.225 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.941 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -149.84 143.6 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.104 -0.998 . . . . 0.0 110.718 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.736 HG21 HG11 ' A' ' 319' ' ' VAL . 85.2 t -65.63 121.94 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.418 -0.801 . . . . 0.0 109.906 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 305' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -103.16 -30.25 5.46 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.3 t -145.85 142.32 28.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.004 -1.292 . . . . 0.0 110.911 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.518 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 15.0 p90 -152.6 174.65 13.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.544 -0.722 . . . . 0.0 109.38 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.479 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -163.84 159.55 21.26 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.848 -1.158 . . . . 0.0 111.486 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.452 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.7 OUTLIER 55.68 26.41 9.3 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.564 -0.71 . . . . 0.0 111.116 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.716 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.68 139.25 0.7 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.195 -0.941 . . . . 0.0 109.897 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.541 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.6 m120 -77.42 121.24 23.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.062 -1.024 . . . . 0.0 109.488 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.533 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.3 ttpt -88.33 142.81 27.44 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.844 0.83 . . . . 0.0 110.552 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.622 ' O ' HG22 ' A' ' 319' ' ' VAL . 5.8 mt-30 -130.25 176.48 8.07 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.255 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.454 ' OE1' ' O ' ' A' ' 318' ' ' TYR . 5.3 mm-40 -135.79 113.32 10.8 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.115 -0.99 . . . . 0.0 110.545 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.6 42.13 2.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.47 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 20.6 t-20 57.41 81.49 0.14 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.335 -1.097 . . . . 0.0 110.269 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.82 3.74 58.08 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.843 ' O ' HG23 ' A' ' 319' ' ' VAL . 0.8 OUTLIER -147.08 -167.72 2.85 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.353 -1.087 . . . . 0.0 109.055 179.532 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.843 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.7 t -163.28 147.73 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.195 -0.94 . . . . 0.0 109.733 178.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.619 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.6 mm -112.35 152.06 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.005 -1.06 . . . . 0.0 110.998 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 58.4 m-85 -129.24 125.86 37.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.812 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.663 ' CG2' HG23 ' A' ' 293' ' ' THR . 7.2 p -129.04 167.7 18.71 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 120.488 -1.382 . . . . 0.0 109.965 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.552 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 38.7 Cg_endo -65.74 119.36 6.37 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.78 1.411 . . . . 0.0 111.087 -179.233 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.567 HG23 ' H ' ' A' ' 326' ' ' TRP . 31.3 m -64.73 -121.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.485 -0.759 . . . . 0.0 110.297 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.512 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -106.18 -19.9 13.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.809 -1.182 . . . . 0.0 110.666 -179.649 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.567 ' H ' HG23 ' A' ' 324' ' ' VAL . 21.6 p-90 -126.2 3.17 7.13 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.08 -1.012 . . . . 0.0 110.653 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.532 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 1.9 t-20 -108.08 31.72 5.32 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.093 -1.005 . . . . 0.0 110.576 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.552 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -110.46 -2.6 16.47 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.102 -0.999 . . . . 0.0 109.547 179.433 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.05 -153.33 0.02 OUTLIER Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.565 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.6 Cg_endo -69.8 -48.89 0.62 Allowed 'Trans proline' 0 C--N 1.301 -1.935 0 O-C-N 123.987 1.52 . . . . 0.0 109.474 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.08 125.58 52.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.527 -0.733 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.74 108.09 6.86 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.36 -0.838 . . . . 0.0 109.993 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.891 ' OG1' HG23 ' A' ' 283' ' ' THR . 3.3 m -103.17 138.92 39.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 110.227 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.805 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.0 p90 -144.74 174.63 10.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.374 -0.829 . . . . 0.0 109.138 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.04 158.26 27.59 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 118.984 -1.579 . . . . 0.0 110.336 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.914 ' CZ ' HG11 ' A' ' 296' ' ' VAL . 0.9 OUTLIER -147.93 143.87 27.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.57 -0.959 . . . . 0.0 109.553 179.321 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.887 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -118.01 129.67 74.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.073 -1.017 . . . . 0.0 110.107 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.8 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.3 t -104.92 148.48 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.027 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -120.7 135.47 55.12 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 110.181 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.431 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.658 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.1 mtmt . . . . . 0 N--CA 1.488 1.467 0 CA-C-O 121.25 0.548 . . . . 0.0 110.335 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.628 HG11 ' CE1' ' A' ' 280' ' ' TYR . 6.8 p -128.91 117.4 44.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.309 -0.869 . . . . 0.0 110.107 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.2 OUTLIER -47.57 -47.88 28.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.046 -1.034 . . . . 0.0 110.068 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.409 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.7 OUTLIER -177.2 158.33 1.47 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.289 -0.882 . . . . 0.0 110.35 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.661 HG12 HG13 ' A' ' 296' ' ' VAL . 17.0 mt -117.34 110.37 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 110.215 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.67 144.03 41.59 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.271 -0.893 . . . . 0.0 110.2 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.66 132.77 50.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.18 -0.95 . . . . 0.0 110.249 179.869 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -139.07 113.13 8.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.945 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.717 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.8 mt -91.64 112.53 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.913 -1.117 . . . . 0.0 110.088 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.436 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.5 m-20 37.84 29.72 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.782 -0.574 . . . . 0.0 111.295 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.26 -10.24 14.98 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.667 -1.254 . . . . 0.0 110.6 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.402 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 43.1 mm-40 -101.45 115.06 29.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.878 -1.366 . . . . 0.0 110.364 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.79 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.1 p -75.13 139.09 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.279 -0.888 . . . . 0.0 110.493 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.79 HD13 ' O ' ' A' ' 357' ' ' VAL . 26.6 mm . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.196 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.583 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.3 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.528 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.8 OUTLIER -136.0 167.06 21.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.447 -1.031 . . . . 0.0 109.495 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.953 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.9 tm? -161.06 136.84 8.05 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.515 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.821 ' N ' HD22 ' A' ' 267' ' ' LEU . 8.0 mm-40 -135.69 156.12 49.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.865 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.9 t -146.96 146.29 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.648 -1.283 . . . . 0.0 111.617 -179.249 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.418 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.2 OUTLIER -132.4 157.6 44.14 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.186 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 279' ' ' GLU . 86.7 t -144.88 147.2 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 120.262 -1.524 . . . . 0.0 112.401 -179.258 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.522 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.46 114.58 8.66 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.906 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.0 p-10 -97.81 148.73 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.087 -1.008 . . . . 0.0 111.366 -178.677 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.8 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.1 p90 -134.85 17.42 3.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.608 -0.682 . . . . 0.0 109.96 179.381 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 92.46 -66.28 2.05 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.489 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 57.4 m -64.3 -18.77 64.92 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.322 -1.105 . . . . 0.0 110.581 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.532 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -179.24 178.65 48.82 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.164 -1.493 . . . . 0.0 110.246 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.54 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.66 145.99 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.505 -0.997 . . . . 0.0 110.019 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.724 ' O ' HG13 ' A' ' 271' ' ' VAL . 11.4 mt-10 -96.36 146.86 24.38 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.433 -0.792 . . . . 0.0 109.425 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.2 m-85 -138.33 89.17 2.36 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.31 -0.869 . . . . 0.0 110.584 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.865 ' O ' HG13 ' A' ' 269' ' ' VAL . 71.4 m-20 -69.64 147.49 50.57 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.679 -0.638 . . . . 0.0 109.828 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.693 HG11 HG11 ' A' ' 294' ' ' VAL . 3.4 t -142.76 89.96 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.355 -0.84 . . . . 0.0 109.543 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.876 HG23 ' OG1' ' A' ' 333' ' ' THR . 27.3 m -86.49 120.51 27.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.106 -0.996 . . . . 0.0 109.857 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.34 149.37 28.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.602 -179.478 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.907 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.2 m120 -128.04 136.21 50.93 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.395 -0.816 . . . . 0.0 110.084 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.907 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.2 mt -142.17 154.52 44.9 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.721 -1.237 . . . . 0.0 109.854 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -85.77 36.27 0.65 Allowed 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.381 -0.825 . . . . 0.0 110.311 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.486 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 150.56 -104.12 0.26 Allowed Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.082 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.5 mm-40 -139.87 113.67 8.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.015 -1.285 . . . . 0.0 111.429 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.639 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 4.8 m-85 -138.75 129.93 26.95 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.536 ' O ' HG23 ' A' ' 353' ' ' ILE . 90.0 m-20 -65.16 99.69 0.39 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.817 -1.177 . . . . 0.0 109.266 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.897 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.4 p-90 -98.77 115.86 29.72 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.335 -0.853 . . . . 0.0 110.868 -179.27 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.6 HG22 ' CG2' ' A' ' 320' ' ' ILE . 9.8 m -105.98 116.26 31.63 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.66 -0.65 . . . . 0.0 109.299 179.538 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.774 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.75 111.44 26.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.02 -1.05 . . . . 0.0 110.662 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.793 ' HA ' HD13 ' A' ' 320' ' ' ILE . 2.8 ttpt -85.44 144.03 28.22 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.431 -0.793 . . . . 0.0 109.156 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.958 HG22 HG23 ' A' ' 349' ' ' ILE . 99.0 t -144.34 106.84 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.028 -1.045 . . . . 0.0 110.662 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.564 ' HD3' ' CG ' ' A' ' 318' ' ' TYR . 35.7 mmtt -70.57 130.38 41.67 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.27 -0.894 . . . . 0.0 109.804 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.958 HD13 ' HA ' ' A' ' 303' ' ' THR . 77.2 mt -85.38 155.08 21.45 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.516 -0.74 . . . . 0.0 111.398 -178.972 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.784 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -59.7 176.23 0.33 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.54 -0.725 . . . . 0.0 109.409 179.106 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.784 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.5 Cg_endo -69.19 81.07 0.69 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.612 1.322 . . . . 0.0 109.895 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.2 4.9 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.303 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.811 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -110.24 149.7 29.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.417 -1.049 . . . . 0.0 110.188 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.958 ' HA ' HD13 ' A' ' 298' ' ' LEU . 9.5 p -150.15 145.08 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 110.573 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.724 HG21 HG11 ' A' ' 319' ' ' VAL . 77.5 t -71.25 122.6 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.527 -0.733 . . . . 0.0 109.865 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -103.5 -37.99 2.91 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.461 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -132.29 136.4 46.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.076 -1.249 . . . . 0.0 111.035 -179.559 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.59 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 50.3 p90 -147.67 159.91 43.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.458 -0.776 . . . . 0.0 109.468 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.516 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -154.65 158.13 39.19 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.976 -1.077 . . . . 0.0 111.239 -179.46 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.534 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.2 OUTLIER 63.98 20.39 12.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.553 -0.717 . . . . 0.0 110.532 179.63 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.543 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.76 147.44 1.03 Allowed 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.564 -0.71 . . . . 0.0 110.022 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.578 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -82.07 123.81 29.27 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.109 -0.994 . . . . 0.0 108.982 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.59 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 11.6 ttpt -89.42 137.96 31.87 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.63 0.729 . . . . 0.0 111.217 -178.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.682 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.15 172.36 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.776 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -139.28 104.49 5.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.201 -0.937 . . . . 0.0 110.506 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.466 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -92.31 40.37 2.89 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.466 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 7.3 m-20 58.08 86.13 0.08 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.352 -1.087 . . . . 0.0 110.418 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.596 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.51 -4.54 58.25 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.693 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.0 OUTLIER -144.94 -172.05 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.4 -1.059 . . . . 0.0 109.243 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.724 HG11 HG21 ' A' ' 304' ' ' VAL . 3.3 t -159.08 161.45 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.211 -0.931 . . . . 0.0 109.739 178.978 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.793 HD13 ' HA ' ' A' ' 295' ' ' LYS . 42.4 mm -129.26 151.13 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.275 -0.89 . . . . 0.0 111.184 -179.66 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.628 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 97.4 m-85 -128.9 125.2 37.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.315 -0.866 . . . . 0.0 109.915 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.54 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 10.7 p -124.82 168.36 13.51 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 120.799 -1.188 . . . . 0.0 109.715 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.529 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.7 Cg_endo -66.73 121.71 8.97 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.692 1.364 . . . . 0.0 110.808 -179.539 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.829 HG22 ' HB2' ' A' ' 327' ' ' ASN . 31.2 m -69.5 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.554 -0.716 . . . . 0.0 110.083 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.479 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -100.44 -20.89 15.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 110.606 -179.76 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.57 ' H ' HG23 ' A' ' 324' ' ' VAL . 8.4 p-90 -127.15 5.89 6.45 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.126 -0.984 . . . . 0.0 110.564 -179.728 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.829 ' HB2' HG22 ' A' ' 324' ' ' VAL . 7.3 t30 -103.39 37.53 1.98 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.125 -0.984 . . . . 0.0 110.473 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -117.47 -9.0 10.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.282 -0.886 . . . . 0.0 109.619 179.689 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.463 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -56.31 -162.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.451 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 47.6 Cg_endo -74.14 5.16 3.72 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.228 1.646 . . . . 0.0 110.953 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.1 m -164.81 115.7 1.17 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.254 -0.904 . . . . 0.0 109.987 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.815 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -134.14 117.93 17.11 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.143 -0.973 . . . . 0.0 110.319 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.876 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.6 m -108.78 136.61 48.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.407 -0.808 . . . . 0.0 109.995 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.774 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.3 p90 -140.63 172.09 13.19 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.692 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.527 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.21 158.51 27.71 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.935 -1.602 . . . . 0.0 110.075 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.942 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -146.22 147.28 31.28 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.437 -1.037 . . . . 0.0 109.906 179.614 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.942 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.58 119.58 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.056 -1.028 . . . . 0.0 109.809 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.811 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.8 t -97.17 149.1 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.194 -0.941 . . . . 0.0 110.37 -179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.5 m120 -120.21 134.07 55.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.473 -0.767 . . . . 0.0 109.807 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.481 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.923 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.675 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.488 1.435 0 CA-C-O 121.385 0.612 . . . . 0.0 110.722 . . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.629 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.0 p -133.41 112.64 17.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.224 -0.922 . . . . 0.0 109.79 179.168 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.48 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.07 5.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.465 -0.772 . . . . 0.0 110.587 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 25.7 pt-20 -177.14 158.94 1.57 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.224 -0.923 . . . . 0.0 110.86 -179.528 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.958 HG23 HG22 ' A' ' 296' ' ' VAL . 19.0 mt -119.4 108.65 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.249 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.24 146.24 33.12 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.249 -0.907 . . . . 0.0 109.797 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.38 133.1 49.83 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.99 -1.068 . . . . 0.0 110.465 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.431 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 47.8 tt0 -138.98 110.2 6.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.795 . . . . 0.0 109.79 179.473 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.536 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.06 109.27 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.047 -1.033 . . . . 0.0 109.863 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.45 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 6.1 m-20 41.12 32.76 0.2 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.596 -0.69 . . . . 0.0 110.328 -179.538 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.69 -21.4 16.52 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 1.1 mp0 -80.17 104.22 10.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.225 -1.162 . . . . 0.0 110.292 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.635 ' O ' HD13 ' A' ' 358' ' ' ILE . 14.6 p -75.62 135.29 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 110.081 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.635 HD13 ' O ' ' A' ' 357' ' ' VAL . 13.0 mm . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.154 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.37 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.538 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.48 167.79 21.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.376 -1.073 . . . . 0.0 110.038 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.982 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.76 135.43 6.52 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.139 -0.976 . . . . 0.0 111.044 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.694 ' N ' HD22 ' A' ' 267' ' ' LEU . 96.4 mt-10 -134.96 126.95 29.63 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.08 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.799 HG23 HD11 ' A' ' 267' ' ' LEU . 64.6 t -117.76 138.61 47.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 C-N-CA 118.828 -1.149 . . . . 0.0 112.137 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.422 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.3 OUTLIER -122.83 157.55 32.2 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.802 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.3 t -144.56 146.28 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.35 -1.469 . . . . 0.0 112.232 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.569 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 2.1 m-20 -134.34 110.64 9.6 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.771 -0.58 . . . . 0.0 109.528 179.205 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 13.9 m-20 -97.85 127.55 43.88 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.336 -0.853 . . . . 0.0 111.456 -178.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.845 ' CH2' HG23 ' A' ' 337' ' ' ILE . 30.5 p90 -113.04 18.76 17.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.372 -0.83 . . . . 0.0 109.723 178.957 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.33 -64.33 3.81 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.401 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 1.5 m -63.66 -23.4 67.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.238 -1.154 . . . . 0.0 110.418 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.561 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -167.25 -179.46 40.19 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.543 -1.313 . . . . 0.0 109.941 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.556 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -135.28 141.57 45.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.33 -1.1 . . . . 0.0 109.986 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.816 ' O ' HG13 ' A' ' 271' ' ' VAL . 2.6 mt-10 -96.34 147.32 23.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -0.778 . . . . 0.0 110.32 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.79 ' CE2' HG11 ' A' ' 346' ' ' VAL . 97.0 m-85 -139.04 85.14 2.05 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 110.753 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.585 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.4 t0 -74.53 119.81 19.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.566 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.703 HG11 HG11 ' A' ' 294' ' ' VAL . 15.6 t -111.6 92.78 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.594 -0.691 . . . . 0.0 109.871 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.846 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.3 m -86.48 124.31 32.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.987 . . . . 0.0 109.367 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.11 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.69 152.27 27.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.091 -1.005 . . . . 0.0 110.718 -179.115 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.749 ' O ' HD23 ' A' ' 286' ' ' LEU . 1.7 m120 -130.62 128.55 41.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.33 -0.856 . . . . 0.0 110.408 -179.563 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.749 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.1 mt -138.62 149.55 45.33 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.823 -1.173 . . . . 0.0 109.31 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.02 38.92 0.78 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.305 -0.872 . . . . 0.0 110.003 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 159.23 -110.31 0.44 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.095 -1.526 . . . . 0.0 109.95 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.521 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 4.8 mt-30 -145.27 118.17 8.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.248 . . . . 0.0 110.359 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.64 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 5.6 m-85 -141.06 147.82 39.21 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.276 -0.89 . . . . 0.0 110.103 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.762 ' O ' HG23 ' A' ' 353' ' ' ILE . 34.6 m-20 -75.2 96.8 3.37 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.102 -0.999 . . . . 0.0 109.15 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.851 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.8 p-90 -98.73 114.38 26.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.38 -0.825 . . . . 0.0 110.241 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.92 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.3 m -109.15 112.1 24.07 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.423 -0.798 . . . . 0.0 109.403 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.803 HG22 ' CD2' ' A' ' 351' ' ' LEU . 2.8 t -96.33 110.73 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -0.931 . . . . 0.0 110.402 -179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.581 ' HE2' HD11 ' A' ' 320' ' ' ILE . 30.7 ttmt -88.65 147.15 24.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.214 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.791 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 79.5 t -140.64 107.73 2.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.163 -0.961 . . . . 0.0 110.367 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.606 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 23.0 mmtt -69.96 133.82 47.7 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.129 -0.982 . . . . 0.0 109.362 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.911 HD13 ' HA ' ' A' ' 303' ' ' THR . 70.7 mt -88.23 156.98 18.93 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.217 -0.927 . . . . 0.0 111.505 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.688 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.54 173.49 2.36 Favored Pre-proline 0 C--N 1.302 -1.471 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.065 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.688 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -66.84 82.75 0.32 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.438 1.231 . . . . 0.0 109.806 179.583 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.23 22.56 5.17 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.793 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.82 143.34 42.93 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.405 -1.056 . . . . 0.0 110.125 -179.702 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.911 ' HA ' HD13 ' A' ' 298' ' ' LEU . 15.3 p -147.36 144.07 28.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 110.688 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.957 ' CG2' HG21 ' A' ' 319' ' ' VAL . 43.8 t -67.4 135.72 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.478 -0.764 . . . . 0.0 109.985 179.619 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.35 -44.52 0.56 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 8.8 m -131.27 128.7 40.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.06 -1.259 . . . . 0.0 110.811 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.637 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 4.9 p90 -140.74 168.8 18.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.414 -0.804 . . . . 0.0 109.423 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.458 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -159.92 154.19 23.6 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.875 -1.141 . . . . 0.0 111.366 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 65.22 24.28 12.27 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.546 -0.721 . . . . 0.0 110.716 179.594 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.689 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 146.74 0.9 Allowed 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.232 -0.918 . . . . 0.0 110.347 179.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.624 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.1 m120 -81.8 125.06 30.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.091 -1.006 . . . . 0.0 108.895 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 2.4 ttpt -96.58 137.11 36.16 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 121.819 0.818 . . . . 0.0 111.018 -178.816 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.759 ' O ' HG22 ' A' ' 319' ' ' VAL . 4.1 mp0 -124.16 179.37 4.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.618 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.472 ' HG2' ' O ' ' A' ' 313' ' ' GLN . 2.5 mt-10 -139.98 102.05 4.31 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.138 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.518 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.55 46.9 3.65 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.41 82.05 0.12 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -1.126 . . . . 0.0 110.113 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.618 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.87 2.77 62.57 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.837 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.0 m-85 -143.28 -168.41 2.8 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.443 -1.034 . . . . 0.0 109.221 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.957 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.5 t -163.37 153.29 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.176 -0.952 . . . . 0.0 109.727 179.341 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.753 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 17.3 mm -119.77 150.75 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.992 -1.067 . . . . 0.0 110.711 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.4 m-85 -128.91 125.26 37.19 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.387 -0.821 . . . . 0.0 110.164 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.92 ' CG2' HG23 ' A' ' 293' ' ' THR . 35.9 p -131.05 166.44 27.65 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.676 -1.265 . . . . 0.0 109.91 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.513 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.56 119.55 6.59 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.695 1.366 . . . . 0.0 110.882 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.714 HG22 ' HB2' ' A' ' 327' ' ' ASN . 24.9 m -64.57 -121.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.532 -0.73 . . . . 0.0 110.197 -179.737 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.478 ' N ' HG23 ' A' ' 324' ' ' VAL . 5.9 m -100.55 -23.5 14.68 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.746 -1.222 . . . . 0.0 110.57 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.478 ' H ' HG23 ' A' ' 324' ' ' VAL . 9.4 p-90 -124.4 -7.75 7.53 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.128 -0.983 . . . . 0.0 110.447 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.714 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.3 t-20 -89.13 31.83 0.86 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.221 -0.924 . . . . 0.0 110.598 -179.528 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.451 ' CE ' ' O ' ' A' ' 325' ' ' SER . 0.0 OUTLIER -117.48 7.24 12.68 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.17 -0.956 . . . . 0.0 110.045 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -67.62 -150.09 0.19 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.559 ' N ' ' O ' ' A' ' 288' ' ' GLY . 46.1 Cg_endo -73.09 -51.61 0.16 Allowed 'Trans proline' 0 C--N 1.3 -2.024 0 O-C-N 123.835 1.439 . . . . 0.0 109.246 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -108.09 124.23 49.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.617 -0.677 . . . . 0.0 110.184 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -135.44 110.97 9.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.846 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.1 m -105.58 129.57 53.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 110.286 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.739 ' HE2' HG21 ' A' ' 294' ' ' VAL . 12.7 p90 -135.33 175.06 9.93 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.237 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.9 162.46 29.73 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 118.684 -1.722 . . . . 0.0 110.308 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.893 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -149.52 145.37 26.82 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 109.483 179.308 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.893 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.73 119.25 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.005 -1.059 . . . . 0.0 110.017 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.793 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -98.32 144.18 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.201 -0.937 . . . . 0.0 110.105 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.2 m120 -117.91 137.38 52.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.415 -0.803 . . . . 0.0 110.213 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 179.999 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.685 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.5 mtmt . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 121.435 0.636 . . . . 0.0 110.659 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.79 HG11 ' CE2' ' A' ' 280' ' ' TYR . 2.7 p -127.67 113.87 33.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.095 -1.003 . . . . 0.0 110.244 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.86 5.96 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.27 -0.894 . . . . 0.0 109.713 179.916 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.441 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.4 OUTLIER -177.59 158.34 1.35 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.238 -0.914 . . . . 0.0 110.947 179.461 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.595 HG12 HG13 ' A' ' 296' ' ' VAL . 27.7 mt -115.34 104.81 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.5 132.13 53.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.204 -0.935 . . . . 0.0 110.266 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.11 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -94.6 130.42 41.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 110.284 179.897 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.531 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 7.5 tt0 -138.91 114.19 9.58 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.241 -0.912 . . . . 0.0 110.12 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.762 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.32 105.45 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.047 -1.033 . . . . 0.0 109.801 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.449 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 3.4 m-20 40.31 29.21 0.05 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.735 -0.603 . . . . 0.0 110.887 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 126.02 -26.73 5.26 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.525 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 30.1 mm-40 -84.98 118.13 24.37 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.953 -1.322 . . . . 0.0 110.485 -179.53 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.886 ' O ' HD13 ' A' ' 358' ' ' ILE . 11.4 p -81.91 126.86 39.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.276 -0.89 . . . . 0.0 110.108 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.886 HD13 ' O ' ' A' ' 357' ' ' VAL . 13.0 mm . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.21 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.562 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.64 169.77 17.16 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.446 -1.032 . . . . 0.0 109.841 179.809 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.651 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -161.09 125.41 3.49 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.229 -0.92 . . . . 0.0 110.665 -179.733 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.489 ' N ' HD23 ' A' ' 267' ' ' LEU . 40.4 mt-10 -121.31 111.34 17.23 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.494 -0.754 . . . . 0.0 108.986 179.279 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 281' ' ' ASP . 40.5 t -109.21 137.39 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.99 -1.068 . . . . 0.0 111.798 -178.74 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 11.9 tttp -127.55 155.98 42.94 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 178.813 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.802 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.8 t -142.68 147.17 21.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.25 -1.531 . . . . 0.0 112.097 -178.971 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.518 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.21 114.23 8.98 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.056 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.2 m-20 -96.51 147.89 23.38 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.165 -0.959 . . . . 0.0 111.525 -178.601 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.4 p90 -135.34 18.88 3.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.486 -0.759 . . . . 0.0 109.969 179.206 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.39 -62.78 4.25 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.58 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 3.1 m -62.44 -20.15 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -1.136 . . . . 0.0 110.156 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.92 179.42 48.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.563 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -132.34 143.62 49.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -1.145 . . . . 0.0 110.305 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.802 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.1 mt-10 -95.06 146.24 24.41 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.377 -0.827 . . . . 0.0 109.949 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.689 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 85.1 m-85 -139.6 83.6 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.402 -0.811 . . . . 0.0 110.252 -179.746 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.732 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.89 150.49 48.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.44 -0.787 . . . . 0.0 109.935 179.62 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.731 HG11 HG11 ' A' ' 294' ' ' VAL . 3.3 t -142.78 87.76 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.613 -0.679 . . . . 0.0 109.402 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 283' ' ' THR . . . . . 1.009 HG23 ' OG1' ' A' ' 333' ' ' THR . 20.6 m -85.9 111.63 20.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.25 -0.906 . . . . 0.0 109.556 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -96.62 150.55 20.53 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.223 -0.923 . . . . 0.0 111.059 -179.053 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.562 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.3 m120 -133.23 106.02 7.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.575 -0.703 . . . . 0.0 110.056 -179.496 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.606 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 9.6 mt -115.96 152.37 33.62 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.793 -1.192 . . . . 0.0 109.715 179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.67 38.19 0.78 Allowed 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.091 -1.006 . . . . 0.0 110.003 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.456 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.23 -134.02 3.4 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.368 -1.396 . . . . 0.0 109.751 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.448 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 8.8 mm-40 -124.31 116.65 22.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.136 -1.214 . . . . 0.0 110.531 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.606 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 0.9 OUTLIER -146.67 129.41 16.17 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.317 -0.865 . . . . 0.0 109.741 179.558 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.664 ' O ' HG23 ' A' ' 353' ' ' ILE . 10.2 t70 -57.45 102.56 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.961 -1.087 . . . . 0.0 109.431 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.828 ' CE3' HD13 ' A' ' 284' ' ' LEU . 45.7 p-90 -99.77 110.28 22.67 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.38 -0.825 . . . . 0.0 110.183 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.56 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 29.7 m -102.3 114.95 29.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.327 -0.858 . . . . 0.0 109.798 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.787 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.82 111.09 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.188 -0.945 . . . . 0.0 110.258 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.693 ' HA ' HD13 ' A' ' 320' ' ' ILE . 30.4 ttpt -87.33 149.82 24.26 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.314 -0.866 . . . . 0.0 109.591 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.684 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 94.3 t -148.24 106.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.17 -0.957 . . . . 0.0 110.417 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.581 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtm -70.04 134.35 48.17 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.269 179.709 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.92 HD13 ' HA ' ' A' ' 303' ' ' THR . 94.4 mt -87.26 160.53 18.41 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.393 -0.817 . . . . 0.0 111.369 -178.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.837 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.57 175.8 1.25 Allowed Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.672 -0.642 . . . . 0.0 109.78 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.785 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.3 Cg_endo -68.65 80.57 0.61 Allowed 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.752 1.396 . . . . 0.0 109.6 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.78 20.79 5.94 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.837 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.79 143.47 36.31 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.583 -0.951 . . . . 0.0 110.125 -179.649 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.92 ' HA ' HD13 ' A' ' 298' ' ' LEU . 56.0 p -145.1 143.16 30.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 110.635 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.676 HG21 HG11 ' A' ' 319' ' ' VAL . 31.7 t -69.98 129.0 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.319 -0.863 . . . . 0.0 109.957 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.61 -32.72 1.54 Allowed Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.097 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.418 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 4.8 m -132.88 121.06 22.33 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.999 -1.295 . . . . 0.0 110.951 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.548 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 45.4 p90 -140.12 154.31 46.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.398 -0.814 . . . . 0.0 109.593 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.497 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -147.55 158.3 43.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.954 -1.091 . . . . 0.0 111.332 -179.132 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.507 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 61.36 24.72 14.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.473 -0.767 . . . . 0.0 110.973 179.481 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.704 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.82 140.01 0.54 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 110.13 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.566 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.3 m120 -77.14 121.25 23.35 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.042 -1.036 . . . . 0.0 109.159 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.591 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 20.2 ttpt -88.44 138.58 31.3 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.826 0.822 . . . . 0.0 111.048 -178.927 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.603 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.57 174.45 7.41 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.065 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -138.46 109.26 6.67 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.368 -0.833 . . . . 0.0 110.419 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.57 39.9 2.7 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.21 80.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -1.152 . . . . 0.0 110.23 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.619 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.87 3.1 57.11 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.699 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -147.46 -173.84 4.37 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.431 -1.041 . . . . 0.0 109.065 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.6 t -159.13 159.85 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.103 -0.998 . . . . 0.0 109.526 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.693 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.2 mm -129.38 151.2 35.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.074 -179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.66 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 39.5 m-85 -127.49 130.02 48.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.248 -0.907 . . . . 0.0 110.287 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.533 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -130.1 169.36 13.61 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.826 -1.171 . . . . 0.0 110.117 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.533 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.3 Cg_endo -65.04 123.82 12.15 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.859 1.452 . . . . 0.0 110.809 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.747 HG22 ' HB2' ' A' ' 327' ' ' ASN . 20.3 m -73.22 -116.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.537 -0.727 . . . . 0.0 110.211 -179.529 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.504 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -108.16 -23.98 11.73 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.699 -1.251 . . . . 0.0 110.668 -179.544 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.435 ' H ' HG23 ' A' ' 324' ' ' VAL . 4.4 p-90 -124.0 5.61 8.63 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.181 -0.949 . . . . 0.0 110.306 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.747 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -108.57 49.95 0.79 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 110.37 -179.818 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.474 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -124.29 -11.35 7.46 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.317 -0.864 . . . . 0.0 109.882 179.732 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.8 -158.28 0.02 OUTLIER Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.831 -1.307 . . . . 0.0 109.831 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -75.59 6.83 3.4 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.115 1.587 . . . . 0.0 110.738 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -161.26 124.39 3.21 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 120.964 -1.085 . . . . 0.0 109.68 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.574 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -142.65 106.04 4.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.227 -0.92 . . . . 0.0 109.887 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 333' ' ' THR . . . . . 1.009 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.1 m -98.76 131.74 44.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.283 -0.886 . . . . 0.0 110.291 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.787 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.1 p90 -139.34 175.14 9.81 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.548 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.69 158.42 27.75 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.852 -1.642 . . . . 0.0 110.015 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.935 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.7 OUTLIER -143.27 145.18 32.51 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.556 -0.967 . . . . 0.0 109.709 179.371 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.935 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.51 120.32 61.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.812 HG11 ' HB1' ' A' ' 302' ' ' ALA . 9.9 t -96.24 160.61 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 109.858 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -130.66 129.62 42.87 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.2 -0.937 . . . . 0.0 110.722 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.887 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.617 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.5 mtmt . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 121.237 0.542 . . . . 0.0 110.791 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.642 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.6 p -140.28 118.04 10.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 110.475 179.727 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.458 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -50.08 -44.43 51.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.478 -0.764 . . . . 0.0 110.607 -179.734 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.44 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.7 pt-20 -176.73 158.66 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.076 -1.015 . . . . 0.0 110.9 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.593 ' CG1' HG13 ' A' ' 296' ' ' VAL . 54.1 mt -121.79 114.79 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.44 -0.787 . . . . 0.0 109.823 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.68 150.35 36.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.331 -0.856 . . . . 0.0 110.55 -179.504 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -105.44 127.6 53.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.3 -0.875 . . . . 0.0 109.773 179.597 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -138.52 112.85 8.73 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.137 -0.977 . . . . 0.0 110.447 -179.919 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.664 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -92.1 109.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.945 . . . . 0.0 109.981 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 354' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 46.08 32.85 1.51 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.52 -0.737 . . . . 0.0 110.433 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.39 -21.26 26.68 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.457 ' O ' ' N ' ' A' ' 353' ' ' ILE . 69.0 mm-40 -83.23 109.41 17.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.271 -1.135 . . . . 0.0 110.29 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 4.5 p -70.38 131.03 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -0.882 . . . . 0.0 110.09 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.641 HG22 ' O ' ' A' ' 358' ' ' ILE . 29.8 mm . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.152 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.4 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.564 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.74 163.05 31.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -1.126 . . . . 0.0 109.948 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.955 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.22 132.68 5.53 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.197 -179.704 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.663 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mt-10 -133.49 132.38 40.95 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 179.262 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.685 HG13 ' O ' ' A' ' 281' ' ' ASP . 21.9 t -123.75 134.14 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.71 -1.244 . . . . 0.0 111.976 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.94 151.84 38.32 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 178.657 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.787 HG13 ' O ' ' A' ' 279' ' ' GLU . 77.9 t -140.8 146.16 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 120.368 -1.458 . . . . 0.0 112.018 -179.004 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.513 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.0 113.83 9.23 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.707 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.8 m-20 -101.29 140.87 34.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.893 -1.129 . . . . 0.0 111.395 -178.481 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.821 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.0 p90 -123.87 19.76 9.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.654 -0.654 . . . . 0.0 109.375 179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.53 -62.21 4.62 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.511 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 0.5 OUTLIER -60.62 -18.15 51.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.259 -1.142 . . . . 0.0 109.951 179.655 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.58 177.23 48.39 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.569 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -133.31 137.8 46.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -1.115 . . . . 0.0 110.124 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.787 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.5 mt-10 -93.99 145.54 24.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.251 -0.906 . . . . 0.0 110.163 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.682 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.1 m-85 -139.99 85.02 2.0 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.448 -0.782 . . . . 0.0 110.746 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.685 ' O ' HG13 ' A' ' 269' ' ' VAL . 3.7 t0 -69.54 141.46 53.83 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.334 -0.853 . . . . 0.0 109.555 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.733 HG11 HG11 ' A' ' 294' ' ' VAL . 4.0 t -132.85 91.71 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.486 -0.759 . . . . 0.0 109.506 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.883 HG23 ' OG1' ' A' ' 333' ' ' THR . 2.7 m -86.67 122.31 30.4 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.32 -0.862 . . . . 0.0 109.982 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.102 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.67 149.04 32.13 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.296 -0.877 . . . . 0.0 110.149 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.564 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.4 m120 -134.03 109.4 8.95 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.316 -0.865 . . . . 0.0 110.637 -178.758 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.633 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.1 mt -119.59 157.47 28.35 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.722 -1.236 . . . . 0.0 110.251 179.731 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 287' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 287' ' ' ASP . 15.3 p-10 -91.43 36.61 0.94 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.125 -0.984 . . . . 0.0 109.544 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.5 -136.1 4.18 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.464 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -121.81 116.31 24.21 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.201 -1.176 . . . . 0.0 110.847 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.633 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.3 m-85 -142.39 138.28 31.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.313 -0.867 . . . . 0.0 109.435 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.622 ' O ' HG23 ' A' ' 353' ' ' ILE . 14.5 t0 -67.7 97.46 0.63 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.841 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.829 ' CE3' HD13 ' A' ' 284' ' ' LEU . 46.3 p-90 -96.17 109.86 22.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.037 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.838 HG23 ' CG2' ' A' ' 322' ' ' THR . 3.1 m -102.06 115.33 30.31 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.846 . . . . 0.0 109.592 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.76 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.46 110.99 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 110.461 -179.535 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.724 ' HA ' HD13 ' A' ' 320' ' ' ILE . 28.5 ttpt -86.37 149.59 24.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.364 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.66 HG13 HG12 ' A' ' 349' ' ' ILE . 70.8 t -148.14 108.17 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.123 -0.985 . . . . 0.0 110.706 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.578 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.0 mmtp -70.81 131.79 44.34 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.132 -0.98 . . . . 0.0 109.675 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.978 HD13 ' HA ' ' A' ' 303' ' ' THR . 98.5 mt -85.52 156.05 20.94 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.259 -0.901 . . . . 0.0 111.599 -179.095 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.759 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -66.66 171.04 4.79 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.615 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.7 Cg_endo -66.87 81.86 0.34 Allowed 'Trans proline' 0 C--N 1.305 -1.757 0 O-C-N 123.518 1.273 . . . . 0.0 109.727 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.76 18.06 5.76 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.801 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -108.65 149.19 29.3 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.385 -1.068 . . . . 0.0 110.105 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.978 ' HA ' HD13 ' A' ' 298' ' ' LEU . 24.8 p -154.56 144.21 21.53 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.122 -0.987 . . . . 0.0 110.897 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.776 HG21 HG11 ' A' ' 319' ' ' VAL . 24.7 t -68.9 124.06 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -106.39 -33.71 3.32 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -142.0 131.21 23.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.005 -1.291 . . . . 0.0 110.868 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.551 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 39.2 p90 -141.78 162.89 34.36 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.29 -0.881 . . . . 0.0 109.855 179.485 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.503 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -152.31 159.51 43.47 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.928 -1.107 . . . . 0.0 110.946 -179.524 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 59.84 23.91 12.9 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.472 -0.767 . . . . 0.0 111.091 179.471 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.71 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.09 145.46 0.8 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.325 -0.86 . . . . 0.0 110.179 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.514 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.3 m120 -83.81 120.03 25.55 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.202 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.723 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.8 ttpt -87.03 145.38 26.5 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.946 0.879 . . . . 0.0 111.044 -178.981 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.794 ' O ' HG22 ' A' ' 319' ' ' VAL . 1.7 mp0 -130.41 179.03 6.16 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.013 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.602 ' HG2' HG22 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -140.0 101.76 4.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.702 -0.624 . . . . 0.0 110.108 179.546 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -87.51 40.4 3.08 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.493 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 9.5 t30 63.65 79.71 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.304 -1.115 . . . . 0.0 110.084 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.591 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 95.0 3.81 61.78 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.774 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.791 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.7 m-85 -143.3 -170.66 3.32 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.996 . . . . 0.0 108.784 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.794 HG22 ' O ' ' A' ' 313' ' ' GLN . 3.3 t -161.68 154.29 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 120.976 -1.077 . . . . 0.0 110.019 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.8 ' CG2' HG22 ' A' ' 293' ' ' THR . 22.0 mm -125.17 142.85 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.756 -179.583 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.0 m-85 -119.6 127.05 52.59 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.435 -0.791 . . . . 0.0 109.637 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.838 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.1 p -126.65 169.15 12.52 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 120.877 -1.14 . . . . 0.0 110.5 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.528 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.5 Cg_endo -65.04 112.23 1.98 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 O-C-N 124.049 1.552 . . . . 0.0 111.044 -179.5 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.637 HG22 ' HB2' ' A' ' 327' ' ' ASN . 16.5 m -56.96 -114.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.634 -0.666 . . . . 0.0 109.918 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.494 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -117.17 -20.26 9.32 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.7 -1.25 . . . . 0.0 110.417 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.49 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 5.1 p-90 -120.78 -20.65 6.92 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.204 -0.935 . . . . 0.0 110.408 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.637 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -84.23 46.14 1.18 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.081 -1.012 . . . . 0.0 109.989 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.491 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 10.7 mtmt -119.84 -9.63 9.66 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.359 -0.838 . . . . 0.0 109.675 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.5 -157.45 0.01 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.535 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.68 5.32 4.39 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.065 1.561 . . . . 0.0 110.682 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.408 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 4.2 m -162.83 119.88 1.94 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.998 -1.064 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.08 112.0 7.52 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.299 -0.875 . . . . 0.0 110.247 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.883 ' OG1' HG23 ' A' ' 283' ' ' THR . 35.1 m -103.72 132.26 50.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 110.049 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.76 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.4 p90 -135.17 173.93 11.17 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.436 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.46 151.76 23.65 Favored Glycine 0 N--CA 1.486 1.977 0 C-N-CA 118.827 -1.654 . . . . 0.0 110.242 -179.357 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.92 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -139.0 147.93 42.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.684 -0.892 . . . . 0.0 109.476 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.92 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.6 119.46 59.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.006 -1.059 . . . . 0.0 110.025 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.801 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -96.84 145.2 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.94 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.507 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 2.0 m-80 -115.63 133.23 56.24 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.391 -0.818 . . . . 0.0 110.341 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.507 ' N ' ' HE3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.487 2.06 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.759 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 3.1 mtpt . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 121.467 0.651 . . . . 0.0 110.13 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.621 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.1 p -126.03 113.71 35.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.448 -0.783 . . . . 0.0 109.779 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.501 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.4 mm-40 -41.97 -47.33 4.34 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.995 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 18.1 pt-20 -177.28 158.52 1.48 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.872 . . . . 0.0 110.524 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.66 HG12 HG13 ' A' ' 296' ' ' VAL . 11.9 mt -118.14 122.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.237 -0.914 . . . . 0.0 110.068 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.11 132.19 50.66 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.219 -0.926 . . . . 0.0 110.175 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.102 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -92.66 131.22 37.94 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.174 -0.954 . . . . 0.0 110.22 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.4 tt0 -139.68 114.53 9.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.168 -0.957 . . . . 0.0 110.358 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.622 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.1 mt -92.05 110.9 23.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.976 -1.077 . . . . 0.0 110.28 179.665 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 353' ' ' ILE . 4.2 m-20 37.47 32.1 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.716 -0.615 . . . . 0.0 111.115 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 112.26 8.86 21.01 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.513 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 2.5 mp0 -116.4 111.46 20.06 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.11 -1.229 . . . . 0.0 110.058 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -75.3 135.67 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.227 -0.92 . . . . 0.0 110.433 -179.662 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.478 HD13 ' O ' ' A' ' 357' ' ' VAL . 31.9 mm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.223 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.44 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.464 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.78 168.31 19.79 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.523 -0.986 . . . . 0.0 109.631 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.96 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.3 tm? -160.24 136.86 8.96 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.996 -1.065 . . . . 0.0 111.165 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.662 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.5 OUTLIER -136.19 123.36 21.71 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.553 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.83 HG23 HD11 ' A' ' 267' ' ' LEU . 50.2 t -116.97 134.69 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.969 -1.082 . . . . 0.0 111.738 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 37.0 mttm -118.29 157.35 27.23 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.681 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.58 142.2 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.256 -1.528 . . . . 0.0 112.115 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.517 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -138.04 113.04 9.14 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.102 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.633 ' OD1' ' HB1' ' A' ' 278' ' ' ALA . 80.2 m-20 -98.78 146.21 26.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.958 -1.089 . . . . 0.0 111.444 -178.766 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.826 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.6 p90 -131.71 23.16 4.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.608 -0.682 . . . . 0.0 109.474 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 80.55 -64.23 4.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.49 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -59.13 -22.6 61.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.293 -1.122 . . . . 0.0 110.226 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.516 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.44 -171.88 38.4 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.633 ' HB1' ' OD1' ' A' ' 273' ' ' ASP . . . -142.87 142.05 31.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -1.072 . . . . 0.0 110.009 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.681 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.7 mt-10 -97.98 146.14 25.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.414 -0.804 . . . . 0.0 110.329 -179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.692 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 81.6 m-85 -141.15 82.99 1.86 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.398 -0.814 . . . . 0.0 110.653 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.782 ' O ' HG13 ' A' ' 269' ' ' VAL . 9.3 t0 -64.91 151.53 45.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.769 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.798 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.9 t -145.05 89.34 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.55 -0.719 . . . . 0.0 109.964 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.655 HG23 ' OG1' ' A' ' 333' ' ' THR . 72.2 m -86.75 126.36 34.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.131 -0.981 . . . . 0.0 109.717 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.075 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.96 148.24 39.01 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.04 -1.038 . . . . 0.0 110.902 -179.172 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.93 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.3 m120 -128.4 134.82 48.89 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.484 -0.76 . . . . 0.0 109.949 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.93 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.2 mt -143.7 149.97 37.99 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.62 -1.3 . . . . 0.0 110.158 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -88.41 38.49 0.87 Allowed 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.278 -0.889 . . . . 0.0 109.398 179.222 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.97 -145.47 11.05 Favored Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.787 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.507 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 4.8 mt-30 -112.36 98.43 7.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -1.167 . . . . 0.0 110.665 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.643 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -120.21 154.97 34.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.257 -0.902 . . . . 0.0 110.295 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.876 ' O ' HG23 ' A' ' 353' ' ' ILE . 23.0 t0 -85.76 97.46 10.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 109.242 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.951 ' CE3' HD13 ' A' ' 284' ' ' LEU . 51.9 p-90 -95.38 108.03 20.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.169 -0.957 . . . . 0.0 110.819 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.944 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.8 m -100.11 115.13 29.09 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.543 -0.723 . . . . 0.0 109.304 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.835 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.1 t -96.71 111.38 26.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 121.187 -0.946 . . . . 0.0 110.162 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.717 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.3 ttpp -87.74 149.37 24.24 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.404 -0.81 . . . . 0.0 109.247 179.461 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.692 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 84.4 t -148.23 107.71 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.079 -1.013 . . . . 0.0 110.225 -179.603 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.582 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 21.0 mmtp -69.95 132.37 45.84 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.344 -0.848 . . . . 0.0 109.587 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.973 HD13 ' HA ' ' A' ' 303' ' ' THR . 87.8 mt -87.37 158.71 18.96 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.646 -0.659 . . . . 0.0 110.943 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.839 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.32 173.86 2.06 Favored Pre-proline 0 C--N 1.303 -1.426 0 O-C-N 121.459 -0.775 . . . . 0.0 109.285 179.07 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.712 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.34 79.7 0.59 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 123.619 1.326 . . . . 0.0 109.637 179.576 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.26 17.02 5.87 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.221 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.839 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -104.26 147.09 27.88 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.467 -1.019 . . . . 0.0 110.12 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.973 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.6 p -148.68 143.86 26.76 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.873 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.821 ' CG2' HG21 ' A' ' 319' ' ' VAL . 92.1 t -71.55 121.74 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.317 -0.864 . . . . 0.0 109.951 179.623 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.48 -21.34 6.92 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.5 OUTLIER -139.51 124.14 18.37 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.029 -1.277 . . . . 0.0 111.216 -179.464 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -145.23 164.57 30.96 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.311 -0.868 . . . . 0.0 109.884 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.473 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.4 p90 -158.34 161.29 37.6 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.948 -1.095 . . . . 0.0 110.995 -179.409 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.547 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.1 OUTLIER 54.47 29.03 10.44 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.471 -0.768 . . . . 0.0 110.843 179.517 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.697 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.33 144.43 0.71 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.285 -0.885 . . . . 0.0 109.872 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.646 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.2 m120 -82.23 115.81 21.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.092 -1.005 . . . . 0.0 109.355 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 8.7 ttpt -83.27 142.13 31.34 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.803 0.811 . . . . 0.0 110.757 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.559 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 2.9 tm0? -129.38 173.81 10.2 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.062 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.579 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.4 mt-10 -139.49 101.36 4.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.309 -0.869 . . . . 0.0 110.497 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.12 42.84 2.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 14.2 m-20 53.8 86.16 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.311 -1.111 . . . . 0.0 110.174 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.33 -0.27 55.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.612 ' O ' HG23 ' A' ' 319' ' ' VAL . 0.5 OUTLIER -150.26 -172.79 4.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.371 -1.076 . . . . 0.0 109.642 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.821 HG21 ' CG2' ' A' ' 304' ' ' VAL . 6.1 t -156.89 156.37 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.425 -0.797 . . . . 0.0 109.337 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.717 HD13 ' HA ' ' A' ' 295' ' ' LYS . 45.6 mm -126.56 147.83 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.08 -1.012 . . . . 0.0 111.22 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 83.3 m-85 -125.29 125.1 43.0 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.399 -0.813 . . . . 0.0 109.661 179.055 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.944 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.6 p -127.7 169.86 11.52 Favored Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 120.82 -1.175 . . . . 0.0 110.232 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.7 Cg_endo -64.26 115.76 3.35 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.898 1.473 . . . . 0.0 111.52 -179.088 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.826 HG22 ' CG ' ' A' ' 327' ' ' ASN . 17.3 m -64.16 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.66 -0.65 . . . . 0.0 110.192 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.495 ' N ' HG23 ' A' ' 324' ' ' VAL . 19.9 m -116.78 -12.57 10.8 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.696 -1.253 . . . . 0.0 111.198 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.495 ' H ' HG23 ' A' ' 324' ' ' VAL . 13.3 p-90 -133.72 1.37 3.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.811 -1.18 . . . . 0.0 111.133 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.826 ' CG ' HG22 ' A' ' 324' ' ' VAL . 28.3 p-10 -110.38 50.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.987 -1.071 . . . . 0.0 110.508 -179.589 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -129.09 10.51 5.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.267 -0.896 . . . . 0.0 109.664 179.466 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.418 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -73.89 -151.58 2.13 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.517 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -74.09 2.26 6.3 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.094 1.576 . . . . 0.0 110.838 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.48 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 27.5 m -167.28 122.74 1.08 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.35 -0.843 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.479 ' HB1' ' HB2' ' A' ' 327' ' ' ASN . . . -142.56 118.17 10.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.134 -0.979 . . . . 0.0 110.321 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.655 ' OG1' HG23 ' A' ' 283' ' ' THR . 18.0 m -104.36 148.55 26.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 110.214 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.835 ' HE2' HG21 ' A' ' 294' ' ' VAL . 5.9 p90 -153.88 175.22 13.59 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -156.44 157.91 28.29 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.838 -1.649 . . . . 0.0 110.548 -179.418 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.921 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -141.52 147.6 38.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.411 -1.052 . . . . 0.0 110.308 179.594 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.921 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.96 122.69 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.078 -1.014 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.697 HG11 ' HB1' ' A' ' 302' ' ' ALA . 6.3 t -100.45 156.23 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.132 -0.98 . . . . 0.0 110.782 -179.29 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -123.97 132.72 53.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.506 -0.746 . . . . 0.0 110.337 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.416 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.492 2.384 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.619 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.394 0 CA-C-O 121.201 0.524 . . . . 0.0 111.077 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.63 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.7 p -135.13 117.72 22.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.163 -0.961 . . . . 0.0 110.11 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.459 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -50.34 -45.15 54.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.343 -0.848 . . . . 0.0 110.425 -179.534 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -176.61 154.19 1.2 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -0.994 . . . . 0.0 110.703 -179.876 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.651 HG12 HG13 ' A' ' 296' ' ' VAL . 23.3 mt -113.97 124.8 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.175 -0.953 . . . . 0.0 110.133 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.21 154.39 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.389 -0.82 . . . . 0.0 109.974 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.075 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -120.65 124.51 45.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.188 -0.945 . . . . 0.0 109.659 179.478 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.508 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 34.6 tt0 -138.63 117.11 12.05 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.221 -0.925 . . . . 0.0 110.181 -179.796 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.876 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.4 107.68 19.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.165 -0.959 . . . . 0.0 109.76 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 354' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 43.66 26.74 0.13 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 110.381 -179.647 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 123.41 -31.92 4.48 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 52.3 mm-40 -75.99 114.56 14.76 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.084 -1.244 . . . . 0.0 110.47 -179.65 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.791 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -79.09 133.34 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.146 -0.972 . . . . 0.0 110.226 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.791 HD13 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.068 -0.967 . . . . 0.0 110.299 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.571 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.33 163.79 31.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.366 -1.079 . . . . 0.0 110.049 -179.774 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.653 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -156.73 122.8 4.9 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.106 -0.996 . . . . 0.0 110.737 -179.868 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.3 mt-10 -123.31 114.29 20.01 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 57.6 t -110.05 124.51 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.971 -1.081 . . . . 0.0 112.347 -178.105 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.9 mmtt -111.61 156.79 21.26 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.136 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.752 HG13 ' O ' ' A' ' 279' ' ' GLU . 83.0 t -144.61 147.92 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.426 -1.421 . . . . 0.0 112.238 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -136.8 110.05 7.83 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.928 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.4 p30 -95.34 146.35 24.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.074 -1.016 . . . . 0.0 111.247 -178.746 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.854 ' CH2' HG23 ' A' ' 337' ' ' ILE . 29.4 p90 -129.0 16.86 6.21 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.517 -0.739 . . . . 0.0 109.963 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.4 -54.57 3.52 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.494 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 2.8 m -74.63 -19.35 60.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.226 -1.161 . . . . 0.0 110.256 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.19 -175.85 42.98 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.86 ' HB2' ' NZ ' ' A' ' 345' ' ' LYS . . . -140.6 140.1 35.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -1.15 . . . . 0.0 110.238 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.752 ' O ' HG13 ' A' ' 271' ' ' VAL . 10.7 mt-10 -92.88 146.12 23.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.402 -0.811 . . . . 0.0 110.077 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.699 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 96.5 m-85 -133.33 89.96 2.67 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.44 -0.788 . . . . 0.0 110.64 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.586 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -77.21 105.03 8.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 109.821 179.525 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.716 HG11 HG11 ' A' ' 294' ' ' VAL . 6.6 t -97.72 92.53 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.466 -0.772 . . . . 0.0 110.368 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.927 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.3 m -86.87 112.77 22.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.022 -1.049 . . . . 0.0 109.931 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.041 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -100.41 149.73 23.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.124 -0.985 . . . . 0.0 110.497 -179.504 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.571 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -133.49 106.71 7.6 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.347 -0.846 . . . . 0.0 110.541 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.598 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 8.9 mt -113.63 164.88 13.11 Favored 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.778 -1.201 . . . . 0.0 110.302 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -97.97 35.63 1.69 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.269 -0.894 . . . . 0.0 110.11 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.45 -116.01 0.69 Allowed Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.277 -1.44 . . . . 0.0 109.887 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.438 ' HG2' ' O ' ' A' ' 288' ' ' GLY . 11.8 mm-40 -139.81 107.14 5.52 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.175 -1.191 . . . . 0.0 110.55 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.598 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.2 m-85 -137.08 129.17 29.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.2 -0.937 . . . . 0.0 109.723 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.643 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.4 OUTLIER -57.81 101.59 0.08 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.458 179.565 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.836 ' CE3' HD13 ' A' ' 284' ' ' LEU . 45.6 p-90 -98.4 107.72 20.24 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.373 -0.829 . . . . 0.0 109.968 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.86 HG22 ' CG2' ' A' ' 320' ' ' ILE . 2.0 m -98.87 115.07 28.01 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.328 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.759 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.3 t -96.27 111.67 26.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.114 -0.991 . . . . 0.0 110.548 -179.202 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.711 ' HA ' HD13 ' A' ' 320' ' ' ILE . 8.4 ttpt -85.71 148.03 26.06 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.365 -0.834 . . . . 0.0 109.541 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.616 HG13 HG12 ' A' ' 349' ' ' ILE . 54.0 t -148.41 110.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 120.965 -1.084 . . . . 0.0 110.762 -179.314 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.6 ' O ' HG23 ' A' ' 346' ' ' VAL . 47.2 mmtt -74.36 131.82 41.46 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.292 -0.88 . . . . 0.0 109.628 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.979 HD13 ' HA ' ' A' ' 303' ' ' THR . 83.5 mt -83.95 151.65 24.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.261 -0.899 . . . . 0.0 111.445 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.824 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -55.55 173.69 0.25 Allowed Pre-proline 0 N--CA 1.487 1.401 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.158 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.681 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -68.76 78.27 0.71 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.592 1.312 . . . . 0.0 109.516 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.86 22.95 3.78 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 -179.279 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.824 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -109.03 154.79 21.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.307 -1.114 . . . . 0.0 110.337 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.979 ' HA ' HD13 ' A' ' 298' ' ' LEU . 41.0 p -152.33 144.36 23.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.179 -0.951 . . . . 0.0 110.716 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.9 ' CG2' HG21 ' A' ' 319' ' ' VAL . 49.0 t -72.22 117.74 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.462 -0.774 . . . . 0.0 109.89 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.94 -36.44 3.69 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.5 m -134.64 145.7 48.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.05 -1.265 . . . . 0.0 111.026 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.583 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 33.8 p90 -160.23 165.08 32.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.525 -0.734 . . . . 0.0 109.565 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.512 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -154.3 165.13 37.28 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 120.901 -1.124 . . . . 0.0 111.356 -179.408 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.44 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 51.58 28.55 4.75 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.54 -0.725 . . . . 0.0 111.488 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.751 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 138.83 0.47 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.083 -1.01 . . . . 0.0 110.302 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.651 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.6 m120 -77.64 115.39 17.36 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 109.112 179.326 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.601 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.1 ttpt -84.28 140.22 31.8 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.805 0.812 . . . . 0.0 110.738 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.686 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.66 174.95 7.13 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 179.204 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -137.61 109.42 7.11 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.331 -0.856 . . . . 0.0 110.276 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.426 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -99.85 46.87 1.35 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 58.47 85.72 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 110.5 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.552 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 89.86 -0.09 78.98 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.833 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.5 m-85 -138.78 -170.04 2.76 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.235 -1.156 . . . . 0.0 109.281 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -163.08 157.31 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.81 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.86 ' CG2' HG22 ' A' ' 293' ' ' THR . 7.1 mm -127.58 151.8 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.227 -0.921 . . . . 0.0 110.929 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.627 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 99.4 m-85 -128.72 125.56 38.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.928 -1.108 . . . . 0.0 110.144 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.762 ' CG2' HG23 ' A' ' 293' ' ' THR . 11.9 p -124.75 167.83 14.9 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 120.876 -1.14 . . . . 0.0 109.596 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.48 123.84 12.01 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 O-C-N 123.737 1.388 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.651 HG12 ' OD1' ' A' ' 311' ' ' ASN . 18.5 m -70.61 -114.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.497 -0.752 . . . . 0.0 109.855 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.51 ' N ' HG23 ' A' ' 324' ' ' VAL . 2.6 m -110.46 -13.36 14.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.743 -1.223 . . . . 0.0 110.547 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.536 ' H ' HG23 ' A' ' 324' ' ' VAL . 7.3 p-90 -132.86 -6.17 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.155 -0.965 . . . . 0.0 110.928 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.555 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -97.49 46.68 1.02 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.046 -1.034 . . . . 0.0 110.216 -179.785 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -124.43 -8.05 7.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.099 -1.0 . . . . 0.0 109.92 -179.966 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.22 -157.87 0.02 OUTLIER Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.534 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -75.88 8.16 2.87 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.804 1.423 . . . . 0.0 111.0 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.407 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.1 m -165.17 115.53 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.525 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -132.83 109.04 9.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.237 -0.915 . . . . 0.0 110.27 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.927 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.2 m -100.03 122.26 42.65 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.308 -0.87 . . . . 0.0 110.111 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.759 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.7 p90 -128.9 175.17 8.86 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.628 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.44 157.8 27.48 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.823 -1.656 . . . . 0.0 110.268 -179.368 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.949 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -145.28 148.98 34.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.7 -0.882 . . . . 0.0 109.265 179.449 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.949 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.24 118.25 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.023 -1.048 . . . . 0.0 109.679 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.1 t -96.23 152.22 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.206 -0.934 . . . . 0.0 109.801 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.2 m120 -124.76 133.26 53.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.199 -0.938 . . . . 0.0 110.756 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.859 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.86 ' NZ ' ' HB2' ' A' ' 278' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 CA-C-O 121.097 0.475 . . . . 0.0 110.955 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 297' ' ' LYS . 3.3 p -130.55 113.55 25.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.223 -0.923 . . . . 0.0 109.7 179.212 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.547 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 35.2 mt-10 -41.55 -45.93 3.43 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.247 -0.908 . . . . 0.0 110.304 -179.488 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.59 158.55 1.76 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.135 -0.978 . . . . 0.0 110.64 179.847 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.616 HG12 HG13 ' A' ' 296' ' ' VAL . 12.1 mt -119.74 129.05 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 110.193 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -131.2 151.74 51.17 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.266 -0.896 . . . . 0.0 110.297 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.041 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.43 130.5 54.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.232 -0.917 . . . . 0.0 109.914 179.815 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 48.1 tt0 -138.37 113.38 9.23 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.189 -0.945 . . . . 0.0 110.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.643 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -96.31 108.76 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.985 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.447 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.4 m-20 39.42 34.6 0.14 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.544 -0.722 . . . . 0.0 110.629 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 112.59 -19.05 22.1 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.463 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.1 OUTLIER -85.18 100.54 11.82 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.27 -1.135 . . . . 0.0 110.317 -179.823 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.3 p -71.15 121.65 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.512 HD13 ' O ' ' A' ' 357' ' ' VAL . 35.7 mm . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.279 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 110.17 -1.172 . . . . 0.0 110.17 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.578 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.87 157.24 46.47 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.485 -1.009 . . . . 0.0 109.791 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.898 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -149.33 124.66 10.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 110.615 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.565 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.1 mp0 -124.47 111.34 15.6 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.089 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.579 HG11 HD12 ' A' ' 349' ' ' ILE . 41.0 t -105.07 129.57 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.024 -1.047 . . . . 0.0 111.959 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.402 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.7 ttmt -117.38 156.89 27.11 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.507 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.613 HG22 ' CD2' ' A' ' 280' ' ' TYR . 78.5 t -144.86 146.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.424 -1.422 . . . . 0.0 112.399 -179.094 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -138.22 109.39 6.84 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.15 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.7 p-10 -95.75 147.95 23.08 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.127 -0.983 . . . . 0.0 111.111 -178.783 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.841 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.9 p90 -133.66 16.97 3.94 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.515 -0.741 . . . . 0.0 110.019 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.05 -58.48 3.96 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.565 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 6.0 t -68.8 -20.31 64.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -1.141 . . . . 0.0 110.103 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -177.7 179.09 48.41 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -132.55 141.84 48.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -1.125 . . . . 0.0 110.121 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.577 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 6.3 mt-10 -95.62 147.45 23.58 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.47 -0.769 . . . . 0.0 110.209 -179.546 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.694 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 93.5 m-85 -138.6 95.08 2.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 110.709 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.57 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.71 108.49 16.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.526 -0.734 . . . . 0.0 110.091 179.657 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.704 HG11 HG11 ' A' ' 294' ' ' VAL . 6.7 t -100.11 92.72 2.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.6 -0.688 . . . . 0.0 109.85 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.671 HG23 ' OG1' ' A' ' 333' ' ' THR . 3.6 m -86.57 113.89 22.84 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.932 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.039 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.98 149.74 23.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.096 -1.003 . . . . 0.0 110.806 -179.322 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.578 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.1 m120 -134.56 106.37 6.97 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -179.61 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.607 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 8.1 mt -116.91 162.54 17.59 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.688 -1.257 . . . . 0.0 109.94 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.86 36.24 1.2 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.974 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.447 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.4 -135.5 3.9 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.325 -1.417 . . . . 0.0 110.039 -179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.489 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.5 mt-30 -121.43 104.65 9.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.152 -1.205 . . . . 0.0 110.978 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.607 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -132.6 129.24 38.69 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.3 -0.875 . . . . 0.0 109.702 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.583 ' O ' HG23 ' A' ' 353' ' ' ILE . 39.1 m-20 -58.58 99.57 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.4 179.435 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.857 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.0 p-90 -97.94 113.07 24.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 110.418 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.564 HG23 ' CG2' ' A' ' 322' ' ' THR . 23.5 m -105.17 113.8 27.61 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.336 -0.853 . . . . 0.0 109.478 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.775 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.1 t -96.08 110.54 24.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.799 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.444 ' HE2' HD11 ' A' ' 320' ' ' ILE . 31.9 ttmt -83.44 146.77 28.23 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.301 -0.875 . . . . 0.0 109.217 179.378 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.711 HG22 HG23 ' A' ' 349' ' ' ILE . 42.4 t -140.93 105.13 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.518 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 10.6 mmtp -70.18 132.33 45.62 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.189 -0.945 . . . . 0.0 109.136 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.956 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.9 mt -87.41 152.13 22.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.441 -0.787 . . . . 0.0 111.376 -178.875 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.749 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -61.71 174.74 0.61 Allowed Pre-proline 0 C--N 1.301 -1.505 0 O-C-N 121.63 -0.668 . . . . 0.0 109.293 179.002 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.749 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.9 Cg_endo -68.48 82.87 0.51 Allowed 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.703 1.37 . . . . 0.0 110.041 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.1 24.48 4.82 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.777 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -114.41 148.89 37.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -1.09 . . . . 0.0 110.155 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.956 ' HA ' HD13 ' A' ' 298' ' ' LEU . 21.0 p -151.76 144.35 24.24 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 110.614 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.89 HG21 HG11 ' A' ' 319' ' ' VAL . 61.3 t -64.65 129.7 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.458 -0.776 . . . . 0.0 110.357 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.74 -34.41 2.05 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.417 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -142.21 131.72 23.83 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.194 -1.18 . . . . 0.0 110.59 -179.827 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 13.6 p90 -145.96 163.92 33.65 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.263 -0.898 . . . . 0.0 109.817 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.519 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.7 OUTLIER -154.33 166.75 32.21 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.99 -1.068 . . . . 0.0 110.982 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.458 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.5 OUTLIER 54.99 23.07 4.8 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.561 -0.712 . . . . 0.0 111.03 179.772 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.696 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.92 149.39 1.13 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.423 179.635 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.543 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.3 m120 -87.77 124.65 33.82 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.163 -0.961 . . . . 0.0 109.263 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 7.8 ttpt -92.29 139.77 30.27 Favored 'General case' 0 N--CA 1.489 1.486 0 CA-C-O 121.697 0.76 . . . . 0.0 110.976 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.735 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.96 175.18 7.49 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 178.808 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.617 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.6 mt-10 -136.34 109.69 7.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.083 -1.01 . . . . 0.0 110.629 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -98.59 39.58 2.71 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 61.26 90.22 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 0.0 110.095 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.09 0.87 82.65 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.856 ' O ' HG23 ' A' ' 319' ' ' VAL . 4.0 m-85 -143.83 -171.31 3.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.466 -1.02 . . . . 0.0 109.567 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.89 HG11 HG21 ' A' ' 304' ' ' VAL . 2.9 t -163.43 156.73 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -0.854 . . . . 0.0 109.467 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.549 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 15.2 mm -122.43 147.52 26.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.92 -1.112 . . . . 0.0 110.715 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.661 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.0 m-85 -124.28 129.6 51.04 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.212 -0.93 . . . . 0.0 109.855 179.389 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.564 ' CG2' HG23 ' A' ' 293' ' ' THR . 16.1 p -132.41 167.22 23.6 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 120.575 -1.328 . . . . 0.0 110.178 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.535 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -65.99 115.95 3.72 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.839 1.442 . . . . 0.0 111.01 -179.698 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.631 HG22 ' HB2' ' A' ' 327' ' ' ASN . 9.2 m -58.36 -111.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.427 -0.795 . . . . 0.0 110.006 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.43 ' H ' HG23 ' A' ' 324' ' ' VAL . 2.2 p -117.78 -18.43 9.6 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.742 -1.224 . . . . 0.0 110.379 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.4 ' H ' HG23 ' A' ' 324' ' ' VAL . 6.9 p-90 -125.93 -4.13 6.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.244 -0.91 . . . . 0.0 110.401 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.631 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.3 t30 -97.73 50.29 1.04 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.288 -0.882 . . . . 0.0 109.977 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.504 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 4.2 mtmt -124.72 -9.82 7.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.344 -0.847 . . . . 0.0 109.894 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.53 -160.57 0.02 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.23 6.08 3.71 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.059 1.557 . . . . 0.0 110.744 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.433 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.7 m -163.07 116.55 1.62 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.066 -1.022 . . . . 0.0 109.943 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.453 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.53 105.79 5.75 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.22 -0.925 . . . . 0.0 110.324 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.671 ' OG1' HG23 ' A' ' 283' ' ' THR . 13.9 m -96.0 123.23 39.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.775 ' HE2' HG21 ' A' ' 294' ' ' VAL . 9.8 p90 -127.48 172.67 10.49 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.366 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.89 160.29 28.34 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.653 -1.736 . . . . 0.0 110.397 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.889 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -147.08 143.75 28.55 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.717 -0.873 . . . . 0.0 109.348 179.379 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.889 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -117.65 117.25 54.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.797 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.2 t -96.9 152.03 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.997 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.79 134.72 54.41 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 110.353 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.41 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.618 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.1 mtmt . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 121.299 0.571 . . . . 0.0 110.728 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.63 HG21 HG13 ' A' ' 296' ' ' VAL . 7.4 p -136.12 114.74 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.474 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.518 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 3.1 mm-40 -44.07 -47.2 8.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.879 . . . . 0.0 110.045 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -176.8 153.46 1.06 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.124 -0.985 . . . . 0.0 110.733 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.711 HG23 HG22 ' A' ' 296' ' ' VAL . 18.5 mt -115.38 104.23 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.153 -0.967 . . . . 0.0 110.033 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.78 154.03 20.04 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.228 -0.92 . . . . 0.0 110.448 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.039 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.38 127.56 55.7 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.296 -0.877 . . . . 0.0 110.261 179.996 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 27.3 tt0 -138.21 112.65 8.77 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.083 -1.011 . . . . 0.0 109.895 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.583 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.74 108.03 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 110.669 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.444 ' C ' ' O ' ' A' ' 353' ' ' ILE . 4.7 m-20 37.76 35.84 0.08 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.674 -0.641 . . . . 0.0 111.139 179.563 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.1 -0.07 28.4 Favored Glycine 0 N--CA 1.493 2.433 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.485 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -108.68 104.5 13.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.126 -1.22 . . . . 0.0 110.134 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.65 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.3 p -71.9 114.11 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.332 -0.855 . . . . 0.0 110.283 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.702 ' HB ' HD13 ' A' ' 351' ' ' LEU . 41.6 mm . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.112 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.143 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.537 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.22 166.39 24.67 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.486 -1.008 . . . . 0.0 109.488 179.759 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.933 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.69 140.2 9.44 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.001 -1.062 . . . . 0.0 111.11 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.721 ' H ' HD22 ' A' ' 267' ' ' LEU . 9.5 mt-10 -141.94 123.89 15.33 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 179.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 281' ' ' ASP . 71.8 t -117.14 141.61 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 120.845 -1.16 . . . . 0.0 111.607 -178.973 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -126.88 157.55 39.05 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.923 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.668 HG13 ' O ' ' A' ' 279' ' ' GLU . 74.1 t -144.73 146.95 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.416 -1.427 . . . . 0.0 112.085 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.516 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -144.5 114.9 7.58 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.643 -0.661 . . . . 0.0 109.288 179.056 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.5 p30 -96.04 148.01 23.12 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.2 -0.938 . . . . 0.0 111.291 -178.798 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.757 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.2 p90 -132.78 19.17 4.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.489 -0.757 . . . . 0.0 109.949 179.23 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.61 -62.43 3.4 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.521 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 22.0 m -66.37 -21.14 66.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -1.149 . . . . 0.0 110.481 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.486 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -176.4 -179.55 46.91 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.43 -1.366 . . . . 0.0 109.776 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.55 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.99 143.94 48.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.258 -1.142 . . . . 0.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.668 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.0 mt-10 -96.37 147.35 23.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.439 -0.788 . . . . 0.0 110.332 -179.546 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.675 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.0 m-85 -141.2 86.63 2.04 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.474 -0.766 . . . . 0.0 110.372 -179.52 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.82 ' O ' HG13 ' A' ' 269' ' ' VAL . 3.9 t0 -71.09 152.19 43.73 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.367 -0.833 . . . . 0.0 110.092 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 294' ' ' VAL . 4.8 t -144.83 89.84 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.601 -0.687 . . . . 0.0 109.812 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.855 HG23 ' OG1' ' A' ' 333' ' ' THR . 13.5 m -86.29 127.9 34.84 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.951 -1.093 . . . . 0.0 109.596 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.107 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -116.53 151.16 36.71 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.02 -1.05 . . . . 0.0 110.862 -179.35 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.3 m120 -131.62 136.0 47.4 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.402 -0.811 . . . . 0.0 109.88 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 17.9 mt -140.67 172.69 12.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.773 -1.204 . . . . 0.0 109.965 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -94.55 29.16 2.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.22 -0.925 . . . . 0.0 110.967 -179.157 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.528 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 149.91 -82.84 0.18 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.484 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.2 tt0 -151.59 107.94 3.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.092 -1.24 . . . . 0.0 110.737 -179.343 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.634 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.4 m-85 -133.27 140.89 47.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.299 -0.876 . . . . 0.0 109.829 179.51 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.699 ' O ' HG23 ' A' ' 353' ' ' ILE . 18.3 m-20 -74.01 97.09 2.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.05 -1.031 . . . . 0.0 109.001 179.022 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.956 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.8 p-90 -98.63 115.27 28.29 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.206 -0.934 . . . . 0.0 110.64 -179.193 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.613 HG23 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -108.09 113.9 27.4 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.506 -0.746 . . . . 0.0 109.547 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.816 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.7 t -96.75 110.88 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 109.948 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.531 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 26.7 ttmt -84.84 148.24 26.39 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.344 -0.847 . . . . 0.0 109.768 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.779 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 46.3 t -144.58 108.51 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.256 -0.902 . . . . 0.0 110.398 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.585 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 2.6 mmtp -73.25 141.59 47.25 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.291 -0.88 . . . . 0.0 109.054 179.444 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.992 HD13 ' HA ' ' A' ' 303' ' ' THR . 97.9 mt -93.45 156.7 16.61 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.164 -0.96 . . . . 0.0 111.708 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -69.65 172.45 5.42 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.629 -0.67 . . . . 0.0 109.49 179.073 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.0 Cg_endo -67.61 84.34 0.39 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.73 1.384 . . . . 0.0 109.704 179.199 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.29 28.05 3.19 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 -179.244 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.887 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -123.42 145.25 48.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.331 -1.099 . . . . 0.0 110.623 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.992 ' HA ' HD13 ' A' ' 298' ' ' LEU . 42.0 p -145.68 144.4 30.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.254 -0.904 . . . . 0.0 110.367 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.99 ' CG2' HG21 ' A' ' 319' ' ' VAL . 19.6 t -78.62 136.86 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 110.179 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -136.67 -34.01 0.22 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -114.22 113.08 24.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.142 -1.21 . . . . 0.0 110.712 -179.632 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 28.9 p90 -144.4 164.37 31.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.297 -0.877 . . . . 0.0 109.844 179.503 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -157.64 161.56 38.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.076 -1.015 . . . . 0.0 111.102 -179.297 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.521 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 57.91 23.66 10.06 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.797 . . . . 0.0 111.22 179.31 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.676 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.46 141.85 0.72 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.185 -0.947 . . . . 0.0 110.057 179.469 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.541 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.6 m120 -77.24 119.46 20.94 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.135 -0.978 . . . . 0.0 109.399 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.4 ttpt -90.33 141.45 28.71 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.658 0.742 . . . . 0.0 110.404 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.818 ' O ' HG22 ' A' ' 319' ' ' VAL . 1.5 mp0 -128.99 178.47 6.38 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.609 ' HG3' HG22 ' A' ' 319' ' ' VAL . 2.5 mt-10 -141.48 104.69 4.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.686 -0.634 . . . . 0.0 110.024 179.511 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.38 42.05 2.93 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.59 78.78 0.27 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.225 -1.162 . . . . 0.0 110.436 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.613 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 102.7 -1.64 48.94 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.845 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -144.38 -165.67 2.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.337 -1.096 . . . . 0.0 109.42 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.99 HG21 ' CG2' ' A' ' 304' ' ' VAL . 2.8 t -163.48 154.25 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.331 -0.856 . . . . 0.0 109.7 179.341 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.815 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 13.4 mm -121.11 148.02 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.027 -1.046 . . . . 0.0 110.693 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.651 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.8 m-85 -126.27 124.53 40.57 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.357 -0.839 . . . . 0.0 109.815 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.613 ' CG2' HG23 ' A' ' 293' ' ' THR . 8.7 p -128.9 166.51 24.45 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.935 -1.103 . . . . 0.0 109.576 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.43 120.43 7.64 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.853 1.449 . . . . 0.0 110.912 -179.076 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.778 HG22 ' HB2' ' A' ' 327' ' ' ASN . 31.1 m -64.48 -123.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.576 -0.702 . . . . 0.0 110.205 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.484 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.8 OUTLIER -102.35 -17.7 15.75 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.815 -1.178 . . . . 0.0 110.669 -179.673 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.605 ' H ' HG23 ' A' ' 324' ' ' VAL . 20.4 p-90 -126.74 -8.78 6.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.018 -1.051 . . . . 0.0 110.505 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.778 ' HB2' HG22 ' A' ' 324' ' ' VAL . 6.6 t30 -89.82 38.98 0.94 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.416 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -118.47 -6.35 10.74 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.137 -0.977 . . . . 0.0 109.715 179.75 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.26 -164.69 0.06 OUTLIER Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.528 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.6 Cg_endo -72.35 1.05 6.54 Favored 'Trans proline' 0 C--N 1.307 -1.633 0 O-C-N 124.236 1.65 . . . . 0.0 110.793 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -160.04 114.74 2.29 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.421 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.764 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -136.43 120.92 18.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -0.89 . . . . 0.0 110.499 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.855 ' OG1' HG23 ' A' ' 283' ' ' THR . 97.4 m -110.37 142.38 42.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -0.872 . . . . 0.0 110.099 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.816 ' HE2' HG21 ' A' ' 294' ' ' VAL . 16.4 p90 -145.22 174.39 11.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.419 -0.801 . . . . 0.0 108.918 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.14 164.62 30.12 Favored Glycine 0 N--CA 1.488 2.148 0 C-N-CA 118.913 -1.613 . . . . 0.0 110.146 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.896 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -151.54 143.4 23.78 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.512 -0.993 . . . . 0.0 109.642 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.896 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -119.42 123.16 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.07 -1.019 . . . . 0.0 109.569 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.887 HG11 ' HB1' ' A' ' 302' ' ' ALA . 13.3 t -96.26 154.91 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.098 -1.002 . . . . 0.0 110.353 -179.522 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -124.58 135.03 52.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.368 -0.832 . . . . 0.0 110.582 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.459 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.49 2.246 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.559 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.434 0 CA-C-O 121.312 0.577 . . . . 0.0 110.526 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.595 HG21 HG13 ' A' ' 296' ' ' VAL . 7.5 p -129.21 123.13 57.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.302 -0.874 . . . . 0.0 110.103 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.533 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 8.8 mt-10 -56.11 -41.38 75.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.314 -0.866 . . . . 0.0 110.907 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.424 ' OE2' HG23 ' A' ' 350' ' ' THR . 2.4 tp10 -177.14 156.13 1.23 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.93 -1.106 . . . . 0.0 110.623 -179.352 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.696 HG23 HG22 ' A' ' 296' ' ' VAL . 38.6 mt -123.98 104.02 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.121 -0.987 . . . . 0.0 110.063 179.283 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 350' ' ' THR . . . . . 0.424 HG23 ' OE2' ' A' ' 348' ' ' GLU . 0.0 OUTLIER -108.73 148.46 30.45 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.211 -0.931 . . . . 0.0 110.129 -179.836 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.107 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -109.84 129.51 55.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.946 . . . . 0.0 110.347 179.844 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 24.2 tp10 -138.46 114.37 10.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.895 . . . . 0.0 109.779 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.699 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.54 104.86 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.101 -0.999 . . . . 0.0 110.462 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' A' ' 353' ' ' ILE . 3.4 m-20 38.94 36.1 0.14 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.831 -0.543 . . . . 0.0 110.794 179.752 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.41 12.72 16.54 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 1.4 mp0 -120.88 105.45 10.71 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.979 -1.307 . . . . 0.0 110.358 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.887 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -72.22 128.02 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.275 -0.891 . . . . 0.0 110.324 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.887 HD13 ' O ' ' A' ' 357' ' ' VAL . 10.7 mm . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.097 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.497 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.53 166.29 24.97 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.722 -0.87 . . . . 0.0 109.495 179.908 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.914 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.5 tm? -161.59 137.58 7.94 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.497 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.821 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.8 OUTLIER -137.27 151.0 48.21 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.032 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.848 HG13 ' O ' ' A' ' 281' ' ' ASP . 66.1 t -138.93 138.83 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.683 -1.261 . . . . 0.0 111.431 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.422 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -120.69 157.77 28.9 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.215 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.702 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.4 t -144.9 146.76 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.287 -1.508 . . . . 0.0 112.169 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -143.7 113.5 7.13 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.451 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 4.8 m-20 -98.1 143.72 28.34 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.209 -0.932 . . . . 0.0 111.016 -178.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.83 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.8 p90 -128.99 17.75 6.14 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 110.079 179.56 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.76 -58.3 4.36 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.94 -18.31 64.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.229 -1.16 . . . . 0.0 110.093 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.551 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.72 178.14 48.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.542 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -132.14 143.49 50.02 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -1.111 . . . . 0.0 110.111 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.702 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -97.52 147.13 24.57 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.459 -0.776 . . . . 0.0 110.031 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 94.3 m-85 -142.41 84.52 1.87 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.336 -0.853 . . . . 0.0 110.749 -179.598 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.848 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -66.41 152.12 45.75 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.408 -0.808 . . . . 0.0 110.03 179.288 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.719 HG11 HG11 ' A' ' 294' ' ' VAL . 10.6 t -144.41 90.33 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.66 -0.65 . . . . 0.0 109.572 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 333' ' ' THR . 81.9 m -86.43 124.56 32.9 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.146 -0.971 . . . . 0.0 109.465 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.058 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.07 147.51 37.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.308 -0.87 . . . . 0.0 110.531 -179.243 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.904 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.3 m120 -126.33 134.17 51.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.382 -0.824 . . . . 0.0 109.804 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.904 HD23 ' O ' ' A' ' 285' ' ' ASN . 16.5 mt -141.63 150.42 41.95 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.607 -1.308 . . . . 0.0 110.208 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.51 35.59 0.77 Allowed 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.484 -0.76 . . . . 0.0 109.374 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.59 -128.94 2.04 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.256 -1.45 . . . . 0.0 109.91 -179.7 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.498 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -124.59 96.07 4.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -1.195 . . . . 0.0 110.714 -179.531 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.547 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.7 m-85 -118.53 129.44 55.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.33 -0.857 . . . . 0.0 109.74 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.687 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.3 OUTLIER -63.49 100.57 0.27 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.948 -1.095 . . . . 0.0 109.224 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.954 ' CE3' HD13 ' A' ' 284' ' ' LEU . 54.7 p-90 -99.85 112.98 25.21 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.213 -0.929 . . . . 0.0 111.065 -179.257 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.874 HG23 ' CG2' ' A' ' 322' ' ' THR . 14.8 m -106.01 115.81 30.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.648 -0.658 . . . . 0.0 109.271 179.256 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.771 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.2 t -96.27 110.95 25.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.035 -1.04 . . . . 0.0 110.388 -179.424 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.524 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.9 ttpt -86.0 145.95 26.88 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.469 -0.769 . . . . 0.0 109.223 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.923 HG22 HG23 ' A' ' 349' ' ' ILE . 55.1 t -146.3 108.04 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 110.448 -179.501 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.519 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 30.8 mmtp -70.38 139.88 52.0 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.186 -0.946 . . . . 0.0 109.324 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.96 HD13 ' HA ' ' A' ' 303' ' ' THR . 81.8 mt -94.71 158.45 15.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.454 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.819 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.65 177.12 0.88 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.684 -0.635 . . . . 0.0 109.748 179.33 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.819 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.4 Cg_endo -68.47 87.38 0.42 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.758 1.399 . . . . 0.0 109.838 179.501 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 107.32 22.28 7.55 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.76 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -112.9 139.15 48.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.262 -1.14 . . . . 0.0 110.161 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.96 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.3 p -143.68 145.65 32.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 110.524 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 1.008 ' CG2' HG21 ' A' ' 319' ' ' VAL . 22.7 t -76.04 129.63 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.214 -0.929 . . . . 0.0 109.939 179.756 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.29 -17.98 3.51 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.148 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.404 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -143.78 129.76 19.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.046 -1.267 . . . . 0.0 111.245 -179.588 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.8 p90 -150.04 -178.14 6.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.545 -0.722 . . . . 0.0 109.636 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.485 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -166.06 151.15 8.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.534 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.6 OUTLIER 61.67 30.82 18.65 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.471 -0.768 . . . . 0.0 110.819 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.778 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.68 141.66 0.51 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.237 -0.915 . . . . 0.0 110.045 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.691 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -81.17 112.4 18.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.074 -1.016 . . . . 0.0 109.317 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.559 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 2.3 ttpt -84.93 142.72 29.47 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.957 0.884 . . . . 0.0 110.981 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.751 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.7 mp0 -129.34 179.08 5.99 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.099 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.536 ' HG2' HG22 ' A' ' 319' ' ' VAL . 2.4 mt-10 -142.04 100.04 3.65 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.091 -0.644 . . . . 0.0 110.189 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.436 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -86.13 42.46 3.15 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 19.6 m120 59.69 80.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.239 -1.154 . . . . 0.0 110.328 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.605 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.86 2.61 56.14 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.821 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.1 m-85 -147.29 -166.87 2.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.396 -1.061 . . . . 0.0 109.382 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 1.008 HG21 ' CG2' ' A' ' 304' ' ' VAL . 4.0 t -163.16 154.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.283 -0.885 . . . . 0.0 109.975 178.99 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.751 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 5.2 mm -125.86 138.69 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.174 -0.953 . . . . 0.0 111.545 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.655 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.9 m-85 -117.4 122.61 44.28 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.326 -0.859 . . . . 0.0 109.515 178.911 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.874 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -124.4 168.75 12.2 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 120.61 -1.306 . . . . 0.0 110.554 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.539 ' HG3' ' HA ' ' A' ' 291' ' ' ASP . 38.9 Cg_endo -64.66 112.2 1.9 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 124.04 1.548 . . . . 0.0 110.908 -179.362 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.841 HG22 ' CG ' ' A' ' 327' ' ' ASN . 33.8 m -58.69 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.687 -0.633 . . . . 0.0 109.961 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.602 ' N ' HG23 ' A' ' 324' ' ' VAL . 3.1 p -112.39 -12.72 13.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.636 -1.29 . . . . 0.0 111.01 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.643 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.8 p-90 -129.85 -12.31 4.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.984 -1.073 . . . . 0.0 111.226 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.841 ' CG ' HG22 ' A' ' 324' ' ' VAL . 23.1 p-10 -96.28 40.83 1.12 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.047 -1.033 . . . . 0.0 110.985 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.461 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -114.14 -3.0 13.29 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.162 -0.961 . . . . 0.0 109.51 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.81 -157.74 0.02 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.524 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -74.66 6.97 2.93 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.052 1.553 . . . . 0.0 110.956 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 5.6 m -165.35 122.11 1.46 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.099 -1.001 . . . . 0.0 110.088 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.56 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -138.91 116.25 11.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.933 . . . . 0.0 110.617 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.542 HG23 ' HA ' ' A' ' 283' ' ' THR . 13.3 m -108.36 134.16 51.56 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.243 -0.91 . . . . 0.0 110.046 179.737 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.778 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 11.0 p90 -142.65 174.89 10.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.058 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.61 156.96 27.01 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.014 -1.565 . . . . 0.0 110.272 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.942 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -141.7 147.74 37.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.496 -1.002 . . . . 0.0 110.04 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.942 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.75 122.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.179 -0.951 . . . . 0.0 109.623 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.76 HG11 ' HB1' ' A' ' 302' ' ' ALA . 18.3 t -97.29 153.28 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.934 . . . . 0.0 110.554 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -121.02 132.76 55.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.561 -0.712 . . . . 0.0 109.867 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.453 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.545 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 121.231 0.539 . . . . 0.0 111.06 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 346' ' ' VAL . 14.7 p -132.87 119.03 35.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.282 -0.886 . . . . 0.0 110.187 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.446 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -51.26 -46.96 62.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.444 -0.785 . . . . 0.0 110.268 -179.743 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.499 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 6.8 pt-20 -177.05 158.66 1.56 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.267 -0.896 . . . . 0.0 110.627 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.923 HG23 HG22 ' A' ' 296' ' ' VAL . 77.2 mt -121.29 112.41 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 110.245 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -116.54 137.47 52.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.238 -0.913 . . . . 0.0 110.177 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.058 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -93.04 135.3 34.35 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.12 -0.988 . . . . 0.0 110.523 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.47 108.26 5.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.402 -0.811 . . . . 0.0 110.012 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.687 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.8 mt -91.67 108.85 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.992 -1.067 . . . . 0.0 110.068 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.4 m-20 38.88 31.51 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.746 -0.596 . . . . 0.0 110.796 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.13 -12.14 22.07 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.438 ' O ' HG12 ' A' ' 358' ' ' ILE . 2.2 mp0 -95.03 105.55 17.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.1 -1.236 . . . . 0.0 110.487 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.9 p -68.83 133.97 30.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.882 . . . . 0.0 110.185 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.506 HD13 ' O ' ' A' ' 357' ' ' VAL . 22.1 mm . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.289 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.525 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.69 164.59 27.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.378 -1.072 . . . . 0.0 110.049 179.992 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.847 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.3 tm? -161.34 131.93 5.15 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.226 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.845 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.6 mt-10 -128.91 151.34 49.76 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.28 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.85 HG13 ' O ' ' A' ' 281' ' ' ASP . 96.5 t -142.71 138.83 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.712 -1.242 . . . . 0.0 111.509 -179.26 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -122.19 157.46 31.52 Favored 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.278 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.755 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.9 t -143.2 146.98 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.324 -1.485 . . . . 0.0 111.957 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -143.5 112.22 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 179.485 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.484 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.9 m-20 -96.49 143.95 27.04 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.014 -1.054 . . . . 0.0 111.125 -179.214 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.82 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.7 p90 -128.38 16.79 6.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 109.847 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.27 -63.17 2.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.6 -20.42 64.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -1.133 . . . . 0.0 110.306 -179.751 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.554 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.88 177.98 42.44 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.15 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.541 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.13 142.65 47.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.339 -1.094 . . . . 0.0 109.704 179.599 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.755 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.8 mt-10 -98.91 147.11 25.3 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.281 -0.887 . . . . 0.0 110.429 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.668 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.9 m-85 -143.09 84.2 1.82 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.511 -0.743 . . . . 0.0 110.649 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.85 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.87 151.69 46.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.347 -0.846 . . . . 0.0 109.967 179.407 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.756 HG11 HG11 ' A' ' 294' ' ' VAL . 14.0 t -143.93 91.38 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.459 -0.776 . . . . 0.0 110.131 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.825 HG23 ' OG1' ' A' ' 333' ' ' THR . 88.4 m -86.74 123.89 32.4 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.39 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -111.27 147.49 34.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.017 -1.052 . . . . 0.0 110.976 -179.037 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.915 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.3 m120 -126.5 132.32 51.42 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.462 -0.774 . . . . 0.0 110.163 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.915 HD23 ' O ' ' A' ' 285' ' ' ASN . 18.1 mt -142.77 157.52 44.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.43 36.86 1.06 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.194 -0.941 . . . . 0.0 109.671 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 160.68 -144.31 9.82 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.401 -1.381 . . . . 0.0 109.896 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.557 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -108.76 94.22 4.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -1.126 . . . . 0.0 110.711 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.618 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.7 m-30 -114.65 143.67 44.66 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 109.901 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.815 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.6 m-20 -76.97 97.21 4.57 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.198 -0.939 . . . . 0.0 109.078 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.898 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.4 p-90 -96.75 112.37 24.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.378 -0.826 . . . . 0.0 110.596 -179.185 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 293' ' ' THR . . . . . 1.021 HG23 ' CG2' ' A' ' 322' ' ' THR . 1.5 m -105.44 113.78 27.56 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.416 -0.802 . . . . 0.0 109.515 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.757 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.4 t -96.07 110.67 24.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.076 -1.015 . . . . 0.0 109.829 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.647 ' NZ ' HD11 ' A' ' 320' ' ' ILE . 8.4 ttmt -87.78 149.54 24.11 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.234 -0.916 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.761 HG13 HG12 ' A' ' 349' ' ' ILE . 98.6 t -144.89 108.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.419 -0.801 . . . . 0.0 110.352 -179.604 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.511 ' HB2' ' HB3' ' A' ' 347' ' ' GLU . 14.5 mmtt -71.95 132.53 44.45 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.242 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.943 HD13 ' HA ' ' A' ' 303' ' ' THR . 84.5 mt -88.0 156.05 19.51 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.233 -0.917 . . . . 0.0 111.594 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.694 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.29 173.08 3.57 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.581 -0.699 . . . . 0.0 109.318 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.694 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.6 Cg_endo -66.95 81.49 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.436 1.23 . . . . 0.0 110.067 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.79 23.09 4.09 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.851 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.03 144.94 42.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.366 -1.079 . . . . 0.0 110.085 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.943 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.9 p -150.35 145.88 26.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.104 -0.998 . . . . 0.0 110.782 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.833 HG21 HG11 ' A' ' 319' ' ' VAL . 37.6 t -66.42 126.3 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.383 -0.823 . . . . 0.0 110.071 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.51 -16.19 6.11 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 337' ' ' ILE . 14.7 t -152.04 113.33 4.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.064 -1.257 . . . . 0.0 111.009 -179.624 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 18.7 p90 -134.39 163.64 29.22 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.396 -0.815 . . . . 0.0 109.43 179.135 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -153.91 160.92 42.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.995 -1.066 . . . . 0.0 111.246 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.511 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 54.13 29.08 9.79 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.694 . . . . 0.0 110.95 179.774 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.753 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.32 139.56 0.61 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.256 -0.903 . . . . 0.0 110.112 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.685 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.2 m120 -79.17 118.8 21.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.308 179.616 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.473 ' HG3' HG11 ' A' ' 304' ' ' VAL . 8.1 ttpt -87.53 134.92 33.54 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.688 0.756 . . . . 0.0 111.235 -179.126 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.623 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.4 OUTLIER -116.95 172.68 7.1 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -131.71 112.62 12.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.343 -0.848 . . . . 0.0 110.082 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.567 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.58 47.81 1.15 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 8.0 t30 49.49 77.04 0.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.287 -1.125 . . . . 0.0 110.142 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.615 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.01 2.12 54.92 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.851 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.8 m-85 -143.67 -170.78 3.38 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.998 . . . . 0.0 109.13 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.851 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.9 t -163.95 154.5 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.254 -0.904 . . . . 0.0 109.11 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.91 HG23 HG22 ' A' ' 293' ' ' THR . 17.6 mt -131.75 135.83 58.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 120.711 -1.243 . . . . 0.0 111.298 -179.591 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.7 ' HE2' HG21 ' A' ' 296' ' ' VAL . 52.9 m-85 -106.36 138.76 41.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.301 -0.874 . . . . 0.0 110.537 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 322' ' ' THR . . . . . 1.021 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.0 OUTLIER -136.41 169.92 12.24 Favored Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.934 -1.104 . . . . 0.0 110.023 179.427 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 41.0 Cg_endo -67.86 116.39 4.27 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 O-C-N 123.797 1.42 . . . . 0.0 110.816 -179.175 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.785 HG23 ' H ' ' A' ' 326' ' ' TRP . 19.9 m -65.69 -129.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.578 -0.701 . . . . 0.0 110.098 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.638 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -98.33 -12.82 21.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.912 -1.117 . . . . 0.0 110.712 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.785 ' H ' HG23 ' A' ' 324' ' ' VAL . 36.2 p-90 -135.41 7.57 3.34 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.033 -1.042 . . . . 0.0 110.676 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.809 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 2.1 t-20 -111.32 42.62 1.63 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.18 -0.95 . . . . 0.0 110.119 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -122.79 -5.87 8.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 0.0 110.092 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.22 -160.35 0.02 OUTLIER Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.736 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 286' ' ' LEU . 45.9 Cg_endo -74.63 4.13 4.81 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 124.056 1.556 . . . . 0.0 110.592 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.425 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.7 m -164.61 116.1 1.24 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.925 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.809 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.18 119.15 15.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.189 -0.945 . . . . 0.0 110.325 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.825 ' OG1' HG23 ' A' ' 283' ' ' THR . 3.3 m -105.03 142.26 35.14 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.948 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.757 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.2 p90 -148.6 174.89 11.67 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.524 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.94 159.87 29.02 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.61 -1.757 . . . . 0.0 110.447 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.929 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.5 OUTLIER -143.55 147.61 34.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.506 -0.996 . . . . 0.0 110.034 179.572 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.929 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -123.29 119.18 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.922 . . . . 0.0 109.188 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.851 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 5.9 t -96.55 146.2 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.143 -0.973 . . . . 0.0 110.352 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.4 m120 -117.08 137.04 52.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.497 -0.752 . . . . 0.0 110.088 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.452 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.628 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.067 0.461 . . . . 0.0 110.814 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.581 HG21 ' CG1' ' A' ' 296' ' ' VAL . 7.1 p -127.64 116.92 45.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.927 . . . . 0.0 110.081 179.418 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -47.84 -46.82 31.48 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.363 -0.835 . . . . 0.0 110.482 -179.69 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.18 158.78 1.54 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.103 -0.998 . . . . 0.0 110.861 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.761 HG12 HG13 ' A' ' 296' ' ' VAL . 69.1 mt -120.39 122.97 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.026 -1.046 . . . . 0.0 110.278 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.42 137.58 52.76 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.193 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -96.34 130.57 43.42 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.059 -1.026 . . . . 0.0 110.367 179.975 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.45 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 30.4 tt0 -139.06 110.06 6.8 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.841 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.815 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.69 110.22 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.081 -1.012 . . . . 0.0 110.231 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 354' ' ' ASN . . . . . . . . . . . . . 7.9 m-20 43.31 30.6 0.32 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.645 -0.659 . . . . 0.0 110.969 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.09 -3.8 28.55 Favored Glycine 0 N--CA 1.492 2.39 0 C-N-CA 119.811 -1.185 . . . . 0.0 110.295 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.45 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 37.2 mm-40 -102.39 114.5 28.73 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.093 -1.239 . . . . 0.0 110.518 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.935 ' O ' HD13 ' A' ' 358' ' ' ILE . 4.5 p -73.69 136.22 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.251 -0.905 . . . . 0.0 110.363 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.935 HD13 ' O ' ' A' ' 357' ' ' VAL . 20.6 mm . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.051 -0.976 . . . . 0.0 110.267 -179.769 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.42 ' O ' ' CG2' ' A' ' 358' ' ' ILE . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.571 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -119.3 163.39 17.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.424 -1.045 . . . . 0.0 109.932 179.733 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.796 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -152.06 122.11 7.12 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.09 -1.006 . . . . 0.0 110.817 -179.822 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.443 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.9 mt-10 -118.72 111.15 18.13 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.696 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.753 HG13 ' O ' ' A' ' 281' ' ' ASP . 71.4 t -113.23 141.2 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.011 -1.056 . . . . 0.0 111.861 -178.479 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.1 157.63 41.88 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.858 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.887 HG13 ' O ' ' A' ' 279' ' ' GLU . 88.5 t -142.41 147.03 21.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.312 -1.492 . . . . 0.0 112.141 -179.064 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.562 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -135.83 107.5 6.99 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.958 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.4 p30 -93.66 146.03 24.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.031 . . . . 0.0 111.572 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.5 p90 -134.84 23.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.563 -0.71 . . . . 0.0 109.694 179.293 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.4 -69.23 3.38 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.875 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -27.67 48.16 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 110.425 179.888 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.537 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.83 -173.57 38.74 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.817 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.557 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -141.39 143.77 34.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -1.162 . . . . 0.0 110.379 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.887 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -93.67 145.61 24.43 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.475 -0.766 . . . . 0.0 109.578 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.1 m-85 -137.9 82.66 1.93 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.332 -0.855 . . . . 0.0 110.422 -179.543 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.753 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -67.91 144.11 55.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.485 -0.76 . . . . 0.0 109.676 179.433 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.874 HG11 HG11 ' A' ' 294' ' ' VAL . 6.7 t -137.71 88.4 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.484 -0.76 . . . . 0.0 109.772 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.865 HG23 ' OG1' ' A' ' 333' ' ' THR . 60.6 m -86.25 120.47 27.64 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 109.245 179.808 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.092 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -104.32 149.02 25.72 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.076 -1.015 . . . . 0.0 111.106 -178.69 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.571 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -131.57 107.19 8.69 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.505 -0.747 . . . . 0.0 110.224 -179.298 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 330' ' ' PRO . 4.8 mt -122.24 172.78 8.04 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.525 -1.359 . . . . 0.0 110.177 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -101.1 28.19 5.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.355 -0.841 . . . . 0.0 110.926 -179.603 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.637 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 161.92 -179.43 37.29 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 119.177 -1.487 . . . . 0.0 110.6 179.739 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.46 ' O ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -71.41 109.0 5.12 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.426 -1.044 . . . . 0.0 111.039 -179.417 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.637 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 10.2 m-85 -137.08 151.55 49.03 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.251 -0.906 . . . . 0.0 109.786 178.963 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.776 ' O ' HG23 ' A' ' 353' ' ' ILE . 57.8 m-20 -80.42 97.09 6.92 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.273 179.074 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.8 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.4 p-90 -97.18 110.67 23.17 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.406 -179.605 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.67 HG22 ' CG2' ' A' ' 320' ' ' ILE . 4.0 m -103.02 116.76 33.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.5 -0.75 . . . . 0.0 109.485 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.874 HG11 HG11 ' A' ' 282' ' ' VAL . 4.7 t -96.91 111.19 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.131 -0.981 . . . . 0.0 110.432 -179.465 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.651 ' HA ' HD13 ' A' ' 320' ' ' ILE . 17.5 ttpt -82.96 147.85 27.97 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.219 -0.925 . . . . 0.0 109.47 179.433 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 1.011 HG22 HG23 ' A' ' 349' ' ' ILE . 77.3 t -146.61 105.01 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.135 -0.978 . . . . 0.0 110.629 -179.323 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.562 ' O ' HG23 ' A' ' 346' ' ' VAL . 19.2 mmtt -71.26 130.51 41.6 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.259 -0.9 . . . . 0.0 109.393 179.404 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.983 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.2 mt -83.8 161.42 20.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.46 -0.775 . . . . 0.0 111.6 -178.921 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.968 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -63.56 179.12 0.35 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.675 -0.641 . . . . 0.0 109.674 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.9 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.5 Cg_endo -69.24 76.46 0.93 Allowed 'Trans proline' 0 C--N 1.305 -1.745 0 O-C-N 123.742 1.391 . . . . 0.0 109.825 179.369 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.73 19.68 6.0 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.24 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.968 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -101.08 152.69 20.31 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.399 -1.059 . . . . 0.0 110.271 -179.596 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.983 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -150.6 144.62 25.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 110.588 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.853 HG21 HG11 ' A' ' 319' ' ' VAL . 55.2 t -68.07 140.95 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.35 -0.844 . . . . 0.0 109.734 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.79 -39.04 0.51 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.665 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 19.5 m -137.05 129.36 29.75 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.007 -1.29 . . . . 0.0 111.117 -179.678 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.516 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 30.1 p90 -141.2 167.09 23.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.387 -0.821 . . . . 0.0 109.434 179.27 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.467 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.06 157.15 37.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.877 -1.14 . . . . 0.0 111.083 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.475 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 58.79 25.23 13.25 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.477 -0.764 . . . . 0.0 111.106 179.797 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.725 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.18 140.03 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.242 -0.911 . . . . 0.0 109.997 179.465 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.515 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.3 m120 -79.47 121.96 25.84 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.104 -0.998 . . . . 0.0 109.312 179.569 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.686 ' HG3' HG11 ' A' ' 304' ' ' VAL . 0.6 OUTLIER -88.75 145.75 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.771 0.796 . . . . 0.0 110.991 -179.119 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.824 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.17 175.23 9.28 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.524 ' HG2' HG22 ' A' ' 319' ' ' VAL . 3.4 mm-40 -138.68 112.99 8.74 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.228 -0.92 . . . . 0.0 110.457 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -99.76 40.63 2.38 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.79 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 59.27 82.27 0.15 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.29 -1.123 . . . . 0.0 110.179 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.56 -1.56 57.07 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.683 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.2 m-85 -146.37 -172.72 4.01 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.499 -1.0 . . . . 0.0 109.317 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.853 HG11 HG21 ' A' ' 304' ' ' VAL . 2.5 t -158.67 160.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.137 -0.977 . . . . 0.0 109.743 179.355 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.67 ' CG2' HG22 ' A' ' 293' ' ' THR . 35.8 mm -127.93 146.82 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.163 -0.961 . . . . 0.0 111.304 -179.25 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.673 ' HE2' HG21 ' A' ' 296' ' ' VAL . 51.8 m-85 -123.67 132.68 53.9 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 110.003 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.597 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.1 p -131.54 169.69 13.17 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.924 -1.11 . . . . 0.0 110.135 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.538 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.3 Cg_endo -65.76 116.49 3.99 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.065 -179.482 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.482 HG23 ' H ' ' A' ' 326' ' ' TRP . 12.1 m -57.62 -111.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.479 -0.763 . . . . 0.0 109.951 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.466 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.1 t -119.6 -14.25 9.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.785 -1.197 . . . . 0.0 110.376 179.945 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.482 ' H ' HG23 ' A' ' 324' ' ' VAL . 6.5 p-90 -126.66 -24.75 3.51 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.229 -0.919 . . . . 0.0 110.614 -179.846 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 0.3 OUTLIER -86.92 40.8 0.93 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.236 -0.915 . . . . 0.0 110.137 -179.898 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.467 ' HD3' ' O ' ' A' ' 324' ' ' VAL . 0.0 OUTLIER -112.33 -6.22 14.07 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.292 -0.88 . . . . 0.0 109.995 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.69 -143.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.801 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 47.5 Cg_endo -74.85 -49.52 0.15 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.05 1.553 . . . . 0.0 110.395 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 19.0 m -111.08 134.48 52.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.247 -0.908 . . . . 0.0 110.511 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -148.72 123.26 9.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.349 -0.845 . . . . 0.0 109.863 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.865 ' OG1' HG23 ' A' ' 283' ' ' THR . 45.5 m -111.48 137.22 49.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 110.504 -179.826 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.797 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.2 p90 -145.45 174.59 11.01 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.21 159.14 28.05 Favored Glycine 0 N--CA 1.488 2.144 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.358 -179.397 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.929 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -144.98 146.24 31.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.572 -0.958 . . . . 0.0 109.781 179.686 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.929 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.03 125.66 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.175 -0.953 . . . . 0.0 110.091 -179.669 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.787 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.0 t -102.13 153.87 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.23 -0.918 . . . . 0.0 110.007 179.818 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.83 126.77 46.11 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.434 -0.791 . . . . 0.0 109.848 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.884 . . . . . . . . 0 0 . 1 . 021 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.77 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 1.7 mtmt . . . . . 0 N--CA 1.488 1.432 0 CA-C-O 121.105 0.479 . . . . 0.0 111.418 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.572 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.2 p -136.66 119.17 20.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.065 -1.022 . . . . 0.0 110.316 179.238 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.32 -46.46 46.74 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.286 -0.884 . . . . 0.0 110.38 -179.653 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -177.02 158.37 1.54 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.242 -0.911 . . . . 0.0 110.479 -179.756 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 1.011 HG23 HG22 ' A' ' 296' ' ' VAL . 23.6 mt -121.08 118.81 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.842 -1.161 . . . . 0.0 110.523 179.939 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.57 156.24 25.03 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.336 -0.852 . . . . 0.0 110.121 179.819 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.092 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -115.49 125.7 53.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.289 -0.882 . . . . 0.0 110.033 179.909 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.5 tt0 -139.06 118.4 12.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.966 -1.084 . . . . 0.0 110.618 179.869 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.776 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.4 mt -94.58 115.8 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.077 -1.015 . . . . 0.0 110.376 179.502 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.45 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.0 m-20 37.34 31.47 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.597 -0.689 . . . . 0.0 111.159 179.741 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 110.53 4.53 28.47 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.535 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 2.6 mp0 -108.05 105.93 15.92 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.149 -1.207 . . . . 0.0 110.087 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 357' ' ' VAL . 14.5 p -70.83 120.31 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.347 -0.845 . . . . 0.0 110.589 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.571 ' HB ' HD13 ' A' ' 351' ' ' LEU . 17.1 mm . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 117.978 -1.011 . . . . 0.0 110.172 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.561 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.1 159.68 38.16 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.497 -1.002 . . . . 0.0 109.985 179.843 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.94 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -147.99 122.59 9.82 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 110.586 -179.626 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.461 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 14.7 mt-10 -123.59 114.26 19.79 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.958 HG13 ' O ' ' A' ' 281' ' ' ASP . 62.1 t -111.84 146.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.984 -1.072 . . . . 0.0 112.164 -178.417 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -130.68 157.21 43.4 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.844 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.829 HG13 ' O ' ' A' ' 279' ' ' GLU . 89.6 t -142.66 147.02 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.317 -1.489 . . . . 0.0 112.112 -179.203 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.537 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -141.12 111.13 6.61 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.216 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.502 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -97.48 148.43 23.23 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.906 -1.121 . . . . 0.0 111.459 -178.526 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.845 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.7 p90 -134.52 20.21 3.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.59 -0.694 . . . . 0.0 109.903 179.459 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.91 -68.42 3.38 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.402 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.6 t -58.33 -24.02 58.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -1.206 . . . . 0.0 110.455 -179.838 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.9 179.73 43.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.917 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.587 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.5 143.49 47.49 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.309 -1.112 . . . . 0.0 110.245 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.829 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -96.82 146.55 24.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.332 -0.855 . . . . 0.0 110.178 -179.644 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.683 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 87.4 m-85 -143.32 81.53 1.71 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.414 -0.804 . . . . 0.0 110.539 -179.553 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.958 ' O ' HG13 ' A' ' 269' ' ' VAL . 2.0 t0 -66.28 154.03 41.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 110.124 179.57 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.808 HG11 HG11 ' A' ' 294' ' ' VAL . 4.0 t -143.2 88.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.493 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.598 HG23 ' OG1' ' A' ' 333' ' ' THR . 8.8 m -85.93 115.38 23.51 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.294 -0.878 . . . . 0.0 109.376 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.06 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.14 148.55 24.47 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.327 -0.858 . . . . 0.0 110.818 -178.921 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.561 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.6 m120 -131.15 106.34 8.28 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.492 -0.755 . . . . 0.0 110.316 -179.521 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.546 ' HB2' ' HA ' ' A' ' 330' ' ' PRO . 4.6 mt -121.03 169.25 10.67 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.648 -1.282 . . . . 0.0 109.801 179.447 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 287' ' ' ASP . . . . . 0.403 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -103.15 32.8 3.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 110.253 -179.856 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.552 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 163.79 -165.17 36.8 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.384 -1.389 . . . . 0.0 110.281 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.0 mm-40 -89.28 110.58 21.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.268 -1.137 . . . . 0.0 111.046 -179.447 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.552 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 7.9 m-85 -137.8 142.07 40.86 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.179 -0.951 . . . . 0.0 109.706 179.169 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.666 ' O ' HG23 ' A' ' 353' ' ' ILE . 10.0 t70 -72.6 97.89 2.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.34 179.215 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.776 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.5 p-90 -97.32 112.32 24.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.272 -0.893 . . . . 0.0 110.383 -179.357 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.825 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.1 m -105.78 113.87 27.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.359 -0.838 . . . . 0.0 110.043 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.821 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.6 t -96.61 111.1 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 110.047 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.544 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.1 ttpt -87.87 149.29 24.2 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.28 -0.888 . . . . 0.0 109.319 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.793 HG13 HG12 ' A' ' 349' ' ' ILE . 98.8 t -146.2 108.93 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 121.077 -1.014 . . . . 0.0 110.543 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.526 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 9.3 mmtm -70.13 135.41 49.14 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.112 -0.992 . . . . 0.0 109.228 179.585 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.95 HD13 ' HA ' ' A' ' 303' ' ' THR . 88.4 mt -89.63 162.52 15.58 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.455 -0.778 . . . . 0.0 111.572 -178.879 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.853 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -69.48 177.47 1.23 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.756 -0.59 . . . . 0.0 109.759 179.358 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.853 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.7 Cg_endo -69.32 81.97 0.68 Allowed 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.735 1.387 . . . . 0.0 109.786 179.351 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.26 22.58 5.8 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.357 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.876 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.47 146.2 37.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.379 -1.071 . . . . 0.0 110.388 -179.623 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.95 ' HA ' HD13 ' A' ' 298' ' ' LEU . 5.4 p -149.86 145.74 26.73 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.274 -0.891 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.894 HG21 HG11 ' A' ' 319' ' ' VAL . 92.2 t -68.09 131.31 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.263 -0.898 . . . . 0.0 109.852 179.744 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.12 -28.83 2.11 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.7 t -142.33 115.99 9.16 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.103 -1.233 . . . . 0.0 111.116 -179.635 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.522 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.1 p90 -131.52 178.33 6.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.376 -0.828 . . . . 0.0 109.365 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.504 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -167.91 160.7 12.47 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.872 -1.143 . . . . 0.0 111.073 -179.643 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 57.81 23.61 9.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.496 -0.752 . . . . 0.0 110.881 179.789 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.671 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 146.79 1.0 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.301 -0.874 . . . . 0.0 110.074 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.629 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.5 m120 -82.48 119.74 24.59 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.168 -0.958 . . . . 0.0 109.283 179.46 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.596 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.6 ttpt -88.78 146.15 25.18 Favored 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.813 0.816 . . . . 0.0 110.657 -179.486 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.733 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -130.74 172.71 11.67 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.52 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.49 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 53.2 mt-10 -138.79 104.95 5.22 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.32 -0.863 . . . . 0.0 110.486 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.463 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -93.7 38.7 3.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.463 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 11.3 t-20 59.97 83.48 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.277 -1.131 . . . . 0.0 110.344 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.627 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.09 -2.71 55.13 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 179.709 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.822 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.1 m-85 -145.76 -167.58 2.75 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.349 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.894 HG11 HG21 ' A' ' 304' ' ' VAL . 2.9 t -163.3 157.45 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.178 -0.952 . . . . 0.0 109.428 178.974 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.544 HD13 ' HA ' ' A' ' 295' ' ' LYS . 11.1 mm -127.38 142.99 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.021 -179.641 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 47.8 m-85 -119.31 136.21 54.35 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.146 -0.971 . . . . 0.0 109.808 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.825 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.3 p -138.48 169.98 11.4 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.792 -1.193 . . . . 0.0 110.122 -179.928 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.519 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.79 123.97 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.926 1.487 . . . . 0.0 111.09 -179.292 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.653 HG22 ' HB2' ' A' ' 327' ' ' ASN . 18.6 m -74.35 -116.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.499 -0.751 . . . . 0.0 110.135 -179.938 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.5 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -105.68 -32.55 8.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.709 -1.245 . . . . 0.0 110.808 -179.588 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 4.1 p-90 -116.34 -1.77 12.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.12 -0.987 . . . . 0.0 110.502 -179.778 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.653 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.27 50.01 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.107 -0.995 . . . . 0.0 109.79 179.796 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -125.68 -2.6 7.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.376 -0.828 . . . . 0.0 109.716 -179.804 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.463 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -72.34 -143.91 0.48 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.735 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.546 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 49.2 Cg_endo -73.58 -53.73 0.12 Allowed 'Trans proline' 0 C--N 1.303 -1.838 0 O-C-N 124.166 1.614 . . . . 0.0 110.473 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.25 130.61 50.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.259 -0.901 . . . . 0.0 110.467 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.552 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -145.03 104.48 3.98 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.435 -0.791 . . . . 0.0 109.749 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.598 ' OG1' HG23 ' A' ' 283' ' ' THR . 27.8 m -100.68 133.73 44.71 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.084 -1.01 . . . . 0.0 110.604 -179.61 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.821 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.8 p90 -141.85 174.73 10.31 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.336 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.522 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.71 153.65 25.06 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.905 -1.617 . . . . 0.0 110.226 -179.542 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -138.72 146.73 41.85 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.468 -1.019 . . . . 0.0 109.794 179.354 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.88 122.09 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.238 -0.914 . . . . 0.0 109.798 -179.891 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.876 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 10.0 t -99.89 154.08 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.1 -1.0 . . . . 0.0 110.644 -179.398 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -124.91 130.65 52.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.464 -0.772 . . . . 0.0 110.065 -179.96 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.833 . . . . . . . . 0 0 . 1 . 022 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.622 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 121.114 0.483 . . . . 0.0 111.281 . . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' A' ' 296' ' ' VAL . 12.2 p -138.74 118.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.152 -0.968 . . . . 0.0 110.303 179.391 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 5.7 mt-10 -49.26 -48.45 45.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.415 -0.803 . . . . 0.0 110.368 -179.728 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.458 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.8 pt-20 -177.21 158.74 1.52 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.188 -0.945 . . . . 0.0 111.008 -179.852 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.793 HG12 HG13 ' A' ' 296' ' ' VAL . 57.0 mt -117.46 121.44 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.324 -0.86 . . . . 0.0 109.993 179.509 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.56 136.97 54.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.246 -0.909 . . . . 0.0 110.291 -179.792 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.06 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -95.98 127.85 42.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.196 -0.94 . . . . 0.0 110.378 179.966 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.8 OUTLIER -139.39 113.02 8.43 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.16 -0.963 . . . . 0.0 110.399 179.746 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.666 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.3 mt -91.78 112.26 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.003 -1.061 . . . . 0.0 110.0 179.473 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.438 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.0 m-20 41.19 29.02 0.07 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.501 -0.749 . . . . 0.0 110.393 -179.69 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 113.15 -13.03 23.99 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.69 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.446 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 0.2 OUTLIER -88.6 110.86 21.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.306 -1.114 . . . . 0.0 110.431 -179.842 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.3 p -68.66 119.33 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.172 -0.955 . . . . 0.0 110.171 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.842 ' HB ' HD13 ' A' ' 351' ' ' LEU . 42.9 mm . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.268 -179.88 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 . . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.556 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.1 158.41 44.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.535 -0.98 . . . . 0.0 109.431 179.754 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.926 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -157.32 141.34 16.13 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.943 -1.098 . . . . 0.0 110.93 -179.488 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.752 ' H ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -140.34 122.02 15.31 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.797 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.844 HG23 HD11 ' A' ' 267' ' ' LEU . 50.9 t -115.39 133.14 62.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.01 -1.056 . . . . 0.0 111.559 -178.934 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.16 157.19 32.08 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.734 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 279' ' ' GLU . 71.6 t -143.12 147.04 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.286 -1.509 . . . . 0.0 112.251 -178.879 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.24 113.93 8.75 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.706 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 17.6 p-10 -98.81 148.21 24.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.039 -1.038 . . . . 0.0 111.718 -178.098 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.815 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.1 p90 -134.11 19.07 3.74 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.652 -0.655 . . . . 0.0 109.453 179.14 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.43 -65.83 3.91 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -58.48 -21.43 51.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -1.133 . . . . 0.0 110.255 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.531 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.35 -179.08 46.61 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.558 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -136.76 140.73 42.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.42 -1.047 . . . . 0.0 109.983 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.797 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.0 mt-10 -93.66 146.58 23.72 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.466 -0.771 . . . . 0.0 110.37 -179.534 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 91.0 m-85 -140.81 84.47 1.94 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.524 -0.735 . . . . 0.0 110.405 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.676 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -67.24 151.75 46.95 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.418 -0.801 . . . . 0.0 109.487 179.208 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.767 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.6 t -145.72 88.6 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.564 -0.71 . . . . 0.0 109.615 -179.537 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.68 HG23 ' OG1' ' A' ' 333' ' ' THR . 88.6 m -87.01 123.83 32.54 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.081 -1.012 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.057 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.85 150.51 30.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 110.408 -179.76 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.556 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 2.0 m120 -134.1 115.86 14.76 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.376 -0.827 . . . . 0.0 110.103 -179.377 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.618 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 13.2 mt -124.09 154.88 39.32 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 120.759 -1.213 . . . . 0.0 110.454 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -89.9 37.22 0.88 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.248 -0.908 . . . . 0.0 109.786 179.627 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.61 -141.86 7.71 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.528 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 tp60 -111.67 92.62 4.1 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.162 -1.199 . . . . 0.0 110.489 -179.758 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.618 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.1 m-30 -116.93 129.99 56.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.268 -0.895 . . . . 0.0 110.074 179.396 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.876 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.5 m-20 -64.16 103.67 0.64 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.146 -0.972 . . . . 0.0 109.557 179.549 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.897 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.0 p-90 -101.95 109.32 21.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.189 -0.944 . . . . 0.0 110.391 -179.756 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.787 HG22 ' CG2' ' A' ' 320' ' ' ILE . 3.1 m -101.04 116.18 32.23 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.463 -0.773 . . . . 0.0 109.526 179.641 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.786 HG21 ' HE2' ' A' ' 334' ' ' PHE . 20.6 t -96.67 111.1 26.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 110.487 -179.378 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.477 ' HA ' HG12 ' A' ' 320' ' ' ILE . 22.8 ttpt -87.36 147.25 25.55 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.496 -0.752 . . . . 0.0 109.024 179.0 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.671 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 55.6 t -146.67 105.45 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 110.702 -178.981 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.547 ' O ' HG23 ' A' ' 346' ' ' VAL . 26.4 mmtt -70.93 133.51 46.47 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.15 -0.969 . . . . 0.0 109.732 179.628 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.953 HD13 ' HA ' ' A' ' 303' ' ' THR . 90.7 mt -86.31 162.44 18.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.323 -0.861 . . . . 0.0 111.573 -178.93 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.707 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -71.28 173.48 4.96 Favored Pre-proline 0 N--CA 1.488 1.441 0 O-C-N 121.582 -0.699 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.694 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -67.92 82.4 0.46 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 O-C-N 123.508 1.267 . . . . 0.0 109.932 179.531 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.63 25.71 3.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.424 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.872 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -117.79 148.45 42.05 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -1.113 . . . . 0.0 110.144 -179.748 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.953 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.4 p -149.82 144.52 26.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 110.239 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.822 HG21 HG11 ' A' ' 319' ' ' VAL . 38.2 t -63.99 119.9 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.232 -0.918 . . . . 0.0 109.886 179.767 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -105.95 -20.35 9.41 Favored Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.818 -1.182 . . . . 0.0 110.339 -179.392 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.489 ' O ' ' N ' ' A' ' 337' ' ' ILE . 42.2 t -154.8 134.28 12.64 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.983 -1.304 . . . . 0.0 110.889 -179.695 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -149.43 176.42 10.6 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.354 -0.841 . . . . 0.0 109.773 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.472 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -166.72 158.84 13.38 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.794 -1.191 . . . . 0.0 111.719 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.51 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.8 OUTLIER 59.4 26.08 14.92 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.667 -0.646 . . . . 0.0 111.407 179.363 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.667 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 140.89 0.65 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.17 -0.956 . . . . 0.0 109.936 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.553 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.5 m120 -77.34 114.14 15.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.078 -1.014 . . . . 0.0 109.586 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.751 ' CD ' HG11 ' A' ' 304' ' ' VAL . 1.9 ttpp -83.01 144.6 29.84 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.695 0.76 . . . . 0.0 110.691 -179.444 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.676 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -126.85 173.84 9.27 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.412 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.423 ' HG2' HG22 ' A' ' 319' ' ' VAL . 2.1 mm-40 -137.93 105.13 5.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.448 -0.782 . . . . 0.0 110.344 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -97.17 35.78 4.27 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.442 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.4 OUTLIER 65.65 91.96 0.08 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -1.182 . . . . 0.0 110.135 -179.962 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.58 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 87.47 0.69 84.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.857 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.826 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -143.28 -172.75 3.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.339 -1.095 . . . . 0.0 109.654 179.629 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.7 t -163.46 152.52 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.575 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.787 ' CG2' HG22 ' A' ' 293' ' ' THR . 68.8 mt -131.99 132.17 61.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.648 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 70.8 m-85 -104.76 141.47 36.42 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.374 -0.829 . . . . 0.0 110.748 -179.725 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.738 ' CG2' HG23 ' A' ' 293' ' ' THR . 0.9 OUTLIER -137.05 171.02 9.3 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 120.969 -1.082 . . . . 0.0 110.143 179.762 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.53 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.3 Cg_endo -67.29 114.68 3.33 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 O-C-N 123.822 1.433 . . . . 0.0 110.986 -179.461 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.963 HG22 ' HB2' ' A' ' 327' ' ' ASN . 7.3 m -65.44 -134.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.464 -0.773 . . . . 0.0 109.894 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.707 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.7 OUTLIER -92.09 -14.73 28.78 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.021 -1.049 . . . . 0.0 110.602 -179.697 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.836 ' H ' HG23 ' A' ' 324' ' ' VAL . 26.4 p-90 -136.06 15.97 3.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.241 -0.912 . . . . 0.0 110.444 -179.841 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.963 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -116.24 31.17 6.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.097 -1.002 . . . . 0.0 110.8 -179.481 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -114.6 -6.47 12.78 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.244 -0.91 . . . . 0.0 109.801 179.539 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.1 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.869 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.529 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 50.2 Cg_endo -75.42 5.75 4.0 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.04 1.547 . . . . 0.0 110.987 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.7 m -165.36 121.64 1.41 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 120.96 -1.087 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -143.44 112.74 6.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.139 -0.975 . . . . 0.0 110.446 -179.894 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.68 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.9 m -103.04 139.05 39.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.407 -0.808 . . . . 0.0 110.009 179.864 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.786 ' HE2' HG21 ' A' ' 294' ' ' VAL . 17.7 p90 -144.72 172.77 12.54 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.403 -0.81 . . . . 0.0 108.834 179.566 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.37 160.01 28.37 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 118.954 -1.594 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.931 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -145.33 146.4 31.59 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.582 -0.952 . . . . 0.0 109.63 179.237 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.931 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.85 120.25 61.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.836 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.872 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 6.0 t -96.74 146.3 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.13 -0.981 . . . . 0.0 110.621 -179.519 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -120.02 131.9 55.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.49 -0.756 . . . . 0.0 110.219 -179.935 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.912 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.707 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.0 mtmt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.024 0.44 . . . . 0.0 111.1 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.62 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -130.77 122.45 52.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.126 -0.984 . . . . 0.0 110.18 179.22 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.48 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -51.83 -45.45 63.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -0.941 . . . . 0.0 110.16 -179.703 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.475 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 6.9 pt-20 -177.03 158.27 1.52 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.253 -0.904 . . . . 0.0 110.324 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.589 HG12 HG13 ' A' ' 296' ' ' VAL . 11.5 mt -118.11 110.31 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.318 -0.864 . . . . 0.0 110.055 179.904 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.45 149.47 29.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.057 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -113.6 127.25 56.0 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.228 -0.92 . . . . 0.0 109.509 179.252 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 15.4 pt-20 -138.31 118.78 13.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.135 -0.978 . . . . 0.0 110.086 -179.797 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.876 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -97.73 104.7 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.197 -0.939 . . . . 0.0 110.351 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.463 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.2 m120 35.16 30.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.057 0.455 . . . . 0.0 111.073 179.805 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 133.61 -43.41 1.27 Allowed Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.276 179.706 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.508 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 35.2 mm-40 -73.97 120.71 19.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.124 -1.221 . . . . 0.0 110.627 -179.505 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.712 HG13 ' O ' ' A' ' 357' ' ' VAL . 12.9 p -91.3 111.51 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.066 -1.022 . . . . 0.0 110.08 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.549 ' HB ' HD13 ' A' ' 351' ' ' LEU . 9.4 mm . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.187 -179.837 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.45 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.478 ' HB2' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.92 169.28 18.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.53 -0.983 . . . . 0.0 109.729 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.886 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.77 133.34 5.44 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.039 -1.038 . . . . 0.0 111.396 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.829 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.3 OUTLIER -129.76 138.38 51.05 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.404 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 281' ' ' ASP . 49.0 t -131.54 134.04 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.869 -1.145 . . . . 0.0 111.653 -179.3 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.24 157.08 29.89 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.705 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.659 HG13 ' O ' ' A' ' 279' ' ' GLU . 75.7 t -141.26 145.34 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.494 -1.378 . . . . 0.0 111.879 -179.392 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.57 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.15 110.17 8.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.666 -0.646 . . . . 0.0 109.825 179.631 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.414 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.8 m-20 -96.39 128.41 43.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.167 -0.958 . . . . 0.0 111.102 -179.412 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.83 ' CH2' HG23 ' A' ' 337' ' ' ILE . 29.0 p90 -113.17 16.59 19.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.879 . . . . 0.0 109.762 178.995 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.06 -59.0 3.93 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.45 -22.01 63.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -1.143 . . . . 0.0 110.18 179.858 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.583 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.78 -178.39 40.29 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.821 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -136.56 139.37 42.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.339 -1.095 . . . . 0.0 110.167 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.659 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.6 mt-10 -93.58 147.53 22.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.508 -0.745 . . . . 0.0 110.11 -179.511 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.3 m-85 -141.75 82.16 1.8 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.279 -0.888 . . . . 0.0 110.432 -179.661 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.643 ' O ' HG13 ' A' ' 269' ' ' VAL . 1.6 m-20 -67.38 146.01 54.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.509 -0.745 . . . . 0.0 109.695 179.557 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.773 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.8 t -139.12 88.78 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 109.931 -179.738 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 333' ' ' THR . 25.9 m -86.04 125.35 33.36 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.058 -1.026 . . . . 0.0 109.218 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -112.06 153.7 26.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.109 -0.994 . . . . 0.0 110.882 -179.072 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.936 ' O ' HD23 ' A' ' 286' ' ' LEU . 1.9 m120 -131.63 128.37 38.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.474 -0.766 . . . . 0.0 110.162 -179.582 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.936 HD23 ' O ' ' A' ' 285' ' ' ASN . 9.8 mt -143.69 157.09 44.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.771 -1.206 . . . . 0.0 109.938 179.862 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -94.38 35.7 1.19 Allowed 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.401 -0.812 . . . . 0.0 109.732 179.526 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 162.21 -174.61 38.66 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.908 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.537 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 4.2 mt-30 -83.93 96.3 8.78 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.308 -1.113 . . . . 0.0 110.406 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.603 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.74 153.38 32.51 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.227 -0.92 . . . . 0.0 109.749 179.586 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.844 ' O ' HG23 ' A' ' 353' ' ' ILE . 53.9 m-20 -82.85 95.74 8.03 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.328 179.327 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.893 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.5 p-90 -97.13 116.42 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 110.226 -179.737 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 293' ' ' THR . . . . . 1.042 HG23 HG22 ' A' ' 322' ' ' THR . 1.9 m -111.03 114.07 27.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.541 -0.724 . . . . 0.0 109.93 -179.83 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.776 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.4 t -96.2 111.33 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.097 -1.002 . . . . 0.0 110.205 -179.689 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 27.3 ttmt -86.63 149.81 24.65 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.368 -0.833 . . . . 0.0 109.622 179.361 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.862 HG22 HG23 ' A' ' 349' ' ' ILE . 54.5 t -147.69 109.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.117 -0.99 . . . . 0.0 110.599 -179.575 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.571 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 51.9 mmtt -72.6 141.42 48.37 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.107 -0.996 . . . . 0.0 109.591 179.441 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.966 HD13 ' HA ' ' A' ' 303' ' ' THR . 81.2 mt -94.03 156.2 16.72 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.26 -0.9 . . . . 0.0 111.481 -179.059 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -65.27 174.45 1.4 Allowed Pre-proline 0 C--N 1.303 -1.442 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.961 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.8 Cg_endo -68.74 83.42 0.53 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.531 1.28 . . . . 0.0 109.848 179.65 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.37 4.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 -179.468 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.709 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -114.69 149.41 36.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.298 -1.119 . . . . 0.0 109.753 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.966 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.6 p -150.69 143.46 24.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.062 . . . . 0.0 111.214 -179.796 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.93 ' CG2' HG21 ' A' ' 319' ' ' VAL . 58.6 t -70.89 116.46 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.56 -0.713 . . . . 0.0 110.013 179.515 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.43 -38.49 3.48 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.82 -1.181 . . . . 0.0 110.359 -179.264 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -129.94 140.33 50.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.004 -1.292 . . . . 0.0 111.139 -179.457 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.599 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 13.1 p90 -152.88 160.96 43.1 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 109.577 179.334 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.518 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -155.38 155.18 33.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.902 -1.124 . . . . 0.0 111.394 -179.48 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.441 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.9 OUTLIER 63.11 26.8 15.5 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 111.337 179.373 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.56 ' N ' HG13 ' A' ' 324' ' ' VAL . . . -174.29 148.6 1.29 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.049 -1.032 . . . . 0.0 110.805 179.573 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.508 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 3.8 m120 -77.59 114.02 16.01 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 179.259 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.599 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 23.3 ttpt -89.51 122.45 32.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.435 -0.791 . . . . 0.0 110.831 -179.57 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.618 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 2.6 tt0 -111.87 177.54 4.61 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.518 -0.739 . . . . 0.0 109.284 179.008 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.436 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.9 mt-10 -137.26 105.14 5.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.278 -0.889 . . . . 0.0 110.286 179.593 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.57 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -92.22 47.19 2.63 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.755 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 55.21 78.97 0.16 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.126 -1.22 . . . . 0.0 110.376 179.818 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.621 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.86 3.68 58.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 179.697 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.731 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -144.85 -172.63 3.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.42 -1.047 . . . . 0.0 109.061 179.545 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.93 HG21 ' CG2' ' A' ' 304' ' ' VAL . 12.1 t -158.89 150.08 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.988 -1.07 . . . . 0.0 110.286 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.639 ' CG2' HG22 ' A' ' 293' ' ' THR . 6.4 mm -114.96 151.85 16.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.104 -0.998 . . . . 0.0 110.687 -179.656 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 35.0 m-85 -131.74 112.2 12.32 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.199 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 322' ' ' THR . . . . . 1.042 HG22 HG23 ' A' ' 293' ' ' THR . 1.7 p -113.22 -176.46 0.38 Allowed Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 120.374 -1.454 . . . . 0.0 109.591 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.587 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 45.6 Cg_endo -77.63 117.44 4.28 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.446 1.235 . . . . 0.0 111.458 -178.502 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.579 HG22 ' OD1' ' A' ' 327' ' ' ASN . 3.7 m -53.58 -105.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.424 -0.797 . . . . 0.0 110.592 179.905 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.484 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.5 m -133.79 -12.37 2.61 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.691 -1.256 . . . . 0.0 111.428 -179.448 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.621 ' CE3' ' HB3' ' A' ' 327' ' ' ASN . 2.0 p-90 -126.47 -25.6 3.43 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.776 -1.202 . . . . 0.0 111.228 -179.586 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.631 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 1.4 p-10 -96.0 36.66 1.29 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.762 -1.211 . . . . 0.0 110.963 -179.697 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -99.71 -6.23 27.46 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.157 -0.964 . . . . 0.0 108.736 178.179 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.55 -138.38 0.01 OUTLIER Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.474 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.599 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 46.0 Cg_endo -73.01 -54.62 0.11 Allowed 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 124.205 1.634 . . . . 0.0 111.054 -179.721 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -102.61 140.25 37.13 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.156 -0.965 . . . . 0.0 110.77 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.721 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -152.26 107.77 3.31 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 283' ' ' THR . 53.8 m -105.41 135.9 45.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.907 -1.121 . . . . 0.0 110.166 179.67 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.776 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.0 p90 -145.32 174.6 10.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.631 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.26 158.08 27.75 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.659 -1.734 . . . . 0.0 110.435 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.897 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -143.42 146.5 33.51 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.669 -0.901 . . . . 0.0 109.33 179.252 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.897 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.74 121.31 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.968 -1.083 . . . . 0.0 109.831 179.904 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.709 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.5 t -96.6 145.92 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.184 -0.947 . . . . 0.0 109.634 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -121.33 135.43 55.09 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 110.905 -179.234 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.265 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.735 . . . . . . . . 0 0 . 1 . 024 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.643 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.092 0.473 . . . . 0.0 111.187 . . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.571 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 7.4 p -126.53 119.05 52.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.911 -1.118 . . . . 0.0 110.241 179.378 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 4.1 mm-40 -49.67 -44.56 47.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -0.91 . . . . 0.0 110.523 -179.533 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.446 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.1 pt-20 -176.68 158.85 1.76 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.09 -1.006 . . . . 0.0 110.718 -179.713 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.862 HG23 HG22 ' A' ' 296' ' ' VAL . 29.6 mt -124.42 110.17 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.095 -1.003 . . . . 0.0 110.228 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.67 160.05 19.8 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.415 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.52 129.72 54.83 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.906 . . . . 0.0 110.554 -179.903 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.9 tt0 -139.32 118.35 12.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.824 . . . . 0.0 109.456 179.405 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.844 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.08 100.66 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.892 -1.13 . . . . 0.0 110.399 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.444 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 2.8 m-20 38.27 40.08 0.32 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.949 -0.47 . . . . 0.0 111.396 179.492 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.44 ' O ' ' CD ' ' A' ' 356' ' ' GLN . . . 113.06 23.37 5.27 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.793 179.056 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 56.7 mm-40 -141.46 101.47 4.0 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.015 -1.285 . . . . 0.0 110.238 179.661 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.706 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -65.7 136.35 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.252 -0.905 . . . . 0.0 110.552 -179.827 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.706 HD13 ' O ' ' A' ' 357' ' ' VAL . 22.9 mm . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.215 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.247 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 . . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.566 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -138.6 165.86 25.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.602 -0.94 . . . . 0.0 109.593 179.908 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.927 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.63 141.35 10.25 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.94 -1.104 . . . . 0.0 111.436 -179.554 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.746 ' H ' HD22 ' A' ' 267' ' ' LEU . 0.2 OUTLIER -139.48 149.5 44.06 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.853 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 281' ' ' ASP . 39.8 t -138.19 137.9 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.694 -1.254 . . . . 0.0 111.654 -179.337 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.444 ' HG2' ' OE2' ' A' ' 268' ' ' GLU . 3.2 mmtp -125.27 156.93 37.81 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.111 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.703 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.1 t -145.07 145.84 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 120.374 -1.454 . . . . 0.0 112.15 -179.193 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.533 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.8 112.56 7.59 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.796 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.1 p-10 -97.37 144.84 26.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.955 -1.091 . . . . 0.0 111.602 -178.338 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 36.1 p90 -129.9 21.54 5.41 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.472 0.654 . . . . 0.0 109.681 179.281 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.24 -68.53 3.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.502 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 8.1 t -56.93 -23.73 47.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.144 -1.209 . . . . 0.0 110.35 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.423 ' HA2' ' HA ' ' A' ' 339' ' ' ASN . . . -174.46 -170.02 37.19 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.387 -1.387 . . . . 0.0 109.987 179.918 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.632 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -141.88 143.78 33.5 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.337 -1.096 . . . . 0.0 110.514 -179.905 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.703 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.4 mt-10 -94.87 147.34 23.47 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.412 -0.805 . . . . 0.0 109.904 -179.853 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.658 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 88.1 m-85 -142.91 90.27 2.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.396 -0.815 . . . . 0.0 110.514 -179.63 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.709 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -74.16 153.02 39.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.365 -0.835 . . . . 0.0 110.117 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.859 HG11 HG11 ' A' ' 294' ' ' VAL . 3.3 t -145.12 90.61 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.83 -179.665 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 283' ' ' THR . . . . . 1.006 HG23 ' OG1' ' A' ' 333' ' ' THR . 7.5 m -87.04 122.61 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 0.0 110.457 -179.746 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.089 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -108.14 151.09 26.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 110.122 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.566 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.6 m120 -134.58 106.57 7.06 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.211 -0.93 . . . . 0.0 110.646 -179.036 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.632 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.6 mt -113.07 173.9 6.16 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.666 -1.272 . . . . 0.0 110.006 179.671 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -109.5 30.19 6.87 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.434 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 170.19 -102.79 0.18 Allowed Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.357 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.487 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.1 OUTLIER -150.7 105.38 3.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -1.181 . . . . 0.0 110.463 -179.395 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.632 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -136.33 132.74 36.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 110.025 179.596 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.768 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.2 OUTLIER -61.04 100.25 0.11 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.289 -0.882 . . . . 0.0 109.366 179.337 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.881 ' CZ2' ' HB1' ' A' ' 332' ' ' ALA . 56.4 p-90 -98.34 111.07 23.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.345 -0.847 . . . . 0.0 110.447 -179.637 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.901 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.4 m -105.37 114.58 28.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.859 HG11 HG11 ' A' ' 282' ' ' VAL . 3.5 t -96.92 110.74 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.145 -0.972 . . . . 0.0 110.085 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.586 ' HA ' HD13 ' A' ' 320' ' ' ILE . 18.8 ttpt -87.41 149.01 24.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.227 -0.92 . . . . 0.0 109.362 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.709 HG13 HG12 ' A' ' 349' ' ' ILE . 71.0 t -145.78 110.53 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.193 -0.942 . . . . 0.0 110.745 -179.325 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.614 ' O ' HG23 ' A' ' 346' ' ' VAL . 29.3 mmtp -71.51 132.71 45.1 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.246 -0.909 . . . . 0.0 109.73 179.343 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.936 HD13 ' HA ' ' A' ' 303' ' ' THR . 83.0 mt -85.42 159.06 20.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.375 -0.828 . . . . 0.0 111.445 -179.036 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.801 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -62.94 174.77 0.77 Allowed Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.699 -0.626 . . . . 0.0 109.454 179.08 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.733 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -69.4 78.88 0.86 Allowed 'Trans proline' 0 C--N 1.304 -1.812 0 O-C-N 123.575 1.303 . . . . 0.0 109.754 179.451 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.19 24.58 3.81 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.166 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.808 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -112.22 152.93 27.84 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -1.152 . . . . 0.0 110.338 -179.479 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.936 ' HA ' HD13 ' A' ' 298' ' ' LEU . 21.5 p -153.31 143.61 22.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.235 -0.915 . . . . 0.0 110.502 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.933 HG21 HG11 ' A' ' 319' ' ' VAL . 76.4 t -64.72 139.75 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.463 -0.773 . . . . 0.0 110.215 179.881 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 305' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -123.28 -33.69 0.81 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.442 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.9 OUTLIER -138.23 124.42 20.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -1.19 . . . . 0.0 110.98 -179.667 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.562 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 52.9 p90 -141.08 156.37 46.0 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.323 -0.861 . . . . 0.0 109.714 179.362 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.493 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -150.0 157.31 43.02 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.955 -1.091 . . . . 0.0 111.368 -179.288 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.606 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 64.57 21.66 12.48 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.609 -0.682 . . . . 0.0 110.906 179.803 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.559 ' CA ' HG13 ' A' ' 324' ' ' VAL . . . -174.57 150.2 1.35 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.272 -0.893 . . . . 0.0 110.394 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.539 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.2 m120 -83.84 125.34 31.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.119 -0.988 . . . . 0.0 109.586 179.485 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.562 ' HD3' ' CD2' ' A' ' 307' ' ' PHE . 3.7 ttpt -92.85 135.91 33.72 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.838 0.828 . . . . 0.0 110.751 -179.582 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.723 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 4.9 mp0 -122.37 179.46 4.56 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.63 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.411 ' HA ' ' O ' ' A' ' 318' ' ' TYR . 3.5 mt-10 -142.49 113.07 7.31 Favored 'General case' 0 N--CA 1.492 1.634 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.444 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.09 49.71 1.05 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.83 79.37 0.2 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -1.167 . . . . 0.0 110.093 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.595 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.95 5.34 66.24 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.778 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.811 ' O ' HG23 ' A' ' 319' ' ' VAL . 5.4 m-85 -138.88 -174.31 3.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.401 -1.058 . . . . 0.0 109.167 179.449 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.933 HG11 HG21 ' A' ' 304' ' ' VAL . 5.7 t -163.14 156.96 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.287 -0.883 . . . . 0.0 109.767 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.723 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 12.8 mm -127.08 148.91 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.074 -1.016 . . . . 0.0 111.361 -179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.675 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 86.0 m-85 -124.85 122.01 36.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.446 -0.784 . . . . 0.0 109.703 179.01 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.901 ' CG2' HG23 ' A' ' 293' ' ' THR . 5.5 p -124.52 169.01 11.59 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 120.738 -1.226 . . . . 0.0 109.953 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.54 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 37.3 Cg_endo -63.89 112.38 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.769 1.405 . . . . 0.0 111.415 -179.319 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.704 HG23 ' H ' ' A' ' 325' ' ' SER . 3.6 m -50.4 -58.24 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.545 -0.722 . . . . 0.0 110.746 179.74 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.704 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.2 OUTLIER 178.65 -26.11 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.081 -1.012 . . . . 0.0 110.947 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.518 ' CE2' HG21 ' A' ' 324' ' ' VAL . 6.3 p-90 -110.43 -27.03 9.22 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.853 -1.154 . . . . 0.0 110.98 -179.79 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 1.003 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 46.2 p-10 -83.34 14.56 3.52 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 120.979 -1.076 . . . . 0.0 111.06 179.934 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.49 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 11.4 mtmt -77.12 -8.58 57.74 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.174 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.18 -153.14 0.01 OUTLIER Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 -179.322 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -76.12 9.61 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 124.267 1.667 . . . . 0.0 111.153 -179.581 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.5 m -164.87 135.15 3.86 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 1.003 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -147.87 104.19 3.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.171 -0.956 . . . . 0.0 110.378 -179.463 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 333' ' ' THR . . . . . 1.006 ' OG1' HG23 ' A' ' 283' ' ' THR . 4.8 m -101.12 133.22 45.98 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.287 -0.883 . . . . 0.0 110.313 179.883 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.754 ' HE2' HG21 ' A' ' 294' ' ' VAL . 24.2 p90 -144.2 168.21 20.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 108.957 179.553 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -141.65 165.3 26.5 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.078 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.5 OUTLIER -150.52 143.88 24.98 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.689 -0.889 . . . . 0.0 109.379 179.191 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.51 118.79 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.028 -1.045 . . . . 0.0 110.223 -179.67 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.808 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.7 t -97.64 153.18 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.163 -0.96 . . . . 0.0 110.153 -179.795 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.5 m120 -122.56 131.65 53.93 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 110.212 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.403 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -179.98 . . . . . . . . 0 0 . 1 . 025 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.8 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 121.475 0.655 . . . . 0.0 110.275 . . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 297' ' ' LYS . 7.2 p -134.7 117.09 22.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.406 -0.809 . . . . 0.0 110.13 179.739 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.514 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -45.66 -45.84 14.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 110.455 -179.61 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.47 ' OE2' ' HG3' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -176.79 158.71 1.68 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.072 -1.017 . . . . 0.0 110.673 -179.713 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.709 HG12 HG13 ' A' ' 296' ' ' VAL . 65.1 mt -120.76 119.39 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.118 -0.989 . . . . 0.0 110.304 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.33 159.89 24.12 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.341 -0.85 . . . . 0.0 110.173 179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.089 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -120.99 129.7 53.52 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.887 . . . . 0.0 110.361 -179.852 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -139.29 122.87 17.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.13 -0.981 . . . . 0.0 110.103 179.58 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.768 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -97.15 106.16 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.031 -1.043 . . . . 0.0 109.742 179.474 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.423 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.4 m-20 41.06 29.25 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.565 -0.71 . . . . 0.0 110.649 -179.752 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.81 -22.83 7.17 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.363 179.379 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.494 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 40.5 mm-40 -87.96 110.95 20.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.004 -1.292 . . . . 0.0 110.552 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.653 ' O ' HD13 ' A' ' 358' ' ' ILE . 6.2 p -76.81 142.02 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.284 -0.885 . . . . 0.0 110.527 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.653 HD13 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.494 1.729 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.139 179.801 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 . . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.544 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.3 OUTLIER -139.53 164.4 30.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.401 -1.058 . . . . 0.0 109.765 179.848 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.992 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.31 133.76 6.0 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.047 -1.033 . . . . 0.0 111.003 -179.044 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.49 ' N ' HD13 ' A' ' 267' ' ' LEU . 0.4 OUTLIER -136.77 131.45 33.4 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.532 -0.73 . . . . 0.0 109.242 179.476 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.882 HG13 ' O ' ' A' ' 281' ' ' ASP . 89.4 t -126.38 143.11 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.79 -1.194 . . . . 0.0 111.653 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.7 ttpt -126.98 157.38 39.69 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.996 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.736 HG22 ' CD1' ' A' ' 280' ' ' TYR . 91.7 t -139.74 146.97 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.298 -1.501 . . . . 0.0 112.375 -179.171 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.542 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.2 109.43 6.46 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.127 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 p30 -96.14 146.75 24.41 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.008 -1.057 . . . . 0.0 111.189 -178.863 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.829 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.4 p90 -132.02 17.85 4.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.777 179.32 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.5 -62.78 4.0 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.947 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.444 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.4 t -63.68 -21.24 66.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.383 -1.069 . . . . 0.0 110.239 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -174.31 179.92 45.34 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.557 ' HB3' ' HE2' ' A' ' 280' ' ' TYR . . . -133.22 141.19 47.93 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.352 -1.087 . . . . 0.0 110.245 179.941 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.729 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.3 mt-10 -96.84 147.65 23.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.346 -0.846 . . . . 0.0 110.159 -179.683 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.736 ' CD1' HG22 ' A' ' 271' ' ' VAL . 98.1 m-85 -143.51 90.2 2.14 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.214 -0.929 . . . . 0.0 110.84 -179.776 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.882 ' O ' HG13 ' A' ' 269' ' ' VAL . 6.6 t0 -70.87 152.75 43.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.384 -0.823 . . . . 0.0 109.555 179.237 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.753 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 2.9 t -147.26 89.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 110.205 -179.535 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.719 HG23 ' OG1' ' A' ' 333' ' ' THR . 93.1 m -86.97 121.96 30.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.08 -1.013 . . . . 0.0 109.615 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -109.7 150.89 27.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 110.754 -179.323 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.917 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.1 m120 -131.25 137.06 48.72 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.468 -0.77 . . . . 0.0 109.934 -179.767 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.917 HD23 ' O ' ' A' ' 285' ' ' ASN . 16.8 mt -142.32 159.87 41.37 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.926 -1.109 . . . . 0.0 109.513 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.61 34.66 0.82 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.296 -0.877 . . . . 0.0 110.458 -179.538 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.473 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 153.3 -97.47 0.17 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.052 -1.546 . . . . 0.0 110.358 179.902 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 11.7 mm-40 -144.3 105.26 4.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.25 -1.147 . . . . 0.0 110.561 -179.577 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.616 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 4.4 m-85 -128.9 130.29 46.63 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.338 -0.851 . . . . 0.0 109.671 179.645 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.809 ' O ' HG23 ' A' ' 353' ' ' ILE . 42.5 m-20 -65.61 100.11 0.49 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.782 -1.199 . . . . 0.0 109.084 179.19 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.935 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.4 p-90 -100.12 109.67 21.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 111.127 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 293' ' ' THR . . . . . 1.085 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.0 m -103.78 114.83 29.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.466 -0.772 . . . . 0.0 109.108 179.003 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.727 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -95.95 111.31 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 110.568 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.413 ' HA ' HG12 ' A' ' 320' ' ' ILE . 5.7 ttpt -85.71 145.16 27.41 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.471 -0.768 . . . . 0.0 109.327 179.17 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.674 HG13 HG12 ' A' ' 349' ' ' ILE . 79.7 t -144.36 106.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 110.177 -179.49 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 347' ' ' GLU . 43.4 mmtt -70.02 133.9 47.71 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.108 -0.995 . . . . 0.0 109.168 179.537 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.962 HD13 ' HA ' ' A' ' 303' ' ' THR . 66.8 mt -90.32 157.24 17.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 111.392 -178.826 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.7 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.22 173.25 2.35 Favored Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.806 -0.558 . . . . 0.0 109.533 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.7 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.15 83.52 0.35 Allowed 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.621 1.327 . . . . 0.0 109.826 179.627 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.6 21.14 5.87 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -179.359 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.75 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.29 140.89 47.61 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.33 -1.1 . . . . 0.0 109.951 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.962 ' HA ' HD13 ' A' ' 298' ' ' LEU . 22.2 p -145.2 146.11 31.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.958 . . . . 0.0 110.628 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.798 HG21 HG11 ' A' ' 319' ' ' VAL . 53.3 t -70.11 122.82 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.148 -0.97 . . . . 0.0 109.958 179.695 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.08 -28.32 4.19 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.034 -1.226 . . . . 0.0 110.034 -179.592 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.507 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 49.4 m -137.46 130.26 30.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.973 -1.31 . . . . 0.0 110.85 -179.637 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.538 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 50.2 p90 -150.38 160.09 43.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.491 -0.756 . . . . 0.0 109.512 179.369 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.47 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -151.85 159.46 43.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.89 -1.131 . . . . 0.0 111.284 -179.333 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.9 OUTLIER 56.91 28.34 14.46 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.617 -0.677 . . . . 0.0 110.683 179.855 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.736 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.11 138.23 0.58 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.161 -0.962 . . . . 0.0 110.22 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.642 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -77.9 112.91 15.27 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.454 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.754 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.0 ttpt -83.16 137.65 33.97 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.658 0.742 . . . . 0.0 110.8 -179.25 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.715 ' O ' HG22 ' A' ' 319' ' ' VAL . 2.0 mp0 -120.64 170.61 9.26 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.135 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.439 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 15.8 mt-10 -143.24 95.97 2.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.531 -0.731 . . . . 0.0 109.688 179.588 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.97 -82.9 0.36 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.804 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.442 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 5.4 t-20 -154.38 81.15 1.12 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.467 -1.019 . . . . 0.0 108.59 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.608 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.42 17.87 56.29 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 107.993 -2.043 . . . . 0.0 107.993 -178.009 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.822 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.7 m-85 -144.45 -171.84 3.68 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.822 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.0 t -163.26 153.72 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.231 -0.918 . . . . 0.0 109.322 178.502 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.816 ' CG2' HG22 ' A' ' 293' ' ' THR . 42.1 mt -132.45 133.81 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.78 -1.2 . . . . 0.0 111.639 -179.313 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.645 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 82.6 m-85 -105.9 139.09 41.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.459 -0.775 . . . . 0.0 110.651 -179.791 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 322' ' ' THR . . . . . 1.085 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.1 p -134.62 169.06 14.83 Favored Pre-proline 0 C--N 1.3 -1.578 0 O-C-N 120.912 -1.117 . . . . 0.0 110.324 179.154 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.551 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 39.7 Cg_endo -65.67 112.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.061 1.559 . . . . 0.0 111.045 -179.259 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.81 HG22 ' HB2' ' A' ' 327' ' ' ASN . 32.9 m -60.83 -127.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.422 -0.799 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.568 ' N ' HG23 ' A' ' 324' ' ' VAL . 18.9 m -101.9 -17.02 16.35 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.739 -1.226 . . . . 0.0 111.167 -179.361 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.646 ' H ' HG23 ' A' ' 324' ' ' VAL . 22.5 p-90 -129.86 -3.85 4.62 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.943 -1.098 . . . . 0.0 110.649 -179.688 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.81 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.6 t30 -98.64 45.04 1.01 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.233 -0.917 . . . . 0.0 110.473 -179.476 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.551 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.32 -4.48 8.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.345 -0.847 . . . . 0.0 109.77 179.829 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.81 -159.92 0.08 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.456 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 46.8 Cg_endo -72.9 2.64 5.18 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 124.191 1.627 . . . . 0.0 110.829 -179.852 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.406 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.8 m -162.56 114.87 1.63 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -136.53 115.65 12.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 110.069 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.719 ' OG1' HG23 ' A' ' 283' ' ' THR . 99.9 m -105.78 147.5 28.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 110.395 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.753 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 6.4 p90 -150.76 174.45 13.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.415 -0.803 . . . . 0.0 109.188 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.2 162.24 28.94 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.209 -179.564 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.913 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -151.37 143.8 24.19 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -1.077 . . . . 0.0 109.994 179.554 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.913 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.06 119.73 61.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.171 -0.956 . . . . 0.0 109.744 179.437 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.75 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.6 t -96.23 139.79 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.136 -0.978 . . . . 0.0 110.111 -179.661 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -111.1 142.2 43.58 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.384 -0.822 . . . . 0.0 110.422 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.906 . . . . . . . . 0 0 . 1 . 026 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.614 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 121.142 0.496 . . . . 0.0 111.114 . . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 346' ' ' VAL . 7.1 p -126.71 113.84 34.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 121.056 -1.027 . . . . 0.0 110.136 179.375 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -45.36 -47.07 13.4 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 110.47 -179.564 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.55 158.76 1.81 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.209 -0.932 . . . . 0.0 110.263 -179.838 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.674 HG12 HG13 ' A' ' 296' ' ' VAL . 28.2 mt -121.93 113.22 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.116 -0.99 . . . . 0.0 110.13 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -117.76 133.71 55.66 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.25 -0.907 . . . . 0.0 110.077 -179.934 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -90.85 132.46 35.88 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.168 -0.958 . . . . 0.0 109.774 179.529 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.429 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 3.7 tt0 -138.01 111.72 8.24 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.38 -0.825 . . . . 0.0 109.956 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.809 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.1 mt -94.91 114.0 30.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.21 -0.931 . . . . 0.0 110.42 -179.851 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.433 ' C ' ' O ' ' A' ' 353' ' ' ILE . 3.8 m-20 37.85 31.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.758 -0.589 . . . . 0.0 111.136 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.78 -15.62 19.16 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.736 -1.221 . . . . 0.0 110.306 179.415 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.495 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 20.9 mm-40 -93.17 112.03 23.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.084 -1.245 . . . . 0.0 110.424 -179.758 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.557 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 1.2 t -76.35 125.63 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.236 -0.915 . . . . 0.0 109.961 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.557 HD13 ' O ' ' A' ' 357' ' ' VAL . 10.2 mm . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.098 179.802 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 027 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.55 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.6 161.64 37.03 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -1.156 . . . . 0.0 110.006 179.823 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.863 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.5 tm? -161.32 137.17 7.98 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.613 -179.546 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.854 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mm-40 -134.03 147.14 50.92 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.799 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.9 t -138.55 144.43 30.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.66 -1.275 . . . . 0.0 111.769 -179.091 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.88 157.38 41.71 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.902 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.757 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.7 t -144.17 146.13 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.28 -1.512 . . . . 0.0 112.199 -179.492 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.576 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.63 108.76 7.21 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.182 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.413 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.0 m-20 -95.26 140.38 30.24 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.278 -0.889 . . . . 0.0 111.277 -179.003 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 40.9 p90 -131.94 20.42 4.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.431 -0.793 . . . . 0.0 109.868 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.59 -60.4 4.87 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.899 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -65.8 -18.94 65.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.369 -1.077 . . . . 0.0 110.293 -179.86 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.568 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -179.38 175.85 47.35 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.582 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -131.26 140.98 49.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -1.186 . . . . 0.0 110.119 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.757 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -93.28 147.1 23.21 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.424 -0.798 . . . . 0.0 109.99 -179.969 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.7 m-85 -142.11 86.39 1.97 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.929 -179.412 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 269' ' ' VAL . 12.1 t70 -69.67 152.6 44.5 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.86 . . . . 0.0 109.464 179.206 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.591 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 2.7 t -148.39 90.17 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.283 -0.885 . . . . 0.0 110.177 -179.51 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.849 HG23 ' OG1' ' A' ' 333' ' ' THR . 56.6 m -86.99 122.31 30.65 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.1 -1.0 . . . . 0.0 109.692 179.515 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.083 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.75 150.78 28.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.952 . . . . 0.0 110.8 -179.357 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.93 ' O ' HD23 ' A' ' 286' ' ' LEU . 1.8 m120 -131.43 138.42 49.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.469 -0.769 . . . . 0.0 109.446 179.949 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.93 HD23 ' O ' ' A' ' 285' ' ' ASN . 18.8 mt -140.46 163.4 32.93 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.77 -1.206 . . . . 0.0 109.824 -179.816 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.12 30.61 0.59 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.228 -0.92 . . . . 0.0 111.086 -178.95 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.509 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.26 -75.39 0.28 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 118.952 -1.594 . . . . 0.0 110.479 179.616 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.558 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.3 tt0 -160.26 106.88 1.56 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.07 -1.253 . . . . 0.0 110.85 -179.371 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.642 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.38 135.35 40.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 179.384 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.722 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.0 OUTLIER -66.84 102.77 1.0 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.987 -1.071 . . . . 0.0 109.515 179.425 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.957 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.9 p-90 -101.18 111.32 23.51 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 110.645 -179.53 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.686 HG22 ' CG2' ' A' ' 320' ' ' ILE . 6.6 m -104.48 115.66 30.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.532 -0.73 . . . . 0.0 109.726 179.692 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.756 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -97.05 111.41 26.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.864 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.809 ' HA ' HD13 ' A' ' 320' ' ' ILE . 27.1 ttpt -84.99 144.1 28.52 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.387 -0.821 . . . . 0.0 109.511 179.464 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.937 HG22 HG23 ' A' ' 349' ' ' ILE . 99.8 t -141.32 104.98 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.249 -0.907 . . . . 0.0 110.823 -179.179 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 38.0 mmtt -69.8 131.11 44.0 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.078 -1.014 . . . . 0.0 109.066 179.226 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.982 HD13 ' HA ' ' A' ' 303' ' ' THR . 93.6 mt -87.85 148.77 24.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.371 -0.831 . . . . 0.0 111.166 -178.895 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.703 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -58.66 172.22 0.54 Allowed Pre-proline 0 C--N 1.303 -1.432 0 O-C-N 121.624 -0.672 . . . . 0.0 109.306 179.093 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.671 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -67.32 80.57 0.41 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.575 1.303 . . . . 0.0 110.111 179.777 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.64 23.29 4.08 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 -179.546 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.789 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.58 148.54 35.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.365 -1.08 . . . . 0.0 110.376 -179.534 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.982 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.4 p -150.7 144.61 25.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.195 -0.94 . . . . 0.0 110.399 179.789 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 1.035 HG11 ' CE ' ' A' ' 312' ' ' LYS . 21.3 t -64.02 116.04 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.066 -1.021 . . . . 0.0 110.04 179.723 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -102.35 -20.51 12.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -147.36 154.44 40.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.26 -1.141 . . . . 0.0 110.317 -179.784 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.507 ' CG ' ' NZ ' ' A' ' 312' ' ' LYS . 25.1 p90 -178.54 175.52 1.11 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.594 -0.691 . . . . 0.0 109.738 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.459 ' O ' ' CB ' ' A' ' 309' ' ' SER . 1.1 p90 -170.0 151.11 3.95 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.991 -1.068 . . . . 0.0 111.637 -179.437 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.537 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 67.93 30.22 6.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.684 -0.635 . . . . 0.0 111.45 179.173 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.746 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 137.48 0.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.144 -0.972 . . . . 0.0 110.168 179.57 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.551 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.3 m120 -77.19 129.09 35.49 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.073 -1.017 . . . . 0.0 109.353 179.621 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 1.035 ' CE ' HG11 ' A' ' 304' ' ' VAL . 0.0 OUTLIER -92.07 149.15 21.67 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.907 0.861 . . . . 0.0 111.642 -178.622 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.705 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -133.34 171.39 14.11 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.306 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -137.09 114.85 11.28 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.046 -1.034 . . . . 0.0 110.858 -179.473 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -103.96 42.76 1.81 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.454 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.45 83.48 0.07 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -1.113 . . . . 0.0 110.066 -179.788 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.34 -0.55 57.1 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.89 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.842 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.5 m-85 -145.6 -170.9 3.56 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.463 -1.022 . . . . 0.0 109.157 179.365 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.92 HG11 HG21 ' A' ' 304' ' ' VAL . 2.6 t -163.82 161.99 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.366 -0.834 . . . . 0.0 109.347 179.427 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.809 HD13 ' HA ' ' A' ' 295' ' ' LYS . 28.5 mm -131.02 150.17 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.876 -1.14 . . . . 0.0 111.468 -179.514 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.626 ' CE2' ' HB3' ' A' ' 336' ' ' PHE . 96.5 m-85 -120.42 139.12 53.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.549 -0.719 . . . . 0.0 109.38 178.908 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.611 HG23 HG23 ' A' ' 293' ' ' THR . 1.0 OUTLIER -140.66 170.74 8.89 Favored Pre-proline 0 C--N 1.302 -1.461 0 O-C-N 120.79 -1.194 . . . . 0.0 110.244 -179.998 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.1 Cg_endo -65.72 122.01 9.53 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 123.98 1.516 . . . . 0.0 110.692 -179.505 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.911 HG22 ' HB2' ' A' ' 327' ' ' ASN . 12.8 m -76.16 -136.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.384 -0.823 . . . . 0.0 110.363 -179.752 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.63 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -88.45 -12.63 42.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.209 -0.932 . . . . 0.0 110.886 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.833 ' H ' HG23 ' A' ' 324' ' ' VAL . 20.9 p-90 -140.17 13.39 2.41 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.95 -1.094 . . . . 0.0 111.118 -179.475 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.911 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.1 t30 -119.99 50.59 1.27 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.886 -1.134 . . . . 0.0 110.776 -179.651 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.505 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.1 OUTLIER -130.46 -0.95 4.44 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.257 -0.902 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -66.58 -153.72 0.25 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.791 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.509 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.5 Cg_endo -73.97 3.08 5.35 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 124.12 1.59 . . . . 0.0 110.653 -179.858 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.432 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.9 m -163.93 117.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.197 -0.94 . . . . 0.0 110.244 179.944 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.478 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -139.43 111.93 7.71 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.878 . . . . 0.0 110.12 179.943 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.849 ' OG1' HG23 ' A' ' 283' ' ' THR . 7.0 m -101.09 151.78 21.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.181 -0.949 . . . . 0.0 110.275 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.756 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.7 p90 -159.03 155.19 27.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.519 -0.738 . . . . 0.0 109.156 179.712 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -133.24 165.96 23.89 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.264 -1.446 . . . . 0.0 110.035 -179.634 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.957 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -152.44 147.04 25.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -1.171 . . . . 0.0 110.288 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.957 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.74 119.56 59.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.049 -1.032 . . . . 0.0 109.88 179.687 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.789 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.6 t -96.43 147.94 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.163 -0.961 . . . . 0.0 110.13 -179.907 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.5 m120 -117.14 132.93 56.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.375 -0.828 . . . . 0.0 110.142 -179.867 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.457 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.493 2.453 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 179.943 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.703 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.3 mtmt . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 121.522 0.677 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.516 HG13 ' O ' ' A' ' 346' ' ' VAL . 4.5 p -127.17 113.28 31.65 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.497 -0.752 . . . . 0.0 109.566 179.429 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.18 -48.33 4.81 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.269 -0.894 . . . . 0.0 110.129 -179.44 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -177.63 149.9 0.64 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.31 -0.869 . . . . 0.0 110.468 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.937 HG23 HG22 ' A' ' 296' ' ' VAL . 12.9 mt -113.62 127.92 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.111 -0.993 . . . . 0.0 110.207 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -132.21 140.51 48.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.959 -179.81 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.083 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -99.44 130.75 45.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.055 -1.028 . . . . 0.0 110.395 -179.93 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.8 tt0 -138.28 113.87 9.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.308 -0.87 . . . . 0.0 109.788 179.645 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.722 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.2 mt -91.77 110.51 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.121 -0.987 . . . . 0.0 110.249 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.446 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.7 m-20 37.84 28.51 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.802 -0.561 . . . . 0.0 110.952 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 123.22 -20.94 7.43 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.739 -1.219 . . . . 0.0 110.298 179.451 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 9.0 mp0 -86.53 112.66 21.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.03 -1.276 . . . . 0.0 110.58 -179.756 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.669 HG13 ' O ' ' A' ' 357' ' ' VAL . 7.3 p -79.0 118.13 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.323 -0.861 . . . . 0.0 110.169 179.797 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.467 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.7 mm . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.214 -179.942 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.02 152.19 51.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.221 -1.164 . . . . 0.0 109.908 179.866 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.794 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.59 117.71 6.81 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.198 -0.939 . . . . 0.0 110.962 -179.592 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -118.36 116.63 27.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.649 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.595 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 52.0 t -109.37 144.52 17.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.863 -1.148 . . . . 0.0 112.154 -178.305 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.427 ' C ' HG23 ' A' ' 271' ' ' VAL . 9.1 mtmt -128.59 156.42 43.38 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.618 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.828 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.9 t -145.29 147.03 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.288 -1.508 . . . . 0.0 112.29 -179.068 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.519 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -137.9 111.08 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.757 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.9 p-10 -100.5 140.02 35.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.882 -1.136 . . . . 0.0 111.407 -178.437 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.802 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.4 p90 -123.98 20.64 9.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.82 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.72 -68.01 3.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 7.8 m -61.06 -22.02 64.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.261 -1.141 . . . . 0.0 110.485 -179.833 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -168.32 176.74 42.67 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.641 -1.266 . . . . 0.0 110.016 -179.936 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.573 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.06 143.54 46.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.381 -1.07 . . . . 0.0 109.864 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.828 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.1 mt-10 -100.71 145.63 28.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.271 -0.893 . . . . 0.0 110.042 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.695 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -139.12 90.96 2.47 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.362 -0.836 . . . . 0.0 110.545 -179.701 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.595 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -79.58 118.64 21.61 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.534 -0.729 . . . . 0.0 110.136 179.657 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.822 HG11 HG11 ' A' ' 294' ' ' VAL . 8.8 t -107.41 95.82 4.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.63 -0.669 . . . . 0.0 110.041 179.747 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.546 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.2 m -86.5 120.17 27.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.131 -0.98 . . . . 0.0 109.437 179.551 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 0.999 HD21 HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -109.1 148.9 30.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 110.991 -179.042 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.1 m120 -134.04 107.13 7.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.618 -0.676 . . . . 0.0 109.679 -179.659 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.575 HD11 ' CD1' ' A' ' 292' ' ' TRP . 11.8 mt -114.67 156.57 24.51 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.837 -1.164 . . . . 0.0 110.243 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 287' ' ' ASP . . . . . 0.432 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 20.1 m-20 -86.7 33.86 0.65 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.513 -0.742 . . . . 0.0 110.413 -179.811 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.519 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.87 -154.04 25.07 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 119.499 -1.334 . . . . 0.0 109.79 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.542 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.0 OUTLIER -101.89 93.85 5.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.173 -1.192 . . . . 0.0 110.608 -179.708 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.523 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 2.3 m-85 -118.12 163.49 16.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.79 179.627 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.654 ' O ' HG23 ' A' ' 353' ' ' ILE . 15.2 m-20 -90.26 98.97 12.08 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.249 -0.907 . . . . 0.0 109.43 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.848 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.0 p-90 -99.82 117.26 33.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.192 -0.943 . . . . 0.0 110.749 -179.369 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.564 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 89.2 m -110.86 114.65 28.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.482 -0.761 . . . . 0.0 109.589 179.665 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.822 HG11 HG11 ' A' ' 282' ' ' VAL . 3.2 t -97.18 111.46 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.16 -0.963 . . . . 0.0 110.633 -179.284 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.527 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 18.3 ttmt -86.51 149.89 24.65 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.617 179.299 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.799 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 90.4 t -143.95 108.36 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.054 -1.029 . . . . 0.0 110.672 -179.459 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.574 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 14.5 mmtp -70.5 133.86 47.19 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.27 -0.894 . . . . 0.0 109.318 179.411 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.978 HD13 ' HA ' ' A' ' 303' ' ' THR . 85.0 mt -89.71 158.13 17.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -0.788 . . . . 0.0 111.717 -178.727 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.771 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -64.78 173.32 1.69 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.637 -0.665 . . . . 0.0 109.44 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.69 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.64 78.6 0.51 Allowed 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.555 1.292 . . . . 0.0 109.913 179.738 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.74 23.27 4.05 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 -179.393 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.792 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.08 146.68 38.74 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.361 -1.082 . . . . 0.0 110.141 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.978 ' HA ' HD13 ' A' ' 298' ' ' LEU . 8.8 p -147.93 145.08 28.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.225 -0.922 . . . . 0.0 110.505 179.766 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.857 HG21 HG11 ' A' ' 319' ' ' VAL . 71.4 t -65.62 132.18 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.911 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.21 -36.97 1.71 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.476 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -140.97 139.49 34.23 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -1.209 . . . . 0.0 110.819 -179.735 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.5 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.1 p90 -150.63 167.01 28.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.471 -0.768 . . . . 0.0 109.599 179.56 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.508 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -154.98 155.2 33.79 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.946 -1.096 . . . . 0.0 111.585 -179.558 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.511 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 62.71 25.49 15.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.527 -0.733 . . . . 0.0 110.854 179.742 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.68 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 141.22 0.65 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.891 . . . . 0.0 110.365 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.6 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -78.65 117.54 19.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.136 -0.977 . . . . 0.0 109.17 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.631 ' HG3' HG11 ' A' ' 304' ' ' VAL . 2.0 ttpt -87.84 145.67 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.791 0.805 . . . . 0.0 110.824 -179.274 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.822 ' O ' HG22 ' A' ' 319' ' ' VAL . 3.0 mp0 -133.19 178.6 6.78 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.35 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -141.45 106.57 4.97 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.533 -0.729 . . . . 0.0 110.539 179.509 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.93 51.83 2.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 51.51 80.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.277 -1.131 . . . . 0.0 110.317 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.602 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.47 -0.12 58.22 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.823 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.6 m-85 -141.23 -166.96 2.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -1.115 . . . . 0.0 109.435 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.857 HG11 HG21 ' A' ' 304' ' ' VAL . 2.7 t -163.61 157.84 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.21 -0.931 . . . . 0.0 109.839 179.286 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.775 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 9.2 mm -127.1 146.61 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 120.915 -1.116 . . . . 0.0 110.685 179.486 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 74.8 m-85 -125.42 124.83 42.31 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.364 -0.835 . . . . 0.0 109.729 179.263 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.541 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 8.3 p -126.96 168.04 15.85 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.491 -1.381 . . . . 0.0 110.39 179.857 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.544 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.4 Cg_endo -65.92 119.07 6.04 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.868 1.457 . . . . 0.0 111.13 -179.306 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.718 HG22 ' HB2' ' A' ' 327' ' ' ASN . 34.2 m -67.29 -124.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.527 -0.733 . . . . 0.0 109.895 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.592 ' N ' HG23 ' A' ' 324' ' ' VAL . 32.1 t -107.15 -12.92 15.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.763 -1.211 . . . . 0.0 110.693 -179.877 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.708 ' H ' HG23 ' A' ' 324' ' ' VAL . 19.6 p-90 -130.34 4.32 4.74 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.069 -1.02 . . . . 0.0 110.526 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.718 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -113.85 40.91 2.33 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.247 -0.908 . . . . 0.0 110.351 -179.546 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -115.97 -11.17 11.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 179.821 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.508 ' HA2' ' NE2' ' A' ' 289' ' ' GLN . . . -57.08 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.424 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.519 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.8 Cg_endo -75.41 7.05 3.2 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 124.143 1.602 . . . . 0.0 111.119 -179.663 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.424 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 1.5 m -162.41 124.15 2.69 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.021 -1.049 . . . . 0.0 109.957 179.992 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.538 ' HB1' ' OD1' ' A' ' 327' ' ' ASN . . . -145.93 110.81 5.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 110.311 -179.821 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.546 ' OG1' HG23 ' A' ' 283' ' ' THR . 24.9 m -102.68 123.13 45.81 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.153 -0.967 . . . . 0.0 110.235 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.803 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.2 p90 -128.67 175.48 8.55 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.191 -0.943 . . . . 0.0 108.952 179.456 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.5 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.41 162.58 29.07 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.074 -1.536 . . . . 0.0 109.967 -179.222 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.925 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.7 OUTLIER -152.0 144.81 24.36 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.487 -1.008 . . . . 0.0 109.256 179.378 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.925 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.77 121.25 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.97 -1.081 . . . . 0.0 109.935 -179.743 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.792 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.5 t -96.88 151.7 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.107 -0.996 . . . . 0.0 109.835 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -123.36 132.3 53.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.277 -0.889 . . . . 0.0 110.307 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.246 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.768 . . . . . . . . 0 0 . 1 . 028 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.733 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 121.443 0.639 . . . . 0.0 110.547 . . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.4 p -132.39 117.4 31.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.319 -0.863 . . . . 0.0 109.927 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.449 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -49.64 -45.43 48.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.851 . . . . 0.0 110.784 -179.243 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -176.95 158.83 1.63 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.942 -1.099 . . . . 0.0 110.916 -179.737 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.688 HG12 HG22 ' A' ' 296' ' ' VAL . 42.5 mt -121.06 109.82 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.187 -0.946 . . . . 0.0 110.088 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.64 158.19 16.88 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 0.999 HD11 HD21 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.29 125.83 50.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.357 -0.839 . . . . 0.0 110.056 179.807 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.529 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.9 tt0 -137.96 116.26 11.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.14 -0.975 . . . . 0.0 110.248 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.654 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.31 95.87 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 110.162 179.903 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 354' ' ' ASN . . . . . . . . . . . . . 2.0 m120 49.51 32.3 4.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.641 -0.662 . . . . 0.0 110.742 179.834 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.18 -31.31 4.94 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 79.3 mm-40 -81.77 119.75 24.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.148 -1.207 . . . . 0.0 110.519 -179.596 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.834 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.0 p -79.04 135.64 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.176 -0.952 . . . . 0.0 110.087 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.912 ' HB ' HD13 ' A' ' 351' ' ' LEU . 27.5 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.201 -179.778 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.572 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.15 158.06 44.84 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.364 -1.08 . . . . 0.0 109.9 -179.955 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.959 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -146.94 113.47 5.98 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.177 -0.952 . . . . 0.0 110.532 180.0 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -114.69 114.76 26.07 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.067 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.631 HG23 HD22 ' A' ' 267' ' ' LEU . 61.4 t -112.62 133.3 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.894 -1.129 . . . . 0.0 112.588 -178.233 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.401 ' C ' HG23 ' A' ' 271' ' ' VAL . 1.7 mptm? -116.73 156.66 26.78 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 177.959 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.795 HG13 ' O ' ' A' ' 279' ' ' GLU . 87.1 t -144.64 147.05 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.231 -1.543 . . . . 0.0 112.235 -179.201 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.559 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -133.7 106.95 7.64 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.096 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.8 p-10 -93.09 145.92 24.03 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.087 -1.008 . . . . 0.0 111.254 -178.884 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.834 ' CH2' HG23 ' A' ' 337' ' ' ILE . 38.1 p90 -134.04 16.98 3.82 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.421 -0.799 . . . . 0.0 109.902 179.423 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.52 -59.26 4.38 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.14 -17.64 64.85 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.357 -1.084 . . . . 0.0 110.09 179.822 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.585 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.38 -178.7 48.66 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.776 -1.329 . . . . 0.0 109.776 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.867 ' HB2' ' NZ ' ' A' ' 345' ' ' LYS . . . -135.1 138.54 43.89 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.378 -1.072 . . . . 0.0 110.229 -179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.795 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.2 mt-10 -92.28 146.18 23.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.434 -0.791 . . . . 0.0 110.093 -179.812 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.707 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.5 m-85 -136.0 95.28 3.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 110.726 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.576 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.4 103.78 12.21 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.496 -0.752 . . . . 0.0 109.94 179.562 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.657 HG11 HG11 ' A' ' 294' ' ' VAL . 5.2 t -93.93 91.79 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.402 -0.811 . . . . 0.0 110.42 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.912 HG23 ' OG1' ' A' ' 333' ' ' THR . 8.9 m -86.54 112.47 21.59 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.158 179.337 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.08 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -97.55 153.0 18.46 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.098 -1.001 . . . . 0.0 111.096 -178.913 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.601 ' C ' HD23 ' A' ' 286' ' ' LEU . 0.9 OUTLIER -135.51 106.43 6.63 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.452 -0.78 . . . . 0.0 109.978 -179.699 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.601 HD23 ' C ' ' A' ' 285' ' ' ASN . 2.3 mt -117.05 169.51 9.36 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.689 -1.257 . . . . 0.0 110.026 179.799 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 287' ' ' ASP . . . . . 0.421 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 10.7 m-20 -100.85 32.29 3.23 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.268 -0.895 . . . . 0.0 110.455 -179.705 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.498 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 162.87 -145.54 10.73 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.272 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.508 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -106.87 105.86 16.1 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.362 -1.081 . . . . 0.0 110.871 -179.442 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.498 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 3.7 m-85 -135.67 150.47 49.6 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.233 -0.917 . . . . 0.0 109.756 179.356 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.419 ' HB2' ' CG ' ' A' ' 354' ' ' ASN . 86.8 m-20 -78.97 96.91 5.87 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 108.97 179.098 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.857 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.3 p-90 -94.19 112.11 23.89 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.35 -0.844 . . . . 0.0 110.474 -179.46 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.751 HG23 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -106.5 116.52 32.07 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.411 -0.806 . . . . 0.0 109.261 179.641 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.782 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -96.29 110.79 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 110.667 -179.103 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.596 ' HA ' HD13 ' A' ' 320' ' ' ILE . 9.0 ttpt -83.07 148.85 27.28 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.379 -0.826 . . . . 0.0 108.792 178.696 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.617 ' CG1' HG21 ' A' ' 346' ' ' VAL . 76.2 t -148.55 108.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.005 -1.059 . . . . 0.0 111.11 -178.941 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.59 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 56.3 mmtt -70.69 141.56 51.58 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.233 -0.917 . . . . 0.0 109.302 179.167 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 1.0 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.3 mt -94.07 157.97 15.84 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.273 -0.892 . . . . 0.0 111.854 -178.608 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.698 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.06 173.12 3.41 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.709 -0.62 . . . . 0.0 109.734 179.404 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.698 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.5 Cg_endo -68.25 83.66 0.47 Allowed 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.715 1.376 . . . . 0.0 109.76 179.58 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.72 24.45 5.25 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.353 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.732 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -118.44 142.67 47.33 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.423 -1.046 . . . . 0.0 110.11 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 303' ' ' THR . . . . . 1.0 ' HA ' HD13 ' A' ' 298' ' ' LEU . 9.6 p -143.6 144.45 31.92 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.202 -0.936 . . . . 0.0 110.764 179.753 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.885 ' CG2' HG21 ' A' ' 319' ' ' VAL . 36.2 t -69.87 134.1 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 179.456 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.5 -46.76 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.332 -179.329 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.543 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 31.0 t -119.63 140.27 50.88 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.063 -1.257 . . . . 0.0 110.91 -179.432 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.628 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.3 p90 -157.99 170.7 21.71 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.54 -0.725 . . . . 0.0 109.695 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.523 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -160.46 162.68 33.23 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.09 -1.006 . . . . 0.0 111.044 -179.585 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.613 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.8 OUTLIER 54.77 24.8 5.95 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.585 -0.697 . . . . 0.0 110.774 179.816 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.73 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.86 144.45 1.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.404 -0.81 . . . . 0.0 109.882 179.455 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.523 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -86.4 122.2 30.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.031 -1.043 . . . . 0.0 109.754 179.747 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.7 ttpt -87.5 141.42 28.63 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 121.888 0.851 . . . . 0.0 110.374 -179.749 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.606 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -128.02 175.7 8.19 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.688 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -134.46 117.71 16.55 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.111 -0.993 . . . . 0.0 110.382 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.498 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -108.0 33.65 6.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 17.8 t-20 70.08 85.57 0.13 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.295 -1.121 . . . . 0.0 110.37 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.56 5.11 75.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.84 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.0 OUTLIER -146.16 -168.24 2.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.362 -1.081 . . . . 0.0 109.173 179.513 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.885 HG21 ' CG2' ' A' ' 304' ' ' VAL . 4.2 t -163.45 161.54 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.235 -0.916 . . . . 0.0 109.765 179.369 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.596 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.4 mm -128.2 143.38 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.122 -0.986 . . . . 0.0 111.271 -179.84 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.664 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 65.4 m-85 -120.05 127.29 52.43 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 178.997 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.751 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -128.25 169.92 11.64 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.693 -1.254 . . . . 0.0 110.213 -179.498 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -65.31 112.74 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 123.944 1.497 . . . . 0.0 111.15 -179.354 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.684 HG23 ' H ' ' A' ' 325' ' ' SER . 3.6 m -53.3 -59.03 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.435 -0.79 . . . . 0.0 110.994 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.684 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -179.29 -24.72 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.959 -1.088 . . . . 0.0 111.307 -179.67 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.471 ' CA ' ' HD2' ' A' ' 328' ' ' LYS . 5.3 p-90 -115.78 -24.84 8.02 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.92 -1.112 . . . . 0.0 110.718 -179.72 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.856 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 53.2 p-10 -85.22 29.36 0.66 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.144 -0.972 . . . . 0.0 111.303 -179.817 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -90.87 -6.27 54.42 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.207 -0.933 . . . . 0.0 109.45 179.599 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.58 -157.69 0.01 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.492 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.519 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -75.86 6.54 3.69 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 124.14 1.6 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -159.02 131.64 6.87 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.734 -179.932 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.856 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -144.99 109.08 4.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.185 -0.947 . . . . 0.0 110.385 -179.691 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.912 ' OG1' HG23 ' A' ' 283' ' ' THR . 51.8 m -104.12 118.38 36.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.163 -0.961 . . . . 0.0 110.558 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.782 ' HE2' HG21 ' A' ' 294' ' ' VAL . 9.7 p90 -128.56 174.67 9.18 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.463 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.1 162.37 28.76 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 118.801 -1.666 . . . . 0.0 110.477 -179.247 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.91 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -151.39 143.85 24.2 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.685 -0.891 . . . . 0.0 109.32 179.25 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.91 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -117.95 119.34 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.959 -1.088 . . . . 0.0 110.283 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.732 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -97.01 142.8 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 109.71 179.768 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.7 m120 -111.23 136.1 50.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.188 -0.945 . . . . 0.0 110.215 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.344 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.927 . . . . . . . . 0 0 . 1 . 029 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.867 ' NZ ' ' HB2' ' A' ' 278' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 121.173 0.511 . . . . 0.0 110.903 . . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 346' ' ' VAL . 12.8 p -128.31 115.01 36.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.077 179.525 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.501 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 6.9 mt-10 -43.45 -46.93 6.96 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.244 -0.91 . . . . 0.0 110.102 -179.641 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.474 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -177.19 158.54 1.51 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.105 -0.997 . . . . 0.0 110.833 -179.968 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.539 HG12 HG22 ' A' ' 296' ' ' VAL . 16.6 mt -117.75 105.63 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.877 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.81 141.96 35.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.327 -0.858 . . . . 0.0 110.005 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.08 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -100.88 131.42 46.77 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.064 -1.023 . . . . 0.0 110.177 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 1.4 tp10 -139.03 110.48 7.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 110.019 179.677 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.463 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 1.3 mt -91.45 105.21 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.045 -1.034 . . . . 0.0 109.894 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.419 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 4.6 m-20 45.19 40.56 5.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.48 -0.762 . . . . 0.0 110.619 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 105.05 -22.47 33.23 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.448 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 76.1 mm-40 -84.03 110.3 18.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.093 -1.24 . . . . 0.0 110.27 -179.87 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.776 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -72.41 130.24 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 357' ' ' VAL . 17.0 mm . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.241 179.893 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.14 155.39 49.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.277 -1.131 . . . . 0.0 109.832 179.968 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.811 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.48 121.53 8.85 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.124 -0.985 . . . . 0.0 110.884 -179.353 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.447 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 23.9 mt-10 -121.61 127.35 50.77 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.875 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.589 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 48.1 t -121.33 138.45 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 120.634 -1.291 . . . . 0.0 112.428 -178.402 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 6.6 mtpp -125.3 157.82 35.71 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.968 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.803 HG13 ' O ' ' A' ' 279' ' ' GLU . 84.4 t -144.62 144.93 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.379 -1.45 . . . . 0.0 112.021 -179.577 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.539 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -132.99 108.14 8.71 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.974 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 19.2 m-20 -96.4 144.83 26.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.999 -1.063 . . . . 0.0 111.077 -178.793 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.851 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.1 p90 -131.51 20.03 4.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.496 -0.752 . . . . 0.0 110.025 179.551 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.48 -61.49 4.59 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.816 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -67.53 -18.98 65.23 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -1.171 . . . . 0.0 110.465 -179.735 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.582 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.99 177.75 45.31 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.909 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.545 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.2 137.53 42.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.313 -1.11 . . . . 0.0 109.989 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.803 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.4 mt-10 -94.33 146.4 24.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.276 -0.89 . . . . 0.0 110.205 -179.68 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.806 ' CE2' HG11 ' A' ' 346' ' ' VAL . 90.3 m-85 -137.68 88.81 2.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.268 -0.895 . . . . 0.0 110.624 -179.747 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.589 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -75.97 117.78 18.06 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 110.325 179.734 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.787 HG11 HG11 ' A' ' 294' ' ' VAL . 11.1 t -109.83 94.37 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.436 -0.79 . . . . 0.0 110.131 179.626 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.797 HG23 ' OG1' ' A' ' 333' ' ' THR . 19.8 m -86.97 120.42 28.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.182 -0.949 . . . . 0.0 109.778 179.546 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.001 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -107.25 149.94 27.2 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.195 -0.941 . . . . 0.0 110.828 -179.346 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -133.72 106.94 7.63 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.401 -0.812 . . . . 0.0 110.147 -179.33 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.575 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 12.2 mt -114.99 155.6 26.65 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.568 -1.332 . . . . 0.0 110.638 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 287' ' ' ASP . . . . . 0.429 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -88.09 37.76 0.82 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.488 -0.758 . . . . 0.0 109.746 179.572 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.33 -147.29 14.05 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.55 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 4.7 mt-30 -111.56 95.02 5.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.151 -1.205 . . . . 0.0 110.633 -179.71 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.575 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -122.43 141.34 51.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.262 -0.899 . . . . 0.0 110.05 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.907 ' O ' HG23 ' A' ' 353' ' ' ILE . 13.2 t70 -71.94 108.73 5.35 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.149 -0.97 . . . . 0.0 109.72 179.564 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.868 ' CE3' HD13 ' A' ' 284' ' ' LEU . 42.9 p-90 -105.22 114.89 29.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 110.544 -179.651 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.792 HG22 ' CG2' ' A' ' 320' ' ' ILE . 3.2 m -102.27 113.96 27.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.418 -0.801 . . . . 0.0 109.534 179.751 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.846 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.1 t -96.67 113.33 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 110.448 -179.516 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.791 ' HA ' HD13 ' A' ' 320' ' ' ILE . 4.1 ttpt -87.9 149.6 23.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.7 179.535 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.635 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 71.5 t -149.35 110.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.079 -1.013 . . . . 0.0 110.273 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.567 ' O ' HG23 ' A' ' 346' ' ' VAL . 52.1 mmtt -72.18 138.68 47.79 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.197 -0.939 . . . . 0.0 109.58 179.575 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.936 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.8 mt -91.93 158.36 16.32 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.262 -0.899 . . . . 0.0 111.696 -178.779 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.858 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.5 175.24 1.17 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 121.792 -0.567 . . . . 0.0 109.586 179.216 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.748 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -66.36 81.27 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 O-C-N 123.581 1.306 . . . . 0.0 109.902 179.42 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.69 6.3 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.364 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.862 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -104.86 153.32 21.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.337 -1.096 . . . . 0.0 110.213 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.936 ' HA ' HD13 ' A' ' 298' ' ' LEU . 64.8 p -156.51 145.42 20.23 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.074 -1.016 . . . . 0.0 110.719 -179.864 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.753 HG21 HG11 ' A' ' 319' ' ' VAL . 61.6 t -74.21 131.56 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.395 -0.816 . . . . 0.0 109.908 179.562 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.55 -25.14 2.01 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -139.68 112.71 8.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.039 -1.271 . . . . 0.0 110.95 -179.698 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.511 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -132.97 163.75 28.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.323 -0.861 . . . . 0.0 109.782 179.361 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.509 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.95 162.8 40.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.033 -1.042 . . . . 0.0 110.843 -179.612 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.493 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.5 OUTLIER 57.49 22.6 8.22 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.583 -0.698 . . . . 0.0 111.025 179.55 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.695 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.06 143.28 0.69 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.295 -0.878 . . . . 0.0 110.401 179.514 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.63 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.5 m120 -80.71 120.79 25.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.271 -0.893 . . . . 0.0 109.117 179.255 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.584 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 0.6 OUTLIER -87.92 127.7 35.36 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.733 0.778 . . . . 0.0 111.1 -178.982 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.525 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -108.54 174.5 5.85 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.323 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -134.29 114.58 13.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.131 -0.98 . . . . 0.0 110.784 -179.637 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.59 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -103.76 57.43 0.55 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.53 ' O ' ' ND2' ' A' ' 316' ' ' ASN . 2.3 p-10 37.75 75.7 0.06 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.951 . . . . 0.0 110.754 -179.687 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.584 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 108.39 -2.17 32.77 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.778 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.801 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -142.24 -169.69 3.0 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.288 -1.125 . . . . 0.0 109.299 179.673 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.801 HG23 ' O ' ' A' ' 318' ' ' TYR . 6.7 t -162.45 158.39 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 179.165 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.792 ' CG2' HG22 ' A' ' 293' ' ' THR . 32.3 mm -128.9 148.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.001 -1.062 . . . . 0.0 111.338 -179.394 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.4 m-85 -124.58 122.8 38.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.988 -1.07 . . . . 0.0 110.164 179.284 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.645 ' CG2' HG23 ' A' ' 293' ' ' THR . 5.9 p -121.21 168.09 11.79 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.924 -1.11 . . . . 0.0 110.002 179.756 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.516 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.7 Cg_endo -66.78 119.47 6.5 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 O-C-N 123.805 1.424 . . . . 0.0 110.963 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.709 HG23 ' H ' ' A' ' 326' ' ' TRP . 35.4 m -67.88 -128.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.364 -179.889 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.499 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -97.35 -13.03 22.14 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.836 -1.165 . . . . 0.0 110.878 -179.473 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.709 ' H ' HG23 ' A' ' 324' ' ' VAL . 10.0 p-90 -135.35 5.34 3.22 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.054 -1.029 . . . . 0.0 110.63 -179.918 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.867 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 11.6 t30 -108.67 42.62 1.37 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.109 -0.994 . . . . 0.0 110.722 -179.701 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -123.43 -2.81 8.44 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.118 -0.989 . . . . 0.0 110.09 179.689 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.97 -157.11 0.08 OUTLIER Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.537 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.8 Cg_endo -75.96 5.3 4.55 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 124.006 1.53 . . . . 0.0 110.574 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.442 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.1 m -165.09 118.57 1.24 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.126 -0.984 . . . . 0.0 110.195 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.867 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.41 118.78 12.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -0.972 . . . . 0.0 110.225 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.797 ' OG1' HG23 ' A' ' 283' ' ' THR . 91.2 m -107.21 126.9 53.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.398 -0.814 . . . . 0.0 110.32 -179.957 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.846 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.8 p90 -131.37 175.35 9.21 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.364 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -155.37 156.63 27.11 Favored Glycine 0 N--CA 1.487 2.073 0 C-N-CA 118.861 -1.638 . . . . 0.0 110.076 -179.44 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.97 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.5 p90 -142.09 151.85 42.73 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.548 -0.972 . . . . 0.0 109.687 179.519 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.97 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -123.02 119.14 56.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.125 -0.984 . . . . 0.0 109.38 179.377 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.862 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -96.27 147.27 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 110.291 -179.398 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.514 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.5 m120 -118.17 131.29 56.41 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 109.987 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.893 . . . . . . . . 0 0 . 1 . 030 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.756 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 121.557 0.694 . . . . 0.0 110.383 . . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.806 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.1 p -127.27 123.74 62.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.094 -1.004 . . . . 0.0 109.709 179.199 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.543 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -55.06 -43.88 74.27 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.218 -179.258 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.469 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.9 pt-20 -177.31 159.23 1.55 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.113 -0.992 . . . . 0.0 111.119 -179.896 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.581 HG12 HG13 ' A' ' 296' ' ' VAL . 36.2 mt -121.34 122.33 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 110.104 179.517 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.39 160.05 27.63 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.892 . . . . 0.0 110.046 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.001 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.18 126.95 52.78 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.234 -0.916 . . . . 0.0 110.278 -179.922 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.3 tt0 -138.59 113.31 9.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.185 -0.947 . . . . 0.0 109.942 179.665 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.907 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.6 113.22 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.108 -0.995 . . . . 0.0 110.144 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.43 ' C ' ' O ' ' A' ' 353' ' ' ILE . 1.4 m120 40.08 40.56 0.78 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.537 -0.727 . . . . 0.0 111.031 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.86 -20.84 37.73 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.83 -1.176 . . . . 0.0 110.342 179.185 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.472 ' O ' ' N ' ' A' ' 353' ' ' ILE . 39.1 mm-40 -87.0 111.3 20.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.045 -1.268 . . . . 0.0 110.5 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.642 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -73.44 141.88 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.299 -0.876 . . . . 0.0 110.222 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.642 HD13 ' O ' ' A' ' 357' ' ' VAL . 28.8 mm . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.199 179.975 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 . . . . . . . . . 0 0 . 1 . 031 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -140.12 166.52 24.45 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.61 -0.936 . . . . 0.0 109.597 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.872 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.6 tm? -161.02 130.83 4.92 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.944 -1.097 . . . . 0.0 110.952 -179.8 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.783 ' N ' HD22 ' A' ' 267' ' ' LEU . 25.7 mt-10 -131.86 122.92 26.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.64 -0.662 . . . . 0.0 109.414 179.879 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 281' ' ' ASP . 96.5 t -117.1 137.29 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 111.478 -179.058 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -120.25 157.42 29.17 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.91 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.668 HG13 ' O ' ' A' ' 279' ' ' GLU . 96.2 t -143.67 146.72 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.269 -1.519 . . . . 0.0 112.265 -179.266 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -147.89 117.5 7.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.639 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.593 ' OD1' ' HB1' ' A' ' 278' ' ' ALA . 1.0 OUTLIER -100.13 147.59 25.51 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.205 -0.934 . . . . 0.0 111.195 -178.663 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.782 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.9 p90 -130.14 18.61 5.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.541 -0.724 . . . . 0.0 109.864 179.398 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.19 -57.23 4.57 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.735 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.65 -14.91 62.19 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -1.162 . . . . 0.0 110.264 -179.895 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.548 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . 179.6 175.08 46.14 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.892 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.593 ' HB1' ' OD1' ' A' ' 273' ' ' ASP . . . -130.39 147.34 52.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.315 -1.109 . . . . 0.0 109.999 179.851 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.668 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.8 mt-10 -103.12 147.64 26.74 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.264 -0.897 . . . . 0.0 110.519 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 84.2 m-85 -142.59 81.09 1.72 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.556 -0.715 . . . . 0.0 110.625 -179.816 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -62.63 153.97 30.61 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.384 -0.822 . . . . 0.0 109.825 179.335 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.75 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.7 t -147.62 86.77 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.571 -0.705 . . . . 0.0 109.982 -179.473 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.765 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.9 m -86.21 118.72 25.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.092 -1.005 . . . . 0.0 109.387 179.656 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.079 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -106.04 147.24 29.12 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.196 -0.94 . . . . 0.0 110.374 -179.341 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.843 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.2 m120 -127.07 133.07 50.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.175 -0.953 . . . . 0.0 110.458 -179.432 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.843 HD23 ' O ' ' A' ' 285' ' ' ASN . 9.2 mt -142.1 158.54 43.63 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.896 -1.128 . . . . 0.0 108.992 179.332 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.66 35.56 0.96 Allowed 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.531 -179.588 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 158.21 -110.14 0.43 Allowed Glycine 0 N--CA 1.493 2.468 0 C-N-CA 118.758 -1.687 . . . . 0.0 110.982 179.779 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.505 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -135.07 122.37 21.68 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.061 -1.258 . . . . 0.0 111.051 -178.594 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.665 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 8.6 m-85 -150.88 147.02 26.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.245 -0.91 . . . . 0.0 109.998 179.172 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.787 ' O ' HG23 ' A' ' 353' ' ' ILE . 18.8 m-20 -80.58 96.79 6.94 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.371 179.316 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.954 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.9 p-90 -96.82 115.64 27.78 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.365 -0.835 . . . . 0.0 110.424 -179.589 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 293' ' ' THR . . . . . 1.073 HG23 HG22 ' A' ' 322' ' ' THR . 3.3 m -109.31 113.72 26.79 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.465 -0.772 . . . . 0.0 109.753 179.927 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.76 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.5 t -97.07 113.06 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.287 -0.883 . . . . 0.0 110.339 -179.463 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.548 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 31.3 ttmt -94.55 135.58 35.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.598 179.362 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.875 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 81.1 t -130.25 112.34 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.187 -0.946 . . . . 0.0 110.579 -179.548 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.524 ' O ' HG23 ' A' ' 346' ' ' VAL . 53.3 mmtt -70.32 136.08 49.46 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.063 -1.023 . . . . 0.0 109.472 179.421 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.991 HD13 ' HA ' ' A' ' 303' ' ' THR . 88.3 mt -90.49 163.12 14.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.296 -0.878 . . . . 0.0 111.838 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.863 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.78 178.06 0.97 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.82 -0.55 . . . . 0.0 109.846 179.583 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.863 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.2 77.39 0.87 Allowed 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.757 1.398 . . . . 0.0 109.811 179.449 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.7 18.69 5.97 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 -179.275 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.855 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -105.04 141.68 36.18 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.417 -1.049 . . . . 0.0 109.677 -179.856 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.991 ' HA ' HD13 ' A' ' 298' ' ' LEU . 82.2 p -143.99 143.95 31.45 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.84 -1.162 . . . . 0.0 111.058 179.859 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.888 ' CG2' HG21 ' A' ' 319' ' ' VAL . 88.5 t -67.13 116.86 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.658 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.74 -31.6 5.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.341 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.465 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.3 OUTLIER -140.63 132.03 26.81 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.927 -1.337 . . . . 0.0 111.136 -179.414 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.576 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 16.4 p90 -146.42 168.93 19.94 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.411 -0.805 . . . . 0.0 109.496 179.287 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.51 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.9 OUTLIER -159.56 157.07 29.2 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.881 -1.137 . . . . 0.0 111.546 -179.558 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.549 ' HB3' ' CH2' ' A' ' 326' ' ' TRP . 0.4 OUTLIER 60.76 27.09 16.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.749 -0.595 . . . . 0.0 111.186 179.47 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.672 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 142.7 0.86 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 110.102 179.627 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.491 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.0 m120 -76.3 114.49 15.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.171 -0.956 . . . . 0.0 109.421 179.628 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.584 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 1.1 ttpp -87.08 132.95 33.67 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.76 0.79 . . . . 0.0 110.782 -179.579 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.577 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.5 OUTLIER -120.03 174.52 6.42 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.991 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -137.71 103.14 4.93 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.195 -0.94 . . . . 0.0 110.242 179.764 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.499 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -90.44 30.44 6.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.893 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.499 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 5.8 t-20 69.89 89.03 0.1 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.224 -1.162 . . . . 0.0 110.378 -179.992 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.632 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.55 1.32 71.54 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.861 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.805 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.2 m-85 -146.72 -168.6 3.07 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.463 -1.022 . . . . 0.0 108.921 179.396 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.888 HG21 ' CG2' ' A' ' 304' ' ' VAL . 6.4 t -162.18 158.15 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.973 -1.08 . . . . 0.0 110.123 179.116 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.584 ' O ' ' HA ' ' A' ' 312' ' ' LYS . 6.5 mm -122.41 152.38 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.896 -1.128 . . . . 0.0 110.747 -179.677 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 76.2 m-85 -132.54 115.12 15.07 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.167 -0.958 . . . . 0.0 110.026 179.224 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 322' ' ' THR . . . . . 1.073 HG22 HG23 ' A' ' 293' ' ' THR . 5.6 p -118.03 169.47 7.64 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 120.65 -1.281 . . . . 0.0 109.676 179.456 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.571 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.7 Cg_endo -67.57 121.28 8.35 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.619 1.326 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 1.057 HG22 ' HB2' ' A' ' 327' ' ' ASN . 2.7 m -75.75 -141.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -0.769 . . . . 0.0 110.458 -179.563 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.786 ' N ' HG23 ' A' ' 324' ' ' VAL . 3.2 m -76.24 -37.25 57.9 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 110.775 -179.626 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.58 ' H ' HG23 ' A' ' 324' ' ' VAL . 42.0 p-90 -117.77 22.24 12.44 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.16 -0.962 . . . . 0.0 110.803 -179.57 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 1.057 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -122.73 32.62 5.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.096 -1.003 . . . . 0.0 110.897 -179.172 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.498 ' CB ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -120.64 9.86 10.9 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.085 -1.009 . . . . 0.0 110.061 179.785 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -72.05 -149.5 0.87 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 179.895 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.556 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.3 Cg_endo -73.32 -52.46 0.14 Allowed 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.934 1.492 . . . . 0.0 109.64 179.811 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.0 m -111.89 115.73 29.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -125.52 117.45 23.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.379 -0.825 . . . . 0.0 109.958 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.765 ' OG1' HG23 ' A' ' 283' ' ' THR . 53.2 m -107.6 142.87 36.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.287 -0.883 . . . . 0.0 110.32 -179.859 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.76 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.4 p90 -151.7 173.06 15.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.766 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.525 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.89 153.73 25.02 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.021 -1.562 . . . . 0.0 110.1 -179.465 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.892 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -137.98 145.96 42.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.531 -0.982 . . . . 0.0 109.876 179.662 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.892 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.05 125.4 74.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.133 -0.979 . . . . 0.0 109.593 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.761 HG21 ' CD2' ' A' ' 298' ' ' LEU . 3.5 t -99.49 161.42 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.175 -0.953 . . . . 0.0 110.726 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.7 m120 -128.47 137.06 51.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.447 -0.783 . . . . 0.0 110.205 179.869 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.405 ' H ' ' HE3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.494 2.517 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.951 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.686 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.322 0 CA-C-O 121.362 0.601 . . . . 0.0 111.044 . . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.632 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.9 p -138.44 119.18 16.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 110.064 179.062 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.413 ' N ' ' O ' ' A' ' 297' ' ' LYS . 4.2 mt-10 -54.34 -42.22 69.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.412 -0.805 . . . . 0.0 110.928 -179.152 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.4 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.6 OUTLIER -176.66 158.77 1.76 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.94 -1.1 . . . . 0.0 110.867 -179.666 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.725 HG12 HG13 ' A' ' 296' ' ' VAL . 14.6 mt -119.28 120.22 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.144 -0.973 . . . . 0.0 110.36 179.858 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.11 141.9 51.66 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.113 -0.992 . . . . 0.0 110.16 179.825 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.079 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.89 130.11 54.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.193 -0.942 . . . . 0.0 110.386 179.803 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.8 tt0 -139.47 116.62 11.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.239 -0.913 . . . . 0.0 109.582 179.642 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.787 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -90.52 102.86 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.792 -1.193 . . . . 0.0 110.45 -179.704 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.465 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 2.3 m120 35.72 44.89 0.24 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.433 179.647 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.45 8.4 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.408 179.106 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.522 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 78.2 mm-40 -137.2 101.31 4.5 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.062 -1.258 . . . . 0.0 110.042 179.765 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.549 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.1 p -66.91 138.22 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.278 -0.889 . . . . 0.0 110.732 -179.672 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.549 HD13 ' O ' ' A' ' 357' ' ' VAL . 19.6 mm . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.171 179.596 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 265' ' ' GLY . . . . . 0.428 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 . . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.513 ' HB2' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.39 162.82 34.11 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.371 -1.076 . . . . 0.0 109.736 179.762 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.983 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.4 tm? -155.23 131.39 10.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.048 -1.032 . . . . 0.0 110.565 -179.148 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.562 ' N ' HD13 ' A' ' 267' ' ' LEU . 18.0 mt-10 -133.28 124.02 26.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.542 -0.724 . . . . 0.0 109.285 179.455 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.675 HG23 HD11 ' A' ' 267' ' ' LEU . 32.0 t -115.54 139.08 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.924 -1.11 . . . . 0.0 111.809 -178.714 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.412 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.6 mttt -123.21 156.65 34.72 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.492 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.672 HG22 ' CD1' ' A' ' 280' ' ' TYR . 91.4 t -145.08 144.94 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.276 -1.515 . . . . 0.0 112.152 -179.275 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.549 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -139.27 109.05 6.27 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.175 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -94.62 146.17 24.32 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.208 -0.932 . . . . 0.0 111.36 -178.763 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.819 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.6 p90 -134.63 22.94 3.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.589 -0.694 . . . . 0.0 109.897 179.275 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.69 -66.81 3.84 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.827 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.41 -24.85 65.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.28 -1.129 . . . . 0.0 110.431 -179.668 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.535 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.92 -177.8 41.76 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.533 -1.318 . . . . 0.0 109.84 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.584 ' HB2' ' HE3' ' A' ' 345' ' ' LYS . . . -136.5 144.8 44.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -1.1 . . . . 0.0 110.247 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.644 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.1 mt-10 -97.01 147.05 24.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.421 -0.8 . . . . 0.0 109.816 -179.629 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.7 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -143.74 86.79 1.89 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.204 -0.935 . . . . 0.0 110.894 -179.619 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.647 ' O ' HG13 ' A' ' 269' ' ' VAL . 4.6 t0 -71.06 151.58 44.39 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.641 179.11 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.735 HG21 ' CE1' ' A' ' 334' ' ' PHE . 3.4 t -143.52 91.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.46 -0.775 . . . . 0.0 109.717 -179.689 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.904 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.6 m -85.82 123.14 30.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.104 179.66 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.076 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -113.89 145.18 41.85 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.148 -0.97 . . . . 0.0 110.467 -179.034 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.904 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.6 m120 -127.15 134.26 50.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -179.642 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.904 HD23 ' O ' ' A' ' 285' ' ' ASN . 15.9 mt -142.94 148.66 37.24 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.808 -1.183 . . . . 0.0 109.83 179.638 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -85.68 38.7 0.76 Allowed 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.593 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 159.53 -136.42 4.61 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.301 -1.428 . . . . 0.0 109.752 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.51 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -117.82 94.25 4.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.192 -1.181 . . . . 0.0 110.815 -179.49 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.616 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.05 137.14 52.38 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.192 -0.943 . . . . 0.0 109.918 179.311 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.782 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.1 m-20 -71.85 97.6 1.84 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.104 -0.998 . . . . 0.0 109.287 179.248 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.967 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.9 p-90 -97.1 113.74 25.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 110.663 -179.376 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.898 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.0 m -107.11 117.05 33.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.523 -0.735 . . . . 0.0 109.258 179.527 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.739 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.1 t -97.14 111.0 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.121 -0.987 . . . . 0.0 110.655 -179.247 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.687 ' HA ' HD13 ' A' ' 320' ' ' ILE . 18.7 ttpt -84.68 138.97 32.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.258 -0.901 . . . . 0.0 108.933 178.923 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.957 HG22 HG23 ' A' ' 349' ' ' ILE . 85.1 t -136.22 107.11 6.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 110.906 -179.116 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.59 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 8.2 mmtm -69.96 130.72 42.96 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 121.075 -1.016 . . . . 0.0 108.881 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.997 HD13 ' HA ' ' A' ' 303' ' ' THR . 66.2 mt -87.02 157.9 19.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.336 -0.853 . . . . 0.0 111.304 -178.816 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.9 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -59.14 177.89 0.24 Allowed Pre-proline 0 C--N 1.303 -1.438 0 O-C-N 121.764 -0.585 . . . . 0.0 109.803 179.503 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.839 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.06 81.0 0.66 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.717 1.377 . . . . 0.0 109.449 179.294 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.05 21.98 6.1 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 -179.102 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.9 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -104.91 149.77 25.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.313 -1.11 . . . . 0.0 110.397 -179.661 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.997 ' HA ' HD13 ' A' ' 298' ' ' LEU . 4.7 p -148.9 145.63 27.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.294 -0.879 . . . . 0.0 110.424 179.729 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.786 HG21 HG11 ' A' ' 319' ' ' VAL . 55.5 t -71.64 117.66 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 110.044 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -97.38 -45.26 2.58 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 68.1 m -126.15 148.76 49.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -1.161 . . . . 0.0 110.843 -179.77 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.513 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.0 p90 -162.95 160.03 24.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.462 -0.773 . . . . 0.0 109.479 179.473 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.498 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -153.35 162.46 41.26 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.835 -1.166 . . . . 0.0 111.172 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.513 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 58.19 21.83 8.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.963 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.712 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.84 137.76 0.6 Allowed 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.426 -0.796 . . . . 0.0 110.057 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.547 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -77.31 124.96 28.57 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.117 -0.989 . . . . 0.0 109.538 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.757 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -92.2 139.83 30.23 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.719 0.771 . . . . 0.0 110.882 -179.25 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.636 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -122.61 170.5 9.96 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.135 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.579 ' HG2' HG22 ' A' ' 319' ' ' VAL . 46.3 mt-10 -141.55 100.98 3.89 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.137 -0.977 . . . . 0.0 110.518 -179.767 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -81.41 -76.68 1.05 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.209 -1.557 . . . . 0.0 109.209 179.595 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.57 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 2.8 m120 -163.85 86.79 0.5 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.423 -1.045 . . . . 0.0 109.001 179.553 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 86.63 14.4 65.6 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -178.57 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.837 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.4 m-85 -146.79 -168.76 3.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.836 -0.803 . . . . 0.0 109.096 179.642 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.837 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.8 t -163.85 161.59 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.177 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.687 HD13 ' HA ' ' A' ' 295' ' ' LYS . 40.6 mm -127.24 144.97 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 111.184 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 49.2 m-85 -120.55 133.59 55.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.212 -0.93 . . . . 0.0 109.912 179.56 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.898 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -134.53 167.81 20.95 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 120.852 -1.155 . . . . 0.0 109.881 179.64 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.498 ' HB3' ' O ' ' A' ' 327' ' ' ASN . 42.2 Cg_endo -67.72 115.51 3.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.858 1.451 . . . . 0.0 110.725 -179.384 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 1.061 HG22 ' HB2' ' A' ' 327' ' ' ASN . 23.0 m -61.18 -135.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.334 -0.854 . . . . 0.0 110.245 -179.88 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.525 ' N ' HG23 ' A' ' 324' ' ' VAL . 2.0 m -90.47 -18.68 24.92 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.059 -1.026 . . . . 0.0 110.763 -179.475 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.777 ' H ' HG23 ' A' ' 324' ' ' VAL . 27.7 p-90 -132.97 21.56 4.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.182 -0.949 . . . . 0.0 110.404 -179.742 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 1.061 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.7 m120 -120.25 38.25 4.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.073 -1.017 . . . . 0.0 110.614 -179.365 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.51 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -120.06 -4.95 10.04 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.184 -0.948 . . . . 0.0 109.889 179.565 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.99 -160.64 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -74.52 4.09 4.79 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.998 1.526 . . . . 0.0 110.72 -179.868 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.429 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.4 m -163.66 117.05 1.51 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.19 -0.944 . . . . 0.0 110.048 -179.853 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -140.12 114.61 9.31 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.961 . . . . 0.0 110.357 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.904 ' OG1' HG23 ' A' ' 283' ' ' THR . 21.7 m -105.15 139.17 40.22 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.23 -0.919 . . . . 0.0 110.022 179.793 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.739 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.5 p90 -141.57 174.5 10.51 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.349 -0.844 . . . . 0.0 109.019 179.891 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.23 156.33 26.61 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.162 -1.494 . . . . 0.0 110.015 -179.525 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.899 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -146.25 144.65 30.0 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.385 -1.068 . . . . 0.0 110.328 179.752 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.899 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.71 123.06 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.184 -0.948 . . . . 0.0 109.215 179.321 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.82 HG11 ' HB1' ' A' ' 302' ' ' ALA . 4.1 t -96.59 162.11 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 110.699 -179.144 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 0.7 OUTLIER -126.07 127.38 45.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.568 -0.707 . . . . 0.0 109.56 -179.967 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 C-N-CA 119.494 -1.336 . . . . 0.0 110.042 179.977 . . . . . . . . 0 0 . 1 . 032 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.68 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 2.5 mtmt . . . . . 0 N--CA 1.488 1.471 0 CA-C-O 121.298 0.571 . . . . 0.0 110.492 . . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.8 p -136.85 118.35 18.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.415 -0.803 . . . . 0.0 110.026 179.272 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.466 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -50.96 -45.84 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.348 -0.845 . . . . 0.0 110.38 -179.513 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.436 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.0 pt-20 -176.61 157.84 1.65 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.272 -0.892 . . . . 0.0 110.426 -179.695 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.957 HG23 HG22 ' A' ' 296' ' ' VAL . 64.5 mt -120.59 106.54 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.157 -0.964 . . . . 0.0 110.232 179.644 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.82 130.91 53.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 110.286 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.076 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -91.3 129.37 37.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.101 -0.999 . . . . 0.0 110.241 179.782 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.401 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.0 tt0 -138.83 112.69 8.46 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.183 -0.948 . . . . 0.0 109.934 179.81 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.782 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.4 110.7 22.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.065 -1.022 . . . . 0.0 110.165 179.961 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.421 ' C ' ' O ' ' A' ' 353' ' ' ILE . 6.8 m-20 38.89 29.25 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.774 -0.578 . . . . 0.0 110.639 179.922 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 118.59 -21.68 9.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.41 ' O ' ' N ' ' A' ' 353' ' ' ILE . 1.2 mp0 -86.2 112.53 21.43 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.055 -1.262 . . . . 0.0 110.392 -179.755 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.843 ' O ' HD13 ' A' ' 358' ' ' ILE . 14.8 p -74.84 141.63 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.138 -0.976 . . . . 0.0 110.407 179.842 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.843 HD13 ' O ' ' A' ' 357' ' ' VAL . 30.8 mm . . . . . 0 N--CA 1.494 1.755 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.309 179.837 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -128.52 165.94 19.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.617 -0.931 . . . . 0.0 109.664 179.665 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.748 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -159.43 126.21 4.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.977 -1.077 . . . . 0.0 111.17 -179.555 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.52 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.4 OUTLIER -123.78 118.05 26.3 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.681 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 281' ' ' ASP . 55.2 t -117.15 142.15 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.851 -1.156 . . . . 0.0 112.14 -178.428 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 7.9 tttm -128.5 157.28 41.59 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.969 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.625 HG13 ' O ' ' A' ' 279' ' ' GLU . 86.5 t -144.2 145.42 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.367 -1.458 . . . . 0.0 111.947 -179.445 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.65 113.23 7.71 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.483 179.534 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.514 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.86 145.76 25.11 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.151 -0.968 . . . . 0.0 110.942 -179.016 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.813 ' CH2' HG23 ' A' ' 337' ' ' ILE . 27.9 p90 -127.83 16.04 6.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.305 179.377 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 95.01 -56.11 1.82 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.483 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.6 m -78.53 -17.86 55.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -1.151 . . . . 0.0 110.453 -179.678 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -174.1 177.71 46.24 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.35 -1.405 . . . . 0.0 109.922 -179.952 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.561 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.65 144.84 48.07 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.329 -1.1 . . . . 0.0 110.066 179.862 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.625 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.2 mt-10 -96.88 147.48 23.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.365 -0.835 . . . . 0.0 109.878 -179.441 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 92.8 m-85 -139.38 86.43 2.12 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.302 -0.874 . . . . 0.0 110.69 -179.294 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.797 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.6 OUTLIER -69.77 145.65 52.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.431 -0.793 . . . . 0.0 109.809 179.317 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 294' ' ' VAL . 3.8 t -139.06 87.55 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.577 -0.702 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 333' ' ' THR . 19.2 m -86.12 117.12 24.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.102 -0.999 . . . . 0.0 109.645 -179.886 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.104 HD21 HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -103.05 150.43 23.6 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.109 -0.994 . . . . 0.0 110.769 -179.279 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.1 m120 -133.62 106.63 7.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.576 -0.702 . . . . 0.0 110.098 -179.324 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.61 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.1 mt -113.98 157.16 22.83 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.824 -1.172 . . . . 0.0 109.987 179.772 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.47 35.16 0.76 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.356 -0.84 . . . . 0.0 110.501 -179.432 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.491 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.15 -103.39 0.23 Allowed Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.878 -1.63 . . . . 0.0 110.423 179.855 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.443 ' HG3' ' O ' ' A' ' 328' ' ' LYS . 3.3 tt0 -149.95 111.06 4.37 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.053 -1.263 . . . . 0.0 110.705 -179.252 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.61 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 2.4 m-85 -140.14 138.54 35.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.405 -0.809 . . . . 0.0 109.866 179.542 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.694 ' O ' HG23 ' A' ' 353' ' ' ILE . 29.5 m-20 -64.92 97.09 0.21 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.102 -0.999 . . . . 0.0 109.294 179.349 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.884 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.5 p-90 -96.41 110.71 23.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.262 -0.899 . . . . 0.0 110.67 -179.502 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.669 HG22 ' CG2' ' A' ' 320' ' ' ILE . 5.5 m -102.81 114.94 29.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.518 -0.739 . . . . 0.0 109.314 179.459 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 282' ' ' VAL . 4.5 t -96.18 113.08 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.102 -0.999 . . . . 0.0 110.007 -179.547 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.699 ' HA ' HD13 ' A' ' 320' ' ' ILE . 12.9 ttpt -89.73 149.47 22.73 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.527 -0.733 . . . . 0.0 109.184 179.657 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.793 HG13 HD13 ' A' ' 349' ' ' ILE . 77.4 t -148.16 109.33 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.005 -1.059 . . . . 0.0 110.763 -179.327 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.581 ' O ' HG23 ' A' ' 346' ' ' VAL . 9.0 mmtt -71.81 135.03 46.51 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.102 -0.999 . . . . 0.0 109.324 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.919 HD13 ' HA ' ' A' ' 303' ' ' THR . 89.6 mt -86.11 167.13 15.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.28 -0.888 . . . . 0.0 111.755 -178.75 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.787 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -72.18 176.17 2.56 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.672 -0.643 . . . . 0.0 109.353 179.068 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.787 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.9 Cg_endo -69.3 80.3 0.76 Allowed 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.554 1.291 . . . . 0.0 109.918 179.564 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.41 23.45 4.79 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.985 -1.646 . . . . 0.0 108.985 -179.446 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.913 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.7 150.4 30.26 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.373 -1.075 . . . . 0.0 110.401 -179.558 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.919 ' HA ' HD13 ' A' ' 298' ' ' LEU . 77.3 p -150.43 144.14 25.23 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.286 -0.884 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.846 HG21 HG11 ' A' ' 319' ' ' VAL . 55.2 t -64.81 133.32 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 110.16 179.69 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.2 -37.6 1.48 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.843 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.41 138.22 32.8 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.182 -1.187 . . . . 0.0 110.768 -179.681 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.529 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 48.1 p90 -147.11 163.78 35.2 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.326 -0.858 . . . . 0.0 109.776 179.486 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.464 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.47 158.2 38.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.941 -1.099 . . . . 0.0 111.554 -179.434 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.518 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.52 21.6 12.74 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.719 -0.613 . . . . 0.0 110.818 179.479 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.638 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.7 143.6 0.78 Allowed 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.465 -0.772 . . . . 0.0 109.956 179.538 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.537 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -79.33 119.71 22.76 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.035 . . . . 0.0 109.351 179.579 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.596 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -86.2 140.33 30.25 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.767 0.794 . . . . 0.0 110.59 -179.612 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.661 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.13 173.2 8.9 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.423 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -136.7 112.7 9.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 110.167 179.926 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -102.73 43.56 1.66 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 57.75 80.15 0.18 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.354 -1.086 . . . . 0.0 110.395 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.39 -1.02 57.12 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.64 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.826 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.1 m-85 -142.55 -170.1 3.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.377 -1.072 . . . . 0.0 109.472 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.846 HG11 HG21 ' A' ' 304' ' ' VAL . 3.9 t -162.81 156.12 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.177 -0.952 . . . . 0.0 109.922 179.2 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.699 HD13 ' HA ' ' A' ' 295' ' ' LYS . 37.2 mm -125.65 151.78 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.114 -0.991 . . . . 0.0 111.294 -179.462 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 78.5 m-85 -129.54 126.49 38.7 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.166 -0.959 . . . . 0.0 110.408 179.421 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.604 ' CG2' HG23 ' A' ' 293' ' ' THR . 6.4 p -126.5 167.56 16.91 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 120.919 -1.113 . . . . 0.0 109.579 179.195 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.504 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.4 Cg_endo -65.15 119.93 7.05 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.225 -179.164 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.723 HG22 ' HB2' ' A' ' 327' ' ' ASN . 12.4 m -63.74 -111.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.439 -0.788 . . . . 0.0 110.166 179.987 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.482 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.1 OUTLIER -111.67 -23.32 10.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.697 -1.252 . . . . 0.0 110.534 -179.811 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 3.9 p-90 -125.73 1.49 7.47 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 -179.874 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.723 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.2 OUTLIER -99.91 40.97 1.19 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.233 -0.917 . . . . 0.0 110.38 -179.69 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -120.05 -8.4 9.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.25 -0.907 . . . . 0.0 109.532 179.736 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.89 -159.06 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.939 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.1 Cg_endo -74.76 5.75 3.69 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.978 1.515 . . . . 0.0 110.821 -179.899 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.1 m -163.14 121.23 1.98 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.959 -1.088 . . . . 0.0 109.897 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.61 113.75 8.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.957 . . . . 0.0 110.26 -179.776 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.542 HG23 ' HA ' ' A' ' 283' ' ' THR . 11.8 m -103.04 133.42 48.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.392 -0.817 . . . . 0.0 110.364 -179.739 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.8 ' HE2' HG21 ' A' ' 294' ' ' VAL . 15.0 p90 -141.77 164.6 29.75 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.379 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -144.24 158.27 27.41 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.843 -1.646 . . . . 0.0 110.32 -179.397 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.926 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -144.01 147.65 34.17 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.556 -0.967 . . . . 0.0 109.882 179.417 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.926 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.74 122.81 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.992 -1.068 . . . . 0.0 110.048 -179.969 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.913 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.9 t -97.07 157.28 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.884 . . . . 0.0 109.999 179.712 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -125.85 131.32 52.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.84 . . . . 0.0 110.396 -179.575 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.851 . . . . . . . . 0 0 . 1 . 033 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.74 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.3 mtmt . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 121.113 0.482 . . . . 0.0 111.234 . . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.641 HG11 ' CE1' ' A' ' 280' ' ' TYR . 9.0 p -132.2 125.51 54.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.022 -1.049 . . . . 0.0 110.412 179.231 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.547 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 3.8 mt-10 -53.08 -45.74 68.29 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.313 -0.867 . . . . 0.0 110.149 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.454 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 1.8 pt-20 -177.55 158.63 1.4 Allowed 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.185 -179.704 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.793 HD13 HG13 ' A' ' 296' ' ' VAL . 3.5 mm -109.13 122.58 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.603 -0.686 . . . . 0.0 109.709 179.419 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.42 141.76 51.67 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.33 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.104 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.68 126.84 52.62 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 109.952 179.633 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 11.5 tt0 -138.99 113.8 9.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.643 179.92 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.694 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -92.97 112.14 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.154 -0.966 . . . . 0.0 109.913 179.522 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.435 ' C ' ' O ' ' A' ' 353' ' ' ILE . 3.4 m-20 41.74 34.11 0.38 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.492 -0.755 . . . . 0.0 110.113 -179.579 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 108.9 -25.12 19.89 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.933 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.471 ' N ' ' CD ' ' A' ' 356' ' ' GLN . 3.2 mp0 -77.41 106.07 8.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.223 -1.163 . . . . 0.0 110.523 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.622 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.5 p -70.92 120.93 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.259 -0.901 . . . . 0.0 110.184 179.719 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.514 ' HB ' HD13 ' A' ' 351' ' ' LEU . 35.5 mm . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.009 179.777 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 . . . . . . . . . 0 0 . 1 . 034 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.514 ' HB2' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.79 169.35 17.87 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.585 -0.95 . . . . 0.0 109.33 179.909 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.904 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.38 134.49 6.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.36 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.777 ' N ' HD22 ' A' ' 267' ' ' LEU . 8.4 mm-40 -133.96 138.46 45.47 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.294 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.4 t -131.35 142.0 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 120.858 -1.151 . . . . 0.0 111.753 -178.846 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.17 156.99 40.93 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.771 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.81 147.07 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 120.401 -1.437 . . . . 0.0 112.344 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -143.18 113.91 7.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.669 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.6 m-20 -100.07 142.87 30.96 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.872 -1.142 . . . . 0.0 111.205 -178.538 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.8 ' CH2' HG23 ' A' ' 337' ' ' ILE . 26.8 p90 -122.77 20.1 10.17 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.576 -0.703 . . . . 0.0 109.475 179.451 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 84.44 -58.32 5.0 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.744 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.484 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -66.87 -19.34 65.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.25 -1.147 . . . . 0.0 110.216 179.793 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.553 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.93 -172.69 38.79 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -143.69 136.89 27.77 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -1.122 . . . . 0.0 109.894 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.641 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.2 mt-10 -95.93 146.4 24.62 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 110.446 -179.447 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.662 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.1 m-85 -140.01 86.36 2.08 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 110.766 -179.699 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.706 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -66.54 143.64 56.93 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 179.155 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.811 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.4 t -138.35 89.36 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.191 -0.943 . . . . 0.0 110.014 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.463 ' HA ' HG23 ' A' ' 333' ' ' THR . 87.4 m -86.76 126.96 34.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.181 -0.949 . . . . 0.0 109.568 179.799 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.81 147.08 40.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 110.77 -179.204 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.91 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.5 m120 -125.3 135.21 52.25 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.35 -0.844 . . . . 0.0 110.467 -179.453 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.91 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.3 mt -144.77 161.69 38.61 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.731 -1.23 . . . . 0.0 109.595 179.8 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.09 37.47 1.16 Allowed 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.776 179.733 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.473 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 148.55 -129.89 3.25 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.33 -1.414 . . . . 0.0 109.973 -179.68 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.546 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.1 mm-40 -108.3 114.06 27.62 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.891 -1.358 . . . . 0.0 111.132 -179.326 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.721 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.3 m-85 -134.43 133.09 40.12 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.444 -0.785 . . . . 0.0 109.234 179.205 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.84 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.1 m-20 -73.5 96.26 2.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.808 -1.183 . . . . 0.0 108.857 179.236 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.903 ' CE3' HD13 ' A' ' 284' ' ' LEU . 64.2 p-90 -98.98 117.47 33.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.893 . . . . 0.0 110.996 -179.038 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 293' ' ' THR . . . . . 1.067 HG23 HG22 ' A' ' 322' ' ' THR . 17.3 m -112.68 113.98 26.37 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.425 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.787 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.2 t -96.68 110.92 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.058 -1.026 . . . . 0.0 110.265 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.537 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 17.6 ttmt -89.51 148.21 23.54 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.381 -0.825 . . . . 0.0 109.187 179.144 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.811 HG13 HG12 ' A' ' 349' ' ' ILE . 71.3 t -144.26 111.66 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.126 -0.984 . . . . 0.0 110.204 -179.666 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 72.6 mmtt -70.24 135.44 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.219 -0.926 . . . . 0.0 109.154 179.653 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 1.027 HD13 ' HA ' ' A' ' 303' ' ' THR . 93.9 mt -89.84 155.59 19.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.316 -0.865 . . . . 0.0 111.447 -178.851 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.781 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -59.4 173.86 0.46 Allowed Pre-proline 0 N--CA 1.487 1.378 0 O-C-N 121.493 -0.755 . . . . 0.0 109.086 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.695 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -69.23 79.33 0.78 Allowed 'Trans proline' 0 C--N 1.302 -1.913 0 O-C-N 123.608 1.32 . . . . 0.0 109.874 179.747 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.93 20.15 4.99 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.425 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.781 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -109.99 148.39 31.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.407 -1.055 . . . . 0.0 109.859 -179.884 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 303' ' ' THR . . . . . 1.027 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.8 p -147.52 146.15 29.36 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.953 -1.092 . . . . 0.0 111.247 -179.747 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.746 ' CG2' HG21 ' A' ' 319' ' ' VAL . 53.7 t -69.28 129.02 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.287 -0.883 . . . . 0.0 109.821 179.542 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.66 -40.22 1.13 Allowed Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.73 -1.224 . . . . 0.0 110.201 -179.466 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -126.96 129.65 48.55 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 0.0 110.686 -179.463 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.552 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.6 p90 -145.44 162.02 38.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.36 -0.837 . . . . 0.0 109.823 179.59 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.503 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -158.16 156.09 30.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.927 -1.108 . . . . 0.0 111.171 -179.579 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.538 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 63.5 24.31 14.02 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.575 -0.703 . . . . 0.0 110.941 179.598 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.542 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.18 146.1 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.908 . . . . 0.0 110.497 179.474 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.496 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 3.7 m120 -77.31 123.46 26.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.375 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.552 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 12.0 ttpt -93.03 121.94 34.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.5 -0.75 . . . . 0.0 111.025 -179.448 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.597 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 4.2 tt0 -109.86 175.13 5.56 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.324 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -138.17 101.99 4.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.347 -0.846 . . . . 0.0 110.12 179.773 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.451 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -90.11 37.05 3.41 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.868 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 316' ' ' ASN . . . . . 0.451 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 5.8 m-20 63.78 88.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -1.168 . . . . 0.0 110.266 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.08 3.07 70.47 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.729 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.751 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.34 -169.38 3.25 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.376 -1.073 . . . . 0.0 109.338 179.491 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.751 HG23 ' O ' ' A' ' 318' ' ' TYR . 22.6 t -160.8 161.08 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.119 -0.988 . . . . 0.0 109.97 178.964 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.597 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 4.4 mm -126.55 152.33 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.133 -0.98 . . . . 0.0 110.93 -179.378 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.65 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 79.2 m-85 -131.76 112.48 12.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.232 -0.918 . . . . 0.0 109.888 178.791 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 322' ' ' THR . . . . . 1.067 HG22 HG23 ' A' ' 293' ' ' THR . 6.5 p -115.67 170.28 5.86 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 120.725 -1.234 . . . . 0.0 109.529 179.561 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.577 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.0 Cg_endo -67.24 120.62 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.495 1.261 . . . . 0.0 110.943 -179.199 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.727 HG22 ' HB2' ' A' ' 327' ' ' ASN . 30.7 m -68.24 -123.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.488 -0.757 . . . . 0.0 110.143 -179.922 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.481 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -104.74 -18.1 14.39 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.776 -1.202 . . . . 0.0 110.67 -179.734 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.591 ' H ' HG23 ' A' ' 324' ' ' VAL . 19.7 p-90 -126.73 3.53 6.73 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.93 -1.106 . . . . 0.0 110.539 -179.994 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.727 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.6 t30 -110.92 34.76 3.83 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.141 -0.975 . . . . 0.0 110.646 -179.429 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.531 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -114.22 2.8 14.94 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.158 -0.964 . . . . 0.0 109.636 179.54 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -68.85 -153.4 0.58 Allowed Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 179.888 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.9 Cg_endo -69.24 -50.45 0.52 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.906 1.477 . . . . 0.0 109.863 179.974 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.56 116.66 31.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -0.839 . . . . 0.0 110.34 179.779 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -130.34 113.62 14.6 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.271 -0.893 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.463 HG23 ' HA ' ' A' ' 283' ' ' THR . 57.2 m -105.73 149.84 26.05 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.175 -0.953 . . . . 0.0 110.37 -179.966 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.811 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 8.3 p90 -154.73 170.74 20.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.408 -0.808 . . . . 0.0 108.905 179.67 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.542 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.71 149.73 21.62 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.057 -179.3 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.92 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -136.15 147.98 47.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.496 -1.002 . . . . 0.0 110.019 179.573 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.92 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.65 122.49 68.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 120.997 -1.065 . . . . 0.0 109.925 179.501 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.729 HG21 ' CD2' ' A' ' 298' ' ' LEU . 2.1 t -96.55 150.23 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.082 -1.011 . . . . 0.0 110.003 -179.968 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -119.1 132.36 56.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.437 -0.789 . . . . 0.0 109.946 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.462 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.177 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.997 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.691 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.433 0 CA-C-O 121.291 0.567 . . . . 0.0 110.575 . . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.5 p -130.02 126.74 62.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.386 -0.821 . . . . 0.0 109.667 179.106 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.1 mt-10 -62.85 -38.43 90.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 111.106 -179.072 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.457 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.7 pt-20 -176.86 158.9 1.68 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 110.897 -179.479 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.811 HG12 HG13 ' A' ' 296' ' ' VAL . 14.7 mt -123.42 103.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.143 -0.973 . . . . 0.0 110.03 179.627 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.0 145.58 31.18 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.306 -0.871 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.07 128.36 55.85 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.308 179.693 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.461 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 13.9 tt0 -138.61 120.86 15.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.875 179.689 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.84 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -90.81 93.82 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.092 -1.005 . . . . 0.0 110.026 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.403 ' OD1' ' HB3' ' A' ' 291' ' ' ASP . 5.7 m-20 46.34 26.38 0.47 Allowed 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.909 -0.495 . . . . 0.0 110.797 179.923 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 135.66 -29.66 2.85 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.658 179.398 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.485 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 58.7 mm-40 -89.06 110.18 20.93 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.911 -1.347 . . . . 0.0 110.65 -179.442 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.858 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.9 p -74.13 140.36 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.255 -0.903 . . . . 0.0 109.917 179.408 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.858 HD13 ' O ' ' A' ' 357' ' ' VAL . 9.7 mm . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.114 -0.991 . . . . 0.0 110.234 -179.752 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.542 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.43 164.69 29.19 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.402 -1.057 . . . . 0.0 109.841 179.933 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.858 HD22 ' N ' ' A' ' 268' ' ' GLU . 1.6 tm? -161.04 135.37 7.13 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.124 -179.436 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.858 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -132.31 144.25 50.44 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.175 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.795 HG13 ' O ' ' A' ' 281' ' ' ASP . 49.9 t -135.58 140.95 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.689 -1.257 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.47 156.7 41.72 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.734 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.761 HG13 ' O ' ' A' ' 279' ' ' GLU . 94.4 t -143.31 146.93 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.391 -1.443 . . . . 0.0 112.162 -179.338 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.534 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.94 113.8 8.79 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.084 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 m-20 -97.52 148.84 22.83 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.002 -1.061 . . . . 0.0 111.339 -178.818 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.1 p90 -133.74 17.68 3.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.487 -0.758 . . . . 0.0 109.942 179.417 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.37 -57.04 3.9 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.711 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -72.78 -17.12 61.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -1.164 . . . . 0.0 110.226 -179.827 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.543 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.14 -178.04 47.31 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.49 -1.338 . . . . 0.0 109.981 179.876 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.528 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -138.35 141.23 39.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.388 -1.066 . . . . 0.0 110.125 -179.898 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.761 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.8 mt-10 -93.01 147.21 23.03 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.294 -0.879 . . . . 0.0 110.0 -179.838 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.6 m-85 -139.13 84.54 2.01 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.406 -0.809 . . . . 0.0 110.444 -179.581 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.795 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -66.26 150.68 48.44 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.525 -0.734 . . . . 0.0 109.736 179.419 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.767 HG11 HG11 ' A' ' 294' ' ' VAL . 3.2 t -146.47 89.37 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.392 -0.818 . . . . 0.0 110.019 -179.555 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.862 HG23 ' OG1' ' A' ' 333' ' ' THR . 26.2 m -86.04 126.15 33.95 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 109.342 179.601 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.12 152.18 29.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.119 -0.988 . . . . 0.0 110.929 -178.894 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.898 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.1 m120 -131.39 134.73 46.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.731 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.954 HD13 ' HB2' ' A' ' 290' ' ' TYR . 17.2 mt -142.72 162.04 36.51 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.871 -1.143 . . . . 0.0 110.332 -179.846 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.68 34.94 0.71 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.29 -0.881 . . . . 0.0 109.984 179.731 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 144.98 -128.08 3.08 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.825 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.48 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.6 mm-40 -106.25 108.0 19.28 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.033 -1.275 . . . . 0.0 110.969 -179.621 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.954 ' HB2' HD13 ' A' ' 286' ' ' LEU . 8.4 m-85 -127.02 134.76 50.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.336 -0.853 . . . . 0.0 109.493 179.523 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.864 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.0 t70 -73.85 96.37 2.58 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.808 -1.183 . . . . 0.0 108.785 179.02 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.864 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.0 p-90 -98.66 109.26 22.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 111.36 -178.853 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.837 HG22 ' CG2' ' A' ' 320' ' ' ILE . 2.8 m -100.82 115.65 30.83 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.769 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.874 HG21 ' HE2' ' A' ' 334' ' ' PHE . 6.6 t -96.59 111.01 25.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.132 -0.98 . . . . 0.0 110.83 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.439 ' HB3' ' HE3' ' A' ' 295' ' ' LYS . 2.9 ttpp -87.87 145.32 26.12 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.459 -0.776 . . . . 0.0 109.346 179.118 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.829 HG13 HG12 ' A' ' 349' ' ' ILE . 84.6 t -145.4 107.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.153 -0.967 . . . . 0.0 110.452 -179.439 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.584 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.1 mmtt -70.33 133.06 46.58 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.194 -0.941 . . . . 0.0 109.773 179.806 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.947 HD13 ' HA ' ' A' ' 303' ' ' THR . 72.4 mt -87.43 157.83 19.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.441 -0.787 . . . . 0.0 111.731 -178.735 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.822 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -64.95 176.95 0.68 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.6 -0.688 . . . . 0.0 109.571 179.237 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.822 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.6 Cg_endo -68.1 82.47 0.48 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.62 1.327 . . . . 0.0 110.001 179.628 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.7 22.62 5.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.38 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.891 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -110.48 144.7 38.89 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.357 -1.084 . . . . 0.0 110.227 -179.747 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.947 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.5 p -147.57 146.12 29.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 110.391 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.731 HG21 HG11 ' A' ' 319' ' ' VAL . 77.8 t -73.11 125.73 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.374 -0.829 . . . . 0.0 110.101 179.896 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.63 -15.8 5.72 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.44 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.3 OUTLIER -144.73 126.99 15.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.207 -1.173 . . . . 0.0 110.837 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.541 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -149.69 173.46 13.66 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.361 -0.837 . . . . 0.0 109.835 179.531 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.419 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -163.54 158.06 20.33 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.797 -1.189 . . . . 0.0 111.713 -179.761 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 1.2 m 58.87 26.32 14.73 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.292 0.568 . . . . 0.0 111.052 179.575 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.618 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.87 141.47 0.61 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 110.089 179.405 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.5 m120 -77.09 117.76 18.96 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.017 -1.052 . . . . 0.0 109.35 179.61 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.618 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.2 ttpt -86.21 133.16 33.86 Favored 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.719 0.771 . . . . 0.0 110.877 -179.355 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.577 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -115.17 172.3 7.15 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.903 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -134.75 103.12 5.5 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 110.177 -179.868 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.496 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.21 49.82 3.01 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 47.92 80.85 0.05 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.146 -1.208 . . . . 0.0 109.971 -179.947 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.79 -1.26 58.05 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.6 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.3 m-85 -141.71 179.48 6.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.464 -1.021 . . . . 0.0 109.256 179.502 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.731 HG11 HG21 ' A' ' 304' ' ' VAL . 5.2 t -154.22 153.8 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.932 . . . . 0.0 109.286 178.721 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.837 ' CG2' HG22 ' A' ' 293' ' ' THR . 78.3 mt -132.19 138.69 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.996 -1.065 . . . . 0.0 111.337 -179.536 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.5 m-85 -113.42 133.61 55.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.084 -1.01 . . . . 0.0 111.066 -179.629 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.696 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.3 p -127.74 169.19 12.99 Favored Pre-proline 0 C--N 1.3 -1.546 0 O-C-N 121.072 -1.017 . . . . 0.0 109.672 179.011 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.5 Cg_endo -66.34 117.23 4.54 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.812 1.428 . . . . 0.0 111.1 -179.22 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.599 HG22 ' HB2' ' A' ' 327' ' ' ASN . 13.3 m -62.12 -112.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.455 -0.778 . . . . 0.0 110.059 179.872 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.468 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -114.46 -19.38 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 179.873 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.46 ' H ' HG23 ' A' ' 324' ' ' VAL . 7.9 p-90 -122.48 -17.96 6.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.232 -0.917 . . . . 0.0 110.287 -179.904 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.734 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 4.5 t30 -83.9 46.47 1.19 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 0.0 110.066 -179.885 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.5 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.61 -11.95 7.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.393 -0.817 . . . . 0.0 109.783 -179.933 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.49 -163.77 0.02 OUTLIER Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.735 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 330' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.13 2.24 5.75 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 124.07 1.563 . . . . 0.0 110.625 179.9 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.8 m -159.61 114.98 2.43 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.619 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.734 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.76 128.23 26.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.136 -0.978 . . . . 0.0 110.13 -179.767 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.862 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.0 m -117.27 148.9 41.26 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.151 -0.968 . . . . 0.0 110.496 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.874 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.8 p90 -150.4 169.2 22.0 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.448 -0.782 . . . . 0.0 108.952 179.796 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -145.48 158.66 27.73 Favored Glycine 0 N--CA 1.489 2.21 0 C-N-CA 118.737 -1.697 . . . . 0.0 110.128 -179.704 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.95 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -145.03 148.18 33.43 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.521 -0.988 . . . . 0.0 109.876 179.397 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.95 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.48 120.19 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.839 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.891 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.7 t -97.89 149.37 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.264 -0.897 . . . . 0.0 110.266 -179.749 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.514 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.6 m120 -118.96 131.36 56.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.398 -0.814 . . . . 0.0 110.396 -179.776 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 179.869 . . . . . . . . 0 0 . 1 . 035 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.642 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 121.177 0.513 . . . . 0.0 110.757 . . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 7.2 p -132.46 119.66 39.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.305 -0.872 . . . . 0.0 110.148 179.335 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.558 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.87 -44.71 50.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.874 . . . . 0.0 110.151 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.83 158.49 1.64 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.287 -0.883 . . . . 0.0 110.524 -179.967 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.829 HG12 HG13 ' A' ' 296' ' ' VAL . 35.5 mt -118.89 104.85 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.198 -0.939 . . . . 0.0 110.04 179.521 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.03 138.76 43.74 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -0.873 . . . . 0.0 110.325 -179.921 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.33 133.43 42.74 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.229 179.832 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 28.6 tt0 -139.24 108.83 6.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.192 -0.942 . . . . 0.0 110.262 179.985 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.864 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.64 108.62 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.932 -1.105 . . . . 0.0 109.816 179.447 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.42 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.2 m-20 40.45 33.14 0.16 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.688 -0.633 . . . . 0.0 110.474 -179.724 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 115.29 -22.33 12.25 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.842 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.47 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 0.1 OUTLIER -79.77 104.41 10.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.148 -1.207 . . . . 0.0 110.139 179.988 . . . . . . . . 3 3 . 1 . 035 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.2 p -74.5 109.9 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 110.358 -179.775 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.582 ' HB ' HD13 ' A' ' 351' ' ' LEU . 23.0 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.199 179.86 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 . . . . . . . . . 0 0 . 1 . 036 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -138.76 164.86 28.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -1.075 . . . . 0.0 110.234 179.958 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.88 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -160.59 133.9 6.7 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.066 -179.703 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.84 ' N ' HD22 ' A' ' 267' ' ' LEU . 3.0 mp0 -131.35 146.72 52.4 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.175 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.824 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -139.99 145.66 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.587 -1.321 . . . . 0.0 111.551 -178.966 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.97 157.59 44.8 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.203 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 279' ' ' GLU . 76.5 t -143.77 147.06 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.413 -1.429 . . . . 0.0 112.18 -179.175 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.541 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.63 111.12 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.594 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -96.29 147.87 23.34 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.982 -1.074 . . . . 0.0 111.179 -179.101 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.836 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.8 p90 -133.05 16.68 4.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.497 -0.752 . . . . 0.0 110.096 179.388 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 92.0 -60.28 2.72 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.694 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.481 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 22.9 t -71.03 -17.73 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -1.178 . . . . 0.0 110.293 -179.864 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.541 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.45 179.4 47.51 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.315 -1.422 . . . . 0.0 110.148 179.926 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.592 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -135.82 140.38 44.18 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.39 -1.065 . . . . 0.0 110.168 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.657 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.5 mt-10 -93.11 147.06 23.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.734 -179.936 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 93.7 m-85 -140.64 87.77 2.15 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.202 -0.937 . . . . 0.0 110.383 -179.615 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.824 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.16 150.05 46.91 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.436 -0.79 . . . . 0.0 109.854 179.573 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.748 HG11 HG11 ' A' ' 294' ' ' VAL . 3.6 t -143.21 90.35 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.409 -0.807 . . . . 0.0 109.87 -179.61 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.855 HG23 ' OG1' ' A' ' 333' ' ' THR . 10.6 m -86.49 122.45 30.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.995 . . . . 0.0 109.6 179.745 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.22 149.95 29.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.205 -0.934 . . . . 0.0 110.801 -179.166 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.916 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -129.67 132.4 46.67 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.281 -0.887 . . . . 0.0 110.324 -179.557 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 1.039 HD13 ' HB2' ' A' ' 290' ' ' TYR . 16.4 mt -142.7 159.88 41.37 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.107 . . . . 0.0 109.859 179.458 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -87.86 32.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 110.154 -179.952 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.504 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 150.97 -134.11 4.56 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 8.7 mm-40 -101.52 106.95 18.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.253 -1.145 . . . . 0.0 110.476 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 1.039 ' HB2' HD13 ' A' ' 286' ' ' LEU . 7.2 m-85 -126.17 130.4 50.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.372 -0.83 . . . . 0.0 109.185 179.588 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.811 ' O ' HG23 ' A' ' 353' ' ' ILE . 24.7 m-20 -68.67 96.93 0.76 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.718 -1.239 . . . . 0.0 109.291 179.576 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.949 ' CE3' HD13 ' A' ' 284' ' ' LEU . 60.7 p-90 -100.51 114.26 27.73 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.139 -0.976 . . . . 0.0 110.776 -179.424 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.718 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.9 m -109.34 114.57 28.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.528 -0.732 . . . . 0.0 109.325 179.495 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.812 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.78 111.6 27.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.075 -1.016 . . . . 0.0 110.752 -179.198 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.634 ' HA ' HD13 ' A' ' 320' ' ' ILE . 32.7 ttpt -91.41 141.03 29.19 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.328 -0.857 . . . . 0.0 109.362 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.647 HG13 HG12 ' A' ' 349' ' ' ILE . 71.8 t -137.54 112.27 9.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.262 -0.899 . . . . 0.0 110.564 -179.311 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.6 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 10.4 mmtp -71.72 131.53 43.25 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.183 -0.948 . . . . 0.0 109.308 179.454 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.985 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.1 mt -83.53 161.45 21.22 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.282 -0.886 . . . . 0.0 111.889 -178.658 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.908 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.16 176.99 0.84 Allowed Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.686 -0.634 . . . . 0.0 109.77 179.354 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.807 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.9 Cg_endo -67.43 80.2 0.43 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.615 1.324 . . . . 0.0 109.79 179.288 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.2 19.88 6.95 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.377 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.908 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -101.33 156.37 17.49 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.365 -1.079 . . . . 0.0 110.351 -179.759 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.985 ' HA ' HD13 ' A' ' 298' ' ' LEU . 74.3 p -156.85 144.19 18.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.92 . . . . 0.0 110.474 179.93 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.755 HG21 HG11 ' A' ' 319' ' ' VAL . 30.1 t -71.1 133.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.353 -0.842 . . . . 0.0 110.123 179.784 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.17 -42.11 0.78 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.706 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.61 136.41 46.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.108 -1.231 . . . . 0.0 110.998 -179.554 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.524 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.9 p90 -149.08 174.99 11.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.413 -0.805 . . . . 0.0 109.693 179.469 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.499 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.57 159.29 21.71 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.041 -1.037 . . . . 0.0 111.136 -179.751 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.555 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 58.57 23.81 11.28 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.561 -0.712 . . . . 0.0 111.077 179.668 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.667 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 140.92 0.61 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 110.262 179.494 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.539 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -79.45 124.64 28.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.022 -1.049 . . . . 0.0 109.053 179.387 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.596 ' CD ' HG11 ' A' ' 304' ' ' VAL . 6.2 ttpt -91.85 133.18 35.88 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.796 0.808 . . . . 0.0 111.199 -179.148 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.532 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.51 175.43 5.57 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.61 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.453 ' HG2' HG22 ' A' ' 319' ' ' VAL . 1.2 mm-40 -135.77 103.6 5.47 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.251 -0.906 . . . . 0.0 110.286 -179.975 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -90.07 47.57 3.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.828 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 m120 51.9 82.62 0.06 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.343 -1.093 . . . . 0.0 110.416 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.29 1.43 60.91 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.797 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -143.32 -168.37 2.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -1.027 . . . . 0.0 109.102 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 318' ' ' TYR . 6.8 t -162.52 158.21 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.325 -0.859 . . . . 0.0 109.832 178.964 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.634 HD13 ' HA ' ' A' ' 295' ' ' LYS . 21.6 mm -127.88 148.44 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.096 -1.003 . . . . 0.0 111.114 -179.717 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.632 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 84.8 m-85 -124.85 127.02 46.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.235 -0.916 . . . . 0.0 109.836 179.116 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.718 ' CG2' HG23 ' A' ' 293' ' ' THR . 3.2 p -126.76 168.77 13.56 Favored Pre-proline 0 C--N 1.301 -1.533 0 C-N-CA 119.068 -1.053 . . . . 0.0 110.307 179.984 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.8 Cg_endo -66.05 116.09 3.81 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.84 1.442 . . . . 0.0 111.056 -179.448 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.608 HG22 ' HB2' ' A' ' 327' ' ' ASN . 16.0 m -63.18 -115.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.335 -0.853 . . . . 0.0 109.839 179.865 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.489 ' N ' HG23 ' A' ' 324' ' ' VAL . 73.6 m -118.18 -13.31 9.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.797 -1.189 . . . . 0.0 110.295 179.933 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.573 ' H ' HG23 ' A' ' 324' ' ' VAL . 18.6 p-90 -127.76 -3.36 5.93 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 0.0 110.411 -179.932 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.608 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.99 41.59 1.32 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.269 -0.894 . . . . 0.0 110.31 -179.72 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.492 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -115.91 -9.26 11.83 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 179.825 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.81 -161.73 0.02 OUTLIER Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.607 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.504 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.5 Cg_endo -74.37 4.77 4.12 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 O-C-N 123.992 1.522 . . . . 0.0 111.097 -179.837 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 6.6 m -163.96 114.99 1.33 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.842 179.741 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.0 127.45 28.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.185 -0.947 . . . . 0.0 110.267 -179.774 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.855 ' OG1' HG23 ' A' ' 283' ' ' THR . 91.3 m -115.3 137.51 51.96 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.915 . . . . 0.0 110.308 -179.95 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.812 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.9 p90 -138.87 174.95 9.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.303 -0.873 . . . . 0.0 109.014 179.568 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.524 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.31 156.87 26.94 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 119.034 -1.555 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.947 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -144.37 149.09 35.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.594 -0.945 . . . . 0.0 109.689 179.445 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.947 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.47 117.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.078 -1.014 . . . . 0.0 109.833 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.759 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -96.77 152.05 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -0.871 . . . . 0.0 110.204 -179.598 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.491 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -122.78 134.59 54.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.409 -0.807 . . . . 0.0 109.88 179.866 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.453 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 179.951 . . . . . . . . 0 0 . 1 . 036 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.817 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 121.427 0.632 . . . . 0.0 110.8 . . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.595 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.9 p -132.55 116.94 29.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.231 -0.918 . . . . 0.0 109.938 179.561 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.529 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -45.3 -46.1 12.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.021 -1.049 . . . . 0.0 110.116 -179.604 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.418 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.3 pt-20 -177.12 158.5 1.52 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 110.473 179.979 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.647 HG12 HG13 ' A' ' 296' ' ' VAL . 27.3 mt -116.32 117.86 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.24 -0.912 . . . . 0.0 110.216 179.677 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.88 145.42 47.67 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.162 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.63 133.67 51.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.015 -1.053 . . . . 0.0 110.679 179.903 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -138.82 112.88 8.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.371 -0.83 . . . . 0.0 109.901 179.617 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.811 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.55 94.04 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.979 -1.075 . . . . 0.0 110.051 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.45 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 3.3 m-20 50.68 31.23 5.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.699 -0.626 . . . . 0.0 110.704 179.981 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.65 -26.06 6.36 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.683 -1.246 . . . . 0.0 110.45 179.351 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.475 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 41.7 mm-40 -85.92 103.66 14.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.045 -1.267 . . . . 0.0 110.499 -179.576 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.67 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.3 p -73.6 116.47 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.265 -0.897 . . . . 0.0 110.162 179.891 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.491 ' OXT' HG22 ' A' ' 358' ' ' ILE . 36.9 mm . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.24 -179.992 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.545 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.28 163.61 28.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.428 -1.042 . . . . 0.0 109.511 179.628 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.865 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.28 134.73 6.54 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 111.736 -179.611 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.832 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.0 mt-10 -130.38 149.61 51.99 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.975 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.75 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.6 t -141.3 141.23 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.628 -1.295 . . . . 0.0 111.684 -179.306 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -126.81 157.99 37.78 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.908 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.658 HG13 ' O ' ' A' ' 279' ' ' GLU . 89.0 t -144.02 146.39 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.333 -1.479 . . . . 0.0 112.193 -179.325 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.517 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.16 110.87 6.47 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.005 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 46.1 p30 -96.15 147.82 23.35 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.163 -0.961 . . . . 0.0 111.378 -178.493 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.809 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.4 p90 -134.95 23.65 3.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.586 -0.696 . . . . 0.0 109.884 179.42 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.97 -66.96 3.84 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 276' ' ' SER . . . . . 0.54 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 9.2 m -59.85 -26.35 65.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.197 -1.178 . . . . 0.0 110.615 -179.881 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.562 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -170.96 -177.8 41.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.972 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.554 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.22 144.07 42.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.244 -1.15 . . . . 0.0 110.18 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.658 ' O ' HG13 ' A' ' 271' ' ' VAL . 6.3 mt-10 -97.41 147.43 24.22 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.385 -0.822 . . . . 0.0 109.967 -179.523 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.745 ' CE2' HG11 ' A' ' 346' ' ' VAL . 91.1 m-85 -141.43 83.89 1.89 Allowed 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.341 -0.849 . . . . 0.0 110.787 -179.344 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.75 ' O ' HG13 ' A' ' 269' ' ' VAL . 1.8 t70 -64.52 146.98 53.74 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.434 -0.791 . . . . 0.0 109.623 179.144 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.739 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 6.7 t -142.58 89.08 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 -179.647 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.721 HG23 ' OG1' ' A' ' 333' ' ' THR . 97.8 m -86.46 123.5 31.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.203 -0.935 . . . . 0.0 109.756 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.083 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.48 150.47 28.84 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.168 -0.957 . . . . 0.0 110.517 -179.525 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -129.12 135.77 49.32 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 109.958 -179.687 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 11.6 mt -143.18 160.68 39.98 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.075 -1.016 . . . . 0.0 109.481 179.564 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.76 31.76 1.76 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 110.528 -179.598 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.0 -94.6 0.13 Allowed Glycine 0 N--CA 1.491 2.312 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.425 179.876 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.5 tt0 -152.48 106.51 3.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.055 -1.262 . . . . 0.0 110.695 -179.322 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.644 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 5.0 m-85 -128.38 134.85 48.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 179.585 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.532 ' O ' HG23 ' A' ' 353' ' ' ILE . 96.7 m-20 -67.34 96.92 0.52 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.846 -1.159 . . . . 0.0 108.754 178.859 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.931 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.5 p-90 -97.68 108.89 21.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.146 -0.971 . . . . 0.0 111.166 -178.862 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.756 HG22 ' CG2' ' A' ' 320' ' ' ILE . 8.6 m -102.18 114.85 29.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.643 -0.661 . . . . 0.0 109.233 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.752 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.5 t -96.71 111.88 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.1 -1.0 . . . . 0.0 111.076 -178.964 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 6.3 ttpt -86.63 149.39 24.95 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.476 -0.765 . . . . 0.0 109.351 179.008 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.899 HG22 HG23 ' A' ' 349' ' ' ILE . 43.4 t -148.67 108.0 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.033 -1.042 . . . . 0.0 110.585 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.561 ' HD2' ' CE1' ' A' ' 318' ' ' TYR . 9.1 mmtm -71.01 134.3 47.02 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.131 -0.981 . . . . 0.0 110.044 179.781 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 0.872 HD13 ' HA ' ' A' ' 303' ' ' THR . 74.9 mt -87.5 165.56 15.42 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.331 -0.855 . . . . 0.0 111.131 -179.37 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -79.73 173.98 6.85 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 178.883 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.4 Cg_endo -66.09 84.52 0.26 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.496 1.261 . . . . 0.0 110.125 179.816 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.11 24.15 4.62 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.62 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.938 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.73 149.29 38.68 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -1.127 . . . . 0.0 110.202 -179.761 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 303' ' ' THR . . . . . 0.872 ' HA ' HD13 ' A' ' 298' ' ' LEU . 14.1 p -153.96 144.57 22.43 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.664 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.683 HG21 HG11 ' A' ' 319' ' ' VAL . 75.0 t -75.09 135.04 28.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 110.09 179.803 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -128.81 -31.33 0.65 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.707 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.5 m -126.56 109.54 12.25 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.033 -1.275 . . . . 0.0 110.92 -179.555 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.581 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 55.4 p90 -133.44 156.54 47.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.631 179.213 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.491 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -149.32 158.42 44.16 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.966 -1.084 . . . . 0.0 111.201 -179.411 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.522 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 65.46 21.12 11.82 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.741 -0.599 . . . . 0.0 111.279 179.55 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.637 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.97 150.49 1.23 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.231 -0.918 . . . . 0.0 110.516 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.608 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.5 m120 -83.62 119.25 24.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.148 -0.97 . . . . 0.0 108.979 179.134 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.581 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 6.7 ttpt -90.44 131.22 36.33 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.916 0.865 . . . . 0.0 111.407 -178.891 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.622 ' O ' HG22 ' A' ' 319' ' ' VAL . 27.9 mt-30 -112.18 178.69 4.22 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.61 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 314' ' ' GLU . . . . . 0.561 ' HG2' HG22 ' A' ' 319' ' ' VAL . 7.5 mm-40 -143.78 108.13 4.8 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.458 -0.776 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.44 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -96.53 50.65 1.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 52.48 84.7 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.315 -1.109 . . . . 0.0 110.003 -179.948 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 93.97 -2.28 68.98 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.892 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.626 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -137.19 -179.59 5.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -1.109 . . . . 0.0 109.683 179.665 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.683 HG11 HG21 ' A' ' 304' ' ' VAL . 3.8 t -157.63 155.69 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.444 -0.785 . . . . 0.0 109.421 178.771 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.756 ' CG2' HG22 ' A' ' 293' ' ' THR . 1.9 mt -131.99 140.31 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 111.674 -179.147 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 67.5 m-85 -115.74 130.17 56.75 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 110.384 179.548 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.621 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.4 p -127.97 169.96 11.41 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 120.963 -1.086 . . . . 0.0 109.57 179.657 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.525 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -66.16 126.6 16.03 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.594 1.313 . . . . 0.0 110.915 -179.301 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.885 HG22 ' HB2' ' A' ' 327' ' ' ASN . 35.4 m -77.79 -123.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.826 -179.985 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.583 ' N ' HG23 ' A' ' 324' ' ' VAL . 19.8 m -100.32 -12.98 19.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.766 -1.209 . . . . 0.0 110.586 -179.911 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.693 ' H ' HG23 ' A' ' 324' ' ' VAL . 15.3 p-90 -137.25 5.33 2.74 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.144 -0.972 . . . . 0.0 110.679 -179.887 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.885 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t30 -107.09 43.14 1.2 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.068 -1.02 . . . . 0.0 110.381 -179.639 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.495 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 1.2 pttt -126.82 -5.71 6.28 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.38 -0.825 . . . . 0.0 109.969 179.704 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.0 -156.13 0.03 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 -179.882 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.456 ' O ' ' OG1' ' A' ' 331' ' ' THR . 47.8 Cg_endo -72.23 2.5 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 124.134 1.597 . . . . 0.0 110.964 -179.89 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.9 m -165.4 121.67 1.4 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.257 -0.902 . . . . 0.0 109.946 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.93 107.94 6.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.188 -0.945 . . . . 0.0 110.45 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.721 ' OG1' HG23 ' A' ' 283' ' ' THR . 25.6 m -98.41 142.04 30.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.192 -0.943 . . . . 0.0 109.96 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.752 ' HE2' HG21 ' A' ' 294' ' ' VAL . 7.2 p90 -149.14 169.82 19.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.771 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.553 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.45 151.68 23.84 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.141 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.941 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -136.44 149.46 48.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.563 -0.963 . . . . 0.0 109.83 179.569 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.941 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -122.86 119.34 57.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.144 -0.973 . . . . 0.0 109.529 179.356 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.938 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -95.95 143.74 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.077 -1.014 . . . . 0.0 109.239 179.702 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -120.07 140.48 50.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.176 -0.953 . . . . 0.0 110.86 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.234 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.817 . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.582 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.289 0.566 . . . . 0.0 110.436 . . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.745 HG11 ' CE2' ' A' ' 280' ' ' TYR . 6.2 p -127.61 120.18 53.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.168 -0.957 . . . . 0.0 110.133 179.614 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.551 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 0.8 OUTLIER -48.43 -46.38 37.53 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.074 -1.016 . . . . 0.0 109.717 -179.825 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.409 ' OE1' ' HB3' ' A' ' 347' ' ' GLU . 1.6 pt-20 -176.99 158.59 1.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.351 -0.843 . . . . 0.0 110.429 179.679 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.899 HG23 HG22 ' A' ' 296' ' ' VAL . 11.3 mt -117.07 103.53 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.887 . . . . 0.0 109.793 179.675 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.61 146.45 28.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.292 -0.88 . . . . 0.0 110.306 -179.737 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.083 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -106.62 132.95 52.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.161 -0.962 . . . . 0.0 110.135 179.576 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.4 tt0 -138.53 112.69 8.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.948 179.86 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.532 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.7 mt -91.61 113.17 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.104 -0.997 . . . . 0.0 110.099 179.963 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.439 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.8 m-20 38.54 29.54 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.752 -0.592 . . . . 0.0 110.918 -179.809 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 355' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.84 -13.85 12.91 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.523 179.23 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.514 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 72.7 mm-40 -93.8 113.98 26.14 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.885 -1.362 . . . . 0.0 110.368 -179.836 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.925 ' O ' HD13 ' A' ' 358' ' ' ILE . 2.2 p -74.23 138.35 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.183 179.998 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.925 HD13 ' O ' ' A' ' 357' ' ' VAL . 19.1 mm . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.277 -179.909 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 038 nuclear build core ' A' A ' 266' ' ' SER . . . . . 0.574 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -134.62 165.95 24.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.532 -0.981 . . . . 0.0 109.69 179.866 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 267' ' ' LEU . . . . . 0.906 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.37 139.17 9.19 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.193 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 268' ' ' GLU . . . . . 0.749 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.0 mp0 -138.02 130.38 29.16 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.542 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 269' ' ' VAL . . . . . 0.788 HG13 ' O ' ' A' ' 281' ' ' ASP . 94.9 t -124.32 138.13 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.804 -1.185 . . . . 0.0 111.681 -178.854 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 270' ' ' LYS . . . . . 0.407 ' C ' HG23 ' A' ' 271' ' ' VAL . 20.1 tttt -121.19 157.64 29.78 Favored 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.131 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 271' ' ' VAL . . . . . 0.766 HG22 ' CD1' ' A' ' 280' ' ' TYR . 86.7 t -144.15 147.07 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 120.404 -1.435 . . . . 0.0 112.531 -179.049 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 272' ' ' ASN . . . . . 0.528 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -141.35 109.98 6.04 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.864 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 273' ' ' ASP . . . . . 0.51 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 m-20 -94.82 146.71 24.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.114 -0.991 . . . . 0.0 111.535 -178.718 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 274' ' ' TRP . . . . . 0.807 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.0 p90 -134.67 23.52 3.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.616 -0.678 . . . . 0.0 109.667 179.062 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.39 -65.33 4.11 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.932 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.0 -23.99 65.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -1.186 . . . . 0.0 110.354 -179.929 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 277' ' ' GLY . . . . . 0.557 ' O ' ' CD2' ' A' ' 274' ' ' TRP . . . -176.57 176.43 47.87 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 278' ' ' ALA . . . . . 0.562 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -131.36 148.55 52.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.359 -1.083 . . . . 0.0 110.259 -179.879 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 279' ' ' GLU . . . . . 0.666 ' O ' HG13 ' A' ' 271' ' ' VAL . 16.3 mt-10 -97.63 147.07 24.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.513 -0.742 . . . . 0.0 109.683 -179.81 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 280' ' ' TYR . . . . . 0.766 ' CD1' HG22 ' A' ' 271' ' ' VAL . 80.1 m-85 -141.7 85.98 1.97 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.362 -0.836 . . . . 0.0 111.045 -179.242 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 281' ' ' ASP . . . . . 0.788 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -69.22 150.22 47.7 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.389 -0.82 . . . . 0.0 109.54 179.115 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 282' ' ' VAL . . . . . 0.727 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.9 t -143.86 87.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.353 -0.842 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 283' ' ' THR . . . . . 0.794 HG23 ' OG1' ' A' ' 333' ' ' THR . 98.0 m -86.68 123.44 31.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.093 -1.005 . . . . 0.0 109.885 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 284' ' ' LEU . . . . . 1.056 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.4 148.25 30.41 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.201 -0.937 . . . . 0.0 110.062 -179.66 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 285' ' ' ASN . . . . . 0.574 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.6 m120 -129.6 111.98 13.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.221 -0.924 . . . . 0.0 111.134 -178.742 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 286' ' ' LEU . . . . . 0.642 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 10.2 mt -121.47 158.66 27.92 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.809 -1.182 . . . . 0.0 109.407 178.982 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.97 35.62 1.25 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.201 -0.937 . . . . 0.0 110.38 -179.69 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 288' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 163.79 -103.14 0.21 Allowed Glycine 0 N--CA 1.492 2.379 0 C-N-CA 118.879 -1.629 . . . . 0.0 110.561 179.983 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 289' ' ' GLN . . . . . 0.52 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 1.7 mt-30 -148.27 120.45 8.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -1.132 . . . . 0.0 110.411 -179.343 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 290' ' ' TYR . . . . . 0.642 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -151.27 131.29 13.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.826 179.553 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 291' ' ' ASP . . . . . 0.822 ' O ' HG23 ' A' ' 353' ' ' ILE . 4.9 t70 -62.1 103.81 0.41 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.096 -1.002 . . . . 0.0 109.568 179.59 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 292' ' ' TRP . . . . . 0.912 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.9 p-90 -103.0 111.07 23.23 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.291 -0.881 . . . . 0.0 110.49 -179.758 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 293' ' ' THR . . . . . 0.703 HG23 ' CG2' ' A' ' 322' ' ' THR . 25.3 m -105.08 114.71 29.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.776 179.639 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 294' ' ' VAL . . . . . 0.783 HG22 ' CD2' ' A' ' 351' ' ' LEU . 3.1 t -97.07 110.86 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 110.077 -179.732 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 295' ' ' LYS . . . . . 0.439 ' HG3' HD13 ' A' ' 320' ' ' ILE . 21.2 ttmt -86.32 149.4 25.07 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.189 -0.945 . . . . 0.0 109.42 179.148 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 296' ' ' VAL . . . . . 0.734 HG13 HG12 ' A' ' 349' ' ' ILE . 86.3 t -145.6 107.04 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.275 -0.891 . . . . 0.0 110.749 -179.161 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 297' ' ' LYS . . . . . 0.598 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 4.4 mmtt -70.47 136.95 49.88 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.13 -0.981 . . . . 0.0 109.157 179.188 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 298' ' ' LEU . . . . . 1.011 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.8 mt -90.47 157.43 17.57 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.23 -0.919 . . . . 0.0 111.673 -178.573 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 299' ' ' ALA . . . . . 0.804 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.02 175.43 1.01 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.574 -0.704 . . . . 0.0 109.771 179.443 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 300' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -67.25 81.81 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 123.707 1.372 . . . . 0.0 110.049 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.76 19.14 7.5 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.54 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 302' ' ' ALA . . . . . 0.804 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 144.2 34.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.414 -1.051 . . . . 0.0 110.026 -179.812 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 303' ' ' THR . . . . . 1.011 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.4 p -145.09 145.04 31.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.137 -0.977 . . . . 0.0 110.886 -179.985 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 304' ' ' VAL . . . . . 0.801 ' CG2' HG21 ' A' ' 319' ' ' VAL . 75.4 t -70.39 142.41 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.46 -0.775 . . . . 0.0 109.96 179.697 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.65 -40.68 0.2 Allowed Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.663 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 306' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -120.76 118.69 30.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.051 -1.264 . . . . 0.0 110.631 -179.599 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 307' ' ' PHE . . . . . 0.558 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.7 p90 -141.86 156.78 45.52 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.255 -0.903 . . . . 0.0 109.641 179.671 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 308' ' ' TRP . . . . . 0.485 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.83 158.72 42.62 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.087 -1.008 . . . . 0.0 111.188 -179.206 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 309' ' ' SER . . . . . 0.489 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 60.47 25.43 15.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.592 -0.692 . . . . 0.0 110.926 179.611 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 310' ' ' ALA . . . . . 0.61 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.61 142.24 0.71 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.183 -0.948 . . . . 0.0 110.282 179.679 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 311' ' ' ASN . . . . . 0.542 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.0 m120 -77.21 123.74 26.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.115 -0.991 . . . . 0.0 109.296 179.355 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 312' ' ' LYS . . . . . 0.558 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 1.7 ttpt -94.5 123.4 37.9 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.555 0.693 . . . . 0.0 110.95 -179.341 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 313' ' ' GLN . . . . . 0.647 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 6.5 mt-30 -109.65 177.21 4.8 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.549 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -136.28 99.69 4.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.468 -0.77 . . . . 0.0 110.129 179.939 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.58 41.3 3.08 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.777 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.8 t30 58.31 83.98 0.11 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.155 -1.203 . . . . 0.0 110.158 179.981 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 317' ' ' GLY . . . . . 0.612 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.14 3.99 63.22 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 318' ' ' TYR . . . . . 0.786 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.47 -169.87 3.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.398 -1.06 . . . . 0.0 108.988 179.54 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 319' ' ' VAL . . . . . 0.801 HG21 ' CG2' ' A' ' 304' ' ' VAL . 12.8 t -161.44 149.98 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 0.0 109.843 179.147 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 320' ' ' ILE . . . . . 0.647 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 8.7 mm -114.76 151.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 120.937 -1.102 . . . . 0.0 110.836 -179.946 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.8 m-85 -130.06 115.68 17.45 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.166 -0.959 . . . . 0.0 109.963 178.977 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 322' ' ' THR . . . . . 0.703 ' CG2' HG23 ' A' ' 293' ' ' THR . 24.7 p -122.23 167.0 15.02 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 120.728 -1.232 . . . . 0.0 109.654 179.551 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 323' ' ' PRO . . . . . 0.526 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.1 Cg_endo -64.81 120.05 7.22 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.803 1.423 . . . . 0.0 110.893 -179.362 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 324' ' ' VAL . . . . . 0.658 HG22 ' HB2' ' A' ' 327' ' ' ASN . 28.9 m -63.31 -126.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.498 -0.751 . . . . 0.0 110.149 -179.873 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 325' ' ' SER . . . . . 0.496 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -101.09 -20.78 15.2 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.847 -1.158 . . . . 0.0 110.869 -179.585 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 326' ' ' TRP . . . . . 0.581 ' H ' HG23 ' A' ' 324' ' ' VAL . 23.9 p-90 -124.57 -1.68 7.99 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.998 -1.063 . . . . 0.0 110.699 -179.753 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 327' ' ' ASN . . . . . 0.658 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.7 t30 -104.7 44.52 1.02 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.107 -0.996 . . . . 0.0 110.614 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 328' ' ' LYS . . . . . 0.447 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -126.13 10.86 7.55 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.055 -1.028 . . . . 0.0 109.961 179.704 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 329' ' ' GLY . . . . . 0.452 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -73.89 -143.37 0.73 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.615 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 330' ' ' PRO . . . . . 0.554 ' O ' ' N ' ' A' ' 286' ' ' LEU . 43.7 Cg_endo -72.75 -56.15 0.09 OUTLIER 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.463 . . . . 0.0 109.756 179.602 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 7.2 m -107.94 126.43 52.69 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.177 -0.952 . . . . 0.0 110.204 179.76 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 332' ' ' ALA . . . . . 0.43 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -138.66 109.48 6.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.379 -0.826 . . . . 0.0 109.945 179.902 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 333' ' ' THR . . . . . 0.794 ' OG1' HG23 ' A' ' 283' ' ' THR . 8.8 m -100.81 145.33 28.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.432 -179.715 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 334' ' ' PHE . . . . . 0.727 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 10.1 p90 -151.54 174.92 12.85 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.552 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 335' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.9 165.45 31.13 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 118.838 -1.648 . . . . 0.0 110.518 -179.319 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 336' ' ' PHE . . . . . 0.868 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -152.27 143.58 23.3 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.525 -0.986 . . . . 0.0 109.9 179.634 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 337' ' ' ILE . . . . . 0.868 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -117.76 125.27 74.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.064 -1.022 . . . . 0.0 109.886 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 338' ' ' VAL . . . . . 0.726 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.7 t -101.9 145.47 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.276 -0.89 . . . . 0.0 109.945 179.835 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 339' ' ' ASN . . . . . 0.496 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 3.0 m120 -113.84 126.76 55.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.344 -0.847 . . . . 0.0 110.098 179.873 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 340' ' ' GLY . . . . . 0.423 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.994 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 345' ' ' LYS . . . . . 0.661 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.126 0.489 . . . . 0.0 110.809 . . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 346' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 346' ' ' VAL . 12.6 p -132.5 116.93 29.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.195 -0.941 . . . . 0.0 110.245 179.632 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 347' ' ' GLU . . . . . 0.483 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -46.65 -45.39 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.895 . . . . 0.0 110.319 -179.937 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 348' ' ' GLU . . . . . 0.431 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 13.9 pt-20 -176.67 158.34 1.69 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.125 -0.984 . . . . 0.0 110.686 -179.781 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 349' ' ' ILE . . . . . 0.734 HG12 HG13 ' A' ' 296' ' ' VAL . 39.8 mt -122.31 105.94 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.121 -0.987 . . . . 0.0 109.918 179.516 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.78 143.92 35.66 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.085 -1.009 . . . . 0.0 110.283 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 351' ' ' LEU . . . . . 1.056 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.6 128.59 53.7 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.194 -0.941 . . . . 0.0 109.953 179.694 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 352' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.3 OUTLIER -138.62 119.26 14.01 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.974 . . . . 0.0 110.123 179.814 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 353' ' ' ILE . . . . . 0.822 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -92.8 109.7 21.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.16 -0.963 . . . . 0.0 110.271 179.934 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 354' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 353' ' ' ILE . 4.4 m-20 38.27 46.36 0.88 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.592 . . . . 0.0 111.202 -179.979 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.37 -36.24 4.38 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.385 179.246 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 356' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 38.3 mm-40 -66.88 176.07 2.2 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.012 -1.287 . . . . 0.0 110.311 -179.587 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 357' ' ' VAL . . . . . 0.787 ' O ' HD13 ' A' ' 358' ' ' ILE . 5.6 p -140.65 129.82 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.305 -0.872 . . . . 0.0 109.969 -179.955 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 358' ' ' ILE . . . . . 0.787 HD13 ' O ' ' A' ' 357' ' ' VAL . 8.3 mm . . . . . 0 N--CA 1.494 1.726 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.303 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -73.19 -178.62 3.71 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 124.017 1.535 . . . . 0.0 110.668 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.644 HG23 ' O ' ' A' ' 258' ' ' THR . 9.1 t -60.23 120.21 9.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.349 -0.844 . . . . 0.0 110.206 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 89.0 m -112.57 134.03 21.72 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.923 . . . . 0.0 110.179 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.93 160.21 46.43 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.928 1.488 . . . . 0.0 110.491 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.598 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -105.82 142.83 25.62 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.291 -0.881 . . . . 0.0 110.472 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.598 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.8 Cg_endo -72.67 146.14 42.83 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 O-C-N 124.122 1.591 . . . . 0.0 110.449 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.59 HG12 ' O ' ' A' ' 263' ' ' VAL . 40.8 t -139.88 29.82 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.238 -0.914 . . . . 0.0 110.01 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.4 m 179.32 74.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.298 -0.876 . . . . 0.0 110.477 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 128.8 174.97 13.88 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.77 -1.205 . . . . 0.0 110.122 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.559 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.78 158.58 44.05 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.473 -1.016 . . . . 0.0 109.699 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.575 HD12 ' CG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -153.02 123.89 7.38 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.08 -1.012 . . . . 0.0 110.749 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.473 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 3.3 mt-10 -122.05 113.72 19.93 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.903 HG13 ' O ' ' A' ' 281' ' ' ASP . 47.5 t -108.11 145.8 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.957 -1.089 . . . . 0.0 111.734 -178.513 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 5.5 mttp -130.16 156.91 43.8 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.003 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.646 HG13 ' O ' ' A' ' 279' ' ' GLU . 75.4 t -144.75 139.44 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.407 -1.433 . . . . 0.0 111.647 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.529 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -134.52 110.89 9.66 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.174 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.9 m-20 -98.72 135.42 40.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.939 -1.101 . . . . 0.0 111.71 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.812 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.6 p90 -119.75 20.15 12.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.507 -0.746 . . . . 0.0 109.209 178.919 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.47 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 87.06 -77.97 1.93 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 32.0 m -51.22 -24.63 4.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.366 -1.079 . . . . 0.0 110.465 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.541 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -165.62 174.28 41.35 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.298 -1.429 . . . . 0.0 110.311 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.558 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -133.58 141.77 47.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.46 -1.024 . . . . 0.0 110.028 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.646 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.3 mt-10 -97.66 146.65 25.12 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.325 -0.859 . . . . 0.0 109.915 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 94.4 m-85 -141.84 85.24 1.93 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.442 -0.786 . . . . 0.0 110.405 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.903 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -69.6 154.21 42.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.864 . . . . 0.0 109.997 179.498 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.613 HG11 HG11 ' A' ' 294' ' ' VAL . 4.2 t -145.03 89.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 O-C-N 121.629 -0.669 . . . . 0.0 109.506 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.898 HG23 ' OG1' ' A' ' 333' ' ' THR . 10.5 m -86.08 117.48 24.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.126 -0.984 . . . . 0.0 109.626 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.023 HD21 HD11 ' A' ' 351' ' ' LEU . 0.9 OUTLIER -106.25 144.08 33.45 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.202 -0.936 . . . . 0.0 110.766 -179.07 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.559 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 2.2 m120 -126.65 115.9 20.18 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.604 -0.685 . . . . 0.0 109.825 -179.653 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.599 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 11.0 mt -124.9 155.21 39.9 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.633 -1.292 . . . . 0.0 110.262 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -89.8 34.87 0.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.195 -0.94 . . . . 0.0 110.105 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 161.57 -157.44 29.12 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.518 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.2 OUTLIER -96.42 93.62 6.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -1.118 . . . . 0.0 110.706 -179.663 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.599 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.9 m-30 -116.36 143.09 45.99 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.218 -0.926 . . . . 0.0 110.109 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.825 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.6 m-20 -77.89 98.71 5.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.083 -1.011 . . . . 0.0 109.201 179.032 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.844 ' CE3' HD13 ' A' ' 284' ' ' LEU . 54.8 p-90 -98.31 113.32 25.23 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.286 -0.884 . . . . 0.0 110.785 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.623 HG23 ' CG2' ' A' ' 322' ' ' THR . 10.5 m -105.71 115.58 30.48 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 109.526 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.755 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -97.19 113.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.101 -0.999 . . . . 0.0 110.49 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.585 ' HA ' HD13 ' A' ' 320' ' ' ILE . 9.2 ttpt -92.5 135.09 34.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.333 -0.854 . . . . 0.0 109.599 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.758 HG13 HG12 ' A' ' 349' ' ' ILE . 95.0 t -132.26 108.05 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.064 -1.023 . . . . 0.0 110.691 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.477 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtt -70.0 134.55 48.43 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.086 -1.009 . . . . 0.0 109.178 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.967 HD13 ' HA ' ' A' ' 303' ' ' THR . 61.5 mt -88.51 162.48 16.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.181 -0.95 . . . . 0.0 111.723 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.87 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -64.37 176.77 0.65 Allowed Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.779 -0.576 . . . . 0.0 109.877 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.809 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.82 77.28 0.57 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.657 1.346 . . . . 0.0 109.903 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.43 19.73 5.71 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.87 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -103.65 150.18 24.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.415 -1.05 . . . . 0.0 110.248 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.967 ' HA ' HD13 ' A' ' 298' ' ' LEU . 27.0 p -149.92 144.36 25.85 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.267 -0.895 . . . . 0.0 110.642 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.71 HG21 HG11 ' A' ' 319' ' ' VAL . 29.5 t -67.45 136.54 26.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.356 -0.84 . . . . 0.0 109.975 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.8 -41.98 0.54 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.437 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 1.0 OUTLIER -128.94 129.96 46.14 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.134 -1.215 . . . . 0.0 110.756 -179.659 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.593 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.1 p90 -146.39 169.09 19.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.398 -0.814 . . . . 0.0 109.463 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.96 160.98 22.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.878 -1.139 . . . . 0.0 111.23 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.85 20.99 12.55 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.485 -0.759 . . . . 0.0 111.003 179.433 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.573 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 144.33 0.76 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.355 -0.841 . . . . 0.0 110.05 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.542 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.6 m120 -78.51 124.44 28.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.023 -1.048 . . . . 0.0 109.166 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 1.1 ttpt -91.92 138.34 31.62 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.775 0.797 . . . . 0.0 110.916 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.589 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -121.41 173.7 7.21 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.003 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.441 ' HG3' ' HE3' ' A' ' 312' ' ' LYS . 2.5 mt-10 -136.35 106.48 6.34 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.392 -0.817 . . . . 0.0 110.487 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -94.04 40.82 2.69 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 25.1 m120 57.43 82.33 0.13 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.249 -1.148 . . . . 0.0 110.195 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.623 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.84 0.87 57.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.809 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -145.77 -169.62 3.27 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.333 -1.098 . . . . 0.0 109.279 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.809 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.7 t -162.55 157.84 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.216 -0.928 . . . . 0.0 109.8 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.585 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.3 mm -126.65 145.91 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.156 -0.965 . . . . 0.0 111.086 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.637 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.3 m-85 -123.16 128.5 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.125 -0.984 . . . . 0.0 110.195 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.623 ' CG2' HG23 ' A' ' 293' ' ' THR . 25.0 p -129.58 166.37 26.33 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 120.802 -1.187 . . . . 0.0 109.394 179.442 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.509 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.8 Cg_endo -65.22 121.17 8.55 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.698 1.367 . . . . 0.0 111.132 -179.138 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.812 HG22 ' HB2' ' A' ' 327' ' ' ASN . 28.5 m -64.39 -125.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.626 -0.672 . . . . 0.0 110.182 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.482 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.4 m -100.69 -13.12 18.64 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.832 -1.168 . . . . 0.0 110.658 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.688 ' H ' HG23 ' A' ' 324' ' ' VAL . 15.9 p-90 -136.35 6.57 3.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.139 -0.975 . . . . 0.0 110.6 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.812 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.7 OUTLIER -108.4 38.14 2.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.136 -0.977 . . . . 0.0 110.41 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.7 OUTLIER -118.72 -7.69 10.48 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.283 -0.886 . . . . 0.0 110.184 179.76 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.45 -153.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.503 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.4 Cg_endo -76.64 8.34 3.08 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.938 1.494 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.423 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.5 m -163.77 128.08 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.926 -1.109 . . . . 0.0 110.089 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.625 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -146.39 111.33 5.31 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.159 -0.963 . . . . 0.0 110.579 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.898 ' OG1' HG23 ' A' ' 283' ' ' THR . 50.2 m -104.41 126.75 51.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.925 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.755 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.8 p90 -137.08 175.38 9.67 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -154.98 163.3 31.32 Favored Glycine 0 N--CA 1.486 1.982 0 C-N-CA 118.831 -1.652 . . . . 0.0 109.953 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.933 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -147.04 148.34 31.57 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.566 -0.961 . . . . 0.0 109.631 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.933 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.12 121.05 63.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.968 -1.083 . . . . 0.0 109.311 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.706 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.0 t -97.09 159.61 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.683 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -128.03 129.57 46.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.463 -0.773 . . . . 0.0 110.161 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.478 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . 179.26 -129.64 1.4 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.516 ' O ' ' NZ ' ' A' ' 345' ' ' LYS . 43.5 Cg_endo -69.61 171.6 14.01 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.891 1.469 . . . . 0.0 110.486 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.487 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 16.2 mm-40 -94.56 131.47 40.27 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.236 -0.915 . . . . 0.0 110.854 -179.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 115.93 -87.47 0.44 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 344' ' ' ASP . 21.8 p-10 -115.62 131.38 56.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.447 -1.031 . . . . 0.0 109.168 179.254 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.715 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.2 mtmt -129.21 10.54 5.82 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.959 -1.088 . . . . 0.0 110.475 -179.564 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.1 p -133.3 120.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.233 -0.917 . . . . 0.0 110.189 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.436 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -52.5 -45.39 66.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.293 -0.88 . . . . 0.0 110.346 -179.652 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.422 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 5.4 pt-20 -177.09 158.4 1.52 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.049 -1.032 . . . . 0.0 110.905 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.758 HG12 HG13 ' A' ' 296' ' ' VAL . 72.1 mt -120.57 109.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.333 -0.854 . . . . 0.0 110.093 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.05 150.97 26.47 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.319 -0.863 . . . . 0.0 110.384 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.023 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.73 126.31 52.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.35 -0.844 . . . . 0.0 109.995 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.2 tp10 -138.2 110.17 7.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.163 -0.961 . . . . 0.0 109.935 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.825 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.27 111.26 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.469 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 2.1 m-20 39.17 32.35 0.07 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.762 -0.586 . . . . 0.0 110.918 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 114.91 -17.75 17.27 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.351 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.512 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 56.3 mm-40 -89.49 115.64 27.07 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.019 -1.283 . . . . 0.0 110.366 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.837 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.3 p -79.11 130.07 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.294 -0.879 . . . . 0.0 110.224 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.837 HD13 ' O ' ' A' ' 357' ' ' VAL . 18.6 mm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.24 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.72 -177.74 2.68 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.002 1.528 . . . . 0.0 110.762 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 13.3 t -56.9 147.4 23.72 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.489 -0.757 . . . . 0.0 110.693 -179.574 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 259' ' ' THR . . . . . 0.488 HG23 ' O ' ' A' ' 259' ' ' THR . 1.8 t -126.14 115.69 23.8 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.34 -0.85 . . . . 0.0 109.82 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.65 149.32 48.75 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.902 1.474 . . . . 0.0 110.732 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.575 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -79.42 142.67 58.57 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.357 -0.84 . . . . 0.0 110.271 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.575 ' HD2' HG23 ' A' ' 261' ' ' VAL . 47.3 Cg_endo -73.13 125.48 10.35 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 O-C-N 124.125 1.592 . . . . 0.0 110.514 179.763 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.685 HG12 ' O ' ' A' ' 263' ' ' VAL . 64.4 t -117.39 28.98 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.264 -0.897 . . . . 0.0 110.185 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.4 96.18 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.34 -0.85 . . . . 0.0 110.264 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 102.22 166.3 26.73 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.508 ' HB2' ' HB2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -126.84 164.83 20.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.347 -1.09 . . . . 0.0 109.497 179.59 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.929 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.19 140.52 10.33 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.008 -1.077 . . . . 0.0 111.068 -179.561 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.765 ' H ' HD22 ' A' ' 267' ' ' LEU . 5.2 mt-10 -140.07 134.33 31.2 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 109.182 -0.674 . . . . 0.0 109.182 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.741 HG13 ' O ' ' A' ' 281' ' ' ASP . 60.1 t -125.41 136.86 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.807 -1.183 . . . . 0.0 111.648 -178.892 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.51 ' HG3' ' CB ' ' A' ' 281' ' ' ASP . 0.0 OUTLIER -122.96 157.06 33.48 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.55 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.746 HG13 ' O ' ' A' ' 279' ' ' GLU . 88.7 t -142.77 146.9 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.295 -1.503 . . . . 0.0 112.378 -178.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.523 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.49 113.16 8.5 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.986 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.9 p-10 -96.21 147.22 23.99 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.069 -1.02 . . . . 0.0 111.425 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.796 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.7 p90 -132.08 20.86 4.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.489 -0.757 . . . . 0.0 110.056 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.92 -59.52 4.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.04 -24.63 64.21 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.295 -1.121 . . . . 0.0 110.488 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.535 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -173.26 178.6 45.15 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.555 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.75 145.18 49.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -1.166 . . . . 0.0 110.528 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.746 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.3 mt-10 -95.83 147.31 23.79 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.612 -0.68 . . . . 0.0 110.04 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.649 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 94.8 m-85 -140.43 86.1 2.05 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.353 -0.842 . . . . 0.0 110.417 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.741 ' O ' HG13 ' A' ' 269' ' ' VAL . 2.7 t70 -68.88 152.9 44.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.294 -0.879 . . . . 0.0 109.846 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.658 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.6 t -145.21 90.4 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.579 -0.701 . . . . 0.0 109.938 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.691 HG23 ' OG1' ' A' ' 333' ' ' THR . 85.1 m -86.72 126.36 34.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.007 . . . . 0.0 109.865 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.056 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.74 151.13 32.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.264 -0.897 . . . . 0.0 110.905 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.527 ' O ' HD23 ' A' ' 286' ' ' LEU . 1.9 m120 -132.43 128.05 36.65 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.825 . . . . 0.0 110.543 -179.42 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.643 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 5.6 mt -140.41 156.32 46.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.533 -1.355 . . . . 0.0 109.596 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -89.04 39.13 0.92 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.79 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 157.23 -142.8 8.93 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 119.397 -1.382 . . . . 0.0 109.739 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.78 120.96 43.3 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.945 -1.327 . . . . 0.0 110.814 -179.547 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.643 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 10.8 m-85 -142.77 146.81 34.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.283 -0.886 . . . . 0.0 109.909 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.633 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.3 m-20 -75.9 97.33 3.93 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.156 -0.965 . . . . 0.0 109.421 179.287 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.822 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.3 p-90 -98.21 111.59 23.87 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.203 -0.936 . . . . 0.0 110.485 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.662 HG22 ' CG2' ' A' ' 320' ' ' ILE . 6.4 m -104.7 115.98 31.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.642 -0.661 . . . . 0.0 109.894 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.7 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.8 t -97.01 110.89 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.06 -1.025 . . . . 0.0 110.42 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.735 ' HA ' HD13 ' A' ' 320' ' ' ILE . 6.5 ttpt -85.69 144.86 27.58 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.27 -0.893 . . . . 0.0 109.016 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.9 HG22 HG23 ' A' ' 349' ' ' ILE . 30.9 t -141.94 109.72 2.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.779 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.51 ' O ' ' N ' ' A' ' 347' ' ' GLU . 22.4 mmtp -72.57 132.01 43.23 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.212 -0.93 . . . . 0.0 109.476 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.989 HD13 ' HA ' ' A' ' 303' ' ' THR . 67.4 mt -87.31 152.95 21.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.108 -0.995 . . . . 0.0 111.695 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.709 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -60.46 173.76 0.58 Allowed Pre-proline 0 N--CA 1.488 1.439 0 O-C-N 121.62 -0.675 . . . . 0.0 109.364 178.989 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.709 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -68.73 84.59 0.5 Allowed 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.696 1.366 . . . . 0.0 110.038 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.37 26.44 3.71 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.863 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -120.5 145.98 46.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -1.148 . . . . 0.0 110.601 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.989 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.5 p -147.63 145.99 29.18 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.294 -0.879 . . . . 0.0 110.399 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.667 HG21 HG11 ' A' ' 319' ' ' VAL . 70.4 t -74.46 142.41 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.214 -0.929 . . . . 0.0 110.45 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.55 -32.96 0.41 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.3 m -128.87 127.94 42.84 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 111.092 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.501 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.8 p90 -146.59 160.81 41.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.433 -0.792 . . . . 0.0 109.239 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -150.9 157.42 42.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.946 -1.096 . . . . 0.0 110.975 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.498 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.6 OUTLIER 58.6 23.6 11.1 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.765 179.708 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.698 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 140.68 0.71 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.369 -0.832 . . . . 0.0 110.088 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.534 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -78.62 122.4 25.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.07 -1.019 . . . . 0.0 109.735 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.63 ' HG3' HG11 ' A' ' 304' ' ' VAL . 11.1 ttpt -88.85 144.33 26.29 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.766 0.793 . . . . 0.0 110.847 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.772 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -129.7 173.7 10.38 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.39 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.466 ' HG2' HG22 ' A' ' 319' ' ' VAL . 5.3 mt-10 -135.3 103.09 5.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 110.588 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.463 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -89.85 39.09 3.13 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.463 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 5.9 m120 58.5 89.42 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.304 -1.115 . . . . 0.0 110.075 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.39 -0.76 75.26 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.833 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -144.56 -167.89 2.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.446 -1.032 . . . . 0.0 109.095 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.833 HG23 ' O ' ' A' ' 318' ' ' TYR . 2.7 t -163.4 161.64 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 109.713 179.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.735 HD13 ' HA ' ' A' ' 295' ' ' LYS . 25.2 mm -129.28 151.93 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.074 -1.016 . . . . 0.0 110.997 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.641 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 73.4 m-85 -128.36 130.67 48.08 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.225 -0.922 . . . . 0.0 109.963 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.618 HG23 HG23 ' A' ' 293' ' ' THR . 2.2 p -132.96 168.87 15.78 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.727 -1.233 . . . . 0.0 109.991 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.51 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.7 Cg_endo -65.55 121.5 8.91 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.813 1.428 . . . . 0.0 110.981 -179.237 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.684 HG22 ' HB2' ' A' ' 327' ' ' ASN . 19.1 m -66.8 -117.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.47 -0.769 . . . . 0.0 110.087 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.507 ' N ' HG23 ' A' ' 324' ' ' VAL . 57.7 m -108.98 -16.46 14.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.814 -1.179 . . . . 0.0 110.339 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.578 ' H ' HG23 ' A' ' 324' ' ' VAL . 10.6 p-90 -125.96 -18.53 5.05 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.237 -0.915 . . . . 0.0 110.617 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.684 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t30 -87.43 33.21 0.69 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.96 12.07 22.16 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.319 -0.863 . . . . 0.0 109.656 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -84.99 -152.13 16.4 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.564 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 41.4 Cg_endo -68.86 -55.57 0.2 Allowed 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.938 1.494 . . . . 0.0 110.021 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.26 115.22 30.1 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.418 -0.802 . . . . 0.0 110.415 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.494 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -134.49 107.83 7.78 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.251 -0.906 . . . . 0.0 110.101 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.691 ' OG1' HG23 ' A' ' 283' ' ' THR . 97.6 m -103.82 147.64 27.05 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.148 -0.97 . . . . 0.0 110.733 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.7 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.8 p90 -152.35 175.06 13.07 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.493 -0.754 . . . . 0.0 109.102 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.7 160.77 28.95 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.401 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.941 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -147.46 147.4 30.15 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.388 -1.066 . . . . 0.0 110.041 179.633 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.941 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -121.71 123.31 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.013 -1.054 . . . . 0.0 109.958 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.863 HG11 ' HB1' ' A' ' 302' ' ' ALA . 4.6 t -97.12 154.26 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.199 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.32 133.38 53.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.221 -0.924 . . . . 0.0 110.557 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.452 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.18 -132.07 1.87 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.504 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 42.8 Cg_endo -68.86 -158.75 0.05 OUTLIER 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 123.824 1.434 . . . . 0.0 110.298 179.551 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.452 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 1.8 pm0 -122.58 144.72 48.93 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.122 -0.987 . . . . 0.0 110.557 -179.683 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.473 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 97.14 68.25 0.95 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.473 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 3.7 m-20 66.85 140.45 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.41 -1.053 . . . . 0.0 108.966 -179.142 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.574 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.3 OUTLIER -137.92 21.89 2.85 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.911 -1.118 . . . . 0.0 111.119 -179.226 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.62 HG21 HG13 ' A' ' 296' ' ' VAL . 9.0 p -127.53 123.87 62.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.224 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.51 ' N ' ' O ' ' A' ' 297' ' ' LYS . 6.8 mt-10 -55.47 -43.64 75.71 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 110.223 -179.528 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -177.09 159.02 1.6 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 110.513 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 296' ' ' VAL . 45.7 mt -123.13 109.58 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 110.218 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.78 140.66 43.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.32 -0.863 . . . . 0.0 110.143 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.056 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -101.05 130.86 47.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.247 -0.908 . . . . 0.0 110.271 179.995 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -138.86 111.78 7.84 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 110.115 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.633 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 107.82 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.079 -1.013 . . . . 0.0 110.3 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.439 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 4.7 m-20 38.94 37.56 0.22 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.585 -0.697 . . . . 0.0 111.56 179.611 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 106.77 11.12 27.28 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.582 -1.294 . . . . 0.0 110.664 178.866 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 26.4 mm-40 -121.57 101.48 7.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.013 -1.286 . . . . 0.0 110.034 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 1.04 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.9 p -66.56 135.66 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.234 -0.916 . . . . 0.0 110.4 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 1.04 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.3 mm . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.187 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -73.8 -178.26 3.67 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 124.047 1.551 . . . . 0.0 110.505 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.566 HG23 ' O ' ' A' ' 258' ' ' THR . 7.0 t -60.01 125.29 23.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.407 -0.808 . . . . 0.0 110.295 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 8.0 t -62.76 146.3 94.87 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.311 -0.868 . . . . 0.0 110.35 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.23 154.63 56.72 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.046 1.551 . . . . 0.0 110.32 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.437 ' H ' HG12 ' A' ' 261' ' ' VAL . 2.8 p -108.76 139.64 21.06 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.224 -0.922 . . . . 0.0 110.613 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.432 ' HD2' HG23 ' A' ' 261' ' ' VAL . 49.6 Cg_endo -77.33 146.36 24.8 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 124.167 1.614 . . . . 0.0 109.968 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.607 HG12 ' O ' ' A' ' 263' ' ' VAL . 46.3 t -140.31 29.51 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.169 -0.957 . . . . 0.0 110.433 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.481 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 29.0 t 178.96 76.94 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.202 -0.936 . . . . 0.0 110.7 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 122.84 176.97 15.06 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.575 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.61 153.6 51.54 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.504 -0.998 . . . . 0.0 109.473 179.904 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.764 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -147.99 123.56 10.43 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 120.932 -1.105 . . . . 0.0 111.03 -179.451 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.8 OUTLIER -122.36 111.04 16.4 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 178.902 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.575 HG11 HD12 ' A' ' 349' ' ' ILE . 45.4 t -104.99 124.62 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.893 -1.129 . . . . 0.0 111.953 -178.722 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -111.89 156.74 21.57 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.644 HG22 ' CD2' ' A' ' 280' ' ' TYR . 56.9 t -144.84 143.66 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.341 -1.475 . . . . 0.0 112.148 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.544 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -134.52 108.76 8.28 Favored 'General case' 0 N--CA 1.486 1.37 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.08 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 21.0 p30 -96.18 146.78 24.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 111.083 -178.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.856 ' CH2' HG23 ' A' ' 337' ' ' ILE . 31.7 p90 -130.38 17.98 5.38 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.412 -0.805 . . . . 0.0 109.958 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.27 -58.77 3.86 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -73.18 -19.32 61.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 110.458 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.581 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.98 179.44 41.72 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.635 -1.269 . . . . 0.0 109.983 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -138.09 136.6 36.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.442 -1.034 . . . . 0.0 109.97 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.574 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.7 mt-10 -93.84 147.15 23.34 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.378 -0.826 . . . . 0.0 110.478 -179.462 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.832 ' CE2' HG11 ' A' ' 346' ' ' VAL . 92.8 m-85 -139.05 94.96 2.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 110.674 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.543 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -83.5 106.41 15.22 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.538 -0.726 . . . . 0.0 110.271 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.684 HG11 HG11 ' A' ' 294' ' ' VAL . 5.5 t -97.28 94.28 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.493 -0.754 . . . . 0.0 110.17 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.84 HG23 ' OG1' ' A' ' 333' ' ' THR . 3.8 m -86.95 113.47 22.75 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.172 -0.955 . . . . 0.0 109.815 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 0.998 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -102.18 147.94 26.03 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.096 -1.003 . . . . 0.0 110.507 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.575 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -133.36 106.7 7.66 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.516 -0.74 . . . . 0.0 109.636 -179.571 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.603 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.8 mt -113.83 160.75 18.39 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.622 -1.299 . . . . 0.0 110.763 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -89.79 36.64 0.86 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 110.03 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 155.3 -135.25 4.54 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.473 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.2 mm-40 -120.67 113.41 20.18 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.05 -1.265 . . . . 0.0 110.911 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.603 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.1 m-85 -138.74 148.92 44.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.36 -0.838 . . . . 0.0 109.641 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.635 ' O ' HG23 ' A' ' 353' ' ' ILE . 5.4 m-20 -75.53 97.9 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.205 -0.935 . . . . 0.0 109.512 179.488 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.832 ' CE3' HD13 ' A' ' 284' ' ' LEU . 51.5 p-90 -97.07 110.17 22.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.583 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.682 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.2 m -102.34 115.21 30.09 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.331 -0.856 . . . . 0.0 109.44 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.778 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.8 t -97.0 111.09 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 110.54 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.633 ' HA ' HD13 ' A' ' 320' ' ' ILE . 4.5 ttpt -83.15 149.17 27.02 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 108.966 178.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.688 HG22 HG23 ' A' ' 349' ' ' ILE . 53.7 t -145.75 104.73 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.971 -1.081 . . . . 0.0 110.761 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.502 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 7.6 mmtt -70.88 131.28 43.53 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.208 -0.933 . . . . 0.0 109.391 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.994 HD13 ' HA ' ' A' ' 303' ' ' THR . 70.3 mt -87.12 152.49 22.3 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 111.507 -179.056 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.765 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -56.47 176.0 0.21 Allowed Pre-proline 0 C--N 1.301 -1.504 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.081 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.76 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -68.99 79.87 0.69 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 123.554 1.292 . . . . 0.0 109.891 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.19 20.9 5.42 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.482 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.765 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -106.73 149.0 27.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.395 -1.062 . . . . 0.0 109.936 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.994 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.5 p -150.03 144.2 25.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.106 -0.997 . . . . 0.0 111.152 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.771 HG21 HG11 ' A' ' 319' ' ' VAL . 87.4 t -69.59 129.79 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -0.862 . . . . 0.0 109.928 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.25 -28.18 2.91 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 6.8 t -144.66 141.4 29.32 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.007 -1.29 . . . . 0.0 110.744 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.517 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.3 p90 -155.54 168.81 25.93 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.403 -0.811 . . . . 0.0 110.053 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.502 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -158.53 163.72 36.8 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.057 -1.027 . . . . 0.0 110.645 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.521 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.5 OUTLIER 58.41 21.31 8.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.5 -0.75 . . . . 0.0 110.757 179.739 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.683 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 148.84 1.21 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.442 -0.786 . . . . 0.0 110.328 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.683 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.3 m120 -86.78 120.12 27.74 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.225 -0.922 . . . . 0.0 109.379 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.689 ' HG3' HG11 ' A' ' 304' ' ' VAL . 3.6 ttpt -87.63 140.03 29.93 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.892 0.853 . . . . 0.0 110.601 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.648 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.5 175.22 7.28 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -134.84 116.55 14.92 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.316 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.448 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -109.93 39.25 2.97 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 1.4 t30 66.23 90.92 0.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.29 -1.123 . . . . 0.0 110.286 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 81.53 3.31 90.66 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.836 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.9 m-85 -141.52 -172.67 3.58 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -1.135 . . . . 0.0 109.544 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.836 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.5 t -163.38 157.85 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.212 -0.93 . . . . 0.0 109.775 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.648 ' CG2' HG22 ' A' ' 293' ' ' THR . 17.4 mm -125.98 144.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.012 -1.055 . . . . 0.0 111.474 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 56.9 m-85 -121.18 129.33 53.18 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.005 -1.059 . . . . 0.0 109.93 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.682 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.9 p -129.94 168.52 16.29 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 120.864 -1.148 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.53 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.2 Cg_endo -65.95 117.09 4.36 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.76 1.4 . . . . 0.0 111.029 -179.54 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.683 HG12 ' OD1' ' A' ' 311' ' ' ASN . 25.4 m -64.29 -120.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 110.041 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.501 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -104.44 -15.88 15.26 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.776 -1.202 . . . . 0.0 110.665 -179.849 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.599 ' H ' HG23 ' A' ' 324' ' ' VAL . 5.3 p-90 -131.11 -6.85 3.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.132 -0.98 . . . . 0.0 110.822 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.936 ' ND2' ' HB1' ' A' ' 332' ' ' ALA . 12.0 t30 -90.96 38.67 0.96 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.063 -1.023 . . . . 0.0 110.115 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.483 ' HE2' ' O ' ' A' ' 325' ' ' SER . 5.5 pttt -121.26 4.99 10.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.06 -1.025 . . . . 0.0 110.332 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -69.16 -156.38 1.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 50.5 Cg_endo -76.72 7.16 3.66 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.77 1.405 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 19.5 m -164.2 128.25 2.64 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.288 -0.882 . . . . 0.0 109.725 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.936 ' HB1' ' ND2' ' A' ' 327' ' ' ASN . . . -143.89 108.63 4.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 110.319 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.84 ' OG1' HG23 ' A' ' 283' ' ' THR . 89.8 m -100.77 117.54 35.07 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.309 -0.87 . . . . 0.0 109.953 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.778 ' HE2' HG21 ' A' ' 294' ' ' VAL . 7.9 p90 -124.49 171.96 9.56 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.34 158.04 27.5 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.945 -1.597 . . . . 0.0 109.951 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -145.89 146.13 30.98 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.633 -0.922 . . . . 0.0 109.186 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.23 120.23 63.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.684 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.725 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.8 t -95.78 147.84 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.195 -0.941 . . . . 0.0 109.576 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -118.6 134.69 54.91 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.384 -0.822 . . . . 0.0 110.617 -179.37 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.426 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -179.53 -137.91 3.13 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.517 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 44.4 Cg_endo -71.44 -158.28 0.06 OUTLIER 'Trans proline' 0 C--N 1.304 -1.788 0 O-C-N 123.982 1.517 . . . . 0.0 110.142 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 342' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 -118.92 144.55 46.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.034 -1.041 . . . . 0.0 110.456 -179.898 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.439 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 100.31 65.76 0.81 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.439 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 10.5 t70 65.77 134.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.282 -1.128 . . . . 0.0 109.593 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.65 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.6 OUTLIER -133.05 25.17 4.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.23 -0.919 . . . . 0.0 110.685 -179.516 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.832 HG11 ' CE2' ' A' ' 280' ' ' TYR . 4.2 p -132.78 116.5 27.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.028 -1.045 . . . . 0.0 110.831 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.502 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -44.67 -50.08 10.06 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.912 -1.117 . . . . 0.0 109.533 179.787 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -177.48 158.06 1.36 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.382 -0.824 . . . . 0.0 110.482 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.688 HG23 HG22 ' A' ' 296' ' ' VAL . 14.4 mt -117.15 111.62 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.255 -0.903 . . . . 0.0 110.076 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.69 151.65 24.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.285 -0.885 . . . . 0.0 110.376 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 0.998 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -110.27 125.71 53.41 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.321 -0.862 . . . . 0.0 109.812 179.604 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.5 tt0 -137.26 111.41 8.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.184 -0.948 . . . . 0.0 109.832 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.635 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -92.02 109.97 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 110.521 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.443 ' C ' ' O ' ' A' ' 353' ' ' ILE . 5.0 m-20 38.36 31.22 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.546 -0.721 . . . . 0.0 111.061 179.457 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.48 -10.04 16.9 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.563 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.444 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.0 mp0 -97.16 108.4 21.12 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.061 -1.258 . . . . 0.0 110.214 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 357' ' ' VAL . 7.3 p -76.58 110.42 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.335 -0.853 . . . . 0.0 110.249 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.736 ' HB ' HD13 ' A' ' 351' ' ' LEU . 24.2 mm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.146 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.77 -177.57 3.22 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.989 1.52 . . . . 0.0 110.859 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.518 ' CG2' ' O ' ' A' ' 258' ' ' THR . 2.0 t -83.6 123.27 29.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.511 -0.743 . . . . 0.0 110.502 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 21.6 p -119.94 101.59 47.53 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.227 -0.921 . . . . 0.0 110.068 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.99 143.03 35.66 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.918 1.483 . . . . 0.0 110.512 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.61 HG23 ' HD2' ' A' ' 262' ' ' PRO . 6.7 p -66.03 143.84 98.57 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.18 -0.95 . . . . 0.0 110.226 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.811 ' HB2' HG23 ' A' ' 358' ' ' ILE . 50.9 Cg_endo -79.01 149.4 22.56 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 124.153 1.607 . . . . 0.0 110.398 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 3.5 t -115.74 28.38 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.226 -0.921 . . . . 0.0 109.992 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.44 97.69 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.268 -0.895 . . . . 0.0 110.465 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 103.5 173.89 25.98 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.57 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -136.88 157.11 47.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.477 -1.013 . . . . 0.0 109.535 179.863 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.813 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.56 124.38 10.57 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.943 -1.098 . . . . 0.0 110.989 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.482 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 1.4 mm-40 -121.38 113.32 19.73 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.736 HG13 ' O ' ' A' ' 281' ' ' ASP . 38.4 t -109.44 139.67 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 111.668 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.421 ' C ' HG23 ' A' ' 271' ' ' VAL . 4.2 mmtm -123.83 156.58 35.92 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.3 t -145.19 144.7 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.462 -1.399 . . . . 0.0 112.092 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -143.14 112.21 6.61 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 179.315 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.7 p-10 -97.03 144.82 26.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.047 -1.033 . . . . 0.0 111.297 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.5 p90 -129.82 18.62 5.63 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.399 -0.813 . . . . 0.0 109.786 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.507 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 87.58 -61.92 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.67 -23.79 67.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -1.158 . . . . 0.0 110.224 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.82 177.68 46.02 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.603 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -130.58 146.6 52.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.329 -1.101 . . . . 0.0 110.201 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.595 ' O ' HG13 ' A' ' 271' ' ' VAL . 6.2 mt-10 -98.0 147.32 24.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.514 -0.741 . . . . 0.0 109.942 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 95.2 m-85 -144.28 86.37 1.83 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.233 -0.917 . . . . 0.0 110.999 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.736 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.1 OUTLIER -71.17 153.5 42.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.403 -0.811 . . . . 0.0 109.88 179.376 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.646 HG11 HG11 ' A' ' 294' ' ' VAL . 3.5 t -144.82 88.09 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 109.615 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.79 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.5 m -86.03 114.92 23.29 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.683 -179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.018 HD21 HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -101.73 145.57 28.94 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.259 -0.901 . . . . 0.0 110.736 -179.16 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.57 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.8 m120 -129.67 106.86 9.0 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.391 -0.818 . . . . 0.0 110.093 -179.458 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.572 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 7.6 mt -116.62 164.34 14.75 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.648 -1.283 . . . . 0.0 110.299 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -94.04 34.59 1.23 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.402 -0.811 . . . . 0.0 110.458 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.449 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 157.11 -137.52 5.44 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.876 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.484 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mm-40 -113.84 108.26 16.83 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.184 -1.186 . . . . 0.0 111.391 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.572 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.26 135.27 40.77 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.301 -0.874 . . . . 0.0 109.67 178.538 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.537 ' O ' HG23 ' A' ' 353' ' ' ILE . 4.5 m-20 -64.88 97.02 0.2 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.05 -1.032 . . . . 0.0 109.402 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.862 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.3 p-90 -95.07 108.07 20.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.279 -0.888 . . . . 0.0 110.494 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.596 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 32.4 m -101.67 115.48 30.61 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.782 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -96.72 111.54 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.092 -1.005 . . . . 0.0 110.925 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.644 ' HA ' HD13 ' A' ' 320' ' ' ILE . 7.9 ttpt -82.01 149.84 27.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.264 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.822 HG13 HG12 ' A' ' 349' ' ' ILE . 88.7 t -149.02 104.77 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.951 -1.093 . . . . 0.0 110.719 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.521 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 18.9 mmtp -70.35 128.54 36.56 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.223 -0.923 . . . . 0.0 109.658 179.511 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.956 HD13 ' HA ' ' A' ' 303' ' ' THR . 85.5 mt -84.06 165.81 18.24 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.763 0.792 . . . . 0.0 111.377 -179.065 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.788 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -74.33 175.81 3.47 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.623 -0.673 . . . . 0.0 109.726 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.788 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.5 Cg_endo -67.24 83.2 0.36 Allowed 'Trans proline' 0 C--N 1.304 -1.786 0 O-C-N 123.598 1.315 . . . . 0.0 109.84 179.421 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 110.99 22.72 6.12 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.879 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -112.14 144.17 41.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -1.085 . . . . 0.0 110.13 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.956 ' HA ' HD13 ' A' ' 298' ' ' LEU . 13.0 p -147.06 145.18 29.58 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.879 . . . . 0.0 110.332 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.855 HG21 HG11 ' A' ' 319' ' ' VAL . 71.4 t -64.97 120.94 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.38 -0.825 . . . . 0.0 110.11 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.29 -38.6 3.48 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.509 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 24.9 m -139.03 144.25 38.77 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.144 -1.209 . . . . 0.0 110.781 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 5.6 p90 -155.02 160.34 40.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.466 -0.771 . . . . 0.0 109.463 179.553 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.432 ' C ' ' OG ' ' A' ' 309' ' ' SER . 1.0 OUTLIER -151.04 152.87 34.08 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.923 -1.111 . . . . 0.0 111.491 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.522 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.9 OUTLIER 67.24 24.19 9.2 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.663 -0.648 . . . . 0.0 111.054 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.673 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.27 143.41 0.87 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.276 -0.89 . . . . 0.0 110.138 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.669 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.6 m120 -82.37 122.9 28.58 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.15 -0.969 . . . . 0.0 109.182 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.602 ' HG3' HG11 ' A' ' 304' ' ' VAL . 3.1 ttmt -88.7 148.09 24.17 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.861 0.839 . . . . 0.0 111.05 -178.957 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.733 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.74 171.85 13.0 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.36 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -132.96 109.7 9.75 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.179 -0.95 . . . . 0.0 110.345 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.73 39.81 2.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.405 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 8.4 t-20 60.86 92.25 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.346 -1.091 . . . . 0.0 110.474 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.3 2.27 87.76 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.823 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.1 m-85 -145.81 -169.48 3.24 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.339 -1.095 . . . . 0.0 109.27 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.855 HG11 HG21 ' A' ' 304' ' ' VAL . 2.8 t -163.44 161.92 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 179.129 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.644 HD13 ' HA ' ' A' ' 295' ' ' LYS . 5.5 mm -130.19 143.57 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.174 -0.954 . . . . 0.0 111.084 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.652 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 98.6 m-85 -118.61 136.79 53.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.938 . . . . 0.0 109.515 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.549 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.5 p -135.3 168.88 15.47 Favored Pre-proline 0 C--N 1.301 -1.527 0 O-C-N 120.844 -1.16 . . . . 0.0 110.303 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.557 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 40.5 Cg_endo -67.03 121.09 8.21 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 124.127 1.593 . . . . 0.0 110.85 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.877 HG22 ' HB2' ' A' ' 327' ' ' ASN . 27.0 m -73.22 -129.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.845 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.606 ' N ' HG23 ' A' ' 324' ' ' VAL . 18.1 p -100.17 -19.15 16.57 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.904 -1.122 . . . . 0.0 110.346 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.758 ' H ' HG23 ' A' ' 324' ' ' VAL . 23.7 p-90 -125.96 11.08 7.68 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.108 -0.995 . . . . 0.0 110.507 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.877 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -117.63 49.58 1.21 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.073 -1.017 . . . . 0.0 110.254 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.557 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -125.57 -12.47 6.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -0.865 . . . . 0.0 110.134 -179.902 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.09 -160.95 0.02 OUTLIER Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.9 Cg_endo -73.4 3.53 4.66 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.905 1.477 . . . . 0.0 110.872 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.97 117.67 3.28 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.171 -0.955 . . . . 0.0 110.088 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.565 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.03 108.6 5.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.253 -0.904 . . . . 0.0 110.077 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.79 ' OG1' HG23 ' A' ' 283' ' ' THR . 60.7 m -99.81 138.63 36.62 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.287 -0.883 . . . . 0.0 110.449 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.782 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.9 p90 -145.92 157.36 43.9 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -134.33 164.27 24.57 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.088 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.878 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -149.74 143.4 25.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.483 -1.01 . . . . 0.0 109.469 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.878 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -117.16 120.55 65.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.115 -0.991 . . . . 0.0 109.689 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.879 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.6 t -96.79 149.93 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.203 -0.936 . . . . 0.0 109.817 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.2 m120 -121.77 131.54 54.12 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.16 -0.963 . . . . 0.0 111.061 -179.167 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.54 -120.79 0.73 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.52 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 41.4 Cg_endo -68.01 -151.7 0.03 OUTLIER 'Trans proline' 0 C--N 1.306 -1.71 0 O-C-N 123.819 1.431 . . . . 0.0 109.61 178.792 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.507 ' HB3' ' HA2' ' A' ' 275' ' ' GLY . 0.0 OUTLIER -134.17 139.99 46.23 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.737 -1.227 . . . . 0.0 110.731 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 100.78 -79.73 0.44 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -115.81 119.85 37.35 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.476 -1.014 . . . . 0.0 109.118 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.69 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.4 OUTLIER -124.03 10.99 8.86 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.084 -1.01 . . . . 0.0 110.24 -179.49 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.58 HG13 ' O ' ' A' ' 346' ' ' VAL . 10.7 p -133.84 116.73 24.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.399 -0.813 . . . . 0.0 110.002 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 1.5 mt-10 -47.16 -47.1 23.91 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.174 -0.954 . . . . 0.0 110.164 -179.549 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -177.01 158.92 1.61 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.401 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.822 HG12 HG13 ' A' ' 296' ' ' VAL . 26.4 mt -118.2 119.42 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.23 -0.919 . . . . 0.0 110.101 179.788 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.49 151.33 33.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.301 -0.874 . . . . 0.0 110.267 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.018 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -108.96 126.83 53.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.252 -0.905 . . . . 0.0 109.725 179.661 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.444 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.5 tp10 -138.19 113.11 9.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.077 -1.014 . . . . 0.0 110.373 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.537 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -93.07 103.66 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.183 -0.948 . . . . 0.0 110.003 179.725 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.407 ' OD1' ' HB2' ' A' ' 291' ' ' ASP . 4.1 m-20 43.55 30.55 0.35 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.459 -0.775 . . . . 0.0 110.46 -179.85 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 117.63 -22.65 9.95 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.445 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 3.3 mp0 -82.41 99.58 9.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 110.127 -179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.686 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.4 p -69.96 113.76 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.246 -0.909 . . . . 0.0 110.173 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.811 HG23 ' HB2' ' A' ' 262' ' ' PRO . 25.9 mm . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.119 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.74 179.37 5.3 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 124.035 1.545 . . . . 0.0 110.629 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 5.4 t -58.71 146.39 36.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -0.897 . . . . 0.0 110.191 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -88.37 168.7 15.5 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.244 -0.91 . . . . 0.0 110.13 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.88 133.9 20.79 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.993 1.523 . . . . 0.0 110.371 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.636 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.5 p -79.16 144.85 63.64 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.285 -0.885 . . . . 0.0 110.337 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.636 ' HD2' HG23 ' A' ' 261' ' ' VAL . 49.4 Cg_endo -76.11 151.04 34.24 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 124.094 1.576 . . . . 0.0 110.671 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.744 HG12 ' O ' ' A' ' 263' ' ' VAL . 68.7 t -130.54 25.43 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.341 -0.849 . . . . 0.0 109.884 179.618 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.498 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.4 OUTLIER 168.49 55.43 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.184 -0.947 . . . . 0.0 110.449 179.922 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 158.94 165.28 15.7 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.585 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -130.81 150.54 51.94 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.4 -1.059 . . . . 0.0 109.978 179.924 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.873 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -145.2 125.87 14.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.036 -1.04 . . . . 0.0 110.781 -179.676 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.488 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 15.0 mm-40 -124.51 110.99 15.17 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.491 -0.756 . . . . 0.0 108.996 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.936 HG13 ' O ' ' A' ' 281' ' ' ASP . 85.6 t -110.53 145.19 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 120.942 -1.098 . . . . 0.0 111.827 -178.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -130.86 157.74 42.07 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.136 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.81 HG13 ' O ' ' A' ' 279' ' ' GLU . 97.5 t -141.69 146.75 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 120.237 -1.539 . . . . 0.0 112.454 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.02 110.28 6.91 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.11 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 43.8 p-10 -95.68 145.36 25.34 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.062 -1.024 . . . . 0.0 111.379 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.835 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.4 p90 -130.95 22.77 4.93 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.36 -0.837 . . . . 0.0 109.858 179.088 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.602 ' O ' ' NE2' ' A' ' 342' ' ' GLN . . . 85.81 -68.82 3.32 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.482 ' HG ' ' HE1' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -61.22 -27.41 68.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.253 -1.145 . . . . 0.0 110.685 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.533 ' C ' ' CE2' ' A' ' 274' ' ' TRP . . . -166.3 178.52 40.8 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.568 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.72 145.28 48.33 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.275 -1.132 . . . . 0.0 110.512 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.81 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -97.22 147.17 24.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 109.973 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.657 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 88.5 m-85 -142.08 83.77 1.85 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.274 -0.891 . . . . 0.0 110.523 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.936 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.14 153.19 44.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.289 -0.882 . . . . 0.0 110.123 179.551 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 294' ' ' VAL . 5.4 t -144.87 90.36 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.531 -0.73 . . . . 0.0 109.667 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.832 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.5 m -86.28 123.66 31.79 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.134 -0.979 . . . . 0.0 109.362 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.082 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -109.71 148.26 31.71 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.072 -1.017 . . . . 0.0 111.28 -178.85 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.585 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -134.33 107.37 7.59 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.607 -0.683 . . . . 0.0 109.975 -179.45 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.534 ' N ' ' O ' ' A' ' 330' ' ' PRO . 9.7 mt -115.53 163.27 16.0 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.897 -1.127 . . . . 0.0 109.805 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 287' ' ' ASP . . . . . 0.469 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 2.1 t0 -91.64 31.28 1.21 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.552 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.54 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 163.76 -164.33 36.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.545 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -93.76 94.87 8.79 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.176 -1.19 . . . . 0.0 110.599 -179.738 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 1.9 m-85 -120.96 171.44 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.181 -0.95 . . . . 0.0 109.793 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.834 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.2 OUTLIER -95.78 99.34 11.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.655 179.392 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.905 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.1 p-90 -97.29 113.99 25.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.309 -0.869 . . . . 0.0 110.624 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.576 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 99.1 m -106.75 113.38 26.84 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.464 -0.773 . . . . 0.0 109.176 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 282' ' ' VAL . 4.6 t -96.37 110.81 25.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.184 -0.948 . . . . 0.0 110.137 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.517 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 6.4 ttmt -84.77 149.07 26.0 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.208 -0.933 . . . . 0.0 109.197 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.857 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 45.9 t -144.63 106.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 O-C-N 121.403 -0.811 . . . . 0.0 109.93 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.513 ' O ' HG23 ' A' ' 346' ' ' VAL . 34.9 mmtt -71.1 134.69 47.21 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.114 -0.991 . . . . 0.0 109.704 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.906 HD13 ' HA ' ' A' ' 303' ' ' THR . 92.7 mt -87.59 162.57 17.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 111.569 -179.083 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.661 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -75.65 171.57 11.59 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.661 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.4 84.61 0.47 Allowed 'Trans proline' 0 C--N 1.301 -1.945 0 O-C-N 123.684 1.36 . . . . 0.0 109.798 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 301' ' ' GLY . . . . . 0.442 ' O ' ' HA3' ' A' ' 340' ' ' GLY . . . 116.26 26.02 3.33 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 1.024 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -126.51 138.26 53.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -1.139 . . . . 0.0 110.257 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.906 ' HA ' HD13 ' A' ' 298' ' ' LEU . 7.2 p -141.43 145.83 35.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 110.419 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.749 ' CG2' HG21 ' A' ' 319' ' ' VAL . 98.2 t -71.82 124.28 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.366 -0.834 . . . . 0.0 110.225 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.4 -34.84 1.26 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.433 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 2.7 m -122.45 110.15 15.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.025 -1.28 . . . . 0.0 110.716 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.602 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 11.9 p90 -134.23 153.92 51.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.856 . . . . 0.0 109.788 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.475 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -149.19 161.37 42.13 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.05 -1.031 . . . . 0.0 111.155 -179.35 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.545 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.23 28.71 15.54 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.542 -0.723 . . . . 0.0 111.224 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.711 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.9 145.44 0.66 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.038 -1.039 . . . . 0.0 110.553 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 3.7 m120 -78.13 118.74 20.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -0.998 . . . . 0.0 109.238 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.602 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 19.9 ttpt -92.2 115.7 28.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.546 -0.721 . . . . 0.0 111.083 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.616 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.6 tt0 -102.97 176.31 5.19 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.327 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.447 ' HG3' HG22 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -139.02 105.95 5.42 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -0.981 . . . . 0.0 110.773 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -95.26 43.79 2.2 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 58.52 91.06 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.321 -1.105 . . . . 0.0 110.126 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.629 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 84.33 5.12 87.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.707 ' O ' HG23 ' A' ' 319' ' ' VAL . 7.0 m-85 -141.93 -178.53 5.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.413 -1.051 . . . . 0.0 109.078 179.404 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.749 HG21 ' CG2' ' A' ' 304' ' ' VAL . 39.9 t -159.4 148.98 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.149 -0.969 . . . . 0.0 109.986 179.126 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.616 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 1.7 mm -114.9 151.56 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.112 -0.992 . . . . 0.0 110.497 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.659 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 76.5 m-85 -130.69 112.78 13.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.101 -0.999 . . . . 0.0 109.866 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.584 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 3.7 p -116.49 171.07 5.09 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 120.627 -1.296 . . . . 0.0 109.786 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.584 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.9 Cg_endo -69.2 120.96 7.77 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 O-C-N 123.652 1.343 . . . . 0.0 110.727 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.656 HG22 ' CG ' ' A' ' 327' ' ' ASN . 16.0 m -64.12 -113.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.482 -0.761 . . . . 0.0 110.224 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.531 ' HG ' ' HD1' ' A' ' 326' ' ' TRP . 14.1 p -120.17 -12.47 9.06 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.753 -1.217 . . . . 0.0 110.688 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.531 ' HD1' ' HG ' ' A' ' 325' ' ' SER . 24.8 p-90 -128.9 17.01 6.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 0.0 110.921 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.656 ' CG ' HG22 ' A' ' 324' ' ' VAL . 28.8 p-10 -135.56 45.07 2.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.079 . . . . 0.0 110.921 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.539 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -116.05 7.96 14.41 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.097 -1.002 . . . . 0.0 109.847 179.774 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 329' ' ' GLY . . . . . . . . . . . . . . . -74.67 -153.72 3.54 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.124 -1.191 . . . . 0.0 110.124 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.54 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 50.5 Cg_endo -75.61 4.66 4.85 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 124.182 1.622 . . . . 0.0 110.925 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.6 m -165.25 123.54 1.64 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.158 -0.964 . . . . 0.0 110.253 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.627 ' HB1' ' HB2' ' A' ' 327' ' ' ASN . . . -150.72 120.28 6.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.848 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.832 ' OG1' HG23 ' A' ' 283' ' ' THR . 34.0 m -104.32 144.66 31.33 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.229 -0.92 . . . . 0.0 110.441 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.779 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.0 p90 -149.78 168.82 22.62 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.37 159.84 28.16 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 118.744 -1.693 . . . . 0.0 110.535 -179.209 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.882 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.6 p90 -144.2 145.02 31.81 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.648 -0.913 . . . . 0.0 109.679 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.882 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.98 120.99 65.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.626 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 1.024 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 19.8 t -97.71 142.65 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 110.399 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.6 m120 -115.55 130.09 56.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 110.133 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 301' ' ' GLY . . . -175.93 -136.38 2.33 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.487 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 47.0 Cg_endo -72.14 -169.42 0.45 Allowed 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 124.078 1.567 . . . . 0.0 110.579 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.602 ' NE2' ' O ' ' A' ' 275' ' ' GLY . 3.8 mm100 -107.43 145.38 33.06 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.235 -0.915 . . . . 0.0 110.087 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 97.9 72.16 1.06 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.473 ' O ' ' O ' ' A' ' 343' ' ' GLY . 1.2 t70 61.1 140.81 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.328 -1.101 . . . . 0.0 109.171 -179.24 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.628 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.3 mtmt -134.65 18.09 3.59 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.006 -1.059 . . . . 0.0 110.463 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.582 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.8 p -130.58 118.21 41.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.311 -0.868 . . . . 0.0 110.22 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.432 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -48.33 -45.9 35.8 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.378 -0.826 . . . . 0.0 110.575 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.42 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 2.5 pt-20 -177.02 159.39 1.67 Allowed 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.847 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.549 HG12 HG13 ' A' ' 296' ' ' VAL . 14.2 mt -119.6 114.6 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.254 -0.904 . . . . 0.0 110.439 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -113.91 158.2 21.41 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.148 -0.97 . . . . 0.0 109.855 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.082 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.42 126.63 51.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.253 -0.905 . . . . 0.0 110.633 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.0 OUTLIER -139.25 119.76 13.99 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.864 179.45 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.834 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -90.81 93.01 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.924 -1.11 . . . . 0.0 110.22 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.448 ' CG ' ' HB3' ' A' ' 291' ' ' ASP . 5.1 m-20 46.94 31.96 1.68 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.817 -0.552 . . . . 0.0 111.249 179.496 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 132.13 -33.86 2.63 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.651 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 66.0 mm-40 -89.92 117.61 28.87 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.987 -1.302 . . . . 0.0 110.745 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 4.0 p -78.93 124.07 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.298 -0.876 . . . . 0.0 110.135 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.683 ' HB ' HD13 ' A' ' 351' ' ' LEU . 21.5 mm . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.092 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.37 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.26 -177.75 2.87 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 O-C-N 123.935 1.492 . . . . 0.0 110.575 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.618 HG23 ' O ' ' A' ' 258' ' ' THR . 14.4 t -57.13 122.8 13.26 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -0.82 . . . . 0.0 110.598 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 19.7 p -133.82 94.43 18.87 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.344 -0.848 . . . . 0.0 109.858 179.705 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.29 130.14 15.91 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.059 1.557 . . . . 0.0 110.606 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.622 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -66.59 143.56 98.21 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.281 -0.887 . . . . 0.0 110.025 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.622 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.7 Cg_endo -73.53 125.67 10.29 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 O-C-N 124.044 1.549 . . . . 0.0 110.542 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.512 HG12 ' O ' ' A' ' 263' ' ' VAL . 19.8 t -124.13 30.42 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.212 -0.93 . . . . 0.0 110.07 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -163.24 102.85 0.97 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.237 -0.914 . . . . 0.0 110.442 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 84.28 -169.88 46.22 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.554 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.58 162.67 33.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.371 -1.076 . . . . 0.0 109.87 179.837 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.947 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -159.92 138.27 10.33 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.143 -1.023 . . . . 0.0 111.15 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.74 ' N ' HD22 ' A' ' 267' ' ' LEU . 18.8 mt-10 -141.15 136.57 31.98 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.819 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -128.11 144.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.618 -1.301 . . . . 0.0 112.306 -178.509 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.405 ' C ' HG23 ' A' ' 271' ' ' VAL . 63.3 mttt -128.65 157.74 40.49 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.844 HG13 ' O ' ' A' ' 279' ' ' GLU . 98.7 t -144.36 147.38 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 120.346 -1.472 . . . . 0.0 112.319 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.525 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.12 110.63 6.38 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.737 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -96.13 149.08 22.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.988 -1.07 . . . . 0.0 111.503 -178.465 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.82 ' CH2' HG23 ' A' ' 337' ' ' ILE . 28.1 p90 -129.46 18.42 5.84 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-O 121.447 0.641 . . . . 0.0 109.691 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.42 -61.63 3.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.67 -25.26 65.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 110.383 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.522 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -167.56 178.93 41.31 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.449 -1.358 . . . . 0.0 109.95 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.3 144.63 48.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -1.103 . . . . 0.0 110.345 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.844 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -97.47 145.92 25.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.396 -0.815 . . . . 0.0 109.828 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.731 ' CE1' HG11 ' A' ' 346' ' ' VAL . 98.9 m-85 -137.9 87.72 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.827 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.819 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -70.88 140.91 51.21 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.483 179.13 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.675 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.8 t -133.89 91.7 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.568 -0.708 . . . . 0.0 109.803 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.861 HG23 ' OG1' ' A' ' 333' ' ' THR . 9.0 m -86.49 124.2 32.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 109.977 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.82 148.41 38.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 110.832 -179.427 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -128.66 137.43 51.64 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.434 -0.791 . . . . 0.0 109.823 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.5 mt -142.42 159.7 41.71 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.794 -1.191 . . . . 0.0 109.759 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.94 36.02 0.97 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.361 -0.837 . . . . 0.0 110.31 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.479 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 152.07 -100.94 0.21 Allowed Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.139 -1.505 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.554 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 15.9 mm-40 -141.8 111.93 6.88 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.024 -1.28 . . . . 0.0 110.881 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.639 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 5.5 m-85 -135.51 138.36 43.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.687 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.801 ' O ' HG23 ' A' ' 353' ' ' ILE . 5.5 m-20 -74.17 96.87 2.82 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.002 -1.061 . . . . 0.0 108.905 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.938 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.1 p-90 -97.45 114.87 26.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 0.0 110.568 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.707 HG23 HG23 ' A' ' 322' ' ' THR . 28.7 m -109.45 116.09 31.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.694 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.8 t -96.83 111.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 0.0 110.528 -179.486 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.577 ' HA ' HD13 ' A' ' 320' ' ' ILE . 28.9 ttpt -91.64 130.19 37.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.659 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.745 HG13 HG12 ' A' ' 349' ' ' ILE . 80.2 t -126.58 115.87 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.185 -0.947 . . . . 0.0 111.103 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.571 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 55.7 mmtt -73.21 134.23 44.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.149 -0.97 . . . . 0.0 109.269 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.974 HD13 ' HA ' ' A' ' 303' ' ' THR . 80.1 mt -88.15 159.38 18.22 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.324 -0.86 . . . . 0.0 111.466 -178.833 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.881 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.18 178.09 0.56 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.68 -0.638 . . . . 0.0 110.025 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.864 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.24 79.06 0.6 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.718 1.378 . . . . 0.0 109.662 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.89 21.15 6.11 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.881 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -106.05 144.37 32.85 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.417 -1.049 . . . . 0.0 110.241 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.974 ' HA ' HD13 ' A' ' 298' ' ' LEU . 10.8 p -145.75 145.95 31.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.3 -0.875 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.822 HG21 HG11 ' A' ' 319' ' ' VAL . 76.1 t -70.99 134.83 29.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.329 -0.857 . . . . 0.0 109.88 179.676 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.45 -37.29 0.8 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.081 -179.507 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 67.6 m -131.55 128.15 38.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.06 -1.259 . . . . 0.0 110.919 -179.563 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.7 p90 -144.78 157.73 44.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.377 -0.827 . . . . 0.0 109.794 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.487 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -150.55 159.52 44.44 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.007 -1.058 . . . . 0.0 111.236 -179.329 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.53 ' OG ' ' CZ3' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 59.45 24.81 13.49 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.562 -0.712 . . . . 0.0 110.679 179.735 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.72 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 142.56 0.77 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 110.213 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.706 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.6 m120 -81.09 113.97 19.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.084 -1.01 . . . . 0.0 109.383 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.559 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 18.6 ttpt -82.56 149.71 27.33 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-O 121.762 0.792 . . . . 0.0 110.459 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.823 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -134.13 170.63 15.39 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.481 ' HG2' HG22 ' A' ' 319' ' ' VAL . 15.8 mt-10 -142.41 95.17 2.75 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.595 -0.69 . . . . 0.0 110.165 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.14 -80.28 0.44 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -160.93 77.5 0.58 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.433 -1.04 . . . . 0.0 108.812 179.687 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.617 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.34 11.25 54.64 Favored Glycine 0 N--CA 1.487 2.082 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.812 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.3 m-85 -143.06 -166.97 2.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.736 -0.861 . . . . 0.0 108.709 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.823 HG22 ' O ' ' A' ' 313' ' ' GLN . 2.5 t -163.52 160.19 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.01 -1.056 . . . . 0.0 109.454 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.773 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.3 mm -128.98 145.22 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.891 -1.131 . . . . 0.0 111.136 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.0 m-85 -123.04 129.33 51.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.156 -0.965 . . . . 0.0 110.378 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.707 HG23 HG23 ' A' ' 293' ' ' THR . 3.0 p -131.01 167.73 20.32 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 120.72 -1.237 . . . . 0.0 110.014 179.33 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.512 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.0 Cg_endo -66.1 128.68 20.07 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.861 1.453 . . . . 0.0 110.915 -179.293 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.772 HG22 ' HB2' ' A' ' 327' ' ' ASN . 34.6 m -78.01 -122.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.51 -0.744 . . . . 0.0 110.114 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.598 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -101.83 -21.43 14.58 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.757 -1.214 . . . . 0.0 110.631 -179.651 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.61 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.9 p-90 -126.46 5.55 6.91 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.173 -0.955 . . . . 0.0 110.578 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.772 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.8 OUTLIER -108.39 49.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.156 -0.965 . . . . 0.0 110.125 -179.8 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.478 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -133.84 -4.83 2.82 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.107 -0.996 . . . . 0.0 110.404 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.466 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.56 -155.72 0.05 OUTLIER Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.426 ' C ' ' OG1' ' A' ' 331' ' ' THR . 46.9 Cg_endo -73.65 3.06 5.18 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.915 1.482 . . . . 0.0 110.749 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.426 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.8 m -163.03 120.52 1.94 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 110.061 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.561 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -141.0 112.71 7.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.261 -0.899 . . . . 0.0 110.277 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.861 ' OG1' HG23 ' A' ' 283' ' ' THR . 38.1 m -104.49 138.92 40.16 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 110.049 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.72 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 13.6 p90 -142.85 172.37 12.79 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.89 160.29 28.44 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 118.755 -1.688 . . . . 0.0 110.333 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.919 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -147.32 145.24 29.28 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.481 -1.011 . . . . 0.0 110.048 179.485 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.919 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.81 119.86 61.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.094 -1.004 . . . . 0.0 109.783 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.799 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.8 t -96.96 145.83 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.8 m120 -112.68 126.51 55.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 110.014 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -172.42 -132.35 1.49 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 43.6 Cg_endo -69.15 -163.14 0.09 OUTLIER 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 123.807 1.425 . . . . 0.0 110.754 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.442 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 2.6 pm0 -126.53 126.53 43.84 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.187 -0.946 . . . . 0.0 110.845 -179.362 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.402 ' O ' ' HB3' ' A' ' 344' ' ' ASP . . . 118.08 -21.28 10.27 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.402 ' HB3' ' O ' ' A' ' 343' ' ' GLY . 2.6 p-10 176.79 124.54 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.686 -0.891 . . . . 0.0 108.803 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.698 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.3 mtmt -127.48 11.18 6.8 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 118.773 -1.171 . . . . 0.0 111.076 -179.148 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.731 HG11 ' CE1' ' A' ' 280' ' ' TYR . 4.3 p -133.59 120.08 36.38 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.203 -0.935 . . . . 0.0 110.402 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.5 mm-40 -50.2 -47.02 54.91 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.979 -1.076 . . . . 0.0 109.643 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.444 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 1.2 pt-20 -177.88 158.99 1.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.616 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.745 HG12 HG13 ' A' ' 296' ' ' VAL . 62.9 mt -118.67 121.77 67.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.268 -0.895 . . . . 0.0 110.22 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.76 139.75 53.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.193 -0.942 . . . . 0.0 110.215 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.41 130.61 45.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.177 -0.952 . . . . 0.0 110.284 179.818 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.442 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.8 OUTLIER -138.0 110.64 7.57 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.354 -0.842 . . . . 0.0 109.572 179.784 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.801 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 110.01 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.973 . . . . 0.0 110.464 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.463 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 5.9 m-20 39.12 31.21 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.661 -0.649 . . . . 0.0 110.52 179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.54 -19.3 12.83 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.411 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.8 OUTLIER -85.82 104.39 15.45 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.2 -1.176 . . . . 0.0 110.437 -179.868 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.848 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.0 p -72.03 128.66 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.09 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.848 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.1 mm . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.156 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -74.24 -178.82 4.18 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.102 1.58 . . . . 0.0 110.535 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.452 HG23 ' O ' ' A' ' 258' ' ' THR . 6.0 t -59.21 130.65 47.98 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 110.081 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 9.4 t -135.83 145.03 51.14 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.206 -0.934 . . . . 0.0 110.476 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.83 162.03 42.19 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.098 1.578 . . . . 0.0 110.185 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.629 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.0 p -113.64 144.53 31.56 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.15 -0.968 . . . . 0.0 110.359 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.629 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.1 Cg_endo -76.75 127.55 9.58 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.07 1.563 . . . . 0.0 110.627 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.711 HG12 ' O ' ' A' ' 263' ' ' VAL . 86.7 t -117.18 30.44 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.227 -0.921 . . . . 0.0 110.325 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 4.3 t 174.21 129.26 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.24 -0.913 . . . . 0.0 110.563 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 74.61 179.27 41.71 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.56 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.553 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -133.74 163.24 29.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.397 -1.061 . . . . 0.0 109.865 179.862 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.87 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.6 tm? -161.59 133.34 5.58 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.055 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.794 ' N ' HD22 ' A' ' 267' ' ' LEU . 7.9 mt-10 -132.92 128.1 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 281' ' ' ASP . 61.9 t -120.28 137.28 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 120.894 -1.129 . . . . 0.0 111.569 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.51 156.93 33.13 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.703 HG13 ' O ' ' A' ' 279' ' ' GLU . 78.1 t -142.56 145.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.325 -1.484 . . . . 0.0 112.288 -179.305 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.547 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -138.57 111.38 7.72 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.443 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.0 147.04 23.83 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.209 -0.932 . . . . 0.0 111.304 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.843 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.2 p90 -131.92 16.16 4.72 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.455 -0.778 . . . . 0.0 109.818 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.62 -60.27 3.24 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.49 -23.3 66.23 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.124 . . . . 0.0 110.302 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.579 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.14 -178.53 45.06 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.618 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.31 142.9 47.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 110.554 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.703 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.6 mt-10 -93.93 147.21 23.31 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.53 -0.731 . . . . 0.0 109.653 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.661 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 96.9 m-85 -141.53 83.93 1.88 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.38 -0.825 . . . . 0.0 110.45 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.772 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.12 151.74 47.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.377 -0.827 . . . . 0.0 109.943 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.699 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -143.96 88.56 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.436 -0.79 . . . . 0.0 109.691 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.602 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.3 m -86.09 117.25 24.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 109.628 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.063 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -105.52 150.4 25.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.242 -0.912 . . . . 0.0 110.575 -179.263 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.897 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -131.15 134.95 47.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.451 -0.78 . . . . 0.0 110.016 -179.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.3 mt -142.32 152.07 42.59 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.811 -1.181 . . . . 0.0 109.535 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.89 38.49 0.92 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.31 -0.869 . . . . 0.0 109.3 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.98 -139.12 5.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.558 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 3.6 mt-30 -118.09 96.05 5.17 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.059 -1.26 . . . . 0.0 110.959 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.6 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -121.29 133.58 55.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.362 -0.836 . . . . 0.0 110.025 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.789 ' O ' HG23 ' A' ' 353' ' ' ILE . 67.6 m-20 -65.35 109.92 2.45 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.122 -0.986 . . . . 0.0 109.624 179.438 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.88 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.0 p-90 -107.99 116.15 31.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.105 -0.997 . . . . 0.0 110.835 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.604 HG23 HG23 ' A' ' 322' ' ' THR . 54.8 m -110.25 115.92 30.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.426 -0.797 . . . . 0.0 109.902 179.835 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.771 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.7 t -96.8 111.3 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.16 -0.963 . . . . 0.0 110.608 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.507 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.3 ttpt -90.07 130.11 36.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.254 -0.904 . . . . 0.0 109.404 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.82 HG22 HG23 ' A' ' 349' ' ' ILE . 76.3 t -127.86 108.1 17.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.254 -0.903 . . . . 0.0 110.513 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.662 ' O ' HG23 ' A' ' 346' ' ' VAL . 24.9 mmtt -70.08 138.3 51.91 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.148 -0.97 . . . . 0.0 109.09 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.968 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.7 mt -90.61 156.58 18.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.495 -0.753 . . . . 0.0 111.609 -178.553 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.801 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -60.72 175.33 0.44 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.629 -0.669 . . . . 0.0 109.381 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.57 80.53 0.6 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.547 1.288 . . . . 0.0 110.009 179.755 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.76 21.27 5.77 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.801 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 152.89 23.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -1.045 . . . . 0.0 110.064 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.968 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -153.16 146.51 24.85 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.077 -1.014 . . . . 0.0 111.312 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.879 HG21 HG11 ' A' ' 319' ' ' VAL . 63.7 t -63.88 142.16 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.372 -0.83 . . . . 0.0 109.97 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 305' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -121.77 -39.63 0.56 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -142.01 120.17 12.18 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.045 -1.268 . . . . 0.0 110.713 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.511 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.7 p90 -132.88 166.41 22.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.905 . . . . 0.0 110.021 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -157.68 160.6 38.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.161 -0.962 . . . . 0.0 111.197 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 60.25 23.17 12.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 110.881 179.502 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.591 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.99 144.88 0.78 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.352 -0.843 . . . . 0.0 109.854 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.517 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.3 m120 -83.43 122.48 28.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.028 -1.045 . . . . 0.0 109.43 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.508 ' HG2' HG13 ' A' ' 319' ' ' VAL . 4.2 ttpt -89.7 140.29 29.72 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.877 0.846 . . . . 0.0 110.609 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.561 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.41 176.11 7.03 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -137.63 107.15 6.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.409 -0.807 . . . . 0.0 110.247 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.47 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -98.06 37.4 3.49 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.47 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.6 OUTLIER 68.43 88.17 0.11 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.226 -1.161 . . . . 0.0 110.448 179.852 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.37 6.95 83.34 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.801 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.0 m-85 -146.35 -170.81 3.59 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.305 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.879 HG11 HG21 ' A' ' 304' ' ' VAL . 6.5 t -162.28 156.25 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.894 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.53 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.2 mm -125.79 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.888 -1.133 . . . . 0.0 111.476 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 36.9 m-85 -114.37 131.18 56.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.273 -0.892 . . . . 0.0 109.532 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.604 HG23 HG23 ' A' ' 293' ' ' THR . 1.8 p -132.06 169.94 12.59 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 120.624 -1.297 . . . . 0.0 110.317 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -64.92 109.37 1.27 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.883 1.465 . . . . 0.0 110.923 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.735 HG23 ' H ' ' A' ' 325' ' ' SER . 6.2 m -48.18 -59.0 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.427 -0.796 . . . . 0.0 110.63 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.735 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.6 t 177.89 -25.91 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.991 -1.068 . . . . 0.0 111.133 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.428 ' CE2' HG21 ' A' ' 324' ' ' VAL . 7.1 p-90 -113.85 -22.87 9.93 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.958 -1.089 . . . . 0.0 110.912 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.985 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 46.0 p-10 -83.36 12.18 5.79 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.991 -1.068 . . . . 0.0 110.929 179.928 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 12.1 mtmt -74.12 -11.07 60.2 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.46 -0.775 . . . . 0.0 109.329 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.21 -158.13 0.01 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.542 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -73.06 7.14 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 124.069 1.562 . . . . 0.0 111.388 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 4.4 m -162.32 131.23 4.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.123 -0.986 . . . . 0.0 109.841 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.985 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -144.23 104.37 4.1 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.231 -0.918 . . . . 0.0 110.355 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.602 ' OG1' HG23 ' A' ' 283' ' ' THR . 48.2 m -100.98 135.16 42.87 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.058 -1.027 . . . . 0.0 110.312 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.771 ' HE2' HG21 ' A' ' 294' ' ' VAL . 6.6 p90 -144.39 173.14 12.04 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.439 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.67 157.54 27.24 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.478 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.911 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -144.35 144.81 31.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.598 -0.943 . . . . 0.0 110.01 179.512 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.911 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.31 118.65 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.099 -1.001 . . . . 0.0 109.589 179.614 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.732 HG21 ' CD2' ' A' ' 298' ' ' LEU . 2.2 t -96.67 150.06 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.241 -0.912 . . . . 0.0 109.855 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -122.57 133.8 54.55 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.437 -0.789 . . . . 0.0 110.333 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -176.97 -140.03 3.46 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.516 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 47.6 Cg_endo -75.28 -170.42 0.8 Allowed 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 124.035 1.545 . . . . 0.0 110.382 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.444 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 2.6 mp0 -101.19 153.36 19.67 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.128 -0.983 . . . . 0.0 110.295 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.48 ' O ' ' HB3' ' A' ' 344' ' ' ASP . . . 91.81 71.6 1.2 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.48 ' HB3' ' O ' ' A' ' 343' ' ' GLY . 16.5 t70 59.87 147.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.4 -1.059 . . . . 0.0 109.626 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.778 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.2 mtmt -140.9 19.72 2.31 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.998 -1.064 . . . . 0.0 110.812 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 297' ' ' LYS . 7.5 p -132.08 118.17 35.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 110.46 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.498 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -46.76 -46.61 20.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.457 -0.777 . . . . 0.0 110.504 -179.845 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.417 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 9.2 pt-20 -177.27 158.93 1.53 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.041 -1.037 . . . . 0.0 110.803 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.82 HG23 HG22 ' A' ' 296' ' ' VAL . 44.9 mt -120.46 106.69 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.131 -0.98 . . . . 0.0 110.392 179.7 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.49 136.48 51.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.225 -0.922 . . . . 0.0 110.228 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.063 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -95.71 134.35 38.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.238 -0.914 . . . . 0.0 110.332 179.83 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 6.2 tt0 -138.94 112.43 8.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.361 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.789 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.71 105.2 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.066 -1.021 . . . . 0.0 109.942 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 353' ' ' ILE . 4.5 m-20 40.15 31.51 0.1 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.591 -0.693 . . . . 0.0 110.625 -179.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 119.14 -22.08 9.15 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.403 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -85.35 105.29 15.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.255 -1.144 . . . . 0.0 110.096 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.58 ' O ' HD13 ' A' ' 358' ' ' ILE . 4.1 p -75.73 130.52 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.58 HD13 ' O ' ' A' ' 357' ' ' VAL . 27.0 mm . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.276 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.86 -177.93 3.18 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.995 1.524 . . . . 0.0 110.545 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.572 HG23 ' O ' ' A' ' 258' ' ' THR . 13.5 t -57.1 125.03 20.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.305 -0.872 . . . . 0.0 110.537 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 12.4 m -117.37 121.84 31.7 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.258 -0.901 . . . . 0.0 110.195 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -74.99 125.63 9.45 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 O-C-N 123.945 1.497 . . . . 0.0 110.568 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.602 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.4 p -109.04 143.28 27.32 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.139 -0.975 . . . . 0.0 110.114 179.688 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.602 ' HD2' HG23 ' A' ' 261' ' ' VAL . 44.0 Cg_endo -71.55 137.78 31.08 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 124.02 1.537 . . . . 0.0 110.725 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 263' ' ' VAL . 9.6 t -130.97 28.9 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.34 -0.85 . . . . 0.0 110.293 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.417 ' OG ' HD11 ' A' ' 358' ' ' ILE . 0.3 OUTLIER -179.52 97.61 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 110.446 179.926 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 98.06 -177.94 31.66 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.485 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.7 OUTLIER -133.62 165.85 23.96 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -1.079 . . . . 0.0 109.883 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.926 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.31 137.2 8.02 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.412 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.798 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mm-40 -132.94 154.09 50.78 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.225 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.702 HG13 ' O ' ' A' ' 281' ' ' ASP . 46.2 t -145.41 139.74 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.62 -1.3 . . . . 0.0 111.739 -179.307 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.08 154.84 45.24 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.746 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.609 HG13 ' O ' ' A' ' 279' ' ' GLU . 70.8 t -140.67 141.43 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.466 -1.396 . . . . 0.0 111.984 -179.294 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -134.41 110.25 9.3 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 179.205 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.483 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.2 m-20 -96.77 142.19 29.08 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.071 -1.018 . . . . 0.0 110.926 -178.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.838 ' CH2' HG23 ' A' ' 337' ' ' ILE . 26.0 p90 -123.16 15.31 9.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.312 -0.867 . . . . 0.0 110.223 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.14 -53.62 3.22 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -76.9 -16.6 59.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -1.136 . . . . 0.0 110.066 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.559 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.74 -178.68 43.87 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.851 -1.299 . . . . 0.0 109.851 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.546 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.88 138.63 39.27 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -1.111 . . . . 0.0 110.053 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.609 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.0 mt-10 -95.22 147.14 23.79 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.351 -0.843 . . . . 0.0 110.017 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.686 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.0 m-85 -140.17 89.27 2.28 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 110.814 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.702 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -71.34 148.48 47.01 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.324 -0.86 . . . . 0.0 109.639 179.239 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.694 HG11 HG11 ' A' ' 294' ' ' VAL . 3.6 t -142.69 92.29 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.413 -0.805 . . . . 0.0 109.968 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.934 HG23 ' OG1' ' A' ' 333' ' ' THR . 15.4 m -86.45 126.46 34.42 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.032 -1.043 . . . . 0.0 109.77 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.113 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -115.19 149.6 37.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.969 -1.082 . . . . 0.0 110.987 -179.081 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.892 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.2 m120 -129.67 133.78 47.29 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.334 -0.854 . . . . 0.0 110.071 -179.691 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 1.059 HD13 ' HB2' ' A' ' 290' ' ' TYR . 17.8 mt -142.1 162.94 34.2 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.65 -1.281 . . . . 0.0 110.055 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -87.65 29.71 0.87 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.921 . . . . 0.0 110.473 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.514 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.09 -136.82 6.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.47 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 32.4 mm-40 -90.11 104.74 17.28 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.276 -1.132 . . . . 0.0 110.873 -179.561 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 1.059 ' HB2' HD13 ' A' ' 286' ' ' LEU . 8.4 m-85 -128.43 129.61 46.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.398 -0.814 . . . . 0.0 109.265 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.781 ' O ' HG23 ' A' ' 353' ' ' ILE . 58.9 m-20 -74.6 96.31 2.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.742 -1.224 . . . . 0.0 109.369 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.935 ' CE3' HD13 ' A' ' 284' ' ' LEU . 60.3 p-90 -98.01 115.43 28.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 110.689 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.872 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.6 m -109.51 115.78 30.56 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.52 -0.738 . . . . 0.0 109.425 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.781 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.6 t -96.89 111.27 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.106 -0.996 . . . . 0.0 110.394 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.593 ' HA ' HD13 ' A' ' 320' ' ' ILE . 21.2 ttpt -91.29 136.5 33.05 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.804 HG22 HG23 ' A' ' 349' ' ' ILE . 69.9 t -135.46 109.2 10.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.136 -0.978 . . . . 0.0 110.634 -179.152 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.54 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 53.8 mmtt -69.97 132.77 46.46 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.243 -0.911 . . . . 0.0 109.32 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.899 HD13 ' HA ' ' A' ' 303' ' ' THR . 60.1 mt -86.68 165.45 16.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.304 -0.872 . . . . 0.0 111.198 -179.062 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.773 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -75.69 176.43 3.21 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.752 -0.593 . . . . 0.0 109.43 179.208 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.773 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.0 Cg_endo -67.6 84.94 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.527 1.278 . . . . 0.0 109.955 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.87 20.95 6.57 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.2 142.37 43.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.274 -1.133 . . . . 0.0 110.23 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.899 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.0 p -150.28 144.36 25.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -0.941 . . . . 0.0 110.834 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.803 HG21 HG11 ' A' ' 319' ' ' VAL . 14.7 t -63.75 137.37 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.388 -0.82 . . . . 0.0 110.193 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -120.69 -33.15 1.03 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 24.7 m -138.86 117.14 11.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.223 -1.163 . . . . 0.0 110.441 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.518 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.4 p90 -133.91 148.38 51.22 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.288 -0.883 . . . . 0.0 109.908 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.5 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -141.23 164.53 30.01 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.14 -0.975 . . . . 0.0 111.173 -179.433 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.501 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 54.33 25.13 5.64 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.728 -0.607 . . . . 0.0 111.173 179.499 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.679 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 138.65 0.64 Allowed 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.099 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.544 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -76.89 120.08 21.53 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.074 -1.017 . . . . 0.0 108.711 179.337 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.672 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.3 ttpt -88.43 128.05 35.52 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.824 0.821 . . . . 0.0 110.799 -178.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.557 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -113.31 175.73 5.32 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -135.5 110.56 8.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.292 -0.88 . . . . 0.0 110.731 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.574 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -95.35 40.56 2.64 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.0 77.65 0.26 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.233 -1.157 . . . . 0.0 109.962 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.616 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.96 3.56 54.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.772 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -145.12 -170.76 3.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.486 -1.008 . . . . 0.0 109.003 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.803 HG11 HG21 ' A' ' 304' ' ' VAL . 18.2 t -161.39 157.74 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.199 -0.938 . . . . 0.0 109.691 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.624 ' CG2' HG22 ' A' ' 293' ' ' THR . 13.0 mm -127.03 146.79 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -0.922 . . . . 0.0 110.885 -179.563 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 91.0 m-85 -124.12 119.19 28.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.321 -0.862 . . . . 0.0 109.814 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.872 ' CG2' HG23 ' A' ' 293' ' ' THR . 12.6 p -121.11 168.0 11.92 Favored Pre-proline 0 C--N 1.301 -1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.641 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.524 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.5 Cg_endo -66.28 117.97 5.13 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.692 1.364 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.797 HG23 ' H ' ' A' ' 326' ' ' TRP . 23.9 m -65.72 -130.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.507 -0.746 . . . . 0.0 110.332 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.613 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.9 t -96.94 -12.84 22.89 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.08 -1.013 . . . . 0.0 110.554 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.797 ' H ' HG23 ' A' ' 324' ' ' VAL . 34.0 p-90 -133.46 5.53 3.75 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.07 -1.019 . . . . 0.0 110.946 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.783 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.3 t-20 -112.45 42.89 1.73 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.998 -1.064 . . . . 0.0 110.768 -179.479 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.504 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.8 OUTLIER -122.97 0.95 9.23 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.338 -0.851 . . . . 0.0 109.71 179.064 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -63.69 -158.79 0.23 Allowed Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.514 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 47.8 Cg_endo -75.36 3.88 5.41 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.999 1.526 . . . . 0.0 110.767 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.6 m -165.02 117.6 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.16 -0.963 . . . . 0.0 109.814 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.561 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.18 123.7 17.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.274 -0.891 . . . . 0.0 110.373 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.934 ' OG1' HG23 ' A' ' 283' ' ' THR . 40.9 m -111.58 142.07 44.36 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 109.99 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.781 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.0 p90 -143.95 174.82 10.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.515 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.04 158.05 27.49 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.288 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.943 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -144.97 147.44 32.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.476 -1.014 . . . . 0.0 110.041 179.627 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.943 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.6 118.93 58.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.005 -1.059 . . . . 0.0 109.704 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.5 t -96.73 147.27 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.113 -0.992 . . . . 0.0 110.095 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.475 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -120.15 137.85 53.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.339 -0.85 . . . . 0.0 110.332 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.435 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 176.66 -134.53 2.58 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.502 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 43.9 Cg_endo -71.48 -158.82 0.06 OUTLIER 'Trans proline' 0 C--N 1.303 -1.844 0 O-C-N 124.019 1.537 . . . . 0.0 110.326 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.491 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 0.5 OUTLIER -122.97 141.31 52.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.094 -1.004 . . . . 0.0 110.121 -179.818 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.484 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 101.45 66.86 0.79 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 108.811 -1.716 . . . . 0.0 108.811 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.7 OUTLIER 68.39 128.72 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.291 -1.123 . . . . 0.0 109.279 -179.165 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.534 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -127.45 19.61 6.81 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.096 -1.003 . . . . 0.0 110.29 -179.461 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.594 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 7.5 p -130.22 117.84 41.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -0.839 . . . . 0.0 110.568 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.0 mt-10 -47.08 -46.98 23.03 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 110.141 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.437 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.74 158.34 1.66 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.291 -0.88 . . . . 0.0 110.59 -179.843 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.804 HG23 HG22 ' A' ' 296' ' ' VAL . 33.1 mt -118.26 105.99 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.336 -0.852 . . . . 0.0 110.289 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.86 143.02 38.62 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.959 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.113 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.37 130.91 54.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.115 -0.991 . . . . 0.0 110.442 -179.867 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 15.0 tt0 -139.13 114.69 9.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.875 . . . . 0.0 109.823 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.781 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -91.38 111.52 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.014 -1.054 . . . . 0.0 109.744 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.447 ' C ' ' O ' ' A' ' 353' ' ' ILE . 3.2 m-20 39.86 30.28 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.793 -0.567 . . . . 0.0 110.44 -179.677 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 115.88 -15.02 16.69 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.473 ' O ' ' N ' ' A' ' 353' ' ' ILE . 0.0 OUTLIER -89.54 108.06 19.44 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.128 -1.219 . . . . 0.0 110.412 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.677 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -73.09 123.99 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.165 -0.959 . . . . 0.0 110.125 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.677 HD13 ' O ' ' A' ' 357' ' ' VAL . 20.6 mm . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.423 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.701 -1.359 . . . . 0.0 109.701 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.13 -178.56 3.97 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 123.975 1.513 . . . . 0.0 109.988 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 6.1 t -58.21 141.32 51.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 110.025 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 14.4 t -132.76 138.67 32.48 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.279 -0.888 . . . . 0.0 110.052 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.95 155.58 52.93 Favored 'Trans proline' 0 C--N 1.304 -1.815 0 O-C-N 123.966 1.508 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.536 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -83.09 141.62 43.52 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.936 . . . . 0.0 110.581 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.551 ' CB ' HG23 ' A' ' 358' ' ' ILE . 47.4 Cg_endo -74.53 139.43 25.59 Favored 'Trans proline' 0 C--N 1.304 -1.815 0 O-C-N 124.213 1.639 . . . . 0.0 110.005 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.537 HG12 ' O ' ' A' ' 263' ' ' VAL . 24.5 t -117.53 30.62 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.182 -0.949 . . . . 0.0 110.496 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.488 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 170.18 105.35 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.191 -0.943 . . . . 0.0 110.9 179.881 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 89.28 -170.82 37.78 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 120.064 -1.065 . . . . 0.0 110.505 179.07 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.558 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.79 167.89 21.0 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.64 -0.918 . . . . 0.0 109.533 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.862 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.47 133.96 5.98 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.0 -1.08 . . . . 0.0 111.266 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.828 ' N ' HD22 ' A' ' 267' ' ' LEU . 14.3 mm-40 -134.33 129.62 35.77 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 281' ' ' ASP . 89.5 t -125.9 139.54 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.853 -1.154 . . . . 0.0 111.625 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.1 mtmt -124.9 157.56 35.67 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.745 HG13 ' O ' ' A' ' 279' ' ' GLU . 74.5 t -141.62 146.73 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.43 -1.418 . . . . 0.0 112.068 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.557 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.28 107.9 6.99 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.309 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.2 m-20 -94.74 142.44 27.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.997 -1.064 . . . . 0.0 111.1 -179.03 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.811 ' CH2' HG23 ' A' ' 337' ' ' ILE . 25.6 p90 -123.97 17.06 9.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.44 -0.787 . . . . 0.0 109.831 179.173 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.43 -55.54 3.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.31 -18.94 58.7 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.227 -1.161 . . . . 0.0 110.286 -179.785 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.24 -179.37 40.63 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.551 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -139.06 137.13 35.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -1.111 . . . . 0.0 110.173 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.745 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.6 mt-10 -92.7 146.84 23.35 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.264 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.2 m-85 -139.98 90.34 2.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.201 -0.937 . . . . 0.0 111.265 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.796 ' O ' HG13 ' A' ' 269' ' ' VAL . 4.7 t70 -72.62 146.92 46.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.51 -0.744 . . . . 0.0 109.408 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.71 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.4 t -140.77 86.94 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.184 -0.947 . . . . 0.0 110.094 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 283' ' ' THR . . . . . 1.003 HG23 ' OG1' ' A' ' 333' ' ' THR . 13.2 m -86.74 122.88 31.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.069 -1.019 . . . . 0.0 110.04 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.09 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.56 154.05 22.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 0.0 110.226 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.558 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.7 m120 -133.69 113.75 12.7 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.106 -0.996 . . . . 0.0 110.89 -179.071 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.988 HD13 ' HB2' ' A' ' 290' ' ' TYR . 13.3 mt -123.83 158.59 31.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.549 -1.345 . . . . 0.0 109.884 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.1 35.22 0.85 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.292 -0.88 . . . . 0.0 109.807 179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 154.92 -134.25 4.15 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.515 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 47.5 mm-40 -106.84 111.63 24.24 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.177 -1.19 . . . . 0.0 111.026 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.988 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.9 m-85 -132.06 136.96 47.59 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.336 -0.852 . . . . 0.0 109.301 179.175 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.778 ' O ' HG23 ' A' ' 353' ' ' ILE . 31.1 m-20 -75.37 96.42 3.4 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.756 -1.215 . . . . 0.0 108.617 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.932 ' CE3' HD13 ' A' ' 284' ' ' LEU . 61.3 p-90 -99.6 114.1 26.93 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.449 -0.782 . . . . 0.0 110.904 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 293' ' ' THR . . . . . 1.011 HG23 HG22 ' A' ' 322' ' ' THR . 27.3 m -111.43 118.09 34.84 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.155 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.755 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.1 t -96.75 111.0 25.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.183 -0.948 . . . . 0.0 110.737 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.585 ' HA ' HD13 ' A' ' 320' ' ' ILE . 7.0 ttpp -83.34 148.6 27.24 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.441 -0.787 . . . . 0.0 109.012 178.778 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.594 HG13 ' CG2' ' A' ' 346' ' ' VAL . 44.5 t -147.3 104.99 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.096 -1.003 . . . . 0.0 110.707 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.604 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.7 mmtp -70.63 133.14 46.42 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 179.517 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 1.038 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.0 mt -86.37 150.28 24.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 111.474 -179.071 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.675 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -61.0 171.89 1.01 Allowed Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.686 -0.634 . . . . 0.0 109.681 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.675 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.2 Cg_endo -67.53 82.58 0.41 Allowed 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.785 1.413 . . . . 0.0 109.642 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.11 28.27 2.68 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.72 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -122.32 146.36 47.38 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.373 -1.075 . . . . 0.0 110.557 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 303' ' ' THR . . . . . 1.038 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.3 p -149.57 143.59 25.68 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.185 -0.947 . . . . 0.0 110.748 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.988 ' CG2' HG21 ' A' ' 319' ' ' VAL . 66.8 t -68.48 130.76 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 110.246 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -114.04 -39.33 1.06 Allowed Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 18.1 m -132.64 141.67 48.75 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.188 -1.184 . . . . 0.0 110.913 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.569 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 28.5 p90 -153.75 167.96 27.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.363 -0.836 . . . . 0.0 109.656 179.465 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.505 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -160.67 158.43 28.82 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.995 -1.066 . . . . 0.0 111.253 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.555 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.61 31.96 21.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.631 -0.668 . . . . 0.0 111.245 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.785 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.91 150.85 1.04 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.049 -1.032 . . . . 0.0 110.457 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.51 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 3.4 m120 -81.22 109.7 16.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.088 -1.007 . . . . 0.0 109.439 179.012 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.569 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 27.6 ttpt -84.97 132.52 34.34 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.46 -0.775 . . . . 0.0 110.603 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.695 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.07 174.73 7.83 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.53 -0.731 . . . . 0.0 109.465 179.329 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -138.2 104.68 5.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.523 -0.736 . . . . 0.0 110.064 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -92.0 37.93 3.29 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.12 81.24 0.21 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.048 -1.266 . . . . 0.0 110.253 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.25 -0.04 57.12 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.716 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.33 -171.33 3.71 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.347 -1.09 . . . . 0.0 109.359 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.988 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -159.46 157.91 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.117 -0.989 . . . . 0.0 109.844 178.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.585 HD13 ' HA ' ' A' ' 295' ' ' LYS . 8.7 mm -125.87 150.32 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.073 -1.017 . . . . 0.0 111.376 -179.176 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.638 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 89.3 m-85 -130.98 112.49 12.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.301 -0.874 . . . . 0.0 110.285 179.436 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 322' ' ' THR . . . . . 1.011 HG22 HG23 ' A' ' 293' ' ' THR . 2.8 p -115.02 174.23 2.48 Favored Pre-proline 0 N--CA 1.498 1.973 0 O-C-N 120.512 -1.367 . . . . 0.0 109.54 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.601 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 43.1 Cg_endo -71.13 125.07 11.07 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.607 1.319 . . . . 0.0 111.283 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.764 HG22 ' CG ' ' A' ' 327' ' ' ASN . 14.9 m -70.06 -110.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.518 -0.739 . . . . 0.0 110.438 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.522 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.1 OUTLIER -119.42 -16.95 8.88 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.715 -1.241 . . . . 0.0 111.299 -179.277 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.499 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 3.1 p-90 -125.93 -18.9 4.97 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.914 -1.116 . . . . 0.0 111.077 -179.507 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.764 ' CG ' HG22 ' A' ' 324' ' ' VAL . 34.0 p-10 -89.7 47.28 1.45 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.928 -1.108 . . . . 0.0 110.046 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.501 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 13.5 mtmt -118.26 -10.09 10.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.493 -0.754 . . . . 0.0 109.426 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.24 -157.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.549 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -74.73 5.69 3.71 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.03 1.542 . . . . 0.0 111.077 -179.741 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 3.6 m -161.93 120.03 2.25 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.874 179.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.41 117.78 14.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.222 -0.924 . . . . 0.0 110.361 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 333' ' ' THR . . . . . 1.003 ' OG1' HG23 ' A' ' 283' ' ' THR . 26.2 m -109.68 135.28 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 110.434 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.785 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 13.4 p90 -142.82 174.44 10.65 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.09 162.94 29.35 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.582 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.899 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -150.84 145.05 25.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.567 -0.961 . . . . 0.0 109.558 179.352 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.899 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -118.89 122.4 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.058 -1.026 . . . . 0.0 110.069 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.72 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -98.36 146.06 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.22 -0.925 . . . . 0.0 109.695 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -119.39 137.22 53.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 110.729 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.469 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.49 -136.59 2.98 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.725 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.513 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 45.3 Cg_endo -72.01 -156.83 0.05 OUTLIER 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.836 1.44 . . . . 0.0 109.697 179.159 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.415 ' OE1' ' N ' ' A' ' 342' ' ' GLN . 4.5 pm0 -120.41 144.18 48.07 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.007 -1.058 . . . . 0.0 110.119 -179.936 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 103.08 66.59 0.74 Allowed Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 16.3 m-20 61.51 134.61 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.296 -1.12 . . . . 0.0 109.782 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.576 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.8 OUTLIER -133.12 28.71 4.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.193 -0.942 . . . . 0.0 110.742 -179.506 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 346' ' ' VAL . 7.1 p -131.46 111.22 18.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.1 mm-40 -43.14 -46.83 6.03 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.202 -0.936 . . . . 0.0 110.425 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -175.95 157.78 1.95 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 110.357 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.586 HG12 HG22 ' A' ' 296' ' ' VAL . 13.5 mt -118.43 104.36 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.243 -0.911 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.03 126.83 52.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 110.499 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.09 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -91.11 130.17 37.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.03 -1.044 . . . . 0.0 110.025 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -138.55 117.59 12.54 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.31 -0.869 . . . . 0.0 109.549 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.778 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.11 98.19 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.921 -1.112 . . . . 0.0 110.118 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.542 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 38.57 28.24 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.296 179.634 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 134.94 -19.47 3.92 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.889 179.201 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 11.1 mm100 -102.78 113.15 26.33 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.871 -1.37 . . . . 0.0 110.905 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.587 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.7 p -76.89 121.17 28.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.485 -0.759 . . . . 0.0 110.354 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.551 HG23 ' CB ' ' A' ' 262' ' ' PRO . 26.7 mm . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.165 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -73.17 -178.27 3.49 Favored 'Trans proline' 0 C--N 1.303 -1.834 0 O-C-N 124.048 1.551 . . . . 0.0 110.505 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.582 HG23 ' O ' ' A' ' 258' ' ' THR . 5.2 t -65.79 122.77 18.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.328 -0.858 . . . . 0.0 110.349 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 17.0 p -112.0 125.44 30.22 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.88 142.15 31.23 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.884 1.465 . . . . 0.0 110.25 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.677 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -110.39 145.65 32.66 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.23 -0.919 . . . . 0.0 110.423 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.677 ' HD2' HG23 ' A' ' 261' ' ' VAL . 44.5 Cg_endo -71.21 157.67 56.66 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 124.113 1.586 . . . . 0.0 110.441 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.553 HG12 ' O ' ' A' ' 263' ' ' VAL . 23.5 t -144.61 29.41 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.165 -0.959 . . . . 0.0 110.536 -179.846 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 176.05 104.04 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.285 -0.885 . . . . 0.0 110.424 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 92.59 -172.78 34.7 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.536 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.41 166.08 25.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.334 -1.098 . . . . 0.0 110.043 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.927 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.65 139.77 9.22 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.025 -1.047 . . . . 0.0 111.409 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.793 ' N ' HD22 ' A' ' 267' ' ' LEU . 3.7 mt-10 -136.12 153.78 51.19 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.704 HG13 ' O ' ' A' ' 281' ' ' ASP . 54.0 t -145.27 135.67 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.697 -1.252 . . . . 0.0 111.567 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.411 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.7 mtpt -122.88 157.05 33.38 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.822 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.5 t -144.81 147.2 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.478 -1.389 . . . . 0.0 112.167 -179.144 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.64 112.64 7.35 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.791 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 p-10 -97.53 141.76 30.19 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.948 -1.095 . . . . 0.0 111.402 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.779 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.3 p90 -124.5 19.99 8.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.502 -0.748 . . . . 0.0 109.8 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.665 ' HA2' HE21 ' A' ' 342' ' ' GLN . . . 85.74 -59.58 4.75 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.99 -20.07 66.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -1.159 . . . . 0.0 110.11 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.48 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.12 -175.03 44.93 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.4 143.94 42.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -1.138 . . . . 0.0 110.225 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.822 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.9 mt-10 -96.97 145.83 25.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.385 -0.822 . . . . 0.0 109.789 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.681 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 96.1 m-85 -138.93 86.73 2.16 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.452 -0.78 . . . . 0.0 110.92 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.704 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.59 146.83 49.84 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.316 -0.865 . . . . 0.0 109.442 179.105 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.825 HG11 HG11 ' A' ' 294' ' ' VAL . 5.6 t -140.22 90.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 121.336 -0.853 . . . . 0.0 109.932 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.891 HG23 ' OG1' ' A' ' 333' ' ' THR . 53.9 m -86.58 127.92 34.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.058 -1.026 . . . . 0.0 109.681 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.89 152.1 32.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.127 -0.983 . . . . 0.0 110.687 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.902 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -130.56 134.54 47.1 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.282 -0.886 . . . . 0.0 110.263 -179.865 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.902 HD23 ' O ' ' A' ' 285' ' ' ASN . 12.7 mt -143.72 155.55 44.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.938 -1.101 . . . . 0.0 109.491 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -88.6 40.02 0.95 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 109.723 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 150.3 -116.69 0.79 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.991 -1.576 . . . . 0.0 110.242 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.559 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.6 mt-30 -128.62 116.31 19.4 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.022 -1.281 . . . . 0.0 110.926 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.599 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 8.8 m-85 -138.23 137.03 37.15 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.191 -0.943 . . . . 0.0 109.664 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.717 ' O ' HG23 ' A' ' 353' ' ' ILE . 23.2 m-20 -71.02 96.81 1.36 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.815 -1.178 . . . . 0.0 108.981 179.043 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.867 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.2 p-90 -98.08 113.1 24.89 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.221 -0.924 . . . . 0.0 110.833 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.663 HG23 ' CG2' ' A' ' 322' ' ' THR . 10.3 m -106.23 111.75 24.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.417 -0.802 . . . . 0.0 109.243 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.825 HG11 HG11 ' A' ' 282' ' ' VAL . 3.1 t -96.21 111.24 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.167 -0.958 . . . . 0.0 110.371 -179.328 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.53 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 5.1 ttmt -89.19 149.51 23.09 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.438 -0.788 . . . . 0.0 109.51 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.914 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 56.1 t -142.34 107.87 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.288 -0.882 . . . . 0.0 110.31 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.555 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 11.5 mmtt -70.2 131.34 44.07 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.179 -0.95 . . . . 0.0 109.645 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.941 HD13 ' HA ' ' A' ' 303' ' ' THR . 94.8 mt -85.25 160.89 19.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.81 . . . . 0.0 111.312 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.714 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -71.43 174.32 4.01 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 121.571 -0.705 . . . . 0.0 109.212 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.43 84.08 0.37 Allowed 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 123.492 1.259 . . . . 0.0 110.096 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.97 24.66 4.79 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.8 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.9 148.32 40.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -1.104 . . . . 0.0 110.225 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.941 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -149.84 143.6 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.104 -0.998 . . . . 0.0 110.718 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.736 HG21 HG11 ' A' ' 319' ' ' VAL . 85.2 t -65.63 121.94 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.418 -0.801 . . . . 0.0 109.906 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 305' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -103.16 -30.25 5.46 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.3 t -145.85 142.32 28.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.004 -1.292 . . . . 0.0 110.911 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.518 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 15.0 p90 -152.6 174.65 13.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.544 -0.722 . . . . 0.0 109.38 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.479 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -163.84 159.55 21.26 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.848 -1.158 . . . . 0.0 111.486 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.452 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.7 OUTLIER 55.68 26.41 9.3 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.564 -0.71 . . . . 0.0 111.116 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.716 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.68 139.25 0.7 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.195 -0.941 . . . . 0.0 109.897 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.541 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.6 m120 -77.42 121.24 23.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.062 -1.024 . . . . 0.0 109.488 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.533 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.3 ttpt -88.33 142.81 27.44 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.844 0.83 . . . . 0.0 110.552 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.622 ' O ' HG22 ' A' ' 319' ' ' VAL . 5.8 mt-30 -130.25 176.48 8.07 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.255 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.454 ' OE1' ' O ' ' A' ' 318' ' ' TYR . 5.3 mm-40 -135.79 113.32 10.8 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.115 -0.99 . . . . 0.0 110.545 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.6 42.13 2.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.47 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 20.6 t-20 57.41 81.49 0.14 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.335 -1.097 . . . . 0.0 110.269 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.82 3.74 58.08 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.843 ' O ' HG23 ' A' ' 319' ' ' VAL . 0.8 OUTLIER -147.08 -167.72 2.85 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.353 -1.087 . . . . 0.0 109.055 179.532 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.843 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.7 t -163.28 147.73 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.195 -0.94 . . . . 0.0 109.733 178.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.619 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.6 mm -112.35 152.06 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.005 -1.06 . . . . 0.0 110.998 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 58.4 m-85 -129.24 125.86 37.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.812 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.663 ' CG2' HG23 ' A' ' 293' ' ' THR . 7.2 p -129.04 167.7 18.71 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 120.488 -1.382 . . . . 0.0 109.965 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.552 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 38.7 Cg_endo -65.74 119.36 6.37 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.78 1.411 . . . . 0.0 111.087 -179.233 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.567 HG23 ' H ' ' A' ' 326' ' ' TRP . 31.3 m -64.73 -121.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.485 -0.759 . . . . 0.0 110.297 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.512 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -106.18 -19.9 13.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.809 -1.182 . . . . 0.0 110.666 -179.649 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.567 ' H ' HG23 ' A' ' 324' ' ' VAL . 21.6 p-90 -126.2 3.17 7.13 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.08 -1.012 . . . . 0.0 110.653 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.532 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 1.9 t-20 -108.08 31.72 5.32 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.093 -1.005 . . . . 0.0 110.576 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.552 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -110.46 -2.6 16.47 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.102 -0.999 . . . . 0.0 109.547 179.433 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.05 -153.33 0.02 OUTLIER Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.565 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.6 Cg_endo -69.8 -48.89 0.62 Allowed 'Trans proline' 0 C--N 1.301 -1.935 0 O-C-N 123.987 1.52 . . . . 0.0 109.474 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.08 125.58 52.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.527 -0.733 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.74 108.09 6.86 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.36 -0.838 . . . . 0.0 109.993 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.891 ' OG1' HG23 ' A' ' 283' ' ' THR . 3.3 m -103.17 138.92 39.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 110.227 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.805 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.0 p90 -144.74 174.63 10.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.374 -0.829 . . . . 0.0 109.138 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.04 158.26 27.59 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 118.984 -1.579 . . . . 0.0 110.336 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.914 ' CZ ' HG11 ' A' ' 296' ' ' VAL . 0.9 OUTLIER -147.93 143.87 27.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.57 -0.959 . . . . 0.0 109.553 179.321 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.887 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -118.01 129.67 74.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.073 -1.017 . . . . 0.0 110.107 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.8 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.3 t -104.92 148.48 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.027 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -120.7 135.47 55.12 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 110.181 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.431 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -179.73 -138.63 3.41 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.411 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 50.0 Cg_endo -74.91 -166.14 0.33 Allowed 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 124.0 1.526 . . . . 0.0 110.479 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.665 HE21 ' HA2' ' A' ' 275' ' ' GLY . 5.4 mm100 -110.29 143.27 40.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.201 -0.937 . . . . 0.0 110.284 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 103.52 69.37 0.8 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.467 ' O ' ' O ' ' A' ' 343' ' ' GLY . 15.3 m-20 61.52 134.76 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.337 -1.096 . . . . 0.0 109.466 -179.27 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.658 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.1 mtmt -129.13 15.7 6.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.035 -1.04 . . . . 0.0 110.335 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.628 HG11 ' CE1' ' A' ' 280' ' ' TYR . 6.8 p -128.91 117.4 44.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.309 -0.869 . . . . 0.0 110.107 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.2 OUTLIER -47.57 -47.88 28.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.046 -1.034 . . . . 0.0 110.068 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.409 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.7 OUTLIER -177.2 158.33 1.47 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.289 -0.882 . . . . 0.0 110.35 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.661 HG12 HG13 ' A' ' 296' ' ' VAL . 17.0 mt -117.34 110.37 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 110.215 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.67 144.03 41.59 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.271 -0.893 . . . . 0.0 110.2 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.66 132.77 50.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.18 -0.95 . . . . 0.0 110.249 179.869 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -139.07 113.13 8.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.945 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.717 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.8 mt -91.64 112.53 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.913 -1.117 . . . . 0.0 110.088 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.436 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.5 m-20 37.84 29.72 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.782 -0.574 . . . . 0.0 111.295 -179.961 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.26 -10.24 14.98 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.667 -1.254 . . . . 0.0 110.6 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.402 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 43.1 mm-40 -101.45 115.06 29.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.878 -1.366 . . . . 0.0 110.364 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.79 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.1 p -75.13 139.09 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.279 -0.888 . . . . 0.0 110.493 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.79 HD13 ' O ' ' A' ' 357' ' ' VAL . 26.6 mm . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.196 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.82 -178.24 3.35 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 O-C-N 124.149 1.605 . . . . 0.0 110.619 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 11.1 t -57.6 145.51 33.55 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.358 -0.838 . . . . 0.0 110.39 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -110.52 95.67 23.94 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.344 -0.848 . . . . 0.0 110.245 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.86 158.12 50.56 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.984 1.518 . . . . 0.0 110.638 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.671 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.8 p -85.06 145.72 43.9 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.179 -0.95 . . . . 0.0 110.269 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.671 ' HD2' HG23 ' A' ' 261' ' ' VAL . 50.2 Cg_endo -74.62 125.9 9.84 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 O-C-N 124.08 1.568 . . . . 0.0 110.577 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 263' ' ' VAL . 96.3 t -114.28 28.71 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.305 -0.872 . . . . 0.0 109.781 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.727 ' HB2' HD11 ' A' ' 358' ' ' ILE . 3.1 t -141.22 -139.84 0.13 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.385 -0.822 . . . . 0.0 110.408 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.583 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . -59.78 -139.4 0.01 OUTLIER Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.528 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.8 OUTLIER -136.0 167.06 21.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.447 -1.031 . . . . 0.0 109.495 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.953 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.9 tm? -161.06 136.84 8.05 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.515 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.821 ' N ' HD22 ' A' ' 267' ' ' LEU . 8.0 mm-40 -135.69 156.12 49.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.865 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.9 t -146.96 146.29 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.648 -1.283 . . . . 0.0 111.617 -179.249 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.418 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.2 OUTLIER -132.4 157.6 44.14 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.186 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 279' ' ' GLU . 86.7 t -144.88 147.2 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 120.262 -1.524 . . . . 0.0 112.401 -179.258 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.522 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.46 114.58 8.66 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.906 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.0 p-10 -97.81 148.73 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.087 -1.008 . . . . 0.0 111.366 -178.677 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.8 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.1 p90 -134.85 17.42 3.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.608 -0.682 . . . . 0.0 109.96 179.381 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.531 ' O ' ' NE2' ' A' ' 342' ' ' GLN . . . 92.46 -66.28 2.05 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.489 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 57.4 m -64.3 -18.77 64.92 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.322 -1.105 . . . . 0.0 110.581 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.532 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -179.24 178.65 48.82 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.164 -1.493 . . . . 0.0 110.246 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.54 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.66 145.99 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.505 -0.997 . . . . 0.0 110.019 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.724 ' O ' HG13 ' A' ' 271' ' ' VAL . 11.4 mt-10 -96.36 146.86 24.38 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.433 -0.792 . . . . 0.0 109.425 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.2 m-85 -138.33 89.17 2.36 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.31 -0.869 . . . . 0.0 110.584 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.865 ' O ' HG13 ' A' ' 269' ' ' VAL . 71.4 m-20 -69.64 147.49 50.57 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.679 -0.638 . . . . 0.0 109.828 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.693 HG11 HG11 ' A' ' 294' ' ' VAL . 3.4 t -142.76 89.96 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.355 -0.84 . . . . 0.0 109.543 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.876 HG23 ' OG1' ' A' ' 333' ' ' THR . 27.3 m -86.49 120.51 27.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.106 -0.996 . . . . 0.0 109.857 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.34 149.37 28.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.602 -179.478 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.907 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.2 m120 -128.04 136.21 50.93 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.395 -0.816 . . . . 0.0 110.084 -179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.907 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.2 mt -142.17 154.52 44.9 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.721 -1.237 . . . . 0.0 109.854 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -85.77 36.27 0.65 Allowed 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.381 -0.825 . . . . 0.0 110.311 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.486 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 150.56 -104.12 0.26 Allowed Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.082 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.5 mm-40 -139.87 113.67 8.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.015 -1.285 . . . . 0.0 111.429 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.639 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 4.8 m-85 -138.75 129.93 26.95 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.536 ' O ' HG23 ' A' ' 353' ' ' ILE . 90.0 m-20 -65.16 99.69 0.39 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.817 -1.177 . . . . 0.0 109.266 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.897 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.4 p-90 -98.77 115.86 29.72 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.335 -0.853 . . . . 0.0 110.868 -179.27 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.6 HG22 ' CG2' ' A' ' 320' ' ' ILE . 9.8 m -105.98 116.26 31.63 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.66 -0.65 . . . . 0.0 109.299 179.538 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.774 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.75 111.44 26.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.02 -1.05 . . . . 0.0 110.662 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.793 ' HA ' HD13 ' A' ' 320' ' ' ILE . 2.8 ttpt -85.44 144.03 28.22 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.431 -0.793 . . . . 0.0 109.156 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.958 HG22 HG23 ' A' ' 349' ' ' ILE . 99.0 t -144.34 106.84 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.028 -1.045 . . . . 0.0 110.662 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.564 ' HD3' ' CG ' ' A' ' 318' ' ' TYR . 35.7 mmtt -70.57 130.38 41.67 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.27 -0.894 . . . . 0.0 109.804 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.958 HD13 ' HA ' ' A' ' 303' ' ' THR . 77.2 mt -85.38 155.08 21.45 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.516 -0.74 . . . . 0.0 111.398 -178.972 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.784 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -59.7 176.23 0.33 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.54 -0.725 . . . . 0.0 109.409 179.106 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.784 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.5 Cg_endo -69.19 81.07 0.69 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.612 1.322 . . . . 0.0 109.895 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.2 4.9 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.303 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.811 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -110.24 149.7 29.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.417 -1.049 . . . . 0.0 110.188 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.958 ' HA ' HD13 ' A' ' 298' ' ' LEU . 9.5 p -150.15 145.08 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 110.573 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.724 HG21 HG11 ' A' ' 319' ' ' VAL . 77.5 t -71.25 122.6 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.527 -0.733 . . . . 0.0 109.865 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -103.5 -37.99 2.91 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.461 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -132.29 136.4 46.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.076 -1.249 . . . . 0.0 111.035 -179.559 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.59 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 50.3 p90 -147.67 159.91 43.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.458 -0.776 . . . . 0.0 109.468 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.516 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -154.65 158.13 39.19 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.976 -1.077 . . . . 0.0 111.239 -179.46 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.534 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.2 OUTLIER 63.98 20.39 12.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.553 -0.717 . . . . 0.0 110.532 179.63 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.543 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.76 147.44 1.03 Allowed 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.564 -0.71 . . . . 0.0 110.022 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.578 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -82.07 123.81 29.27 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.109 -0.994 . . . . 0.0 108.982 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.59 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 11.6 ttpt -89.42 137.96 31.87 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.63 0.729 . . . . 0.0 111.217 -178.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.682 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.15 172.36 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.776 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -139.28 104.49 5.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.201 -0.937 . . . . 0.0 110.506 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.466 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -92.31 40.37 2.89 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.466 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 7.3 m-20 58.08 86.13 0.08 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.352 -1.087 . . . . 0.0 110.418 -179.966 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.596 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.51 -4.54 58.25 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.693 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.0 OUTLIER -144.94 -172.05 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.4 -1.059 . . . . 0.0 109.243 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.724 HG11 HG21 ' A' ' 304' ' ' VAL . 3.3 t -159.08 161.45 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.211 -0.931 . . . . 0.0 109.739 178.978 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.793 HD13 ' HA ' ' A' ' 295' ' ' LYS . 42.4 mm -129.26 151.13 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.275 -0.89 . . . . 0.0 111.184 -179.66 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.628 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 97.4 m-85 -128.9 125.2 37.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.315 -0.866 . . . . 0.0 109.915 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.54 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 10.7 p -124.82 168.36 13.51 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 120.799 -1.188 . . . . 0.0 109.715 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.529 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.7 Cg_endo -66.73 121.71 8.97 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.692 1.364 . . . . 0.0 110.808 -179.539 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.829 HG22 ' HB2' ' A' ' 327' ' ' ASN . 31.2 m -69.5 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.554 -0.716 . . . . 0.0 110.083 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.479 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -100.44 -20.89 15.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 110.606 -179.76 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.57 ' H ' HG23 ' A' ' 324' ' ' VAL . 8.4 p-90 -127.15 5.89 6.45 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.126 -0.984 . . . . 0.0 110.564 -179.728 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.829 ' HB2' HG22 ' A' ' 324' ' ' VAL . 7.3 t30 -103.39 37.53 1.98 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.125 -0.984 . . . . 0.0 110.473 -179.689 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -117.47 -9.0 10.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.282 -0.886 . . . . 0.0 109.619 179.689 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.463 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -56.31 -162.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.451 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 47.6 Cg_endo -74.14 5.16 3.72 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.228 1.646 . . . . 0.0 110.953 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.1 m -164.81 115.7 1.17 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.254 -0.904 . . . . 0.0 109.987 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.815 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -134.14 117.93 17.11 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.143 -0.973 . . . . 0.0 110.319 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.876 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.6 m -108.78 136.61 48.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.407 -0.808 . . . . 0.0 109.995 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.774 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.3 p90 -140.63 172.09 13.19 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.692 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.527 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.21 158.51 27.71 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.935 -1.602 . . . . 0.0 110.075 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.942 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -146.22 147.28 31.28 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.437 -1.037 . . . . 0.0 109.906 179.614 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.942 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.58 119.58 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.056 -1.028 . . . . 0.0 109.809 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.811 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.8 t -97.17 149.1 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.194 -0.941 . . . . 0.0 110.37 -179.713 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.5 m120 -120.21 134.07 55.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.473 -0.767 . . . . 0.0 109.807 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.94 -124.98 0.95 Allowed Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.533 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 41.6 Cg_endo -66.4 -159.36 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.82 1.431 . . . . 0.0 110.565 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.531 ' NE2' ' O ' ' A' ' 275' ' ' GLY . 6.4 mp0 -119.35 132.2 55.83 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.15 -0.969 . . . . 0.0 111.041 -179.192 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 102.35 -87.91 0.64 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -103.07 133.7 47.75 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.424 -1.045 . . . . 0.0 109.234 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.675 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.4 OUTLIER -135.57 7.51 3.3 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.962 -1.086 . . . . 0.0 110.722 -179.559 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.629 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.0 p -133.41 112.64 17.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.224 -0.922 . . . . 0.0 109.79 179.168 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.48 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.07 5.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.465 -0.772 . . . . 0.0 110.587 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 25.7 pt-20 -177.14 158.94 1.57 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.224 -0.923 . . . . 0.0 110.86 -179.528 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.958 HG23 HG22 ' A' ' 296' ' ' VAL . 19.0 mt -119.4 108.65 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.249 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.24 146.24 33.12 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.249 -0.907 . . . . 0.0 109.797 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.38 133.1 49.83 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.99 -1.068 . . . . 0.0 110.465 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.431 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 47.8 tt0 -138.98 110.2 6.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.795 . . . . 0.0 109.79 179.473 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.536 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.06 109.27 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.047 -1.033 . . . . 0.0 109.863 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.45 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 6.1 m-20 41.12 32.76 0.2 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.596 -0.69 . . . . 0.0 110.328 -179.538 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.69 -21.4 16.52 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 1.1 mp0 -80.17 104.22 10.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.225 -1.162 . . . . 0.0 110.292 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.635 ' O ' HD13 ' A' ' 358' ' ' ILE . 14.6 p -75.62 135.29 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 110.081 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.727 HD11 ' HB2' ' A' ' 264' ' ' SER . 13.0 mm . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.154 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.15 -178.93 4.23 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 124.011 1.532 . . . . 0.0 110.549 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 6.1 t -58.83 146.07 38.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.138 -0.976 . . . . 0.0 110.122 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 45.7 p -104.89 122.53 42.99 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 110.406 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -74.17 161.04 41.55 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.847 1.446 . . . . 0.0 110.225 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.435 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.4 p -94.28 137.95 22.63 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.146 -0.971 . . . . 0.0 110.067 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.435 ' HD2' HG23 ' A' ' 261' ' ' VAL . 50.0 Cg_endo -75.18 153.79 41.16 Favored 'Trans proline' 0 C--N 1.303 -1.866 0 O-C-N 124.081 1.569 . . . . 0.0 110.592 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.607 HG12 ' O ' ' A' ' 263' ' ' VAL . 49.0 t -127.2 26.55 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.273 -0.892 . . . . 0.0 109.932 179.676 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 1.5 p 166.38 142.05 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.446 -0.783 . . . . 0.0 110.327 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 64.21 -173.53 14.8 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.538 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.48 167.79 21.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.376 -1.073 . . . . 0.0 110.038 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.982 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.76 135.43 6.52 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.139 -0.976 . . . . 0.0 111.044 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.694 ' N ' HD22 ' A' ' 267' ' ' LEU . 96.4 mt-10 -134.96 126.95 29.63 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.08 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.799 HG23 HD11 ' A' ' 267' ' ' LEU . 64.6 t -117.76 138.61 47.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 C-N-CA 118.828 -1.149 . . . . 0.0 112.137 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.422 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.3 OUTLIER -122.83 157.55 32.2 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.802 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.3 t -144.56 146.28 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.35 -1.469 . . . . 0.0 112.232 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.569 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 2.1 m-20 -134.34 110.64 9.6 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.771 -0.58 . . . . 0.0 109.528 179.205 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 13.9 m-20 -97.85 127.55 43.88 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.336 -0.853 . . . . 0.0 111.456 -178.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.845 ' CH2' HG23 ' A' ' 337' ' ' ILE . 30.5 p90 -113.04 18.76 17.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.372 -0.83 . . . . 0.0 109.723 178.957 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.611 ' O ' ' NE2' ' A' ' 342' ' ' GLN . . . 87.33 -64.33 3.81 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.401 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 1.5 m -63.66 -23.4 67.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.238 -1.154 . . . . 0.0 110.418 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.561 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -167.25 -179.46 40.19 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.543 -1.313 . . . . 0.0 109.941 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.556 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -135.28 141.57 45.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.33 -1.1 . . . . 0.0 109.986 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.816 ' O ' HG13 ' A' ' 271' ' ' VAL . 2.6 mt-10 -96.34 147.32 23.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -0.778 . . . . 0.0 110.32 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.79 ' CE2' HG11 ' A' ' 346' ' ' VAL . 97.0 m-85 -139.04 85.14 2.05 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 110.753 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.585 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.4 t0 -74.53 119.81 19.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.566 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.703 HG11 HG11 ' A' ' 294' ' ' VAL . 15.6 t -111.6 92.78 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.594 -0.691 . . . . 0.0 109.871 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.846 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.3 m -86.48 124.31 32.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.987 . . . . 0.0 109.367 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.11 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.69 152.27 27.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.091 -1.005 . . . . 0.0 110.718 -179.115 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.749 ' O ' HD23 ' A' ' 286' ' ' LEU . 1.7 m120 -130.62 128.55 41.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.33 -0.856 . . . . 0.0 110.408 -179.563 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.749 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.1 mt -138.62 149.55 45.33 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.823 -1.173 . . . . 0.0 109.31 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.02 38.92 0.78 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.305 -0.872 . . . . 0.0 110.003 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 159.23 -110.31 0.44 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.095 -1.526 . . . . 0.0 109.95 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.521 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 4.8 mt-30 -145.27 118.17 8.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.248 . . . . 0.0 110.359 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.64 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 5.6 m-85 -141.06 147.82 39.21 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.276 -0.89 . . . . 0.0 110.103 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.762 ' O ' HG23 ' A' ' 353' ' ' ILE . 34.6 m-20 -75.2 96.8 3.37 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.102 -0.999 . . . . 0.0 109.15 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.851 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.8 p-90 -98.73 114.38 26.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.38 -0.825 . . . . 0.0 110.241 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.92 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.3 m -109.15 112.1 24.07 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.423 -0.798 . . . . 0.0 109.403 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.803 HG22 ' CD2' ' A' ' 351' ' ' LEU . 2.8 t -96.33 110.73 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -0.931 . . . . 0.0 110.402 -179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.581 ' HE2' HD11 ' A' ' 320' ' ' ILE . 30.7 ttmt -88.65 147.15 24.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.214 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.791 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 79.5 t -140.64 107.73 2.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.163 -0.961 . . . . 0.0 110.367 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.606 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 23.0 mmtt -69.96 133.82 47.7 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.129 -0.982 . . . . 0.0 109.362 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.911 HD13 ' HA ' ' A' ' 303' ' ' THR . 70.7 mt -88.23 156.98 18.93 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.217 -0.927 . . . . 0.0 111.505 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.688 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.54 173.49 2.36 Favored Pre-proline 0 C--N 1.302 -1.471 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.065 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.688 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -66.84 82.75 0.32 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.438 1.231 . . . . 0.0 109.806 179.583 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.23 22.56 5.17 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.793 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.82 143.34 42.93 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.405 -1.056 . . . . 0.0 110.125 -179.702 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.911 ' HA ' HD13 ' A' ' 298' ' ' LEU . 15.3 p -147.36 144.07 28.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 110.688 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.957 ' CG2' HG21 ' A' ' 319' ' ' VAL . 43.8 t -67.4 135.72 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.478 -0.764 . . . . 0.0 109.985 179.619 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.35 -44.52 0.56 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 8.8 m -131.27 128.7 40.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.06 -1.259 . . . . 0.0 110.811 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.637 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 4.9 p90 -140.74 168.8 18.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.414 -0.804 . . . . 0.0 109.423 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.458 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -159.92 154.19 23.6 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.875 -1.141 . . . . 0.0 111.366 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 65.22 24.28 12.27 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.546 -0.721 . . . . 0.0 110.716 179.594 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.689 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 146.74 0.9 Allowed 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.232 -0.918 . . . . 0.0 110.347 179.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.624 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.1 m120 -81.8 125.06 30.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.091 -1.006 . . . . 0.0 108.895 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 2.4 ttpt -96.58 137.11 36.16 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 121.819 0.818 . . . . 0.0 111.018 -178.816 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.759 ' O ' HG22 ' A' ' 319' ' ' VAL . 4.1 mp0 -124.16 179.37 4.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.618 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.472 ' HG2' ' O ' ' A' ' 313' ' ' GLN . 2.5 mt-10 -139.98 102.05 4.31 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.138 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.518 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.55 46.9 3.65 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.41 82.05 0.12 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -1.126 . . . . 0.0 110.113 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.618 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.87 2.77 62.57 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.837 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.0 m-85 -143.28 -168.41 2.8 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.443 -1.034 . . . . 0.0 109.221 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.957 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.5 t -163.37 153.29 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.176 -0.952 . . . . 0.0 109.727 179.341 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.753 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 17.3 mm -119.77 150.75 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.992 -1.067 . . . . 0.0 110.711 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.4 m-85 -128.91 125.26 37.19 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.387 -0.821 . . . . 0.0 110.164 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.92 ' CG2' HG23 ' A' ' 293' ' ' THR . 35.9 p -131.05 166.44 27.65 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.676 -1.265 . . . . 0.0 109.91 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.513 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.56 119.55 6.59 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.695 1.366 . . . . 0.0 110.882 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.714 HG22 ' HB2' ' A' ' 327' ' ' ASN . 24.9 m -64.57 -121.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.532 -0.73 . . . . 0.0 110.197 -179.737 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.478 ' N ' HG23 ' A' ' 324' ' ' VAL . 5.9 m -100.55 -23.5 14.68 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.746 -1.222 . . . . 0.0 110.57 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.478 ' H ' HG23 ' A' ' 324' ' ' VAL . 9.4 p-90 -124.4 -7.75 7.53 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.128 -0.983 . . . . 0.0 110.447 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.714 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.3 t-20 -89.13 31.83 0.86 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.221 -0.924 . . . . 0.0 110.598 -179.528 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.451 ' CE ' ' O ' ' A' ' 325' ' ' SER . 0.0 OUTLIER -117.48 7.24 12.68 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.17 -0.956 . . . . 0.0 110.045 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -67.62 -150.09 0.19 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.559 ' N ' ' O ' ' A' ' 288' ' ' GLY . 46.1 Cg_endo -73.09 -51.61 0.16 Allowed 'Trans proline' 0 C--N 1.3 -2.024 0 O-C-N 123.835 1.439 . . . . 0.0 109.246 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -108.09 124.23 49.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.617 -0.677 . . . . 0.0 110.184 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -135.44 110.97 9.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.846 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.1 m -105.58 129.57 53.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 110.286 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.739 ' HE2' HG21 ' A' ' 294' ' ' VAL . 12.7 p90 -135.33 175.06 9.93 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.237 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.9 162.46 29.73 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 118.684 -1.722 . . . . 0.0 110.308 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.893 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -149.52 145.37 26.82 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 109.483 179.308 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.893 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.73 119.25 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.005 -1.059 . . . . 0.0 110.017 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.793 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -98.32 144.18 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.201 -0.937 . . . . 0.0 110.105 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.2 m120 -117.91 137.38 52.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.415 -0.803 . . . . 0.0 110.213 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 177.93 -128.42 1.29 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.534 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.1 Cg_endo -66.67 -157.95 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.822 1.433 . . . . 0.0 110.532 179.625 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.611 ' NE2' ' O ' ' A' ' 275' ' ' GLY . 8.9 mp0 -121.01 131.83 54.53 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.033 -1.042 . . . . 0.0 111.099 -179.273 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 107.37 -87.49 0.5 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.535 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.77 126.0 52.54 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.384 -1.068 . . . . 0.0 109.401 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.685 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.5 mtmt -128.27 4.47 5.76 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.041 -1.037 . . . . 0.0 110.659 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.79 HG11 ' CE2' ' A' ' 280' ' ' TYR . 2.7 p -127.67 113.87 33.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.095 -1.003 . . . . 0.0 110.244 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.86 5.96 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.27 -0.894 . . . . 0.0 109.713 179.916 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.441 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.4 OUTLIER -177.59 158.34 1.35 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.238 -0.914 . . . . 0.0 110.947 179.461 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.595 HG12 HG13 ' A' ' 296' ' ' VAL . 27.7 mt -115.34 104.81 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.5 132.13 53.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.204 -0.935 . . . . 0.0 110.266 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.11 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -94.6 130.42 41.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 110.284 179.897 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.531 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 7.5 tt0 -138.91 114.19 9.58 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.241 -0.912 . . . . 0.0 110.12 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.762 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.32 105.45 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.047 -1.033 . . . . 0.0 109.801 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.449 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 3.4 m-20 40.31 29.21 0.05 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.735 -0.603 . . . . 0.0 110.887 -179.873 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 126.02 -26.73 5.26 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.525 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 30.1 mm-40 -84.98 118.13 24.37 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.953 -1.322 . . . . 0.0 110.485 -179.53 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.886 ' O ' HD13 ' A' ' 358' ' ' ILE . 11.4 p -81.91 126.86 39.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.276 -0.89 . . . . 0.0 110.108 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.886 HD13 ' O ' ' A' ' 357' ' ' VAL . 13.0 mm . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.21 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.51 -178.32 3.29 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.918 1.483 . . . . 0.0 110.354 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.504 HG23 ' O ' ' A' ' 258' ' ' THR . 6.1 t -58.09 128.74 38.64 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.272 -0.892 . . . . 0.0 110.055 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 3.0 m -132.16 138.82 33.16 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.187 -0.946 . . . . 0.0 110.466 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -77.23 135.17 14.91 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 O-C-N 124.091 1.574 . . . . 0.0 110.581 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.542 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.5 p -106.25 141.77 23.47 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.375 -0.828 . . . . 0.0 110.215 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.542 ' HD2' HG23 ' A' ' 261' ' ' VAL . 45.2 Cg_endo -71.61 126.48 12.15 Favored 'Trans proline' 0 C--N 1.304 -1.801 0 O-C-N 124.124 1.592 . . . . 0.0 110.481 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.581 HG12 ' O ' ' A' ' 263' ' ' VAL . 39.7 t -122.83 31.15 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.224 -0.923 . . . . 0.0 110.342 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -173.86 60.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.116 -0.99 . . . . 0.0 110.815 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 133.75 -177.89 18.72 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.562 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.64 169.77 17.16 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.446 -1.032 . . . . 0.0 109.841 179.809 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.651 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -161.09 125.41 3.49 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.229 -0.92 . . . . 0.0 110.665 -179.733 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.489 ' N ' HD23 ' A' ' 267' ' ' LEU . 40.4 mt-10 -121.31 111.34 17.23 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.494 -0.754 . . . . 0.0 108.986 179.279 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 281' ' ' ASP . 40.5 t -109.21 137.39 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.99 -1.068 . . . . 0.0 111.798 -178.74 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 11.9 tttp -127.55 155.98 42.94 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 178.813 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.802 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.8 t -142.68 147.17 21.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.25 -1.531 . . . . 0.0 112.097 -178.971 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.518 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.21 114.23 8.98 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.056 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.2 m-20 -96.51 147.89 23.38 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.165 -0.959 . . . . 0.0 111.525 -178.601 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.4 p90 -135.34 18.88 3.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.486 -0.759 . . . . 0.0 109.969 179.206 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.39 -62.78 4.25 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.58 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 3.1 m -62.44 -20.15 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -1.136 . . . . 0.0 110.156 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.92 179.42 48.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.563 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -132.34 143.62 49.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -1.145 . . . . 0.0 110.305 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.802 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.1 mt-10 -95.06 146.24 24.41 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.377 -0.827 . . . . 0.0 109.949 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.689 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 85.1 m-85 -139.6 83.6 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.402 -0.811 . . . . 0.0 110.252 -179.746 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.732 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.89 150.49 48.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.44 -0.787 . . . . 0.0 109.935 179.62 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.731 HG11 HG11 ' A' ' 294' ' ' VAL . 3.3 t -142.78 87.76 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.613 -0.679 . . . . 0.0 109.402 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 283' ' ' THR . . . . . 1.009 HG23 ' OG1' ' A' ' 333' ' ' THR . 20.6 m -85.9 111.63 20.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.25 -0.906 . . . . 0.0 109.556 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -96.62 150.55 20.53 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.223 -0.923 . . . . 0.0 111.059 -179.053 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.562 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.3 m120 -133.23 106.02 7.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.575 -0.703 . . . . 0.0 110.056 -179.496 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.606 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 9.6 mt -115.96 152.37 33.62 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.793 -1.192 . . . . 0.0 109.715 179.478 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.67 38.19 0.78 Allowed 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.091 -1.006 . . . . 0.0 110.003 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.456 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.23 -134.02 3.4 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.368 -1.396 . . . . 0.0 109.751 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.448 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 8.8 mm-40 -124.31 116.65 22.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.136 -1.214 . . . . 0.0 110.531 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.606 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 0.9 OUTLIER -146.67 129.41 16.17 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.317 -0.865 . . . . 0.0 109.741 179.558 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.664 ' O ' HG23 ' A' ' 353' ' ' ILE . 10.2 t70 -57.45 102.56 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.961 -1.087 . . . . 0.0 109.431 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.828 ' CE3' HD13 ' A' ' 284' ' ' LEU . 45.7 p-90 -99.77 110.28 22.67 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.38 -0.825 . . . . 0.0 110.183 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.56 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 29.7 m -102.3 114.95 29.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.327 -0.858 . . . . 0.0 109.798 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.787 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.82 111.09 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.188 -0.945 . . . . 0.0 110.258 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.693 ' HA ' HD13 ' A' ' 320' ' ' ILE . 30.4 ttpt -87.33 149.82 24.26 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.314 -0.866 . . . . 0.0 109.591 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.684 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 94.3 t -148.24 106.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.17 -0.957 . . . . 0.0 110.417 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.581 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtm -70.04 134.35 48.17 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.269 179.709 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.92 HD13 ' HA ' ' A' ' 303' ' ' THR . 94.4 mt -87.26 160.53 18.41 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.393 -0.817 . . . . 0.0 111.369 -178.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.837 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.57 175.8 1.25 Allowed Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.672 -0.642 . . . . 0.0 109.78 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.785 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.3 Cg_endo -68.65 80.57 0.61 Allowed 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.752 1.396 . . . . 0.0 109.6 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.78 20.79 5.94 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.837 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.79 143.47 36.31 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.583 -0.951 . . . . 0.0 110.125 -179.649 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.92 ' HA ' HD13 ' A' ' 298' ' ' LEU . 56.0 p -145.1 143.16 30.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 110.635 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.676 HG21 HG11 ' A' ' 319' ' ' VAL . 31.7 t -69.98 129.0 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.319 -0.863 . . . . 0.0 109.957 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.61 -32.72 1.54 Allowed Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.097 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.418 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 4.8 m -132.88 121.06 22.33 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.999 -1.295 . . . . 0.0 110.951 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.548 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 45.4 p90 -140.12 154.31 46.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.398 -0.814 . . . . 0.0 109.593 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.497 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -147.55 158.3 43.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.954 -1.091 . . . . 0.0 111.332 -179.132 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.507 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 61.36 24.72 14.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.473 -0.767 . . . . 0.0 110.973 179.481 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.704 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.82 140.01 0.54 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 110.13 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.566 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.3 m120 -77.14 121.25 23.35 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.042 -1.036 . . . . 0.0 109.159 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.591 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 20.2 ttpt -88.44 138.58 31.3 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.826 0.822 . . . . 0.0 111.048 -178.927 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.603 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.57 174.45 7.41 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.065 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -138.46 109.26 6.67 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.368 -0.833 . . . . 0.0 110.419 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.57 39.9 2.7 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.21 80.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -1.152 . . . . 0.0 110.23 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.619 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.87 3.1 57.11 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.699 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -147.46 -173.84 4.37 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.431 -1.041 . . . . 0.0 109.065 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.6 t -159.13 159.85 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.103 -0.998 . . . . 0.0 109.526 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.693 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.2 mm -129.38 151.2 35.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.074 -179.494 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.66 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 39.5 m-85 -127.49 130.02 48.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.248 -0.907 . . . . 0.0 110.287 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.533 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -130.1 169.36 13.61 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.826 -1.171 . . . . 0.0 110.117 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.533 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.3 Cg_endo -65.04 123.82 12.15 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.859 1.452 . . . . 0.0 110.809 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.747 HG22 ' HB2' ' A' ' 327' ' ' ASN . 20.3 m -73.22 -116.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.537 -0.727 . . . . 0.0 110.211 -179.529 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.504 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -108.16 -23.98 11.73 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.699 -1.251 . . . . 0.0 110.668 -179.544 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.435 ' H ' HG23 ' A' ' 324' ' ' VAL . 4.4 p-90 -124.0 5.61 8.63 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.181 -0.949 . . . . 0.0 110.306 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.747 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -108.57 49.95 0.79 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 110.37 -179.818 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.474 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -124.29 -11.35 7.46 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.317 -0.864 . . . . 0.0 109.882 179.732 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.8 -158.28 0.02 OUTLIER Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.831 -1.307 . . . . 0.0 109.831 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -75.59 6.83 3.4 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.115 1.587 . . . . 0.0 110.738 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -161.26 124.39 3.21 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 120.964 -1.085 . . . . 0.0 109.68 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.574 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -142.65 106.04 4.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.227 -0.92 . . . . 0.0 109.887 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 333' ' ' THR . . . . . 1.009 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.1 m -98.76 131.74 44.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.283 -0.886 . . . . 0.0 110.291 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.787 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.1 p90 -139.34 175.14 9.81 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.548 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.69 158.42 27.75 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.852 -1.642 . . . . 0.0 110.015 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.935 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.7 OUTLIER -143.27 145.18 32.51 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.556 -0.967 . . . . 0.0 109.709 179.371 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.935 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.51 120.32 61.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.812 HG11 ' HB1' ' A' ' 302' ' ' ALA . 9.9 t -96.24 160.61 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 109.858 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -130.66 129.62 42.87 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.2 -0.937 . . . . 0.0 110.722 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -177.58 -125.11 0.89 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.532 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.8 Cg_endo -67.44 -161.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 123.87 1.458 . . . . 0.0 110.256 179.415 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 342' ' ' GLN . . . . . . . . . . . . . 1.6 mp0 -118.16 124.28 47.58 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.024 -1.048 . . . . 0.0 111.032 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 118.6 -85.58 0.39 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.596 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -113.64 136.86 52.37 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.276 -1.132 . . . . 0.0 109.758 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.617 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.5 mtmt -137.97 18.52 2.82 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.074 -1.017 . . . . 0.0 110.791 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.642 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.6 p -140.28 118.04 10.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 110.475 179.727 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.458 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -50.08 -44.43 51.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.478 -0.764 . . . . 0.0 110.607 -179.734 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.44 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.7 pt-20 -176.73 158.66 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.076 -1.015 . . . . 0.0 110.9 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.593 ' CG1' HG13 ' A' ' 296' ' ' VAL . 54.1 mt -121.79 114.79 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.44 -0.787 . . . . 0.0 109.823 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.68 150.35 36.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.331 -0.856 . . . . 0.0 110.55 -179.504 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -105.44 127.6 53.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.3 -0.875 . . . . 0.0 109.773 179.597 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -138.52 112.85 8.73 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.137 -0.977 . . . . 0.0 110.447 -179.919 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.664 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -92.1 109.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.945 . . . . 0.0 109.981 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 354' ' ' ASN . . . . . . . . . . . . . 3.9 m-20 46.08 32.85 1.51 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.52 -0.737 . . . . 0.0 110.433 -179.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.39 -21.26 26.68 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.457 ' O ' ' N ' ' A' ' 353' ' ' ILE . 69.0 mm-40 -83.23 109.41 17.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.271 -1.135 . . . . 0.0 110.29 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 4.5 p -70.38 131.03 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -0.882 . . . . 0.0 110.09 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.641 HG22 ' O ' ' A' ' 358' ' ' ILE . 29.8 mm . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.152 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -73.2 -178.24 3.48 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 123.999 1.526 . . . . 0.0 110.137 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.633 HG23 ' O ' ' A' ' 258' ' ' THR . 6.6 t -57.56 119.32 6.36 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.2 -0.938 . . . . 0.0 109.859 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 7.3 p -112.84 128.95 24.95 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.106 -0.996 . . . . 0.0 110.343 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.65 139.65 31.33 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 124.041 1.548 . . . . 0.0 110.254 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.528 HG23 ' HD2' ' A' ' 262' ' ' PRO . 7.4 p -78.04 143.34 65.65 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.258 -0.901 . . . . 0.0 110.565 -179.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.588 ' HA ' ' HA ' ' A' ' 358' ' ' ILE . 50.2 Cg_endo -81.57 124.63 4.71 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 O-C-N 124.117 1.588 . . . . 0.0 110.528 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.644 ' H ' HD13 ' A' ' 358' ' ' ILE . 4.1 t -112.71 25.2 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.171 -0.956 . . . . 0.0 109.508 179.38 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.625 ' HB2' HD11 ' A' ' 358' ' ' ILE . 0.5 OUTLIER 172.8 75.49 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.367 -0.833 . . . . 0.0 110.492 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.4 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . 111.45 -164.27 12.15 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.564 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.74 163.05 31.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -1.126 . . . . 0.0 109.948 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.955 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.22 132.68 5.53 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.197 -179.704 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.663 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mt-10 -133.49 132.38 40.95 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 179.262 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.685 HG13 ' O ' ' A' ' 281' ' ' ASP . 21.9 t -123.75 134.14 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.71 -1.244 . . . . 0.0 111.976 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.94 151.84 38.32 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 178.657 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.787 HG13 ' O ' ' A' ' 279' ' ' GLU . 77.9 t -140.8 146.16 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 120.368 -1.458 . . . . 0.0 112.018 -179.004 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.513 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.0 113.83 9.23 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.707 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.8 m-20 -101.29 140.87 34.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.893 -1.129 . . . . 0.0 111.395 -178.481 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.821 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.0 p90 -123.87 19.76 9.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.654 -0.654 . . . . 0.0 109.375 179.506 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.561 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 82.53 -62.21 4.62 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.474 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.511 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 0.5 OUTLIER -60.62 -18.15 51.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.259 -1.142 . . . . 0.0 109.951 179.655 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.58 177.23 48.39 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.569 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -133.31 137.8 46.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -1.115 . . . . 0.0 110.124 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.787 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.5 mt-10 -93.99 145.54 24.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.251 -0.906 . . . . 0.0 110.163 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.682 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.1 m-85 -139.99 85.02 2.0 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.448 -0.782 . . . . 0.0 110.746 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.685 ' O ' HG13 ' A' ' 269' ' ' VAL . 3.7 t0 -69.54 141.46 53.83 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.334 -0.853 . . . . 0.0 109.555 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.733 HG11 HG11 ' A' ' 294' ' ' VAL . 4.0 t -132.85 91.71 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.486 -0.759 . . . . 0.0 109.506 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.883 HG23 ' OG1' ' A' ' 333' ' ' THR . 2.7 m -86.67 122.31 30.4 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.32 -0.862 . . . . 0.0 109.982 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.102 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.67 149.04 32.13 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.296 -0.877 . . . . 0.0 110.149 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.564 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.4 m120 -134.03 109.4 8.95 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.316 -0.865 . . . . 0.0 110.637 -178.758 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.633 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.1 mt -119.59 157.47 28.35 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.722 -1.236 . . . . 0.0 110.251 179.731 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 287' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 287' ' ' ASP . 15.3 p-10 -91.43 36.61 0.94 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.125 -0.984 . . . . 0.0 109.544 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.5 -136.1 4.18 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.464 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -121.81 116.31 24.21 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.201 -1.176 . . . . 0.0 110.847 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.633 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.3 m-85 -142.39 138.28 31.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.313 -0.867 . . . . 0.0 109.435 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.622 ' O ' HG23 ' A' ' 353' ' ' ILE . 14.5 t0 -67.7 97.46 0.63 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.841 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.829 ' CE3' HD13 ' A' ' 284' ' ' LEU . 46.3 p-90 -96.17 109.86 22.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.037 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.838 HG23 ' CG2' ' A' ' 322' ' ' THR . 3.1 m -102.06 115.33 30.31 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.846 . . . . 0.0 109.592 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.76 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.46 110.99 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 110.461 -179.535 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.724 ' HA ' HD13 ' A' ' 320' ' ' ILE . 28.5 ttpt -86.37 149.59 24.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.364 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.66 HG13 HG12 ' A' ' 349' ' ' ILE . 70.8 t -148.14 108.17 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.123 -0.985 . . . . 0.0 110.706 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.578 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.0 mmtp -70.81 131.79 44.34 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.132 -0.98 . . . . 0.0 109.675 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.978 HD13 ' HA ' ' A' ' 303' ' ' THR . 98.5 mt -85.52 156.05 20.94 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.259 -0.901 . . . . 0.0 111.599 -179.095 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.759 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -66.66 171.04 4.79 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.615 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.7 Cg_endo -66.87 81.86 0.34 Allowed 'Trans proline' 0 C--N 1.305 -1.757 0 O-C-N 123.518 1.273 . . . . 0.0 109.727 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.76 18.06 5.76 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.801 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -108.65 149.19 29.3 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.385 -1.068 . . . . 0.0 110.105 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.978 ' HA ' HD13 ' A' ' 298' ' ' LEU . 24.8 p -154.56 144.21 21.53 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.122 -0.987 . . . . 0.0 110.897 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.776 HG21 HG11 ' A' ' 319' ' ' VAL . 24.7 t -68.9 124.06 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -106.39 -33.71 3.32 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -142.0 131.21 23.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.005 -1.291 . . . . 0.0 110.868 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.551 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 39.2 p90 -141.78 162.89 34.36 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.29 -0.881 . . . . 0.0 109.855 179.485 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.503 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -152.31 159.51 43.47 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.928 -1.107 . . . . 0.0 110.946 -179.524 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 59.84 23.91 12.9 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.472 -0.767 . . . . 0.0 111.091 179.471 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.71 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.09 145.46 0.8 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.325 -0.86 . . . . 0.0 110.179 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.514 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.3 m120 -83.81 120.03 25.55 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.202 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.723 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.8 ttpt -87.03 145.38 26.5 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.946 0.879 . . . . 0.0 111.044 -178.981 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.794 ' O ' HG22 ' A' ' 319' ' ' VAL . 1.7 mp0 -130.41 179.03 6.16 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.013 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.602 ' HG2' HG22 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -140.0 101.76 4.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.702 -0.624 . . . . 0.0 110.108 179.546 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -87.51 40.4 3.08 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.493 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 9.5 t30 63.65 79.71 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.304 -1.115 . . . . 0.0 110.084 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.591 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 95.0 3.81 61.78 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.774 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.791 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.7 m-85 -143.3 -170.66 3.32 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.996 . . . . 0.0 108.784 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.794 HG22 ' O ' ' A' ' 313' ' ' GLN . 3.3 t -161.68 154.29 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 120.976 -1.077 . . . . 0.0 110.019 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.8 ' CG2' HG22 ' A' ' 293' ' ' THR . 22.0 mm -125.17 142.85 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.756 -179.583 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.0 m-85 -119.6 127.05 52.59 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.435 -0.791 . . . . 0.0 109.637 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.838 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.1 p -126.65 169.15 12.52 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 120.877 -1.14 . . . . 0.0 110.5 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.528 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.5 Cg_endo -65.04 112.23 1.98 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 O-C-N 124.049 1.552 . . . . 0.0 111.044 -179.5 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.637 HG22 ' HB2' ' A' ' 327' ' ' ASN . 16.5 m -56.96 -114.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.634 -0.666 . . . . 0.0 109.918 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.494 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -117.17 -20.26 9.32 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.7 -1.25 . . . . 0.0 110.417 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.49 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 5.1 p-90 -120.78 -20.65 6.92 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.204 -0.935 . . . . 0.0 110.408 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.637 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -84.23 46.14 1.18 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.081 -1.012 . . . . 0.0 109.989 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.491 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 10.7 mtmt -119.84 -9.63 9.66 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.359 -0.838 . . . . 0.0 109.675 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.5 -157.45 0.01 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.535 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.68 5.32 4.39 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.065 1.561 . . . . 0.0 110.682 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.408 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 4.2 m -162.83 119.88 1.94 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.998 -1.064 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.08 112.0 7.52 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.299 -0.875 . . . . 0.0 110.247 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.883 ' OG1' HG23 ' A' ' 283' ' ' THR . 35.1 m -103.72 132.26 50.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 110.049 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.76 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.4 p90 -135.17 173.93 11.17 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.436 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.46 151.76 23.65 Favored Glycine 0 N--CA 1.486 1.977 0 C-N-CA 118.827 -1.654 . . . . 0.0 110.242 -179.357 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.92 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -139.0 147.93 42.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.684 -0.892 . . . . 0.0 109.476 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.92 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.6 119.46 59.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.006 -1.059 . . . . 0.0 110.025 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.801 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -96.84 145.2 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.94 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.507 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 2.0 m-80 -115.63 133.23 56.24 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.391 -0.818 . . . . 0.0 110.341 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.507 ' N ' ' HE3' ' A' ' 345' ' ' LYS . . . 179.33 -140.31 4.29 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.483 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 50.3 Cg_endo -82.63 116.15 2.55 Favored 'Trans proline' 0 C--N 1.302 -1.896 0 O-C-N 124.065 1.561 . . . . 0.0 110.903 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.561 ' HB3' ' HA2' ' A' ' 275' ' ' GLY . 1.7 pm0 -41.09 153.34 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.295 -0.878 . . . . 0.0 110.568 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 96.45 66.42 0.94 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.439 ' O ' ' O ' ' A' ' 343' ' ' GLY . 0.7 OUTLIER 61.23 118.86 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.324 -1.103 . . . . 0.0 109.373 -179.479 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.759 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 3.1 mtpt -123.61 16.09 9.55 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.004 -1.06 . . . . 0.0 110.13 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.621 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.1 p -126.03 113.71 35.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.448 -0.783 . . . . 0.0 109.779 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.501 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.4 mm-40 -41.97 -47.33 4.34 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.995 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 18.1 pt-20 -177.28 158.52 1.48 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.872 . . . . 0.0 110.524 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.66 HG12 HG13 ' A' ' 296' ' ' VAL . 11.9 mt -118.14 122.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.237 -0.914 . . . . 0.0 110.068 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.11 132.19 50.66 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.219 -0.926 . . . . 0.0 110.175 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.102 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -92.66 131.22 37.94 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.174 -0.954 . . . . 0.0 110.22 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.4 tt0 -139.68 114.53 9.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.168 -0.957 . . . . 0.0 110.358 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.622 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.1 mt -92.05 110.9 23.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.976 -1.077 . . . . 0.0 110.28 179.665 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.453 ' C ' ' O ' ' A' ' 353' ' ' ILE . 4.2 m-20 37.47 32.1 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.716 -0.615 . . . . 0.0 111.115 179.587 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 112.26 8.86 21.01 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.513 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 2.5 mp0 -116.4 111.46 20.06 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.11 -1.229 . . . . 0.0 110.058 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -75.3 135.67 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.227 -0.92 . . . . 0.0 110.433 -179.662 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.644 HD13 ' H ' ' A' ' 263' ' ' VAL . 31.9 mm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.223 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -78.12 179.99 5.98 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.955 1.503 . . . . 0.0 110.582 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.435 HG23 ' O ' ' A' ' 258' ' ' THR . 4.3 t -63.48 130.46 44.5 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.352 -0.842 . . . . 0.0 110.046 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.3 p -98.92 162.33 21.89 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.221 -0.924 . . . . 0.0 110.204 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.07 131.06 17.45 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.981 1.517 . . . . 0.0 110.503 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.594 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.6 p -93.13 143.67 27.13 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.267 -0.896 . . . . 0.0 110.237 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.594 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.0 Cg_endo -75.54 155.36 40.44 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 O-C-N 124.122 1.59 . . . . 0.0 110.019 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.474 HG12 ' O ' ' A' ' 263' ' ' VAL . 18.5 t -145.88 30.14 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.195 -0.941 . . . . 0.0 110.064 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -177.52 78.1 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.249 -0.907 . . . . 0.0 110.749 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.44 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . 106.46 -169.27 15.26 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.3 179.289 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.464 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.78 168.31 19.79 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.523 -0.986 . . . . 0.0 109.631 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.96 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.3 tm? -160.24 136.86 8.96 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.996 -1.065 . . . . 0.0 111.165 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.662 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.5 OUTLIER -136.19 123.36 21.71 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.553 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.83 HG23 HD11 ' A' ' 267' ' ' LEU . 50.2 t -116.97 134.69 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.969 -1.082 . . . . 0.0 111.738 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 37.0 mttm -118.29 157.35 27.23 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.681 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.58 142.2 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.256 -1.528 . . . . 0.0 112.115 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.517 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -138.04 113.04 9.14 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.102 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.633 ' OD1' ' HB1' ' A' ' 278' ' ' ALA . 80.2 m-20 -98.78 146.21 26.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.958 -1.089 . . . . 0.0 111.444 -178.766 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.826 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.6 p90 -131.71 23.16 4.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.608 -0.682 . . . . 0.0 109.474 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.496 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 80.55 -64.23 4.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.49 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -59.13 -22.6 61.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.293 -1.122 . . . . 0.0 110.226 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.516 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.44 -171.88 38.4 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.633 ' HB1' ' OD1' ' A' ' 273' ' ' ASP . . . -142.87 142.05 31.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -1.072 . . . . 0.0 110.009 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.681 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.7 mt-10 -97.98 146.14 25.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.414 -0.804 . . . . 0.0 110.329 -179.508 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.692 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 81.6 m-85 -141.15 82.99 1.86 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.398 -0.814 . . . . 0.0 110.653 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.782 ' O ' HG13 ' A' ' 269' ' ' VAL . 9.3 t0 -64.91 151.53 45.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.769 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.798 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.9 t -145.05 89.34 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.55 -0.719 . . . . 0.0 109.964 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.655 HG23 ' OG1' ' A' ' 333' ' ' THR . 72.2 m -86.75 126.36 34.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.131 -0.981 . . . . 0.0 109.717 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.075 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.96 148.24 39.01 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.04 -1.038 . . . . 0.0 110.902 -179.172 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.93 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.3 m120 -128.4 134.82 48.89 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.484 -0.76 . . . . 0.0 109.949 -179.696 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.93 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.2 mt -143.7 149.97 37.99 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.62 -1.3 . . . . 0.0 110.158 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -88.41 38.49 0.87 Allowed 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.278 -0.889 . . . . 0.0 109.398 179.222 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.97 -145.47 11.05 Favored Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.787 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.507 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 4.8 mt-30 -112.36 98.43 7.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -1.167 . . . . 0.0 110.665 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.643 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -120.21 154.97 34.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.257 -0.902 . . . . 0.0 110.295 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.876 ' O ' HG23 ' A' ' 353' ' ' ILE . 23.0 t0 -85.76 97.46 10.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 109.242 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.951 ' CE3' HD13 ' A' ' 284' ' ' LEU . 51.9 p-90 -95.38 108.03 20.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.169 -0.957 . . . . 0.0 110.819 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.944 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.8 m -100.11 115.13 29.09 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.543 -0.723 . . . . 0.0 109.304 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.835 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.1 t -96.71 111.38 26.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 121.187 -0.946 . . . . 0.0 110.162 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.717 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.3 ttpp -87.74 149.37 24.24 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.404 -0.81 . . . . 0.0 109.247 179.461 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.692 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 84.4 t -148.23 107.71 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.079 -1.013 . . . . 0.0 110.225 -179.603 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.582 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 21.0 mmtp -69.95 132.37 45.84 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.344 -0.848 . . . . 0.0 109.587 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.973 HD13 ' HA ' ' A' ' 303' ' ' THR . 87.8 mt -87.37 158.71 18.96 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.646 -0.659 . . . . 0.0 110.943 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.839 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.32 173.86 2.06 Favored Pre-proline 0 C--N 1.303 -1.426 0 O-C-N 121.459 -0.775 . . . . 0.0 109.285 179.07 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.712 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.34 79.7 0.59 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 123.619 1.326 . . . . 0.0 109.637 179.576 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.26 17.02 5.87 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.221 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.839 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -104.26 147.09 27.88 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.467 -1.019 . . . . 0.0 110.12 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.973 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.6 p -148.68 143.86 26.76 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.873 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.821 ' CG2' HG21 ' A' ' 319' ' ' VAL . 92.1 t -71.55 121.74 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.317 -0.864 . . . . 0.0 109.951 179.623 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.48 -21.34 6.92 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.5 OUTLIER -139.51 124.14 18.37 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.029 -1.277 . . . . 0.0 111.216 -179.464 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -145.23 164.57 30.96 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.311 -0.868 . . . . 0.0 109.884 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.473 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.4 p90 -158.34 161.29 37.6 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.948 -1.095 . . . . 0.0 110.995 -179.409 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.547 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.1 OUTLIER 54.47 29.03 10.44 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.471 -0.768 . . . . 0.0 110.843 179.517 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.697 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.33 144.43 0.71 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.285 -0.885 . . . . 0.0 109.872 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.646 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.2 m120 -82.23 115.81 21.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.092 -1.005 . . . . 0.0 109.355 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 8.7 ttpt -83.27 142.13 31.34 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.803 0.811 . . . . 0.0 110.757 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.559 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 2.9 tm0? -129.38 173.81 10.2 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.062 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.579 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.4 mt-10 -139.49 101.36 4.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.309 -0.869 . . . . 0.0 110.497 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.12 42.84 2.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 14.2 m-20 53.8 86.16 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.311 -1.111 . . . . 0.0 110.174 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.33 -0.27 55.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.612 ' O ' HG23 ' A' ' 319' ' ' VAL . 0.5 OUTLIER -150.26 -172.79 4.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.371 -1.076 . . . . 0.0 109.642 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.821 HG21 ' CG2' ' A' ' 304' ' ' VAL . 6.1 t -156.89 156.37 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.425 -0.797 . . . . 0.0 109.337 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.717 HD13 ' HA ' ' A' ' 295' ' ' LYS . 45.6 mm -126.56 147.83 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.08 -1.012 . . . . 0.0 111.22 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 83.3 m-85 -125.29 125.1 43.0 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.399 -0.813 . . . . 0.0 109.661 179.055 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.944 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.6 p -127.7 169.86 11.52 Favored Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 120.82 -1.175 . . . . 0.0 110.232 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.7 Cg_endo -64.26 115.76 3.35 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.898 1.473 . . . . 0.0 111.52 -179.088 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.826 HG22 ' CG ' ' A' ' 327' ' ' ASN . 17.3 m -64.16 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.66 -0.65 . . . . 0.0 110.192 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.495 ' N ' HG23 ' A' ' 324' ' ' VAL . 19.9 m -116.78 -12.57 10.8 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.696 -1.253 . . . . 0.0 111.198 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.495 ' H ' HG23 ' A' ' 324' ' ' VAL . 13.3 p-90 -133.72 1.37 3.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.811 -1.18 . . . . 0.0 111.133 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.826 ' CG ' HG22 ' A' ' 324' ' ' VAL . 28.3 p-10 -110.38 50.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.987 -1.071 . . . . 0.0 110.508 -179.589 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -129.09 10.51 5.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.267 -0.896 . . . . 0.0 109.664 179.466 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.418 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -73.89 -151.58 2.13 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.517 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -74.09 2.26 6.3 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.094 1.576 . . . . 0.0 110.838 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.48 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 27.5 m -167.28 122.74 1.08 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.35 -0.843 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.479 ' HB1' ' HB2' ' A' ' 327' ' ' ASN . . . -142.56 118.17 10.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.134 -0.979 . . . . 0.0 110.321 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.655 ' OG1' HG23 ' A' ' 283' ' ' THR . 18.0 m -104.36 148.55 26.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 110.214 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.835 ' HE2' HG21 ' A' ' 294' ' ' VAL . 5.9 p90 -153.88 175.22 13.59 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -156.44 157.91 28.29 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.838 -1.649 . . . . 0.0 110.548 -179.418 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.921 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -141.52 147.6 38.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.411 -1.052 . . . . 0.0 110.308 179.594 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.921 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.96 122.69 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.078 -1.014 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.697 HG11 ' HB1' ' A' ' 302' ' ' ALA . 6.3 t -100.45 156.23 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.132 -0.98 . . . . 0.0 110.782 -179.29 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -123.97 132.72 53.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.506 -0.746 . . . . 0.0 110.337 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.416 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -176.67 -132.52 1.65 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.539 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.1 Cg_endo -67.29 -165.63 0.11 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 123.885 1.466 . . . . 0.0 110.691 179.744 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.496 ' HG3' ' HA2' ' A' ' 275' ' ' GLY . 18.5 mp0 -115.59 21.32 14.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.117 -0.989 . . . . 0.0 110.633 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.498 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . -134.97 76.86 0.38 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.498 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.7 OUTLIER 68.17 141.93 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.371 -1.076 . . . . 0.0 108.726 -178.844 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.619 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.2 OUTLIER -135.42 15.92 3.43 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.8 -1.188 . . . . 0.0 111.077 -179.163 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.63 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.7 p -135.13 117.72 22.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.163 -0.961 . . . . 0.0 110.11 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.459 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -50.34 -45.15 54.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.343 -0.848 . . . . 0.0 110.425 -179.534 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -176.61 154.19 1.2 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -0.994 . . . . 0.0 110.703 -179.876 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.651 HG12 HG13 ' A' ' 296' ' ' VAL . 23.3 mt -113.97 124.8 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.175 -0.953 . . . . 0.0 110.133 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.21 154.39 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.389 -0.82 . . . . 0.0 109.974 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.075 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -120.65 124.51 45.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.188 -0.945 . . . . 0.0 109.659 179.478 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.508 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 34.6 tt0 -138.63 117.11 12.05 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.221 -0.925 . . . . 0.0 110.181 -179.796 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.876 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.4 107.68 19.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.165 -0.959 . . . . 0.0 109.76 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 354' ' ' ASN . . . . . . . . . . . . . 5.7 m-20 43.66 26.74 0.13 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 110.381 -179.647 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 123.41 -31.92 4.48 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 52.3 mm-40 -75.99 114.56 14.76 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.084 -1.244 . . . . 0.0 110.47 -179.65 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.791 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -79.09 133.34 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.146 -0.972 . . . . 0.0 110.226 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.791 HD13 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.068 -0.967 . . . . 0.0 110.299 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.52 -178.3 3.28 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.119 1.589 . . . . 0.0 110.66 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.528 HG23 ' O ' ' A' ' 258' ' ' THR . 7.4 t -59.15 128.55 37.74 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.422 -0.799 . . . . 0.0 110.423 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 5.3 m -141.57 112.32 6.47 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.201 -0.937 . . . . 0.0 110.192 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -76.37 144.53 26.02 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 123.917 1.483 . . . . 0.0 110.503 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.485 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.5 p -108.65 140.75 22.12 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.199 -0.938 . . . . 0.0 110.445 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.485 ' HD2' HG23 ' A' ' 261' ' ' VAL . 51.0 Cg_endo -78.64 151.55 25.28 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 124.128 1.594 . . . . 0.0 110.531 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 4.8 t -143.03 26.82 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.366 -0.833 . . . . 0.0 109.95 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 2.6 m -177.46 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.341 -0.849 . . . . 0.0 110.308 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.38 -174.04 25.67 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.696 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.571 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.33 163.79 31.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.366 -1.079 . . . . 0.0 110.049 -179.774 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.653 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -156.73 122.8 4.9 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.106 -0.996 . . . . 0.0 110.737 -179.868 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.3 mt-10 -123.31 114.29 20.01 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 57.6 t -110.05 124.51 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.971 -1.081 . . . . 0.0 112.347 -178.105 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.9 mmtt -111.61 156.79 21.26 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.136 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.752 HG13 ' O ' ' A' ' 279' ' ' GLU . 83.0 t -144.61 147.92 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.426 -1.421 . . . . 0.0 112.238 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -136.8 110.05 7.83 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.928 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.4 p30 -95.34 146.35 24.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.074 -1.016 . . . . 0.0 111.247 -178.746 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.854 ' CH2' HG23 ' A' ' 337' ' ' ILE . 29.4 p90 -129.0 16.86 6.21 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.517 -0.739 . . . . 0.0 109.963 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.4 -54.57 3.52 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.494 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 2.8 m -74.63 -19.35 60.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.226 -1.161 . . . . 0.0 110.256 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.19 -175.85 42.98 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.86 ' HB2' ' NZ ' ' A' ' 345' ' ' LYS . . . -140.6 140.1 35.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -1.15 . . . . 0.0 110.238 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.752 ' O ' HG13 ' A' ' 271' ' ' VAL . 10.7 mt-10 -92.88 146.12 23.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.402 -0.811 . . . . 0.0 110.077 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.699 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 96.5 m-85 -133.33 89.96 2.67 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.44 -0.788 . . . . 0.0 110.64 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.586 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -77.21 105.03 8.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 109.821 179.525 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.716 HG11 HG11 ' A' ' 294' ' ' VAL . 6.6 t -97.72 92.53 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.466 -0.772 . . . . 0.0 110.368 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.927 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.3 m -86.87 112.77 22.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.022 -1.049 . . . . 0.0 109.931 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.041 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -100.41 149.73 23.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.124 -0.985 . . . . 0.0 110.497 -179.504 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.571 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -133.49 106.71 7.6 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.347 -0.846 . . . . 0.0 110.541 -179.252 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.598 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 8.9 mt -113.63 164.88 13.11 Favored 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.778 -1.201 . . . . 0.0 110.302 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -97.97 35.63 1.69 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.269 -0.894 . . . . 0.0 110.11 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.45 -116.01 0.69 Allowed Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.277 -1.44 . . . . 0.0 109.887 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.438 ' HG2' ' O ' ' A' ' 288' ' ' GLY . 11.8 mm-40 -139.81 107.14 5.52 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.175 -1.191 . . . . 0.0 110.55 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.598 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.2 m-85 -137.08 129.17 29.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.2 -0.937 . . . . 0.0 109.723 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.643 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.4 OUTLIER -57.81 101.59 0.08 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.458 179.565 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.836 ' CE3' HD13 ' A' ' 284' ' ' LEU . 45.6 p-90 -98.4 107.72 20.24 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.373 -0.829 . . . . 0.0 109.968 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.86 HG22 ' CG2' ' A' ' 320' ' ' ILE . 2.0 m -98.87 115.07 28.01 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.328 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.759 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.3 t -96.27 111.67 26.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.114 -0.991 . . . . 0.0 110.548 -179.202 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.711 ' HA ' HD13 ' A' ' 320' ' ' ILE . 8.4 ttpt -85.71 148.03 26.06 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.365 -0.834 . . . . 0.0 109.541 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.616 HG13 HG12 ' A' ' 349' ' ' ILE . 54.0 t -148.41 110.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 120.965 -1.084 . . . . 0.0 110.762 -179.314 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.6 ' O ' HG23 ' A' ' 346' ' ' VAL . 47.2 mmtt -74.36 131.82 41.46 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.292 -0.88 . . . . 0.0 109.628 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.979 HD13 ' HA ' ' A' ' 303' ' ' THR . 83.5 mt -83.95 151.65 24.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.261 -0.899 . . . . 0.0 111.445 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.824 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -55.55 173.69 0.25 Allowed Pre-proline 0 N--CA 1.487 1.401 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.158 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.681 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -68.76 78.27 0.71 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.592 1.312 . . . . 0.0 109.516 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.86 22.95 3.78 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 -179.279 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.824 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -109.03 154.79 21.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.307 -1.114 . . . . 0.0 110.337 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.979 ' HA ' HD13 ' A' ' 298' ' ' LEU . 41.0 p -152.33 144.36 23.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.179 -0.951 . . . . 0.0 110.716 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.9 ' CG2' HG21 ' A' ' 319' ' ' VAL . 49.0 t -72.22 117.74 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.462 -0.774 . . . . 0.0 109.89 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.94 -36.44 3.69 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.5 m -134.64 145.7 48.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.05 -1.265 . . . . 0.0 111.026 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.583 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 33.8 p90 -160.23 165.08 32.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.525 -0.734 . . . . 0.0 109.565 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.512 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -154.3 165.13 37.28 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 120.901 -1.124 . . . . 0.0 111.356 -179.408 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.44 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 51.58 28.55 4.75 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.54 -0.725 . . . . 0.0 111.488 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.751 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 138.83 0.47 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.083 -1.01 . . . . 0.0 110.302 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.651 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.6 m120 -77.64 115.39 17.36 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 109.112 179.326 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.601 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.1 ttpt -84.28 140.22 31.8 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.805 0.812 . . . . 0.0 110.738 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.686 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.66 174.95 7.13 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 179.204 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -137.61 109.42 7.11 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.331 -0.856 . . . . 0.0 110.276 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.426 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -99.85 46.87 1.35 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 58.47 85.72 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 110.5 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.552 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 89.86 -0.09 78.98 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.833 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.5 m-85 -138.78 -170.04 2.76 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.235 -1.156 . . . . 0.0 109.281 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -163.08 157.31 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.81 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.86 ' CG2' HG22 ' A' ' 293' ' ' THR . 7.1 mm -127.58 151.8 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.227 -0.921 . . . . 0.0 110.929 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.627 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 99.4 m-85 -128.72 125.56 38.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.928 -1.108 . . . . 0.0 110.144 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.762 ' CG2' HG23 ' A' ' 293' ' ' THR . 11.9 p -124.75 167.83 14.9 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 120.876 -1.14 . . . . 0.0 109.596 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.48 123.84 12.01 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 O-C-N 123.737 1.388 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.651 HG12 ' OD1' ' A' ' 311' ' ' ASN . 18.5 m -70.61 -114.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.497 -0.752 . . . . 0.0 109.855 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.51 ' N ' HG23 ' A' ' 324' ' ' VAL . 2.6 m -110.46 -13.36 14.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.743 -1.223 . . . . 0.0 110.547 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.536 ' H ' HG23 ' A' ' 324' ' ' VAL . 7.3 p-90 -132.86 -6.17 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.155 -0.965 . . . . 0.0 110.928 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.555 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -97.49 46.68 1.02 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.046 -1.034 . . . . 0.0 110.216 -179.785 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -124.43 -8.05 7.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.099 -1.0 . . . . 0.0 109.92 -179.966 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.22 -157.87 0.02 OUTLIER Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.534 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -75.88 8.16 2.87 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.804 1.423 . . . . 0.0 111.0 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.407 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.1 m -165.17 115.53 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.525 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -132.83 109.04 9.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.237 -0.915 . . . . 0.0 110.27 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.927 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.2 m -100.03 122.26 42.65 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.308 -0.87 . . . . 0.0 110.111 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.759 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.7 p90 -128.9 175.17 8.86 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.628 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.44 157.8 27.48 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.823 -1.656 . . . . 0.0 110.268 -179.368 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.949 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -145.28 148.98 34.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.7 -0.882 . . . . 0.0 109.265 179.449 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.949 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.24 118.25 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.023 -1.048 . . . . 0.0 109.679 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.1 t -96.23 152.22 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.206 -0.934 . . . . 0.0 109.801 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.2 m120 -124.76 133.26 53.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.199 -0.938 . . . . 0.0 110.756 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.33 -120.3 0.69 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.51 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.1 Cg_endo -67.19 -157.39 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.836 1.44 . . . . 0.0 110.417 179.433 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.471 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 0.6 OUTLIER -120.91 132.02 54.71 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.021 -1.05 . . . . 0.0 110.549 -179.498 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 95.33 -86.98 1.01 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -94.92 128.9 42.05 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.267 -1.137 . . . . 0.0 109.516 179.591 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.86 ' NZ ' ' HB2' ' A' ' 278' ' ' ALA . 0.4 OUTLIER -136.38 5.41 2.97 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.965 -1.084 . . . . 0.0 110.955 -179.619 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 297' ' ' LYS . 3.3 p -130.55 113.55 25.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.223 -0.923 . . . . 0.0 109.7 179.212 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.547 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 35.2 mt-10 -41.55 -45.93 3.43 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.247 -0.908 . . . . 0.0 110.304 -179.488 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.59 158.55 1.76 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.135 -0.978 . . . . 0.0 110.64 179.847 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.616 HG12 HG13 ' A' ' 296' ' ' VAL . 12.1 mt -119.74 129.05 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 110.193 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -131.2 151.74 51.17 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.266 -0.896 . . . . 0.0 110.297 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.041 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.43 130.5 54.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.232 -0.917 . . . . 0.0 109.914 179.815 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 48.1 tt0 -138.37 113.38 9.23 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.189 -0.945 . . . . 0.0 110.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.643 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -96.31 108.76 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.985 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.447 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.4 m-20 39.42 34.6 0.14 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.544 -0.722 . . . . 0.0 110.629 -179.82 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 112.59 -19.05 22.1 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.463 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.1 OUTLIER -85.18 100.54 11.82 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.27 -1.135 . . . . 0.0 110.317 -179.823 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.3 p -71.15 121.65 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.512 HD13 ' O ' ' A' ' 357' ' ' VAL . 35.7 mm . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.279 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.338 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.1 -178.54 3.64 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 124.016 1.535 . . . . 0.0 110.295 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 6.6 t -57.76 143.06 43.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.157 -0.964 . . . . 0.0 110.098 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.1 p -112.3 150.0 41.86 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.181 -0.949 . . . . 0.0 110.23 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.67 142.12 35.4 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 124.056 1.556 . . . . 0.0 110.37 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.53 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -74.42 140.97 76.21 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 110.514 -179.759 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.53 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.5 Cg_endo -74.16 149.25 40.63 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 124.192 1.628 . . . . 0.0 110.324 179.677 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.775 HG12 ' O ' ' A' ' 263' ' ' VAL . 76.5 t -137.72 29.69 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.293 -0.88 . . . . 0.0 110.083 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.3 t -166.49 45.66 0.07 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 0.0 110.79 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 142.35 -178.1 21.14 Favored Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.17 179.493 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.578 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.87 157.24 46.47 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.485 -1.009 . . . . 0.0 109.791 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.898 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -149.33 124.66 10.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 110.615 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.565 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.1 mp0 -124.47 111.34 15.6 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.089 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.579 HG11 HD12 ' A' ' 349' ' ' ILE . 41.0 t -105.07 129.57 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.024 -1.047 . . . . 0.0 111.959 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.402 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.7 ttmt -117.38 156.89 27.11 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.507 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.613 HG22 ' CD2' ' A' ' 280' ' ' TYR . 78.5 t -144.86 146.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.424 -1.422 . . . . 0.0 112.399 -179.094 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -138.22 109.39 6.84 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.15 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.7 p-10 -95.75 147.95 23.08 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.127 -0.983 . . . . 0.0 111.111 -178.783 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.841 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.9 p90 -133.66 16.97 3.94 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.515 -0.741 . . . . 0.0 110.019 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.05 -58.48 3.96 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.565 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 6.0 t -68.8 -20.31 64.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -1.141 . . . . 0.0 110.103 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -177.7 179.09 48.41 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -132.55 141.84 48.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -1.125 . . . . 0.0 110.121 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.577 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 6.3 mt-10 -95.62 147.45 23.58 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.47 -0.769 . . . . 0.0 110.209 -179.546 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.694 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 93.5 m-85 -138.6 95.08 2.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 110.709 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.57 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.71 108.49 16.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.526 -0.734 . . . . 0.0 110.091 179.657 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.704 HG11 HG11 ' A' ' 294' ' ' VAL . 6.7 t -100.11 92.72 2.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.6 -0.688 . . . . 0.0 109.85 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.671 HG23 ' OG1' ' A' ' 333' ' ' THR . 3.6 m -86.57 113.89 22.84 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.932 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.039 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.98 149.74 23.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.096 -1.003 . . . . 0.0 110.806 -179.322 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.578 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.1 m120 -134.56 106.37 6.97 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -179.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.607 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 8.1 mt -116.91 162.54 17.59 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.688 -1.257 . . . . 0.0 109.94 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.86 36.24 1.2 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.974 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.447 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.4 -135.5 3.9 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.325 -1.417 . . . . 0.0 110.039 -179.853 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.489 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.5 mt-30 -121.43 104.65 9.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.152 -1.205 . . . . 0.0 110.978 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.607 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -132.6 129.24 38.69 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.3 -0.875 . . . . 0.0 109.702 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.583 ' O ' HG23 ' A' ' 353' ' ' ILE . 39.1 m-20 -58.58 99.57 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.4 179.435 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.857 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.0 p-90 -97.94 113.07 24.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 110.418 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.564 HG23 ' CG2' ' A' ' 322' ' ' THR . 23.5 m -105.17 113.8 27.61 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.336 -0.853 . . . . 0.0 109.478 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.775 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.1 t -96.08 110.54 24.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.799 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.444 ' HE2' HD11 ' A' ' 320' ' ' ILE . 31.9 ttmt -83.44 146.77 28.23 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.301 -0.875 . . . . 0.0 109.217 179.378 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.711 HG22 HG23 ' A' ' 349' ' ' ILE . 42.4 t -140.93 105.13 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.518 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 10.6 mmtp -70.18 132.33 45.62 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.189 -0.945 . . . . 0.0 109.136 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.956 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.9 mt -87.41 152.13 22.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.441 -0.787 . . . . 0.0 111.376 -178.875 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.749 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -61.71 174.74 0.61 Allowed Pre-proline 0 C--N 1.301 -1.505 0 O-C-N 121.63 -0.668 . . . . 0.0 109.293 179.002 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.749 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.9 Cg_endo -68.48 82.87 0.51 Allowed 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.703 1.37 . . . . 0.0 110.041 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.1 24.48 4.82 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.777 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -114.41 148.89 37.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -1.09 . . . . 0.0 110.155 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.956 ' HA ' HD13 ' A' ' 298' ' ' LEU . 21.0 p -151.76 144.35 24.24 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 110.614 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.89 HG21 HG11 ' A' ' 319' ' ' VAL . 61.3 t -64.65 129.7 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.458 -0.776 . . . . 0.0 110.357 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.74 -34.41 2.05 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.417 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -142.21 131.72 23.83 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.194 -1.18 . . . . 0.0 110.59 -179.827 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 13.6 p90 -145.96 163.92 33.65 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.263 -0.898 . . . . 0.0 109.817 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.519 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.7 OUTLIER -154.33 166.75 32.21 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.99 -1.068 . . . . 0.0 110.982 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.458 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.5 OUTLIER 54.99 23.07 4.8 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.561 -0.712 . . . . 0.0 111.03 179.772 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.696 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.92 149.39 1.13 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.423 179.635 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.543 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.3 m120 -87.77 124.65 33.82 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.163 -0.961 . . . . 0.0 109.263 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 7.8 ttpt -92.29 139.77 30.27 Favored 'General case' 0 N--CA 1.489 1.486 0 CA-C-O 121.697 0.76 . . . . 0.0 110.976 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.735 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.96 175.18 7.49 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 178.808 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.617 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.6 mt-10 -136.34 109.69 7.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.083 -1.01 . . . . 0.0 110.629 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -98.59 39.58 2.71 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 61.26 90.22 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 0.0 110.095 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.09 0.87 82.65 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.856 ' O ' HG23 ' A' ' 319' ' ' VAL . 4.0 m-85 -143.83 -171.31 3.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.466 -1.02 . . . . 0.0 109.567 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.89 HG11 HG21 ' A' ' 304' ' ' VAL . 2.9 t -163.43 156.73 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -0.854 . . . . 0.0 109.467 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.549 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 15.2 mm -122.43 147.52 26.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.92 -1.112 . . . . 0.0 110.715 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.661 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.0 m-85 -124.28 129.6 51.04 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.212 -0.93 . . . . 0.0 109.855 179.389 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.564 ' CG2' HG23 ' A' ' 293' ' ' THR . 16.1 p -132.41 167.22 23.6 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 120.575 -1.328 . . . . 0.0 110.178 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.535 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -65.99 115.95 3.72 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.839 1.442 . . . . 0.0 111.01 -179.698 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.631 HG22 ' HB2' ' A' ' 327' ' ' ASN . 9.2 m -58.36 -111.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.427 -0.795 . . . . 0.0 110.006 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.43 ' H ' HG23 ' A' ' 324' ' ' VAL . 2.2 p -117.78 -18.43 9.6 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.742 -1.224 . . . . 0.0 110.379 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.4 ' H ' HG23 ' A' ' 324' ' ' VAL . 6.9 p-90 -125.93 -4.13 6.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.244 -0.91 . . . . 0.0 110.401 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.631 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.3 t30 -97.73 50.29 1.04 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.288 -0.882 . . . . 0.0 109.977 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.504 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 4.2 mtmt -124.72 -9.82 7.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.344 -0.847 . . . . 0.0 109.894 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.53 -160.57 0.02 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.23 6.08 3.71 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.059 1.557 . . . . 0.0 110.744 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.433 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.7 m -163.07 116.55 1.62 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.066 -1.022 . . . . 0.0 109.943 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.453 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.53 105.79 5.75 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.22 -0.925 . . . . 0.0 110.324 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.671 ' OG1' HG23 ' A' ' 283' ' ' THR . 13.9 m -96.0 123.23 39.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.775 ' HE2' HG21 ' A' ' 294' ' ' VAL . 9.8 p90 -127.48 172.67 10.49 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.366 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.89 160.29 28.34 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.653 -1.736 . . . . 0.0 110.397 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.889 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -147.08 143.75 28.55 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.717 -0.873 . . . . 0.0 109.348 179.379 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.889 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -117.65 117.25 54.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.797 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.2 t -96.9 152.03 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.997 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.79 134.72 54.41 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 110.353 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.41 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . 179.2 -127.45 1.14 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.523 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.1 Cg_endo -67.11 -157.75 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.815 1.429 . . . . 0.0 110.468 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 342' ' ' GLN . . . . . . . . . . . . . 2.7 mp0 -122.9 128.93 50.97 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.173 -0.955 . . . . 0.0 110.543 -179.728 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 116.09 -87.89 0.45 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -115.33 131.0 57.07 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.426 -1.044 . . . . 0.0 109.041 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.618 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.1 mtmt -127.38 15.46 7.16 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.944 -1.098 . . . . 0.0 110.728 -179.329 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.63 HG21 HG13 ' A' ' 296' ' ' VAL . 7.4 p -136.12 114.74 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.474 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.518 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 3.1 mm-40 -44.07 -47.2 8.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.879 . . . . 0.0 110.045 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -176.8 153.46 1.06 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.124 -0.985 . . . . 0.0 110.733 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.711 HG23 HG22 ' A' ' 296' ' ' VAL . 18.5 mt -115.38 104.23 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.153 -0.967 . . . . 0.0 110.033 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.78 154.03 20.04 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.228 -0.92 . . . . 0.0 110.448 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.039 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.38 127.56 55.7 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.296 -0.877 . . . . 0.0 110.261 179.996 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 27.3 tt0 -138.21 112.65 8.77 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.083 -1.011 . . . . 0.0 109.895 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.583 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.74 108.03 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 110.669 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.444 ' C ' ' O ' ' A' ' 353' ' ' ILE . 4.7 m-20 37.76 35.84 0.08 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.674 -0.641 . . . . 0.0 111.139 179.563 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.1 -0.07 28.4 Favored Glycine 0 N--CA 1.493 2.433 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.485 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -108.68 104.5 13.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.126 -1.22 . . . . 0.0 110.134 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.65 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.3 p -71.9 114.11 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.332 -0.855 . . . . 0.0 110.283 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.702 ' HB ' HD13 ' A' ' 351' ' ' LEU . 41.6 mm . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.112 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.244 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.2 -178.7 4.09 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.969 1.51 . . . . 0.0 110.782 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 258' ' ' THR . 5.0 t -66.64 124.53 23.1 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.323 -0.861 . . . . 0.0 110.171 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 7.2 t -129.87 145.22 56.22 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.178 -0.951 . . . . 0.0 110.372 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.28 138.65 30.7 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.131 1.595 . . . . 0.0 110.063 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.417 ' H ' HG12 ' A' ' 261' ' ' VAL . 3.2 p -65.78 138.85 96.69 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.074 -1.016 . . . . 0.0 110.517 -179.503 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.48 ' CB ' HG23 ' A' ' 358' ' ' ILE . 51.1 Cg_endo -79.99 126.49 6.45 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 O-C-N 124.105 1.581 . . . . 0.0 110.264 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.737 HG12 ' O ' ' A' ' 263' ' ' VAL . 94.1 t -114.26 30.28 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.248 -0.908 . . . . 0.0 110.237 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 4.2 t 178.8 97.52 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.205 -0.934 . . . . 0.0 110.671 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.25 -177.27 34.9 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.537 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.22 166.39 24.67 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.486 -1.008 . . . . 0.0 109.488 179.759 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.933 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.69 140.2 9.44 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.001 -1.062 . . . . 0.0 111.11 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.721 ' H ' HD22 ' A' ' 267' ' ' LEU . 9.5 mt-10 -141.94 123.89 15.33 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 179.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 281' ' ' ASP . 71.8 t -117.14 141.61 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 120.845 -1.16 . . . . 0.0 111.607 -178.973 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -126.88 157.55 39.05 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.668 HG13 ' O ' ' A' ' 279' ' ' GLU . 74.1 t -144.73 146.95 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.416 -1.427 . . . . 0.0 112.085 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.516 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -144.5 114.9 7.58 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.643 -0.661 . . . . 0.0 109.288 179.056 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.5 p30 -96.04 148.01 23.12 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.2 -0.938 . . . . 0.0 111.291 -178.798 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.757 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.2 p90 -132.78 19.17 4.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.489 -0.757 . . . . 0.0 109.949 179.23 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.61 -62.43 3.4 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.521 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 22.0 m -66.37 -21.14 66.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -1.149 . . . . 0.0 110.481 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.486 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -176.4 -179.55 46.91 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.43 -1.366 . . . . 0.0 109.776 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.55 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.99 143.94 48.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.258 -1.142 . . . . 0.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.668 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.0 mt-10 -96.37 147.35 23.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.439 -0.788 . . . . 0.0 110.332 -179.546 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.675 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.0 m-85 -141.2 86.63 2.04 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.474 -0.766 . . . . 0.0 110.372 -179.52 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.82 ' O ' HG13 ' A' ' 269' ' ' VAL . 3.9 t0 -71.09 152.19 43.73 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.367 -0.833 . . . . 0.0 110.092 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 294' ' ' VAL . 4.8 t -144.83 89.84 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.601 -0.687 . . . . 0.0 109.812 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.855 HG23 ' OG1' ' A' ' 333' ' ' THR . 13.5 m -86.29 127.9 34.84 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.951 -1.093 . . . . 0.0 109.596 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.107 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -116.53 151.16 36.71 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.02 -1.05 . . . . 0.0 110.862 -179.35 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.3 m120 -131.62 136.0 47.4 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.402 -0.811 . . . . 0.0 109.88 -179.853 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 17.9 mt -140.67 172.69 12.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.773 -1.204 . . . . 0.0 109.965 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -94.55 29.16 2.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.22 -0.925 . . . . 0.0 110.967 -179.157 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.528 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 149.91 -82.84 0.18 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.484 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.2 tt0 -151.59 107.94 3.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.092 -1.24 . . . . 0.0 110.737 -179.343 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.634 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.4 m-85 -133.27 140.89 47.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.299 -0.876 . . . . 0.0 109.829 179.51 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.699 ' O ' HG23 ' A' ' 353' ' ' ILE . 18.3 m-20 -74.01 97.09 2.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.05 -1.031 . . . . 0.0 109.001 179.022 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.956 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.8 p-90 -98.63 115.27 28.29 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.206 -0.934 . . . . 0.0 110.64 -179.193 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.613 HG23 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -108.09 113.9 27.4 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.506 -0.746 . . . . 0.0 109.547 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.816 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.7 t -96.75 110.88 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 109.948 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.531 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 26.7 ttmt -84.84 148.24 26.39 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.344 -0.847 . . . . 0.0 109.768 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.779 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 46.3 t -144.58 108.51 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.256 -0.902 . . . . 0.0 110.398 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.585 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 2.6 mmtp -73.25 141.59 47.25 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.291 -0.88 . . . . 0.0 109.054 179.444 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.992 HD13 ' HA ' ' A' ' 303' ' ' THR . 97.9 mt -93.45 156.7 16.61 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.164 -0.96 . . . . 0.0 111.708 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -69.65 172.45 5.42 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.629 -0.67 . . . . 0.0 109.49 179.073 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.0 Cg_endo -67.61 84.34 0.39 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.73 1.384 . . . . 0.0 109.704 179.199 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.29 28.05 3.19 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 -179.244 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.887 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -123.42 145.25 48.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.331 -1.099 . . . . 0.0 110.623 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.992 ' HA ' HD13 ' A' ' 298' ' ' LEU . 42.0 p -145.68 144.4 30.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.254 -0.904 . . . . 0.0 110.367 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.99 ' CG2' HG21 ' A' ' 319' ' ' VAL . 19.6 t -78.62 136.86 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 110.179 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -136.67 -34.01 0.22 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -114.22 113.08 24.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.142 -1.21 . . . . 0.0 110.712 -179.632 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 28.9 p90 -144.4 164.37 31.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.297 -0.877 . . . . 0.0 109.844 179.503 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -157.64 161.56 38.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.076 -1.015 . . . . 0.0 111.102 -179.297 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.521 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 57.91 23.66 10.06 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.797 . . . . 0.0 111.22 179.31 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.676 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.46 141.85 0.72 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.185 -0.947 . . . . 0.0 110.057 179.469 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.541 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.6 m120 -77.24 119.46 20.94 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.135 -0.978 . . . . 0.0 109.399 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.4 ttpt -90.33 141.45 28.71 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.658 0.742 . . . . 0.0 110.404 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.818 ' O ' HG22 ' A' ' 319' ' ' VAL . 1.5 mp0 -128.99 178.47 6.38 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.609 ' HG3' HG22 ' A' ' 319' ' ' VAL . 2.5 mt-10 -141.48 104.69 4.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.686 -0.634 . . . . 0.0 110.024 179.511 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.38 42.05 2.93 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.59 78.78 0.27 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.225 -1.162 . . . . 0.0 110.436 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.613 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 102.7 -1.64 48.94 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.845 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -144.38 -165.67 2.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.337 -1.096 . . . . 0.0 109.42 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.99 HG21 ' CG2' ' A' ' 304' ' ' VAL . 2.8 t -163.48 154.25 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.331 -0.856 . . . . 0.0 109.7 179.341 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.815 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 13.4 mm -121.11 148.02 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.027 -1.046 . . . . 0.0 110.693 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.651 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.8 m-85 -126.27 124.53 40.57 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.357 -0.839 . . . . 0.0 109.815 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.613 ' CG2' HG23 ' A' ' 293' ' ' THR . 8.7 p -128.9 166.51 24.45 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.935 -1.103 . . . . 0.0 109.576 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.43 120.43 7.64 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.853 1.449 . . . . 0.0 110.912 -179.076 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.778 HG22 ' HB2' ' A' ' 327' ' ' ASN . 31.1 m -64.48 -123.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.576 -0.702 . . . . 0.0 110.205 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.484 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.8 OUTLIER -102.35 -17.7 15.75 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.815 -1.178 . . . . 0.0 110.669 -179.673 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.605 ' H ' HG23 ' A' ' 324' ' ' VAL . 20.4 p-90 -126.74 -8.78 6.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.018 -1.051 . . . . 0.0 110.505 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.778 ' HB2' HG22 ' A' ' 324' ' ' VAL . 6.6 t30 -89.82 38.98 0.94 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.416 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -118.47 -6.35 10.74 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.137 -0.977 . . . . 0.0 109.715 179.75 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.26 -164.69 0.06 OUTLIER Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.528 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.6 Cg_endo -72.35 1.05 6.54 Favored 'Trans proline' 0 C--N 1.307 -1.633 0 O-C-N 124.236 1.65 . . . . 0.0 110.793 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -160.04 114.74 2.29 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.421 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.764 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -136.43 120.92 18.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -0.89 . . . . 0.0 110.499 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.855 ' OG1' HG23 ' A' ' 283' ' ' THR . 97.4 m -110.37 142.38 42.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -0.872 . . . . 0.0 110.099 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.816 ' HE2' HG21 ' A' ' 294' ' ' VAL . 16.4 p90 -145.22 174.39 11.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.419 -0.801 . . . . 0.0 108.918 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.14 164.62 30.12 Favored Glycine 0 N--CA 1.488 2.148 0 C-N-CA 118.913 -1.613 . . . . 0.0 110.146 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.896 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -151.54 143.4 23.78 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.512 -0.993 . . . . 0.0 109.642 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.896 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -119.42 123.16 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.07 -1.019 . . . . 0.0 109.569 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.887 HG11 ' HB1' ' A' ' 302' ' ' ALA . 13.3 t -96.26 154.91 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.098 -1.002 . . . . 0.0 110.353 -179.522 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -124.58 135.03 52.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.368 -0.832 . . . . 0.0 110.582 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.459 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 176.3 -133.34 2.3 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 179.765 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.483 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 44.8 Cg_endo -72.54 -158.13 0.06 OUTLIER 'Trans proline' 0 C--N 1.306 -1.696 0 O-C-N 123.86 1.453 . . . . 0.0 109.965 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.433 ' OE1' ' N ' ' A' ' 342' ' ' GLN . 2.4 pm0 -121.76 144.56 48.73 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.114 -0.991 . . . . 0.0 110.446 -179.642 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.471 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 100.61 66.04 0.81 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.5 OUTLIER 67.15 130.98 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.282 -1.128 . . . . 0.0 109.288 -179.545 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.559 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER -130.48 23.77 5.12 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.101 -0.999 . . . . 0.0 110.526 -179.292 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.595 HG21 HG13 ' A' ' 296' ' ' VAL . 7.5 p -129.21 123.13 57.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.302 -0.874 . . . . 0.0 110.103 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.533 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 8.8 mt-10 -56.11 -41.38 75.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.314 -0.866 . . . . 0.0 110.907 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.424 ' OE2' HG23 ' A' ' 350' ' ' THR . 2.4 tp10 -177.14 156.13 1.23 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.93 -1.106 . . . . 0.0 110.623 -179.352 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.696 HG23 HG22 ' A' ' 296' ' ' VAL . 38.6 mt -123.98 104.02 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.121 -0.987 . . . . 0.0 110.063 179.283 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 350' ' ' THR . . . . . 0.424 HG23 ' OE2' ' A' ' 348' ' ' GLU . 0.0 OUTLIER -108.73 148.46 30.45 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.211 -0.931 . . . . 0.0 110.129 -179.836 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.107 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -109.84 129.51 55.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.946 . . . . 0.0 110.347 179.844 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 24.2 tp10 -138.46 114.37 10.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.895 . . . . 0.0 109.779 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.699 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.54 104.86 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.101 -0.999 . . . . 0.0 110.462 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.427 ' C ' ' O ' ' A' ' 353' ' ' ILE . 3.4 m-20 38.94 36.1 0.14 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.831 -0.543 . . . . 0.0 110.794 179.752 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.41 12.72 16.54 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 1.4 mp0 -120.88 105.45 10.71 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.979 -1.307 . . . . 0.0 110.358 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.887 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -72.22 128.02 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.275 -0.891 . . . . 0.0 110.324 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.887 HD13 ' O ' ' A' ' 357' ' ' VAL . 10.7 mm . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.097 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.21 -178.02 3.35 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.059 1.557 . . . . 0.0 110.482 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 8.2 t -57.16 142.18 43.62 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.211 -0.931 . . . . 0.0 110.162 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 259' ' ' THR . . . . . 0.608 HG23 ' O ' ' A' ' 259' ' ' THR . 5.2 t -115.85 112.31 42.75 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.145 -0.972 . . . . 0.0 110.558 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.37 139.51 26.15 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 O-C-N 123.946 1.498 . . . . 0.0 110.055 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.591 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.1 p -69.58 144.04 93.58 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.165 -0.959 . . . . 0.0 110.383 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.597 ' HB2' HG23 ' A' ' 358' ' ' ILE . 49.3 Cg_endo -76.36 138.07 19.48 Favored 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 124.082 1.569 . . . . 0.0 110.509 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.522 HG12 ' O ' ' A' ' 263' ' ' VAL . 21.2 t -103.69 30.92 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.241 -0.912 . . . . 0.0 110.132 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.465 ' O ' HD12 ' A' ' 358' ' ' ILE . 0.1 OUTLIER -175.24 145.47 0.78 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.241 -0.912 . . . . 0.0 110.62 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' A' ' 264' ' ' SER . . . 45.34 -169.7 0.02 OUTLIER Glycine 0 N--CA 1.491 2.314 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.501 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.497 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.53 166.29 24.97 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.722 -0.87 . . . . 0.0 109.495 179.908 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.914 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.5 tm? -161.59 137.58 7.94 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.497 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.821 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.8 OUTLIER -137.27 151.0 48.21 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.032 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.848 HG13 ' O ' ' A' ' 281' ' ' ASP . 66.1 t -138.93 138.83 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.683 -1.261 . . . . 0.0 111.431 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.422 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -120.69 157.77 28.9 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.215 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.702 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.4 t -144.9 146.76 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.287 -1.508 . . . . 0.0 112.169 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -143.7 113.5 7.13 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.451 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 4.8 m-20 -98.1 143.72 28.34 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.209 -0.932 . . . . 0.0 111.016 -178.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.83 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.8 p90 -128.99 17.75 6.14 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 110.079 179.56 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.504 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 87.76 -58.3 4.36 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.94 -18.31 64.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.229 -1.16 . . . . 0.0 110.093 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.551 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.72 178.14 48.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.542 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -132.14 143.49 50.02 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -1.111 . . . . 0.0 110.111 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.702 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -97.52 147.13 24.57 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.459 -0.776 . . . . 0.0 110.031 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 94.3 m-85 -142.41 84.52 1.87 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.336 -0.853 . . . . 0.0 110.749 -179.598 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.848 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -66.41 152.12 45.75 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.408 -0.808 . . . . 0.0 110.03 179.288 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.719 HG11 HG11 ' A' ' 294' ' ' VAL . 10.6 t -144.41 90.33 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.66 -0.65 . . . . 0.0 109.572 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 333' ' ' THR . 81.9 m -86.43 124.56 32.9 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.146 -0.971 . . . . 0.0 109.465 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.058 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.07 147.51 37.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.308 -0.87 . . . . 0.0 110.531 -179.243 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.904 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.3 m120 -126.33 134.17 51.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.382 -0.824 . . . . 0.0 109.804 -179.881 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.904 HD23 ' O ' ' A' ' 285' ' ' ASN . 16.5 mt -141.63 150.42 41.95 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.607 -1.308 . . . . 0.0 110.208 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.51 35.59 0.77 Allowed 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.484 -0.76 . . . . 0.0 109.374 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.59 -128.94 2.04 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.256 -1.45 . . . . 0.0 109.91 -179.7 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.498 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -124.59 96.07 4.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -1.195 . . . . 0.0 110.714 -179.531 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.547 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.7 m-85 -118.53 129.44 55.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.33 -0.857 . . . . 0.0 109.74 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.687 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.3 OUTLIER -63.49 100.57 0.27 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.948 -1.095 . . . . 0.0 109.224 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.954 ' CE3' HD13 ' A' ' 284' ' ' LEU . 54.7 p-90 -99.85 112.98 25.21 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.213 -0.929 . . . . 0.0 111.065 -179.257 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.874 HG23 ' CG2' ' A' ' 322' ' ' THR . 14.8 m -106.01 115.81 30.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.648 -0.658 . . . . 0.0 109.271 179.256 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.771 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.2 t -96.27 110.95 25.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.035 -1.04 . . . . 0.0 110.388 -179.424 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.524 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.9 ttpt -86.0 145.95 26.88 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.469 -0.769 . . . . 0.0 109.223 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.923 HG22 HG23 ' A' ' 349' ' ' ILE . 55.1 t -146.3 108.04 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 110.448 -179.501 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.519 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 30.8 mmtp -70.38 139.88 52.0 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.186 -0.946 . . . . 0.0 109.324 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.96 HD13 ' HA ' ' A' ' 303' ' ' THR . 81.8 mt -94.71 158.45 15.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.454 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.819 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.65 177.12 0.88 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.684 -0.635 . . . . 0.0 109.748 179.33 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.819 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.4 Cg_endo -68.47 87.38 0.42 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.758 1.399 . . . . 0.0 109.838 179.501 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 107.32 22.28 7.55 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.76 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -112.9 139.15 48.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.262 -1.14 . . . . 0.0 110.161 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.96 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.3 p -143.68 145.65 32.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 110.524 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 1.008 ' CG2' HG21 ' A' ' 319' ' ' VAL . 22.7 t -76.04 129.63 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.214 -0.929 . . . . 0.0 109.939 179.756 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.29 -17.98 3.51 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.148 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.404 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -143.78 129.76 19.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.046 -1.267 . . . . 0.0 111.245 -179.588 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.8 p90 -150.04 -178.14 6.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.545 -0.722 . . . . 0.0 109.636 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.485 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -166.06 151.15 8.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.534 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.6 OUTLIER 61.67 30.82 18.65 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.471 -0.768 . . . . 0.0 110.819 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.778 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.68 141.66 0.51 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.237 -0.915 . . . . 0.0 110.045 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.691 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -81.17 112.4 18.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.074 -1.016 . . . . 0.0 109.317 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.559 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 2.3 ttpt -84.93 142.72 29.47 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.957 0.884 . . . . 0.0 110.981 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.751 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.7 mp0 -129.34 179.08 5.99 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.099 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.536 ' HG2' HG22 ' A' ' 319' ' ' VAL . 2.4 mt-10 -142.04 100.04 3.65 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.091 -0.644 . . . . 0.0 110.189 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.436 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -86.13 42.46 3.15 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 19.6 m120 59.69 80.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.239 -1.154 . . . . 0.0 110.328 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.605 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.86 2.61 56.14 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.821 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.1 m-85 -147.29 -166.87 2.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.396 -1.061 . . . . 0.0 109.382 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 1.008 HG21 ' CG2' ' A' ' 304' ' ' VAL . 4.0 t -163.16 154.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.283 -0.885 . . . . 0.0 109.975 178.99 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.751 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 5.2 mm -125.86 138.69 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.174 -0.953 . . . . 0.0 111.545 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.655 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.9 m-85 -117.4 122.61 44.28 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.326 -0.859 . . . . 0.0 109.515 178.911 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.874 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -124.4 168.75 12.2 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 120.61 -1.306 . . . . 0.0 110.554 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.539 ' HG3' ' HA ' ' A' ' 291' ' ' ASP . 38.9 Cg_endo -64.66 112.2 1.9 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 124.04 1.548 . . . . 0.0 110.908 -179.362 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.841 HG22 ' CG ' ' A' ' 327' ' ' ASN . 33.8 m -58.69 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.687 -0.633 . . . . 0.0 109.961 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.602 ' N ' HG23 ' A' ' 324' ' ' VAL . 3.1 p -112.39 -12.72 13.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.636 -1.29 . . . . 0.0 111.01 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.643 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.8 p-90 -129.85 -12.31 4.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.984 -1.073 . . . . 0.0 111.226 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.841 ' CG ' HG22 ' A' ' 324' ' ' VAL . 23.1 p-10 -96.28 40.83 1.12 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.047 -1.033 . . . . 0.0 110.985 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.461 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -114.14 -3.0 13.29 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.162 -0.961 . . . . 0.0 109.51 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.81 -157.74 0.02 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.524 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -74.66 6.97 2.93 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.052 1.553 . . . . 0.0 110.956 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 5.6 m -165.35 122.11 1.46 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.099 -1.001 . . . . 0.0 110.088 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.56 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -138.91 116.25 11.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.933 . . . . 0.0 110.617 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.542 HG23 ' HA ' ' A' ' 283' ' ' THR . 13.3 m -108.36 134.16 51.56 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.243 -0.91 . . . . 0.0 110.046 179.737 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.778 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 11.0 p90 -142.65 174.89 10.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.058 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.61 156.96 27.01 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.014 -1.565 . . . . 0.0 110.272 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.942 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -141.7 147.74 37.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.496 -1.002 . . . . 0.0 110.04 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.942 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.75 122.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.179 -0.951 . . . . 0.0 109.623 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.76 HG11 ' HB1' ' A' ' 302' ' ' ALA . 18.3 t -97.29 153.28 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.934 . . . . 0.0 110.554 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -121.02 132.76 55.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.561 -0.712 . . . . 0.0 109.867 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.453 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -178.24 -138.03 2.99 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.482 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 45.8 Cg_endo -73.19 -159.28 0.08 OUTLIER 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 124.085 1.571 . . . . 0.0 110.684 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.504 ' HG3' ' HA2' ' A' ' 275' ' ' GLY . 17.6 mp0 -115.34 135.59 53.97 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.189 -0.944 . . . . 0.0 110.445 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.477 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 111.53 60.1 0.46 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.2 OUTLIER 66.5 142.07 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.397 -1.06 . . . . 0.0 108.66 -179.052 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.545 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER -135.11 28.4 3.46 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.981 -1.074 . . . . 0.0 111.06 -178.88 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 346' ' ' VAL . 14.7 p -132.87 119.03 35.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.282 -0.886 . . . . 0.0 110.187 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.446 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -51.26 -46.96 62.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.444 -0.785 . . . . 0.0 110.268 -179.743 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.499 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 6.8 pt-20 -177.05 158.66 1.56 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.267 -0.896 . . . . 0.0 110.627 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.923 HG23 HG22 ' A' ' 296' ' ' VAL . 77.2 mt -121.29 112.41 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 110.245 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -116.54 137.47 52.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.238 -0.913 . . . . 0.0 110.177 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.058 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -93.04 135.3 34.35 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.12 -0.988 . . . . 0.0 110.523 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.47 108.26 5.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.402 -0.811 . . . . 0.0 110.012 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.687 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.8 mt -91.67 108.85 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.992 -1.067 . . . . 0.0 110.068 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.4 m-20 38.88 31.51 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.746 -0.596 . . . . 0.0 110.796 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.13 -12.14 22.07 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.438 ' O ' HG12 ' A' ' 358' ' ' ILE . 2.2 mp0 -95.03 105.55 17.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.1 -1.236 . . . . 0.0 110.487 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.9 p -68.83 133.97 30.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.882 . . . . 0.0 110.185 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.597 HG23 ' HB2' ' A' ' 262' ' ' PRO . 22.1 mm . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.289 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -75.18 -178.28 4.1 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 124.026 1.54 . . . . 0.0 110.509 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 258' ' ' THR . 6.7 t -64.11 132.08 49.42 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.334 -0.854 . . . . 0.0 110.136 179.739 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 259' ' ' THR . . . . . 0.405 HG22 ' HD2' ' A' ' 260' ' ' PRO . 0.0 OUTLIER -141.15 146.51 43.38 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.146 -0.971 . . . . 0.0 110.302 179.809 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 260' ' ' PRO . . . . . 0.405 ' HD2' HG22 ' A' ' 259' ' ' THR . 49.0 Cg_endo -75.55 135.9 18.66 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 124.034 1.544 . . . . 0.0 110.292 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.615 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.8 p -67.8 143.1 96.29 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.19 -0.944 . . . . 0.0 110.419 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.633 ' HB2' HG23 ' A' ' 358' ' ' ILE . 46.4 Cg_endo -75.3 157.0 41.74 Favored 'Trans proline' 0 C--N 1.303 -1.819 0 O-C-N 124.126 1.593 . . . . 0.0 110.692 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.759 HG12 ' O ' ' A' ' 263' ' ' VAL . 69.8 t -137.75 26.12 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.583 179.445 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -164.78 63.63 0.13 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.361 -0.837 . . . . 0.0 110.117 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 117.13 -169.19 13.03 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.525 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.69 164.59 27.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.378 -1.072 . . . . 0.0 110.049 179.992 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.847 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.3 tm? -161.34 131.93 5.15 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.226 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.845 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.6 mt-10 -128.91 151.34 49.76 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.28 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.85 HG13 ' O ' ' A' ' 281' ' ' ASP . 96.5 t -142.71 138.83 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.712 -1.242 . . . . 0.0 111.509 -179.26 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -122.19 157.46 31.52 Favored 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.278 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.755 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.9 t -143.2 146.98 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.324 -1.485 . . . . 0.0 111.957 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -143.5 112.22 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 179.485 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.484 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.9 m-20 -96.49 143.95 27.04 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.014 -1.054 . . . . 0.0 111.125 -179.214 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.82 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.7 p90 -128.38 16.79 6.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 109.847 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.27 -63.17 2.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.6 -20.42 64.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -1.133 . . . . 0.0 110.306 -179.751 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.554 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.88 177.98 42.44 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.15 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.541 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.13 142.65 47.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.339 -1.094 . . . . 0.0 109.704 179.599 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.755 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.8 mt-10 -98.91 147.11 25.3 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.281 -0.887 . . . . 0.0 110.429 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.668 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.9 m-85 -143.09 84.2 1.82 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.511 -0.743 . . . . 0.0 110.649 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.85 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.87 151.69 46.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.347 -0.846 . . . . 0.0 109.967 179.407 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.756 HG11 HG11 ' A' ' 294' ' ' VAL . 14.0 t -143.93 91.38 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.459 -0.776 . . . . 0.0 110.131 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.825 HG23 ' OG1' ' A' ' 333' ' ' THR . 88.4 m -86.74 123.89 32.4 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.39 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -111.27 147.49 34.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.017 -1.052 . . . . 0.0 110.976 -179.037 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.915 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.3 m120 -126.5 132.32 51.42 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.462 -0.774 . . . . 0.0 110.163 -179.787 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.915 HD23 ' O ' ' A' ' 285' ' ' ASN . 18.1 mt -142.77 157.52 44.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.43 36.86 1.06 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.194 -0.941 . . . . 0.0 109.671 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 160.68 -144.31 9.82 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.401 -1.381 . . . . 0.0 109.896 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.557 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -108.76 94.22 4.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -1.126 . . . . 0.0 110.711 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.618 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.7 m-30 -114.65 143.67 44.66 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 109.901 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.815 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.6 m-20 -76.97 97.21 4.57 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.198 -0.939 . . . . 0.0 109.078 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.898 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.4 p-90 -96.75 112.37 24.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.378 -0.826 . . . . 0.0 110.596 -179.185 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 293' ' ' THR . . . . . 1.021 HG23 ' CG2' ' A' ' 322' ' ' THR . 1.5 m -105.44 113.78 27.56 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.416 -0.802 . . . . 0.0 109.515 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.757 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.4 t -96.07 110.67 24.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.076 -1.015 . . . . 0.0 109.829 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.647 ' NZ ' HD11 ' A' ' 320' ' ' ILE . 8.4 ttmt -87.78 149.54 24.11 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.234 -0.916 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.761 HG13 HG12 ' A' ' 349' ' ' ILE . 98.6 t -144.89 108.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.419 -0.801 . . . . 0.0 110.352 -179.604 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.511 ' HB2' ' HB3' ' A' ' 347' ' ' GLU . 14.5 mmtt -71.95 132.53 44.45 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.242 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.943 HD13 ' HA ' ' A' ' 303' ' ' THR . 84.5 mt -88.0 156.05 19.51 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.233 -0.917 . . . . 0.0 111.594 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.694 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.29 173.08 3.57 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.581 -0.699 . . . . 0.0 109.318 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.694 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.6 Cg_endo -66.95 81.49 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.436 1.23 . . . . 0.0 110.067 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.79 23.09 4.09 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.851 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.03 144.94 42.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.366 -1.079 . . . . 0.0 110.085 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.943 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.9 p -150.35 145.88 26.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.104 -0.998 . . . . 0.0 110.782 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.833 HG21 HG11 ' A' ' 319' ' ' VAL . 37.6 t -66.42 126.3 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.383 -0.823 . . . . 0.0 110.071 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.51 -16.19 6.11 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 337' ' ' ILE . 14.7 t -152.04 113.33 4.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.064 -1.257 . . . . 0.0 111.009 -179.624 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 18.7 p90 -134.39 163.64 29.22 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.396 -0.815 . . . . 0.0 109.43 179.135 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -153.91 160.92 42.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.995 -1.066 . . . . 0.0 111.246 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.511 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 54.13 29.08 9.79 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.694 . . . . 0.0 110.95 179.774 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.753 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.32 139.56 0.61 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.256 -0.903 . . . . 0.0 110.112 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.685 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.2 m120 -79.17 118.8 21.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.308 179.616 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.473 ' HG3' HG11 ' A' ' 304' ' ' VAL . 8.1 ttpt -87.53 134.92 33.54 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.688 0.756 . . . . 0.0 111.235 -179.126 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.623 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.4 OUTLIER -116.95 172.68 7.1 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -131.71 112.62 12.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.343 -0.848 . . . . 0.0 110.082 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.567 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.58 47.81 1.15 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 8.0 t30 49.49 77.04 0.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.287 -1.125 . . . . 0.0 110.142 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.615 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.01 2.12 54.92 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.851 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.8 m-85 -143.67 -170.78 3.38 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.998 . . . . 0.0 109.13 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.851 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.9 t -163.95 154.5 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.254 -0.904 . . . . 0.0 109.11 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.91 HG23 HG22 ' A' ' 293' ' ' THR . 17.6 mt -131.75 135.83 58.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 120.711 -1.243 . . . . 0.0 111.298 -179.591 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.7 ' HE2' HG21 ' A' ' 296' ' ' VAL . 52.9 m-85 -106.36 138.76 41.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.301 -0.874 . . . . 0.0 110.537 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 322' ' ' THR . . . . . 1.021 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.0 OUTLIER -136.41 169.92 12.24 Favored Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.934 -1.104 . . . . 0.0 110.023 179.427 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 41.0 Cg_endo -67.86 116.39 4.27 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 O-C-N 123.797 1.42 . . . . 0.0 110.816 -179.175 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.785 HG23 ' H ' ' A' ' 326' ' ' TRP . 19.9 m -65.69 -129.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.578 -0.701 . . . . 0.0 110.098 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.638 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -98.33 -12.82 21.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.912 -1.117 . . . . 0.0 110.712 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.785 ' H ' HG23 ' A' ' 324' ' ' VAL . 36.2 p-90 -135.41 7.57 3.34 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.033 -1.042 . . . . 0.0 110.676 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.809 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 2.1 t-20 -111.32 42.62 1.63 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.18 -0.95 . . . . 0.0 110.119 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -122.79 -5.87 8.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 0.0 110.092 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.22 -160.35 0.02 OUTLIER Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.736 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 286' ' ' LEU . 45.9 Cg_endo -74.63 4.13 4.81 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 124.056 1.556 . . . . 0.0 110.592 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.425 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.7 m -164.61 116.1 1.24 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.925 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.809 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.18 119.15 15.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.189 -0.945 . . . . 0.0 110.325 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.825 ' OG1' HG23 ' A' ' 283' ' ' THR . 3.3 m -105.03 142.26 35.14 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.948 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.757 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.2 p90 -148.6 174.89 11.67 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.524 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.94 159.87 29.02 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.61 -1.757 . . . . 0.0 110.447 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.929 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.5 OUTLIER -143.55 147.61 34.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.506 -0.996 . . . . 0.0 110.034 179.572 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.929 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -123.29 119.18 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.922 . . . . 0.0 109.188 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.851 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 5.9 t -96.55 146.2 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.143 -0.973 . . . . 0.0 110.352 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.4 m120 -117.08 137.04 52.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.497 -0.752 . . . . 0.0 110.088 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.452 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 177.18 -138.62 4.0 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.507 ' O ' ' NZ ' ' A' ' 345' ' ' LYS . 47.0 Cg_endo -76.56 165.5 28.88 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 O-C-N 124.074 1.565 . . . . 0.0 110.231 179.856 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.457 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 1.8 mp0 -85.28 142.57 29.27 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.15 -0.968 . . . . 0.0 110.435 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 105.83 65.4 0.65 Allowed Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.453 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 0.2 OUTLIER 64.25 140.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -1.149 . . . . 0.0 109.377 -179.196 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.628 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -137.3 15.41 3.0 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.994 -1.066 . . . . 0.0 110.814 -179.534 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.581 HG21 ' CG1' ' A' ' 296' ' ' VAL . 7.1 p -127.64 116.92 45.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.927 . . . . 0.0 110.081 179.418 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -47.84 -46.82 31.48 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.363 -0.835 . . . . 0.0 110.482 -179.69 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.18 158.78 1.54 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.103 -0.998 . . . . 0.0 110.861 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.761 HG12 HG13 ' A' ' 296' ' ' VAL . 69.1 mt -120.39 122.97 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.026 -1.046 . . . . 0.0 110.278 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.42 137.58 52.76 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.193 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -96.34 130.57 43.42 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.059 -1.026 . . . . 0.0 110.367 179.975 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.45 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 30.4 tt0 -139.06 110.06 6.8 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.841 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.815 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.69 110.22 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.081 -1.012 . . . . 0.0 110.231 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 354' ' ' ASN . . . . . . . . . . . . . 7.9 m-20 43.31 30.6 0.32 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.645 -0.659 . . . . 0.0 110.969 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.09 -3.8 28.55 Favored Glycine 0 N--CA 1.492 2.39 0 C-N-CA 119.811 -1.185 . . . . 0.0 110.295 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.45 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 37.2 mm-40 -102.39 114.5 28.73 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.093 -1.239 . . . . 0.0 110.518 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.935 ' O ' HD13 ' A' ' 358' ' ' ILE . 4.5 p -73.69 136.22 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.251 -0.905 . . . . 0.0 110.363 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.935 HD13 ' O ' ' A' ' 357' ' ' VAL . 20.6 mm . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.051 -0.976 . . . . 0.0 110.267 -179.769 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -73.1 -179.47 4.37 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 124.025 1.539 . . . . 0.0 110.552 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 258' ' ' THR . 3.7 t -57.75 131.03 49.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.186 -0.946 . . . . 0.0 110.469 -179.908 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 19.1 m -68.21 122.34 83.78 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.159 -0.963 . . . . 0.0 110.338 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -72.92 144.96 39.4 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 O-C-N 123.961 1.506 . . . . 0.0 110.213 179.824 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.712 HG23 ' HD2' ' A' ' 262' ' ' PRO . 5.3 p -74.82 146.44 82.94 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.076 -1.015 . . . . 0.0 110.551 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.712 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.7 Cg_endo -75.68 149.94 34.67 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 124.051 1.553 . . . . 0.0 110.252 179.742 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 4.1 t -131.87 30.94 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -0.944 . . . . 0.0 110.3 -179.928 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 177.96 35.8 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.194 -0.941 . . . . 0.0 110.514 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.42 ' O ' ' CG2' ' A' ' 358' ' ' ILE . . . 163.64 154.34 7.7 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.667 -1.254 . . . . 0.0 110.24 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.571 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -119.3 163.39 17.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.424 -1.045 . . . . 0.0 109.932 179.733 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.796 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -152.06 122.11 7.12 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.09 -1.006 . . . . 0.0 110.817 -179.822 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.443 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.9 mt-10 -118.72 111.15 18.13 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.696 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.753 HG13 ' O ' ' A' ' 281' ' ' ASP . 71.4 t -113.23 141.2 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.011 -1.056 . . . . 0.0 111.861 -178.479 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.1 157.63 41.88 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.858 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.887 HG13 ' O ' ' A' ' 279' ' ' GLU . 88.5 t -142.41 147.03 21.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.312 -1.492 . . . . 0.0 112.141 -179.064 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.562 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -135.83 107.5 6.99 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.958 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.4 p30 -93.66 146.03 24.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.031 . . . . 0.0 111.572 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.5 p90 -134.84 23.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.563 -0.71 . . . . 0.0 109.694 179.293 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.425 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 82.4 -69.23 3.38 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -27.67 48.16 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 110.425 179.888 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.537 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.83 -173.57 38.74 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.817 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.557 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -141.39 143.77 34.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -1.162 . . . . 0.0 110.379 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.887 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -93.67 145.61 24.43 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.475 -0.766 . . . . 0.0 109.578 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.1 m-85 -137.9 82.66 1.93 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.332 -0.855 . . . . 0.0 110.422 -179.543 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.753 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -67.91 144.11 55.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.485 -0.76 . . . . 0.0 109.676 179.433 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.874 HG11 HG11 ' A' ' 294' ' ' VAL . 6.7 t -137.71 88.4 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.484 -0.76 . . . . 0.0 109.772 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.865 HG23 ' OG1' ' A' ' 333' ' ' THR . 60.6 m -86.25 120.47 27.64 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 109.245 179.808 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.092 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -104.32 149.02 25.72 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.076 -1.015 . . . . 0.0 111.106 -178.69 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.571 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -131.57 107.19 8.69 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.505 -0.747 . . . . 0.0 110.224 -179.298 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 330' ' ' PRO . 4.8 mt -122.24 172.78 8.04 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.525 -1.359 . . . . 0.0 110.177 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -101.1 28.19 5.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.355 -0.841 . . . . 0.0 110.926 -179.603 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.637 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 161.92 -179.43 37.29 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 119.177 -1.487 . . . . 0.0 110.6 179.739 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.46 ' O ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -71.41 109.0 5.12 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.426 -1.044 . . . . 0.0 111.039 -179.417 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.637 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 10.2 m-85 -137.08 151.55 49.03 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.251 -0.906 . . . . 0.0 109.786 178.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.776 ' O ' HG23 ' A' ' 353' ' ' ILE . 57.8 m-20 -80.42 97.09 6.92 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.273 179.074 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.8 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.4 p-90 -97.18 110.67 23.17 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.406 -179.605 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.67 HG22 ' CG2' ' A' ' 320' ' ' ILE . 4.0 m -103.02 116.76 33.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.5 -0.75 . . . . 0.0 109.485 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.874 HG11 HG11 ' A' ' 282' ' ' VAL . 4.7 t -96.91 111.19 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.131 -0.981 . . . . 0.0 110.432 -179.465 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.651 ' HA ' HD13 ' A' ' 320' ' ' ILE . 17.5 ttpt -82.96 147.85 27.97 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.219 -0.925 . . . . 0.0 109.47 179.433 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 1.011 HG22 HG23 ' A' ' 349' ' ' ILE . 77.3 t -146.61 105.01 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.135 -0.978 . . . . 0.0 110.629 -179.323 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.562 ' O ' HG23 ' A' ' 346' ' ' VAL . 19.2 mmtt -71.26 130.51 41.6 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.259 -0.9 . . . . 0.0 109.393 179.404 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.983 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.2 mt -83.8 161.42 20.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.46 -0.775 . . . . 0.0 111.6 -178.921 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.968 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -63.56 179.12 0.35 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.675 -0.641 . . . . 0.0 109.674 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.9 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.5 Cg_endo -69.24 76.46 0.93 Allowed 'Trans proline' 0 C--N 1.305 -1.745 0 O-C-N 123.742 1.391 . . . . 0.0 109.825 179.369 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.73 19.68 6.0 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.24 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.968 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -101.08 152.69 20.31 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.399 -1.059 . . . . 0.0 110.271 -179.596 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.983 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -150.6 144.62 25.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 110.588 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.853 HG21 HG11 ' A' ' 319' ' ' VAL . 55.2 t -68.07 140.95 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.35 -0.844 . . . . 0.0 109.734 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.79 -39.04 0.51 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.665 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 19.5 m -137.05 129.36 29.75 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.007 -1.29 . . . . 0.0 111.117 -179.678 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.516 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 30.1 p90 -141.2 167.09 23.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.387 -0.821 . . . . 0.0 109.434 179.27 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.467 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.06 157.15 37.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.877 -1.14 . . . . 0.0 111.083 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.475 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 58.79 25.23 13.25 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.477 -0.764 . . . . 0.0 111.106 179.797 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.725 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.18 140.03 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.242 -0.911 . . . . 0.0 109.997 179.465 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.515 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.3 m120 -79.47 121.96 25.84 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.104 -0.998 . . . . 0.0 109.312 179.569 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.686 ' HG3' HG11 ' A' ' 304' ' ' VAL . 0.6 OUTLIER -88.75 145.75 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.771 0.796 . . . . 0.0 110.991 -179.119 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.824 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.17 175.23 9.28 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.524 ' HG2' HG22 ' A' ' 319' ' ' VAL . 3.4 mm-40 -138.68 112.99 8.74 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.228 -0.92 . . . . 0.0 110.457 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -99.76 40.63 2.38 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.79 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 59.27 82.27 0.15 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.29 -1.123 . . . . 0.0 110.179 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.56 -1.56 57.07 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.683 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.2 m-85 -146.37 -172.72 4.01 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.499 -1.0 . . . . 0.0 109.317 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.853 HG11 HG21 ' A' ' 304' ' ' VAL . 2.5 t -158.67 160.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.137 -0.977 . . . . 0.0 109.743 179.355 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.67 ' CG2' HG22 ' A' ' 293' ' ' THR . 35.8 mm -127.93 146.82 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.163 -0.961 . . . . 0.0 111.304 -179.25 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.673 ' HE2' HG21 ' A' ' 296' ' ' VAL . 51.8 m-85 -123.67 132.68 53.9 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 110.003 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.597 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.1 p -131.54 169.69 13.17 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.924 -1.11 . . . . 0.0 110.135 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.538 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.3 Cg_endo -65.76 116.49 3.99 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.065 -179.482 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.482 HG23 ' H ' ' A' ' 326' ' ' TRP . 12.1 m -57.62 -111.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.479 -0.763 . . . . 0.0 109.951 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.466 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.1 t -119.6 -14.25 9.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.785 -1.197 . . . . 0.0 110.376 179.945 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.482 ' H ' HG23 ' A' ' 324' ' ' VAL . 6.5 p-90 -126.66 -24.75 3.51 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.229 -0.919 . . . . 0.0 110.614 -179.846 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 0.3 OUTLIER -86.92 40.8 0.93 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.236 -0.915 . . . . 0.0 110.137 -179.898 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.467 ' HD3' ' O ' ' A' ' 324' ' ' VAL . 0.0 OUTLIER -112.33 -6.22 14.07 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.292 -0.88 . . . . 0.0 109.995 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.69 -143.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.801 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 47.5 Cg_endo -74.85 -49.52 0.15 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.05 1.553 . . . . 0.0 110.395 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 19.0 m -111.08 134.48 52.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.247 -0.908 . . . . 0.0 110.511 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -148.72 123.26 9.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.349 -0.845 . . . . 0.0 109.863 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.865 ' OG1' HG23 ' A' ' 283' ' ' THR . 45.5 m -111.48 137.22 49.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 110.504 -179.826 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.797 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.2 p90 -145.45 174.59 11.01 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.21 159.14 28.05 Favored Glycine 0 N--CA 1.488 2.144 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.358 -179.397 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.929 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -144.98 146.24 31.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.572 -0.958 . . . . 0.0 109.781 179.686 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.929 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.03 125.66 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.175 -0.953 . . . . 0.0 110.091 -179.669 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.787 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.0 t -102.13 153.87 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.23 -0.918 . . . . 0.0 110.007 179.818 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -124.83 126.77 46.11 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.434 -0.791 . . . . 0.0 109.848 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -168.8 -125.57 0.8 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.431 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.2 Cg_endo -71.13 -158.38 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.864 1.455 . . . . 0.0 110.552 -179.899 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.439 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 16.7 mp0 -117.14 132.5 56.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.272 -0.892 . . . . 0.0 110.52 -179.707 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 113.87 -88.33 0.48 Allowed Glycine 0 N--CA 1.493 2.433 0 N-CA-C 108.986 -1.645 . . . . 0.0 108.986 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -114.6 151.27 33.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.374 -1.074 . . . . 0.0 108.817 179.057 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.77 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 1.7 mtmt -142.45 13.53 1.97 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.733 -1.229 . . . . 0.0 111.418 -179.577 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.572 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.2 p -136.66 119.17 20.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.065 -1.022 . . . . 0.0 110.316 179.238 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.32 -46.46 46.74 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.286 -0.884 . . . . 0.0 110.38 -179.653 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -177.02 158.37 1.54 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.242 -0.911 . . . . 0.0 110.479 -179.756 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 1.011 HG23 HG22 ' A' ' 296' ' ' VAL . 23.6 mt -121.08 118.81 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.842 -1.161 . . . . 0.0 110.523 179.939 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.57 156.24 25.03 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.336 -0.852 . . . . 0.0 110.121 179.819 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.092 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -115.49 125.7 53.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.289 -0.882 . . . . 0.0 110.033 179.909 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.5 tt0 -139.06 118.4 12.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.966 -1.084 . . . . 0.0 110.618 179.869 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.776 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.4 mt -94.58 115.8 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.077 -1.015 . . . . 0.0 110.376 179.502 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.45 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.0 m-20 37.34 31.47 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.597 -0.689 . . . . 0.0 111.159 179.741 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 110.53 4.53 28.47 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.535 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 2.6 mp0 -108.05 105.93 15.92 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.149 -1.207 . . . . 0.0 110.087 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 357' ' ' VAL . 14.5 p -70.83 120.31 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.347 -0.845 . . . . 0.0 110.589 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.629 HG23 ' CB ' ' A' ' 262' ' ' PRO . 17.1 mm . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 117.978 -1.011 . . . . 0.0 110.172 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -73.3 175.85 10.01 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 O-C-N 123.985 1.519 . . . . 0.0 110.528 -179.974 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.51 ' CG2' ' O ' ' A' ' 258' ' ' THR . 1.2 t -67.12 124.49 23.21 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.311 -0.868 . . . . 0.0 110.135 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -133.71 104.37 11.94 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.213 -0.93 . . . . 0.0 110.319 -179.889 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.86 156.51 48.16 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 O-C-N 124.086 1.572 . . . . 0.0 110.431 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.549 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -72.79 141.78 82.56 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.151 -0.968 . . . . 0.0 110.35 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.549 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.9 Cg_endo -73.88 146.64 37.96 Favored 'Trans proline' 0 C--N 1.304 -1.803 0 O-C-N 124.08 1.569 . . . . 0.0 110.357 179.781 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.484 ' O ' ' CB ' ' A' ' 264' ' ' SER . 2.9 t -113.62 27.64 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.139 -0.976 . . . . 0.0 110.221 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.484 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.6 OUTLIER 171.04 79.76 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.26 -0.9 . . . . 0.0 110.668 179.925 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 119.08 175.81 16.21 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.262 179.456 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.561 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.1 159.68 38.16 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.497 -1.002 . . . . 0.0 109.985 179.843 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.94 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -147.99 122.59 9.82 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 110.586 -179.626 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.461 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 14.7 mt-10 -123.59 114.26 19.79 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.958 HG13 ' O ' ' A' ' 281' ' ' ASP . 62.1 t -111.84 146.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.984 -1.072 . . . . 0.0 112.164 -178.417 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -130.68 157.21 43.4 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.844 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.829 HG13 ' O ' ' A' ' 279' ' ' GLU . 89.6 t -142.66 147.02 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.317 -1.489 . . . . 0.0 112.112 -179.203 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.537 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -141.12 111.13 6.61 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.216 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.502 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -97.48 148.43 23.23 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.906 -1.121 . . . . 0.0 111.459 -178.526 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.845 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.7 p90 -134.52 20.21 3.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.59 -0.694 . . . . 0.0 109.903 179.459 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.619 ' O ' ' NE2' ' A' ' 342' ' ' GLN . . . 85.91 -68.42 3.38 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.402 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.6 t -58.33 -24.02 58.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -1.206 . . . . 0.0 110.455 -179.838 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.9 179.73 43.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.917 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.587 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.5 143.49 47.49 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.309 -1.112 . . . . 0.0 110.245 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.829 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -96.82 146.55 24.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.332 -0.855 . . . . 0.0 110.178 -179.644 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.683 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 87.4 m-85 -143.32 81.53 1.71 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.414 -0.804 . . . . 0.0 110.539 -179.553 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.958 ' O ' HG13 ' A' ' 269' ' ' VAL . 2.0 t0 -66.28 154.03 41.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 110.124 179.57 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.808 HG11 HG11 ' A' ' 294' ' ' VAL . 4.0 t -143.2 88.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.493 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.598 HG23 ' OG1' ' A' ' 333' ' ' THR . 8.8 m -85.93 115.38 23.51 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.294 -0.878 . . . . 0.0 109.376 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.06 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.14 148.55 24.47 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.327 -0.858 . . . . 0.0 110.818 -178.921 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.561 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.6 m120 -131.15 106.34 8.28 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.492 -0.755 . . . . 0.0 110.316 -179.521 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.546 ' HB2' ' HA ' ' A' ' 330' ' ' PRO . 4.6 mt -121.03 169.25 10.67 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.648 -1.282 . . . . 0.0 109.801 179.447 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 287' ' ' ASP . . . . . 0.403 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -103.15 32.8 3.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 110.253 -179.856 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.552 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 163.79 -165.17 36.8 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.384 -1.389 . . . . 0.0 110.281 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.0 mm-40 -89.28 110.58 21.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.268 -1.137 . . . . 0.0 111.046 -179.447 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.552 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 7.9 m-85 -137.8 142.07 40.86 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.179 -0.951 . . . . 0.0 109.706 179.169 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.666 ' O ' HG23 ' A' ' 353' ' ' ILE . 10.0 t70 -72.6 97.89 2.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.34 179.215 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.776 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.5 p-90 -97.32 112.32 24.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.272 -0.893 . . . . 0.0 110.383 -179.357 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.825 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.1 m -105.78 113.87 27.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.359 -0.838 . . . . 0.0 110.043 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.821 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.6 t -96.61 111.1 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 110.047 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.544 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.1 ttpt -87.87 149.29 24.2 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.28 -0.888 . . . . 0.0 109.319 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.793 HG13 HG12 ' A' ' 349' ' ' ILE . 98.8 t -146.2 108.93 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 121.077 -1.014 . . . . 0.0 110.543 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.526 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 9.3 mmtm -70.13 135.41 49.14 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.112 -0.992 . . . . 0.0 109.228 179.585 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.95 HD13 ' HA ' ' A' ' 303' ' ' THR . 88.4 mt -89.63 162.52 15.58 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.455 -0.778 . . . . 0.0 111.572 -178.879 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.853 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -69.48 177.47 1.23 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.756 -0.59 . . . . 0.0 109.759 179.358 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.853 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.7 Cg_endo -69.32 81.97 0.68 Allowed 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.735 1.387 . . . . 0.0 109.786 179.351 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.26 22.58 5.8 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.357 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.876 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.47 146.2 37.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.379 -1.071 . . . . 0.0 110.388 -179.623 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.95 ' HA ' HD13 ' A' ' 298' ' ' LEU . 5.4 p -149.86 145.74 26.73 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.274 -0.891 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.894 HG21 HG11 ' A' ' 319' ' ' VAL . 92.2 t -68.09 131.31 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.263 -0.898 . . . . 0.0 109.852 179.744 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.12 -28.83 2.11 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.7 t -142.33 115.99 9.16 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.103 -1.233 . . . . 0.0 111.116 -179.635 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.522 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.1 p90 -131.52 178.33 6.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.376 -0.828 . . . . 0.0 109.365 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.504 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -167.91 160.7 12.47 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.872 -1.143 . . . . 0.0 111.073 -179.643 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 57.81 23.61 9.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.496 -0.752 . . . . 0.0 110.881 179.789 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.671 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 146.79 1.0 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.301 -0.874 . . . . 0.0 110.074 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.629 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.5 m120 -82.48 119.74 24.59 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.168 -0.958 . . . . 0.0 109.283 179.46 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.596 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.6 ttpt -88.78 146.15 25.18 Favored 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.813 0.816 . . . . 0.0 110.657 -179.486 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.733 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -130.74 172.71 11.67 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.52 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.49 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 53.2 mt-10 -138.79 104.95 5.22 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.32 -0.863 . . . . 0.0 110.486 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.463 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -93.7 38.7 3.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.463 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 11.3 t-20 59.97 83.48 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.277 -1.131 . . . . 0.0 110.344 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.627 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.09 -2.71 55.13 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 179.709 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.822 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.1 m-85 -145.76 -167.58 2.75 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.349 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.894 HG11 HG21 ' A' ' 304' ' ' VAL . 2.9 t -163.3 157.45 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.178 -0.952 . . . . 0.0 109.428 178.974 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.544 HD13 ' HA ' ' A' ' 295' ' ' LYS . 11.1 mm -127.38 142.99 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.021 -179.641 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 47.8 m-85 -119.31 136.21 54.35 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.146 -0.971 . . . . 0.0 109.808 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.825 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.3 p -138.48 169.98 11.4 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.792 -1.193 . . . . 0.0 110.122 -179.928 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.519 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.79 123.97 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.926 1.487 . . . . 0.0 111.09 -179.292 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.653 HG22 ' HB2' ' A' ' 327' ' ' ASN . 18.6 m -74.35 -116.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.499 -0.751 . . . . 0.0 110.135 -179.938 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.5 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -105.68 -32.55 8.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.709 -1.245 . . . . 0.0 110.808 -179.588 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 4.1 p-90 -116.34 -1.77 12.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.12 -0.987 . . . . 0.0 110.502 -179.778 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.653 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.27 50.01 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.107 -0.995 . . . . 0.0 109.79 179.796 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -125.68 -2.6 7.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.376 -0.828 . . . . 0.0 109.716 -179.804 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.463 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -72.34 -143.91 0.48 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.735 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.546 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 49.2 Cg_endo -73.58 -53.73 0.12 Allowed 'Trans proline' 0 C--N 1.303 -1.838 0 O-C-N 124.166 1.614 . . . . 0.0 110.473 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.25 130.61 50.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.259 -0.901 . . . . 0.0 110.467 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.552 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -145.03 104.48 3.98 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.435 -0.791 . . . . 0.0 109.749 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.598 ' OG1' HG23 ' A' ' 283' ' ' THR . 27.8 m -100.68 133.73 44.71 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.084 -1.01 . . . . 0.0 110.604 -179.61 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.821 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.8 p90 -141.85 174.73 10.31 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.336 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.522 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.71 153.65 25.06 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.905 -1.617 . . . . 0.0 110.226 -179.542 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -138.72 146.73 41.85 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.468 -1.019 . . . . 0.0 109.794 179.354 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.88 122.09 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.238 -0.914 . . . . 0.0 109.798 -179.891 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.876 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 10.0 t -99.89 154.08 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.1 -1.0 . . . . 0.0 110.644 -179.398 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -124.91 130.65 52.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.464 -0.772 . . . . 0.0 110.065 -179.96 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.74 -123.22 0.83 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.833 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.517 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.7 Cg_endo -68.62 174.99 7.66 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 123.856 1.451 . . . . 0.0 110.438 -179.944 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.619 ' NE2' ' O ' ' A' ' 275' ' ' GLY . 5.0 mm100 -99.2 127.29 45.15 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.176 -0.953 . . . . 0.0 110.532 -179.295 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.453 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 115.82 -87.09 0.43 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.24 140.72 44.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -1.118 . . . . 0.0 109.097 179.345 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.622 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER -139.03 13.27 2.65 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.822 -1.174 . . . . 0.0 111.281 -179.563 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' A' ' 296' ' ' VAL . 12.2 p -138.74 118.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.152 -0.968 . . . . 0.0 110.303 179.391 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 5.7 mt-10 -49.26 -48.45 45.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.415 -0.803 . . . . 0.0 110.368 -179.728 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.458 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.8 pt-20 -177.21 158.74 1.52 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.188 -0.945 . . . . 0.0 111.008 -179.852 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.793 HG12 HG13 ' A' ' 296' ' ' VAL . 57.0 mt -117.46 121.44 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.324 -0.86 . . . . 0.0 109.993 179.509 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.56 136.97 54.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.246 -0.909 . . . . 0.0 110.291 -179.792 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.06 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -95.98 127.85 42.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.196 -0.94 . . . . 0.0 110.378 179.966 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.8 OUTLIER -139.39 113.02 8.43 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.16 -0.963 . . . . 0.0 110.399 179.746 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.666 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.3 mt -91.78 112.26 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.003 -1.061 . . . . 0.0 110.0 179.473 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.438 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.0 m-20 41.19 29.02 0.07 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.501 -0.749 . . . . 0.0 110.393 -179.69 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 113.15 -13.03 23.99 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.69 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.446 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 0.2 OUTLIER -88.6 110.86 21.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.306 -1.114 . . . . 0.0 110.431 -179.842 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.3 p -68.66 119.33 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.172 -0.955 . . . . 0.0 110.171 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.842 ' HB ' HD13 ' A' ' 351' ' ' LEU . 42.9 mm . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.268 -179.88 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -74.1 -178.65 4.03 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.98 1.516 . . . . 0.0 110.377 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 258' ' ' THR . 3.1 t -67.99 123.39 20.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -0.896 . . . . 0.0 109.988 179.83 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 5.4 t -131.16 144.15 52.31 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.163 -0.961 . . . . 0.0 110.497 -179.748 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -78.09 151.0 26.75 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.929 1.489 . . . . 0.0 110.479 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.651 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.5 p -103.85 145.14 30.07 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.265 -0.897 . . . . 0.0 110.071 179.764 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.651 ' HD2' HG23 ' A' ' 261' ' ' VAL . 50.3 Cg_endo -74.39 140.66 27.56 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.056 1.556 . . . . 0.0 110.399 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.749 HG12 ' O ' ' A' ' 263' ' ' VAL . 63.6 t -110.06 23.96 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.148 -0.97 . . . . 0.0 110.011 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.558 ' O ' HD12 ' A' ' 358' ' ' ILE . 0.4 OUTLIER 167.12 139.81 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.438 -0.789 . . . . 0.0 110.33 179.873 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 75.47 -179.46 46.15 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 179.716 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.556 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.1 158.41 44.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.535 -0.98 . . . . 0.0 109.431 179.754 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.926 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -157.32 141.34 16.13 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.943 -1.098 . . . . 0.0 110.93 -179.488 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.752 ' H ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -140.34 122.02 15.31 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.797 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.844 HG23 HD11 ' A' ' 267' ' ' LEU . 50.9 t -115.39 133.14 62.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.01 -1.056 . . . . 0.0 111.559 -178.934 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.16 157.19 32.08 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.734 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 279' ' ' GLU . 71.6 t -143.12 147.04 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.286 -1.509 . . . . 0.0 112.251 -178.879 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.24 113.93 8.75 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.706 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 17.6 p-10 -98.81 148.21 24.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.039 -1.038 . . . . 0.0 111.718 -178.098 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.815 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.1 p90 -134.11 19.07 3.74 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.652 -0.655 . . . . 0.0 109.453 179.14 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.467 ' HA2' HE21 ' A' ' 342' ' ' GLN . . . 85.43 -65.83 3.91 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.939 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -58.48 -21.43 51.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -1.133 . . . . 0.0 110.255 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.531 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.35 -179.08 46.61 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.938 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.558 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -136.76 140.73 42.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.42 -1.047 . . . . 0.0 109.983 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.797 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.0 mt-10 -93.66 146.58 23.72 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.466 -0.771 . . . . 0.0 110.37 -179.534 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 91.0 m-85 -140.81 84.47 1.94 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.524 -0.735 . . . . 0.0 110.405 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.676 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -67.24 151.75 46.95 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.418 -0.801 . . . . 0.0 109.487 179.208 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.767 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.6 t -145.72 88.6 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.564 -0.71 . . . . 0.0 109.615 -179.537 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.68 HG23 ' OG1' ' A' ' 333' ' ' THR . 88.6 m -87.01 123.83 32.54 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.081 -1.012 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.057 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.85 150.51 30.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 110.408 -179.76 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.556 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 2.0 m120 -134.1 115.86 14.76 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.376 -0.827 . . . . 0.0 110.103 -179.377 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.618 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 13.2 mt -124.09 154.88 39.32 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 120.759 -1.213 . . . . 0.0 110.454 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -89.9 37.22 0.88 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.248 -0.908 . . . . 0.0 109.786 179.627 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.61 -141.86 7.71 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.528 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 tp60 -111.67 92.62 4.1 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.162 -1.199 . . . . 0.0 110.489 -179.758 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.618 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.1 m-30 -116.93 129.99 56.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.268 -0.895 . . . . 0.0 110.074 179.396 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.876 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.5 m-20 -64.16 103.67 0.64 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.146 -0.972 . . . . 0.0 109.557 179.549 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.897 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.0 p-90 -101.95 109.32 21.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.189 -0.944 . . . . 0.0 110.391 -179.756 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.787 HG22 ' CG2' ' A' ' 320' ' ' ILE . 3.1 m -101.04 116.18 32.23 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.463 -0.773 . . . . 0.0 109.526 179.641 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.786 HG21 ' HE2' ' A' ' 334' ' ' PHE . 20.6 t -96.67 111.1 26.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 110.487 -179.378 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.477 ' HA ' HG12 ' A' ' 320' ' ' ILE . 22.8 ttpt -87.36 147.25 25.55 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.496 -0.752 . . . . 0.0 109.024 179.0 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.671 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 55.6 t -146.67 105.45 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 110.702 -178.981 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.547 ' O ' HG23 ' A' ' 346' ' ' VAL . 26.4 mmtt -70.93 133.51 46.47 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.15 -0.969 . . . . 0.0 109.732 179.628 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.953 HD13 ' HA ' ' A' ' 303' ' ' THR . 90.7 mt -86.31 162.44 18.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.323 -0.861 . . . . 0.0 111.573 -178.93 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.707 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -71.28 173.48 4.96 Favored Pre-proline 0 N--CA 1.488 1.441 0 O-C-N 121.582 -0.699 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.694 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -67.92 82.4 0.46 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 O-C-N 123.508 1.267 . . . . 0.0 109.932 179.531 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.63 25.71 3.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.424 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.872 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -117.79 148.45 42.05 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -1.113 . . . . 0.0 110.144 -179.748 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.953 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.4 p -149.82 144.52 26.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 110.239 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.822 HG21 HG11 ' A' ' 319' ' ' VAL . 38.2 t -63.99 119.9 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.232 -0.918 . . . . 0.0 109.886 179.767 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -105.95 -20.35 9.41 Favored Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.818 -1.182 . . . . 0.0 110.339 -179.392 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.489 ' O ' ' N ' ' A' ' 337' ' ' ILE . 42.2 t -154.8 134.28 12.64 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.983 -1.304 . . . . 0.0 110.889 -179.695 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -149.43 176.42 10.6 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.354 -0.841 . . . . 0.0 109.773 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.472 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -166.72 158.84 13.38 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.794 -1.191 . . . . 0.0 111.719 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.51 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.8 OUTLIER 59.4 26.08 14.92 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.667 -0.646 . . . . 0.0 111.407 179.363 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.667 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 140.89 0.65 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.17 -0.956 . . . . 0.0 109.936 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.553 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.5 m120 -77.34 114.14 15.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.078 -1.014 . . . . 0.0 109.586 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.751 ' CD ' HG11 ' A' ' 304' ' ' VAL . 1.9 ttpp -83.01 144.6 29.84 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.695 0.76 . . . . 0.0 110.691 -179.444 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.676 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -126.85 173.84 9.27 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.412 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.423 ' HG2' HG22 ' A' ' 319' ' ' VAL . 2.1 mm-40 -137.93 105.13 5.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.448 -0.782 . . . . 0.0 110.344 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -97.17 35.78 4.27 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.442 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.4 OUTLIER 65.65 91.96 0.08 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -1.182 . . . . 0.0 110.135 -179.962 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.58 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 87.47 0.69 84.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.857 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.826 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -143.28 -172.75 3.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.339 -1.095 . . . . 0.0 109.654 179.629 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.7 t -163.46 152.52 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.575 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.787 ' CG2' HG22 ' A' ' 293' ' ' THR . 68.8 mt -131.99 132.17 61.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.648 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 70.8 m-85 -104.76 141.47 36.42 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.374 -0.829 . . . . 0.0 110.748 -179.725 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.738 ' CG2' HG23 ' A' ' 293' ' ' THR . 0.9 OUTLIER -137.05 171.02 9.3 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 120.969 -1.082 . . . . 0.0 110.143 179.762 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.53 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.3 Cg_endo -67.29 114.68 3.33 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 O-C-N 123.822 1.433 . . . . 0.0 110.986 -179.461 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.963 HG22 ' HB2' ' A' ' 327' ' ' ASN . 7.3 m -65.44 -134.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.464 -0.773 . . . . 0.0 109.894 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.707 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.7 OUTLIER -92.09 -14.73 28.78 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.021 -1.049 . . . . 0.0 110.602 -179.697 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.836 ' H ' HG23 ' A' ' 324' ' ' VAL . 26.4 p-90 -136.06 15.97 3.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.241 -0.912 . . . . 0.0 110.444 -179.841 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.963 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -116.24 31.17 6.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.097 -1.002 . . . . 0.0 110.8 -179.481 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -114.6 -6.47 12.78 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.244 -0.91 . . . . 0.0 109.801 179.539 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.1 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.869 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.529 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 50.2 Cg_endo -75.42 5.75 4.0 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.04 1.547 . . . . 0.0 110.987 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.7 m -165.36 121.64 1.41 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 120.96 -1.087 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -143.44 112.74 6.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.139 -0.975 . . . . 0.0 110.446 -179.894 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.68 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.9 m -103.04 139.05 39.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.407 -0.808 . . . . 0.0 110.009 179.864 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.786 ' HE2' HG21 ' A' ' 294' ' ' VAL . 17.7 p90 -144.72 172.77 12.54 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.403 -0.81 . . . . 0.0 108.834 179.566 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.37 160.01 28.37 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 118.954 -1.594 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.931 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -145.33 146.4 31.59 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.582 -0.952 . . . . 0.0 109.63 179.237 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.931 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.85 120.25 61.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.836 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.872 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 6.0 t -96.74 146.3 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.13 -0.981 . . . . 0.0 110.621 -179.519 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.4 m120 -120.02 131.9 55.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.49 -0.756 . . . . 0.0 110.219 -179.935 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.18 -134.09 2.01 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.912 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.446 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 45.9 Cg_endo -71.08 -170.31 0.47 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 123.926 1.487 . . . . 0.0 110.287 -179.723 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.48 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 5.1 mm100 -107.62 149.08 28.49 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.144 -0.973 . . . . 0.0 110.255 -179.595 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.425 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 92.51 72.85 1.22 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 -179.863 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.425 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 1.0 OUTLIER 64.04 147.55 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.249 -1.148 . . . . 0.0 109.369 -179.48 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.707 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.0 mtmt -142.01 18.23 2.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.904 -1.123 . . . . 0.0 111.1 -179.762 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.62 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -130.77 122.45 52.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.126 -0.984 . . . . 0.0 110.18 179.22 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.48 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -51.83 -45.45 63.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -0.941 . . . . 0.0 110.16 -179.703 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.475 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 6.9 pt-20 -177.03 158.27 1.52 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.253 -0.904 . . . . 0.0 110.324 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.589 HG12 HG13 ' A' ' 296' ' ' VAL . 11.5 mt -118.11 110.31 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.318 -0.864 . . . . 0.0 110.055 179.904 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.45 149.47 29.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.949 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.057 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -113.6 127.25 56.0 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.228 -0.92 . . . . 0.0 109.509 179.252 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 15.4 pt-20 -138.31 118.78 13.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.135 -0.978 . . . . 0.0 110.086 -179.797 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.876 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -97.73 104.7 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.197 -0.939 . . . . 0.0 110.351 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.463 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.2 m120 35.16 30.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.057 0.455 . . . . 0.0 111.073 179.805 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 133.61 -43.41 1.27 Allowed Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.276 179.706 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.508 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 35.2 mm-40 -73.97 120.71 19.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.124 -1.221 . . . . 0.0 110.627 -179.505 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.712 HG13 ' O ' ' A' ' 357' ' ' VAL . 12.9 p -91.3 111.51 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.066 -1.022 . . . . 0.0 110.08 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.609 HG23 ' CB ' ' A' ' 262' ' ' PRO . 9.4 mm . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.187 -179.837 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -74.06 -178.31 3.79 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.999 1.526 . . . . 0.0 110.656 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.406 ' O ' HG23 ' A' ' 258' ' ' THR . 5.0 t -70.44 134.97 48.3 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.477 -0.764 . . . . 0.0 110.378 -179.9 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 34.1 p -85.12 129.88 54.24 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.206 -0.934 . . . . 0.0 110.124 179.892 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -71.94 133.76 22.26 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.899 1.473 . . . . 0.0 110.398 179.946 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.431 ' H ' HG12 ' A' ' 261' ' ' VAL . 2.6 p -73.66 138.31 77.2 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.343 -0.848 . . . . 0.0 110.44 -179.812 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 358' ' ' ILE . 50.7 Cg_endo -78.46 143.82 19.67 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 124.172 1.617 . . . . 0.0 110.493 -179.993 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 3.6 t -139.07 29.7 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.252 -0.905 . . . . 0.0 110.107 179.676 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.628 ' HB3' HD11 ' A' ' 358' ' ' ILE . 12.3 t -163.27 69.07 0.21 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 110.68 179.915 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.45 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . 108.09 -163.51 12.9 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 179.425 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.478 ' HB2' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.92 169.28 18.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.53 -0.983 . . . . 0.0 109.729 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.886 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.77 133.34 5.44 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.039 -1.038 . . . . 0.0 111.396 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.829 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.3 OUTLIER -129.76 138.38 51.05 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.404 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 281' ' ' ASP . 49.0 t -131.54 134.04 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.869 -1.145 . . . . 0.0 111.653 -179.3 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.24 157.08 29.89 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.705 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.659 HG13 ' O ' ' A' ' 279' ' ' GLU . 75.7 t -141.26 145.34 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.494 -1.378 . . . . 0.0 111.879 -179.392 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.57 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.15 110.17 8.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.666 -0.646 . . . . 0.0 109.825 179.631 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.414 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.8 m-20 -96.39 128.41 43.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.167 -0.958 . . . . 0.0 111.102 -179.412 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.83 ' CH2' HG23 ' A' ' 337' ' ' ILE . 29.0 p90 -113.17 16.59 19.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.879 . . . . 0.0 109.762 178.995 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.06 -59.0 3.93 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.45 -22.01 63.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -1.143 . . . . 0.0 110.18 179.858 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.583 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.78 -178.39 40.29 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.821 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -136.56 139.37 42.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.339 -1.095 . . . . 0.0 110.167 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.659 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.6 mt-10 -93.58 147.53 22.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.508 -0.745 . . . . 0.0 110.11 -179.511 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.3 m-85 -141.75 82.16 1.8 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.279 -0.888 . . . . 0.0 110.432 -179.661 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.643 ' O ' HG13 ' A' ' 269' ' ' VAL . 1.6 m-20 -67.38 146.01 54.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.509 -0.745 . . . . 0.0 109.695 179.557 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.773 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.8 t -139.12 88.78 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 109.931 -179.738 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 333' ' ' THR . 25.9 m -86.04 125.35 33.36 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.058 -1.026 . . . . 0.0 109.218 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -112.06 153.7 26.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.109 -0.994 . . . . 0.0 110.882 -179.072 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.936 ' O ' HD23 ' A' ' 286' ' ' LEU . 1.9 m120 -131.63 128.37 38.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.474 -0.766 . . . . 0.0 110.162 -179.582 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.936 HD23 ' O ' ' A' ' 285' ' ' ASN . 9.8 mt -143.69 157.09 44.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.771 -1.206 . . . . 0.0 109.938 179.862 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -94.38 35.7 1.19 Allowed 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.401 -0.812 . . . . 0.0 109.732 179.526 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 162.21 -174.61 38.66 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.908 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.537 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 4.2 mt-30 -83.93 96.3 8.78 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.308 -1.113 . . . . 0.0 110.406 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.603 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.74 153.38 32.51 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.227 -0.92 . . . . 0.0 109.749 179.586 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.844 ' O ' HG23 ' A' ' 353' ' ' ILE . 53.9 m-20 -82.85 95.74 8.03 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.328 179.327 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.893 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.5 p-90 -97.13 116.42 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 110.226 -179.737 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 293' ' ' THR . . . . . 1.042 HG23 HG22 ' A' ' 322' ' ' THR . 1.9 m -111.03 114.07 27.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.541 -0.724 . . . . 0.0 109.93 -179.83 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.776 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.4 t -96.2 111.33 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.097 -1.002 . . . . 0.0 110.205 -179.689 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 27.3 ttmt -86.63 149.81 24.65 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.368 -0.833 . . . . 0.0 109.622 179.361 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.862 HG22 HG23 ' A' ' 349' ' ' ILE . 54.5 t -147.69 109.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.117 -0.99 . . . . 0.0 110.599 -179.575 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.571 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 51.9 mmtt -72.6 141.42 48.37 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.107 -0.996 . . . . 0.0 109.591 179.441 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.966 HD13 ' HA ' ' A' ' 303' ' ' THR . 81.2 mt -94.03 156.2 16.72 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.26 -0.9 . . . . 0.0 111.481 -179.059 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -65.27 174.45 1.4 Allowed Pre-proline 0 C--N 1.303 -1.442 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.961 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.8 Cg_endo -68.74 83.42 0.53 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.531 1.28 . . . . 0.0 109.848 179.65 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.37 4.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 -179.468 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.709 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -114.69 149.41 36.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.298 -1.119 . . . . 0.0 109.753 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.966 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.6 p -150.69 143.46 24.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.062 . . . . 0.0 111.214 -179.796 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.93 ' CG2' HG21 ' A' ' 319' ' ' VAL . 58.6 t -70.89 116.46 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.56 -0.713 . . . . 0.0 110.013 179.515 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.43 -38.49 3.48 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.82 -1.181 . . . . 0.0 110.359 -179.264 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -129.94 140.33 50.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.004 -1.292 . . . . 0.0 111.139 -179.457 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.599 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 13.1 p90 -152.88 160.96 43.1 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 109.577 179.334 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.518 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -155.38 155.18 33.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.902 -1.124 . . . . 0.0 111.394 -179.48 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.441 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.9 OUTLIER 63.11 26.8 15.5 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 111.337 179.373 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.56 ' N ' HG13 ' A' ' 324' ' ' VAL . . . -174.29 148.6 1.29 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.049 -1.032 . . . . 0.0 110.805 179.573 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.508 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 3.8 m120 -77.59 114.02 16.01 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 179.259 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.599 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 23.3 ttpt -89.51 122.45 32.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.435 -0.791 . . . . 0.0 110.831 -179.57 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.618 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 2.6 tt0 -111.87 177.54 4.61 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.518 -0.739 . . . . 0.0 109.284 179.008 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.436 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.9 mt-10 -137.26 105.14 5.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.278 -0.889 . . . . 0.0 110.286 179.593 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.57 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -92.22 47.19 2.63 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.755 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 55.21 78.97 0.16 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.126 -1.22 . . . . 0.0 110.376 179.818 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.621 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.86 3.68 58.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 179.697 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.731 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -144.85 -172.63 3.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.42 -1.047 . . . . 0.0 109.061 179.545 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.93 HG21 ' CG2' ' A' ' 304' ' ' VAL . 12.1 t -158.89 150.08 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.988 -1.07 . . . . 0.0 110.286 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.639 ' CG2' HG22 ' A' ' 293' ' ' THR . 6.4 mm -114.96 151.85 16.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.104 -0.998 . . . . 0.0 110.687 -179.656 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 35.0 m-85 -131.74 112.2 12.32 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.199 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 322' ' ' THR . . . . . 1.042 HG22 HG23 ' A' ' 293' ' ' THR . 1.7 p -113.22 -176.46 0.38 Allowed Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 120.374 -1.454 . . . . 0.0 109.591 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.587 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 45.6 Cg_endo -77.63 117.44 4.28 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.446 1.235 . . . . 0.0 111.458 -178.502 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.579 HG22 ' OD1' ' A' ' 327' ' ' ASN . 3.7 m -53.58 -105.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.424 -0.797 . . . . 0.0 110.592 179.905 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.484 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.5 m -133.79 -12.37 2.61 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.691 -1.256 . . . . 0.0 111.428 -179.448 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.621 ' CE3' ' HB3' ' A' ' 327' ' ' ASN . 2.0 p-90 -126.47 -25.6 3.43 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.776 -1.202 . . . . 0.0 111.228 -179.586 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.631 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 1.4 p-10 -96.0 36.66 1.29 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.762 -1.211 . . . . 0.0 110.963 -179.697 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -99.71 -6.23 27.46 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.157 -0.964 . . . . 0.0 108.736 178.179 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.55 -138.38 0.01 OUTLIER Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.474 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.599 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 46.0 Cg_endo -73.01 -54.62 0.11 Allowed 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 124.205 1.634 . . . . 0.0 111.054 -179.721 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -102.61 140.25 37.13 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.156 -0.965 . . . . 0.0 110.77 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.721 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -152.26 107.77 3.31 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 283' ' ' THR . 53.8 m -105.41 135.9 45.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.907 -1.121 . . . . 0.0 110.166 179.67 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.776 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.0 p90 -145.32 174.6 10.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.631 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.26 158.08 27.75 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.659 -1.734 . . . . 0.0 110.435 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.897 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -143.42 146.5 33.51 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.669 -0.901 . . . . 0.0 109.33 179.252 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.897 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.74 121.31 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.968 -1.083 . . . . 0.0 109.831 179.904 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.709 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.5 t -96.6 145.92 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.184 -0.947 . . . . 0.0 109.634 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.1 m120 -121.33 135.43 55.09 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 110.905 -179.234 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.26 -134.33 2.06 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.735 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.504 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.4 Cg_endo -71.33 -155.82 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.877 1.461 . . . . 0.0 110.275 179.728 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.419 ' CD ' ' N ' ' A' ' 342' ' ' GLN . 3.1 pm0 -126.13 128.44 47.32 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.965 -1.085 . . . . 0.0 110.202 -179.852 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 117.69 61.95 0.3 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 -179.825 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 10.4 t0 70.24 132.74 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.38 -1.071 . . . . 0.0 108.966 -179.066 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.643 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.0 OUTLIER -135.06 19.82 3.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.836 -1.165 . . . . 0.0 111.187 -179.098 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.571 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 7.4 p -126.53 119.05 52.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.911 -1.118 . . . . 0.0 110.241 179.378 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 4.1 mm-40 -49.67 -44.56 47.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -0.91 . . . . 0.0 110.523 -179.533 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.446 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.1 pt-20 -176.68 158.85 1.76 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.09 -1.006 . . . . 0.0 110.718 -179.713 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.862 HG23 HG22 ' A' ' 296' ' ' VAL . 29.6 mt -124.42 110.17 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.095 -1.003 . . . . 0.0 110.228 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.67 160.05 19.8 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.415 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.52 129.72 54.83 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.906 . . . . 0.0 110.554 -179.903 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.9 tt0 -139.32 118.35 12.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.824 . . . . 0.0 109.456 179.405 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.844 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.08 100.66 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.892 -1.13 . . . . 0.0 110.399 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.444 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 2.8 m-20 38.27 40.08 0.32 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.949 -0.47 . . . . 0.0 111.396 179.492 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.44 ' O ' ' CD ' ' A' ' 356' ' ' GLN . . . 113.06 23.37 5.27 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.793 179.056 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 56.7 mm-40 -141.46 101.47 4.0 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.015 -1.285 . . . . 0.0 110.238 179.661 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.706 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -65.7 136.35 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.252 -0.905 . . . . 0.0 110.552 -179.827 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.706 HD13 ' O ' ' A' ' 357' ' ' VAL . 22.9 mm . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.215 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.8 179.45 5.65 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.967 1.509 . . . . 0.0 110.432 -179.846 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 5.0 t -59.42 134.72 57.26 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.299 -0.876 . . . . 0.0 110.043 -179.903 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 259' ' ' THR . . . . . 0.462 HG23 ' O ' ' A' ' 259' ' ' THR . 1.4 t -119.12 101.61 49.59 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.139 -0.976 . . . . 0.0 110.586 -179.704 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.6 142.52 26.19 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.892 1.469 . . . . 0.0 109.969 179.716 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.653 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -68.91 144.51 95.85 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.047 -1.033 . . . . 0.0 110.319 -179.806 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.653 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.0 Cg_endo -73.87 154.8 48.55 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.128 1.594 . . . . 0.0 110.417 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.744 HG12 ' O ' ' A' ' 263' ' ' VAL . 90.9 t -139.49 28.91 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.308 -0.87 . . . . 0.0 110.105 179.799 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -179.83 91.1 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.24 -0.912 . . . . 0.0 110.72 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.32 -170.07 22.12 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.254 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.566 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -138.6 165.86 25.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.602 -0.94 . . . . 0.0 109.593 179.908 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.927 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.63 141.35 10.25 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.94 -1.104 . . . . 0.0 111.436 -179.554 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.746 ' H ' HD22 ' A' ' 267' ' ' LEU . 0.2 OUTLIER -139.48 149.5 44.06 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.853 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 281' ' ' ASP . 39.8 t -138.19 137.9 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.694 -1.254 . . . . 0.0 111.654 -179.337 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.444 ' HG2' ' OE2' ' A' ' 268' ' ' GLU . 3.2 mmtp -125.27 156.93 37.81 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.111 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.703 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.1 t -145.07 145.84 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 120.374 -1.454 . . . . 0.0 112.15 -179.193 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.533 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.8 112.56 7.59 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.796 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.1 p-10 -97.37 144.84 26.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.955 -1.091 . . . . 0.0 111.602 -178.338 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 36.1 p90 -129.9 21.54 5.41 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.472 0.654 . . . . 0.0 109.681 179.281 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.529 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 87.24 -68.53 3.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.502 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 8.1 t -56.93 -23.73 47.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.144 -1.209 . . . . 0.0 110.35 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.423 ' HA2' ' HA ' ' A' ' 339' ' ' ASN . . . -174.46 -170.02 37.19 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.387 -1.387 . . . . 0.0 109.987 179.918 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.632 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -141.88 143.78 33.5 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.337 -1.096 . . . . 0.0 110.514 -179.905 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.703 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.4 mt-10 -94.87 147.34 23.47 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.412 -0.805 . . . . 0.0 109.904 -179.853 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.658 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 88.1 m-85 -142.91 90.27 2.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.396 -0.815 . . . . 0.0 110.514 -179.63 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.709 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -74.16 153.02 39.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.365 -0.835 . . . . 0.0 110.117 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.859 HG11 HG11 ' A' ' 294' ' ' VAL . 3.3 t -145.12 90.61 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.83 -179.665 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 283' ' ' THR . . . . . 1.006 HG23 ' OG1' ' A' ' 333' ' ' THR . 7.5 m -87.04 122.61 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 0.0 110.457 -179.746 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.089 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -108.14 151.09 26.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 110.122 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.566 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.6 m120 -134.58 106.57 7.06 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.211 -0.93 . . . . 0.0 110.646 -179.036 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.632 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.6 mt -113.07 173.9 6.16 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.666 -1.272 . . . . 0.0 110.006 179.671 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -109.5 30.19 6.87 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.434 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 170.19 -102.79 0.18 Allowed Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.357 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.487 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.1 OUTLIER -150.7 105.38 3.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -1.181 . . . . 0.0 110.463 -179.395 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.632 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -136.33 132.74 36.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 110.025 179.596 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.768 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.2 OUTLIER -61.04 100.25 0.11 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.289 -0.882 . . . . 0.0 109.366 179.337 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.881 ' CZ2' ' HB1' ' A' ' 332' ' ' ALA . 56.4 p-90 -98.34 111.07 23.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.345 -0.847 . . . . 0.0 110.447 -179.637 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.901 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.4 m -105.37 114.58 28.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.859 HG11 HG11 ' A' ' 282' ' ' VAL . 3.5 t -96.92 110.74 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.145 -0.972 . . . . 0.0 110.085 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.586 ' HA ' HD13 ' A' ' 320' ' ' ILE . 18.8 ttpt -87.41 149.01 24.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.227 -0.92 . . . . 0.0 109.362 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.709 HG13 HG12 ' A' ' 349' ' ' ILE . 71.0 t -145.78 110.53 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.193 -0.942 . . . . 0.0 110.745 -179.325 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.614 ' O ' HG23 ' A' ' 346' ' ' VAL . 29.3 mmtp -71.51 132.71 45.1 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.246 -0.909 . . . . 0.0 109.73 179.343 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.936 HD13 ' HA ' ' A' ' 303' ' ' THR . 83.0 mt -85.42 159.06 20.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.375 -0.828 . . . . 0.0 111.445 -179.036 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.801 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -62.94 174.77 0.77 Allowed Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.699 -0.626 . . . . 0.0 109.454 179.08 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.733 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -69.4 78.88 0.86 Allowed 'Trans proline' 0 C--N 1.304 -1.812 0 O-C-N 123.575 1.303 . . . . 0.0 109.754 179.451 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.19 24.58 3.81 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.166 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.808 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -112.22 152.93 27.84 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -1.152 . . . . 0.0 110.338 -179.479 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.936 ' HA ' HD13 ' A' ' 298' ' ' LEU . 21.5 p -153.31 143.61 22.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.235 -0.915 . . . . 0.0 110.502 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.933 HG21 HG11 ' A' ' 319' ' ' VAL . 76.4 t -64.72 139.75 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.463 -0.773 . . . . 0.0 110.215 179.881 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 305' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -123.28 -33.69 0.81 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.442 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.9 OUTLIER -138.23 124.42 20.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -1.19 . . . . 0.0 110.98 -179.667 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.562 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 52.9 p90 -141.08 156.37 46.0 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.323 -0.861 . . . . 0.0 109.714 179.362 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.493 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -150.0 157.31 43.02 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.955 -1.091 . . . . 0.0 111.368 -179.288 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.606 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 64.57 21.66 12.48 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.609 -0.682 . . . . 0.0 110.906 179.803 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.559 ' CA ' HG13 ' A' ' 324' ' ' VAL . . . -174.57 150.2 1.35 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.272 -0.893 . . . . 0.0 110.394 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.539 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.2 m120 -83.84 125.34 31.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.119 -0.988 . . . . 0.0 109.586 179.485 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.562 ' HD3' ' CD2' ' A' ' 307' ' ' PHE . 3.7 ttpt -92.85 135.91 33.72 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.838 0.828 . . . . 0.0 110.751 -179.582 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.723 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 4.9 mp0 -122.37 179.46 4.56 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.63 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.411 ' HA ' ' O ' ' A' ' 318' ' ' TYR . 3.5 mt-10 -142.49 113.07 7.31 Favored 'General case' 0 N--CA 1.492 1.634 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.444 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.09 49.71 1.05 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.83 79.37 0.2 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -1.167 . . . . 0.0 110.093 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.595 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.95 5.34 66.24 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.778 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.811 ' O ' HG23 ' A' ' 319' ' ' VAL . 5.4 m-85 -138.88 -174.31 3.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.401 -1.058 . . . . 0.0 109.167 179.449 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.933 HG11 HG21 ' A' ' 304' ' ' VAL . 5.7 t -163.14 156.96 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.287 -0.883 . . . . 0.0 109.767 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.723 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 12.8 mm -127.08 148.91 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.074 -1.016 . . . . 0.0 111.361 -179.946 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.675 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 86.0 m-85 -124.85 122.01 36.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.446 -0.784 . . . . 0.0 109.703 179.01 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.901 ' CG2' HG23 ' A' ' 293' ' ' THR . 5.5 p -124.52 169.01 11.59 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 120.738 -1.226 . . . . 0.0 109.953 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.54 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 37.3 Cg_endo -63.89 112.38 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.769 1.405 . . . . 0.0 111.415 -179.319 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.704 HG23 ' H ' ' A' ' 325' ' ' SER . 3.6 m -50.4 -58.24 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.545 -0.722 . . . . 0.0 110.746 179.74 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.704 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.2 OUTLIER 178.65 -26.11 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.081 -1.012 . . . . 0.0 110.947 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.518 ' CE2' HG21 ' A' ' 324' ' ' VAL . 6.3 p-90 -110.43 -27.03 9.22 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.853 -1.154 . . . . 0.0 110.98 -179.79 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 1.003 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 46.2 p-10 -83.34 14.56 3.52 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 120.979 -1.076 . . . . 0.0 111.06 179.934 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.49 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 11.4 mtmt -77.12 -8.58 57.74 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.174 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.18 -153.14 0.01 OUTLIER Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 -179.322 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -76.12 9.61 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 124.267 1.667 . . . . 0.0 111.153 -179.581 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.5 m -164.87 135.15 3.86 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 1.003 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -147.87 104.19 3.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.171 -0.956 . . . . 0.0 110.378 -179.463 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 333' ' ' THR . . . . . 1.006 ' OG1' HG23 ' A' ' 283' ' ' THR . 4.8 m -101.12 133.22 45.98 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.287 -0.883 . . . . 0.0 110.313 179.883 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.754 ' HE2' HG21 ' A' ' 294' ' ' VAL . 24.2 p90 -144.2 168.21 20.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 108.957 179.553 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -141.65 165.3 26.5 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.078 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.5 OUTLIER -150.52 143.88 24.98 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.689 -0.889 . . . . 0.0 109.379 179.191 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.51 118.79 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.028 -1.045 . . . . 0.0 110.223 -179.67 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.808 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.7 t -97.64 153.18 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.163 -0.96 . . . . 0.0 110.153 -179.795 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.5 m120 -122.56 131.65 53.93 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 110.212 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.89 -125.35 0.95 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.528 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.9 Cg_endo -66.58 -158.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.532 0 O-C-N 123.821 1.432 . . . . 0.0 111.117 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.529 ' HG3' ' HA2' ' A' ' 275' ' ' GLY . 8.5 mp0 -117.8 131.37 56.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.23 -0.919 . . . . 0.0 111.23 -179.055 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 98.18 -86.4 0.78 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.189 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -101.74 124.24 47.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.299 -1.118 . . . . 0.0 109.828 -179.882 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.8 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -127.64 10.26 6.6 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.119 -0.988 . . . . 0.0 110.275 -179.987 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 297' ' ' LYS . 7.2 p -134.7 117.09 22.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.406 -0.809 . . . . 0.0 110.13 179.739 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.514 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -45.66 -45.84 14.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 110.455 -179.61 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.47 ' OE2' ' HG3' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -176.79 158.71 1.68 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.072 -1.017 . . . . 0.0 110.673 -179.713 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.709 HG12 HG13 ' A' ' 296' ' ' VAL . 65.1 mt -120.76 119.39 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.118 -0.989 . . . . 0.0 110.304 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.33 159.89 24.12 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.341 -0.85 . . . . 0.0 110.173 179.99 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.089 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -120.99 129.7 53.52 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.887 . . . . 0.0 110.361 -179.852 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -139.29 122.87 17.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.13 -0.981 . . . . 0.0 110.103 179.58 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.768 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -97.15 106.16 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.031 -1.043 . . . . 0.0 109.742 179.474 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.423 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.4 m-20 41.06 29.25 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.565 -0.71 . . . . 0.0 110.649 -179.752 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.81 -22.83 7.17 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.363 179.379 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.494 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 40.5 mm-40 -87.96 110.95 20.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.004 -1.292 . . . . 0.0 110.552 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.653 ' O ' HD13 ' A' ' 358' ' ' ILE . 6.2 p -76.81 142.02 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.284 -0.885 . . . . 0.0 110.527 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.653 HD13 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.494 1.729 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.139 179.801 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -73.81 -178.71 3.97 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 123.995 1.523 . . . . 0.0 110.454 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.647 HG23 ' O ' ' A' ' 258' ' ' THR . 6.5 t -58.81 119.02 6.39 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.252 -0.905 . . . . 0.0 110.107 179.9 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 259' ' ' THR . . . . . 0.585 HG22 ' HD2' ' A' ' 260' ' ' PRO . 0.0 OUTLIER -102.0 154.6 37.24 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.173 -0.954 . . . . 0.0 110.268 -179.847 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 260' ' ' PRO . . . . . 0.585 ' HD2' HG22 ' A' ' 259' ' ' THR . 46.9 Cg_endo -74.0 148.27 39.93 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.101 1.579 . . . . 0.0 110.16 179.886 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.486 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.2 p -81.24 140.66 49.19 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.08 -1.012 . . . . 0.0 110.394 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.533 ' HB3' ' HA ' ' A' ' 358' ' ' ILE . 45.9 Cg_endo -76.17 146.36 28.53 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 124.06 1.558 . . . . 0.0 109.981 179.582 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.438 HG12 ' O ' ' A' ' 263' ' ' VAL . 12.4 t -141.64 30.19 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.292 -0.88 . . . . 0.0 110.067 -179.88 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 26.4 t -163.63 83.02 0.46 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.315 -0.865 . . . . 0.0 110.637 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 104.29 -167.93 16.19 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.517 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.544 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.3 OUTLIER -139.53 164.4 30.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.401 -1.058 . . . . 0.0 109.765 179.848 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.992 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.31 133.76 6.0 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.047 -1.033 . . . . 0.0 111.003 -179.044 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.49 ' N ' HD13 ' A' ' 267' ' ' LEU . 0.4 OUTLIER -136.77 131.45 33.4 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.532 -0.73 . . . . 0.0 109.242 179.476 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.882 HG13 ' O ' ' A' ' 281' ' ' ASP . 89.4 t -126.38 143.11 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.79 -1.194 . . . . 0.0 111.653 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.7 ttpt -126.98 157.38 39.69 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.996 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.736 HG22 ' CD1' ' A' ' 280' ' ' TYR . 91.7 t -139.74 146.97 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.298 -1.501 . . . . 0.0 112.375 -179.171 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.542 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.2 109.43 6.46 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.127 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 p30 -96.14 146.75 24.41 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.008 -1.057 . . . . 0.0 111.189 -178.863 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.829 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.4 p90 -132.02 17.85 4.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.777 179.32 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.5 -62.78 4.0 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.947 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.444 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.4 t -63.68 -21.24 66.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.383 -1.069 . . . . 0.0 110.239 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -174.31 179.92 45.34 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.557 ' HB3' ' HE2' ' A' ' 280' ' ' TYR . . . -133.22 141.19 47.93 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.352 -1.087 . . . . 0.0 110.245 179.941 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.729 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.3 mt-10 -96.84 147.65 23.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.346 -0.846 . . . . 0.0 110.159 -179.683 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.736 ' CD1' HG22 ' A' ' 271' ' ' VAL . 98.1 m-85 -143.51 90.2 2.14 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.214 -0.929 . . . . 0.0 110.84 -179.776 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.882 ' O ' HG13 ' A' ' 269' ' ' VAL . 6.6 t0 -70.87 152.75 43.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.384 -0.823 . . . . 0.0 109.555 179.237 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.753 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 2.9 t -147.26 89.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 110.205 -179.535 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.719 HG23 ' OG1' ' A' ' 333' ' ' THR . 93.1 m -86.97 121.96 30.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.08 -1.013 . . . . 0.0 109.615 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -109.7 150.89 27.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 110.754 -179.323 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.917 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.1 m120 -131.25 137.06 48.72 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.468 -0.77 . . . . 0.0 109.934 -179.767 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.917 HD23 ' O ' ' A' ' 285' ' ' ASN . 16.8 mt -142.32 159.87 41.37 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.926 -1.109 . . . . 0.0 109.513 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.61 34.66 0.82 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.296 -0.877 . . . . 0.0 110.458 -179.538 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.473 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 153.3 -97.47 0.17 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.052 -1.546 . . . . 0.0 110.358 179.902 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 11.7 mm-40 -144.3 105.26 4.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.25 -1.147 . . . . 0.0 110.561 -179.577 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.616 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 4.4 m-85 -128.9 130.29 46.63 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.338 -0.851 . . . . 0.0 109.671 179.645 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.809 ' O ' HG23 ' A' ' 353' ' ' ILE . 42.5 m-20 -65.61 100.11 0.49 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.782 -1.199 . . . . 0.0 109.084 179.19 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.935 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.4 p-90 -100.12 109.67 21.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 111.127 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 293' ' ' THR . . . . . 1.085 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.0 m -103.78 114.83 29.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.466 -0.772 . . . . 0.0 109.108 179.003 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.727 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -95.95 111.31 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 110.568 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.413 ' HA ' HG12 ' A' ' 320' ' ' ILE . 5.7 ttpt -85.71 145.16 27.41 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.471 -0.768 . . . . 0.0 109.327 179.17 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.674 HG13 HG12 ' A' ' 349' ' ' ILE . 79.7 t -144.36 106.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 110.177 -179.49 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 347' ' ' GLU . 43.4 mmtt -70.02 133.9 47.71 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.108 -0.995 . . . . 0.0 109.168 179.537 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.962 HD13 ' HA ' ' A' ' 303' ' ' THR . 66.8 mt -90.32 157.24 17.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 111.392 -178.826 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.7 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.22 173.25 2.35 Favored Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.806 -0.558 . . . . 0.0 109.533 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.7 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.15 83.52 0.35 Allowed 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.621 1.327 . . . . 0.0 109.826 179.627 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.6 21.14 5.87 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -179.359 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.75 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.29 140.89 47.61 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.33 -1.1 . . . . 0.0 109.951 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.962 ' HA ' HD13 ' A' ' 298' ' ' LEU . 22.2 p -145.2 146.11 31.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.958 . . . . 0.0 110.628 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.798 HG21 HG11 ' A' ' 319' ' ' VAL . 53.3 t -70.11 122.82 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.148 -0.97 . . . . 0.0 109.958 179.695 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.08 -28.32 4.19 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.034 -1.226 . . . . 0.0 110.034 -179.592 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.507 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 49.4 m -137.46 130.26 30.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.973 -1.31 . . . . 0.0 110.85 -179.637 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.538 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 50.2 p90 -150.38 160.09 43.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.491 -0.756 . . . . 0.0 109.512 179.369 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.47 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -151.85 159.46 43.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.89 -1.131 . . . . 0.0 111.284 -179.333 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.9 OUTLIER 56.91 28.34 14.46 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.617 -0.677 . . . . 0.0 110.683 179.855 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.736 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.11 138.23 0.58 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.161 -0.962 . . . . 0.0 110.22 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.642 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -77.9 112.91 15.27 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.454 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.754 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.0 ttpt -83.16 137.65 33.97 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.658 0.742 . . . . 0.0 110.8 -179.25 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.715 ' O ' HG22 ' A' ' 319' ' ' VAL . 2.0 mp0 -120.64 170.61 9.26 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.135 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.439 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 15.8 mt-10 -143.24 95.97 2.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.531 -0.731 . . . . 0.0 109.688 179.588 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.97 -82.9 0.36 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.804 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.442 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 5.4 t-20 -154.38 81.15 1.12 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.467 -1.019 . . . . 0.0 108.59 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.608 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.42 17.87 56.29 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 107.993 -2.043 . . . . 0.0 107.993 -178.009 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.822 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.7 m-85 -144.45 -171.84 3.68 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.822 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.0 t -163.26 153.72 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.231 -0.918 . . . . 0.0 109.322 178.502 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.816 ' CG2' HG22 ' A' ' 293' ' ' THR . 42.1 mt -132.45 133.81 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.78 -1.2 . . . . 0.0 111.639 -179.313 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.645 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 82.6 m-85 -105.9 139.09 41.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.459 -0.775 . . . . 0.0 110.651 -179.791 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 322' ' ' THR . . . . . 1.085 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.1 p -134.62 169.06 14.83 Favored Pre-proline 0 C--N 1.3 -1.578 0 O-C-N 120.912 -1.117 . . . . 0.0 110.324 179.154 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.551 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 39.7 Cg_endo -65.67 112.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.061 1.559 . . . . 0.0 111.045 -179.259 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.81 HG22 ' HB2' ' A' ' 327' ' ' ASN . 32.9 m -60.83 -127.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.422 -0.799 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.568 ' N ' HG23 ' A' ' 324' ' ' VAL . 18.9 m -101.9 -17.02 16.35 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.739 -1.226 . . . . 0.0 111.167 -179.361 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.646 ' H ' HG23 ' A' ' 324' ' ' VAL . 22.5 p-90 -129.86 -3.85 4.62 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.943 -1.098 . . . . 0.0 110.649 -179.688 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.81 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.6 t30 -98.64 45.04 1.01 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.233 -0.917 . . . . 0.0 110.473 -179.476 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.551 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.32 -4.48 8.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.345 -0.847 . . . . 0.0 109.77 179.829 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.81 -159.92 0.08 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.456 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 46.8 Cg_endo -72.9 2.64 5.18 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 124.191 1.627 . . . . 0.0 110.829 -179.852 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.406 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.8 m -162.56 114.87 1.63 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -136.53 115.65 12.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 110.069 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.719 ' OG1' HG23 ' A' ' 283' ' ' THR . 99.9 m -105.78 147.5 28.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 110.395 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.753 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 6.4 p90 -150.76 174.45 13.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.415 -0.803 . . . . 0.0 109.188 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.2 162.24 28.94 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.209 -179.564 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.913 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -151.37 143.8 24.19 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -1.077 . . . . 0.0 109.994 179.554 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.913 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.06 119.73 61.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.171 -0.956 . . . . 0.0 109.744 179.437 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.75 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.6 t -96.23 139.79 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.136 -0.978 . . . . 0.0 110.111 -179.661 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -111.1 142.2 43.58 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.384 -0.822 . . . . 0.0 110.422 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 176.37 -137.49 3.66 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.906 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.51 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 44.9 Cg_endo -71.75 -156.65 0.05 OUTLIER 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.984 1.518 . . . . 0.0 110.083 179.695 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.423 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 2.9 pm0 -120.86 134.36 55.29 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.027 -1.045 . . . . 0.0 110.432 -179.96 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.499 ' O ' ' HB3' ' A' ' 344' ' ' ASP . . . 109.34 64.41 0.55 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.819 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.499 ' HB3' ' O ' ' A' ' 343' ' ' GLY . 33.4 t0 67.14 143.19 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.482 -1.011 . . . . 0.0 109.251 -179.164 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.614 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.1 OUTLIER -142.18 22.55 2.05 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.979 -1.076 . . . . 0.0 111.114 -179.49 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 346' ' ' VAL . 7.1 p -126.71 113.84 34.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 121.056 -1.027 . . . . 0.0 110.136 179.375 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -45.36 -47.07 13.4 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 110.47 -179.564 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.55 158.76 1.81 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.209 -0.932 . . . . 0.0 110.263 -179.838 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.674 HG12 HG13 ' A' ' 296' ' ' VAL . 28.2 mt -121.93 113.22 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.116 -0.99 . . . . 0.0 110.13 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -117.76 133.71 55.66 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.25 -0.907 . . . . 0.0 110.077 -179.934 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -90.85 132.46 35.88 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.168 -0.958 . . . . 0.0 109.774 179.529 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.429 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 3.7 tt0 -138.01 111.72 8.24 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.38 -0.825 . . . . 0.0 109.956 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.809 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.1 mt -94.91 114.0 30.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.21 -0.931 . . . . 0.0 110.42 -179.851 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.433 ' C ' ' O ' ' A' ' 353' ' ' ILE . 3.8 m-20 37.85 31.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.758 -0.589 . . . . 0.0 111.136 179.75 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.78 -15.62 19.16 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.736 -1.221 . . . . 0.0 110.306 179.415 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.495 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 20.9 mm-40 -93.17 112.03 23.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.084 -1.245 . . . . 0.0 110.424 -179.758 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.557 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 1.2 t -76.35 125.63 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.236 -0.915 . . . . 0.0 109.961 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.557 HD13 ' O ' ' A' ' 357' ' ' VAL . 10.2 mm . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.098 179.802 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.86 -179.32 4.83 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 124.06 1.558 . . . . 0.0 110.425 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.602 HG23 ' O ' ' A' ' 258' ' ' THR . 5.2 t -61.98 121.5 13.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.901 179.814 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 2.3 p -116.15 133.66 22.88 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.186 -0.946 . . . . 0.0 110.239 -179.816 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -71.76 126.51 12.08 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 O-C-N 124.031 1.542 . . . . 0.0 110.009 179.677 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.547 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.9 p -65.91 141.91 97.82 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.19 -0.944 . . . . 0.0 110.451 -179.497 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.549 ' CB ' HG23 ' A' ' 358' ' ' ILE . 50.2 Cg_endo -78.28 126.4 7.66 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 124.118 1.588 . . . . 0.0 110.387 179.781 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.555 HG12 ' O ' ' A' ' 263' ' ' VAL . 35.4 t -114.73 28.79 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -0.866 . . . . 0.0 110.063 179.852 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 179.72 131.9 0.09 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 110.299 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 71.89 -177.37 38.41 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.55 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.6 161.64 37.03 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -1.156 . . . . 0.0 110.006 179.823 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.863 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.5 tm? -161.32 137.17 7.98 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.613 -179.546 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.854 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mm-40 -134.03 147.14 50.92 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.799 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.9 t -138.55 144.43 30.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.66 -1.275 . . . . 0.0 111.769 -179.091 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.88 157.38 41.71 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.902 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.757 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.7 t -144.17 146.13 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.28 -1.512 . . . . 0.0 112.199 -179.492 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.576 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.63 108.76 7.21 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.182 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.413 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.0 m-20 -95.26 140.38 30.24 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.278 -0.889 . . . . 0.0 111.277 -179.003 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 40.9 p90 -131.94 20.42 4.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.431 -0.793 . . . . 0.0 109.868 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.59 -60.4 4.87 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.899 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -65.8 -18.94 65.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.369 -1.077 . . . . 0.0 110.293 -179.86 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.568 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -179.38 175.85 47.35 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.582 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -131.26 140.98 49.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -1.186 . . . . 0.0 110.119 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.757 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -93.28 147.1 23.21 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.424 -0.798 . . . . 0.0 109.99 -179.969 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.7 m-85 -142.11 86.39 1.97 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.929 -179.412 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 269' ' ' VAL . 12.1 t70 -69.67 152.6 44.5 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.86 . . . . 0.0 109.464 179.206 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.591 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 2.7 t -148.39 90.17 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.283 -0.885 . . . . 0.0 110.177 -179.51 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.849 HG23 ' OG1' ' A' ' 333' ' ' THR . 56.6 m -86.99 122.31 30.65 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.1 -1.0 . . . . 0.0 109.692 179.515 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.083 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.75 150.78 28.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.952 . . . . 0.0 110.8 -179.357 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.93 ' O ' HD23 ' A' ' 286' ' ' LEU . 1.8 m120 -131.43 138.42 49.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.469 -0.769 . . . . 0.0 109.446 179.949 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.93 HD23 ' O ' ' A' ' 285' ' ' ASN . 18.8 mt -140.46 163.4 32.93 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.77 -1.206 . . . . 0.0 109.824 -179.816 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.12 30.61 0.59 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.228 -0.92 . . . . 0.0 111.086 -178.95 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.509 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.26 -75.39 0.28 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 118.952 -1.594 . . . . 0.0 110.479 179.616 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.558 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.3 tt0 -160.26 106.88 1.56 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.07 -1.253 . . . . 0.0 110.85 -179.371 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.642 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.38 135.35 40.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 179.384 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.722 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.0 OUTLIER -66.84 102.77 1.0 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.987 -1.071 . . . . 0.0 109.515 179.425 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.957 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.9 p-90 -101.18 111.32 23.51 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 110.645 -179.53 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.686 HG22 ' CG2' ' A' ' 320' ' ' ILE . 6.6 m -104.48 115.66 30.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.532 -0.73 . . . . 0.0 109.726 179.692 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.756 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -97.05 111.41 26.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.864 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.809 ' HA ' HD13 ' A' ' 320' ' ' ILE . 27.1 ttpt -84.99 144.1 28.52 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.387 -0.821 . . . . 0.0 109.511 179.464 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.937 HG22 HG23 ' A' ' 349' ' ' ILE . 99.8 t -141.32 104.98 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.249 -0.907 . . . . 0.0 110.823 -179.179 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 38.0 mmtt -69.8 131.11 44.0 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.078 -1.014 . . . . 0.0 109.066 179.226 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.982 HD13 ' HA ' ' A' ' 303' ' ' THR . 93.6 mt -87.85 148.77 24.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.371 -0.831 . . . . 0.0 111.166 -178.895 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.703 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -58.66 172.22 0.54 Allowed Pre-proline 0 C--N 1.303 -1.432 0 O-C-N 121.624 -0.672 . . . . 0.0 109.306 179.093 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.671 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -67.32 80.57 0.41 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.575 1.303 . . . . 0.0 110.111 179.777 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.64 23.29 4.08 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 -179.546 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.789 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.58 148.54 35.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.365 -1.08 . . . . 0.0 110.376 -179.534 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.982 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.4 p -150.7 144.61 25.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.195 -0.94 . . . . 0.0 110.399 179.789 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 1.035 HG11 ' CE ' ' A' ' 312' ' ' LYS . 21.3 t -64.02 116.04 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.066 -1.021 . . . . 0.0 110.04 179.723 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -102.35 -20.51 12.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -147.36 154.44 40.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.26 -1.141 . . . . 0.0 110.317 -179.784 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.507 ' CG ' ' NZ ' ' A' ' 312' ' ' LYS . 25.1 p90 -178.54 175.52 1.11 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.594 -0.691 . . . . 0.0 109.738 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.459 ' O ' ' CB ' ' A' ' 309' ' ' SER . 1.1 p90 -170.0 151.11 3.95 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.991 -1.068 . . . . 0.0 111.637 -179.437 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.537 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 67.93 30.22 6.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.684 -0.635 . . . . 0.0 111.45 179.173 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.746 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 137.48 0.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.144 -0.972 . . . . 0.0 110.168 179.57 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.551 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.3 m120 -77.19 129.09 35.49 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.073 -1.017 . . . . 0.0 109.353 179.621 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 1.035 ' CE ' HG11 ' A' ' 304' ' ' VAL . 0.0 OUTLIER -92.07 149.15 21.67 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.907 0.861 . . . . 0.0 111.642 -178.622 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.705 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -133.34 171.39 14.11 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.306 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -137.09 114.85 11.28 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.046 -1.034 . . . . 0.0 110.858 -179.473 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -103.96 42.76 1.81 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.454 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.45 83.48 0.07 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -1.113 . . . . 0.0 110.066 -179.788 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.34 -0.55 57.1 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.89 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.842 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.5 m-85 -145.6 -170.9 3.56 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.463 -1.022 . . . . 0.0 109.157 179.365 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.92 HG11 HG21 ' A' ' 304' ' ' VAL . 2.6 t -163.82 161.99 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.366 -0.834 . . . . 0.0 109.347 179.427 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.809 HD13 ' HA ' ' A' ' 295' ' ' LYS . 28.5 mm -131.02 150.17 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.876 -1.14 . . . . 0.0 111.468 -179.514 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.626 ' CE2' ' HB3' ' A' ' 336' ' ' PHE . 96.5 m-85 -120.42 139.12 53.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.549 -0.719 . . . . 0.0 109.38 178.908 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.611 HG23 HG23 ' A' ' 293' ' ' THR . 1.0 OUTLIER -140.66 170.74 8.89 Favored Pre-proline 0 C--N 1.302 -1.461 0 O-C-N 120.79 -1.194 . . . . 0.0 110.244 -179.998 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.1 Cg_endo -65.72 122.01 9.53 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 123.98 1.516 . . . . 0.0 110.692 -179.505 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.911 HG22 ' HB2' ' A' ' 327' ' ' ASN . 12.8 m -76.16 -136.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.384 -0.823 . . . . 0.0 110.363 -179.752 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.63 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -88.45 -12.63 42.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.209 -0.932 . . . . 0.0 110.886 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.833 ' H ' HG23 ' A' ' 324' ' ' VAL . 20.9 p-90 -140.17 13.39 2.41 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.95 -1.094 . . . . 0.0 111.118 -179.475 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.911 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.1 t30 -119.99 50.59 1.27 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.886 -1.134 . . . . 0.0 110.776 -179.651 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.505 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.1 OUTLIER -130.46 -0.95 4.44 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.257 -0.902 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -66.58 -153.72 0.25 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.791 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.509 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.5 Cg_endo -73.97 3.08 5.35 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 124.12 1.59 . . . . 0.0 110.653 -179.858 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.432 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.9 m -163.93 117.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.197 -0.94 . . . . 0.0 110.244 179.944 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.478 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -139.43 111.93 7.71 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.878 . . . . 0.0 110.12 179.943 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.849 ' OG1' HG23 ' A' ' 283' ' ' THR . 7.0 m -101.09 151.78 21.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.181 -0.949 . . . . 0.0 110.275 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.756 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.7 p90 -159.03 155.19 27.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.519 -0.738 . . . . 0.0 109.156 179.712 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -133.24 165.96 23.89 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.264 -1.446 . . . . 0.0 110.035 -179.634 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.957 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -152.44 147.04 25.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -1.171 . . . . 0.0 110.288 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.957 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.74 119.56 59.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.049 -1.032 . . . . 0.0 109.88 179.687 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.789 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.6 t -96.43 147.94 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.163 -0.961 . . . . 0.0 110.13 -179.907 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.5 m120 -117.14 132.93 56.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.375 -0.828 . . . . 0.0 110.142 -179.867 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.457 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.88 -138.64 3.66 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 179.943 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.479 ' O ' ' CD ' ' A' ' 345' ' ' LYS . 46.3 Cg_endo -72.68 177.07 8.0 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 124.01 1.531 . . . . 0.0 110.548 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.433 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 2.2 mp0 -98.07 146.79 25.19 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.212 -0.93 . . . . 0.0 110.286 -179.911 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.509 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 95.19 67.78 1.01 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 -179.834 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.509 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 7.5 t0 69.6 128.73 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.351 -1.088 . . . . 0.0 109.445 -179.415 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.703 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.3 mtmt -126.84 13.92 7.41 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.135 -0.978 . . . . 0.0 110.164 -179.791 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.516 HG13 ' O ' ' A' ' 346' ' ' VAL . 4.5 p -127.17 113.28 31.65 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.497 -0.752 . . . . 0.0 109.566 179.429 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.18 -48.33 4.81 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.269 -0.894 . . . . 0.0 110.129 -179.44 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -177.63 149.9 0.64 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.31 -0.869 . . . . 0.0 110.468 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.937 HG23 HG22 ' A' ' 296' ' ' VAL . 12.9 mt -113.62 127.92 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.111 -0.993 . . . . 0.0 110.207 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -132.21 140.51 48.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.959 -179.81 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.083 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -99.44 130.75 45.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.055 -1.028 . . . . 0.0 110.395 -179.93 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.8 tt0 -138.28 113.87 9.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.308 -0.87 . . . . 0.0 109.788 179.645 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.722 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.2 mt -91.77 110.51 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.121 -0.987 . . . . 0.0 110.249 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.446 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.7 m-20 37.84 28.51 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.802 -0.561 . . . . 0.0 110.952 179.885 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 123.22 -20.94 7.43 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.739 -1.219 . . . . 0.0 110.298 179.451 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 9.0 mp0 -86.53 112.66 21.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.03 -1.276 . . . . 0.0 110.58 -179.756 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.669 HG13 ' O ' ' A' ' 357' ' ' VAL . 7.3 p -79.0 118.13 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.323 -0.861 . . . . 0.0 110.169 179.797 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.549 HG23 ' CB ' ' A' ' 262' ' ' PRO . 12.7 mm . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.214 -179.942 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.333 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -74.48 179.84 5.51 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 124.064 1.56 . . . . 0.0 110.541 -179.881 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 258' ' ' THR . 5.3 t -61.04 127.4 31.34 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.348 -0.845 . . . . 0.0 110.168 179.986 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.3 p -141.12 143.2 30.13 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.107 -0.996 . . . . 0.0 110.598 -179.844 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -73.81 162.1 40.16 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.084 1.571 . . . . 0.0 110.102 179.687 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.454 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.6 p -109.47 139.88 21.56 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.126 -0.984 . . . . 0.0 110.39 179.944 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.454 ' HD2' HG23 ' A' ' 261' ' ' VAL . 49.6 Cg_endo -79.48 137.0 12.79 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.142 1.601 . . . . 0.0 110.338 179.875 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.452 ' O ' ' HB2' ' A' ' 264' ' ' SER . 3.1 t -122.84 28.04 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.207 -0.933 . . . . 0.0 110.007 179.857 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 0.2 OUTLIER 175.31 80.12 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.408 -0.808 . . . . 0.0 110.027 179.993 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 122.5 176.38 14.98 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.868 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.02 152.19 51.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.221 -1.164 . . . . 0.0 109.908 179.866 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.794 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.59 117.71 6.81 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.198 -0.939 . . . . 0.0 110.962 -179.592 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -118.36 116.63 27.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.649 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.595 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 52.0 t -109.37 144.52 17.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.863 -1.148 . . . . 0.0 112.154 -178.305 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.427 ' C ' HG23 ' A' ' 271' ' ' VAL . 9.1 mtmt -128.59 156.42 43.38 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.618 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.828 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.9 t -145.29 147.03 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.288 -1.508 . . . . 0.0 112.29 -179.068 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.519 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -137.9 111.08 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.757 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.9 p-10 -100.5 140.02 35.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.882 -1.136 . . . . 0.0 111.407 -178.437 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.802 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.4 p90 -123.98 20.64 9.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.82 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.72 -68.01 3.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 7.8 m -61.06 -22.02 64.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.261 -1.141 . . . . 0.0 110.485 -179.833 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -168.32 176.74 42.67 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.641 -1.266 . . . . 0.0 110.016 -179.936 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.573 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.06 143.54 46.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.381 -1.07 . . . . 0.0 109.864 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.828 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.1 mt-10 -100.71 145.63 28.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.271 -0.893 . . . . 0.0 110.042 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.695 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -139.12 90.96 2.47 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.362 -0.836 . . . . 0.0 110.545 -179.701 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.595 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -79.58 118.64 21.61 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.534 -0.729 . . . . 0.0 110.136 179.657 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.822 HG11 HG11 ' A' ' 294' ' ' VAL . 8.8 t -107.41 95.82 4.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.63 -0.669 . . . . 0.0 110.041 179.747 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.546 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.2 m -86.5 120.17 27.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.131 -0.98 . . . . 0.0 109.437 179.551 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 0.999 HD21 HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -109.1 148.9 30.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 110.991 -179.042 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.1 m120 -134.04 107.13 7.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.618 -0.676 . . . . 0.0 109.679 -179.659 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.575 HD11 ' CD1' ' A' ' 292' ' ' TRP . 11.8 mt -114.67 156.57 24.51 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.837 -1.164 . . . . 0.0 110.243 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 287' ' ' ASP . . . . . 0.432 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 20.1 m-20 -86.7 33.86 0.65 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.513 -0.742 . . . . 0.0 110.413 -179.811 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.519 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.87 -154.04 25.07 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 119.499 -1.334 . . . . 0.0 109.79 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.542 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.0 OUTLIER -101.89 93.85 5.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.173 -1.192 . . . . 0.0 110.608 -179.708 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.523 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 2.3 m-85 -118.12 163.49 16.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.79 179.627 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.654 ' O ' HG23 ' A' ' 353' ' ' ILE . 15.2 m-20 -90.26 98.97 12.08 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.249 -0.907 . . . . 0.0 109.43 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.848 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.0 p-90 -99.82 117.26 33.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.192 -0.943 . . . . 0.0 110.749 -179.369 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.564 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 89.2 m -110.86 114.65 28.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.482 -0.761 . . . . 0.0 109.589 179.665 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.822 HG11 HG11 ' A' ' 282' ' ' VAL . 3.2 t -97.18 111.46 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.16 -0.963 . . . . 0.0 110.633 -179.284 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.527 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 18.3 ttmt -86.51 149.89 24.65 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.617 179.299 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.799 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 90.4 t -143.95 108.36 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.054 -1.029 . . . . 0.0 110.672 -179.459 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.574 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 14.5 mmtp -70.5 133.86 47.19 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.27 -0.894 . . . . 0.0 109.318 179.411 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.978 HD13 ' HA ' ' A' ' 303' ' ' THR . 85.0 mt -89.71 158.13 17.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -0.788 . . . . 0.0 111.717 -178.727 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.771 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -64.78 173.32 1.69 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.637 -0.665 . . . . 0.0 109.44 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.69 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.64 78.6 0.51 Allowed 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.555 1.292 . . . . 0.0 109.913 179.738 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.74 23.27 4.05 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 -179.393 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.792 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.08 146.68 38.74 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.361 -1.082 . . . . 0.0 110.141 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.978 ' HA ' HD13 ' A' ' 298' ' ' LEU . 8.8 p -147.93 145.08 28.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.225 -0.922 . . . . 0.0 110.505 179.766 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.857 HG21 HG11 ' A' ' 319' ' ' VAL . 71.4 t -65.62 132.18 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.911 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.21 -36.97 1.71 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.476 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -140.97 139.49 34.23 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -1.209 . . . . 0.0 110.819 -179.735 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.5 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.1 p90 -150.63 167.01 28.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.471 -0.768 . . . . 0.0 109.599 179.56 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.508 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -154.98 155.2 33.79 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.946 -1.096 . . . . 0.0 111.585 -179.558 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.511 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 62.71 25.49 15.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.527 -0.733 . . . . 0.0 110.854 179.742 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.68 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 141.22 0.65 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.891 . . . . 0.0 110.365 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.6 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -78.65 117.54 19.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.136 -0.977 . . . . 0.0 109.17 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.631 ' HG3' HG11 ' A' ' 304' ' ' VAL . 2.0 ttpt -87.84 145.67 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.791 0.805 . . . . 0.0 110.824 -179.274 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.822 ' O ' HG22 ' A' ' 319' ' ' VAL . 3.0 mp0 -133.19 178.6 6.78 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.35 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -141.45 106.57 4.97 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.533 -0.729 . . . . 0.0 110.539 179.509 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.93 51.83 2.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 51.51 80.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.277 -1.131 . . . . 0.0 110.317 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.602 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.47 -0.12 58.22 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.823 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.6 m-85 -141.23 -166.96 2.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -1.115 . . . . 0.0 109.435 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.857 HG11 HG21 ' A' ' 304' ' ' VAL . 2.7 t -163.61 157.84 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.21 -0.931 . . . . 0.0 109.839 179.286 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.775 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 9.2 mm -127.1 146.61 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 120.915 -1.116 . . . . 0.0 110.685 179.486 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 74.8 m-85 -125.42 124.83 42.31 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.364 -0.835 . . . . 0.0 109.729 179.263 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.541 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 8.3 p -126.96 168.04 15.85 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.491 -1.381 . . . . 0.0 110.39 179.857 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.544 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.4 Cg_endo -65.92 119.07 6.04 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.868 1.457 . . . . 0.0 111.13 -179.306 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.718 HG22 ' HB2' ' A' ' 327' ' ' ASN . 34.2 m -67.29 -124.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.527 -0.733 . . . . 0.0 109.895 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.592 ' N ' HG23 ' A' ' 324' ' ' VAL . 32.1 t -107.15 -12.92 15.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.763 -1.211 . . . . 0.0 110.693 -179.877 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.708 ' H ' HG23 ' A' ' 324' ' ' VAL . 19.6 p-90 -130.34 4.32 4.74 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.069 -1.02 . . . . 0.0 110.526 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.718 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -113.85 40.91 2.33 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.247 -0.908 . . . . 0.0 110.351 -179.546 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -115.97 -11.17 11.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 179.821 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.508 ' HA2' ' NE2' ' A' ' 289' ' ' GLN . . . -57.08 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.424 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.519 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.8 Cg_endo -75.41 7.05 3.2 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 124.143 1.602 . . . . 0.0 111.119 -179.663 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.424 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 1.5 m -162.41 124.15 2.69 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.021 -1.049 . . . . 0.0 109.957 179.992 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.538 ' HB1' ' OD1' ' A' ' 327' ' ' ASN . . . -145.93 110.81 5.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 110.311 -179.821 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.546 ' OG1' HG23 ' A' ' 283' ' ' THR . 24.9 m -102.68 123.13 45.81 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.153 -0.967 . . . . 0.0 110.235 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.803 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.2 p90 -128.67 175.48 8.55 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.191 -0.943 . . . . 0.0 108.952 179.456 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.5 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.41 162.58 29.07 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.074 -1.536 . . . . 0.0 109.967 -179.222 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.925 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.7 OUTLIER -152.0 144.81 24.36 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.487 -1.008 . . . . 0.0 109.256 179.378 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.925 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.77 121.25 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.97 -1.081 . . . . 0.0 109.935 -179.743 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.792 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.5 t -96.88 151.7 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.107 -0.996 . . . . 0.0 109.835 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -123.36 132.3 53.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.277 -0.889 . . . . 0.0 110.307 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.43 -124.05 0.88 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.768 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.535 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.3 Cg_endo -66.67 -158.61 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.753 0 O-C-N 123.761 1.401 . . . . 0.0 110.139 179.28 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.422 ' OE1' ' N ' ' A' ' 342' ' ' GLN . 3.3 pm0 -123.68 131.69 53.67 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.078 -1.014 . . . . 0.0 110.49 -179.538 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 101.72 -75.29 0.35 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.799 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -111.29 126.01 54.45 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.415 -1.05 . . . . 0.0 109.477 179.503 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.733 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -135.06 2.87 3.12 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.169 -0.957 . . . . 0.0 110.547 -179.679 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.4 p -132.39 117.4 31.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.319 -0.863 . . . . 0.0 109.927 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.449 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -49.64 -45.43 48.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.851 . . . . 0.0 110.784 -179.243 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -176.95 158.83 1.63 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.942 -1.099 . . . . 0.0 110.916 -179.737 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.688 HG12 HG22 ' A' ' 296' ' ' VAL . 42.5 mt -121.06 109.82 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.187 -0.946 . . . . 0.0 110.088 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.64 158.19 16.88 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 0.999 HD11 HD21 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.29 125.83 50.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.357 -0.839 . . . . 0.0 110.056 179.807 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.529 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.9 tt0 -137.96 116.26 11.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.14 -0.975 . . . . 0.0 110.248 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.654 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.31 95.87 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 110.162 179.903 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 354' ' ' ASN . . . . . . . . . . . . . 2.0 m120 49.51 32.3 4.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.641 -0.662 . . . . 0.0 110.742 179.834 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.18 -31.31 4.94 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 79.3 mm-40 -81.77 119.75 24.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.148 -1.207 . . . . 0.0 110.519 -179.596 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.834 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.0 p -79.04 135.64 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.176 -0.952 . . . . 0.0 110.087 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.912 ' HB ' HD13 ' A' ' 351' ' ' LEU . 27.5 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.201 -179.778 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.17 -178.04 3.34 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 123.997 1.525 . . . . 0.0 110.492 -179.995 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 14.4 t -56.77 145.62 28.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.871 . . . . 0.0 110.062 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.26 159.79 31.54 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.235 -0.916 . . . . 0.0 110.192 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.45 133.85 19.72 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.957 1.503 . . . . 0.0 110.22 179.84 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.6 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.8 p -93.69 143.04 25.93 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.243 -0.911 . . . . 0.0 110.553 -179.7 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.6 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.3 Cg_endo -75.53 149.02 34.05 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.179 1.621 . . . . 0.0 110.282 179.557 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.775 HG12 ' O ' ' A' ' 263' ' ' VAL . 83.2 t -133.87 29.03 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.237 -0.915 . . . . 0.0 110.501 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 170.76 83.51 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -0.927 . . . . 0.0 110.283 -179.994 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 123.31 176.52 14.83 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.813 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.572 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.15 158.06 44.84 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.364 -1.08 . . . . 0.0 109.9 -179.955 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.959 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -146.94 113.47 5.98 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.177 -0.952 . . . . 0.0 110.532 180.0 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -114.69 114.76 26.07 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.067 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.631 HG23 HD22 ' A' ' 267' ' ' LEU . 61.4 t -112.62 133.3 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.894 -1.129 . . . . 0.0 112.588 -178.233 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.401 ' C ' HG23 ' A' ' 271' ' ' VAL . 1.7 mptm? -116.73 156.66 26.78 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 177.959 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.795 HG13 ' O ' ' A' ' 279' ' ' GLU . 87.1 t -144.64 147.05 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.231 -1.543 . . . . 0.0 112.235 -179.201 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.559 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -133.7 106.95 7.64 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.096 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.8 p-10 -93.09 145.92 24.03 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.087 -1.008 . . . . 0.0 111.254 -178.884 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.834 ' CH2' HG23 ' A' ' 337' ' ' ILE . 38.1 p90 -134.04 16.98 3.82 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.421 -0.799 . . . . 0.0 109.902 179.423 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.52 -59.26 4.38 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.14 -17.64 64.85 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.357 -1.084 . . . . 0.0 110.09 179.822 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.585 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.38 -178.7 48.66 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.776 -1.329 . . . . 0.0 109.776 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.867 ' HB2' ' NZ ' ' A' ' 345' ' ' LYS . . . -135.1 138.54 43.89 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.378 -1.072 . . . . 0.0 110.229 -179.965 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.795 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.2 mt-10 -92.28 146.18 23.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.434 -0.791 . . . . 0.0 110.093 -179.812 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.707 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.5 m-85 -136.0 95.28 3.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 110.726 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.576 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.4 103.78 12.21 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.496 -0.752 . . . . 0.0 109.94 179.562 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.657 HG11 HG11 ' A' ' 294' ' ' VAL . 5.2 t -93.93 91.79 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.402 -0.811 . . . . 0.0 110.42 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.912 HG23 ' OG1' ' A' ' 333' ' ' THR . 8.9 m -86.54 112.47 21.59 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.158 179.337 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.08 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -97.55 153.0 18.46 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.098 -1.001 . . . . 0.0 111.096 -178.913 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.601 ' C ' HD23 ' A' ' 286' ' ' LEU . 0.9 OUTLIER -135.51 106.43 6.63 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.452 -0.78 . . . . 0.0 109.978 -179.699 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.601 HD23 ' C ' ' A' ' 285' ' ' ASN . 2.3 mt -117.05 169.51 9.36 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.689 -1.257 . . . . 0.0 110.026 179.799 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 287' ' ' ASP . . . . . 0.421 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 10.7 m-20 -100.85 32.29 3.23 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.268 -0.895 . . . . 0.0 110.455 -179.705 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.498 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 162.87 -145.54 10.73 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.272 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.508 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -106.87 105.86 16.1 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.362 -1.081 . . . . 0.0 110.871 -179.442 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.498 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 3.7 m-85 -135.67 150.47 49.6 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.233 -0.917 . . . . 0.0 109.756 179.356 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.419 ' HB2' ' CG ' ' A' ' 354' ' ' ASN . 86.8 m-20 -78.97 96.91 5.87 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 108.97 179.098 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.857 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.3 p-90 -94.19 112.11 23.89 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.35 -0.844 . . . . 0.0 110.474 -179.46 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.751 HG23 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -106.5 116.52 32.07 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.411 -0.806 . . . . 0.0 109.261 179.641 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.782 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -96.29 110.79 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 110.667 -179.103 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.596 ' HA ' HD13 ' A' ' 320' ' ' ILE . 9.0 ttpt -83.07 148.85 27.28 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.379 -0.826 . . . . 0.0 108.792 178.696 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.617 ' CG1' HG21 ' A' ' 346' ' ' VAL . 76.2 t -148.55 108.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.005 -1.059 . . . . 0.0 111.11 -178.941 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.59 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 56.3 mmtt -70.69 141.56 51.58 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.233 -0.917 . . . . 0.0 109.302 179.167 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 1.0 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.3 mt -94.07 157.97 15.84 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.273 -0.892 . . . . 0.0 111.854 -178.608 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.698 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.06 173.12 3.41 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.709 -0.62 . . . . 0.0 109.734 179.404 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.698 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.5 Cg_endo -68.25 83.66 0.47 Allowed 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.715 1.376 . . . . 0.0 109.76 179.58 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.72 24.45 5.25 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.353 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.732 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -118.44 142.67 47.33 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.423 -1.046 . . . . 0.0 110.11 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 303' ' ' THR . . . . . 1.0 ' HA ' HD13 ' A' ' 298' ' ' LEU . 9.6 p -143.6 144.45 31.92 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.202 -0.936 . . . . 0.0 110.764 179.753 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.885 ' CG2' HG21 ' A' ' 319' ' ' VAL . 36.2 t -69.87 134.1 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 179.456 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.5 -46.76 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.332 -179.329 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.543 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 31.0 t -119.63 140.27 50.88 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.063 -1.257 . . . . 0.0 110.91 -179.432 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.628 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.3 p90 -157.99 170.7 21.71 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.54 -0.725 . . . . 0.0 109.695 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.523 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -160.46 162.68 33.23 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.09 -1.006 . . . . 0.0 111.044 -179.585 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.613 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.8 OUTLIER 54.77 24.8 5.95 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.585 -0.697 . . . . 0.0 110.774 179.816 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.73 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.86 144.45 1.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.404 -0.81 . . . . 0.0 109.882 179.455 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.523 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -86.4 122.2 30.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.031 -1.043 . . . . 0.0 109.754 179.747 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.7 ttpt -87.5 141.42 28.63 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 121.888 0.851 . . . . 0.0 110.374 -179.749 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.606 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -128.02 175.7 8.19 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.688 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -134.46 117.71 16.55 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.111 -0.993 . . . . 0.0 110.382 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.498 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -108.0 33.65 6.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 17.8 t-20 70.08 85.57 0.13 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.295 -1.121 . . . . 0.0 110.37 179.993 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.56 5.11 75.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.84 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.0 OUTLIER -146.16 -168.24 2.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.362 -1.081 . . . . 0.0 109.173 179.513 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.885 HG21 ' CG2' ' A' ' 304' ' ' VAL . 4.2 t -163.45 161.54 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.235 -0.916 . . . . 0.0 109.765 179.369 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.596 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.4 mm -128.2 143.38 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.122 -0.986 . . . . 0.0 111.271 -179.84 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.664 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 65.4 m-85 -120.05 127.29 52.43 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 178.997 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.751 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -128.25 169.92 11.64 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.693 -1.254 . . . . 0.0 110.213 -179.498 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -65.31 112.74 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 123.944 1.497 . . . . 0.0 111.15 -179.354 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.684 HG23 ' H ' ' A' ' 325' ' ' SER . 3.6 m -53.3 -59.03 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.435 -0.79 . . . . 0.0 110.994 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.684 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -179.29 -24.72 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.959 -1.088 . . . . 0.0 111.307 -179.67 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.471 ' CA ' ' HD2' ' A' ' 328' ' ' LYS . 5.3 p-90 -115.78 -24.84 8.02 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.92 -1.112 . . . . 0.0 110.718 -179.72 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.856 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 53.2 p-10 -85.22 29.36 0.66 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.144 -0.972 . . . . 0.0 111.303 -179.817 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -90.87 -6.27 54.42 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.207 -0.933 . . . . 0.0 109.45 179.599 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.58 -157.69 0.01 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.492 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.519 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -75.86 6.54 3.69 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 124.14 1.6 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -159.02 131.64 6.87 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.734 -179.932 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.856 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -144.99 109.08 4.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.185 -0.947 . . . . 0.0 110.385 -179.691 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.912 ' OG1' HG23 ' A' ' 283' ' ' THR . 51.8 m -104.12 118.38 36.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.163 -0.961 . . . . 0.0 110.558 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.782 ' HE2' HG21 ' A' ' 294' ' ' VAL . 9.7 p90 -128.56 174.67 9.18 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.463 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.1 162.37 28.76 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 118.801 -1.666 . . . . 0.0 110.477 -179.247 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.91 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -151.39 143.85 24.2 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.685 -0.891 . . . . 0.0 109.32 179.25 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.91 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -117.95 119.34 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.959 -1.088 . . . . 0.0 110.283 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.732 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -97.01 142.8 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 109.71 179.768 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.7 m120 -111.23 136.1 50.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.188 -0.945 . . . . 0.0 110.215 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.47 -141.76 4.45 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.927 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.55 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 43.9 Cg_endo -71.58 -158.61 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.757 0 O-C-N 123.983 1.518 . . . . 0.0 110.476 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 342' ' ' GLN . . . . . . . . . . . . . 2.3 mp0 -113.6 143.51 44.44 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.217 -0.927 . . . . 0.0 110.421 -179.792 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.445 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 99.63 64.53 0.82 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 -179.793 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.445 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 8.2 t0 65.18 147.96 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.373 -1.075 . . . . 0.0 109.384 -179.335 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.867 ' NZ ' ' HB2' ' A' ' 278' ' ' ALA . 0.0 OUTLIER -140.83 21.49 2.31 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.016 -1.053 . . . . 0.0 110.903 -179.471 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 346' ' ' VAL . 12.8 p -128.31 115.01 36.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.077 179.525 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.501 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 6.9 mt-10 -43.45 -46.93 6.96 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.244 -0.91 . . . . 0.0 110.102 -179.641 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.474 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -177.19 158.54 1.51 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.105 -0.997 . . . . 0.0 110.833 -179.968 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.539 HG12 HG22 ' A' ' 296' ' ' VAL . 16.6 mt -117.75 105.63 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.877 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.81 141.96 35.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.327 -0.858 . . . . 0.0 110.005 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.08 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -100.88 131.42 46.77 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.064 -1.023 . . . . 0.0 110.177 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 1.4 tp10 -139.03 110.48 7.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 110.019 179.677 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.463 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 1.3 mt -91.45 105.21 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.045 -1.034 . . . . 0.0 109.894 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.419 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 4.6 m-20 45.19 40.56 5.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.48 -0.762 . . . . 0.0 110.619 -179.887 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 105.05 -22.47 33.23 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.448 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 76.1 mm-40 -84.03 110.3 18.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.093 -1.24 . . . . 0.0 110.27 -179.87 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.776 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -72.41 130.24 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 357' ' ' VAL . 17.0 mm . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.241 179.893 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -74.36 -178.72 4.16 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 O-C-N 124.029 1.542 . . . . 0.0 110.45 179.992 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.55 HG23 ' O ' ' A' ' 258' ' ' THR . 7.4 t -59.81 127.69 33.19 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.437 -0.79 . . . . 0.0 110.291 179.901 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.8 154.63 37.19 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.141 -0.974 . . . . 0.0 110.124 179.951 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.63 154.13 54.6 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.945 1.497 . . . . 0.0 110.2 179.867 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.506 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.0 p -79.82 141.26 55.18 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.158 -0.964 . . . . 0.0 110.495 -179.646 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.506 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.5 Cg_endo -80.13 128.6 7.39 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 124.175 1.618 . . . . 0.0 110.598 -179.889 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.456 ' O ' ' CB ' ' A' ' 264' ' ' SER . 5.1 t -115.93 22.7 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -0.889 . . . . 0.0 109.824 179.525 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.3 OUTLIER 169.34 104.33 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.499 -0.751 . . . . 0.0 110.222 179.819 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 106.64 175.49 23.14 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 179.922 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.14 155.39 49.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.277 -1.131 . . . . 0.0 109.832 179.968 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.811 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.48 121.53 8.85 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.124 -0.985 . . . . 0.0 110.884 -179.353 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.447 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 23.9 mt-10 -121.61 127.35 50.77 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.875 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.589 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 48.1 t -121.33 138.45 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 120.634 -1.291 . . . . 0.0 112.428 -178.402 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 6.6 mtpp -125.3 157.82 35.71 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.968 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.803 HG13 ' O ' ' A' ' 279' ' ' GLU . 84.4 t -144.62 144.93 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.379 -1.45 . . . . 0.0 112.021 -179.577 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.539 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -132.99 108.14 8.71 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.974 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 19.2 m-20 -96.4 144.83 26.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.999 -1.063 . . . . 0.0 111.077 -178.793 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.851 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.1 p90 -131.51 20.03 4.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.496 -0.752 . . . . 0.0 110.025 179.551 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.48 -61.49 4.59 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.816 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -67.53 -18.98 65.23 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -1.171 . . . . 0.0 110.465 -179.735 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.582 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.99 177.75 45.31 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.909 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.545 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.2 137.53 42.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.313 -1.11 . . . . 0.0 109.989 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.803 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.4 mt-10 -94.33 146.4 24.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.276 -0.89 . . . . 0.0 110.205 -179.68 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.806 ' CE2' HG11 ' A' ' 346' ' ' VAL . 90.3 m-85 -137.68 88.81 2.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.268 -0.895 . . . . 0.0 110.624 -179.747 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.589 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -75.97 117.78 18.06 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 110.325 179.734 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.787 HG11 HG11 ' A' ' 294' ' ' VAL . 11.1 t -109.83 94.37 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.436 -0.79 . . . . 0.0 110.131 179.626 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.797 HG23 ' OG1' ' A' ' 333' ' ' THR . 19.8 m -86.97 120.42 28.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.182 -0.949 . . . . 0.0 109.778 179.546 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.001 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -107.25 149.94 27.2 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.195 -0.941 . . . . 0.0 110.828 -179.346 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.2 m120 -133.72 106.94 7.63 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.401 -0.812 . . . . 0.0 110.147 -179.33 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.575 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 12.2 mt -114.99 155.6 26.65 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.568 -1.332 . . . . 0.0 110.638 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 287' ' ' ASP . . . . . 0.429 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -88.09 37.76 0.82 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.488 -0.758 . . . . 0.0 109.746 179.572 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.33 -147.29 14.05 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.55 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 4.7 mt-30 -111.56 95.02 5.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.151 -1.205 . . . . 0.0 110.633 -179.71 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.575 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -122.43 141.34 51.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.262 -0.899 . . . . 0.0 110.05 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.907 ' O ' HG23 ' A' ' 353' ' ' ILE . 13.2 t70 -71.94 108.73 5.35 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.149 -0.97 . . . . 0.0 109.72 179.564 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.868 ' CE3' HD13 ' A' ' 284' ' ' LEU . 42.9 p-90 -105.22 114.89 29.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 110.544 -179.651 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.792 HG22 ' CG2' ' A' ' 320' ' ' ILE . 3.2 m -102.27 113.96 27.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.418 -0.801 . . . . 0.0 109.534 179.751 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.846 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.1 t -96.67 113.33 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 110.448 -179.516 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.791 ' HA ' HD13 ' A' ' 320' ' ' ILE . 4.1 ttpt -87.9 149.6 23.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.7 179.535 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.635 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 71.5 t -149.35 110.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.079 -1.013 . . . . 0.0 110.273 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.567 ' O ' HG23 ' A' ' 346' ' ' VAL . 52.1 mmtt -72.18 138.68 47.79 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.197 -0.939 . . . . 0.0 109.58 179.575 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.936 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.8 mt -91.93 158.36 16.32 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.262 -0.899 . . . . 0.0 111.696 -178.779 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.858 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.5 175.24 1.17 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 121.792 -0.567 . . . . 0.0 109.586 179.216 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.748 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -66.36 81.27 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 O-C-N 123.581 1.306 . . . . 0.0 109.902 179.42 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.69 6.3 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.364 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.862 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -104.86 153.32 21.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.337 -1.096 . . . . 0.0 110.213 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.936 ' HA ' HD13 ' A' ' 298' ' ' LEU . 64.8 p -156.51 145.42 20.23 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.074 -1.016 . . . . 0.0 110.719 -179.864 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.753 HG21 HG11 ' A' ' 319' ' ' VAL . 61.6 t -74.21 131.56 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.395 -0.816 . . . . 0.0 109.908 179.562 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.55 -25.14 2.01 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -139.68 112.71 8.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.039 -1.271 . . . . 0.0 110.95 -179.698 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.511 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -132.97 163.75 28.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.323 -0.861 . . . . 0.0 109.782 179.361 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.509 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.95 162.8 40.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.033 -1.042 . . . . 0.0 110.843 -179.612 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.493 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.5 OUTLIER 57.49 22.6 8.22 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.583 -0.698 . . . . 0.0 111.025 179.55 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.695 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.06 143.28 0.69 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.295 -0.878 . . . . 0.0 110.401 179.514 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.63 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.5 m120 -80.71 120.79 25.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.271 -0.893 . . . . 0.0 109.117 179.255 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.584 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 0.6 OUTLIER -87.92 127.7 35.36 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.733 0.778 . . . . 0.0 111.1 -178.982 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.525 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -108.54 174.5 5.85 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.323 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -134.29 114.58 13.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.131 -0.98 . . . . 0.0 110.784 -179.637 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.59 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -103.76 57.43 0.55 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.53 ' O ' ' ND2' ' A' ' 316' ' ' ASN . 2.3 p-10 37.75 75.7 0.06 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.951 . . . . 0.0 110.754 -179.687 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.584 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 108.39 -2.17 32.77 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.778 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.801 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -142.24 -169.69 3.0 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.288 -1.125 . . . . 0.0 109.299 179.673 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.801 HG23 ' O ' ' A' ' 318' ' ' TYR . 6.7 t -162.45 158.39 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 179.165 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.792 ' CG2' HG22 ' A' ' 293' ' ' THR . 32.3 mm -128.9 148.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.001 -1.062 . . . . 0.0 111.338 -179.394 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.4 m-85 -124.58 122.8 38.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.988 -1.07 . . . . 0.0 110.164 179.284 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.645 ' CG2' HG23 ' A' ' 293' ' ' THR . 5.9 p -121.21 168.09 11.79 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.924 -1.11 . . . . 0.0 110.002 179.756 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.516 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.7 Cg_endo -66.78 119.47 6.5 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 O-C-N 123.805 1.424 . . . . 0.0 110.963 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.709 HG23 ' H ' ' A' ' 326' ' ' TRP . 35.4 m -67.88 -128.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.364 -179.889 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.499 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -97.35 -13.03 22.14 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.836 -1.165 . . . . 0.0 110.878 -179.473 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.709 ' H ' HG23 ' A' ' 324' ' ' VAL . 10.0 p-90 -135.35 5.34 3.22 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.054 -1.029 . . . . 0.0 110.63 -179.918 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.867 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 11.6 t30 -108.67 42.62 1.37 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.109 -0.994 . . . . 0.0 110.722 -179.701 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -123.43 -2.81 8.44 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.118 -0.989 . . . . 0.0 110.09 179.689 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.97 -157.11 0.08 OUTLIER Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.537 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.8 Cg_endo -75.96 5.3 4.55 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 124.006 1.53 . . . . 0.0 110.574 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.442 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.1 m -165.09 118.57 1.24 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.126 -0.984 . . . . 0.0 110.195 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.867 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.41 118.78 12.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -0.972 . . . . 0.0 110.225 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.797 ' OG1' HG23 ' A' ' 283' ' ' THR . 91.2 m -107.21 126.9 53.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.398 -0.814 . . . . 0.0 110.32 -179.957 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.846 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.8 p90 -131.37 175.35 9.21 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.364 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -155.37 156.63 27.11 Favored Glycine 0 N--CA 1.487 2.073 0 C-N-CA 118.861 -1.638 . . . . 0.0 110.076 -179.44 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.97 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.5 p90 -142.09 151.85 42.73 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.548 -0.972 . . . . 0.0 109.687 179.519 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.97 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -123.02 119.14 56.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.125 -0.984 . . . . 0.0 109.38 179.377 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.862 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -96.27 147.27 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 110.291 -179.398 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.514 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.5 m120 -118.17 131.29 56.41 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 109.987 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -179.27 -125.53 0.95 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.893 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.508 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.4 Cg_endo -69.28 -167.09 0.19 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.819 1.431 . . . . 0.0 110.675 -179.816 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 342' ' ' GLN . . . . . . . . . . . . . 1.8 mp0 -111.2 132.16 54.55 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.288 -0.883 . . . . 0.0 110.954 -179.281 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 103.5 -86.71 0.54 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.604 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -104.32 128.97 52.21 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.322 -1.105 . . . . 0.0 109.356 179.597 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.756 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.0 OUTLIER -129.62 1.5 4.97 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.845 -1.159 . . . . 0.0 110.383 -179.869 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.806 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.1 p -127.27 123.74 62.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.094 -1.004 . . . . 0.0 109.709 179.199 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.543 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -55.06 -43.88 74.27 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.218 -179.258 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.469 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.9 pt-20 -177.31 159.23 1.55 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.113 -0.992 . . . . 0.0 111.119 -179.896 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.581 HG12 HG13 ' A' ' 296' ' ' VAL . 36.2 mt -121.34 122.33 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 110.104 179.517 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.39 160.05 27.63 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.892 . . . . 0.0 110.046 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.001 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.18 126.95 52.78 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.234 -0.916 . . . . 0.0 110.278 -179.922 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.3 tt0 -138.59 113.31 9.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.185 -0.947 . . . . 0.0 109.942 179.665 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.907 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.6 113.22 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.108 -0.995 . . . . 0.0 110.144 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.43 ' C ' ' O ' ' A' ' 353' ' ' ILE . 1.4 m120 40.08 40.56 0.78 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.537 -0.727 . . . . 0.0 111.031 179.879 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.86 -20.84 37.73 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.83 -1.176 . . . . 0.0 110.342 179.185 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.472 ' O ' ' N ' ' A' ' 353' ' ' ILE . 39.1 mm-40 -87.0 111.3 20.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.045 -1.268 . . . . 0.0 110.5 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.642 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -73.44 141.88 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.299 -0.876 . . . . 0.0 110.222 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.642 HD13 ' O ' ' A' ' 357' ' ' VAL . 28.8 mm . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.199 179.975 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -73.12 -178.19 3.42 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 123.886 1.467 . . . . 0.0 110.798 -179.912 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 1.4 t -84.36 146.23 27.81 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.442 -0.786 . . . . 0.0 110.391 -179.826 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.13 117.88 59.31 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.324 -0.86 . . . . 0.0 110.149 179.995 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -74.09 150.03 42.27 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 O-C-N 123.925 1.487 . . . . 0.0 110.432 -179.931 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.666 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.1 p -100.31 145.21 29.87 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.25 -0.906 . . . . 0.0 110.094 179.788 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.666 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.2 Cg_endo -73.33 146.81 40.75 Favored 'Trans proline' 0 C--N 1.302 -1.876 0 O-C-N 123.973 1.512 . . . . 0.0 110.106 179.729 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 3.7 t -133.92 28.76 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.946 . . . . 0.0 110.325 -179.742 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.4 t -174.22 103.22 0.1 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.085 -1.009 . . . . 0.0 110.917 179.987 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 87.17 -165.47 35.94 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.95 -1.119 . . . . 0.0 110.305 179.284 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -140.12 166.52 24.45 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.61 -0.936 . . . . 0.0 109.597 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.872 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.6 tm? -161.02 130.83 4.92 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.944 -1.097 . . . . 0.0 110.952 -179.8 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.783 ' N ' HD22 ' A' ' 267' ' ' LEU . 25.7 mt-10 -131.86 122.92 26.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.64 -0.662 . . . . 0.0 109.414 179.879 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 281' ' ' ASP . 96.5 t -117.1 137.29 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 111.478 -179.058 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -120.25 157.42 29.17 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.91 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.668 HG13 ' O ' ' A' ' 279' ' ' GLU . 96.2 t -143.67 146.72 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.269 -1.519 . . . . 0.0 112.265 -179.266 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -147.89 117.5 7.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.639 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.593 ' OD1' ' HB1' ' A' ' 278' ' ' ALA . 1.0 OUTLIER -100.13 147.59 25.51 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.205 -0.934 . . . . 0.0 111.195 -178.663 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.782 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.9 p90 -130.14 18.61 5.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.541 -0.724 . . . . 0.0 109.864 179.398 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.19 -57.23 4.57 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.735 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.65 -14.91 62.19 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -1.162 . . . . 0.0 110.264 -179.895 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.548 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . 179.6 175.08 46.14 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.892 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.593 ' HB1' ' OD1' ' A' ' 273' ' ' ASP . . . -130.39 147.34 52.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.315 -1.109 . . . . 0.0 109.999 179.851 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.668 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.8 mt-10 -103.12 147.64 26.74 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.264 -0.897 . . . . 0.0 110.519 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 84.2 m-85 -142.59 81.09 1.72 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.556 -0.715 . . . . 0.0 110.625 -179.816 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -62.63 153.97 30.61 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.384 -0.822 . . . . 0.0 109.825 179.335 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.75 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.7 t -147.62 86.77 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.571 -0.705 . . . . 0.0 109.982 -179.473 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.765 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.9 m -86.21 118.72 25.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.092 -1.005 . . . . 0.0 109.387 179.656 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.079 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -106.04 147.24 29.12 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.196 -0.94 . . . . 0.0 110.374 -179.341 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.843 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.2 m120 -127.07 133.07 50.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.175 -0.953 . . . . 0.0 110.458 -179.432 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.843 HD23 ' O ' ' A' ' 285' ' ' ASN . 9.2 mt -142.1 158.54 43.63 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.896 -1.128 . . . . 0.0 108.992 179.332 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.66 35.56 0.96 Allowed 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.531 -179.588 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 158.21 -110.14 0.43 Allowed Glycine 0 N--CA 1.493 2.468 0 C-N-CA 118.758 -1.687 . . . . 0.0 110.982 179.779 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.505 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -135.07 122.37 21.68 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.061 -1.258 . . . . 0.0 111.051 -178.594 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.665 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 8.6 m-85 -150.88 147.02 26.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.245 -0.91 . . . . 0.0 109.998 179.172 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.787 ' O ' HG23 ' A' ' 353' ' ' ILE . 18.8 m-20 -80.58 96.79 6.94 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.371 179.316 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.954 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.9 p-90 -96.82 115.64 27.78 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.365 -0.835 . . . . 0.0 110.424 -179.589 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 293' ' ' THR . . . . . 1.073 HG23 HG22 ' A' ' 322' ' ' THR . 3.3 m -109.31 113.72 26.79 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.465 -0.772 . . . . 0.0 109.753 179.927 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.76 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.5 t -97.07 113.06 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.287 -0.883 . . . . 0.0 110.339 -179.463 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.548 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 31.3 ttmt -94.55 135.58 35.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.598 179.362 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.875 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 81.1 t -130.25 112.34 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.187 -0.946 . . . . 0.0 110.579 -179.548 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.524 ' O ' HG23 ' A' ' 346' ' ' VAL . 53.3 mmtt -70.32 136.08 49.46 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.063 -1.023 . . . . 0.0 109.472 179.421 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.991 HD13 ' HA ' ' A' ' 303' ' ' THR . 88.3 mt -90.49 163.12 14.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.296 -0.878 . . . . 0.0 111.838 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.863 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.78 178.06 0.97 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.82 -0.55 . . . . 0.0 109.846 179.583 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.863 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.2 77.39 0.87 Allowed 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.757 1.398 . . . . 0.0 109.811 179.449 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.7 18.69 5.97 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 -179.275 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.855 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -105.04 141.68 36.18 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.417 -1.049 . . . . 0.0 109.677 -179.856 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.991 ' HA ' HD13 ' A' ' 298' ' ' LEU . 82.2 p -143.99 143.95 31.45 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.84 -1.162 . . . . 0.0 111.058 179.859 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.888 ' CG2' HG21 ' A' ' 319' ' ' VAL . 88.5 t -67.13 116.86 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.658 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.74 -31.6 5.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.341 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.465 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.3 OUTLIER -140.63 132.03 26.81 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.927 -1.337 . . . . 0.0 111.136 -179.414 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.576 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 16.4 p90 -146.42 168.93 19.94 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.411 -0.805 . . . . 0.0 109.496 179.287 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.51 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.9 OUTLIER -159.56 157.07 29.2 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.881 -1.137 . . . . 0.0 111.546 -179.558 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.549 ' HB3' ' CH2' ' A' ' 326' ' ' TRP . 0.4 OUTLIER 60.76 27.09 16.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.749 -0.595 . . . . 0.0 111.186 179.47 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.672 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 142.7 0.86 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 110.102 179.627 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.491 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.0 m120 -76.3 114.49 15.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.171 -0.956 . . . . 0.0 109.421 179.628 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.584 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 1.1 ttpp -87.08 132.95 33.67 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.76 0.79 . . . . 0.0 110.782 -179.579 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.577 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.5 OUTLIER -120.03 174.52 6.42 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.991 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -137.71 103.14 4.93 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.195 -0.94 . . . . 0.0 110.242 179.764 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.499 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -90.44 30.44 6.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.893 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.499 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 5.8 t-20 69.89 89.03 0.1 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.224 -1.162 . . . . 0.0 110.378 -179.992 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.632 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.55 1.32 71.54 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.861 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.805 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.2 m-85 -146.72 -168.6 3.07 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.463 -1.022 . . . . 0.0 108.921 179.396 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.888 HG21 ' CG2' ' A' ' 304' ' ' VAL . 6.4 t -162.18 158.15 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.973 -1.08 . . . . 0.0 110.123 179.116 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.584 ' O ' ' HA ' ' A' ' 312' ' ' LYS . 6.5 mm -122.41 152.38 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.896 -1.128 . . . . 0.0 110.747 -179.677 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 76.2 m-85 -132.54 115.12 15.07 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.167 -0.958 . . . . 0.0 110.026 179.224 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 322' ' ' THR . . . . . 1.073 HG22 HG23 ' A' ' 293' ' ' THR . 5.6 p -118.03 169.47 7.64 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 120.65 -1.281 . . . . 0.0 109.676 179.456 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.571 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.7 Cg_endo -67.57 121.28 8.35 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.619 1.326 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 1.057 HG22 ' HB2' ' A' ' 327' ' ' ASN . 2.7 m -75.75 -141.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -0.769 . . . . 0.0 110.458 -179.563 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.786 ' N ' HG23 ' A' ' 324' ' ' VAL . 3.2 m -76.24 -37.25 57.9 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 110.775 -179.626 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.58 ' H ' HG23 ' A' ' 324' ' ' VAL . 42.0 p-90 -117.77 22.24 12.44 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.16 -0.962 . . . . 0.0 110.803 -179.57 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 1.057 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -122.73 32.62 5.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.096 -1.003 . . . . 0.0 110.897 -179.172 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.498 ' CB ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -120.64 9.86 10.9 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.085 -1.009 . . . . 0.0 110.061 179.785 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -72.05 -149.5 0.87 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 179.895 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.556 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.3 Cg_endo -73.32 -52.46 0.14 Allowed 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.934 1.492 . . . . 0.0 109.64 179.811 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.0 m -111.89 115.73 29.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -125.52 117.45 23.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.379 -0.825 . . . . 0.0 109.958 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.765 ' OG1' HG23 ' A' ' 283' ' ' THR . 53.2 m -107.6 142.87 36.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.287 -0.883 . . . . 0.0 110.32 -179.859 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.76 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.4 p90 -151.7 173.06 15.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.766 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.525 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.89 153.73 25.02 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.021 -1.562 . . . . 0.0 110.1 -179.465 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.892 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -137.98 145.96 42.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.531 -0.982 . . . . 0.0 109.876 179.662 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.892 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.05 125.4 74.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.133 -0.979 . . . . 0.0 109.593 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.761 HG21 ' CD2' ' A' ' 298' ' ' LEU . 3.5 t -99.49 161.42 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.175 -0.953 . . . . 0.0 110.726 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.7 m120 -128.47 137.06 51.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.447 -0.783 . . . . 0.0 110.205 179.869 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.405 ' H ' ' HE3' ' A' ' 345' ' ' LYS . . . 172.9 -128.99 1.62 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.951 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.536 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 39.2 Cg_endo -65.53 -158.68 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.645 0 O-C-N 123.859 1.452 . . . . 0.0 110.223 179.467 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.442 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 2.0 pm0 -125.22 130.25 51.71 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.028 -1.045 . . . . 0.0 111.342 -179.098 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 117.22 -75.33 0.28 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 179.464 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -130.14 133.65 46.78 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.533 -0.98 . . . . 0.0 108.776 179.149 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.686 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 0.0 OUTLIER -133.67 25.35 4.04 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.899 -1.126 . . . . 0.0 111.044 -179.35 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.632 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.9 p -138.44 119.18 16.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 110.064 179.062 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.413 ' N ' ' O ' ' A' ' 297' ' ' LYS . 4.2 mt-10 -54.34 -42.22 69.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.412 -0.805 . . . . 0.0 110.928 -179.152 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.4 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.6 OUTLIER -176.66 158.77 1.76 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.94 -1.1 . . . . 0.0 110.867 -179.666 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.725 HG12 HG13 ' A' ' 296' ' ' VAL . 14.6 mt -119.28 120.22 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.144 -0.973 . . . . 0.0 110.36 179.858 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.11 141.9 51.66 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.113 -0.992 . . . . 0.0 110.16 179.825 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.079 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.89 130.11 54.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.193 -0.942 . . . . 0.0 110.386 179.803 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.8 tt0 -139.47 116.62 11.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.239 -0.913 . . . . 0.0 109.582 179.642 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.787 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -90.52 102.86 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.792 -1.193 . . . . 0.0 110.45 -179.704 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.465 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 2.3 m120 35.72 44.89 0.24 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.433 179.647 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.45 8.4 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.408 179.106 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.522 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 78.2 mm-40 -137.2 101.31 4.5 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.062 -1.258 . . . . 0.0 110.042 179.765 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.549 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.1 p -66.91 138.22 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.278 -0.889 . . . . 0.0 110.732 -179.672 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.549 HD13 ' O ' ' A' ' 357' ' ' VAL . 19.6 mm . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.171 179.596 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -73.6 -178.34 3.67 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.002 1.528 . . . . 0.0 110.553 -179.951 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.401 ' O ' HG23 ' A' ' 258' ' ' THR . 5.8 t -66.27 135.37 54.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.358 -0.839 . . . . 0.0 110.159 179.826 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 259' ' ' THR . . . . . 0.47 HG23 ' O ' ' A' ' 259' ' ' THR . 1.5 t -141.69 92.74 7.89 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.154 -0.966 . . . . 0.0 110.471 -179.981 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.9 141.68 30.5 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.853 1.449 . . . . 0.0 110.102 179.759 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.409 ' H ' HG12 ' A' ' 261' ' ' VAL . 2.4 p -102.65 138.04 19.51 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.116 -0.99 . . . . 0.0 110.554 -179.906 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.518 ' HB3' ' HA ' ' A' ' 358' ' ' ILE . 49.2 Cg_endo -75.29 158.1 41.24 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 124.081 1.569 . . . . 0.0 110.626 179.916 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.752 HG12 ' O ' ' A' ' 263' ' ' VAL . 75.6 t -127.46 26.61 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.28 -0.888 . . . . 0.0 109.979 179.688 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.621 ' O ' HD12 ' A' ' 358' ' ' ILE . 1.4 t 169.87 143.49 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.277 -0.89 . . . . 0.0 110.45 179.929 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 265' ' ' GLY . . . . . 0.428 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . 61.9 -169.89 11.8 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.621 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.513 ' HB2' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.39 162.82 34.11 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.371 -1.076 . . . . 0.0 109.736 179.762 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.983 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.4 tm? -155.23 131.39 10.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.048 -1.032 . . . . 0.0 110.565 -179.148 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.562 ' N ' HD13 ' A' ' 267' ' ' LEU . 18.0 mt-10 -133.28 124.02 26.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.542 -0.724 . . . . 0.0 109.285 179.455 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.675 HG23 HD11 ' A' ' 267' ' ' LEU . 32.0 t -115.54 139.08 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.924 -1.11 . . . . 0.0 111.809 -178.714 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.412 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.6 mttt -123.21 156.65 34.72 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.492 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.672 HG22 ' CD1' ' A' ' 280' ' ' TYR . 91.4 t -145.08 144.94 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.276 -1.515 . . . . 0.0 112.152 -179.275 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.549 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -139.27 109.05 6.27 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.175 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -94.62 146.17 24.32 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.208 -0.932 . . . . 0.0 111.36 -178.763 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.819 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.6 p90 -134.63 22.94 3.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.589 -0.694 . . . . 0.0 109.897 179.275 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.69 -66.81 3.84 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.827 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.41 -24.85 65.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.28 -1.129 . . . . 0.0 110.431 -179.668 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.535 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.92 -177.8 41.76 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.533 -1.318 . . . . 0.0 109.84 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.584 ' HB2' ' HE3' ' A' ' 345' ' ' LYS . . . -136.5 144.8 44.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -1.1 . . . . 0.0 110.247 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.644 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.1 mt-10 -97.01 147.05 24.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.421 -0.8 . . . . 0.0 109.816 -179.629 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.7 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -143.74 86.79 1.89 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.204 -0.935 . . . . 0.0 110.894 -179.619 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.647 ' O ' HG13 ' A' ' 269' ' ' VAL . 4.6 t0 -71.06 151.58 44.39 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.641 179.11 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.735 HG21 ' CE1' ' A' ' 334' ' ' PHE . 3.4 t -143.52 91.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.46 -0.775 . . . . 0.0 109.717 -179.689 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.904 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.6 m -85.82 123.14 30.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.104 179.66 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.076 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -113.89 145.18 41.85 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.148 -0.97 . . . . 0.0 110.467 -179.034 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.904 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.6 m120 -127.15 134.26 50.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -179.642 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.904 HD23 ' O ' ' A' ' 285' ' ' ASN . 15.9 mt -142.94 148.66 37.24 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.808 -1.183 . . . . 0.0 109.83 179.638 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -85.68 38.7 0.76 Allowed 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.593 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 159.53 -136.42 4.61 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.301 -1.428 . . . . 0.0 109.752 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.51 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -117.82 94.25 4.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.192 -1.181 . . . . 0.0 110.815 -179.49 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.616 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.05 137.14 52.38 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.192 -0.943 . . . . 0.0 109.918 179.311 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.782 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.1 m-20 -71.85 97.6 1.84 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.104 -0.998 . . . . 0.0 109.287 179.248 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.967 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.9 p-90 -97.1 113.74 25.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 110.663 -179.376 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.898 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.0 m -107.11 117.05 33.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.523 -0.735 . . . . 0.0 109.258 179.527 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.739 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.1 t -97.14 111.0 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.121 -0.987 . . . . 0.0 110.655 -179.247 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.687 ' HA ' HD13 ' A' ' 320' ' ' ILE . 18.7 ttpt -84.68 138.97 32.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.258 -0.901 . . . . 0.0 108.933 178.923 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.957 HG22 HG23 ' A' ' 349' ' ' ILE . 85.1 t -136.22 107.11 6.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 110.906 -179.116 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.59 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 8.2 mmtm -69.96 130.72 42.96 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 121.075 -1.016 . . . . 0.0 108.881 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.997 HD13 ' HA ' ' A' ' 303' ' ' THR . 66.2 mt -87.02 157.9 19.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.336 -0.853 . . . . 0.0 111.304 -178.816 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.9 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -59.14 177.89 0.24 Allowed Pre-proline 0 C--N 1.303 -1.438 0 O-C-N 121.764 -0.585 . . . . 0.0 109.803 179.503 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.839 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.06 81.0 0.66 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.717 1.377 . . . . 0.0 109.449 179.294 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.05 21.98 6.1 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 -179.102 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.9 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -104.91 149.77 25.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.313 -1.11 . . . . 0.0 110.397 -179.661 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.997 ' HA ' HD13 ' A' ' 298' ' ' LEU . 4.7 p -148.9 145.63 27.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.294 -0.879 . . . . 0.0 110.424 179.729 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.786 HG21 HG11 ' A' ' 319' ' ' VAL . 55.5 t -71.64 117.66 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 110.044 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -97.38 -45.26 2.58 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 68.1 m -126.15 148.76 49.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -1.161 . . . . 0.0 110.843 -179.77 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.513 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.0 p90 -162.95 160.03 24.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.462 -0.773 . . . . 0.0 109.479 179.473 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.498 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -153.35 162.46 41.26 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.835 -1.166 . . . . 0.0 111.172 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.513 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 58.19 21.83 8.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.963 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.712 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.84 137.76 0.6 Allowed 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.426 -0.796 . . . . 0.0 110.057 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.547 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.4 m120 -77.31 124.96 28.57 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.117 -0.989 . . . . 0.0 109.538 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.757 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -92.2 139.83 30.23 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.719 0.771 . . . . 0.0 110.882 -179.25 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.636 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -122.61 170.5 9.96 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.135 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.579 ' HG2' HG22 ' A' ' 319' ' ' VAL . 46.3 mt-10 -141.55 100.98 3.89 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.137 -0.977 . . . . 0.0 110.518 -179.767 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -81.41 -76.68 1.05 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.209 -1.557 . . . . 0.0 109.209 179.595 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.57 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 2.8 m120 -163.85 86.79 0.5 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.423 -1.045 . . . . 0.0 109.001 179.553 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 86.63 14.4 65.6 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -178.57 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.837 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.4 m-85 -146.79 -168.76 3.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.836 -0.803 . . . . 0.0 109.096 179.642 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.837 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.8 t -163.85 161.59 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.177 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.687 HD13 ' HA ' ' A' ' 295' ' ' LYS . 40.6 mm -127.24 144.97 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 111.184 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 49.2 m-85 -120.55 133.59 55.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.212 -0.93 . . . . 0.0 109.912 179.56 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.898 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -134.53 167.81 20.95 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 120.852 -1.155 . . . . 0.0 109.881 179.64 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.498 ' HB3' ' O ' ' A' ' 327' ' ' ASN . 42.2 Cg_endo -67.72 115.51 3.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.858 1.451 . . . . 0.0 110.725 -179.384 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 1.061 HG22 ' HB2' ' A' ' 327' ' ' ASN . 23.0 m -61.18 -135.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.334 -0.854 . . . . 0.0 110.245 -179.88 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.525 ' N ' HG23 ' A' ' 324' ' ' VAL . 2.0 m -90.47 -18.68 24.92 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.059 -1.026 . . . . 0.0 110.763 -179.475 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.777 ' H ' HG23 ' A' ' 324' ' ' VAL . 27.7 p-90 -132.97 21.56 4.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.182 -0.949 . . . . 0.0 110.404 -179.742 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 1.061 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.7 m120 -120.25 38.25 4.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.073 -1.017 . . . . 0.0 110.614 -179.365 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.51 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -120.06 -4.95 10.04 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.184 -0.948 . . . . 0.0 109.889 179.565 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.99 -160.64 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -74.52 4.09 4.79 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.998 1.526 . . . . 0.0 110.72 -179.868 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.429 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.4 m -163.66 117.05 1.51 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.19 -0.944 . . . . 0.0 110.048 -179.853 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -140.12 114.61 9.31 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.961 . . . . 0.0 110.357 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.904 ' OG1' HG23 ' A' ' 283' ' ' THR . 21.7 m -105.15 139.17 40.22 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.23 -0.919 . . . . 0.0 110.022 179.793 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.739 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.5 p90 -141.57 174.5 10.51 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.349 -0.844 . . . . 0.0 109.019 179.891 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.23 156.33 26.61 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.162 -1.494 . . . . 0.0 110.015 -179.525 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.899 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -146.25 144.65 30.0 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.385 -1.068 . . . . 0.0 110.328 179.752 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.899 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.71 123.06 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.184 -0.948 . . . . 0.0 109.215 179.321 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.82 HG11 ' HB1' ' A' ' 302' ' ' ALA . 4.1 t -96.59 162.11 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 110.699 -179.144 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 0.7 OUTLIER -126.07 127.38 45.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.568 -0.707 . . . . 0.0 109.56 -179.967 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.52 -126.94 1.03 Allowed Glycine 0 N--CA 1.49 2.288 0 C-N-CA 119.494 -1.336 . . . . 0.0 110.042 179.977 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.509 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 43.5 Cg_endo -70.75 -174.79 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 O-C-N 123.921 1.484 . . . . 0.0 110.647 -179.676 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.458 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 2.8 mp0 -104.65 135.34 46.24 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.237 -0.914 . . . . 0.0 110.655 -179.623 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.452 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 109.64 -88.94 0.53 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.728 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -113.64 137.5 51.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.458 -1.025 . . . . 0.0 108.757 178.948 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.68 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 2.5 mtmt -129.32 14.43 6.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.834 -1.166 . . . . 0.0 110.492 -179.461 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.8 p -136.85 118.35 18.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.415 -0.803 . . . . 0.0 110.026 179.272 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.466 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -50.96 -45.84 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.348 -0.845 . . . . 0.0 110.38 -179.513 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.436 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.0 pt-20 -176.61 157.84 1.65 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.272 -0.892 . . . . 0.0 110.426 -179.695 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.957 HG23 HG22 ' A' ' 296' ' ' VAL . 64.5 mt -120.59 106.54 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.157 -0.964 . . . . 0.0 110.232 179.644 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.82 130.91 53.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 110.286 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.076 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -91.3 129.37 37.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.101 -0.999 . . . . 0.0 110.241 179.782 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.401 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.0 tt0 -138.83 112.69 8.46 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.183 -0.948 . . . . 0.0 109.934 179.81 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.782 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.4 110.7 22.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.065 -1.022 . . . . 0.0 110.165 179.961 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.421 ' C ' ' O ' ' A' ' 353' ' ' ILE . 6.8 m-20 38.89 29.25 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.774 -0.578 . . . . 0.0 110.639 179.922 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 118.59 -21.68 9.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.41 ' O ' ' N ' ' A' ' 353' ' ' ILE . 1.2 mp0 -86.2 112.53 21.43 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.055 -1.262 . . . . 0.0 110.392 -179.755 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.843 ' O ' HD13 ' A' ' 358' ' ' ILE . 14.8 p -74.84 141.63 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.138 -0.976 . . . . 0.0 110.407 179.842 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.843 HD13 ' O ' ' A' ' 357' ' ' VAL . 30.8 mm . . . . . 0 N--CA 1.494 1.755 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.309 179.837 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -76.73 178.8 7.14 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.995 1.523 . . . . 0.0 110.611 -179.931 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.469 HG23 ' O ' ' A' ' 258' ' ' THR . 4.3 t -60.73 128.91 38.87 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.291 -0.881 . . . . 0.0 109.938 179.798 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 25.0 m -61.55 137.24 94.78 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.151 -0.968 . . . . 0.0 110.177 -179.853 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.61 142.0 35.43 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 123.967 1.509 . . . . 0.0 110.365 -179.779 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.733 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.5 p -81.88 147.13 57.52 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.362 -0.836 . . . . 0.0 110.266 -179.883 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.733 ' HD2' HG23 ' A' ' 261' ' ' VAL . 44.7 Cg_endo -71.11 138.18 33.06 Favored 'Trans proline' 0 C--N 1.303 -1.824 0 O-C-N 124.061 1.559 . . . . 0.0 110.035 179.582 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.511 ' O ' ' CB ' ' A' ' 264' ' ' SER . 12.1 t -125.12 28.79 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 110.418 -179.696 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.511 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 3.0 t 169.13 64.64 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.273 -0.892 . . . . 0.0 110.638 179.866 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 136.86 171.25 12.15 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.245 179.442 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -128.52 165.94 19.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.617 -0.931 . . . . 0.0 109.664 179.665 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.748 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -159.43 126.21 4.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.977 -1.077 . . . . 0.0 111.17 -179.555 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.52 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.4 OUTLIER -123.78 118.05 26.3 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.681 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 281' ' ' ASP . 55.2 t -117.15 142.15 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.851 -1.156 . . . . 0.0 112.14 -178.428 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 7.9 tttm -128.5 157.28 41.59 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.969 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.625 HG13 ' O ' ' A' ' 279' ' ' GLU . 86.5 t -144.2 145.42 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.367 -1.458 . . . . 0.0 111.947 -179.445 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.65 113.23 7.71 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.483 179.534 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.514 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.86 145.76 25.11 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.151 -0.968 . . . . 0.0 110.942 -179.016 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.813 ' CH2' HG23 ' A' ' 337' ' ' ILE . 27.9 p90 -127.83 16.04 6.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.305 179.377 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 95.01 -56.11 1.82 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.483 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.6 m -78.53 -17.86 55.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -1.151 . . . . 0.0 110.453 -179.678 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -174.1 177.71 46.24 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.35 -1.405 . . . . 0.0 109.922 -179.952 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.561 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.65 144.84 48.07 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.329 -1.1 . . . . 0.0 110.066 179.862 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.625 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.2 mt-10 -96.88 147.48 23.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.365 -0.835 . . . . 0.0 109.878 -179.441 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 92.8 m-85 -139.38 86.43 2.12 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.302 -0.874 . . . . 0.0 110.69 -179.294 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.797 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.6 OUTLIER -69.77 145.65 52.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.431 -0.793 . . . . 0.0 109.809 179.317 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 294' ' ' VAL . 3.8 t -139.06 87.55 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.577 -0.702 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 333' ' ' THR . 19.2 m -86.12 117.12 24.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.102 -0.999 . . . . 0.0 109.645 -179.886 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.104 HD21 HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -103.05 150.43 23.6 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.109 -0.994 . . . . 0.0 110.769 -179.279 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.1 m120 -133.62 106.63 7.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.576 -0.702 . . . . 0.0 110.098 -179.324 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.61 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.1 mt -113.98 157.16 22.83 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.824 -1.172 . . . . 0.0 109.987 179.772 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.47 35.16 0.76 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.356 -0.84 . . . . 0.0 110.501 -179.432 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.491 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.15 -103.39 0.23 Allowed Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.878 -1.63 . . . . 0.0 110.423 179.855 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.443 ' HG3' ' O ' ' A' ' 328' ' ' LYS . 3.3 tt0 -149.95 111.06 4.37 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.053 -1.263 . . . . 0.0 110.705 -179.252 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.61 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 2.4 m-85 -140.14 138.54 35.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.405 -0.809 . . . . 0.0 109.866 179.542 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.694 ' O ' HG23 ' A' ' 353' ' ' ILE . 29.5 m-20 -64.92 97.09 0.21 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.102 -0.999 . . . . 0.0 109.294 179.349 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.884 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.5 p-90 -96.41 110.71 23.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.262 -0.899 . . . . 0.0 110.67 -179.502 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.669 HG22 ' CG2' ' A' ' 320' ' ' ILE . 5.5 m -102.81 114.94 29.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.518 -0.739 . . . . 0.0 109.314 179.459 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 282' ' ' VAL . 4.5 t -96.18 113.08 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.102 -0.999 . . . . 0.0 110.007 -179.547 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.699 ' HA ' HD13 ' A' ' 320' ' ' ILE . 12.9 ttpt -89.73 149.47 22.73 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.527 -0.733 . . . . 0.0 109.184 179.657 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.793 HG13 HD13 ' A' ' 349' ' ' ILE . 77.4 t -148.16 109.33 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.005 -1.059 . . . . 0.0 110.763 -179.327 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.581 ' O ' HG23 ' A' ' 346' ' ' VAL . 9.0 mmtt -71.81 135.03 46.51 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.102 -0.999 . . . . 0.0 109.324 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.919 HD13 ' HA ' ' A' ' 303' ' ' THR . 89.6 mt -86.11 167.13 15.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.28 -0.888 . . . . 0.0 111.755 -178.75 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.787 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -72.18 176.17 2.56 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.672 -0.643 . . . . 0.0 109.353 179.068 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.787 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.9 Cg_endo -69.3 80.3 0.76 Allowed 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.554 1.291 . . . . 0.0 109.918 179.564 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.41 23.45 4.79 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.985 -1.646 . . . . 0.0 108.985 -179.446 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.913 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.7 150.4 30.26 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.373 -1.075 . . . . 0.0 110.401 -179.558 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.919 ' HA ' HD13 ' A' ' 298' ' ' LEU . 77.3 p -150.43 144.14 25.23 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.286 -0.884 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.846 HG21 HG11 ' A' ' 319' ' ' VAL . 55.2 t -64.81 133.32 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 110.16 179.69 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.2 -37.6 1.48 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.843 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.41 138.22 32.8 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.182 -1.187 . . . . 0.0 110.768 -179.681 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.529 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 48.1 p90 -147.11 163.78 35.2 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.326 -0.858 . . . . 0.0 109.776 179.486 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.464 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.47 158.2 38.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.941 -1.099 . . . . 0.0 111.554 -179.434 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.518 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.52 21.6 12.74 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.719 -0.613 . . . . 0.0 110.818 179.479 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.638 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.7 143.6 0.78 Allowed 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.465 -0.772 . . . . 0.0 109.956 179.538 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.537 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -79.33 119.71 22.76 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.035 . . . . 0.0 109.351 179.579 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.596 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -86.2 140.33 30.25 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.767 0.794 . . . . 0.0 110.59 -179.612 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.661 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.13 173.2 8.9 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.423 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -136.7 112.7 9.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 110.167 179.926 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -102.73 43.56 1.66 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 57.75 80.15 0.18 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.354 -1.086 . . . . 0.0 110.395 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.39 -1.02 57.12 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.64 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.826 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.1 m-85 -142.55 -170.1 3.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.377 -1.072 . . . . 0.0 109.472 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.846 HG11 HG21 ' A' ' 304' ' ' VAL . 3.9 t -162.81 156.12 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.177 -0.952 . . . . 0.0 109.922 179.2 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.699 HD13 ' HA ' ' A' ' 295' ' ' LYS . 37.2 mm -125.65 151.78 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.114 -0.991 . . . . 0.0 111.294 -179.462 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 78.5 m-85 -129.54 126.49 38.7 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.166 -0.959 . . . . 0.0 110.408 179.421 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.604 ' CG2' HG23 ' A' ' 293' ' ' THR . 6.4 p -126.5 167.56 16.91 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 120.919 -1.113 . . . . 0.0 109.579 179.195 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.504 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.4 Cg_endo -65.15 119.93 7.05 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.225 -179.164 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.723 HG22 ' HB2' ' A' ' 327' ' ' ASN . 12.4 m -63.74 -111.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.439 -0.788 . . . . 0.0 110.166 179.987 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.482 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.1 OUTLIER -111.67 -23.32 10.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.697 -1.252 . . . . 0.0 110.534 -179.811 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 3.9 p-90 -125.73 1.49 7.47 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 -179.874 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.723 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.2 OUTLIER -99.91 40.97 1.19 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.233 -0.917 . . . . 0.0 110.38 -179.69 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -120.05 -8.4 9.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.25 -0.907 . . . . 0.0 109.532 179.736 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.89 -159.06 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.939 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.1 Cg_endo -74.76 5.75 3.69 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.978 1.515 . . . . 0.0 110.821 -179.899 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.1 m -163.14 121.23 1.98 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.959 -1.088 . . . . 0.0 109.897 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.61 113.75 8.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.957 . . . . 0.0 110.26 -179.776 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.542 HG23 ' HA ' ' A' ' 283' ' ' THR . 11.8 m -103.04 133.42 48.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.392 -0.817 . . . . 0.0 110.364 -179.739 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.8 ' HE2' HG21 ' A' ' 294' ' ' VAL . 15.0 p90 -141.77 164.6 29.75 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.379 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -144.24 158.27 27.41 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.843 -1.646 . . . . 0.0 110.32 -179.397 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.926 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -144.01 147.65 34.17 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.556 -0.967 . . . . 0.0 109.882 179.417 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.926 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.74 122.81 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.992 -1.068 . . . . 0.0 110.048 -179.969 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.913 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.9 t -97.07 157.28 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.884 . . . . 0.0 109.999 179.712 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -125.85 131.32 52.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.84 . . . . 0.0 110.396 -179.575 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -179.84 -122.09 0.76 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.851 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.547 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 41.2 Cg_endo -67.59 -158.28 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.864 1.455 . . . . 0.0 110.625 179.632 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.406 ' N ' ' OE1' ' A' ' 342' ' ' GLN . 4.5 pm0 -125.39 126.58 45.23 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.11 -0.994 . . . . 0.0 110.628 -179.467 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 113.81 -71.61 0.23 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.941 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -123.62 141.44 52.01 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.329 -1.101 . . . . 0.0 109.045 179.306 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.74 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.3 mtmt -141.68 10.25 2.02 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.83 -1.169 . . . . 0.0 111.234 -179.369 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.641 HG11 ' CE1' ' A' ' 280' ' ' TYR . 9.0 p -132.2 125.51 54.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.022 -1.049 . . . . 0.0 110.412 179.231 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.547 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 3.8 mt-10 -53.08 -45.74 68.29 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.313 -0.867 . . . . 0.0 110.149 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.454 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 1.8 pt-20 -177.55 158.63 1.4 Allowed 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.185 -179.704 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.793 HD13 HG13 ' A' ' 296' ' ' VAL . 3.5 mm -109.13 122.58 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.603 -0.686 . . . . 0.0 109.709 179.419 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.42 141.76 51.67 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.33 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.104 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.68 126.84 52.62 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 109.952 179.633 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 11.5 tt0 -138.99 113.8 9.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.643 179.92 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.694 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -92.97 112.14 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.154 -0.966 . . . . 0.0 109.913 179.522 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.435 ' C ' ' O ' ' A' ' 353' ' ' ILE . 3.4 m-20 41.74 34.11 0.38 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.492 -0.755 . . . . 0.0 110.113 -179.579 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 108.9 -25.12 19.89 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.933 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.471 ' N ' ' CD ' ' A' ' 356' ' ' GLN . 3.2 mp0 -77.41 106.07 8.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.223 -1.163 . . . . 0.0 110.523 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.622 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.5 p -70.92 120.93 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.259 -0.901 . . . . 0.0 110.184 179.719 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.514 ' HB ' HD13 ' A' ' 351' ' ' LEU . 35.5 mm . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.009 179.777 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.426 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.87 -178.38 3.46 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 O-C-N 123.879 1.463 . . . . 0.0 110.545 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.437 HG23 ' O ' ' A' ' 258' ' ' THR . 5.1 t -68.26 131.85 46.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.426 -0.797 . . . . 0.0 110.61 -179.805 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 10.1 p -133.44 111.1 12.66 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.223 -0.923 . . . . 0.0 110.141 179.813 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -71.83 154.31 58.69 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.998 1.526 . . . . 0.0 110.254 179.672 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.563 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -89.7 141.59 28.59 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.228 -0.92 . . . . 0.0 110.496 -179.833 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.563 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.7 Cg_endo -75.39 133.57 16.16 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.094 1.576 . . . . 0.0 110.14 179.785 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 2.8 t -115.64 29.06 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.108 -0.995 . . . . 0.0 110.222 -179.721 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -176.11 118.1 0.14 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.168 -0.958 . . . . 0.0 110.799 179.923 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 73.29 -173.42 48.86 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.365 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.514 ' HB2' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.79 169.35 17.87 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.585 -0.95 . . . . 0.0 109.33 179.909 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.904 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.38 134.49 6.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.36 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.777 ' N ' HD22 ' A' ' 267' ' ' LEU . 8.4 mm-40 -133.96 138.46 45.47 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.294 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.4 t -131.35 142.0 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 120.858 -1.151 . . . . 0.0 111.753 -178.846 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.17 156.99 40.93 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.771 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.81 147.07 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 120.401 -1.437 . . . . 0.0 112.344 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -143.18 113.91 7.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.669 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.6 m-20 -100.07 142.87 30.96 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.872 -1.142 . . . . 0.0 111.205 -178.538 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.8 ' CH2' HG23 ' A' ' 337' ' ' ILE . 26.8 p90 -122.77 20.1 10.17 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.576 -0.703 . . . . 0.0 109.475 179.451 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.536 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 84.44 -58.32 5.0 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.744 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.484 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -66.87 -19.34 65.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.25 -1.147 . . . . 0.0 110.216 179.793 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.553 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.93 -172.69 38.79 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -143.69 136.89 27.77 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -1.122 . . . . 0.0 109.894 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.641 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.2 mt-10 -95.93 146.4 24.62 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 110.446 -179.447 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.662 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.1 m-85 -140.01 86.36 2.08 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 110.766 -179.699 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.706 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -66.54 143.64 56.93 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 179.155 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.811 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.4 t -138.35 89.36 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.191 -0.943 . . . . 0.0 110.014 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.463 ' HA ' HG23 ' A' ' 333' ' ' THR . 87.4 m -86.76 126.96 34.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.181 -0.949 . . . . 0.0 109.568 179.799 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.81 147.08 40.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 110.77 -179.204 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.91 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.5 m120 -125.3 135.21 52.25 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.35 -0.844 . . . . 0.0 110.467 -179.453 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.91 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.3 mt -144.77 161.69 38.61 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.731 -1.23 . . . . 0.0 109.595 179.8 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.09 37.47 1.16 Allowed 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.776 179.733 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.473 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 148.55 -129.89 3.25 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.33 -1.414 . . . . 0.0 109.973 -179.68 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.546 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.1 mm-40 -108.3 114.06 27.62 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.891 -1.358 . . . . 0.0 111.132 -179.326 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.721 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.3 m-85 -134.43 133.09 40.12 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.444 -0.785 . . . . 0.0 109.234 179.205 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.84 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.1 m-20 -73.5 96.26 2.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.808 -1.183 . . . . 0.0 108.857 179.236 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.903 ' CE3' HD13 ' A' ' 284' ' ' LEU . 64.2 p-90 -98.98 117.47 33.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.893 . . . . 0.0 110.996 -179.038 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 293' ' ' THR . . . . . 1.067 HG23 HG22 ' A' ' 322' ' ' THR . 17.3 m -112.68 113.98 26.37 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.425 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.787 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.2 t -96.68 110.92 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.058 -1.026 . . . . 0.0 110.265 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.537 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 17.6 ttmt -89.51 148.21 23.54 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.381 -0.825 . . . . 0.0 109.187 179.144 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.811 HG13 HG12 ' A' ' 349' ' ' ILE . 71.3 t -144.26 111.66 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.126 -0.984 . . . . 0.0 110.204 -179.666 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 72.6 mmtt -70.24 135.44 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.219 -0.926 . . . . 0.0 109.154 179.653 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 1.027 HD13 ' HA ' ' A' ' 303' ' ' THR . 93.9 mt -89.84 155.59 19.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.316 -0.865 . . . . 0.0 111.447 -178.851 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.781 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -59.4 173.86 0.46 Allowed Pre-proline 0 N--CA 1.487 1.378 0 O-C-N 121.493 -0.755 . . . . 0.0 109.086 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.695 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -69.23 79.33 0.78 Allowed 'Trans proline' 0 C--N 1.302 -1.913 0 O-C-N 123.608 1.32 . . . . 0.0 109.874 179.747 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.93 20.15 4.99 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.425 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.781 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -109.99 148.39 31.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.407 -1.055 . . . . 0.0 109.859 -179.884 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 303' ' ' THR . . . . . 1.027 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.8 p -147.52 146.15 29.36 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.953 -1.092 . . . . 0.0 111.247 -179.747 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.746 ' CG2' HG21 ' A' ' 319' ' ' VAL . 53.7 t -69.28 129.02 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.287 -0.883 . . . . 0.0 109.821 179.542 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.66 -40.22 1.13 Allowed Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.73 -1.224 . . . . 0.0 110.201 -179.466 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -126.96 129.65 48.55 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 0.0 110.686 -179.463 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.552 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.6 p90 -145.44 162.02 38.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.36 -0.837 . . . . 0.0 109.823 179.59 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.503 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -158.16 156.09 30.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.927 -1.108 . . . . 0.0 111.171 -179.579 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.538 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 63.5 24.31 14.02 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.575 -0.703 . . . . 0.0 110.941 179.598 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.542 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.18 146.1 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.908 . . . . 0.0 110.497 179.474 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.496 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 3.7 m120 -77.31 123.46 26.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.375 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.552 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 12.0 ttpt -93.03 121.94 34.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.5 -0.75 . . . . 0.0 111.025 -179.448 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.597 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 4.2 tt0 -109.86 175.13 5.56 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.324 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -138.17 101.99 4.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.347 -0.846 . . . . 0.0 110.12 179.773 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.451 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -90.11 37.05 3.41 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.868 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 316' ' ' ASN . . . . . 0.451 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 5.8 m-20 63.78 88.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -1.168 . . . . 0.0 110.266 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.08 3.07 70.47 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.729 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.751 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.34 -169.38 3.25 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.376 -1.073 . . . . 0.0 109.338 179.491 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.751 HG23 ' O ' ' A' ' 318' ' ' TYR . 22.6 t -160.8 161.08 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.119 -0.988 . . . . 0.0 109.97 178.964 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.597 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 4.4 mm -126.55 152.33 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.133 -0.98 . . . . 0.0 110.93 -179.378 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.65 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 79.2 m-85 -131.76 112.48 12.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.232 -0.918 . . . . 0.0 109.888 178.791 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 322' ' ' THR . . . . . 1.067 HG22 HG23 ' A' ' 293' ' ' THR . 6.5 p -115.67 170.28 5.86 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 120.725 -1.234 . . . . 0.0 109.529 179.561 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.577 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.0 Cg_endo -67.24 120.62 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.495 1.261 . . . . 0.0 110.943 -179.199 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.727 HG22 ' HB2' ' A' ' 327' ' ' ASN . 30.7 m -68.24 -123.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.488 -0.757 . . . . 0.0 110.143 -179.922 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.481 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -104.74 -18.1 14.39 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.776 -1.202 . . . . 0.0 110.67 -179.734 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.591 ' H ' HG23 ' A' ' 324' ' ' VAL . 19.7 p-90 -126.73 3.53 6.73 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.93 -1.106 . . . . 0.0 110.539 -179.994 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.727 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.6 t30 -110.92 34.76 3.83 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.141 -0.975 . . . . 0.0 110.646 -179.429 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.531 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -114.22 2.8 14.94 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.158 -0.964 . . . . 0.0 109.636 179.54 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -68.85 -153.4 0.58 Allowed Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 179.888 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.9 Cg_endo -69.24 -50.45 0.52 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.906 1.477 . . . . 0.0 109.863 179.974 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.56 116.66 31.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -0.839 . . . . 0.0 110.34 179.779 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -130.34 113.62 14.6 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.271 -0.893 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.463 HG23 ' HA ' ' A' ' 283' ' ' THR . 57.2 m -105.73 149.84 26.05 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.175 -0.953 . . . . 0.0 110.37 -179.966 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.811 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 8.3 p90 -154.73 170.74 20.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.408 -0.808 . . . . 0.0 108.905 179.67 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.542 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.71 149.73 21.62 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.057 -179.3 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.92 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -136.15 147.98 47.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.496 -1.002 . . . . 0.0 110.019 179.573 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.92 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.65 122.49 68.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 120.997 -1.065 . . . . 0.0 109.925 179.501 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.729 HG21 ' CD2' ' A' ' 298' ' ' LEU . 2.1 t -96.55 150.23 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.082 -1.011 . . . . 0.0 110.003 -179.968 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -119.1 132.36 56.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.437 -0.789 . . . . 0.0 109.946 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.462 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.57 -149.38 8.94 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.499 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 47.3 Cg_endo -76.52 116.77 4.38 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 124.071 1.564 . . . . 0.0 110.735 179.894 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.536 ' HB3' ' HA2' ' A' ' 275' ' ' GLY . 1.7 pm0 -37.41 158.49 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.502 -0.748 . . . . 0.0 110.99 -179.887 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.489 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 94.86 60.55 1.07 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 -179.89 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.489 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 39.2 m-20 59.27 127.61 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.567 -0.961 . . . . 0.0 109.629 -179.406 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.691 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.5 OUTLIER -128.3 24.15 5.92 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.767 -1.208 . . . . 0.0 110.575 -179.681 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.5 p -130.02 126.74 62.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.386 -0.821 . . . . 0.0 109.667 179.106 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.1 mt-10 -62.85 -38.43 90.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 111.106 -179.072 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.457 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.7 pt-20 -176.86 158.9 1.68 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 110.897 -179.479 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.811 HG12 HG13 ' A' ' 296' ' ' VAL . 14.7 mt -123.42 103.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.143 -0.973 . . . . 0.0 110.03 179.627 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.0 145.58 31.18 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.306 -0.871 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.07 128.36 55.85 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.308 179.693 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.461 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 13.9 tt0 -138.61 120.86 15.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.875 179.689 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.84 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -90.81 93.82 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.092 -1.005 . . . . 0.0 110.026 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.403 ' OD1' ' HB3' ' A' ' 291' ' ' ASP . 5.7 m-20 46.34 26.38 0.47 Allowed 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.909 -0.495 . . . . 0.0 110.797 179.923 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 135.66 -29.66 2.85 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.658 179.398 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.485 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 58.7 mm-40 -89.06 110.18 20.93 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.911 -1.347 . . . . 0.0 110.65 -179.442 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.858 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.9 p -74.13 140.36 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.255 -0.903 . . . . 0.0 109.917 179.408 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.858 HD13 ' O ' ' A' ' 357' ' ' VAL . 9.7 mm . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.114 -0.991 . . . . 0.0 110.234 -179.752 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -74.57 -178.42 4.02 Favored 'Trans proline' 0 C--N 1.306 -1.706 0 O-C-N 124.073 1.565 . . . . 0.0 110.48 179.993 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 11.9 t -60.04 142.03 54.7 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.394 -0.816 . . . . 0.0 110.309 179.836 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 96.6 m -121.99 133.29 24.26 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.229 -0.919 . . . . 0.0 110.22 179.88 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.33 145.52 38.58 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.968 1.51 . . . . 0.0 110.364 179.83 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.726 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.1 p -86.58 146.83 42.5 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.279 -0.888 . . . . 0.0 110.125 -179.985 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.726 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.6 Cg_endo -73.57 150.23 45.32 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 O-C-N 124.153 1.607 . . . . 0.0 110.065 179.681 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.714 HG12 ' O ' ' A' ' 263' ' ' VAL . 90.3 t -122.51 30.03 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.262 -0.899 . . . . 0.0 110.301 -179.863 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.411 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 0.4 OUTLIER 179.83 139.73 0.12 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.268 -0.895 . . . . 0.0 110.558 -179.99 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 59.9 -172.56 5.31 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.635 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.542 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.43 164.69 29.19 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.402 -1.057 . . . . 0.0 109.841 179.933 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.858 HD22 ' N ' ' A' ' 268' ' ' GLU . 1.6 tm? -161.04 135.37 7.13 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.124 -179.436 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.858 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -132.31 144.25 50.44 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.175 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.795 HG13 ' O ' ' A' ' 281' ' ' ASP . 49.9 t -135.58 140.95 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.689 -1.257 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.47 156.7 41.72 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.734 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.761 HG13 ' O ' ' A' ' 279' ' ' GLU . 94.4 t -143.31 146.93 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.391 -1.443 . . . . 0.0 112.162 -179.338 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.534 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.94 113.8 8.79 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.084 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.471 ' OD2' ' O ' ' A' ' 343' ' ' GLY . 2.3 m-20 -97.52 148.84 22.83 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.002 -1.061 . . . . 0.0 111.339 -178.818 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.1 p90 -133.74 17.68 3.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.487 -0.758 . . . . 0.0 109.942 179.417 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.37 -57.04 3.9 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.711 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -72.78 -17.12 61.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -1.164 . . . . 0.0 110.226 -179.827 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.543 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.14 -178.04 47.31 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.49 -1.338 . . . . 0.0 109.981 179.876 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.528 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -138.35 141.23 39.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.388 -1.066 . . . . 0.0 110.125 -179.898 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.761 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.8 mt-10 -93.01 147.21 23.03 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.294 -0.879 . . . . 0.0 110.0 -179.838 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.6 m-85 -139.13 84.54 2.01 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.406 -0.809 . . . . 0.0 110.444 -179.581 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.795 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -66.26 150.68 48.44 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.525 -0.734 . . . . 0.0 109.736 179.419 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.767 HG11 HG11 ' A' ' 294' ' ' VAL . 3.2 t -146.47 89.37 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.392 -0.818 . . . . 0.0 110.019 -179.555 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.862 HG23 ' OG1' ' A' ' 333' ' ' THR . 26.2 m -86.04 126.15 33.95 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 109.342 179.601 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.12 152.18 29.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.119 -0.988 . . . . 0.0 110.929 -178.894 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.898 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.1 m120 -131.39 134.73 46.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.731 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.954 HD13 ' HB2' ' A' ' 290' ' ' TYR . 17.2 mt -142.72 162.04 36.51 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.871 -1.143 . . . . 0.0 110.332 -179.846 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.68 34.94 0.71 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.29 -0.881 . . . . 0.0 109.984 179.731 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 144.98 -128.08 3.08 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.825 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.48 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.6 mm-40 -106.25 108.0 19.28 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.033 -1.275 . . . . 0.0 110.969 -179.621 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.954 ' HB2' HD13 ' A' ' 286' ' ' LEU . 8.4 m-85 -127.02 134.76 50.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.336 -0.853 . . . . 0.0 109.493 179.523 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.864 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.0 t70 -73.85 96.37 2.58 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.808 -1.183 . . . . 0.0 108.785 179.02 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.864 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.0 p-90 -98.66 109.26 22.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 111.36 -178.853 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.837 HG22 ' CG2' ' A' ' 320' ' ' ILE . 2.8 m -100.82 115.65 30.83 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.769 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.874 HG21 ' HE2' ' A' ' 334' ' ' PHE . 6.6 t -96.59 111.01 25.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.132 -0.98 . . . . 0.0 110.83 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.439 ' HB3' ' HE3' ' A' ' 295' ' ' LYS . 2.9 ttpp -87.87 145.32 26.12 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.459 -0.776 . . . . 0.0 109.346 179.118 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.829 HG13 HG12 ' A' ' 349' ' ' ILE . 84.6 t -145.4 107.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.153 -0.967 . . . . 0.0 110.452 -179.439 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.584 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.1 mmtt -70.33 133.06 46.58 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.194 -0.941 . . . . 0.0 109.773 179.806 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.947 HD13 ' HA ' ' A' ' 303' ' ' THR . 72.4 mt -87.43 157.83 19.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.441 -0.787 . . . . 0.0 111.731 -178.735 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.822 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -64.95 176.95 0.68 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.6 -0.688 . . . . 0.0 109.571 179.237 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.822 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.6 Cg_endo -68.1 82.47 0.48 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.62 1.327 . . . . 0.0 110.001 179.628 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.7 22.62 5.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.38 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.891 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -110.48 144.7 38.89 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.357 -1.084 . . . . 0.0 110.227 -179.747 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.947 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.5 p -147.57 146.12 29.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 110.391 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.731 HG21 HG11 ' A' ' 319' ' ' VAL . 77.8 t -73.11 125.73 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.374 -0.829 . . . . 0.0 110.101 179.896 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.63 -15.8 5.72 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.44 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.3 OUTLIER -144.73 126.99 15.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.207 -1.173 . . . . 0.0 110.837 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.541 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -149.69 173.46 13.66 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.361 -0.837 . . . . 0.0 109.835 179.531 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.419 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -163.54 158.06 20.33 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.797 -1.189 . . . . 0.0 111.713 -179.761 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 1.2 m 58.87 26.32 14.73 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.292 0.568 . . . . 0.0 111.052 179.575 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.618 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.87 141.47 0.61 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 110.089 179.405 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.5 m120 -77.09 117.76 18.96 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.017 -1.052 . . . . 0.0 109.35 179.61 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.618 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.2 ttpt -86.21 133.16 33.86 Favored 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.719 0.771 . . . . 0.0 110.877 -179.355 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.577 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -115.17 172.3 7.15 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.903 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -134.75 103.12 5.5 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 110.177 -179.868 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.496 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.21 49.82 3.01 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 47.92 80.85 0.05 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.146 -1.208 . . . . 0.0 109.971 -179.947 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.79 -1.26 58.05 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.6 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.3 m-85 -141.71 179.48 6.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.464 -1.021 . . . . 0.0 109.256 179.502 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.731 HG11 HG21 ' A' ' 304' ' ' VAL . 5.2 t -154.22 153.8 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.932 . . . . 0.0 109.286 178.721 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.837 ' CG2' HG22 ' A' ' 293' ' ' THR . 78.3 mt -132.19 138.69 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.996 -1.065 . . . . 0.0 111.337 -179.536 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.5 m-85 -113.42 133.61 55.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.084 -1.01 . . . . 0.0 111.066 -179.629 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.696 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.3 p -127.74 169.19 12.99 Favored Pre-proline 0 C--N 1.3 -1.546 0 O-C-N 121.072 -1.017 . . . . 0.0 109.672 179.011 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.5 Cg_endo -66.34 117.23 4.54 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.812 1.428 . . . . 0.0 111.1 -179.22 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.599 HG22 ' HB2' ' A' ' 327' ' ' ASN . 13.3 m -62.12 -112.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.455 -0.778 . . . . 0.0 110.059 179.872 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.468 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -114.46 -19.38 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 179.873 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.46 ' H ' HG23 ' A' ' 324' ' ' VAL . 7.9 p-90 -122.48 -17.96 6.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.232 -0.917 . . . . 0.0 110.287 -179.904 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.734 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 4.5 t30 -83.9 46.47 1.19 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 0.0 110.066 -179.885 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.5 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.61 -11.95 7.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.393 -0.817 . . . . 0.0 109.783 -179.933 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.49 -163.77 0.02 OUTLIER Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.735 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 330' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.13 2.24 5.75 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 124.07 1.563 . . . . 0.0 110.625 179.9 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.8 m -159.61 114.98 2.43 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.619 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.734 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.76 128.23 26.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.136 -0.978 . . . . 0.0 110.13 -179.767 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.862 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.0 m -117.27 148.9 41.26 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.151 -0.968 . . . . 0.0 110.496 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.874 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.8 p90 -150.4 169.2 22.0 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.448 -0.782 . . . . 0.0 108.952 179.796 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -145.48 158.66 27.73 Favored Glycine 0 N--CA 1.489 2.21 0 C-N-CA 118.737 -1.697 . . . . 0.0 110.128 -179.704 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.95 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -145.03 148.18 33.43 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.521 -0.988 . . . . 0.0 109.876 179.397 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.95 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.48 120.19 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.839 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.891 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.7 t -97.89 149.37 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.264 -0.897 . . . . 0.0 110.266 -179.749 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.514 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.6 m120 -118.96 131.36 56.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.398 -0.814 . . . . 0.0 110.396 -179.776 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.38 -124.33 0.92 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 179.869 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.539 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 39.9 Cg_endo -65.71 -162.19 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.601 0 O-C-N 123.754 1.397 . . . . 0.0 110.448 179.702 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.48 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 0.7 OUTLIER -123.78 127.9 48.77 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.236 -0.915 . . . . 0.0 110.642 -179.199 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.471 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 111.35 -75.17 0.21 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.867 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -119.56 127.99 53.5 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.311 -1.111 . . . . 0.0 108.943 179.13 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.642 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -129.22 9.67 5.7 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.821 -1.174 . . . . 0.0 110.757 -179.353 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 7.2 p -132.46 119.66 39.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.305 -0.872 . . . . 0.0 110.148 179.335 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.558 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.87 -44.71 50.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.874 . . . . 0.0 110.151 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.83 158.49 1.64 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.287 -0.883 . . . . 0.0 110.524 -179.967 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.829 HG12 HG13 ' A' ' 296' ' ' VAL . 35.5 mt -118.89 104.85 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.198 -0.939 . . . . 0.0 110.04 179.521 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.03 138.76 43.74 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -0.873 . . . . 0.0 110.325 -179.921 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.33 133.43 42.74 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.229 179.832 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 28.6 tt0 -139.24 108.83 6.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.192 -0.942 . . . . 0.0 110.262 179.985 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.864 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.64 108.62 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.932 -1.105 . . . . 0.0 109.816 179.447 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.42 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.2 m-20 40.45 33.14 0.16 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.688 -0.633 . . . . 0.0 110.474 -179.724 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 115.29 -22.33 12.25 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.842 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.47 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 0.1 OUTLIER -79.77 104.41 10.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.148 -1.207 . . . . 0.0 110.139 179.988 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.2 p -74.5 109.9 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 110.358 -179.775 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.582 ' HB ' HD13 ' A' ' 351' ' ' LEU . 23.0 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.199 179.86 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 036 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -74.57 -178.32 3.95 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.078 1.567 . . . . 0.0 110.597 -179.833 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 14.1 t -58.83 145.41 40.96 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.473 -0.767 . . . . 0.0 110.33 179.977 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.9 m -102.39 125.14 37.12 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.187 -0.946 . . . . 0.0 110.041 179.892 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.57 150.37 51.09 Favored 'Trans proline' 0 C--N 1.307 -1.627 0 O-C-N 123.792 1.417 . . . . 0.0 110.408 -179.919 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.723 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -66.04 147.07 98.99 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 110.081 -179.986 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.723 ' HD2' HG23 ' A' ' 261' ' ' VAL . 44.4 Cg_endo -71.45 157.2 56.99 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.996 1.524 . . . . 0.0 110.469 -179.994 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.51 ' O ' ' CB ' ' A' ' 264' ' ' SER . 15.5 t -119.03 22.75 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.884 . . . . 0.0 110.45 -179.794 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.51 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 167.49 159.39 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.278 -0.889 . . . . 0.0 110.498 179.923 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 53.25 -177.94 0.15 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 179.554 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -138.76 164.86 28.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -1.075 . . . . 0.0 110.234 179.958 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.88 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -160.59 133.9 6.7 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.066 -179.703 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.84 ' N ' HD22 ' A' ' 267' ' ' LEU . 3.0 mp0 -131.35 146.72 52.4 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.175 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.824 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -139.99 145.66 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.587 -1.321 . . . . 0.0 111.551 -178.966 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.97 157.59 44.8 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.203 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 279' ' ' GLU . 76.5 t -143.77 147.06 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.413 -1.429 . . . . 0.0 112.18 -179.175 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.541 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.63 111.12 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.594 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -96.29 147.87 23.34 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.982 -1.074 . . . . 0.0 111.179 -179.101 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.836 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.8 p90 -133.05 16.68 4.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.497 -0.752 . . . . 0.0 110.096 179.388 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.567 ' O ' ' NE2' ' A' ' 342' ' ' GLN . . . 92.0 -60.28 2.72 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.694 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.481 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 22.9 t -71.03 -17.73 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -1.178 . . . . 0.0 110.293 -179.864 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.541 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.45 179.4 47.51 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.315 -1.422 . . . . 0.0 110.148 179.926 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.592 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -135.82 140.38 44.18 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.39 -1.065 . . . . 0.0 110.168 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.657 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.5 mt-10 -93.11 147.06 23.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.734 -179.936 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 93.7 m-85 -140.64 87.77 2.15 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.202 -0.937 . . . . 0.0 110.383 -179.615 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.824 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.16 150.05 46.91 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.436 -0.79 . . . . 0.0 109.854 179.573 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.748 HG11 HG11 ' A' ' 294' ' ' VAL . 3.6 t -143.21 90.35 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.409 -0.807 . . . . 0.0 109.87 -179.61 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.855 HG23 ' OG1' ' A' ' 333' ' ' THR . 10.6 m -86.49 122.45 30.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.995 . . . . 0.0 109.6 179.745 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.22 149.95 29.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.205 -0.934 . . . . 0.0 110.801 -179.166 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.916 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -129.67 132.4 46.67 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.281 -0.887 . . . . 0.0 110.324 -179.557 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 1.039 HD13 ' HB2' ' A' ' 290' ' ' TYR . 16.4 mt -142.7 159.88 41.37 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.107 . . . . 0.0 109.859 179.458 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -87.86 32.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 110.154 -179.952 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.504 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 150.97 -134.11 4.56 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 8.7 mm-40 -101.52 106.95 18.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.253 -1.145 . . . . 0.0 110.476 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 1.039 ' HB2' HD13 ' A' ' 286' ' ' LEU . 7.2 m-85 -126.17 130.4 50.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.372 -0.83 . . . . 0.0 109.185 179.588 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.811 ' O ' HG23 ' A' ' 353' ' ' ILE . 24.7 m-20 -68.67 96.93 0.76 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.718 -1.239 . . . . 0.0 109.291 179.576 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.949 ' CE3' HD13 ' A' ' 284' ' ' LEU . 60.7 p-90 -100.51 114.26 27.73 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.139 -0.976 . . . . 0.0 110.776 -179.424 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.718 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.9 m -109.34 114.57 28.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.528 -0.732 . . . . 0.0 109.325 179.495 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.812 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.78 111.6 27.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.075 -1.016 . . . . 0.0 110.752 -179.198 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.634 ' HA ' HD13 ' A' ' 320' ' ' ILE . 32.7 ttpt -91.41 141.03 29.19 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.328 -0.857 . . . . 0.0 109.362 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.647 HG13 HG12 ' A' ' 349' ' ' ILE . 71.8 t -137.54 112.27 9.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.262 -0.899 . . . . 0.0 110.564 -179.311 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.6 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 10.4 mmtp -71.72 131.53 43.25 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.183 -0.948 . . . . 0.0 109.308 179.454 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.985 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.1 mt -83.53 161.45 21.22 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.282 -0.886 . . . . 0.0 111.889 -178.658 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.908 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.16 176.99 0.84 Allowed Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.686 -0.634 . . . . 0.0 109.77 179.354 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.807 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.9 Cg_endo -67.43 80.2 0.43 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.615 1.324 . . . . 0.0 109.79 179.288 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.2 19.88 6.95 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.377 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.908 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -101.33 156.37 17.49 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.365 -1.079 . . . . 0.0 110.351 -179.759 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.985 ' HA ' HD13 ' A' ' 298' ' ' LEU . 74.3 p -156.85 144.19 18.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.92 . . . . 0.0 110.474 179.93 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.755 HG21 HG11 ' A' ' 319' ' ' VAL . 30.1 t -71.1 133.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.353 -0.842 . . . . 0.0 110.123 179.784 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.17 -42.11 0.78 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.706 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.61 136.41 46.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.108 -1.231 . . . . 0.0 110.998 -179.554 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.524 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.9 p90 -149.08 174.99 11.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.413 -0.805 . . . . 0.0 109.693 179.469 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.499 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.57 159.29 21.71 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.041 -1.037 . . . . 0.0 111.136 -179.751 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.555 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 58.57 23.81 11.28 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.561 -0.712 . . . . 0.0 111.077 179.668 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.667 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 140.92 0.61 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 110.262 179.494 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.539 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.4 m120 -79.45 124.64 28.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.022 -1.049 . . . . 0.0 109.053 179.387 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.596 ' CD ' HG11 ' A' ' 304' ' ' VAL . 6.2 ttpt -91.85 133.18 35.88 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.796 0.808 . . . . 0.0 111.199 -179.148 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.532 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.51 175.43 5.57 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.61 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.453 ' HG2' HG22 ' A' ' 319' ' ' VAL . 1.2 mm-40 -135.77 103.6 5.47 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.251 -0.906 . . . . 0.0 110.286 -179.975 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -90.07 47.57 3.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.828 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 m120 51.9 82.62 0.06 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.343 -1.093 . . . . 0.0 110.416 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.29 1.43 60.91 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.797 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -143.32 -168.37 2.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -1.027 . . . . 0.0 109.102 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 318' ' ' TYR . 6.8 t -162.52 158.21 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.325 -0.859 . . . . 0.0 109.832 178.964 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.634 HD13 ' HA ' ' A' ' 295' ' ' LYS . 21.6 mm -127.88 148.44 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.096 -1.003 . . . . 0.0 111.114 -179.717 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.632 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 84.8 m-85 -124.85 127.02 46.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.235 -0.916 . . . . 0.0 109.836 179.116 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.718 ' CG2' HG23 ' A' ' 293' ' ' THR . 3.2 p -126.76 168.77 13.56 Favored Pre-proline 0 C--N 1.301 -1.533 0 C-N-CA 119.068 -1.053 . . . . 0.0 110.307 179.984 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.8 Cg_endo -66.05 116.09 3.81 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.84 1.442 . . . . 0.0 111.056 -179.448 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.608 HG22 ' HB2' ' A' ' 327' ' ' ASN . 16.0 m -63.18 -115.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.335 -0.853 . . . . 0.0 109.839 179.865 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.489 ' N ' HG23 ' A' ' 324' ' ' VAL . 73.6 m -118.18 -13.31 9.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.797 -1.189 . . . . 0.0 110.295 179.933 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.573 ' H ' HG23 ' A' ' 324' ' ' VAL . 18.6 p-90 -127.76 -3.36 5.93 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 0.0 110.411 -179.932 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.608 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.99 41.59 1.32 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.269 -0.894 . . . . 0.0 110.31 -179.72 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.492 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -115.91 -9.26 11.83 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 179.825 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.81 -161.73 0.02 OUTLIER Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.607 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.504 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.5 Cg_endo -74.37 4.77 4.12 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 O-C-N 123.992 1.522 . . . . 0.0 111.097 -179.837 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 6.6 m -163.96 114.99 1.33 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.842 179.741 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.0 127.45 28.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.185 -0.947 . . . . 0.0 110.267 -179.774 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.855 ' OG1' HG23 ' A' ' 283' ' ' THR . 91.3 m -115.3 137.51 51.96 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.915 . . . . 0.0 110.308 -179.95 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.812 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.9 p90 -138.87 174.95 9.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.303 -0.873 . . . . 0.0 109.014 179.568 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.524 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.31 156.87 26.94 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 119.034 -1.555 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.947 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -144.37 149.09 35.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.594 -0.945 . . . . 0.0 109.689 179.445 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.947 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.47 117.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.078 -1.014 . . . . 0.0 109.833 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.759 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -96.77 152.05 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -0.871 . . . . 0.0 110.204 -179.598 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.491 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -122.78 134.59 54.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.409 -0.807 . . . . 0.0 109.88 179.866 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.21 -122.72 0.83 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 179.951 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.52 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.3 Cg_endo -69.74 -166.83 0.2 Allowed 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.837 1.44 . . . . 0.0 110.477 -179.806 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.567 ' NE2' ' O ' ' A' ' 275' ' ' GLY . 7.7 mp0 -112.68 134.76 54.04 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.318 -0.864 . . . . 0.0 110.366 -179.696 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.43 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 101.59 -88.66 0.72 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 -179.92 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -104.28 132.79 50.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.319 -1.106 . . . . 0.0 109.308 179.376 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.817 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.0 OUTLIER -130.49 7.14 4.87 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 120.916 -1.115 . . . . 0.0 110.8 -179.558 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.595 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.9 p -132.55 116.94 29.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.231 -0.918 . . . . 0.0 109.938 179.561 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.529 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -45.3 -46.1 12.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.021 -1.049 . . . . 0.0 110.116 -179.604 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.418 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.3 pt-20 -177.12 158.5 1.52 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 110.473 179.979 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.647 HG12 HG13 ' A' ' 296' ' ' VAL . 27.3 mt -116.32 117.86 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.24 -0.912 . . . . 0.0 110.216 179.677 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.88 145.42 47.67 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.162 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.63 133.67 51.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.015 -1.053 . . . . 0.0 110.679 179.903 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -138.82 112.88 8.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.371 -0.83 . . . . 0.0 109.901 179.617 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.811 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.55 94.04 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.979 -1.075 . . . . 0.0 110.051 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.45 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 3.3 m-20 50.68 31.23 5.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.699 -0.626 . . . . 0.0 110.704 179.981 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.65 -26.06 6.36 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.683 -1.246 . . . . 0.0 110.45 179.351 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.475 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 41.7 mm-40 -85.92 103.66 14.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.045 -1.267 . . . . 0.0 110.499 -179.576 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.67 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.3 p -73.6 116.47 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.265 -0.897 . . . . 0.0 110.162 179.891 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.564 HG23 ' HB2' ' A' ' 262' ' ' PRO . 36.9 mm . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.24 -179.992 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -75.69 -178.16 4.11 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.978 1.514 . . . . 0.0 110.569 179.976 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 2.1 t -78.17 146.38 35.07 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.406 -0.809 . . . . 0.0 110.279 179.989 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 2.4 m -134.77 93.84 17.45 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.121 -0.987 . . . . 0.0 110.483 179.986 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -74.85 161.18 39.58 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.13 1.595 . . . . 0.0 110.111 179.787 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.597 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -106.8 143.53 27.25 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.159 -0.963 . . . . 0.0 110.307 -179.985 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.597 ' HD2' HG23 ' A' ' 261' ' ' VAL . 45.8 Cg_endo -74.79 133.64 17.19 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 O-C-N 124.106 1.582 . . . . 0.0 110.352 179.911 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.579 HG12 ' O ' ' A' ' 263' ' ' VAL . 41.5 t -120.11 29.35 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.258 -0.901 . . . . 0.0 110.201 179.899 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.437 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 1.4 t -178.69 132.24 0.13 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.197 -0.939 . . . . 0.0 110.492 -179.975 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 64.19 179.0 6.0 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 179.807 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.545 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.28 163.61 28.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.428 -1.042 . . . . 0.0 109.511 179.628 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.865 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.28 134.73 6.54 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 111.736 -179.611 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.832 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.0 mt-10 -130.38 149.61 51.99 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.975 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.75 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.6 t -141.3 141.23 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.628 -1.295 . . . . 0.0 111.684 -179.306 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -126.81 157.99 37.78 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.908 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.658 HG13 ' O ' ' A' ' 279' ' ' GLU . 89.0 t -144.02 146.39 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.333 -1.479 . . . . 0.0 112.193 -179.325 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.517 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.16 110.87 6.47 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.005 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 46.1 p30 -96.15 147.82 23.35 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.163 -0.961 . . . . 0.0 111.378 -178.493 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.809 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.4 p90 -134.95 23.65 3.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.586 -0.696 . . . . 0.0 109.884 179.42 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.476 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 82.97 -66.96 3.84 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 276' ' ' SER . . . . . 0.54 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 9.2 m -59.85 -26.35 65.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.197 -1.178 . . . . 0.0 110.615 -179.881 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.562 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -170.96 -177.8 41.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.972 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.554 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.22 144.07 42.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.244 -1.15 . . . . 0.0 110.18 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.658 ' O ' HG13 ' A' ' 271' ' ' VAL . 6.3 mt-10 -97.41 147.43 24.22 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.385 -0.822 . . . . 0.0 109.967 -179.523 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.745 ' CE2' HG11 ' A' ' 346' ' ' VAL . 91.1 m-85 -141.43 83.89 1.89 Allowed 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.341 -0.849 . . . . 0.0 110.787 -179.344 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.75 ' O ' HG13 ' A' ' 269' ' ' VAL . 1.8 t70 -64.52 146.98 53.74 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.434 -0.791 . . . . 0.0 109.623 179.144 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.739 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 6.7 t -142.58 89.08 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 -179.647 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.721 HG23 ' OG1' ' A' ' 333' ' ' THR . 97.8 m -86.46 123.5 31.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.203 -0.935 . . . . 0.0 109.756 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.083 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.48 150.47 28.84 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.168 -0.957 . . . . 0.0 110.517 -179.525 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 2.0 m120 -129.12 135.77 49.32 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 109.958 -179.687 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 11.6 mt -143.18 160.68 39.98 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.075 -1.016 . . . . 0.0 109.481 179.564 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.76 31.76 1.76 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 110.528 -179.598 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.0 -94.6 0.13 Allowed Glycine 0 N--CA 1.491 2.312 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.425 179.876 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.5 tt0 -152.48 106.51 3.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.055 -1.262 . . . . 0.0 110.695 -179.322 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.644 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 5.0 m-85 -128.38 134.85 48.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 179.585 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.532 ' O ' HG23 ' A' ' 353' ' ' ILE . 96.7 m-20 -67.34 96.92 0.52 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.846 -1.159 . . . . 0.0 108.754 178.859 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.931 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.5 p-90 -97.68 108.89 21.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.146 -0.971 . . . . 0.0 111.166 -178.862 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.756 HG22 ' CG2' ' A' ' 320' ' ' ILE . 8.6 m -102.18 114.85 29.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.643 -0.661 . . . . 0.0 109.233 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.752 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.5 t -96.71 111.88 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.1 -1.0 . . . . 0.0 111.076 -178.964 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 6.3 ttpt -86.63 149.39 24.95 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.476 -0.765 . . . . 0.0 109.351 179.008 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.899 HG22 HG23 ' A' ' 349' ' ' ILE . 43.4 t -148.67 108.0 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.033 -1.042 . . . . 0.0 110.585 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.561 ' HD2' ' CE1' ' A' ' 318' ' ' TYR . 9.1 mmtm -71.01 134.3 47.02 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.131 -0.981 . . . . 0.0 110.044 179.781 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 0.872 HD13 ' HA ' ' A' ' 303' ' ' THR . 74.9 mt -87.5 165.56 15.42 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.331 -0.855 . . . . 0.0 111.131 -179.37 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -79.73 173.98 6.85 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 178.883 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.4 Cg_endo -66.09 84.52 0.26 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.496 1.261 . . . . 0.0 110.125 179.816 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.11 24.15 4.62 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.62 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.938 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.73 149.29 38.68 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -1.127 . . . . 0.0 110.202 -179.761 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 303' ' ' THR . . . . . 0.872 ' HA ' HD13 ' A' ' 298' ' ' LEU . 14.1 p -153.96 144.57 22.43 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.664 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.683 HG21 HG11 ' A' ' 319' ' ' VAL . 75.0 t -75.09 135.04 28.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 110.09 179.803 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -128.81 -31.33 0.65 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.707 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.5 m -126.56 109.54 12.25 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.033 -1.275 . . . . 0.0 110.92 -179.555 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.581 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 55.4 p90 -133.44 156.54 47.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.631 179.213 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.491 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -149.32 158.42 44.16 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.966 -1.084 . . . . 0.0 111.201 -179.411 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.522 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 65.46 21.12 11.82 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.741 -0.599 . . . . 0.0 111.279 179.55 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.637 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.97 150.49 1.23 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.231 -0.918 . . . . 0.0 110.516 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.608 ' OD1' HG12 ' A' ' 324' ' ' VAL . 4.5 m120 -83.62 119.25 24.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.148 -0.97 . . . . 0.0 108.979 179.134 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.581 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 6.7 ttpt -90.44 131.22 36.33 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.916 0.865 . . . . 0.0 111.407 -178.891 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.622 ' O ' HG22 ' A' ' 319' ' ' VAL . 27.9 mt-30 -112.18 178.69 4.22 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.61 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 314' ' ' GLU . . . . . 0.561 ' HG2' HG22 ' A' ' 319' ' ' VAL . 7.5 mm-40 -143.78 108.13 4.8 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.458 -0.776 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.44 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -96.53 50.65 1.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 52.48 84.7 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.315 -1.109 . . . . 0.0 110.003 -179.948 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 93.97 -2.28 68.98 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.892 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.626 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -137.19 -179.59 5.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -1.109 . . . . 0.0 109.683 179.665 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.683 HG11 HG21 ' A' ' 304' ' ' VAL . 3.8 t -157.63 155.69 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.444 -0.785 . . . . 0.0 109.421 178.771 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.756 ' CG2' HG22 ' A' ' 293' ' ' THR . 1.9 mt -131.99 140.31 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 111.674 -179.147 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 67.5 m-85 -115.74 130.17 56.75 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 110.384 179.548 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.621 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.4 p -127.97 169.96 11.41 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 120.963 -1.086 . . . . 0.0 109.57 179.657 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.525 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -66.16 126.6 16.03 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.594 1.313 . . . . 0.0 110.915 -179.301 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.885 HG22 ' HB2' ' A' ' 327' ' ' ASN . 35.4 m -77.79 -123.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.826 -179.985 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.583 ' N ' HG23 ' A' ' 324' ' ' VAL . 19.8 m -100.32 -12.98 19.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.766 -1.209 . . . . 0.0 110.586 -179.911 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.693 ' H ' HG23 ' A' ' 324' ' ' VAL . 15.3 p-90 -137.25 5.33 2.74 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.144 -0.972 . . . . 0.0 110.679 -179.887 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.885 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t30 -107.09 43.14 1.2 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.068 -1.02 . . . . 0.0 110.381 -179.639 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.495 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 1.2 pttt -126.82 -5.71 6.28 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.38 -0.825 . . . . 0.0 109.969 179.704 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.0 -156.13 0.03 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 -179.882 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.456 ' O ' ' OG1' ' A' ' 331' ' ' THR . 47.8 Cg_endo -72.23 2.5 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 124.134 1.597 . . . . 0.0 110.964 -179.89 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.9 m -165.4 121.67 1.4 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.257 -0.902 . . . . 0.0 109.946 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.93 107.94 6.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.188 -0.945 . . . . 0.0 110.45 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.721 ' OG1' HG23 ' A' ' 283' ' ' THR . 25.6 m -98.41 142.04 30.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.192 -0.943 . . . . 0.0 109.96 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.752 ' HE2' HG21 ' A' ' 294' ' ' VAL . 7.2 p90 -149.14 169.82 19.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.771 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.553 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.45 151.68 23.84 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.141 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.941 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -136.44 149.46 48.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.563 -0.963 . . . . 0.0 109.83 179.569 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.941 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -122.86 119.34 57.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.144 -0.973 . . . . 0.0 109.529 179.356 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.938 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -95.95 143.74 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.077 -1.014 . . . . 0.0 109.239 179.702 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 3.3 m120 -120.07 140.48 50.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.176 -0.953 . . . . 0.0 110.86 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 175.78 -128.82 1.43 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.817 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.488 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 44.3 Cg_endo -70.68 -153.42 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 123.739 1.389 . . . . 0.0 109.493 179.2 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.476 ' HB3' ' HA2' ' A' ' 275' ' ' GLY . 0.0 OUTLIER -130.27 143.67 50.92 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.759 -1.213 . . . . 0.0 110.021 179.357 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 98.88 71.28 1.0 Allowed Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.632 -1.787 . . . . 0.0 108.632 -179.315 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.461 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 3.3 m-20 65.76 127.97 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.482 -1.011 . . . . 0.0 109.31 -178.99 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.582 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.1 OUTLIER -129.62 15.83 5.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.056 -1.027 . . . . 0.0 110.436 -179.61 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.745 HG11 ' CE2' ' A' ' 280' ' ' TYR . 6.2 p -127.61 120.18 53.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.168 -0.957 . . . . 0.0 110.133 179.614 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.551 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 0.8 OUTLIER -48.43 -46.38 37.53 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.074 -1.016 . . . . 0.0 109.717 -179.825 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.409 ' OE1' ' HB3' ' A' ' 347' ' ' GLU . 1.6 pt-20 -176.99 158.59 1.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.351 -0.843 . . . . 0.0 110.429 179.679 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.899 HG23 HG22 ' A' ' 296' ' ' VAL . 11.3 mt -117.07 103.53 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.887 . . . . 0.0 109.793 179.675 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.61 146.45 28.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.292 -0.88 . . . . 0.0 110.306 -179.737 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.083 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -106.62 132.95 52.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.161 -0.962 . . . . 0.0 110.135 179.576 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.4 tt0 -138.53 112.69 8.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.948 179.86 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.532 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.7 mt -91.61 113.17 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.104 -0.997 . . . . 0.0 110.099 179.963 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.439 ' C ' ' O ' ' A' ' 353' ' ' ILE . 2.8 m-20 38.54 29.54 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.752 -0.592 . . . . 0.0 110.918 -179.809 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 355' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.84 -13.85 12.91 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.523 179.23 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.514 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 72.7 mm-40 -93.8 113.98 26.14 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.885 -1.362 . . . . 0.0 110.368 -179.836 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.925 ' O ' HD13 ' A' ' 358' ' ' ILE . 2.2 p -74.23 138.35 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.183 179.998 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.925 HD13 ' O ' ' A' ' 357' ' ' VAL . 19.1 mm . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.277 -179.909 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -73.23 -178.93 3.92 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 O-C-N 124.051 1.553 . . . . 0.0 110.395 179.966 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 258' ' ' THR . . . . . 0.558 HG23 ' O ' ' A' ' 258' ' ' THR . 6.1 t -58.79 125.15 22.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.205 -0.935 . . . . 0.0 110.242 -179.849 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 57.6 m -124.68 112.15 27.45 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 0.0 110.362 -179.882 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.67 155.41 54.31 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 124.025 1.54 . . . . 0.0 110.339 179.781 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 261' ' ' VAL . . . . . 0.522 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.9 p -74.89 141.99 75.94 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.345 -0.847 . . . . 0.0 110.388 -179.806 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 262' ' ' PRO . . . . . 0.522 ' HD2' HG23 ' A' ' 261' ' ' VAL . 47.9 Cg_endo -75.97 152.75 36.71 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.078 1.567 . . . . 0.0 110.131 179.705 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 263' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 263' ' ' VAL . 18.0 t -147.4 30.39 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 110.288 179.955 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 264' ' ' SER . . . . . 0.454 ' HB3' HD11 ' A' ' 358' ' ' ILE . 45.3 t -174.29 89.32 0.06 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.209 -0.932 . . . . 0.0 110.637 -179.949 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 98.88 -177.1 30.13 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 179.568 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 266' ' ' SER . . . . . 0.574 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -134.62 165.95 24.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.532 -0.981 . . . . 0.0 109.69 179.866 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 267' ' ' LEU . . . . . 0.906 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.37 139.17 9.19 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.193 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 268' ' ' GLU . . . . . 0.749 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.0 mp0 -138.02 130.38 29.16 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.542 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 269' ' ' VAL . . . . . 0.788 HG13 ' O ' ' A' ' 281' ' ' ASP . 94.9 t -124.32 138.13 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.804 -1.185 . . . . 0.0 111.681 -178.854 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 270' ' ' LYS . . . . . 0.407 ' C ' HG23 ' A' ' 271' ' ' VAL . 20.1 tttt -121.19 157.64 29.78 Favored 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.131 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 271' ' ' VAL . . . . . 0.766 HG22 ' CD1' ' A' ' 280' ' ' TYR . 86.7 t -144.15 147.07 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 120.404 -1.435 . . . . 0.0 112.531 -179.049 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 272' ' ' ASN . . . . . 0.528 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -141.35 109.98 6.04 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.864 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 273' ' ' ASP . . . . . 0.51 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 m-20 -94.82 146.71 24.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.114 -0.991 . . . . 0.0 111.535 -178.718 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 274' ' ' TRP . . . . . 0.807 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.0 p90 -134.67 23.52 3.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.616 -0.678 . . . . 0.0 109.667 179.062 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 275' ' ' GLY . . . . . 0.542 ' HA2' ' CB ' ' A' ' 342' ' ' GLN . . . 82.39 -65.33 4.11 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.932 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.0 -23.99 65.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -1.186 . . . . 0.0 110.354 -179.929 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 277' ' ' GLY . . . . . 0.557 ' O ' ' CD2' ' A' ' 274' ' ' TRP . . . -176.57 176.43 47.87 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 278' ' ' ALA . . . . . 0.562 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -131.36 148.55 52.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.359 -1.083 . . . . 0.0 110.259 -179.879 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 279' ' ' GLU . . . . . 0.666 ' O ' HG13 ' A' ' 271' ' ' VAL . 16.3 mt-10 -97.63 147.07 24.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.513 -0.742 . . . . 0.0 109.683 -179.81 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 280' ' ' TYR . . . . . 0.766 ' CD1' HG22 ' A' ' 271' ' ' VAL . 80.1 m-85 -141.7 85.98 1.97 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.362 -0.836 . . . . 0.0 111.045 -179.242 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 281' ' ' ASP . . . . . 0.788 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -69.22 150.22 47.7 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.389 -0.82 . . . . 0.0 109.54 179.115 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 282' ' ' VAL . . . . . 0.727 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.9 t -143.86 87.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.353 -0.842 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 283' ' ' THR . . . . . 0.794 HG23 ' OG1' ' A' ' 333' ' ' THR . 98.0 m -86.68 123.44 31.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.093 -1.005 . . . . 0.0 109.885 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 284' ' ' LEU . . . . . 1.056 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.4 148.25 30.41 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.201 -0.937 . . . . 0.0 110.062 -179.66 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 285' ' ' ASN . . . . . 0.574 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 1.6 m120 -129.6 111.98 13.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.221 -0.924 . . . . 0.0 111.134 -178.742 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 286' ' ' LEU . . . . . 0.642 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 10.2 mt -121.47 158.66 27.92 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.809 -1.182 . . . . 0.0 109.407 178.982 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.97 35.62 1.25 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.201 -0.937 . . . . 0.0 110.38 -179.69 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 288' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 163.79 -103.14 0.21 Allowed Glycine 0 N--CA 1.492 2.379 0 C-N-CA 118.879 -1.629 . . . . 0.0 110.561 179.983 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 289' ' ' GLN . . . . . 0.52 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 1.7 mt-30 -148.27 120.45 8.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -1.132 . . . . 0.0 110.411 -179.343 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 290' ' ' TYR . . . . . 0.642 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -151.27 131.29 13.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.826 179.553 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 291' ' ' ASP . . . . . 0.822 ' O ' HG23 ' A' ' 353' ' ' ILE . 4.9 t70 -62.1 103.81 0.41 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.096 -1.002 . . . . 0.0 109.568 179.59 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 292' ' ' TRP . . . . . 0.912 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.9 p-90 -103.0 111.07 23.23 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.291 -0.881 . . . . 0.0 110.49 -179.758 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 293' ' ' THR . . . . . 0.703 HG23 ' CG2' ' A' ' 322' ' ' THR . 25.3 m -105.08 114.71 29.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.776 179.639 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 294' ' ' VAL . . . . . 0.783 HG22 ' CD2' ' A' ' 351' ' ' LEU . 3.1 t -97.07 110.86 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 110.077 -179.732 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 295' ' ' LYS . . . . . 0.439 ' HG3' HD13 ' A' ' 320' ' ' ILE . 21.2 ttmt -86.32 149.4 25.07 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.189 -0.945 . . . . 0.0 109.42 179.148 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 296' ' ' VAL . . . . . 0.734 HG13 HG12 ' A' ' 349' ' ' ILE . 86.3 t -145.6 107.04 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.275 -0.891 . . . . 0.0 110.749 -179.161 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 297' ' ' LYS . . . . . 0.598 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 4.4 mmtt -70.47 136.95 49.88 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.13 -0.981 . . . . 0.0 109.157 179.188 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 298' ' ' LEU . . . . . 1.011 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.8 mt -90.47 157.43 17.57 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.23 -0.919 . . . . 0.0 111.673 -178.573 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 299' ' ' ALA . . . . . 0.804 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.02 175.43 1.01 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.574 -0.704 . . . . 0.0 109.771 179.443 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 300' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -67.25 81.81 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 123.707 1.372 . . . . 0.0 110.049 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.76 19.14 7.5 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.54 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 302' ' ' ALA . . . . . 0.804 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 144.2 34.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.414 -1.051 . . . . 0.0 110.026 -179.812 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 303' ' ' THR . . . . . 1.011 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.4 p -145.09 145.04 31.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.137 -0.977 . . . . 0.0 110.886 -179.985 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 304' ' ' VAL . . . . . 0.801 ' CG2' HG21 ' A' ' 319' ' ' VAL . 75.4 t -70.39 142.41 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.46 -0.775 . . . . 0.0 109.96 179.697 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.65 -40.68 0.2 Allowed Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.663 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 306' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -120.76 118.69 30.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.051 -1.264 . . . . 0.0 110.631 -179.599 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 307' ' ' PHE . . . . . 0.558 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.7 p90 -141.86 156.78 45.52 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.255 -0.903 . . . . 0.0 109.641 179.671 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 308' ' ' TRP . . . . . 0.485 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.83 158.72 42.62 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.087 -1.008 . . . . 0.0 111.188 -179.206 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 309' ' ' SER . . . . . 0.489 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 60.47 25.43 15.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.592 -0.692 . . . . 0.0 110.926 179.611 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 310' ' ' ALA . . . . . 0.61 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.61 142.24 0.71 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.183 -0.948 . . . . 0.0 110.282 179.679 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 311' ' ' ASN . . . . . 0.542 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 4.0 m120 -77.21 123.74 26.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.115 -0.991 . . . . 0.0 109.296 179.355 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 312' ' ' LYS . . . . . 0.558 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 1.7 ttpt -94.5 123.4 37.9 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.555 0.693 . . . . 0.0 110.95 -179.341 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 313' ' ' GLN . . . . . 0.647 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 6.5 mt-30 -109.65 177.21 4.8 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.549 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -136.28 99.69 4.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.468 -0.77 . . . . 0.0 110.129 179.939 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.58 41.3 3.08 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.777 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.8 t30 58.31 83.98 0.11 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.155 -1.203 . . . . 0.0 110.158 179.981 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 317' ' ' GLY . . . . . 0.612 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.14 3.99 63.22 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 318' ' ' TYR . . . . . 0.786 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.47 -169.87 3.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.398 -1.06 . . . . 0.0 108.988 179.54 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 319' ' ' VAL . . . . . 0.801 HG21 ' CG2' ' A' ' 304' ' ' VAL . 12.8 t -161.44 149.98 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 0.0 109.843 179.147 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 320' ' ' ILE . . . . . 0.647 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 8.7 mm -114.76 151.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 120.937 -1.102 . . . . 0.0 110.836 -179.946 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.8 m-85 -130.06 115.68 17.45 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.166 -0.959 . . . . 0.0 109.963 178.977 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 322' ' ' THR . . . . . 0.703 ' CG2' HG23 ' A' ' 293' ' ' THR . 24.7 p -122.23 167.0 15.02 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 120.728 -1.232 . . . . 0.0 109.654 179.551 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 323' ' ' PRO . . . . . 0.526 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.1 Cg_endo -64.81 120.05 7.22 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.803 1.423 . . . . 0.0 110.893 -179.362 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 324' ' ' VAL . . . . . 0.658 HG22 ' HB2' ' A' ' 327' ' ' ASN . 28.9 m -63.31 -126.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.498 -0.751 . . . . 0.0 110.149 -179.873 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 325' ' ' SER . . . . . 0.496 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -101.09 -20.78 15.2 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.847 -1.158 . . . . 0.0 110.869 -179.585 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 326' ' ' TRP . . . . . 0.581 ' H ' HG23 ' A' ' 324' ' ' VAL . 23.9 p-90 -124.57 -1.68 7.99 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.998 -1.063 . . . . 0.0 110.699 -179.753 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 327' ' ' ASN . . . . . 0.658 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.7 t30 -104.7 44.52 1.02 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.107 -0.996 . . . . 0.0 110.614 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 328' ' ' LYS . . . . . 0.447 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -126.13 10.86 7.55 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.055 -1.028 . . . . 0.0 109.961 179.704 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 329' ' ' GLY . . . . . 0.452 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -73.89 -143.37 0.73 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.615 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 330' ' ' PRO . . . . . 0.554 ' O ' ' N ' ' A' ' 286' ' ' LEU . 43.7 Cg_endo -72.75 -56.15 0.09 OUTLIER 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.463 . . . . 0.0 109.756 179.602 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 7.2 m -107.94 126.43 52.69 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.177 -0.952 . . . . 0.0 110.204 179.76 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 332' ' ' ALA . . . . . 0.43 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -138.66 109.48 6.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.379 -0.826 . . . . 0.0 109.945 179.902 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 333' ' ' THR . . . . . 0.794 ' OG1' HG23 ' A' ' 283' ' ' THR . 8.8 m -100.81 145.33 28.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.432 -179.715 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 334' ' ' PHE . . . . . 0.727 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 10.1 p90 -151.54 174.92 12.85 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.552 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 335' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.9 165.45 31.13 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 118.838 -1.648 . . . . 0.0 110.518 -179.319 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 336' ' ' PHE . . . . . 0.868 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -152.27 143.58 23.3 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.525 -0.986 . . . . 0.0 109.9 179.634 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 337' ' ' ILE . . . . . 0.868 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -117.76 125.27 74.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.064 -1.022 . . . . 0.0 109.886 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 338' ' ' VAL . . . . . 0.726 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.7 t -101.9 145.47 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.276 -0.89 . . . . 0.0 109.945 179.835 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 339' ' ' ASN . . . . . 0.496 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 3.0 m120 -113.84 126.76 55.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.344 -0.847 . . . . 0.0 110.098 179.873 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 340' ' ' GLY . . . . . 0.423 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -176.4 -147.37 6.45 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.994 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 341' ' ' PRO . . . . . 0.509 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 46.2 Cg_endo -71.33 118.38 5.64 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 124.055 1.555 . . . . 0.0 110.658 -179.732 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 342' ' ' GLN . . . . . 0.542 ' CB ' ' HA2' ' A' ' 275' ' ' GLY . 1.9 pm0 -39.91 155.78 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.389 -0.819 . . . . 0.0 110.851 -179.997 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 343' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 92.32 63.17 1.14 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.665 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 344' ' ' ASP . . . . . 0.475 ' O ' ' O ' ' A' ' 343' ' ' GLY . 16.0 t0 60.97 134.41 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.333 -1.098 . . . . 0.0 109.566 -179.751 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 345' ' ' LYS . . . . . 0.661 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.2 OUTLIER -135.05 28.92 3.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.996 -1.065 . . . . 0.0 110.809 -179.518 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 346' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 346' ' ' VAL . 12.6 p -132.5 116.93 29.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.195 -0.941 . . . . 0.0 110.245 179.632 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 347' ' ' GLU . . . . . 0.483 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -46.65 -45.39 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.895 . . . . 0.0 110.319 -179.937 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 348' ' ' GLU . . . . . 0.431 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 13.9 pt-20 -176.67 158.34 1.69 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.125 -0.984 . . . . 0.0 110.686 -179.781 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 349' ' ' ILE . . . . . 0.734 HG12 HG13 ' A' ' 296' ' ' VAL . 39.8 mt -122.31 105.94 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.121 -0.987 . . . . 0.0 109.918 179.516 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.78 143.92 35.66 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.085 -1.009 . . . . 0.0 110.283 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 351' ' ' LEU . . . . . 1.056 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.6 128.59 53.7 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.194 -0.941 . . . . 0.0 109.953 179.694 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 352' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.3 OUTLIER -138.62 119.26 14.01 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.974 . . . . 0.0 110.123 179.814 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 353' ' ' ILE . . . . . 0.822 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -92.8 109.7 21.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.16 -0.963 . . . . 0.0 110.271 179.934 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 354' ' ' ASN . . . . . 0.442 ' C ' ' O ' ' A' ' 353' ' ' ILE . 4.4 m-20 38.27 46.36 0.88 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.592 . . . . 0.0 111.202 -179.979 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.37 -36.24 4.38 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.385 179.246 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 356' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 38.3 mm-40 -66.88 176.07 2.2 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.012 -1.287 . . . . 0.0 110.311 -179.587 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 357' ' ' VAL . . . . . 0.787 ' O ' HD13 ' A' ' 358' ' ' ILE . 5.6 p -140.65 129.82 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.305 -0.872 . . . . 0.0 109.969 -179.955 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 358' ' ' ILE . . . . . 0.787 HD13 ' O ' ' A' ' 357' ' ' VAL . 8.3 mm . . . . . 0 N--CA 1.494 1.726 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.303 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.214 0 N-CA-C 110.122 -1.191 . . . . 0.0 110.122 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.559 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.78 158.58 44.05 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.473 -1.016 . . . . 0.0 109.699 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.575 HD12 ' CG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -153.02 123.89 7.38 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.08 -1.012 . . . . 0.0 110.749 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.473 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 3.3 mt-10 -122.05 113.72 19.93 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.903 HG13 ' O ' ' A' ' 281' ' ' ASP . 47.5 t -108.11 145.8 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.957 -1.089 . . . . 0.0 111.734 -178.513 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 5.5 mttp -130.16 156.91 43.8 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.646 HG13 ' O ' ' A' ' 279' ' ' GLU . 75.4 t -144.75 139.44 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.407 -1.433 . . . . 0.0 111.647 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.529 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -134.52 110.89 9.66 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.174 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.9 m-20 -98.72 135.42 40.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.939 -1.101 . . . . 0.0 111.71 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.812 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.6 p90 -119.75 20.15 12.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.507 -0.746 . . . . 0.0 109.209 178.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . 0.405 ' O ' ' NZ ' ' A' ' 345' ' ' LYS . . . 87.06 -77.97 1.93 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 32.0 m -51.22 -24.63 4.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.366 -1.079 . . . . 0.0 110.465 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.541 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -165.62 174.28 41.35 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.298 -1.429 . . . . 0.0 110.311 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.558 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -133.58 141.77 47.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.46 -1.024 . . . . 0.0 110.028 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.646 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.3 mt-10 -97.66 146.65 25.12 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.325 -0.859 . . . . 0.0 109.915 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 94.4 m-85 -141.84 85.24 1.93 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.442 -0.786 . . . . 0.0 110.405 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.903 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -69.6 154.21 42.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.864 . . . . 0.0 109.997 179.498 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.613 HG11 HG11 ' A' ' 294' ' ' VAL . 4.2 t -145.03 89.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 O-C-N 121.629 -0.669 . . . . 0.0 109.506 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.898 HG23 ' OG1' ' A' ' 333' ' ' THR . 10.5 m -86.08 117.48 24.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.126 -0.984 . . . . 0.0 109.626 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.023 HD21 HD11 ' A' ' 351' ' ' LEU . 0.9 OUTLIER -106.25 144.08 33.45 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.202 -0.936 . . . . 0.0 110.766 -179.07 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.559 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.5 OUTLIER -126.65 115.9 20.18 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.604 -0.685 . . . . 0.0 109.825 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.599 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 11.0 mt -124.9 155.21 39.9 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.633 -1.292 . . . . 0.0 110.262 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -89.8 34.87 0.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.195 -0.94 . . . . 0.0 110.105 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 161.57 -157.44 29.12 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.518 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.2 OUTLIER -96.42 93.62 6.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -1.118 . . . . 0.0 110.706 -179.663 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.599 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.9 m-30 -116.36 143.09 45.99 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.218 -0.926 . . . . 0.0 110.109 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.825 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.6 m-20 -77.89 98.71 5.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.083 -1.011 . . . . 0.0 109.201 179.032 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.844 ' CE3' HD13 ' A' ' 284' ' ' LEU . 54.8 p-90 -98.31 113.32 25.23 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.286 -0.884 . . . . 0.0 110.785 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.623 HG23 ' CG2' ' A' ' 322' ' ' THR . 10.5 m -105.71 115.58 30.48 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 109.526 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.755 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -97.19 113.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.101 -0.999 . . . . 0.0 110.49 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.585 ' HA ' HD13 ' A' ' 320' ' ' ILE . 9.2 ttpt -92.5 135.09 34.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.333 -0.854 . . . . 0.0 109.599 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.758 HG13 HG12 ' A' ' 349' ' ' ILE . 95.0 t -132.26 108.05 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.064 -1.023 . . . . 0.0 110.691 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.477 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtt -70.0 134.55 48.43 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.086 -1.009 . . . . 0.0 109.178 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.967 HD13 ' HA ' ' A' ' 303' ' ' THR . 61.5 mt -88.51 162.48 16.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.181 -0.95 . . . . 0.0 111.723 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.87 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -64.37 176.77 0.65 Allowed Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.779 -0.576 . . . . 0.0 109.877 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.809 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.82 77.28 0.57 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.657 1.346 . . . . 0.0 109.903 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.43 19.73 5.71 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.87 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -103.65 150.18 24.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.415 -1.05 . . . . 0.0 110.248 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.967 ' HA ' HD13 ' A' ' 298' ' ' LEU . 27.0 p -149.92 144.36 25.85 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.267 -0.895 . . . . 0.0 110.642 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.71 HG21 HG11 ' A' ' 319' ' ' VAL . 29.5 t -67.45 136.54 26.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.356 -0.84 . . . . 0.0 109.975 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.8 -41.98 0.54 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.437 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 1.0 OUTLIER -128.94 129.96 46.14 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.134 -1.215 . . . . 0.0 110.756 -179.659 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.593 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.1 p90 -146.39 169.09 19.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.398 -0.814 . . . . 0.0 109.463 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.96 160.98 22.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.878 -1.139 . . . . 0.0 111.23 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.85 20.99 12.55 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.485 -0.759 . . . . 0.0 111.003 179.433 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.573 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 144.33 0.76 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.355 -0.841 . . . . 0.0 110.05 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.542 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -78.51 124.44 28.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.023 -1.048 . . . . 0.0 109.166 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 1.1 ttpt -91.92 138.34 31.62 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.775 0.797 . . . . 0.0 110.916 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.589 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -121.41 173.7 7.21 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.003 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.441 ' HG3' ' HE3' ' A' ' 312' ' ' LYS . 2.5 mt-10 -136.35 106.48 6.34 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.392 -0.817 . . . . 0.0 110.487 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -94.04 40.82 2.69 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 25.1 m120 57.43 82.33 0.13 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.249 -1.148 . . . . 0.0 110.195 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.623 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.84 0.87 57.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.809 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -145.77 -169.62 3.27 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.333 -1.098 . . . . 0.0 109.279 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.809 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.7 t -162.55 157.84 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.216 -0.928 . . . . 0.0 109.8 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.585 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.3 mm -126.65 145.91 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.156 -0.965 . . . . 0.0 111.086 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.637 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.3 m-85 -123.16 128.5 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.125 -0.984 . . . . 0.0 110.195 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.623 ' CG2' HG23 ' A' ' 293' ' ' THR . 25.0 p -129.58 166.37 26.33 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 120.802 -1.187 . . . . 0.0 109.394 179.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.509 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.8 Cg_endo -65.22 121.17 8.55 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.698 1.367 . . . . 0.0 111.132 -179.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.812 HG22 ' HB2' ' A' ' 327' ' ' ASN . 28.5 m -64.39 -125.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.626 -0.672 . . . . 0.0 110.182 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.482 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.4 m -100.69 -13.12 18.64 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.832 -1.168 . . . . 0.0 110.658 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.688 ' H ' HG23 ' A' ' 324' ' ' VAL . 15.9 p-90 -136.35 6.57 3.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.139 -0.975 . . . . 0.0 110.6 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.812 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.7 OUTLIER -108.4 38.14 2.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.136 -0.977 . . . . 0.0 110.41 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.7 OUTLIER -118.72 -7.69 10.48 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.283 -0.886 . . . . 0.0 110.184 179.76 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.45 -153.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.503 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.4 Cg_endo -76.64 8.34 3.08 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.938 1.494 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.423 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.5 m -163.77 128.08 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.926 -1.109 . . . . 0.0 110.089 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.625 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -146.39 111.33 5.31 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.159 -0.963 . . . . 0.0 110.579 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.898 ' OG1' HG23 ' A' ' 283' ' ' THR . 50.2 m -104.41 126.75 51.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.925 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.755 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.8 p90 -137.08 175.38 9.67 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -154.98 163.3 31.32 Favored Glycine 0 N--CA 1.486 1.982 0 C-N-CA 118.831 -1.652 . . . . 0.0 109.953 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.933 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -147.04 148.34 31.57 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.566 -0.961 . . . . 0.0 109.631 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.933 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.12 121.05 63.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.968 -1.083 . . . . 0.0 109.311 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.706 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.0 t -97.09 159.61 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.683 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -128.03 129.57 46.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.463 -0.773 . . . . 0.0 110.161 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.478 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.492 2.39 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.715 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.2 mtmt . . . . . 0 N--CA 1.487 1.385 0 CA-C-O 121.237 0.541 . . . . 0.0 110.475 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.1 p -133.3 120.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.233 -0.917 . . . . 0.0 110.189 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.436 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -52.5 -45.39 66.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.293 -0.88 . . . . 0.0 110.346 -179.652 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.422 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 5.4 pt-20 -177.09 158.4 1.52 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.049 -1.032 . . . . 0.0 110.905 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.758 HG12 HG13 ' A' ' 296' ' ' VAL . 72.1 mt -120.57 109.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.333 -0.854 . . . . 0.0 110.093 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.05 150.97 26.47 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.319 -0.863 . . . . 0.0 110.384 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.023 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.73 126.31 52.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.35 -0.844 . . . . 0.0 109.995 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.2 tp10 -138.2 110.17 7.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.163 -0.961 . . . . 0.0 109.935 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.825 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.27 111.26 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.564 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 39.17 32.35 0.07 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.762 -0.586 . . . . 0.0 110.918 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 114.91 -17.75 17.27 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.351 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.512 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 56.3 mm-40 -89.49 115.64 27.07 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.019 -1.283 . . . . 0.0 110.366 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.837 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.3 p -79.11 130.07 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.294 -0.879 . . . . 0.0 110.224 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.837 HD13 ' O ' ' A' ' 357' ' ' VAL . 18.6 mm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.24 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.258 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.556 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -126.84 164.83 20.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.347 -1.09 . . . . 0.0 109.497 179.59 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.929 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.19 140.52 10.33 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.008 -1.077 . . . . 0.0 111.068 -179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.765 ' H ' HD22 ' A' ' 267' ' ' LEU . 5.2 mt-10 -140.07 134.33 31.2 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 109.182 -0.674 . . . . 0.0 109.182 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.741 HG13 ' O ' ' A' ' 281' ' ' ASP . 60.1 t -125.41 136.86 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.807 -1.183 . . . . 0.0 111.648 -178.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.51 ' HG3' ' CB ' ' A' ' 281' ' ' ASP . 0.0 OUTLIER -122.96 157.06 33.48 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.55 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.746 HG13 ' O ' ' A' ' 279' ' ' GLU . 88.7 t -142.77 146.9 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.295 -1.503 . . . . 0.0 112.378 -178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.523 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.49 113.16 8.5 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.986 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.9 p-10 -96.21 147.22 23.99 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.069 -1.02 . . . . 0.0 111.425 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.796 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.7 p90 -132.08 20.86 4.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.489 -0.757 . . . . 0.0 110.056 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.92 -59.52 4.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.04 -24.63 64.21 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.295 -1.121 . . . . 0.0 110.488 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.535 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -173.26 178.6 45.15 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.555 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.75 145.18 49.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -1.166 . . . . 0.0 110.528 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.746 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.3 mt-10 -95.83 147.31 23.79 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.612 -0.68 . . . . 0.0 110.04 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.649 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 94.8 m-85 -140.43 86.1 2.05 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.353 -0.842 . . . . 0.0 110.417 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.741 ' O ' HG13 ' A' ' 269' ' ' VAL . 2.7 t70 -68.88 152.9 44.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.294 -0.879 . . . . 0.0 109.846 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.658 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.6 t -145.21 90.4 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.579 -0.701 . . . . 0.0 109.938 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.691 HG23 ' OG1' ' A' ' 333' ' ' THR . 85.1 m -86.72 126.36 34.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.007 . . . . 0.0 109.865 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.056 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.74 151.13 32.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.264 -0.897 . . . . 0.0 110.905 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.556 ' ND2' ' HB2' ' A' ' 266' ' ' SER . 0.4 OUTLIER -132.43 128.05 36.65 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.825 . . . . 0.0 110.543 -179.42 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.643 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 5.6 mt -140.41 156.32 46.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.533 -1.355 . . . . 0.0 109.596 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -89.04 39.13 0.92 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.79 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 157.23 -142.8 8.93 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 119.397 -1.382 . . . . 0.0 109.739 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.78 120.96 43.3 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.945 -1.327 . . . . 0.0 110.814 -179.547 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.643 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 10.8 m-85 -142.77 146.81 34.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.283 -0.886 . . . . 0.0 109.909 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.633 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.3 m-20 -75.9 97.33 3.93 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.156 -0.965 . . . . 0.0 109.421 179.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.822 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.3 p-90 -98.21 111.59 23.87 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.203 -0.936 . . . . 0.0 110.485 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.662 HG22 ' CG2' ' A' ' 320' ' ' ILE . 6.4 m -104.7 115.98 31.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.642 -0.661 . . . . 0.0 109.894 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.7 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.8 t -97.01 110.89 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.06 -1.025 . . . . 0.0 110.42 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.735 ' HA ' HD13 ' A' ' 320' ' ' ILE . 6.5 ttpt -85.69 144.86 27.58 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.27 -0.893 . . . . 0.0 109.016 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.9 HG22 HG23 ' A' ' 349' ' ' ILE . 30.9 t -141.94 109.72 2.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.779 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.51 ' O ' ' N ' ' A' ' 347' ' ' GLU . 22.4 mmtp -72.57 132.01 43.23 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.212 -0.93 . . . . 0.0 109.476 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.989 HD13 ' HA ' ' A' ' 303' ' ' THR . 67.4 mt -87.31 152.95 21.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.108 -0.995 . . . . 0.0 111.695 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.709 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -60.46 173.76 0.58 Allowed Pre-proline 0 N--CA 1.488 1.439 0 O-C-N 121.62 -0.675 . . . . 0.0 109.364 178.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.709 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -68.73 84.59 0.5 Allowed 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.696 1.366 . . . . 0.0 110.038 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.37 26.44 3.71 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.863 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -120.5 145.98 46.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -1.148 . . . . 0.0 110.601 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.989 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.5 p -147.63 145.99 29.18 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.294 -0.879 . . . . 0.0 110.399 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.667 HG21 HG11 ' A' ' 319' ' ' VAL . 70.4 t -74.46 142.41 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.214 -0.929 . . . . 0.0 110.45 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.55 -32.96 0.41 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.3 m -128.87 127.94 42.84 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 111.092 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.501 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.8 p90 -146.59 160.81 41.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.433 -0.792 . . . . 0.0 109.239 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -150.9 157.42 42.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.946 -1.096 . . . . 0.0 110.975 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.498 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.6 OUTLIER 58.6 23.6 11.1 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.765 179.708 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.698 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 140.68 0.71 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.369 -0.832 . . . . 0.0 110.088 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.617 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -78.62 122.4 25.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.07 -1.019 . . . . 0.0 109.735 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.63 ' HG3' HG11 ' A' ' 304' ' ' VAL . 11.1 ttpt -88.85 144.33 26.29 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.766 0.793 . . . . 0.0 110.847 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.772 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -129.7 173.7 10.38 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.39 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.466 ' HG2' HG22 ' A' ' 319' ' ' VAL . 5.3 mt-10 -135.3 103.09 5.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 110.588 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.463 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -89.85 39.09 3.13 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.463 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 5.9 m120 58.5 89.42 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.304 -1.115 . . . . 0.0 110.075 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.39 -0.76 75.26 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.833 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -144.56 -167.89 2.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.446 -1.032 . . . . 0.0 109.095 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.833 HG23 ' O ' ' A' ' 318' ' ' TYR . 2.7 t -163.4 161.64 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 109.713 179.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.735 HD13 ' HA ' ' A' ' 295' ' ' LYS . 25.2 mm -129.28 151.93 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.074 -1.016 . . . . 0.0 110.997 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.641 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 73.4 m-85 -128.36 130.67 48.08 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.225 -0.922 . . . . 0.0 109.963 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.618 HG23 HG23 ' A' ' 293' ' ' THR . 2.2 p -132.96 168.87 15.78 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.727 -1.233 . . . . 0.0 109.991 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.51 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.7 Cg_endo -65.55 121.5 8.91 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.813 1.428 . . . . 0.0 110.981 -179.237 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.684 HG22 ' HB2' ' A' ' 327' ' ' ASN . 19.1 m -66.8 -117.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.47 -0.769 . . . . 0.0 110.087 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.507 ' N ' HG23 ' A' ' 324' ' ' VAL . 57.7 m -108.98 -16.46 14.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.814 -1.179 . . . . 0.0 110.339 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.578 ' H ' HG23 ' A' ' 324' ' ' VAL . 10.6 p-90 -125.96 -18.53 5.05 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.237 -0.915 . . . . 0.0 110.617 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.684 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t30 -87.43 33.21 0.69 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.96 12.07 22.16 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.319 -0.863 . . . . 0.0 109.656 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -84.99 -152.13 16.4 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.564 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 41.4 Cg_endo -68.86 -55.57 0.2 Allowed 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.938 1.494 . . . . 0.0 110.021 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.26 115.22 30.1 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.418 -0.802 . . . . 0.0 110.415 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.494 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -134.49 107.83 7.78 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.251 -0.906 . . . . 0.0 110.101 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.691 ' OG1' HG23 ' A' ' 283' ' ' THR . 97.6 m -103.82 147.64 27.05 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.148 -0.97 . . . . 0.0 110.733 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.7 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.8 p90 -152.35 175.06 13.07 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.493 -0.754 . . . . 0.0 109.102 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.7 160.77 28.95 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.401 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.941 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -147.46 147.4 30.15 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.388 -1.066 . . . . 0.0 110.041 179.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.941 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -121.71 123.31 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.013 -1.054 . . . . 0.0 109.958 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.863 HG11 ' HB1' ' A' ' 302' ' ' ALA . 4.6 t -97.12 154.26 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.199 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.32 133.38 53.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.221 -0.924 . . . . 0.0 110.557 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.452 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.491 2.351 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.574 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.3 OUTLIER . . . . . 0 N--CA 1.488 1.474 0 CA-C-O 121.136 0.493 . . . . 0.0 111.119 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.62 HG21 HG13 ' A' ' 296' ' ' VAL . 9.0 p -127.53 123.87 62.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.224 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.51 ' N ' ' O ' ' A' ' 297' ' ' LYS . 6.8 mt-10 -55.47 -43.64 75.71 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 110.223 -179.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -177.09 159.02 1.6 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 110.513 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 296' ' ' VAL . 45.7 mt -123.13 109.58 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 110.218 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.78 140.66 43.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.32 -0.863 . . . . 0.0 110.143 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.056 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -101.05 130.86 47.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.247 -0.908 . . . . 0.0 110.271 179.995 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -138.86 111.78 7.84 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 110.115 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.633 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 107.82 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.079 -1.013 . . . . 0.0 110.3 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.542 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.94 37.56 0.22 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.585 -0.697 . . . . 0.0 111.56 179.611 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 106.77 11.12 27.28 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.582 -1.294 . . . . 0.0 110.664 178.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 26.4 mm-40 -121.57 101.48 7.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.013 -1.286 . . . . 0.0 110.034 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 1.04 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.9 p -66.56 135.66 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.234 -0.916 . . . . 0.0 110.4 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 1.04 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.3 mm . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.187 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.41 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.575 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.61 153.6 51.54 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.504 -0.998 . . . . 0.0 109.473 179.904 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.764 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -147.99 123.56 10.43 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 120.932 -1.105 . . . . 0.0 111.03 -179.451 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.8 OUTLIER -122.36 111.04 16.4 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 178.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.575 HG11 HD12 ' A' ' 349' ' ' ILE . 45.4 t -104.99 124.62 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.893 -1.129 . . . . 0.0 111.953 -178.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -111.89 156.74 21.57 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.644 HG22 ' CD2' ' A' ' 280' ' ' TYR . 56.9 t -144.84 143.66 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.341 -1.475 . . . . 0.0 112.148 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.544 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -134.52 108.76 8.28 Favored 'General case' 0 N--CA 1.486 1.37 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.08 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 21.0 p30 -96.18 146.78 24.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 111.083 -178.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.856 ' CH2' HG23 ' A' ' 337' ' ' ILE . 31.7 p90 -130.38 17.98 5.38 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.412 -0.805 . . . . 0.0 109.958 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.27 -58.77 3.86 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -73.18 -19.32 61.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 110.458 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.581 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.98 179.44 41.72 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.635 -1.269 . . . . 0.0 109.983 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -138.09 136.6 36.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.442 -1.034 . . . . 0.0 109.97 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.574 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.7 mt-10 -93.84 147.15 23.34 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.378 -0.826 . . . . 0.0 110.478 -179.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.832 ' CE2' HG11 ' A' ' 346' ' ' VAL . 92.8 m-85 -139.05 94.96 2.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 110.674 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.543 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -83.5 106.41 15.22 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.538 -0.726 . . . . 0.0 110.271 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.684 HG11 HG11 ' A' ' 294' ' ' VAL . 5.5 t -97.28 94.28 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.493 -0.754 . . . . 0.0 110.17 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.84 HG23 ' OG1' ' A' ' 333' ' ' THR . 3.8 m -86.95 113.47 22.75 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.172 -0.955 . . . . 0.0 109.815 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 0.998 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -102.18 147.94 26.03 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.096 -1.003 . . . . 0.0 110.507 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.575 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.36 106.7 7.66 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.516 -0.74 . . . . 0.0 109.636 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.603 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.8 mt -113.83 160.75 18.39 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.622 -1.299 . . . . 0.0 110.763 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -89.79 36.64 0.86 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 110.03 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 155.3 -135.25 4.54 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.473 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.2 mm-40 -120.67 113.41 20.18 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.05 -1.265 . . . . 0.0 110.911 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.603 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.1 m-85 -138.74 148.92 44.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.36 -0.838 . . . . 0.0 109.641 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.635 ' O ' HG23 ' A' ' 353' ' ' ILE . 5.4 m-20 -75.53 97.9 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.205 -0.935 . . . . 0.0 109.512 179.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.832 ' CE3' HD13 ' A' ' 284' ' ' LEU . 51.5 p-90 -97.07 110.17 22.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.583 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.682 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.2 m -102.34 115.21 30.09 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.331 -0.856 . . . . 0.0 109.44 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.778 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.8 t -97.0 111.09 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 110.54 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.633 ' HA ' HD13 ' A' ' 320' ' ' ILE . 4.5 ttpt -83.15 149.17 27.02 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 108.966 178.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.688 HG22 HG23 ' A' ' 349' ' ' ILE . 53.7 t -145.75 104.73 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.971 -1.081 . . . . 0.0 110.761 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.502 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 7.6 mmtt -70.88 131.28 43.53 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.208 -0.933 . . . . 0.0 109.391 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.994 HD13 ' HA ' ' A' ' 303' ' ' THR . 70.3 mt -87.12 152.49 22.3 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 111.507 -179.056 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.765 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -56.47 176.0 0.21 Allowed Pre-proline 0 C--N 1.301 -1.504 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.081 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.76 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -68.99 79.87 0.69 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 123.554 1.292 . . . . 0.0 109.891 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.19 20.9 5.42 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.765 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -106.73 149.0 27.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.395 -1.062 . . . . 0.0 109.936 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.994 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.5 p -150.03 144.2 25.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.106 -0.997 . . . . 0.0 111.152 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.771 HG21 HG11 ' A' ' 319' ' ' VAL . 87.4 t -69.59 129.79 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -0.862 . . . . 0.0 109.928 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.25 -28.18 2.91 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 6.8 t -144.66 141.4 29.32 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.007 -1.29 . . . . 0.0 110.744 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.517 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.3 p90 -155.54 168.81 25.93 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.403 -0.811 . . . . 0.0 110.053 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.502 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -158.53 163.72 36.8 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.057 -1.027 . . . . 0.0 110.645 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.437 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.5 OUTLIER 58.41 21.31 8.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.5 -0.75 . . . . 0.0 110.757 179.739 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.683 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 148.84 1.21 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.442 -0.786 . . . . 0.0 110.328 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.844 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -86.78 120.12 27.74 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.225 -0.922 . . . . 0.0 109.379 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.689 ' HG3' HG11 ' A' ' 304' ' ' VAL . 3.6 ttpt -87.63 140.03 29.93 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.892 0.853 . . . . 0.0 110.601 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.648 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.5 175.22 7.28 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -134.84 116.55 14.92 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.316 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.448 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -109.93 39.25 2.97 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 1.4 t30 66.23 90.92 0.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.29 -1.123 . . . . 0.0 110.286 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 81.53 3.31 90.66 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.836 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.9 m-85 -141.52 -172.67 3.58 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -1.135 . . . . 0.0 109.544 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.836 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.5 t -163.38 157.85 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.212 -0.93 . . . . 0.0 109.775 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.648 ' CG2' HG22 ' A' ' 293' ' ' THR . 17.4 mm -125.98 144.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.012 -1.055 . . . . 0.0 111.474 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 56.9 m-85 -121.18 129.33 53.18 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.005 -1.059 . . . . 0.0 109.93 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.682 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.9 p -129.94 168.52 16.29 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 120.864 -1.148 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.53 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.2 Cg_endo -65.95 117.09 4.36 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.76 1.4 . . . . 0.0 111.029 -179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.844 HG12 ' ND2' ' A' ' 311' ' ' ASN . 25.4 m -64.29 -120.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 110.041 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.501 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -104.44 -15.88 15.26 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.776 -1.202 . . . . 0.0 110.665 -179.849 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.599 ' H ' HG23 ' A' ' 324' ' ' VAL . 5.3 p-90 -131.11 -6.85 3.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.132 -0.98 . . . . 0.0 110.822 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.831 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 1.6 t-20 -90.96 38.67 0.96 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.063 -1.023 . . . . 0.0 110.115 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.483 ' HE2' ' O ' ' A' ' 325' ' ' SER . 5.5 pttt -121.26 4.99 10.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.06 -1.025 . . . . 0.0 110.332 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -69.16 -156.38 1.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 50.5 Cg_endo -76.72 7.16 3.66 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.77 1.405 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 19.5 m -164.2 128.25 2.64 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.288 -0.882 . . . . 0.0 109.725 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.831 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -143.89 108.63 4.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 110.319 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.84 ' OG1' HG23 ' A' ' 283' ' ' THR . 89.8 m -100.77 117.54 35.07 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.309 -0.87 . . . . 0.0 109.953 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.778 ' HE2' HG21 ' A' ' 294' ' ' VAL . 7.9 p90 -124.49 171.96 9.56 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.34 158.04 27.5 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.945 -1.597 . . . . 0.0 109.951 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -145.89 146.13 30.98 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.633 -0.922 . . . . 0.0 109.186 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.23 120.23 63.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.684 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.725 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.8 t -95.78 147.84 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.195 -0.941 . . . . 0.0 109.576 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -118.6 134.69 54.91 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.384 -0.822 . . . . 0.0 110.617 -179.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.426 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.172 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.943 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.65 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.559 0 CA-C-O 121.191 0.52 . . . . 0.0 110.685 . . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.832 HG11 ' CE2' ' A' ' 280' ' ' TYR . 4.2 p -132.78 116.5 27.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.028 -1.045 . . . . 0.0 110.831 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.502 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -44.67 -50.08 10.06 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.912 -1.117 . . . . 0.0 109.533 179.787 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -177.48 158.06 1.36 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.382 -0.824 . . . . 0.0 110.482 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.688 HG23 HG22 ' A' ' 296' ' ' VAL . 14.4 mt -117.15 111.62 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.255 -0.903 . . . . 0.0 110.076 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.69 151.65 24.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.285 -0.885 . . . . 0.0 110.376 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 0.998 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -110.27 125.71 53.41 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.321 -0.862 . . . . 0.0 109.812 179.604 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.5 tt0 -137.26 111.41 8.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.184 -0.948 . . . . 0.0 109.832 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.635 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -92.02 109.97 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 110.521 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.528 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 38.36 31.22 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.546 -0.721 . . . . 0.0 111.061 179.457 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.48 -10.04 16.9 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.563 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.444 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.0 mp0 -97.16 108.4 21.12 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.061 -1.258 . . . . 0.0 110.214 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 357' ' ' VAL . 7.3 p -76.58 110.42 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.335 -0.853 . . . . 0.0 110.249 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.736 ' HB ' HD13 ' A' ' 351' ' ' LEU . 24.2 mm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.146 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.235 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.57 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -136.88 157.11 47.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.477 -1.013 . . . . 0.0 109.535 179.863 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.813 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.56 124.38 10.57 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.943 -1.098 . . . . 0.0 110.989 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.482 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 1.4 mm-40 -121.38 113.32 19.73 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.736 HG13 ' O ' ' A' ' 281' ' ' ASP . 38.4 t -109.44 139.67 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 111.668 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.421 ' C ' HG23 ' A' ' 271' ' ' VAL . 4.2 mmtm -123.83 156.58 35.92 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.3 t -145.19 144.7 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.462 -1.399 . . . . 0.0 112.092 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.14 112.21 6.61 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 179.315 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.7 p-10 -97.03 144.82 26.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.047 -1.033 . . . . 0.0 111.297 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.5 p90 -129.82 18.62 5.63 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.399 -0.813 . . . . 0.0 109.786 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.58 -61.92 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.67 -23.79 67.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -1.158 . . . . 0.0 110.224 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.82 177.68 46.02 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.603 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -130.58 146.6 52.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.329 -1.101 . . . . 0.0 110.201 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.595 ' O ' HG13 ' A' ' 271' ' ' VAL . 6.2 mt-10 -98.0 147.32 24.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.514 -0.741 . . . . 0.0 109.942 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 95.2 m-85 -144.28 86.37 1.83 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.233 -0.917 . . . . 0.0 110.999 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.736 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.1 OUTLIER -71.17 153.5 42.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.403 -0.811 . . . . 0.0 109.88 179.376 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.646 HG11 HG11 ' A' ' 294' ' ' VAL . 3.5 t -144.82 88.09 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 109.615 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.79 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.5 m -86.03 114.92 23.29 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.683 -179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.018 HD21 HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -101.73 145.57 28.94 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.259 -0.901 . . . . 0.0 110.736 -179.16 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.57 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -129.67 106.86 9.0 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.391 -0.818 . . . . 0.0 110.093 -179.458 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.572 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 7.6 mt -116.62 164.34 14.75 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.648 -1.283 . . . . 0.0 110.299 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -94.04 34.59 1.23 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.402 -0.811 . . . . 0.0 110.458 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.449 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 157.11 -137.52 5.44 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.876 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.484 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mm-40 -113.84 108.26 16.83 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.184 -1.186 . . . . 0.0 111.391 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.572 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.26 135.27 40.77 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.301 -0.874 . . . . 0.0 109.67 178.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.556 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 4.5 m-20 -64.88 97.02 0.2 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.05 -1.032 . . . . 0.0 109.402 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.862 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.3 p-90 -95.07 108.07 20.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.279 -0.888 . . . . 0.0 110.494 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.596 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 32.4 m -101.67 115.48 30.61 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.782 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -96.72 111.54 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.092 -1.005 . . . . 0.0 110.925 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.644 ' HA ' HD13 ' A' ' 320' ' ' ILE . 7.9 ttpt -82.01 149.84 27.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.264 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.822 HG13 HG12 ' A' ' 349' ' ' ILE . 88.7 t -149.02 104.77 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.951 -1.093 . . . . 0.0 110.719 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.521 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 18.9 mmtp -70.35 128.54 36.56 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.223 -0.923 . . . . 0.0 109.658 179.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.956 HD13 ' HA ' ' A' ' 303' ' ' THR . 85.5 mt -84.06 165.81 18.24 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.763 0.792 . . . . 0.0 111.377 -179.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.788 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -74.33 175.81 3.47 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.623 -0.673 . . . . 0.0 109.726 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.788 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.5 Cg_endo -67.24 83.2 0.36 Allowed 'Trans proline' 0 C--N 1.304 -1.786 0 O-C-N 123.598 1.315 . . . . 0.0 109.84 179.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 110.99 22.72 6.12 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.879 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -112.14 144.17 41.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -1.085 . . . . 0.0 110.13 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.956 ' HA ' HD13 ' A' ' 298' ' ' LEU . 13.0 p -147.06 145.18 29.58 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.879 . . . . 0.0 110.332 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.855 HG21 HG11 ' A' ' 319' ' ' VAL . 71.4 t -64.97 120.94 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.38 -0.825 . . . . 0.0 110.11 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.29 -38.6 3.48 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.509 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 24.9 m -139.03 144.25 38.77 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.144 -1.209 . . . . 0.0 110.781 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 5.6 p90 -155.02 160.34 40.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.466 -0.771 . . . . 0.0 109.463 179.553 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.432 ' C ' ' OG ' ' A' ' 309' ' ' SER . 1.0 OUTLIER -151.04 152.87 34.08 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.923 -1.111 . . . . 0.0 111.491 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.522 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.9 OUTLIER 67.24 24.19 9.2 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.663 -0.648 . . . . 0.0 111.054 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.673 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.27 143.41 0.87 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.276 -0.89 . . . . 0.0 110.138 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.819 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -82.37 122.9 28.58 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.15 -0.969 . . . . 0.0 109.182 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.602 ' HG3' HG11 ' A' ' 304' ' ' VAL . 3.1 ttmt -88.7 148.09 24.17 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.861 0.839 . . . . 0.0 111.05 -178.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.733 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.74 171.85 13.0 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.36 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -132.96 109.7 9.75 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.179 -0.95 . . . . 0.0 110.345 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.73 39.81 2.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.405 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 8.4 t-20 60.86 92.25 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.346 -1.091 . . . . 0.0 110.474 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.3 2.27 87.76 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.823 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.1 m-85 -145.81 -169.48 3.24 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.339 -1.095 . . . . 0.0 109.27 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.855 HG11 HG21 ' A' ' 304' ' ' VAL . 2.8 t -163.44 161.92 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 179.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.644 HD13 ' HA ' ' A' ' 295' ' ' LYS . 5.5 mm -130.19 143.57 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.174 -0.954 . . . . 0.0 111.084 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.652 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 98.6 m-85 -118.61 136.79 53.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.938 . . . . 0.0 109.515 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.549 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.5 p -135.3 168.88 15.47 Favored Pre-proline 0 C--N 1.301 -1.527 0 O-C-N 120.844 -1.16 . . . . 0.0 110.303 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.557 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 40.5 Cg_endo -67.03 121.09 8.21 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 124.127 1.593 . . . . 0.0 110.85 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.877 HG22 ' HB2' ' A' ' 327' ' ' ASN . 27.0 m -73.22 -129.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.845 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.606 ' N ' HG23 ' A' ' 324' ' ' VAL . 18.1 p -100.17 -19.15 16.57 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.904 -1.122 . . . . 0.0 110.346 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.758 ' H ' HG23 ' A' ' 324' ' ' VAL . 23.7 p-90 -125.96 11.08 7.68 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.108 -0.995 . . . . 0.0 110.507 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.877 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -117.63 49.58 1.21 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.073 -1.017 . . . . 0.0 110.254 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.557 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -125.57 -12.47 6.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -0.865 . . . . 0.0 110.134 -179.902 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.09 -160.95 0.02 OUTLIER Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.9 Cg_endo -73.4 3.53 4.66 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.905 1.477 . . . . 0.0 110.872 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.97 117.67 3.28 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.171 -0.955 . . . . 0.0 110.088 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.565 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.03 108.6 5.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.253 -0.904 . . . . 0.0 110.077 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.79 ' OG1' HG23 ' A' ' 283' ' ' THR . 60.7 m -99.81 138.63 36.62 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.287 -0.883 . . . . 0.0 110.449 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.782 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.9 p90 -145.92 157.36 43.9 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -134.33 164.27 24.57 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.088 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.878 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -149.74 143.4 25.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.483 -1.01 . . . . 0.0 109.469 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.878 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -117.16 120.55 65.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.115 -0.991 . . . . 0.0 109.689 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.879 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.6 t -96.79 149.93 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.203 -0.936 . . . . 0.0 109.817 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -121.77 131.54 54.12 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.16 -0.963 . . . . 0.0 111.061 -179.167 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.296 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.742 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.69 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.488 1.442 0 CA-C-O 121.448 0.642 . . . . 0.0 110.24 . . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.58 HG13 ' O ' ' A' ' 346' ' ' VAL . 10.7 p -133.84 116.73 24.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.399 -0.813 . . . . 0.0 110.002 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 1.5 mt-10 -47.16 -47.1 23.91 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.174 -0.954 . . . . 0.0 110.164 -179.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -177.01 158.92 1.61 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.401 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.822 HG12 HG13 ' A' ' 296' ' ' VAL . 26.4 mt -118.2 119.42 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.23 -0.919 . . . . 0.0 110.101 179.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.49 151.33 33.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.301 -0.874 . . . . 0.0 110.267 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.018 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -108.96 126.83 53.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.252 -0.905 . . . . 0.0 109.725 179.661 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.444 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.5 tp10 -138.19 113.11 9.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.077 -1.014 . . . . 0.0 110.373 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.537 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -93.07 103.66 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.183 -0.948 . . . . 0.0 110.003 179.725 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.556 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 43.55 30.55 0.35 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.459 -0.775 . . . . 0.0 110.46 -179.85 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 117.63 -22.65 9.95 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.445 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 1.0 OUTLIER -82.41 99.58 9.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 110.127 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.686 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.4 p -69.96 113.76 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.246 -0.909 . . . . 0.0 110.173 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.653 ' HB ' HD13 ' A' ' 351' ' ' LEU . 25.9 mm . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.119 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.263 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.585 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -130.81 150.54 51.94 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.4 -1.059 . . . . 0.0 109.978 179.924 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.873 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -145.2 125.87 14.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.036 -1.04 . . . . 0.0 110.781 -179.676 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.488 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 15.0 mm-40 -124.51 110.99 15.17 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.491 -0.756 . . . . 0.0 108.996 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.936 HG13 ' O ' ' A' ' 281' ' ' ASP . 85.6 t -110.53 145.19 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 120.942 -1.098 . . . . 0.0 111.827 -178.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -130.86 157.74 42.07 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.81 HG13 ' O ' ' A' ' 279' ' ' GLU . 97.5 t -141.69 146.75 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 120.237 -1.539 . . . . 0.0 112.454 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.02 110.28 6.91 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.11 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 43.8 p-10 -95.68 145.36 25.34 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.062 -1.024 . . . . 0.0 111.379 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.835 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.4 p90 -130.95 22.77 4.93 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.36 -0.837 . . . . 0.0 109.858 179.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.81 -68.82 3.32 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.811 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.482 ' HG ' ' HE1' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -61.22 -27.41 68.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.253 -1.145 . . . . 0.0 110.685 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.533 ' C ' ' CE2' ' A' ' 274' ' ' TRP . . . -166.3 178.52 40.8 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.568 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.72 145.28 48.33 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.275 -1.132 . . . . 0.0 110.512 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.81 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -97.22 147.17 24.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 109.973 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.657 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 88.5 m-85 -142.08 83.77 1.85 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.274 -0.891 . . . . 0.0 110.523 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.936 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.14 153.19 44.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.289 -0.882 . . . . 0.0 110.123 179.551 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 294' ' ' VAL . 5.4 t -144.87 90.36 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.531 -0.73 . . . . 0.0 109.667 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.832 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.5 m -86.28 123.66 31.79 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.134 -0.979 . . . . 0.0 109.362 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.082 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -109.71 148.26 31.71 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.072 -1.017 . . . . 0.0 111.28 -178.85 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.585 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.33 107.37 7.59 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.607 -0.683 . . . . 0.0 109.975 -179.45 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.534 ' N ' ' O ' ' A' ' 330' ' ' PRO . 9.7 mt -115.53 163.27 16.0 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.897 -1.127 . . . . 0.0 109.805 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . 0.469 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 2.1 t0 -91.64 31.28 1.21 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.552 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.54 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 163.76 -164.33 36.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.545 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -93.76 94.87 8.79 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.176 -1.19 . . . . 0.0 110.599 -179.738 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 1.9 m-85 -120.96 171.44 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.181 -0.95 . . . . 0.0 109.793 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.834 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.2 OUTLIER -95.78 99.34 11.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.655 179.392 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.905 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.1 p-90 -97.29 113.99 25.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.309 -0.869 . . . . 0.0 110.624 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.576 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 99.1 m -106.75 113.38 26.84 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.464 -0.773 . . . . 0.0 109.176 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 282' ' ' VAL . 4.6 t -96.37 110.81 25.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.184 -0.948 . . . . 0.0 110.137 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.517 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 6.4 ttmt -84.77 149.07 26.0 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.208 -0.933 . . . . 0.0 109.197 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.857 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 45.9 t -144.63 106.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 O-C-N 121.403 -0.811 . . . . 0.0 109.93 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.513 ' O ' HG23 ' A' ' 346' ' ' VAL . 34.9 mmtt -71.1 134.69 47.21 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.114 -0.991 . . . . 0.0 109.704 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.906 HD13 ' HA ' ' A' ' 303' ' ' THR . 92.7 mt -87.59 162.57 17.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 111.569 -179.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.661 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -75.65 171.57 11.59 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.661 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.4 84.61 0.47 Allowed 'Trans proline' 0 C--N 1.301 -1.945 0 O-C-N 123.684 1.36 . . . . 0.0 109.798 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . 0.442 ' O ' ' HA3' ' A' ' 340' ' ' GLY . . . 116.26 26.02 3.33 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 1.024 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -126.51 138.26 53.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -1.139 . . . . 0.0 110.257 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.906 ' HA ' HD13 ' A' ' 298' ' ' LEU . 7.2 p -141.43 145.83 35.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 110.419 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.749 ' CG2' HG21 ' A' ' 319' ' ' VAL . 98.2 t -71.82 124.28 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.366 -0.834 . . . . 0.0 110.225 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.4 -34.84 1.26 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.433 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 2.7 m -122.45 110.15 15.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.025 -1.28 . . . . 0.0 110.716 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.602 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 11.9 p90 -134.23 153.92 51.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.856 . . . . 0.0 109.788 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.475 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -149.19 161.37 42.13 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.05 -1.031 . . . . 0.0 111.155 -179.35 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.545 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.23 28.71 15.54 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.542 -0.723 . . . . 0.0 111.224 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.711 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.9 145.44 0.66 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.038 -1.039 . . . . 0.0 110.553 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 2.1 m-80 -78.13 118.74 20.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -0.998 . . . . 0.0 109.238 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.602 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 19.9 ttpt -92.2 115.7 28.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.546 -0.721 . . . . 0.0 111.083 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.616 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.4 OUTLIER -102.97 176.31 5.19 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.327 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.447 ' HG3' HG22 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -139.02 105.95 5.42 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -0.981 . . . . 0.0 110.773 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -95.26 43.79 2.2 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 58.52 91.06 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.321 -1.105 . . . . 0.0 110.126 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.629 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 84.33 5.12 87.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.707 ' O ' HG23 ' A' ' 319' ' ' VAL . 7.0 m-85 -141.93 -178.53 5.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.413 -1.051 . . . . 0.0 109.078 179.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.749 HG21 ' CG2' ' A' ' 304' ' ' VAL . 39.9 t -159.4 148.98 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.149 -0.969 . . . . 0.0 109.986 179.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.616 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 1.7 mm -114.9 151.56 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.112 -0.992 . . . . 0.0 110.497 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.659 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 76.5 m-85 -130.69 112.78 13.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.101 -0.999 . . . . 0.0 109.866 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.584 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 3.7 p -116.49 171.07 5.09 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 120.627 -1.296 . . . . 0.0 109.786 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.584 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.9 Cg_endo -69.2 120.96 7.77 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 O-C-N 123.652 1.343 . . . . 0.0 110.727 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.656 HG22 ' CG ' ' A' ' 327' ' ' ASN . 16.0 m -64.12 -113.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.482 -0.761 . . . . 0.0 110.224 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.531 ' HG ' ' HD1' ' A' ' 326' ' ' TRP . 14.1 p -120.17 -12.47 9.06 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.753 -1.217 . . . . 0.0 110.688 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.531 ' HD1' ' HG ' ' A' ' 325' ' ' SER . 24.8 p-90 -128.9 17.01 6.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 0.0 110.921 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.656 ' CG ' HG22 ' A' ' 324' ' ' VAL . 28.8 p-10 -135.56 45.07 2.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.079 . . . . 0.0 110.921 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.539 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -116.05 7.96 14.41 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.097 -1.002 . . . . 0.0 109.847 179.774 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . . . . . . . . . . . -74.67 -153.72 3.54 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.124 -1.191 . . . . 0.0 110.124 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.54 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 50.5 Cg_endo -75.61 4.66 4.85 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 124.182 1.622 . . . . 0.0 110.925 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.6 m -165.25 123.54 1.64 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.158 -0.964 . . . . 0.0 110.253 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.627 ' HB1' ' HB2' ' A' ' 327' ' ' ASN . . . -150.72 120.28 6.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.848 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.832 ' OG1' HG23 ' A' ' 283' ' ' THR . 34.0 m -104.32 144.66 31.33 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.229 -0.92 . . . . 0.0 110.441 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.779 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.0 p90 -149.78 168.82 22.62 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.37 159.84 28.16 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 118.744 -1.693 . . . . 0.0 110.535 -179.209 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.882 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.6 p90 -144.2 145.02 31.81 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.648 -0.913 . . . . 0.0 109.679 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.882 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.98 120.99 65.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.626 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 1.024 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 19.8 t -97.71 142.65 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 110.399 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.6 m-80 -115.55 130.09 56.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 110.133 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 301' ' ' GLY . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.628 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.3 mtmt . . . . . 0 N--CA 1.488 1.472 0 CA-C-O 121.274 0.559 . . . . 0.0 110.463 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.582 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.8 p -130.58 118.21 41.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.311 -0.868 . . . . 0.0 110.22 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.432 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -48.33 -45.9 35.8 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.378 -0.826 . . . . 0.0 110.575 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.42 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 2.5 pt-20 -177.02 159.39 1.67 Allowed 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.847 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.549 HG12 HG13 ' A' ' 296' ' ' VAL . 14.2 mt -119.6 114.6 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.254 -0.904 . . . . 0.0 110.439 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -113.91 158.2 21.41 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.148 -0.97 . . . . 0.0 109.855 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.082 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.42 126.63 51.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.253 -0.905 . . . . 0.0 110.633 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.0 OUTLIER -139.25 119.76 13.99 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.864 179.45 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.834 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -90.81 93.01 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.924 -1.11 . . . . 0.0 110.22 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 46.94 31.96 1.68 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.817 -0.552 . . . . 0.0 111.249 179.496 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 132.13 -33.86 2.63 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.651 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 66.0 mm-40 -89.92 117.61 28.87 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.987 -1.302 . . . . 0.0 110.745 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 4.0 p -78.93 124.07 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.298 -0.876 . . . . 0.0 110.135 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.683 ' HB ' HD13 ' A' ' 351' ' ' LEU . 21.5 mm . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.092 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.403 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.559 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.58 162.67 33.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.371 -1.076 . . . . 0.0 109.87 179.837 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.947 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -159.92 138.27 10.33 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.143 -1.023 . . . . 0.0 111.15 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.74 ' N ' HD22 ' A' ' 267' ' ' LEU . 18.8 mt-10 -141.15 136.57 31.98 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.819 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -128.11 144.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.618 -1.301 . . . . 0.0 112.306 -178.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.405 ' C ' HG23 ' A' ' 271' ' ' VAL . 63.3 mttt -128.65 157.74 40.49 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.844 HG13 ' O ' ' A' ' 279' ' ' GLU . 98.7 t -144.36 147.38 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 120.346 -1.472 . . . . 0.0 112.319 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.525 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.12 110.63 6.38 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.737 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -96.13 149.08 22.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.988 -1.07 . . . . 0.0 111.503 -178.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.82 ' CH2' HG23 ' A' ' 337' ' ' ILE . 28.1 p90 -129.46 18.42 5.84 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-O 121.447 0.641 . . . . 0.0 109.691 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.42 -61.63 3.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.67 -25.26 65.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 110.383 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.522 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -167.56 178.93 41.31 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.449 -1.358 . . . . 0.0 109.95 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.3 144.63 48.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -1.103 . . . . 0.0 110.345 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.844 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -97.47 145.92 25.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.396 -0.815 . . . . 0.0 109.828 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.731 ' CE1' HG11 ' A' ' 346' ' ' VAL . 98.9 m-85 -137.9 87.72 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.827 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.819 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -70.88 140.91 51.21 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.483 179.13 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.675 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.8 t -133.89 91.7 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.568 -0.708 . . . . 0.0 109.803 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.861 HG23 ' OG1' ' A' ' 333' ' ' THR . 9.0 m -86.49 124.2 32.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 109.977 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.82 148.41 38.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 110.832 -179.427 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -128.66 137.43 51.64 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.434 -0.791 . . . . 0.0 109.823 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.5 mt -142.42 159.7 41.71 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.794 -1.191 . . . . 0.0 109.759 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.94 36.02 0.97 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.361 -0.837 . . . . 0.0 110.31 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.479 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 152.07 -100.94 0.21 Allowed Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.139 -1.505 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.554 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 15.9 mm-40 -141.8 111.93 6.88 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.024 -1.28 . . . . 0.0 110.881 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.639 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 5.5 m-85 -135.51 138.36 43.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.687 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.801 ' O ' HG23 ' A' ' 353' ' ' ILE . 5.5 m-20 -74.17 96.87 2.82 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.002 -1.061 . . . . 0.0 108.905 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.938 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.1 p-90 -97.45 114.87 26.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 0.0 110.568 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.707 HG23 HG23 ' A' ' 322' ' ' THR . 28.7 m -109.45 116.09 31.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.694 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.8 t -96.83 111.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 0.0 110.528 -179.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.577 ' HA ' HD13 ' A' ' 320' ' ' ILE . 28.9 ttpt -91.64 130.19 37.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.659 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.745 HG13 HG12 ' A' ' 349' ' ' ILE . 80.2 t -126.58 115.87 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.185 -0.947 . . . . 0.0 111.103 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.571 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 55.7 mmtt -73.21 134.23 44.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.149 -0.97 . . . . 0.0 109.269 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.974 HD13 ' HA ' ' A' ' 303' ' ' THR . 80.1 mt -88.15 159.38 18.22 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.324 -0.86 . . . . 0.0 111.466 -178.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.881 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.18 178.09 0.56 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.68 -0.638 . . . . 0.0 110.025 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.864 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.24 79.06 0.6 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.718 1.378 . . . . 0.0 109.662 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.89 21.15 6.11 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.881 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -106.05 144.37 32.85 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.417 -1.049 . . . . 0.0 110.241 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.974 ' HA ' HD13 ' A' ' 298' ' ' LEU . 10.8 p -145.75 145.95 31.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.3 -0.875 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.822 HG21 HG11 ' A' ' 319' ' ' VAL . 76.1 t -70.99 134.83 29.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.329 -0.857 . . . . 0.0 109.88 179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.45 -37.29 0.8 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.081 -179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 67.6 m -131.55 128.15 38.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.06 -1.259 . . . . 0.0 110.919 -179.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.7 p90 -144.78 157.73 44.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.377 -0.827 . . . . 0.0 109.794 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.487 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -150.55 159.52 44.44 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.007 -1.058 . . . . 0.0 111.236 -179.329 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.53 ' OG ' ' CZ3' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 59.45 24.81 13.49 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.562 -0.712 . . . . 0.0 110.679 179.735 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.72 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 142.56 0.77 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 110.213 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.852 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -81.09 113.97 19.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.084 -1.01 . . . . 0.0 109.383 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.559 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 18.6 ttpt -82.56 149.71 27.33 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-O 121.762 0.792 . . . . 0.0 110.459 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.823 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -134.13 170.63 15.39 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.481 ' HG2' HG22 ' A' ' 319' ' ' VAL . 15.8 mt-10 -142.41 95.17 2.75 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.595 -0.69 . . . . 0.0 110.165 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.14 -80.28 0.44 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -160.93 77.5 0.58 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.433 -1.04 . . . . 0.0 108.812 179.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.617 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.34 11.25 54.64 Favored Glycine 0 N--CA 1.487 2.082 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.812 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.3 m-85 -143.06 -166.97 2.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.736 -0.861 . . . . 0.0 108.709 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.823 HG22 ' O ' ' A' ' 313' ' ' GLN . 2.5 t -163.52 160.19 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.01 -1.056 . . . . 0.0 109.454 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.773 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.3 mm -128.98 145.22 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.891 -1.131 . . . . 0.0 111.136 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.0 m-85 -123.04 129.33 51.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.156 -0.965 . . . . 0.0 110.378 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.707 HG23 HG23 ' A' ' 293' ' ' THR . 3.0 p -131.01 167.73 20.32 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 120.72 -1.237 . . . . 0.0 110.014 179.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.512 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.0 Cg_endo -66.1 128.68 20.07 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.861 1.453 . . . . 0.0 110.915 -179.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.852 HG12 ' ND2' ' A' ' 311' ' ' ASN . 34.6 m -78.01 -122.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.51 -0.744 . . . . 0.0 110.114 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.598 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -101.83 -21.43 14.58 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.757 -1.214 . . . . 0.0 110.631 -179.651 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.61 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.9 p-90 -126.46 5.55 6.91 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.173 -0.955 . . . . 0.0 110.578 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.772 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.8 OUTLIER -108.39 49.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.156 -0.965 . . . . 0.0 110.125 -179.8 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.478 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -133.84 -4.83 2.82 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.107 -0.996 . . . . 0.0 110.404 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.466 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.56 -155.72 0.05 OUTLIER Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.426 ' C ' ' OG1' ' A' ' 331' ' ' THR . 46.9 Cg_endo -73.65 3.06 5.18 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.915 1.482 . . . . 0.0 110.749 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.426 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.8 m -163.03 120.52 1.94 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 110.061 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.561 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -141.0 112.71 7.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.261 -0.899 . . . . 0.0 110.277 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.861 ' OG1' HG23 ' A' ' 283' ' ' THR . 38.1 m -104.49 138.92 40.16 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 110.049 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.72 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 13.6 p90 -142.85 172.37 12.79 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.89 160.29 28.44 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 118.755 -1.688 . . . . 0.0 110.333 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.919 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -147.32 145.24 29.28 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.481 -1.011 . . . . 0.0 110.048 179.485 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.919 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.81 119.86 61.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.094 -1.004 . . . . 0.0 109.783 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.799 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.8 t -96.96 145.83 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -112.68 126.51 55.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 110.014 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.967 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.698 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.3 mtmt . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 121.204 0.526 . . . . 0.0 111.076 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.731 HG11 ' CE1' ' A' ' 280' ' ' TYR . 4.3 p -133.59 120.08 36.38 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.203 -0.935 . . . . 0.0 110.402 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.5 mm-40 -50.2 -47.02 54.91 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.979 -1.076 . . . . 0.0 109.643 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.444 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 1.2 pt-20 -177.88 158.99 1.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.616 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.745 HG12 HG13 ' A' ' 296' ' ' VAL . 62.9 mt -118.67 121.77 67.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.268 -0.895 . . . . 0.0 110.22 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.76 139.75 53.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.193 -0.942 . . . . 0.0 110.215 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.41 130.61 45.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.177 -0.952 . . . . 0.0 110.284 179.818 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.442 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.8 OUTLIER -138.0 110.64 7.57 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.354 -0.842 . . . . 0.0 109.572 179.784 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.801 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 110.01 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.973 . . . . 0.0 110.464 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.53 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 39.12 31.21 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.661 -0.649 . . . . 0.0 110.52 179.758 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.54 -19.3 12.83 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.411 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.8 OUTLIER -85.82 104.39 15.45 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.2 -1.176 . . . . 0.0 110.437 -179.868 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.848 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.0 p -72.03 128.66 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.09 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.848 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.1 mm . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.156 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.264 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.553 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -133.74 163.24 29.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.397 -1.061 . . . . 0.0 109.865 179.862 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.87 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.6 tm? -161.59 133.34 5.58 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.055 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.794 ' N ' HD22 ' A' ' 267' ' ' LEU . 7.9 mt-10 -132.92 128.1 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 281' ' ' ASP . 61.9 t -120.28 137.28 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 120.894 -1.129 . . . . 0.0 111.569 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.51 156.93 33.13 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.703 HG13 ' O ' ' A' ' 279' ' ' GLU . 78.1 t -142.56 145.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.325 -1.484 . . . . 0.0 112.288 -179.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.547 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -138.57 111.38 7.72 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.443 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.0 147.04 23.83 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.209 -0.932 . . . . 0.0 111.304 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.843 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.2 p90 -131.92 16.16 4.72 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.455 -0.778 . . . . 0.0 109.818 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.62 -60.27 3.24 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.49 -23.3 66.23 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.124 . . . . 0.0 110.302 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.579 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.14 -178.53 45.06 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.618 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.31 142.9 47.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 110.554 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.703 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.6 mt-10 -93.93 147.21 23.31 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.53 -0.731 . . . . 0.0 109.653 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.661 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 96.9 m-85 -141.53 83.93 1.88 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.38 -0.825 . . . . 0.0 110.45 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.772 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.12 151.74 47.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.377 -0.827 . . . . 0.0 109.943 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.699 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -143.96 88.56 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.436 -0.79 . . . . 0.0 109.691 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.602 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.3 m -86.09 117.25 24.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 109.628 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.063 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -105.52 150.4 25.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.242 -0.912 . . . . 0.0 110.575 -179.263 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.897 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -131.15 134.95 47.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.451 -0.78 . . . . 0.0 110.016 -179.804 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.3 mt -142.32 152.07 42.59 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.811 -1.181 . . . . 0.0 109.535 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.89 38.49 0.92 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.31 -0.869 . . . . 0.0 109.3 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.98 -139.12 5.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.558 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 3.6 mt-30 -118.09 96.05 5.17 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.059 -1.26 . . . . 0.0 110.959 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.6 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -121.29 133.58 55.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.362 -0.836 . . . . 0.0 110.025 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.789 ' O ' HG23 ' A' ' 353' ' ' ILE . 67.6 m-20 -65.35 109.92 2.45 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.122 -0.986 . . . . 0.0 109.624 179.438 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.88 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.0 p-90 -107.99 116.15 31.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.105 -0.997 . . . . 0.0 110.835 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.604 HG23 HG23 ' A' ' 322' ' ' THR . 54.8 m -110.25 115.92 30.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.426 -0.797 . . . . 0.0 109.902 179.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.771 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.7 t -96.8 111.3 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.16 -0.963 . . . . 0.0 110.608 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.507 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.3 ttpt -90.07 130.11 36.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.254 -0.904 . . . . 0.0 109.404 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.82 HG22 HG23 ' A' ' 349' ' ' ILE . 76.3 t -127.86 108.1 17.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.254 -0.903 . . . . 0.0 110.513 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.662 ' O ' HG23 ' A' ' 346' ' ' VAL . 24.9 mmtt -70.08 138.3 51.91 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.148 -0.97 . . . . 0.0 109.09 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.968 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.7 mt -90.61 156.58 18.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.495 -0.753 . . . . 0.0 111.609 -178.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.801 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -60.72 175.33 0.44 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.629 -0.669 . . . . 0.0 109.381 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.57 80.53 0.6 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.547 1.288 . . . . 0.0 110.009 179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.76 21.27 5.77 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.801 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 152.89 23.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -1.045 . . . . 0.0 110.064 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.968 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -153.16 146.51 24.85 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.077 -1.014 . . . . 0.0 111.312 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.879 HG21 HG11 ' A' ' 319' ' ' VAL . 63.7 t -63.88 142.16 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.372 -0.83 . . . . 0.0 109.97 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -121.77 -39.63 0.56 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -142.01 120.17 12.18 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.045 -1.268 . . . . 0.0 110.713 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.511 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.7 p90 -132.88 166.41 22.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.905 . . . . 0.0 110.021 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -157.68 160.6 38.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.161 -0.962 . . . . 0.0 111.197 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 60.25 23.17 12.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 110.881 179.502 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.591 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.99 144.88 0.78 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.352 -0.843 . . . . 0.0 109.854 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.517 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -83.43 122.48 28.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.028 -1.045 . . . . 0.0 109.43 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.508 ' HG2' HG13 ' A' ' 319' ' ' VAL . 4.2 ttpt -89.7 140.29 29.72 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.877 0.846 . . . . 0.0 110.609 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.561 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.41 176.11 7.03 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -137.63 107.15 6.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.409 -0.807 . . . . 0.0 110.247 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.47 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -98.06 37.4 3.49 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.47 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.6 OUTLIER 68.43 88.17 0.11 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.226 -1.161 . . . . 0.0 110.448 179.852 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.37 6.95 83.34 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.801 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.0 m-85 -146.35 -170.81 3.59 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.305 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.879 HG11 HG21 ' A' ' 304' ' ' VAL . 6.5 t -162.28 156.25 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.894 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.53 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.2 mm -125.79 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.888 -1.133 . . . . 0.0 111.476 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 36.9 m-85 -114.37 131.18 56.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.273 -0.892 . . . . 0.0 109.532 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.604 HG23 HG23 ' A' ' 293' ' ' THR . 1.8 p -132.06 169.94 12.59 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 120.624 -1.297 . . . . 0.0 110.317 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -64.92 109.37 1.27 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.883 1.465 . . . . 0.0 110.923 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.735 HG23 ' H ' ' A' ' 325' ' ' SER . 6.2 m -48.18 -59.0 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.427 -0.796 . . . . 0.0 110.63 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.735 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.6 t 177.89 -25.91 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.991 -1.068 . . . . 0.0 111.133 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.428 ' CE2' HG21 ' A' ' 324' ' ' VAL . 7.1 p-90 -113.85 -22.87 9.93 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.958 -1.089 . . . . 0.0 110.912 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.985 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 0.0 OUTLIER -83.36 12.18 5.79 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.991 -1.068 . . . . 0.0 110.929 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 12.1 mtmt -74.12 -11.07 60.2 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.46 -0.775 . . . . 0.0 109.329 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.21 -158.13 0.01 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.542 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -73.06 7.14 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 124.069 1.562 . . . . 0.0 111.388 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 4.4 m -162.32 131.23 4.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.123 -0.986 . . . . 0.0 109.841 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.985 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -144.23 104.37 4.1 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.231 -0.918 . . . . 0.0 110.355 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.602 ' OG1' HG23 ' A' ' 283' ' ' THR . 48.2 m -100.98 135.16 42.87 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.058 -1.027 . . . . 0.0 110.312 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.771 ' HE2' HG21 ' A' ' 294' ' ' VAL . 6.6 p90 -144.39 173.14 12.04 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.67 157.54 27.24 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.478 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.911 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -144.35 144.81 31.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.598 -0.943 . . . . 0.0 110.01 179.512 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.911 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.31 118.65 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.099 -1.001 . . . . 0.0 109.589 179.614 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.732 HG21 ' CD2' ' A' ' 298' ' ' LEU . 2.2 t -96.67 150.06 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.241 -0.912 . . . . 0.0 109.855 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -122.57 133.8 54.55 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.437 -0.789 . . . . 0.0 110.333 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.153 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.897 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.778 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.2 mtmt . . . . . 0 N--CA 1.489 1.516 0 CA-C-O 121.196 0.522 . . . . 0.0 110.812 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 297' ' ' LYS . 7.5 p -132.08 118.17 35.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 110.46 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.498 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -46.76 -46.61 20.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.457 -0.777 . . . . 0.0 110.504 -179.845 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.417 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 9.2 pt-20 -177.27 158.93 1.53 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.041 -1.037 . . . . 0.0 110.803 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.82 HG23 HG22 ' A' ' 296' ' ' VAL . 44.9 mt -120.46 106.69 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.131 -0.98 . . . . 0.0 110.392 179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.49 136.48 51.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.225 -0.922 . . . . 0.0 110.228 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.063 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -95.71 134.35 38.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.238 -0.914 . . . . 0.0 110.332 179.83 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 6.2 tt0 -138.94 112.43 8.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.361 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.789 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.71 105.2 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.066 -1.021 . . . . 0.0 109.942 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.469 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 40.15 31.51 0.1 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.591 -0.693 . . . . 0.0 110.625 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 119.14 -22.08 9.15 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.403 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -85.35 105.29 15.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.255 -1.144 . . . . 0.0 110.096 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.58 ' O ' HD13 ' A' ' 358' ' ' ILE . 4.1 p -75.73 130.52 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.58 HD13 ' O ' ' A' ' 357' ' ' VAL . 27.0 mm . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.276 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.308 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.562 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.7 OUTLIER -133.62 165.85 23.96 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -1.079 . . . . 0.0 109.883 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.926 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.31 137.2 8.02 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.412 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.798 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mm-40 -132.94 154.09 50.78 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.702 HG13 ' O ' ' A' ' 281' ' ' ASP . 46.2 t -145.41 139.74 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.62 -1.3 . . . . 0.0 111.739 -179.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.08 154.84 45.24 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.609 HG13 ' O ' ' A' ' 279' ' ' GLU . 70.8 t -140.67 141.43 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.466 -1.396 . . . . 0.0 111.984 -179.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -134.41 110.25 9.3 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 179.205 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.483 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.2 m-20 -96.77 142.19 29.08 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.071 -1.018 . . . . 0.0 110.926 -178.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.838 ' CH2' HG23 ' A' ' 337' ' ' ILE . 26.0 p90 -123.16 15.31 9.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.312 -0.867 . . . . 0.0 110.223 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.14 -53.62 3.22 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -76.9 -16.6 59.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -1.136 . . . . 0.0 110.066 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.559 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.74 -178.68 43.87 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.851 -1.299 . . . . 0.0 109.851 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.546 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.88 138.63 39.27 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -1.111 . . . . 0.0 110.053 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.609 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.0 mt-10 -95.22 147.14 23.79 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.351 -0.843 . . . . 0.0 110.017 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.686 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.0 m-85 -140.17 89.27 2.28 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 110.814 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.702 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -71.34 148.48 47.01 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.324 -0.86 . . . . 0.0 109.639 179.239 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.694 HG11 HG11 ' A' ' 294' ' ' VAL . 3.6 t -142.69 92.29 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.413 -0.805 . . . . 0.0 109.968 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.934 HG23 ' OG1' ' A' ' 333' ' ' THR . 15.4 m -86.45 126.46 34.42 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.032 -1.043 . . . . 0.0 109.77 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.113 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -115.19 149.6 37.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.969 -1.082 . . . . 0.0 110.987 -179.081 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.892 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -129.67 133.78 47.29 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.334 -0.854 . . . . 0.0 110.071 -179.691 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 1.059 HD13 ' HB2' ' A' ' 290' ' ' TYR . 17.8 mt -142.1 162.94 34.2 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.65 -1.281 . . . . 0.0 110.055 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -87.65 29.71 0.87 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.921 . . . . 0.0 110.473 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.514 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.09 -136.82 6.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.47 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 32.4 mm-40 -90.11 104.74 17.28 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.276 -1.132 . . . . 0.0 110.873 -179.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 1.059 ' HB2' HD13 ' A' ' 286' ' ' LEU . 8.4 m-85 -128.43 129.61 46.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.398 -0.814 . . . . 0.0 109.265 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.781 ' O ' HG23 ' A' ' 353' ' ' ILE . 58.9 m-20 -74.6 96.31 2.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.742 -1.224 . . . . 0.0 109.369 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.935 ' CE3' HD13 ' A' ' 284' ' ' LEU . 60.3 p-90 -98.01 115.43 28.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 110.689 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.872 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.6 m -109.51 115.78 30.56 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.52 -0.738 . . . . 0.0 109.425 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.781 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.6 t -96.89 111.27 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.106 -0.996 . . . . 0.0 110.394 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.593 ' HA ' HD13 ' A' ' 320' ' ' ILE . 21.2 ttpt -91.29 136.5 33.05 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.804 HG22 HG23 ' A' ' 349' ' ' ILE . 69.9 t -135.46 109.2 10.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.136 -0.978 . . . . 0.0 110.634 -179.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.54 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 53.8 mmtt -69.97 132.77 46.46 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.243 -0.911 . . . . 0.0 109.32 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.899 HD13 ' HA ' ' A' ' 303' ' ' THR . 60.1 mt -86.68 165.45 16.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.304 -0.872 . . . . 0.0 111.198 -179.062 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.773 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -75.69 176.43 3.21 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.752 -0.593 . . . . 0.0 109.43 179.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.773 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.0 Cg_endo -67.6 84.94 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.527 1.278 . . . . 0.0 109.955 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.87 20.95 6.57 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.2 142.37 43.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.274 -1.133 . . . . 0.0 110.23 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.899 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.0 p -150.28 144.36 25.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -0.941 . . . . 0.0 110.834 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.803 HG21 HG11 ' A' ' 319' ' ' VAL . 14.7 t -63.75 137.37 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.388 -0.82 . . . . 0.0 110.193 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -120.69 -33.15 1.03 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 24.7 m -138.86 117.14 11.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.223 -1.163 . . . . 0.0 110.441 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.518 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.4 p90 -133.91 148.38 51.22 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.288 -0.883 . . . . 0.0 109.908 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.5 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -141.23 164.53 30.01 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.14 -0.975 . . . . 0.0 111.173 -179.433 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.501 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 54.33 25.13 5.64 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.728 -0.607 . . . . 0.0 111.173 179.499 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.679 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 138.65 0.64 Allowed 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.099 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.69 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -76.89 120.08 21.53 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.074 -1.017 . . . . 0.0 108.711 179.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.672 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.3 ttpt -88.43 128.05 35.52 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.824 0.821 . . . . 0.0 110.799 -178.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.557 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -113.31 175.73 5.32 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -135.5 110.56 8.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.292 -0.88 . . . . 0.0 110.731 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.574 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -95.35 40.56 2.64 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.0 77.65 0.26 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.233 -1.157 . . . . 0.0 109.962 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.616 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.96 3.56 54.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.772 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -145.12 -170.76 3.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.486 -1.008 . . . . 0.0 109.003 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.803 HG11 HG21 ' A' ' 304' ' ' VAL . 18.2 t -161.39 157.74 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.199 -0.938 . . . . 0.0 109.691 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.624 ' CG2' HG22 ' A' ' 293' ' ' THR . 13.0 mm -127.03 146.79 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -0.922 . . . . 0.0 110.885 -179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 91.0 m-85 -124.12 119.19 28.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.321 -0.862 . . . . 0.0 109.814 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.872 ' CG2' HG23 ' A' ' 293' ' ' THR . 12.6 p -121.11 168.0 11.92 Favored Pre-proline 0 C--N 1.301 -1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.641 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.524 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.5 Cg_endo -66.28 117.97 5.13 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.692 1.364 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.797 HG23 ' H ' ' A' ' 326' ' ' TRP . 23.9 m -65.72 -130.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.507 -0.746 . . . . 0.0 110.332 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.613 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.9 t -96.94 -12.84 22.89 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.08 -1.013 . . . . 0.0 110.554 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.797 ' H ' HG23 ' A' ' 324' ' ' VAL . 34.0 p-90 -133.46 5.53 3.75 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.07 -1.019 . . . . 0.0 110.946 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.783 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.3 t-20 -112.45 42.89 1.73 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.998 -1.064 . . . . 0.0 110.768 -179.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.504 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.8 OUTLIER -122.97 0.95 9.23 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.338 -0.851 . . . . 0.0 109.71 179.064 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -63.69 -158.79 0.23 Allowed Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.514 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 47.8 Cg_endo -75.36 3.88 5.41 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.999 1.526 . . . . 0.0 110.767 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.6 m -165.02 117.6 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.16 -0.963 . . . . 0.0 109.814 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.561 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.18 123.7 17.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.274 -0.891 . . . . 0.0 110.373 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.934 ' OG1' HG23 ' A' ' 283' ' ' THR . 40.9 m -111.58 142.07 44.36 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 109.99 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.781 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.0 p90 -143.95 174.82 10.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.515 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.04 158.05 27.49 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.288 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.943 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -144.97 147.44 32.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.476 -1.014 . . . . 0.0 110.041 179.627 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.943 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.6 118.93 58.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.005 -1.059 . . . . 0.0 109.704 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.5 t -96.73 147.27 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.113 -0.992 . . . . 0.0 110.095 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.475 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.15 137.85 53.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.339 -0.85 . . . . 0.0 110.332 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.435 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.188 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.534 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.488 1.461 0 CA-C-O 121.369 0.604 . . . . 0.0 110.29 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.594 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 7.5 p -130.22 117.84 41.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -0.839 . . . . 0.0 110.568 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.0 mt-10 -47.08 -46.98 23.03 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 110.141 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.437 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.74 158.34 1.66 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.291 -0.88 . . . . 0.0 110.59 -179.843 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.804 HG23 HG22 ' A' ' 296' ' ' VAL . 33.1 mt -118.26 105.99 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.336 -0.852 . . . . 0.0 110.289 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.86 143.02 38.62 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.959 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.113 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.37 130.91 54.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.115 -0.991 . . . . 0.0 110.442 -179.867 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 15.0 tt0 -139.13 114.69 9.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.875 . . . . 0.0 109.823 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.781 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -91.38 111.52 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.014 -1.054 . . . . 0.0 109.744 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.564 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 39.86 30.28 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.793 -0.567 . . . . 0.0 110.44 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 115.88 -15.02 16.69 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.473 ' O ' ' N ' ' A' ' 353' ' ' ILE . 0.0 OUTLIER -89.54 108.06 19.44 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.128 -1.219 . . . . 0.0 110.412 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.677 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -73.09 123.99 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.165 -0.959 . . . . 0.0 110.125 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.677 HD13 ' O ' ' A' ' 357' ' ' VAL . 20.6 mm . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.423 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 110.505 -1.038 . . . . 0.0 110.505 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.558 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.79 167.89 21.0 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.64 -0.918 . . . . 0.0 109.533 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.862 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.47 133.96 5.98 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.0 -1.08 . . . . 0.0 111.266 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.828 ' N ' HD22 ' A' ' 267' ' ' LEU . 14.3 mm-40 -134.33 129.62 35.77 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 281' ' ' ASP . 89.5 t -125.9 139.54 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.853 -1.154 . . . . 0.0 111.625 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.1 mtmt -124.9 157.56 35.67 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.745 HG13 ' O ' ' A' ' 279' ' ' GLU . 74.5 t -141.62 146.73 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.43 -1.418 . . . . 0.0 112.068 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.557 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -136.28 107.9 6.99 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.309 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.2 m-20 -94.74 142.44 27.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.997 -1.064 . . . . 0.0 111.1 -179.03 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.811 ' CH2' HG23 ' A' ' 337' ' ' ILE . 25.6 p90 -123.97 17.06 9.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.44 -0.787 . . . . 0.0 109.831 179.173 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.43 -55.54 3.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.31 -18.94 58.7 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.227 -1.161 . . . . 0.0 110.286 -179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.24 -179.37 40.63 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.551 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -139.06 137.13 35.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -1.111 . . . . 0.0 110.173 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.745 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.6 mt-10 -92.7 146.84 23.35 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.264 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.2 m-85 -139.98 90.34 2.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.201 -0.937 . . . . 0.0 111.265 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.796 ' O ' HG13 ' A' ' 269' ' ' VAL . 4.7 t70 -72.62 146.92 46.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.51 -0.744 . . . . 0.0 109.408 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.71 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.4 t -140.77 86.94 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.184 -0.947 . . . . 0.0 110.094 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 1.003 HG23 ' OG1' ' A' ' 333' ' ' THR . 13.2 m -86.74 122.88 31.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.069 -1.019 . . . . 0.0 110.04 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.09 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.56 154.05 22.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 0.0 110.226 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.558 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -133.69 113.75 12.7 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.106 -0.996 . . . . 0.0 110.89 -179.071 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.988 HD13 ' HB2' ' A' ' 290' ' ' TYR . 13.3 mt -123.83 158.59 31.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.549 -1.345 . . . . 0.0 109.884 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.1 35.22 0.85 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.292 -0.88 . . . . 0.0 109.807 179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 154.92 -134.25 4.15 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.515 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 47.5 mm-40 -106.84 111.63 24.24 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.177 -1.19 . . . . 0.0 111.026 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.988 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.9 m-85 -132.06 136.96 47.59 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.336 -0.852 . . . . 0.0 109.301 179.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.778 ' O ' HG23 ' A' ' 353' ' ' ILE . 31.1 m-20 -75.37 96.42 3.4 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.756 -1.215 . . . . 0.0 108.617 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.932 ' CE3' HD13 ' A' ' 284' ' ' LEU . 61.3 p-90 -99.6 114.1 26.93 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.449 -0.782 . . . . 0.0 110.904 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 1.011 HG23 HG22 ' A' ' 322' ' ' THR . 27.3 m -111.43 118.09 34.84 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.155 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.755 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.1 t -96.75 111.0 25.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.183 -0.948 . . . . 0.0 110.737 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.585 ' HA ' HD13 ' A' ' 320' ' ' ILE . 7.0 ttpp -83.34 148.6 27.24 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.441 -0.787 . . . . 0.0 109.012 178.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.594 HG13 ' CG2' ' A' ' 346' ' ' VAL . 44.5 t -147.3 104.99 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.096 -1.003 . . . . 0.0 110.707 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.604 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.7 mmtp -70.63 133.14 46.42 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 179.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 1.038 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.0 mt -86.37 150.28 24.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 111.474 -179.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.675 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -61.0 171.89 1.01 Allowed Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.686 -0.634 . . . . 0.0 109.681 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.675 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.2 Cg_endo -67.53 82.58 0.41 Allowed 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.785 1.413 . . . . 0.0 109.642 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.11 28.27 2.68 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.72 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -122.32 146.36 47.38 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.373 -1.075 . . . . 0.0 110.557 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 1.038 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.3 p -149.57 143.59 25.68 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.185 -0.947 . . . . 0.0 110.748 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.988 ' CG2' HG21 ' A' ' 319' ' ' VAL . 66.8 t -68.48 130.76 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 110.246 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -114.04 -39.33 1.06 Allowed Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 18.1 m -132.64 141.67 48.75 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.188 -1.184 . . . . 0.0 110.913 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.569 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 28.5 p90 -153.75 167.96 27.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.363 -0.836 . . . . 0.0 109.656 179.465 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.505 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -160.67 158.43 28.82 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.995 -1.066 . . . . 0.0 111.253 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.555 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.61 31.96 21.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.631 -0.668 . . . . 0.0 111.245 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.785 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.91 150.85 1.04 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.049 -1.032 . . . . 0.0 110.457 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.51 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 1.9 m-80 -81.22 109.7 16.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.088 -1.007 . . . . 0.0 109.439 179.012 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.569 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 27.6 ttpt -84.97 132.52 34.34 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.46 -0.775 . . . . 0.0 110.603 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.695 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.07 174.73 7.83 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.53 -0.731 . . . . 0.0 109.465 179.329 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -138.2 104.68 5.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.523 -0.736 . . . . 0.0 110.064 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -92.0 37.93 3.29 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.12 81.24 0.21 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.048 -1.266 . . . . 0.0 110.253 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.25 -0.04 57.12 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.716 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.33 -171.33 3.71 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.347 -1.09 . . . . 0.0 109.359 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.988 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -159.46 157.91 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.117 -0.989 . . . . 0.0 109.844 178.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.585 HD13 ' HA ' ' A' ' 295' ' ' LYS . 8.7 mm -125.87 150.32 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.073 -1.017 . . . . 0.0 111.376 -179.176 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.638 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 89.3 m-85 -130.98 112.49 12.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.301 -0.874 . . . . 0.0 110.285 179.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 1.011 HG22 HG23 ' A' ' 293' ' ' THR . 2.8 p -115.02 174.23 2.48 Favored Pre-proline 0 N--CA 1.498 1.973 0 O-C-N 120.512 -1.367 . . . . 0.0 109.54 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.601 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 43.1 Cg_endo -71.13 125.07 11.07 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.607 1.319 . . . . 0.0 111.283 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.764 HG22 ' CG ' ' A' ' 327' ' ' ASN . 14.9 m -70.06 -110.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.518 -0.739 . . . . 0.0 110.438 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.522 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.1 OUTLIER -119.42 -16.95 8.88 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.715 -1.241 . . . . 0.0 111.299 -179.277 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.499 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 3.1 p-90 -125.93 -18.9 4.97 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.914 -1.116 . . . . 0.0 111.077 -179.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.764 ' CG ' HG22 ' A' ' 324' ' ' VAL . 34.0 p-10 -89.7 47.28 1.45 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.928 -1.108 . . . . 0.0 110.046 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.501 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 13.5 mtmt -118.26 -10.09 10.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.493 -0.754 . . . . 0.0 109.426 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.24 -157.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.549 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -74.73 5.69 3.71 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.03 1.542 . . . . 0.0 111.077 -179.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 3.6 m -161.93 120.03 2.25 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.874 179.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.41 117.78 14.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.222 -0.924 . . . . 0.0 110.361 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 1.003 ' OG1' HG23 ' A' ' 283' ' ' THR . 26.2 m -109.68 135.28 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 110.434 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.785 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 13.4 p90 -142.82 174.44 10.65 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.09 162.94 29.35 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.582 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.899 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -150.84 145.05 25.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.567 -0.961 . . . . 0.0 109.558 179.352 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.899 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -118.89 122.4 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.058 -1.026 . . . . 0.0 110.069 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.72 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -98.36 146.06 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.22 -0.925 . . . . 0.0 109.695 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -119.39 137.22 53.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 110.729 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.469 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.492 2.397 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.725 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.576 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.322 0.582 . . . . 0.0 110.742 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 346' ' ' VAL . 7.1 p -131.46 111.22 18.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.1 mm-40 -43.14 -46.83 6.03 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.202 -0.936 . . . . 0.0 110.425 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -175.95 157.78 1.95 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 110.357 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.586 HG12 HG22 ' A' ' 296' ' ' VAL . 13.5 mt -118.43 104.36 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.243 -0.911 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.03 126.83 52.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 110.499 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.09 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -91.11 130.17 37.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.03 -1.044 . . . . 0.0 110.025 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -138.55 117.59 12.54 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.31 -0.869 . . . . 0.0 109.549 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.778 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.11 98.19 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.921 -1.112 . . . . 0.0 110.118 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.542 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 38.57 28.24 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.296 179.634 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 134.94 -19.47 3.92 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.889 179.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 11.1 mm100 -102.78 113.15 26.33 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.871 -1.37 . . . . 0.0 110.905 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.587 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.7 p -76.89 121.17 28.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.485 -0.759 . . . . 0.0 110.354 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.511 ' HB ' HD13 ' A' ' 351' ' ' LEU . 26.7 mm . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.165 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.538 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.41 166.08 25.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.334 -1.098 . . . . 0.0 110.043 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.927 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.65 139.77 9.22 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.025 -1.047 . . . . 0.0 111.409 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.793 ' N ' HD22 ' A' ' 267' ' ' LEU . 3.7 mt-10 -136.12 153.78 51.19 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.704 HG13 ' O ' ' A' ' 281' ' ' ASP . 54.0 t -145.27 135.67 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.697 -1.252 . . . . 0.0 111.567 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.411 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.7 mtpt -122.88 157.05 33.38 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.822 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.5 t -144.81 147.2 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.478 -1.389 . . . . 0.0 112.167 -179.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.64 112.64 7.35 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.791 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 p-10 -97.53 141.76 30.19 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.948 -1.095 . . . . 0.0 111.402 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.779 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.3 p90 -124.5 19.99 8.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.502 -0.748 . . . . 0.0 109.8 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.74 -59.58 4.75 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.852 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.99 -20.07 66.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -1.159 . . . . 0.0 110.11 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.48 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.12 -175.03 44.93 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.4 143.94 42.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -1.138 . . . . 0.0 110.225 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.822 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.9 mt-10 -96.97 145.83 25.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.385 -0.822 . . . . 0.0 109.789 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.681 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 96.1 m-85 -138.93 86.73 2.16 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.452 -0.78 . . . . 0.0 110.92 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.704 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.59 146.83 49.84 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.316 -0.865 . . . . 0.0 109.442 179.105 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.825 HG11 HG11 ' A' ' 294' ' ' VAL . 5.6 t -140.22 90.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 121.336 -0.853 . . . . 0.0 109.932 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.891 HG23 ' OG1' ' A' ' 333' ' ' THR . 53.9 m -86.58 127.92 34.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.058 -1.026 . . . . 0.0 109.681 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.89 152.1 32.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.127 -0.983 . . . . 0.0 110.687 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.902 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -130.56 134.54 47.1 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.282 -0.886 . . . . 0.0 110.263 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.902 HD23 ' O ' ' A' ' 285' ' ' ASN . 12.7 mt -143.72 155.55 44.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.938 -1.101 . . . . 0.0 109.491 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -88.6 40.02 0.95 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 109.723 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 150.3 -116.69 0.79 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.991 -1.576 . . . . 0.0 110.242 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.559 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.6 mt-30 -128.62 116.31 19.4 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.022 -1.281 . . . . 0.0 110.926 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.599 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 8.8 m-85 -138.23 137.03 37.15 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.191 -0.943 . . . . 0.0 109.664 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.717 ' O ' HG23 ' A' ' 353' ' ' ILE . 23.2 m-20 -71.02 96.81 1.36 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.815 -1.178 . . . . 0.0 108.981 179.043 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.867 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.2 p-90 -98.08 113.1 24.89 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.221 -0.924 . . . . 0.0 110.833 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.663 HG23 ' CG2' ' A' ' 322' ' ' THR . 10.3 m -106.23 111.75 24.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.417 -0.802 . . . . 0.0 109.243 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.825 HG11 HG11 ' A' ' 282' ' ' VAL . 3.1 t -96.21 111.24 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.167 -0.958 . . . . 0.0 110.371 -179.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.53 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 5.1 ttmt -89.19 149.51 23.09 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.438 -0.788 . . . . 0.0 109.51 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.914 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 56.1 t -142.34 107.87 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.288 -0.882 . . . . 0.0 110.31 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.555 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 11.5 mmtt -70.2 131.34 44.07 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.179 -0.95 . . . . 0.0 109.645 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.941 HD13 ' HA ' ' A' ' 303' ' ' THR . 94.8 mt -85.25 160.89 19.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.81 . . . . 0.0 111.312 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.714 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -71.43 174.32 4.01 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 121.571 -0.705 . . . . 0.0 109.212 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.43 84.08 0.37 Allowed 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 123.492 1.259 . . . . 0.0 110.096 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.97 24.66 4.79 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.8 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.9 148.32 40.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -1.104 . . . . 0.0 110.225 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.941 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -149.84 143.6 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.104 -0.998 . . . . 0.0 110.718 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.736 HG21 HG11 ' A' ' 319' ' ' VAL . 85.2 t -65.63 121.94 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.418 -0.801 . . . . 0.0 109.906 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -103.16 -30.25 5.46 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.3 t -145.85 142.32 28.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.004 -1.292 . . . . 0.0 110.911 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.518 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 15.0 p90 -152.6 174.65 13.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.544 -0.722 . . . . 0.0 109.38 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.479 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -163.84 159.55 21.26 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.848 -1.158 . . . . 0.0 111.486 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.452 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.7 OUTLIER 55.68 26.41 9.3 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.564 -0.71 . . . . 0.0 111.116 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.716 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.68 139.25 0.7 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.195 -0.941 . . . . 0.0 109.897 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.68 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.3 m-80 -77.42 121.24 23.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.062 -1.024 . . . . 0.0 109.488 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.533 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.3 ttpt -88.33 142.81 27.44 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.844 0.83 . . . . 0.0 110.552 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.622 ' O ' HG22 ' A' ' 319' ' ' VAL . 1.6 mt-30 -130.25 176.48 8.07 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.255 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.454 ' OE1' ' O ' ' A' ' 318' ' ' TYR . 5.3 mm-40 -135.79 113.32 10.8 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.115 -0.99 . . . . 0.0 110.545 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.6 42.13 2.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.47 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 20.6 t-20 57.41 81.49 0.14 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.335 -1.097 . . . . 0.0 110.269 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.82 3.74 58.08 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.843 ' O ' HG23 ' A' ' 319' ' ' VAL . 0.8 OUTLIER -147.08 -167.72 2.85 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.353 -1.087 . . . . 0.0 109.055 179.532 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.843 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.7 t -163.28 147.73 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.195 -0.94 . . . . 0.0 109.733 178.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.619 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.6 mm -112.35 152.06 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.005 -1.06 . . . . 0.0 110.998 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 58.4 m-85 -129.24 125.86 37.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.812 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.663 ' CG2' HG23 ' A' ' 293' ' ' THR . 7.2 p -129.04 167.7 18.71 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 120.488 -1.382 . . . . 0.0 109.965 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.552 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 38.7 Cg_endo -65.74 119.36 6.37 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.78 1.411 . . . . 0.0 111.087 -179.233 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.68 HG12 ' ND2' ' A' ' 311' ' ' ASN . 31.3 m -64.73 -121.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.485 -0.759 . . . . 0.0 110.297 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.512 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -106.18 -19.9 13.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.809 -1.182 . . . . 0.0 110.666 -179.649 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.567 ' H ' HG23 ' A' ' 324' ' ' VAL . 21.6 p-90 -126.2 3.17 7.13 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.08 -1.012 . . . . 0.0 110.653 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.532 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 1.9 t-20 -108.08 31.72 5.32 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.093 -1.005 . . . . 0.0 110.576 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.552 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -110.46 -2.6 16.47 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.102 -0.999 . . . . 0.0 109.547 179.433 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.05 -153.33 0.02 OUTLIER Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.565 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.6 Cg_endo -69.8 -48.89 0.62 Allowed 'Trans proline' 0 C--N 1.301 -1.935 0 O-C-N 123.987 1.52 . . . . 0.0 109.474 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.08 125.58 52.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.527 -0.733 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.74 108.09 6.86 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.36 -0.838 . . . . 0.0 109.993 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.891 ' OG1' HG23 ' A' ' 283' ' ' THR . 3.3 m -103.17 138.92 39.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 110.227 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.805 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.0 p90 -144.74 174.63 10.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.374 -0.829 . . . . 0.0 109.138 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.04 158.26 27.59 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 118.984 -1.579 . . . . 0.0 110.336 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.914 ' CZ ' HG11 ' A' ' 296' ' ' VAL . 0.9 OUTLIER -147.93 143.87 27.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.57 -0.959 . . . . 0.0 109.553 179.321 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.887 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -118.01 129.67 74.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.073 -1.017 . . . . 0.0 110.107 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.8 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.3 t -104.92 148.48 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.027 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -120.7 135.47 55.12 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 110.181 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.431 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.93 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.658 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.1 mtmt . . . . . 0 N--CA 1.488 1.467 0 CA-C-O 121.25 0.548 . . . . 0.0 110.335 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.628 HG11 ' CE1' ' A' ' 280' ' ' TYR . 6.8 p -128.91 117.4 44.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.309 -0.869 . . . . 0.0 110.107 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.2 OUTLIER -47.57 -47.88 28.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.046 -1.034 . . . . 0.0 110.068 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.409 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.7 OUTLIER -177.2 158.33 1.47 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.289 -0.882 . . . . 0.0 110.35 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.661 HG12 HG13 ' A' ' 296' ' ' VAL . 17.0 mt -117.34 110.37 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 110.215 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.67 144.03 41.59 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.271 -0.893 . . . . 0.0 110.2 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.66 132.77 50.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.18 -0.95 . . . . 0.0 110.249 179.869 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -139.07 113.13 8.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.945 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.717 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.8 mt -91.64 112.53 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.913 -1.117 . . . . 0.0 110.088 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.548 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.84 29.72 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.782 -0.574 . . . . 0.0 111.295 -179.961 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.26 -10.24 14.98 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.667 -1.254 . . . . 0.0 110.6 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.402 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 43.1 mm-40 -101.45 115.06 29.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.878 -1.366 . . . . 0.0 110.364 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.79 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.1 p -75.13 139.09 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.279 -0.888 . . . . 0.0 110.493 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.79 HD13 ' O ' ' A' ' 357' ' ' VAL . 26.6 mm . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.196 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.583 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.3 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.554 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.8 OUTLIER -136.0 167.06 21.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.447 -1.031 . . . . 0.0 109.495 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.953 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.9 tm? -161.06 136.84 8.05 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.515 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.821 ' N ' HD22 ' A' ' 267' ' ' LEU . 8.0 mm-40 -135.69 156.12 49.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.865 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.9 t -146.96 146.29 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.648 -1.283 . . . . 0.0 111.617 -179.249 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.418 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.2 OUTLIER -132.4 157.6 44.14 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.186 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 279' ' ' GLU . 86.7 t -144.88 147.2 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 120.262 -1.524 . . . . 0.0 112.401 -179.258 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.522 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.46 114.58 8.66 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.906 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.0 p-10 -97.81 148.73 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.087 -1.008 . . . . 0.0 111.366 -178.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.8 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.1 p90 -134.85 17.42 3.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.608 -0.682 . . . . 0.0 109.96 179.381 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 92.46 -66.28 2.05 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.489 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 57.4 m -64.3 -18.77 64.92 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.322 -1.105 . . . . 0.0 110.581 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.532 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -179.24 178.65 48.82 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.164 -1.493 . . . . 0.0 110.246 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.54 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.66 145.99 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.505 -0.997 . . . . 0.0 110.019 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.724 ' O ' HG13 ' A' ' 271' ' ' VAL . 11.4 mt-10 -96.36 146.86 24.38 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.433 -0.792 . . . . 0.0 109.425 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.2 m-85 -138.33 89.17 2.36 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.31 -0.869 . . . . 0.0 110.584 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.865 ' O ' HG13 ' A' ' 269' ' ' VAL . 71.4 m-20 -69.64 147.49 50.57 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.679 -0.638 . . . . 0.0 109.828 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.693 HG11 HG11 ' A' ' 294' ' ' VAL . 3.4 t -142.76 89.96 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.355 -0.84 . . . . 0.0 109.543 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.876 HG23 ' OG1' ' A' ' 333' ' ' THR . 27.3 m -86.49 120.51 27.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.106 -0.996 . . . . 0.0 109.857 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.34 149.37 28.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.602 -179.478 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.907 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -128.04 136.21 50.93 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.395 -0.816 . . . . 0.0 110.084 -179.799 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.907 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.2 mt -142.17 154.52 44.9 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.721 -1.237 . . . . 0.0 109.854 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -85.77 36.27 0.65 Allowed 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.381 -0.825 . . . . 0.0 110.311 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.486 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 150.56 -104.12 0.26 Allowed Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.082 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.5 mm-40 -139.87 113.67 8.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.015 -1.285 . . . . 0.0 111.429 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.639 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 4.8 m-85 -138.75 129.93 26.95 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.536 ' O ' HG23 ' A' ' 353' ' ' ILE . 90.0 m-20 -65.16 99.69 0.39 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.817 -1.177 . . . . 0.0 109.266 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.897 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.4 p-90 -98.77 115.86 29.72 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.335 -0.853 . . . . 0.0 110.868 -179.27 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.6 HG22 ' CG2' ' A' ' 320' ' ' ILE . 9.8 m -105.98 116.26 31.63 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.66 -0.65 . . . . 0.0 109.299 179.538 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.774 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.75 111.44 26.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.02 -1.05 . . . . 0.0 110.662 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.793 ' HA ' HD13 ' A' ' 320' ' ' ILE . 2.8 ttpt -85.44 144.03 28.22 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.431 -0.793 . . . . 0.0 109.156 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.958 HG22 HG23 ' A' ' 349' ' ' ILE . 99.0 t -144.34 106.84 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.028 -1.045 . . . . 0.0 110.662 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.564 ' HD3' ' CG ' ' A' ' 318' ' ' TYR . 35.7 mmtt -70.57 130.38 41.67 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.27 -0.894 . . . . 0.0 109.804 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.958 HD13 ' HA ' ' A' ' 303' ' ' THR . 77.2 mt -85.38 155.08 21.45 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.516 -0.74 . . . . 0.0 111.398 -178.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.784 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -59.7 176.23 0.33 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.54 -0.725 . . . . 0.0 109.409 179.106 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.784 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.5 Cg_endo -69.19 81.07 0.69 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.612 1.322 . . . . 0.0 109.895 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.2 4.9 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.811 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -110.24 149.7 29.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.417 -1.049 . . . . 0.0 110.188 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.958 ' HA ' HD13 ' A' ' 298' ' ' LEU . 9.5 p -150.15 145.08 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 110.573 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.724 HG21 HG11 ' A' ' 319' ' ' VAL . 77.5 t -71.25 122.6 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.527 -0.733 . . . . 0.0 109.865 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -103.5 -37.99 2.91 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.461 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -132.29 136.4 46.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.076 -1.249 . . . . 0.0 111.035 -179.559 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.59 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 50.3 p90 -147.67 159.91 43.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.458 -0.776 . . . . 0.0 109.468 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.516 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -154.65 158.13 39.19 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.976 -1.077 . . . . 0.0 111.239 -179.46 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.2 OUTLIER 63.98 20.39 12.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.553 -0.717 . . . . 0.0 110.532 179.63 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.543 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.76 147.44 1.03 Allowed 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.564 -0.71 . . . . 0.0 110.022 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.726 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -82.07 123.81 29.27 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.109 -0.994 . . . . 0.0 108.982 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.59 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 11.6 ttpt -89.42 137.96 31.87 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.63 0.729 . . . . 0.0 111.217 -178.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.682 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.15 172.36 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.776 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -139.28 104.49 5.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.201 -0.937 . . . . 0.0 110.506 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.466 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -92.31 40.37 2.89 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.466 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 0.8 OUTLIER 58.08 86.13 0.08 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.352 -1.087 . . . . 0.0 110.418 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.596 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.51 -4.54 58.25 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.693 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.0 OUTLIER -144.94 -172.05 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.4 -1.059 . . . . 0.0 109.243 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.724 HG11 HG21 ' A' ' 304' ' ' VAL . 3.3 t -159.08 161.45 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.211 -0.931 . . . . 0.0 109.739 178.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.793 HD13 ' HA ' ' A' ' 295' ' ' LYS . 42.4 mm -129.26 151.13 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.275 -0.89 . . . . 0.0 111.184 -179.66 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.628 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 97.4 m-85 -128.9 125.2 37.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.315 -0.866 . . . . 0.0 109.915 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.54 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 10.7 p -124.82 168.36 13.51 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 120.799 -1.188 . . . . 0.0 109.715 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.529 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.7 Cg_endo -66.73 121.71 8.97 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.692 1.364 . . . . 0.0 110.808 -179.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.829 HG22 ' HB2' ' A' ' 327' ' ' ASN . 31.2 m -69.5 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.554 -0.716 . . . . 0.0 110.083 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.479 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -100.44 -20.89 15.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 110.606 -179.76 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.57 ' H ' HG23 ' A' ' 324' ' ' VAL . 8.4 p-90 -127.15 5.89 6.45 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.126 -0.984 . . . . 0.0 110.564 -179.728 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.829 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -103.39 37.53 1.98 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.125 -0.984 . . . . 0.0 110.473 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -117.47 -9.0 10.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.282 -0.886 . . . . 0.0 109.619 179.689 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.463 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -56.31 -162.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.451 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 47.6 Cg_endo -74.14 5.16 3.72 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.228 1.646 . . . . 0.0 110.953 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.1 m -164.81 115.7 1.17 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.254 -0.904 . . . . 0.0 109.987 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.815 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -134.14 117.93 17.11 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.143 -0.973 . . . . 0.0 110.319 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.876 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.6 m -108.78 136.61 48.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.407 -0.808 . . . . 0.0 109.995 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.774 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.3 p90 -140.63 172.09 13.19 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.527 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.21 158.51 27.71 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.935 -1.602 . . . . 0.0 110.075 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.942 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -146.22 147.28 31.28 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.437 -1.037 . . . . 0.0 109.906 179.614 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.942 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.58 119.58 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.056 -1.028 . . . . 0.0 109.809 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.811 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.8 t -97.17 149.1 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.194 -0.941 . . . . 0.0 110.37 -179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.21 134.07 55.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.473 -0.767 . . . . 0.0 109.807 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.481 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.923 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.675 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.488 1.435 0 CA-C-O 121.385 0.612 . . . . 0.0 110.722 . . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.629 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.0 p -133.41 112.64 17.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.224 -0.922 . . . . 0.0 109.79 179.168 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.48 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.07 5.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.465 -0.772 . . . . 0.0 110.587 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 25.7 pt-20 -177.14 158.94 1.57 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.224 -0.923 . . . . 0.0 110.86 -179.528 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.958 HG23 HG22 ' A' ' 296' ' ' VAL . 19.0 mt -119.4 108.65 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.249 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.24 146.24 33.12 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.249 -0.907 . . . . 0.0 109.797 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.38 133.1 49.83 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.99 -1.068 . . . . 0.0 110.465 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.431 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 47.8 tt0 -138.98 110.2 6.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.795 . . . . 0.0 109.79 179.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.536 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.06 109.27 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.047 -1.033 . . . . 0.0 109.863 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.529 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 41.12 32.76 0.2 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.596 -0.69 . . . . 0.0 110.328 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.69 -21.4 16.52 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 1.1 mp0 -80.17 104.22 10.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.225 -1.162 . . . . 0.0 110.292 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.635 ' O ' HD13 ' A' ' 358' ' ' ILE . 14.6 p -75.62 135.29 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 110.081 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.635 HD13 ' O ' ' A' ' 357' ' ' VAL . 13.0 mm . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.154 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.37 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.538 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.48 167.79 21.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.376 -1.073 . . . . 0.0 110.038 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.982 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.76 135.43 6.52 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.139 -0.976 . . . . 0.0 111.044 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.694 ' N ' HD22 ' A' ' 267' ' ' LEU . 96.4 mt-10 -134.96 126.95 29.63 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.08 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.799 HG23 HD11 ' A' ' 267' ' ' LEU . 64.6 t -117.76 138.61 47.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 C-N-CA 118.828 -1.149 . . . . 0.0 112.137 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.422 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.3 OUTLIER -122.83 157.55 32.2 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.802 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.3 t -144.56 146.28 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.35 -1.469 . . . . 0.0 112.232 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.569 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -134.34 110.64 9.6 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.771 -0.58 . . . . 0.0 109.528 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 13.9 m-20 -97.85 127.55 43.88 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.336 -0.853 . . . . 0.0 111.456 -178.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.845 ' CH2' HG23 ' A' ' 337' ' ' ILE . 30.5 p90 -113.04 18.76 17.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.372 -0.83 . . . . 0.0 109.723 178.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.33 -64.33 3.81 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.965 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.401 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 1.5 m -63.66 -23.4 67.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.238 -1.154 . . . . 0.0 110.418 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.561 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -167.25 -179.46 40.19 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.543 -1.313 . . . . 0.0 109.941 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.556 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -135.28 141.57 45.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.33 -1.1 . . . . 0.0 109.986 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.816 ' O ' HG13 ' A' ' 271' ' ' VAL . 2.6 mt-10 -96.34 147.32 23.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -0.778 . . . . 0.0 110.32 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.79 ' CE2' HG11 ' A' ' 346' ' ' VAL . 97.0 m-85 -139.04 85.14 2.05 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 110.753 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.585 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.4 t0 -74.53 119.81 19.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.566 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.703 HG11 HG11 ' A' ' 294' ' ' VAL . 15.6 t -111.6 92.78 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.594 -0.691 . . . . 0.0 109.871 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.846 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.3 m -86.48 124.31 32.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.987 . . . . 0.0 109.367 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.11 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.69 152.27 27.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.091 -1.005 . . . . 0.0 110.718 -179.115 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.749 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.3 OUTLIER -130.62 128.55 41.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.33 -0.856 . . . . 0.0 110.408 -179.563 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.749 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.1 mt -138.62 149.55 45.33 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.823 -1.173 . . . . 0.0 109.31 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.02 38.92 0.78 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.305 -0.872 . . . . 0.0 110.003 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 159.23 -110.31 0.44 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.095 -1.526 . . . . 0.0 109.95 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.521 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 4.8 mt-30 -145.27 118.17 8.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.248 . . . . 0.0 110.359 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.64 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 5.6 m-85 -141.06 147.82 39.21 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.276 -0.89 . . . . 0.0 110.103 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.762 ' O ' HG23 ' A' ' 353' ' ' ILE . 34.6 m-20 -75.2 96.8 3.37 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.102 -0.999 . . . . 0.0 109.15 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.851 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.8 p-90 -98.73 114.38 26.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.38 -0.825 . . . . 0.0 110.241 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.92 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.3 m -109.15 112.1 24.07 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.423 -0.798 . . . . 0.0 109.403 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.803 HG22 ' CD2' ' A' ' 351' ' ' LEU . 2.8 t -96.33 110.73 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -0.931 . . . . 0.0 110.402 -179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.581 ' HE2' HD11 ' A' ' 320' ' ' ILE . 30.7 ttmt -88.65 147.15 24.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.214 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.791 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 79.5 t -140.64 107.73 2.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.163 -0.961 . . . . 0.0 110.367 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.606 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 23.0 mmtt -69.96 133.82 47.7 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.129 -0.982 . . . . 0.0 109.362 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.911 HD13 ' HA ' ' A' ' 303' ' ' THR . 70.7 mt -88.23 156.98 18.93 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.217 -0.927 . . . . 0.0 111.505 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.688 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.54 173.49 2.36 Favored Pre-proline 0 C--N 1.302 -1.471 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.688 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -66.84 82.75 0.32 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.438 1.231 . . . . 0.0 109.806 179.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.23 22.56 5.17 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.793 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.82 143.34 42.93 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.405 -1.056 . . . . 0.0 110.125 -179.702 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.911 ' HA ' HD13 ' A' ' 298' ' ' LEU . 15.3 p -147.36 144.07 28.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 110.688 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.957 ' CG2' HG21 ' A' ' 319' ' ' VAL . 43.8 t -67.4 135.72 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.478 -0.764 . . . . 0.0 109.985 179.619 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.35 -44.52 0.56 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 8.8 m -131.27 128.7 40.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.06 -1.259 . . . . 0.0 110.811 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.637 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 4.9 p90 -140.74 168.8 18.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.414 -0.804 . . . . 0.0 109.423 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.458 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -159.92 154.19 23.6 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.875 -1.141 . . . . 0.0 111.366 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 65.22 24.28 12.27 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.546 -0.721 . . . . 0.0 110.716 179.594 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.689 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 146.74 0.9 Allowed 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.232 -0.918 . . . . 0.0 110.347 179.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.774 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -81.8 125.06 30.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.091 -1.006 . . . . 0.0 108.895 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 2.4 ttpt -96.58 137.11 36.16 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 121.819 0.818 . . . . 0.0 111.018 -178.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.759 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.16 179.37 4.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.618 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.472 ' HG2' ' O ' ' A' ' 313' ' ' GLN . 2.5 mt-10 -139.98 102.05 4.31 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.138 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.518 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.55 46.9 3.65 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.41 82.05 0.12 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -1.126 . . . . 0.0 110.113 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.618 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.87 2.77 62.57 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.837 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.0 m-85 -143.28 -168.41 2.8 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.443 -1.034 . . . . 0.0 109.221 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.957 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.5 t -163.37 153.29 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.176 -0.952 . . . . 0.0 109.727 179.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.753 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 17.3 mm -119.77 150.75 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.992 -1.067 . . . . 0.0 110.711 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.4 m-85 -128.91 125.26 37.19 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.387 -0.821 . . . . 0.0 110.164 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.92 ' CG2' HG23 ' A' ' 293' ' ' THR . 35.9 p -131.05 166.44 27.65 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.676 -1.265 . . . . 0.0 109.91 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.513 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.56 119.55 6.59 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.695 1.366 . . . . 0.0 110.882 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.774 HG12 ' ND2' ' A' ' 311' ' ' ASN . 24.9 m -64.57 -121.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.532 -0.73 . . . . 0.0 110.197 -179.737 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.478 ' N ' HG23 ' A' ' 324' ' ' VAL . 5.9 m -100.55 -23.5 14.68 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.746 -1.222 . . . . 0.0 110.57 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.478 ' H ' HG23 ' A' ' 324' ' ' VAL . 9.4 p-90 -124.4 -7.75 7.53 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.128 -0.983 . . . . 0.0 110.447 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.714 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.3 t-20 -89.13 31.83 0.86 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.221 -0.924 . . . . 0.0 110.598 -179.528 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.451 ' CE ' ' O ' ' A' ' 325' ' ' SER . 0.0 OUTLIER -117.48 7.24 12.68 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.17 -0.956 . . . . 0.0 110.045 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -67.62 -150.09 0.19 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.559 ' N ' ' O ' ' A' ' 288' ' ' GLY . 46.1 Cg_endo -73.09 -51.61 0.16 Allowed 'Trans proline' 0 C--N 1.3 -2.024 0 O-C-N 123.835 1.439 . . . . 0.0 109.246 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -108.09 124.23 49.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.617 -0.677 . . . . 0.0 110.184 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -135.44 110.97 9.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.846 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.1 m -105.58 129.57 53.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 110.286 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.739 ' HE2' HG21 ' A' ' 294' ' ' VAL . 12.7 p90 -135.33 175.06 9.93 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.237 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.9 162.46 29.73 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 118.684 -1.722 . . . . 0.0 110.308 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.893 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -149.52 145.37 26.82 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 109.483 179.308 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.893 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.73 119.25 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.005 -1.059 . . . . 0.0 110.017 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.793 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -98.32 144.18 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.201 -0.937 . . . . 0.0 110.105 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.91 137.38 52.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.415 -0.803 . . . . 0.0 110.213 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.341 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 179.999 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.685 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.5 mtmt . . . . . 0 N--CA 1.487 1.409 0 CA-C-O 121.435 0.636 . . . . 0.0 110.659 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.79 HG11 ' CE2' ' A' ' 280' ' ' TYR . 2.7 p -127.67 113.87 33.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.095 -1.003 . . . . 0.0 110.244 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.86 5.96 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.27 -0.894 . . . . 0.0 109.713 179.916 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.441 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.4 OUTLIER -177.59 158.34 1.35 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.238 -0.914 . . . . 0.0 110.947 179.461 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.595 HG12 HG13 ' A' ' 296' ' ' VAL . 27.7 mt -115.34 104.81 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.5 132.13 53.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.204 -0.935 . . . . 0.0 110.266 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.11 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -94.6 130.42 41.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 110.284 179.897 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.531 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 7.5 tt0 -138.91 114.19 9.58 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.241 -0.912 . . . . 0.0 110.12 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.762 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.32 105.45 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.047 -1.033 . . . . 0.0 109.801 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 40.31 29.21 0.05 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.735 -0.603 . . . . 0.0 110.887 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 126.02 -26.73 5.26 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.525 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 6.5 mm100 -84.98 118.13 24.37 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.953 -1.322 . . . . 0.0 110.485 -179.53 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.886 ' O ' HD13 ' A' ' 358' ' ' ILE . 11.4 p -81.91 126.86 39.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.276 -0.89 . . . . 0.0 110.108 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.886 HD13 ' O ' ' A' ' 357' ' ' VAL . 13.0 mm . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.21 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.562 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.64 169.77 17.16 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.446 -1.032 . . . . 0.0 109.841 179.809 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.651 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -161.09 125.41 3.49 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.229 -0.92 . . . . 0.0 110.665 -179.733 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.489 ' N ' HD23 ' A' ' 267' ' ' LEU . 40.4 mt-10 -121.31 111.34 17.23 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.494 -0.754 . . . . 0.0 108.986 179.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 281' ' ' ASP . 40.5 t -109.21 137.39 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.99 -1.068 . . . . 0.0 111.798 -178.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 11.9 tttp -127.55 155.98 42.94 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 178.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.802 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.8 t -142.68 147.17 21.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.25 -1.531 . . . . 0.0 112.097 -178.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.518 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.21 114.23 8.98 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.056 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.2 m-20 -96.51 147.89 23.38 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.165 -0.959 . . . . 0.0 111.525 -178.601 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.4 p90 -135.34 18.88 3.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.486 -0.759 . . . . 0.0 109.969 179.206 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.39 -62.78 4.25 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.58 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 3.1 m -62.44 -20.15 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -1.136 . . . . 0.0 110.156 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.92 179.42 48.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.563 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -132.34 143.62 49.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -1.145 . . . . 0.0 110.305 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.802 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.1 mt-10 -95.06 146.24 24.41 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.377 -0.827 . . . . 0.0 109.949 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.689 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 85.1 m-85 -139.6 83.6 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.402 -0.811 . . . . 0.0 110.252 -179.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.732 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.89 150.49 48.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.44 -0.787 . . . . 0.0 109.935 179.62 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.731 HG11 HG11 ' A' ' 294' ' ' VAL . 3.3 t -142.78 87.76 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.613 -0.679 . . . . 0.0 109.402 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 1.009 HG23 ' OG1' ' A' ' 333' ' ' THR . 20.6 m -85.9 111.63 20.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.25 -0.906 . . . . 0.0 109.556 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -96.62 150.55 20.53 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.223 -0.923 . . . . 0.0 111.059 -179.053 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.562 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.23 106.02 7.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.575 -0.703 . . . . 0.0 110.056 -179.496 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.606 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 9.6 mt -115.96 152.37 33.62 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.793 -1.192 . . . . 0.0 109.715 179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.67 38.19 0.78 Allowed 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.091 -1.006 . . . . 0.0 110.003 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.456 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.23 -134.02 3.4 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.368 -1.396 . . . . 0.0 109.751 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.448 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 8.8 mm-40 -124.31 116.65 22.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.136 -1.214 . . . . 0.0 110.531 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.606 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 0.9 OUTLIER -146.67 129.41 16.17 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.317 -0.865 . . . . 0.0 109.741 179.558 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.664 ' O ' HG23 ' A' ' 353' ' ' ILE . 10.2 t70 -57.45 102.56 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.961 -1.087 . . . . 0.0 109.431 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.828 ' CE3' HD13 ' A' ' 284' ' ' LEU . 45.7 p-90 -99.77 110.28 22.67 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.38 -0.825 . . . . 0.0 110.183 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.56 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 29.7 m -102.3 114.95 29.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.327 -0.858 . . . . 0.0 109.798 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.787 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.82 111.09 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.188 -0.945 . . . . 0.0 110.258 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.693 ' HA ' HD13 ' A' ' 320' ' ' ILE . 30.4 ttpt -87.33 149.82 24.26 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.314 -0.866 . . . . 0.0 109.591 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.684 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 94.3 t -148.24 106.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.17 -0.957 . . . . 0.0 110.417 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.581 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtm -70.04 134.35 48.17 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.269 179.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.92 HD13 ' HA ' ' A' ' 303' ' ' THR . 94.4 mt -87.26 160.53 18.41 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.393 -0.817 . . . . 0.0 111.369 -178.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.837 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.57 175.8 1.25 Allowed Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.672 -0.642 . . . . 0.0 109.78 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.785 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.3 Cg_endo -68.65 80.57 0.61 Allowed 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.752 1.396 . . . . 0.0 109.6 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.78 20.79 5.94 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.837 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.79 143.47 36.31 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.583 -0.951 . . . . 0.0 110.125 -179.649 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.92 ' HA ' HD13 ' A' ' 298' ' ' LEU . 56.0 p -145.1 143.16 30.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 110.635 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.676 HG21 HG11 ' A' ' 319' ' ' VAL . 31.7 t -69.98 129.0 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.319 -0.863 . . . . 0.0 109.957 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.61 -32.72 1.54 Allowed Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.097 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.418 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 4.8 m -132.88 121.06 22.33 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.999 -1.295 . . . . 0.0 110.951 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.548 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 45.4 p90 -140.12 154.31 46.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.398 -0.814 . . . . 0.0 109.593 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.497 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -147.55 158.3 43.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.954 -1.091 . . . . 0.0 111.332 -179.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.507 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 61.36 24.72 14.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.473 -0.767 . . . . 0.0 110.973 179.481 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.704 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.82 140.01 0.54 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 110.13 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.706 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -77.14 121.25 23.35 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.042 -1.036 . . . . 0.0 109.159 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.591 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 20.2 ttpt -88.44 138.58 31.3 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.826 0.822 . . . . 0.0 111.048 -178.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.603 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.57 174.45 7.41 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.065 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -138.46 109.26 6.67 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.368 -0.833 . . . . 0.0 110.419 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.57 39.9 2.7 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.21 80.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -1.152 . . . . 0.0 110.23 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.619 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.87 3.1 57.11 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.699 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -147.46 -173.84 4.37 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.431 -1.041 . . . . 0.0 109.065 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.6 t -159.13 159.85 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.103 -0.998 . . . . 0.0 109.526 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.693 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.2 mm -129.38 151.2 35.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.074 -179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.66 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 39.5 m-85 -127.49 130.02 48.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.248 -0.907 . . . . 0.0 110.287 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.533 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -130.1 169.36 13.61 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.826 -1.171 . . . . 0.0 110.117 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.533 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.3 Cg_endo -65.04 123.82 12.15 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.859 1.452 . . . . 0.0 110.809 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.747 HG22 ' HB2' ' A' ' 327' ' ' ASN . 20.3 m -73.22 -116.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.537 -0.727 . . . . 0.0 110.211 -179.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.504 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -108.16 -23.98 11.73 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.699 -1.251 . . . . 0.0 110.668 -179.544 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.435 ' H ' HG23 ' A' ' 324' ' ' VAL . 4.4 p-90 -124.0 5.61 8.63 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.181 -0.949 . . . . 0.0 110.306 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.747 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.9 t30 -108.57 49.95 0.79 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 110.37 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.474 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -124.29 -11.35 7.46 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.317 -0.864 . . . . 0.0 109.882 179.732 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.8 -158.28 0.02 OUTLIER Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.831 -1.307 . . . . 0.0 109.831 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -75.59 6.83 3.4 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.115 1.587 . . . . 0.0 110.738 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -161.26 124.39 3.21 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 120.964 -1.085 . . . . 0.0 109.68 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.574 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -142.65 106.04 4.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.227 -0.92 . . . . 0.0 109.887 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 1.009 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.1 m -98.76 131.74 44.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.283 -0.886 . . . . 0.0 110.291 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.787 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.1 p90 -139.34 175.14 9.81 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.548 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.69 158.42 27.75 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.852 -1.642 . . . . 0.0 110.015 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.935 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.7 OUTLIER -143.27 145.18 32.51 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.556 -0.967 . . . . 0.0 109.709 179.371 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.935 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.51 120.32 61.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.812 HG11 ' HB1' ' A' ' 302' ' ' ALA . 9.9 t -96.24 160.61 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 109.858 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -130.66 129.62 42.87 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.2 -0.937 . . . . 0.0 110.722 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.276 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.887 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.617 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.5 mtmt . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 121.237 0.542 . . . . 0.0 110.791 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.642 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.6 p -140.28 118.04 10.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 110.475 179.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.458 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -50.08 -44.43 51.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.478 -0.764 . . . . 0.0 110.607 -179.734 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.44 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.7 pt-20 -176.73 158.66 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.076 -1.015 . . . . 0.0 110.9 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.593 ' CG1' HG13 ' A' ' 296' ' ' VAL . 54.1 mt -121.79 114.79 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.44 -0.787 . . . . 0.0 109.823 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.68 150.35 36.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.331 -0.856 . . . . 0.0 110.55 -179.504 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -105.44 127.6 53.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.3 -0.875 . . . . 0.0 109.773 179.597 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -138.52 112.85 8.73 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.137 -0.977 . . . . 0.0 110.447 -179.919 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.664 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -92.1 109.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.945 . . . . 0.0 109.981 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 46.08 32.85 1.51 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.52 -0.737 . . . . 0.0 110.433 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.39 -21.26 26.68 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.457 ' O ' ' N ' ' A' ' 353' ' ' ILE . 69.0 mm-40 -83.23 109.41 17.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.271 -1.135 . . . . 0.0 110.29 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 4.5 p -70.38 131.03 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -0.882 . . . . 0.0 110.09 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.641 HG22 ' O ' ' A' ' 358' ' ' ILE . 29.8 mm . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.152 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.4 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.255 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.564 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.74 163.05 31.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -1.126 . . . . 0.0 109.948 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.955 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.22 132.68 5.53 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.197 -179.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.663 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mt-10 -133.49 132.38 40.95 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 179.262 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.685 HG13 ' O ' ' A' ' 281' ' ' ASP . 21.9 t -123.75 134.14 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.71 -1.244 . . . . 0.0 111.976 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.94 151.84 38.32 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 178.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.787 HG13 ' O ' ' A' ' 279' ' ' GLU . 77.9 t -140.8 146.16 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 120.368 -1.458 . . . . 0.0 112.018 -179.004 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.513 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.0 113.83 9.23 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.707 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.8 m-20 -101.29 140.87 34.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.893 -1.129 . . . . 0.0 111.395 -178.481 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.821 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.0 p90 -123.87 19.76 9.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.654 -0.654 . . . . 0.0 109.375 179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.53 -62.21 4.62 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.511 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 0.5 OUTLIER -60.62 -18.15 51.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.259 -1.142 . . . . 0.0 109.951 179.655 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.58 177.23 48.39 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.569 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -133.31 137.8 46.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -1.115 . . . . 0.0 110.124 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.787 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.5 mt-10 -93.99 145.54 24.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.251 -0.906 . . . . 0.0 110.163 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.682 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.1 m-85 -139.99 85.02 2.0 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.448 -0.782 . . . . 0.0 110.746 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.685 ' O ' HG13 ' A' ' 269' ' ' VAL . 3.7 t0 -69.54 141.46 53.83 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.334 -0.853 . . . . 0.0 109.555 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.733 HG11 HG11 ' A' ' 294' ' ' VAL . 4.0 t -132.85 91.71 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.486 -0.759 . . . . 0.0 109.506 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.883 HG23 ' OG1' ' A' ' 333' ' ' THR . 2.7 m -86.67 122.31 30.4 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.32 -0.862 . . . . 0.0 109.982 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.102 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.67 149.04 32.13 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.296 -0.877 . . . . 0.0 110.149 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.564 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -134.03 109.4 8.95 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.316 -0.865 . . . . 0.0 110.637 -178.758 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.633 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.1 mt -119.59 157.47 28.35 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.722 -1.236 . . . . 0.0 110.251 179.731 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 287' ' ' ASP . 15.3 p-10 -91.43 36.61 0.94 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.125 -0.984 . . . . 0.0 109.544 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.5 -136.1 4.18 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.464 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -121.81 116.31 24.21 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.201 -1.176 . . . . 0.0 110.847 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.633 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.3 m-85 -142.39 138.28 31.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.313 -0.867 . . . . 0.0 109.435 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.622 ' O ' HG23 ' A' ' 353' ' ' ILE . 14.5 t0 -67.7 97.46 0.63 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.841 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.829 ' CE3' HD13 ' A' ' 284' ' ' LEU . 46.3 p-90 -96.17 109.86 22.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.037 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.838 HG23 ' CG2' ' A' ' 322' ' ' THR . 3.1 m -102.06 115.33 30.31 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.846 . . . . 0.0 109.592 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.76 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.46 110.99 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 110.461 -179.535 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.724 ' HA ' HD13 ' A' ' 320' ' ' ILE . 28.5 ttpt -86.37 149.59 24.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.364 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.66 HG13 HG12 ' A' ' 349' ' ' ILE . 70.8 t -148.14 108.17 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.123 -0.985 . . . . 0.0 110.706 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.578 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.0 mmtp -70.81 131.79 44.34 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.132 -0.98 . . . . 0.0 109.675 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.978 HD13 ' HA ' ' A' ' 303' ' ' THR . 98.5 mt -85.52 156.05 20.94 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.259 -0.901 . . . . 0.0 111.599 -179.095 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.759 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -66.66 171.04 4.79 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.615 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.7 Cg_endo -66.87 81.86 0.34 Allowed 'Trans proline' 0 C--N 1.305 -1.757 0 O-C-N 123.518 1.273 . . . . 0.0 109.727 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.76 18.06 5.76 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.801 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -108.65 149.19 29.3 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.385 -1.068 . . . . 0.0 110.105 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.978 ' HA ' HD13 ' A' ' 298' ' ' LEU . 24.8 p -154.56 144.21 21.53 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.122 -0.987 . . . . 0.0 110.897 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.776 HG21 HG11 ' A' ' 319' ' ' VAL . 24.7 t -68.9 124.06 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -106.39 -33.71 3.32 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -142.0 131.21 23.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.005 -1.291 . . . . 0.0 110.868 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.551 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 39.2 p90 -141.78 162.89 34.36 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.29 -0.881 . . . . 0.0 109.855 179.485 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.503 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -152.31 159.51 43.47 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.928 -1.107 . . . . 0.0 110.946 -179.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 59.84 23.91 12.9 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.472 -0.767 . . . . 0.0 111.091 179.471 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.71 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.09 145.46 0.8 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.325 -0.86 . . . . 0.0 110.179 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.645 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -83.81 120.03 25.55 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.202 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.723 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.8 ttpt -87.03 145.38 26.5 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.946 0.879 . . . . 0.0 111.044 -178.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.794 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -130.41 179.03 6.16 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.013 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.602 ' HG2' HG22 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -140.0 101.76 4.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.702 -0.624 . . . . 0.0 110.108 179.546 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -87.51 40.4 3.08 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.493 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 9.5 t30 63.65 79.71 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.304 -1.115 . . . . 0.0 110.084 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.591 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 95.0 3.81 61.78 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.774 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.791 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.7 m-85 -143.3 -170.66 3.32 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.996 . . . . 0.0 108.784 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.794 HG22 ' O ' ' A' ' 313' ' ' GLN . 3.3 t -161.68 154.29 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 120.976 -1.077 . . . . 0.0 110.019 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.8 ' CG2' HG22 ' A' ' 293' ' ' THR . 22.0 mm -125.17 142.85 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.756 -179.583 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.0 m-85 -119.6 127.05 52.59 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.435 -0.791 . . . . 0.0 109.637 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.838 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.1 p -126.65 169.15 12.52 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 120.877 -1.14 . . . . 0.0 110.5 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.528 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.5 Cg_endo -65.04 112.23 1.98 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 O-C-N 124.049 1.552 . . . . 0.0 111.044 -179.5 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.645 HG12 ' ND2' ' A' ' 311' ' ' ASN . 16.5 m -56.96 -114.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.634 -0.666 . . . . 0.0 109.918 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.494 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -117.17 -20.26 9.32 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.7 -1.25 . . . . 0.0 110.417 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.49 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 5.1 p-90 -120.78 -20.65 6.92 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.204 -0.935 . . . . 0.0 110.408 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.637 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -84.23 46.14 1.18 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.081 -1.012 . . . . 0.0 109.989 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.491 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 10.7 mtmt -119.84 -9.63 9.66 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.359 -0.838 . . . . 0.0 109.675 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.5 -157.45 0.01 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.535 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.68 5.32 4.39 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.065 1.561 . . . . 0.0 110.682 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.408 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 4.2 m -162.83 119.88 1.94 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.998 -1.064 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.08 112.0 7.52 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.299 -0.875 . . . . 0.0 110.247 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.883 ' OG1' HG23 ' A' ' 283' ' ' THR . 35.1 m -103.72 132.26 50.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 110.049 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.76 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.4 p90 -135.17 173.93 11.17 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.46 151.76 23.65 Favored Glycine 0 N--CA 1.486 1.977 0 C-N-CA 118.827 -1.654 . . . . 0.0 110.242 -179.357 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.92 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -139.0 147.93 42.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.684 -0.892 . . . . 0.0 109.476 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.92 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.6 119.46 59.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.006 -1.059 . . . . 0.0 110.025 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.801 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -96.84 145.2 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.94 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.507 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 2.0 m-80 -115.63 133.23 56.24 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.391 -0.818 . . . . 0.0 110.341 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.507 ' N ' ' HE3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.487 2.06 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.831 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.759 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 3.1 mtpt . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 121.467 0.651 . . . . 0.0 110.13 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.621 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.1 p -126.03 113.71 35.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.448 -0.783 . . . . 0.0 109.779 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.501 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.4 mm-40 -41.97 -47.33 4.34 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.995 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 18.1 pt-20 -177.28 158.52 1.48 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.872 . . . . 0.0 110.524 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.66 HG12 HG13 ' A' ' 296' ' ' VAL . 11.9 mt -118.14 122.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.237 -0.914 . . . . 0.0 110.068 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.11 132.19 50.66 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.219 -0.926 . . . . 0.0 110.175 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.102 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -92.66 131.22 37.94 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.174 -0.954 . . . . 0.0 110.22 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.4 tt0 -139.68 114.53 9.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.168 -0.957 . . . . 0.0 110.358 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.622 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.1 mt -92.05 110.9 23.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.976 -1.077 . . . . 0.0 110.28 179.665 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.541 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.47 32.1 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.716 -0.615 . . . . 0.0 111.115 179.587 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 112.26 8.86 21.01 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.513 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 2.5 mp0 -116.4 111.46 20.06 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.11 -1.229 . . . . 0.0 110.058 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -75.3 135.67 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.227 -0.92 . . . . 0.0 110.433 -179.662 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.478 HD13 ' O ' ' A' ' 357' ' ' VAL . 31.9 mm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.223 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.44 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 110.3 -1.12 . . . . 0.0 110.3 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.554 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.78 168.31 19.79 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.523 -0.986 . . . . 0.0 109.631 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.96 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.3 tm? -160.24 136.86 8.96 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.996 -1.065 . . . . 0.0 111.165 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.662 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.5 OUTLIER -136.19 123.36 21.71 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.553 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.83 HG23 HD11 ' A' ' 267' ' ' LEU . 50.2 t -116.97 134.69 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.969 -1.082 . . . . 0.0 111.738 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 37.0 mttm -118.29 157.35 27.23 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.681 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.58 142.2 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.256 -1.528 . . . . 0.0 112.115 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -138.04 113.04 9.14 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.102 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.633 ' OD1' ' HB1' ' A' ' 278' ' ' ALA . 80.2 m-20 -98.78 146.21 26.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.958 -1.089 . . . . 0.0 111.444 -178.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.826 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.6 p90 -131.71 23.16 4.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.608 -0.682 . . . . 0.0 109.474 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 80.55 -64.23 4.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.49 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -59.13 -22.6 61.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.293 -1.122 . . . . 0.0 110.226 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.516 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.44 -171.88 38.4 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.633 ' HB1' ' OD1' ' A' ' 273' ' ' ASP . . . -142.87 142.05 31.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -1.072 . . . . 0.0 110.009 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.681 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.7 mt-10 -97.98 146.14 25.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.414 -0.804 . . . . 0.0 110.329 -179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.692 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 81.6 m-85 -141.15 82.99 1.86 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.398 -0.814 . . . . 0.0 110.653 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.782 ' O ' HG13 ' A' ' 269' ' ' VAL . 9.3 t0 -64.91 151.53 45.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.769 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.798 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.9 t -145.05 89.34 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.55 -0.719 . . . . 0.0 109.964 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.655 HG23 ' OG1' ' A' ' 333' ' ' THR . 72.2 m -86.75 126.36 34.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.131 -0.981 . . . . 0.0 109.717 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.075 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.96 148.24 39.01 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.04 -1.038 . . . . 0.0 110.902 -179.172 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.93 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -128.4 134.82 48.89 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.484 -0.76 . . . . 0.0 109.949 -179.696 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.93 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.2 mt -143.7 149.97 37.99 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.62 -1.3 . . . . 0.0 110.158 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -88.41 38.49 0.87 Allowed 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.278 -0.889 . . . . 0.0 109.398 179.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.97 -145.47 11.05 Favored Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.787 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.507 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.1 mt-30 -112.36 98.43 7.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -1.167 . . . . 0.0 110.665 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.643 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -120.21 154.97 34.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.257 -0.902 . . . . 0.0 110.295 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.876 ' O ' HG23 ' A' ' 353' ' ' ILE . 23.0 t0 -85.76 97.46 10.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 109.242 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.951 ' CE3' HD13 ' A' ' 284' ' ' LEU . 51.9 p-90 -95.38 108.03 20.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.169 -0.957 . . . . 0.0 110.819 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.944 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.8 m -100.11 115.13 29.09 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.543 -0.723 . . . . 0.0 109.304 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.835 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.1 t -96.71 111.38 26.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 121.187 -0.946 . . . . 0.0 110.162 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.717 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.3 ttpp -87.74 149.37 24.24 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.404 -0.81 . . . . 0.0 109.247 179.461 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.692 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 84.4 t -148.23 107.71 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.079 -1.013 . . . . 0.0 110.225 -179.603 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.582 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 21.0 mmtp -69.95 132.37 45.84 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.344 -0.848 . . . . 0.0 109.587 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.973 HD13 ' HA ' ' A' ' 303' ' ' THR . 87.8 mt -87.37 158.71 18.96 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.646 -0.659 . . . . 0.0 110.943 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.839 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.32 173.86 2.06 Favored Pre-proline 0 C--N 1.303 -1.426 0 O-C-N 121.459 -0.775 . . . . 0.0 109.285 179.07 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.712 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.34 79.7 0.59 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 123.619 1.326 . . . . 0.0 109.637 179.576 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.26 17.02 5.87 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.839 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -104.26 147.09 27.88 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.467 -1.019 . . . . 0.0 110.12 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.973 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.6 p -148.68 143.86 26.76 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.873 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.821 ' CG2' HG21 ' A' ' 319' ' ' VAL . 92.1 t -71.55 121.74 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.317 -0.864 . . . . 0.0 109.951 179.623 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.48 -21.34 6.92 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.5 OUTLIER -139.51 124.14 18.37 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.029 -1.277 . . . . 0.0 111.216 -179.464 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -145.23 164.57 30.96 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.311 -0.868 . . . . 0.0 109.884 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.473 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.4 p90 -158.34 161.29 37.6 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.948 -1.095 . . . . 0.0 110.995 -179.409 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.547 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.1 OUTLIER 54.47 29.03 10.44 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.471 -0.768 . . . . 0.0 110.843 179.517 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.697 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.33 144.43 0.71 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.285 -0.885 . . . . 0.0 109.872 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.8 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.3 m-80 -82.23 115.81 21.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.092 -1.005 . . . . 0.0 109.355 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 8.7 ttpt -83.27 142.13 31.34 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.803 0.811 . . . . 0.0 110.757 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.559 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -129.38 173.81 10.2 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.579 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.4 mt-10 -139.49 101.36 4.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.309 -0.869 . . . . 0.0 110.497 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.12 42.84 2.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 4.5 m120 53.8 86.16 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.311 -1.111 . . . . 0.0 110.174 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.33 -0.27 55.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.612 ' O ' HG23 ' A' ' 319' ' ' VAL . 0.5 OUTLIER -150.26 -172.79 4.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.371 -1.076 . . . . 0.0 109.642 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.821 HG21 ' CG2' ' A' ' 304' ' ' VAL . 6.1 t -156.89 156.37 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.425 -0.797 . . . . 0.0 109.337 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.717 HD13 ' HA ' ' A' ' 295' ' ' LYS . 45.6 mm -126.56 147.83 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.08 -1.012 . . . . 0.0 111.22 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 83.3 m-85 -125.29 125.1 43.0 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.399 -0.813 . . . . 0.0 109.661 179.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.944 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.6 p -127.7 169.86 11.52 Favored Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 120.82 -1.175 . . . . 0.0 110.232 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.7 Cg_endo -64.26 115.76 3.35 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.898 1.473 . . . . 0.0 111.52 -179.088 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.826 HG22 ' CG ' ' A' ' 327' ' ' ASN . 17.3 m -64.16 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.66 -0.65 . . . . 0.0 110.192 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.495 ' N ' HG23 ' A' ' 324' ' ' VAL . 19.9 m -116.78 -12.57 10.8 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.696 -1.253 . . . . 0.0 111.198 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.495 ' H ' HG23 ' A' ' 324' ' ' VAL . 13.3 p-90 -133.72 1.37 3.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.811 -1.18 . . . . 0.0 111.133 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.826 ' CG ' HG22 ' A' ' 324' ' ' VAL . 28.3 p-10 -110.38 50.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.987 -1.071 . . . . 0.0 110.508 -179.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -129.09 10.51 5.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.267 -0.896 . . . . 0.0 109.664 179.466 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.418 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -73.89 -151.58 2.13 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.517 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -74.09 2.26 6.3 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.094 1.576 . . . . 0.0 110.838 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.48 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 27.5 m -167.28 122.74 1.08 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.35 -0.843 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.479 ' HB1' ' HB2' ' A' ' 327' ' ' ASN . . . -142.56 118.17 10.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.134 -0.979 . . . . 0.0 110.321 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.655 ' OG1' HG23 ' A' ' 283' ' ' THR . 18.0 m -104.36 148.55 26.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 110.214 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.835 ' HE2' HG21 ' A' ' 294' ' ' VAL . 5.9 p90 -153.88 175.22 13.59 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -156.44 157.91 28.29 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.838 -1.649 . . . . 0.0 110.548 -179.418 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.921 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -141.52 147.6 38.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.411 -1.052 . . . . 0.0 110.308 179.594 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.921 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.96 122.69 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.078 -1.014 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.697 HG11 ' HB1' ' A' ' 302' ' ' ALA . 6.3 t -100.45 156.23 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.132 -0.98 . . . . 0.0 110.782 -179.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -123.97 132.72 53.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.506 -0.746 . . . . 0.0 110.337 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.416 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.492 2.384 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.811 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.619 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.2 OUTLIER . . . . . 0 N--CA 1.487 1.394 0 CA-C-O 121.201 0.524 . . . . 0.0 111.077 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.63 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.7 p -135.13 117.72 22.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.163 -0.961 . . . . 0.0 110.11 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.459 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -50.34 -45.15 54.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.343 -0.848 . . . . 0.0 110.425 -179.534 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -176.61 154.19 1.2 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -0.994 . . . . 0.0 110.703 -179.876 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.651 HG12 HG13 ' A' ' 296' ' ' VAL . 23.3 mt -113.97 124.8 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.175 -0.953 . . . . 0.0 110.133 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.21 154.39 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.389 -0.82 . . . . 0.0 109.974 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.075 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -120.65 124.51 45.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.188 -0.945 . . . . 0.0 109.659 179.478 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.508 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 34.6 tt0 -138.63 117.11 12.05 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.221 -0.925 . . . . 0.0 110.181 -179.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.876 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.4 107.68 19.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.165 -0.959 . . . . 0.0 109.76 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.512 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 43.66 26.74 0.13 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 110.381 -179.647 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 123.41 -31.92 4.48 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 12.2 mm100 -75.99 114.56 14.76 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.084 -1.244 . . . . 0.0 110.47 -179.65 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.791 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -79.09 133.34 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.146 -0.972 . . . . 0.0 110.226 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.791 HD13 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.068 -0.967 . . . . 0.0 110.299 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.243 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.571 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.33 163.79 31.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.366 -1.079 . . . . 0.0 110.049 -179.774 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.653 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -156.73 122.8 4.9 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.106 -0.996 . . . . 0.0 110.737 -179.868 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.3 mt-10 -123.31 114.29 20.01 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 57.6 t -110.05 124.51 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.971 -1.081 . . . . 0.0 112.347 -178.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.9 mmtt -111.61 156.79 21.26 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.752 HG13 ' O ' ' A' ' 279' ' ' GLU . 83.0 t -144.61 147.92 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.426 -1.421 . . . . 0.0 112.238 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -136.8 110.05 7.83 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.928 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.4 p30 -95.34 146.35 24.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.074 -1.016 . . . . 0.0 111.247 -178.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.854 ' CH2' HG23 ' A' ' 337' ' ' ILE . 29.4 p90 -129.0 16.86 6.21 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.517 -0.739 . . . . 0.0 109.963 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.4 -54.57 3.52 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.494 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 2.8 m -74.63 -19.35 60.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.226 -1.161 . . . . 0.0 110.256 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.19 -175.85 42.98 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.86 ' HB2' ' NZ ' ' A' ' 345' ' ' LYS . . . -140.6 140.1 35.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -1.15 . . . . 0.0 110.238 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.752 ' O ' HG13 ' A' ' 271' ' ' VAL . 10.7 mt-10 -92.88 146.12 23.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.402 -0.811 . . . . 0.0 110.077 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.699 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 96.5 m-85 -133.33 89.96 2.67 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.44 -0.788 . . . . 0.0 110.64 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.586 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -77.21 105.03 8.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 109.821 179.525 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.716 HG11 HG11 ' A' ' 294' ' ' VAL . 6.6 t -97.72 92.53 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.466 -0.772 . . . . 0.0 110.368 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.927 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.3 m -86.87 112.77 22.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.022 -1.049 . . . . 0.0 109.931 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.041 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -100.41 149.73 23.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.124 -0.985 . . . . 0.0 110.497 -179.504 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.571 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.49 106.71 7.6 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.347 -0.846 . . . . 0.0 110.541 -179.252 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.598 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 8.9 mt -113.63 164.88 13.11 Favored 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.778 -1.201 . . . . 0.0 110.302 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -97.97 35.63 1.69 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.269 -0.894 . . . . 0.0 110.11 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.45 -116.01 0.69 Allowed Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.277 -1.44 . . . . 0.0 109.887 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.438 ' HG2' ' O ' ' A' ' 288' ' ' GLY . 11.8 mm-40 -139.81 107.14 5.52 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.175 -1.191 . . . . 0.0 110.55 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.598 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.2 m-85 -137.08 129.17 29.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.2 -0.937 . . . . 0.0 109.723 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.643 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.4 OUTLIER -57.81 101.59 0.08 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.458 179.565 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.836 ' CE3' HD13 ' A' ' 284' ' ' LEU . 45.6 p-90 -98.4 107.72 20.24 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.373 -0.829 . . . . 0.0 109.968 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.86 HG22 ' CG2' ' A' ' 320' ' ' ILE . 2.0 m -98.87 115.07 28.01 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.328 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.759 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.3 t -96.27 111.67 26.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.114 -0.991 . . . . 0.0 110.548 -179.202 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.711 ' HA ' HD13 ' A' ' 320' ' ' ILE . 8.4 ttpt -85.71 148.03 26.06 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.365 -0.834 . . . . 0.0 109.541 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.616 HG13 HG12 ' A' ' 349' ' ' ILE . 54.0 t -148.41 110.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 120.965 -1.084 . . . . 0.0 110.762 -179.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.6 ' O ' HG23 ' A' ' 346' ' ' VAL . 47.2 mmtt -74.36 131.82 41.46 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.292 -0.88 . . . . 0.0 109.628 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.979 HD13 ' HA ' ' A' ' 303' ' ' THR . 83.5 mt -83.95 151.65 24.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.261 -0.899 . . . . 0.0 111.445 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.824 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -55.55 173.69 0.25 Allowed Pre-proline 0 N--CA 1.487 1.401 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.681 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -68.76 78.27 0.71 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.592 1.312 . . . . 0.0 109.516 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.86 22.95 3.78 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 -179.279 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.824 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -109.03 154.79 21.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.307 -1.114 . . . . 0.0 110.337 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.979 ' HA ' HD13 ' A' ' 298' ' ' LEU . 41.0 p -152.33 144.36 23.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.179 -0.951 . . . . 0.0 110.716 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.9 ' CG2' HG21 ' A' ' 319' ' ' VAL . 49.0 t -72.22 117.74 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.462 -0.774 . . . . 0.0 109.89 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.94 -36.44 3.69 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.5 m -134.64 145.7 48.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.05 -1.265 . . . . 0.0 111.026 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.583 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 33.8 p90 -160.23 165.08 32.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.525 -0.734 . . . . 0.0 109.565 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.512 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -154.3 165.13 37.28 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 120.901 -1.124 . . . . 0.0 111.356 -179.408 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.44 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 51.58 28.55 4.75 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.54 -0.725 . . . . 0.0 111.488 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.751 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 138.83 0.47 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.083 -1.01 . . . . 0.0 110.302 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.801 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.64 115.39 17.36 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 109.112 179.326 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.601 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.1 ttpt -84.28 140.22 31.8 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.805 0.812 . . . . 0.0 110.738 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.686 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.66 174.95 7.13 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 179.204 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -137.61 109.42 7.11 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.331 -0.856 . . . . 0.0 110.276 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.426 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -99.85 46.87 1.35 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 58.47 85.72 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 110.5 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.552 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 89.86 -0.09 78.98 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.833 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.5 m-85 -138.78 -170.04 2.76 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.235 -1.156 . . . . 0.0 109.281 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -163.08 157.31 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.81 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.86 ' CG2' HG22 ' A' ' 293' ' ' THR . 7.1 mm -127.58 151.8 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.227 -0.921 . . . . 0.0 110.929 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.627 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 99.4 m-85 -128.72 125.56 38.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.928 -1.108 . . . . 0.0 110.144 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.762 ' CG2' HG23 ' A' ' 293' ' ' THR . 11.9 p -124.75 167.83 14.9 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 120.876 -1.14 . . . . 0.0 109.596 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.48 123.84 12.01 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 O-C-N 123.737 1.388 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.801 HG12 ' ND2' ' A' ' 311' ' ' ASN . 18.5 m -70.61 -114.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.497 -0.752 . . . . 0.0 109.855 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.51 ' N ' HG23 ' A' ' 324' ' ' VAL . 2.6 m -110.46 -13.36 14.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.743 -1.223 . . . . 0.0 110.547 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.536 ' H ' HG23 ' A' ' 324' ' ' VAL . 7.3 p-90 -132.86 -6.17 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.155 -0.965 . . . . 0.0 110.928 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.555 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -97.49 46.68 1.02 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.046 -1.034 . . . . 0.0 110.216 -179.785 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -124.43 -8.05 7.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.099 -1.0 . . . . 0.0 109.92 -179.966 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.22 -157.87 0.02 OUTLIER Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.534 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -75.88 8.16 2.87 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.804 1.423 . . . . 0.0 111.0 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.407 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.1 m -165.17 115.53 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.525 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -132.83 109.04 9.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.237 -0.915 . . . . 0.0 110.27 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.927 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.2 m -100.03 122.26 42.65 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.308 -0.87 . . . . 0.0 110.111 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.759 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.7 p90 -128.9 175.17 8.86 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.44 157.8 27.48 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.823 -1.656 . . . . 0.0 110.268 -179.368 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.949 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -145.28 148.98 34.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.7 -0.882 . . . . 0.0 109.265 179.449 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.949 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.24 118.25 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.023 -1.048 . . . . 0.0 109.679 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.1 t -96.23 152.22 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.206 -0.934 . . . . 0.0 109.801 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -124.76 133.26 53.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.199 -0.938 . . . . 0.0 110.756 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.859 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.86 ' NZ ' ' HB2' ' A' ' 278' ' ' ALA . 0.4 OUTLIER . . . . . 0 N--CA 1.489 1.49 0 CA-C-O 121.097 0.475 . . . . 0.0 110.955 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 297' ' ' LYS . 3.3 p -130.55 113.55 25.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.223 -0.923 . . . . 0.0 109.7 179.212 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.547 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 35.2 mt-10 -41.55 -45.93 3.43 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.247 -0.908 . . . . 0.0 110.304 -179.488 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.59 158.55 1.76 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.135 -0.978 . . . . 0.0 110.64 179.847 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.616 HG12 HG13 ' A' ' 296' ' ' VAL . 12.1 mt -119.74 129.05 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 110.193 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -131.2 151.74 51.17 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.266 -0.896 . . . . 0.0 110.297 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.041 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.43 130.5 54.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.232 -0.917 . . . . 0.0 109.914 179.815 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 48.1 tt0 -138.37 113.38 9.23 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.189 -0.945 . . . . 0.0 110.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.643 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -96.31 108.76 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.985 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.551 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 39.42 34.6 0.14 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.544 -0.722 . . . . 0.0 110.629 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 112.59 -19.05 22.1 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.463 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.1 OUTLIER -85.18 100.54 11.82 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.27 -1.135 . . . . 0.0 110.317 -179.823 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.3 p -71.15 121.65 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.512 HD13 ' O ' ' A' ' 357' ' ' VAL . 35.7 mm . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.279 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.328 0 N-CA-C 110.17 -1.172 . . . . 0.0 110.17 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.578 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.87 157.24 46.47 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.485 -1.009 . . . . 0.0 109.791 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.898 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -149.33 124.66 10.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 110.615 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.565 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.1 mp0 -124.47 111.34 15.6 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.089 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.579 HG11 HD12 ' A' ' 349' ' ' ILE . 41.0 t -105.07 129.57 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.024 -1.047 . . . . 0.0 111.959 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.402 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.7 ttmt -117.38 156.89 27.11 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.613 HG22 ' CD2' ' A' ' 280' ' ' TYR . 78.5 t -144.86 146.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.424 -1.422 . . . . 0.0 112.399 -179.094 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -138.22 109.39 6.84 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.15 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.7 p-10 -95.75 147.95 23.08 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.127 -0.983 . . . . 0.0 111.111 -178.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.841 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.9 p90 -133.66 16.97 3.94 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.515 -0.741 . . . . 0.0 110.019 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.05 -58.48 3.96 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.565 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 6.0 t -68.8 -20.31 64.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -1.141 . . . . 0.0 110.103 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -177.7 179.09 48.41 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -132.55 141.84 48.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -1.125 . . . . 0.0 110.121 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.577 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 6.3 mt-10 -95.62 147.45 23.58 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.47 -0.769 . . . . 0.0 110.209 -179.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.694 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 93.5 m-85 -138.6 95.08 2.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 110.709 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.57 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.71 108.49 16.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.526 -0.734 . . . . 0.0 110.091 179.657 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.704 HG11 HG11 ' A' ' 294' ' ' VAL . 6.7 t -100.11 92.72 2.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.6 -0.688 . . . . 0.0 109.85 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.671 HG23 ' OG1' ' A' ' 333' ' ' THR . 3.6 m -86.57 113.89 22.84 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.932 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.039 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.98 149.74 23.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.096 -1.003 . . . . 0.0 110.806 -179.322 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.578 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.56 106.37 6.97 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -179.61 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.607 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 8.1 mt -116.91 162.54 17.59 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.688 -1.257 . . . . 0.0 109.94 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.86 36.24 1.2 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.974 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.447 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.4 -135.5 3.9 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.325 -1.417 . . . . 0.0 110.039 -179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.489 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.5 mt-30 -121.43 104.65 9.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.152 -1.205 . . . . 0.0 110.978 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.607 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -132.6 129.24 38.69 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.3 -0.875 . . . . 0.0 109.702 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.583 ' O ' HG23 ' A' ' 353' ' ' ILE . 39.1 m-20 -58.58 99.57 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.4 179.435 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.857 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.0 p-90 -97.94 113.07 24.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 110.418 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.564 HG23 ' CG2' ' A' ' 322' ' ' THR . 23.5 m -105.17 113.8 27.61 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.336 -0.853 . . . . 0.0 109.478 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.775 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.1 t -96.08 110.54 24.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.799 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.444 ' HE2' HD11 ' A' ' 320' ' ' ILE . 31.9 ttmt -83.44 146.77 28.23 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.301 -0.875 . . . . 0.0 109.217 179.378 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.711 HG22 HG23 ' A' ' 349' ' ' ILE . 42.4 t -140.93 105.13 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.518 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 10.6 mmtp -70.18 132.33 45.62 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.189 -0.945 . . . . 0.0 109.136 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.956 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.9 mt -87.41 152.13 22.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.441 -0.787 . . . . 0.0 111.376 -178.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.749 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -61.71 174.74 0.61 Allowed Pre-proline 0 C--N 1.301 -1.505 0 O-C-N 121.63 -0.668 . . . . 0.0 109.293 179.002 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.749 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.9 Cg_endo -68.48 82.87 0.51 Allowed 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.703 1.37 . . . . 0.0 110.041 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.1 24.48 4.82 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.777 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -114.41 148.89 37.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -1.09 . . . . 0.0 110.155 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.956 ' HA ' HD13 ' A' ' 298' ' ' LEU . 21.0 p -151.76 144.35 24.24 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 110.614 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.89 HG21 HG11 ' A' ' 319' ' ' VAL . 61.3 t -64.65 129.7 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.458 -0.776 . . . . 0.0 110.357 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.74 -34.41 2.05 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.417 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -142.21 131.72 23.83 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.194 -1.18 . . . . 0.0 110.59 -179.827 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 13.6 p90 -145.96 163.92 33.65 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.263 -0.898 . . . . 0.0 109.817 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.519 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.7 OUTLIER -154.33 166.75 32.21 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.99 -1.068 . . . . 0.0 110.982 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.458 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.5 OUTLIER 54.99 23.07 4.8 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.561 -0.712 . . . . 0.0 111.03 179.772 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.696 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.92 149.39 1.13 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.423 179.635 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.666 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -87.77 124.65 33.82 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.163 -0.961 . . . . 0.0 109.263 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 7.8 ttpt -92.29 139.77 30.27 Favored 'General case' 0 N--CA 1.489 1.486 0 CA-C-O 121.697 0.76 . . . . 0.0 110.976 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.735 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.96 175.18 7.49 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 178.808 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.617 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.6 mt-10 -136.34 109.69 7.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.083 -1.01 . . . . 0.0 110.629 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -98.59 39.58 2.71 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 61.26 90.22 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 0.0 110.095 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.09 0.87 82.65 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.856 ' O ' HG23 ' A' ' 319' ' ' VAL . 4.0 m-85 -143.83 -171.31 3.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.466 -1.02 . . . . 0.0 109.567 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.89 HG11 HG21 ' A' ' 304' ' ' VAL . 2.9 t -163.43 156.73 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -0.854 . . . . 0.0 109.467 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.549 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 15.2 mm -122.43 147.52 26.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.92 -1.112 . . . . 0.0 110.715 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.661 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.0 m-85 -124.28 129.6 51.04 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.212 -0.93 . . . . 0.0 109.855 179.389 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.564 ' CG2' HG23 ' A' ' 293' ' ' THR . 16.1 p -132.41 167.22 23.6 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 120.575 -1.328 . . . . 0.0 110.178 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.535 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -65.99 115.95 3.72 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.839 1.442 . . . . 0.0 111.01 -179.698 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.666 HG12 ' ND2' ' A' ' 311' ' ' ASN . 9.2 m -58.36 -111.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.427 -0.795 . . . . 0.0 110.006 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.43 ' H ' HG23 ' A' ' 324' ' ' VAL . 2.2 p -117.78 -18.43 9.6 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.742 -1.224 . . . . 0.0 110.379 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.4 ' H ' HG23 ' A' ' 324' ' ' VAL . 6.9 p-90 -125.93 -4.13 6.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.244 -0.91 . . . . 0.0 110.401 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.631 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.3 t30 -97.73 50.29 1.04 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.288 -0.882 . . . . 0.0 109.977 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.504 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 4.2 mtmt -124.72 -9.82 7.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.344 -0.847 . . . . 0.0 109.894 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.53 -160.57 0.02 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.23 6.08 3.71 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.059 1.557 . . . . 0.0 110.744 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.433 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.7 m -163.07 116.55 1.62 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.066 -1.022 . . . . 0.0 109.943 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.453 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.53 105.79 5.75 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.22 -0.925 . . . . 0.0 110.324 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.671 ' OG1' HG23 ' A' ' 283' ' ' THR . 13.9 m -96.0 123.23 39.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.775 ' HE2' HG21 ' A' ' 294' ' ' VAL . 9.8 p90 -127.48 172.67 10.49 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.366 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.89 160.29 28.34 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.653 -1.736 . . . . 0.0 110.397 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.889 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -147.08 143.75 28.55 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.717 -0.873 . . . . 0.0 109.348 179.379 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.889 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -117.65 117.25 54.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.797 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.2 t -96.9 152.03 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.997 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.79 134.72 54.41 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 110.353 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.41 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.935 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.618 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.1 mtmt . . . . . 0 N--CA 1.486 1.331 0 CA-C-O 121.299 0.571 . . . . 0.0 110.728 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.63 HG21 HG13 ' A' ' 296' ' ' VAL . 7.4 p -136.12 114.74 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.474 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.518 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 3.1 mm-40 -44.07 -47.2 8.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.879 . . . . 0.0 110.045 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -176.8 153.46 1.06 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.124 -0.985 . . . . 0.0 110.733 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.711 HG23 HG22 ' A' ' 296' ' ' VAL . 18.5 mt -115.38 104.23 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.153 -0.967 . . . . 0.0 110.033 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.78 154.03 20.04 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.228 -0.92 . . . . 0.0 110.448 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.039 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.38 127.56 55.7 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.296 -0.877 . . . . 0.0 110.261 179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 27.3 tt0 -138.21 112.65 8.77 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.083 -1.011 . . . . 0.0 109.895 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.583 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.74 108.03 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 110.669 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.54 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 37.76 35.84 0.08 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.674 -0.641 . . . . 0.0 111.139 179.563 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.1 -0.07 28.4 Favored Glycine 0 N--CA 1.493 2.433 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.485 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -108.68 104.5 13.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.126 -1.22 . . . . 0.0 110.134 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.65 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.3 p -71.9 114.11 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.332 -0.855 . . . . 0.0 110.283 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.702 ' HB ' HD13 ' A' ' 351' ' ' LEU . 41.6 mm . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.112 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 2.143 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.553 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.22 166.39 24.67 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.486 -1.008 . . . . 0.0 109.488 179.759 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.933 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.69 140.2 9.44 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.001 -1.062 . . . . 0.0 111.11 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.721 ' H ' HD22 ' A' ' 267' ' ' LEU . 9.5 mt-10 -141.94 123.89 15.33 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 179.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 281' ' ' ASP . 71.8 t -117.14 141.61 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 120.845 -1.16 . . . . 0.0 111.607 -178.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -126.88 157.55 39.05 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.668 HG13 ' O ' ' A' ' 279' ' ' GLU . 74.1 t -144.73 146.95 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.416 -1.427 . . . . 0.0 112.085 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.516 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -144.5 114.9 7.58 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.643 -0.661 . . . . 0.0 109.288 179.056 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.5 p30 -96.04 148.01 23.12 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.2 -0.938 . . . . 0.0 111.291 -178.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.757 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.2 p90 -132.78 19.17 4.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.489 -0.757 . . . . 0.0 109.949 179.23 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.61 -62.43 3.4 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.521 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 22.0 m -66.37 -21.14 66.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -1.149 . . . . 0.0 110.481 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.486 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -176.4 -179.55 46.91 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.43 -1.366 . . . . 0.0 109.776 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.55 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.99 143.94 48.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.258 -1.142 . . . . 0.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.668 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.0 mt-10 -96.37 147.35 23.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.439 -0.788 . . . . 0.0 110.332 -179.546 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.675 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.0 m-85 -141.2 86.63 2.04 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.474 -0.766 . . . . 0.0 110.372 -179.52 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.82 ' O ' HG13 ' A' ' 269' ' ' VAL . 3.9 t0 -71.09 152.19 43.73 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.367 -0.833 . . . . 0.0 110.092 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 294' ' ' VAL . 4.8 t -144.83 89.84 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.601 -0.687 . . . . 0.0 109.812 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.855 HG23 ' OG1' ' A' ' 333' ' ' THR . 13.5 m -86.29 127.9 34.84 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.951 -1.093 . . . . 0.0 109.596 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.107 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -116.53 151.16 36.71 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.02 -1.05 . . . . 0.0 110.862 -179.35 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -131.62 136.0 47.4 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.402 -0.811 . . . . 0.0 109.88 -179.853 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 17.9 mt -140.67 172.69 12.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.773 -1.204 . . . . 0.0 109.965 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -94.55 29.16 2.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.22 -0.925 . . . . 0.0 110.967 -179.157 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.528 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 149.91 -82.84 0.18 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.484 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.2 tt0 -151.59 107.94 3.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.092 -1.24 . . . . 0.0 110.737 -179.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.634 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.4 m-85 -133.27 140.89 47.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.299 -0.876 . . . . 0.0 109.829 179.51 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.699 ' O ' HG23 ' A' ' 353' ' ' ILE . 18.3 m-20 -74.01 97.09 2.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.05 -1.031 . . . . 0.0 109.001 179.022 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.956 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.8 p-90 -98.63 115.27 28.29 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.206 -0.934 . . . . 0.0 110.64 -179.193 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.613 HG23 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -108.09 113.9 27.4 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.506 -0.746 . . . . 0.0 109.547 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.816 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.7 t -96.75 110.88 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 109.948 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.531 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 26.7 ttmt -84.84 148.24 26.39 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.344 -0.847 . . . . 0.0 109.768 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.779 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 46.3 t -144.58 108.51 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.256 -0.902 . . . . 0.0 110.398 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.585 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 2.6 mmtp -73.25 141.59 47.25 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.291 -0.88 . . . . 0.0 109.054 179.444 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.992 HD13 ' HA ' ' A' ' 303' ' ' THR . 97.9 mt -93.45 156.7 16.61 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.164 -0.96 . . . . 0.0 111.708 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -69.65 172.45 5.42 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.629 -0.67 . . . . 0.0 109.49 179.073 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.0 Cg_endo -67.61 84.34 0.39 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.73 1.384 . . . . 0.0 109.704 179.199 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.29 28.05 3.19 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 -179.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.887 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -123.42 145.25 48.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.331 -1.099 . . . . 0.0 110.623 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.992 ' HA ' HD13 ' A' ' 298' ' ' LEU . 42.0 p -145.68 144.4 30.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.254 -0.904 . . . . 0.0 110.367 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.99 ' CG2' HG21 ' A' ' 319' ' ' VAL . 19.6 t -78.62 136.86 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 110.179 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -136.67 -34.01 0.22 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -114.22 113.08 24.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.142 -1.21 . . . . 0.0 110.712 -179.632 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 28.9 p90 -144.4 164.37 31.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.297 -0.877 . . . . 0.0 109.844 179.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -157.64 161.56 38.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.076 -1.015 . . . . 0.0 111.102 -179.297 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.521 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 57.91 23.66 10.06 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.797 . . . . 0.0 111.22 179.31 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.676 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.46 141.85 0.72 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.185 -0.947 . . . . 0.0 110.057 179.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.598 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.3 m-80 -77.24 119.46 20.94 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.135 -0.978 . . . . 0.0 109.399 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.4 ttpt -90.33 141.45 28.71 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.658 0.742 . . . . 0.0 110.404 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.818 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -128.99 178.47 6.38 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.447 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.609 ' HG3' HG22 ' A' ' 319' ' ' VAL . 2.5 mt-10 -141.48 104.69 4.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.686 -0.634 . . . . 0.0 110.024 179.511 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.38 42.05 2.93 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.59 78.78 0.27 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.225 -1.162 . . . . 0.0 110.436 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.613 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 102.7 -1.64 48.94 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.845 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -144.38 -165.67 2.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.337 -1.096 . . . . 0.0 109.42 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.99 HG21 ' CG2' ' A' ' 304' ' ' VAL . 2.8 t -163.48 154.25 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.331 -0.856 . . . . 0.0 109.7 179.341 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.815 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 13.4 mm -121.11 148.02 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.027 -1.046 . . . . 0.0 110.693 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.651 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.8 m-85 -126.27 124.53 40.57 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.357 -0.839 . . . . 0.0 109.815 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.613 ' CG2' HG23 ' A' ' 293' ' ' THR . 8.7 p -128.9 166.51 24.45 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.935 -1.103 . . . . 0.0 109.576 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.43 120.43 7.64 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.853 1.449 . . . . 0.0 110.912 -179.076 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.778 HG22 ' HB2' ' A' ' 327' ' ' ASN . 31.1 m -64.48 -123.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.576 -0.702 . . . . 0.0 110.205 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.484 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.8 OUTLIER -102.35 -17.7 15.75 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.815 -1.178 . . . . 0.0 110.669 -179.673 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.605 ' H ' HG23 ' A' ' 324' ' ' VAL . 20.4 p-90 -126.74 -8.78 6.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.018 -1.051 . . . . 0.0 110.505 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.778 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t-20 -89.82 38.98 0.94 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.416 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -118.47 -6.35 10.74 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.137 -0.977 . . . . 0.0 109.715 179.75 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.26 -164.69 0.06 OUTLIER Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.528 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.6 Cg_endo -72.35 1.05 6.54 Favored 'Trans proline' 0 C--N 1.307 -1.633 0 O-C-N 124.236 1.65 . . . . 0.0 110.793 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -160.04 114.74 2.29 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.421 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.764 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -136.43 120.92 18.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -0.89 . . . . 0.0 110.499 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.855 ' OG1' HG23 ' A' ' 283' ' ' THR . 97.4 m -110.37 142.38 42.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -0.872 . . . . 0.0 110.099 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.816 ' HE2' HG21 ' A' ' 294' ' ' VAL . 16.4 p90 -145.22 174.39 11.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.419 -0.801 . . . . 0.0 108.918 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.14 164.62 30.12 Favored Glycine 0 N--CA 1.488 2.148 0 C-N-CA 118.913 -1.613 . . . . 0.0 110.146 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.896 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -151.54 143.4 23.78 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.512 -0.993 . . . . 0.0 109.642 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.896 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -119.42 123.16 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.07 -1.019 . . . . 0.0 109.569 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.887 HG11 ' HB1' ' A' ' 302' ' ' ALA . 13.3 t -96.26 154.91 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.098 -1.002 . . . . 0.0 110.353 -179.522 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.58 135.03 52.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.368 -0.832 . . . . 0.0 110.582 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.459 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.49 2.246 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 179.765 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.559 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.434 0 CA-C-O 121.312 0.577 . . . . 0.0 110.526 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.595 HG21 HG13 ' A' ' 296' ' ' VAL . 7.5 p -129.21 123.13 57.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.302 -0.874 . . . . 0.0 110.103 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.533 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 8.8 mt-10 -56.11 -41.38 75.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.314 -0.866 . . . . 0.0 110.907 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.424 ' OE2' HG23 ' A' ' 350' ' ' THR . 2.4 tp10 -177.14 156.13 1.23 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.93 -1.106 . . . . 0.0 110.623 -179.352 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.696 HG23 HG22 ' A' ' 296' ' ' VAL . 38.6 mt -123.98 104.02 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.121 -0.987 . . . . 0.0 110.063 179.283 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . 0.424 HG23 ' OE2' ' A' ' 348' ' ' GLU . 0.0 OUTLIER -108.73 148.46 30.45 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.211 -0.931 . . . . 0.0 110.129 -179.836 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.107 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -109.84 129.51 55.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.946 . . . . 0.0 110.347 179.844 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 24.2 tp10 -138.46 114.37 10.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.895 . . . . 0.0 109.779 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.699 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.54 104.86 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.101 -0.999 . . . . 0.0 110.462 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.55 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 38.94 36.1 0.14 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.831 -0.543 . . . . 0.0 110.794 179.752 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.41 12.72 16.54 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 1.4 mp0 -120.88 105.45 10.71 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.979 -1.307 . . . . 0.0 110.358 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.887 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -72.22 128.02 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.275 -0.891 . . . . 0.0 110.324 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.887 HD13 ' O ' ' A' ' 357' ' ' VAL . 10.7 mm . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.097 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.314 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.527 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.53 166.29 24.97 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.722 -0.87 . . . . 0.0 109.495 179.908 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.914 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.5 tm? -161.59 137.58 7.94 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.497 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.821 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.8 OUTLIER -137.27 151.0 48.21 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.032 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.848 HG13 ' O ' ' A' ' 281' ' ' ASP . 66.1 t -138.93 138.83 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.683 -1.261 . . . . 0.0 111.431 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.422 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -120.69 157.77 28.9 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.215 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.702 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.4 t -144.9 146.76 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.287 -1.508 . . . . 0.0 112.169 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.7 113.5 7.13 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.451 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 4.8 m-20 -98.1 143.72 28.34 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.209 -0.932 . . . . 0.0 111.016 -178.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.83 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.8 p90 -128.99 17.75 6.14 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 110.079 179.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.76 -58.3 4.36 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.94 -18.31 64.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.229 -1.16 . . . . 0.0 110.093 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.551 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.72 178.14 48.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.542 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -132.14 143.49 50.02 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -1.111 . . . . 0.0 110.111 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.702 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -97.52 147.13 24.57 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.459 -0.776 . . . . 0.0 110.031 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 94.3 m-85 -142.41 84.52 1.87 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.336 -0.853 . . . . 0.0 110.749 -179.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.848 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -66.41 152.12 45.75 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.408 -0.808 . . . . 0.0 110.03 179.288 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.719 HG11 HG11 ' A' ' 294' ' ' VAL . 10.6 t -144.41 90.33 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.66 -0.65 . . . . 0.0 109.572 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 333' ' ' THR . 81.9 m -86.43 124.56 32.9 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.146 -0.971 . . . . 0.0 109.465 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.058 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.07 147.51 37.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.308 -0.87 . . . . 0.0 110.531 -179.243 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.904 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -126.33 134.17 51.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.382 -0.824 . . . . 0.0 109.804 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.904 HD23 ' O ' ' A' ' 285' ' ' ASN . 16.5 mt -141.63 150.42 41.95 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.607 -1.308 . . . . 0.0 110.208 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.51 35.59 0.77 Allowed 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.484 -0.76 . . . . 0.0 109.374 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.59 -128.94 2.04 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.256 -1.45 . . . . 0.0 109.91 -179.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.498 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -124.59 96.07 4.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -1.195 . . . . 0.0 110.714 -179.531 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.547 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.7 m-85 -118.53 129.44 55.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.33 -0.857 . . . . 0.0 109.74 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.687 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.3 OUTLIER -63.49 100.57 0.27 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.948 -1.095 . . . . 0.0 109.224 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.954 ' CE3' HD13 ' A' ' 284' ' ' LEU . 54.7 p-90 -99.85 112.98 25.21 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.213 -0.929 . . . . 0.0 111.065 -179.257 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.874 HG23 ' CG2' ' A' ' 322' ' ' THR . 14.8 m -106.01 115.81 30.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.648 -0.658 . . . . 0.0 109.271 179.256 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.771 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.2 t -96.27 110.95 25.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.035 -1.04 . . . . 0.0 110.388 -179.424 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.524 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.9 ttpt -86.0 145.95 26.88 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.469 -0.769 . . . . 0.0 109.223 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.923 HG22 HG23 ' A' ' 349' ' ' ILE . 55.1 t -146.3 108.04 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 110.448 -179.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.519 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 30.8 mmtp -70.38 139.88 52.0 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.186 -0.946 . . . . 0.0 109.324 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.96 HD13 ' HA ' ' A' ' 303' ' ' THR . 81.8 mt -94.71 158.45 15.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.454 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.819 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.65 177.12 0.88 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.684 -0.635 . . . . 0.0 109.748 179.33 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.819 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.4 Cg_endo -68.47 87.38 0.42 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.758 1.399 . . . . 0.0 109.838 179.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 107.32 22.28 7.55 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.76 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -112.9 139.15 48.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.262 -1.14 . . . . 0.0 110.161 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.96 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.3 p -143.68 145.65 32.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 110.524 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 1.008 ' CG2' HG21 ' A' ' 319' ' ' VAL . 22.7 t -76.04 129.63 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.214 -0.929 . . . . 0.0 109.939 179.756 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.29 -17.98 3.51 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.148 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.404 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -143.78 129.76 19.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.046 -1.267 . . . . 0.0 111.245 -179.588 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.8 p90 -150.04 -178.14 6.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.545 -0.722 . . . . 0.0 109.636 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.485 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -166.06 151.15 8.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.534 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.6 OUTLIER 61.67 30.82 18.65 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.471 -0.768 . . . . 0.0 110.819 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.778 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.68 141.66 0.51 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.237 -0.915 . . . . 0.0 110.045 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.841 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.3 m-80 -81.17 112.4 18.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.074 -1.016 . . . . 0.0 109.317 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.559 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 2.3 ttpt -84.93 142.72 29.47 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.957 0.884 . . . . 0.0 110.981 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.751 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -129.34 179.08 5.99 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.099 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.536 ' HG2' HG22 ' A' ' 319' ' ' VAL . 2.4 mt-10 -142.04 100.04 3.65 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.091 -0.644 . . . . 0.0 110.189 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.436 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -86.13 42.46 3.15 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 19.6 m120 59.69 80.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.239 -1.154 . . . . 0.0 110.328 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.605 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.86 2.61 56.14 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.821 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.1 m-85 -147.29 -166.87 2.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.396 -1.061 . . . . 0.0 109.382 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 1.008 HG21 ' CG2' ' A' ' 304' ' ' VAL . 4.0 t -163.16 154.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.283 -0.885 . . . . 0.0 109.975 178.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.751 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 5.2 mm -125.86 138.69 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.174 -0.953 . . . . 0.0 111.545 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.655 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.9 m-85 -117.4 122.61 44.28 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.326 -0.859 . . . . 0.0 109.515 178.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.874 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -124.4 168.75 12.2 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 120.61 -1.306 . . . . 0.0 110.554 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.539 ' HG3' ' HA ' ' A' ' 291' ' ' ASP . 38.9 Cg_endo -64.66 112.2 1.9 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 124.04 1.548 . . . . 0.0 110.908 -179.362 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.841 HG12 ' ND2' ' A' ' 311' ' ' ASN . 33.8 m -58.69 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.687 -0.633 . . . . 0.0 109.961 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.602 ' N ' HG23 ' A' ' 324' ' ' VAL . 3.1 p -112.39 -12.72 13.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.636 -1.29 . . . . 0.0 111.01 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.643 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.8 p-90 -129.85 -12.31 4.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.984 -1.073 . . . . 0.0 111.226 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.841 ' CG ' HG22 ' A' ' 324' ' ' VAL . 23.1 p-10 -96.28 40.83 1.12 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.047 -1.033 . . . . 0.0 110.985 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.461 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -114.14 -3.0 13.29 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.162 -0.961 . . . . 0.0 109.51 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.81 -157.74 0.02 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.524 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -74.66 6.97 2.93 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.052 1.553 . . . . 0.0 110.956 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 5.6 m -165.35 122.11 1.46 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.099 -1.001 . . . . 0.0 110.088 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.56 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -138.91 116.25 11.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.933 . . . . 0.0 110.617 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.542 HG23 ' HA ' ' A' ' 283' ' ' THR . 13.3 m -108.36 134.16 51.56 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.243 -0.91 . . . . 0.0 110.046 179.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.778 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 11.0 p90 -142.65 174.89 10.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.058 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.61 156.96 27.01 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.014 -1.565 . . . . 0.0 110.272 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.942 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -141.7 147.74 37.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.496 -1.002 . . . . 0.0 110.04 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.942 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.75 122.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.179 -0.951 . . . . 0.0 109.623 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.76 HG11 ' HB1' ' A' ' 302' ' ' ALA . 18.3 t -97.29 153.28 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.934 . . . . 0.0 110.554 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -121.02 132.76 55.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.561 -0.712 . . . . 0.0 109.867 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.453 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.49 2.237 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.545 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.487 1.382 0 CA-C-O 121.231 0.539 . . . . 0.0 111.06 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 346' ' ' VAL . 14.7 p -132.87 119.03 35.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.282 -0.886 . . . . 0.0 110.187 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.446 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -51.26 -46.96 62.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.444 -0.785 . . . . 0.0 110.268 -179.743 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.499 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 6.8 pt-20 -177.05 158.66 1.56 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.267 -0.896 . . . . 0.0 110.627 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.923 HG23 HG22 ' A' ' 296' ' ' VAL . 77.2 mt -121.29 112.41 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 110.245 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -116.54 137.47 52.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.238 -0.913 . . . . 0.0 110.177 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.058 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -93.04 135.3 34.35 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.12 -0.988 . . . . 0.0 110.523 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.47 108.26 5.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.402 -0.811 . . . . 0.0 110.012 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.687 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.8 mt -91.67 108.85 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.992 -1.067 . . . . 0.0 110.068 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.541 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 38.88 31.51 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.746 -0.596 . . . . 0.0 110.796 -179.855 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.13 -12.14 22.07 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.438 ' O ' HG12 ' A' ' 358' ' ' ILE . 2.2 mp0 -95.03 105.55 17.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.1 -1.236 . . . . 0.0 110.487 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.9 p -68.83 133.97 30.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.882 . . . . 0.0 110.185 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.506 HD13 ' O ' ' A' ' 357' ' ' VAL . 22.1 mm . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.289 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.528 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.69 164.59 27.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.378 -1.072 . . . . 0.0 110.049 179.992 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.847 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.3 tm? -161.34 131.93 5.15 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.226 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.845 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.6 mt-10 -128.91 151.34 49.76 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.28 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.85 HG13 ' O ' ' A' ' 281' ' ' ASP . 96.5 t -142.71 138.83 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.712 -1.242 . . . . 0.0 111.509 -179.26 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -122.19 157.46 31.52 Favored 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.278 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.755 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.9 t -143.2 146.98 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.324 -1.485 . . . . 0.0 111.957 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.5 112.22 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 179.485 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.484 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.9 m-20 -96.49 143.95 27.04 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.014 -1.054 . . . . 0.0 111.125 -179.214 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.82 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.7 p90 -128.38 16.79 6.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 109.847 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.27 -63.17 2.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.6 -20.42 64.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -1.133 . . . . 0.0 110.306 -179.751 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.554 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.88 177.98 42.44 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.15 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.541 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.13 142.65 47.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.339 -1.094 . . . . 0.0 109.704 179.599 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.755 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.8 mt-10 -98.91 147.11 25.3 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.281 -0.887 . . . . 0.0 110.429 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.668 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.9 m-85 -143.09 84.2 1.82 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.511 -0.743 . . . . 0.0 110.649 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.85 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.87 151.69 46.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.347 -0.846 . . . . 0.0 109.967 179.407 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.756 HG11 HG11 ' A' ' 294' ' ' VAL . 14.0 t -143.93 91.38 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.459 -0.776 . . . . 0.0 110.131 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.825 HG23 ' OG1' ' A' ' 333' ' ' THR . 88.4 m -86.74 123.89 32.4 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.39 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -111.27 147.49 34.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.017 -1.052 . . . . 0.0 110.976 -179.037 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.915 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -126.5 132.32 51.42 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.462 -0.774 . . . . 0.0 110.163 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.915 HD23 ' O ' ' A' ' 285' ' ' ASN . 18.1 mt -142.77 157.52 44.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.43 36.86 1.06 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.194 -0.941 . . . . 0.0 109.671 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 160.68 -144.31 9.82 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.401 -1.381 . . . . 0.0 109.896 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.557 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -108.76 94.22 4.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -1.126 . . . . 0.0 110.711 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.618 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.7 m-30 -114.65 143.67 44.66 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 109.901 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.815 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.6 m-20 -76.97 97.21 4.57 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.198 -0.939 . . . . 0.0 109.078 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.898 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.4 p-90 -96.75 112.37 24.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.378 -0.826 . . . . 0.0 110.596 -179.185 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 1.021 HG23 ' CG2' ' A' ' 322' ' ' THR . 1.5 m -105.44 113.78 27.56 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.416 -0.802 . . . . 0.0 109.515 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.757 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.4 t -96.07 110.67 24.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.076 -1.015 . . . . 0.0 109.829 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.647 ' NZ ' HD11 ' A' ' 320' ' ' ILE . 8.4 ttmt -87.78 149.54 24.11 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.234 -0.916 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.761 HG13 HG12 ' A' ' 349' ' ' ILE . 98.6 t -144.89 108.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.419 -0.801 . . . . 0.0 110.352 -179.604 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.511 ' HB2' ' HB3' ' A' ' 347' ' ' GLU . 14.5 mmtt -71.95 132.53 44.45 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.242 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.943 HD13 ' HA ' ' A' ' 303' ' ' THR . 84.5 mt -88.0 156.05 19.51 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.233 -0.917 . . . . 0.0 111.594 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.694 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.29 173.08 3.57 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.581 -0.699 . . . . 0.0 109.318 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.694 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.6 Cg_endo -66.95 81.49 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.436 1.23 . . . . 0.0 110.067 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.79 23.09 4.09 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.851 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.03 144.94 42.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.366 -1.079 . . . . 0.0 110.085 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.943 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.9 p -150.35 145.88 26.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.104 -0.998 . . . . 0.0 110.782 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.833 HG21 HG11 ' A' ' 319' ' ' VAL . 37.6 t -66.42 126.3 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.383 -0.823 . . . . 0.0 110.071 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.51 -16.19 6.11 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 337' ' ' ILE . 14.7 t -152.04 113.33 4.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.064 -1.257 . . . . 0.0 111.009 -179.624 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 18.7 p90 -134.39 163.64 29.22 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.396 -0.815 . . . . 0.0 109.43 179.135 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -153.91 160.92 42.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.995 -1.066 . . . . 0.0 111.246 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.511 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 54.13 29.08 9.79 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.694 . . . . 0.0 110.95 179.774 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.753 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.32 139.56 0.61 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.256 -0.903 . . . . 0.0 110.112 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.835 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -79.17 118.8 21.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.308 179.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.473 ' HG3' HG11 ' A' ' 304' ' ' VAL . 8.1 ttpt -87.53 134.92 33.54 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.688 0.756 . . . . 0.0 111.235 -179.126 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.623 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.95 172.68 7.1 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -131.71 112.62 12.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.343 -0.848 . . . . 0.0 110.082 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.567 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.58 47.81 1.15 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 8.0 t30 49.49 77.04 0.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.287 -1.125 . . . . 0.0 110.142 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.615 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.01 2.12 54.92 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.851 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.8 m-85 -143.67 -170.78 3.38 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.998 . . . . 0.0 109.13 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.851 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.9 t -163.95 154.5 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.254 -0.904 . . . . 0.0 109.11 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.91 HG23 HG22 ' A' ' 293' ' ' THR . 17.6 mt -131.75 135.83 58.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 120.711 -1.243 . . . . 0.0 111.298 -179.591 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.7 ' HE2' HG21 ' A' ' 296' ' ' VAL . 52.9 m-85 -106.36 138.76 41.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.301 -0.874 . . . . 0.0 110.537 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 1.021 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.0 OUTLIER -136.41 169.92 12.24 Favored Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.934 -1.104 . . . . 0.0 110.023 179.427 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 41.0 Cg_endo -67.86 116.39 4.27 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 O-C-N 123.797 1.42 . . . . 0.0 110.816 -179.175 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.835 HG12 ' ND2' ' A' ' 311' ' ' ASN . 19.9 m -65.69 -129.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.578 -0.701 . . . . 0.0 110.098 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.638 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -98.33 -12.82 21.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.912 -1.117 . . . . 0.0 110.712 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.785 ' H ' HG23 ' A' ' 324' ' ' VAL . 36.2 p-90 -135.41 7.57 3.34 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.033 -1.042 . . . . 0.0 110.676 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.809 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 2.1 t-20 -111.32 42.62 1.63 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.18 -0.95 . . . . 0.0 110.119 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -122.79 -5.87 8.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 0.0 110.092 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.22 -160.35 0.02 OUTLIER Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.736 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 286' ' ' LEU . 45.9 Cg_endo -74.63 4.13 4.81 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 124.056 1.556 . . . . 0.0 110.592 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.425 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.7 m -164.61 116.1 1.24 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.925 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.809 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.18 119.15 15.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.189 -0.945 . . . . 0.0 110.325 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.825 ' OG1' HG23 ' A' ' 283' ' ' THR . 3.3 m -105.03 142.26 35.14 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.948 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.757 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.2 p90 -148.6 174.89 11.67 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.524 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.94 159.87 29.02 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.61 -1.757 . . . . 0.0 110.447 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.929 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.5 OUTLIER -143.55 147.61 34.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.506 -0.996 . . . . 0.0 110.034 179.572 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.929 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -123.29 119.18 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.922 . . . . 0.0 109.188 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.851 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 5.9 t -96.55 146.2 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.143 -0.973 . . . . 0.0 110.352 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.08 137.04 52.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.497 -0.752 . . . . 0.0 110.088 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.452 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.491 2.362 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.628 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.491 1.592 0 CA-C-O 121.067 0.461 . . . . 0.0 110.814 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.581 HG21 ' CG1' ' A' ' 296' ' ' VAL . 7.1 p -127.64 116.92 45.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.927 . . . . 0.0 110.081 179.418 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -47.84 -46.82 31.48 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.363 -0.835 . . . . 0.0 110.482 -179.69 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.18 158.78 1.54 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.103 -0.998 . . . . 0.0 110.861 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.761 HG12 HG13 ' A' ' 296' ' ' VAL . 69.1 mt -120.39 122.97 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.026 -1.046 . . . . 0.0 110.278 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.42 137.58 52.76 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.193 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -96.34 130.57 43.42 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.059 -1.026 . . . . 0.0 110.367 179.975 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.45 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 30.4 tt0 -139.06 110.06 6.8 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.841 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.815 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.69 110.22 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.081 -1.012 . . . . 0.0 110.231 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.412 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 43.31 30.6 0.32 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.645 -0.659 . . . . 0.0 110.969 179.917 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.09 -3.8 28.55 Favored Glycine 0 N--CA 1.492 2.39 0 C-N-CA 119.811 -1.185 . . . . 0.0 110.295 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.45 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 37.2 mm-40 -102.39 114.5 28.73 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.093 -1.239 . . . . 0.0 110.518 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.935 ' O ' HD13 ' A' ' 358' ' ' ILE . 4.5 p -73.69 136.22 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.251 -0.905 . . . . 0.0 110.363 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.935 HD13 ' O ' ' A' ' 357' ' ' VAL . 20.6 mm . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.051 -0.976 . . . . 0.0 110.267 -179.769 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.42 ' O ' ' CG2' ' A' ' 358' ' ' ILE . . . . . . . . 0 N--CA 1.491 2.345 0 N-CA-C 110.24 -1.144 . . . . 0.0 110.24 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.571 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -119.3 163.39 17.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.424 -1.045 . . . . 0.0 109.932 179.733 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.796 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -152.06 122.11 7.12 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.09 -1.006 . . . . 0.0 110.817 -179.822 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.443 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.9 mt-10 -118.72 111.15 18.13 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.696 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.753 HG13 ' O ' ' A' ' 281' ' ' ASP . 71.4 t -113.23 141.2 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.011 -1.056 . . . . 0.0 111.861 -178.479 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.1 157.63 41.88 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.858 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.887 HG13 ' O ' ' A' ' 279' ' ' GLU . 88.5 t -142.41 147.03 21.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.312 -1.492 . . . . 0.0 112.141 -179.064 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.562 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -135.83 107.5 6.99 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.958 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.4 p30 -93.66 146.03 24.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.031 . . . . 0.0 111.572 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.5 p90 -134.84 23.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.563 -0.71 . . . . 0.0 109.694 179.293 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.4 -69.23 3.38 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.875 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -27.67 48.16 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 110.425 179.888 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.537 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.83 -173.57 38.74 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.817 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.557 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -141.39 143.77 34.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -1.162 . . . . 0.0 110.379 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.887 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -93.67 145.61 24.43 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.475 -0.766 . . . . 0.0 109.578 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.1 m-85 -137.9 82.66 1.93 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.332 -0.855 . . . . 0.0 110.422 -179.543 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.753 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -67.91 144.11 55.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.485 -0.76 . . . . 0.0 109.676 179.433 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.874 HG11 HG11 ' A' ' 294' ' ' VAL . 6.7 t -137.71 88.4 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.484 -0.76 . . . . 0.0 109.772 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.865 HG23 ' OG1' ' A' ' 333' ' ' THR . 60.6 m -86.25 120.47 27.64 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 109.245 179.808 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.092 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -104.32 149.02 25.72 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.076 -1.015 . . . . 0.0 111.106 -178.69 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.571 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -131.57 107.19 8.69 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.505 -0.747 . . . . 0.0 110.224 -179.298 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 330' ' ' PRO . 4.8 mt -122.24 172.78 8.04 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.525 -1.359 . . . . 0.0 110.177 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -101.1 28.19 5.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.355 -0.841 . . . . 0.0 110.926 -179.603 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.637 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 161.92 -179.43 37.29 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 119.177 -1.487 . . . . 0.0 110.6 179.739 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.46 ' O ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -71.41 109.0 5.12 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.426 -1.044 . . . . 0.0 111.039 -179.417 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.637 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 10.2 m-85 -137.08 151.55 49.03 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.251 -0.906 . . . . 0.0 109.786 178.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.776 ' O ' HG23 ' A' ' 353' ' ' ILE . 57.8 m-20 -80.42 97.09 6.92 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.273 179.074 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.8 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.4 p-90 -97.18 110.67 23.17 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.406 -179.605 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.67 HG22 ' CG2' ' A' ' 320' ' ' ILE . 4.0 m -103.02 116.76 33.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.5 -0.75 . . . . 0.0 109.485 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.874 HG11 HG11 ' A' ' 282' ' ' VAL . 4.7 t -96.91 111.19 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.131 -0.981 . . . . 0.0 110.432 -179.465 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.651 ' HA ' HD13 ' A' ' 320' ' ' ILE . 17.5 ttpt -82.96 147.85 27.97 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.219 -0.925 . . . . 0.0 109.47 179.433 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 1.011 HG22 HG23 ' A' ' 349' ' ' ILE . 77.3 t -146.61 105.01 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.135 -0.978 . . . . 0.0 110.629 -179.323 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.562 ' O ' HG23 ' A' ' 346' ' ' VAL . 19.2 mmtt -71.26 130.51 41.6 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.259 -0.9 . . . . 0.0 109.393 179.404 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.983 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.2 mt -83.8 161.42 20.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.46 -0.775 . . . . 0.0 111.6 -178.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.968 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -63.56 179.12 0.35 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.675 -0.641 . . . . 0.0 109.674 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.9 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.5 Cg_endo -69.24 76.46 0.93 Allowed 'Trans proline' 0 C--N 1.305 -1.745 0 O-C-N 123.742 1.391 . . . . 0.0 109.825 179.369 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.73 19.68 6.0 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.24 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.968 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -101.08 152.69 20.31 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.399 -1.059 . . . . 0.0 110.271 -179.596 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.983 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -150.6 144.62 25.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 110.588 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.853 HG21 HG11 ' A' ' 319' ' ' VAL . 55.2 t -68.07 140.95 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.35 -0.844 . . . . 0.0 109.734 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.79 -39.04 0.51 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.665 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 19.5 m -137.05 129.36 29.75 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.007 -1.29 . . . . 0.0 111.117 -179.678 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.516 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 30.1 p90 -141.2 167.09 23.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.387 -0.821 . . . . 0.0 109.434 179.27 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.467 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.06 157.15 37.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.877 -1.14 . . . . 0.0 111.083 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.475 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 58.79 25.23 13.25 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.477 -0.764 . . . . 0.0 111.106 179.797 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.725 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.18 140.03 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.242 -0.911 . . . . 0.0 109.997 179.465 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.515 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -79.47 121.96 25.84 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.104 -0.998 . . . . 0.0 109.312 179.569 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.686 ' HG3' HG11 ' A' ' 304' ' ' VAL . 0.6 OUTLIER -88.75 145.75 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.771 0.796 . . . . 0.0 110.991 -179.119 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.824 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.17 175.23 9.28 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.524 ' HG2' HG22 ' A' ' 319' ' ' VAL . 3.4 mm-40 -138.68 112.99 8.74 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.228 -0.92 . . . . 0.0 110.457 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -99.76 40.63 2.38 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.79 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 59.27 82.27 0.15 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.29 -1.123 . . . . 0.0 110.179 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.56 -1.56 57.07 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.683 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.2 m-85 -146.37 -172.72 4.01 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.499 -1.0 . . . . 0.0 109.317 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.853 HG11 HG21 ' A' ' 304' ' ' VAL . 2.5 t -158.67 160.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.137 -0.977 . . . . 0.0 109.743 179.355 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.67 ' CG2' HG22 ' A' ' 293' ' ' THR . 35.8 mm -127.93 146.82 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.163 -0.961 . . . . 0.0 111.304 -179.25 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.673 ' HE2' HG21 ' A' ' 296' ' ' VAL . 51.8 m-85 -123.67 132.68 53.9 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 110.003 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.597 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.1 p -131.54 169.69 13.17 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.924 -1.11 . . . . 0.0 110.135 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.538 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.3 Cg_endo -65.76 116.49 3.99 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.065 -179.482 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.482 HG23 ' H ' ' A' ' 326' ' ' TRP . 12.1 m -57.62 -111.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.479 -0.763 . . . . 0.0 109.951 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.466 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.1 t -119.6 -14.25 9.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.785 -1.197 . . . . 0.0 110.376 179.945 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.482 ' H ' HG23 ' A' ' 324' ' ' VAL . 6.5 p-90 -126.66 -24.75 3.51 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.229 -0.919 . . . . 0.0 110.614 -179.846 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 0.3 OUTLIER -86.92 40.8 0.93 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.236 -0.915 . . . . 0.0 110.137 -179.898 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.467 ' HD3' ' O ' ' A' ' 324' ' ' VAL . 0.0 OUTLIER -112.33 -6.22 14.07 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.292 -0.88 . . . . 0.0 109.995 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.69 -143.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.801 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 47.5 Cg_endo -74.85 -49.52 0.15 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.05 1.553 . . . . 0.0 110.395 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 19.0 m -111.08 134.48 52.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.247 -0.908 . . . . 0.0 110.511 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -148.72 123.26 9.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.349 -0.845 . . . . 0.0 109.863 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.865 ' OG1' HG23 ' A' ' 283' ' ' THR . 45.5 m -111.48 137.22 49.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 110.504 -179.826 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.797 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.2 p90 -145.45 174.59 11.01 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.21 159.14 28.05 Favored Glycine 0 N--CA 1.488 2.144 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.358 -179.397 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.929 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -144.98 146.24 31.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.572 -0.958 . . . . 0.0 109.781 179.686 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.929 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.03 125.66 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.175 -0.953 . . . . 0.0 110.091 -179.669 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.787 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.0 t -102.13 153.87 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.23 -0.918 . . . . 0.0 110.007 179.818 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.83 126.77 46.11 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.434 -0.791 . . . . 0.0 109.848 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.884 . . . . . . . . 0 0 . 1 . 021 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.77 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 1.7 mtmt . . . . . 0 N--CA 1.488 1.432 0 CA-C-O 121.105 0.479 . . . . 0.0 111.418 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.572 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.2 p -136.66 119.17 20.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.065 -1.022 . . . . 0.0 110.316 179.238 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.32 -46.46 46.74 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.286 -0.884 . . . . 0.0 110.38 -179.653 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -177.02 158.37 1.54 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.242 -0.911 . . . . 0.0 110.479 -179.756 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 1.011 HG23 HG22 ' A' ' 296' ' ' VAL . 23.6 mt -121.08 118.81 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.842 -1.161 . . . . 0.0 110.523 179.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.57 156.24 25.03 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.336 -0.852 . . . . 0.0 110.121 179.819 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.092 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -115.49 125.7 53.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.289 -0.882 . . . . 0.0 110.033 179.909 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.5 tt0 -139.06 118.4 12.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.966 -1.084 . . . . 0.0 110.618 179.869 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.776 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.4 mt -94.58 115.8 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.077 -1.015 . . . . 0.0 110.376 179.502 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.54 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 37.34 31.47 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.597 -0.689 . . . . 0.0 111.159 179.741 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 110.53 4.53 28.47 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.535 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 2.6 mp0 -108.05 105.93 15.92 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.149 -1.207 . . . . 0.0 110.087 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 357' ' ' VAL . 14.5 p -70.83 120.31 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.347 -0.845 . . . . 0.0 110.589 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.571 ' HB ' HD13 ' A' ' 351' ' ' LEU . 17.1 mm . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 117.978 -1.011 . . . . 0.0 110.172 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.272 0 N-CA-C 110.262 -1.135 . . . . 0.0 110.262 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.561 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.1 159.68 38.16 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.497 -1.002 . . . . 0.0 109.985 179.843 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.94 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -147.99 122.59 9.82 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 110.586 -179.626 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.461 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 14.7 mt-10 -123.59 114.26 19.79 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.958 HG13 ' O ' ' A' ' 281' ' ' ASP . 62.1 t -111.84 146.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.984 -1.072 . . . . 0.0 112.164 -178.417 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -130.68 157.21 43.4 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.829 HG13 ' O ' ' A' ' 279' ' ' GLU . 89.6 t -142.66 147.02 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.317 -1.489 . . . . 0.0 112.112 -179.203 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.537 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -141.12 111.13 6.61 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.216 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.502 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -97.48 148.43 23.23 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.906 -1.121 . . . . 0.0 111.459 -178.526 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.845 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.7 p90 -134.52 20.21 3.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.59 -0.694 . . . . 0.0 109.903 179.459 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.91 -68.42 3.38 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.942 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.402 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.6 t -58.33 -24.02 58.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -1.206 . . . . 0.0 110.455 -179.838 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.9 179.73 43.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.917 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.587 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.5 143.49 47.49 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.309 -1.112 . . . . 0.0 110.245 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.829 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -96.82 146.55 24.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.332 -0.855 . . . . 0.0 110.178 -179.644 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.683 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 87.4 m-85 -143.32 81.53 1.71 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.414 -0.804 . . . . 0.0 110.539 -179.553 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.958 ' O ' HG13 ' A' ' 269' ' ' VAL . 2.0 t0 -66.28 154.03 41.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 110.124 179.57 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.808 HG11 HG11 ' A' ' 294' ' ' VAL . 4.0 t -143.2 88.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.493 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.598 HG23 ' OG1' ' A' ' 333' ' ' THR . 8.8 m -85.93 115.38 23.51 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.294 -0.878 . . . . 0.0 109.376 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.06 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.14 148.55 24.47 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.327 -0.858 . . . . 0.0 110.818 -178.921 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.561 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -131.15 106.34 8.28 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.492 -0.755 . . . . 0.0 110.316 -179.521 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.546 ' HB2' ' HA ' ' A' ' 330' ' ' PRO . 4.6 mt -121.03 169.25 10.67 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.648 -1.282 . . . . 0.0 109.801 179.447 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . 0.403 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -103.15 32.8 3.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 110.253 -179.856 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.552 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 163.79 -165.17 36.8 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.384 -1.389 . . . . 0.0 110.281 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.0 mm-40 -89.28 110.58 21.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.268 -1.137 . . . . 0.0 111.046 -179.447 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.552 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 7.9 m-85 -137.8 142.07 40.86 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.179 -0.951 . . . . 0.0 109.706 179.169 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.666 ' O ' HG23 ' A' ' 353' ' ' ILE . 10.0 t70 -72.6 97.89 2.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.34 179.215 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.776 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.5 p-90 -97.32 112.32 24.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.272 -0.893 . . . . 0.0 110.383 -179.357 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.825 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.1 m -105.78 113.87 27.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.359 -0.838 . . . . 0.0 110.043 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.821 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.6 t -96.61 111.1 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 110.047 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.544 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.1 ttpt -87.87 149.29 24.2 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.28 -0.888 . . . . 0.0 109.319 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.793 HG13 HG12 ' A' ' 349' ' ' ILE . 98.8 t -146.2 108.93 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 121.077 -1.014 . . . . 0.0 110.543 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.526 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 9.3 mmtm -70.13 135.41 49.14 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.112 -0.992 . . . . 0.0 109.228 179.585 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.95 HD13 ' HA ' ' A' ' 303' ' ' THR . 88.4 mt -89.63 162.52 15.58 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.455 -0.778 . . . . 0.0 111.572 -178.879 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.853 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -69.48 177.47 1.23 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.756 -0.59 . . . . 0.0 109.759 179.358 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.853 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.7 Cg_endo -69.32 81.97 0.68 Allowed 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.735 1.387 . . . . 0.0 109.786 179.351 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.26 22.58 5.8 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.357 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.876 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.47 146.2 37.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.379 -1.071 . . . . 0.0 110.388 -179.623 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.95 ' HA ' HD13 ' A' ' 298' ' ' LEU . 5.4 p -149.86 145.74 26.73 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.274 -0.891 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.894 HG21 HG11 ' A' ' 319' ' ' VAL . 92.2 t -68.09 131.31 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.263 -0.898 . . . . 0.0 109.852 179.744 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.12 -28.83 2.11 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.7 t -142.33 115.99 9.16 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.103 -1.233 . . . . 0.0 111.116 -179.635 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.522 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.1 p90 -131.52 178.33 6.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.376 -0.828 . . . . 0.0 109.365 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.504 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -167.91 160.7 12.47 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.872 -1.143 . . . . 0.0 111.073 -179.643 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 57.81 23.61 9.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.496 -0.752 . . . . 0.0 110.881 179.789 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.671 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 146.79 1.0 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.301 -0.874 . . . . 0.0 110.074 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.789 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -82.48 119.74 24.59 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.168 -0.958 . . . . 0.0 109.283 179.46 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.596 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.6 ttpt -88.78 146.15 25.18 Favored 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.813 0.816 . . . . 0.0 110.657 -179.486 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.733 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -130.74 172.71 11.67 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.52 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.49 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 53.2 mt-10 -138.79 104.95 5.22 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.32 -0.863 . . . . 0.0 110.486 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.463 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -93.7 38.7 3.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.463 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 11.3 t-20 59.97 83.48 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.277 -1.131 . . . . 0.0 110.344 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.627 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.09 -2.71 55.13 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 179.709 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.822 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.1 m-85 -145.76 -167.58 2.75 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.349 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.894 HG11 HG21 ' A' ' 304' ' ' VAL . 2.9 t -163.3 157.45 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.178 -0.952 . . . . 0.0 109.428 178.974 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.544 HD13 ' HA ' ' A' ' 295' ' ' LYS . 11.1 mm -127.38 142.99 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.021 -179.641 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 47.8 m-85 -119.31 136.21 54.35 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.146 -0.971 . . . . 0.0 109.808 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.825 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.3 p -138.48 169.98 11.4 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.792 -1.193 . . . . 0.0 110.122 -179.928 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.519 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.79 123.97 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.926 1.487 . . . . 0.0 111.09 -179.292 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.789 HG12 ' ND2' ' A' ' 311' ' ' ASN . 18.6 m -74.35 -116.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.499 -0.751 . . . . 0.0 110.135 -179.938 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.5 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -105.68 -32.55 8.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.709 -1.245 . . . . 0.0 110.808 -179.588 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 4.1 p-90 -116.34 -1.77 12.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.12 -0.987 . . . . 0.0 110.502 -179.778 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.653 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.27 50.01 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.107 -0.995 . . . . 0.0 109.79 179.796 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -125.68 -2.6 7.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.376 -0.828 . . . . 0.0 109.716 -179.804 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.463 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -72.34 -143.91 0.48 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.735 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.546 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 49.2 Cg_endo -73.58 -53.73 0.12 Allowed 'Trans proline' 0 C--N 1.303 -1.838 0 O-C-N 124.166 1.614 . . . . 0.0 110.473 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.25 130.61 50.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.259 -0.901 . . . . 0.0 110.467 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.552 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -145.03 104.48 3.98 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.435 -0.791 . . . . 0.0 109.749 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.598 ' OG1' HG23 ' A' ' 283' ' ' THR . 27.8 m -100.68 133.73 44.71 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.084 -1.01 . . . . 0.0 110.604 -179.61 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.821 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.8 p90 -141.85 174.73 10.31 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.336 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.522 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.71 153.65 25.06 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.905 -1.617 . . . . 0.0 110.226 -179.542 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -138.72 146.73 41.85 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.468 -1.019 . . . . 0.0 109.794 179.354 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.88 122.09 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.238 -0.914 . . . . 0.0 109.798 -179.891 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.876 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 10.0 t -99.89 154.08 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.1 -1.0 . . . . 0.0 110.644 -179.398 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -124.91 130.65 52.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.464 -0.772 . . . . 0.0 110.065 -179.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.391 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.833 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.622 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.487 1.398 0 CA-C-O 121.114 0.483 . . . . 0.0 111.281 . . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' A' ' 296' ' ' VAL . 12.2 p -138.74 118.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.152 -0.968 . . . . 0.0 110.303 179.391 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 5.7 mt-10 -49.26 -48.45 45.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.415 -0.803 . . . . 0.0 110.368 -179.728 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.458 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.8 pt-20 -177.21 158.74 1.52 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.188 -0.945 . . . . 0.0 111.008 -179.852 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.793 HG12 HG13 ' A' ' 296' ' ' VAL . 57.0 mt -117.46 121.44 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.324 -0.86 . . . . 0.0 109.993 179.509 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.56 136.97 54.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.246 -0.909 . . . . 0.0 110.291 -179.792 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.06 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -95.98 127.85 42.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.196 -0.94 . . . . 0.0 110.378 179.966 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.8 OUTLIER -139.39 113.02 8.43 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.16 -0.963 . . . . 0.0 110.399 179.746 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.666 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.3 mt -91.78 112.26 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.003 -1.061 . . . . 0.0 110.0 179.473 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.522 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 41.19 29.02 0.07 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.501 -0.749 . . . . 0.0 110.393 -179.69 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 113.15 -13.03 23.99 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.69 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.446 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 0.2 OUTLIER -88.6 110.86 21.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.306 -1.114 . . . . 0.0 110.431 -179.842 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.3 p -68.66 119.33 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.172 -0.955 . . . . 0.0 110.171 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.842 ' HB ' HD13 ' A' ' 351' ' ' LEU . 42.9 mm . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.268 -179.88 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.311 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.556 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.1 158.41 44.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.535 -0.98 . . . . 0.0 109.431 179.754 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.926 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -157.32 141.34 16.13 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.943 -1.098 . . . . 0.0 110.93 -179.488 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.752 ' H ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -140.34 122.02 15.31 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.797 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.844 HG23 HD11 ' A' ' 267' ' ' LEU . 50.9 t -115.39 133.14 62.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.01 -1.056 . . . . 0.0 111.559 -178.934 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.16 157.19 32.08 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.734 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 279' ' ' GLU . 71.6 t -143.12 147.04 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.286 -1.509 . . . . 0.0 112.251 -178.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.24 113.93 8.75 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.706 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 17.6 p-10 -98.81 148.21 24.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.039 -1.038 . . . . 0.0 111.718 -178.098 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.815 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.1 p90 -134.11 19.07 3.74 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.652 -0.655 . . . . 0.0 109.453 179.14 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.43 -65.83 3.91 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -58.48 -21.43 51.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -1.133 . . . . 0.0 110.255 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.531 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.35 -179.08 46.61 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.558 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -136.76 140.73 42.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.42 -1.047 . . . . 0.0 109.983 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.797 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.0 mt-10 -93.66 146.58 23.72 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.466 -0.771 . . . . 0.0 110.37 -179.534 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 91.0 m-85 -140.81 84.47 1.94 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.524 -0.735 . . . . 0.0 110.405 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.676 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -67.24 151.75 46.95 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.418 -0.801 . . . . 0.0 109.487 179.208 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.767 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.6 t -145.72 88.6 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.564 -0.71 . . . . 0.0 109.615 -179.537 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.68 HG23 ' OG1' ' A' ' 333' ' ' THR . 88.6 m -87.01 123.83 32.54 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.081 -1.012 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.057 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.85 150.51 30.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 110.408 -179.76 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.556 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -134.1 115.86 14.76 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.376 -0.827 . . . . 0.0 110.103 -179.377 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.618 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 13.2 mt -124.09 154.88 39.32 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 120.759 -1.213 . . . . 0.0 110.454 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -89.9 37.22 0.88 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.248 -0.908 . . . . 0.0 109.786 179.627 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.61 -141.86 7.71 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.528 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 tp60 -111.67 92.62 4.1 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.162 -1.199 . . . . 0.0 110.489 -179.758 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.618 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.1 m-30 -116.93 129.99 56.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.268 -0.895 . . . . 0.0 110.074 179.396 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.876 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.5 m-20 -64.16 103.67 0.64 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.146 -0.972 . . . . 0.0 109.557 179.549 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.897 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.0 p-90 -101.95 109.32 21.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.189 -0.944 . . . . 0.0 110.391 -179.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.787 HG22 ' CG2' ' A' ' 320' ' ' ILE . 3.1 m -101.04 116.18 32.23 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.463 -0.773 . . . . 0.0 109.526 179.641 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.786 HG21 ' HE2' ' A' ' 334' ' ' PHE . 20.6 t -96.67 111.1 26.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 110.487 -179.378 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.477 ' HA ' HG12 ' A' ' 320' ' ' ILE . 22.8 ttpt -87.36 147.25 25.55 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.496 -0.752 . . . . 0.0 109.024 179.0 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.671 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 55.6 t -146.67 105.45 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 110.702 -178.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.547 ' O ' HG23 ' A' ' 346' ' ' VAL . 26.4 mmtt -70.93 133.51 46.47 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.15 -0.969 . . . . 0.0 109.732 179.628 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.953 HD13 ' HA ' ' A' ' 303' ' ' THR . 90.7 mt -86.31 162.44 18.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.323 -0.861 . . . . 0.0 111.573 -178.93 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.707 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -71.28 173.48 4.96 Favored Pre-proline 0 N--CA 1.488 1.441 0 O-C-N 121.582 -0.699 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.694 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -67.92 82.4 0.46 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 O-C-N 123.508 1.267 . . . . 0.0 109.932 179.531 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.63 25.71 3.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.424 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.872 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -117.79 148.45 42.05 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -1.113 . . . . 0.0 110.144 -179.748 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.953 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.4 p -149.82 144.52 26.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 110.239 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.822 HG21 HG11 ' A' ' 319' ' ' VAL . 38.2 t -63.99 119.9 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.232 -0.918 . . . . 0.0 109.886 179.767 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -105.95 -20.35 9.41 Favored Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.818 -1.182 . . . . 0.0 110.339 -179.392 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.489 ' O ' ' N ' ' A' ' 337' ' ' ILE . 42.2 t -154.8 134.28 12.64 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.983 -1.304 . . . . 0.0 110.889 -179.695 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -149.43 176.42 10.6 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.354 -0.841 . . . . 0.0 109.773 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.472 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -166.72 158.84 13.38 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.794 -1.191 . . . . 0.0 111.719 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.51 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.8 OUTLIER 59.4 26.08 14.92 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.667 -0.646 . . . . 0.0 111.407 179.363 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.667 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 140.89 0.65 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.17 -0.956 . . . . 0.0 109.936 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.744 HD22 HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.34 114.14 15.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.078 -1.014 . . . . 0.0 109.586 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.751 ' CD ' HG11 ' A' ' 304' ' ' VAL . 1.9 ttpp -83.01 144.6 29.84 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.695 0.76 . . . . 0.0 110.691 -179.444 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.676 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -126.85 173.84 9.27 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.412 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.423 ' HG2' HG22 ' A' ' 319' ' ' VAL . 2.1 mm-40 -137.93 105.13 5.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.448 -0.782 . . . . 0.0 110.344 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -97.17 35.78 4.27 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.442 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.4 OUTLIER 65.65 91.96 0.08 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -1.182 . . . . 0.0 110.135 -179.962 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.58 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 87.47 0.69 84.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.857 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.826 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -143.28 -172.75 3.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.339 -1.095 . . . . 0.0 109.654 179.629 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.7 t -163.46 152.52 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.575 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.787 ' CG2' HG22 ' A' ' 293' ' ' THR . 68.8 mt -131.99 132.17 61.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.648 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 70.8 m-85 -104.76 141.47 36.42 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.374 -0.829 . . . . 0.0 110.748 -179.725 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.738 ' CG2' HG23 ' A' ' 293' ' ' THR . 0.9 OUTLIER -137.05 171.02 9.3 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 120.969 -1.082 . . . . 0.0 110.143 179.762 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.53 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.3 Cg_endo -67.29 114.68 3.33 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 O-C-N 123.822 1.433 . . . . 0.0 110.986 -179.461 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.963 HG22 ' HB2' ' A' ' 327' ' ' ASN . 7.3 m -65.44 -134.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.464 -0.773 . . . . 0.0 109.894 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.707 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.7 OUTLIER -92.09 -14.73 28.78 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.021 -1.049 . . . . 0.0 110.602 -179.697 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.836 ' H ' HG23 ' A' ' 324' ' ' VAL . 26.4 p-90 -136.06 15.97 3.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.241 -0.912 . . . . 0.0 110.444 -179.841 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.963 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -116.24 31.17 6.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.097 -1.002 . . . . 0.0 110.8 -179.481 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -114.6 -6.47 12.78 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.244 -0.91 . . . . 0.0 109.801 179.539 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.1 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.869 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.529 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 50.2 Cg_endo -75.42 5.75 4.0 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.04 1.547 . . . . 0.0 110.987 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.7 m -165.36 121.64 1.41 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 120.96 -1.087 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -143.44 112.74 6.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.139 -0.975 . . . . 0.0 110.446 -179.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.68 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.9 m -103.04 139.05 39.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.407 -0.808 . . . . 0.0 110.009 179.864 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.786 ' HE2' HG21 ' A' ' 294' ' ' VAL . 17.7 p90 -144.72 172.77 12.54 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.403 -0.81 . . . . 0.0 108.834 179.566 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.37 160.01 28.37 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 118.954 -1.594 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.931 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -145.33 146.4 31.59 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.582 -0.952 . . . . 0.0 109.63 179.237 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.931 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.85 120.25 61.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.836 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.872 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 6.0 t -96.74 146.3 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.13 -0.981 . . . . 0.0 110.621 -179.519 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -120.02 131.9 55.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.49 -0.756 . . . . 0.0 110.219 -179.935 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.912 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.707 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.0 mtmt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.024 0.44 . . . . 0.0 111.1 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.62 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -130.77 122.45 52.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.126 -0.984 . . . . 0.0 110.18 179.22 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.48 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -51.83 -45.45 63.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -0.941 . . . . 0.0 110.16 -179.703 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.475 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 6.9 pt-20 -177.03 158.27 1.52 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.253 -0.904 . . . . 0.0 110.324 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.589 HG12 HG13 ' A' ' 296' ' ' VAL . 11.5 mt -118.11 110.31 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.318 -0.864 . . . . 0.0 110.055 179.904 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.45 149.47 29.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.057 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -113.6 127.25 56.0 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.228 -0.92 . . . . 0.0 109.509 179.252 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 15.4 pt-20 -138.31 118.78 13.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.135 -0.978 . . . . 0.0 110.086 -179.797 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.876 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -97.73 104.7 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.197 -0.939 . . . . 0.0 110.351 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.488 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 1.5 m-80 35.16 30.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.057 0.455 . . . . 0.0 111.073 179.805 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 133.61 -43.41 1.27 Allowed Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.276 179.706 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.508 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 35.2 mm-40 -73.97 120.71 19.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.124 -1.221 . . . . 0.0 110.627 -179.505 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.712 HG13 ' O ' ' A' ' 357' ' ' VAL . 12.9 p -91.3 111.51 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.066 -1.022 . . . . 0.0 110.08 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.549 ' HB ' HD13 ' A' ' 351' ' ' LEU . 9.4 mm . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.187 -179.837 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.45 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.256 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.498 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.92 169.28 18.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.53 -0.983 . . . . 0.0 109.729 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.886 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.77 133.34 5.44 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.039 -1.038 . . . . 0.0 111.396 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.829 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.3 OUTLIER -129.76 138.38 51.05 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.404 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 281' ' ' ASP . 49.0 t -131.54 134.04 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.869 -1.145 . . . . 0.0 111.653 -179.3 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.24 157.08 29.89 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.705 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.659 HG13 ' O ' ' A' ' 279' ' ' GLU . 75.7 t -141.26 145.34 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.494 -1.378 . . . . 0.0 111.879 -179.392 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.57 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.15 110.17 8.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.666 -0.646 . . . . 0.0 109.825 179.631 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.414 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.8 m-20 -96.39 128.41 43.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.167 -0.958 . . . . 0.0 111.102 -179.412 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.83 ' CH2' HG23 ' A' ' 337' ' ' ILE . 29.0 p90 -113.17 16.59 19.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.879 . . . . 0.0 109.762 178.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.06 -59.0 3.93 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.45 -22.01 63.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -1.143 . . . . 0.0 110.18 179.858 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.583 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.78 -178.39 40.29 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.821 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -136.56 139.37 42.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.339 -1.095 . . . . 0.0 110.167 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.659 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.6 mt-10 -93.58 147.53 22.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.508 -0.745 . . . . 0.0 110.11 -179.511 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.3 m-85 -141.75 82.16 1.8 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.279 -0.888 . . . . 0.0 110.432 -179.661 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.643 ' O ' HG13 ' A' ' 269' ' ' VAL . 1.6 m-20 -67.38 146.01 54.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.509 -0.745 . . . . 0.0 109.695 179.557 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.773 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.8 t -139.12 88.78 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 109.931 -179.738 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 333' ' ' THR . 25.9 m -86.04 125.35 33.36 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.058 -1.026 . . . . 0.0 109.218 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -112.06 153.7 26.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.109 -0.994 . . . . 0.0 110.882 -179.072 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.936 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -131.63 128.37 38.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.474 -0.766 . . . . 0.0 110.162 -179.582 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.936 HD23 ' O ' ' A' ' 285' ' ' ASN . 9.8 mt -143.69 157.09 44.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.771 -1.206 . . . . 0.0 109.938 179.862 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -94.38 35.7 1.19 Allowed 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.401 -0.812 . . . . 0.0 109.732 179.526 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 162.21 -174.61 38.66 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.908 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.537 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mt-30 -83.93 96.3 8.78 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.308 -1.113 . . . . 0.0 110.406 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.603 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.74 153.38 32.51 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.227 -0.92 . . . . 0.0 109.749 179.586 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.844 ' O ' HG23 ' A' ' 353' ' ' ILE . 53.9 m-20 -82.85 95.74 8.03 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.328 179.327 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.893 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.5 p-90 -97.13 116.42 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 110.226 -179.737 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 1.042 HG23 HG22 ' A' ' 322' ' ' THR . 1.9 m -111.03 114.07 27.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.541 -0.724 . . . . 0.0 109.93 -179.83 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.776 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.4 t -96.2 111.33 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.097 -1.002 . . . . 0.0 110.205 -179.689 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 27.3 ttmt -86.63 149.81 24.65 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.368 -0.833 . . . . 0.0 109.622 179.361 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.862 HG22 HG23 ' A' ' 349' ' ' ILE . 54.5 t -147.69 109.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.117 -0.99 . . . . 0.0 110.599 -179.575 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.571 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 51.9 mmtt -72.6 141.42 48.37 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.107 -0.996 . . . . 0.0 109.591 179.441 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.966 HD13 ' HA ' ' A' ' 303' ' ' THR . 81.2 mt -94.03 156.2 16.72 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.26 -0.9 . . . . 0.0 111.481 -179.059 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -65.27 174.45 1.4 Allowed Pre-proline 0 C--N 1.303 -1.442 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.8 Cg_endo -68.74 83.42 0.53 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.531 1.28 . . . . 0.0 109.848 179.65 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.37 4.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 -179.468 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.709 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -114.69 149.41 36.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.298 -1.119 . . . . 0.0 109.753 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.966 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.6 p -150.69 143.46 24.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.062 . . . . 0.0 111.214 -179.796 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.93 ' CG2' HG21 ' A' ' 319' ' ' VAL . 58.6 t -70.89 116.46 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.56 -0.713 . . . . 0.0 110.013 179.515 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.43 -38.49 3.48 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.82 -1.181 . . . . 0.0 110.359 -179.264 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -129.94 140.33 50.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.004 -1.292 . . . . 0.0 111.139 -179.457 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.599 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 13.1 p90 -152.88 160.96 43.1 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 109.577 179.334 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.518 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -155.38 155.18 33.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.902 -1.124 . . . . 0.0 111.394 -179.48 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.441 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.9 OUTLIER 63.11 26.8 15.5 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 111.337 179.373 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.56 ' N ' HG13 ' A' ' 324' ' ' VAL . . . -174.29 148.6 1.29 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.049 -1.032 . . . . 0.0 110.805 179.573 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.508 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 2.1 m-80 -77.59 114.02 16.01 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 179.259 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.599 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 23.3 ttpt -89.51 122.45 32.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.435 -0.791 . . . . 0.0 110.831 -179.57 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.618 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.9 OUTLIER -111.87 177.54 4.61 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.518 -0.739 . . . . 0.0 109.284 179.008 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.436 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.9 mt-10 -137.26 105.14 5.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.278 -0.889 . . . . 0.0 110.286 179.593 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.57 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -92.22 47.19 2.63 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.755 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 55.21 78.97 0.16 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.126 -1.22 . . . . 0.0 110.376 179.818 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.621 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.86 3.68 58.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 179.697 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.731 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -144.85 -172.63 3.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.42 -1.047 . . . . 0.0 109.061 179.545 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.93 HG21 ' CG2' ' A' ' 304' ' ' VAL . 12.1 t -158.89 150.08 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.988 -1.07 . . . . 0.0 110.286 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.639 ' CG2' HG22 ' A' ' 293' ' ' THR . 6.4 mm -114.96 151.85 16.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.104 -0.998 . . . . 0.0 110.687 -179.656 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 35.0 m-85 -131.74 112.2 12.32 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.199 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 1.042 HG22 HG23 ' A' ' 293' ' ' THR . 1.7 p -113.22 -176.46 0.38 Allowed Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 120.374 -1.454 . . . . 0.0 109.591 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.587 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 45.6 Cg_endo -77.63 117.44 4.28 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.446 1.235 . . . . 0.0 111.458 -178.502 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.73 HG22 ' ND2' ' A' ' 327' ' ' ASN . 3.7 m -53.58 -105.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.424 -0.797 . . . . 0.0 110.592 179.905 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.484 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.5 m -133.79 -12.37 2.61 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.691 -1.256 . . . . 0.0 111.428 -179.448 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.621 ' CE3' ' HB3' ' A' ' 327' ' ' ASN . 2.0 p-90 -126.47 -25.6 3.43 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.776 -1.202 . . . . 0.0 111.228 -179.586 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.73 ' ND2' HG22 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -96.0 36.66 1.29 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.762 -1.211 . . . . 0.0 110.963 -179.697 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -99.71 -6.23 27.46 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.157 -0.964 . . . . 0.0 108.736 178.179 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.55 -138.38 0.01 OUTLIER Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.474 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.599 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 46.0 Cg_endo -73.01 -54.62 0.11 Allowed 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 124.205 1.634 . . . . 0.0 111.054 -179.721 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -102.61 140.25 37.13 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.156 -0.965 . . . . 0.0 110.77 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.721 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -152.26 107.77 3.31 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 283' ' ' THR . 53.8 m -105.41 135.9 45.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.907 -1.121 . . . . 0.0 110.166 179.67 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.776 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.0 p90 -145.32 174.6 10.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.631 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.26 158.08 27.75 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.659 -1.734 . . . . 0.0 110.435 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.897 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -143.42 146.5 33.51 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.669 -0.901 . . . . 0.0 109.33 179.252 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.897 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.74 121.31 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.968 -1.083 . . . . 0.0 109.831 179.904 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.709 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.5 t -96.6 145.92 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.184 -0.947 . . . . 0.0 109.634 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -121.33 135.43 55.09 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 110.905 -179.234 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.265 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.735 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.643 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 121.092 0.473 . . . . 0.0 111.187 . . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.571 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 7.4 p -126.53 119.05 52.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.911 -1.118 . . . . 0.0 110.241 179.378 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 4.1 mm-40 -49.67 -44.56 47.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -0.91 . . . . 0.0 110.523 -179.533 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.446 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.1 pt-20 -176.68 158.85 1.76 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.09 -1.006 . . . . 0.0 110.718 -179.713 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.862 HG23 HG22 ' A' ' 296' ' ' VAL . 29.6 mt -124.42 110.17 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.095 -1.003 . . . . 0.0 110.228 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.67 160.05 19.8 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.415 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.52 129.72 54.83 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.906 . . . . 0.0 110.554 -179.903 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.9 tt0 -139.32 118.35 12.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.824 . . . . 0.0 109.456 179.405 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.844 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.08 100.66 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.892 -1.13 . . . . 0.0 110.399 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.444 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 38.27 40.08 0.32 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.949 -0.47 . . . . 0.0 111.396 179.492 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.44 ' O ' ' CD ' ' A' ' 356' ' ' GLN . . . 113.06 23.37 5.27 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.793 179.056 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 6.2 mm100 -141.46 101.47 4.0 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.015 -1.285 . . . . 0.0 110.238 179.661 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.706 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -65.7 136.35 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.252 -0.905 . . . . 0.0 110.552 -179.827 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.706 HD13 ' O ' ' A' ' 357' ' ' VAL . 22.9 mm . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.215 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.247 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.566 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -138.6 165.86 25.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.602 -0.94 . . . . 0.0 109.593 179.908 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.927 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.63 141.35 10.25 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.94 -1.104 . . . . 0.0 111.436 -179.554 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.746 ' H ' HD22 ' A' ' 267' ' ' LEU . 0.2 OUTLIER -139.48 149.5 44.06 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.853 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 281' ' ' ASP . 39.8 t -138.19 137.9 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.694 -1.254 . . . . 0.0 111.654 -179.337 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.444 ' HG2' ' OE2' ' A' ' 268' ' ' GLU . 3.2 mmtp -125.27 156.93 37.81 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.111 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.703 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.1 t -145.07 145.84 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 120.374 -1.454 . . . . 0.0 112.15 -179.193 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.533 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.8 112.56 7.59 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.796 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.1 p-10 -97.37 144.84 26.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.955 -1.091 . . . . 0.0 111.602 -178.338 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 36.1 p90 -129.9 21.54 5.41 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.472 0.654 . . . . 0.0 109.681 179.281 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.24 -68.53 3.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.955 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.502 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 8.1 t -56.93 -23.73 47.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.144 -1.209 . . . . 0.0 110.35 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.423 ' HA2' ' HA ' ' A' ' 339' ' ' ASN . . . -174.46 -170.02 37.19 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.387 -1.387 . . . . 0.0 109.987 179.918 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.632 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -141.88 143.78 33.5 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.337 -1.096 . . . . 0.0 110.514 -179.905 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.703 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.4 mt-10 -94.87 147.34 23.47 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.412 -0.805 . . . . 0.0 109.904 -179.853 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.658 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 88.1 m-85 -142.91 90.27 2.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.396 -0.815 . . . . 0.0 110.514 -179.63 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.709 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -74.16 153.02 39.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.365 -0.835 . . . . 0.0 110.117 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.859 HG11 HG11 ' A' ' 294' ' ' VAL . 3.3 t -145.12 90.61 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.83 -179.665 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 1.006 HG23 ' OG1' ' A' ' 333' ' ' THR . 7.5 m -87.04 122.61 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 0.0 110.457 -179.746 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.089 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -108.14 151.09 26.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 110.122 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.566 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -134.58 106.57 7.06 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.211 -0.93 . . . . 0.0 110.646 -179.036 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.632 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.6 mt -113.07 173.9 6.16 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.666 -1.272 . . . . 0.0 110.006 179.671 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -109.5 30.19 6.87 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.434 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 170.19 -102.79 0.18 Allowed Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.357 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.487 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.1 OUTLIER -150.7 105.38 3.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -1.181 . . . . 0.0 110.463 -179.395 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.632 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -136.33 132.74 36.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 110.025 179.596 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.768 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.2 OUTLIER -61.04 100.25 0.11 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.289 -0.882 . . . . 0.0 109.366 179.337 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.881 ' CZ2' ' HB1' ' A' ' 332' ' ' ALA . 56.4 p-90 -98.34 111.07 23.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.345 -0.847 . . . . 0.0 110.447 -179.637 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.901 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.4 m -105.37 114.58 28.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.859 HG11 HG11 ' A' ' 282' ' ' VAL . 3.5 t -96.92 110.74 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.145 -0.972 . . . . 0.0 110.085 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.586 ' HA ' HD13 ' A' ' 320' ' ' ILE . 18.8 ttpt -87.41 149.01 24.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.227 -0.92 . . . . 0.0 109.362 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.709 HG13 HG12 ' A' ' 349' ' ' ILE . 71.0 t -145.78 110.53 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.193 -0.942 . . . . 0.0 110.745 -179.325 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.614 ' O ' HG23 ' A' ' 346' ' ' VAL . 29.3 mmtp -71.51 132.71 45.1 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.246 -0.909 . . . . 0.0 109.73 179.343 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.936 HD13 ' HA ' ' A' ' 303' ' ' THR . 83.0 mt -85.42 159.06 20.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.375 -0.828 . . . . 0.0 111.445 -179.036 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.801 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -62.94 174.77 0.77 Allowed Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.699 -0.626 . . . . 0.0 109.454 179.08 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.733 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -69.4 78.88 0.86 Allowed 'Trans proline' 0 C--N 1.304 -1.812 0 O-C-N 123.575 1.303 . . . . 0.0 109.754 179.451 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.19 24.58 3.81 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.166 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.808 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -112.22 152.93 27.84 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -1.152 . . . . 0.0 110.338 -179.479 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.936 ' HA ' HD13 ' A' ' 298' ' ' LEU . 21.5 p -153.31 143.61 22.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.235 -0.915 . . . . 0.0 110.502 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.933 HG21 HG11 ' A' ' 319' ' ' VAL . 76.4 t -64.72 139.75 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.463 -0.773 . . . . 0.0 110.215 179.881 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -123.28 -33.69 0.81 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.442 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.9 OUTLIER -138.23 124.42 20.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -1.19 . . . . 0.0 110.98 -179.667 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.562 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 52.9 p90 -141.08 156.37 46.0 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.323 -0.861 . . . . 0.0 109.714 179.362 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.493 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -150.0 157.31 43.02 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.955 -1.091 . . . . 0.0 111.368 -179.288 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.486 ' HB3' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 64.57 21.66 12.48 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.609 -0.682 . . . . 0.0 110.906 179.803 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.559 ' CA ' HG13 ' A' ' 324' ' ' VAL . . . -174.57 150.2 1.35 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.272 -0.893 . . . . 0.0 110.394 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.539 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -83.84 125.34 31.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.119 -0.988 . . . . 0.0 109.586 179.485 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.562 ' HD3' ' CD2' ' A' ' 307' ' ' PHE . 3.7 ttpt -92.85 135.91 33.72 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.838 0.828 . . . . 0.0 110.751 -179.582 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.723 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.3 OUTLIER -122.37 179.46 4.56 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.63 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.411 ' HA ' ' O ' ' A' ' 318' ' ' TYR . 3.5 mt-10 -142.49 113.07 7.31 Favored 'General case' 0 N--CA 1.492 1.634 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.444 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.09 49.71 1.05 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.83 79.37 0.2 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -1.167 . . . . 0.0 110.093 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.595 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.95 5.34 66.24 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.778 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.811 ' O ' HG23 ' A' ' 319' ' ' VAL . 5.4 m-85 -138.88 -174.31 3.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.401 -1.058 . . . . 0.0 109.167 179.449 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.933 HG11 HG21 ' A' ' 304' ' ' VAL . 5.7 t -163.14 156.96 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.287 -0.883 . . . . 0.0 109.767 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.723 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 12.8 mm -127.08 148.91 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.074 -1.016 . . . . 0.0 111.361 -179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.675 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 86.0 m-85 -124.85 122.01 36.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.446 -0.784 . . . . 0.0 109.703 179.01 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.901 ' CG2' HG23 ' A' ' 293' ' ' THR . 5.5 p -124.52 169.01 11.59 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 120.738 -1.226 . . . . 0.0 109.953 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.54 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 37.3 Cg_endo -63.89 112.38 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.769 1.405 . . . . 0.0 111.415 -179.319 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.704 HG23 ' H ' ' A' ' 325' ' ' SER . 3.6 m -50.4 -58.24 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.545 -0.722 . . . . 0.0 110.746 179.74 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.704 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.2 OUTLIER 178.65 -26.11 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.081 -1.012 . . . . 0.0 110.947 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.518 ' CE2' HG21 ' A' ' 324' ' ' VAL . 6.3 p-90 -110.43 -27.03 9.22 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.853 -1.154 . . . . 0.0 110.98 -179.79 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 1.003 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 0.0 OUTLIER -83.34 14.56 3.52 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 120.979 -1.076 . . . . 0.0 111.06 179.934 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.49 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 11.4 mtmt -77.12 -8.58 57.74 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.174 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.18 -153.14 0.01 OUTLIER Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 -179.322 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -76.12 9.61 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 124.267 1.667 . . . . 0.0 111.153 -179.581 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.5 m -164.87 135.15 3.86 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 1.003 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -147.87 104.19 3.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.171 -0.956 . . . . 0.0 110.378 -179.463 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 1.006 ' OG1' HG23 ' A' ' 283' ' ' THR . 4.8 m -101.12 133.22 45.98 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.287 -0.883 . . . . 0.0 110.313 179.883 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.754 ' HE2' HG21 ' A' ' 294' ' ' VAL . 24.2 p90 -144.2 168.21 20.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 108.957 179.553 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -141.65 165.3 26.5 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.078 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.5 OUTLIER -150.52 143.88 24.98 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.689 -0.889 . . . . 0.0 109.379 179.191 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.51 118.79 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.028 -1.045 . . . . 0.0 110.223 -179.67 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.808 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.7 t -97.64 153.18 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.163 -0.96 . . . . 0.0 110.153 -179.795 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.56 131.65 53.93 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 110.212 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.403 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -179.98 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.8 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.486 1.366 0 CA-C-O 121.475 0.655 . . . . 0.0 110.275 . . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 297' ' ' LYS . 7.2 p -134.7 117.09 22.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.406 -0.809 . . . . 0.0 110.13 179.739 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.514 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -45.66 -45.84 14.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 110.455 -179.61 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.47 ' OE2' ' HG3' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -176.79 158.71 1.68 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.072 -1.017 . . . . 0.0 110.673 -179.713 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.709 HG12 HG13 ' A' ' 296' ' ' VAL . 65.1 mt -120.76 119.39 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.118 -0.989 . . . . 0.0 110.304 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.33 159.89 24.12 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.341 -0.85 . . . . 0.0 110.173 179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.089 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -120.99 129.7 53.52 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.887 . . . . 0.0 110.361 -179.852 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -139.29 122.87 17.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.13 -0.981 . . . . 0.0 110.103 179.58 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.768 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -97.15 106.16 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.031 -1.043 . . . . 0.0 109.742 179.474 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.482 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 41.06 29.25 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.565 -0.71 . . . . 0.0 110.649 -179.752 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.81 -22.83 7.17 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.363 179.379 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.494 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 40.5 mm-40 -87.96 110.95 20.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.004 -1.292 . . . . 0.0 110.552 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.653 ' O ' HD13 ' A' ' 358' ' ' ILE . 6.2 p -76.81 142.02 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.284 -0.885 . . . . 0.0 110.527 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.653 HD13 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.494 1.729 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.139 179.801 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.58 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.3 OUTLIER -139.53 164.4 30.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.401 -1.058 . . . . 0.0 109.765 179.848 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.992 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.31 133.76 6.0 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.047 -1.033 . . . . 0.0 111.003 -179.044 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.49 ' N ' HD13 ' A' ' 267' ' ' LEU . 0.4 OUTLIER -136.77 131.45 33.4 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.532 -0.73 . . . . 0.0 109.242 179.476 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.882 HG13 ' O ' ' A' ' 281' ' ' ASP . 89.4 t -126.38 143.11 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.79 -1.194 . . . . 0.0 111.653 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.7 ttpt -126.98 157.38 39.69 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.736 HG22 ' CD1' ' A' ' 280' ' ' TYR . 91.7 t -139.74 146.97 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.298 -1.501 . . . . 0.0 112.375 -179.171 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.542 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.2 109.43 6.46 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.127 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 p30 -96.14 146.75 24.41 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.008 -1.057 . . . . 0.0 111.189 -178.863 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.829 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.4 p90 -132.02 17.85 4.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.777 179.32 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.5 -62.78 4.0 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.947 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.444 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.4 t -63.68 -21.24 66.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.383 -1.069 . . . . 0.0 110.239 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -174.31 179.92 45.34 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.557 ' HB3' ' HE2' ' A' ' 280' ' ' TYR . . . -133.22 141.19 47.93 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.352 -1.087 . . . . 0.0 110.245 179.941 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.729 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.3 mt-10 -96.84 147.65 23.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.346 -0.846 . . . . 0.0 110.159 -179.683 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.736 ' CD1' HG22 ' A' ' 271' ' ' VAL . 98.1 m-85 -143.51 90.2 2.14 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.214 -0.929 . . . . 0.0 110.84 -179.776 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.882 ' O ' HG13 ' A' ' 269' ' ' VAL . 6.6 t0 -70.87 152.75 43.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.384 -0.823 . . . . 0.0 109.555 179.237 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.753 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 2.9 t -147.26 89.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 110.205 -179.535 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.719 HG23 ' OG1' ' A' ' 333' ' ' THR . 93.1 m -86.97 121.96 30.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.08 -1.013 . . . . 0.0 109.615 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -109.7 150.89 27.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 110.754 -179.323 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.917 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -131.25 137.06 48.72 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.468 -0.77 . . . . 0.0 109.934 -179.767 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.917 HD23 ' O ' ' A' ' 285' ' ' ASN . 16.8 mt -142.32 159.87 41.37 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.926 -1.109 . . . . 0.0 109.513 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.61 34.66 0.82 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.296 -0.877 . . . . 0.0 110.458 -179.538 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.473 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 153.3 -97.47 0.17 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.052 -1.546 . . . . 0.0 110.358 179.902 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 11.7 mm-40 -144.3 105.26 4.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.25 -1.147 . . . . 0.0 110.561 -179.577 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.616 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 4.4 m-85 -128.9 130.29 46.63 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.338 -0.851 . . . . 0.0 109.671 179.645 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.809 ' O ' HG23 ' A' ' 353' ' ' ILE . 42.5 m-20 -65.61 100.11 0.49 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.782 -1.199 . . . . 0.0 109.084 179.19 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.935 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.4 p-90 -100.12 109.67 21.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 111.127 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 1.085 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.0 m -103.78 114.83 29.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.466 -0.772 . . . . 0.0 109.108 179.003 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.727 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -95.95 111.31 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 110.568 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.413 ' HA ' HG12 ' A' ' 320' ' ' ILE . 5.7 ttpt -85.71 145.16 27.41 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.471 -0.768 . . . . 0.0 109.327 179.17 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.674 HG13 HG12 ' A' ' 349' ' ' ILE . 79.7 t -144.36 106.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 110.177 -179.49 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 347' ' ' GLU . 43.4 mmtt -70.02 133.9 47.71 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.108 -0.995 . . . . 0.0 109.168 179.537 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.962 HD13 ' HA ' ' A' ' 303' ' ' THR . 66.8 mt -90.32 157.24 17.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 111.392 -178.826 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.7 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.22 173.25 2.35 Favored Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.806 -0.558 . . . . 0.0 109.533 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.7 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.15 83.52 0.35 Allowed 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.621 1.327 . . . . 0.0 109.826 179.627 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.6 21.14 5.87 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -179.359 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.75 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.29 140.89 47.61 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.33 -1.1 . . . . 0.0 109.951 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.962 ' HA ' HD13 ' A' ' 298' ' ' LEU . 22.2 p -145.2 146.11 31.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.958 . . . . 0.0 110.628 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.798 HG21 HG11 ' A' ' 319' ' ' VAL . 53.3 t -70.11 122.82 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.148 -0.97 . . . . 0.0 109.958 179.695 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.08 -28.32 4.19 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.034 -1.226 . . . . 0.0 110.034 -179.592 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.507 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 49.4 m -137.46 130.26 30.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.973 -1.31 . . . . 0.0 110.85 -179.637 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.538 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 50.2 p90 -150.38 160.09 43.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.491 -0.756 . . . . 0.0 109.512 179.369 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.47 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -151.85 159.46 43.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.89 -1.131 . . . . 0.0 111.284 -179.333 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.9 OUTLIER 56.91 28.34 14.46 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.617 -0.677 . . . . 0.0 110.683 179.855 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.736 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.11 138.23 0.58 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.161 -0.962 . . . . 0.0 110.22 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.792 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.9 112.91 15.27 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.454 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.754 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.0 ttpt -83.16 137.65 33.97 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.658 0.742 . . . . 0.0 110.8 -179.25 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.715 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.1 OUTLIER -120.64 170.61 9.26 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.135 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.439 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 15.8 mt-10 -143.24 95.97 2.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.531 -0.731 . . . . 0.0 109.688 179.588 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.97 -82.9 0.36 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.804 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.442 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 5.4 t-20 -154.38 81.15 1.12 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.467 -1.019 . . . . 0.0 108.59 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.608 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.42 17.87 56.29 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 107.993 -2.043 . . . . 0.0 107.993 -178.009 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.822 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.7 m-85 -144.45 -171.84 3.68 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.822 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.0 t -163.26 153.72 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.231 -0.918 . . . . 0.0 109.322 178.502 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.816 ' CG2' HG22 ' A' ' 293' ' ' THR . 42.1 mt -132.45 133.81 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.78 -1.2 . . . . 0.0 111.639 -179.313 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.645 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 82.6 m-85 -105.9 139.09 41.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.459 -0.775 . . . . 0.0 110.651 -179.791 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 1.085 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.1 p -134.62 169.06 14.83 Favored Pre-proline 0 C--N 1.3 -1.578 0 O-C-N 120.912 -1.117 . . . . 0.0 110.324 179.154 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.551 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 39.7 Cg_endo -65.67 112.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.061 1.559 . . . . 0.0 111.045 -179.259 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.81 HG22 ' HB2' ' A' ' 327' ' ' ASN . 32.9 m -60.83 -127.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.422 -0.799 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.568 ' N ' HG23 ' A' ' 324' ' ' VAL . 18.9 m -101.9 -17.02 16.35 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.739 -1.226 . . . . 0.0 111.167 -179.361 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.646 ' H ' HG23 ' A' ' 324' ' ' VAL . 22.5 p-90 -129.86 -3.85 4.62 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.943 -1.098 . . . . 0.0 110.649 -179.688 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.81 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.6 t30 -98.64 45.04 1.01 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.233 -0.917 . . . . 0.0 110.473 -179.476 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.551 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.32 -4.48 8.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.345 -0.847 . . . . 0.0 109.77 179.829 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.81 -159.92 0.08 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.456 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 46.8 Cg_endo -72.9 2.64 5.18 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 124.191 1.627 . . . . 0.0 110.829 -179.852 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.406 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.8 m -162.56 114.87 1.63 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -136.53 115.65 12.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 110.069 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.719 ' OG1' HG23 ' A' ' 283' ' ' THR . 99.9 m -105.78 147.5 28.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 110.395 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.753 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 6.4 p90 -150.76 174.45 13.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.415 -0.803 . . . . 0.0 109.188 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.2 162.24 28.94 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.209 -179.564 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.913 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -151.37 143.8 24.19 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -1.077 . . . . 0.0 109.994 179.554 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.913 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.06 119.73 61.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.171 -0.956 . . . . 0.0 109.744 179.437 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.75 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.6 t -96.23 139.79 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.136 -0.978 . . . . 0.0 110.111 -179.661 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -111.1 142.2 43.58 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.384 -0.822 . . . . 0.0 110.422 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.215 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.906 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.614 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.513 0 CA-C-O 121.142 0.496 . . . . 0.0 111.114 . . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 346' ' ' VAL . 7.1 p -126.71 113.84 34.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 121.056 -1.027 . . . . 0.0 110.136 179.375 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -45.36 -47.07 13.4 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 110.47 -179.564 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.55 158.76 1.81 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.209 -0.932 . . . . 0.0 110.263 -179.838 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.674 HG12 HG13 ' A' ' 296' ' ' VAL . 28.2 mt -121.93 113.22 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.116 -0.99 . . . . 0.0 110.13 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -117.76 133.71 55.66 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.25 -0.907 . . . . 0.0 110.077 -179.934 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -90.85 132.46 35.88 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.168 -0.958 . . . . 0.0 109.774 179.529 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.429 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 3.7 tt0 -138.01 111.72 8.24 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.38 -0.825 . . . . 0.0 109.956 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.809 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.1 mt -94.91 114.0 30.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.21 -0.931 . . . . 0.0 110.42 -179.851 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.44 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.85 31.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.758 -0.589 . . . . 0.0 111.136 179.75 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.78 -15.62 19.16 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.736 -1.221 . . . . 0.0 110.306 179.415 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.495 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 20.9 mm-40 -93.17 112.03 23.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.084 -1.245 . . . . 0.0 110.424 -179.758 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.557 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 1.2 t -76.35 125.63 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.236 -0.915 . . . . 0.0 109.961 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.557 HD13 ' O ' ' A' ' 357' ' ' VAL . 10.2 mm . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.098 179.802 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.287 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.553 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.6 161.64 37.03 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -1.156 . . . . 0.0 110.006 179.823 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.863 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.5 tm? -161.32 137.17 7.98 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.613 -179.546 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.854 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mm-40 -134.03 147.14 50.92 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.799 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.9 t -138.55 144.43 30.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.66 -1.275 . . . . 0.0 111.769 -179.091 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.88 157.38 41.71 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.902 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.757 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.7 t -144.17 146.13 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.28 -1.512 . . . . 0.0 112.199 -179.492 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.576 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.63 108.76 7.21 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.182 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.413 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.0 m-20 -95.26 140.38 30.24 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.278 -0.889 . . . . 0.0 111.277 -179.003 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 40.9 p90 -131.94 20.42 4.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.431 -0.793 . . . . 0.0 109.868 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.59 -60.4 4.87 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.899 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -65.8 -18.94 65.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.369 -1.077 . . . . 0.0 110.293 -179.86 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.568 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -179.38 175.85 47.35 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.582 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -131.26 140.98 49.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -1.186 . . . . 0.0 110.119 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.757 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -93.28 147.1 23.21 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.424 -0.798 . . . . 0.0 109.99 -179.969 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.7 m-85 -142.11 86.39 1.97 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.929 -179.412 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 269' ' ' VAL . 12.1 t70 -69.67 152.6 44.5 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.86 . . . . 0.0 109.464 179.206 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.591 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 2.7 t -148.39 90.17 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.283 -0.885 . . . . 0.0 110.177 -179.51 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.849 HG23 ' OG1' ' A' ' 333' ' ' THR . 56.6 m -86.99 122.31 30.65 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.1 -1.0 . . . . 0.0 109.692 179.515 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.083 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.75 150.78 28.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.952 . . . . 0.0 110.8 -179.357 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.93 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.3 OUTLIER -131.43 138.42 49.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.469 -0.769 . . . . 0.0 109.446 179.949 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.93 HD23 ' O ' ' A' ' 285' ' ' ASN . 18.8 mt -140.46 163.4 32.93 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.77 -1.206 . . . . 0.0 109.824 -179.816 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.12 30.61 0.59 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.228 -0.92 . . . . 0.0 111.086 -178.95 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.509 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.26 -75.39 0.28 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 118.952 -1.594 . . . . 0.0 110.479 179.616 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.558 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.7 tt0 -160.26 106.88 1.56 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.07 -1.253 . . . . 0.0 110.85 -179.371 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.642 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.38 135.35 40.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 179.384 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.722 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.0 OUTLIER -66.84 102.77 1.0 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.987 -1.071 . . . . 0.0 109.515 179.425 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.957 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.9 p-90 -101.18 111.32 23.51 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 110.645 -179.53 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.686 HG22 ' CG2' ' A' ' 320' ' ' ILE . 6.6 m -104.48 115.66 30.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.532 -0.73 . . . . 0.0 109.726 179.692 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.756 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -97.05 111.41 26.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.864 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.809 ' HA ' HD13 ' A' ' 320' ' ' ILE . 27.1 ttpt -84.99 144.1 28.52 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.387 -0.821 . . . . 0.0 109.511 179.464 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.937 HG22 HG23 ' A' ' 349' ' ' ILE . 99.8 t -141.32 104.98 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.249 -0.907 . . . . 0.0 110.823 -179.179 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 38.0 mmtt -69.8 131.11 44.0 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.078 -1.014 . . . . 0.0 109.066 179.226 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.982 HD13 ' HA ' ' A' ' 303' ' ' THR . 93.6 mt -87.85 148.77 24.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.371 -0.831 . . . . 0.0 111.166 -178.895 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.703 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -58.66 172.22 0.54 Allowed Pre-proline 0 C--N 1.303 -1.432 0 O-C-N 121.624 -0.672 . . . . 0.0 109.306 179.093 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.671 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -67.32 80.57 0.41 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.575 1.303 . . . . 0.0 110.111 179.777 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.64 23.29 4.08 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 -179.546 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.789 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.58 148.54 35.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.365 -1.08 . . . . 0.0 110.376 -179.534 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.982 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.4 p -150.7 144.61 25.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.195 -0.94 . . . . 0.0 110.399 179.789 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 1.035 HG11 ' CE ' ' A' ' 312' ' ' LYS . 21.3 t -64.02 116.04 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.066 -1.021 . . . . 0.0 110.04 179.723 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -102.35 -20.51 12.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -147.36 154.44 40.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.26 -1.141 . . . . 0.0 110.317 -179.784 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.507 ' CG ' ' NZ ' ' A' ' 312' ' ' LYS . 25.1 p90 -178.54 175.52 1.11 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.594 -0.691 . . . . 0.0 109.738 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.459 ' O ' ' CB ' ' A' ' 309' ' ' SER . 1.1 p90 -170.0 151.11 3.95 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.991 -1.068 . . . . 0.0 111.637 -179.437 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.537 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 67.93 30.22 6.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.684 -0.635 . . . . 0.0 111.45 179.173 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.746 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 137.48 0.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.144 -0.972 . . . . 0.0 110.168 179.57 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.753 HD22 HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.19 129.09 35.49 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.073 -1.017 . . . . 0.0 109.353 179.621 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 1.035 ' CE ' HG11 ' A' ' 304' ' ' VAL . 0.0 OUTLIER -92.07 149.15 21.67 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.907 0.861 . . . . 0.0 111.642 -178.622 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.705 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -133.34 171.39 14.11 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.306 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -137.09 114.85 11.28 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.046 -1.034 . . . . 0.0 110.858 -179.473 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -103.96 42.76 1.81 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.454 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.45 83.48 0.07 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -1.113 . . . . 0.0 110.066 -179.788 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.34 -0.55 57.1 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.89 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.842 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.5 m-85 -145.6 -170.9 3.56 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.463 -1.022 . . . . 0.0 109.157 179.365 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.92 HG11 HG21 ' A' ' 304' ' ' VAL . 2.6 t -163.82 161.99 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.366 -0.834 . . . . 0.0 109.347 179.427 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.809 HD13 ' HA ' ' A' ' 295' ' ' LYS . 28.5 mm -131.02 150.17 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.876 -1.14 . . . . 0.0 111.468 -179.514 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.626 ' CE2' ' HB3' ' A' ' 336' ' ' PHE . 96.5 m-85 -120.42 139.12 53.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.549 -0.719 . . . . 0.0 109.38 178.908 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.611 HG23 HG23 ' A' ' 293' ' ' THR . 1.0 OUTLIER -140.66 170.74 8.89 Favored Pre-proline 0 C--N 1.302 -1.461 0 O-C-N 120.79 -1.194 . . . . 0.0 110.244 -179.998 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.1 Cg_endo -65.72 122.01 9.53 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 123.98 1.516 . . . . 0.0 110.692 -179.505 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.911 HG22 ' HB2' ' A' ' 327' ' ' ASN . 12.8 m -76.16 -136.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.384 -0.823 . . . . 0.0 110.363 -179.752 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.63 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -88.45 -12.63 42.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.209 -0.932 . . . . 0.0 110.886 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.833 ' H ' HG23 ' A' ' 324' ' ' VAL . 20.9 p-90 -140.17 13.39 2.41 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.95 -1.094 . . . . 0.0 111.118 -179.475 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.911 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.1 t30 -119.99 50.59 1.27 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.886 -1.134 . . . . 0.0 110.776 -179.651 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.505 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.1 OUTLIER -130.46 -0.95 4.44 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.257 -0.902 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -66.58 -153.72 0.25 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.791 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.509 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.5 Cg_endo -73.97 3.08 5.35 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 124.12 1.59 . . . . 0.0 110.653 -179.858 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.432 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.9 m -163.93 117.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.197 -0.94 . . . . 0.0 110.244 179.944 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.478 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -139.43 111.93 7.71 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.878 . . . . 0.0 110.12 179.943 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.849 ' OG1' HG23 ' A' ' 283' ' ' THR . 7.0 m -101.09 151.78 21.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.181 -0.949 . . . . 0.0 110.275 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.756 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.7 p90 -159.03 155.19 27.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.519 -0.738 . . . . 0.0 109.156 179.712 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -133.24 165.96 23.89 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.264 -1.446 . . . . 0.0 110.035 -179.634 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.957 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -152.44 147.04 25.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -1.171 . . . . 0.0 110.288 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.957 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.74 119.56 59.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.049 -1.032 . . . . 0.0 109.88 179.687 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.789 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.6 t -96.43 147.94 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.163 -0.961 . . . . 0.0 110.13 -179.907 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.14 132.93 56.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.375 -0.828 . . . . 0.0 110.142 -179.867 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.457 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.493 2.453 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 179.943 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.703 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.3 mtmt . . . . . 0 N--CA 1.489 1.514 0 CA-C-O 121.522 0.677 . . . . 0.0 110.164 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.516 HG13 ' O ' ' A' ' 346' ' ' VAL . 4.5 p -127.17 113.28 31.65 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.497 -0.752 . . . . 0.0 109.566 179.429 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.18 -48.33 4.81 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.269 -0.894 . . . . 0.0 110.129 -179.44 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -177.63 149.9 0.64 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.31 -0.869 . . . . 0.0 110.468 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.937 HG23 HG22 ' A' ' 296' ' ' VAL . 12.9 mt -113.62 127.92 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.111 -0.993 . . . . 0.0 110.207 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -132.21 140.51 48.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.959 -179.81 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.083 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -99.44 130.75 45.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.055 -1.028 . . . . 0.0 110.395 -179.93 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.8 tt0 -138.28 113.87 9.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.308 -0.87 . . . . 0.0 109.788 179.645 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.722 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.2 mt -91.77 110.51 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.121 -0.987 . . . . 0.0 110.249 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.558 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 37.84 28.51 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.802 -0.561 . . . . 0.0 110.952 179.885 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 123.22 -20.94 7.43 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.739 -1.219 . . . . 0.0 110.298 179.451 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 1.4 mp0 -86.53 112.66 21.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.03 -1.276 . . . . 0.0 110.58 -179.756 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.669 HG13 ' O ' ' A' ' 357' ' ' VAL . 7.3 p -79.0 118.13 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.323 -0.861 . . . . 0.0 110.169 179.797 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.467 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.7 mm . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.214 -179.942 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.346 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.02 152.19 51.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.221 -1.164 . . . . 0.0 109.908 179.866 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.794 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.59 117.71 6.81 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.198 -0.939 . . . . 0.0 110.962 -179.592 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -118.36 116.63 27.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.649 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.595 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 52.0 t -109.37 144.52 17.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.863 -1.148 . . . . 0.0 112.154 -178.305 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.427 ' C ' HG23 ' A' ' 271' ' ' VAL . 9.1 mtmt -128.59 156.42 43.38 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.618 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.828 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.9 t -145.29 147.03 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.288 -1.508 . . . . 0.0 112.29 -179.068 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.537 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -137.9 111.08 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.757 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.9 p-10 -100.5 140.02 35.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.882 -1.136 . . . . 0.0 111.407 -178.437 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.802 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.4 p90 -123.98 20.64 9.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.82 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.72 -68.01 3.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 7.8 m -61.06 -22.02 64.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.261 -1.141 . . . . 0.0 110.485 -179.833 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -168.32 176.74 42.67 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.641 -1.266 . . . . 0.0 110.016 -179.936 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.573 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.06 143.54 46.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.381 -1.07 . . . . 0.0 109.864 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.828 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.1 mt-10 -100.71 145.63 28.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.271 -0.893 . . . . 0.0 110.042 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.695 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -139.12 90.96 2.47 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.362 -0.836 . . . . 0.0 110.545 -179.701 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.595 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -79.58 118.64 21.61 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.534 -0.729 . . . . 0.0 110.136 179.657 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.822 HG11 HG11 ' A' ' 294' ' ' VAL . 8.8 t -107.41 95.82 4.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.63 -0.669 . . . . 0.0 110.041 179.747 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.546 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.2 m -86.5 120.17 27.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.131 -0.98 . . . . 0.0 109.437 179.551 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 0.999 HD21 HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -109.1 148.9 30.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 110.991 -179.042 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.04 107.13 7.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.618 -0.676 . . . . 0.0 109.679 -179.659 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.575 HD11 ' CD1' ' A' ' 292' ' ' TRP . 11.8 mt -114.67 156.57 24.51 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.837 -1.164 . . . . 0.0 110.243 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . 0.432 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 20.1 m-20 -86.7 33.86 0.65 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.513 -0.742 . . . . 0.0 110.413 -179.811 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.519 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.87 -154.04 25.07 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 119.499 -1.334 . . . . 0.0 109.79 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.542 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.0 OUTLIER -101.89 93.85 5.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.173 -1.192 . . . . 0.0 110.608 -179.708 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.523 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 2.3 m-85 -118.12 163.49 16.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.79 179.627 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.654 ' O ' HG23 ' A' ' 353' ' ' ILE . 15.2 m-20 -90.26 98.97 12.08 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.249 -0.907 . . . . 0.0 109.43 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.848 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.0 p-90 -99.82 117.26 33.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.192 -0.943 . . . . 0.0 110.749 -179.369 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.564 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 89.2 m -110.86 114.65 28.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.482 -0.761 . . . . 0.0 109.589 179.665 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.822 HG11 HG11 ' A' ' 282' ' ' VAL . 3.2 t -97.18 111.46 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.16 -0.963 . . . . 0.0 110.633 -179.284 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.527 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 18.3 ttmt -86.51 149.89 24.65 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.617 179.299 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.799 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 90.4 t -143.95 108.36 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.054 -1.029 . . . . 0.0 110.672 -179.459 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.574 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 14.5 mmtp -70.5 133.86 47.19 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.27 -0.894 . . . . 0.0 109.318 179.411 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.978 HD13 ' HA ' ' A' ' 303' ' ' THR . 85.0 mt -89.71 158.13 17.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -0.788 . . . . 0.0 111.717 -178.727 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.771 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -64.78 173.32 1.69 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.637 -0.665 . . . . 0.0 109.44 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.69 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.64 78.6 0.51 Allowed 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.555 1.292 . . . . 0.0 109.913 179.738 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.74 23.27 4.05 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 -179.393 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.792 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.08 146.68 38.74 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.361 -1.082 . . . . 0.0 110.141 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.978 ' HA ' HD13 ' A' ' 298' ' ' LEU . 8.8 p -147.93 145.08 28.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.225 -0.922 . . . . 0.0 110.505 179.766 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.857 HG21 HG11 ' A' ' 319' ' ' VAL . 71.4 t -65.62 132.18 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.911 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.21 -36.97 1.71 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.476 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -140.97 139.49 34.23 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -1.209 . . . . 0.0 110.819 -179.735 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.5 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.1 p90 -150.63 167.01 28.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.471 -0.768 . . . . 0.0 109.599 179.56 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.508 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -154.98 155.2 33.79 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.946 -1.096 . . . . 0.0 111.585 -179.558 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.511 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 62.71 25.49 15.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.527 -0.733 . . . . 0.0 110.854 179.742 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.68 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 141.22 0.65 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.891 . . . . 0.0 110.365 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.75 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -78.65 117.54 19.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.136 -0.977 . . . . 0.0 109.17 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.631 ' HG3' HG11 ' A' ' 304' ' ' VAL . 2.0 ttpt -87.84 145.67 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.791 0.805 . . . . 0.0 110.824 -179.274 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.822 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -133.19 178.6 6.78 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.35 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -141.45 106.57 4.97 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.533 -0.729 . . . . 0.0 110.539 179.509 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.93 51.83 2.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 51.51 80.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.277 -1.131 . . . . 0.0 110.317 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.602 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.47 -0.12 58.22 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.823 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.6 m-85 -141.23 -166.96 2.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -1.115 . . . . 0.0 109.435 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.857 HG11 HG21 ' A' ' 304' ' ' VAL . 2.7 t -163.61 157.84 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.21 -0.931 . . . . 0.0 109.839 179.286 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.775 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 9.2 mm -127.1 146.61 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 120.915 -1.116 . . . . 0.0 110.685 179.486 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 74.8 m-85 -125.42 124.83 42.31 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.364 -0.835 . . . . 0.0 109.729 179.263 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.541 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 8.3 p -126.96 168.04 15.85 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.491 -1.381 . . . . 0.0 110.39 179.857 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.544 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.4 Cg_endo -65.92 119.07 6.04 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.868 1.457 . . . . 0.0 111.13 -179.306 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.75 HG12 ' ND2' ' A' ' 311' ' ' ASN . 34.2 m -67.29 -124.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.527 -0.733 . . . . 0.0 109.895 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.592 ' N ' HG23 ' A' ' 324' ' ' VAL . 32.1 t -107.15 -12.92 15.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.763 -1.211 . . . . 0.0 110.693 -179.877 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.708 ' H ' HG23 ' A' ' 324' ' ' VAL . 19.6 p-90 -130.34 4.32 4.74 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.069 -1.02 . . . . 0.0 110.526 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.718 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -113.85 40.91 2.33 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.247 -0.908 . . . . 0.0 110.351 -179.546 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -115.97 -11.17 11.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 179.821 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.508 ' HA2' ' NE2' ' A' ' 289' ' ' GLN . . . -57.08 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.424 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.519 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.8 Cg_endo -75.41 7.05 3.2 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 124.143 1.602 . . . . 0.0 111.119 -179.663 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.424 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 1.5 m -162.41 124.15 2.69 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.021 -1.049 . . . . 0.0 109.957 179.992 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.538 ' HB1' ' OD1' ' A' ' 327' ' ' ASN . . . -145.93 110.81 5.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 110.311 -179.821 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.546 ' OG1' HG23 ' A' ' 283' ' ' THR . 24.9 m -102.68 123.13 45.81 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.153 -0.967 . . . . 0.0 110.235 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.803 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.2 p90 -128.67 175.48 8.55 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.191 -0.943 . . . . 0.0 108.952 179.456 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.5 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.41 162.58 29.07 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.074 -1.536 . . . . 0.0 109.967 -179.222 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.925 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.7 OUTLIER -152.0 144.81 24.36 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.487 -1.008 . . . . 0.0 109.256 179.378 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.925 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.77 121.25 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.97 -1.081 . . . . 0.0 109.935 -179.743 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.792 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.5 t -96.88 151.7 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.107 -0.996 . . . . 0.0 109.835 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -123.36 132.3 53.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.277 -0.889 . . . . 0.0 110.307 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.246 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.768 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.733 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.499 0 CA-C-O 121.443 0.639 . . . . 0.0 110.547 . . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.4 p -132.39 117.4 31.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.319 -0.863 . . . . 0.0 109.927 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.449 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -49.64 -45.43 48.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.851 . . . . 0.0 110.784 -179.243 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -176.95 158.83 1.63 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.942 -1.099 . . . . 0.0 110.916 -179.737 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.688 HG12 HG22 ' A' ' 296' ' ' VAL . 42.5 mt -121.06 109.82 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.187 -0.946 . . . . 0.0 110.088 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.64 158.19 16.88 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 0.999 HD11 HD21 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.29 125.83 50.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.357 -0.839 . . . . 0.0 110.056 179.807 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.529 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.9 tt0 -137.96 116.26 11.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.14 -0.975 . . . . 0.0 110.248 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.654 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.31 95.87 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 110.162 179.903 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.546 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 49.51 32.3 4.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.641 -0.662 . . . . 0.0 110.742 179.834 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.18 -31.31 4.94 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 79.3 mm-40 -81.77 119.75 24.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.148 -1.207 . . . . 0.0 110.519 -179.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.834 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.0 p -79.04 135.64 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.176 -0.952 . . . . 0.0 110.087 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.912 ' HB ' HD13 ' A' ' 351' ' ' LEU . 27.5 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.201 -179.778 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.279 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.572 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.15 158.06 44.84 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.364 -1.08 . . . . 0.0 109.9 -179.955 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.959 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -146.94 113.47 5.98 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.177 -0.952 . . . . 0.0 110.532 180.0 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -114.69 114.76 26.07 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.067 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.631 HG23 HD22 ' A' ' 267' ' ' LEU . 61.4 t -112.62 133.3 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.894 -1.129 . . . . 0.0 112.588 -178.233 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.401 ' C ' HG23 ' A' ' 271' ' ' VAL . 1.7 mptm? -116.73 156.66 26.78 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 177.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.795 HG13 ' O ' ' A' ' 279' ' ' GLU . 87.1 t -144.64 147.05 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.231 -1.543 . . . . 0.0 112.235 -179.201 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.559 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -133.7 106.95 7.64 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.096 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.8 p-10 -93.09 145.92 24.03 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.087 -1.008 . . . . 0.0 111.254 -178.884 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.834 ' CH2' HG23 ' A' ' 337' ' ' ILE . 38.1 p90 -134.04 16.98 3.82 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.421 -0.799 . . . . 0.0 109.902 179.423 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.52 -59.26 4.38 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.14 -17.64 64.85 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.357 -1.084 . . . . 0.0 110.09 179.822 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.585 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.38 -178.7 48.66 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.776 -1.329 . . . . 0.0 109.776 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.867 ' HB2' ' NZ ' ' A' ' 345' ' ' LYS . . . -135.1 138.54 43.89 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.378 -1.072 . . . . 0.0 110.229 -179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.795 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.2 mt-10 -92.28 146.18 23.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.434 -0.791 . . . . 0.0 110.093 -179.812 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.707 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.5 m-85 -136.0 95.28 3.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 110.726 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.576 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.4 103.78 12.21 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.496 -0.752 . . . . 0.0 109.94 179.562 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.657 HG11 HG11 ' A' ' 294' ' ' VAL . 5.2 t -93.93 91.79 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.402 -0.811 . . . . 0.0 110.42 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.912 HG23 ' OG1' ' A' ' 333' ' ' THR . 8.9 m -86.54 112.47 21.59 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.158 179.337 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.08 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -97.55 153.0 18.46 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.098 -1.001 . . . . 0.0 111.096 -178.913 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.601 ' C ' HD23 ' A' ' 286' ' ' LEU . 0.1 OUTLIER -135.51 106.43 6.63 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.452 -0.78 . . . . 0.0 109.978 -179.699 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.601 HD23 ' C ' ' A' ' 285' ' ' ASN . 2.3 mt -117.05 169.51 9.36 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.689 -1.257 . . . . 0.0 110.026 179.799 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . 0.421 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 10.7 m-20 -100.85 32.29 3.23 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.268 -0.895 . . . . 0.0 110.455 -179.705 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.498 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 162.87 -145.54 10.73 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.272 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.508 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -106.87 105.86 16.1 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.362 -1.081 . . . . 0.0 110.871 -179.442 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.498 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 3.7 m-85 -135.67 150.47 49.6 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.233 -0.917 . . . . 0.0 109.756 179.356 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.527 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 86.8 m-20 -78.97 96.91 5.87 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 108.97 179.098 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.857 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.3 p-90 -94.19 112.11 23.89 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.35 -0.844 . . . . 0.0 110.474 -179.46 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.751 HG23 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -106.5 116.52 32.07 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.411 -0.806 . . . . 0.0 109.261 179.641 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.782 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -96.29 110.79 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 110.667 -179.103 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.596 ' HA ' HD13 ' A' ' 320' ' ' ILE . 9.0 ttpt -83.07 148.85 27.28 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.379 -0.826 . . . . 0.0 108.792 178.696 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.617 ' CG1' HG21 ' A' ' 346' ' ' VAL . 76.2 t -148.55 108.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.005 -1.059 . . . . 0.0 111.11 -178.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.59 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 56.3 mmtt -70.69 141.56 51.58 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.233 -0.917 . . . . 0.0 109.302 179.167 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 1.0 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.3 mt -94.07 157.97 15.84 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.273 -0.892 . . . . 0.0 111.854 -178.608 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.698 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.06 173.12 3.41 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.709 -0.62 . . . . 0.0 109.734 179.404 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.698 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.5 Cg_endo -68.25 83.66 0.47 Allowed 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.715 1.376 . . . . 0.0 109.76 179.58 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.72 24.45 5.25 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.353 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.732 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -118.44 142.67 47.33 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.423 -1.046 . . . . 0.0 110.11 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 1.0 ' HA ' HD13 ' A' ' 298' ' ' LEU . 9.6 p -143.6 144.45 31.92 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.202 -0.936 . . . . 0.0 110.764 179.753 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.885 ' CG2' HG21 ' A' ' 319' ' ' VAL . 36.2 t -69.87 134.1 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 179.456 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.5 -46.76 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.332 -179.329 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.543 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 31.0 t -119.63 140.27 50.88 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.063 -1.257 . . . . 0.0 110.91 -179.432 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.628 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.3 p90 -157.99 170.7 21.71 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.54 -0.725 . . . . 0.0 109.695 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.523 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -160.46 162.68 33.23 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.09 -1.006 . . . . 0.0 111.044 -179.585 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.467 ' O ' ' OD1' ' A' ' 327' ' ' ASN . 0.8 OUTLIER 54.77 24.8 5.95 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.585 -0.697 . . . . 0.0 110.774 179.816 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.73 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.86 144.45 1.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.404 -0.81 . . . . 0.0 109.882 179.455 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.523 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -86.4 122.2 30.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.031 -1.043 . . . . 0.0 109.754 179.747 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.7 ttpt -87.5 141.42 28.63 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 121.888 0.851 . . . . 0.0 110.374 -179.749 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.606 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -128.02 175.7 8.19 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.688 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -134.46 117.71 16.55 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.111 -0.993 . . . . 0.0 110.382 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.498 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -108.0 33.65 6.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.2 OUTLIER 70.08 85.57 0.13 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.295 -1.121 . . . . 0.0 110.37 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.56 5.11 75.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.84 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.0 OUTLIER -146.16 -168.24 2.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.362 -1.081 . . . . 0.0 109.173 179.513 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.885 HG21 ' CG2' ' A' ' 304' ' ' VAL . 4.2 t -163.45 161.54 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.235 -0.916 . . . . 0.0 109.765 179.369 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.596 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.4 mm -128.2 143.38 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.122 -0.986 . . . . 0.0 111.271 -179.84 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.664 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 65.4 m-85 -120.05 127.29 52.43 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 178.997 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.751 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -128.25 169.92 11.64 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.693 -1.254 . . . . 0.0 110.213 -179.498 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -65.31 112.74 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 123.944 1.497 . . . . 0.0 111.15 -179.354 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.684 HG23 ' H ' ' A' ' 325' ' ' SER . 3.6 m -53.3 -59.03 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.435 -0.79 . . . . 0.0 110.994 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.684 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -179.29 -24.72 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.959 -1.088 . . . . 0.0 111.307 -179.67 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.471 ' CA ' ' HD2' ' A' ' 328' ' ' LYS . 5.3 p-90 -115.78 -24.84 8.02 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.92 -1.112 . . . . 0.0 110.718 -179.72 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.856 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 0.0 OUTLIER -85.22 29.36 0.66 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.144 -0.972 . . . . 0.0 111.303 -179.817 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -90.87 -6.27 54.42 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.207 -0.933 . . . . 0.0 109.45 179.599 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.58 -157.69 0.01 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.492 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.519 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -75.86 6.54 3.69 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 124.14 1.6 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -159.02 131.64 6.87 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.734 -179.932 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.856 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -144.99 109.08 4.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.185 -0.947 . . . . 0.0 110.385 -179.691 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.912 ' OG1' HG23 ' A' ' 283' ' ' THR . 51.8 m -104.12 118.38 36.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.163 -0.961 . . . . 0.0 110.558 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.782 ' HE2' HG21 ' A' ' 294' ' ' VAL . 9.7 p90 -128.56 174.67 9.18 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.463 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.1 162.37 28.76 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 118.801 -1.666 . . . . 0.0 110.477 -179.247 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.91 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -151.39 143.85 24.2 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.685 -0.891 . . . . 0.0 109.32 179.25 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.91 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -117.95 119.34 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.959 -1.088 . . . . 0.0 110.283 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.732 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -97.01 142.8 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 109.71 179.768 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.7 m-80 -111.23 136.1 50.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.188 -0.945 . . . . 0.0 110.215 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.344 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.927 . . . . . . . . 0 0 . 1 . 029 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.867 ' NZ ' ' HB2' ' A' ' 278' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 121.173 0.511 . . . . 0.0 110.903 . . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 346' ' ' VAL . 12.8 p -128.31 115.01 36.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.077 179.525 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.501 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 6.9 mt-10 -43.45 -46.93 6.96 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.244 -0.91 . . . . 0.0 110.102 -179.641 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.474 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -177.19 158.54 1.51 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.105 -0.997 . . . . 0.0 110.833 -179.968 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.539 HG12 HG22 ' A' ' 296' ' ' VAL . 16.6 mt -117.75 105.63 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.877 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.81 141.96 35.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.327 -0.858 . . . . 0.0 110.005 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.08 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -100.88 131.42 46.77 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.064 -1.023 . . . . 0.0 110.177 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 1.4 tp10 -139.03 110.48 7.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 110.019 179.677 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.463 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 1.3 mt -91.45 105.21 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.045 -1.034 . . . . 0.0 109.894 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.527 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 45.19 40.56 5.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.48 -0.762 . . . . 0.0 110.619 -179.887 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 105.05 -22.47 33.23 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.448 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 76.1 mm-40 -84.03 110.3 18.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.093 -1.24 . . . . 0.0 110.27 -179.87 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.776 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -72.41 130.24 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 357' ' ' VAL . 17.0 mm . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.241 179.893 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.14 155.39 49.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.277 -1.131 . . . . 0.0 109.832 179.968 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.811 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.48 121.53 8.85 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.124 -0.985 . . . . 0.0 110.884 -179.353 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.447 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 23.9 mt-10 -121.61 127.35 50.77 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.875 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.589 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 48.1 t -121.33 138.45 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 120.634 -1.291 . . . . 0.0 112.428 -178.402 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 6.6 mtpp -125.3 157.82 35.71 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.968 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.803 HG13 ' O ' ' A' ' 279' ' ' GLU . 84.4 t -144.62 144.93 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.379 -1.45 . . . . 0.0 112.021 -179.577 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.539 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -132.99 108.14 8.71 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.974 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 19.2 m-20 -96.4 144.83 26.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.999 -1.063 . . . . 0.0 111.077 -178.793 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.851 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.1 p90 -131.51 20.03 4.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.496 -0.752 . . . . 0.0 110.025 179.551 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.48 -61.49 4.59 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.816 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -67.53 -18.98 65.23 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -1.171 . . . . 0.0 110.465 -179.735 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.582 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.99 177.75 45.31 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.909 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.545 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.2 137.53 42.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.313 -1.11 . . . . 0.0 109.989 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.803 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.4 mt-10 -94.33 146.4 24.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.276 -0.89 . . . . 0.0 110.205 -179.68 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.806 ' CE2' HG11 ' A' ' 346' ' ' VAL . 90.3 m-85 -137.68 88.81 2.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.268 -0.895 . . . . 0.0 110.624 -179.747 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.589 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -75.97 117.78 18.06 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 110.325 179.734 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.787 HG11 HG11 ' A' ' 294' ' ' VAL . 11.1 t -109.83 94.37 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.436 -0.79 . . . . 0.0 110.131 179.626 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.797 HG23 ' OG1' ' A' ' 333' ' ' THR . 19.8 m -86.97 120.42 28.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.182 -0.949 . . . . 0.0 109.778 179.546 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.001 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -107.25 149.94 27.2 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.195 -0.941 . . . . 0.0 110.828 -179.346 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.72 106.94 7.63 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.401 -0.812 . . . . 0.0 110.147 -179.33 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.575 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 12.2 mt -114.99 155.6 26.65 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.568 -1.332 . . . . 0.0 110.638 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . 0.429 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -88.09 37.76 0.82 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.488 -0.758 . . . . 0.0 109.746 179.572 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.33 -147.29 14.05 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.55 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -111.56 95.02 5.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.151 -1.205 . . . . 0.0 110.633 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.575 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -122.43 141.34 51.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.262 -0.899 . . . . 0.0 110.05 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.907 ' O ' HG23 ' A' ' 353' ' ' ILE . 13.2 t70 -71.94 108.73 5.35 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.149 -0.97 . . . . 0.0 109.72 179.564 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.868 ' CE3' HD13 ' A' ' 284' ' ' LEU . 42.9 p-90 -105.22 114.89 29.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 110.544 -179.651 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.792 HG22 ' CG2' ' A' ' 320' ' ' ILE . 3.2 m -102.27 113.96 27.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.418 -0.801 . . . . 0.0 109.534 179.751 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.846 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.1 t -96.67 113.33 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 110.448 -179.516 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.791 ' HA ' HD13 ' A' ' 320' ' ' ILE . 4.1 ttpt -87.9 149.6 23.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.7 179.535 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.635 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 71.5 t -149.35 110.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.079 -1.013 . . . . 0.0 110.273 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.567 ' O ' HG23 ' A' ' 346' ' ' VAL . 52.1 mmtt -72.18 138.68 47.79 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.197 -0.939 . . . . 0.0 109.58 179.575 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.936 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.8 mt -91.93 158.36 16.32 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.262 -0.899 . . . . 0.0 111.696 -178.779 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.858 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.5 175.24 1.17 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 121.792 -0.567 . . . . 0.0 109.586 179.216 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.748 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -66.36 81.27 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 O-C-N 123.581 1.306 . . . . 0.0 109.902 179.42 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.69 6.3 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.364 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.862 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -104.86 153.32 21.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.337 -1.096 . . . . 0.0 110.213 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.936 ' HA ' HD13 ' A' ' 298' ' ' LEU . 64.8 p -156.51 145.42 20.23 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.074 -1.016 . . . . 0.0 110.719 -179.864 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.753 HG21 HG11 ' A' ' 319' ' ' VAL . 61.6 t -74.21 131.56 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.395 -0.816 . . . . 0.0 109.908 179.562 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.55 -25.14 2.01 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -139.68 112.71 8.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.039 -1.271 . . . . 0.0 110.95 -179.698 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.511 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -132.97 163.75 28.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.323 -0.861 . . . . 0.0 109.782 179.361 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.509 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.95 162.8 40.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.033 -1.042 . . . . 0.0 110.843 -179.612 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.493 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.5 OUTLIER 57.49 22.6 8.22 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.583 -0.698 . . . . 0.0 111.025 179.55 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.695 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.06 143.28 0.69 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.295 -0.878 . . . . 0.0 110.401 179.514 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.779 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -80.71 120.79 25.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.271 -0.893 . . . . 0.0 109.117 179.255 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.584 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 0.6 OUTLIER -87.92 127.7 35.36 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.733 0.778 . . . . 0.0 111.1 -178.982 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.525 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -108.54 174.5 5.85 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.323 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -134.29 114.58 13.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.131 -0.98 . . . . 0.0 110.784 -179.637 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.59 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -103.76 57.43 0.55 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.53 ' O ' ' ND2' ' A' ' 316' ' ' ASN . 2.3 p-10 37.75 75.7 0.06 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.951 . . . . 0.0 110.754 -179.687 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.584 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 108.39 -2.17 32.77 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.778 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.801 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -142.24 -169.69 3.0 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.288 -1.125 . . . . 0.0 109.299 179.673 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.801 HG23 ' O ' ' A' ' 318' ' ' TYR . 6.7 t -162.45 158.39 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 179.165 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.792 ' CG2' HG22 ' A' ' 293' ' ' THR . 32.3 mm -128.9 148.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.001 -1.062 . . . . 0.0 111.338 -179.394 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.4 m-85 -124.58 122.8 38.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.988 -1.07 . . . . 0.0 110.164 179.284 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.645 ' CG2' HG23 ' A' ' 293' ' ' THR . 5.9 p -121.21 168.09 11.79 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.924 -1.11 . . . . 0.0 110.002 179.756 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.516 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.7 Cg_endo -66.78 119.47 6.5 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 O-C-N 123.805 1.424 . . . . 0.0 110.963 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.779 HG12 ' ND2' ' A' ' 311' ' ' ASN . 35.4 m -67.88 -128.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.364 -179.889 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.499 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -97.35 -13.03 22.14 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.836 -1.165 . . . . 0.0 110.878 -179.473 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.709 ' H ' HG23 ' A' ' 324' ' ' VAL . 10.0 p-90 -135.35 5.34 3.22 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.054 -1.029 . . . . 0.0 110.63 -179.918 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.867 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 11.6 t30 -108.67 42.62 1.37 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.109 -0.994 . . . . 0.0 110.722 -179.701 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -123.43 -2.81 8.44 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.118 -0.989 . . . . 0.0 110.09 179.689 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.97 -157.11 0.08 OUTLIER Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.537 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.8 Cg_endo -75.96 5.3 4.55 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 124.006 1.53 . . . . 0.0 110.574 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.442 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.1 m -165.09 118.57 1.24 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.126 -0.984 . . . . 0.0 110.195 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.867 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.41 118.78 12.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -0.972 . . . . 0.0 110.225 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.797 ' OG1' HG23 ' A' ' 283' ' ' THR . 91.2 m -107.21 126.9 53.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.398 -0.814 . . . . 0.0 110.32 -179.957 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.846 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.8 p90 -131.37 175.35 9.21 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.364 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -155.37 156.63 27.11 Favored Glycine 0 N--CA 1.487 2.073 0 C-N-CA 118.861 -1.638 . . . . 0.0 110.076 -179.44 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.97 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.5 p90 -142.09 151.85 42.73 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.548 -0.972 . . . . 0.0 109.687 179.519 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.97 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -123.02 119.14 56.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.125 -0.984 . . . . 0.0 109.38 179.377 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.862 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -96.27 147.27 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 110.291 -179.398 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.514 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -118.17 131.29 56.41 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 109.987 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.383 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.893 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.756 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.486 1.355 0 CA-C-O 121.557 0.694 . . . . 0.0 110.383 . . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.806 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.1 p -127.27 123.74 62.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.094 -1.004 . . . . 0.0 109.709 179.199 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.543 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -55.06 -43.88 74.27 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.218 -179.258 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.469 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.9 pt-20 -177.31 159.23 1.55 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.113 -0.992 . . . . 0.0 111.119 -179.896 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.581 HG12 HG13 ' A' ' 296' ' ' VAL . 36.2 mt -121.34 122.33 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 110.104 179.517 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.39 160.05 27.63 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.892 . . . . 0.0 110.046 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.001 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.18 126.95 52.78 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.234 -0.916 . . . . 0.0 110.278 -179.922 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.3 tt0 -138.59 113.31 9.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.185 -0.947 . . . . 0.0 109.942 179.665 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.907 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.6 113.22 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.108 -0.995 . . . . 0.0 110.144 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.524 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 40.08 40.56 0.78 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.537 -0.727 . . . . 0.0 111.031 179.879 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.86 -20.84 37.73 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.83 -1.176 . . . . 0.0 110.342 179.185 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.472 ' O ' ' N ' ' A' ' 353' ' ' ILE . 39.1 mm-40 -87.0 111.3 20.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.045 -1.268 . . . . 0.0 110.5 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.642 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -73.44 141.88 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.299 -0.876 . . . . 0.0 110.222 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.642 HD13 ' O ' ' A' ' 357' ' ' VAL . 28.8 mm . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.199 179.975 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.192 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -140.12 166.52 24.45 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.61 -0.936 . . . . 0.0 109.597 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.872 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.6 tm? -161.02 130.83 4.92 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.944 -1.097 . . . . 0.0 110.952 -179.8 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.783 ' N ' HD22 ' A' ' 267' ' ' LEU . 25.7 mt-10 -131.86 122.92 26.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.64 -0.662 . . . . 0.0 109.414 179.879 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 281' ' ' ASP . 96.5 t -117.1 137.29 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 111.478 -179.058 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -120.25 157.42 29.17 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.91 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.668 HG13 ' O ' ' A' ' 279' ' ' GLU . 96.2 t -143.67 146.72 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.269 -1.519 . . . . 0.0 112.265 -179.266 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.536 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -147.89 117.5 7.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.639 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.593 ' OD1' ' HB1' ' A' ' 278' ' ' ALA . 1.0 OUTLIER -100.13 147.59 25.51 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.205 -0.934 . . . . 0.0 111.195 -178.663 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.782 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.9 p90 -130.14 18.61 5.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.541 -0.724 . . . . 0.0 109.864 179.398 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.19 -57.23 4.57 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.735 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.65 -14.91 62.19 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -1.162 . . . . 0.0 110.264 -179.895 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.548 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . 179.6 175.08 46.14 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.892 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.593 ' HB1' ' OD1' ' A' ' 273' ' ' ASP . . . -130.39 147.34 52.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.315 -1.109 . . . . 0.0 109.999 179.851 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.668 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.8 mt-10 -103.12 147.64 26.74 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.264 -0.897 . . . . 0.0 110.519 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 84.2 m-85 -142.59 81.09 1.72 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.556 -0.715 . . . . 0.0 110.625 -179.816 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -62.63 153.97 30.61 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.384 -0.822 . . . . 0.0 109.825 179.335 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.75 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.7 t -147.62 86.77 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.571 -0.705 . . . . 0.0 109.982 -179.473 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.765 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.9 m -86.21 118.72 25.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.092 -1.005 . . . . 0.0 109.387 179.656 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.079 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -106.04 147.24 29.12 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.196 -0.94 . . . . 0.0 110.374 -179.341 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.843 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -127.07 133.07 50.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.175 -0.953 . . . . 0.0 110.458 -179.432 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.843 HD23 ' O ' ' A' ' 285' ' ' ASN . 9.2 mt -142.1 158.54 43.63 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.896 -1.128 . . . . 0.0 108.992 179.332 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.66 35.56 0.96 Allowed 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.531 -179.588 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 158.21 -110.14 0.43 Allowed Glycine 0 N--CA 1.493 2.468 0 C-N-CA 118.758 -1.687 . . . . 0.0 110.982 179.779 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.505 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -135.07 122.37 21.68 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.061 -1.258 . . . . 0.0 111.051 -178.594 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.665 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 8.6 m-85 -150.88 147.02 26.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.245 -0.91 . . . . 0.0 109.998 179.172 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.787 ' O ' HG23 ' A' ' 353' ' ' ILE . 18.8 m-20 -80.58 96.79 6.94 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.371 179.316 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.954 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.9 p-90 -96.82 115.64 27.78 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.365 -0.835 . . . . 0.0 110.424 -179.589 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 1.073 HG23 HG22 ' A' ' 322' ' ' THR . 3.3 m -109.31 113.72 26.79 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.465 -0.772 . . . . 0.0 109.753 179.927 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.76 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.5 t -97.07 113.06 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.287 -0.883 . . . . 0.0 110.339 -179.463 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.548 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 31.3 ttmt -94.55 135.58 35.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.598 179.362 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.875 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 81.1 t -130.25 112.34 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.187 -0.946 . . . . 0.0 110.579 -179.548 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.524 ' O ' HG23 ' A' ' 346' ' ' VAL . 53.3 mmtt -70.32 136.08 49.46 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.063 -1.023 . . . . 0.0 109.472 179.421 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.991 HD13 ' HA ' ' A' ' 303' ' ' THR . 88.3 mt -90.49 163.12 14.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.296 -0.878 . . . . 0.0 111.838 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.863 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.78 178.06 0.97 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.82 -0.55 . . . . 0.0 109.846 179.583 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.863 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.2 77.39 0.87 Allowed 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.757 1.398 . . . . 0.0 109.811 179.449 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.7 18.69 5.97 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 -179.275 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.855 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -105.04 141.68 36.18 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.417 -1.049 . . . . 0.0 109.677 -179.856 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.991 ' HA ' HD13 ' A' ' 298' ' ' LEU . 82.2 p -143.99 143.95 31.45 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.84 -1.162 . . . . 0.0 111.058 179.859 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.888 ' CG2' HG21 ' A' ' 319' ' ' VAL . 88.5 t -67.13 116.86 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.658 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.74 -31.6 5.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.341 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.465 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.3 OUTLIER -140.63 132.03 26.81 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.927 -1.337 . . . . 0.0 111.136 -179.414 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.576 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 16.4 p90 -146.42 168.93 19.94 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.411 -0.805 . . . . 0.0 109.496 179.287 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.51 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.9 OUTLIER -159.56 157.07 29.2 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.881 -1.137 . . . . 0.0 111.546 -179.558 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.549 ' HB3' ' CH2' ' A' ' 326' ' ' TRP . 0.4 OUTLIER 60.76 27.09 16.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.749 -0.595 . . . . 0.0 111.186 179.47 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.672 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 142.7 0.86 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 110.102 179.627 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.738 HD22 HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -76.3 114.49 15.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.171 -0.956 . . . . 0.0 109.421 179.628 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.584 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 1.1 ttpp -87.08 132.95 33.67 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.76 0.79 . . . . 0.0 110.782 -179.579 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.577 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -120.03 174.52 6.42 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.991 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -137.71 103.14 4.93 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.195 -0.94 . . . . 0.0 110.242 179.764 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.499 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -90.44 30.44 6.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.893 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.499 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.1 OUTLIER 69.89 89.03 0.1 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.224 -1.162 . . . . 0.0 110.378 -179.992 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.632 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.55 1.32 71.54 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.861 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.805 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.2 m-85 -146.72 -168.6 3.07 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.463 -1.022 . . . . 0.0 108.921 179.396 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.888 HG21 ' CG2' ' A' ' 304' ' ' VAL . 6.4 t -162.18 158.15 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.973 -1.08 . . . . 0.0 110.123 179.116 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.584 ' O ' ' HA ' ' A' ' 312' ' ' LYS . 6.5 mm -122.41 152.38 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.896 -1.128 . . . . 0.0 110.747 -179.677 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 76.2 m-85 -132.54 115.12 15.07 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.167 -0.958 . . . . 0.0 110.026 179.224 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 1.073 HG22 HG23 ' A' ' 293' ' ' THR . 5.6 p -118.03 169.47 7.64 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 120.65 -1.281 . . . . 0.0 109.676 179.456 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.571 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.7 Cg_endo -67.57 121.28 8.35 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.619 1.326 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 1.057 HG22 ' HB2' ' A' ' 327' ' ' ASN . 2.7 m -75.75 -141.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -0.769 . . . . 0.0 110.458 -179.563 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.786 ' N ' HG23 ' A' ' 324' ' ' VAL . 3.2 m -76.24 -37.25 57.9 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 110.775 -179.626 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.58 ' H ' HG23 ' A' ' 324' ' ' VAL . 42.0 p-90 -117.77 22.24 12.44 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.16 -0.962 . . . . 0.0 110.803 -179.57 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 1.057 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -122.73 32.62 5.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.096 -1.003 . . . . 0.0 110.897 -179.172 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.498 ' CB ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -120.64 9.86 10.9 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.085 -1.009 . . . . 0.0 110.061 179.785 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -72.05 -149.5 0.87 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 179.895 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.556 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.3 Cg_endo -73.32 -52.46 0.14 Allowed 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.934 1.492 . . . . 0.0 109.64 179.811 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.0 m -111.89 115.73 29.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -125.52 117.45 23.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.379 -0.825 . . . . 0.0 109.958 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.765 ' OG1' HG23 ' A' ' 283' ' ' THR . 53.2 m -107.6 142.87 36.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.287 -0.883 . . . . 0.0 110.32 -179.859 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.76 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.4 p90 -151.7 173.06 15.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.766 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.525 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.89 153.73 25.02 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.021 -1.562 . . . . 0.0 110.1 -179.465 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.892 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -137.98 145.96 42.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.531 -0.982 . . . . 0.0 109.876 179.662 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.892 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.05 125.4 74.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.133 -0.979 . . . . 0.0 109.593 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.761 HG21 ' CD2' ' A' ' 298' ' ' LEU . 3.5 t -99.49 161.42 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.175 -0.953 . . . . 0.0 110.726 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.9 m-80 -128.47 137.06 51.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.447 -0.783 . . . . 0.0 110.205 179.869 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.405 ' H ' ' HE3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.494 2.517 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.951 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.686 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 0.0 OUTLIER . . . . . 0 N--CA 1.485 1.322 0 CA-C-O 121.362 0.601 . . . . 0.0 111.044 . . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.632 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.9 p -138.44 119.18 16.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 110.064 179.062 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.413 ' N ' ' O ' ' A' ' 297' ' ' LYS . 4.2 mt-10 -54.34 -42.22 69.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.412 -0.805 . . . . 0.0 110.928 -179.152 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.4 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.6 OUTLIER -176.66 158.77 1.76 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.94 -1.1 . . . . 0.0 110.867 -179.666 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.725 HG12 HG13 ' A' ' 296' ' ' VAL . 14.6 mt -119.28 120.22 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.144 -0.973 . . . . 0.0 110.36 179.858 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.11 141.9 51.66 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.113 -0.992 . . . . 0.0 110.16 179.825 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.079 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.89 130.11 54.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.193 -0.942 . . . . 0.0 110.386 179.803 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.8 tt0 -139.47 116.62 11.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.239 -0.913 . . . . 0.0 109.582 179.642 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.787 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -90.52 102.86 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.792 -1.193 . . . . 0.0 110.45 -179.704 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.465 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 1.0 OUTLIER 35.72 44.89 0.24 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.433 179.647 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.45 8.4 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.408 179.106 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.522 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 78.2 mm-40 -137.2 101.31 4.5 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.062 -1.258 . . . . 0.0 110.042 179.765 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.549 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.1 p -66.91 138.22 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.278 -0.889 . . . . 0.0 110.732 -179.672 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.549 HD13 ' O ' ' A' ' 357' ' ' VAL . 19.6 mm . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.171 179.596 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . 0.428 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.572 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.39 162.82 34.11 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.371 -1.076 . . . . 0.0 109.736 179.762 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.983 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.4 tm? -155.23 131.39 10.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.048 -1.032 . . . . 0.0 110.565 -179.148 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.562 ' N ' HD13 ' A' ' 267' ' ' LEU . 18.0 mt-10 -133.28 124.02 26.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.542 -0.724 . . . . 0.0 109.285 179.455 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.675 HG23 HD11 ' A' ' 267' ' ' LEU . 32.0 t -115.54 139.08 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.924 -1.11 . . . . 0.0 111.809 -178.714 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.412 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.6 mttt -123.21 156.65 34.72 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.492 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.672 HG22 ' CD1' ' A' ' 280' ' ' TYR . 91.4 t -145.08 144.94 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.276 -1.515 . . . . 0.0 112.152 -179.275 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.549 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.27 109.05 6.27 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.175 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -94.62 146.17 24.32 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.208 -0.932 . . . . 0.0 111.36 -178.763 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.819 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.6 p90 -134.63 22.94 3.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.589 -0.694 . . . . 0.0 109.897 179.275 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.69 -66.81 3.84 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.827 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.41 -24.85 65.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.28 -1.129 . . . . 0.0 110.431 -179.668 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.535 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.92 -177.8 41.76 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.533 -1.318 . . . . 0.0 109.84 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.584 ' HB2' ' HE3' ' A' ' 345' ' ' LYS . . . -136.5 144.8 44.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -1.1 . . . . 0.0 110.247 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.644 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.1 mt-10 -97.01 147.05 24.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.421 -0.8 . . . . 0.0 109.816 -179.629 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.7 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -143.74 86.79 1.89 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.204 -0.935 . . . . 0.0 110.894 -179.619 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.647 ' O ' HG13 ' A' ' 269' ' ' VAL . 4.6 t0 -71.06 151.58 44.39 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.641 179.11 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.735 HG21 ' CE1' ' A' ' 334' ' ' PHE . 3.4 t -143.52 91.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.46 -0.775 . . . . 0.0 109.717 -179.689 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.904 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.6 m -85.82 123.14 30.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.104 179.66 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.076 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -113.89 145.18 41.85 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.148 -0.97 . . . . 0.0 110.467 -179.034 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.904 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.6 OUTLIER -127.15 134.26 50.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -179.642 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.904 HD23 ' O ' ' A' ' 285' ' ' ASN . 15.9 mt -142.94 148.66 37.24 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.808 -1.183 . . . . 0.0 109.83 179.638 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -85.68 38.7 0.76 Allowed 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.593 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 159.53 -136.42 4.61 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.301 -1.428 . . . . 0.0 109.752 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.51 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -117.82 94.25 4.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.192 -1.181 . . . . 0.0 110.815 -179.49 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.616 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.05 137.14 52.38 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.192 -0.943 . . . . 0.0 109.918 179.311 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.782 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.1 m-20 -71.85 97.6 1.84 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.104 -0.998 . . . . 0.0 109.287 179.248 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.967 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.9 p-90 -97.1 113.74 25.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 110.663 -179.376 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.898 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.0 m -107.11 117.05 33.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.523 -0.735 . . . . 0.0 109.258 179.527 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.739 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.1 t -97.14 111.0 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.121 -0.987 . . . . 0.0 110.655 -179.247 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.687 ' HA ' HD13 ' A' ' 320' ' ' ILE . 18.7 ttpt -84.68 138.97 32.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.258 -0.901 . . . . 0.0 108.933 178.923 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.957 HG22 HG23 ' A' ' 349' ' ' ILE . 85.1 t -136.22 107.11 6.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 110.906 -179.116 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.59 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 8.2 mmtm -69.96 130.72 42.96 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 121.075 -1.016 . . . . 0.0 108.881 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.997 HD13 ' HA ' ' A' ' 303' ' ' THR . 66.2 mt -87.02 157.9 19.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.336 -0.853 . . . . 0.0 111.304 -178.816 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.9 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -59.14 177.89 0.24 Allowed Pre-proline 0 C--N 1.303 -1.438 0 O-C-N 121.764 -0.585 . . . . 0.0 109.803 179.503 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.839 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.06 81.0 0.66 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.717 1.377 . . . . 0.0 109.449 179.294 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.05 21.98 6.1 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 -179.102 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.9 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -104.91 149.77 25.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.313 -1.11 . . . . 0.0 110.397 -179.661 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.997 ' HA ' HD13 ' A' ' 298' ' ' LEU . 4.7 p -148.9 145.63 27.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.294 -0.879 . . . . 0.0 110.424 179.729 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.786 HG21 HG11 ' A' ' 319' ' ' VAL . 55.5 t -71.64 117.66 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 110.044 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -97.38 -45.26 2.58 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 68.1 m -126.15 148.76 49.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -1.161 . . . . 0.0 110.843 -179.77 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.513 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.0 p90 -162.95 160.03 24.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.462 -0.773 . . . . 0.0 109.479 179.473 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.498 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -153.35 162.46 41.26 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.835 -1.166 . . . . 0.0 111.172 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.513 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 58.19 21.83 8.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.963 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.712 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.84 137.76 0.6 Allowed 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.426 -0.796 . . . . 0.0 110.057 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.697 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.31 124.96 28.57 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.117 -0.989 . . . . 0.0 109.538 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.757 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -92.2 139.83 30.23 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.719 0.771 . . . . 0.0 110.882 -179.25 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.636 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -122.61 170.5 9.96 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.135 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.579 ' HG2' HG22 ' A' ' 319' ' ' VAL . 46.3 mt-10 -141.55 100.98 3.89 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.137 -0.977 . . . . 0.0 110.518 -179.767 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -81.41 -76.68 1.05 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.209 -1.557 . . . . 0.0 109.209 179.595 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.57 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 2.8 m120 -163.85 86.79 0.5 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.423 -1.045 . . . . 0.0 109.001 179.553 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 86.63 14.4 65.6 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -178.57 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.837 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.4 m-85 -146.79 -168.76 3.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.836 -0.803 . . . . 0.0 109.096 179.642 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.837 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.8 t -163.85 161.59 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.177 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.687 HD13 ' HA ' ' A' ' 295' ' ' LYS . 40.6 mm -127.24 144.97 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 111.184 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 49.2 m-85 -120.55 133.59 55.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.212 -0.93 . . . . 0.0 109.912 179.56 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.898 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -134.53 167.81 20.95 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 120.852 -1.155 . . . . 0.0 109.881 179.64 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.498 ' HB3' ' O ' ' A' ' 327' ' ' ASN . 42.2 Cg_endo -67.72 115.51 3.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.858 1.451 . . . . 0.0 110.725 -179.384 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 1.061 HG22 ' HB2' ' A' ' 327' ' ' ASN . 23.0 m -61.18 -135.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.334 -0.854 . . . . 0.0 110.245 -179.88 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.525 ' N ' HG23 ' A' ' 324' ' ' VAL . 2.0 m -90.47 -18.68 24.92 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.059 -1.026 . . . . 0.0 110.763 -179.475 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.777 ' H ' HG23 ' A' ' 324' ' ' VAL . 27.7 p-90 -132.97 21.56 4.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.182 -0.949 . . . . 0.0 110.404 -179.742 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 1.061 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.7 m120 -120.25 38.25 4.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.073 -1.017 . . . . 0.0 110.614 -179.365 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.51 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -120.06 -4.95 10.04 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.184 -0.948 . . . . 0.0 109.889 179.565 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.99 -160.64 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -74.52 4.09 4.79 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.998 1.526 . . . . 0.0 110.72 -179.868 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.429 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.4 m -163.66 117.05 1.51 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.19 -0.944 . . . . 0.0 110.048 -179.853 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -140.12 114.61 9.31 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.961 . . . . 0.0 110.357 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.904 ' OG1' HG23 ' A' ' 283' ' ' THR . 21.7 m -105.15 139.17 40.22 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.23 -0.919 . . . . 0.0 110.022 179.793 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.739 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.5 p90 -141.57 174.5 10.51 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.349 -0.844 . . . . 0.0 109.019 179.891 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.23 156.33 26.61 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.162 -1.494 . . . . 0.0 110.015 -179.525 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.899 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -146.25 144.65 30.0 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.385 -1.068 . . . . 0.0 110.328 179.752 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.899 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.71 123.06 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.184 -0.948 . . . . 0.0 109.215 179.321 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.82 HG11 ' HB1' ' A' ' 302' ' ' ALA . 4.1 t -96.59 162.11 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 110.699 -179.144 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 0.7 OUTLIER -126.07 127.38 45.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.568 -0.707 . . . . 0.0 109.56 -179.967 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.288 0 C-N-CA 119.494 -1.336 . . . . 0.0 110.042 179.977 . . . . . . . . 0 0 . 1 . 032 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.68 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 2.5 mtmt . . . . . 0 N--CA 1.488 1.471 0 CA-C-O 121.298 0.571 . . . . 0.0 110.492 . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.8 p -136.85 118.35 18.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.415 -0.803 . . . . 0.0 110.026 179.272 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.466 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -50.96 -45.84 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.348 -0.845 . . . . 0.0 110.38 -179.513 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.436 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.0 pt-20 -176.61 157.84 1.65 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.272 -0.892 . . . . 0.0 110.426 -179.695 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.957 HG23 HG22 ' A' ' 296' ' ' VAL . 64.5 mt -120.59 106.54 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.157 -0.964 . . . . 0.0 110.232 179.644 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.82 130.91 53.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 110.286 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.076 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -91.3 129.37 37.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.101 -0.999 . . . . 0.0 110.241 179.782 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.401 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.0 tt0 -138.83 112.69 8.46 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.183 -0.948 . . . . 0.0 109.934 179.81 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.782 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.4 110.7 22.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.065 -1.022 . . . . 0.0 110.165 179.961 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.423 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 38.89 29.25 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.774 -0.578 . . . . 0.0 110.639 179.922 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 118.59 -21.68 9.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.41 ' O ' ' N ' ' A' ' 353' ' ' ILE . 1.2 mp0 -86.2 112.53 21.43 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.055 -1.262 . . . . 0.0 110.392 -179.755 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.843 ' O ' HD13 ' A' ' 358' ' ' ILE . 14.8 p -74.84 141.63 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.138 -0.976 . . . . 0.0 110.407 179.842 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.843 HD13 ' O ' ' A' ' 357' ' ' VAL . 30.8 mm . . . . . 0 N--CA 1.494 1.755 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.309 179.837 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.301 0 N-CA-C 110.245 -1.142 . . . . 0.0 110.245 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -128.52 165.94 19.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.617 -0.931 . . . . 0.0 109.664 179.665 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.748 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -159.43 126.21 4.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.977 -1.077 . . . . 0.0 111.17 -179.555 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.52 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.4 OUTLIER -123.78 118.05 26.3 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.681 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 281' ' ' ASP . 55.2 t -117.15 142.15 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.851 -1.156 . . . . 0.0 112.14 -178.428 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 7.9 tttm -128.5 157.28 41.59 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.969 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.625 HG13 ' O ' ' A' ' 279' ' ' GLU . 86.5 t -144.2 145.42 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.367 -1.458 . . . . 0.0 111.947 -179.445 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.65 113.23 7.71 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.483 179.534 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.514 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.86 145.76 25.11 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.151 -0.968 . . . . 0.0 110.942 -179.016 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.813 ' CH2' HG23 ' A' ' 337' ' ' ILE . 27.9 p90 -127.83 16.04 6.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.305 179.377 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 95.01 -56.11 1.82 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.483 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.6 m -78.53 -17.86 55.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -1.151 . . . . 0.0 110.453 -179.678 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -174.1 177.71 46.24 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.35 -1.405 . . . . 0.0 109.922 -179.952 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.561 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.65 144.84 48.07 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.329 -1.1 . . . . 0.0 110.066 179.862 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.625 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.2 mt-10 -96.88 147.48 23.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.365 -0.835 . . . . 0.0 109.878 -179.441 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 92.8 m-85 -139.38 86.43 2.12 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.302 -0.874 . . . . 0.0 110.69 -179.294 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.797 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.6 OUTLIER -69.77 145.65 52.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.431 -0.793 . . . . 0.0 109.809 179.317 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 294' ' ' VAL . 3.8 t -139.06 87.55 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.577 -0.702 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 333' ' ' THR . 19.2 m -86.12 117.12 24.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.102 -0.999 . . . . 0.0 109.645 -179.886 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.104 HD21 HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -103.05 150.43 23.6 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.109 -0.994 . . . . 0.0 110.769 -179.279 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.62 106.63 7.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.576 -0.702 . . . . 0.0 110.098 -179.324 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.61 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.1 mt -113.98 157.16 22.83 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.824 -1.172 . . . . 0.0 109.987 179.772 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.47 35.16 0.76 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.356 -0.84 . . . . 0.0 110.501 -179.432 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.491 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.15 -103.39 0.23 Allowed Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.878 -1.63 . . . . 0.0 110.423 179.855 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.443 ' HG3' ' O ' ' A' ' 328' ' ' LYS . 3.0 tt0 -149.95 111.06 4.37 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.053 -1.263 . . . . 0.0 110.705 -179.252 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.61 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 2.4 m-85 -140.14 138.54 35.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.405 -0.809 . . . . 0.0 109.866 179.542 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.694 ' O ' HG23 ' A' ' 353' ' ' ILE . 29.5 m-20 -64.92 97.09 0.21 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.102 -0.999 . . . . 0.0 109.294 179.349 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.884 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.5 p-90 -96.41 110.71 23.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.262 -0.899 . . . . 0.0 110.67 -179.502 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.669 HG22 ' CG2' ' A' ' 320' ' ' ILE . 5.5 m -102.81 114.94 29.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.518 -0.739 . . . . 0.0 109.314 179.459 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 282' ' ' VAL . 4.5 t -96.18 113.08 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.102 -0.999 . . . . 0.0 110.007 -179.547 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.699 ' HA ' HD13 ' A' ' 320' ' ' ILE . 12.9 ttpt -89.73 149.47 22.73 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.527 -0.733 . . . . 0.0 109.184 179.657 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.793 HG13 HD13 ' A' ' 349' ' ' ILE . 77.4 t -148.16 109.33 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.005 -1.059 . . . . 0.0 110.763 -179.327 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.581 ' O ' HG23 ' A' ' 346' ' ' VAL . 9.0 mmtt -71.81 135.03 46.51 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.102 -0.999 . . . . 0.0 109.324 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.919 HD13 ' HA ' ' A' ' 303' ' ' THR . 89.6 mt -86.11 167.13 15.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.28 -0.888 . . . . 0.0 111.755 -178.75 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.787 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -72.18 176.17 2.56 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.672 -0.643 . . . . 0.0 109.353 179.068 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.787 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.9 Cg_endo -69.3 80.3 0.76 Allowed 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.554 1.291 . . . . 0.0 109.918 179.564 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.41 23.45 4.79 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.985 -1.646 . . . . 0.0 108.985 -179.446 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.913 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.7 150.4 30.26 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.373 -1.075 . . . . 0.0 110.401 -179.558 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.919 ' HA ' HD13 ' A' ' 298' ' ' LEU . 77.3 p -150.43 144.14 25.23 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.286 -0.884 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.846 HG21 HG11 ' A' ' 319' ' ' VAL . 55.2 t -64.81 133.32 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 110.16 179.69 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.2 -37.6 1.48 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.843 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.41 138.22 32.8 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.182 -1.187 . . . . 0.0 110.768 -179.681 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.529 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 48.1 p90 -147.11 163.78 35.2 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.326 -0.858 . . . . 0.0 109.776 179.486 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.464 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.47 158.2 38.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.941 -1.099 . . . . 0.0 111.554 -179.434 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.518 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.52 21.6 12.74 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.719 -0.613 . . . . 0.0 110.818 179.479 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.638 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.7 143.6 0.78 Allowed 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.465 -0.772 . . . . 0.0 109.956 179.538 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.546 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -79.33 119.71 22.76 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.035 . . . . 0.0 109.351 179.579 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.596 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -86.2 140.33 30.25 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.767 0.794 . . . . 0.0 110.59 -179.612 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.661 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.13 173.2 8.9 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.423 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -136.7 112.7 9.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 110.167 179.926 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -102.73 43.56 1.66 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 57.75 80.15 0.18 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.354 -1.086 . . . . 0.0 110.395 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.39 -1.02 57.12 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.64 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.826 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.1 m-85 -142.55 -170.1 3.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.377 -1.072 . . . . 0.0 109.472 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.846 HG11 HG21 ' A' ' 304' ' ' VAL . 3.9 t -162.81 156.12 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.177 -0.952 . . . . 0.0 109.922 179.2 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.699 HD13 ' HA ' ' A' ' 295' ' ' LYS . 37.2 mm -125.65 151.78 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.114 -0.991 . . . . 0.0 111.294 -179.462 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 78.5 m-85 -129.54 126.49 38.7 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.166 -0.959 . . . . 0.0 110.408 179.421 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.604 ' CG2' HG23 ' A' ' 293' ' ' THR . 6.4 p -126.5 167.56 16.91 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 120.919 -1.113 . . . . 0.0 109.579 179.195 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.504 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.4 Cg_endo -65.15 119.93 7.05 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.225 -179.164 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.723 HG22 ' HB2' ' A' ' 327' ' ' ASN . 12.4 m -63.74 -111.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.439 -0.788 . . . . 0.0 110.166 179.987 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.482 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.1 OUTLIER -111.67 -23.32 10.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.697 -1.252 . . . . 0.0 110.534 -179.811 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 3.9 p-90 -125.73 1.49 7.47 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 -179.874 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.723 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.2 OUTLIER -99.91 40.97 1.19 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.233 -0.917 . . . . 0.0 110.38 -179.69 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -120.05 -8.4 9.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.25 -0.907 . . . . 0.0 109.532 179.736 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.89 -159.06 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.939 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.1 Cg_endo -74.76 5.75 3.69 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.978 1.515 . . . . 0.0 110.821 -179.899 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.1 m -163.14 121.23 1.98 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.959 -1.088 . . . . 0.0 109.897 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.61 113.75 8.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.957 . . . . 0.0 110.26 -179.776 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.542 HG23 ' HA ' ' A' ' 283' ' ' THR . 11.8 m -103.04 133.42 48.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.392 -0.817 . . . . 0.0 110.364 -179.739 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.8 ' HE2' HG21 ' A' ' 294' ' ' VAL . 15.0 p90 -141.77 164.6 29.75 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.379 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -144.24 158.27 27.41 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.843 -1.646 . . . . 0.0 110.32 -179.397 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.926 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -144.01 147.65 34.17 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.556 -0.967 . . . . 0.0 109.882 179.417 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.926 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.74 122.81 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.992 -1.068 . . . . 0.0 110.048 -179.969 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.913 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.9 t -97.07 157.28 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.884 . . . . 0.0 109.999 179.712 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -125.85 131.32 52.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.84 . . . . 0.0 110.396 -179.575 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.851 . . . . . . . . 0 0 . 1 . 033 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.74 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.3 mtmt . . . . . 0 N--CA 1.486 1.341 0 CA-C-O 121.113 0.482 . . . . 0.0 111.234 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.641 HG11 ' CE1' ' A' ' 280' ' ' TYR . 9.0 p -132.2 125.51 54.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.022 -1.049 . . . . 0.0 110.412 179.231 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.547 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 3.8 mt-10 -53.08 -45.74 68.29 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.313 -0.867 . . . . 0.0 110.149 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.454 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 1.8 pt-20 -177.55 158.63 1.4 Allowed 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.185 -179.704 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.793 HD13 HG13 ' A' ' 296' ' ' VAL . 3.5 mm -109.13 122.58 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.603 -0.686 . . . . 0.0 109.709 179.419 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.42 141.76 51.67 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.33 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.104 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.68 126.84 52.62 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 109.952 179.633 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 11.5 tt0 -138.99 113.8 9.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.643 179.92 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.694 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -92.97 112.14 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.154 -0.966 . . . . 0.0 109.913 179.522 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.533 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 41.74 34.11 0.38 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.492 -0.755 . . . . 0.0 110.113 -179.579 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 108.9 -25.12 19.89 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.933 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.471 ' N ' ' CD ' ' A' ' 356' ' ' GLN . 3.2 mp0 -77.41 106.07 8.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.223 -1.163 . . . . 0.0 110.523 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.622 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.5 p -70.92 120.93 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.259 -0.901 . . . . 0.0 110.184 179.719 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.514 ' HB ' HD13 ' A' ' 351' ' ' LEU . 35.5 mm . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.009 179.777 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.189 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.54 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.79 169.35 17.87 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.585 -0.95 . . . . 0.0 109.33 179.909 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.904 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.38 134.49 6.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.36 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.777 ' N ' HD22 ' A' ' 267' ' ' LEU . 8.4 mm-40 -133.96 138.46 45.47 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.294 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.4 t -131.35 142.0 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 120.858 -1.151 . . . . 0.0 111.753 -178.846 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.17 156.99 40.93 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.771 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.81 147.07 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 120.401 -1.437 . . . . 0.0 112.344 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -143.18 113.91 7.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.669 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.6 m-20 -100.07 142.87 30.96 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.872 -1.142 . . . . 0.0 111.205 -178.538 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.8 ' CH2' HG23 ' A' ' 337' ' ' ILE . 26.8 p90 -122.77 20.1 10.17 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.576 -0.703 . . . . 0.0 109.475 179.451 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 84.44 -58.32 5.0 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.744 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.484 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -66.87 -19.34 65.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.25 -1.147 . . . . 0.0 110.216 179.793 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.553 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.93 -172.69 38.79 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -143.69 136.89 27.77 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -1.122 . . . . 0.0 109.894 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.641 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.2 mt-10 -95.93 146.4 24.62 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 110.446 -179.447 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.662 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.1 m-85 -140.01 86.36 2.08 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 110.766 -179.699 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.706 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -66.54 143.64 56.93 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 179.155 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.811 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.4 t -138.35 89.36 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.191 -0.943 . . . . 0.0 110.014 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.463 ' HA ' HG23 ' A' ' 333' ' ' THR . 87.4 m -86.76 126.96 34.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.181 -0.949 . . . . 0.0 109.568 179.799 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.81 147.08 40.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 110.77 -179.204 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.91 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.6 OUTLIER -125.3 135.21 52.25 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.35 -0.844 . . . . 0.0 110.467 -179.453 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.91 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.3 mt -144.77 161.69 38.61 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.731 -1.23 . . . . 0.0 109.595 179.8 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.09 37.47 1.16 Allowed 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.776 179.733 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.473 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 148.55 -129.89 3.25 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.33 -1.414 . . . . 0.0 109.973 -179.68 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.546 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.1 mm-40 -108.3 114.06 27.62 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.891 -1.358 . . . . 0.0 111.132 -179.326 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.721 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.3 m-85 -134.43 133.09 40.12 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.444 -0.785 . . . . 0.0 109.234 179.205 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.84 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.1 m-20 -73.5 96.26 2.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.808 -1.183 . . . . 0.0 108.857 179.236 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.903 ' CE3' HD13 ' A' ' 284' ' ' LEU . 64.2 p-90 -98.98 117.47 33.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.893 . . . . 0.0 110.996 -179.038 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 1.067 HG23 HG22 ' A' ' 322' ' ' THR . 17.3 m -112.68 113.98 26.37 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.425 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.787 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.2 t -96.68 110.92 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.058 -1.026 . . . . 0.0 110.265 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.537 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 17.6 ttmt -89.51 148.21 23.54 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.381 -0.825 . . . . 0.0 109.187 179.144 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.811 HG13 HG12 ' A' ' 349' ' ' ILE . 71.3 t -144.26 111.66 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.126 -0.984 . . . . 0.0 110.204 -179.666 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 72.6 mmtt -70.24 135.44 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.219 -0.926 . . . . 0.0 109.154 179.653 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 1.027 HD13 ' HA ' ' A' ' 303' ' ' THR . 93.9 mt -89.84 155.59 19.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.316 -0.865 . . . . 0.0 111.447 -178.851 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.781 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -59.4 173.86 0.46 Allowed Pre-proline 0 N--CA 1.487 1.378 0 O-C-N 121.493 -0.755 . . . . 0.0 109.086 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.695 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -69.23 79.33 0.78 Allowed 'Trans proline' 0 C--N 1.302 -1.913 0 O-C-N 123.608 1.32 . . . . 0.0 109.874 179.747 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.93 20.15 4.99 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.425 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.781 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -109.99 148.39 31.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.407 -1.055 . . . . 0.0 109.859 -179.884 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 1.027 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.8 p -147.52 146.15 29.36 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.953 -1.092 . . . . 0.0 111.247 -179.747 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.746 ' CG2' HG21 ' A' ' 319' ' ' VAL . 53.7 t -69.28 129.02 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.287 -0.883 . . . . 0.0 109.821 179.542 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.66 -40.22 1.13 Allowed Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.73 -1.224 . . . . 0.0 110.201 -179.466 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -126.96 129.65 48.55 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 0.0 110.686 -179.463 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.552 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.6 p90 -145.44 162.02 38.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.36 -0.837 . . . . 0.0 109.823 179.59 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.503 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -158.16 156.09 30.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.927 -1.108 . . . . 0.0 111.171 -179.579 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.538 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 63.5 24.31 14.02 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.575 -0.703 . . . . 0.0 110.941 179.598 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.542 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.18 146.1 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.908 . . . . 0.0 110.497 179.474 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.496 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.0 m-80 -77.31 123.46 26.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.375 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.552 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 12.0 ttpt -93.03 121.94 34.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.5 -0.75 . . . . 0.0 111.025 -179.448 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.597 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.6 tt0 -109.86 175.13 5.56 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.324 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -138.17 101.99 4.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.347 -0.846 . . . . 0.0 110.12 179.773 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.451 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -90.11 37.05 3.41 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.868 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . 0.488 ' ND2' ' N ' ' A' ' 316' ' ' ASN . 2.2 m120 63.78 88.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -1.168 . . . . 0.0 110.266 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.08 3.07 70.47 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.729 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.751 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.34 -169.38 3.25 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.376 -1.073 . . . . 0.0 109.338 179.491 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.751 HG23 ' O ' ' A' ' 318' ' ' TYR . 22.6 t -160.8 161.08 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.119 -0.988 . . . . 0.0 109.97 178.964 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.597 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 4.4 mm -126.55 152.33 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.133 -0.98 . . . . 0.0 110.93 -179.378 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.65 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 79.2 m-85 -131.76 112.48 12.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.232 -0.918 . . . . 0.0 109.888 178.791 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 1.067 HG22 HG23 ' A' ' 293' ' ' THR . 6.5 p -115.67 170.28 5.86 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 120.725 -1.234 . . . . 0.0 109.529 179.561 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.577 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.0 Cg_endo -67.24 120.62 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.495 1.261 . . . . 0.0 110.943 -179.199 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.727 HG22 ' HB2' ' A' ' 327' ' ' ASN . 30.7 m -68.24 -123.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.488 -0.757 . . . . 0.0 110.143 -179.922 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.481 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -104.74 -18.1 14.39 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.776 -1.202 . . . . 0.0 110.67 -179.734 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.591 ' H ' HG23 ' A' ' 324' ' ' VAL . 19.7 p-90 -126.73 3.53 6.73 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.93 -1.106 . . . . 0.0 110.539 -179.994 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.727 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.6 t30 -110.92 34.76 3.83 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.141 -0.975 . . . . 0.0 110.646 -179.429 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.531 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -114.22 2.8 14.94 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.158 -0.964 . . . . 0.0 109.636 179.54 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -68.85 -153.4 0.58 Allowed Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 179.888 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.9 Cg_endo -69.24 -50.45 0.52 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.906 1.477 . . . . 0.0 109.863 179.974 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.56 116.66 31.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -0.839 . . . . 0.0 110.34 179.779 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -130.34 113.62 14.6 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.271 -0.893 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.463 HG23 ' HA ' ' A' ' 283' ' ' THR . 57.2 m -105.73 149.84 26.05 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.175 -0.953 . . . . 0.0 110.37 -179.966 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.811 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 8.3 p90 -154.73 170.74 20.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.408 -0.808 . . . . 0.0 108.905 179.67 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.542 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.71 149.73 21.62 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.057 -179.3 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.92 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -136.15 147.98 47.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.496 -1.002 . . . . 0.0 110.019 179.573 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.92 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.65 122.49 68.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 120.997 -1.065 . . . . 0.0 109.925 179.501 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.729 HG21 ' CD2' ' A' ' 298' ' ' LEU . 2.1 t -96.55 150.23 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.082 -1.011 . . . . 0.0 110.003 -179.968 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -119.1 132.36 56.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.437 -0.789 . . . . 0.0 109.946 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.462 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.177 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.997 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.691 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.5 OUTLIER . . . . . 0 N--CA 1.488 1.433 0 CA-C-O 121.291 0.567 . . . . 0.0 110.575 . . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.5 p -130.02 126.74 62.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.386 -0.821 . . . . 0.0 109.667 179.106 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.1 mt-10 -62.85 -38.43 90.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 111.106 -179.072 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.457 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.7 pt-20 -176.86 158.9 1.68 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 110.897 -179.479 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.811 HG12 HG13 ' A' ' 296' ' ' VAL . 14.7 mt -123.42 103.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.143 -0.973 . . . . 0.0 110.03 179.627 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.0 145.58 31.18 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.306 -0.871 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.07 128.36 55.85 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.308 179.693 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.461 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 13.9 tt0 -138.61 120.86 15.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.875 179.689 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.84 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -90.81 93.82 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.092 -1.005 . . . . 0.0 110.026 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.553 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 46.34 26.38 0.47 Allowed 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.909 -0.495 . . . . 0.0 110.797 179.923 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 135.66 -29.66 2.85 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.658 179.398 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.485 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 58.7 mm-40 -89.06 110.18 20.93 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.911 -1.347 . . . . 0.0 110.65 -179.442 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.858 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.9 p -74.13 140.36 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.255 -0.903 . . . . 0.0 109.917 179.408 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.858 HD13 ' O ' ' A' ' 357' ' ' VAL . 9.7 mm . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.114 -0.991 . . . . 0.0 110.234 -179.752 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.363 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.542 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.43 164.69 29.19 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.402 -1.057 . . . . 0.0 109.841 179.933 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.858 HD22 ' N ' ' A' ' 268' ' ' GLU . 1.6 tm? -161.04 135.37 7.13 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.124 -179.436 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.858 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -132.31 144.25 50.44 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.175 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.795 HG13 ' O ' ' A' ' 281' ' ' ASP . 49.9 t -135.58 140.95 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.689 -1.257 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.47 156.7 41.72 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.734 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.761 HG13 ' O ' ' A' ' 279' ' ' GLU . 94.4 t -143.31 146.93 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.391 -1.443 . . . . 0.0 112.162 -179.338 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.534 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.94 113.8 8.79 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.084 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.449 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 m-20 -97.52 148.84 22.83 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.002 -1.061 . . . . 0.0 111.339 -178.818 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.1 p90 -133.74 17.68 3.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.487 -0.758 . . . . 0.0 109.942 179.417 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.37 -57.04 3.9 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.711 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -72.78 -17.12 61.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -1.164 . . . . 0.0 110.226 -179.827 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.543 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.14 -178.04 47.31 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.49 -1.338 . . . . 0.0 109.981 179.876 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.528 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -138.35 141.23 39.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.388 -1.066 . . . . 0.0 110.125 -179.898 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.761 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.8 mt-10 -93.01 147.21 23.03 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.294 -0.879 . . . . 0.0 110.0 -179.838 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.6 m-85 -139.13 84.54 2.01 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.406 -0.809 . . . . 0.0 110.444 -179.581 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.795 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -66.26 150.68 48.44 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.525 -0.734 . . . . 0.0 109.736 179.419 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.767 HG11 HG11 ' A' ' 294' ' ' VAL . 3.2 t -146.47 89.37 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.392 -0.818 . . . . 0.0 110.019 -179.555 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.862 HG23 ' OG1' ' A' ' 333' ' ' THR . 26.2 m -86.04 126.15 33.95 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 109.342 179.601 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.12 152.18 29.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.119 -0.988 . . . . 0.0 110.929 -178.894 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.898 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -131.39 134.73 46.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.731 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.954 HD13 ' HB2' ' A' ' 290' ' ' TYR . 17.2 mt -142.72 162.04 36.51 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.871 -1.143 . . . . 0.0 110.332 -179.846 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.68 34.94 0.71 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.29 -0.881 . . . . 0.0 109.984 179.731 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 144.98 -128.08 3.08 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.825 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.48 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.6 mm-40 -106.25 108.0 19.28 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.033 -1.275 . . . . 0.0 110.969 -179.621 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.954 ' HB2' HD13 ' A' ' 286' ' ' LEU . 8.4 m-85 -127.02 134.76 50.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.336 -0.853 . . . . 0.0 109.493 179.523 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.864 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.0 t70 -73.85 96.37 2.58 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.808 -1.183 . . . . 0.0 108.785 179.02 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.864 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.0 p-90 -98.66 109.26 22.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 111.36 -178.853 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.837 HG22 ' CG2' ' A' ' 320' ' ' ILE . 2.8 m -100.82 115.65 30.83 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.769 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.874 HG21 ' HE2' ' A' ' 334' ' ' PHE . 6.6 t -96.59 111.01 25.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.132 -0.98 . . . . 0.0 110.83 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.439 ' HB3' ' HE3' ' A' ' 295' ' ' LYS . 2.9 ttpp -87.87 145.32 26.12 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.459 -0.776 . . . . 0.0 109.346 179.118 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.829 HG13 HG12 ' A' ' 349' ' ' ILE . 84.6 t -145.4 107.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.153 -0.967 . . . . 0.0 110.452 -179.439 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.584 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.1 mmtt -70.33 133.06 46.58 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.194 -0.941 . . . . 0.0 109.773 179.806 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.947 HD13 ' HA ' ' A' ' 303' ' ' THR . 72.4 mt -87.43 157.83 19.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.441 -0.787 . . . . 0.0 111.731 -178.735 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.822 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -64.95 176.95 0.68 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.6 -0.688 . . . . 0.0 109.571 179.237 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.822 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.6 Cg_endo -68.1 82.47 0.48 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.62 1.327 . . . . 0.0 110.001 179.628 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.7 22.62 5.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.38 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.891 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -110.48 144.7 38.89 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.357 -1.084 . . . . 0.0 110.227 -179.747 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.947 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.5 p -147.57 146.12 29.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 110.391 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.731 HG21 HG11 ' A' ' 319' ' ' VAL . 77.8 t -73.11 125.73 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.374 -0.829 . . . . 0.0 110.101 179.896 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.63 -15.8 5.72 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.44 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.3 OUTLIER -144.73 126.99 15.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.207 -1.173 . . . . 0.0 110.837 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.541 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -149.69 173.46 13.66 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.361 -0.837 . . . . 0.0 109.835 179.531 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.419 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -163.54 158.06 20.33 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.797 -1.189 . . . . 0.0 111.713 -179.761 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 1.2 m 58.87 26.32 14.73 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.292 0.568 . . . . 0.0 111.052 179.575 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.618 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.87 141.47 0.61 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 110.089 179.405 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.09 117.76 18.96 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.017 -1.052 . . . . 0.0 109.35 179.61 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.618 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.2 ttpt -86.21 133.16 33.86 Favored 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.719 0.771 . . . . 0.0 110.877 -179.355 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.577 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -115.17 172.3 7.15 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.903 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -134.75 103.12 5.5 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 110.177 -179.868 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.496 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.21 49.82 3.01 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 47.92 80.85 0.05 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.146 -1.208 . . . . 0.0 109.971 -179.947 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.79 -1.26 58.05 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.6 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.3 m-85 -141.71 179.48 6.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.464 -1.021 . . . . 0.0 109.256 179.502 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.731 HG11 HG21 ' A' ' 304' ' ' VAL . 5.2 t -154.22 153.8 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.932 . . . . 0.0 109.286 178.721 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.837 ' CG2' HG22 ' A' ' 293' ' ' THR . 78.3 mt -132.19 138.69 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.996 -1.065 . . . . 0.0 111.337 -179.536 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.5 m-85 -113.42 133.61 55.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.084 -1.01 . . . . 0.0 111.066 -179.629 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.696 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.3 p -127.74 169.19 12.99 Favored Pre-proline 0 C--N 1.3 -1.546 0 O-C-N 121.072 -1.017 . . . . 0.0 109.672 179.011 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.5 Cg_endo -66.34 117.23 4.54 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.812 1.428 . . . . 0.0 111.1 -179.22 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.599 HG22 ' HB2' ' A' ' 327' ' ' ASN . 13.3 m -62.12 -112.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.455 -0.778 . . . . 0.0 110.059 179.872 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.468 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -114.46 -19.38 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 179.873 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.46 ' H ' HG23 ' A' ' 324' ' ' VAL . 7.9 p-90 -122.48 -17.96 6.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.232 -0.917 . . . . 0.0 110.287 -179.904 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.734 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 4.5 t30 -83.9 46.47 1.19 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 0.0 110.066 -179.885 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.5 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.61 -11.95 7.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.393 -0.817 . . . . 0.0 109.783 -179.933 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.49 -163.77 0.02 OUTLIER Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.735 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.13 2.24 5.75 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 124.07 1.563 . . . . 0.0 110.625 179.9 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.8 m -159.61 114.98 2.43 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.619 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.734 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.76 128.23 26.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.136 -0.978 . . . . 0.0 110.13 -179.767 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.862 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.0 m -117.27 148.9 41.26 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.151 -0.968 . . . . 0.0 110.496 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.874 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.8 p90 -150.4 169.2 22.0 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.448 -0.782 . . . . 0.0 108.952 179.796 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -145.48 158.66 27.73 Favored Glycine 0 N--CA 1.489 2.21 0 C-N-CA 118.737 -1.697 . . . . 0.0 110.128 -179.704 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.95 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -145.03 148.18 33.43 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.521 -0.988 . . . . 0.0 109.876 179.397 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.95 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.48 120.19 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.839 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.891 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.7 t -97.89 149.37 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.264 -0.897 . . . . 0.0 110.266 -179.749 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.514 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -118.96 131.36 56.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.398 -0.814 . . . . 0.0 110.396 -179.776 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.388 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 179.869 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.642 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER . . . . . 0 N--CA 1.489 1.504 0 CA-C-O 121.177 0.513 . . . . 0.0 110.757 . . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 7.2 p -132.46 119.66 39.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.305 -0.872 . . . . 0.0 110.148 179.335 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.558 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.87 -44.71 50.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.874 . . . . 0.0 110.151 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.83 158.49 1.64 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.287 -0.883 . . . . 0.0 110.524 -179.967 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.829 HG12 HG13 ' A' ' 296' ' ' VAL . 35.5 mt -118.89 104.85 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.198 -0.939 . . . . 0.0 110.04 179.521 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.03 138.76 43.74 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -0.873 . . . . 0.0 110.325 -179.921 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.33 133.43 42.74 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.229 179.832 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 28.6 tt0 -139.24 108.83 6.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.192 -0.942 . . . . 0.0 110.262 179.985 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.864 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.64 108.62 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.932 -1.105 . . . . 0.0 109.816 179.447 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.527 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 40.45 33.14 0.16 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.688 -0.633 . . . . 0.0 110.474 -179.724 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 115.29 -22.33 12.25 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.842 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.47 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 0.1 OUTLIER -79.77 104.41 10.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.148 -1.207 . . . . 0.0 110.139 179.988 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.2 p -74.5 109.9 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 110.358 -179.775 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.582 ' HB ' HD13 ' A' ' 351' ' ' LEU . 23.0 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.199 179.86 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.298 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.54 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -138.76 164.86 28.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -1.075 . . . . 0.0 110.234 179.958 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.88 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -160.59 133.9 6.7 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.066 -179.703 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.84 ' N ' HD22 ' A' ' 267' ' ' LEU . 3.0 mp0 -131.35 146.72 52.4 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.175 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.824 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -139.99 145.66 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.587 -1.321 . . . . 0.0 111.551 -178.966 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.97 157.59 44.8 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.203 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 279' ' ' GLU . 76.5 t -143.77 147.06 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.413 -1.429 . . . . 0.0 112.18 -179.175 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.541 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.63 111.12 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.594 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -96.29 147.87 23.34 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.982 -1.074 . . . . 0.0 111.179 -179.101 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.836 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.8 p90 -133.05 16.68 4.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.497 -0.752 . . . . 0.0 110.096 179.388 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 92.0 -60.28 2.72 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.694 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.481 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 22.9 t -71.03 -17.73 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -1.178 . . . . 0.0 110.293 -179.864 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.541 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.45 179.4 47.51 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.315 -1.422 . . . . 0.0 110.148 179.926 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.592 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -135.82 140.38 44.18 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.39 -1.065 . . . . 0.0 110.168 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.657 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.5 mt-10 -93.11 147.06 23.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.734 -179.936 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 93.7 m-85 -140.64 87.77 2.15 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.202 -0.937 . . . . 0.0 110.383 -179.615 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.824 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.16 150.05 46.91 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.436 -0.79 . . . . 0.0 109.854 179.573 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.748 HG11 HG11 ' A' ' 294' ' ' VAL . 3.6 t -143.21 90.35 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.409 -0.807 . . . . 0.0 109.87 -179.61 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.855 HG23 ' OG1' ' A' ' 333' ' ' THR . 10.6 m -86.49 122.45 30.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.995 . . . . 0.0 109.6 179.745 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.22 149.95 29.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.205 -0.934 . . . . 0.0 110.801 -179.166 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.916 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -129.67 132.4 46.67 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.281 -0.887 . . . . 0.0 110.324 -179.557 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 1.039 HD13 ' HB2' ' A' ' 290' ' ' TYR . 16.4 mt -142.7 159.88 41.37 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.107 . . . . 0.0 109.859 179.458 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -87.86 32.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 110.154 -179.952 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.504 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 150.97 -134.11 4.56 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 8.7 mm-40 -101.52 106.95 18.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.253 -1.145 . . . . 0.0 110.476 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 1.039 ' HB2' HD13 ' A' ' 286' ' ' LEU . 7.2 m-85 -126.17 130.4 50.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.372 -0.83 . . . . 0.0 109.185 179.588 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.811 ' O ' HG23 ' A' ' 353' ' ' ILE . 24.7 m-20 -68.67 96.93 0.76 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.718 -1.239 . . . . 0.0 109.291 179.576 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.949 ' CE3' HD13 ' A' ' 284' ' ' LEU . 60.7 p-90 -100.51 114.26 27.73 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.139 -0.976 . . . . 0.0 110.776 -179.424 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.718 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.9 m -109.34 114.57 28.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.528 -0.732 . . . . 0.0 109.325 179.495 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.812 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.78 111.6 27.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.075 -1.016 . . . . 0.0 110.752 -179.198 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.634 ' HA ' HD13 ' A' ' 320' ' ' ILE . 32.7 ttpt -91.41 141.03 29.19 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.328 -0.857 . . . . 0.0 109.362 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.647 HG13 HG12 ' A' ' 349' ' ' ILE . 71.8 t -137.54 112.27 9.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.262 -0.899 . . . . 0.0 110.564 -179.311 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.6 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 10.4 mmtp -71.72 131.53 43.25 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.183 -0.948 . . . . 0.0 109.308 179.454 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.985 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.1 mt -83.53 161.45 21.22 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.282 -0.886 . . . . 0.0 111.889 -178.658 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.908 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.16 176.99 0.84 Allowed Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.686 -0.634 . . . . 0.0 109.77 179.354 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.807 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.9 Cg_endo -67.43 80.2 0.43 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.615 1.324 . . . . 0.0 109.79 179.288 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.2 19.88 6.95 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.377 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.908 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -101.33 156.37 17.49 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.365 -1.079 . . . . 0.0 110.351 -179.759 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.985 ' HA ' HD13 ' A' ' 298' ' ' LEU . 74.3 p -156.85 144.19 18.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.92 . . . . 0.0 110.474 179.93 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.755 HG21 HG11 ' A' ' 319' ' ' VAL . 30.1 t -71.1 133.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.353 -0.842 . . . . 0.0 110.123 179.784 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.17 -42.11 0.78 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.706 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.61 136.41 46.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.108 -1.231 . . . . 0.0 110.998 -179.554 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.524 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.9 p90 -149.08 174.99 11.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.413 -0.805 . . . . 0.0 109.693 179.469 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.499 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.57 159.29 21.71 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.041 -1.037 . . . . 0.0 111.136 -179.751 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.555 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 58.57 23.81 11.28 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.561 -0.712 . . . . 0.0 111.077 179.668 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.667 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 140.92 0.61 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 110.262 179.494 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.637 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -79.45 124.64 28.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.022 -1.049 . . . . 0.0 109.053 179.387 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.596 ' CD ' HG11 ' A' ' 304' ' ' VAL . 6.2 ttpt -91.85 133.18 35.88 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.796 0.808 . . . . 0.0 111.199 -179.148 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.532 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.51 175.43 5.57 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.61 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.453 ' HG2' HG22 ' A' ' 319' ' ' VAL . 1.2 mm-40 -135.77 103.6 5.47 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.251 -0.906 . . . . 0.0 110.286 -179.975 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -90.07 47.57 3.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.828 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 m120 51.9 82.62 0.06 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.343 -1.093 . . . . 0.0 110.416 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.29 1.43 60.91 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.797 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -143.32 -168.37 2.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -1.027 . . . . 0.0 109.102 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 318' ' ' TYR . 6.8 t -162.52 158.21 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.325 -0.859 . . . . 0.0 109.832 178.964 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.634 HD13 ' HA ' ' A' ' 295' ' ' LYS . 21.6 mm -127.88 148.44 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.096 -1.003 . . . . 0.0 111.114 -179.717 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.632 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 84.8 m-85 -124.85 127.02 46.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.235 -0.916 . . . . 0.0 109.836 179.116 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.718 ' CG2' HG23 ' A' ' 293' ' ' THR . 3.2 p -126.76 168.77 13.56 Favored Pre-proline 0 C--N 1.301 -1.533 0 C-N-CA 119.068 -1.053 . . . . 0.0 110.307 179.984 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.8 Cg_endo -66.05 116.09 3.81 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.84 1.442 . . . . 0.0 111.056 -179.448 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.637 HG12 ' ND2' ' A' ' 311' ' ' ASN . 16.0 m -63.18 -115.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.335 -0.853 . . . . 0.0 109.839 179.865 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.489 ' N ' HG23 ' A' ' 324' ' ' VAL . 73.6 m -118.18 -13.31 9.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.797 -1.189 . . . . 0.0 110.295 179.933 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.573 ' H ' HG23 ' A' ' 324' ' ' VAL . 18.6 p-90 -127.76 -3.36 5.93 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 0.0 110.411 -179.932 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.608 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.99 41.59 1.32 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.269 -0.894 . . . . 0.0 110.31 -179.72 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.492 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -115.91 -9.26 11.83 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 179.825 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.81 -161.73 0.02 OUTLIER Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.607 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.504 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.5 Cg_endo -74.37 4.77 4.12 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 O-C-N 123.992 1.522 . . . . 0.0 111.097 -179.837 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 6.6 m -163.96 114.99 1.33 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.842 179.741 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.0 127.45 28.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.185 -0.947 . . . . 0.0 110.267 -179.774 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.855 ' OG1' HG23 ' A' ' 283' ' ' THR . 91.3 m -115.3 137.51 51.96 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.915 . . . . 0.0 110.308 -179.95 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.812 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.9 p90 -138.87 174.95 9.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.303 -0.873 . . . . 0.0 109.014 179.568 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.524 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.31 156.87 26.94 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 119.034 -1.555 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.947 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -144.37 149.09 35.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.594 -0.945 . . . . 0.0 109.689 179.445 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.947 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.47 117.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.078 -1.014 . . . . 0.0 109.833 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.759 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -96.77 152.05 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -0.871 . . . . 0.0 110.204 -179.598 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.491 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -122.78 134.59 54.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.409 -0.807 . . . . 0.0 109.88 179.866 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.493 2.453 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 179.951 . . . . . . . . 0 0 . 1 . 036 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.817 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.0 OUTLIER . . . . . 0 N--CA 1.487 1.396 0 CA-C-O 121.427 0.632 . . . . 0.0 110.8 . . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.595 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.9 p -132.55 116.94 29.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.231 -0.918 . . . . 0.0 109.938 179.561 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.529 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -45.3 -46.1 12.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.021 -1.049 . . . . 0.0 110.116 -179.604 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.418 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.3 pt-20 -177.12 158.5 1.52 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 110.473 179.979 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.647 HG12 HG13 ' A' ' 296' ' ' VAL . 27.3 mt -116.32 117.86 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.24 -0.912 . . . . 0.0 110.216 179.677 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.88 145.42 47.67 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.162 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.63 133.67 51.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.015 -1.053 . . . . 0.0 110.679 179.903 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -138.82 112.88 8.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.371 -0.83 . . . . 0.0 109.901 179.617 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.811 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.55 94.04 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.979 -1.075 . . . . 0.0 110.051 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.45 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 50.68 31.23 5.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.699 -0.626 . . . . 0.0 110.704 179.981 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.65 -26.06 6.36 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.683 -1.246 . . . . 0.0 110.45 179.351 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.475 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 41.7 mm-40 -85.92 103.66 14.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.045 -1.267 . . . . 0.0 110.499 -179.576 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.67 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.3 p -73.6 116.47 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.265 -0.897 . . . . 0.0 110.162 179.891 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.491 ' OXT' HG22 ' A' ' 358' ' ' ILE . 36.9 mm . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.24 -179.992 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 2.204 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.554 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.28 163.61 28.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.428 -1.042 . . . . 0.0 109.511 179.628 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.865 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.28 134.73 6.54 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 111.736 -179.611 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.832 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.0 mt-10 -130.38 149.61 51.99 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.975 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.75 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.6 t -141.3 141.23 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.628 -1.295 . . . . 0.0 111.684 -179.306 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -126.81 157.99 37.78 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.908 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.658 HG13 ' O ' ' A' ' 279' ' ' GLU . 89.0 t -144.02 146.39 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.333 -1.479 . . . . 0.0 112.193 -179.325 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.517 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.16 110.87 6.47 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.005 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 46.1 p30 -96.15 147.82 23.35 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.163 -0.961 . . . . 0.0 111.378 -178.493 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.809 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.4 p90 -134.95 23.65 3.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.586 -0.696 . . . . 0.0 109.884 179.42 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.97 -66.96 3.84 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.965 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . 0.54 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 9.2 m -59.85 -26.35 65.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.197 -1.178 . . . . 0.0 110.615 -179.881 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.562 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -170.96 -177.8 41.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.972 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.554 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.22 144.07 42.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.244 -1.15 . . . . 0.0 110.18 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.658 ' O ' HG13 ' A' ' 271' ' ' VAL . 6.3 mt-10 -97.41 147.43 24.22 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.385 -0.822 . . . . 0.0 109.967 -179.523 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.745 ' CE2' HG11 ' A' ' 346' ' ' VAL . 91.1 m-85 -141.43 83.89 1.89 Allowed 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.341 -0.849 . . . . 0.0 110.787 -179.344 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.75 ' O ' HG13 ' A' ' 269' ' ' VAL . 1.8 t70 -64.52 146.98 53.74 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.434 -0.791 . . . . 0.0 109.623 179.144 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.739 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 6.7 t -142.58 89.08 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 -179.647 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.721 HG23 ' OG1' ' A' ' 333' ' ' THR . 97.8 m -86.46 123.5 31.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.203 -0.935 . . . . 0.0 109.756 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.083 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.48 150.47 28.84 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.168 -0.957 . . . . 0.0 110.517 -179.525 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -129.12 135.77 49.32 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 109.958 -179.687 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 11.6 mt -143.18 160.68 39.98 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.075 -1.016 . . . . 0.0 109.481 179.564 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.76 31.76 1.76 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 110.528 -179.598 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.0 -94.6 0.13 Allowed Glycine 0 N--CA 1.491 2.312 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.425 179.876 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.5 tt0 -152.48 106.51 3.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.055 -1.262 . . . . 0.0 110.695 -179.322 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.644 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 5.0 m-85 -128.38 134.85 48.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 179.585 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.579 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 96.7 m-20 -67.34 96.92 0.52 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.846 -1.159 . . . . 0.0 108.754 178.859 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.931 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.5 p-90 -97.68 108.89 21.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.146 -0.971 . . . . 0.0 111.166 -178.862 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.756 HG22 ' CG2' ' A' ' 320' ' ' ILE . 8.6 m -102.18 114.85 29.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.643 -0.661 . . . . 0.0 109.233 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.752 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.5 t -96.71 111.88 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.1 -1.0 . . . . 0.0 111.076 -178.964 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 6.3 ttpt -86.63 149.39 24.95 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.476 -0.765 . . . . 0.0 109.351 179.008 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.899 HG22 HG23 ' A' ' 349' ' ' ILE . 43.4 t -148.67 108.0 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.033 -1.042 . . . . 0.0 110.585 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.561 ' HD2' ' CE1' ' A' ' 318' ' ' TYR . 9.1 mmtm -71.01 134.3 47.02 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.131 -0.981 . . . . 0.0 110.044 179.781 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 0.872 HD13 ' HA ' ' A' ' 303' ' ' THR . 74.9 mt -87.5 165.56 15.42 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.331 -0.855 . . . . 0.0 111.131 -179.37 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -79.73 173.98 6.85 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 178.883 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.4 Cg_endo -66.09 84.52 0.26 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.496 1.261 . . . . 0.0 110.125 179.816 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.11 24.15 4.62 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.62 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.938 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.73 149.29 38.68 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -1.127 . . . . 0.0 110.202 -179.761 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 0.872 ' HA ' HD13 ' A' ' 298' ' ' LEU . 14.1 p -153.96 144.57 22.43 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.664 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.683 HG21 HG11 ' A' ' 319' ' ' VAL . 75.0 t -75.09 135.04 28.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 110.09 179.803 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -128.81 -31.33 0.65 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.707 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.5 m -126.56 109.54 12.25 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.033 -1.275 . . . . 0.0 110.92 -179.555 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.581 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 55.4 p90 -133.44 156.54 47.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.631 179.213 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.491 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -149.32 158.42 44.16 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.966 -1.084 . . . . 0.0 111.201 -179.411 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.522 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 65.46 21.12 11.82 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.741 -0.599 . . . . 0.0 111.279 179.55 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.637 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.97 150.49 1.23 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.231 -0.918 . . . . 0.0 110.516 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.758 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -83.62 119.25 24.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.148 -0.97 . . . . 0.0 108.979 179.134 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.581 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 6.7 ttpt -90.44 131.22 36.33 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.916 0.865 . . . . 0.0 111.407 -178.891 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.622 ' O ' HG22 ' A' ' 319' ' ' VAL . 4.7 mt-30 -112.18 178.69 4.22 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.61 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . 0.561 ' HG2' HG22 ' A' ' 319' ' ' VAL . 7.5 mm-40 -143.78 108.13 4.8 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.458 -0.776 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.44 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -96.53 50.65 1.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 52.48 84.7 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.315 -1.109 . . . . 0.0 110.003 -179.948 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 93.97 -2.28 68.98 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.892 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.626 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -137.19 -179.59 5.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -1.109 . . . . 0.0 109.683 179.665 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.683 HG11 HG21 ' A' ' 304' ' ' VAL . 3.8 t -157.63 155.69 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.444 -0.785 . . . . 0.0 109.421 178.771 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.756 ' CG2' HG22 ' A' ' 293' ' ' THR . 1.9 mt -131.99 140.31 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 111.674 -179.147 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 67.5 m-85 -115.74 130.17 56.75 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 110.384 179.548 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.621 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.4 p -127.97 169.96 11.41 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 120.963 -1.086 . . . . 0.0 109.57 179.657 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.525 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -66.16 126.6 16.03 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.594 1.313 . . . . 0.0 110.915 -179.301 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.885 HG22 ' HB2' ' A' ' 327' ' ' ASN . 35.4 m -77.79 -123.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.826 -179.985 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.583 ' N ' HG23 ' A' ' 324' ' ' VAL . 19.8 m -100.32 -12.98 19.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.766 -1.209 . . . . 0.0 110.586 -179.911 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.693 ' H ' HG23 ' A' ' 324' ' ' VAL . 15.3 p-90 -137.25 5.33 2.74 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.144 -0.972 . . . . 0.0 110.679 -179.887 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.885 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t30 -107.09 43.14 1.2 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.068 -1.02 . . . . 0.0 110.381 -179.639 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.495 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 1.2 pttt -126.82 -5.71 6.28 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.38 -0.825 . . . . 0.0 109.969 179.704 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.0 -156.13 0.03 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 -179.882 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.456 ' O ' ' OG1' ' A' ' 331' ' ' THR . 47.8 Cg_endo -72.23 2.5 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 124.134 1.597 . . . . 0.0 110.964 -179.89 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.9 m -165.4 121.67 1.4 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.257 -0.902 . . . . 0.0 109.946 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.93 107.94 6.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.188 -0.945 . . . . 0.0 110.45 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.721 ' OG1' HG23 ' A' ' 283' ' ' THR . 25.6 m -98.41 142.04 30.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.192 -0.943 . . . . 0.0 109.96 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.752 ' HE2' HG21 ' A' ' 294' ' ' VAL . 7.2 p90 -149.14 169.82 19.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.771 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.553 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.45 151.68 23.84 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.141 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.941 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -136.44 149.46 48.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.563 -0.963 . . . . 0.0 109.83 179.569 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.941 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -122.86 119.34 57.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.144 -0.973 . . . . 0.0 109.529 179.356 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.938 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -95.95 143.74 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.077 -1.014 . . . . 0.0 109.239 179.702 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.07 140.48 50.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.176 -0.953 . . . . 0.0 110.86 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.234 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.817 . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.582 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 121.289 0.566 . . . . 0.0 110.436 . . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.745 HG11 ' CE2' ' A' ' 280' ' ' TYR . 6.2 p -127.61 120.18 53.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.168 -0.957 . . . . 0.0 110.133 179.614 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.551 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 0.8 OUTLIER -48.43 -46.38 37.53 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.074 -1.016 . . . . 0.0 109.717 -179.825 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.409 ' OE1' ' HB3' ' A' ' 347' ' ' GLU . 1.6 pt-20 -176.99 158.59 1.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.351 -0.843 . . . . 0.0 110.429 179.679 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.899 HG23 HG22 ' A' ' 296' ' ' VAL . 11.3 mt -117.07 103.53 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.887 . . . . 0.0 109.793 179.675 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.61 146.45 28.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.292 -0.88 . . . . 0.0 110.306 -179.737 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.083 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -106.62 132.95 52.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.161 -0.962 . . . . 0.0 110.135 179.576 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.4 tt0 -138.53 112.69 8.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.948 179.86 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.532 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.7 mt -91.61 113.17 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.104 -0.997 . . . . 0.0 110.099 179.963 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.579 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.54 29.54 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.752 -0.592 . . . . 0.0 110.918 -179.809 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.84 -13.85 12.91 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.523 179.23 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.514 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 72.7 mm-40 -93.8 113.98 26.14 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.885 -1.362 . . . . 0.0 110.368 -179.836 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.925 ' O ' HD13 ' A' ' 358' ' ' ILE . 2.2 p -74.23 138.35 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.183 179.998 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.925 HD13 ' O ' ' A' ' 357' ' ' VAL . 19.1 mm . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.277 -179.909 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.29 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild core ' A' A ' 266' ' ' SER . . . . . 0.574 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -134.62 165.95 24.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.532 -0.981 . . . . 0.0 109.69 179.866 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 267' ' ' LEU . . . . . 0.906 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.37 139.17 9.19 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.193 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 268' ' ' GLU . . . . . 0.749 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.0 mp0 -138.02 130.38 29.16 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.542 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 269' ' ' VAL . . . . . 0.788 HG13 ' O ' ' A' ' 281' ' ' ASP . 94.9 t -124.32 138.13 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.804 -1.185 . . . . 0.0 111.681 -178.854 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 270' ' ' LYS . . . . . 0.407 ' C ' HG23 ' A' ' 271' ' ' VAL . 20.1 tttt -121.19 157.64 29.78 Favored 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.131 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 271' ' ' VAL . . . . . 0.766 HG22 ' CD1' ' A' ' 280' ' ' TYR . 86.7 t -144.15 147.07 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 120.404 -1.435 . . . . 0.0 112.531 -179.049 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 272' ' ' ASN . . . . . 0.528 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -141.35 109.98 6.04 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.864 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 273' ' ' ASP . . . . . 0.51 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 m-20 -94.82 146.71 24.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.114 -0.991 . . . . 0.0 111.535 -178.718 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 274' ' ' TRP . . . . . 0.807 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.0 p90 -134.67 23.52 3.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.616 -0.678 . . . . 0.0 109.667 179.062 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 82.39 -65.33 4.11 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.932 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.0 -23.99 65.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -1.186 . . . . 0.0 110.354 -179.929 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 277' ' ' GLY . . . . . 0.557 ' O ' ' CD2' ' A' ' 274' ' ' TRP . . . -176.57 176.43 47.87 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 278' ' ' ALA . . . . . 0.562 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -131.36 148.55 52.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.359 -1.083 . . . . 0.0 110.259 -179.879 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 279' ' ' GLU . . . . . 0.666 ' O ' HG13 ' A' ' 271' ' ' VAL . 16.3 mt-10 -97.63 147.07 24.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.513 -0.742 . . . . 0.0 109.683 -179.81 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 280' ' ' TYR . . . . . 0.766 ' CD1' HG22 ' A' ' 271' ' ' VAL . 80.1 m-85 -141.7 85.98 1.97 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.362 -0.836 . . . . 0.0 111.045 -179.242 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 281' ' ' ASP . . . . . 0.788 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -69.22 150.22 47.7 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.389 -0.82 . . . . 0.0 109.54 179.115 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 282' ' ' VAL . . . . . 0.727 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.9 t -143.86 87.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.353 -0.842 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 283' ' ' THR . . . . . 0.794 HG23 ' OG1' ' A' ' 333' ' ' THR . 98.0 m -86.68 123.44 31.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.093 -1.005 . . . . 0.0 109.885 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 284' ' ' LEU . . . . . 1.056 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.4 148.25 30.41 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.201 -0.937 . . . . 0.0 110.062 -179.66 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 285' ' ' ASN . . . . . 0.574 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -129.6 111.98 13.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.221 -0.924 . . . . 0.0 111.134 -178.742 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 286' ' ' LEU . . . . . 0.642 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 10.2 mt -121.47 158.66 27.92 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.809 -1.182 . . . . 0.0 109.407 178.982 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.97 35.62 1.25 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.201 -0.937 . . . . 0.0 110.38 -179.69 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 288' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 163.79 -103.14 0.21 Allowed Glycine 0 N--CA 1.492 2.379 0 C-N-CA 118.879 -1.629 . . . . 0.0 110.561 179.983 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 289' ' ' GLN . . . . . 0.52 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 1.7 mt-30 -148.27 120.45 8.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -1.132 . . . . 0.0 110.411 -179.343 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 290' ' ' TYR . . . . . 0.642 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -151.27 131.29 13.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.826 179.553 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 291' ' ' ASP . . . . . 0.822 ' O ' HG23 ' A' ' 353' ' ' ILE . 4.9 t70 -62.1 103.81 0.41 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.096 -1.002 . . . . 0.0 109.568 179.59 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 292' ' ' TRP . . . . . 0.912 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.9 p-90 -103.0 111.07 23.23 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.291 -0.881 . . . . 0.0 110.49 -179.758 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 293' ' ' THR . . . . . 0.703 HG23 ' CG2' ' A' ' 322' ' ' THR . 25.3 m -105.08 114.71 29.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.776 179.639 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 294' ' ' VAL . . . . . 0.783 HG22 ' CD2' ' A' ' 351' ' ' LEU . 3.1 t -97.07 110.86 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 110.077 -179.732 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 295' ' ' LYS . . . . . 0.439 ' HG3' HD13 ' A' ' 320' ' ' ILE . 21.2 ttmt -86.32 149.4 25.07 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.189 -0.945 . . . . 0.0 109.42 179.148 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 296' ' ' VAL . . . . . 0.734 HG13 HG12 ' A' ' 349' ' ' ILE . 86.3 t -145.6 107.04 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.275 -0.891 . . . . 0.0 110.749 -179.161 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 297' ' ' LYS . . . . . 0.598 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 4.4 mmtt -70.47 136.95 49.88 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.13 -0.981 . . . . 0.0 109.157 179.188 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 298' ' ' LEU . . . . . 1.011 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.8 mt -90.47 157.43 17.57 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.23 -0.919 . . . . 0.0 111.673 -178.573 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 299' ' ' ALA . . . . . 0.804 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.02 175.43 1.01 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.574 -0.704 . . . . 0.0 109.771 179.443 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 300' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -67.25 81.81 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 123.707 1.372 . . . . 0.0 110.049 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.76 19.14 7.5 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.54 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 302' ' ' ALA . . . . . 0.804 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 144.2 34.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.414 -1.051 . . . . 0.0 110.026 -179.812 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 303' ' ' THR . . . . . 1.011 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.4 p -145.09 145.04 31.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.137 -0.977 . . . . 0.0 110.886 -179.985 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 304' ' ' VAL . . . . . 0.801 ' CG2' HG21 ' A' ' 319' ' ' VAL . 75.4 t -70.39 142.41 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.46 -0.775 . . . . 0.0 109.96 179.697 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.65 -40.68 0.2 Allowed Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.663 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 306' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -120.76 118.69 30.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.051 -1.264 . . . . 0.0 110.631 -179.599 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 307' ' ' PHE . . . . . 0.558 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.7 p90 -141.86 156.78 45.52 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.255 -0.903 . . . . 0.0 109.641 179.671 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 308' ' ' TRP . . . . . 0.485 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.83 158.72 42.62 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.087 -1.008 . . . . 0.0 111.188 -179.206 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 309' ' ' SER . . . . . 0.489 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 60.47 25.43 15.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.592 -0.692 . . . . 0.0 110.926 179.611 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 310' ' ' ALA . . . . . 0.61 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.61 142.24 0.71 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.183 -0.948 . . . . 0.0 110.282 179.679 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 311' ' ' ASN . . . . . 0.542 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -77.21 123.74 26.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.115 -0.991 . . . . 0.0 109.296 179.355 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 312' ' ' LYS . . . . . 0.558 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 1.7 ttpt -94.5 123.4 37.9 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.555 0.693 . . . . 0.0 110.95 -179.341 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 313' ' ' GLN . . . . . 0.647 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 2.1 mt-30 -109.65 177.21 4.8 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.549 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -136.28 99.69 4.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.468 -0.77 . . . . 0.0 110.129 179.939 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.58 41.3 3.08 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.777 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 58.31 83.98 0.11 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.155 -1.203 . . . . 0.0 110.158 179.981 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 317' ' ' GLY . . . . . 0.612 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.14 3.99 63.22 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 318' ' ' TYR . . . . . 0.786 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.47 -169.87 3.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.398 -1.06 . . . . 0.0 108.988 179.54 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 319' ' ' VAL . . . . . 0.801 HG21 ' CG2' ' A' ' 304' ' ' VAL . 12.8 t -161.44 149.98 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 0.0 109.843 179.147 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 320' ' ' ILE . . . . . 0.647 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 8.7 mm -114.76 151.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 120.937 -1.102 . . . . 0.0 110.836 -179.946 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.8 m-85 -130.06 115.68 17.45 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.166 -0.959 . . . . 0.0 109.963 178.977 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 322' ' ' THR . . . . . 0.703 ' CG2' HG23 ' A' ' 293' ' ' THR . 24.7 p -122.23 167.0 15.02 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 120.728 -1.232 . . . . 0.0 109.654 179.551 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 323' ' ' PRO . . . . . 0.526 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.1 Cg_endo -64.81 120.05 7.22 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.803 1.423 . . . . 0.0 110.893 -179.362 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 324' ' ' VAL . . . . . 0.658 HG22 ' HB2' ' A' ' 327' ' ' ASN . 28.9 m -63.31 -126.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.498 -0.751 . . . . 0.0 110.149 -179.873 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 325' ' ' SER . . . . . 0.496 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -101.09 -20.78 15.2 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.847 -1.158 . . . . 0.0 110.869 -179.585 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 326' ' ' TRP . . . . . 0.581 ' H ' HG23 ' A' ' 324' ' ' VAL . 23.9 p-90 -124.57 -1.68 7.99 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.998 -1.063 . . . . 0.0 110.699 -179.753 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 327' ' ' ASN . . . . . 0.658 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.7 t30 -104.7 44.52 1.02 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.107 -0.996 . . . . 0.0 110.614 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 328' ' ' LYS . . . . . 0.447 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -126.13 10.86 7.55 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.055 -1.028 . . . . 0.0 109.961 179.704 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 329' ' ' GLY . . . . . 0.452 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -73.89 -143.37 0.73 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.615 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 330' ' ' PRO . . . . . 0.554 ' O ' ' N ' ' A' ' 286' ' ' LEU . 43.7 Cg_endo -72.75 -56.15 0.09 OUTLIER 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.463 . . . . 0.0 109.756 179.602 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 7.2 m -107.94 126.43 52.69 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.177 -0.952 . . . . 0.0 110.204 179.76 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 332' ' ' ALA . . . . . 0.43 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -138.66 109.48 6.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.379 -0.826 . . . . 0.0 109.945 179.902 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 333' ' ' THR . . . . . 0.794 ' OG1' HG23 ' A' ' 283' ' ' THR . 8.8 m -100.81 145.33 28.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.432 -179.715 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 334' ' ' PHE . . . . . 0.727 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 10.1 p90 -151.54 174.92 12.85 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.552 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 335' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.9 165.45 31.13 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 118.838 -1.648 . . . . 0.0 110.518 -179.319 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 336' ' ' PHE . . . . . 0.868 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -152.27 143.58 23.3 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.525 -0.986 . . . . 0.0 109.9 179.634 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 337' ' ' ILE . . . . . 0.868 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -117.76 125.27 74.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.064 -1.022 . . . . 0.0 109.886 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 338' ' ' VAL . . . . . 0.726 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.7 t -101.9 145.47 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.276 -0.89 . . . . 0.0 109.945 179.835 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 339' ' ' ASN . . . . . 0.496 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 1.9 m-80 -113.84 126.76 55.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.344 -0.847 . . . . 0.0 110.098 179.873 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 340' ' ' GLY . . . . . 0.423 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . . . . . . 0 N--CA 1.489 2.22 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.994 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 345' ' ' LYS . . . . . 0.661 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.2 OUTLIER . . . . . 0 N--CA 1.49 1.532 0 CA-C-O 121.126 0.489 . . . . 0.0 110.809 . . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 346' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 346' ' ' VAL . 12.6 p -132.5 116.93 29.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.195 -0.941 . . . . 0.0 110.245 179.632 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 347' ' ' GLU . . . . . 0.483 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -46.65 -45.39 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.895 . . . . 0.0 110.319 -179.937 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 348' ' ' GLU . . . . . 0.431 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 13.9 pt-20 -176.67 158.34 1.69 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.125 -0.984 . . . . 0.0 110.686 -179.781 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 349' ' ' ILE . . . . . 0.734 HG12 HG13 ' A' ' 296' ' ' VAL . 39.8 mt -122.31 105.94 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.121 -0.987 . . . . 0.0 109.918 179.516 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.78 143.92 35.66 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.085 -1.009 . . . . 0.0 110.283 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 351' ' ' LEU . . . . . 1.056 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.6 128.59 53.7 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.194 -0.941 . . . . 0.0 109.953 179.694 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 352' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.3 OUTLIER -138.62 119.26 14.01 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.974 . . . . 0.0 110.123 179.814 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 353' ' ' ILE . . . . . 0.822 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -92.8 109.7 21.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.16 -0.963 . . . . 0.0 110.271 179.934 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 354' ' ' ASN . . . . . 0.526 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.27 46.36 0.88 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.592 . . . . 0.0 111.202 -179.979 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.37 -36.24 4.38 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.385 179.246 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 356' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 38.3 mm-40 -66.88 176.07 2.2 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.012 -1.287 . . . . 0.0 110.311 -179.587 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 357' ' ' VAL . . . . . 0.787 ' O ' HD13 ' A' ' 358' ' ' ILE . 5.6 p -140.65 129.82 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.305 -0.872 . . . . 0.0 109.969 -179.955 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 358' ' ' ILE . . . . . 0.787 HD13 ' O ' ' A' ' 357' ' ' VAL . 8.3 mm . . . . . 0 N--CA 1.494 1.726 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.303 -179.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.305 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -73.19 -178.62 3.71 Favored 'Trans proline' 0 C--N 1.304 -1.771 0 O-C-N 124.017 1.535 . . . . 0.0 110.668 -179.963 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.644 HG23 ' O ' ' A' ' 258' ' ' THR . 9.1 t -60.23 120.21 9.36 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.349 -0.844 . . . . 0.0 110.206 179.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 89.0 m -112.57 134.03 21.72 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 121.224 -0.923 . . . . 0.0 110.179 179.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -72.93 160.21 46.43 Favored 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.928 1.488 . . . . 0.0 110.491 -179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.598 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -105.82 142.83 25.62 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.291 -0.881 . . . . 0.0 110.472 179.984 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.598 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.8 Cg_endo -72.67 146.14 42.83 Favored 'Trans proline' 0 C--N 1.303 -1.835 0 O-C-N 124.122 1.591 . . . . 0.0 110.449 179.73 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.59 HG12 ' O ' ' A' ' 263' ' ' VAL . 40.8 t -139.88 29.82 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.238 -0.914 . . . . 0.0 110.01 179.837 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.4 m 179.32 74.33 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.298 -0.876 . . . . 0.0 110.477 -179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 128.8 174.97 13.88 Favored Glycine 0 N--CA 1.489 2.214 0 C-N-CA 119.77 -1.205 . . . . 0.0 110.122 179.585 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.559 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.78 158.58 44.05 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.473 -1.016 . . . . 0.0 109.699 179.903 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.575 HD12 ' CG ' ' A' ' 351' ' ' LEU . 0.0 OUTLIER -153.02 123.89 7.38 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.08 -1.012 . . . . 0.0 110.749 -179.491 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.473 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 3.3 mt-10 -122.05 113.72 19.93 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.911 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.903 HG13 ' O ' ' A' ' 281' ' ' ASP . 47.5 t -108.11 145.8 14.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 120.957 -1.089 . . . . 0.0 111.734 -178.513 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 5.5 mttp -130.16 156.91 43.8 Favored 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 108.366 -0.975 . . . . 0.0 108.366 179.003 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.646 HG13 ' O ' ' A' ' 279' ' ' GLU . 75.4 t -144.75 139.44 23.22 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.407 -1.433 . . . . 0.0 111.647 -179.799 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.529 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -134.52 110.89 9.66 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 179.174 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.495 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.9 m-20 -98.72 135.42 40.23 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 120.939 -1.101 . . . . 0.0 111.71 -178.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.812 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.6 p90 -119.75 20.15 12.34 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.507 -0.746 . . . . 0.0 109.209 178.919 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.47 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 87.06 -77.97 1.93 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.272 -1.531 . . . . 0.0 109.272 -179.868 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 32.0 m -51.22 -24.63 4.53 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.366 -1.079 . . . . 0.0 110.465 -179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.541 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -165.62 174.28 41.35 Favored Glycine 0 N--CA 1.491 2.327 0 C-N-CA 119.298 -1.429 . . . . 0.0 110.311 -179.855 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.558 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -133.58 141.77 47.83 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.46 -1.024 . . . . 0.0 110.028 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.646 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.3 mt-10 -97.66 146.65 25.12 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.325 -0.859 . . . . 0.0 109.915 -179.886 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 94.4 m-85 -141.84 85.24 1.93 Allowed 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.442 -0.786 . . . . 0.0 110.405 -179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.903 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -69.6 154.21 42.32 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.317 -0.864 . . . . 0.0 109.997 179.498 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.613 HG11 HG11 ' A' ' 294' ' ' VAL . 4.2 t -145.03 89.35 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.692 0 O-C-N 121.629 -0.669 . . . . 0.0 109.506 -179.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.898 HG23 ' OG1' ' A' ' 333' ' ' THR . 10.5 m -86.08 117.48 24.94 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.126 -0.984 . . . . 0.0 109.626 -179.768 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.023 HD21 HD11 ' A' ' 351' ' ' LEU . 0.9 OUTLIER -106.25 144.08 33.45 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.202 -0.936 . . . . 0.0 110.766 -179.07 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.559 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.5 OUTLIER -126.65 115.9 20.18 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.604 -0.685 . . . . 0.0 109.825 -179.653 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.599 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 11.0 mt -124.9 155.21 39.9 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 120.633 -1.292 . . . . 0.0 110.262 -179.676 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 58.5 t0 -89.8 34.87 0.83 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 121.195 -0.94 . . . . 0.0 110.105 -179.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 161.57 -157.44 29.12 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.724 -1.35 . . . . 0.0 109.724 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.518 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.2 OUTLIER -96.42 93.62 6.94 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.3 -1.118 . . . . 0.0 110.706 -179.663 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.599 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.9 m-30 -116.36 143.09 45.99 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.218 -0.926 . . . . 0.0 110.109 179.389 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.825 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.6 m-20 -77.89 98.71 5.72 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.083 -1.011 . . . . 0.0 109.201 179.032 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.844 ' CE3' HD13 ' A' ' 284' ' ' LEU . 54.8 p-90 -98.31 113.32 25.23 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 121.286 -0.884 . . . . 0.0 110.785 -179.206 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.623 HG23 ' CG2' ' A' ' 322' ' ' THR . 10.5 m -105.71 115.58 30.48 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.417 -0.802 . . . . 0.0 109.526 179.575 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.755 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -97.19 113.91 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.101 -0.999 . . . . 0.0 110.49 -179.386 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.585 ' HA ' HD13 ' A' ' 320' ' ' ILE . 9.2 ttpt -92.5 135.09 34.35 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.333 -0.854 . . . . 0.0 109.599 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.758 HG13 HG12 ' A' ' 349' ' ' ILE . 95.0 t -132.26 108.05 13.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.064 -1.023 . . . . 0.0 110.691 -179.316 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.477 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtt -70.0 134.55 48.43 Favored 'General case' 0 C--N 1.305 -1.352 0 O-C-N 121.086 -1.009 . . . . 0.0 109.178 179.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.967 HD13 ' HA ' ' A' ' 303' ' ' THR . 61.5 mt -88.51 162.48 16.41 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.181 -0.95 . . . . 0.0 111.723 -178.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.87 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -64.37 176.77 0.65 Allowed Pre-proline 0 C--N 1.303 -1.416 0 O-C-N 121.779 -0.576 . . . . 0.0 109.877 179.554 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.809 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.82 77.28 0.57 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.657 1.346 . . . . 0.0 109.903 179.558 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.43 19.73 5.71 Favored Glycine 0 N--CA 1.488 2.165 0 N-CA-C 108.787 -1.725 . . . . 0.0 108.787 -179.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.87 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -103.65 150.18 24.24 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.415 -1.05 . . . . 0.0 110.248 -179.763 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.967 ' HA ' HD13 ' A' ' 298' ' ' LEU . 27.0 p -149.92 144.36 25.85 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.267 -0.895 . . . . 0.0 110.642 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.71 HG21 HG11 ' A' ' 319' ' ' VAL . 29.5 t -67.45 136.54 26.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.356 -0.84 . . . . 0.0 109.975 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.8 -41.98 0.54 Allowed Glycine 0 N--CA 1.489 2.205 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.818 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.437 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 1.0 OUTLIER -128.94 129.96 46.14 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.134 -1.215 . . . . 0.0 110.756 -179.659 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.593 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.1 p90 -146.39 169.09 19.57 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.398 -0.814 . . . . 0.0 109.463 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.96 160.98 22.53 Favored 'General case' 0 N--CA 1.496 1.862 0 O-C-N 120.878 -1.139 . . . . 0.0 111.23 -179.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.85 20.99 12.55 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.485 -0.759 . . . . 0.0 111.003 179.433 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.573 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 144.33 0.76 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.355 -0.841 . . . . 0.0 110.05 179.638 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.542 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -78.51 124.44 28.15 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.023 -1.048 . . . . 0.0 109.166 179.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 1.1 ttpt -91.92 138.34 31.62 Favored 'General case' 0 C--N 1.298 -1.659 0 CA-C-O 121.775 0.797 . . . . 0.0 110.916 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.589 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -121.41 173.7 7.21 Favored 'General case' 0 C--N 1.299 -1.597 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 179.003 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.441 ' HG3' ' HE3' ' A' ' 312' ' ' LYS . 2.5 mt-10 -136.35 106.48 6.34 Favored 'General case' 0 N--CA 1.494 1.772 0 O-C-N 121.392 -0.817 . . . . 0.0 110.487 -179.806 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -94.04 40.82 2.69 Favored Glycine 0 N--CA 1.491 2.336 0 N-CA-C 109.586 -1.405 . . . . 0.0 109.586 179.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 25.1 m120 57.43 82.33 0.13 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.249 -1.148 . . . . 0.0 110.195 -179.975 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.623 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.84 0.87 57.46 Favored Glycine 0 N--CA 1.491 2.357 0 N-CA-C 109.629 -1.389 . . . . 0.0 109.629 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.809 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -145.77 -169.62 3.27 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.333 -1.098 . . . . 0.0 109.279 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.809 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.7 t -162.55 157.84 1.98 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.216 -0.928 . . . . 0.0 109.8 179.017 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.585 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.3 mm -126.65 145.91 33.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.156 -0.965 . . . . 0.0 111.086 -179.483 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.637 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.3 m-85 -123.16 128.5 50.14 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.125 -0.984 . . . . 0.0 110.195 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.623 ' CG2' HG23 ' A' ' 293' ' ' THR . 25.0 p -129.58 166.37 26.33 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 120.802 -1.187 . . . . 0.0 109.394 179.442 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.509 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.8 Cg_endo -65.22 121.17 8.55 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.698 1.367 . . . . 0.0 111.132 -179.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.812 HG22 ' HB2' ' A' ' 327' ' ' ASN . 28.5 m -64.39 -125.67 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.626 -0.672 . . . . 0.0 110.182 -179.865 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.482 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.4 m -100.69 -13.12 18.64 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.832 -1.168 . . . . 0.0 110.658 -179.701 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.688 ' H ' HG23 ' A' ' 324' ' ' VAL . 15.9 p-90 -136.35 6.57 3.04 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.139 -0.975 . . . . 0.0 110.6 -179.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.812 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.7 OUTLIER -108.4 38.14 2.31 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.136 -0.977 . . . . 0.0 110.41 -179.665 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.518 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.7 OUTLIER -118.72 -7.69 10.48 Favored 'General case' 0 N--CA 1.495 1.796 0 O-C-N 121.283 -0.886 . . . . 0.0 110.184 179.76 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.474 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.45 -153.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.721 -1.352 . . . . 0.0 109.721 -179.997 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.503 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.4 Cg_endo -76.64 8.34 3.08 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.938 1.494 . . . . 0.0 111.104 -179.881 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.423 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.5 m -163.77 128.08 2.8 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 120.926 -1.109 . . . . 0.0 110.089 -179.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.625 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -146.39 111.33 5.31 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.159 -0.963 . . . . 0.0 110.579 -179.831 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.898 ' OG1' HG23 ' A' ' 283' ' ' THR . 50.2 m -104.41 126.75 51.78 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.232 -0.917 . . . . 0.0 109.925 179.714 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.755 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.8 p90 -137.08 175.38 9.67 Favored 'General case' 0 N--CA 1.487 1.421 0 N-CA-C 108.589 -0.893 . . . . 0.0 108.589 179.759 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -154.98 163.3 31.32 Favored Glycine 0 N--CA 1.486 1.982 0 C-N-CA 118.831 -1.652 . . . . 0.0 109.953 -179.485 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.933 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -147.04 148.34 31.57 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.566 -0.961 . . . . 0.0 109.631 179.527 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.933 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.12 121.05 63.92 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.624 0 O-C-N 120.968 -1.083 . . . . 0.0 109.311 179.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.706 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.0 t -97.09 159.61 3.04 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.178 -0.951 . . . . 0.0 110.683 -179.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.9 m-80 -128.03 129.57 46.9 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.463 -0.773 . . . . 0.0 110.161 179.887 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.478 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . 179.26 -129.64 1.4 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.664 -1.375 . . . . 0.0 109.664 179.961 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.516 ' O ' ' NZ ' ' A' ' 345' ' ' LYS . 43.5 Cg_endo -69.61 171.6 14.01 Favored 'Trans proline' 0 C--N 1.308 -1.584 0 O-C-N 123.891 1.469 . . . . 0.0 110.486 -179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.487 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 16.2 mm-40 -94.56 131.47 40.27 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.236 -0.915 . . . . 0.0 110.854 -179.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 115.93 -87.47 0.44 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.27 -1.532 . . . . 0.0 109.27 179.731 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.482 ' OD1' ' N ' ' A' ' 344' ' ' ASP . 21.8 p-10 -115.62 131.38 56.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.447 -1.031 . . . . 0.0 109.168 179.254 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.715 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.2 mtmt -129.21 10.54 5.82 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 120.959 -1.088 . . . . 0.0 110.475 -179.564 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.593 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.1 p -133.3 120.03 37.66 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.233 -0.917 . . . . 0.0 110.189 179.651 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.436 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -52.5 -45.39 66.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.293 -0.88 . . . . 0.0 110.346 -179.652 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.422 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 5.4 pt-20 -177.09 158.4 1.52 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.049 -1.032 . . . . 0.0 110.905 -179.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.758 HG12 HG13 ' A' ' 296' ' ' VAL . 72.1 mt -120.57 109.33 25.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.333 -0.854 . . . . 0.0 110.093 179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.05 150.97 26.47 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.319 -0.863 . . . . 0.0 110.384 -179.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.023 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.73 126.31 52.45 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.35 -0.844 . . . . 0.0 109.995 179.785 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.451 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.2 tp10 -138.2 110.17 7.24 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.163 -0.961 . . . . 0.0 109.935 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.825 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.27 111.26 23.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.275 -0.891 . . . . 0.0 110.218 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.564 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 39.17 32.35 0.07 Allowed 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.762 -0.586 . . . . 0.0 110.918 179.974 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 114.91 -17.75 17.27 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.637 -1.268 . . . . 0.0 110.351 179.342 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.512 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 56.3 mm-40 -89.49 115.64 27.07 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.019 -1.283 . . . . 0.0 110.366 -179.737 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.837 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.3 p -79.11 130.07 36.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.675 0 O-C-N 121.294 -0.879 . . . . 0.0 110.224 179.969 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.837 HD13 ' O ' ' A' ' 357' ' ' VAL . 18.6 mm . . . . . 0 N--CA 1.491 1.587 0 CA-C-O 117.933 -1.032 . . . . 0.0 110.24 179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.32 0 N-CA-C 109.496 -1.441 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_endo -71.72 -177.74 2.68 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 124.002 1.528 . . . . 0.0 110.762 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 13.3 t -56.9 147.4 23.72 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.489 -0.757 . . . . 0.0 110.693 -179.574 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . 0.488 HG23 ' O ' ' A' ' 259' ' ' THR . 1.8 t -126.14 115.69 23.8 Favored Pre-proline 0 N--CA 1.491 1.621 0 O-C-N 121.34 -0.85 . . . . 0.0 109.82 179.757 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -72.65 149.32 48.75 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 123.902 1.474 . . . . 0.0 110.732 -179.637 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.575 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -79.42 142.67 58.57 Favored Pre-proline 0 N--CA 1.492 1.648 0 O-C-N 121.357 -0.84 . . . . 0.0 110.271 179.905 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.575 ' HD2' HG23 ' A' ' 261' ' ' VAL . 47.3 Cg_endo -73.13 125.48 10.35 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 O-C-N 124.125 1.592 . . . . 0.0 110.514 179.763 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.685 HG12 ' O ' ' A' ' 263' ' ' VAL . 64.4 t -117.39 28.98 2.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.264 -0.897 . . . . 0.0 110.185 179.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.4 96.18 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.34 -0.85 . . . . 0.0 110.264 179.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 102.22 166.3 26.73 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 109.734 -1.347 . . . . 0.0 109.734 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.556 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -126.84 164.83 20.54 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.347 -1.09 . . . . 0.0 109.497 179.59 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.929 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.19 140.52 10.33 Favored 'General case' 0 C--N 1.302 -1.482 0 C-N-CA 119.008 -1.077 . . . . 0.0 111.068 -179.561 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.765 ' H ' HD22 ' A' ' 267' ' ' LEU . 5.2 mt-10 -140.07 134.33 31.2 Favored 'General case' 0 N--CA 1.49 1.536 0 N-CA-C 109.182 -0.674 . . . . 0.0 109.182 179.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.741 HG13 ' O ' ' A' ' 281' ' ' ASP . 60.1 t -125.41 136.86 59.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.494 0 O-C-N 120.807 -1.183 . . . . 0.0 111.648 -178.892 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.51 ' HG3' ' CB ' ' A' ' 281' ' ' ASP . 0.0 OUTLIER -122.96 157.06 33.48 Favored 'General case' 0 N--CA 1.494 1.75 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 178.55 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.746 HG13 ' O ' ' A' ' 279' ' ' GLU . 88.7 t -142.77 146.9 21.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.295 -1.503 . . . . 0.0 112.378 -178.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.523 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.49 113.16 8.5 Favored 'General case' 0 N--CA 1.49 1.57 0 N-CA-C 109.0 -0.741 . . . . 0.0 109.0 178.986 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.461 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.9 p-10 -96.21 147.22 23.99 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.069 -1.02 . . . . 0.0 111.425 -178.683 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.796 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.7 p90 -132.08 20.86 4.48 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.489 -0.757 . . . . 0.0 110.056 179.318 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.92 -59.52 4.53 Favored Glycine 0 N--CA 1.491 2.338 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.723 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -69.04 -24.63 64.21 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.295 -1.121 . . . . 0.0 110.488 -179.823 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.535 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -173.26 178.6 45.15 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.699 -1.36 . . . . 0.0 109.699 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.555 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.75 145.18 49.58 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.217 -1.166 . . . . 0.0 110.528 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.746 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.3 mt-10 -95.83 147.31 23.79 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.612 -0.68 . . . . 0.0 110.04 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.649 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 94.8 m-85 -140.43 86.1 2.05 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.353 -0.842 . . . . 0.0 110.417 -179.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.741 ' O ' HG13 ' A' ' 269' ' ' VAL . 2.7 t70 -68.88 152.9 44.69 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.294 -0.879 . . . . 0.0 109.846 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.658 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.6 t -145.21 90.4 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.552 0 O-C-N 121.579 -0.701 . . . . 0.0 109.938 -179.661 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.691 HG23 ' OG1' ' A' ' 333' ' ' THR . 85.1 m -86.72 126.36 34.52 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.09 -1.007 . . . . 0.0 109.865 179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.056 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.74 151.13 32.37 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.264 -0.897 . . . . 0.0 110.905 -179.105 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.556 ' ND2' ' HB2' ' A' ' 266' ' ' SER . 0.4 OUTLIER -132.43 128.05 36.65 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.381 -0.825 . . . . 0.0 110.543 -179.42 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.643 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 5.6 mt -140.41 156.32 46.42 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.533 -1.355 . . . . 0.0 109.596 179.458 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 53.3 t0 -89.04 39.13 0.92 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.242 -0.911 . . . . 0.0 109.79 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.48 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 157.23 -142.8 8.93 Favored Glycine 0 N--CA 1.493 2.471 0 C-N-CA 119.397 -1.382 . . . . 0.0 109.739 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -112.78 120.96 43.3 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.945 -1.327 . . . . 0.0 110.814 -179.547 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.643 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 10.8 m-85 -142.77 146.81 34.63 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.283 -0.886 . . . . 0.0 109.909 179.481 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.633 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.3 m-20 -75.9 97.33 3.93 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.156 -0.965 . . . . 0.0 109.421 179.287 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.822 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.3 p-90 -98.21 111.59 23.87 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.203 -0.936 . . . . 0.0 110.485 -179.584 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.662 HG22 ' CG2' ' A' ' 320' ' ' ILE . 6.4 m -104.7 115.98 31.25 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.642 -0.661 . . . . 0.0 109.894 -179.918 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.7 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.8 t -97.01 110.89 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.06 -1.025 . . . . 0.0 110.42 -179.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.735 ' HA ' HD13 ' A' ' 320' ' ' ILE . 6.5 ttpt -85.69 144.86 27.58 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.27 -0.893 . . . . 0.0 109.016 178.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.9 HG22 HG23 ' A' ' 349' ' ' ILE . 30.9 t -141.94 109.72 2.2 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 O-C-N 121.151 -0.968 . . . . 0.0 110.779 -179.022 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.51 ' O ' ' N ' ' A' ' 347' ' ' GLU . 22.4 mmtp -72.57 132.01 43.23 Favored 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.212 -0.93 . . . . 0.0 109.476 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.989 HD13 ' HA ' ' A' ' 303' ' ' THR . 67.4 mt -87.31 152.95 21.85 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.108 -0.995 . . . . 0.0 111.695 -179.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.709 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -60.46 173.76 0.58 Allowed Pre-proline 0 N--CA 1.488 1.439 0 O-C-N 121.62 -0.675 . . . . 0.0 109.364 178.989 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.709 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -68.73 84.59 0.5 Allowed 'Trans proline' 0 C--N 1.303 -1.826 0 O-C-N 123.696 1.366 . . . . 0.0 110.038 179.628 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.37 26.44 3.71 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.08 -1.608 . . . . 0.0 109.08 -179.508 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.863 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -120.5 145.98 46.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.248 -1.148 . . . . 0.0 110.601 -179.63 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.989 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.5 p -147.63 145.99 29.18 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.294 -0.879 . . . . 0.0 110.399 179.759 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.667 HG21 HG11 ' A' ' 319' ' ' VAL . 70.4 t -74.46 142.41 14.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.214 -0.929 . . . . 0.0 110.45 -179.84 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.55 -32.96 0.41 Allowed Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.3 m -128.87 127.94 42.84 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.078 -1.248 . . . . 0.0 111.092 -179.654 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.501 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.8 p90 -146.59 160.81 41.69 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.433 -0.792 . . . . 0.0 109.239 179.111 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -150.9 157.42 42.88 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.946 -1.096 . . . . 0.0 110.975 -179.269 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.498 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.6 OUTLIER 58.6 23.6 11.1 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.562 -0.711 . . . . 0.0 110.765 179.708 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.698 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 140.68 0.71 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.369 -0.832 . . . . 0.0 110.088 179.618 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.617 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -78.62 122.4 25.9 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.07 -1.019 . . . . 0.0 109.735 179.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.63 ' HG3' HG11 ' A' ' 304' ' ' VAL . 11.1 ttpt -88.85 144.33 26.29 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.766 0.793 . . . . 0.0 110.847 -179.575 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.772 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -129.7 173.7 10.38 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.39 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.466 ' HG2' HG22 ' A' ' 319' ' ' VAL . 5.3 mt-10 -135.3 103.09 5.38 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.228 -0.92 . . . . 0.0 110.588 -179.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.463 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -89.85 39.09 3.13 Favored Glycine 0 N--CA 1.489 2.219 0 N-CA-C 109.327 -1.509 . . . . 0.0 109.327 179.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.463 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 5.9 m120 58.5 89.42 0.06 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.304 -1.115 . . . . 0.0 110.075 -179.865 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.39 -0.76 75.26 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 109.455 -1.458 . . . . 0.0 109.455 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.833 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -144.56 -167.89 2.76 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.446 -1.032 . . . . 0.0 109.095 179.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.833 HG23 ' O ' ' A' ' 318' ' ' TYR . 2.7 t -163.4 161.64 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.711 0 O-C-N 121.218 -0.926 . . . . 0.0 109.713 179.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.735 HD13 ' HA ' ' A' ' 295' ' ' LYS . 25.2 mm -129.28 151.93 36.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.074 -1.016 . . . . 0.0 110.997 -179.605 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.641 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 73.4 m-85 -128.36 130.67 48.08 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.225 -0.922 . . . . 0.0 109.963 179.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.618 HG23 HG23 ' A' ' 293' ' ' THR . 2.2 p -132.96 168.87 15.78 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.727 -1.233 . . . . 0.0 109.991 179.952 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.51 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.7 Cg_endo -65.55 121.5 8.91 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.813 1.428 . . . . 0.0 110.981 -179.237 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.684 HG22 ' HB2' ' A' ' 327' ' ' ASN . 19.1 m -66.8 -117.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.47 -0.769 . . . . 0.0 110.087 -179.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.507 ' N ' HG23 ' A' ' 324' ' ' VAL . 57.7 m -108.98 -16.46 14.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.814 -1.179 . . . . 0.0 110.339 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.578 ' H ' HG23 ' A' ' 324' ' ' VAL . 10.6 p-90 -125.96 -18.53 5.05 Favored 'General case' 0 N--CA 1.495 1.8 0 O-C-N 121.237 -0.915 . . . . 0.0 110.617 -179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.684 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t30 -87.43 33.21 0.69 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.257 -0.902 . . . . 0.0 110.436 -179.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.96 12.07 22.16 Favored 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.319 -0.863 . . . . 0.0 109.656 179.856 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -84.99 -152.13 16.4 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.564 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 41.4 Cg_endo -68.86 -55.57 0.2 Allowed 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.938 1.494 . . . . 0.0 110.021 179.921 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -102.26 115.22 30.1 Favored 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.418 -0.802 . . . . 0.0 110.415 179.766 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.494 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -134.49 107.83 7.78 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.251 -0.906 . . . . 0.0 110.101 179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.691 ' OG1' HG23 ' A' ' 283' ' ' THR . 97.6 m -103.82 147.64 27.05 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.148 -0.97 . . . . 0.0 110.733 -179.604 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.7 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.8 p90 -152.35 175.06 13.07 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.493 -0.754 . . . . 0.0 109.102 179.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.501 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.7 160.77 28.95 Favored Glycine 0 N--CA 1.493 2.488 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.401 -179.54 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.941 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -147.46 147.4 30.15 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.388 -1.066 . . . . 0.0 110.041 179.633 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.941 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -121.71 123.31 69.08 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.816 0 O-C-N 121.013 -1.054 . . . . 0.0 109.958 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.863 HG11 ' HB1' ' A' ' 302' ' ' ALA . 4.6 t -97.12 154.26 3.7 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 121.191 -0.943 . . . . 0.0 110.199 179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.32 133.38 53.47 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.221 -0.924 . . . . 0.0 110.557 -179.596 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.452 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.18 -132.07 1.87 Allowed Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.204 -1.559 . . . . 0.0 109.204 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.504 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 42.8 Cg_endo -68.86 -158.75 0.05 OUTLIER 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 123.824 1.434 . . . . 0.0 110.298 179.551 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.592 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -122.58 144.72 48.93 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.122 -0.987 . . . . 0.0 110.557 -179.683 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.473 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 97.14 68.25 0.95 Allowed Glycine 0 N--CA 1.49 2.24 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.473 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 3.7 m-20 66.85 140.45 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.41 -1.053 . . . . 0.0 108.966 -179.142 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.574 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.3 OUTLIER -137.92 21.89 2.85 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 120.911 -1.118 . . . . 0.0 111.119 -179.226 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.62 HG21 HG13 ' A' ' 296' ' ' VAL . 9.0 p -127.53 123.87 62.41 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.12 -0.987 . . . . 0.0 110.224 179.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.51 ' N ' ' O ' ' A' ' 297' ' ' LYS . 6.8 mt-10 -55.47 -43.64 75.71 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.241 -0.912 . . . . 0.0 110.223 -179.528 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 1.6 pt-20 -177.09 159.02 1.6 Allowed 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.305 -0.872 . . . . 0.0 110.513 -179.857 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.9 HG23 HG22 ' A' ' 296' ' ' VAL . 45.7 mt -123.13 109.58 23.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.563 0 O-C-N 121.155 -0.965 . . . . 0.0 110.218 179.736 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.78 140.66 43.42 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.32 -0.863 . . . . 0.0 110.143 179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.056 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -101.05 130.86 47.13 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.247 -0.908 . . . . 0.0 110.271 179.995 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 1.3 tp10 -138.86 111.78 7.84 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.169 -0.957 . . . . 0.0 110.115 179.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.633 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 107.82 19.27 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.079 -1.013 . . . . 0.0 110.3 179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.542 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.94 37.56 0.22 Allowed 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.585 -0.697 . . . . 0.0 111.56 179.611 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 106.77 11.12 27.28 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.582 -1.294 . . . . 0.0 110.664 178.866 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 26.4 mm-40 -121.57 101.48 7.63 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.013 -1.286 . . . . 0.0 110.034 179.697 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 1.04 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.9 p -66.56 135.66 28.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.234 -0.916 . . . . 0.0 110.4 -179.723 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 1.04 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.3 mm . . . . . 0 N--CA 1.492 1.673 0 CA-C-O 118.038 -0.982 . . . . 0.0 110.187 179.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.503 -1.439 . . . . 0.0 109.503 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.6 Cg_endo -73.8 -178.26 3.67 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 124.047 1.551 . . . . 0.0 110.505 179.98 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.566 HG23 ' O ' ' A' ' 258' ' ' THR . 7.0 t -60.01 125.29 23.09 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.407 -0.808 . . . . 0.0 110.295 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 8.0 t -62.76 146.3 94.87 Favored Pre-proline 0 N--CA 1.492 1.656 0 O-C-N 121.311 -0.868 . . . . 0.0 110.35 -179.893 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.23 154.63 56.72 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.046 1.551 . . . . 0.0 110.32 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.437 ' H ' HG12 ' A' ' 261' ' ' VAL . 2.8 p -108.76 139.64 21.06 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 121.224 -0.922 . . . . 0.0 110.613 -179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.432 ' HD2' HG23 ' A' ' 261' ' ' VAL . 49.6 Cg_endo -77.33 146.36 24.8 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 124.167 1.614 . . . . 0.0 109.968 179.515 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.607 HG12 ' O ' ' A' ' 263' ' ' VAL . 46.3 t -140.31 29.51 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.169 -0.957 . . . . 0.0 110.433 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.481 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 29.0 t 178.96 76.94 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.202 -0.936 . . . . 0.0 110.7 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 122.84 176.97 15.06 Favored Glycine 0 N--CA 1.492 2.41 0 N-CA-C 110.045 -1.222 . . . . 0.0 110.045 179.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.575 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.61 153.6 51.54 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.504 -0.998 . . . . 0.0 109.473 179.904 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.764 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -147.99 123.56 10.43 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 120.932 -1.105 . . . . 0.0 111.03 -179.451 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.8 OUTLIER -122.36 111.04 16.4 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 108.817 -0.809 . . . . 0.0 108.817 178.902 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.575 HG11 HD12 ' A' ' 349' ' ' ILE . 45.4 t -104.99 124.62 59.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 120.893 -1.129 . . . . 0.0 111.953 -178.722 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.5 tptt -111.89 156.74 21.57 Favored 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 178.193 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.644 HG22 ' CD2' ' A' ' 280' ' ' TYR . 56.9 t -144.84 143.66 22.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 120.341 -1.475 . . . . 0.0 112.148 -179.448 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.544 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -134.52 108.76 8.28 Favored 'General case' 0 N--CA 1.486 1.37 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 179.08 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.491 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 21.0 p30 -96.18 146.78 24.39 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 111.083 -178.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.856 ' CH2' HG23 ' A' ' 337' ' ' ILE . 31.7 p90 -130.38 17.98 5.38 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.412 -0.805 . . . . 0.0 109.958 179.519 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.27 -58.77 3.86 Favored Glycine 0 N--CA 1.49 2.299 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.561 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.9 t -73.18 -19.32 61.13 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.218 -1.166 . . . . 0.0 110.458 -179.722 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.581 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.98 179.44 41.72 Favored Glycine 0 N--CA 1.491 2.303 0 C-N-CA 119.635 -1.269 . . . . 0.0 109.983 -179.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.577 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -138.09 136.6 36.94 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.442 -1.034 . . . . 0.0 109.97 179.868 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.574 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.7 mt-10 -93.84 147.15 23.34 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.378 -0.826 . . . . 0.0 110.478 -179.462 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.832 ' CE2' HG11 ' A' ' 346' ' ' VAL . 92.8 m-85 -139.05 94.96 2.87 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.33 -0.856 . . . . 0.0 110.674 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.543 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.5 OUTLIER -83.5 106.41 15.22 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.538 -0.726 . . . . 0.0 110.271 179.888 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.684 HG11 HG11 ' A' ' 294' ' ' VAL . 5.5 t -97.28 94.28 3.87 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.493 -0.754 . . . . 0.0 110.17 179.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.84 HG23 ' OG1' ' A' ' 333' ' ' THR . 3.8 m -86.95 113.47 22.75 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.172 -0.955 . . . . 0.0 109.815 179.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 0.998 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -102.18 147.94 26.03 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.096 -1.003 . . . . 0.0 110.507 -179.38 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.575 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.36 106.7 7.66 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.516 -0.74 . . . . 0.0 109.636 -179.571 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.603 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.8 mt -113.83 160.75 18.39 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 120.622 -1.299 . . . . 0.0 110.763 -179.667 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 66.1 t0 -89.79 36.64 0.86 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 121.562 -0.711 . . . . 0.0 110.03 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 155.3 -135.25 4.54 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 -179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.473 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.2 mm-40 -120.67 113.41 20.18 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.05 -1.265 . . . . 0.0 110.911 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.603 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.1 m-85 -138.74 148.92 44.47 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.36 -0.838 . . . . 0.0 109.641 179.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.635 ' O ' HG23 ' A' ' 353' ' ' ILE . 5.4 m-20 -75.53 97.9 3.84 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.205 -0.935 . . . . 0.0 109.512 179.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.832 ' CE3' HD13 ' A' ' 284' ' ' LEU . 51.5 p-90 -97.07 110.17 22.77 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.244 -0.91 . . . . 0.0 110.583 -179.621 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.682 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.2 m -102.34 115.21 30.09 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.331 -0.856 . . . . 0.0 109.44 179.742 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.778 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.8 t -97.0 111.09 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.283 -0.886 . . . . 0.0 110.54 -179.294 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.633 ' HA ' HD13 ' A' ' 320' ' ' ILE . 4.5 ttpt -83.15 149.17 27.02 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.356 -0.84 . . . . 0.0 108.966 178.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.688 HG22 HG23 ' A' ' 349' ' ' ILE . 53.7 t -145.75 104.73 0.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.559 0 O-C-N 120.971 -1.081 . . . . 0.0 110.761 -179.36 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.502 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 7.6 mmtt -70.88 131.28 43.53 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.208 -0.933 . . . . 0.0 109.391 179.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.994 HD13 ' HA ' ' A' ' 303' ' ' THR . 70.3 mt -87.12 152.49 22.3 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.257 -0.902 . . . . 0.0 111.507 -179.056 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.765 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -56.47 176.0 0.21 Allowed Pre-proline 0 C--N 1.301 -1.504 0 N-CA-C 109.294 -0.632 . . . . 0.0 109.294 179.081 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.76 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -68.99 79.87 0.69 Allowed 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 123.554 1.292 . . . . 0.0 109.891 179.701 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.19 20.9 5.42 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.482 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.765 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -106.73 149.0 27.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.395 -1.062 . . . . 0.0 109.936 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.994 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.5 p -150.03 144.2 25.64 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.106 -0.997 . . . . 0.0 111.152 -179.912 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.771 HG21 HG11 ' A' ' 319' ' ' VAL . 87.4 t -69.59 129.79 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.321 -0.862 . . . . 0.0 109.928 179.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.25 -28.18 2.91 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.933 -1.267 . . . . 0.0 109.933 -179.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.453 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 6.8 t -144.66 141.4 29.32 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.007 -1.29 . . . . 0.0 110.744 -179.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.517 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.3 p90 -155.54 168.81 25.93 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.403 -0.811 . . . . 0.0 110.053 179.647 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.502 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -158.53 163.72 36.8 Favored 'General case' 0 N--CA 1.495 1.784 0 O-C-N 121.057 -1.027 . . . . 0.0 110.645 -179.757 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.437 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.5 OUTLIER 58.41 21.31 8.27 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.5 -0.75 . . . . 0.0 110.757 179.739 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.683 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 148.84 1.21 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.442 -0.786 . . . . 0.0 110.328 179.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.844 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -86.78 120.12 27.74 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.225 -0.922 . . . . 0.0 109.379 179.423 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.689 ' HG3' HG11 ' A' ' 304' ' ' VAL . 3.6 ttpt -87.63 140.03 29.93 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.892 0.853 . . . . 0.0 110.601 -179.43 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.648 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.5 175.22 7.28 Favored 'General case' 0 C--N 1.298 -1.645 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.351 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -134.84 116.55 14.92 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.313 -0.867 . . . . 0.0 110.316 179.992 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.448 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -109.93 39.25 2.97 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.364 -1.494 . . . . 0.0 109.364 179.894 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.448 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 1.4 t30 66.23 90.92 0.09 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.29 -1.123 . . . . 0.0 110.286 179.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 81.53 3.31 90.66 Favored Glycine 0 N--CA 1.49 2.252 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.836 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.9 m-85 -141.52 -172.67 3.58 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.271 -1.135 . . . . 0.0 109.544 179.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.836 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.5 t -163.38 157.85 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.76 0 O-C-N 121.212 -0.93 . . . . 0.0 109.775 179.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.648 ' CG2' HG22 ' A' ' 293' ' ' THR . 17.4 mm -125.98 144.44 36.09 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.012 -1.055 . . . . 0.0 111.474 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 56.9 m-85 -121.18 129.33 53.18 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.005 -1.059 . . . . 0.0 109.93 178.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.682 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.9 p -129.94 168.52 16.29 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 120.864 -1.148 . . . . 0.0 110.192 179.777 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.53 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.2 Cg_endo -65.95 117.09 4.36 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.76 1.4 . . . . 0.0 111.029 -179.54 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.844 HG12 ' ND2' ' A' ' 311' ' ' ASN . 25.4 m -64.29 -120.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.396 -0.815 . . . . 0.0 110.041 179.875 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.501 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -104.44 -15.88 15.26 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.776 -1.202 . . . . 0.0 110.665 -179.849 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.599 ' H ' HG23 ' A' ' 324' ' ' VAL . 5.3 p-90 -131.11 -6.85 3.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.132 -0.98 . . . . 0.0 110.822 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.831 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 1.6 t-20 -90.96 38.67 0.96 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.063 -1.023 . . . . 0.0 110.115 179.915 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.483 ' HE2' ' O ' ' A' ' 325' ' ' SER . 5.5 pttt -121.26 4.99 10.27 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.06 -1.025 . . . . 0.0 110.332 -179.913 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -69.16 -156.38 1.12 Allowed Glycine 0 N--CA 1.49 2.252 0 N-CA-C 108.836 -1.706 . . . . 0.0 108.836 179.406 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 50.5 Cg_endo -76.72 7.16 3.66 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 123.77 1.405 . . . . 0.0 110.55 179.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.415 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 19.5 m -164.2 128.25 2.64 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.288 -0.882 . . . . 0.0 109.725 -179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.831 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -143.89 108.63 4.9 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.207 -0.933 . . . . 0.0 110.319 -179.74 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.84 ' OG1' HG23 ' A' ' 283' ' ' THR . 89.8 m -100.77 117.54 35.07 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.309 -0.87 . . . . 0.0 109.953 179.683 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.778 ' HE2' HG21 ' A' ' 294' ' ' VAL . 7.9 p90 -124.49 171.96 9.56 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 179.509 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.517 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.34 158.04 27.5 Favored Glycine 0 N--CA 1.486 1.986 0 C-N-CA 118.945 -1.597 . . . . 0.0 109.951 -179.326 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -145.89 146.13 30.98 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.633 -0.922 . . . . 0.0 109.186 179.384 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.23 120.23 63.15 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.61 0 C-N-CA 119.192 -1.003 . . . . 0.0 109.684 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.725 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.8 t -95.78 147.84 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.195 -0.941 . . . . 0.0 109.576 -179.914 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -118.6 134.69 54.91 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.384 -0.822 . . . . 0.0 110.617 -179.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.426 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -179.53 -137.91 3.13 Favored Glycine 0 N--CA 1.489 2.172 0 N-CA-C 108.994 -1.642 . . . . 0.0 108.994 179.943 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.517 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 44.4 Cg_endo -71.44 -158.28 0.06 OUTLIER 'Trans proline' 0 C--N 1.304 -1.788 0 O-C-N 123.982 1.517 . . . . 0.0 110.142 179.483 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.48 ' NE2' ' HA ' ' A' ' 341' ' ' PRO . 10.7 mp0 -118.92 144.55 46.37 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.034 -1.041 . . . . 0.0 110.456 -179.898 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.439 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 100.31 65.76 0.81 Allowed Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.172 -1.571 . . . . 0.0 109.172 -179.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.439 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 10.5 t70 65.77 134.93 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.282 -1.128 . . . . 0.0 109.593 -179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.65 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.6 OUTLIER -133.05 25.17 4.25 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.23 -0.919 . . . . 0.0 110.685 -179.516 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.832 HG11 ' CE2' ' A' ' 280' ' ' TYR . 4.2 p -132.78 116.5 27.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.028 -1.045 . . . . 0.0 110.831 179.979 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.502 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -44.67 -50.08 10.06 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.912 -1.117 . . . . 0.0 109.533 179.787 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 6.2 pt-20 -177.48 158.06 1.36 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.382 -0.824 . . . . 0.0 110.482 179.648 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.688 HG23 HG22 ' A' ' 296' ' ' VAL . 14.4 mt -117.15 111.62 35.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.255 -0.903 . . . . 0.0 110.076 179.567 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.69 151.65 24.82 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.285 -0.885 . . . . 0.0 110.376 -179.772 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 0.998 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -110.27 125.71 53.41 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.321 -0.862 . . . . 0.0 109.812 179.604 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.426 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.5 tt0 -137.26 111.41 8.41 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.184 -0.948 . . . . 0.0 109.832 179.84 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.635 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -92.02 109.97 22.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.187 -0.945 . . . . 0.0 110.521 -179.766 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.528 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 38.36 31.22 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.546 -0.721 . . . . 0.0 111.061 179.457 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.427 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.48 -10.04 16.9 Favored Glycine 0 N--CA 1.492 2.406 0 N-CA-C 110.097 -1.201 . . . . 0.0 110.097 179.563 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.444 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.0 mp0 -97.16 108.4 21.12 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.061 -1.258 . . . . 0.0 110.214 -179.976 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.627 HG13 ' O ' ' A' ' 357' ' ' VAL . 7.3 p -76.58 110.42 12.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.335 -0.853 . . . . 0.0 110.249 -179.954 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.736 ' HB ' HD13 ' A' ' 351' ' ' LEU . 24.2 mm . . . . . 0 N--CA 1.49 1.568 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.146 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.318 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.77 -177.57 3.22 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.989 1.52 . . . . 0.0 110.859 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.518 ' CG2' ' O ' ' A' ' 258' ' ' THR . 2.0 t -83.6 123.27 29.61 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.511 -0.743 . . . . 0.0 110.502 -179.754 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 21.6 p -119.94 101.59 47.53 Favored Pre-proline 0 N--CA 1.491 1.59 0 O-C-N 121.227 -0.921 . . . . 0.0 110.068 179.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.99 143.03 35.66 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.918 1.483 . . . . 0.0 110.512 -179.957 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.61 HG23 ' HD2' ' A' ' 262' ' ' PRO . 6.7 p -66.03 143.84 98.57 Favored Pre-proline 0 N--CA 1.494 1.736 0 O-C-N 121.18 -0.95 . . . . 0.0 110.226 -179.849 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.811 ' HB2' HG23 ' A' ' 358' ' ' ILE . 50.9 Cg_endo -79.01 149.4 22.56 Favored 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 124.153 1.607 . . . . 0.0 110.398 179.966 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 3.5 t -115.74 28.38 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 121.226 -0.921 . . . . 0.0 109.992 179.731 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER 179.44 97.69 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.268 -0.895 . . . . 0.0 110.465 -179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 103.5 173.89 25.98 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.57 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -136.88 157.11 47.5 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.477 -1.013 . . . . 0.0 109.535 179.863 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.813 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.56 124.38 10.57 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 120.943 -1.098 . . . . 0.0 110.989 -179.51 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.482 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 1.4 mm-40 -121.38 113.32 19.73 Favored 'General case' 0 N--CA 1.492 1.627 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 179.019 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.736 HG13 ' O ' ' A' ' 281' ' ' ASP . 38.4 t -109.44 139.67 31.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.88 -1.137 . . . . 0.0 111.668 -178.808 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.421 ' C ' HG23 ' A' ' 271' ' ' VAL . 4.2 mmtm -123.83 156.58 35.92 Favored 'General case' 0 N--CA 1.491 1.621 0 N-CA-C 108.595 -0.891 . . . . 0.0 108.595 178.717 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.595 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.3 t -145.19 144.7 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.462 -1.399 . . . . 0.0 112.092 -179.372 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.14 112.21 6.61 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 179.315 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.7 p-10 -97.03 144.82 26.54 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.047 -1.033 . . . . 0.0 111.297 -178.917 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.5 p90 -129.82 18.62 5.63 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.399 -0.813 . . . . 0.0 109.786 179.306 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.507 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 87.58 -61.92 4.09 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.458 -1.457 . . . . 0.0 109.458 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -64.67 -23.79 67.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.231 -1.158 . . . . 0.0 110.224 179.948 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.82 177.68 46.02 Favored Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.719 -1.352 . . . . 0.0 109.719 179.923 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.603 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -130.58 146.6 52.13 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.329 -1.101 . . . . 0.0 110.201 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.595 ' O ' HG13 ' A' ' 271' ' ' VAL . 6.2 mt-10 -98.0 147.32 24.62 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.514 -0.741 . . . . 0.0 109.942 -179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 95.2 m-85 -144.28 86.37 1.83 Allowed 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.233 -0.917 . . . . 0.0 110.999 -179.387 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.736 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.1 OUTLIER -71.17 153.5 42.45 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.403 -0.811 . . . . 0.0 109.88 179.376 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.646 HG11 HG11 ' A' ' 294' ' ' VAL . 3.5 t -144.82 88.09 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.42 -0.8 . . . . 0.0 109.615 -179.851 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.79 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.5 m -86.03 114.92 23.29 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.683 -179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.018 HD21 HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -101.73 145.57 28.94 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.259 -0.901 . . . . 0.0 110.736 -179.16 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.57 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -129.67 106.86 9.0 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.391 -0.818 . . . . 0.0 110.093 -179.458 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.572 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 7.6 mt -116.62 164.34 14.75 Favored 'General case' 0 C--N 1.299 -1.591 0 O-C-N 120.648 -1.283 . . . . 0.0 110.299 179.86 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -94.04 34.59 1.23 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.402 -0.811 . . . . 0.0 110.458 -179.675 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.449 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 157.11 -137.52 5.44 Favored Glycine 0 N--CA 1.492 2.374 0 C-N-CA 119.434 -1.365 . . . . 0.0 109.876 -179.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.484 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mm-40 -113.84 108.26 16.83 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.184 -1.186 . . . . 0.0 111.391 -179.341 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.572 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.26 135.27 40.77 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.301 -0.874 . . . . 0.0 109.67 178.538 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.556 ' HB2' ' ND2' ' A' ' 354' ' ' ASN . 4.5 m-20 -64.88 97.02 0.2 Allowed 'General case' 0 C--N 1.299 -1.602 0 O-C-N 121.05 -1.032 . . . . 0.0 109.402 179.207 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.862 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.3 p-90 -95.07 108.07 20.14 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.279 -0.888 . . . . 0.0 110.494 -179.652 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.596 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 32.4 m -101.67 115.48 30.61 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.285 -0.884 . . . . 0.0 109.439 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.782 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -96.72 111.54 26.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.092 -1.005 . . . . 0.0 110.925 -179.043 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.644 ' HA ' HD13 ' A' ' 320' ' ' ILE . 7.9 ttpt -82.01 149.84 27.92 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.359 -0.838 . . . . 0.0 109.264 178.949 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.822 HG13 HG12 ' A' ' 349' ' ' ILE . 88.7 t -149.02 104.77 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.951 -1.093 . . . . 0.0 110.719 -179.565 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.521 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 18.9 mmtp -70.35 128.54 36.56 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.223 -0.923 . . . . 0.0 109.658 179.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.956 HD13 ' HA ' ' A' ' 303' ' ' THR . 85.5 mt -84.06 165.81 18.24 Favored 'General case' 0 N--CA 1.492 1.637 0 CA-C-O 121.763 0.792 . . . . 0.0 111.377 -179.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.788 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -74.33 175.81 3.47 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.623 -0.673 . . . . 0.0 109.726 179.411 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.788 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.5 Cg_endo -67.24 83.2 0.36 Allowed 'Trans proline' 0 C--N 1.304 -1.786 0 O-C-N 123.598 1.315 . . . . 0.0 109.84 179.421 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 110.99 22.72 6.12 Favored Glycine 0 N--CA 1.487 2.035 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 -179.344 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.879 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -112.14 144.17 41.96 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.355 -1.085 . . . . 0.0 110.13 -179.744 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.956 ' HA ' HD13 ' A' ' 298' ' ' LEU . 13.0 p -147.06 145.18 29.58 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.294 -0.879 . . . . 0.0 110.332 179.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.855 HG21 HG11 ' A' ' 319' ' ' VAL . 71.4 t -64.97 120.94 13.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.38 -0.825 . . . . 0.0 110.11 179.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.29 -38.6 3.48 Favored Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.739 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.509 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 24.9 m -139.03 144.25 38.77 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.144 -1.209 . . . . 0.0 110.781 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.549 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 5.6 p90 -155.02 160.34 40.98 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.466 -0.771 . . . . 0.0 109.463 179.553 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.432 ' C ' ' OG ' ' A' ' 309' ' ' SER . 1.0 OUTLIER -151.04 152.87 34.08 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 120.923 -1.111 . . . . 0.0 111.491 -179.754 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.522 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.9 OUTLIER 67.24 24.19 9.2 Favored 'General case' 0 N--CA 1.495 1.804 0 O-C-N 121.663 -0.648 . . . . 0.0 111.054 179.6 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.673 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.27 143.41 0.87 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.276 -0.89 . . . . 0.0 110.138 179.56 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.819 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -82.37 122.9 28.58 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.15 -0.969 . . . . 0.0 109.182 179.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.602 ' HG3' HG11 ' A' ' 304' ' ' VAL . 3.1 ttmt -88.7 148.09 24.17 Favored 'General case' 0 N--CA 1.492 1.674 0 CA-C-O 121.861 0.839 . . . . 0.0 111.05 -178.957 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.733 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.74 171.85 13.0 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 179.36 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 32.4 mt-10 -132.96 109.7 9.75 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.179 -0.95 . . . . 0.0 110.345 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.73 39.81 2.62 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.489 -1.445 . . . . 0.0 109.489 179.867 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.405 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 8.4 t-20 60.86 92.25 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.346 -1.091 . . . . 0.0 110.474 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.3 2.27 87.76 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 109.73 -1.348 . . . . 0.0 109.73 179.764 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.823 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.1 m-85 -145.81 -169.48 3.24 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.339 -1.095 . . . . 0.0 109.27 179.48 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.855 HG11 HG21 ' A' ' 304' ' ' VAL . 2.8 t -163.44 161.92 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.718 0 O-C-N 121.26 -0.9 . . . . 0.0 109.506 179.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.644 HD13 ' HA ' ' A' ' 295' ' ' LYS . 5.5 mm -130.19 143.57 40.62 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.174 -0.954 . . . . 0.0 111.084 -179.506 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.652 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 98.6 m-85 -118.61 136.79 53.69 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.198 -0.938 . . . . 0.0 109.515 179.23 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.549 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 1.5 p -135.3 168.88 15.47 Favored Pre-proline 0 C--N 1.301 -1.527 0 O-C-N 120.844 -1.16 . . . . 0.0 110.303 -179.729 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.557 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 40.5 Cg_endo -67.03 121.09 8.21 Favored 'Trans proline' 0 C--N 1.306 -1.677 0 O-C-N 124.127 1.593 . . . . 0.0 110.85 -179.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.877 HG22 ' HB2' ' A' ' 327' ' ' ASN . 27.0 m -73.22 -129.37 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.459 -0.776 . . . . 0.0 109.845 179.77 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.606 ' N ' HG23 ' A' ' 324' ' ' VAL . 18.1 p -100.17 -19.15 16.57 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.904 -1.122 . . . . 0.0 110.346 179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.758 ' H ' HG23 ' A' ' 324' ' ' VAL . 23.7 p-90 -125.96 11.08 7.68 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.108 -0.995 . . . . 0.0 110.507 179.773 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.877 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -117.63 49.58 1.21 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.073 -1.017 . . . . 0.0 110.254 -179.906 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.557 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -125.57 -12.47 6.66 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.316 -0.865 . . . . 0.0 110.134 -179.902 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.09 -160.95 0.02 OUTLIER Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 -179.789 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.9 Cg_endo -73.4 3.53 4.66 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 123.905 1.477 . . . . 0.0 110.872 -179.82 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -157.97 117.67 3.28 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.171 -0.955 . . . . 0.0 110.088 -179.969 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.565 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.03 108.6 5.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.253 -0.904 . . . . 0.0 110.077 179.932 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.79 ' OG1' HG23 ' A' ' 283' ' ' THR . 60.7 m -99.81 138.63 36.62 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.287 -0.883 . . . . 0.0 110.449 -179.893 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.782 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.9 p90 -145.92 157.36 43.9 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.755 -0.832 . . . . 0.0 108.755 179.554 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -134.33 164.27 24.57 Favored Glycine 0 N--CA 1.489 2.228 0 C-N-CA 119.043 -1.551 . . . . 0.0 110.088 -179.448 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.878 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -149.74 143.4 25.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.483 -1.01 . . . . 0.0 109.469 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.878 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -117.16 120.55 65.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.115 -0.991 . . . . 0.0 109.689 179.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.879 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.6 t -96.79 149.93 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.203 -0.936 . . . . 0.0 109.817 -179.836 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.455 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -121.77 131.54 54.12 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.16 -0.963 . . . . 0.0 111.061 -179.167 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.54 -120.79 0.73 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 108.554 -1.818 . . . . 0.0 108.554 179.742 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.52 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 41.4 Cg_endo -68.01 -151.7 0.03 OUTLIER 'Trans proline' 0 C--N 1.306 -1.71 0 O-C-N 123.819 1.431 . . . . 0.0 109.61 178.792 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.507 ' HB3' ' HA2' ' A' ' 275' ' ' GLY . 0.0 OUTLIER -134.17 139.99 46.23 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 120.737 -1.227 . . . . 0.0 110.731 -179.79 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 100.78 -79.73 0.44 Allowed Glycine 0 N--CA 1.492 2.417 0 N-CA-C 108.884 -1.686 . . . . 0.0 108.884 -179.857 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -115.81 119.85 37.35 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.476 -1.014 . . . . 0.0 109.118 179.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.69 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.4 OUTLIER -124.03 10.99 8.86 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.084 -1.01 . . . . 0.0 110.24 -179.49 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.58 HG13 ' O ' ' A' ' 346' ' ' VAL . 10.7 p -133.84 116.73 24.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 O-C-N 121.399 -0.813 . . . . 0.0 110.002 179.657 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 1.5 mt-10 -47.16 -47.1 23.91 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.174 -0.954 . . . . 0.0 110.164 -179.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -177.01 158.92 1.61 Allowed 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.302 -0.874 . . . . 0.0 110.401 -179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.822 HG12 HG13 ' A' ' 296' ' ' VAL . 26.4 mt -118.2 119.42 61.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.23 -0.919 . . . . 0.0 110.101 179.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.49 151.33 33.45 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.301 -0.874 . . . . 0.0 110.267 -179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.018 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -108.96 126.83 53.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.252 -0.905 . . . . 0.0 109.725 179.661 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.444 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.5 tp10 -138.19 113.11 9.11 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.077 -1.014 . . . . 0.0 110.373 -179.934 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.537 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -93.07 103.66 14.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.183 -0.948 . . . . 0.0 110.003 179.725 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.556 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 43.55 30.55 0.35 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.459 -0.775 . . . . 0.0 110.46 -179.85 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 117.63 -22.65 9.95 Favored Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.789 -1.324 . . . . 0.0 109.789 179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.445 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 1.0 OUTLIER -82.41 99.58 9.5 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.147 -1.208 . . . . 0.0 110.127 -179.918 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.686 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.4 p -69.96 113.76 6.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.246 -0.909 . . . . 0.0 110.173 -179.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.811 HG23 ' HB2' ' A' ' 262' ' ' PRO . 25.9 mm . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 117.997 -1.002 . . . . 0.0 110.119 179.895 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.248 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -72.74 179.37 5.3 Favored 'Trans proline' 0 C--N 1.304 -1.78 0 O-C-N 124.035 1.545 . . . . 0.0 110.629 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 5.4 t -58.71 146.39 36.78 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.264 -0.897 . . . . 0.0 110.191 179.926 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -88.37 168.7 15.5 Favored Pre-proline 0 N--CA 1.492 1.665 0 O-C-N 121.244 -0.91 . . . . 0.0 110.13 179.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.2 Cg_endo -72.88 133.9 20.79 Favored 'Trans proline' 0 C--N 1.307 -1.658 0 O-C-N 123.993 1.523 . . . . 0.0 110.371 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.636 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.5 p -79.16 144.85 63.64 Favored Pre-proline 0 N--CA 1.491 1.58 0 O-C-N 121.285 -0.885 . . . . 0.0 110.337 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.636 ' HD2' HG23 ' A' ' 261' ' ' VAL . 49.4 Cg_endo -76.11 151.04 34.24 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 124.094 1.576 . . . . 0.0 110.671 179.901 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.744 HG12 ' O ' ' A' ' 263' ' ' VAL . 68.7 t -130.54 25.43 1.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.341 -0.849 . . . . 0.0 109.884 179.618 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.498 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.4 OUTLIER 168.49 55.43 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.184 -0.947 . . . . 0.0 110.449 179.922 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 158.94 165.28 15.7 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.859 -1.296 . . . . 0.0 109.859 179.724 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.585 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -130.81 150.54 51.94 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.4 -1.059 . . . . 0.0 109.978 179.924 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.873 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -145.2 125.87 14.22 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.036 -1.04 . . . . 0.0 110.781 -179.676 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.488 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 15.0 mm-40 -124.51 110.99 15.17 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.491 -0.756 . . . . 0.0 108.996 179.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.936 HG13 ' O ' ' A' ' 281' ' ' ASP . 85.6 t -110.53 145.19 17.25 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 120.942 -1.098 . . . . 0.0 111.827 -178.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -130.86 157.74 42.07 Favored 'General case' 0 N--CA 1.494 1.767 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 179.136 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.81 HG13 ' O ' ' A' ' 279' ' ' GLU . 97.5 t -141.69 146.75 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 120.237 -1.539 . . . . 0.0 112.454 -179.289 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.02 110.28 6.91 Favored 'General case' 0 N--CA 1.488 1.469 0 N-CA-C 108.65 -0.87 . . . . 0.0 108.65 179.11 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 43.8 p-10 -95.68 145.36 25.34 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.062 -1.024 . . . . 0.0 111.379 -178.743 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.835 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.4 p90 -130.95 22.77 4.93 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.36 -0.837 . . . . 0.0 109.858 179.088 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.456 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 85.81 -68.82 3.32 Favored Glycine 0 N--CA 1.488 2.147 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.811 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.482 ' HG ' ' HE1' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -61.22 -27.41 68.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.253 -1.145 . . . . 0.0 110.685 -179.605 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.533 ' C ' ' CE2' ' A' ' 274' ' ' TRP . . . -166.3 178.52 40.8 Favored Glycine 0 N--CA 1.493 2.473 0 C-N-CA 119.465 -1.35 . . . . 0.0 110.092 -179.865 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.568 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.72 145.28 48.33 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.275 -1.132 . . . . 0.0 110.512 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.81 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -97.22 147.17 24.38 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 109.973 -179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.657 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 88.5 m-85 -142.08 83.77 1.85 Allowed 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.274 -0.891 . . . . 0.0 110.523 -179.551 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.936 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.14 153.19 44.27 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.289 -0.882 . . . . 0.0 110.123 179.551 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 294' ' ' VAL . 5.4 t -144.87 90.36 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.531 -0.73 . . . . 0.0 109.667 -179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.832 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.5 m -86.28 123.66 31.79 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.134 -0.979 . . . . 0.0 109.362 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.082 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -109.71 148.26 31.71 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.072 -1.017 . . . . 0.0 111.28 -178.85 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.585 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.33 107.37 7.59 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.607 -0.683 . . . . 0.0 109.975 -179.45 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.534 ' N ' ' O ' ' A' ' 330' ' ' PRO . 9.7 mt -115.53 163.27 16.0 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.897 -1.127 . . . . 0.0 109.805 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . 0.469 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 2.1 t0 -91.64 31.28 1.21 Allowed 'General case' 0 C--N 1.3 -1.586 0 O-C-N 121.285 -0.884 . . . . 0.0 110.552 -179.293 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.54 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 163.76 -164.33 36.31 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.714 -1.355 . . . . 0.0 109.714 179.831 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.545 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -93.76 94.87 8.79 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.176 -1.19 . . . . 0.0 110.599 -179.738 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.545 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 1.9 m-85 -120.96 171.44 8.64 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.181 -0.95 . . . . 0.0 109.793 179.806 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.834 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.2 OUTLIER -95.78 99.34 11.18 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.162 -0.961 . . . . 0.0 109.655 179.392 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.905 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.1 p-90 -97.29 113.99 25.69 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.309 -0.869 . . . . 0.0 110.624 -179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.576 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 99.1 m -106.75 113.38 26.84 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.464 -0.773 . . . . 0.0 109.176 179.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 282' ' ' VAL . 4.6 t -96.37 110.81 25.31 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.184 -0.948 . . . . 0.0 110.137 -179.362 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.517 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 6.4 ttmt -84.77 149.07 26.0 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.208 -0.933 . . . . 0.0 109.197 179.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.857 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 45.9 t -144.63 106.31 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.717 0 O-C-N 121.403 -0.811 . . . . 0.0 109.93 -179.34 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.513 ' O ' HG23 ' A' ' 346' ' ' VAL . 34.9 mmtt -71.1 134.69 47.21 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.114 -0.991 . . . . 0.0 109.704 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.906 HD13 ' HA ' ' A' ' 303' ' ' THR . 92.7 mt -87.59 162.57 17.09 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.316 -0.865 . . . . 0.0 111.569 -179.083 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.661 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -75.65 171.57 11.59 Favored Pre-proline 0 N--CA 1.487 1.399 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 178.723 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.661 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.4 84.61 0.47 Allowed 'Trans proline' 0 C--N 1.301 -1.945 0 O-C-N 123.684 1.36 . . . . 0.0 109.798 179.515 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . 0.442 ' O ' ' HA3' ' A' ' 340' ' ' GLY . . . 116.26 26.02 3.33 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.815 -1.714 . . . . 0.0 108.815 -179.434 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 1.024 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -126.51 138.26 53.47 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.263 -1.139 . . . . 0.0 110.257 -179.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.906 ' HA ' HD13 ' A' ' 298' ' ' LEU . 7.2 p -141.43 145.83 35.78 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.22 -0.925 . . . . 0.0 110.419 179.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.749 ' CG2' HG21 ' A' ' 319' ' ' VAL . 98.2 t -71.82 124.28 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.366 -0.834 . . . . 0.0 110.225 179.998 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.4 -34.84 1.26 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 -179.698 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.433 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 2.7 m -122.45 110.15 15.26 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.025 -1.28 . . . . 0.0 110.716 -179.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.602 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 11.9 p90 -134.23 153.92 51.57 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.33 -0.856 . . . . 0.0 109.788 179.504 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.475 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -149.19 161.37 42.13 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.05 -1.031 . . . . 0.0 111.155 -179.35 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.545 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.23 28.71 15.54 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.542 -0.723 . . . . 0.0 111.224 179.454 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.711 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.9 145.44 0.66 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.038 -1.039 . . . . 0.0 110.553 179.549 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.497 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 2.1 m-80 -78.13 118.74 20.66 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.103 -0.998 . . . . 0.0 109.238 178.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.602 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 19.9 ttpt -92.2 115.7 28.31 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.546 -0.721 . . . . 0.0 111.083 -179.1 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.616 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.4 OUTLIER -102.97 176.31 5.19 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 108.565 -0.902 . . . . 0.0 108.565 178.327 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.447 ' HG3' HG22 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -139.02 105.95 5.42 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.131 -0.981 . . . . 0.0 110.773 -179.843 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -95.26 43.79 2.2 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.352 -1.499 . . . . 0.0 109.352 179.663 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 3.7 t-20 58.52 91.06 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.321 -1.105 . . . . 0.0 110.126 -179.914 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.629 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 84.33 5.12 87.48 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.607 -1.397 . . . . 0.0 109.607 179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.707 ' O ' HG23 ' A' ' 319' ' ' VAL . 7.0 m-85 -141.93 -178.53 5.73 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.413 -1.051 . . . . 0.0 109.078 179.404 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.749 HG21 ' CG2' ' A' ' 304' ' ' VAL . 39.9 t -159.4 148.98 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.149 -0.969 . . . . 0.0 109.986 179.126 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.616 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 1.7 mm -114.9 151.56 16.62 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.112 -0.992 . . . . 0.0 110.497 -179.892 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.659 ' CG ' ' CE1' ' A' ' 334' ' ' PHE . 76.5 m-85 -130.69 112.78 13.42 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.101 -0.999 . . . . 0.0 109.866 179.174 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.584 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 3.7 p -116.49 171.07 5.09 Favored Pre-proline 0 N--CA 1.496 1.847 0 O-C-N 120.627 -1.296 . . . . 0.0 109.786 179.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.584 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.9 Cg_endo -69.2 120.96 7.77 Favored 'Trans proline' 0 C--N 1.309 -1.527 0 O-C-N 123.652 1.343 . . . . 0.0 110.727 -179.431 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.656 HG22 ' CG ' ' A' ' 327' ' ' ASN . 16.0 m -64.12 -113.89 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.425 0 O-C-N 121.482 -0.761 . . . . 0.0 110.224 -179.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.531 ' HG ' ' HD1' ' A' ' 326' ' ' TRP . 14.1 p -120.17 -12.47 9.06 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.753 -1.217 . . . . 0.0 110.688 -179.665 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.531 ' HD1' ' HG ' ' A' ' 325' ' ' SER . 24.8 p-90 -128.9 17.01 6.26 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.122 -0.986 . . . . 0.0 110.921 -179.741 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.656 ' CG ' HG22 ' A' ' 324' ' ' VAL . 28.8 p-10 -135.56 45.07 2.48 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.973 -1.079 . . . . 0.0 110.921 -179.487 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.539 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -116.05 7.96 14.41 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.097 -1.002 . . . . 0.0 109.847 179.774 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . . . . . . . . . . . -74.67 -153.72 3.54 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 110.124 -1.191 . . . . 0.0 110.124 -179.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.54 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 50.5 Cg_endo -75.61 4.66 4.85 Favored 'Trans proline' 0 C--N 1.309 -1.552 0 O-C-N 124.182 1.622 . . . . 0.0 110.925 -179.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.6 m -165.25 123.54 1.64 Allowed 'General case' 0 C--N 1.298 -1.632 0 O-C-N 121.158 -0.964 . . . . 0.0 110.253 -179.913 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.627 ' HB1' ' HB2' ' A' ' 327' ' ' ASN . . . -150.72 120.28 6.95 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.848 -179.994 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.832 ' OG1' HG23 ' A' ' 283' ' ' THR . 34.0 m -104.32 144.66 31.33 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.229 -0.92 . . . . 0.0 110.441 -179.523 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.779 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.0 p90 -149.78 168.82 22.62 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.459 -0.941 . . . . 0.0 108.459 179.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.37 159.84 28.16 Favored Glycine 0 N--CA 1.489 2.169 0 C-N-CA 118.744 -1.693 . . . . 0.0 110.535 -179.209 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.882 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.6 p90 -144.2 145.02 31.81 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 121.648 -0.913 . . . . 0.0 109.679 179.528 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.882 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.98 120.99 65.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.229 -0.919 . . . . 0.0 109.626 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 1.024 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 19.8 t -97.71 142.65 14.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.219 -0.926 . . . . 0.0 110.399 -179.735 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.494 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.6 m-80 -115.55 130.09 56.75 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.319 -0.863 . . . . 0.0 110.133 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 301' ' ' GLY . . . -175.93 -136.38 2.33 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.685 -1.366 . . . . 0.0 109.685 -179.878 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.505 ' C ' ' NE2' ' A' ' 342' ' ' GLN . 47.0 Cg_endo -72.14 -169.42 0.45 Allowed 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 124.078 1.567 . . . . 0.0 110.579 -179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.505 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 12.6 mm-40 -107.43 145.38 33.06 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.235 -0.915 . . . . 0.0 110.087 -179.55 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 97.9 72.16 1.06 Allowed Glycine 0 N--CA 1.491 2.343 0 N-CA-C 109.004 -1.638 . . . . 0.0 109.004 -179.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.473 ' O ' ' O ' ' A' ' 343' ' ' GLY . 1.2 t70 61.1 140.81 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.328 -1.101 . . . . 0.0 109.171 -179.24 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.628 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.3 mtmt -134.65 18.09 3.59 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.006 -1.059 . . . . 0.0 110.463 -179.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.582 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.8 p -130.58 118.21 41.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 O-C-N 121.311 -0.868 . . . . 0.0 110.22 179.323 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.432 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -48.33 -45.9 35.8 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.378 -0.826 . . . . 0.0 110.575 -179.582 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.42 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 2.5 pt-20 -177.02 159.39 1.67 Allowed 'General case' 0 N--CA 1.494 1.767 0 C-N-CA 119.243 -0.983 . . . . 0.0 110.847 -179.805 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.549 HG12 HG13 ' A' ' 296' ' ' VAL . 14.2 mt -119.6 114.6 44.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.254 -0.904 . . . . 0.0 110.439 179.843 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -113.91 158.2 21.41 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.148 -0.97 . . . . 0.0 109.855 179.661 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.082 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.42 126.63 51.82 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.253 -0.905 . . . . 0.0 110.633 -179.79 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.482 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.0 OUTLIER -139.25 119.76 13.99 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.158 -0.964 . . . . 0.0 109.864 179.45 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.834 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -90.81 93.01 4.14 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 120.924 -1.11 . . . . 0.0 110.22 -179.985 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 46.94 31.96 1.68 Allowed 'General case' 0 C--N 1.299 -1.597 0 O-C-N 121.817 -0.552 . . . . 0.0 111.249 179.496 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 132.13 -33.86 2.63 Favored Glycine 0 N--CA 1.493 2.453 0 C-N-CA 119.507 -1.33 . . . . 0.0 110.651 179.076 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.465 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 66.0 mm-40 -89.92 117.61 28.87 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 120.987 -1.302 . . . . 0.0 110.745 -179.378 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.482 ' HA ' ' HA ' ' A' ' 352' ' ' GLU . 4.0 p -78.93 124.07 36.79 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.298 -0.876 . . . . 0.0 110.135 179.821 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.683 ' HB ' HD13 ' A' ' 351' ' ' LEU . 21.5 mm . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.949 -1.024 . . . . 0.0 110.092 -179.998 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.37 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.26 -177.75 2.87 Favored 'Trans proline' 0 C--N 1.304 -1.788 0 O-C-N 123.935 1.492 . . . . 0.0 110.575 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.618 HG23 ' O ' ' A' ' 258' ' ' THR . 14.4 t -57.13 122.8 13.26 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -0.82 . . . . 0.0 110.598 -179.79 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 19.7 p -133.82 94.43 18.87 Favored Pre-proline 0 N--CA 1.491 1.601 0 O-C-N 121.344 -0.848 . . . . 0.0 109.858 179.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.29 130.14 15.91 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.059 1.557 . . . . 0.0 110.606 -179.67 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.622 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -66.59 143.56 98.21 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.281 -0.887 . . . . 0.0 110.025 179.854 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.622 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.7 Cg_endo -73.53 125.67 10.29 Favored 'Trans proline' 0 C--N 1.303 -1.829 0 O-C-N 124.044 1.549 . . . . 0.0 110.542 179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.512 HG12 ' O ' ' A' ' 263' ' ' VAL . 19.8 t -124.13 30.42 2.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.212 -0.93 . . . . 0.0 110.07 179.885 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -163.24 102.85 0.97 Allowed 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.237 -0.914 . . . . 0.0 110.442 -179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 84.28 -169.88 46.22 Favored Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.559 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.58 162.67 33.99 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.371 -1.076 . . . . 0.0 109.87 179.837 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.947 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -159.92 138.27 10.33 Favored 'General case' 0 C--N 1.303 -1.416 0 C-N-CA 119.143 -1.023 . . . . 0.0 111.15 -179.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.74 ' N ' HD22 ' A' ' 267' ' ' LEU . 18.8 mt-10 -141.15 136.57 31.98 Favored 'General case' 0 C--N 1.299 -1.596 0 N-CA-C 108.71 -0.848 . . . . 0.0 108.71 179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.819 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -128.11 144.88 36.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 120.618 -1.301 . . . . 0.0 112.306 -178.509 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.405 ' C ' HG23 ' A' ' 271' ' ' VAL . 63.3 mttt -128.65 157.74 40.49 Favored 'General case' 0 N--CA 1.494 1.752 0 N-CA-C 108.615 -0.883 . . . . 0.0 108.615 178.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.844 HG13 ' O ' ' A' ' 279' ' ' GLU . 98.7 t -144.36 147.38 19.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 120.346 -1.472 . . . . 0.0 112.319 -179.056 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.525 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.12 110.63 6.38 Favored 'General case' 0 N--CA 1.492 1.635 0 N-CA-C 109.008 -0.738 . . . . 0.0 109.008 178.737 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.527 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -96.13 149.08 22.02 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.988 -1.07 . . . . 0.0 111.503 -178.465 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.82 ' CH2' HG23 ' A' ' 337' ' ' ILE . 28.1 p90 -129.46 18.42 5.84 Favored 'General case' 0 N--CA 1.486 1.373 0 CA-C-O 121.447 0.641 . . . . 0.0 109.691 179.322 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.42 -61.63 3.2 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.634 -1.386 . . . . 0.0 109.634 179.684 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -67.67 -25.26 65.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.221 -1.164 . . . . 0.0 110.383 -179.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.522 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -167.56 178.93 41.31 Favored Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.449 -1.358 . . . . 0.0 109.95 -179.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.3 144.63 48.44 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.325 -1.103 . . . . 0.0 110.345 179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.844 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -97.47 145.92 25.74 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.396 -0.815 . . . . 0.0 109.828 -179.765 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.731 ' CE1' HG11 ' A' ' 346' ' ' VAL . 98.9 m-85 -137.9 87.72 2.27 Favored 'General case' 0 N--CA 1.489 1.496 0 C-N-CA 119.658 -0.817 . . . . 0.0 110.827 -179.543 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.819 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -70.88 140.91 51.21 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.439 -0.788 . . . . 0.0 109.483 179.13 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.675 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.8 t -133.89 91.7 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.689 0 O-C-N 121.568 -0.708 . . . . 0.0 109.803 -179.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.861 HG23 ' OG1' ' A' ' 333' ' ' THR . 9.0 m -86.49 124.2 32.55 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.085 -1.01 . . . . 0.0 109.977 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.82 148.41 38.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.285 -0.884 . . . . 0.0 110.832 -179.427 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -128.66 137.43 51.64 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.434 -0.791 . . . . 0.0 109.823 -179.996 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.5 mt -142.42 159.7 41.71 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 120.794 -1.191 . . . . 0.0 109.759 179.807 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -91.94 36.02 0.97 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 121.361 -0.837 . . . . 0.0 110.31 -179.872 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.479 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 152.07 -100.94 0.21 Allowed Glycine 0 N--CA 1.491 2.324 0 C-N-CA 119.139 -1.505 . . . . 0.0 110.269 -179.817 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.554 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 15.9 mm-40 -141.8 111.93 6.88 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.024 -1.28 . . . . 0.0 110.881 -179.34 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.639 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 5.5 m-85 -135.51 138.36 43.0 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.241 -0.912 . . . . 0.0 109.687 179.402 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.801 ' O ' HG23 ' A' ' 353' ' ' ILE . 5.5 m-20 -74.17 96.87 2.82 Favored 'General case' 0 C--N 1.3 -1.557 0 O-C-N 121.002 -1.061 . . . . 0.0 108.905 179.052 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.938 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.1 p-90 -97.45 114.87 26.8 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.192 -0.942 . . . . 0.0 110.568 -179.253 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.707 HG23 HG23 ' A' ' 322' ' ' THR . 28.7 m -109.45 116.09 31.17 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.694 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.8 t -96.83 111.72 27.41 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 121.161 -0.962 . . . . 0.0 110.528 -179.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.577 ' HA ' HD13 ' A' ' 320' ' ' ILE . 28.9 ttpt -91.64 130.19 37.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.273 -0.892 . . . . 0.0 109.659 179.4 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.745 HG13 HG12 ' A' ' 349' ' ' ILE . 80.2 t -126.58 115.87 43.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.185 -0.947 . . . . 0.0 111.103 -179.164 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.571 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 55.7 mmtt -73.21 134.23 44.27 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.149 -0.97 . . . . 0.0 109.269 178.9 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.974 HD13 ' HA ' ' A' ' 303' ' ' THR . 80.1 mt -88.15 159.38 18.22 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.324 -0.86 . . . . 0.0 111.466 -178.833 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.881 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.18 178.09 0.56 Allowed Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.68 -0.638 . . . . 0.0 110.025 179.712 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.864 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.24 79.06 0.6 Allowed 'Trans proline' 0 C--N 1.306 -1.69 0 O-C-N 123.718 1.378 . . . . 0.0 109.662 179.229 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.89 21.15 6.11 Favored Glycine 0 N--CA 1.489 2.209 0 N-CA-C 108.75 -1.74 . . . . 0.0 108.75 -179.196 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.881 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -106.05 144.37 32.85 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.417 -1.049 . . . . 0.0 110.241 -179.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.974 ' HA ' HD13 ' A' ' 298' ' ' LEU . 10.8 p -145.75 145.95 31.04 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.3 -0.875 . . . . 0.0 110.532 179.841 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.822 HG21 HG11 ' A' ' 319' ' ' VAL . 76.1 t -70.99 134.83 29.29 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.329 -0.857 . . . . 0.0 109.88 179.676 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -119.45 -37.29 0.8 Allowed Glycine 0 N--CA 1.491 2.302 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.081 -179.507 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.427 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 67.6 m -131.55 128.15 38.67 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.06 -1.259 . . . . 0.0 110.919 -179.563 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.7 p90 -144.78 157.73 44.06 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.377 -0.827 . . . . 0.0 109.794 179.307 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.487 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -150.55 159.52 44.44 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.007 -1.058 . . . . 0.0 111.236 -179.329 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.53 ' OG ' ' CZ3' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 59.45 24.81 13.49 Favored 'General case' 0 N--CA 1.495 1.806 0 O-C-N 121.562 -0.712 . . . . 0.0 110.679 179.735 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.72 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 142.56 0.77 Allowed 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.277 -0.889 . . . . 0.0 110.213 179.711 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.852 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -81.09 113.97 19.63 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.084 -1.01 . . . . 0.0 109.383 179.497 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.559 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 18.6 ttpt -82.56 149.71 27.33 Favored 'General case' 0 N--CA 1.49 1.544 0 CA-C-O 121.762 0.792 . . . . 0.0 110.459 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.823 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -134.13 170.63 15.39 Favored 'General case' 0 C--N 1.299 -1.629 0 N-CA-C 109.26 -0.645 . . . . 0.0 109.26 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.481 ' HG2' HG22 ' A' ' 319' ' ' VAL . 15.8 mt-10 -142.41 95.17 2.75 Favored 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.595 -0.69 . . . . 0.0 110.165 179.618 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.14 -80.28 0.44 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.391 -1.484 . . . . 0.0 109.391 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 p30 -160.93 77.5 0.58 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.433 -1.04 . . . . 0.0 108.812 179.687 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.617 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.34 11.25 54.64 Favored Glycine 0 N--CA 1.487 2.082 0 N-CA-C 108.287 -1.925 . . . . 0.0 108.287 -178.349 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.812 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.3 m-85 -143.06 -166.97 2.43 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.736 -0.861 . . . . 0.0 108.709 179.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.823 HG22 ' O ' ' A' ' 313' ' ' GLN . 2.5 t -163.52 160.19 1.28 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 121.01 -1.056 . . . . 0.0 109.454 179.362 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.773 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.3 mm -128.98 145.22 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.729 0 O-C-N 120.891 -1.131 . . . . 0.0 111.136 179.834 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.0 m-85 -123.04 129.33 51.36 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.156 -0.965 . . . . 0.0 110.378 179.755 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.707 HG23 HG23 ' A' ' 293' ' ' THR . 3.0 p -131.01 167.73 20.32 Favored Pre-proline 0 N--CA 1.491 1.587 0 O-C-N 120.72 -1.237 . . . . 0.0 110.014 179.33 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.512 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.0 Cg_endo -66.1 128.68 20.07 Favored 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.861 1.453 . . . . 0.0 110.915 -179.293 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.852 HG12 ' ND2' ' A' ' 311' ' ' ASN . 34.6 m -78.01 -122.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.51 -0.744 . . . . 0.0 110.114 -179.794 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.598 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -101.83 -21.43 14.58 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.757 -1.214 . . . . 0.0 110.631 -179.651 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.61 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.9 p-90 -126.46 5.55 6.91 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.173 -0.955 . . . . 0.0 110.578 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.772 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.8 OUTLIER -108.39 49.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.156 -0.965 . . . . 0.0 110.125 -179.8 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.478 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -133.84 -4.83 2.82 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 121.107 -0.996 . . . . 0.0 110.404 179.91 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.466 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.56 -155.72 0.05 OUTLIER Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.147 -1.581 . . . . 0.0 109.147 179.723 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.426 ' C ' ' OG1' ' A' ' 331' ' ' THR . 46.9 Cg_endo -73.65 3.06 5.18 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.915 1.482 . . . . 0.0 110.749 -179.968 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.426 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.8 m -163.03 120.52 1.94 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.172 -0.955 . . . . 0.0 110.061 179.992 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.561 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -141.0 112.71 7.61 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.261 -0.899 . . . . 0.0 110.277 -179.903 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.861 ' OG1' HG23 ' A' ' 283' ' ' THR . 38.1 m -104.49 138.92 40.16 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.222 -0.924 . . . . 0.0 110.049 179.877 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.72 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 13.6 p90 -142.85 172.37 12.79 Favored 'General case' 0 N--CA 1.488 1.462 0 N-CA-C 108.706 -0.85 . . . . 0.0 108.706 179.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.89 160.29 28.44 Favored Glycine 0 N--CA 1.49 2.29 0 C-N-CA 118.755 -1.688 . . . . 0.0 110.333 -179.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.919 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -147.32 145.24 29.28 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.481 -1.011 . . . . 0.0 110.048 179.485 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.919 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.81 119.86 61.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.094 -1.004 . . . . 0.0 109.783 179.757 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.799 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.8 t -96.96 145.83 8.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.178 -0.951 . . . . 0.0 110.068 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.6 m-80 -112.68 126.51 55.47 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.328 -0.858 . . . . 0.0 110.014 179.735 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -172.42 -132.35 1.49 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 -179.967 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.541 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 43.6 Cg_endo -69.15 -163.14 0.09 OUTLIER 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 123.807 1.425 . . . . 0.0 110.754 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.579 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -126.53 126.53 43.84 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.187 -0.946 . . . . 0.0 110.845 -179.362 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.402 ' O ' ' HB3' ' A' ' 344' ' ' ASP . . . 118.08 -21.28 10.27 Favored Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.801 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.402 ' HB3' ' O ' ' A' ' 343' ' ' GLY . 2.6 p-10 176.79 124.54 0.03 OUTLIER 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.686 -0.891 . . . . 0.0 108.803 -179.979 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.698 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.3 mtmt -127.48 11.18 6.8 Favored 'General case' 0 C--N 1.303 -1.451 0 C-N-CA 118.773 -1.171 . . . . 0.0 111.076 -179.148 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.731 HG11 ' CE1' ' A' ' 280' ' ' TYR . 4.3 p -133.59 120.08 36.38 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.748 0 O-C-N 121.203 -0.935 . . . . 0.0 110.402 179.638 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.5 mm-40 -50.2 -47.02 54.91 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 120.979 -1.076 . . . . 0.0 109.643 -179.951 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.444 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 1.2 pt-20 -177.88 158.99 1.33 Allowed 'General case' 0 N--CA 1.492 1.625 0 C-N-CA 119.563 -0.855 . . . . 0.0 110.616 179.901 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.745 HG12 HG13 ' A' ' 296' ' ' VAL . 62.9 mt -118.67 121.77 67.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 121.268 -0.895 . . . . 0.0 110.22 179.798 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.76 139.75 53.56 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.193 -0.942 . . . . 0.0 110.215 -179.976 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.41 130.61 45.04 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.177 -0.952 . . . . 0.0 110.284 179.818 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.442 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 0.8 OUTLIER -138.0 110.64 7.57 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.354 -0.842 . . . . 0.0 109.572 179.784 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.801 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.7 110.01 22.03 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.144 -0.973 . . . . 0.0 110.464 -179.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.53 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 39.12 31.21 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.661 -0.649 . . . . 0.0 110.52 179.758 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.42 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 116.54 -19.3 12.83 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.863 -1.295 . . . . 0.0 109.863 179.792 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.411 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.8 OUTLIER -85.82 104.39 15.45 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.2 -1.176 . . . . 0.0 110.437 -179.868 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.848 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.0 p -72.03 128.66 35.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.276 -0.89 . . . . 0.0 110.09 179.893 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.848 HD13 ' O ' ' A' ' 357' ' ' VAL . 12.1 mm . . . . . 0 N--CA 1.492 1.668 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.156 -179.948 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.277 0 N-CA-C 109.567 -1.413 . . . . 0.0 109.567 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -74.24 -178.82 4.18 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.102 1.58 . . . . 0.0 110.535 179.972 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.452 HG23 ' O ' ' A' ' 258' ' ' THR . 6.0 t -59.21 130.65 47.98 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.198 -0.939 . . . . 0.0 110.081 179.927 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 9.4 t -135.83 145.03 51.14 Favored Pre-proline 0 N--CA 1.49 1.561 0 O-C-N 121.206 -0.934 . . . . 0.0 110.476 -179.728 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -72.83 162.03 42.19 Favored 'Trans proline' 0 C--N 1.305 -1.726 0 O-C-N 124.098 1.578 . . . . 0.0 110.185 179.771 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.629 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.0 p -113.64 144.53 31.56 Favored Pre-proline 0 N--CA 1.491 1.62 0 O-C-N 121.15 -0.968 . . . . 0.0 110.359 179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.629 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.1 Cg_endo -76.75 127.55 9.58 Favored 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 124.07 1.563 . . . . 0.0 110.627 179.84 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.711 HG12 ' O ' ' A' ' 263' ' ' VAL . 86.7 t -117.18 30.44 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.227 -0.921 . . . . 0.0 110.325 179.975 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.446 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 4.3 t 174.21 129.26 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.24 -0.913 . . . . 0.0 110.563 179.976 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 74.61 179.27 41.71 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.939 -1.265 . . . . 0.0 109.939 179.56 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.553 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -133.74 163.24 29.9 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.397 -1.061 . . . . 0.0 109.865 179.862 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.87 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.6 tm? -161.59 133.34 5.58 Favored 'General case' 0 C--N 1.302 -1.464 0 C-N-CA 119.171 -1.012 . . . . 0.0 111.055 -179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.794 ' N ' HD22 ' A' ' 267' ' ' LEU . 7.9 mt-10 -132.92 128.1 35.76 Favored 'General case' 0 N--CA 1.491 1.607 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 179.643 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.772 HG13 ' O ' ' A' ' 281' ' ' ASP . 61.9 t -120.28 137.28 54.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 120.894 -1.129 . . . . 0.0 111.569 -179.062 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -122.51 156.93 33.13 Favored 'General case' 0 N--CA 1.494 1.742 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 178.808 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.703 HG13 ' O ' ' A' ' 279' ' ' GLU . 78.1 t -142.56 145.1 23.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.325 -1.484 . . . . 0.0 112.288 -179.305 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.547 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -138.57 111.38 7.72 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.865 -0.791 . . . . 0.0 108.865 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.443 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.0 147.04 23.83 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.209 -0.932 . . . . 0.0 111.304 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.843 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.2 p90 -131.92 16.16 4.72 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.455 -0.778 . . . . 0.0 109.818 179.203 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.62 -60.27 3.24 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 109.243 -1.543 . . . . 0.0 109.243 -179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -66.49 -23.3 66.23 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.29 -1.124 . . . . 0.0 110.302 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.579 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.14 -178.53 45.06 Favored Glycine 0 N--CA 1.492 2.395 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 -179.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.618 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.31 142.9 47.43 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.296 -1.12 . . . . 0.0 110.554 -179.874 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.703 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.6 mt-10 -93.93 147.21 23.31 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.53 -0.731 . . . . 0.0 109.653 179.879 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.661 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 96.9 m-85 -141.53 83.93 1.88 Allowed 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.38 -0.825 . . . . 0.0 110.45 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.772 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.12 151.74 47.04 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.377 -0.827 . . . . 0.0 109.943 179.487 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.699 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.4 t -143.96 88.56 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.536 0 O-C-N 121.436 -0.79 . . . . 0.0 109.691 -179.937 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.602 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.3 m -86.09 117.25 24.8 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.176 -0.952 . . . . 0.0 109.628 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.063 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -105.52 150.4 25.37 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.242 -0.912 . . . . 0.0 110.575 -179.263 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.897 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -131.15 134.95 47.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.451 -0.78 . . . . 0.0 110.016 -179.804 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.897 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.3 mt -142.32 152.07 42.59 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.811 -1.181 . . . . 0.0 109.535 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -89.89 38.49 0.92 Allowed 'General case' 0 C--N 1.296 -1.759 0 O-C-N 121.31 -0.869 . . . . 0.0 109.3 179.483 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.451 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.98 -139.12 5.85 Favored Glycine 0 N--CA 1.491 2.351 0 N-CA-C 109.674 -1.37 . . . . 0.0 109.674 -179.759 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.558 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 3.6 mt-30 -118.09 96.05 5.17 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.059 -1.26 . . . . 0.0 110.959 -179.581 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.6 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -121.29 133.58 55.14 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.362 -0.836 . . . . 0.0 110.025 179.636 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.789 ' O ' HG23 ' A' ' 353' ' ' ILE . 67.6 m-20 -65.35 109.92 2.45 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.122 -0.986 . . . . 0.0 109.624 179.438 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.88 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.0 p-90 -107.99 116.15 31.43 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.105 -0.997 . . . . 0.0 110.835 -179.377 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.604 HG23 HG23 ' A' ' 322' ' ' THR . 54.8 m -110.25 115.92 30.57 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.426 -0.797 . . . . 0.0 109.902 179.835 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.771 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.7 t -96.8 111.3 26.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.16 -0.963 . . . . 0.0 110.608 -179.574 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.507 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.3 ttpt -90.07 130.11 36.29 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.254 -0.904 . . . . 0.0 109.404 179.243 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.82 HG22 HG23 ' A' ' 349' ' ' ILE . 76.3 t -127.86 108.1 17.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.254 -0.903 . . . . 0.0 110.513 -179.148 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.662 ' O ' HG23 ' A' ' 346' ' ' VAL . 24.9 mmtt -70.08 138.3 51.91 Favored 'General case' 0 C--N 1.304 -1.377 0 O-C-N 121.148 -0.97 . . . . 0.0 109.09 179.326 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.968 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.7 mt -90.61 156.58 18.03 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.495 -0.753 . . . . 0.0 111.609 -178.553 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.801 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -60.72 175.33 0.44 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.629 -0.669 . . . . 0.0 109.381 179.009 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.742 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.1 Cg_endo -68.57 80.53 0.6 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 123.547 1.288 . . . . 0.0 110.009 179.755 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.76 21.27 5.77 Favored Glycine 0 N--CA 1.489 2.205 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.506 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.801 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 152.89 23.55 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.423 -1.045 . . . . 0.0 110.064 -179.792 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.968 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -153.16 146.51 24.85 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.077 -1.014 . . . . 0.0 111.312 -179.818 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.879 HG21 HG11 ' A' ' 319' ' ' VAL . 63.7 t -63.88 142.16 17.21 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 121.372 -0.83 . . . . 0.0 109.97 179.672 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . 0.464 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -121.77 -39.63 0.56 Allowed Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.552 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -142.01 120.17 12.18 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.045 -1.268 . . . . 0.0 110.713 -179.61 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.511 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.7 p90 -132.88 166.41 22.39 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.251 -0.905 . . . . 0.0 110.021 179.427 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.492 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -157.68 160.6 38.14 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.161 -0.962 . . . . 0.0 111.197 -179.407 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.483 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 60.25 23.17 12.57 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.552 -0.717 . . . . 0.0 110.881 179.502 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.591 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.99 144.88 0.78 Allowed 'General case' 0 C--N 1.298 -1.647 0 O-C-N 121.352 -0.843 . . . . 0.0 109.854 179.739 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.517 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -83.43 122.48 28.56 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.028 -1.045 . . . . 0.0 109.43 179.54 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.508 ' HG2' HG13 ' A' ' 319' ' ' VAL . 4.2 ttpt -89.7 140.29 29.72 Favored 'General case' 0 C--N 1.302 -1.474 0 CA-C-O 121.877 0.846 . . . . 0.0 110.609 -179.475 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.561 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.41 176.11 7.03 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.401 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 25.9 mt-10 -137.63 107.15 6.15 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.409 -0.807 . . . . 0.0 110.247 179.936 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.47 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -98.06 37.4 3.49 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 -179.884 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.47 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.6 OUTLIER 68.43 88.17 0.11 Allowed 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.226 -1.161 . . . . 0.0 110.448 179.852 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 85.37 6.95 83.34 Favored Glycine 0 N--CA 1.49 2.274 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.836 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.801 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.0 m-85 -146.35 -170.81 3.59 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.305 179.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.879 HG11 HG21 ' A' ' 304' ' ' VAL . 6.5 t -162.28 156.25 2.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.206 -0.934 . . . . 0.0 109.894 179.499 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.53 ' CG2' ' CG2' ' A' ' 293' ' ' THR . 7.2 mm -125.79 137.95 56.06 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 120.888 -1.133 . . . . 0.0 111.476 -179.774 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 36.9 m-85 -114.37 131.18 56.65 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.273 -0.892 . . . . 0.0 109.532 179.054 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.604 HG23 HG23 ' A' ' 293' ' ' THR . 1.8 p -132.06 169.94 12.59 Favored Pre-proline 0 C--N 1.3 -1.57 0 O-C-N 120.624 -1.297 . . . . 0.0 110.317 -179.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -64.92 109.37 1.27 Allowed 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.883 1.465 . . . . 0.0 110.923 -179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.735 HG23 ' H ' ' A' ' 325' ' ' SER . 6.2 m -48.18 -59.0 0.88 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.427 -0.796 . . . . 0.0 110.63 -179.88 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.735 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.6 t 177.89 -25.91 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.991 -1.068 . . . . 0.0 111.133 179.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.428 ' CE2' HG21 ' A' ' 324' ' ' VAL . 7.1 p-90 -113.85 -22.87 9.93 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.958 -1.089 . . . . 0.0 110.912 -179.565 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.985 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 0.0 OUTLIER -83.36 12.18 5.79 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.991 -1.068 . . . . 0.0 110.929 179.928 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.558 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 12.1 mtmt -74.12 -11.07 60.2 Favored 'General case' 0 C--N 1.295 -1.796 0 O-C-N 121.46 -0.775 . . . . 0.0 109.329 179.291 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.21 -158.13 0.01 OUTLIER Glycine 0 N--CA 1.492 2.372 0 N-CA-C 110.678 -0.969 . . . . 0.0 110.678 -179.231 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.542 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -73.06 7.14 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.644 0 O-C-N 124.069 1.562 . . . . 0.0 111.388 -179.546 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 4.4 m -162.32 131.23 4.24 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.123 -0.986 . . . . 0.0 109.841 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.985 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -144.23 104.37 4.1 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.231 -0.918 . . . . 0.0 110.355 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.602 ' OG1' HG23 ' A' ' 283' ' ' THR . 48.2 m -100.98 135.16 42.87 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.058 -1.027 . . . . 0.0 110.312 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.771 ' HE2' HG21 ' A' ' 294' ' ' VAL . 6.6 p90 -144.39 173.14 12.04 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 108.59 -0.893 . . . . 0.0 108.59 179.439 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.67 157.54 27.24 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.478 -179.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.911 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -144.35 144.81 31.62 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.598 -0.943 . . . . 0.0 110.01 179.512 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.911 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.31 118.65 58.16 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.099 -1.001 . . . . 0.0 109.589 179.614 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.732 HG21 ' CD2' ' A' ' 298' ' ' LEU . 2.2 t -96.67 150.06 4.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.241 -0.912 . . . . 0.0 109.855 -179.81 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -122.57 133.8 54.55 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.437 -0.789 . . . . 0.0 110.333 -179.578 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -176.97 -140.03 3.46 Favored Glycine 0 N--CA 1.488 2.153 0 N-CA-C 109.512 -1.435 . . . . 0.0 109.512 179.897 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.516 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 47.6 Cg_endo -75.28 -170.42 0.8 Allowed 'Trans proline' 0 C--N 1.303 -1.839 0 O-C-N 124.035 1.545 . . . . 0.0 110.382 -179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.444 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 5.9 mp0 -101.19 153.36 19.67 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.128 -0.983 . . . . 0.0 110.295 179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.48 ' O ' ' HB3' ' A' ' 344' ' ' ASP . . . 91.81 71.6 1.2 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.176 -1.57 . . . . 0.0 109.176 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.48 ' HB3' ' O ' ' A' ' 343' ' ' GLY . 16.5 t70 59.87 147.67 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.4 -1.059 . . . . 0.0 109.626 -179.59 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.778 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.2 mtmt -140.9 19.72 2.31 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 120.998 -1.064 . . . . 0.0 110.812 -179.708 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.662 HG23 ' O ' ' A' ' 297' ' ' LYS . 7.5 p -132.08 118.17 35.93 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 O-C-N 121.227 -0.921 . . . . 0.0 110.46 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.498 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -46.76 -46.61 20.56 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.457 -0.777 . . . . 0.0 110.504 -179.845 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.417 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 9.2 pt-20 -177.27 158.93 1.53 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.041 -1.037 . . . . 0.0 110.803 -179.771 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.82 HG23 HG22 ' A' ' 296' ' ' VAL . 44.9 mt -120.46 106.69 19.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.131 -0.98 . . . . 0.0 110.392 179.7 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -112.49 136.48 51.95 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.225 -0.922 . . . . 0.0 110.228 179.941 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.063 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -95.71 134.35 38.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.238 -0.914 . . . . 0.0 110.332 179.83 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 6.2 tt0 -138.94 112.43 8.23 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.225 -0.922 . . . . 0.0 110.361 179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.789 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.71 105.2 16.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.066 -1.021 . . . . 0.0 109.942 179.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.469 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 40.15 31.51 0.1 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.591 -0.693 . . . . 0.0 110.625 -179.984 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 119.14 -22.08 9.15 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.794 -1.323 . . . . 0.0 109.794 179.789 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.403 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -85.35 105.29 15.9 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.255 -1.144 . . . . 0.0 110.096 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.58 ' O ' HD13 ' A' ' 358' ' ' ILE . 4.1 p -75.73 130.52 36.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.246 -0.909 . . . . 0.0 110.448 -179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.58 HD13 ' O ' ' A' ' 357' ' ' VAL . 27.0 mm . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 117.989 -1.005 . . . . 0.0 110.276 179.736 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.353 0 N-CA-C 109.542 -1.423 . . . . 0.0 109.542 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -72.86 -177.93 3.18 Favored 'Trans proline' 0 C--N 1.305 -1.75 0 O-C-N 123.995 1.524 . . . . 0.0 110.545 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.572 HG23 ' O ' ' A' ' 258' ' ' THR . 13.5 t -57.1 125.03 20.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.305 -0.872 . . . . 0.0 110.537 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 12.4 m -117.37 121.84 31.7 Favored Pre-proline 0 N--CA 1.493 1.703 0 O-C-N 121.258 -0.901 . . . . 0.0 110.195 179.947 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.0 Cg_endo -74.99 125.63 9.45 Favored 'Trans proline' 0 C--N 1.307 -1.649 0 O-C-N 123.945 1.497 . . . . 0.0 110.568 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.602 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.4 p -109.04 143.28 27.32 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.139 -0.975 . . . . 0.0 110.114 179.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.602 ' HD2' HG23 ' A' ' 261' ' ' VAL . 44.0 Cg_endo -71.55 137.78 31.08 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 124.02 1.537 . . . . 0.0 110.725 -179.829 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.414 HG12 ' O ' ' A' ' 263' ' ' VAL . 9.6 t -130.97 28.9 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.34 -0.85 . . . . 0.0 110.293 -179.97 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.417 ' OG ' HD11 ' A' ' 358' ' ' ILE . 0.3 OUTLIER -179.52 97.61 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.228 -0.92 . . . . 0.0 110.446 179.926 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 98.06 -177.94 31.66 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.891 -1.284 . . . . 0.0 109.891 179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.562 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.7 OUTLIER -133.62 165.85 23.96 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.366 -1.079 . . . . 0.0 109.883 179.791 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.926 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.31 137.2 8.02 Favored 'General case' 0 C--N 1.303 -1.431 0 C-N-CA 119.108 -1.037 . . . . 0.0 111.412 -179.452 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.798 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mm-40 -132.94 154.09 50.78 Favored 'General case' 0 N--CA 1.491 1.583 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 179.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.702 HG13 ' O ' ' A' ' 281' ' ' ASP . 46.2 t -145.41 139.74 22.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 120.62 -1.3 . . . . 0.0 111.739 -179.307 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.08 154.84 45.24 Favored 'General case' 0 N--CA 1.494 1.755 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 178.746 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.609 HG13 ' O ' ' A' ' 279' ' ' GLU . 70.8 t -140.67 141.43 32.23 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 120.466 -1.396 . . . . 0.0 111.984 -179.294 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -134.41 110.25 9.3 Favored 'General case' 0 N--CA 1.488 1.433 0 N-CA-C 108.766 -0.828 . . . . 0.0 108.766 179.205 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.483 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.2 m-20 -96.77 142.19 29.08 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.071 -1.018 . . . . 0.0 110.926 -178.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.838 ' CH2' HG23 ' A' ' 337' ' ' ILE . 26.0 p90 -123.16 15.31 9.84 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.312 -0.867 . . . . 0.0 110.223 179.613 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.14 -53.62 3.22 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.449 -1.46 . . . . 0.0 109.449 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -76.9 -16.6 59.34 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.269 -1.136 . . . . 0.0 110.066 179.916 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.559 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.74 -178.68 43.87 Favored Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.851 -1.299 . . . . 0.0 109.851 179.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.546 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.88 138.63 39.27 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.311 -1.111 . . . . 0.0 110.053 179.99 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.609 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.0 mt-10 -95.22 147.14 23.79 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.351 -0.843 . . . . 0.0 110.017 -179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.686 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.0 m-85 -140.17 89.27 2.28 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.275 -0.89 . . . . 0.0 110.814 -179.462 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.702 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -71.34 148.48 47.01 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.324 -0.86 . . . . 0.0 109.639 179.239 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.694 HG11 HG11 ' A' ' 294' ' ' VAL . 3.6 t -142.69 92.29 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.58 0 O-C-N 121.413 -0.805 . . . . 0.0 109.968 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.934 HG23 ' OG1' ' A' ' 333' ' ' THR . 15.4 m -86.45 126.46 34.42 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.032 -1.043 . . . . 0.0 109.77 179.929 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.113 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -115.19 149.6 37.43 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 120.969 -1.082 . . . . 0.0 110.987 -179.081 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.892 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -129.67 133.78 47.29 Favored 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.334 -0.854 . . . . 0.0 110.071 -179.691 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 1.059 HD13 ' HB2' ' A' ' 290' ' ' TYR . 17.8 mt -142.1 162.94 34.2 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.65 -1.281 . . . . 0.0 110.055 179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 4.2 t0 -87.65 29.71 0.87 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.227 -0.921 . . . . 0.0 110.473 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.514 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.09 -136.82 6.31 Favored Glycine 0 N--CA 1.491 2.366 0 N-CA-C 109.857 -1.297 . . . . 0.0 109.857 179.881 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.47 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 32.4 mm-40 -90.11 104.74 17.28 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.276 -1.132 . . . . 0.0 110.873 -179.561 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 1.059 ' HB2' HD13 ' A' ' 286' ' ' LEU . 8.4 m-85 -128.43 129.61 46.4 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.398 -0.814 . . . . 0.0 109.265 179.342 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.781 ' O ' HG23 ' A' ' 353' ' ' ILE . 58.9 m-20 -74.6 96.31 2.96 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.742 -1.224 . . . . 0.0 109.369 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.935 ' CE3' HD13 ' A' ' 284' ' ' LEU . 60.3 p-90 -98.01 115.43 28.18 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.397 -0.814 . . . . 0.0 110.689 -179.392 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.872 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.6 m -109.51 115.78 30.56 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.52 -0.738 . . . . 0.0 109.425 179.567 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.781 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.6 t -96.89 111.27 26.52 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.106 -0.996 . . . . 0.0 110.394 -179.467 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.593 ' HA ' HD13 ' A' ' 320' ' ' ILE . 21.2 ttpt -91.29 136.5 33.05 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 121.358 -0.839 . . . . 0.0 109.504 179.619 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.804 HG22 HG23 ' A' ' 349' ' ' ILE . 69.9 t -135.46 109.2 10.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.136 -0.978 . . . . 0.0 110.634 -179.152 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.54 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 53.8 mmtt -69.97 132.77 46.46 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.243 -0.911 . . . . 0.0 109.32 179.583 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.899 HD13 ' HA ' ' A' ' 303' ' ' THR . 60.1 mt -86.68 165.45 16.1 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.304 -0.872 . . . . 0.0 111.198 -179.062 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.773 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -75.69 176.43 3.21 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.752 -0.593 . . . . 0.0 109.43 179.208 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.773 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.0 Cg_endo -67.6 84.94 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.527 1.278 . . . . 0.0 109.955 179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.87 20.95 6.57 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.129 -1.588 . . . . 0.0 109.129 -179.45 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.803 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.2 142.37 43.49 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.274 -1.133 . . . . 0.0 110.23 -179.796 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.899 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.0 p -150.28 144.36 25.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.195 -0.941 . . . . 0.0 110.834 179.887 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.803 HG21 HG11 ' A' ' 319' ' ' VAL . 14.7 t -63.75 137.37 24.85 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.388 -0.82 . . . . 0.0 110.193 179.837 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -120.69 -33.15 1.03 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.892 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 24.7 m -138.86 117.14 11.88 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.223 -1.163 . . . . 0.0 110.441 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.518 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 41.4 p90 -133.91 148.38 51.22 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.288 -0.883 . . . . 0.0 109.908 179.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.5 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -141.23 164.53 30.01 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.14 -0.975 . . . . 0.0 111.173 -179.433 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.501 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 54.33 25.13 5.64 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.728 -0.607 . . . . 0.0 111.173 179.499 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.679 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 138.65 0.64 Allowed 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.099 179.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.69 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -76.89 120.08 21.53 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.074 -1.017 . . . . 0.0 108.711 179.337 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.672 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.3 ttpt -88.43 128.05 35.52 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-O 121.824 0.821 . . . . 0.0 110.799 -178.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.557 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -113.31 175.73 5.32 Favored 'General case' 0 C--N 1.297 -1.683 0 N-CA-C 108.692 -0.855 . . . . 0.0 108.692 178.708 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -135.5 110.56 8.87 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.292 -0.88 . . . . 0.0 110.731 -179.743 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.574 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -95.35 40.56 2.64 Favored Glycine 0 N--CA 1.491 2.36 0 N-CA-C 109.361 -1.496 . . . . 0.0 109.361 179.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 57.0 77.65 0.26 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.233 -1.157 . . . . 0.0 109.962 -179.739 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.616 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.96 3.56 54.74 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.772 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -145.12 -170.76 3.5 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.486 -1.008 . . . . 0.0 109.003 179.628 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.803 HG11 HG21 ' A' ' 304' ' ' VAL . 18.2 t -161.39 157.74 2.34 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.199 -0.938 . . . . 0.0 109.691 179.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.624 ' CG2' HG22 ' A' ' 293' ' ' THR . 13.0 mm -127.03 146.79 32.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.225 -0.922 . . . . 0.0 110.885 -179.563 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.649 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 91.0 m-85 -124.12 119.19 28.73 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.321 -0.862 . . . . 0.0 109.814 179.344 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.872 ' CG2' HG23 ' A' ' 293' ' ' THR . 12.6 p -121.11 168.0 11.92 Favored Pre-proline 0 C--N 1.301 -1.536 0 O-C-N 120.966 -1.084 . . . . 0.0 109.641 179.638 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.524 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.5 Cg_endo -66.28 117.97 5.13 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.692 1.364 . . . . 0.0 110.946 -179.444 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.797 HG23 ' H ' ' A' ' 326' ' ' TRP . 23.9 m -65.72 -130.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.507 -0.746 . . . . 0.0 110.332 -179.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.613 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.9 t -96.94 -12.84 22.89 Favored 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.08 -1.013 . . . . 0.0 110.554 -179.698 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.797 ' H ' HG23 ' A' ' 324' ' ' VAL . 34.0 p-90 -133.46 5.53 3.75 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.07 -1.019 . . . . 0.0 110.946 -179.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.783 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.3 t-20 -112.45 42.89 1.73 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.998 -1.064 . . . . 0.0 110.768 -179.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.504 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.8 OUTLIER -122.97 0.95 9.23 Favored 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.338 -0.851 . . . . 0.0 109.71 179.064 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.432 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -63.69 -158.79 0.23 Allowed Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.418 -1.473 . . . . 0.0 109.418 179.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.514 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 47.8 Cg_endo -75.36 3.88 5.41 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.999 1.526 . . . . 0.0 110.767 179.967 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.471 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.6 m -165.02 117.6 1.21 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.16 -0.963 . . . . 0.0 109.814 179.937 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.561 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.18 123.7 17.11 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.274 -0.891 . . . . 0.0 110.373 -179.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.934 ' OG1' HG23 ' A' ' 283' ' ' THR . 40.9 m -111.58 142.07 44.36 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.29 -0.881 . . . . 0.0 109.99 179.838 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.781 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.0 p90 -143.95 174.82 10.51 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.321 -0.862 . . . . 0.0 109.515 -179.923 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.04 158.05 27.49 Favored Glycine 0 N--CA 1.491 2.309 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.288 -179.659 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.943 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -144.97 147.44 32.67 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.476 -1.014 . . . . 0.0 110.041 179.627 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.943 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.6 118.93 58.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.005 -1.059 . . . . 0.0 109.704 179.459 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.803 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.5 t -96.73 147.27 6.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.113 -0.992 . . . . 0.0 110.095 -179.936 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.475 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.15 137.85 53.93 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.339 -0.85 . . . . 0.0 110.332 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.435 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 176.66 -134.53 2.58 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.336 -1.506 . . . . 0.0 109.336 179.828 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.502 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 43.9 Cg_endo -71.48 -158.82 0.06 OUTLIER 'Trans proline' 0 C--N 1.303 -1.844 0 O-C-N 124.019 1.537 . . . . 0.0 110.326 179.741 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.579 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -122.97 141.31 52.08 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.094 -1.004 . . . . 0.0 110.121 -179.818 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.484 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 101.45 66.86 0.79 Allowed Glycine 0 N--CA 1.489 2.213 0 N-CA-C 108.811 -1.716 . . . . 0.0 108.811 -179.615 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.484 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.7 OUTLIER 68.39 128.72 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.291 -1.123 . . . . 0.0 109.279 -179.165 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.534 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -127.45 19.61 6.81 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.096 -1.003 . . . . 0.0 110.29 -179.461 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.594 ' CG2' ' CG1' ' A' ' 296' ' ' VAL . 7.5 p -130.22 117.84 41.54 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.358 -0.839 . . . . 0.0 110.568 179.817 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.49 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.0 mt-10 -47.08 -46.98 23.03 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.217 -0.927 . . . . 0.0 110.141 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.437 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.74 158.34 1.66 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.291 -0.88 . . . . 0.0 110.59 -179.843 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.804 HG23 HG22 ' A' ' 296' ' ' VAL . 33.1 mt -118.26 105.99 18.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.336 -0.852 . . . . 0.0 110.289 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.86 143.02 38.62 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.271 -0.893 . . . . 0.0 109.959 179.889 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.113 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.37 130.91 54.11 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.115 -0.991 . . . . 0.0 110.442 -179.867 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 15.0 tt0 -139.13 114.69 9.85 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.299 -0.875 . . . . 0.0 109.823 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.781 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -91.38 111.52 24.01 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.014 -1.054 . . . . 0.0 109.744 179.677 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.564 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 39.86 30.28 0.06 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.793 -0.567 . . . . 0.0 110.44 -179.677 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 115.88 -15.02 16.69 Favored Glycine 0 N--CA 1.491 2.329 0 N-CA-C 109.968 -1.253 . . . . 0.0 109.968 179.773 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.473 ' O ' ' N ' ' A' ' 353' ' ' ILE . 0.0 OUTLIER -89.54 108.06 19.44 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.128 -1.219 . . . . 0.0 110.412 -179.784 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.677 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -73.09 123.99 29.11 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.165 -0.959 . . . . 0.0 110.125 179.804 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.677 HD13 ' O ' ' A' ' 357' ' ' VAL . 20.6 mm . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 117.941 -1.028 . . . . 0.0 110.423 -179.986 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.257 0 N-CA-C 109.701 -1.359 . . . . 0.0 109.701 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -74.13 -178.56 3.97 Favored 'Trans proline' 0 C--N 1.305 -1.724 0 O-C-N 123.975 1.513 . . . . 0.0 109.988 179.698 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 6.1 t -58.21 141.32 51.03 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.215 -0.928 . . . . 0.0 110.025 179.862 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 14.4 t -132.76 138.67 32.48 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.279 -0.888 . . . . 0.0 110.052 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.95 155.58 52.93 Favored 'Trans proline' 0 C--N 1.304 -1.815 0 O-C-N 123.966 1.508 . . . . 0.0 110.243 179.911 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.536 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -83.09 141.62 43.52 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.203 -0.936 . . . . 0.0 110.581 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.551 ' CB ' HG23 ' A' ' 358' ' ' ILE . 47.4 Cg_endo -74.53 139.43 25.59 Favored 'Trans proline' 0 C--N 1.304 -1.815 0 O-C-N 124.213 1.639 . . . . 0.0 110.005 179.552 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.537 HG12 ' O ' ' A' ' 263' ' ' VAL . 24.5 t -117.53 30.62 2.17 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.182 -0.949 . . . . 0.0 110.496 -179.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.488 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 170.18 105.35 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.191 -0.943 . . . . 0.0 110.9 179.881 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 89.28 -170.82 37.78 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 120.064 -1.065 . . . . 0.0 110.505 179.07 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.558 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -138.79 167.89 21.0 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.64 -0.918 . . . . 0.0 109.533 179.944 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.862 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.47 133.96 5.98 Favored 'General case' 0 C--N 1.301 -1.51 0 C-N-CA 119.0 -1.08 . . . . 0.0 111.266 -179.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.828 ' N ' HD22 ' A' ' 267' ' ' LEU . 14.3 mm-40 -134.33 129.62 35.77 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.992 -0.744 . . . . 0.0 108.992 179.546 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.796 HG13 ' O ' ' A' ' 281' ' ' ASP . 89.5 t -125.9 139.54 51.16 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.853 -1.154 . . . . 0.0 111.625 -178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.1 mtmt -124.9 157.56 35.67 Favored 'General case' 0 N--CA 1.495 1.79 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 178.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.745 HG13 ' O ' ' A' ' 279' ' ' GLU . 74.5 t -141.62 146.73 22.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 120.43 -1.418 . . . . 0.0 112.068 -179.225 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.557 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -136.28 107.9 6.99 Favored 'General case' 0 N--CA 1.485 1.32 0 N-CA-C 108.641 -0.874 . . . . 0.0 108.641 179.309 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.486 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.2 m-20 -94.74 142.44 27.45 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 120.997 -1.064 . . . . 0.0 111.1 -179.03 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.811 ' CH2' HG23 ' A' ' 337' ' ' ILE . 25.6 p90 -123.97 17.06 9.32 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.44 -0.787 . . . . 0.0 109.831 179.173 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.43 -55.54 3.88 Favored Glycine 0 N--CA 1.491 2.309 0 N-CA-C 109.807 -1.317 . . . . 0.0 109.807 179.624 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -76.31 -18.94 58.7 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.227 -1.161 . . . . 0.0 110.286 -179.785 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.24 -179.37 40.63 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.683 -1.367 . . . . 0.0 109.683 -179.976 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.551 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -139.06 137.13 35.96 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.311 -1.111 . . . . 0.0 110.173 -179.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.745 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.6 mt-10 -92.7 146.84 23.35 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.348 -0.845 . . . . 0.0 110.264 -179.584 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.2 m-85 -139.98 90.34 2.37 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.201 -0.937 . . . . 0.0 111.265 -179.369 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.796 ' O ' HG13 ' A' ' 269' ' ' VAL . 4.7 t70 -72.62 146.92 46.29 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.51 -0.744 . . . . 0.0 109.408 178.816 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.71 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.4 t -140.77 86.94 0.44 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 O-C-N 121.184 -0.947 . . . . 0.0 110.094 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 1.003 HG23 ' OG1' ' A' ' 333' ' ' THR . 13.2 m -86.74 122.88 31.25 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.069 -1.019 . . . . 0.0 110.04 179.827 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.09 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.56 154.05 22.5 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.273 -0.892 . . . . 0.0 110.226 -179.644 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.558 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -133.69 113.75 12.7 Favored 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.106 -0.996 . . . . 0.0 110.89 -179.071 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.988 HD13 ' HB2' ' A' ' 290' ' ' TYR . 13.3 mt -123.83 158.59 31.47 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 120.549 -1.345 . . . . 0.0 109.884 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -90.1 35.22 0.85 Allowed 'General case' 0 C--N 1.3 -1.549 0 O-C-N 121.292 -0.88 . . . . 0.0 109.807 179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.438 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 154.92 -134.25 4.15 Favored Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.819 -1.312 . . . . 0.0 109.819 -179.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.515 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 47.5 mm-40 -106.84 111.63 24.24 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.177 -1.19 . . . . 0.0 111.026 -179.55 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.988 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.9 m-85 -132.06 136.96 47.59 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.336 -0.852 . . . . 0.0 109.301 179.175 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.778 ' O ' HG23 ' A' ' 353' ' ' ILE . 31.1 m-20 -75.37 96.42 3.4 Favored 'General case' 0 C--N 1.299 -1.616 0 O-C-N 120.756 -1.215 . . . . 0.0 108.617 178.897 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.932 ' CE3' HD13 ' A' ' 284' ' ' LEU . 61.3 p-90 -99.6 114.1 26.93 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.449 -0.782 . . . . 0.0 110.904 -178.982 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 1.011 HG23 HG22 ' A' ' 322' ' ' THR . 27.3 m -111.43 118.09 34.84 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 179.155 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.755 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.1 t -96.75 111.0 25.86 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.183 -0.948 . . . . 0.0 110.737 -179.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.585 ' HA ' HD13 ' A' ' 320' ' ' ILE . 7.0 ttpp -83.34 148.6 27.24 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.441 -0.787 . . . . 0.0 109.012 178.778 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.594 HG13 ' CG2' ' A' ' 346' ' ' VAL . 44.5 t -147.3 104.99 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.6 0 O-C-N 121.096 -1.003 . . . . 0.0 110.707 -179.25 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.604 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.7 mmtp -70.63 133.14 46.42 Favored 'General case' 0 N--CA 1.486 1.368 0 O-C-N 121.297 -0.877 . . . . 0.0 109.431 179.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 1.038 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.0 mt -86.37 150.28 24.43 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.115 -0.991 . . . . 0.0 111.474 -179.071 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.675 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -61.0 171.89 1.01 Allowed Pre-proline 0 N--CA 1.489 1.48 0 O-C-N 121.686 -0.634 . . . . 0.0 109.681 179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.675 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.2 Cg_endo -67.53 82.58 0.41 Allowed 'Trans proline' 0 C--N 1.303 -1.853 0 O-C-N 123.785 1.413 . . . . 0.0 109.642 179.539 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.11 28.27 2.68 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.666 -1.774 . . . . 0.0 108.666 -179.168 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.72 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -122.32 146.36 47.38 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.373 -1.075 . . . . 0.0 110.557 -179.437 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 1.038 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.3 p -149.57 143.59 25.68 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.185 -0.947 . . . . 0.0 110.748 179.514 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.988 ' CG2' HG21 ' A' ' 319' ' ' VAL . 66.8 t -68.48 130.76 33.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.316 -0.865 . . . . 0.0 110.246 179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -114.04 -39.33 1.06 Allowed Glycine 0 N--CA 1.49 2.256 0 N-CA-C 109.938 -1.265 . . . . 0.0 109.938 -179.594 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.513 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 18.1 m -132.64 141.67 48.75 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.188 -1.184 . . . . 0.0 110.913 -179.631 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.569 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 28.5 p90 -153.75 167.96 27.89 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.363 -0.836 . . . . 0.0 109.656 179.465 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.505 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -160.67 158.43 28.82 Favored 'General case' 0 N--CA 1.495 1.809 0 O-C-N 120.995 -1.066 . . . . 0.0 111.253 -179.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.555 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.3 OUTLIER 57.61 31.96 21.13 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.631 -0.668 . . . . 0.0 111.245 179.473 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.785 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.91 150.85 1.04 Allowed 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.049 -1.032 . . . . 0.0 110.457 179.349 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.51 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 1.9 m-80 -81.22 109.7 16.0 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.088 -1.007 . . . . 0.0 109.439 179.012 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.569 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 27.6 ttpt -84.97 132.52 34.34 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.46 -0.775 . . . . 0.0 110.603 -179.433 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.695 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.07 174.73 7.83 Favored 'General case' 0 C--N 1.302 -1.491 0 O-C-N 121.53 -0.731 . . . . 0.0 109.465 179.329 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 85.0 mt-10 -138.2 104.68 5.27 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.523 -0.736 . . . . 0.0 110.064 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -92.0 37.93 3.29 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 110.085 -1.206 . . . . 0.0 110.085 -179.642 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 63.12 81.24 0.21 Allowed 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.048 -1.266 . . . . 0.0 110.253 179.88 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.25 -0.04 57.12 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.827 -1.309 . . . . 0.0 109.827 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.716 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.33 -171.33 3.71 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.347 -1.09 . . . . 0.0 109.359 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.988 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -159.46 157.91 2.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.117 -0.989 . . . . 0.0 109.844 178.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.585 HD13 ' HA ' ' A' ' 295' ' ' LYS . 8.7 mm -125.87 150.32 31.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.073 -1.017 . . . . 0.0 111.376 -179.176 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.638 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 89.3 m-85 -130.98 112.49 12.98 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.301 -0.874 . . . . 0.0 110.285 179.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 1.011 HG22 HG23 ' A' ' 293' ' ' THR . 2.8 p -115.02 174.23 2.48 Favored Pre-proline 0 N--CA 1.498 1.973 0 O-C-N 120.512 -1.367 . . . . 0.0 109.54 179.238 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.601 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 43.1 Cg_endo -71.13 125.07 11.07 Favored 'Trans proline' 0 C--N 1.312 -1.366 0 O-C-N 123.607 1.319 . . . . 0.0 111.283 -178.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.764 HG22 ' CG ' ' A' ' 327' ' ' ASN . 14.9 m -70.06 -110.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.518 -0.739 . . . . 0.0 110.438 -179.865 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.522 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.1 OUTLIER -119.42 -16.95 8.88 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.715 -1.241 . . . . 0.0 111.299 -179.277 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.499 ' CH2' ' HA ' ' A' ' 309' ' ' SER . 3.1 p-90 -125.93 -18.9 4.97 Favored 'General case' 0 N--CA 1.498 1.965 0 O-C-N 120.914 -1.116 . . . . 0.0 111.077 -179.507 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.764 ' CG ' HG22 ' A' ' 324' ' ' VAL . 34.0 p-10 -89.7 47.28 1.45 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.928 -1.108 . . . . 0.0 110.046 -179.862 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.501 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 13.5 mtmt -118.26 -10.09 10.31 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.493 -0.754 . . . . 0.0 109.426 179.711 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.472 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.24 -157.07 0.01 OUTLIER Glycine 0 N--CA 1.491 2.342 0 N-CA-C 109.9 -1.28 . . . . 0.0 109.9 -179.698 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.549 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -74.73 5.69 3.71 Favored 'Trans proline' 0 C--N 1.306 -1.662 0 O-C-N 124.03 1.542 . . . . 0.0 111.077 -179.741 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 3.6 m -161.93 120.03 2.25 Favored 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.223 -0.923 . . . . 0.0 109.874 179.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.534 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.41 117.78 14.67 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.222 -0.924 . . . . 0.0 110.361 -179.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 1.003 ' OG1' HG23 ' A' ' 283' ' ' THR . 26.2 m -109.68 135.28 50.87 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.367 -0.833 . . . . 0.0 110.434 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.785 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 13.4 p90 -142.82 174.44 10.65 Favored 'General case' 0 N--CA 1.489 1.513 0 N-CA-C 108.83 -0.804 . . . . 0.0 108.83 179.461 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.09 162.94 29.35 Favored Glycine 0 N--CA 1.489 2.233 0 C-N-CA 118.888 -1.625 . . . . 0.0 110.582 -179.297 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.899 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -150.84 145.05 25.43 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.567 -0.961 . . . . 0.0 109.558 179.352 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.899 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -118.89 122.4 69.26 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.679 0 O-C-N 121.058 -1.026 . . . . 0.0 110.069 -179.803 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.72 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -98.36 146.06 8.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.22 -0.925 . . . . 0.0 109.695 179.596 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -119.39 137.22 53.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.275 -0.891 . . . . 0.0 110.729 -179.511 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.469 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.49 -136.59 2.98 Favored Glycine 0 N--CA 1.492 2.397 0 N-CA-C 108.939 -1.665 . . . . 0.0 108.939 179.725 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.513 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 45.3 Cg_endo -72.01 -156.83 0.05 OUTLIER 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 123.836 1.44 . . . . 0.0 109.697 179.159 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.563 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -120.41 144.18 48.07 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.007 -1.058 . . . . 0.0 110.119 -179.936 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.46 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 103.08 66.59 0.74 Allowed Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.163 -1.575 . . . . 0.0 109.163 -179.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.46 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 16.3 m-20 61.51 134.61 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.296 -1.12 . . . . 0.0 109.782 -179.632 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.576 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.8 OUTLIER -133.12 28.71 4.1 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.193 -0.942 . . . . 0.0 110.742 -179.506 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 346' ' ' VAL . 7.1 p -131.46 111.22 18.76 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.265 -0.897 . . . . 0.0 109.907 179.49 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.516 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.1 mm-40 -43.14 -46.83 6.03 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.202 -0.936 . . . . 0.0 110.425 -179.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -175.95 157.78 1.95 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.217 -0.927 . . . . 0.0 110.357 179.956 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.586 HG12 HG22 ' A' ' 296' ' ' VAL . 13.5 mt -118.43 104.36 15.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.243 -0.911 . . . . 0.0 109.945 179.906 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.03 126.83 52.49 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.271 -0.893 . . . . 0.0 110.499 -179.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.09 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -91.11 130.17 37.03 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.03 -1.044 . . . . 0.0 110.025 179.557 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 15.9 tt0 -138.55 117.59 12.54 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.31 -0.869 . . . . 0.0 109.549 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.778 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.11 98.19 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 120.921 -1.112 . . . . 0.0 110.118 -179.868 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.542 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 38.57 28.24 0.02 OUTLIER 'General case' 0 C--N 1.296 -1.738 0 CA-C-N 116.101 -0.5 . . . . 0.0 111.296 179.634 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.474 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 134.94 -19.47 3.92 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.538 -1.315 . . . . 0.0 110.889 179.201 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.487 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 11.1 mm100 -102.78 113.15 26.33 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 120.871 -1.37 . . . . 0.0 110.905 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.587 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.7 p -76.89 121.17 28.62 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.734 0 O-C-N 121.485 -0.759 . . . . 0.0 110.354 179.889 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.551 HG23 ' CB ' ' A' ' 262' ' ' PRO . 26.7 mm . . . . . 0 N--CA 1.49 1.556 0 CA-C-O 118.018 -0.991 . . . . 0.0 110.165 179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.297 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -73.17 -178.27 3.49 Favored 'Trans proline' 0 C--N 1.303 -1.834 0 O-C-N 124.048 1.551 . . . . 0.0 110.505 -179.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.582 HG23 ' O ' ' A' ' 258' ' ' THR . 5.2 t -65.79 122.77 18.06 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.328 -0.858 . . . . 0.0 110.349 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 17.0 p -112.0 125.44 30.22 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.236 -0.915 . . . . 0.0 110.279 -179.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -73.88 142.15 31.23 Favored 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.884 1.465 . . . . 0.0 110.25 179.877 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.677 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -110.39 145.65 32.66 Favored Pre-proline 0 N--CA 1.491 1.588 0 O-C-N 121.23 -0.919 . . . . 0.0 110.423 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.677 ' HD2' HG23 ' A' ' 261' ' ' VAL . 44.5 Cg_endo -71.21 157.67 56.66 Favored 'Trans proline' 0 C--N 1.306 -1.698 0 O-C-N 124.113 1.586 . . . . 0.0 110.441 179.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.553 HG12 ' O ' ' A' ' 263' ' ' VAL . 23.5 t -144.61 29.41 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 121.165 -0.959 . . . . 0.0 110.536 -179.846 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER 176.05 104.04 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.285 -0.885 . . . . 0.0 110.424 179.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 92.59 -172.78 34.7 Favored Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.902 -1.279 . . . . 0.0 109.902 179.761 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.538 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.41 166.08 25.5 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.334 -1.098 . . . . 0.0 110.043 179.971 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.927 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.65 139.77 9.22 Favored 'General case' 0 N--CA 1.487 1.39 0 O-C-N 121.025 -1.047 . . . . 0.0 111.409 -179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.793 ' N ' HD22 ' A' ' 267' ' ' LEU . 3.7 mt-10 -136.12 153.78 51.19 Favored 'General case' 0 N--CA 1.489 1.507 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 179.146 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.704 HG13 ' O ' ' A' ' 281' ' ' ASP . 54.0 t -145.27 135.67 19.09 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 120.697 -1.252 . . . . 0.0 111.567 -179.332 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.411 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.7 mtpt -122.88 157.05 33.38 Favored 'General case' 0 N--CA 1.491 1.623 0 N-CA-C 108.616 -0.883 . . . . 0.0 108.616 178.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.822 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.5 t -144.81 147.2 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 120.478 -1.389 . . . . 0.0 112.167 -179.144 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.524 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.64 112.64 7.35 Favored 'General case' 0 N--CA 1.491 1.59 0 N-CA-C 109.08 -0.711 . . . . 0.0 109.08 178.791 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 p-10 -97.53 141.76 30.19 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.948 -1.095 . . . . 0.0 111.402 -178.499 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.779 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.3 p90 -124.5 19.99 8.75 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.502 -0.748 . . . . 0.0 109.8 179.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.464 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 85.74 -59.58 4.75 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 109.321 -1.512 . . . . 0.0 109.321 -179.852 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -64.99 -20.07 66.31 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.23 -1.159 . . . . 0.0 110.11 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.48 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.12 -175.03 44.93 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 179.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.4 143.94 42.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.265 -1.138 . . . . 0.0 110.225 179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.822 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.9 mt-10 -96.97 145.83 25.54 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.385 -0.822 . . . . 0.0 109.789 -179.573 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.681 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 96.1 m-85 -138.93 86.73 2.16 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.452 -0.78 . . . . 0.0 110.92 -179.501 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.704 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.59 146.83 49.84 Favored 'General case' 0 C--N 1.304 -1.402 0 O-C-N 121.316 -0.865 . . . . 0.0 109.442 179.105 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.825 HG11 HG11 ' A' ' 294' ' ' VAL . 5.6 t -140.22 90.26 0.56 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 121.336 -0.853 . . . . 0.0 109.932 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.891 HG23 ' OG1' ' A' ' 333' ' ' THR . 53.9 m -86.58 127.92 34.94 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.058 -1.026 . . . . 0.0 109.681 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.89 152.1 32.84 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.127 -0.983 . . . . 0.0 110.687 -179.245 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.902 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -130.56 134.54 47.1 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.282 -0.886 . . . . 0.0 110.263 -179.865 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.902 HD23 ' O ' ' A' ' 285' ' ' ASN . 12.7 mt -143.72 155.55 44.24 Favored 'General case' 0 C--N 1.3 -1.552 0 O-C-N 120.938 -1.101 . . . . 0.0 109.491 179.797 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -88.6 40.02 0.95 Allowed 'General case' 0 C--N 1.295 -1.769 0 O-C-N 121.284 -0.885 . . . . 0.0 109.723 179.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.54 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 150.3 -116.69 0.79 Allowed Glycine 0 N--CA 1.492 2.381 0 C-N-CA 118.991 -1.576 . . . . 0.0 110.242 -179.653 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.559 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.6 mt-30 -128.62 116.31 19.4 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.022 -1.281 . . . . 0.0 110.926 -179.297 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.599 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 8.8 m-85 -138.23 137.03 37.15 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.191 -0.943 . . . . 0.0 109.664 179.462 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.717 ' O ' HG23 ' A' ' 353' ' ' ILE . 23.2 m-20 -71.02 96.81 1.36 Allowed 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.815 -1.178 . . . . 0.0 108.981 179.043 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.867 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.2 p-90 -98.08 113.1 24.89 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.221 -0.924 . . . . 0.0 110.833 -179.231 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.663 HG23 ' CG2' ' A' ' 322' ' ' THR . 10.3 m -106.23 111.75 24.49 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.417 -0.802 . . . . 0.0 109.243 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.825 HG11 HG11 ' A' ' 282' ' ' VAL . 3.1 t -96.21 111.24 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.167 -0.958 . . . . 0.0 110.371 -179.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.53 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 5.1 ttmt -89.19 149.51 23.09 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.438 -0.788 . . . . 0.0 109.51 179.408 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.914 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 56.1 t -142.34 107.87 1.63 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.288 -0.882 . . . . 0.0 110.31 -179.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.555 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 11.5 mmtt -70.2 131.34 44.07 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.179 -0.95 . . . . 0.0 109.645 179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.941 HD13 ' HA ' ' A' ' 303' ' ' THR . 94.8 mt -85.25 160.89 19.76 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.403 -0.81 . . . . 0.0 111.312 -179.13 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.714 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -71.43 174.32 4.01 Favored Pre-proline 0 N--CA 1.487 1.389 0 O-C-N 121.571 -0.705 . . . . 0.0 109.212 179.099 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.714 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.43 84.08 0.37 Allowed 'Trans proline' 0 C--N 1.306 -1.702 0 O-C-N 123.492 1.259 . . . . 0.0 110.096 179.715 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.97 24.66 4.79 Favored Glycine 0 N--CA 1.489 2.208 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 -179.546 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.8 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.9 148.32 40.13 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.323 -1.104 . . . . 0.0 110.225 -179.824 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.941 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -149.84 143.6 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.104 -0.998 . . . . 0.0 110.718 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.736 HG21 HG11 ' A' ' 319' ' ' VAL . 85.2 t -65.63 121.94 15.65 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.418 -0.801 . . . . 0.0 109.906 179.588 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . 0.434 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -103.16 -30.25 5.46 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 110.042 -1.223 . . . . 0.0 110.042 -179.483 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.439 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.3 t -145.85 142.32 28.71 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.004 -1.292 . . . . 0.0 110.911 -179.748 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.518 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 15.0 p90 -152.6 174.65 13.69 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.544 -0.722 . . . . 0.0 109.38 179.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.479 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -163.84 159.55 21.26 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 120.848 -1.158 . . . . 0.0 111.486 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.452 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.7 OUTLIER 55.68 26.41 9.3 Favored 'General case' 0 N--CA 1.497 1.883 0 O-C-N 121.564 -0.71 . . . . 0.0 111.116 179.591 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.716 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.68 139.25 0.7 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.195 -0.941 . . . . 0.0 109.897 179.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.68 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.3 m-80 -77.42 121.24 23.53 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.062 -1.024 . . . . 0.0 109.488 179.798 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.533 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.3 ttpt -88.33 142.81 27.44 Favored 'General case' 0 C--N 1.301 -1.533 0 CA-C-O 121.844 0.83 . . . . 0.0 110.552 -179.42 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.622 ' O ' HG22 ' A' ' 319' ' ' VAL . 1.6 mt-30 -130.25 176.48 8.07 Favored 'General case' 0 C--N 1.297 -1.678 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 179.255 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.454 ' OE1' ' O ' ' A' ' 318' ' ' TYR . 5.3 mm-40 -135.79 113.32 10.8 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.115 -0.99 . . . . 0.0 110.545 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.558 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -100.6 42.13 2.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 179.683 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.47 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 20.6 t-20 57.41 81.49 0.14 Allowed 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.335 -1.097 . . . . 0.0 110.269 -179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.597 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.82 3.74 58.08 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.795 -1.322 . . . . 0.0 109.795 179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.843 ' O ' HG23 ' A' ' 319' ' ' VAL . 0.8 OUTLIER -147.08 -167.72 2.85 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.353 -1.087 . . . . 0.0 109.055 179.532 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.843 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.7 t -163.28 147.73 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.195 -0.94 . . . . 0.0 109.733 178.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.619 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 7.6 mm -112.35 152.06 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 121.005 -1.06 . . . . 0.0 110.998 -179.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.657 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 58.4 m-85 -129.24 125.86 37.83 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.322 -0.861 . . . . 0.0 109.812 179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.663 ' CG2' HG23 ' A' ' 293' ' ' THR . 7.2 p -129.04 167.7 18.71 Favored Pre-proline 0 N--CA 1.49 1.55 0 O-C-N 120.488 -1.382 . . . . 0.0 109.965 179.443 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.552 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 38.7 Cg_endo -65.74 119.36 6.37 Favored 'Trans proline' 0 C--N 1.306 -1.689 0 O-C-N 123.78 1.411 . . . . 0.0 111.087 -179.233 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.68 HG12 ' ND2' ' A' ' 311' ' ' ASN . 31.3 m -64.73 -121.38 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.485 -0.759 . . . . 0.0 110.297 -179.967 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.512 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -106.18 -19.9 13.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 120.809 -1.182 . . . . 0.0 110.666 -179.649 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.567 ' H ' HG23 ' A' ' 324' ' ' VAL . 21.6 p-90 -126.2 3.17 7.13 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.08 -1.012 . . . . 0.0 110.653 -179.894 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.532 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 1.9 t-20 -108.08 31.72 5.32 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.093 -1.005 . . . . 0.0 110.576 -179.551 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.552 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -110.46 -2.6 16.47 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 121.102 -0.999 . . . . 0.0 109.547 179.433 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.478 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.05 -153.33 0.02 OUTLIER Glycine 0 N--CA 1.486 2.017 0 N-CA-C 108.822 -1.711 . . . . 0.0 108.822 179.942 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.565 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.6 Cg_endo -69.8 -48.89 0.62 Allowed 'Trans proline' 0 C--N 1.301 -1.935 0 O-C-N 123.987 1.52 . . . . 0.0 109.474 -179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -109.08 125.58 52.27 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.527 -0.733 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.532 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.74 108.09 6.86 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.36 -0.838 . . . . 0.0 109.993 179.956 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.891 ' OG1' HG23 ' A' ' 283' ' ' THR . 3.3 m -103.17 138.92 39.34 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.258 -0.901 . . . . 0.0 110.227 -179.904 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.805 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.0 p90 -144.74 174.63 10.81 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.374 -0.829 . . . . 0.0 109.138 179.543 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.04 158.26 27.59 Favored Glycine 0 N--CA 1.488 2.15 0 C-N-CA 118.984 -1.579 . . . . 0.0 110.336 -179.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.914 ' CZ ' HG11 ' A' ' 296' ' ' VAL . 0.9 OUTLIER -147.93 143.87 27.65 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.57 -0.959 . . . . 0.0 109.553 179.321 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.887 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -118.01 129.67 74.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.073 -1.017 . . . . 0.0 110.107 -179.789 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.8 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.3 t -104.92 148.48 9.39 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.132 -0.98 . . . . 0.0 110.027 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -120.7 135.47 55.12 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.326 -0.859 . . . . 0.0 110.181 -179.836 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.431 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -179.73 -138.63 3.41 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 109.499 -1.441 . . . . 0.0 109.499 179.93 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.503 ' C ' ' NE2' ' A' ' 342' ' ' GLN . 50.0 Cg_endo -74.91 -166.14 0.33 Allowed 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 124.0 1.526 . . . . 0.0 110.479 -179.98 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.503 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 21.3 mm-40 -110.29 143.27 40.73 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.201 -0.937 . . . . 0.0 110.284 -179.633 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 103.52 69.37 0.8 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 -179.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.467 ' O ' ' O ' ' A' ' 343' ' ' GLY . 15.3 m-20 61.52 134.76 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.337 -1.096 . . . . 0.0 109.466 -179.27 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.658 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.1 mtmt -129.13 15.7 6.21 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.035 -1.04 . . . . 0.0 110.335 -179.726 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.628 HG11 ' CE1' ' A' ' 280' ' ' TYR . 6.8 p -128.91 117.4 44.22 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.309 -0.869 . . . . 0.0 110.107 179.461 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.2 OUTLIER -47.57 -47.88 28.2 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.046 -1.034 . . . . 0.0 110.068 -179.771 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.409 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.7 OUTLIER -177.2 158.33 1.47 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.289 -0.882 . . . . 0.0 110.35 -179.934 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.661 HG12 HG13 ' A' ' 296' ' ' VAL . 17.0 mt -117.34 110.37 30.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.1 -1.0 . . . . 0.0 110.215 179.719 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.67 144.03 41.59 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.271 -0.893 . . . . 0.0 110.2 -179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.66 132.77 50.52 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.18 -0.95 . . . . 0.0 110.249 179.869 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 5.4 tt0 -139.07 113.13 8.64 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.373 -0.829 . . . . 0.0 109.945 179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.717 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.8 mt -91.64 112.53 25.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 120.913 -1.117 . . . . 0.0 110.088 179.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.548 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.84 29.72 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.782 -0.574 . . . . 0.0 111.295 -179.961 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.458 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.26 -10.24 14.98 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.667 -1.254 . . . . 0.0 110.6 179.123 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.402 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 43.1 mm-40 -101.45 115.06 29.65 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.878 -1.366 . . . . 0.0 110.364 -179.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.79 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.1 p -75.13 139.09 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.279 -0.888 . . . . 0.0 110.493 -179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.79 HD13 ' O ' ' A' ' 357' ' ' VAL . 26.6 mm . . . . . 0 N--CA 1.493 1.705 0 CA-C-O 118.009 -0.996 . . . . 0.0 110.196 179.889 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.259 0 N-CA-C 109.496 -1.442 . . . . 0.0 109.496 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.82 -178.24 3.35 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 O-C-N 124.149 1.605 . . . . 0.0 110.619 -179.976 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 11.1 t -57.6 145.51 33.55 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.358 -0.838 . . . . 0.0 110.39 -179.801 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -110.52 95.67 23.94 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 121.344 -0.848 . . . . 0.0 110.245 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -72.86 158.12 50.56 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 123.984 1.518 . . . . 0.0 110.638 179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.671 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.8 p -85.06 145.72 43.9 Favored Pre-proline 0 N--CA 1.492 1.663 0 O-C-N 121.179 -0.95 . . . . 0.0 110.269 179.891 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.671 ' HD2' HG23 ' A' ' 261' ' ' VAL . 50.2 Cg_endo -74.62 125.9 9.84 Favored 'Trans proline' 0 C--N 1.303 -1.821 0 O-C-N 124.08 1.568 . . . . 0.0 110.577 179.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.733 HG12 ' O ' ' A' ' 263' ' ' VAL . 96.3 t -114.28 28.71 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.305 -0.872 . . . . 0.0 109.781 179.456 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.727 ' HB2' HD11 ' A' ' 358' ' ' ILE . 3.1 t -141.22 -139.84 0.13 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.385 -0.822 . . . . 0.0 110.408 -179.816 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.583 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . -59.78 -139.4 0.01 OUTLIER Glycine 0 N--CA 1.491 2.3 0 N-CA-C 110.127 -1.189 . . . . 0.0 110.127 -179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.554 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.8 OUTLIER -136.0 167.06 21.92 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.447 -1.031 . . . . 0.0 109.495 179.841 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.953 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.9 tm? -161.06 136.84 8.05 Favored 'General case' 0 C--N 1.302 -1.476 0 C-N-CA 118.757 -1.177 . . . . 0.0 111.515 -179.266 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.821 ' N ' HD22 ' A' ' 267' ' ' LEU . 8.0 mm-40 -135.69 156.12 49.34 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 108.619 -0.882 . . . . 0.0 108.619 179.405 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.865 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.9 t -146.96 146.29 18.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.628 0 O-C-N 120.648 -1.283 . . . . 0.0 111.617 -179.249 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.418 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.2 OUTLIER -132.4 157.6 44.14 Favored 'General case' 0 N--CA 1.495 1.822 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 179.186 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.724 HG13 ' O ' ' A' ' 279' ' ' GLU . 86.7 t -144.88 147.2 19.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 120.262 -1.524 . . . . 0.0 112.401 -179.258 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.522 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.46 114.58 8.66 Favored 'General case' 0 N--CA 1.49 1.554 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 178.906 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 7.0 p-10 -97.81 148.73 23.1 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.087 -1.008 . . . . 0.0 111.366 -178.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.8 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.1 p90 -134.85 17.42 3.53 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.608 -0.682 . . . . 0.0 109.96 179.381 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.439 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 92.46 -66.28 2.05 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.549 -1.421 . . . . 0.0 109.549 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.489 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 57.4 m -64.3 -18.77 64.92 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.322 -1.105 . . . . 0.0 110.581 -179.809 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.532 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -179.24 178.65 48.82 Favored Glycine 0 N--CA 1.491 2.304 0 C-N-CA 119.164 -1.493 . . . . 0.0 110.246 179.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.54 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.66 145.99 50.46 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.505 -0.997 . . . . 0.0 110.019 179.904 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.724 ' O ' HG13 ' A' ' 271' ' ' VAL . 11.4 mt-10 -96.36 146.86 24.38 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.433 -0.792 . . . . 0.0 109.425 179.993 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.676 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.2 m-85 -138.33 89.17 2.36 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.31 -0.869 . . . . 0.0 110.584 -179.339 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.865 ' O ' HG13 ' A' ' 269' ' ' VAL . 71.4 m-20 -69.64 147.49 50.57 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.679 -0.638 . . . . 0.0 109.828 179.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.693 HG11 HG11 ' A' ' 294' ' ' VAL . 3.4 t -142.76 89.96 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.355 -0.84 . . . . 0.0 109.543 179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.876 HG23 ' OG1' ' A' ' 333' ' ' THR . 27.3 m -86.49 120.51 27.89 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.106 -0.996 . . . . 0.0 109.857 -179.838 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.34 149.37 28.77 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.22 -0.925 . . . . 0.0 110.602 -179.478 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.907 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -128.04 136.21 50.93 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.395 -0.816 . . . . 0.0 110.084 -179.799 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.907 HD23 ' O ' ' A' ' 285' ' ' ASN . 14.2 mt -142.17 154.52 44.9 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 120.721 -1.237 . . . . 0.0 109.854 179.826 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -85.77 36.27 0.65 Allowed 'General case' 0 C--N 1.299 -1.594 0 O-C-N 121.381 -0.825 . . . . 0.0 110.311 -179.823 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.486 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 150.56 -104.12 0.26 Allowed Glycine 0 N--CA 1.49 2.291 0 C-N-CA 119.056 -1.545 . . . . 0.0 110.082 -179.665 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.5 mm-40 -139.87 113.67 8.73 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.015 -1.285 . . . . 0.0 111.429 -179.11 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.639 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 4.8 m-85 -138.75 129.93 26.95 Favored 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.26 -0.9 . . . . 0.0 109.461 178.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.536 ' O ' HG23 ' A' ' 353' ' ' ILE . 90.0 m-20 -65.16 99.69 0.39 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.817 -1.177 . . . . 0.0 109.266 179.493 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.897 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.4 p-90 -98.77 115.86 29.72 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.335 -0.853 . . . . 0.0 110.868 -179.27 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.6 HG22 ' CG2' ' A' ' 320' ' ' ILE . 9.8 m -105.98 116.26 31.63 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.66 -0.65 . . . . 0.0 109.299 179.538 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.774 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.75 111.44 26.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 O-C-N 121.02 -1.05 . . . . 0.0 110.662 -179.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.793 ' HA ' HD13 ' A' ' 320' ' ' ILE . 2.8 ttpt -85.44 144.03 28.22 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.431 -0.793 . . . . 0.0 109.156 179.121 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.958 HG22 HG23 ' A' ' 349' ' ' ILE . 99.0 t -144.34 106.84 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.028 -1.045 . . . . 0.0 110.662 -179.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.564 ' HD3' ' CG ' ' A' ' 318' ' ' TYR . 35.7 mmtt -70.57 130.38 41.67 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.27 -0.894 . . . . 0.0 109.804 179.736 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.958 HD13 ' HA ' ' A' ' 303' ' ' THR . 77.2 mt -85.38 155.08 21.45 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.516 -0.74 . . . . 0.0 111.398 -178.972 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.784 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -59.7 176.23 0.33 Allowed Pre-proline 0 N--CA 1.489 1.504 0 O-C-N 121.54 -0.725 . . . . 0.0 109.409 179.106 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.784 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.5 Cg_endo -69.19 81.07 0.69 Allowed 'Trans proline' 0 C--N 1.305 -1.725 0 O-C-N 123.612 1.322 . . . . 0.0 109.895 179.508 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.2 4.9 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.779 -1.728 . . . . 0.0 108.779 -179.303 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.811 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -110.24 149.7 29.77 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.417 -1.049 . . . . 0.0 110.188 -179.797 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.958 ' HA ' HD13 ' A' ' 298' ' ' LEU . 9.5 p -150.15 145.08 26.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.151 -0.968 . . . . 0.0 110.573 179.677 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.724 HG21 HG11 ' A' ' 319' ' ' VAL . 77.5 t -71.25 122.6 23.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.527 -0.733 . . . . 0.0 109.865 179.82 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -103.5 -37.99 2.91 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.941 -1.264 . . . . 0.0 109.941 -179.619 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.461 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -132.29 136.4 46.89 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.076 -1.249 . . . . 0.0 111.035 -179.559 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.59 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 50.3 p90 -147.67 159.91 43.27 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.458 -0.776 . . . . 0.0 109.468 179.341 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.516 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -154.65 158.13 39.19 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.976 -1.077 . . . . 0.0 111.239 -179.46 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.2 OUTLIER 63.98 20.39 12.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.553 -0.717 . . . . 0.0 110.532 179.63 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.543 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.76 147.44 1.03 Allowed 'General case' 0 C--N 1.298 -1.648 0 O-C-N 121.564 -0.71 . . . . 0.0 110.022 179.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.726 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -82.07 123.81 29.27 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.109 -0.994 . . . . 0.0 108.982 179.394 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.59 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 11.6 ttpt -89.42 137.96 31.87 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.63 0.729 . . . . 0.0 111.217 -178.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.682 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.15 172.36 8.63 Favored 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.742 -0.836 . . . . 0.0 108.742 178.776 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 7.6 mt-10 -139.28 104.49 5.0 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.201 -0.937 . . . . 0.0 110.506 -179.832 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.466 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -92.31 40.37 2.89 Favored Glycine 0 N--CA 1.489 2.224 0 N-CA-C 109.411 -1.476 . . . . 0.0 109.411 179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.466 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 0.8 OUTLIER 58.08 86.13 0.08 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.352 -1.087 . . . . 0.0 110.418 -179.966 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.596 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.51 -4.54 58.25 Favored Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.821 -1.312 . . . . 0.0 109.821 179.657 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.693 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.0 OUTLIER -144.94 -172.05 3.76 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.4 -1.059 . . . . 0.0 109.243 179.624 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.724 HG11 HG21 ' A' ' 304' ' ' VAL . 3.3 t -159.08 161.45 1.59 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.714 0 O-C-N 121.211 -0.931 . . . . 0.0 109.739 178.978 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.793 HD13 ' HA ' ' A' ' 295' ' ' LYS . 42.4 mm -129.26 151.13 35.34 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.275 -0.89 . . . . 0.0 111.184 -179.66 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.628 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 97.4 m-85 -128.9 125.2 37.08 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.315 -0.866 . . . . 0.0 109.915 179.153 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.54 ' OG1' ' HB2' ' A' ' 311' ' ' ASN . 10.7 p -124.82 168.36 13.51 Favored Pre-proline 0 N--CA 1.493 1.724 0 O-C-N 120.799 -1.188 . . . . 0.0 109.715 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.529 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.7 Cg_endo -66.73 121.71 8.97 Favored 'Trans proline' 0 C--N 1.308 -1.599 0 O-C-N 123.692 1.364 . . . . 0.0 110.808 -179.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.829 HG22 ' HB2' ' A' ' 327' ' ' ASN . 31.2 m -69.5 -123.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.554 -0.716 . . . . 0.0 110.083 -179.941 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.479 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -100.44 -20.89 15.57 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 120.874 -1.141 . . . . 0.0 110.606 -179.76 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.57 ' H ' HG23 ' A' ' 324' ' ' VAL . 8.4 p-90 -127.15 5.89 6.45 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.126 -0.984 . . . . 0.0 110.564 -179.728 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.829 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -103.39 37.53 1.98 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.125 -0.984 . . . . 0.0 110.473 -179.689 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.473 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -117.47 -9.0 10.93 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.282 -0.886 . . . . 0.0 109.619 179.689 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.463 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -56.31 -162.6 0.02 OUTLIER Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -179.748 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.451 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 47.6 Cg_endo -74.14 5.16 3.72 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.228 1.646 . . . . 0.0 110.953 -179.693 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.444 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.1 m -164.81 115.7 1.17 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.254 -0.904 . . . . 0.0 109.987 179.911 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.815 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -134.14 117.93 17.11 Favored 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.143 -0.973 . . . . 0.0 110.319 -179.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.876 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.6 m -108.78 136.61 48.06 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.407 -0.808 . . . . 0.0 109.995 179.799 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.774 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.3 p90 -140.63 172.09 13.19 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.692 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.527 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.21 158.51 27.71 Favored Glycine 0 N--CA 1.489 2.187 0 C-N-CA 118.935 -1.602 . . . . 0.0 110.075 -179.469 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.942 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -146.22 147.28 31.28 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.437 -1.037 . . . . 0.0 109.906 179.614 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.942 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.58 119.58 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.056 -1.028 . . . . 0.0 109.809 -179.989 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.811 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.8 t -97.17 149.1 5.1 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.194 -0.941 . . . . 0.0 110.37 -179.713 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.21 134.07 55.34 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.473 -0.767 . . . . 0.0 109.807 179.625 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.94 -124.98 0.95 Allowed Glycine 0 N--CA 1.493 2.481 0 N-CA-C 109.591 -1.403 . . . . 0.0 109.591 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.533 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 41.6 Cg_endo -66.4 -159.36 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.583 0 O-C-N 123.82 1.431 . . . . 0.0 110.565 179.898 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.484 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 0.9 OUTLIER -119.35 132.2 55.83 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.15 -0.969 . . . . 0.0 111.041 -179.192 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 102.35 -87.91 0.64 Allowed Glycine 0 N--CA 1.492 2.376 0 N-CA-C 109.281 -1.528 . . . . 0.0 109.281 179.785 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -103.07 133.7 47.75 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.424 -1.045 . . . . 0.0 109.234 179.393 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.675 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.4 OUTLIER -135.57 7.51 3.3 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 120.962 -1.086 . . . . 0.0 110.722 -179.559 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.629 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.0 p -133.41 112.64 17.79 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.594 0 O-C-N 121.224 -0.922 . . . . 0.0 109.79 179.168 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.48 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.07 5.82 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.465 -0.772 . . . . 0.0 110.587 -179.419 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 25.7 pt-20 -177.14 158.94 1.57 Allowed 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.224 -0.923 . . . . 0.0 110.86 -179.528 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.958 HG23 HG22 ' A' ' 296' ' ' VAL . 19.0 mt -119.4 108.65 24.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.249 179.646 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.24 146.24 33.12 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.249 -0.907 . . . . 0.0 109.797 179.735 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -104.38 133.1 49.83 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 120.99 -1.068 . . . . 0.0 110.465 -179.972 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.431 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 47.8 tt0 -138.98 110.2 6.9 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.427 -0.795 . . . . 0.0 109.79 179.473 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.536 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.06 109.27 20.83 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.047 -1.033 . . . . 0.0 109.863 179.952 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.529 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 41.12 32.76 0.2 Allowed 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.596 -0.69 . . . . 0.0 110.328 -179.538 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 113.69 -21.4 16.52 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 1.1 mp0 -80.17 104.22 10.58 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.225 -1.162 . . . . 0.0 110.292 -179.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.635 ' O ' HD13 ' A' ' 358' ' ' ILE . 14.6 p -75.62 135.29 27.4 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.274 -0.891 . . . . 0.0 110.081 179.851 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.727 HD11 ' HB2' ' A' ' 264' ' ' SER . 13.0 mm . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 117.951 -1.024 . . . . 0.0 110.154 -179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.312 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.15 -178.93 4.23 Favored 'Trans proline' 0 C--N 1.306 -1.669 0 O-C-N 124.011 1.532 . . . . 0.0 110.549 179.981 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 6.1 t -58.83 146.07 38.55 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.138 -0.976 . . . . 0.0 110.122 179.958 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 45.7 p -104.89 122.53 42.99 Favored Pre-proline 0 N--CA 1.491 1.582 0 O-C-N 121.266 -0.896 . . . . 0.0 110.406 -179.757 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_endo -74.17 161.04 41.55 Favored 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.847 1.446 . . . . 0.0 110.225 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.435 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.4 p -94.28 137.95 22.63 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.146 -0.971 . . . . 0.0 110.067 179.697 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.435 ' HD2' HG23 ' A' ' 261' ' ' VAL . 50.0 Cg_endo -75.18 153.79 41.16 Favored 'Trans proline' 0 C--N 1.303 -1.866 0 O-C-N 124.081 1.569 . . . . 0.0 110.592 -179.852 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.607 HG12 ' O ' ' A' ' 263' ' ' VAL . 49.0 t -127.2 26.55 2.37 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.502 0 O-C-N 121.273 -0.892 . . . . 0.0 109.932 179.676 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.504 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 1.5 p 166.38 142.05 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.446 -0.783 . . . . 0.0 110.327 -179.9 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 64.21 -173.53 14.8 Favored Glycine 0 N--CA 1.492 2.37 0 N-CA-C 109.996 -1.242 . . . . 0.0 109.996 179.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.538 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.48 167.79 21.3 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.376 -1.073 . . . . 0.0 110.038 -179.971 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.982 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.76 135.43 6.52 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.139 -0.976 . . . . 0.0 111.044 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.694 ' N ' HD22 ' A' ' 267' ' ' LEU . 96.4 mt-10 -134.96 126.95 29.63 Favored 'General case' 0 N--CA 1.49 1.552 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.08 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.799 HG23 HD11 ' A' ' 267' ' ' LEU . 64.6 t -117.76 138.61 47.88 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 C-N-CA 118.828 -1.149 . . . . 0.0 112.137 -178.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.422 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.3 OUTLIER -122.83 157.55 32.2 Favored 'General case' 0 N--CA 1.492 1.632 0 N-CA-C 108.388 -0.967 . . . . 0.0 108.388 178.802 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.816 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.3 t -144.56 146.28 20.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 120.35 -1.469 . . . . 0.0 112.232 -179.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.569 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -134.34 110.64 9.6 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.771 -0.58 . . . . 0.0 109.528 179.205 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.42 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 13.9 m-20 -97.85 127.55 43.88 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.336 -0.853 . . . . 0.0 111.456 -178.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.845 ' CH2' HG23 ' A' ' 337' ' ' ILE . 30.5 p90 -113.04 18.76 17.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.372 -0.83 . . . . 0.0 109.723 178.957 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.499 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 87.33 -64.33 3.81 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 109.477 -1.449 . . . . 0.0 109.477 -179.965 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.401 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 1.5 m -63.66 -23.4 67.36 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.238 -1.154 . . . . 0.0 110.418 -179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.561 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -167.25 -179.46 40.19 Favored Glycine 0 N--CA 1.491 2.352 0 C-N-CA 119.543 -1.313 . . . . 0.0 109.941 -179.813 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.556 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -135.28 141.57 45.73 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.33 -1.1 . . . . 0.0 109.986 179.85 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.816 ' O ' HG13 ' A' ' 271' ' ' VAL . 2.6 mt-10 -96.34 147.32 23.93 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -0.778 . . . . 0.0 110.32 -179.266 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.79 ' CE2' HG11 ' A' ' 346' ' ' VAL . 97.0 m-85 -139.04 85.14 2.05 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.277 -0.889 . . . . 0.0 110.753 -179.638 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.585 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 1.4 t0 -74.53 119.81 19.23 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.406 -0.809 . . . . 0.0 109.566 179.17 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.703 HG11 HG11 ' A' ' 294' ' ' VAL . 15.6 t -111.6 92.78 2.18 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.594 -0.691 . . . . 0.0 109.871 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.846 HG23 ' OG1' ' A' ' 333' ' ' THR . 17.3 m -86.48 124.31 32.66 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.12 -0.987 . . . . 0.0 109.367 179.793 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.11 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.69 152.27 27.93 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.091 -1.005 . . . . 0.0 110.718 -179.115 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.749 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.3 OUTLIER -130.62 128.55 41.23 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.33 -0.856 . . . . 0.0 110.408 -179.563 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.749 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.1 mt -138.62 149.55 45.33 Favored 'General case' 0 C--N 1.299 -1.601 0 O-C-N 120.823 -1.173 . . . . 0.0 109.31 179.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -86.02 38.92 0.78 Allowed 'General case' 0 C--N 1.297 -1.689 0 O-C-N 121.305 -0.872 . . . . 0.0 110.003 -179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.559 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 159.23 -110.31 0.44 Allowed Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.095 -1.526 . . . . 0.0 109.95 -179.821 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.521 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 4.8 mt-30 -145.27 118.17 8.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.248 . . . . 0.0 110.359 -179.671 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.64 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 5.6 m-85 -141.06 147.82 39.21 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.276 -0.89 . . . . 0.0 110.103 179.943 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.762 ' O ' HG23 ' A' ' 353' ' ' ILE . 34.6 m-20 -75.2 96.8 3.37 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.102 -0.999 . . . . 0.0 109.15 179.226 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.851 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.8 p-90 -98.73 114.38 26.87 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.38 -0.825 . . . . 0.0 110.241 -179.539 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.92 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.3 m -109.15 112.1 24.07 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.423 -0.798 . . . . 0.0 109.403 179.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.803 HG22 ' CD2' ' A' ' 351' ' ' LEU . 2.8 t -96.33 110.73 25.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.21 -0.931 . . . . 0.0 110.402 -179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.581 ' HE2' HD11 ' A' ' 320' ' ' ILE . 30.7 ttmt -88.65 147.15 24.69 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.207 -0.933 . . . . 0.0 109.214 179.066 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.791 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 79.5 t -140.64 107.73 2.37 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.163 -0.961 . . . . 0.0 110.367 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.606 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 23.0 mmtt -69.96 133.82 47.7 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.129 -0.982 . . . . 0.0 109.362 179.724 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.911 HD13 ' HA ' ' A' ' 303' ' ' THR . 70.7 mt -88.23 156.98 18.93 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.217 -0.927 . . . . 0.0 111.505 -178.818 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.688 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.54 173.49 2.36 Favored Pre-proline 0 C--N 1.302 -1.471 0 N-CA-C 109.379 -0.6 . . . . 0.0 109.379 179.065 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.688 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -66.84 82.75 0.32 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.438 1.231 . . . . 0.0 109.806 179.583 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.23 22.56 5.17 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -179.287 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.793 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.82 143.34 42.93 Favored 'General case' 0 N--CA 1.486 1.361 0 O-C-N 121.405 -1.056 . . . . 0.0 110.125 -179.702 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.911 ' HA ' HD13 ' A' ' 298' ' ' LEU . 15.3 p -147.36 144.07 28.47 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.267 -0.896 . . . . 0.0 110.688 179.801 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.957 ' CG2' HG21 ' A' ' 319' ' ' VAL . 43.8 t -67.4 135.72 27.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.478 -0.764 . . . . 0.0 109.985 179.619 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.35 -44.52 0.56 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.98 -1.248 . . . . 0.0 109.98 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 8.8 m -131.27 128.7 40.37 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.06 -1.259 . . . . 0.0 110.811 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.637 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 4.9 p90 -140.74 168.8 18.94 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.414 -0.804 . . . . 0.0 109.423 179.203 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.458 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -159.92 154.19 23.6 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 120.875 -1.141 . . . . 0.0 111.366 -179.393 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.489 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 65.22 24.28 12.27 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.546 -0.721 . . . . 0.0 110.716 179.594 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.689 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 146.74 0.9 Allowed 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.232 -0.918 . . . . 0.0 110.347 179.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.774 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -81.8 125.06 30.22 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.091 -1.006 . . . . 0.0 108.895 179.217 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.542 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 2.4 ttpt -96.58 137.11 36.16 Favored 'General case' 0 N--CA 1.491 1.59 0 CA-C-O 121.819 0.818 . . . . 0.0 111.018 -178.816 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.759 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.16 179.37 4.9 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.618 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.472 ' HG2' ' O ' ' A' ' 313' ' ' GLN . 2.5 mt-10 -139.98 102.05 4.31 Favored 'General case' 0 C--N 1.299 -1.622 0 C-N-CA 120.221 -0.592 . . . . 0.0 110.138 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.518 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.55 46.9 3.65 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.507 -1.437 . . . . 0.0 109.507 -179.969 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.1 OUTLIER 56.41 82.05 0.12 Allowed 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.286 -1.126 . . . . 0.0 110.113 -179.925 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.618 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.87 2.77 62.57 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 -179.893 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.837 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.0 m-85 -143.28 -168.41 2.8 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.443 -1.034 . . . . 0.0 109.221 179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.957 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.5 t -163.37 153.29 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.176 -0.952 . . . . 0.0 109.727 179.341 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.753 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 17.3 mm -119.77 150.75 22.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.857 0 O-C-N 120.992 -1.067 . . . . 0.0 110.711 -179.908 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.4 m-85 -128.91 125.26 37.19 Favored 'General case' 0 N--CA 1.494 1.765 0 O-C-N 121.387 -0.821 . . . . 0.0 110.164 179.618 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.92 ' CG2' HG23 ' A' ' 293' ' ' THR . 35.9 p -131.05 166.44 27.65 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.676 -1.265 . . . . 0.0 109.91 179.417 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.513 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.56 119.55 6.59 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 O-C-N 123.695 1.366 . . . . 0.0 110.882 -179.425 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.774 HG12 ' ND2' ' A' ' 311' ' ' ASN . 24.9 m -64.57 -121.19 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.532 -0.73 . . . . 0.0 110.197 -179.737 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.478 ' N ' HG23 ' A' ' 324' ' ' VAL . 5.9 m -100.55 -23.5 14.68 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 120.746 -1.222 . . . . 0.0 110.57 -179.674 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.478 ' H ' HG23 ' A' ' 324' ' ' VAL . 9.4 p-90 -124.4 -7.75 7.53 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.128 -0.983 . . . . 0.0 110.447 -179.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.714 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.3 t-20 -89.13 31.83 0.86 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.221 -0.924 . . . . 0.0 110.598 -179.528 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.451 ' CE ' ' O ' ' A' ' 325' ' ' SER . 0.0 OUTLIER -117.48 7.24 12.68 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.17 -0.956 . . . . 0.0 110.045 179.737 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -67.62 -150.09 0.19 Allowed Glycine 0 N--CA 1.486 2.023 0 N-CA-C 108.486 -1.846 . . . . 0.0 108.486 179.376 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.559 ' N ' ' O ' ' A' ' 288' ' ' GLY . 46.1 Cg_endo -73.09 -51.61 0.16 Allowed 'Trans proline' 0 C--N 1.3 -2.024 0 O-C-N 123.835 1.439 . . . . 0.0 109.246 179.503 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -108.09 124.23 49.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.617 -0.677 . . . . 0.0 110.184 179.424 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.465 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -135.44 110.97 9.16 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 -179.934 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.846 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.1 m -105.58 129.57 53.81 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.324 -0.86 . . . . 0.0 110.286 179.983 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.739 ' HE2' HG21 ' A' ' 294' ' ' VAL . 12.7 p90 -135.33 175.06 9.93 Favored 'General case' 0 C--N 1.302 -1.5 0 N-CA-C 108.315 -0.994 . . . . 0.0 108.315 179.237 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.9 162.46 29.73 Favored Glycine 0 N--CA 1.488 2.104 0 C-N-CA 118.684 -1.722 . . . . 0.0 110.308 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.893 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -149.52 145.37 26.82 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.518 -0.99 . . . . 0.0 109.483 179.308 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.893 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.73 119.25 60.49 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.005 -1.059 . . . . 0.0 110.017 -179.84 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.793 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -98.32 144.18 11.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.201 -0.937 . . . . 0.0 110.105 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.493 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.91 137.38 52.85 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.415 -0.803 . . . . 0.0 110.213 -179.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 177.93 -128.42 1.29 Allowed Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.161 -1.576 . . . . 0.0 109.161 179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.534 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.1 Cg_endo -66.67 -157.95 0.04 OUTLIER 'Trans proline' 0 C--N 1.306 -1.67 0 O-C-N 123.822 1.433 . . . . 0.0 110.532 179.625 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.499 ' HG3' ' HA2' ' A' ' 275' ' ' GLY . 1.4 mp0 -121.01 131.83 54.53 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.033 -1.042 . . . . 0.0 111.099 -179.273 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 107.37 -87.49 0.5 Allowed Glycine 0 N--CA 1.491 2.317 0 N-CA-C 109.509 -1.436 . . . . 0.0 109.509 179.535 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -108.77 126.0 52.54 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.384 -1.068 . . . . 0.0 109.401 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.685 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.5 mtmt -128.27 4.47 5.76 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.041 -1.037 . . . . 0.0 110.659 -179.61 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.79 HG11 ' CE2' ' A' ' 280' ' ' TYR . 2.7 p -127.67 113.87 33.25 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.095 -1.003 . . . . 0.0 110.244 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.511 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.94 -48.86 5.96 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.27 -0.894 . . . . 0.0 109.713 179.916 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.441 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.4 OUTLIER -177.59 158.34 1.35 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.238 -0.914 . . . . 0.0 110.947 179.461 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.595 HG12 HG13 ' A' ' 296' ' ' VAL . 27.7 mt -115.34 104.81 17.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.369 -0.832 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.1 OUTLIER -107.5 132.13 53.56 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.204 -0.935 . . . . 0.0 110.266 -179.827 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.11 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -94.6 130.42 41.05 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.266 -0.896 . . . . 0.0 110.284 179.897 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.531 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 7.5 tt0 -138.91 114.19 9.58 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.241 -0.912 . . . . 0.0 110.12 179.72 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.762 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.32 105.45 16.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.047 -1.033 . . . . 0.0 109.801 179.623 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 40.31 29.21 0.05 Allowed 'General case' 0 C--N 1.297 -1.681 0 O-C-N 121.735 -0.603 . . . . 0.0 110.887 -179.873 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.419 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 126.02 -26.73 5.26 Favored Glycine 0 N--CA 1.493 2.489 0 C-N-CA 119.698 -1.239 . . . . 0.0 110.525 179.346 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.531 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 6.5 mm100 -84.98 118.13 24.37 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 120.953 -1.322 . . . . 0.0 110.485 -179.53 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.886 ' O ' HD13 ' A' ' 358' ' ' ILE . 11.4 p -81.91 126.86 39.97 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.276 -0.89 . . . . 0.0 110.108 179.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.886 HD13 ' O ' ' A' ' 357' ' ' VAL . 13.0 mm . . . . . 0 N--CA 1.491 1.593 0 CA-C-O 117.946 -1.026 . . . . 0.0 110.21 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.374 0 N-CA-C 109.707 -1.357 . . . . 0.0 109.707 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.51 -178.32 3.29 Favored 'Trans proline' 0 C--N 1.306 -1.676 0 O-C-N 123.918 1.483 . . . . 0.0 110.354 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.504 HG23 ' O ' ' A' ' 258' ' ' THR . 6.1 t -58.09 128.74 38.64 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.272 -0.892 . . . . 0.0 110.055 179.886 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 3.0 m -132.16 138.82 33.16 Favored Pre-proline 0 N--CA 1.491 1.614 0 O-C-N 121.187 -0.946 . . . . 0.0 110.466 -179.822 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -77.23 135.17 14.91 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 O-C-N 124.091 1.574 . . . . 0.0 110.581 179.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.542 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.5 p -106.25 141.77 23.47 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 121.375 -0.828 . . . . 0.0 110.215 179.912 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.542 ' HD2' HG23 ' A' ' 261' ' ' VAL . 45.2 Cg_endo -71.61 126.48 12.15 Favored 'Trans proline' 0 C--N 1.304 -1.801 0 O-C-N 124.124 1.592 . . . . 0.0 110.481 179.821 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.581 HG12 ' O ' ' A' ' 263' ' ' VAL . 39.7 t -122.83 31.15 2.09 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.224 -0.923 . . . . 0.0 110.342 -179.869 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -173.86 60.68 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.116 -0.99 . . . . 0.0 110.815 -179.887 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 133.75 -177.89 18.72 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 110.05 -1.22 . . . . 0.0 110.05 179.55 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.562 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.64 169.77 17.16 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.446 -1.032 . . . . 0.0 109.841 179.809 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.651 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -161.09 125.41 3.49 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.229 -0.92 . . . . 0.0 110.665 -179.733 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.489 ' N ' HD23 ' A' ' 267' ' ' LEU . 40.4 mt-10 -121.31 111.34 17.23 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.494 -0.754 . . . . 0.0 108.986 179.279 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.732 HG13 ' O ' ' A' ' 281' ' ' ASP . 40.5 t -109.21 137.39 41.52 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 120.99 -1.068 . . . . 0.0 111.798 -178.74 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 11.9 tttp -127.55 155.98 42.94 Favored 'General case' 0 N--CA 1.493 1.722 0 N-CA-C 108.212 -1.033 . . . . 0.0 108.212 178.813 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.802 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.8 t -142.68 147.17 21.18 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.792 0 O-C-N 120.25 -1.531 . . . . 0.0 112.097 -178.971 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.518 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.21 114.23 8.98 Favored 'General case' 0 N--CA 1.49 1.567 0 N-CA-C 109.129 -0.693 . . . . 0.0 109.129 179.056 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.2 m-20 -96.51 147.89 23.38 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.165 -0.959 . . . . 0.0 111.525 -178.601 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.4 p90 -135.34 18.88 3.38 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.486 -0.759 . . . . 0.0 109.969 179.206 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 86.39 -62.78 4.25 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.419 -1.472 . . . . 0.0 109.419 -179.91 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.58 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 3.1 m -62.44 -20.15 64.22 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.268 -1.136 . . . . 0.0 110.156 179.816 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.557 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.92 179.42 48.65 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.793 -1.323 . . . . 0.0 109.793 179.944 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.563 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -132.34 143.62 49.98 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -1.145 . . . . 0.0 110.305 -179.997 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.802 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.1 mt-10 -95.06 146.24 24.41 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.377 -0.827 . . . . 0.0 109.949 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.689 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 85.1 m-85 -139.6 83.6 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.402 -0.811 . . . . 0.0 110.252 -179.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.732 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -67.89 150.49 48.49 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.44 -0.787 . . . . 0.0 109.935 179.62 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.731 HG11 HG11 ' A' ' 294' ' ' VAL . 3.3 t -142.78 87.76 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.613 -0.679 . . . . 0.0 109.402 -179.835 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 1.009 HG23 ' OG1' ' A' ' 333' ' ' THR . 20.6 m -85.9 111.63 20.41 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.25 -0.906 . . . . 0.0 109.556 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -96.62 150.55 20.53 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.223 -0.923 . . . . 0.0 111.059 -179.053 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.562 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.23 106.02 7.32 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.575 -0.703 . . . . 0.0 110.056 -179.496 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.606 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 9.6 mt -115.96 152.37 33.62 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 120.793 -1.192 . . . . 0.0 109.715 179.478 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -86.67 38.19 0.78 Allowed 'General case' 0 C--N 1.294 -1.818 0 O-C-N 121.091 -1.006 . . . . 0.0 110.003 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.456 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.23 -134.02 3.4 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.368 -1.396 . . . . 0.0 109.751 -179.738 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.448 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 8.8 mm-40 -124.31 116.65 22.97 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.136 -1.214 . . . . 0.0 110.531 -179.799 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.606 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 0.9 OUTLIER -146.67 129.41 16.17 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.317 -0.865 . . . . 0.0 109.741 179.558 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.664 ' O ' HG23 ' A' ' 353' ' ' ILE . 10.2 t70 -57.45 102.56 0.09 Allowed 'General case' 0 C--N 1.302 -1.49 0 O-C-N 120.961 -1.087 . . . . 0.0 109.431 179.619 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.828 ' CE3' HD13 ' A' ' 284' ' ' LEU . 45.7 p-90 -99.77 110.28 22.67 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.38 -0.825 . . . . 0.0 110.183 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.56 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 29.7 m -102.3 114.95 29.56 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.327 -0.858 . . . . 0.0 109.798 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.787 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.82 111.09 26.09 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.454 0 O-C-N 121.188 -0.945 . . . . 0.0 110.258 -179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.693 ' HA ' HD13 ' A' ' 320' ' ' ILE . 30.4 ttpt -87.33 149.82 24.26 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.314 -0.866 . . . . 0.0 109.591 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.684 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 94.3 t -148.24 106.96 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.601 0 O-C-N 121.17 -0.957 . . . . 0.0 110.417 -179.294 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.581 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 9.8 mmtm -70.04 134.35 48.17 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.081 -1.012 . . . . 0.0 109.269 179.709 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.92 HD13 ' HA ' ' A' ' 303' ' ' THR . 94.4 mt -87.26 160.53 18.41 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.393 -0.817 . . . . 0.0 111.369 -178.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.837 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.57 175.8 1.25 Allowed Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 121.672 -0.642 . . . . 0.0 109.78 179.315 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.785 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.3 Cg_endo -68.65 80.57 0.61 Allowed 'Trans proline' 0 C--N 1.304 -1.772 0 O-C-N 123.752 1.396 . . . . 0.0 109.6 179.285 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.78 20.79 5.94 Favored Glycine 0 N--CA 1.489 2.187 0 N-CA-C 108.655 -1.778 . . . . 0.0 108.655 -179.086 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.837 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.79 143.47 36.31 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.583 -0.951 . . . . 0.0 110.125 -179.649 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.92 ' HA ' HD13 ' A' ' 298' ' ' LEU . 56.0 p -145.1 143.16 30.25 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.077 -1.014 . . . . 0.0 110.635 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.676 HG21 HG11 ' A' ' 319' ' ' VAL . 31.7 t -69.98 129.0 34.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.319 -0.863 . . . . 0.0 109.957 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -116.61 -32.72 1.54 Allowed Glycine 0 N--CA 1.49 2.257 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.097 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.418 ' HB2' ' HB ' ' A' ' 337' ' ' ILE . 4.8 m -132.88 121.06 22.33 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.999 -1.295 . . . . 0.0 110.951 -179.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.548 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 45.4 p90 -140.12 154.31 46.97 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.398 -0.814 . . . . 0.0 109.593 179.29 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.497 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -147.55 158.3 43.93 Favored 'General case' 0 N--CA 1.496 1.839 0 O-C-N 120.954 -1.091 . . . . 0.0 111.332 -179.132 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.507 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 61.36 24.72 14.79 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.473 -0.767 . . . . 0.0 110.973 179.481 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.704 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.82 140.01 0.54 Allowed 'General case' 0 C--N 1.3 -1.561 0 O-C-N 121.256 -0.903 . . . . 0.0 110.13 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.706 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -77.14 121.25 23.35 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.042 -1.036 . . . . 0.0 109.159 179.4 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.591 ' CD ' ' CG1' ' A' ' 304' ' ' VAL . 20.2 ttpt -88.44 138.58 31.3 Favored 'General case' 0 N--CA 1.492 1.655 0 CA-C-O 121.826 0.822 . . . . 0.0 111.048 -178.927 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.603 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.57 174.45 7.41 Favored 'General case' 0 C--N 1.299 -1.604 0 N-CA-C 108.872 -0.788 . . . . 0.0 108.872 179.065 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 12.1 mt-10 -138.46 109.26 6.67 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.368 -0.833 . . . . 0.0 110.419 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -96.57 39.9 2.7 Favored Glycine 0 N--CA 1.491 2.34 0 N-CA-C 109.545 -1.422 . . . . 0.0 109.545 179.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.21 80.53 0.2 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.241 -1.152 . . . . 0.0 110.23 -179.986 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.619 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.87 3.1 57.11 Favored Glycine 0 N--CA 1.493 2.457 0 N-CA-C 109.641 -1.384 . . . . 0.0 109.641 -179.862 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.699 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.8 m-85 -147.46 -173.84 4.37 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.431 -1.041 . . . . 0.0 109.065 179.535 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.699 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.6 t -159.13 159.85 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.103 -0.998 . . . . 0.0 109.526 179.096 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.693 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.2 mm -129.38 151.2 35.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 C-N-CA 119.365 -0.934 . . . . 0.0 111.074 -179.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.66 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 39.5 m-85 -127.49 130.02 48.46 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.248 -0.907 . . . . 0.0 110.287 179.445 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.533 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 2.1 p -130.1 169.36 13.61 Favored Pre-proline 0 N--CA 1.491 1.589 0 O-C-N 120.826 -1.171 . . . . 0.0 110.117 179.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.533 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.3 Cg_endo -65.04 123.82 12.15 Favored 'Trans proline' 0 C--N 1.307 -1.626 0 O-C-N 123.859 1.452 . . . . 0.0 110.809 -179.523 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.747 HG22 ' HB2' ' A' ' 327' ' ' ASN . 20.3 m -73.22 -116.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.537 -0.727 . . . . 0.0 110.211 -179.529 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.504 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -108.16 -23.98 11.73 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.699 -1.251 . . . . 0.0 110.668 -179.544 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.435 ' H ' HG23 ' A' ' 324' ' ' VAL . 4.4 p-90 -124.0 5.61 8.63 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.181 -0.949 . . . . 0.0 110.306 -179.913 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.747 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.9 t30 -108.57 49.95 0.79 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.214 -0.929 . . . . 0.0 110.37 -179.818 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.474 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -124.29 -11.35 7.46 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.317 -0.864 . . . . 0.0 109.882 179.732 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.456 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.8 -158.28 0.02 OUTLIER Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.831 -1.307 . . . . 0.0 109.831 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.527 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.1 Cg_endo -75.59 6.83 3.4 Favored 'Trans proline' 0 C--N 1.309 -1.55 0 O-C-N 124.115 1.587 . . . . 0.0 110.738 -179.985 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -161.26 124.39 3.21 Favored 'General case' 0 C--N 1.3 -1.578 0 O-C-N 120.964 -1.085 . . . . 0.0 109.68 179.997 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.574 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -142.65 106.04 4.62 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.227 -0.92 . . . . 0.0 109.887 -179.822 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 1.009 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.1 m -98.76 131.74 44.67 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.283 -0.886 . . . . 0.0 110.291 -179.768 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.787 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.1 p90 -139.34 175.14 9.81 Favored 'General case' 0 N--CA 1.491 1.575 0 N-CA-C 108.577 -0.897 . . . . 0.0 108.577 179.608 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.548 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.69 158.42 27.75 Favored Glycine 0 N--CA 1.489 2.175 0 C-N-CA 118.852 -1.642 . . . . 0.0 110.015 -179.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.935 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.7 OUTLIER -143.27 145.18 32.51 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.556 -0.967 . . . . 0.0 109.709 179.371 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.935 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.51 120.32 61.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.609 0 O-C-N 121.26 -0.9 . . . . 0.0 109.762 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.812 HG11 ' HB1' ' A' ' 302' ' ' ALA . 9.9 t -96.24 160.61 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.226 -0.921 . . . . 0.0 109.858 -179.915 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 1.8 m-80 -130.66 129.62 42.87 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.2 -0.937 . . . . 0.0 110.722 -179.521 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -177.58 -125.11 0.89 Allowed Glycine 0 N--CA 1.49 2.276 0 N-CA-C 109.082 -1.607 . . . . 0.0 109.082 179.887 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.532 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.8 Cg_endo -67.44 -161.85 0.06 OUTLIER 'Trans proline' 0 C--N 1.306 -1.68 0 O-C-N 123.87 1.458 . . . . 0.0 110.256 179.415 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . . . . . . . . . 6.0 mp0 -118.16 124.28 47.58 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.024 -1.048 . . . . 0.0 111.032 -179.477 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 118.6 -85.58 0.39 Allowed Glycine 0 N--CA 1.492 2.373 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.596 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -113.64 136.86 52.37 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.276 -1.132 . . . . 0.0 109.758 179.74 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.617 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.5 mtmt -137.97 18.52 2.82 Favored 'General case' 0 C--N 1.302 -1.482 0 O-C-N 121.074 -1.017 . . . . 0.0 110.791 -179.782 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.642 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.6 p -140.28 118.04 10.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.482 0 O-C-N 121.195 -0.941 . . . . 0.0 110.475 179.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.458 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -50.08 -44.43 51.83 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.478 -0.764 . . . . 0.0 110.607 -179.734 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.44 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.7 pt-20 -176.73 158.66 1.71 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.076 -1.015 . . . . 0.0 110.9 -179.664 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.593 ' CG1' HG13 ' A' ' 296' ' ' VAL . 54.1 mt -121.79 114.79 44.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.44 -0.787 . . . . 0.0 109.823 179.378 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -115.68 150.35 36.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.331 -0.856 . . . . 0.0 110.55 -179.504 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -105.44 127.6 53.08 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.3 -0.875 . . . . 0.0 109.773 179.597 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.436 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -138.52 112.85 8.73 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.137 -0.977 . . . . 0.0 110.447 -179.919 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.664 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -92.1 109.21 21.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.187 -0.945 . . . . 0.0 109.981 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.518 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 46.08 32.85 1.51 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.52 -0.737 . . . . 0.0 110.433 -179.855 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 109.39 -21.26 26.68 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 179.581 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.457 ' O ' ' N ' ' A' ' 353' ' ' ILE . 69.0 mm-40 -83.23 109.41 17.2 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.271 -1.135 . . . . 0.0 110.29 -179.872 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.517 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 4.5 p -70.38 131.03 34.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.289 -0.882 . . . . 0.0 110.09 -179.954 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.641 HG22 ' O ' ' A' ' 358' ' ' ILE . 29.8 mm . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 118.0 -1.0 . . . . 0.0 110.152 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.282 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_endo -73.2 -178.24 3.48 Favored 'Trans proline' 0 C--N 1.304 -1.791 0 O-C-N 123.999 1.526 . . . . 0.0 110.137 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.633 HG23 ' O ' ' A' ' 258' ' ' THR . 6.6 t -57.56 119.32 6.36 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.2 -0.938 . . . . 0.0 109.859 179.884 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 7.3 p -112.84 128.95 24.95 Favored Pre-proline 0 N--CA 1.489 1.499 0 O-C-N 121.106 -0.996 . . . . 0.0 110.343 -179.631 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.7 Cg_endo -72.65 139.65 31.33 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 124.041 1.548 . . . . 0.0 110.254 -179.963 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.528 HG23 ' HD2' ' A' ' 262' ' ' PRO . 7.4 p -78.04 143.34 65.65 Favored Pre-proline 0 N--CA 1.492 1.658 0 O-C-N 121.258 -0.901 . . . . 0.0 110.565 -179.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.588 ' HA ' ' HA ' ' A' ' 358' ' ' ILE . 50.2 Cg_endo -81.57 124.63 4.71 Favored 'Trans proline' 0 C--N 1.304 -1.792 0 O-C-N 124.117 1.588 . . . . 0.0 110.528 179.815 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.644 ' H ' HD13 ' A' ' 358' ' ' ILE . 4.1 t -112.71 25.2 3.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.171 -0.956 . . . . 0.0 109.508 179.38 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.625 ' HB2' HD11 ' A' ' 358' ' ' ILE . 0.5 OUTLIER 172.8 75.49 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.367 -0.833 . . . . 0.0 110.492 179.977 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.4 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . 111.45 -164.27 12.15 Favored Glycine 0 N--CA 1.49 2.255 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 179.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.564 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.74 163.05 31.52 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.285 -1.126 . . . . 0.0 109.948 179.966 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.955 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.22 132.68 5.53 Favored 'General case' 0 C--N 1.302 -1.477 0 C-N-CA 119.069 -1.052 . . . . 0.0 111.197 -179.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.663 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mt-10 -133.49 132.38 40.95 Favored 'General case' 0 N--CA 1.491 1.61 0 N-CA-C 108.666 -0.864 . . . . 0.0 108.666 179.262 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.685 HG13 ' O ' ' A' ' 281' ' ' ASP . 21.9 t -123.75 134.14 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 120.71 -1.244 . . . . 0.0 111.976 -178.645 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -119.94 151.84 38.32 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.587 -0.894 . . . . 0.0 108.587 178.657 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.787 HG13 ' O ' ' A' ' 279' ' ' GLU . 77.9 t -140.8 146.16 24.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.802 0 O-C-N 120.368 -1.458 . . . . 0.0 112.018 -179.004 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.513 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -139.0 113.83 9.23 Favored 'General case' 0 N--CA 1.491 1.581 0 N-CA-C 108.634 -0.876 . . . . 0.0 108.634 178.707 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.8 m-20 -101.29 140.87 34.98 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 120.893 -1.129 . . . . 0.0 111.395 -178.481 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.821 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.0 p90 -123.87 19.76 9.29 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.654 -0.654 . . . . 0.0 109.375 179.506 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.561 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 82.53 -62.21 4.62 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.016 -1.634 . . . . 0.0 109.016 -179.474 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.511 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 0.5 OUTLIER -60.62 -18.15 51.43 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.259 -1.142 . . . . 0.0 109.951 179.655 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.58 177.23 48.39 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.769 -1.333 . . . . 0.0 109.769 179.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.569 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -133.31 137.8 46.12 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.305 -1.115 . . . . 0.0 110.124 179.987 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.787 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.5 mt-10 -93.99 145.54 24.57 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.251 -0.906 . . . . 0.0 110.163 -179.777 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.682 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.1 m-85 -139.99 85.02 2.0 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.448 -0.782 . . . . 0.0 110.746 -179.801 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.685 ' O ' HG13 ' A' ' 269' ' ' VAL . 3.7 t0 -69.54 141.46 53.83 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.334 -0.853 . . . . 0.0 109.555 179.009 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.733 HG11 HG11 ' A' ' 294' ' ' VAL . 4.0 t -132.85 91.71 1.32 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 O-C-N 121.486 -0.759 . . . . 0.0 109.506 -179.776 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.883 HG23 ' OG1' ' A' ' 333' ' ' THR . 2.7 m -86.67 122.31 30.4 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.32 -0.862 . . . . 0.0 109.982 -179.652 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.102 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.67 149.04 32.13 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.296 -0.877 . . . . 0.0 110.149 -179.713 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.564 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -134.03 109.4 8.95 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.316 -0.865 . . . . 0.0 110.637 -178.758 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.633 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 9.1 mt -119.59 157.47 28.35 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.722 -1.236 . . . . 0.0 110.251 179.731 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . 0.514 ' OD1' ' N ' ' A' ' 287' ' ' ASP . 15.3 p-10 -91.43 36.61 0.94 Allowed 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.125 -0.984 . . . . 0.0 109.544 179.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.439 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.5 -136.1 4.18 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 109.706 -1.358 . . . . 0.0 109.706 -179.547 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.464 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -121.81 116.31 24.21 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.201 -1.176 . . . . 0.0 110.847 -179.581 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.633 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.3 m-85 -142.39 138.28 31.03 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.313 -0.867 . . . . 0.0 109.435 179.36 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.622 ' O ' HG23 ' A' ' 353' ' ' ILE . 14.5 t0 -67.7 97.46 0.63 Allowed 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.066 -1.021 . . . . 0.0 109.841 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.829 ' CE3' HD13 ' A' ' 284' ' ' LEU . 46.3 p-90 -96.17 109.86 22.24 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.227 -0.921 . . . . 0.0 110.037 179.922 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.838 HG23 ' CG2' ' A' ' 322' ' ' THR . 3.1 m -102.06 115.33 30.31 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.347 -0.846 . . . . 0.0 109.592 179.986 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.76 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.46 110.99 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.134 -0.979 . . . . 0.0 110.461 -179.535 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.724 ' HA ' HD13 ' A' ' 320' ' ' ILE . 28.5 ttpt -86.37 149.59 24.91 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.294 -0.879 . . . . 0.0 109.493 179.364 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.66 HG13 HG12 ' A' ' 349' ' ' ILE . 70.8 t -148.14 108.17 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.123 -0.985 . . . . 0.0 110.706 -179.036 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.578 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.0 mmtp -70.81 131.79 44.34 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.132 -0.98 . . . . 0.0 109.675 179.555 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.978 HD13 ' HA ' ' A' ' 303' ' ' THR . 98.5 mt -85.52 156.05 20.94 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.259 -0.901 . . . . 0.0 111.599 -179.095 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.759 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -66.66 171.04 4.79 Favored Pre-proline 0 N--CA 1.488 1.441 0 N-CA-C 109.123 -0.695 . . . . 0.0 109.123 178.894 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.615 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.7 Cg_endo -66.87 81.86 0.34 Allowed 'Trans proline' 0 C--N 1.305 -1.757 0 O-C-N 123.518 1.273 . . . . 0.0 109.727 179.861 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.76 18.06 5.76 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.899 -1.68 . . . . 0.0 108.899 -179.281 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.801 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -108.65 149.19 29.3 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.385 -1.068 . . . . 0.0 110.105 -179.706 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.978 ' HA ' HD13 ' A' ' 298' ' ' LEU . 24.8 p -154.56 144.21 21.53 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.122 -0.987 . . . . 0.0 110.897 179.843 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.776 HG21 HG11 ' A' ' 319' ' ' VAL . 24.7 t -68.9 124.06 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.495 -0.753 . . . . 0.0 110.264 179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -106.39 -33.71 3.32 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 -179.623 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -142.0 131.21 23.42 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.005 -1.291 . . . . 0.0 110.868 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.551 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 39.2 p90 -141.78 162.89 34.36 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.29 -0.881 . . . . 0.0 109.855 179.485 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.503 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -152.31 159.51 43.47 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.928 -1.107 . . . . 0.0 110.946 -179.524 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.474 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 59.84 23.91 12.9 Favored 'General case' 0 N--CA 1.497 1.924 0 O-C-N 121.472 -0.767 . . . . 0.0 111.091 179.471 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.71 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.09 145.46 0.8 Allowed 'General case' 0 C--N 1.298 -1.642 0 O-C-N 121.325 -0.86 . . . . 0.0 110.179 179.653 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.645 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -83.81 120.03 25.55 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.156 -0.965 . . . . 0.0 109.202 179.387 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.723 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.8 ttpt -87.03 145.38 26.5 Favored 'General case' 0 N--CA 1.494 1.732 0 CA-C-O 121.946 0.879 . . . . 0.0 111.044 -178.981 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.794 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -130.41 179.03 6.16 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.013 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.602 ' HG2' HG22 ' A' ' 319' ' ' VAL . 0.6 OUTLIER -140.0 101.76 4.24 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.702 -0.624 . . . . 0.0 110.108 179.546 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.493 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -87.51 40.4 3.08 Favored Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.493 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 9.5 t30 63.65 79.71 0.25 Allowed 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.304 -1.115 . . . . 0.0 110.084 179.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.591 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 95.0 3.81 61.78 Favored Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.51 -1.436 . . . . 0.0 109.51 -179.774 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.791 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.7 m-85 -143.3 -170.66 3.32 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.507 -0.996 . . . . 0.0 108.784 179.493 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.794 HG22 ' O ' ' A' ' 313' ' ' GLN . 3.3 t -161.68 154.29 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 120.976 -1.077 . . . . 0.0 110.019 179.223 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.8 ' CG2' HG22 ' A' ' 293' ' ' THR . 22.0 mm -125.17 142.85 40.73 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 C-N-CA 119.264 -0.974 . . . . 0.0 111.756 -179.583 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.0 m-85 -119.6 127.05 52.59 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.435 -0.791 . . . . 0.0 109.637 178.892 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.838 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.1 p -126.65 169.15 12.52 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 120.877 -1.14 . . . . 0.0 110.5 -179.87 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.528 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.5 Cg_endo -65.04 112.23 1.98 Allowed 'Trans proline' 0 C--N 1.307 -1.615 0 O-C-N 124.049 1.552 . . . . 0.0 111.044 -179.5 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.645 HG12 ' ND2' ' A' ' 311' ' ' ASN . 16.5 m -56.96 -114.22 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.634 -0.666 . . . . 0.0 109.918 179.898 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.494 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -117.17 -20.26 9.32 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.7 -1.25 . . . . 0.0 110.417 179.914 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.49 ' CD1' ' N ' ' A' ' 326' ' ' TRP . 5.1 p-90 -120.78 -20.65 6.92 Favored 'General case' 0 N--CA 1.495 1.788 0 O-C-N 121.204 -0.935 . . . . 0.0 110.408 -179.765 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.637 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.9 OUTLIER -84.23 46.14 1.18 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.081 -1.012 . . . . 0.0 109.989 179.837 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.491 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 10.7 mtmt -119.84 -9.63 9.66 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.359 -0.838 . . . . 0.0 109.675 179.746 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.468 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.5 -157.45 0.01 OUTLIER Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.839 -1.304 . . . . 0.0 109.839 -179.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.535 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.68 5.32 4.39 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.065 1.561 . . . . 0.0 110.682 179.977 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.408 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 4.2 m -162.83 119.88 1.94 Allowed 'General case' 0 C--N 1.298 -1.64 0 O-C-N 120.998 -1.064 . . . . 0.0 110.225 179.917 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.47 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.08 112.0 7.52 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.299 -0.875 . . . . 0.0 110.247 -179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.883 ' OG1' HG23 ' A' ' 283' ' ' THR . 35.1 m -103.72 132.26 50.14 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.233 -0.917 . . . . 0.0 110.049 179.906 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.76 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.4 p90 -135.17 173.93 11.17 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 179.436 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.543 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.46 151.76 23.65 Favored Glycine 0 N--CA 1.486 1.977 0 C-N-CA 118.827 -1.654 . . . . 0.0 110.242 -179.357 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.92 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -139.0 147.93 42.78 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.684 -0.892 . . . . 0.0 109.476 179.469 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.92 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.6 119.46 59.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.549 0 O-C-N 121.006 -1.059 . . . . 0.0 110.025 179.895 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.801 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -96.84 145.2 9.24 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.242 -0.911 . . . . 0.0 109.94 -179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.507 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 2.0 m-80 -115.63 133.23 56.24 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.391 -0.818 . . . . 0.0 110.341 -179.81 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.507 ' N ' ' HE3' ' A' ' 345' ' ' LYS . . . 179.33 -140.31 4.29 Favored Glycine 0 N--CA 1.487 2.06 0 N-CA-C 109.334 -1.506 . . . . 0.0 109.334 -179.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.483 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 50.3 Cg_endo -82.63 116.15 2.55 Favored 'Trans proline' 0 C--N 1.302 -1.896 0 O-C-N 124.065 1.561 . . . . 0.0 110.903 -179.804 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.561 ' HB3' ' HA2' ' A' ' 275' ' ' GLY . 0.0 OUTLIER -41.09 153.34 0.04 OUTLIER 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.295 -0.878 . . . . 0.0 110.568 179.993 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.439 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 96.45 66.42 0.94 Allowed Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.2 -1.56 . . . . 0.0 109.2 -179.911 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.439 ' O ' ' O ' ' A' ' 343' ' ' GLY . 0.7 OUTLIER 61.23 118.86 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.324 -1.103 . . . . 0.0 109.373 -179.479 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.759 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 3.1 mtpt -123.61 16.09 9.55 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.004 -1.06 . . . . 0.0 110.13 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.621 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.1 p -126.03 113.71 35.45 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 121.448 -0.783 . . . . 0.0 109.779 179.626 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.501 ' N ' ' O ' ' A' ' 297' ' ' LYS . 3.4 mm-40 -41.97 -47.33 4.34 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.258 -0.901 . . . . 0.0 109.995 -179.638 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 18.1 pt-20 -177.28 158.52 1.48 Allowed 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.306 -0.872 . . . . 0.0 110.524 179.755 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.66 HG12 HG13 ' A' ' 296' ' ' VAL . 11.9 mt -118.14 122.71 70.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.237 -0.914 . . . . 0.0 110.068 179.671 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.11 132.19 50.66 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.219 -0.926 . . . . 0.0 110.175 -179.813 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.102 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -92.66 131.22 37.94 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.174 -0.954 . . . . 0.0 110.22 179.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.513 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.4 tt0 -139.68 114.53 9.46 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.168 -0.957 . . . . 0.0 110.358 179.876 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.622 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.1 mt -92.05 110.9 23.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.976 -1.077 . . . . 0.0 110.28 179.665 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.541 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.47 32.1 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.716 -0.615 . . . . 0.0 111.115 179.587 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.431 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 112.26 8.86 21.01 Favored Glycine 0 N--CA 1.493 2.458 0 N-CA-C 110.086 -1.206 . . . . 0.0 110.086 179.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.513 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 2.5 mp0 -116.4 111.46 20.06 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 121.11 -1.229 . . . . 0.0 110.058 179.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 0.3 OUTLIER -75.3 135.67 26.68 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.538 0 O-C-N 121.227 -0.92 . . . . 0.0 110.433 -179.662 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.644 HD13 ' H ' ' A' ' 263' ' ' VAL . 31.9 mm . . . . . 0 N--CA 1.49 1.542 0 CA-C-O 118.081 -0.962 . . . . 0.0 110.223 179.796 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.36 0 N-CA-C 109.611 -1.396 . . . . 0.0 109.611 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -78.12 179.99 5.98 Favored 'Trans proline' 0 C--N 1.307 -1.636 0 O-C-N 123.955 1.503 . . . . 0.0 110.582 -179.753 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.435 HG23 ' O ' ' A' ' 258' ' ' THR . 4.3 t -63.48 130.46 44.5 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.352 -0.842 . . . . 0.0 110.046 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.3 p -98.92 162.33 21.89 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.221 -0.924 . . . . 0.0 110.204 179.948 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -72.07 131.06 17.45 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 123.981 1.517 . . . . 0.0 110.503 179.966 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.594 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.6 p -93.13 143.67 27.13 Favored Pre-proline 0 N--CA 1.491 1.611 0 O-C-N 121.267 -0.896 . . . . 0.0 110.237 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.594 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.0 Cg_endo -75.54 155.36 40.44 Favored 'Trans proline' 0 C--N 1.302 -1.87 0 O-C-N 124.122 1.59 . . . . 0.0 110.019 179.7 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.474 HG12 ' O ' ' A' ' 263' ' ' VAL . 18.5 t -145.88 30.14 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.195 -0.941 . . . . 0.0 110.064 179.945 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -177.52 78.1 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.249 -0.907 . . . . 0.0 110.749 -179.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.44 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . 106.46 -169.27 15.26 Favored Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.885 -1.15 . . . . 0.0 110.3 179.289 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.554 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -136.78 168.31 19.79 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.523 -0.986 . . . . 0.0 109.631 179.978 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.96 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.3 tm? -160.24 136.86 8.96 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.996 -1.065 . . . . 0.0 111.165 -179.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.662 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.5 OUTLIER -136.19 123.36 21.71 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 109.133 -0.692 . . . . 0.0 109.133 179.553 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.83 HG23 HD11 ' A' ' 267' ' ' LEU . 50.2 t -116.97 134.69 59.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 120.969 -1.082 . . . . 0.0 111.738 -178.717 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 37.0 mttm -118.29 157.35 27.23 Favored 'General case' 0 N--CA 1.493 1.719 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 178.708 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.681 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.58 142.2 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.256 -1.528 . . . . 0.0 112.115 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.522 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -138.04 113.04 9.14 Favored 'General case' 0 N--CA 1.487 1.407 0 N-CA-C 108.584 -0.895 . . . . 0.0 108.584 179.102 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.633 ' OD1' ' HB1' ' A' ' 278' ' ' ALA . 80.2 m-20 -98.78 146.21 26.15 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.958 -1.089 . . . . 0.0 111.444 -178.766 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.826 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.6 p90 -131.71 23.16 4.65 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.608 -0.682 . . . . 0.0 109.474 179.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.496 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 80.55 -64.23 4.08 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.49 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -59.13 -22.6 61.14 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.293 -1.122 . . . . 0.0 110.226 -179.913 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.516 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -173.44 -171.88 38.4 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 109.487 -1.445 . . . . 0.0 109.487 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.633 ' HB1' ' OD1' ' A' ' 273' ' ' ASP . . . -142.87 142.05 31.69 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -1.072 . . . . 0.0 110.009 179.901 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.681 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.7 mt-10 -97.98 146.14 25.79 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.414 -0.804 . . . . 0.0 110.329 -179.508 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.692 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 81.6 m-85 -141.15 82.99 1.86 Allowed 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.398 -0.814 . . . . 0.0 110.653 -179.646 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.782 ' O ' HG13 ' A' ' 269' ' ' VAL . 9.3 t0 -64.91 151.53 45.45 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.295 -0.878 . . . . 0.0 109.769 179.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.798 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.9 t -145.05 89.34 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 O-C-N 121.55 -0.719 . . . . 0.0 109.964 -179.432 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.655 HG23 ' OG1' ' A' ' 333' ' ' THR . 72.2 m -86.75 126.36 34.53 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.131 -0.981 . . . . 0.0 109.717 179.783 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.075 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -114.96 148.24 39.01 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.04 -1.038 . . . . 0.0 110.902 -179.172 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.93 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -128.4 134.82 48.89 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.484 -0.76 . . . . 0.0 109.949 -179.696 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.93 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.2 mt -143.7 149.97 37.99 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 120.62 -1.3 . . . . 0.0 110.158 -179.726 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 23.7 t0 -88.41 38.49 0.87 Allowed 'General case' 0 C--N 1.297 -1.679 0 O-C-N 121.278 -0.889 . . . . 0.0 109.398 179.222 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.418 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.97 -145.47 11.05 Favored Glycine 0 N--CA 1.489 2.232 0 C-N-CA 119.51 -1.329 . . . . 0.0 109.787 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.507 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.1 mt-30 -112.36 98.43 7.28 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.217 -1.167 . . . . 0.0 110.665 -179.582 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.643 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -120.21 154.97 34.08 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.257 -0.902 . . . . 0.0 110.295 179.627 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.876 ' O ' HG23 ' A' ' 353' ' ' ILE . 23.0 t0 -85.76 97.46 10.17 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.259 -0.901 . . . . 0.0 109.242 179.264 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.951 ' CE3' HD13 ' A' ' 284' ' ' LEU . 51.9 p-90 -95.38 108.03 20.2 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.169 -0.957 . . . . 0.0 110.819 -179.466 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.944 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.8 m -100.11 115.13 29.09 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.543 -0.723 . . . . 0.0 109.304 179.238 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.835 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.1 t -96.71 111.38 26.62 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.488 0 O-C-N 121.187 -0.946 . . . . 0.0 110.162 -179.652 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.717 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.3 ttpp -87.74 149.37 24.24 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.404 -0.81 . . . . 0.0 109.247 179.461 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.692 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 84.4 t -148.23 107.71 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 O-C-N 121.079 -1.013 . . . . 0.0 110.225 -179.603 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.582 ' CD ' ' CD1' ' A' ' 318' ' ' TYR . 21.0 mmtp -69.95 132.37 45.84 Favored 'General case' 0 C--N 1.304 -1.404 0 O-C-N 121.344 -0.848 . . . . 0.0 109.587 179.82 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.973 HD13 ' HA ' ' A' ' 303' ' ' THR . 87.8 mt -87.37 158.71 18.96 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.646 -0.659 . . . . 0.0 110.943 -179.121 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.839 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.32 173.86 2.06 Favored Pre-proline 0 C--N 1.303 -1.426 0 O-C-N 121.459 -0.775 . . . . 0.0 109.285 179.07 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.712 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.2 Cg_endo -68.34 79.7 0.59 Allowed 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 123.619 1.326 . . . . 0.0 109.637 179.576 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.26 17.02 5.87 Favored Glycine 0 N--CA 1.489 2.19 0 N-CA-C 108.725 -1.75 . . . . 0.0 108.725 -179.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.839 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -104.26 147.09 27.88 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.467 -1.019 . . . . 0.0 110.12 -179.809 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.973 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.6 p -148.68 143.86 26.76 Favored 'General case' 0 N--CA 1.492 1.659 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.873 179.477 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.821 ' CG2' HG21 ' A' ' 319' ' ' VAL . 92.1 t -71.55 121.74 22.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.317 -0.864 . . . . 0.0 109.951 179.623 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.48 -21.34 6.92 Favored Glycine 0 N--CA 1.489 2.21 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 -179.768 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.501 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.5 OUTLIER -139.51 124.14 18.37 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.029 -1.277 . . . . 0.0 111.216 -179.464 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.507 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -145.23 164.57 30.96 Favored 'General case' 0 N--CA 1.495 1.799 0 O-C-N 121.311 -0.868 . . . . 0.0 109.884 179.13 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.473 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.4 p90 -158.34 161.29 37.6 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.948 -1.095 . . . . 0.0 110.995 -179.409 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.547 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.1 OUTLIER 54.47 29.03 10.44 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.471 -0.768 . . . . 0.0 110.843 179.517 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.697 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.33 144.43 0.71 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.285 -0.885 . . . . 0.0 109.872 179.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.8 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.3 m-80 -82.23 115.81 21.48 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.092 -1.005 . . . . 0.0 109.355 179.341 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.521 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 8.7 ttpt -83.27 142.13 31.34 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.803 0.811 . . . . 0.0 110.757 -179.38 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.559 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -129.38 173.81 10.2 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 108.387 -0.968 . . . . 0.0 108.387 179.062 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.579 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.4 mt-10 -139.49 101.36 4.21 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.309 -0.869 . . . . 0.0 110.497 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.12 42.84 2.94 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 179.757 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 4.5 m120 53.8 86.16 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.311 -1.111 . . . . 0.0 110.174 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 100.33 -0.27 55.82 Favored Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.806 -1.317 . . . . 0.0 109.806 179.877 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.612 ' O ' HG23 ' A' ' 319' ' ' VAL . 0.5 OUTLIER -150.26 -172.79 4.26 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.371 -1.076 . . . . 0.0 109.642 179.688 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.821 HG21 ' CG2' ' A' ' 304' ' ' VAL . 6.1 t -156.89 156.37 4.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.425 -0.797 . . . . 0.0 109.337 178.91 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.717 HD13 ' HA ' ' A' ' 295' ' ' LYS . 45.6 mm -126.56 147.83 31.38 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.08 -1.012 . . . . 0.0 111.22 -179.676 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 83.3 m-85 -125.29 125.1 43.0 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.399 -0.813 . . . . 0.0 109.661 179.055 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.944 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.6 p -127.7 169.86 11.52 Favored Pre-proline 0 C--N 1.302 -1.483 0 O-C-N 120.82 -1.175 . . . . 0.0 110.232 -179.882 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.549 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.7 Cg_endo -64.26 115.76 3.35 Favored 'Trans proline' 0 C--N 1.308 -1.566 0 O-C-N 123.898 1.473 . . . . 0.0 111.52 -179.088 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.826 HG22 ' CG ' ' A' ' 327' ' ' ASN . 17.3 m -64.16 -115.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.425 0 O-C-N 121.66 -0.65 . . . . 0.0 110.192 179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.495 ' N ' HG23 ' A' ' 324' ' ' VAL . 19.9 m -116.78 -12.57 10.8 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 120.696 -1.253 . . . . 0.0 111.198 -179.539 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.495 ' H ' HG23 ' A' ' 324' ' ' VAL . 13.3 p-90 -133.72 1.37 3.34 Favored 'General case' 0 N--CA 1.497 1.878 0 O-C-N 120.811 -1.18 . . . . 0.0 111.133 -179.849 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.826 ' CG ' HG22 ' A' ' 324' ' ' VAL . 28.3 p-10 -110.38 50.4 0.81 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.987 -1.071 . . . . 0.0 110.508 -179.589 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.507 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -129.09 10.51 5.87 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 121.267 -0.896 . . . . 0.0 109.664 179.466 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.418 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -73.89 -151.58 2.13 Favored Glycine 0 N--CA 1.488 2.162 0 N-CA-C 109.499 -1.44 . . . . 0.0 109.499 179.973 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.517 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -74.09 2.26 6.3 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.094 1.576 . . . . 0.0 110.838 179.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.48 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 27.5 m -167.28 122.74 1.08 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.35 -0.843 . . . . 0.0 110.134 179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.479 ' HB1' ' HB2' ' A' ' 327' ' ' ASN . . . -142.56 118.17 10.39 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.134 -0.979 . . . . 0.0 110.321 179.844 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.655 ' OG1' HG23 ' A' ' 283' ' ' THR . 18.0 m -104.36 148.55 26.28 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.341 -0.85 . . . . 0.0 110.214 179.976 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.835 ' HE2' HG21 ' A' ' 294' ' ' VAL . 5.9 p90 -153.88 175.22 13.59 Favored 'General case' 0 N--CA 1.492 1.63 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 179.733 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.507 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -156.44 157.91 28.29 Favored Glycine 0 N--CA 1.493 2.438 0 C-N-CA 118.838 -1.649 . . . . 0.0 110.548 -179.418 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.921 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -141.52 147.6 38.03 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.411 -1.052 . . . . 0.0 110.308 179.594 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.921 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.96 122.69 67.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.078 -1.014 . . . . 0.0 109.335 179.357 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.697 HG11 ' HB1' ' A' ' 302' ' ' ALA . 6.3 t -100.45 156.23 4.22 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.132 -0.98 . . . . 0.0 110.782 -179.29 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -123.97 132.72 53.75 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.506 -0.746 . . . . 0.0 110.337 -179.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.416 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -176.67 -132.52 1.65 Allowed Glycine 0 N--CA 1.492 2.384 0 N-CA-C 109.464 -1.454 . . . . 0.0 109.464 179.811 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.539 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.1 Cg_endo -67.29 -165.63 0.11 Allowed 'Trans proline' 0 C--N 1.307 -1.648 0 O-C-N 123.885 1.466 . . . . 0.0 110.691 179.744 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.583 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 2.6 mp0 -115.59 21.32 14.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.117 -0.989 . . . . 0.0 110.633 -179.39 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.498 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . -134.97 76.86 0.38 Allowed Glycine 0 N--CA 1.49 2.287 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.649 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.498 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.7 OUTLIER 68.17 141.93 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.371 -1.076 . . . . 0.0 108.726 -178.844 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.619 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 0.2 OUTLIER -135.42 15.92 3.43 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 120.8 -1.188 . . . . 0.0 111.077 -179.163 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.63 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.7 p -135.13 117.72 22.48 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.163 -0.961 . . . . 0.0 110.11 179.597 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.459 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -50.34 -45.15 54.8 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.343 -0.848 . . . . 0.0 110.425 -179.534 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.43 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -176.61 154.19 1.2 Allowed 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.11 -0.994 . . . . 0.0 110.703 -179.876 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.651 HG12 HG13 ' A' ' 296' ' ' VAL . 23.3 mt -113.97 124.8 70.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.175 -0.953 . . . . 0.0 110.133 179.729 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.21 154.39 40.21 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.389 -0.82 . . . . 0.0 109.974 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.075 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -120.65 124.51 45.41 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.188 -0.945 . . . . 0.0 109.659 179.478 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.508 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 34.6 tt0 -138.63 117.11 12.05 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.221 -0.925 . . . . 0.0 110.181 -179.796 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.876 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.4 107.68 19.02 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.445 0 O-C-N 121.165 -0.959 . . . . 0.0 109.76 179.645 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.512 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 43.66 26.74 0.13 Allowed 'General case' 0 C--N 1.3 -1.563 0 O-C-N 121.553 -0.717 . . . . 0.0 110.381 -179.647 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 123.41 -31.92 4.48 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 110.156 -1.178 . . . . 0.0 110.156 179.588 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.508 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 12.2 mm100 -75.99 114.56 14.76 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.084 -1.244 . . . . 0.0 110.47 -179.65 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.791 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -79.09 133.34 30.18 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.146 -0.972 . . . . 0.0 110.226 179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.791 HD13 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.492 1.667 0 CA-C-O 118.068 -0.967 . . . . 0.0 110.299 -179.889 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.289 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 44.1 Cg_endo -72.52 -178.3 3.28 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.119 1.589 . . . . 0.0 110.66 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.528 HG23 ' O ' ' A' ' 258' ' ' THR . 7.4 t -59.15 128.55 37.74 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.422 -0.799 . . . . 0.0 110.423 -179.823 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 5.3 m -141.57 112.32 6.47 Favored Pre-proline 0 N--CA 1.491 1.607 0 O-C-N 121.201 -0.937 . . . . 0.0 110.192 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 49.1 Cg_endo -76.37 144.53 26.02 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 123.917 1.483 . . . . 0.0 110.503 -179.891 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.485 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.5 p -108.65 140.75 22.12 Favored Pre-proline 0 N--CA 1.492 1.668 0 O-C-N 121.199 -0.938 . . . . 0.0 110.445 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.485 ' HD2' HG23 ' A' ' 261' ' ' VAL . 51.0 Cg_endo -78.64 151.55 25.28 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 124.128 1.594 . . . . 0.0 110.531 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 4.8 t -143.03 26.82 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.366 -0.833 . . . . 0.0 109.95 179.703 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 2.6 m -177.46 98.73 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.341 -0.849 . . . . 0.0 110.308 179.955 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.38 -174.04 25.67 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.79 -1.324 . . . . 0.0 109.79 179.696 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.571 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.33 163.79 31.56 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.366 -1.079 . . . . 0.0 110.049 -179.774 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.653 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -156.73 122.8 4.9 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.106 -0.996 . . . . 0.0 110.737 -179.868 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.47 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.3 mt-10 -123.31 114.29 20.01 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 178.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.586 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 57.6 t -110.05 124.51 66.85 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 120.971 -1.081 . . . . 0.0 112.347 -178.105 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 3.9 mmtt -111.61 156.79 21.26 Favored 'General case' 0 N--CA 1.491 1.604 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 178.136 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.752 HG13 ' O ' ' A' ' 279' ' ' GLU . 83.0 t -144.61 147.92 18.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.426 -1.421 . . . . 0.0 112.238 -178.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -136.8 110.05 7.83 Favored 'General case' 0 N--CA 1.49 1.564 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 178.928 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.457 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.4 p30 -95.34 146.35 24.44 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.074 -1.016 . . . . 0.0 111.247 -178.746 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.854 ' CH2' HG23 ' A' ' 337' ' ' ILE . 29.4 p90 -129.0 16.86 6.21 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.517 -0.739 . . . . 0.0 109.963 179.563 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 90.4 -54.57 3.52 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.589 -1.404 . . . . 0.0 109.589 179.875 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.494 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 2.8 m -74.63 -19.35 60.32 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.226 -1.161 . . . . 0.0 110.256 -179.957 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -175.19 -175.85 42.98 Favored Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.818 -1.313 . . . . 0.0 109.818 -179.946 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.86 ' HB2' ' NZ ' ' A' ' 345' ' ' LYS . . . -140.6 140.1 35.04 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.246 -1.15 . . . . 0.0 110.238 179.982 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.752 ' O ' HG13 ' A' ' 271' ' ' VAL . 10.7 mt-10 -92.88 146.12 23.87 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.402 -0.811 . . . . 0.0 110.077 -179.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.699 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 96.5 m-85 -133.33 89.96 2.67 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.44 -0.788 . . . . 0.0 110.64 -179.6 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.586 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.2 OUTLIER -77.21 105.03 8.06 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.513 -0.742 . . . . 0.0 109.821 179.525 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.716 HG11 HG11 ' A' ' 294' ' ' VAL . 6.6 t -97.72 92.53 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.466 -0.772 . . . . 0.0 110.368 -179.737 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.927 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.3 m -86.87 112.77 22.08 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.022 -1.049 . . . . 0.0 109.931 179.796 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.041 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -100.41 149.73 23.35 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.124 -0.985 . . . . 0.0 110.497 -179.504 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.571 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.49 106.71 7.6 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.347 -0.846 . . . . 0.0 110.541 -179.252 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.598 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 8.9 mt -113.63 164.88 13.11 Favored 'General case' 0 C--N 1.298 -1.646 0 O-C-N 120.778 -1.201 . . . . 0.0 110.302 179.881 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 14.8 p-10 -97.97 35.63 1.69 Allowed 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.269 -0.894 . . . . 0.0 110.11 179.944 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.452 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.45 -116.01 0.69 Allowed Glycine 0 N--CA 1.492 2.368 0 C-N-CA 119.277 -1.44 . . . . 0.0 109.887 -179.798 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.438 ' HG2' ' O ' ' A' ' 288' ' ' GLY . 11.8 mm-40 -139.81 107.14 5.52 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.175 -1.191 . . . . 0.0 110.55 -179.687 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.598 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.2 m-85 -137.08 129.17 29.4 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.2 -0.937 . . . . 0.0 109.723 179.495 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.643 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.4 OUTLIER -57.81 101.59 0.08 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.171 -0.956 . . . . 0.0 109.458 179.565 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.836 ' CE3' HD13 ' A' ' 284' ' ' LEU . 45.6 p-90 -98.4 107.72 20.24 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.373 -0.829 . . . . 0.0 109.968 -179.845 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.86 HG22 ' CG2' ' A' ' 320' ' ' ILE . 2.0 m -98.87 115.07 28.01 Favored 'General case' 0 C--N 1.302 -1.49 0 O-C-N 121.155 -0.966 . . . . 0.0 109.328 179.851 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.759 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.3 t -96.27 111.67 26.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.114 -0.991 . . . . 0.0 110.548 -179.202 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.711 ' HA ' HD13 ' A' ' 320' ' ' ILE . 8.4 ttpt -85.71 148.03 26.06 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.365 -0.834 . . . . 0.0 109.541 179.443 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.616 HG13 HG12 ' A' ' 349' ' ' ILE . 54.0 t -148.41 110.67 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.446 0 O-C-N 120.965 -1.084 . . . . 0.0 110.762 -179.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.6 ' O ' HG23 ' A' ' 346' ' ' VAL . 47.2 mmtt -74.36 131.82 41.46 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.292 -0.88 . . . . 0.0 109.628 179.574 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.979 HD13 ' HA ' ' A' ' 303' ' ' THR . 83.5 mt -83.95 151.65 24.93 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.261 -0.899 . . . . 0.0 111.445 -179.009 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.824 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -55.55 173.69 0.25 Allowed Pre-proline 0 N--CA 1.487 1.401 0 N-CA-C 109.194 -0.669 . . . . 0.0 109.194 179.158 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.681 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -68.76 78.27 0.71 Allowed 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.592 1.312 . . . . 0.0 109.516 179.524 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 117.86 22.95 3.78 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.852 -1.699 . . . . 0.0 108.852 -179.279 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.824 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -109.03 154.79 21.72 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.307 -1.114 . . . . 0.0 110.337 -179.622 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.979 ' HA ' HD13 ' A' ' 298' ' ' LEU . 41.0 p -152.33 144.36 23.79 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.179 -0.951 . . . . 0.0 110.716 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.9 ' CG2' HG21 ' A' ' 319' ' ' VAL . 49.0 t -72.22 117.74 16.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.599 0 O-C-N 121.462 -0.774 . . . . 0.0 109.89 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.94 -36.44 3.69 Favored Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -179.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.455 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 3.5 m -134.64 145.7 48.84 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.05 -1.265 . . . . 0.0 111.026 -179.442 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.583 ' CE2' ' HD3' ' A' ' 312' ' ' LYS . 33.8 p90 -160.23 165.08 32.15 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.525 -0.734 . . . . 0.0 109.565 179.527 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.512 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -154.3 165.13 37.28 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 120.901 -1.124 . . . . 0.0 111.356 -179.408 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.44 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 51.58 28.55 4.75 Favored 'General case' 0 N--CA 1.497 1.918 0 O-C-N 121.54 -0.725 . . . . 0.0 111.488 179.426 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.751 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.98 138.83 0.47 Allowed 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.083 -1.01 . . . . 0.0 110.302 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.801 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.64 115.39 17.36 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.13 -0.981 . . . . 0.0 109.112 179.326 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.601 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.1 ttpt -84.28 140.22 31.8 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-O 121.805 0.812 . . . . 0.0 110.738 -179.497 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.686 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -123.66 174.95 7.13 Favored 'General case' 0 C--N 1.297 -1.695 0 N-CA-C 108.504 -0.925 . . . . 0.0 108.504 179.204 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -137.61 109.42 7.11 Favored 'General case' 0 C--N 1.299 -1.63 0 O-C-N 121.331 -0.856 . . . . 0.0 110.276 -179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.426 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -99.85 46.87 1.35 Allowed Glycine 0 N--CA 1.49 2.247 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 6.2 t-20 58.47 85.72 0.09 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.237 -1.155 . . . . 0.0 110.5 179.915 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.552 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 89.86 -0.09 78.98 Favored Glycine 0 N--CA 1.494 2.506 0 N-CA-C 110.055 -1.218 . . . . 0.0 110.055 179.57 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.833 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.5 m-85 -138.78 -170.04 2.76 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.235 -1.156 . . . . 0.0 109.281 179.668 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.9 HG21 ' CG2' ' A' ' 304' ' ' VAL . 3.3 t -163.08 157.31 1.96 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.195 -0.94 . . . . 0.0 109.81 179.002 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.86 ' CG2' HG22 ' A' ' 293' ' ' THR . 7.1 mm -127.58 151.8 34.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 121.227 -0.921 . . . . 0.0 110.929 -179.545 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.627 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 99.4 m-85 -128.72 125.56 38.21 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 120.928 -1.108 . . . . 0.0 110.144 179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.762 ' CG2' HG23 ' A' ' 293' ' ' THR . 11.9 p -124.75 167.83 14.9 Favored Pre-proline 0 N--CA 1.492 1.669 0 O-C-N 120.876 -1.14 . . . . 0.0 109.596 179.304 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.48 123.84 12.01 Favored 'Trans proline' 0 C--N 1.307 -1.641 0 O-C-N 123.737 1.388 . . . . 0.0 110.772 -179.646 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.801 HG12 ' ND2' ' A' ' 311' ' ' ASN . 18.5 m -70.61 -114.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.497 -0.752 . . . . 0.0 109.855 -179.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.51 ' N ' HG23 ' A' ' 324' ' ' VAL . 2.6 m -110.46 -13.36 14.27 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 120.743 -1.223 . . . . 0.0 110.547 -179.789 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.536 ' H ' HG23 ' A' ' 324' ' ' VAL . 7.3 p-90 -132.86 -6.17 3.15 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.155 -0.965 . . . . 0.0 110.928 -179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.555 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -97.49 46.68 1.02 Allowed 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.046 -1.034 . . . . 0.0 110.216 -179.785 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -124.43 -8.05 7.51 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 121.099 -1.0 . . . . 0.0 109.92 -179.966 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.467 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.22 -157.87 0.02 OUTLIER Glycine 0 N--CA 1.49 2.25 0 N-CA-C 109.106 -1.598 . . . . 0.0 109.106 179.441 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.534 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.8 Cg_endo -75.88 8.16 2.87 Favored 'Trans proline' 0 C--N 1.305 -1.735 0 O-C-N 123.804 1.423 . . . . 0.0 111.0 -179.766 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.407 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 10.1 m -165.17 115.53 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 179.819 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.525 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -132.83 109.04 9.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.237 -0.915 . . . . 0.0 110.27 179.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.927 ' OG1' HG23 ' A' ' 283' ' ' THR . 54.2 m -100.03 122.26 42.65 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.308 -0.87 . . . . 0.0 110.111 -179.942 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.759 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.7 p90 -128.9 175.17 8.86 Favored 'General case' 0 C--N 1.301 -1.511 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.528 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.44 157.8 27.48 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 118.823 -1.656 . . . . 0.0 110.268 -179.368 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.949 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -145.28 148.98 34.05 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.7 -0.882 . . . . 0.0 109.265 179.449 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.949 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.24 118.25 55.46 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.023 -1.048 . . . . 0.0 109.679 179.744 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.1 t -96.23 152.22 3.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.206 -0.934 . . . . 0.0 109.801 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -124.76 133.26 53.22 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.199 -0.938 . . . . 0.0 110.756 -179.568 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.33 -120.3 0.69 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.0 -1.64 . . . . 0.0 109.0 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.51 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.1 Cg_endo -67.19 -157.39 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.712 0 O-C-N 123.836 1.44 . . . . 0.0 110.417 179.433 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.587 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -120.91 132.02 54.71 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.021 -1.05 . . . . 0.0 110.549 -179.498 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 95.33 -86.98 1.01 Allowed Glycine 0 N--CA 1.491 2.314 0 N-CA-C 109.392 -1.483 . . . . 0.0 109.392 179.904 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 29.9 m-20 -94.92 128.9 42.05 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.267 -1.137 . . . . 0.0 109.516 179.591 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.86 ' NZ ' ' HB2' ' A' ' 278' ' ' ALA . 0.4 OUTLIER -136.38 5.41 2.97 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 120.965 -1.084 . . . . 0.0 110.955 -179.619 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.6 HG23 ' O ' ' A' ' 297' ' ' LYS . 3.3 p -130.55 113.55 25.6 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 O-C-N 121.223 -0.923 . . . . 0.0 109.7 179.212 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.547 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 35.2 mt-10 -41.55 -45.93 3.43 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.247 -0.908 . . . . 0.0 110.304 -179.488 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.448 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.59 158.55 1.76 Allowed 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.135 -0.978 . . . . 0.0 110.64 179.847 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.616 HG12 HG13 ' A' ' 296' ' ' VAL . 12.1 mt -119.74 129.05 75.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.231 -0.918 . . . . 0.0 110.193 -179.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -131.2 151.74 51.17 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.266 -0.896 . . . . 0.0 110.297 -179.924 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.041 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.43 130.5 54.81 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.232 -0.917 . . . . 0.0 109.914 179.815 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.456 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 48.1 tt0 -138.37 113.38 9.23 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.189 -0.945 . . . . 0.0 110.22 179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.643 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -96.31 108.76 21.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.227 -0.921 . . . . 0.0 109.985 179.841 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.551 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 39.42 34.6 0.14 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.544 -0.722 . . . . 0.0 110.629 -179.82 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 112.59 -19.05 22.1 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 109.737 -1.345 . . . . 0.0 109.737 179.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.463 ' O ' HG12 ' A' ' 358' ' ' ILE . 0.1 OUTLIER -85.18 100.54 11.82 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.27 -1.135 . . . . 0.0 110.317 -179.823 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.3 p -71.15 121.65 21.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.348 -0.845 . . . . 0.0 110.202 179.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.512 HD13 ' O ' ' A' ' 357' ' ' VAL . 35.7 mm . . . . . 0 N--CA 1.491 1.596 0 CA-C-O 117.974 -1.013 . . . . 0.0 110.279 -179.774 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.338 0 N-CA-C 109.534 -1.426 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -73.1 -178.54 3.64 Favored 'Trans proline' 0 C--N 1.304 -1.79 0 O-C-N 124.016 1.535 . . . . 0.0 110.295 179.95 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 6.6 t -57.76 143.06 43.39 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.157 -0.964 . . . . 0.0 110.098 179.948 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.1 p -112.3 150.0 41.86 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.181 -0.949 . . . . 0.0 110.23 -179.966 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.67 142.12 35.4 Favored 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 124.056 1.556 . . . . 0.0 110.37 -179.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.53 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -74.42 140.97 76.21 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.196 -0.94 . . . . 0.0 110.514 -179.759 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.53 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.5 Cg_endo -74.16 149.25 40.63 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 124.192 1.628 . . . . 0.0 110.324 179.677 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.775 HG12 ' O ' ' A' ' 263' ' ' VAL . 76.5 t -137.72 29.69 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.293 -0.88 . . . . 0.0 110.083 179.816 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.3 t -166.49 45.66 0.07 Allowed 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.268 -0.895 . . . . 0.0 110.79 -179.783 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 142.35 -178.1 21.14 Favored Glycine 0 N--CA 1.491 2.328 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.17 179.493 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.578 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -133.87 157.24 46.47 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.485 -1.009 . . . . 0.0 109.791 179.895 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.898 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -149.33 124.66 10.22 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.166 -0.959 . . . . 0.0 110.615 -179.576 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.565 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.1 mp0 -124.47 111.34 15.6 Favored 'General case' 0 N--CA 1.491 1.624 0 N-CA-C 109.03 -0.73 . . . . 0.0 109.03 179.089 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.579 HG11 HD12 ' A' ' 349' ' ' ILE . 41.0 t -105.07 129.57 57.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.024 -1.047 . . . . 0.0 111.959 -178.822 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.402 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.7 ttmt -117.38 156.89 27.11 Favored 'General case' 0 N--CA 1.492 1.64 0 N-CA-C 108.305 -0.998 . . . . 0.0 108.305 178.507 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.613 HG22 ' CD2' ' A' ' 280' ' ' TYR . 78.5 t -144.86 146.59 19.89 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.424 -1.422 . . . . 0.0 112.399 -179.094 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -138.22 109.39 6.84 Favored 'General case' 0 N--CA 1.488 1.443 0 N-CA-C 108.754 -0.832 . . . . 0.0 108.754 179.15 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.482 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.7 p-10 -95.75 147.95 23.08 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.127 -0.983 . . . . 0.0 111.111 -178.783 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.841 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.9 p90 -133.66 16.97 3.94 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.515 -0.741 . . . . 0.0 110.019 179.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.05 -58.48 3.96 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 179.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.565 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 6.0 t -68.8 -20.31 64.33 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.26 -1.141 . . . . 0.0 110.103 179.985 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.573 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -177.7 179.09 48.41 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.727 -1.349 . . . . 0.0 109.727 -179.909 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.561 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -132.55 141.84 48.9 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.288 -1.125 . . . . 0.0 110.121 -179.978 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.577 ' HG3' ' CZ3' ' A' ' 274' ' ' TRP . 6.3 mt-10 -95.62 147.45 23.58 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.47 -0.769 . . . . 0.0 110.209 -179.546 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.694 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 93.5 m-85 -138.6 95.08 2.92 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.244 -0.91 . . . . 0.0 110.709 -179.661 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.57 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.71 108.49 16.11 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.526 -0.734 . . . . 0.0 110.091 179.657 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.704 HG11 HG11 ' A' ' 294' ' ' VAL . 6.7 t -100.11 92.72 2.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.6 -0.688 . . . . 0.0 109.85 179.797 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.671 HG23 ' OG1' ' A' ' 333' ' ' THR . 3.6 m -86.57 113.89 22.84 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.236 -0.915 . . . . 0.0 109.932 -179.996 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.039 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.98 149.74 23.61 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.096 -1.003 . . . . 0.0 110.806 -179.322 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.578 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.56 106.37 6.97 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -179.61 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.607 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 8.1 mt -116.91 162.54 17.59 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.688 -1.257 . . . . 0.0 109.94 179.531 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.86 36.24 1.2 Allowed 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.107 -0.995 . . . . 0.0 109.974 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.447 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 162.4 -135.5 3.9 Favored Glycine 0 N--CA 1.491 2.31 0 C-N-CA 119.325 -1.417 . . . . 0.0 110.039 -179.853 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.489 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.5 mt-30 -121.43 104.65 9.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.152 -1.205 . . . . 0.0 110.978 -179.265 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.607 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 2.0 m-85 -132.6 129.24 38.69 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.3 -0.875 . . . . 0.0 109.702 179.175 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.583 ' O ' HG23 ' A' ' 353' ' ' ILE . 39.1 m-20 -58.58 99.57 0.05 OUTLIER 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.072 -1.017 . . . . 0.0 109.4 179.435 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.857 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.0 p-90 -97.94 113.07 24.8 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.168 -0.957 . . . . 0.0 110.418 -179.51 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.564 HG23 ' CG2' ' A' ' 322' ' ' THR . 23.5 m -105.17 113.8 27.61 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.336 -0.853 . . . . 0.0 109.478 179.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.775 HG21 ' HE2' ' A' ' 334' ' ' PHE . 4.1 t -96.08 110.54 24.68 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.424 0 O-C-N 121.145 -0.972 . . . . 0.0 109.799 -179.671 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.444 ' HE2' HD11 ' A' ' 320' ' ' ILE . 31.9 ttmt -83.44 146.77 28.23 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.301 -0.875 . . . . 0.0 109.217 179.378 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.711 HG22 HG23 ' A' ' 349' ' ' ILE . 42.4 t -140.93 105.13 1.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.585 0 O-C-N 121.265 -0.897 . . . . 0.0 110.733 -179.021 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.518 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 10.6 mmtp -70.18 132.33 45.62 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.189 -0.945 . . . . 0.0 109.136 179.369 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.956 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.9 mt -87.41 152.13 22.5 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.441 -0.787 . . . . 0.0 111.376 -178.875 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.749 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -61.71 174.74 0.61 Allowed Pre-proline 0 C--N 1.301 -1.505 0 O-C-N 121.63 -0.668 . . . . 0.0 109.293 179.002 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.749 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.9 Cg_endo -68.48 82.87 0.51 Allowed 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.703 1.37 . . . . 0.0 110.041 179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.1 24.48 4.82 Favored Glycine 0 N--CA 1.488 2.156 0 N-CA-C 109.021 -1.632 . . . . 0.0 109.021 -179.531 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.777 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -114.41 148.89 37.03 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -1.09 . . . . 0.0 110.155 -179.801 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.956 ' HA ' HD13 ' A' ' 298' ' ' LEU . 21.0 p -151.76 144.35 24.24 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.231 -0.918 . . . . 0.0 110.614 179.857 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.89 HG21 HG11 ' A' ' 319' ' ' VAL . 61.3 t -64.65 129.7 28.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.458 -0.776 . . . . 0.0 110.357 179.893 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.74 -34.41 2.05 Favored Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.797 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.417 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -142.21 131.72 23.83 Favored 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.194 -1.18 . . . . 0.0 110.59 -179.827 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.561 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 13.6 p90 -145.96 163.92 33.65 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.263 -0.898 . . . . 0.0 109.817 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.519 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.7 OUTLIER -154.33 166.75 32.21 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.99 -1.068 . . . . 0.0 110.982 -179.899 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.458 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.5 OUTLIER 54.99 23.07 4.8 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.561 -0.712 . . . . 0.0 111.03 179.772 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.696 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.92 149.39 1.13 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.294 -0.879 . . . . 0.0 110.423 179.635 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.666 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -87.77 124.65 33.82 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.163 -0.961 . . . . 0.0 109.263 179.31 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.53 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 7.8 ttpt -92.29 139.77 30.27 Favored 'General case' 0 N--CA 1.489 1.486 0 CA-C-O 121.697 0.76 . . . . 0.0 110.976 -179.349 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.735 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -124.96 175.18 7.49 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 178.808 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.617 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.6 mt-10 -136.34 109.69 7.87 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.083 -1.01 . . . . 0.0 110.629 -179.815 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -98.59 39.58 2.71 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.407 -1.477 . . . . 0.0 109.407 179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER 61.26 90.22 0.07 Allowed 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.316 -1.108 . . . . 0.0 110.095 -179.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.09 0.87 82.65 Favored Glycine 0 N--CA 1.489 2.191 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 -179.77 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.856 ' O ' HG23 ' A' ' 319' ' ' VAL . 4.0 m-85 -143.83 -171.31 3.51 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.466 -1.02 . . . . 0.0 109.567 179.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.89 HG11 HG21 ' A' ' 304' ' ' VAL . 2.9 t -163.43 156.73 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.333 -0.854 . . . . 0.0 109.467 179.4 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.549 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 15.2 mm -122.43 147.52 26.53 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 120.92 -1.112 . . . . 0.0 110.715 -179.418 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.661 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.0 m-85 -124.28 129.6 51.04 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.212 -0.93 . . . . 0.0 109.855 179.389 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.564 ' CG2' HG23 ' A' ' 293' ' ' THR . 16.1 p -132.41 167.22 23.6 Favored Pre-proline 0 N--CA 1.494 1.746 0 O-C-N 120.575 -1.328 . . . . 0.0 110.178 179.653 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.535 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.5 Cg_endo -65.99 115.95 3.72 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.839 1.442 . . . . 0.0 111.01 -179.698 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.666 HG12 ' ND2' ' A' ' 311' ' ' ASN . 9.2 m -58.36 -111.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.427 -0.795 . . . . 0.0 110.006 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.43 ' H ' HG23 ' A' ' 324' ' ' VAL . 2.2 p -117.78 -18.43 9.6 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 120.742 -1.224 . . . . 0.0 110.379 -179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.4 ' H ' HG23 ' A' ' 324' ' ' VAL . 6.9 p-90 -125.93 -4.13 6.98 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.244 -0.91 . . . . 0.0 110.401 -179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.631 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.3 t30 -97.73 50.29 1.04 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.288 -0.882 . . . . 0.0 109.977 -179.962 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.504 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 4.2 mtmt -124.72 -9.82 7.3 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.344 -0.847 . . . . 0.0 109.894 -179.735 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.466 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.53 -160.57 0.02 OUTLIER Glycine 0 N--CA 1.492 2.416 0 N-CA-C 109.911 -1.276 . . . . 0.0 109.911 -179.617 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.2 Cg_endo -75.23 6.08 3.71 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 O-C-N 124.059 1.557 . . . . 0.0 110.744 -179.938 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.433 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.7 m -163.07 116.55 1.62 Allowed 'General case' 0 C--N 1.301 -1.51 0 O-C-N 121.066 -1.022 . . . . 0.0 109.943 179.999 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.453 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.53 105.79 5.75 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.22 -0.925 . . . . 0.0 110.324 -179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.671 ' OG1' HG23 ' A' ' 283' ' ' THR . 13.9 m -96.0 123.23 39.51 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.249 -0.907 . . . . 0.0 110.14 179.717 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.775 ' HE2' HG21 ' A' ' 294' ' ' VAL . 9.8 p90 -127.48 172.67 10.49 Favored 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 108.391 -0.966 . . . . 0.0 108.391 179.366 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.89 160.29 28.34 Favored Glycine 0 N--CA 1.487 2.078 0 C-N-CA 118.653 -1.736 . . . . 0.0 110.397 -179.29 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.889 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -147.08 143.75 28.55 Favored 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.717 -0.873 . . . . 0.0 109.348 179.379 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.889 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -117.65 117.25 54.43 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.55 0 O-C-N 121.116 -0.99 . . . . 0.0 109.797 179.926 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.777 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.2 t -96.9 152.03 4.02 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.22 -0.925 . . . . 0.0 109.997 179.859 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.484 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.79 134.72 54.41 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.344 -0.848 . . . . 0.0 110.353 -179.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.41 ' N ' ' HD3' ' A' ' 345' ' ' LYS . . . 179.2 -127.45 1.14 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.409 -1.476 . . . . 0.0 109.409 179.935 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.523 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.1 Cg_endo -67.11 -157.75 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.619 0 O-C-N 123.815 1.429 . . . . 0.0 110.468 179.878 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.458 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 10.4 mp0 -122.9 128.93 50.97 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.173 -0.955 . . . . 0.0 110.543 -179.728 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 116.09 -87.89 0.45 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 109.038 -1.625 . . . . 0.0 109.038 -179.885 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -115.33 131.0 57.07 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.426 -1.044 . . . . 0.0 109.041 179.285 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.618 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.1 mtmt -127.38 15.46 7.16 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 120.944 -1.098 . . . . 0.0 110.728 -179.329 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.63 HG21 HG13 ' A' ' 296' ' ' VAL . 7.4 p -136.12 114.74 15.47 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.31 -0.869 . . . . 0.0 110.474 179.837 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.518 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 3.1 mm-40 -44.07 -47.2 8.81 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.293 -0.879 . . . . 0.0 110.045 179.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 13.4 pt-20 -176.8 153.46 1.06 Allowed 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.124 -0.985 . . . . 0.0 110.733 179.99 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.711 HG23 HG22 ' A' ' 296' ' ' VAL . 18.5 mt -115.38 104.23 16.5 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.153 -0.967 . . . . 0.0 110.033 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.78 154.03 20.04 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.228 -0.92 . . . . 0.0 110.448 -179.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.039 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.38 127.56 55.7 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.296 -0.877 . . . . 0.0 110.261 179.996 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.413 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 27.3 tt0 -138.21 112.65 8.77 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.083 -1.011 . . . . 0.0 109.895 179.606 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.583 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.74 108.03 19.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.076 -1.015 . . . . 0.0 110.669 -179.736 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.54 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 37.76 35.84 0.08 Allowed 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.674 -0.641 . . . . 0.0 111.139 179.563 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.1 -0.07 28.4 Favored Glycine 0 N--CA 1.493 2.433 0 N-CA-C 110.008 -1.237 . . . . 0.0 110.008 179.605 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.485 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 2.3 mp0 -108.68 104.5 13.81 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.126 -1.22 . . . . 0.0 110.134 179.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.65 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.3 p -71.9 114.11 9.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.611 0 O-C-N 121.332 -0.855 . . . . 0.0 110.283 -179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.702 ' HB ' HD13 ' A' ' 351' ' ' LEU . 41.6 mm . . . . . 0 N--CA 1.492 1.627 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.112 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.244 0 N-CA-C 109.595 -1.402 . . . . 0.0 109.595 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -74.2 -178.7 4.09 Favored 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.969 1.51 . . . . 0.0 110.782 -179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.532 HG23 ' O ' ' A' ' 258' ' ' THR . 5.0 t -66.64 124.53 23.1 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.323 -0.861 . . . . 0.0 110.171 179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 7.2 t -129.87 145.22 56.22 Favored Pre-proline 0 N--CA 1.491 1.577 0 O-C-N 121.178 -0.951 . . . . 0.0 110.372 -179.83 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.28 138.65 30.7 Favored 'Trans proline' 0 C--N 1.304 -1.798 0 O-C-N 124.131 1.595 . . . . 0.0 110.063 179.682 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.417 ' H ' HG12 ' A' ' 261' ' ' VAL . 3.2 p -65.78 138.85 96.69 Favored Pre-proline 0 N--CA 1.49 1.546 0 O-C-N 121.074 -1.016 . . . . 0.0 110.517 -179.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.48 ' CB ' HG23 ' A' ' 358' ' ' ILE . 51.1 Cg_endo -79.99 126.49 6.45 Favored 'Trans proline' 0 C--N 1.304 -1.808 0 O-C-N 124.105 1.581 . . . . 0.0 110.264 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.737 HG12 ' O ' ' A' ' 263' ' ' VAL . 94.1 t -114.26 30.28 1.97 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.248 -0.908 . . . . 0.0 110.237 179.82 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 4.2 t 178.8 97.52 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.205 -0.934 . . . . 0.0 110.671 -179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 95.25 -177.27 34.9 Favored Glycine 0 N--CA 1.488 2.143 0 N-CA-C 110.08 -1.208 . . . . 0.0 110.08 179.473 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.553 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.22 166.39 24.67 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.486 -1.008 . . . . 0.0 109.488 179.759 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.933 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.69 140.2 9.44 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.001 -1.062 . . . . 0.0 111.11 -179.164 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.721 ' H ' HD22 ' A' ' 267' ' ' LEU . 9.5 mt-10 -141.94 123.89 15.33 Favored 'General case' 0 N--CA 1.493 1.675 0 O-C-N 121.747 -0.596 . . . . 0.0 109.41 179.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.82 HG13 ' O ' ' A' ' 281' ' ' ASP . 71.8 t -117.14 141.61 34.79 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 120.845 -1.16 . . . . 0.0 111.607 -178.973 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 4.7 tttt -126.88 157.55 39.05 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.839 -0.8 . . . . 0.0 108.839 178.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.668 HG13 ' O ' ' A' ' 279' ' ' GLU . 74.1 t -144.73 146.95 19.64 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 120.416 -1.427 . . . . 0.0 112.085 -179.236 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.516 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -144.5 114.9 7.58 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.643 -0.661 . . . . 0.0 109.288 179.056 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.47 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.5 p30 -96.04 148.01 23.12 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.2 -0.938 . . . . 0.0 111.291 -178.798 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.757 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.2 p90 -132.78 19.17 4.2 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.489 -0.757 . . . . 0.0 109.949 179.23 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.61 -62.43 3.4 Favored Glycine 0 N--CA 1.49 2.24 0 N-CA-C 109.656 -1.378 . . . . 0.0 109.656 179.569 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.521 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 22.0 m -66.37 -21.14 66.23 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.247 -1.149 . . . . 0.0 110.481 -179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.486 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -176.4 -179.55 46.91 Favored Glycine 0 N--CA 1.491 2.356 0 C-N-CA 119.43 -1.366 . . . . 0.0 109.776 179.959 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.55 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -133.99 143.94 48.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.258 -1.142 . . . . 0.0 110.242 179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.668 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.0 mt-10 -96.37 147.35 23.9 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.439 -0.788 . . . . 0.0 110.332 -179.546 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.675 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 87.0 m-85 -141.2 86.63 2.04 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.474 -0.766 . . . . 0.0 110.372 -179.52 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.82 ' O ' HG13 ' A' ' 269' ' ' VAL . 3.9 t0 -71.09 152.19 43.73 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.367 -0.833 . . . . 0.0 110.092 179.594 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.813 HG11 HG11 ' A' ' 294' ' ' VAL . 4.8 t -144.83 89.84 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.601 -0.687 . . . . 0.0 109.812 -179.789 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.855 HG23 ' OG1' ' A' ' 333' ' ' THR . 13.5 m -86.29 127.9 34.84 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 120.951 -1.093 . . . . 0.0 109.596 -179.992 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.107 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -116.53 151.16 36.71 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.02 -1.05 . . . . 0.0 110.862 -179.35 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -131.62 136.0 47.4 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.402 -0.811 . . . . 0.0 109.88 -179.853 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 17.9 mt -140.67 172.69 12.36 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.773 -1.204 . . . . 0.0 109.965 -179.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -94.55 29.16 2.36 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.22 -0.925 . . . . 0.0 110.967 -179.157 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.528 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 149.91 -82.84 0.18 Allowed Glycine 0 N--CA 1.492 2.388 0 C-N-CA 118.988 -1.577 . . . . 0.0 110.484 179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.547 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.2 tt0 -151.59 107.94 3.45 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.092 -1.24 . . . . 0.0 110.737 -179.343 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.634 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.4 m-85 -133.27 140.89 47.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.299 -0.876 . . . . 0.0 109.829 179.51 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.699 ' O ' HG23 ' A' ' 353' ' ' ILE . 18.3 m-20 -74.01 97.09 2.78 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.05 -1.031 . . . . 0.0 109.001 179.022 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.956 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.8 p-90 -98.63 115.27 28.29 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.206 -0.934 . . . . 0.0 110.64 -179.193 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.613 HG23 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -108.09 113.9 27.4 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.506 -0.746 . . . . 0.0 109.547 179.475 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.816 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.7 t -96.75 110.88 25.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.253 -0.904 . . . . 0.0 109.948 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.531 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 26.7 ttmt -84.84 148.24 26.39 Favored 'General case' 0 C--N 1.302 -1.468 0 O-C-N 121.344 -0.847 . . . . 0.0 109.768 179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.779 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 46.3 t -144.58 108.51 1.06 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.256 -0.902 . . . . 0.0 110.398 -179.782 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.585 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 2.6 mmtp -73.25 141.59 47.25 Favored 'General case' 0 C--N 1.304 -1.376 0 O-C-N 121.291 -0.88 . . . . 0.0 109.054 179.444 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.992 HD13 ' HA ' ' A' ' 303' ' ' THR . 97.9 mt -93.45 156.7 16.61 Favored 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.164 -0.96 . . . . 0.0 111.708 -178.779 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.669 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -69.65 172.45 5.42 Favored Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.629 -0.67 . . . . 0.0 109.49 179.073 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.669 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.0 Cg_endo -67.61 84.34 0.39 Allowed 'Trans proline' 0 C--N 1.303 -1.817 0 O-C-N 123.73 1.384 . . . . 0.0 109.704 179.199 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.29 28.05 3.19 Favored Glycine 0 N--CA 1.488 2.16 0 N-CA-C 108.851 -1.7 . . . . 0.0 108.851 -179.244 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.887 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -123.42 145.25 48.94 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.331 -1.099 . . . . 0.0 110.623 -179.614 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.992 ' HA ' HD13 ' A' ' 298' ' ' LEU . 42.0 p -145.68 144.4 30.37 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.254 -0.904 . . . . 0.0 110.367 179.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.99 ' CG2' HG21 ' A' ' 319' ' ' VAL . 19.6 t -78.62 136.86 23.04 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 O-C-N 121.347 -0.845 . . . . 0.0 110.179 -179.886 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -136.67 -34.01 0.22 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.847 -1.301 . . . . 0.0 109.847 -179.902 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.503 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -114.22 113.08 24.16 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.142 -1.21 . . . . 0.0 110.712 -179.632 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.504 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 28.9 p90 -144.4 164.37 31.03 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.297 -0.877 . . . . 0.0 109.844 179.503 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.488 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -157.64 161.56 38.64 Favored 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.076 -1.015 . . . . 0.0 111.102 -179.297 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.521 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.4 OUTLIER 57.91 23.66 10.06 Favored 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.424 -0.797 . . . . 0.0 111.22 179.31 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.676 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.46 141.85 0.72 Allowed 'General case' 0 C--N 1.297 -1.68 0 O-C-N 121.185 -0.947 . . . . 0.0 110.057 179.469 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.598 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.3 m-80 -77.24 119.46 20.94 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.135 -0.978 . . . . 0.0 109.399 179.748 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.512 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 9.4 ttpt -90.33 141.45 28.71 Favored 'General case' 0 C--N 1.299 -1.616 0 CA-C-O 121.658 0.742 . . . . 0.0 110.404 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.818 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -128.99 178.47 6.38 Favored 'General case' 0 C--N 1.3 -1.578 0 N-CA-C 108.927 -0.768 . . . . 0.0 108.927 179.447 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.609 ' HG3' HG22 ' A' ' 319' ' ' VAL . 2.5 mt-10 -141.48 104.69 4.62 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.686 -0.634 . . . . 0.0 110.024 179.511 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -90.38 42.05 2.93 Favored Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.569 -1.412 . . . . 0.0 109.569 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 60.59 78.78 0.27 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.225 -1.162 . . . . 0.0 110.436 179.871 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.613 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 102.7 -1.64 48.94 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.637 -1.385 . . . . 0.0 109.637 179.865 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.845 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -144.38 -165.67 2.19 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.337 -1.096 . . . . 0.0 109.42 179.564 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.99 HG21 ' CG2' ' A' ' 304' ' ' VAL . 2.8 t -163.48 154.25 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.331 -0.856 . . . . 0.0 109.7 179.341 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.815 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 13.4 mm -121.11 148.02 24.64 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.925 0 O-C-N 121.027 -1.046 . . . . 0.0 110.693 179.822 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.651 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 68.8 m-85 -126.27 124.53 40.57 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.357 -0.839 . . . . 0.0 109.815 179.376 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.613 ' CG2' HG23 ' A' ' 293' ' ' THR . 8.7 p -128.9 166.51 24.45 Favored Pre-proline 0 N--CA 1.489 1.506 0 O-C-N 120.935 -1.103 . . . . 0.0 109.576 179.528 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.3 Cg_endo -65.43 120.43 7.64 Favored 'Trans proline' 0 C--N 1.303 -1.845 0 O-C-N 123.853 1.449 . . . . 0.0 110.912 -179.076 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.778 HG22 ' HB2' ' A' ' 327' ' ' ASN . 31.1 m -64.48 -123.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.537 0 O-C-N 121.576 -0.702 . . . . 0.0 110.205 -179.945 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.484 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.8 OUTLIER -102.35 -17.7 15.75 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 120.815 -1.178 . . . . 0.0 110.669 -179.673 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.605 ' H ' HG23 ' A' ' 324' ' ' VAL . 20.4 p-90 -126.74 -8.78 6.14 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.018 -1.051 . . . . 0.0 110.505 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.778 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t-20 -89.82 38.98 0.94 Allowed 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.271 -0.893 . . . . 0.0 110.416 -179.708 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.482 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -118.47 -6.35 10.74 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.137 -0.977 . . . . 0.0 109.715 179.75 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.451 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -57.26 -164.69 0.06 OUTLIER Glycine 0 N--CA 1.489 2.226 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.768 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.528 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.6 Cg_endo -72.35 1.05 6.54 Favored 'Trans proline' 0 C--N 1.307 -1.633 0 O-C-N 124.236 1.65 . . . . 0.0 110.793 -179.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.1 m -160.04 114.74 2.29 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.303 -0.873 . . . . 0.0 109.421 179.75 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.764 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -136.43 120.92 18.19 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.275 -0.89 . . . . 0.0 110.499 -179.541 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.855 ' OG1' HG23 ' A' ' 283' ' ' THR . 97.4 m -110.37 142.38 42.12 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.304 -0.872 . . . . 0.0 110.099 179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.816 ' HE2' HG21 ' A' ' 294' ' ' VAL . 16.4 p90 -145.22 174.39 11.13 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.419 -0.801 . . . . 0.0 108.918 179.448 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.14 164.62 30.12 Favored Glycine 0 N--CA 1.488 2.148 0 C-N-CA 118.913 -1.613 . . . . 0.0 110.146 -179.488 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.896 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -151.54 143.4 23.78 Favored 'General case' 0 C--N 1.304 -1.383 0 O-C-N 121.512 -0.993 . . . . 0.0 109.642 179.31 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.896 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -119.42 123.16 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.07 -1.019 . . . . 0.0 109.569 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.887 HG11 ' HB1' ' A' ' 302' ' ' ALA . 13.3 t -96.26 154.91 3.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 121.098 -1.002 . . . . 0.0 110.353 -179.522 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.58 135.03 52.8 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.368 -0.832 . . . . 0.0 110.582 -179.558 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.459 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 176.3 -133.34 2.3 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.141 -1.583 . . . . 0.0 109.141 179.765 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.483 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 44.8 Cg_endo -72.54 -158.13 0.06 OUTLIER 'Trans proline' 0 C--N 1.306 -1.696 0 O-C-N 123.86 1.453 . . . . 0.0 109.965 179.447 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.581 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -121.76 144.56 48.73 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 121.114 -0.991 . . . . 0.0 110.446 -179.642 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.471 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 100.61 66.04 0.81 Allowed Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.232 -1.547 . . . . 0.0 109.232 -179.85 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.471 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.5 OUTLIER 67.15 130.98 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.282 -1.128 . . . . 0.0 109.288 -179.545 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.559 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER -130.48 23.77 5.12 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.101 -0.999 . . . . 0.0 110.526 -179.292 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.595 HG21 HG13 ' A' ' 296' ' ' VAL . 7.5 p -129.21 123.13 57.66 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.302 -0.874 . . . . 0.0 110.103 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.533 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 8.8 mt-10 -56.11 -41.38 75.18 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.314 -0.866 . . . . 0.0 110.907 -179.265 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.424 ' OE2' HG23 ' A' ' 350' ' ' THR . 2.4 tp10 -177.14 156.13 1.23 Allowed 'General case' 0 N--CA 1.494 1.769 0 O-C-N 120.93 -1.106 . . . . 0.0 110.623 -179.352 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.696 HG23 HG22 ' A' ' 296' ' ' VAL . 38.6 mt -123.98 104.02 13.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.121 -0.987 . . . . 0.0 110.063 179.283 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . 0.424 HG23 ' OE2' ' A' ' 348' ' ' GLU . 0.0 OUTLIER -108.73 148.46 30.45 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.211 -0.931 . . . . 0.0 110.129 -179.836 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.107 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -109.84 129.51 55.63 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.186 -0.946 . . . . 0.0 110.347 179.844 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.475 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 24.2 tp10 -138.46 114.37 10.0 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.267 -0.895 . . . . 0.0 109.779 179.611 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.699 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.54 104.86 15.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.101 -0.999 . . . . 0.0 110.462 -179.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.55 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 38.94 36.1 0.14 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.831 -0.543 . . . . 0.0 110.794 179.752 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.41 12.72 16.54 Favored Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.156 -1.177 . . . . 0.0 110.156 179.513 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.475 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 1.4 mp0 -120.88 105.45 10.71 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 120.979 -1.307 . . . . 0.0 110.358 179.964 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.887 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -72.22 128.02 34.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.275 -0.891 . . . . 0.0 110.324 179.979 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.887 HD13 ' O ' ' A' ' 357' ' ' VAL . 10.7 mm . . . . . 0 N--CA 1.492 1.639 0 CA-C-O 117.975 -1.012 . . . . 0.0 110.097 -179.998 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.269 0 N-CA-C 109.644 -1.382 . . . . 0.0 109.644 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.3 Cg_endo -73.21 -178.02 3.35 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 124.059 1.557 . . . . 0.0 110.482 179.882 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 8.2 t -57.16 142.18 43.62 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.211 -0.931 . . . . 0.0 110.162 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . 0.608 HG23 ' O ' ' A' ' 259' ' ' THR . 5.2 t -115.85 112.31 42.75 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.145 -0.972 . . . . 0.0 110.558 -179.876 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -74.37 139.51 26.15 Favored 'Trans proline' 0 C--N 1.308 -1.605 0 O-C-N 123.946 1.498 . . . . 0.0 110.055 179.723 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.591 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.1 p -69.58 144.04 93.58 Favored Pre-proline 0 N--CA 1.491 1.598 0 O-C-N 121.165 -0.959 . . . . 0.0 110.383 -179.844 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.597 ' HB2' HG23 ' A' ' 358' ' ' ILE . 49.3 Cg_endo -76.36 138.07 19.48 Favored 'Trans proline' 0 C--N 1.305 -1.763 0 O-C-N 124.082 1.569 . . . . 0.0 110.509 179.915 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.522 HG12 ' O ' ' A' ' 263' ' ' VAL . 21.2 t -103.69 30.92 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.241 -0.912 . . . . 0.0 110.132 179.926 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.465 ' O ' HD12 ' A' ' 358' ' ' ILE . 0.1 OUTLIER -175.24 145.47 0.78 Allowed 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.241 -0.912 . . . . 0.0 110.62 -179.937 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.413 ' O ' ' O ' ' A' ' 264' ' ' SER . . . 45.34 -169.7 0.02 OUTLIER Glycine 0 N--CA 1.491 2.314 0 N-CA-C 110.481 -1.048 . . . . 0.0 110.481 179.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.527 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.53 166.29 24.97 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.722 -0.87 . . . . 0.0 109.495 179.908 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.914 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.5 tm? -161.59 137.58 7.94 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 118.825 -1.15 . . . . 0.0 111.497 -179.471 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.821 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.8 OUTLIER -137.27 151.0 48.21 Favored 'General case' 0 N--CA 1.489 1.517 0 N-CA-C 108.704 -0.85 . . . . 0.0 108.704 179.032 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.848 HG13 ' O ' ' A' ' 281' ' ' ASP . 66.1 t -138.93 138.83 41.45 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 120.683 -1.261 . . . . 0.0 111.431 -179.296 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.422 ' C ' HG23 ' A' ' 271' ' ' VAL . 0.0 OUTLIER -120.69 157.77 28.9 Favored 'General case' 0 N--CA 1.494 1.741 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 179.215 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.702 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.4 t -144.9 146.76 19.68 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.287 -1.508 . . . . 0.0 112.169 -179.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.7 113.5 7.13 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.777 -0.823 . . . . 0.0 108.777 179.451 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.463 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 4.8 m-20 -98.1 143.72 28.34 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.209 -0.932 . . . . 0.0 111.016 -178.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.83 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.8 p90 -128.99 17.75 6.14 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.434 -0.792 . . . . 0.0 110.079 179.56 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.504 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 87.76 -58.3 4.36 Favored Glycine 0 N--CA 1.491 2.361 0 N-CA-C 109.572 -1.411 . . . . 0.0 109.572 179.928 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -68.94 -18.31 64.07 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.229 -1.16 . . . . 0.0 110.093 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.551 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.72 178.14 48.64 Favored Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.866 -1.294 . . . . 0.0 109.866 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.542 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -132.14 143.49 50.02 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.311 -1.111 . . . . 0.0 110.111 179.91 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.702 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -97.52 147.13 24.57 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.459 -0.776 . . . . 0.0 110.031 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.68 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 94.3 m-85 -142.41 84.52 1.87 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.336 -0.853 . . . . 0.0 110.749 -179.598 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.848 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -66.41 152.12 45.75 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.408 -0.808 . . . . 0.0 110.03 179.288 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.719 HG11 HG11 ' A' ' 294' ' ' VAL . 10.6 t -144.41 90.33 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.666 0 O-C-N 121.66 -0.65 . . . . 0.0 109.572 -179.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 333' ' ' THR . 81.9 m -86.43 124.56 32.9 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.146 -0.971 . . . . 0.0 109.465 179.898 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.058 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.07 147.51 37.11 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.308 -0.87 . . . . 0.0 110.531 -179.243 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.904 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -126.33 134.17 51.17 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.382 -0.824 . . . . 0.0 109.804 -179.881 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.904 HD23 ' O ' ' A' ' 285' ' ' ASN . 16.5 mt -141.63 150.42 41.95 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 120.607 -1.308 . . . . 0.0 110.208 179.65 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -88.51 35.59 0.77 Allowed 'General case' 0 C--N 1.297 -1.692 0 O-C-N 121.484 -0.76 . . . . 0.0 109.374 179.391 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.455 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.59 -128.94 2.04 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.256 -1.45 . . . . 0.0 109.91 -179.7 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.498 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -124.59 96.07 4.76 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.169 -1.195 . . . . 0.0 110.714 -179.531 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.547 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.7 m-85 -118.53 129.44 55.35 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.33 -0.857 . . . . 0.0 109.74 179.44 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.687 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.3 OUTLIER -63.49 100.57 0.27 Allowed 'General case' 0 C--N 1.3 -1.565 0 O-C-N 120.948 -1.095 . . . . 0.0 109.224 179.252 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.954 ' CE3' HD13 ' A' ' 284' ' ' LEU . 54.7 p-90 -99.85 112.98 25.21 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.213 -0.929 . . . . 0.0 111.065 -179.257 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.874 HG23 ' CG2' ' A' ' 322' ' ' THR . 14.8 m -106.01 115.81 30.86 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.648 -0.658 . . . . 0.0 109.271 179.256 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.771 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.2 t -96.27 110.95 25.49 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.035 -1.04 . . . . 0.0 110.388 -179.424 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.524 ' HA ' HD13 ' A' ' 320' ' ' ILE . 3.9 ttpt -86.0 145.95 26.88 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.469 -0.769 . . . . 0.0 109.223 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.923 HG22 HG23 ' A' ' 349' ' ' ILE . 55.1 t -146.3 108.04 0.75 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 O-C-N 121.182 -0.949 . . . . 0.0 110.448 -179.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.519 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 30.8 mmtp -70.38 139.88 52.0 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.186 -0.946 . . . . 0.0 109.324 179.509 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.96 HD13 ' HA ' ' A' ' 303' ' ' THR . 81.8 mt -94.71 158.45 15.51 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.324 -0.86 . . . . 0.0 111.454 -178.883 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.819 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.65 177.12 0.88 Allowed Pre-proline 0 N--CA 1.49 1.563 0 O-C-N 121.684 -0.635 . . . . 0.0 109.748 179.33 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.819 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.4 Cg_endo -68.47 87.38 0.42 Allowed 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.758 1.399 . . . . 0.0 109.838 179.501 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 107.32 22.28 7.55 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.76 ' HB1' HG11 ' A' ' 338' ' ' VAL . . . -112.9 139.15 48.79 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.262 -1.14 . . . . 0.0 110.161 -179.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.96 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.3 p -143.68 145.65 32.61 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.208 -0.933 . . . . 0.0 110.524 179.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 1.008 ' CG2' HG21 ' A' ' 319' ' ' VAL . 22.7 t -76.04 129.63 36.93 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.567 0 O-C-N 121.214 -0.929 . . . . 0.0 109.939 179.756 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.29 -17.98 3.51 Favored Glycine 0 N--CA 1.49 2.261 0 C-N-CA 119.639 -1.267 . . . . 0.0 110.148 -179.608 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.404 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.4 OUTLIER -143.78 129.76 19.53 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.046 -1.267 . . . . 0.0 111.245 -179.588 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.559 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 52.8 p90 -150.04 -178.14 6.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.545 -0.722 . . . . 0.0 109.636 179.359 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.485 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -166.06 151.15 8.41 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 120.977 -1.077 . . . . 0.0 111.113 -179.992 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.534 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.6 OUTLIER 61.67 30.82 18.65 Favored 'General case' 0 N--CA 1.497 1.91 0 O-C-N 121.471 -0.768 . . . . 0.0 110.819 179.977 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.778 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.68 141.66 0.51 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.237 -0.915 . . . . 0.0 110.045 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.841 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.3 m-80 -81.17 112.4 18.48 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.074 -1.016 . . . . 0.0 109.317 179.122 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.559 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 2.3 ttpt -84.93 142.72 29.47 Favored 'General case' 0 N--CA 1.489 1.502 0 CA-C-O 121.957 0.884 . . . . 0.0 110.981 -179.079 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.751 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -129.34 179.08 5.99 Favored 'General case' 0 C--N 1.298 -1.659 0 N-CA-C 108.676 -0.861 . . . . 0.0 108.676 179.099 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.536 ' HG2' HG22 ' A' ' 319' ' ' VAL . 2.4 mt-10 -142.04 100.04 3.65 Favored 'General case' 0 C--N 1.298 -1.637 0 C-N-CA 120.091 -0.644 . . . . 0.0 110.189 179.712 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.436 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -86.13 42.46 3.15 Favored Glycine 0 N--CA 1.49 2.239 0 N-CA-C 109.68 -1.368 . . . . 0.0 109.68 -179.902 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.436 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 19.6 m120 59.69 80.85 0.19 Allowed 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.239 -1.154 . . . . 0.0 110.328 179.796 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.605 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.86 2.61 56.14 Favored Glycine 0 N--CA 1.49 2.262 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.839 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.821 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.1 m-85 -147.29 -166.87 2.63 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.396 -1.061 . . . . 0.0 109.382 179.522 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 1.008 HG21 ' CG2' ' A' ' 304' ' ' VAL . 4.0 t -163.16 154.22 2.75 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.283 -0.885 . . . . 0.0 109.975 178.99 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.751 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 5.2 mm -125.86 138.69 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.844 0 O-C-N 121.174 -0.953 . . . . 0.0 111.545 -179.783 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.655 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 61.9 m-85 -117.4 122.61 44.28 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.326 -0.859 . . . . 0.0 109.515 178.911 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.874 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -124.4 168.75 12.2 Favored Pre-proline 0 C--N 1.301 -1.539 0 O-C-N 120.61 -1.306 . . . . 0.0 110.554 -179.583 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.539 ' HG3' ' HA ' ' A' ' 291' ' ' ASP . 38.9 Cg_endo -64.66 112.2 1.9 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 124.04 1.548 . . . . 0.0 110.908 -179.362 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.841 HG12 ' ND2' ' A' ' 311' ' ' ASN . 33.8 m -58.69 -122.07 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.442 0 O-C-N 121.687 -0.633 . . . . 0.0 109.961 179.859 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.602 ' N ' HG23 ' A' ' 324' ' ' VAL . 3.1 p -112.39 -12.72 13.5 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 120.636 -1.29 . . . . 0.0 111.01 -179.644 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.643 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.8 p-90 -129.85 -12.31 4.25 Favored 'General case' 0 N--CA 1.496 1.87 0 O-C-N 120.984 -1.073 . . . . 0.0 111.226 -179.275 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.841 ' CG ' HG22 ' A' ' 324' ' ' VAL . 23.1 p-10 -96.28 40.83 1.12 Allowed 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.047 -1.033 . . . . 0.0 110.985 -179.058 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.461 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -114.14 -3.0 13.29 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 121.162 -0.961 . . . . 0.0 109.51 179.249 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.461 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.81 -157.74 0.02 OUTLIER Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.735 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.524 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -74.66 6.97 2.93 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 124.052 1.553 . . . . 0.0 110.956 -179.729 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.461 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 5.6 m -165.35 122.11 1.46 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.099 -1.001 . . . . 0.0 110.088 179.989 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.56 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -138.91 116.25 11.17 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.206 -0.933 . . . . 0.0 110.617 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.542 HG23 ' HA ' ' A' ' 283' ' ' THR . 13.3 m -108.36 134.16 51.56 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.243 -0.91 . . . . 0.0 110.046 179.737 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.778 ' CB ' ' HB2' ' A' ' 310' ' ' ALA . 11.0 p90 -142.65 174.89 10.24 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.258 -0.901 . . . . 0.0 109.058 179.854 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.51 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.61 156.96 27.01 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.014 -1.565 . . . . 0.0 110.272 -179.541 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.942 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -141.7 147.74 37.95 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.496 -1.002 . . . . 0.0 110.04 179.588 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.942 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.75 122.99 68.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.179 -0.951 . . . . 0.0 109.623 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.76 HG11 ' HB1' ' A' ' 302' ' ' ALA . 18.3 t -97.29 153.28 3.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.205 -0.934 . . . . 0.0 110.554 -179.538 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -121.02 132.76 55.1 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.561 -0.712 . . . . 0.0 109.867 179.881 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.453 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -178.24 -138.03 2.99 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.771 -1.331 . . . . 0.0 109.771 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.482 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 45.8 Cg_endo -73.19 -159.28 0.08 OUTLIER 'Trans proline' 0 C--N 1.306 -1.674 0 O-C-N 124.085 1.571 . . . . 0.0 110.684 -179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.523 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 2.5 mp0 -115.34 135.59 53.97 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.189 -0.944 . . . . 0.0 110.445 -179.971 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.477 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 111.53 60.1 0.46 Allowed Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.477 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 0.2 OUTLIER 66.5 142.07 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.397 -1.06 . . . . 0.0 108.66 -179.052 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.545 ' HB3' ' CG1' ' A' ' 338' ' ' VAL . 0.0 OUTLIER -135.11 28.4 3.46 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.981 -1.074 . . . . 0.0 111.06 -178.88 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.572 HG13 ' O ' ' A' ' 346' ' ' VAL . 14.7 p -132.87 119.03 35.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 O-C-N 121.282 -0.886 . . . . 0.0 110.187 179.308 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.446 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -51.26 -46.96 62.54 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.444 -0.785 . . . . 0.0 110.268 -179.743 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.499 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 6.8 pt-20 -177.05 158.66 1.56 Allowed 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.267 -0.896 . . . . 0.0 110.627 -179.869 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.923 HG23 HG22 ' A' ' 296' ' ' VAL . 77.2 mt -121.29 112.41 35.43 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.258 -0.901 . . . . 0.0 110.245 179.912 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -116.54 137.47 52.14 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.238 -0.913 . . . . 0.0 110.177 -179.917 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.058 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.2 OUTLIER -93.04 135.3 34.35 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.12 -0.988 . . . . 0.0 110.523 179.989 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.47 108.26 5.95 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.402 -0.811 . . . . 0.0 110.012 179.801 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.687 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.8 mt -91.67 108.85 20.49 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 120.992 -1.067 . . . . 0.0 110.068 179.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.541 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 38.88 31.51 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.746 -0.596 . . . . 0.0 110.796 -179.855 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.412 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.13 -12.14 22.07 Favored Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.155 -1.178 . . . . 0.0 110.155 179.477 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.438 ' O ' HG12 ' A' ' 358' ' ' ILE . 2.2 mp0 -95.03 105.55 17.47 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.1 -1.236 . . . . 0.0 110.487 -179.913 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 13.9 p -68.83 133.97 30.95 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.288 -0.882 . . . . 0.0 110.185 179.959 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.597 HG23 ' HB2' ' A' ' 262' ' ' PRO . 22.1 mm . . . . . 0 N--CA 1.492 1.657 0 CA-C-O 118.075 -0.964 . . . . 0.0 110.289 -179.984 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.309 0 N-CA-C 109.441 -1.463 . . . . 0.0 109.441 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -75.18 -178.28 4.1 Favored 'Trans proline' 0 C--N 1.305 -1.741 0 O-C-N 124.026 1.54 . . . . 0.0 110.509 -179.891 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.485 HG23 ' O ' ' A' ' 258' ' ' THR . 6.7 t -64.11 132.08 49.42 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.334 -0.854 . . . . 0.0 110.136 179.739 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . 0.405 HG22 ' HD2' ' A' ' 260' ' ' PRO . 0.0 OUTLIER -141.15 146.51 43.38 Favored Pre-proline 0 N--CA 1.492 1.633 0 O-C-N 121.146 -0.971 . . . . 0.0 110.302 179.809 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . 0.405 ' HD2' HG22 ' A' ' 259' ' ' THR . 49.0 Cg_endo -75.55 135.9 18.66 Favored 'Trans proline' 0 C--N 1.307 -1.637 0 O-C-N 124.034 1.544 . . . . 0.0 110.292 -179.816 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.615 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.8 p -67.8 143.1 96.29 Favored Pre-proline 0 N--CA 1.492 1.659 0 O-C-N 121.19 -0.944 . . . . 0.0 110.419 179.992 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.633 ' HB2' HG23 ' A' ' 358' ' ' ILE . 46.4 Cg_endo -75.3 157.0 41.74 Favored 'Trans proline' 0 C--N 1.303 -1.819 0 O-C-N 124.126 1.593 . . . . 0.0 110.692 179.884 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.759 HG12 ' O ' ' A' ' 263' ' ' VAL . 69.8 t -137.75 26.12 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.284 -0.885 . . . . 0.0 109.583 179.445 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -164.78 63.63 0.13 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.361 -0.837 . . . . 0.0 110.117 179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 117.13 -169.19 13.03 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.712 -1.355 . . . . 0.0 109.712 179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.528 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.69 164.59 27.53 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.378 -1.072 . . . . 0.0 110.049 179.992 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.847 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.3 tm? -161.34 131.93 5.15 Favored 'General case' 0 C--N 1.302 -1.469 0 C-N-CA 119.085 -1.046 . . . . 0.0 111.226 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.845 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.6 mt-10 -128.91 151.34 49.76 Favored 'General case' 0 N--CA 1.49 1.542 0 N-CA-C 108.728 -0.841 . . . . 0.0 108.728 179.28 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.85 HG13 ' O ' ' A' ' 281' ' ' ASP . 96.5 t -142.71 138.83 28.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.712 -1.242 . . . . 0.0 111.509 -179.26 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 17.2 mtpt -122.19 157.46 31.52 Favored 'General case' 0 N--CA 1.494 1.761 0 N-CA-C 108.891 -0.781 . . . . 0.0 108.891 179.278 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.755 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.9 t -143.2 146.98 20.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 120.324 -1.485 . . . . 0.0 111.957 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.531 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -143.5 112.22 6.51 Favored 'General case' 0 N--CA 1.491 1.582 0 N-CA-C 109.022 -0.732 . . . . 0.0 109.022 179.485 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.484 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.9 m-20 -96.49 143.95 27.04 Favored 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.014 -1.054 . . . . 0.0 111.125 -179.214 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.82 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.7 p90 -128.38 16.79 6.56 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.335 -0.853 . . . . 0.0 109.847 179.289 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 91.27 -63.17 2.75 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 179.627 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -68.6 -20.42 64.5 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.274 -1.133 . . . . 0.0 110.306 -179.751 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.554 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.88 177.98 42.44 Favored Glycine 0 N--CA 1.491 2.329 0 C-N-CA 119.359 -1.401 . . . . 0.0 110.15 -179.832 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.541 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.13 142.65 47.56 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.339 -1.094 . . . . 0.0 109.704 179.599 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.755 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.8 mt-10 -98.91 147.11 25.3 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.281 -0.887 . . . . 0.0 110.429 -179.455 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.668 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.9 m-85 -143.09 84.2 1.82 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.511 -0.743 . . . . 0.0 110.649 -179.603 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.85 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.5 OUTLIER -67.87 151.69 46.75 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.347 -0.846 . . . . 0.0 109.967 179.407 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.756 HG11 HG11 ' A' ' 294' ' ' VAL . 14.0 t -143.93 91.38 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.493 0 O-C-N 121.459 -0.776 . . . . 0.0 110.131 -179.673 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.825 HG23 ' OG1' ' A' ' 333' ' ' THR . 88.4 m -86.74 123.89 32.4 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.116 -0.99 . . . . 0.0 109.39 179.504 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.068 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -111.27 147.49 34.95 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.017 -1.052 . . . . 0.0 110.976 -179.037 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.915 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -126.5 132.32 51.42 Favored 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.462 -0.774 . . . . 0.0 110.163 -179.787 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.915 HD23 ' O ' ' A' ' 285' ' ' ASN . 18.1 mt -142.77 157.52 44.55 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.793 -1.192 . . . . 0.0 110.005 179.452 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -93.43 36.86 1.06 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.194 -0.941 . . . . 0.0 109.671 179.537 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . . . . . . . . . . . 160.68 -144.31 9.82 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.401 -1.381 . . . . 0.0 109.896 -179.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.557 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.7 OUTLIER -108.76 94.22 4.94 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.286 -1.126 . . . . 0.0 110.711 -179.723 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.618 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.7 m-30 -114.65 143.67 44.66 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.159 -0.963 . . . . 0.0 109.901 179.425 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.815 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.6 m-20 -76.97 97.21 4.57 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.198 -0.939 . . . . 0.0 109.078 178.946 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.898 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.4 p-90 -96.75 112.37 24.15 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.378 -0.826 . . . . 0.0 110.596 -179.185 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 1.021 HG23 ' CG2' ' A' ' 322' ' ' THR . 1.5 m -105.44 113.78 27.56 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.416 -0.802 . . . . 0.0 109.515 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.757 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.4 t -96.07 110.67 24.9 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.076 -1.015 . . . . 0.0 109.829 -179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.647 ' NZ ' HD11 ' A' ' 320' ' ' ILE . 8.4 ttmt -87.78 149.54 24.11 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.234 -0.916 . . . . 0.0 109.986 179.849 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.761 HG13 HG12 ' A' ' 349' ' ' ILE . 98.6 t -144.89 108.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.587 0 O-C-N 121.419 -0.801 . . . . 0.0 110.352 -179.604 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.511 ' HB2' ' HB3' ' A' ' 347' ' ' GLU . 14.5 mmtt -71.95 132.53 44.45 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.222 -0.924 . . . . 0.0 109.242 179.475 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.943 HD13 ' HA ' ' A' ' 303' ' ' THR . 84.5 mt -88.0 156.05 19.51 Favored 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.233 -0.917 . . . . 0.0 111.594 -178.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.694 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.29 173.08 3.57 Favored Pre-proline 0 N--CA 1.488 1.467 0 O-C-N 121.581 -0.699 . . . . 0.0 109.318 179.29 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.694 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.6 Cg_endo -66.95 81.49 0.35 Allowed 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.436 1.23 . . . . 0.0 110.067 179.88 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.79 23.09 4.09 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.639 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.851 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.03 144.94 42.84 Favored 'General case' 0 N--CA 1.488 1.429 0 O-C-N 121.366 -1.079 . . . . 0.0 110.085 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.943 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.9 p -150.35 145.88 26.39 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.104 -0.998 . . . . 0.0 110.782 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.833 HG21 HG11 ' A' ' 319' ' ' VAL . 37.6 t -66.42 126.3 25.51 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.383 -0.823 . . . . 0.0 110.071 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -117.51 -16.19 6.11 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.898 -1.281 . . . . 0.0 109.898 -179.757 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.438 ' HB3' ' HB ' ' A' ' 337' ' ' ILE . 14.7 t -152.04 113.33 4.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.064 -1.257 . . . . 0.0 111.009 -179.624 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.539 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 18.7 p90 -134.39 163.64 29.22 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 121.396 -0.815 . . . . 0.0 109.43 179.135 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.506 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -153.91 160.92 42.32 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.995 -1.066 . . . . 0.0 111.246 -179.459 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.511 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 54.13 29.08 9.79 Favored 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.589 -0.694 . . . . 0.0 110.95 179.774 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.753 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.32 139.56 0.61 Allowed 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.256 -0.903 . . . . 0.0 110.112 179.748 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.835 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -79.17 118.8 21.46 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.308 179.616 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.473 ' HG3' HG11 ' A' ' 304' ' ' VAL . 8.1 ttpt -87.53 134.92 33.54 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.688 0.756 . . . . 0.0 111.235 -179.126 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.623 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.95 172.68 7.1 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 178.832 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 3.8 mt-10 -131.71 112.62 12.7 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.343 -0.848 . . . . 0.0 110.082 179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.567 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.58 47.81 1.15 Allowed Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.588 -1.405 . . . . 0.0 109.588 -179.907 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 8.0 t30 49.49 77.04 0.12 Allowed 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.287 -1.125 . . . . 0.0 110.142 -179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.615 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.01 2.12 54.92 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.485 -1.446 . . . . 0.0 109.485 -179.862 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.851 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.8 m-85 -143.67 -170.78 3.38 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.503 -0.998 . . . . 0.0 109.13 179.572 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.851 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.9 t -163.95 154.5 2.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.254 -0.904 . . . . 0.0 109.11 178.778 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.91 HG23 HG22 ' A' ' 293' ' ' THR . 17.6 mt -131.75 135.83 58.13 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 120.711 -1.243 . . . . 0.0 111.298 -179.591 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.7 ' HE2' HG21 ' A' ' 296' ' ' VAL . 52.9 m-85 -106.36 138.76 41.97 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.301 -0.874 . . . . 0.0 110.537 -179.865 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 1.021 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.0 OUTLIER -136.41 169.92 12.24 Favored Pre-proline 0 C--N 1.301 -1.521 0 O-C-N 120.934 -1.104 . . . . 0.0 110.023 179.427 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.522 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 41.0 Cg_endo -67.86 116.39 4.27 Favored 'Trans proline' 0 C--N 1.307 -1.64 0 O-C-N 123.797 1.42 . . . . 0.0 110.816 -179.175 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.835 HG12 ' ND2' ' A' ' 311' ' ' ASN . 19.9 m -65.69 -129.94 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.578 -0.701 . . . . 0.0 110.098 179.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.638 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -98.33 -12.82 21.11 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.912 -1.117 . . . . 0.0 110.712 -179.801 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.785 ' H ' HG23 ' A' ' 324' ' ' VAL . 36.2 p-90 -135.41 7.57 3.34 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.033 -1.042 . . . . 0.0 110.676 -179.529 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.809 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 2.1 t-20 -111.32 42.62 1.63 Allowed 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.18 -0.95 . . . . 0.0 110.119 -179.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.557 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -122.79 -5.87 8.56 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.327 -0.858 . . . . 0.0 110.092 -179.903 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.479 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.22 -160.35 0.02 OUTLIER Glycine 0 N--CA 1.493 2.475 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 -179.736 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.458 ' O ' ' O ' ' A' ' 286' ' ' LEU . 45.9 Cg_endo -74.63 4.13 4.81 Favored 'Trans proline' 0 C--N 1.306 -1.661 0 O-C-N 124.056 1.556 . . . . 0.0 110.592 179.989 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.425 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.7 m -164.61 116.1 1.24 Allowed 'General case' 0 C--N 1.301 -1.518 0 O-C-N 121.154 -0.966 . . . . 0.0 109.925 -179.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.809 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.18 119.15 15.31 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.189 -0.945 . . . . 0.0 110.325 -179.831 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.825 ' OG1' HG23 ' A' ' 283' ' ' THR . 3.3 m -105.03 142.26 35.14 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.268 -0.895 . . . . 0.0 109.948 179.863 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.757 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.2 p90 -148.6 174.89 11.67 Favored 'General case' 0 N--CA 1.49 1.533 0 N-CA-C 108.778 -0.823 . . . . 0.0 108.778 179.881 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.524 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.94 159.87 29.02 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.61 -1.757 . . . . 0.0 110.447 -179.377 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.929 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.5 OUTLIER -143.55 147.61 34.7 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.506 -0.996 . . . . 0.0 110.034 179.572 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.929 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -123.29 119.18 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.224 -0.922 . . . . 0.0 109.188 179.206 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.851 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 5.9 t -96.55 146.2 7.68 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.68 0 O-C-N 121.143 -0.973 . . . . 0.0 110.352 -179.45 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.08 137.04 52.54 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.497 -0.752 . . . . 0.0 110.088 -179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.452 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 177.18 -138.62 4.0 Favored Glycine 0 N--CA 1.491 2.362 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.984 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.507 ' O ' ' NZ ' ' A' ' 345' ' ' LYS . 47.0 Cg_endo -76.56 165.5 28.88 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 O-C-N 124.074 1.565 . . . . 0.0 110.231 179.856 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.57 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 2.8 mp0 -85.28 142.57 29.27 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.15 -0.968 . . . . 0.0 110.435 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.453 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 105.83 65.4 0.65 Allowed Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.908 -1.677 . . . . 0.0 108.908 -179.706 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.453 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 0.2 OUTLIER 64.25 140.99 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.247 -1.149 . . . . 0.0 109.377 -179.196 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.628 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -137.3 15.41 3.0 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 120.994 -1.066 . . . . 0.0 110.814 -179.534 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.581 HG21 ' CG1' ' A' ' 296' ' ' VAL . 7.1 p -127.64 116.92 45.07 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.611 0 O-C-N 121.218 -0.927 . . . . 0.0 110.081 179.418 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.511 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -47.84 -46.82 31.48 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.363 -0.835 . . . . 0.0 110.482 -179.69 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -177.18 158.78 1.54 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.103 -0.998 . . . . 0.0 110.861 -179.928 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.761 HG12 HG13 ' A' ' 296' ' ' VAL . 69.1 mt -120.39 122.97 69.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.026 -1.046 . . . . 0.0 110.278 179.721 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -127.42 137.58 52.76 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.203 -0.936 . . . . 0.0 110.193 179.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.068 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -96.34 130.57 43.42 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.059 -1.026 . . . . 0.0 110.367 179.975 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.45 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 30.4 tt0 -139.06 110.06 6.8 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.244 -0.91 . . . . 0.0 109.841 179.683 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.815 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.5 mt -91.69 110.22 22.31 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.081 -1.012 . . . . 0.0 110.231 -179.906 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.412 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 43.31 30.6 0.32 Allowed 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.645 -0.659 . . . . 0.0 110.969 179.917 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 111.09 -3.8 28.55 Favored Glycine 0 N--CA 1.492 2.39 0 C-N-CA 119.811 -1.185 . . . . 0.0 110.295 179.199 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.45 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 37.2 mm-40 -102.39 114.5 28.73 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.093 -1.239 . . . . 0.0 110.518 -179.772 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.935 ' O ' HD13 ' A' ' 358' ' ' ILE . 4.5 p -73.69 136.22 25.86 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.251 -0.905 . . . . 0.0 110.363 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.935 HD13 ' O ' ' A' ' 357' ' ' VAL . 20.6 mm . . . . . 0 N--CA 1.493 1.692 0 CA-C-O 118.051 -0.976 . . . . 0.0 110.267 -179.769 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.364 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -73.1 -179.47 4.37 Favored 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 124.025 1.539 . . . . 0.0 110.552 179.969 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.43 ' O ' HG23 ' A' ' 258' ' ' THR . 3.7 t -57.75 131.03 49.08 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.186 -0.946 . . . . 0.0 110.469 -179.908 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 19.1 m -68.21 122.34 83.78 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.159 -0.963 . . . . 0.0 110.338 -179.986 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -72.92 144.96 39.4 Favored 'Trans proline' 0 C--N 1.306 -1.664 0 O-C-N 123.961 1.506 . . . . 0.0 110.213 179.824 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.712 HG23 ' HD2' ' A' ' 262' ' ' PRO . 5.3 p -74.82 146.44 82.94 Favored Pre-proline 0 N--CA 1.492 1.632 0 O-C-N 121.076 -1.015 . . . . 0.0 110.551 -179.757 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.712 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.7 Cg_endo -75.68 149.94 34.67 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 124.051 1.553 . . . . 0.0 110.252 179.742 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 4.1 t -131.87 30.94 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -0.944 . . . . 0.0 110.3 -179.928 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 177.96 35.8 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.194 -0.941 . . . . 0.0 110.514 -179.952 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.42 ' O ' ' CG2' ' A' ' 358' ' ' ILE . . . 163.64 154.34 7.7 Favored Glycine 0 N--CA 1.491 2.345 0 C-N-CA 119.667 -1.254 . . . . 0.0 110.24 179.87 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.571 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -119.3 163.39 17.22 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.424 -1.045 . . . . 0.0 109.932 179.733 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.796 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -152.06 122.11 7.12 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 121.09 -1.006 . . . . 0.0 110.817 -179.822 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.443 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 4.9 mt-10 -118.72 111.15 18.13 Favored 'General case' 0 N--CA 1.491 1.608 0 N-CA-C 108.596 -0.89 . . . . 0.0 108.596 178.696 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.753 HG13 ' O ' ' A' ' 281' ' ' ASP . 71.4 t -113.23 141.2 29.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.011 -1.056 . . . . 0.0 111.861 -178.479 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -130.1 157.63 41.88 Favored 'General case' 0 N--CA 1.492 1.671 0 N-CA-C 108.426 -0.953 . . . . 0.0 108.426 178.858 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.887 HG13 ' O ' ' A' ' 279' ' ' GLU . 88.5 t -142.41 147.03 21.59 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.602 0 O-C-N 120.312 -1.492 . . . . 0.0 112.141 -179.064 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.562 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -135.83 107.5 6.99 Favored 'General case' 0 N--CA 1.487 1.397 0 N-CA-C 108.453 -0.943 . . . . 0.0 108.453 178.958 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.498 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.4 p30 -93.66 146.03 24.12 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.05 -1.031 . . . . 0.0 111.572 -178.363 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.5 p90 -134.84 23.72 3.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.563 -0.71 . . . . 0.0 109.694 179.293 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.425 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 82.4 -69.23 3.38 Favored Glycine 0 N--CA 1.488 2.148 0 N-CA-C 109.486 -1.446 . . . . 0.0 109.486 -179.875 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -55.27 -27.67 48.16 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.33 -1.1 . . . . 0.0 110.425 179.888 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.537 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.83 -173.57 38.74 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 109.667 -1.373 . . . . 0.0 109.667 -179.817 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.557 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -141.39 143.77 34.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.224 -1.162 . . . . 0.0 110.379 -179.958 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.887 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.7 mt-10 -93.67 145.61 24.43 Favored 'General case' 0 N--CA 1.487 1.425 0 O-C-N 121.475 -0.766 . . . . 0.0 109.578 -180.0 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.1 m-85 -137.9 82.66 1.93 Allowed 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.332 -0.855 . . . . 0.0 110.422 -179.543 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.753 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -67.91 144.11 55.38 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.485 -0.76 . . . . 0.0 109.676 179.433 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.874 HG11 HG11 ' A' ' 294' ' ' VAL . 6.7 t -137.71 88.4 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.484 -0.76 . . . . 0.0 109.772 -179.982 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.865 HG23 ' OG1' ' A' ' 333' ' ' THR . 60.6 m -86.25 120.47 27.64 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.189 -0.944 . . . . 0.0 109.245 179.808 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.092 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -104.32 149.02 25.72 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.076 -1.015 . . . . 0.0 111.106 -178.69 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.571 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -131.57 107.19 8.69 Favored 'General case' 0 N--CA 1.496 1.868 0 O-C-N 121.505 -0.747 . . . . 0.0 110.224 -179.298 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.524 ' N ' ' O ' ' A' ' 330' ' ' PRO . 4.8 mt -122.24 172.78 8.04 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 120.525 -1.359 . . . . 0.0 110.177 179.967 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 t0 -101.1 28.19 5.53 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.355 -0.841 . . . . 0.0 110.926 -179.603 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.637 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 161.92 -179.43 37.29 Favored Glycine 0 N--CA 1.495 2.571 0 C-N-CA 119.177 -1.487 . . . . 0.0 110.6 179.739 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.46 ' O ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -71.41 109.0 5.12 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.426 -1.044 . . . . 0.0 111.039 -179.417 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.637 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 10.2 m-85 -137.08 151.55 49.03 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.251 -0.906 . . . . 0.0 109.786 178.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.776 ' O ' HG23 ' A' ' 353' ' ' ILE . 57.8 m-20 -80.42 97.09 6.92 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.22 -0.925 . . . . 0.0 109.273 179.074 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.8 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.4 p-90 -97.18 110.67 23.17 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.294 -0.879 . . . . 0.0 110.406 -179.605 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.67 HG22 ' CG2' ' A' ' 320' ' ' ILE . 4.0 m -103.02 116.76 33.14 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.5 -0.75 . . . . 0.0 109.485 179.777 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.874 HG11 HG11 ' A' ' 282' ' ' VAL . 4.7 t -96.91 111.19 26.36 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.131 -0.981 . . . . 0.0 110.432 -179.465 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.651 ' HA ' HD13 ' A' ' 320' ' ' ILE . 17.5 ttpt -82.96 147.85 27.97 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.219 -0.925 . . . . 0.0 109.47 179.433 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 1.011 HG22 HG23 ' A' ' 349' ' ' ILE . 77.3 t -146.61 105.01 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.135 -0.978 . . . . 0.0 110.629 -179.323 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.562 ' O ' HG23 ' A' ' 346' ' ' VAL . 19.2 mmtt -71.26 130.51 41.6 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.259 -0.9 . . . . 0.0 109.393 179.404 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.983 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.2 mt -83.8 161.42 20.95 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.46 -0.775 . . . . 0.0 111.6 -178.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.968 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -63.56 179.12 0.35 Allowed Pre-proline 0 N--CA 1.489 1.502 0 O-C-N 121.675 -0.641 . . . . 0.0 109.674 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.9 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.5 Cg_endo -69.24 76.46 0.93 Allowed 'Trans proline' 0 C--N 1.305 -1.745 0 O-C-N 123.742 1.391 . . . . 0.0 109.825 179.369 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.73 19.68 6.0 Favored Glycine 0 N--CA 1.488 2.114 0 N-CA-C 108.7 -1.76 . . . . 0.0 108.7 -179.24 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.968 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -101.08 152.69 20.31 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.399 -1.059 . . . . 0.0 110.271 -179.596 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.983 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.8 p -150.6 144.62 25.38 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.309 -0.869 . . . . 0.0 110.588 179.85 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.853 HG21 HG11 ' A' ' 319' ' ' VAL . 55.2 t -68.07 140.95 18.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.35 -0.844 . . . . 0.0 109.734 179.541 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.79 -39.04 0.51 Allowed Glycine 0 N--CA 1.489 2.185 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.665 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 19.5 m -137.05 129.36 29.75 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.007 -1.29 . . . . 0.0 111.117 -179.678 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.516 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 30.1 p90 -141.2 167.09 23.02 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.387 -0.821 . . . . 0.0 109.434 179.27 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.467 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.06 157.15 37.12 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 120.877 -1.14 . . . . 0.0 111.083 -179.806 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.475 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 58.79 25.23 13.25 Favored 'General case' 0 N--CA 1.496 1.865 0 O-C-N 121.477 -0.764 . . . . 0.0 111.106 179.797 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.725 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.18 140.03 0.66 Allowed 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.242 -0.911 . . . . 0.0 109.997 179.465 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.515 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -79.47 121.96 25.84 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.104 -0.998 . . . . 0.0 109.312 179.569 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.686 ' HG3' HG11 ' A' ' 304' ' ' VAL . 0.6 OUTLIER -88.75 145.75 25.43 Favored 'General case' 0 N--CA 1.491 1.613 0 CA-C-O 121.771 0.796 . . . . 0.0 110.991 -179.119 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.824 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -131.17 175.23 9.28 Favored 'General case' 0 C--N 1.301 -1.508 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 179.35 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.524 ' HG2' HG22 ' A' ' 319' ' ' VAL . 3.4 mm-40 -138.68 112.99 8.74 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.228 -0.92 . . . . 0.0 110.457 -179.963 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -99.76 40.63 2.38 Favored Glycine 0 N--CA 1.489 2.231 0 N-CA-C 109.389 -1.484 . . . . 0.0 109.389 179.79 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 59.27 82.27 0.15 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.29 -1.123 . . . . 0.0 110.179 -179.921 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.614 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.56 -1.56 57.07 Favored Glycine 0 N--CA 1.49 2.261 0 N-CA-C 109.676 -1.37 . . . . 0.0 109.676 -179.965 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.683 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.2 m-85 -146.37 -172.72 4.01 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.499 -1.0 . . . . 0.0 109.317 179.627 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.853 HG11 HG21 ' A' ' 304' ' ' VAL . 2.5 t -158.67 160.16 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.137 -0.977 . . . . 0.0 109.743 179.355 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.67 ' CG2' HG22 ' A' ' 293' ' ' THR . 35.8 mm -127.93 146.82 32.92 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 121.163 -0.961 . . . . 0.0 111.304 -179.25 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.673 ' HE2' HG21 ' A' ' 296' ' ' VAL . 51.8 m-85 -123.67 132.68 53.9 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.223 -0.923 . . . . 0.0 110.003 179.163 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.597 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.1 p -131.54 169.69 13.17 Favored Pre-proline 0 N--CA 1.491 1.585 0 O-C-N 120.924 -1.11 . . . . 0.0 110.135 179.978 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.538 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 39.3 Cg_endo -65.76 116.49 3.99 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.065 -179.482 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.482 HG23 ' H ' ' A' ' 326' ' ' TRP . 12.1 m -57.62 -111.72 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.43 0 O-C-N 121.479 -0.763 . . . . 0.0 109.951 179.914 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.466 ' N ' HG23 ' A' ' 324' ' ' VAL . 1.1 t -119.6 -14.25 9.1 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.785 -1.197 . . . . 0.0 110.376 179.945 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.482 ' H ' HG23 ' A' ' 324' ' ' VAL . 6.5 p-90 -126.66 -24.75 3.51 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.229 -0.919 . . . . 0.0 110.614 -179.846 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.431 ' O ' ' CB ' ' A' ' 332' ' ' ALA . 0.3 OUTLIER -86.92 40.8 0.93 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.236 -0.915 . . . . 0.0 110.137 -179.898 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.467 ' HD3' ' O ' ' A' ' 324' ' ' VAL . 0.0 OUTLIER -112.33 -6.22 14.07 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 121.292 -0.88 . . . . 0.0 109.995 -179.89 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.448 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.69 -143.58 0.01 OUTLIER Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.642 -1.383 . . . . 0.0 109.642 -179.801 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.524 ' O ' ' N ' ' A' ' 286' ' ' LEU . 47.5 Cg_endo -74.85 -49.52 0.15 Allowed 'Trans proline' 0 C--N 1.304 -1.787 0 O-C-N 124.05 1.553 . . . . 0.0 110.395 179.973 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 19.0 m -111.08 134.48 52.65 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.247 -0.908 . . . . 0.0 110.511 -179.843 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.44 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -148.72 123.26 9.76 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.349 -0.845 . . . . 0.0 109.863 179.897 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.865 ' OG1' HG23 ' A' ' 283' ' ' THR . 45.5 m -111.48 137.22 49.57 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.169 -0.957 . . . . 0.0 110.504 -179.826 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.797 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.2 p90 -145.45 174.59 11.01 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.411 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.516 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.21 159.14 28.05 Favored Glycine 0 N--CA 1.488 2.144 0 C-N-CA 118.798 -1.668 . . . . 0.0 110.358 -179.397 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.929 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -144.98 146.24 31.85 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.572 -0.958 . . . . 0.0 109.781 179.686 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.929 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.03 125.66 74.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.175 -0.953 . . . . 0.0 110.091 -179.669 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.787 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.0 t -102.13 153.87 5.19 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 121.23 -0.918 . . . . 0.0 110.007 179.818 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -124.83 126.77 46.11 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.434 -0.791 . . . . 0.0 109.848 179.944 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -168.8 -125.57 0.8 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 179.884 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.431 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.2 Cg_endo -71.13 -158.38 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.594 0 O-C-N 123.864 1.455 . . . . 0.0 110.552 -179.899 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.548 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 3.0 mp0 -117.14 132.5 56.64 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.272 -0.892 . . . . 0.0 110.52 -179.707 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 113.87 -88.33 0.48 Allowed Glycine 0 N--CA 1.493 2.433 0 N-CA-C 108.986 -1.645 . . . . 0.0 108.986 179.948 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 12.5 p-10 -114.6 151.27 33.74 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.374 -1.074 . . . . 0.0 108.817 179.057 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.77 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 1.7 mtmt -142.45 13.53 1.97 Allowed 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.733 -1.229 . . . . 0.0 111.418 -179.577 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.572 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 11.2 p -136.66 119.17 20.69 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.065 -1.022 . . . . 0.0 110.316 179.238 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.481 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.32 -46.46 46.74 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.286 -0.884 . . . . 0.0 110.38 -179.653 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 2.0 pt-20 -177.02 158.37 1.54 Allowed 'General case' 0 N--CA 1.494 1.764 0 O-C-N 121.242 -0.911 . . . . 0.0 110.479 -179.756 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 1.011 HG23 HG22 ' A' ' 296' ' ' VAL . 23.6 mt -121.08 118.81 57.4 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.842 -1.161 . . . . 0.0 110.523 179.939 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.57 156.24 25.03 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.336 -0.852 . . . . 0.0 110.121 179.819 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.092 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -115.49 125.7 53.39 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.289 -0.882 . . . . 0.0 110.033 179.909 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.537 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.5 tt0 -139.06 118.4 12.79 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.966 -1.084 . . . . 0.0 110.618 179.869 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.776 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.4 mt -94.58 115.8 34.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.077 -1.015 . . . . 0.0 110.376 179.502 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.54 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 37.34 31.47 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.597 -0.689 . . . . 0.0 111.159 179.741 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.45 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 110.53 4.53 28.47 Favored Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.99 -1.244 . . . . 0.0 109.99 179.535 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.537 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 2.6 mp0 -108.05 105.93 15.92 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.149 -1.207 . . . . 0.0 110.087 179.992 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 357' ' ' VAL . 14.5 p -70.83 120.31 18.55 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.347 -0.845 . . . . 0.0 110.589 -179.87 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.629 HG23 ' CB ' ' A' ' 262' ' ' PRO . 17.1 mm . . . . . 0 N--CA 1.492 1.661 0 CA-C-O 117.978 -1.011 . . . . 0.0 110.172 179.743 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.313 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -73.3 175.85 10.01 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 O-C-N 123.985 1.519 . . . . 0.0 110.528 -179.974 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.51 ' CG2' ' O ' ' A' ' 258' ' ' THR . 1.2 t -67.12 124.49 23.21 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.311 -0.868 . . . . 0.0 110.135 179.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -133.71 104.37 11.94 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.213 -0.93 . . . . 0.0 110.319 -179.889 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.86 156.51 48.16 Favored 'Trans proline' 0 C--N 1.305 -1.745 0 O-C-N 124.086 1.572 . . . . 0.0 110.431 -180.0 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.549 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -72.79 141.78 82.56 Favored Pre-proline 0 N--CA 1.493 1.687 0 O-C-N 121.151 -0.968 . . . . 0.0 110.35 -179.964 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.549 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.9 Cg_endo -73.88 146.64 37.96 Favored 'Trans proline' 0 C--N 1.304 -1.803 0 O-C-N 124.08 1.569 . . . . 0.0 110.357 179.781 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.484 ' O ' ' CB ' ' A' ' 264' ' ' SER . 2.9 t -113.62 27.64 2.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 121.139 -0.976 . . . . 0.0 110.221 -179.945 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.484 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.6 OUTLIER 171.04 79.76 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.26 -0.9 . . . . 0.0 110.668 179.925 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 119.08 175.81 16.21 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 119.849 -1.167 . . . . 0.0 110.262 179.456 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.561 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.1 159.68 38.16 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.497 -1.002 . . . . 0.0 109.985 179.843 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.94 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -147.99 122.59 9.82 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.221 -0.924 . . . . 0.0 110.586 -179.626 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.461 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 14.7 mt-10 -123.59 114.26 19.79 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.997 -0.742 . . . . 0.0 108.997 179.189 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.958 HG13 ' O ' ' A' ' 281' ' ' ASP . 62.1 t -111.84 146.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.649 0 O-C-N 120.984 -1.072 . . . . 0.0 112.164 -178.417 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 2.9 tptt -130.68 157.21 43.4 Favored 'General case' 0 N--CA 1.494 1.729 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.844 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.829 HG13 ' O ' ' A' ' 279' ' ' GLU . 89.6 t -142.66 147.02 21.35 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.77 0 O-C-N 120.317 -1.489 . . . . 0.0 112.112 -179.203 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.537 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -141.12 111.13 6.61 Favored 'General case' 0 N--CA 1.489 1.52 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 179.216 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.502 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.8 m-20 -97.48 148.43 23.23 Favored 'General case' 0 N--CA 1.494 1.756 0 O-C-N 120.906 -1.121 . . . . 0.0 111.459 -178.526 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.845 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.7 p90 -134.52 20.21 3.62 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.59 -0.694 . . . . 0.0 109.903 179.459 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.471 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 85.91 -68.42 3.38 Favored Glycine 0 N--CA 1.489 2.218 0 N-CA-C 109.456 -1.458 . . . . 0.0 109.456 -179.942 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.402 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.6 t -58.33 -24.02 58.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.151 -1.206 . . . . 0.0 110.455 -179.838 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.9 179.73 43.39 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 109.903 -1.279 . . . . 0.0 109.903 -179.917 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.587 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -134.5 143.49 47.49 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.309 -1.112 . . . . 0.0 110.245 179.95 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.829 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -96.82 146.55 24.81 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.332 -0.855 . . . . 0.0 110.178 -179.644 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.683 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 87.4 m-85 -143.32 81.53 1.71 Allowed 'General case' 0 C--N 1.304 -1.41 0 O-C-N 121.414 -0.804 . . . . 0.0 110.539 -179.553 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.958 ' O ' HG13 ' A' ' 269' ' ' VAL . 2.0 t0 -66.28 154.03 41.01 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.22 -0.925 . . . . 0.0 110.124 179.57 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.808 HG11 HG11 ' A' ' 294' ' ' VAL . 4.0 t -143.2 88.92 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.558 0 O-C-N 121.567 -0.708 . . . . 0.0 109.493 179.891 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.598 HG23 ' OG1' ' A' ' 333' ' ' THR . 8.8 m -85.93 115.38 23.51 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.294 -0.878 . . . . 0.0 109.376 179.941 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.06 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -100.14 148.55 24.47 Favored 'General case' 0 C--N 1.301 -1.514 0 O-C-N 121.327 -0.858 . . . . 0.0 110.818 -178.921 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.561 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -131.15 106.34 8.28 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 121.492 -0.755 . . . . 0.0 110.316 -179.521 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.546 ' HB2' ' HA ' ' A' ' 330' ' ' PRO . 4.6 mt -121.03 169.25 10.67 Favored 'General case' 0 C--N 1.3 -1.574 0 O-C-N 120.648 -1.282 . . . . 0.0 109.801 179.447 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . 0.403 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -103.15 32.8 3.57 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.261 -0.899 . . . . 0.0 110.253 -179.856 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.552 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 163.79 -165.17 36.8 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.384 -1.389 . . . . 0.0 110.281 -179.977 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 5.0 mm-40 -89.28 110.58 21.34 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.268 -1.137 . . . . 0.0 111.046 -179.447 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.552 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 7.9 m-85 -137.8 142.07 40.86 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.179 -0.951 . . . . 0.0 109.706 179.169 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.666 ' O ' HG23 ' A' ' 353' ' ' ILE . 10.0 t70 -72.6 97.89 2.23 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.052 -1.03 . . . . 0.0 109.34 179.215 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.776 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.5 p-90 -97.32 112.32 24.19 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.272 -0.893 . . . . 0.0 110.383 -179.357 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.825 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.1 m -105.78 113.87 27.68 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.359 -0.838 . . . . 0.0 110.043 -179.999 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.821 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.6 t -96.61 111.1 25.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.263 -0.898 . . . . 0.0 110.047 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.544 ' HA ' HD13 ' A' ' 320' ' ' ILE . 23.1 ttpt -87.87 149.29 24.2 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.28 -0.888 . . . . 0.0 109.319 179.51 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.793 HG13 HG12 ' A' ' 349' ' ' ILE . 98.8 t -146.2 108.93 0.81 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.625 0 O-C-N 121.077 -1.014 . . . . 0.0 110.543 -179.505 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.526 ' HB2' ' CB ' ' A' ' 347' ' ' GLU . 9.3 mmtm -70.13 135.41 49.14 Favored 'General case' 0 N--CA 1.485 1.306 0 O-C-N 121.112 -0.992 . . . . 0.0 109.228 179.585 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.95 HD13 ' HA ' ' A' ' 303' ' ' THR . 88.4 mt -89.63 162.52 15.58 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.455 -0.778 . . . . 0.0 111.572 -178.879 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.853 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -69.48 177.47 1.23 Allowed Pre-proline 0 N--CA 1.488 1.449 0 O-C-N 121.756 -0.59 . . . . 0.0 109.759 179.358 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.853 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.7 Cg_endo -69.32 81.97 0.68 Allowed 'Trans proline' 0 C--N 1.304 -1.774 0 O-C-N 123.735 1.387 . . . . 0.0 109.786 179.351 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.26 22.58 5.8 Favored Glycine 0 N--CA 1.489 2.197 0 N-CA-C 108.947 -1.661 . . . . 0.0 108.947 -179.357 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.876 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.47 146.2 37.66 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.379 -1.071 . . . . 0.0 110.388 -179.623 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.95 ' HA ' HD13 ' A' ' 298' ' ' LEU . 5.4 p -149.86 145.74 26.73 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.274 -0.891 . . . . 0.0 110.327 179.643 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.894 HG21 HG11 ' A' ' 319' ' ' VAL . 92.2 t -68.09 131.31 33.42 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.263 -0.898 . . . . 0.0 109.852 179.744 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.12 -28.83 2.11 Favored Glycine 0 N--CA 1.489 2.181 0 N-CA-C 109.961 -1.256 . . . . 0.0 109.961 -179.542 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.7 t -142.33 115.99 9.16 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.103 -1.233 . . . . 0.0 111.116 -179.635 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.522 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 39.1 p90 -131.52 178.33 6.82 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.376 -0.828 . . . . 0.0 109.365 179.183 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.504 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -167.91 160.7 12.47 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 120.872 -1.143 . . . . 0.0 111.073 -179.643 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.475 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 57.81 23.61 9.84 Favored 'General case' 0 N--CA 1.495 1.815 0 O-C-N 121.496 -0.752 . . . . 0.0 110.881 179.789 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.671 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 146.79 1.0 Allowed 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.301 -0.874 . . . . 0.0 110.074 179.738 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.789 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -82.48 119.74 24.59 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.168 -0.958 . . . . 0.0 109.283 179.46 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.596 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.6 ttpt -88.78 146.15 25.18 Favored 'General case' 0 N--CA 1.491 1.612 0 CA-C-O 121.813 0.816 . . . . 0.0 110.657 -179.486 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.733 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -130.74 172.71 11.67 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 108.645 -0.872 . . . . 0.0 108.645 179.52 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.49 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 53.2 mt-10 -138.79 104.95 5.22 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.32 -0.863 . . . . 0.0 110.486 -179.706 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.463 ' O ' ' HB3' ' A' ' 316' ' ' ASN . . . -93.7 38.7 3.08 Favored Glycine 0 N--CA 1.489 2.232 0 N-CA-C 109.554 -1.418 . . . . 0.0 109.554 179.862 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.463 ' HB3' ' O ' ' A' ' 315' ' ' GLY . 11.3 t-20 59.97 83.48 0.13 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.277 -1.131 . . . . 0.0 110.344 179.817 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.627 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 101.09 -2.71 55.13 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.88 -1.288 . . . . 0.0 109.88 179.709 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.822 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.1 m-85 -145.76 -167.58 2.75 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.366 -1.079 . . . . 0.0 109.349 179.427 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.894 HG11 HG21 ' A' ' 304' ' ' VAL . 2.9 t -163.3 157.45 1.87 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.178 -0.952 . . . . 0.0 109.428 178.974 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.544 HD13 ' HA ' ' A' ' 295' ' ' LYS . 11.1 mm -127.38 142.99 42.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 119.301 -0.96 . . . . 0.0 111.021 -179.641 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 47.8 m-85 -119.31 136.21 54.35 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.146 -0.971 . . . . 0.0 109.808 179.504 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.825 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.3 p -138.48 169.98 11.4 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 120.792 -1.193 . . . . 0.0 110.122 -179.928 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.519 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.6 Cg_endo -65.79 123.97 12.08 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 123.926 1.487 . . . . 0.0 111.09 -179.292 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.789 HG12 ' ND2' ' A' ' 311' ' ' ASN . 18.6 m -74.35 -116.14 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.666 0 O-C-N 121.499 -0.751 . . . . 0.0 110.135 -179.938 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.5 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -105.68 -32.55 8.39 Favored 'General case' 0 N--CA 1.494 1.727 0 O-C-N 120.709 -1.245 . . . . 0.0 110.808 -179.588 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 4.1 p-90 -116.34 -1.77 12.24 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 121.12 -0.987 . . . . 0.0 110.502 -179.778 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.653 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.27 50.01 0.8 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.107 -0.995 . . . . 0.0 109.79 179.796 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.479 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -125.68 -2.6 7.28 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.376 -0.828 . . . . 0.0 109.716 -179.804 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.463 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -72.34 -143.91 0.48 Allowed Glycine 0 N--CA 1.488 2.15 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.735 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.546 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 49.2 Cg_endo -73.58 -53.73 0.12 Allowed 'Trans proline' 0 C--N 1.303 -1.838 0 O-C-N 124.166 1.614 . . . . 0.0 110.473 -179.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.25 130.61 50.53 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.259 -0.901 . . . . 0.0 110.467 -179.696 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.552 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -145.03 104.48 3.98 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.435 -0.791 . . . . 0.0 109.749 179.825 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.598 ' OG1' HG23 ' A' ' 283' ' ' THR . 27.8 m -100.68 133.73 44.71 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.084 -1.01 . . . . 0.0 110.604 -179.61 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.821 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.8 p90 -141.85 174.73 10.31 Favored 'General case' 0 N--CA 1.489 1.503 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.336 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.522 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.71 153.65 25.06 Favored Glycine 0 N--CA 1.491 2.332 0 C-N-CA 118.905 -1.617 . . . . 0.0 110.226 -179.542 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -138.72 146.73 41.85 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.468 -1.019 . . . . 0.0 109.794 179.354 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.88 122.09 65.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.635 0 O-C-N 121.238 -0.914 . . . . 0.0 109.798 -179.891 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.876 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 10.0 t -99.89 154.08 4.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.1 -1.0 . . . . 0.0 110.644 -179.398 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -124.91 130.65 52.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.464 -0.772 . . . . 0.0 110.065 -179.96 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.74 -123.22 0.83 Allowed Glycine 0 N--CA 1.492 2.391 0 N-CA-C 109.762 -1.335 . . . . 0.0 109.762 179.833 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.517 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 42.7 Cg_endo -68.62 174.99 7.66 Favored 'Trans proline' 0 C--N 1.307 -1.618 0 O-C-N 123.856 1.451 . . . . 0.0 110.438 -179.944 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.498 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 21.4 mm-40 -99.2 127.29 45.15 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.176 -0.953 . . . . 0.0 110.532 -179.295 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.453 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 115.82 -87.09 0.43 Allowed Glycine 0 N--CA 1.491 2.327 0 N-CA-C 109.217 -1.553 . . . . 0.0 109.217 -179.971 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -110.24 140.72 44.09 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.299 -1.118 . . . . 0.0 109.097 179.345 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.622 ' HA ' ' CB ' ' A' ' 299' ' ' ALA . 1.0 OUTLIER -139.03 13.27 2.65 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.822 -1.174 . . . . 0.0 111.281 -179.563 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' A' ' 296' ' ' VAL . 12.2 p -138.74 118.43 14.46 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.152 -0.968 . . . . 0.0 110.303 179.391 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 5.7 mt-10 -49.26 -48.45 45.84 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.415 -0.803 . . . . 0.0 110.368 -179.728 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.458 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.8 pt-20 -177.21 158.74 1.52 Allowed 'General case' 0 N--CA 1.496 1.844 0 O-C-N 121.188 -0.945 . . . . 0.0 111.008 -179.852 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.793 HG12 HG13 ' A' ' 296' ' ' VAL . 57.0 mt -117.46 121.44 67.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 121.324 -0.86 . . . . 0.0 109.993 179.509 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.56 136.97 54.64 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.246 -0.909 . . . . 0.0 110.291 -179.792 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.06 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -95.98 127.85 42.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.196 -0.94 . . . . 0.0 110.378 179.966 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.8 OUTLIER -139.39 113.02 8.43 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.16 -0.963 . . . . 0.0 110.399 179.746 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.666 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.3 mt -91.78 112.26 25.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.622 0 O-C-N 121.003 -1.061 . . . . 0.0 110.0 179.473 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.522 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.5 OUTLIER 41.19 29.02 0.07 Allowed 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.501 -0.749 . . . . 0.0 110.393 -179.69 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.417 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 113.15 -13.03 23.99 Favored Glycine 0 N--CA 1.494 2.507 0 N-CA-C 109.865 -1.294 . . . . 0.0 109.865 179.69 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.446 ' HB2' ' O ' ' A' ' 353' ' ' ILE . 0.2 OUTLIER -88.6 110.86 21.27 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.306 -1.114 . . . . 0.0 110.431 -179.842 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.635 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.3 p -68.66 119.33 14.3 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.172 -0.955 . . . . 0.0 110.171 179.975 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.842 ' HB ' HD13 ' A' ' 351' ' ' LEU . 42.9 mm . . . . . 0 N--CA 1.493 1.706 0 CA-C-O 118.007 -0.997 . . . . 0.0 110.268 -179.88 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.299 0 N-CA-C 109.463 -1.455 . . . . 0.0 109.463 . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.5 Cg_endo -74.1 -178.65 4.03 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.98 1.516 . . . . 0.0 110.377 -179.976 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.548 HG23 ' O ' ' A' ' 258' ' ' THR . 3.1 t -67.99 123.39 20.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.267 -0.896 . . . . 0.0 109.988 179.83 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 5.4 t -131.16 144.15 52.31 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 121.163 -0.961 . . . . 0.0 110.497 -179.748 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_endo -78.09 151.0 26.75 Favored 'Trans proline' 0 C--N 1.308 -1.585 0 O-C-N 123.929 1.489 . . . . 0.0 110.479 -179.973 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.651 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.5 p -103.85 145.14 30.07 Favored Pre-proline 0 N--CA 1.493 1.685 0 O-C-N 121.265 -0.897 . . . . 0.0 110.071 179.764 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.651 ' HD2' HG23 ' A' ' 261' ' ' VAL . 50.3 Cg_endo -74.39 140.66 27.56 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.056 1.556 . . . . 0.0 110.399 179.86 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.749 HG12 ' O ' ' A' ' 263' ' ' VAL . 63.6 t -110.06 23.96 3.91 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.148 -0.97 . . . . 0.0 110.011 179.948 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.558 ' O ' HD12 ' A' ' 358' ' ' ILE . 0.4 OUTLIER 167.12 139.81 0.02 OUTLIER 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.438 -0.789 . . . . 0.0 110.33 179.873 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 75.47 -179.46 46.15 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.871 -1.292 . . . . 0.0 109.871 179.716 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.556 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.1 158.41 44.23 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.535 -0.98 . . . . 0.0 109.431 179.754 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.926 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -157.32 141.34 16.13 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 120.943 -1.098 . . . . 0.0 110.93 -179.488 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.752 ' H ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -140.34 122.02 15.31 Favored 'General case' 0 C--N 1.301 -1.534 0 N-CA-C 109.248 -0.649 . . . . 0.0 109.248 179.797 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.844 HG23 HD11 ' A' ' 267' ' ' LEU . 50.9 t -115.39 133.14 62.63 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.01 -1.056 . . . . 0.0 111.559 -178.934 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -122.16 157.19 32.08 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.335 -0.987 . . . . 0.0 108.335 178.734 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 279' ' ' GLU . 71.6 t -143.12 147.04 20.9 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 120.286 -1.509 . . . . 0.0 112.251 -178.879 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.24 113.93 8.75 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.684 -0.858 . . . . 0.0 108.684 178.706 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 17.6 p-10 -98.81 148.21 24.13 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.039 -1.038 . . . . 0.0 111.718 -178.098 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.815 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.1 p90 -134.11 19.07 3.74 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.652 -0.655 . . . . 0.0 109.453 179.14 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.43 -65.83 3.91 Favored Glycine 0 N--CA 1.489 2.193 0 N-CA-C 109.322 -1.511 . . . . 0.0 109.322 -179.939 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -58.48 -21.43 51.61 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.274 -1.133 . . . . 0.0 110.255 179.719 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.531 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.35 -179.08 46.61 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.766 -1.334 . . . . 0.0 109.766 -179.938 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.558 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -136.76 140.73 42.77 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.42 -1.047 . . . . 0.0 109.983 179.776 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.797 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.0 mt-10 -93.66 146.58 23.72 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.466 -0.771 . . . . 0.0 110.37 -179.534 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 91.0 m-85 -140.81 84.47 1.94 Allowed 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.524 -0.735 . . . . 0.0 110.405 -179.883 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.676 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -67.24 151.75 46.95 Favored 'General case' 0 C--N 1.303 -1.417 0 O-C-N 121.418 -0.801 . . . . 0.0 109.487 179.208 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.767 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.6 t -145.72 88.6 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.618 0 O-C-N 121.564 -0.71 . . . . 0.0 109.615 -179.537 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.68 HG23 ' OG1' ' A' ' 333' ' ' THR . 88.6 m -87.01 123.83 32.54 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.081 -1.012 . . . . 0.0 110.226 -179.701 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.057 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -111.85 150.51 30.28 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.223 -0.923 . . . . 0.0 110.408 -179.76 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.556 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.4 OUTLIER -134.1 115.86 14.76 Favored 'General case' 0 N--CA 1.495 1.797 0 O-C-N 121.376 -0.827 . . . . 0.0 110.103 -179.377 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.618 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 13.2 mt -124.09 154.88 39.32 Favored 'General case' 0 C--N 1.298 -1.631 0 O-C-N 120.759 -1.213 . . . . 0.0 110.454 -179.936 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 74.3 m-20 -89.9 37.22 0.88 Allowed 'General case' 0 C--N 1.298 -1.649 0 O-C-N 121.248 -0.908 . . . . 0.0 109.786 179.627 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.425 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.61 -141.86 7.71 Favored Glycine 0 N--CA 1.492 2.367 0 N-CA-C 109.624 -1.391 . . . . 0.0 109.624 179.983 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.528 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 tp60 -111.67 92.62 4.1 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.162 -1.199 . . . . 0.0 110.489 -179.758 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.618 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 3.1 m-30 -116.93 129.99 56.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.268 -0.895 . . . . 0.0 110.074 179.396 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.876 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.5 m-20 -64.16 103.67 0.64 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.146 -0.972 . . . . 0.0 109.557 179.549 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.897 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.0 p-90 -101.95 109.32 21.03 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.189 -0.944 . . . . 0.0 110.391 -179.756 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.787 HG22 ' CG2' ' A' ' 320' ' ' ILE . 3.1 m -101.04 116.18 32.23 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.463 -0.773 . . . . 0.0 109.526 179.641 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.786 HG21 ' HE2' ' A' ' 334' ' ' PHE . 20.6 t -96.67 111.1 26.02 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 O-C-N 121.27 -0.894 . . . . 0.0 110.487 -179.378 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.477 ' HA ' HG12 ' A' ' 320' ' ' ILE . 22.8 ttpt -87.36 147.25 25.55 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.496 -0.752 . . . . 0.0 109.024 179.0 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.671 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 55.6 t -146.67 105.45 0.6 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.157 -0.964 . . . . 0.0 110.702 -178.981 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.547 ' O ' HG23 ' A' ' 346' ' ' VAL . 26.4 mmtt -70.93 133.51 46.47 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.15 -0.969 . . . . 0.0 109.732 179.628 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.953 HD13 ' HA ' ' A' ' 303' ' ' THR . 90.7 mt -86.31 162.44 18.24 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.323 -0.861 . . . . 0.0 111.573 -178.93 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.707 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -71.28 173.48 4.96 Favored Pre-proline 0 N--CA 1.488 1.441 0 O-C-N 121.582 -0.699 . . . . 0.0 109.264 179.067 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.694 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -67.92 82.4 0.46 Allowed 'Trans proline' 0 C--N 1.306 -1.681 0 O-C-N 123.508 1.267 . . . . 0.0 109.932 179.531 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.63 25.71 3.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.424 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.872 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -117.79 148.45 42.05 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.307 -1.113 . . . . 0.0 110.144 -179.748 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.953 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.4 p -149.82 144.52 26.04 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.207 -0.933 . . . . 0.0 110.239 179.918 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.822 HG21 HG11 ' A' ' 319' ' ' VAL . 38.2 t -63.99 119.9 9.35 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.232 -0.918 . . . . 0.0 109.886 179.767 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -105.95 -20.35 9.41 Favored Glycine 0 N--CA 1.49 2.292 0 C-N-CA 119.818 -1.182 . . . . 0.0 110.339 -179.392 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.489 ' O ' ' N ' ' A' ' 337' ' ' ILE . 42.2 t -154.8 134.28 12.64 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.983 -1.304 . . . . 0.0 110.889 -179.695 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.526 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -149.43 176.42 10.6 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.354 -0.841 . . . . 0.0 109.773 179.592 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.472 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -166.72 158.84 13.38 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.794 -1.191 . . . . 0.0 111.719 -179.632 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.51 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.8 OUTLIER 59.4 26.08 14.92 Favored 'General case' 0 N--CA 1.497 1.923 0 O-C-N 121.667 -0.646 . . . . 0.0 111.407 179.363 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.667 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.47 140.89 0.65 Allowed 'General case' 0 C--N 1.3 -1.578 0 O-C-N 121.17 -0.956 . . . . 0.0 109.936 179.336 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.744 HD22 HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.34 114.14 15.86 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.078 -1.014 . . . . 0.0 109.586 179.878 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.751 ' CD ' HG11 ' A' ' 304' ' ' VAL . 1.9 ttpp -83.01 144.6 29.84 Favored 'General case' 0 N--CA 1.491 1.601 0 CA-C-O 121.695 0.76 . . . . 0.0 110.691 -179.444 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.676 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -126.85 173.84 9.27 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 108.762 -0.829 . . . . 0.0 108.762 179.412 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.423 ' HG2' HG22 ' A' ' 319' ' ' VAL . 2.1 mm-40 -137.93 105.13 5.46 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.448 -0.782 . . . . 0.0 110.344 -179.931 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.442 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -97.17 35.78 4.27 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.389 -1.485 . . . . 0.0 109.389 179.899 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.442 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.4 OUTLIER 65.65 91.96 0.08 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.19 -1.182 . . . . 0.0 110.135 -179.962 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.58 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 87.47 0.69 84.28 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.568 -1.413 . . . . 0.0 109.568 -179.857 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.826 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -143.28 -172.75 3.76 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.339 -1.095 . . . . 0.0 109.654 179.629 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.826 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.7 t -163.46 152.52 2.97 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.518 0 N-CA-C 109.045 -0.724 . . . . 0.0 109.045 178.575 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.787 ' CG2' HG22 ' A' ' 293' ' ' THR . 68.8 mt -131.99 132.17 61.42 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 C-N-CA 118.661 -1.216 . . . . 0.0 111.648 -179.381 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.656 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 70.8 m-85 -104.76 141.47 36.42 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.374 -0.829 . . . . 0.0 110.748 -179.725 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.738 ' CG2' HG23 ' A' ' 293' ' ' THR . 0.9 OUTLIER -137.05 171.02 9.3 Favored Pre-proline 0 N--CA 1.491 1.612 0 O-C-N 120.969 -1.082 . . . . 0.0 110.143 179.762 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.53 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.3 Cg_endo -67.29 114.68 3.33 Favored 'Trans proline' 0 C--N 1.307 -1.61 0 O-C-N 123.822 1.433 . . . . 0.0 110.986 -179.461 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.963 HG22 ' HB2' ' A' ' 327' ' ' ASN . 7.3 m -65.44 -134.36 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.464 -0.773 . . . . 0.0 109.894 179.747 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.707 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.7 OUTLIER -92.09 -14.73 28.78 Favored 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.021 -1.049 . . . . 0.0 110.602 -179.697 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.836 ' H ' HG23 ' A' ' 324' ' ' VAL . 26.4 p-90 -136.06 15.97 3.27 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.241 -0.912 . . . . 0.0 110.444 -179.841 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.963 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -116.24 31.17 6.89 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.097 -1.002 . . . . 0.0 110.8 -179.481 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.528 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -114.6 -6.47 12.78 Favored 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.244 -0.91 . . . . 0.0 109.801 179.539 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.1 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.491 2.347 0 N-CA-C 109.837 -1.305 . . . . 0.0 109.837 -179.869 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.529 ' CA ' ' O ' ' A' ' 286' ' ' LEU . 50.2 Cg_endo -75.42 5.75 4.0 Favored 'Trans proline' 0 C--N 1.305 -1.744 0 O-C-N 124.04 1.547 . . . . 0.0 110.987 -179.787 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.459 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 7.7 m -165.36 121.64 1.41 Allowed 'General case' 0 C--N 1.298 -1.639 0 O-C-N 120.96 -1.087 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.521 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -143.44 112.74 6.8 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.139 -0.975 . . . . 0.0 110.446 -179.894 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.68 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.9 m -103.04 139.05 39.08 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.407 -0.808 . . . . 0.0 110.009 179.864 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.786 ' HE2' HG21 ' A' ' 294' ' ' VAL . 17.7 p90 -144.72 172.77 12.54 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.403 -0.81 . . . . 0.0 108.834 179.566 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.526 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.37 160.01 28.37 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 118.954 -1.594 . . . . 0.0 109.973 -179.645 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.931 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -145.33 146.4 31.59 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.582 -0.952 . . . . 0.0 109.63 179.237 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.931 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.85 120.25 61.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.215 -0.928 . . . . 0.0 109.836 179.98 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.872 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 6.0 t -96.74 146.3 7.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.13 -0.981 . . . . 0.0 110.621 -179.519 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -120.02 131.9 55.29 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.49 -0.756 . . . . 0.0 110.219 -179.935 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.18 -134.09 2.01 Favored Glycine 0 N--CA 1.491 2.326 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.912 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.496 ' C ' ' NE2' ' A' ' 342' ' ' GLN . 45.9 Cg_endo -71.08 -170.31 0.47 Allowed 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 123.926 1.487 . . . . 0.0 110.287 -179.723 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.496 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 20.8 mm-40 -107.62 149.08 28.49 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.144 -0.973 . . . . 0.0 110.255 -179.595 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.425 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 92.51 72.85 1.22 Allowed Glycine 0 N--CA 1.491 2.322 0 N-CA-C 109.046 -1.622 . . . . 0.0 109.046 -179.863 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.425 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 1.0 OUTLIER 64.04 147.55 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.249 -1.148 . . . . 0.0 109.369 -179.48 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.707 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.0 mtmt -142.01 18.23 2.12 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 120.904 -1.123 . . . . 0.0 111.1 -179.762 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.62 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.2 p -130.77 122.45 52.43 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.126 -0.984 . . . . 0.0 110.18 179.22 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.48 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -51.83 -45.45 63.95 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.195 -0.941 . . . . 0.0 110.16 -179.703 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.475 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 6.9 pt-20 -177.03 158.27 1.52 Allowed 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.253 -0.904 . . . . 0.0 110.324 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.589 HG12 HG13 ' A' ' 296' ' ' VAL . 11.5 mt -118.11 110.31 30.11 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.318 -0.864 . . . . 0.0 110.055 179.904 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -109.45 149.47 29.51 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.305 -0.872 . . . . 0.0 110.235 -179.949 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.057 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -113.6 127.25 56.0 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.228 -0.92 . . . . 0.0 109.509 179.252 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 15.4 pt-20 -138.31 118.78 13.82 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.135 -0.978 . . . . 0.0 110.086 -179.797 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.876 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -97.73 104.7 16.23 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.452 0 O-C-N 121.197 -0.939 . . . . 0.0 110.351 179.928 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.488 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 1.5 m-80 35.16 30.94 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.761 0 CA-C-O 121.057 0.455 . . . . 0.0 111.073 179.805 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.509 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 133.61 -43.41 1.27 Allowed Glycine 0 N--CA 1.493 2.477 0 C-N-CA 119.644 -1.265 . . . . 0.0 110.276 179.706 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.508 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 35.2 mm-40 -73.97 120.71 19.93 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.124 -1.221 . . . . 0.0 110.627 -179.505 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.712 HG13 ' O ' ' A' ' 357' ' ' VAL . 12.9 p -91.3 111.51 23.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.066 -1.022 . . . . 0.0 110.08 179.781 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.609 HG23 ' CB ' ' A' ' 262' ' ' PRO . 9.4 mm . . . . . 0 N--CA 1.493 1.698 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.187 -179.837 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.326 0 N-CA-C 109.714 -1.354 . . . . 0.0 109.714 . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.0 Cg_endo -74.06 -178.31 3.79 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.999 1.526 . . . . 0.0 110.656 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.406 ' O ' HG23 ' A' ' 258' ' ' THR . 5.0 t -70.44 134.97 48.3 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.477 -0.764 . . . . 0.0 110.378 -179.9 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 34.1 p -85.12 129.88 54.24 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.206 -0.934 . . . . 0.0 110.124 179.892 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.2 Cg_endo -71.94 133.76 22.26 Favored 'Trans proline' 0 C--N 1.307 -1.612 0 O-C-N 123.899 1.473 . . . . 0.0 110.398 179.946 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.431 ' H ' HG12 ' A' ' 261' ' ' VAL . 2.6 p -73.66 138.31 77.2 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.343 -0.848 . . . . 0.0 110.44 -179.812 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 358' ' ' ILE . 50.7 Cg_endo -78.46 143.82 19.67 Favored 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 124.172 1.617 . . . . 0.0 110.493 -179.993 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 3.6 t -139.07 29.7 0.53 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.252 -0.905 . . . . 0.0 110.107 179.676 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.628 ' HB3' HD11 ' A' ' 358' ' ' ILE . 12.3 t -163.27 69.07 0.21 Allowed 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.233 -0.917 . . . . 0.0 110.68 179.915 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.45 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . 108.09 -163.51 12.9 Favored Glycine 0 N--CA 1.49 2.256 0 N-CA-C 110.177 -1.169 . . . . 0.0 110.177 179.425 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.498 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.92 169.28 18.05 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.53 -0.983 . . . . 0.0 109.729 180.0 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.886 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -161.77 133.34 5.44 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.039 -1.038 . . . . 0.0 111.396 179.984 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.829 ' N ' HD22 ' A' ' 267' ' ' LEU . 0.3 OUTLIER -129.76 138.38 51.05 Favored 'General case' 0 N--CA 1.491 1.598 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 179.404 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.643 HG13 ' O ' ' A' ' 281' ' ' ASP . 49.0 t -131.54 134.04 61.08 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.869 -1.145 . . . . 0.0 111.653 -179.3 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -120.24 157.08 29.89 Favored 'General case' 0 N--CA 1.491 1.622 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 178.705 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.659 HG13 ' O ' ' A' ' 279' ' ' GLU . 75.7 t -141.26 145.34 25.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.494 -1.378 . . . . 0.0 111.879 -179.392 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.57 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.15 110.17 8.26 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.666 -0.646 . . . . 0.0 109.825 179.631 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.414 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 10.8 m-20 -96.39 128.41 43.28 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.167 -0.958 . . . . 0.0 111.102 -179.412 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.83 ' CH2' HG23 ' A' ' 337' ' ' ILE . 29.0 p90 -113.17 16.59 19.12 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.293 -0.879 . . . . 0.0 109.762 178.995 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.06 -59.0 3.93 Favored Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.523 -1.431 . . . . 0.0 109.523 179.923 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -69.45 -22.01 63.68 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.257 -1.143 . . . . 0.0 110.18 179.858 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.583 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -168.78 -178.39 40.29 Favored Glycine 0 N--CA 1.492 2.387 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.821 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.553 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -136.56 139.37 42.13 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.339 -1.095 . . . . 0.0 110.167 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.659 ' O ' HG13 ' A' ' 271' ' ' VAL . 3.6 mt-10 -93.58 147.53 22.92 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.508 -0.745 . . . . 0.0 110.11 -179.511 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.3 m-85 -141.75 82.16 1.8 Allowed 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.279 -0.888 . . . . 0.0 110.432 -179.661 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.643 ' O ' HG13 ' A' ' 269' ' ' VAL . 1.6 m-20 -67.38 146.01 54.48 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.509 -0.745 . . . . 0.0 109.695 179.557 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.773 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.8 t -139.12 88.78 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.598 0 O-C-N 121.397 -0.814 . . . . 0.0 109.931 -179.738 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.599 HG23 ' OG1' ' A' ' 333' ' ' THR . 25.9 m -86.04 125.35 33.36 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.058 -1.026 . . . . 0.0 109.218 179.746 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -112.06 153.7 26.5 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.109 -0.994 . . . . 0.0 110.882 -179.072 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.936 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -131.63 128.37 38.96 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.474 -0.766 . . . . 0.0 110.162 -179.582 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.936 HD23 ' O ' ' A' ' 285' ' ' ASN . 9.8 mt -143.69 157.09 44.65 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.771 -1.206 . . . . 0.0 109.938 179.862 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.7 t0 -94.38 35.7 1.19 Allowed 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.401 -0.812 . . . . 0.0 109.732 179.526 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' HA ' ' A' ' 330' ' ' PRO . . . 162.21 -174.61 38.66 Favored Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.854 -1.298 . . . . 0.0 109.854 -179.908 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.537 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.6 mt-30 -83.93 96.3 8.78 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.308 -1.113 . . . . 0.0 110.406 -179.622 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.603 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.74 153.38 32.51 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.227 -0.92 . . . . 0.0 109.749 179.586 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.844 ' O ' HG23 ' A' ' 353' ' ' ILE . 53.9 m-20 -82.85 95.74 8.03 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.196 -0.94 . . . . 0.0 109.328 179.327 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.893 ' CE3' HD13 ' A' ' 284' ' ' LEU . 55.5 p-90 -97.13 116.42 29.29 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.263 -0.898 . . . . 0.0 110.226 -179.737 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 1.042 HG23 HG22 ' A' ' 322' ' ' THR . 1.9 m -111.03 114.07 27.09 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.541 -0.724 . . . . 0.0 109.93 -179.83 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.776 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.4 t -96.2 111.33 26.2 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.097 -1.002 . . . . 0.0 110.205 -179.689 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 27.3 ttmt -86.63 149.81 24.65 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.368 -0.833 . . . . 0.0 109.622 179.361 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.862 HG22 HG23 ' A' ' 349' ' ' ILE . 54.5 t -147.69 109.27 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.117 -0.99 . . . . 0.0 110.599 -179.575 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.571 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 51.9 mmtt -72.6 141.42 48.37 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.107 -0.996 . . . . 0.0 109.591 179.441 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.966 HD13 ' HA ' ' A' ' 303' ' ' THR . 81.2 mt -94.03 156.2 16.72 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.26 -0.9 . . . . 0.0 111.481 -179.059 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -65.27 174.45 1.4 Allowed Pre-proline 0 C--N 1.303 -1.442 0 N-CA-C 109.323 -0.621 . . . . 0.0 109.323 178.961 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.8 Cg_endo -68.74 83.42 0.53 Allowed 'Trans proline' 0 C--N 1.306 -1.705 0 O-C-N 123.531 1.28 . . . . 0.0 109.848 179.65 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.34 23.37 4.84 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 -179.468 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.709 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -114.69 149.41 36.82 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.298 -1.119 . . . . 0.0 109.753 -179.949 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.966 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.6 p -150.69 143.46 24.56 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.0 -1.062 . . . . 0.0 111.214 -179.796 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.93 ' CG2' HG21 ' A' ' 319' ' ' VAL . 58.6 t -70.89 116.46 12.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.657 0 O-C-N 121.56 -0.713 . . . . 0.0 110.013 179.515 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -100.43 -38.49 3.48 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.82 -1.181 . . . . 0.0 110.359 -179.264 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.467 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -129.94 140.33 50.95 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.004 -1.292 . . . . 0.0 111.139 -179.457 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.599 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 13.1 p90 -152.88 160.96 43.1 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.456 -0.778 . . . . 0.0 109.577 179.334 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.518 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.3 p90 -155.38 155.18 33.17 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.902 -1.124 . . . . 0.0 111.394 -179.48 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.441 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 0.9 OUTLIER 63.11 26.8 15.5 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.671 -0.643 . . . . 0.0 111.337 179.373 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.56 ' N ' HG13 ' A' ' 324' ' ' VAL . . . -174.29 148.6 1.29 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.049 -1.032 . . . . 0.0 110.805 179.573 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.508 ' O ' ' HA ' ' A' ' 321' ' ' PHE . 2.1 m-80 -77.59 114.02 16.01 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.183 -0.948 . . . . 0.0 109.474 179.259 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.599 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 23.3 ttpt -89.51 122.45 32.7 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.435 -0.791 . . . . 0.0 110.831 -179.57 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.618 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.9 OUTLIER -111.87 177.54 4.61 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.518 -0.739 . . . . 0.0 109.284 179.008 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.436 ' HG2' HG22 ' A' ' 319' ' ' VAL . 4.9 mt-10 -137.26 105.14 5.61 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.278 -0.889 . . . . 0.0 110.286 179.593 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.57 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -92.22 47.19 2.63 Favored Glycine 0 N--CA 1.491 2.349 0 N-CA-C 109.883 -1.287 . . . . 0.0 109.883 -179.755 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 55.21 78.97 0.16 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.126 -1.22 . . . . 0.0 110.376 179.818 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.621 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 97.86 3.68 58.06 Favored Glycine 0 N--CA 1.49 2.288 0 N-CA-C 109.929 -1.268 . . . . 0.0 109.929 179.697 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.731 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -144.85 -172.63 3.87 Favored 'General case' 0 N--CA 1.495 1.805 0 O-C-N 121.42 -1.047 . . . . 0.0 109.061 179.545 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.93 HG21 ' CG2' ' A' ' 304' ' ' VAL . 12.1 t -158.89 150.08 7.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.988 -1.07 . . . . 0.0 110.286 179.225 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.639 ' CG2' HG22 ' A' ' 293' ' ' THR . 6.4 mm -114.96 151.85 16.65 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.913 0 O-C-N 121.104 -0.998 . . . . 0.0 110.687 -179.656 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.658 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 35.0 m-85 -131.74 112.2 12.32 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.199 179.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 1.042 HG22 HG23 ' A' ' 293' ' ' THR . 1.7 p -113.22 -176.46 0.38 Allowed Pre-proline 0 N--CA 1.497 1.884 0 O-C-N 120.374 -1.454 . . . . 0.0 109.591 179.189 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.587 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 45.6 Cg_endo -77.63 117.44 4.28 Favored 'Trans proline' 0 C--N 1.309 -1.543 0 O-C-N 123.446 1.235 . . . . 0.0 111.458 -178.502 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.73 HG22 ' ND2' ' A' ' 327' ' ' ASN . 3.7 m -53.58 -105.21 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.632 0 O-C-N 121.424 -0.797 . . . . 0.0 110.592 179.905 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.484 ' H ' HG23 ' A' ' 324' ' ' VAL . 14.5 m -133.79 -12.37 2.61 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 120.691 -1.256 . . . . 0.0 111.428 -179.448 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.621 ' CE3' ' HB3' ' A' ' 327' ' ' ASN . 2.0 p-90 -126.47 -25.6 3.43 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 120.776 -1.202 . . . . 0.0 111.228 -179.586 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.73 ' ND2' HG22 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -96.0 36.66 1.29 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.762 -1.211 . . . . 0.0 110.963 -179.697 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -99.71 -6.23 27.46 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.157 -0.964 . . . . 0.0 108.736 178.179 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.434 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -61.55 -138.38 0.01 OUTLIER Glycine 0 N--CA 1.487 2.037 0 N-CA-C 109.792 -1.323 . . . . 0.0 109.792 -179.474 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.599 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 46.0 Cg_endo -73.01 -54.62 0.11 Allowed 'Trans proline' 0 C--N 1.304 -1.778 0 O-C-N 124.205 1.634 . . . . 0.0 111.054 -179.721 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -102.61 140.25 37.13 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.156 -0.965 . . . . 0.0 110.77 -179.286 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.721 ' HB1' ' CZ2' ' A' ' 292' ' ' TRP . . . -152.26 107.77 3.31 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.295 -0.878 . . . . 0.0 110.559 -179.917 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.599 ' OG1' HG23 ' A' ' 283' ' ' THR . 53.8 m -105.41 135.9 45.94 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 120.907 -1.121 . . . . 0.0 110.166 179.67 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.776 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.0 p90 -145.32 174.6 10.96 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.555 -0.906 . . . . 0.0 108.555 179.631 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.551 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.26 158.08 27.75 Favored Glycine 0 N--CA 1.487 2.089 0 C-N-CA 118.659 -1.734 . . . . 0.0 110.435 -179.357 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.897 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.9 OUTLIER -143.42 146.5 33.51 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 121.669 -0.901 . . . . 0.0 109.33 179.252 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.897 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.74 121.31 65.84 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.968 -1.083 . . . . 0.0 109.831 179.904 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.709 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.5 t -96.6 145.92 8.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.184 -0.947 . . . . 0.0 109.634 179.866 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -121.33 135.43 55.09 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.266 -0.896 . . . . 0.0 110.905 -179.234 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.26 -134.33 2.06 Favored Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.218 -1.553 . . . . 0.0 109.218 179.735 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.504 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.4 Cg_endo -71.33 -155.82 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.717 0 O-C-N 123.877 1.461 . . . . 0.0 110.275 179.728 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.565 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -126.13 128.44 47.32 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.965 -1.085 . . . . 0.0 110.202 -179.852 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.515 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 117.69 61.95 0.3 Allowed Glycine 0 N--CA 1.49 2.278 0 N-CA-C 108.871 -1.692 . . . . 0.0 108.871 -179.825 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.515 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 10.4 t0 70.24 132.74 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.38 -1.071 . . . . 0.0 108.966 -179.066 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.643 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.0 OUTLIER -135.06 19.82 3.45 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.836 -1.165 . . . . 0.0 111.187 -179.098 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.571 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 7.4 p -126.53 119.05 52.69 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.617 0 O-C-N 120.911 -1.118 . . . . 0.0 110.241 179.378 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 4.1 mm-40 -49.67 -44.56 47.92 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.244 -0.91 . . . . 0.0 110.523 -179.533 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.446 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.1 pt-20 -176.68 158.85 1.76 Allowed 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.09 -1.006 . . . . 0.0 110.718 -179.713 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.862 HG23 HG22 ' A' ' 296' ' ' VAL . 29.6 mt -124.42 110.17 24.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.095 -1.003 . . . . 0.0 110.228 179.992 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -114.67 160.05 19.8 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.18 -0.95 . . . . 0.0 110.415 179.999 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.52 129.72 54.83 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.25 -0.906 . . . . 0.0 110.554 -179.903 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.511 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 2.9 tt0 -139.32 118.35 12.57 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.382 -0.824 . . . . 0.0 109.456 179.405 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.844 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -91.08 100.66 11.53 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.892 -1.13 . . . . 0.0 110.399 -179.848 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.444 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 38.27 40.08 0.32 Allowed 'General case' 0 C--N 1.299 -1.607 0 O-C-N 121.949 -0.47 . . . . 0.0 111.396 179.492 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.44 ' O ' ' CD ' ' A' ' 356' ' ' GLN . . . 113.06 23.37 5.27 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.666 -1.254 . . . . 0.0 110.793 179.056 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.511 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 6.2 mm100 -141.46 101.47 4.0 Favored 'General case' 0 N--CA 1.495 1.81 0 O-C-N 121.015 -1.285 . . . . 0.0 110.238 179.661 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.706 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -65.7 136.35 26.84 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.252 -0.905 . . . . 0.0 110.552 -179.827 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.706 HD13 ' O ' ' A' ' 357' ' ' VAL . 22.9 mm . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 118.046 -0.978 . . . . 0.0 110.215 179.963 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.359 0 N-CA-C 109.544 -1.422 . . . . 0.0 109.544 . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -73.8 179.45 5.65 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 123.967 1.509 . . . . 0.0 110.432 -179.846 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 5.0 t -59.42 134.72 57.26 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.299 -0.876 . . . . 0.0 110.043 -179.903 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . 0.462 HG23 ' O ' ' A' ' 259' ' ' THR . 1.4 t -119.12 101.61 49.59 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.139 -0.976 . . . . 0.0 110.586 -179.704 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -75.6 142.52 26.19 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.892 1.469 . . . . 0.0 109.969 179.716 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.653 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -68.91 144.51 95.85 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.047 -1.033 . . . . 0.0 110.319 -179.806 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.653 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.0 Cg_endo -73.87 154.8 48.55 Favored 'Trans proline' 0 C--N 1.305 -1.721 0 O-C-N 124.128 1.594 . . . . 0.0 110.417 179.899 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.744 HG12 ' O ' ' A' ' 263' ' ' VAL . 90.9 t -139.49 28.91 0.52 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.308 -0.87 . . . . 0.0 110.105 179.799 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -179.83 91.1 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.24 -0.912 . . . . 0.0 110.72 -179.937 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 100.32 -170.07 22.12 Favored Glycine 0 N--CA 1.49 2.247 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.254 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.566 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -138.6 165.86 25.82 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.602 -0.94 . . . . 0.0 109.593 179.908 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.927 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.1 tm? -161.63 141.35 10.25 Favored 'General case' 0 C--N 1.302 -1.494 0 C-N-CA 118.94 -1.104 . . . . 0.0 111.436 -179.554 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.746 ' H ' HD22 ' A' ' 267' ' ' LEU . 0.2 OUTLIER -139.48 149.5 44.06 Favored 'General case' 0 N--CA 1.491 1.605 0 N-CA-C 108.836 -0.802 . . . . 0.0 108.836 178.853 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 281' ' ' ASP . 39.8 t -138.19 137.9 43.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.694 -1.254 . . . . 0.0 111.654 -179.337 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.444 ' HG2' ' OE2' ' A' ' 268' ' ' GLU . 3.2 mmtp -125.27 156.93 37.81 Favored 'General case' 0 N--CA 1.494 1.762 0 N-CA-C 108.855 -0.794 . . . . 0.0 108.855 179.111 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.703 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.1 t -145.07 145.84 20.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.692 0 O-C-N 120.374 -1.454 . . . . 0.0 112.15 -179.193 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.533 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -140.8 112.56 7.59 Favored 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.796 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.492 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.1 p-10 -97.37 144.84 26.73 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.955 -1.091 . . . . 0.0 111.602 -178.338 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 36.1 p90 -129.9 21.54 5.41 Favored 'General case' 0 N--CA 1.49 1.557 0 CA-C-O 121.472 0.654 . . . . 0.0 109.681 179.281 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.529 ' HA2' ' HG3' ' A' ' 342' ' ' GLN . . . 87.24 -68.53 3.16 Favored Glycine 0 N--CA 1.488 2.164 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -179.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.502 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 8.1 t -56.93 -23.73 47.41 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.144 -1.209 . . . . 0.0 110.35 -179.898 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.423 ' HA2' ' HA ' ' A' ' 339' ' ' ASN . . . -174.46 -170.02 37.19 Favored Glycine 0 N--CA 1.491 2.353 0 C-N-CA 119.387 -1.387 . . . . 0.0 109.987 179.918 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.632 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -141.88 143.78 33.5 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.337 -1.096 . . . . 0.0 110.514 -179.905 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.703 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.4 mt-10 -94.87 147.34 23.47 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.412 -0.805 . . . . 0.0 109.904 -179.853 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.658 ' CB ' ' CE2' ' A' ' 336' ' ' PHE . 88.1 m-85 -142.91 90.27 2.19 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.396 -0.815 . . . . 0.0 110.514 -179.63 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.709 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -74.16 153.02 39.7 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.365 -0.835 . . . . 0.0 110.117 179.539 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.859 HG11 HG11 ' A' ' 294' ' ' VAL . 3.3 t -145.12 90.61 0.32 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 O-C-N 121.468 -0.77 . . . . 0.0 109.83 -179.665 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 1.006 HG23 ' OG1' ' A' ' 333' ' ' THR . 7.5 m -87.04 122.61 31.11 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.179 -0.951 . . . . 0.0 110.457 -179.746 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.089 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -108.14 151.09 26.37 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.32 -0.862 . . . . 0.0 110.122 179.926 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.566 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -134.58 106.57 7.06 Favored 'General case' 0 N--CA 1.495 1.795 0 O-C-N 121.211 -0.93 . . . . 0.0 110.646 -179.036 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.632 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.6 mt -113.07 173.9 6.16 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 120.666 -1.272 . . . . 0.0 110.006 179.671 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 2.2 t0 -109.5 30.19 6.87 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.22 -0.925 . . . . 0.0 110.281 -179.772 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.434 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 170.19 -102.79 0.18 Allowed Glycine 0 N--CA 1.49 2.263 0 C-N-CA 119.096 -1.526 . . . . 0.0 110.357 -179.95 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.487 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.1 OUTLIER -150.7 105.38 3.28 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.192 -1.181 . . . . 0.0 110.463 -179.395 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.632 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -136.33 132.74 36.04 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.206 -0.934 . . . . 0.0 110.025 179.596 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.768 ' O ' HG23 ' A' ' 353' ' ' ILE . 0.2 OUTLIER -61.04 100.25 0.11 Allowed 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.289 -0.882 . . . . 0.0 109.366 179.337 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.881 ' CZ2' ' HB1' ' A' ' 332' ' ' ALA . 56.4 p-90 -98.34 111.07 23.53 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.345 -0.847 . . . . 0.0 110.447 -179.637 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.901 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.4 m -105.37 114.58 28.85 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.348 -0.845 . . . . 0.0 109.804 -179.999 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.859 HG11 HG11 ' A' ' 282' ' ' VAL . 3.5 t -96.92 110.74 25.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.485 0 O-C-N 121.145 -0.972 . . . . 0.0 110.085 -179.809 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.586 ' HA ' HD13 ' A' ' 320' ' ' ILE . 18.8 ttpt -87.41 149.01 24.74 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.227 -0.92 . . . . 0.0 109.362 179.441 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.709 HG13 HG12 ' A' ' 349' ' ' ILE . 71.0 t -145.78 110.53 1.0 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.193 -0.942 . . . . 0.0 110.745 -179.325 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.614 ' O ' HG23 ' A' ' 346' ' ' VAL . 29.3 mmtp -71.51 132.71 45.1 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.246 -0.909 . . . . 0.0 109.73 179.343 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.936 HD13 ' HA ' ' A' ' 303' ' ' THR . 83.0 mt -85.42 159.06 20.06 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.375 -0.828 . . . . 0.0 111.445 -179.036 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.801 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -62.94 174.77 0.77 Allowed Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.699 -0.626 . . . . 0.0 109.454 179.08 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.733 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 43.0 Cg_endo -69.4 78.88 0.86 Allowed 'Trans proline' 0 C--N 1.304 -1.812 0 O-C-N 123.575 1.303 . . . . 0.0 109.754 179.451 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.19 24.58 3.81 Favored Glycine 0 N--CA 1.487 2.058 0 N-CA-C 108.527 -1.829 . . . . 0.0 108.527 -179.166 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.808 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -112.22 152.93 27.84 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.241 -1.152 . . . . 0.0 110.338 -179.479 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.936 ' HA ' HD13 ' A' ' 298' ' ' LEU . 21.5 p -153.31 143.61 22.38 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.235 -0.915 . . . . 0.0 110.502 179.816 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.933 HG21 HG11 ' A' ' 319' ' ' VAL . 76.4 t -64.72 139.75 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.463 -0.773 . . . . 0.0 110.215 179.881 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . 0.471 ' N ' ' O ' ' A' ' 337' ' ' ILE . . . -123.28 -33.69 0.81 Allowed Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.703 -1.359 . . . . 0.0 109.703 -179.847 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.442 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.9 OUTLIER -138.23 124.42 20.37 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.178 -1.19 . . . . 0.0 110.98 -179.667 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.562 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 52.9 p90 -141.08 156.37 46.0 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.323 -0.861 . . . . 0.0 109.714 179.362 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.493 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -150.0 157.31 43.02 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 120.955 -1.091 . . . . 0.0 111.368 -179.288 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.486 ' HB3' ' HA ' ' A' ' 334' ' ' PHE . 0.3 OUTLIER 64.57 21.66 12.48 Favored 'General case' 0 N--CA 1.496 1.84 0 O-C-N 121.609 -0.682 . . . . 0.0 110.906 179.803 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.559 ' CA ' HG13 ' A' ' 324' ' ' VAL . . . -174.57 150.2 1.35 Allowed 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.272 -0.893 . . . . 0.0 110.394 179.674 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.539 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -83.84 125.34 31.86 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.119 -0.988 . . . . 0.0 109.586 179.485 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.562 ' HD3' ' CD2' ' A' ' 307' ' ' PHE . 3.7 ttpt -92.85 135.91 33.72 Favored 'General case' 0 C--N 1.301 -1.518 0 CA-C-O 121.838 0.828 . . . . 0.0 110.751 -179.582 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.723 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.3 OUTLIER -122.37 179.46 4.56 Favored 'General case' 0 C--N 1.297 -1.698 0 N-CA-C 108.64 -0.874 . . . . 0.0 108.64 178.63 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.411 ' HA ' ' O ' ' A' ' 318' ' ' TYR . 3.5 mt-10 -142.49 113.07 7.31 Favored 'General case' 0 N--CA 1.492 1.634 0 C-N-CA 120.06 -0.656 . . . . 0.0 110.444 179.913 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.53 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -101.09 49.71 1.05 Allowed Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.875 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER 57.83 79.37 0.2 Allowed 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -1.167 . . . . 0.0 110.093 -179.969 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.595 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.95 5.34 66.24 Favored Glycine 0 N--CA 1.491 2.312 0 N-CA-C 109.5 -1.44 . . . . 0.0 109.5 -179.778 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.811 ' O ' HG23 ' A' ' 319' ' ' VAL . 5.4 m-85 -138.88 -174.31 3.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.401 -1.058 . . . . 0.0 109.167 179.449 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.933 HG11 HG21 ' A' ' 304' ' ' VAL . 5.7 t -163.14 156.96 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.759 0 O-C-N 121.287 -0.883 . . . . 0.0 109.767 179.247 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.723 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 12.8 mm -127.08 148.91 31.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.788 0 O-C-N 121.074 -1.016 . . . . 0.0 111.361 -179.946 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.675 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 86.0 m-85 -124.85 122.01 36.18 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.446 -0.784 . . . . 0.0 109.703 179.01 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.901 ' CG2' HG23 ' A' ' 293' ' ' THR . 5.5 p -124.52 169.01 11.59 Favored Pre-proline 0 C--N 1.302 -1.492 0 O-C-N 120.738 -1.226 . . . . 0.0 109.953 179.953 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.54 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 37.3 Cg_endo -63.89 112.38 1.81 Allowed 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 123.769 1.405 . . . . 0.0 111.415 -179.319 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.704 HG23 ' H ' ' A' ' 325' ' ' SER . 3.6 m -50.4 -58.24 1.85 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.545 -0.722 . . . . 0.0 110.746 179.74 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.704 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.2 OUTLIER 178.65 -26.11 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.081 -1.012 . . . . 0.0 110.947 179.97 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.518 ' CE2' HG21 ' A' ' 324' ' ' VAL . 6.3 p-90 -110.43 -27.03 9.22 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.853 -1.154 . . . . 0.0 110.98 -179.79 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 1.003 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 0.0 OUTLIER -83.34 14.56 3.52 Favored 'General case' 0 N--CA 1.496 1.838 0 O-C-N 120.979 -1.076 . . . . 0.0 111.06 179.934 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.49 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 11.4 mtmt -77.12 -8.58 57.74 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.375 -0.828 . . . . 0.0 109.191 179.174 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.454 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -58.18 -153.14 0.01 OUTLIER Glycine 0 N--CA 1.489 2.216 0 N-CA-C 110.543 -1.023 . . . . 0.0 110.543 -179.322 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.522 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.6 Cg_endo -76.12 9.61 2.37 Favored 'Trans proline' 0 C--N 1.308 -1.591 0 O-C-N 124.267 1.667 . . . . 0.0 111.153 -179.581 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.404 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.5 m -164.87 135.15 3.86 Favored 'General case' 0 C--N 1.302 -1.484 0 O-C-N 121.177 -0.952 . . . . 0.0 109.803 179.817 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 1.003 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -147.87 104.19 3.56 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.171 -0.956 . . . . 0.0 110.378 -179.463 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 1.006 ' OG1' HG23 ' A' ' 283' ' ' THR . 4.8 m -101.12 133.22 45.98 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.287 -0.883 . . . . 0.0 110.313 179.883 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.754 ' HE2' HG21 ' A' ' 294' ' ' VAL . 24.2 p90 -144.2 168.21 20.58 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.44 -0.788 . . . . 0.0 108.957 179.553 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.518 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -141.65 165.3 26.5 Favored Glycine 0 N--CA 1.49 2.272 0 C-N-CA 118.948 -1.596 . . . . 0.0 110.078 -179.488 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.924 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.5 OUTLIER -150.52 143.88 24.98 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.689 -0.889 . . . . 0.0 109.379 179.191 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.51 118.79 58.5 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.028 -1.045 . . . . 0.0 110.223 -179.67 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.808 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.7 t -97.64 153.18 3.94 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.163 -0.96 . . . . 0.0 110.153 -179.795 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.464 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -122.56 131.65 53.93 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.215 -0.928 . . . . 0.0 110.212 179.866 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.89 -125.35 0.95 Allowed Glycine 0 N--CA 1.492 2.403 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 -179.98 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.528 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.9 Cg_endo -66.58 -158.16 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.532 0 O-C-N 123.821 1.432 . . . . 0.0 111.117 -179.963 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.529 ' HG3' ' HA2' ' A' ' 275' ' ' GLY . 1.2 mp0 -117.8 131.37 56.58 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.23 -0.919 . . . . 0.0 111.23 -179.055 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 98.18 -86.4 0.78 Allowed Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.984 -1.246 . . . . 0.0 109.984 179.189 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 14.3 t0 -101.74 124.24 47.04 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.299 -1.118 . . . . 0.0 109.828 -179.882 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.8 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -127.64 10.26 6.6 Favored 'General case' 0 N--CA 1.486 1.366 0 O-C-N 121.119 -0.988 . . . . 0.0 110.275 -179.987 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.614 HG23 ' O ' ' A' ' 297' ' ' LYS . 7.2 p -134.7 117.09 22.44 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.544 0 O-C-N 121.406 -0.809 . . . . 0.0 110.13 179.739 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.514 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -45.66 -45.84 14.31 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.212 -0.93 . . . . 0.0 110.455 -179.61 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.47 ' OE2' ' HG3' ' A' ' 297' ' ' LYS . 0.4 OUTLIER -176.79 158.71 1.68 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.072 -1.017 . . . . 0.0 110.673 -179.713 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.709 HG12 HG13 ' A' ' 296' ' ' VAL . 65.1 mt -120.76 119.39 59.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.118 -0.989 . . . . 0.0 110.304 179.9 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.33 159.89 24.12 Favored 'General case' 0 N--CA 1.493 1.709 0 O-C-N 121.341 -0.85 . . . . 0.0 110.173 179.99 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.089 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -120.99 129.7 53.52 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.28 -0.887 . . . . 0.0 110.361 -179.852 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.447 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 1.0 OUTLIER -139.29 122.87 17.37 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.13 -0.981 . . . . 0.0 110.103 179.58 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.768 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.2 mt -97.15 106.16 18.13 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.031 -1.043 . . . . 0.0 109.742 179.474 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.482 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 41.06 29.25 0.07 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.565 -0.71 . . . . 0.0 110.649 -179.752 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.81 -22.83 7.17 Favored Glycine 0 N--CA 1.492 2.401 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.363 179.379 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.494 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 40.5 mm-40 -87.96 110.95 20.96 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 121.004 -1.292 . . . . 0.0 110.552 -179.492 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.653 ' O ' HD13 ' A' ' 358' ' ' ILE . 6.2 p -76.81 142.02 14.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.284 -0.885 . . . . 0.0 110.527 -179.976 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.653 HD13 ' O ' ' A' ' 357' ' ' VAL . 11.5 mm . . . . . 0 N--CA 1.494 1.729 0 CA-C-O 118.054 -0.974 . . . . 0.0 110.139 179.801 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.35 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.7 Cg_endo -73.81 -178.71 3.97 Favored 'Trans proline' 0 C--N 1.305 -1.72 0 O-C-N 123.995 1.523 . . . . 0.0 110.454 179.975 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.647 HG23 ' O ' ' A' ' 258' ' ' THR . 6.5 t -58.81 119.02 6.39 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.252 -0.905 . . . . 0.0 110.107 179.9 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . 0.585 HG22 ' HD2' ' A' ' 260' ' ' PRO . 0.0 OUTLIER -102.0 154.6 37.24 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.173 -0.954 . . . . 0.0 110.268 -179.847 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . 0.585 ' HD2' HG22 ' A' ' 259' ' ' THR . 46.9 Cg_endo -74.0 148.27 39.93 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.101 1.579 . . . . 0.0 110.16 179.886 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.486 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.2 p -81.24 140.66 49.19 Favored Pre-proline 0 N--CA 1.492 1.636 0 O-C-N 121.08 -1.012 . . . . 0.0 110.394 -179.987 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.533 ' HB3' ' HA ' ' A' ' 358' ' ' ILE . 45.9 Cg_endo -76.17 146.36 28.53 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 124.06 1.558 . . . . 0.0 109.981 179.582 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.438 HG12 ' O ' ' A' ' 263' ' ' VAL . 12.4 t -141.64 30.19 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 121.292 -0.88 . . . . 0.0 110.067 -179.88 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 26.4 t -163.63 83.02 0.46 Allowed 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.315 -0.865 . . . . 0.0 110.637 -180.0 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 104.29 -167.93 16.19 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.923 -1.271 . . . . 0.0 109.923 179.517 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.58 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.3 OUTLIER -139.53 164.4 30.0 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.401 -1.058 . . . . 0.0 109.765 179.848 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.992 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.31 133.76 6.0 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.047 -1.033 . . . . 0.0 111.003 -179.044 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.49 ' N ' HD13 ' A' ' 267' ' ' LEU . 0.4 OUTLIER -136.77 131.45 33.4 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.532 -0.73 . . . . 0.0 109.242 179.476 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.882 HG13 ' O ' ' A' ' 281' ' ' ASP . 89.4 t -126.38 143.11 40.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 120.79 -1.194 . . . . 0.0 111.653 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.7 ttpt -126.98 157.38 39.69 Favored 'General case' 0 N--CA 1.493 1.723 0 N-CA-C 108.744 -0.836 . . . . 0.0 108.744 178.996 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.736 HG22 ' CD1' ' A' ' 280' ' ' TYR . 91.7 t -139.74 146.97 24.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.298 -1.501 . . . . 0.0 112.375 -179.171 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.542 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.2 109.43 6.46 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.411 -0.959 . . . . 0.0 108.411 179.127 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.476 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 2.3 p30 -96.14 146.75 24.41 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.008 -1.057 . . . . 0.0 111.189 -178.863 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.829 ' CH2' HG23 ' A' ' 337' ' ' ILE . 35.4 p90 -132.02 17.85 4.59 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.52 -0.738 . . . . 0.0 109.777 179.32 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.5 -62.78 4.0 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.441 -1.464 . . . . 0.0 109.441 179.947 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.444 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 1.4 t -63.68 -21.24 66.28 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.383 -1.069 . . . . 0.0 110.239 179.962 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.575 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -174.31 179.92 45.34 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.872 -1.291 . . . . 0.0 109.872 -179.887 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.557 ' HB3' ' HE2' ' A' ' 280' ' ' TYR . . . -133.22 141.19 47.93 Favored 'General case' 0 N--CA 1.492 1.654 0 O-C-N 121.352 -1.087 . . . . 0.0 110.245 179.941 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.729 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.3 mt-10 -96.84 147.65 23.73 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.346 -0.846 . . . . 0.0 110.159 -179.683 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.736 ' CD1' HG22 ' A' ' 271' ' ' VAL . 98.1 m-85 -143.51 90.2 2.14 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.214 -0.929 . . . . 0.0 110.84 -179.776 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.882 ' O ' HG13 ' A' ' 269' ' ' VAL . 6.6 t0 -70.87 152.75 43.36 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.384 -0.823 . . . . 0.0 109.555 179.237 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.753 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 2.9 t -147.26 89.74 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.529 0 O-C-N 121.362 -0.836 . . . . 0.0 110.205 -179.535 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.719 HG23 ' OG1' ' A' ' 333' ' ' THR . 93.1 m -86.97 121.96 30.16 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.08 -1.013 . . . . 0.0 109.615 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -109.7 150.89 27.63 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.176 -0.952 . . . . 0.0 110.754 -179.323 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.917 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -131.25 137.06 48.72 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.468 -0.77 . . . . 0.0 109.934 -179.767 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.917 HD23 ' O ' ' A' ' 285' ' ' ASN . 16.8 mt -142.32 159.87 41.37 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 120.926 -1.109 . . . . 0.0 109.513 179.958 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -89.61 34.66 0.82 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.296 -0.877 . . . . 0.0 110.458 -179.538 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.473 ' O ' ' HG2' ' A' ' 289' ' ' GLN . . . 153.3 -97.47 0.17 Allowed Glycine 0 N--CA 1.491 2.337 0 C-N-CA 119.052 -1.546 . . . . 0.0 110.358 179.902 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 11.7 mm-40 -144.3 105.26 4.19 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.25 -1.147 . . . . 0.0 110.561 -179.577 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.616 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 4.4 m-85 -128.9 130.29 46.63 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.338 -0.851 . . . . 0.0 109.671 179.645 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.809 ' O ' HG23 ' A' ' 353' ' ' ILE . 42.5 m-20 -65.61 100.11 0.49 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.782 -1.199 . . . . 0.0 109.084 179.19 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.935 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.4 p-90 -100.12 109.67 21.95 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.246 -0.909 . . . . 0.0 111.127 -179.091 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 1.085 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.0 m -103.78 114.83 29.38 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.466 -0.772 . . . . 0.0 109.108 179.003 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.727 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -95.95 111.31 25.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.508 0 O-C-N 121.045 -1.034 . . . . 0.0 110.568 -179.135 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.413 ' HA ' HG12 ' A' ' 320' ' ' ILE . 5.7 ttpt -85.71 145.16 27.41 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.471 -0.768 . . . . 0.0 109.327 179.17 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.674 HG13 HG12 ' A' ' 349' ' ' ILE . 79.7 t -144.36 106.51 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 O-C-N 121.252 -0.905 . . . . 0.0 110.177 -179.49 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.476 ' O ' ' N ' ' A' ' 347' ' ' GLU . 43.4 mmtt -70.02 133.9 47.71 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.108 -0.995 . . . . 0.0 109.168 179.537 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.962 HD13 ' HA ' ' A' ' 303' ' ' THR . 66.8 mt -90.32 157.24 17.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.087 -1.008 . . . . 0.0 111.392 -178.826 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.7 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -66.22 173.25 2.35 Favored Pre-proline 0 C--N 1.303 -1.444 0 O-C-N 121.806 -0.558 . . . . 0.0 109.533 179.219 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.7 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.1 Cg_endo -67.15 83.52 0.35 Allowed 'Trans proline' 0 C--N 1.304 -1.804 0 O-C-N 123.621 1.327 . . . . 0.0 109.826 179.627 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 113.6 21.14 5.87 Favored Glycine 0 N--CA 1.489 2.211 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -179.359 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.75 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.29 140.89 47.61 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.33 -1.1 . . . . 0.0 109.951 -179.884 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.962 ' HA ' HD13 ' A' ' 298' ' ' LEU . 22.2 p -145.2 146.11 31.6 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.168 -0.958 . . . . 0.0 110.628 -179.89 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.798 HG21 HG11 ' A' ' 319' ' ' VAL . 53.3 t -70.11 122.82 22.6 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 121.148 -0.97 . . . . 0.0 109.958 179.695 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -110.08 -28.32 4.19 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 110.034 -1.226 . . . . 0.0 110.034 -179.592 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.507 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 49.4 m -137.46 130.26 30.2 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 120.973 -1.31 . . . . 0.0 110.85 -179.637 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.538 ' CD2' ' HD3' ' A' ' 312' ' ' LYS . 50.2 p90 -150.38 160.09 43.99 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.491 -0.756 . . . . 0.0 109.512 179.369 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.47 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -151.85 159.46 43.86 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.89 -1.131 . . . . 0.0 111.284 -179.333 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.526 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.9 OUTLIER 56.91 28.34 14.46 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.617 -0.677 . . . . 0.0 110.683 179.855 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.736 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.11 138.23 0.58 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.161 -0.962 . . . . 0.0 110.22 179.775 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.792 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.9 112.91 15.27 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.454 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.754 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.0 ttpt -83.16 137.65 33.97 Favored 'General case' 0 N--CA 1.494 1.729 0 CA-C-O 121.658 0.742 . . . . 0.0 110.8 -179.25 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.715 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.1 OUTLIER -120.64 170.61 9.26 Favored 'General case' 0 C--N 1.301 -1.505 0 N-CA-C 108.973 -0.751 . . . . 0.0 108.973 179.135 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.439 ' CG ' ' HE3' ' A' ' 312' ' ' LYS . 15.8 mt-10 -143.24 95.97 2.84 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.531 -0.731 . . . . 0.0 109.688 179.588 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -73.97 -82.9 0.36 Allowed Glycine 0 N--CA 1.492 2.414 0 N-CA-C 109.532 -1.427 . . . . 0.0 109.532 -179.804 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.442 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 5.4 t-20 -154.38 81.15 1.12 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.467 -1.019 . . . . 0.0 108.59 179.753 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.608 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.42 17.87 56.29 Favored Glycine 0 N--CA 1.485 1.936 0 N-CA-C 107.993 -2.043 . . . . 0.0 107.993 -178.009 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.822 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.7 m-85 -144.45 -171.84 3.68 Favored 'General case' 0 N--CA 1.492 1.643 0 N-CA-C 108.841 -0.8 . . . . 0.0 108.841 179.684 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.822 HG23 ' O ' ' A' ' 318' ' ' TYR . 4.0 t -163.26 153.72 2.83 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.634 0 O-C-N 121.231 -0.918 . . . . 0.0 109.322 178.502 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.816 ' CG2' HG22 ' A' ' 293' ' ' THR . 42.1 mt -132.45 133.81 59.54 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 120.78 -1.2 . . . . 0.0 111.639 -179.313 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.645 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 82.6 m-85 -105.9 139.09 41.0 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.459 -0.775 . . . . 0.0 110.651 -179.791 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 1.085 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.1 p -134.62 169.06 14.83 Favored Pre-proline 0 C--N 1.3 -1.578 0 O-C-N 120.912 -1.117 . . . . 0.0 110.324 179.154 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.551 ' HB2' ' CG ' ' A' ' 328' ' ' LYS . 39.7 Cg_endo -65.67 112.33 2.15 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.061 1.559 . . . . 0.0 111.045 -179.259 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.81 HG22 ' HB2' ' A' ' 327' ' ' ASN . 32.9 m -60.83 -127.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.422 -0.799 . . . . 0.0 110.07 179.895 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.568 ' N ' HG23 ' A' ' 324' ' ' VAL . 18.9 m -101.9 -17.02 16.35 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.739 -1.226 . . . . 0.0 111.167 -179.361 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.646 ' H ' HG23 ' A' ' 324' ' ' VAL . 22.5 p-90 -129.86 -3.85 4.62 Favored 'General case' 0 N--CA 1.496 1.829 0 O-C-N 120.943 -1.098 . . . . 0.0 110.649 -179.688 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.81 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.6 t30 -98.64 45.04 1.01 Allowed 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.233 -0.917 . . . . 0.0 110.473 -179.476 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.551 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.32 -4.48 8.36 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 121.345 -0.847 . . . . 0.0 109.77 179.829 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.455 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.81 -159.92 0.08 OUTLIER Glycine 0 N--CA 1.49 2.27 0 N-CA-C 110.067 -1.213 . . . . 0.0 110.067 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.456 ' HA ' ' HB2' ' A' ' 286' ' ' LEU . 46.8 Cg_endo -72.9 2.64 5.18 Favored 'Trans proline' 0 C--N 1.307 -1.62 0 O-C-N 124.191 1.627 . . . . 0.0 110.829 -179.852 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.406 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.8 m -162.56 114.87 1.63 Allowed 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.209 -0.932 . . . . 0.0 109.787 179.67 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.477 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -136.53 115.65 12.46 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.2 -0.937 . . . . 0.0 110.069 -179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.719 ' OG1' HG23 ' A' ' 283' ' ' THR . 99.9 m -105.78 147.5 28.55 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.294 -0.879 . . . . 0.0 110.395 -179.928 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.753 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 6.4 p90 -150.76 174.45 13.03 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.415 -0.803 . . . . 0.0 109.188 179.681 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.2 162.24 28.94 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 119.19 -1.481 . . . . 0.0 110.209 -179.564 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.913 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -151.37 143.8 24.19 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -1.077 . . . . 0.0 109.994 179.554 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.913 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -119.06 119.73 61.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.477 0 O-C-N 121.171 -0.956 . . . . 0.0 109.744 179.437 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.75 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.6 t -96.23 139.79 18.52 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.136 -0.978 . . . . 0.0 110.111 -179.661 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.474 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -111.1 142.2 43.58 Favored 'General case' 0 N--CA 1.487 1.412 0 O-C-N 121.384 -0.822 . . . . 0.0 110.422 -179.627 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 176.37 -137.49 3.66 Favored Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 179.906 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.51 ' O ' ' CE ' ' A' ' 345' ' ' LYS . 44.9 Cg_endo -71.75 -156.65 0.05 OUTLIER 'Trans proline' 0 C--N 1.303 -1.848 0 O-C-N 123.984 1.518 . . . . 0.0 110.083 179.695 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.581 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -120.86 134.36 55.29 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.027 -1.045 . . . . 0.0 110.432 -179.96 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.499 ' O ' ' HB3' ' A' ' 344' ' ' ASP . . . 109.34 64.41 0.55 Allowed Glycine 0 N--CA 1.489 2.182 0 N-CA-C 108.874 -1.69 . . . . 0.0 108.874 -179.819 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.499 ' HB3' ' O ' ' A' ' 343' ' ' GLY . 33.4 t0 67.14 143.19 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.482 -1.011 . . . . 0.0 109.251 -179.164 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.614 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.1 OUTLIER -142.18 22.55 2.05 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 120.979 -1.076 . . . . 0.0 111.114 -179.49 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 346' ' ' VAL . 7.1 p -126.71 113.84 34.99 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.547 0 O-C-N 121.056 -1.027 . . . . 0.0 110.136 179.375 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.476 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -45.36 -47.07 13.4 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.279 -0.888 . . . . 0.0 110.47 -179.564 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -176.55 158.76 1.81 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.209 -0.932 . . . . 0.0 110.263 -179.838 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.674 HG12 HG13 ' A' ' 296' ' ' VAL . 28.2 mt -121.93 113.22 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.548 0 O-C-N 121.116 -0.99 . . . . 0.0 110.13 -179.976 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -117.76 133.71 55.66 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.25 -0.907 . . . . 0.0 110.077 -179.934 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -90.85 132.46 35.88 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.168 -0.958 . . . . 0.0 109.774 179.529 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.429 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 3.7 tt0 -138.01 111.72 8.24 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.38 -0.825 . . . . 0.0 109.956 -179.845 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.809 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.1 mt -94.91 114.0 30.52 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.434 0 O-C-N 121.21 -0.931 . . . . 0.0 110.42 -179.851 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.44 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 37.85 31.98 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.758 -0.589 . . . . 0.0 111.136 179.75 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.423 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 114.78 -15.62 19.16 Favored Glycine 0 N--CA 1.492 2.431 0 C-N-CA 119.736 -1.221 . . . . 0.0 110.306 179.415 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.495 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 20.9 mm-40 -93.17 112.03 23.85 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.084 -1.245 . . . . 0.0 110.424 -179.758 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.557 ' HA ' ' O ' ' A' ' 351' ' ' LEU . 1.2 t -76.35 125.63 36.26 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.627 0 O-C-N 121.236 -0.915 . . . . 0.0 109.961 179.975 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.557 HD13 ' O ' ' A' ' 357' ' ' VAL . 10.2 mm . . . . . 0 N--CA 1.493 1.721 0 CA-C-O 118.02 -0.99 . . . . 0.0 110.098 179.802 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.306 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.2 Cg_endo -74.86 -179.32 4.83 Favored 'Trans proline' 0 C--N 1.304 -1.783 0 O-C-N 124.06 1.558 . . . . 0.0 110.425 -179.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.602 HG23 ' O ' ' A' ' 258' ' ' THR . 5.2 t -61.98 121.5 13.13 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.298 -0.876 . . . . 0.0 109.901 179.814 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 2.3 p -116.15 133.66 22.88 Favored Pre-proline 0 N--CA 1.491 1.595 0 O-C-N 121.186 -0.946 . . . . 0.0 110.239 -179.816 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -71.76 126.51 12.08 Favored 'Trans proline' 0 C--N 1.304 -1.789 0 O-C-N 124.031 1.542 . . . . 0.0 110.009 179.677 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.547 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.9 p -65.91 141.91 97.82 Favored Pre-proline 0 N--CA 1.49 1.553 0 O-C-N 121.19 -0.944 . . . . 0.0 110.451 -179.497 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.549 ' CB ' HG23 ' A' ' 358' ' ' ILE . 50.2 Cg_endo -78.28 126.4 7.66 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 O-C-N 124.118 1.588 . . . . 0.0 110.387 179.781 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.555 HG12 ' O ' ' A' ' 263' ' ' VAL . 35.4 t -114.73 28.79 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.315 -0.866 . . . . 0.0 110.063 179.852 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER 179.72 131.9 0.09 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.318 -0.864 . . . . 0.0 110.299 -179.918 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 71.89 -177.37 38.41 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.947 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.553 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.6 161.64 37.03 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.234 -1.156 . . . . 0.0 110.006 179.823 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.863 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.5 tm? -161.32 137.17 7.98 Favored 'General case' 0 N--CA 1.488 1.467 0 C-N-CA 119.061 -1.056 . . . . 0.0 111.613 -179.546 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.854 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.3 mm-40 -134.03 147.14 50.92 Favored 'General case' 0 N--CA 1.491 1.62 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 178.799 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.9 t -138.55 144.43 30.14 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 120.66 -1.275 . . . . 0.0 111.769 -179.091 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -128.88 157.38 41.71 Favored 'General case' 0 N--CA 1.495 1.781 0 N-CA-C 108.65 -0.871 . . . . 0.0 108.65 178.902 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.757 HG13 ' O ' ' A' ' 279' ' ' GLU . 92.7 t -144.17 146.13 20.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.28 -1.512 . . . . 0.0 112.199 -179.492 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.576 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.4 OUTLIER -136.63 108.76 7.21 Favored 'General case' 0 N--CA 1.489 1.523 0 N-CA-C 109.327 -0.62 . . . . 0.0 109.327 179.182 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.413 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 11.0 m-20 -95.26 140.38 30.24 Favored 'General case' 0 N--CA 1.493 1.7 0 O-C-N 121.278 -0.889 . . . . 0.0 111.277 -179.003 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.827 ' CH2' HG23 ' A' ' 337' ' ' ILE . 40.9 p90 -131.94 20.42 4.55 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.431 -0.793 . . . . 0.0 109.868 179.292 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.59 -60.4 4.87 Favored Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.511 -1.435 . . . . 0.0 109.511 179.899 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -65.8 -18.94 65.68 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.369 -1.077 . . . . 0.0 110.293 -179.86 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.568 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -179.38 175.85 47.35 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.63 -1.388 . . . . 0.0 109.63 179.977 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.582 ' HB3' ' CE2' ' A' ' 280' ' ' TYR . . . -131.26 140.98 49.92 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.184 -1.186 . . . . 0.0 110.119 179.946 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.757 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.4 mt-10 -93.28 147.1 23.21 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.424 -0.798 . . . . 0.0 109.99 -179.969 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.688 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 98.7 m-85 -142.11 86.39 1.97 Allowed 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.229 -0.919 . . . . 0.0 110.929 -179.412 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 269' ' ' VAL . 12.1 t70 -69.67 152.6 44.5 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.323 -0.86 . . . . 0.0 109.464 179.206 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.591 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 2.7 t -148.39 90.17 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.283 -0.885 . . . . 0.0 110.177 -179.51 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.849 HG23 ' OG1' ' A' ' 333' ' ' THR . 56.6 m -86.99 122.31 30.65 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.1 -1.0 . . . . 0.0 109.692 179.515 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.083 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.75 150.78 28.6 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.176 -0.952 . . . . 0.0 110.8 -179.357 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.93 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.3 OUTLIER -131.43 138.42 49.05 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.469 -0.769 . . . . 0.0 109.446 179.949 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.93 HD23 ' O ' ' A' ' 285' ' ' ASN . 18.8 mt -140.46 163.4 32.93 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 120.77 -1.206 . . . . 0.0 109.824 -179.816 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -85.12 30.61 0.59 Allowed 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.228 -0.92 . . . . 0.0 111.086 -178.95 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.509 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 147.26 -75.39 0.28 Allowed Glycine 0 N--CA 1.491 2.32 0 C-N-CA 118.952 -1.594 . . . . 0.0 110.479 179.616 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.558 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 2.7 tt0 -160.26 106.88 1.56 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.07 -1.253 . . . . 0.0 110.85 -179.371 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.642 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 5.0 m-85 -135.38 135.35 40.61 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.22 -0.925 . . . . 0.0 109.547 179.384 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.722 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.0 OUTLIER -66.84 102.77 1.0 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 120.987 -1.071 . . . . 0.0 109.515 179.425 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.957 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.9 p-90 -101.18 111.32 23.51 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.185 -0.947 . . . . 0.0 110.645 -179.53 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.686 HG22 ' CG2' ' A' ' 320' ' ' ILE . 6.6 m -104.48 115.66 30.75 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.532 -0.73 . . . . 0.0 109.726 179.692 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.756 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -97.05 111.41 26.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.128 -0.982 . . . . 0.0 110.289 -179.864 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.809 ' HA ' HD13 ' A' ' 320' ' ' ILE . 27.1 ttpt -84.99 144.1 28.52 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.387 -0.821 . . . . 0.0 109.511 179.464 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.937 HG22 HG23 ' A' ' 349' ' ' ILE . 99.8 t -141.32 104.98 1.47 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.527 0 O-C-N 121.249 -0.907 . . . . 0.0 110.823 -179.179 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 38.0 mmtt -69.8 131.11 44.0 Favored 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.078 -1.014 . . . . 0.0 109.066 179.226 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.982 HD13 ' HA ' ' A' ' 303' ' ' THR . 93.6 mt -87.85 148.77 24.5 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.371 -0.831 . . . . 0.0 111.166 -178.895 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.703 ' HB2' ' C ' ' A' ' 345' ' ' LYS . . . -58.66 172.22 0.54 Allowed Pre-proline 0 C--N 1.303 -1.432 0 O-C-N 121.624 -0.672 . . . . 0.0 109.306 179.093 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.671 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.8 Cg_endo -67.32 80.57 0.41 Allowed 'Trans proline' 0 C--N 1.304 -1.769 0 O-C-N 123.575 1.303 . . . . 0.0 110.111 179.777 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.64 23.29 4.08 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 -179.546 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.789 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.58 148.54 35.98 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.365 -1.08 . . . . 0.0 110.376 -179.534 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.982 ' HA ' HD13 ' A' ' 298' ' ' LEU . 37.4 p -150.7 144.61 25.28 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.195 -0.94 . . . . 0.0 110.399 179.789 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 1.035 HG11 ' CE ' ' A' ' 312' ' ' LYS . 21.3 t -64.02 116.04 3.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.066 -1.021 . . . . 0.0 110.04 179.723 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -102.35 -20.51 12.08 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.688 -1.365 . . . . 0.0 109.688 -179.835 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.546 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -147.36 154.44 40.89 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.26 -1.141 . . . . 0.0 110.317 -179.784 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.507 ' CG ' ' NZ ' ' A' ' 312' ' ' LYS . 25.1 p90 -178.54 175.52 1.11 Allowed 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.594 -0.691 . . . . 0.0 109.738 179.964 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.459 ' O ' ' CB ' ' A' ' 309' ' ' SER . 1.1 p90 -170.0 151.11 3.95 Favored 'General case' 0 N--CA 1.495 1.817 0 O-C-N 120.991 -1.068 . . . . 0.0 111.637 -179.437 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.537 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.7 OUTLIER 67.93 30.22 6.2 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.684 -0.635 . . . . 0.0 111.45 179.173 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.746 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.88 137.48 0.58 Allowed 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.144 -0.972 . . . . 0.0 110.168 179.57 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.753 HD22 HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.19 129.09 35.49 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.073 -1.017 . . . . 0.0 109.353 179.621 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 1.035 ' CE ' HG11 ' A' ' 304' ' ' VAL . 0.0 OUTLIER -92.07 149.15 21.67 Favored 'General case' 0 N--CA 1.49 1.572 0 CA-C-O 121.907 0.861 . . . . 0.0 111.642 -178.622 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.705 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -133.34 171.39 14.11 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 178.306 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -137.09 114.85 11.28 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.046 -1.034 . . . . 0.0 110.858 -179.473 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -103.96 42.76 1.81 Allowed Glycine 0 N--CA 1.489 2.222 0 N-CA-C 109.277 -1.529 . . . . 0.0 109.277 179.454 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER 53.45 83.48 0.07 Allowed 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -1.113 . . . . 0.0 110.066 -179.788 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.61 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.34 -0.55 57.1 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -179.89 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.842 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.5 m-85 -145.6 -170.9 3.56 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.463 -1.022 . . . . 0.0 109.157 179.365 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.92 HG11 HG21 ' A' ' 304' ' ' VAL . 2.6 t -163.82 161.99 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.492 0 O-C-N 121.366 -0.834 . . . . 0.0 109.347 179.427 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.809 HD13 ' HA ' ' A' ' 295' ' ' LYS . 28.5 mm -131.02 150.17 34.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 120.876 -1.14 . . . . 0.0 111.468 -179.514 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.626 ' CE2' ' HB3' ' A' ' 336' ' ' PHE . 96.5 m-85 -120.42 139.12 53.29 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.549 -0.719 . . . . 0.0 109.38 178.908 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.611 HG23 HG23 ' A' ' 293' ' ' THR . 1.0 OUTLIER -140.66 170.74 8.89 Favored Pre-proline 0 C--N 1.302 -1.461 0 O-C-N 120.79 -1.194 . . . . 0.0 110.244 -179.998 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.1 Cg_endo -65.72 122.01 9.53 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 123.98 1.516 . . . . 0.0 110.692 -179.505 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.911 HG22 ' HB2' ' A' ' 327' ' ' ASN . 12.8 m -76.16 -136.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.384 -0.823 . . . . 0.0 110.363 -179.752 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.63 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -88.45 -12.63 42.53 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.209 -0.932 . . . . 0.0 110.886 -179.387 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.833 ' H ' HG23 ' A' ' 324' ' ' VAL . 20.9 p-90 -140.17 13.39 2.41 Favored 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.95 -1.094 . . . . 0.0 111.118 -179.475 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.911 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.1 t30 -119.99 50.59 1.27 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 120.886 -1.134 . . . . 0.0 110.776 -179.651 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.505 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.1 OUTLIER -130.46 -0.95 4.44 Favored 'General case' 0 N--CA 1.496 1.875 0 O-C-N 121.257 -0.902 . . . . 0.0 109.933 179.323 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.442 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -66.58 -153.72 0.25 Allowed Glycine 0 N--CA 1.488 2.112 0 N-CA-C 109.708 -1.357 . . . . 0.0 109.708 -179.791 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.509 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 46.5 Cg_endo -73.97 3.08 5.35 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 124.12 1.59 . . . . 0.0 110.653 -179.858 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.432 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.9 m -163.93 117.54 1.47 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.197 -0.94 . . . . 0.0 110.244 179.944 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.478 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -139.43 111.93 7.71 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.878 . . . . 0.0 110.12 179.943 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.849 ' OG1' HG23 ' A' ' 283' ' ' THR . 7.0 m -101.09 151.78 21.41 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.181 -0.949 . . . . 0.0 110.275 -179.919 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.756 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.7 p90 -159.03 155.19 27.01 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.519 -0.738 . . . . 0.0 109.156 179.712 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.496 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -133.24 165.96 23.89 Favored Glycine 0 N--CA 1.491 2.311 0 C-N-CA 119.264 -1.446 . . . . 0.0 110.035 -179.634 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.957 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.4 OUTLIER -152.44 147.04 25.79 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.209 -1.171 . . . . 0.0 110.288 179.613 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.957 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.74 119.56 59.13 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.049 -1.032 . . . . 0.0 109.88 179.687 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.789 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.6 t -96.43 147.94 5.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.163 -0.961 . . . . 0.0 110.13 -179.907 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -117.14 132.93 56.55 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.375 -0.828 . . . . 0.0 110.142 -179.867 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.457 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.88 -138.64 3.66 Favored Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 179.943 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.479 ' O ' ' CD ' ' A' ' 345' ' ' LYS . 46.3 Cg_endo -72.68 177.07 8.0 Favored 'Trans proline' 0 C--N 1.306 -1.66 0 O-C-N 124.01 1.531 . . . . 0.0 110.548 -179.981 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.433 ' N ' ' CD ' ' A' ' 342' ' ' GLN . 5.8 mp0 -98.07 146.79 25.19 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.212 -0.93 . . . . 0.0 110.286 -179.911 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.509 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 95.19 67.78 1.01 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 108.972 -1.651 . . . . 0.0 108.972 -179.834 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.509 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 7.5 t0 69.6 128.73 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.351 -1.088 . . . . 0.0 109.445 -179.415 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.703 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 2.3 mtmt -126.84 13.92 7.41 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.135 -0.978 . . . . 0.0 110.164 -179.791 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.516 HG13 ' O ' ' A' ' 346' ' ' VAL . 4.5 p -127.17 113.28 31.65 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 121.497 -0.752 . . . . 0.0 109.566 179.429 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -42.18 -48.33 4.81 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.269 -0.894 . . . . 0.0 110.129 -179.44 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -177.63 149.9 0.64 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.31 -0.869 . . . . 0.0 110.468 179.919 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.937 HG23 HG22 ' A' ' 296' ' ' VAL . 12.9 mt -113.62 127.92 70.74 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.111 -0.993 . . . . 0.0 110.207 179.758 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -132.21 140.51 48.72 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.341 -0.85 . . . . 0.0 109.959 -179.81 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.083 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -99.44 130.75 45.73 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.055 -1.028 . . . . 0.0 110.395 -179.93 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.8 tt0 -138.28 113.87 9.69 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.308 -0.87 . . . . 0.0 109.788 179.645 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.722 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.2 mt -91.77 110.51 22.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.467 0 O-C-N 121.121 -0.987 . . . . 0.0 110.249 -179.955 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.558 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 37.84 28.51 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.802 -0.561 . . . . 0.0 110.952 179.885 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.489 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 123.22 -20.94 7.43 Favored Glycine 0 N--CA 1.492 2.408 0 C-N-CA 119.739 -1.219 . . . . 0.0 110.298 179.451 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 1.4 mp0 -86.53 112.66 21.76 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.03 -1.276 . . . . 0.0 110.58 -179.756 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.669 HG13 ' O ' ' A' ' 357' ' ' VAL . 7.3 p -79.0 118.13 25.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.629 0 O-C-N 121.323 -0.861 . . . . 0.0 110.169 179.797 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.549 HG23 ' CB ' ' A' ' 262' ' ' PRO . 12.7 mm . . . . . 0 N--CA 1.492 1.67 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.214 -179.942 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.333 0 N-CA-C 109.564 -1.415 . . . . 0.0 109.564 . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -74.48 179.84 5.51 Favored 'Trans proline' 0 C--N 1.307 -1.654 0 O-C-N 124.064 1.56 . . . . 0.0 110.541 -179.881 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.508 HG23 ' O ' ' A' ' 258' ' ' THR . 5.3 t -61.04 127.4 31.34 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.348 -0.845 . . . . 0.0 110.168 179.986 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.3 p -141.12 143.2 30.13 Favored Pre-proline 0 N--CA 1.492 1.655 0 O-C-N 121.107 -0.996 . . . . 0.0 110.598 -179.844 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -73.81 162.1 40.16 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 124.084 1.571 . . . . 0.0 110.102 179.687 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.454 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.6 p -109.47 139.88 21.56 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.126 -0.984 . . . . 0.0 110.39 179.944 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.454 ' HD2' HG23 ' A' ' 261' ' ' VAL . 49.6 Cg_endo -79.48 137.0 12.79 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 124.142 1.601 . . . . 0.0 110.338 179.875 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.452 ' O ' ' HB2' ' A' ' 264' ' ' SER . 3.1 t -122.84 28.04 2.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.643 0 O-C-N 121.207 -0.933 . . . . 0.0 110.007 179.857 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.452 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 0.2 OUTLIER 175.31 80.12 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.408 -0.808 . . . . 0.0 110.027 179.993 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 122.5 176.38 14.98 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.868 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -135.02 152.19 51.49 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.221 -1.164 . . . . 0.0 109.908 179.866 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.794 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.59 117.71 6.81 Favored 'General case' 0 C--N 1.303 -1.43 0 O-C-N 121.198 -0.939 . . . . 0.0 110.962 -179.592 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 -118.36 116.63 27.12 Favored 'General case' 0 N--CA 1.491 1.617 0 N-CA-C 108.418 -0.956 . . . . 0.0 108.418 178.649 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.595 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 52.0 t -109.37 144.52 17.51 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 120.863 -1.148 . . . . 0.0 112.154 -178.305 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.427 ' C ' HG23 ' A' ' 271' ' ' VAL . 9.1 mtmt -128.59 156.42 43.38 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 178.618 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.828 HG13 ' O ' ' A' ' 279' ' ' GLU . 99.9 t -145.29 147.03 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.288 -1.508 . . . . 0.0 112.29 -179.068 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.537 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -137.9 111.08 7.85 Favored 'General case' 0 C--N 1.305 -1.329 0 N-CA-C 108.255 -1.017 . . . . 0.0 108.255 178.757 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.489 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 5.9 p-10 -100.5 140.02 35.36 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.882 -1.136 . . . . 0.0 111.407 -178.437 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.802 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.4 p90 -123.98 20.64 9.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.57 -0.706 . . . . 0.0 109.82 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.72 -68.01 3.47 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 109.59 -1.404 . . . . 0.0 109.59 179.783 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.406 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 7.8 m -61.06 -22.02 64.19 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.261 -1.141 . . . . 0.0 110.485 -179.833 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -168.32 176.74 42.67 Favored Glycine 0 N--CA 1.491 2.316 0 C-N-CA 119.641 -1.266 . . . . 0.0 110.016 -179.936 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.573 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.06 143.54 46.74 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.381 -1.07 . . . . 0.0 109.864 179.982 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.828 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.1 mt-10 -100.71 145.63 28.22 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.271 -0.893 . . . . 0.0 110.042 -179.774 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.695 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -139.12 90.96 2.47 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.362 -0.836 . . . . 0.0 110.545 -179.701 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.595 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -79.58 118.64 21.61 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.534 -0.729 . . . . 0.0 110.136 179.657 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.822 HG11 HG11 ' A' ' 294' ' ' VAL . 8.8 t -107.41 95.82 4.12 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.63 -0.669 . . . . 0.0 110.041 179.747 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.546 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.2 m -86.5 120.17 27.55 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.131 -0.98 . . . . 0.0 109.437 179.551 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 0.999 HD21 HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -109.1 148.9 30.11 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.134 -0.979 . . . . 0.0 110.991 -179.042 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -134.04 107.13 7.59 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.618 -0.676 . . . . 0.0 109.679 -179.659 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.575 HD11 ' CD1' ' A' ' 292' ' ' TRP . 11.8 mt -114.67 156.57 24.51 Favored 'General case' 0 C--N 1.299 -1.603 0 O-C-N 120.837 -1.164 . . . . 0.0 110.243 -179.768 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . 0.432 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 20.1 m-20 -86.7 33.86 0.65 Allowed 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.513 -0.742 . . . . 0.0 110.413 -179.811 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.519 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.87 -154.04 25.07 Favored Glycine 0 N--CA 1.491 2.325 0 C-N-CA 119.499 -1.334 . . . . 0.0 109.79 -179.996 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.542 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.0 OUTLIER -101.89 93.85 5.5 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.173 -1.192 . . . . 0.0 110.608 -179.708 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.523 ' CD1' ' C ' ' A' ' 289' ' ' GLN . 2.3 m-85 -118.12 163.49 16.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.262 -0.899 . . . . 0.0 109.79 179.627 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.654 ' O ' HG23 ' A' ' 353' ' ' ILE . 15.2 m-20 -90.26 98.97 12.08 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.249 -0.907 . . . . 0.0 109.43 179.334 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.848 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.0 p-90 -99.82 117.26 33.77 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.192 -0.943 . . . . 0.0 110.749 -179.369 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.564 ' CG2' ' CG2' ' A' ' 320' ' ' ILE . 89.2 m -110.86 114.65 28.14 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.482 -0.761 . . . . 0.0 109.589 179.665 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.822 HG11 HG11 ' A' ' 282' ' ' VAL . 3.2 t -97.18 111.46 27.12 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.16 -0.963 . . . . 0.0 110.633 -179.284 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.527 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 18.3 ttmt -86.51 149.89 24.65 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.231 -0.918 . . . . 0.0 109.617 179.299 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.799 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 90.4 t -143.95 108.36 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.054 -1.029 . . . . 0.0 110.672 -179.459 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.574 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 14.5 mmtp -70.5 133.86 47.19 Favored 'General case' 0 C--N 1.306 -1.311 0 O-C-N 121.27 -0.894 . . . . 0.0 109.318 179.411 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.978 HD13 ' HA ' ' A' ' 303' ' ' THR . 85.0 mt -89.71 158.13 17.68 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.439 -0.788 . . . . 0.0 111.717 -178.727 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.771 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -64.78 173.32 1.69 Allowed Pre-proline 0 N--CA 1.487 1.409 0 O-C-N 121.637 -0.665 . . . . 0.0 109.44 179.331 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.69 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.7 Cg_endo -67.64 78.6 0.51 Allowed 'Trans proline' 0 C--N 1.304 -1.775 0 O-C-N 123.555 1.292 . . . . 0.0 109.913 179.738 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.74 23.27 4.05 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.595 -1.802 . . . . 0.0 108.595 -179.393 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.792 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -113.08 146.68 38.74 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.361 -1.082 . . . . 0.0 110.141 -179.68 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.978 ' HA ' HD13 ' A' ' 298' ' ' LEU . 8.8 p -147.93 145.08 28.46 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.225 -0.922 . . . . 0.0 110.505 179.766 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.857 HG21 HG11 ' A' ' 319' ' ' VAL . 71.4 t -65.62 132.18 31.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.215 -0.928 . . . . 0.0 109.911 179.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -111.21 -36.97 1.71 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.131 -1.188 . . . . 0.0 110.131 -179.476 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.483 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.5 OUTLIER -140.97 139.49 34.23 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.144 -1.209 . . . . 0.0 110.819 -179.735 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.5 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.1 p90 -150.63 167.01 28.59 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.471 -0.768 . . . . 0.0 109.599 179.56 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.508 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -154.98 155.2 33.79 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 120.946 -1.096 . . . . 0.0 111.585 -179.558 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.511 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 62.71 25.49 15.14 Favored 'General case' 0 N--CA 1.495 1.787 0 O-C-N 121.527 -0.733 . . . . 0.0 110.854 179.742 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.68 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.57 141.22 0.65 Allowed 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.274 -0.891 . . . . 0.0 110.365 179.838 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.75 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -78.65 117.54 19.9 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.136 -0.977 . . . . 0.0 109.17 179.386 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.631 ' HG3' HG11 ' A' ' 304' ' ' VAL . 2.0 ttpt -87.84 145.67 25.97 Favored 'General case' 0 N--CA 1.492 1.641 0 CA-C-O 121.791 0.805 . . . . 0.0 110.824 -179.274 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.822 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -133.19 178.6 6.78 Favored 'General case' 0 C--N 1.3 -1.544 0 N-CA-C 108.735 -0.839 . . . . 0.0 108.735 179.35 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 30.7 mt-10 -141.45 106.57 4.97 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.533 -0.729 . . . . 0.0 110.539 179.509 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.435 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.93 51.83 2.89 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.426 -1.47 . . . . 0.0 109.426 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.3 m-80 51.51 80.16 0.09 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.277 -1.131 . . . . 0.0 110.317 -179.975 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.602 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.47 -0.12 58.22 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.869 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.823 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.6 m-85 -141.23 -166.96 2.29 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -1.115 . . . . 0.0 109.435 179.504 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.857 HG11 HG21 ' A' ' 304' ' ' VAL . 2.7 t -163.61 157.84 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.765 0 O-C-N 121.21 -0.931 . . . . 0.0 109.839 179.286 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.775 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 9.2 mm -127.1 146.61 32.69 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.988 0 O-C-N 120.915 -1.116 . . . . 0.0 110.685 179.486 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.648 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 74.8 m-85 -125.42 124.83 42.31 Favored 'General case' 0 N--CA 1.494 1.748 0 O-C-N 121.364 -0.835 . . . . 0.0 109.729 179.263 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.541 ' HB ' ' HD2' ' A' ' 323' ' ' PRO . 8.3 p -126.96 168.04 15.85 Favored Pre-proline 0 N--CA 1.493 1.679 0 O-C-N 120.491 -1.381 . . . . 0.0 110.39 179.857 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.544 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 38.4 Cg_endo -65.92 119.07 6.04 Favored 'Trans proline' 0 C--N 1.307 -1.639 0 O-C-N 123.868 1.457 . . . . 0.0 111.13 -179.306 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.75 HG12 ' ND2' ' A' ' 311' ' ' ASN . 34.2 m -67.29 -124.08 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.527 -0.733 . . . . 0.0 109.895 179.799 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.592 ' N ' HG23 ' A' ' 324' ' ' VAL . 32.1 t -107.15 -12.92 15.28 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.763 -1.211 . . . . 0.0 110.693 -179.877 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.708 ' H ' HG23 ' A' ' 324' ' ' VAL . 19.6 p-90 -130.34 4.32 4.74 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.069 -1.02 . . . . 0.0 110.526 -179.874 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.718 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.5 OUTLIER -113.85 40.91 2.33 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.247 -0.908 . . . . 0.0 110.351 -179.546 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.542 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -115.97 -11.17 11.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.136 -0.977 . . . . 0.0 109.786 179.821 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.508 ' HA2' ' NE2' ' A' ' 289' ' ' GLN . . . -57.08 -158.59 0.01 OUTLIER Glycine 0 N--CA 1.492 2.392 0 N-CA-C 110.324 -1.11 . . . . 0.0 110.324 -179.424 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.519 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.8 Cg_endo -75.41 7.05 3.2 Favored 'Trans proline' 0 C--N 1.308 -1.588 0 O-C-N 124.143 1.602 . . . . 0.0 111.119 -179.663 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.424 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 1.5 m -162.41 124.15 2.69 Favored 'General case' 0 C--N 1.301 -1.537 0 O-C-N 121.021 -1.049 . . . . 0.0 109.957 179.992 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.538 ' HB1' ' OD1' ' A' ' 327' ' ' ASN . . . -145.93 110.81 5.21 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.2 -0.937 . . . . 0.0 110.311 -179.821 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.546 ' OG1' HG23 ' A' ' 283' ' ' THR . 24.9 m -102.68 123.13 45.81 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.153 -0.967 . . . . 0.0 110.235 179.967 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.803 ' HE2' HG21 ' A' ' 294' ' ' VAL . 13.2 p90 -128.67 175.48 8.55 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.191 -0.943 . . . . 0.0 108.952 179.456 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.5 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -149.41 162.58 29.07 Favored Glycine 0 N--CA 1.487 2.083 0 C-N-CA 119.074 -1.536 . . . . 0.0 109.967 -179.222 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.925 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.7 OUTLIER -152.0 144.81 24.36 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.487 -1.008 . . . . 0.0 109.256 179.378 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.925 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -119.77 121.25 65.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.97 -1.081 . . . . 0.0 109.935 -179.743 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.792 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.5 t -96.88 151.7 4.08 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 121.107 -0.996 . . . . 0.0 109.835 -179.976 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.499 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -123.36 132.3 53.93 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.277 -0.889 . . . . 0.0 110.307 -179.896 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 179.43 -124.05 0.88 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 179.768 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.535 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 40.3 Cg_endo -66.67 -158.61 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.753 0 O-C-N 123.761 1.401 . . . . 0.0 110.139 179.28 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.568 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -123.68 131.69 53.67 Favored 'General case' 0 N--CA 1.493 1.724 0 O-C-N 121.078 -1.014 . . . . 0.0 110.49 -179.538 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 101.72 -75.29 0.35 Allowed Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.308 -1.517 . . . . 0.0 109.308 179.799 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 2.9 p-10 -111.29 126.01 54.45 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.415 -1.05 . . . . 0.0 109.477 179.503 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.733 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -135.06 2.87 3.12 Favored 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.169 -0.957 . . . . 0.0 110.547 -179.679 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.576 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.4 p -132.39 117.4 31.71 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.319 -0.863 . . . . 0.0 109.927 179.698 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.449 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.3 OUTLIER -49.64 -45.43 48.39 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.339 -0.851 . . . . 0.0 110.784 -179.243 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -176.95 158.83 1.63 Allowed 'General case' 0 N--CA 1.496 1.837 0 O-C-N 120.942 -1.099 . . . . 0.0 110.916 -179.737 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.688 HG12 HG22 ' A' ' 296' ' ' VAL . 42.5 mt -121.06 109.82 26.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.187 -0.946 . . . . 0.0 110.088 179.64 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.64 158.19 16.88 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.326 -0.859 . . . . 0.0 110.369 -179.926 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 0.999 HD11 HD21 ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.29 125.83 50.02 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.357 -0.839 . . . . 0.0 110.056 179.807 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.529 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.9 tt0 -137.96 116.26 11.89 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.14 -0.975 . . . . 0.0 110.248 179.86 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.654 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.31 95.87 5.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.132 -0.98 . . . . 0.0 110.162 179.903 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.546 ' ND2' ' HB2' ' A' ' 291' ' ' ASP . 0.9 OUTLIER 49.51 32.3 4.71 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.641 -0.662 . . . . 0.0 110.742 179.834 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.18 -31.31 4.94 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 110.096 -1.202 . . . . 0.0 110.096 179.441 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.529 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 79.3 mm-40 -81.77 119.75 24.27 Favored 'General case' 0 N--CA 1.492 1.669 0 O-C-N 121.148 -1.207 . . . . 0.0 110.519 -179.596 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.834 ' O ' HD13 ' A' ' 358' ' ' ILE . 12.0 p -79.04 135.64 25.36 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.641 0 O-C-N 121.176 -0.952 . . . . 0.0 110.087 179.749 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.912 ' HB ' HD13 ' A' ' 351' ' ' LEU . 27.5 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 118.031 -0.985 . . . . 0.0 110.201 -179.778 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.278 0 N-CA-C 109.673 -1.371 . . . . 0.0 109.673 . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.5 Cg_endo -73.17 -178.04 3.34 Favored 'Trans proline' 0 C--N 1.304 -1.796 0 O-C-N 123.997 1.525 . . . . 0.0 110.492 -179.995 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 14.4 t -56.77 145.62 28.63 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.307 -0.871 . . . . 0.0 110.062 179.949 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -111.26 159.79 31.54 Favored Pre-proline 0 N--CA 1.492 1.637 0 O-C-N 121.235 -0.916 . . . . 0.0 110.192 -179.93 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.45 133.85 19.72 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 123.957 1.503 . . . . 0.0 110.22 179.84 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.6 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.8 p -93.69 143.04 25.93 Favored Pre-proline 0 N--CA 1.492 1.641 0 O-C-N 121.243 -0.911 . . . . 0.0 110.553 -179.7 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.6 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.3 Cg_endo -75.53 149.02 34.05 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 124.179 1.621 . . . . 0.0 110.282 179.557 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.775 HG12 ' O ' ' A' ' 263' ' ' VAL . 83.2 t -133.87 29.03 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.237 -0.915 . . . . 0.0 110.501 -179.962 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.468 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 170.76 83.51 0.0 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.217 -0.927 . . . . 0.0 110.283 -179.994 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 123.31 176.52 14.83 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.813 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.572 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.15 158.06 44.84 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.364 -1.08 . . . . 0.0 109.9 -179.955 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.959 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -146.94 113.47 5.98 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.177 -0.952 . . . . 0.0 110.532 180.0 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -114.69 114.76 26.07 Favored 'General case' 0 N--CA 1.492 1.659 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 179.067 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.631 HG23 HD22 ' A' ' 267' ' ' LEU . 61.4 t -112.62 133.3 58.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.894 -1.129 . . . . 0.0 112.588 -178.233 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.401 ' C ' HG23 ' A' ' 271' ' ' VAL . 1.7 mptm? -116.73 156.66 26.78 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 107.996 -1.112 . . . . 0.0 107.996 177.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.795 HG13 ' O ' ' A' ' 279' ' ' GLU . 87.1 t -144.64 147.05 19.61 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 120.231 -1.543 . . . . 0.0 112.235 -179.201 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.559 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -133.7 106.95 7.64 Favored 'General case' 0 N--CA 1.486 1.346 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.096 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.446 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 20.8 p-10 -93.09 145.92 24.03 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.087 -1.008 . . . . 0.0 111.254 -178.884 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.834 ' CH2' HG23 ' A' ' 337' ' ' ILE . 38.1 p90 -134.04 16.98 3.82 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.421 -0.799 . . . . 0.0 109.902 179.423 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.52 -59.26 4.38 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.203 -1.559 . . . . 0.0 109.203 179.998 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -66.14 -17.64 64.85 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.357 -1.084 . . . . 0.0 110.09 179.822 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.585 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . 178.38 -178.7 48.66 Favored Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.776 -1.329 . . . . 0.0 109.776 179.934 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.867 ' HB2' ' NZ ' ' A' ' 345' ' ' LYS . . . -135.1 138.54 43.89 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.378 -1.072 . . . . 0.0 110.229 -179.965 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.795 ' O ' HG13 ' A' ' 271' ' ' VAL . 8.2 mt-10 -92.28 146.18 23.91 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.434 -0.791 . . . . 0.0 110.093 -179.812 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.707 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 97.5 m-85 -136.0 95.28 3.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.305 -0.872 . . . . 0.0 110.726 -179.631 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.576 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.3 OUTLIER -82.4 103.78 12.21 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.496 -0.752 . . . . 0.0 109.94 179.562 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.657 HG11 HG11 ' A' ' 294' ' ' VAL . 5.2 t -93.93 91.79 3.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.402 -0.811 . . . . 0.0 110.42 -179.983 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.912 HG23 ' OG1' ' A' ' 333' ' ' THR . 8.9 m -86.54 112.47 21.59 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.25 -0.906 . . . . 0.0 109.158 179.337 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.08 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -97.55 153.0 18.46 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.098 -1.001 . . . . 0.0 111.096 -178.913 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.601 ' C ' HD23 ' A' ' 286' ' ' LEU . 0.1 OUTLIER -135.51 106.43 6.63 Favored 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.452 -0.78 . . . . 0.0 109.978 -179.699 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.601 HD23 ' C ' ' A' ' 285' ' ' ASN . 2.3 mt -117.05 169.51 9.36 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 120.689 -1.257 . . . . 0.0 110.026 179.799 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . 0.421 ' C ' ' OH ' ' A' ' 290' ' ' TYR . 10.7 m-20 -100.85 32.29 3.23 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.268 -0.895 . . . . 0.0 110.455 -179.705 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.498 ' N ' ' CE2' ' A' ' 290' ' ' TYR . . . 162.87 -145.54 10.73 Favored Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.14 -1.505 . . . . 0.0 110.272 179.959 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.508 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -106.87 105.86 16.1 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.362 -1.081 . . . . 0.0 110.871 -179.442 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.498 ' CE2' ' N ' ' A' ' 288' ' ' GLY . 3.7 m-85 -135.67 150.47 49.6 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.233 -0.917 . . . . 0.0 109.756 179.356 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.527 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 86.8 m-20 -78.97 96.91 5.87 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.227 -0.921 . . . . 0.0 108.97 179.098 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.857 ' CE3' HD13 ' A' ' 284' ' ' LEU . 52.3 p-90 -94.19 112.11 23.89 Favored 'General case' 0 C--N 1.302 -1.493 0 O-C-N 121.35 -0.844 . . . . 0.0 110.474 -179.46 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.751 HG23 ' CG2' ' A' ' 322' ' ' THR . 15.2 m -106.5 116.52 32.07 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.411 -0.806 . . . . 0.0 109.261 179.641 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.782 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.3 t -96.29 110.79 25.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.185 -0.947 . . . . 0.0 110.667 -179.103 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.596 ' HA ' HD13 ' A' ' 320' ' ' ILE . 9.0 ttpt -83.07 148.85 27.28 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.379 -0.826 . . . . 0.0 108.792 178.696 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.617 ' CG1' HG21 ' A' ' 346' ' ' VAL . 76.2 t -148.55 108.24 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.005 -1.059 . . . . 0.0 111.11 -178.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.59 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 56.3 mmtt -70.69 141.56 51.58 Favored 'General case' 0 C--N 1.305 -1.354 0 O-C-N 121.233 -0.917 . . . . 0.0 109.302 179.167 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 1.0 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.3 mt -94.07 157.97 15.84 Favored 'General case' 0 N--CA 1.493 1.689 0 O-C-N 121.273 -0.892 . . . . 0.0 111.854 -178.608 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.698 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.06 173.12 3.41 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.709 -0.62 . . . . 0.0 109.734 179.404 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.698 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.5 Cg_endo -68.25 83.66 0.47 Allowed 'Trans proline' 0 C--N 1.305 -1.762 0 O-C-N 123.715 1.376 . . . . 0.0 109.76 179.58 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.72 24.45 5.25 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 -179.353 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.732 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -118.44 142.67 47.33 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.423 -1.046 . . . . 0.0 110.11 -179.838 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 1.0 ' HA ' HD13 ' A' ' 298' ' ' LEU . 9.6 p -143.6 144.45 31.92 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.202 -0.936 . . . . 0.0 110.764 179.753 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.885 ' CG2' HG21 ' A' ' 319' ' ' VAL . 36.2 t -69.87 134.1 30.7 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.423 -0.798 . . . . 0.0 109.721 179.456 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -123.5 -46.76 0.26 Allowed Glycine 0 N--CA 1.49 2.237 0 C-N-CA 119.681 -1.247 . . . . 0.0 110.332 -179.329 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.543 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 31.0 t -119.63 140.27 50.88 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.063 -1.257 . . . . 0.0 110.91 -179.432 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.628 ' CD1' ' N ' ' A' ' 307' ' ' PHE . 6.3 p90 -157.99 170.7 21.71 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.54 -0.725 . . . . 0.0 109.695 179.483 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.523 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.8 OUTLIER -160.46 162.68 33.23 Favored 'General case' 0 N--CA 1.496 1.854 0 O-C-N 121.09 -1.006 . . . . 0.0 111.044 -179.585 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.467 ' O ' ' OD1' ' A' ' 327' ' ' ASN . 0.8 OUTLIER 54.77 24.8 5.95 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.585 -0.697 . . . . 0.0 110.774 179.816 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.73 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.86 144.45 1.05 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.404 -0.81 . . . . 0.0 109.882 179.455 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.523 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -86.4 122.2 30.03 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.031 -1.043 . . . . 0.0 109.754 179.747 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.536 ' HG3' HG11 ' A' ' 304' ' ' VAL . 1.7 ttpt -87.5 141.42 28.63 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 121.888 0.851 . . . . 0.0 110.374 -179.749 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.606 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -128.02 175.7 8.19 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 179.688 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -134.46 117.71 16.55 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.111 -0.993 . . . . 0.0 110.382 -179.941 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.498 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -108.0 33.65 6.14 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.497 -1.441 . . . . 0.0 109.497 -179.984 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.498 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.2 OUTLIER 70.08 85.57 0.13 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.295 -1.121 . . . . 0.0 110.37 179.993 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 88.56 5.11 75.55 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.758 -1.337 . . . . 0.0 109.758 179.87 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.84 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.0 OUTLIER -146.16 -168.24 2.94 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.362 -1.081 . . . . 0.0 109.173 179.513 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.885 HG21 ' CG2' ' A' ' 304' ' ' VAL . 4.2 t -163.45 161.54 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.235 -0.916 . . . . 0.0 109.765 179.369 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.596 HD13 ' HA ' ' A' ' 295' ' ' LYS . 7.4 mm -128.2 143.38 41.1 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 121.122 -0.986 . . . . 0.0 111.271 -179.84 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.664 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 65.4 m-85 -120.05 127.29 52.43 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.263 -0.898 . . . . 0.0 109.421 178.997 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.751 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -128.25 169.92 11.64 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 120.693 -1.254 . . . . 0.0 110.213 -179.498 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -65.31 112.74 2.19 Favored 'Trans proline' 0 C--N 1.307 -1.609 0 O-C-N 123.944 1.497 . . . . 0.0 111.15 -179.354 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.684 HG23 ' H ' ' A' ' 325' ' ' SER . 3.6 m -53.3 -59.03 2.02 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.435 -0.79 . . . . 0.0 110.994 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.684 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -179.29 -24.72 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 O-C-N 120.959 -1.088 . . . . 0.0 111.307 -179.67 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.471 ' CA ' ' HD2' ' A' ' 328' ' ' LYS . 5.3 p-90 -115.78 -24.84 8.02 Favored 'General case' 0 N--CA 1.497 1.913 0 O-C-N 120.92 -1.112 . . . . 0.0 110.718 -179.72 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.856 ' O ' ' HB2' ' A' ' 332' ' ' ALA . 0.0 OUTLIER -85.22 29.36 0.66 Allowed 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.144 -0.972 . . . . 0.0 111.303 -179.817 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.508 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -90.87 -6.27 54.42 Favored 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.207 -0.933 . . . . 0.0 109.45 179.599 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.465 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.58 -157.69 0.01 OUTLIER Glycine 0 N--CA 1.49 2.265 0 N-CA-C 110.309 -1.116 . . . . 0.0 110.309 -179.492 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.519 ' O ' ' N ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -75.86 6.54 3.69 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 124.14 1.6 . . . . 0.0 110.878 -179.928 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.9 OUTLIER -159.02 131.64 6.87 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.258 -0.901 . . . . 0.0 109.734 -179.932 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.856 ' HB2' ' O ' ' A' ' 327' ' ' ASN . . . -144.99 109.08 4.78 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.185 -0.947 . . . . 0.0 110.385 -179.691 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.912 ' OG1' HG23 ' A' ' 283' ' ' THR . 51.8 m -104.12 118.38 36.52 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.163 -0.961 . . . . 0.0 110.558 -179.882 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.782 ' HE2' HG21 ' A' ' 294' ' ' VAL . 9.7 p90 -128.56 174.67 9.18 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 108.685 -0.857 . . . . 0.0 108.685 179.463 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.495 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.1 162.37 28.76 Favored Glycine 0 N--CA 1.487 2.076 0 C-N-CA 118.801 -1.666 . . . . 0.0 110.477 -179.247 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.91 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -151.39 143.85 24.2 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.685 -0.891 . . . . 0.0 109.32 179.25 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.91 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -117.95 119.34 61.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.959 -1.088 . . . . 0.0 110.283 -179.634 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.732 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -97.01 142.8 13.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 121.272 -0.893 . . . . 0.0 109.71 179.768 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.469 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.7 m-80 -111.23 136.1 50.8 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.188 -0.945 . . . . 0.0 110.215 -179.977 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.47 -141.76 4.45 Favored Glycine 0 N--CA 1.491 2.344 0 N-CA-C 109.555 -1.418 . . . . 0.0 109.555 -179.927 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.55 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 43.9 Cg_endo -71.58 -158.61 0.06 OUTLIER 'Trans proline' 0 C--N 1.305 -1.757 0 O-C-N 123.983 1.518 . . . . 0.0 110.476 -179.986 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . . . . . . . . . 10.9 mp0 -113.6 143.51 44.44 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.217 -0.927 . . . . 0.0 110.421 -179.792 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.445 ' O ' ' CB ' ' A' ' 344' ' ' ASP . . . 99.63 64.53 0.82 Allowed Glycine 0 N--CA 1.49 2.238 0 N-CA-C 108.995 -1.642 . . . . 0.0 108.995 -179.793 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.445 ' CB ' ' O ' ' A' ' 343' ' ' GLY . 8.2 t0 65.18 147.96 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.373 -1.075 . . . . 0.0 109.384 -179.335 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.867 ' NZ ' ' HB2' ' A' ' 278' ' ' ALA . 0.0 OUTLIER -140.83 21.49 2.31 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.016 -1.053 . . . . 0.0 110.903 -179.471 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.62 HG13 ' O ' ' A' ' 346' ' ' VAL . 12.8 p -128.31 115.01 36.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.603 0 O-C-N 121.07 -1.019 . . . . 0.0 110.077 179.525 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.501 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 6.9 mt-10 -43.45 -46.93 6.96 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.244 -0.91 . . . . 0.0 110.102 -179.641 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.474 ' HG3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -177.19 158.54 1.51 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.105 -0.997 . . . . 0.0 110.833 -179.968 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.539 HG12 HG22 ' A' ' 296' ' ' VAL . 16.6 mt -117.75 105.63 18.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.296 -0.877 . . . . 0.0 109.952 179.577 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -103.81 141.96 35.21 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.327 -0.858 . . . . 0.0 110.005 -179.924 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.08 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -100.88 131.42 46.77 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.064 -1.023 . . . . 0.0 110.177 179.967 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.404 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 1.4 tp10 -139.03 110.48 7.0 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.253 -0.905 . . . . 0.0 110.019 179.677 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.463 ' HB ' ' HB2' ' A' ' 356' ' ' GLN . 1.3 mt -91.45 105.21 16.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.045 -1.034 . . . . 0.0 109.894 179.733 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.527 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 45.19 40.56 5.08 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.48 -0.762 . . . . 0.0 110.619 -179.887 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 105.05 -22.47 33.23 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 179.448 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.463 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 76.1 mm-40 -84.03 110.3 18.34 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.093 -1.24 . . . . 0.0 110.27 -179.87 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.776 ' O ' HD13 ' A' ' 358' ' ' ILE . 8.5 p -72.41 130.24 35.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.261 -0.899 . . . . 0.0 110.076 179.998 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.776 HD13 ' O ' ' A' ' 357' ' ' VAL . 17.0 mm . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 117.947 -1.025 . . . . 0.0 110.241 179.893 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.281 0 N-CA-C 109.528 -1.429 . . . . 0.0 109.528 . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 49.7 Cg_endo -74.36 -178.72 4.16 Favored 'Trans proline' 0 C--N 1.304 -1.764 0 O-C-N 124.029 1.542 . . . . 0.0 110.45 179.992 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.55 HG23 ' O ' ' A' ' 258' ' ' THR . 7.4 t -59.81 127.69 33.19 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.437 -0.79 . . . . 0.0 110.291 179.901 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -101.8 154.63 37.19 Favored Pre-proline 0 N--CA 1.49 1.568 0 O-C-N 121.141 -0.974 . . . . 0.0 110.124 179.951 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.63 154.13 54.6 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 123.945 1.497 . . . . 0.0 110.2 179.867 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.506 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.0 p -79.82 141.26 55.18 Favored Pre-proline 0 N--CA 1.491 1.617 0 O-C-N 121.158 -0.964 . . . . 0.0 110.495 -179.646 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.506 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.5 Cg_endo -80.13 128.6 7.39 Favored 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 124.175 1.618 . . . . 0.0 110.598 -179.889 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.456 ' O ' ' CB ' ' A' ' 264' ' ' SER . 5.1 t -115.93 22.7 5.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.277 -0.889 . . . . 0.0 109.824 179.525 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.456 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.3 OUTLIER 169.34 104.33 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.723 0 O-C-N 121.499 -0.751 . . . . 0.0 110.222 179.819 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 106.64 175.49 23.14 Favored Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.783 -1.327 . . . . 0.0 109.783 179.922 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -137.14 155.39 49.64 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.277 -1.131 . . . . 0.0 109.832 179.968 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.811 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -148.48 121.53 8.85 Favored 'General case' 0 C--N 1.303 -1.456 0 O-C-N 121.124 -0.985 . . . . 0.0 110.884 -179.353 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.447 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 23.9 mt-10 -121.61 127.35 50.77 Favored 'General case' 0 N--CA 1.492 1.649 0 N-CA-C 108.306 -0.998 . . . . 0.0 108.306 178.875 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.589 ' HA ' ' O ' ' A' ' 281' ' ' ASP . 48.1 t -121.33 138.45 51.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 120.634 -1.291 . . . . 0.0 112.428 -178.402 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 6.6 mtpp -125.3 157.82 35.71 Favored 'General case' 0 N--CA 1.492 1.633 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 178.968 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.803 HG13 ' O ' ' A' ' 279' ' ' GLU . 84.4 t -144.62 144.93 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.687 0 O-C-N 120.379 -1.45 . . . . 0.0 112.021 -179.577 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.539 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -132.99 108.14 8.71 Favored 'General case' 0 C--N 1.306 -1.321 0 N-CA-C 108.406 -0.961 . . . . 0.0 108.406 178.974 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.48 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 19.2 m-20 -96.4 144.83 26.17 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.999 -1.063 . . . . 0.0 111.077 -178.793 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.851 ' CH2' HG23 ' A' ' 337' ' ' ILE . 37.1 p90 -131.51 20.03 4.74 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.496 -0.752 . . . . 0.0 110.025 179.551 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 85.48 -61.49 4.59 Favored Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.778 -1.329 . . . . 0.0 109.778 179.816 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -67.53 -18.98 65.23 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.209 -1.171 . . . . 0.0 110.465 -179.735 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.582 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.99 177.75 45.31 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.909 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.545 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -135.2 137.53 42.74 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.313 -1.11 . . . . 0.0 109.989 179.766 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.803 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.4 mt-10 -94.33 146.4 24.07 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.276 -0.89 . . . . 0.0 110.205 -179.68 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.806 ' CE2' HG11 ' A' ' 346' ' ' VAL . 90.3 m-85 -137.68 88.81 2.36 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.268 -0.895 . . . . 0.0 110.624 -179.747 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.589 ' O ' ' HA ' ' A' ' 269' ' ' VAL . 0.4 OUTLIER -75.97 117.78 18.06 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.369 -0.832 . . . . 0.0 110.325 179.734 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.787 HG11 HG11 ' A' ' 294' ' ' VAL . 11.1 t -109.83 94.37 3.07 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.496 0 O-C-N 121.436 -0.79 . . . . 0.0 110.131 179.626 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.797 HG23 ' OG1' ' A' ' 333' ' ' THR . 19.8 m -86.97 120.42 28.22 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.182 -0.949 . . . . 0.0 109.778 179.546 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.001 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -107.25 149.94 27.2 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.195 -0.941 . . . . 0.0 110.828 -179.346 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.72 106.94 7.63 Favored 'General case' 0 N--CA 1.497 1.925 0 O-C-N 121.401 -0.812 . . . . 0.0 110.147 -179.33 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.575 ' HB3' ' CD2' ' A' ' 290' ' ' TYR . 12.2 mt -114.99 155.6 26.65 Favored 'General case' 0 C--N 1.299 -1.627 0 O-C-N 120.568 -1.332 . . . . 0.0 110.638 -179.975 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . 0.429 ' O ' ' OH ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -88.09 37.76 0.82 Allowed 'General case' 0 C--N 1.299 -1.601 0 O-C-N 121.488 -0.758 . . . . 0.0 109.746 179.572 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.44 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 160.33 -147.29 14.05 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.774 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.55 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 0.0 OUTLIER -111.56 95.02 5.26 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.151 -1.205 . . . . 0.0 110.633 -179.71 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.575 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 1.5 m-85 -122.43 141.34 51.71 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 121.262 -0.899 . . . . 0.0 110.05 179.98 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.907 ' O ' HG23 ' A' ' 353' ' ' ILE . 13.2 t70 -71.94 108.73 5.35 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.149 -0.97 . . . . 0.0 109.72 179.564 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.868 ' CE3' HD13 ' A' ' 284' ' ' LEU . 42.9 p-90 -105.22 114.89 29.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.144 -0.972 . . . . 0.0 110.544 -179.651 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.792 HG22 ' CG2' ' A' ' 320' ' ' ILE . 3.2 m -102.27 113.96 27.71 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.418 -0.801 . . . . 0.0 109.534 179.751 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.846 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.1 t -96.67 113.33 30.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.061 -1.024 . . . . 0.0 110.448 -179.516 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.791 ' HA ' HD13 ' A' ' 320' ' ' ILE . 4.1 ttpt -87.9 149.6 23.99 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.7 179.535 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.635 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 71.5 t -149.35 110.04 0.54 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 O-C-N 121.079 -1.013 . . . . 0.0 110.273 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.567 ' O ' HG23 ' A' ' 346' ' ' VAL . 52.1 mmtt -72.18 138.68 47.79 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.197 -0.939 . . . . 0.0 109.58 179.575 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.936 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.8 mt -91.93 158.36 16.32 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.262 -0.899 . . . . 0.0 111.696 -178.779 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.858 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.5 175.24 1.17 Allowed Pre-proline 0 N--CA 1.488 1.466 0 O-C-N 121.792 -0.567 . . . . 0.0 109.586 179.216 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.748 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -66.36 81.27 0.3 Allowed 'Trans proline' 0 C--N 1.306 -1.687 0 O-C-N 123.581 1.306 . . . . 0.0 109.902 179.42 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.8 21.69 6.3 Favored Glycine 0 N--CA 1.489 2.183 0 N-CA-C 108.957 -1.657 . . . . 0.0 108.957 -179.364 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.862 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -104.86 153.32 21.52 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.337 -1.096 . . . . 0.0 110.213 -179.851 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.936 ' HA ' HD13 ' A' ' 298' ' ' LEU . 64.8 p -156.51 145.42 20.23 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.074 -1.016 . . . . 0.0 110.719 -179.864 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.753 HG21 HG11 ' A' ' 319' ' ' VAL . 61.6 t -74.21 131.56 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 121.395 -0.816 . . . . 0.0 109.908 179.562 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -122.55 -25.14 2.01 Favored Glycine 0 N--CA 1.49 2.263 0 N-CA-C 109.962 -1.255 . . . . 0.0 109.962 -179.728 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -139.68 112.71 8.12 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.039 -1.271 . . . . 0.0 110.95 -179.698 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.511 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 53.2 p90 -132.97 163.75 28.51 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.323 -0.861 . . . . 0.0 109.782 179.361 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.509 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.95 162.8 40.87 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.033 -1.042 . . . . 0.0 110.843 -179.612 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.493 ' O ' ' ND2' ' A' ' 327' ' ' ASN . 0.5 OUTLIER 57.49 22.6 8.22 Favored 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.583 -0.698 . . . . 0.0 111.025 179.55 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.695 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -175.06 143.28 0.69 Allowed 'General case' 0 N--CA 1.492 1.668 0 O-C-N 121.295 -0.878 . . . . 0.0 110.401 179.514 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.779 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -80.71 120.79 25.07 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.271 -0.893 . . . . 0.0 109.117 179.255 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.584 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 0.6 OUTLIER -87.92 127.7 35.36 Favored 'General case' 0 N--CA 1.492 1.649 0 CA-C-O 121.733 0.778 . . . . 0.0 111.1 -178.982 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.525 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -108.54 174.5 5.85 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 178.323 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 14.5 mt-10 -134.29 114.58 13.16 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.131 -0.98 . . . . 0.0 110.784 -179.637 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.59 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -103.76 57.43 0.55 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.169 -1.573 . . . . 0.0 109.169 179.437 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.53 ' O ' ' ND2' ' A' ' 316' ' ' ASN . 2.3 p-10 37.75 75.7 0.06 Allowed 'General case' 0 N--CA 1.496 1.831 0 O-C-N 121.583 -0.951 . . . . 0.0 110.754 -179.687 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.584 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 108.39 -2.17 32.77 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.785 -1.326 . . . . 0.0 109.785 179.778 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.801 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.9 m-85 -142.24 -169.69 3.0 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.288 -1.125 . . . . 0.0 109.299 179.673 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.801 HG23 ' O ' ' A' ' 318' ' ' TYR . 6.7 t -162.45 158.39 1.86 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.825 0 O-C-N 121.201 -0.937 . . . . 0.0 109.583 179.165 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.792 ' CG2' HG22 ' A' ' 293' ' ' THR . 32.3 mm -128.9 148.98 33.21 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 O-C-N 121.001 -1.062 . . . . 0.0 111.338 -179.394 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 72.4 m-85 -124.58 122.8 38.56 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 120.988 -1.07 . . . . 0.0 110.164 179.284 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.645 ' CG2' HG23 ' A' ' 293' ' ' THR . 5.9 p -121.21 168.09 11.79 Favored Pre-proline 0 N--CA 1.492 1.639 0 O-C-N 120.924 -1.11 . . . . 0.0 110.002 179.756 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.516 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.7 Cg_endo -66.78 119.47 6.5 Favored 'Trans proline' 0 C--N 1.307 -1.628 0 O-C-N 123.805 1.424 . . . . 0.0 110.963 -179.502 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.779 HG12 ' ND2' ' A' ' 311' ' ' ASN . 35.4 m -67.88 -128.79 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.487 -0.758 . . . . 0.0 110.364 -179.889 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.499 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.4 OUTLIER -97.35 -13.03 22.14 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.836 -1.165 . . . . 0.0 110.878 -179.473 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.709 ' H ' HG23 ' A' ' 324' ' ' VAL . 10.0 p-90 -135.35 5.34 3.22 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.054 -1.029 . . . . 0.0 110.63 -179.918 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.867 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 11.6 t30 -108.67 42.62 1.37 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.109 -0.994 . . . . 0.0 110.722 -179.701 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.546 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.1 OUTLIER -123.43 -2.81 8.44 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.118 -0.989 . . . . 0.0 110.09 179.689 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.44 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -61.97 -157.11 0.08 OUTLIER Glycine 0 N--CA 1.492 2.396 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 -179.967 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.537 ' O ' ' N ' ' A' ' 286' ' ' LEU . 49.8 Cg_endo -75.96 5.3 4.55 Favored 'Trans proline' 0 C--N 1.306 -1.668 0 O-C-N 124.006 1.53 . . . . 0.0 110.574 -179.966 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.442 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 4.1 m -165.09 118.57 1.24 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.126 -0.984 . . . . 0.0 110.195 -179.826 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.867 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -140.41 118.78 12.14 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.144 -0.972 . . . . 0.0 110.225 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.797 ' OG1' HG23 ' A' ' 283' ' ' THR . 91.2 m -107.21 126.9 53.0 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 121.398 -0.814 . . . . 0.0 110.32 -179.957 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.846 ' HE2' HG21 ' A' ' 294' ' ' VAL . 10.8 p90 -131.37 175.35 9.21 Favored 'General case' 0 N--CA 1.488 1.453 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.364 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -155.37 156.63 27.11 Favored Glycine 0 N--CA 1.487 2.073 0 C-N-CA 118.861 -1.638 . . . . 0.0 110.076 -179.44 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.97 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.5 p90 -142.09 151.85 42.73 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.548 -0.972 . . . . 0.0 109.687 179.519 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.97 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -123.02 119.14 56.98 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.607 0 O-C-N 121.125 -0.984 . . . . 0.0 109.38 179.377 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.862 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -96.27 147.27 6.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.258 -0.901 . . . . 0.0 110.291 -179.398 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.514 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -118.17 131.29 56.41 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 109.987 179.979 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -179.27 -125.53 0.95 Allowed Glycine 0 N--CA 1.492 2.383 0 N-CA-C 109.742 -1.343 . . . . 0.0 109.742 -179.893 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.508 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.4 Cg_endo -69.28 -167.09 0.19 Allowed 'Trans proline' 0 C--N 1.309 -1.551 0 O-C-N 123.819 1.431 . . . . 0.0 110.675 -179.816 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.503 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 3.5 mp0 -111.2 132.16 54.55 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.288 -0.883 . . . . 0.0 110.954 -179.281 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 103.5 -86.71 0.54 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.403 -1.479 . . . . 0.0 109.403 179.604 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -104.32 128.97 52.21 Favored 'General case' 0 N--CA 1.49 1.525 0 O-C-N 121.322 -1.105 . . . . 0.0 109.356 179.597 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.756 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.0 OUTLIER -129.62 1.5 4.97 Favored 'General case' 0 N--CA 1.486 1.355 0 O-C-N 120.845 -1.159 . . . . 0.0 110.383 -179.869 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.806 HG11 ' CE2' ' A' ' 280' ' ' TYR . 7.1 p -127.27 123.74 62.63 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.635 0 O-C-N 121.094 -1.004 . . . . 0.0 109.709 179.199 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.543 ' CB ' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -55.06 -43.88 74.27 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.124 -0.985 . . . . 0.0 110.218 -179.258 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.469 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 16.9 pt-20 -177.31 159.23 1.55 Allowed 'General case' 0 N--CA 1.495 1.813 0 O-C-N 121.113 -0.992 . . . . 0.0 111.119 -179.896 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.581 HG12 HG13 ' A' ' 296' ' ' VAL . 36.2 mt -121.34 122.33 67.05 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.255 -0.903 . . . . 0.0 110.104 179.517 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.39 160.05 27.63 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.272 -0.892 . . . . 0.0 110.046 -179.858 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.001 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -119.18 126.95 52.78 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.234 -0.916 . . . . 0.0 110.278 -179.922 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.3 tt0 -138.59 113.31 9.05 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.185 -0.947 . . . . 0.0 109.942 179.665 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.907 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.6 113.22 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.108 -0.995 . . . . 0.0 110.144 179.957 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.524 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 40.08 40.56 0.78 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.537 -0.727 . . . . 0.0 111.031 179.879 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 104.86 -20.84 37.73 Favored Glycine 0 N--CA 1.493 2.435 0 C-N-CA 119.83 -1.176 . . . . 0.0 110.342 179.185 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.472 ' O ' ' N ' ' A' ' 353' ' ' ILE . 39.1 mm-40 -87.0 111.3 20.72 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.045 -1.268 . . . . 0.0 110.5 -179.75 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.642 ' O ' HD13 ' A' ' 358' ' ' ILE . 9.8 p -73.44 141.88 15.7 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.299 -0.876 . . . . 0.0 110.222 179.845 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.642 HD13 ' O ' ' A' ' 357' ' ' VAL . 28.8 mm . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 117.994 -1.003 . . . . 0.0 110.199 179.975 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.357 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 43.7 Cg_endo -73.12 -178.19 3.42 Favored 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 123.886 1.467 . . . . 0.0 110.798 -179.912 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 1.4 t -84.36 146.23 27.81 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.442 -0.786 . . . . 0.0 110.391 -179.826 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -103.13 117.88 59.31 Favored Pre-proline 0 N--CA 1.492 1.653 0 O-C-N 121.324 -0.86 . . . . 0.0 110.149 179.995 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -74.09 150.03 42.27 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 O-C-N 123.925 1.487 . . . . 0.0 110.432 -179.931 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.666 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.1 p -100.31 145.21 29.87 Favored Pre-proline 0 N--CA 1.492 1.628 0 O-C-N 121.25 -0.906 . . . . 0.0 110.094 179.788 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.666 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.2 Cg_endo -73.33 146.81 40.75 Favored 'Trans proline' 0 C--N 1.302 -1.876 0 O-C-N 123.973 1.512 . . . . 0.0 110.106 179.729 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 3.7 t -133.92 28.76 1.01 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.946 . . . . 0.0 110.325 -179.742 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 1.4 t -174.22 103.22 0.1 Allowed 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.085 -1.009 . . . . 0.0 110.917 179.987 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 87.17 -165.47 35.94 Favored Glycine 0 N--CA 1.489 2.192 0 C-N-CA 119.95 -1.119 . . . . 0.0 110.305 179.284 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.532 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -140.12 166.52 24.45 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.61 -0.936 . . . . 0.0 109.597 179.942 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.872 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.6 tm? -161.02 130.83 4.92 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.944 -1.097 . . . . 0.0 110.952 -179.8 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.783 ' N ' HD22 ' A' ' 267' ' ' LEU . 25.7 mt-10 -131.86 122.92 26.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.64 -0.662 . . . . 0.0 109.414 179.879 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 281' ' ' ASP . 96.5 t -117.1 137.29 51.5 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 111.478 -179.058 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 1.3 ttpt -120.25 157.42 29.17 Favored 'General case' 0 N--CA 1.494 1.747 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 178.91 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.668 HG13 ' O ' ' A' ' 279' ' ' GLU . 96.2 t -143.67 146.72 20.78 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.685 0 O-C-N 120.269 -1.519 . . . . 0.0 112.265 -179.266 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.536 ' ND2' ' O ' ' A' ' 272' ' ' ASN . 0.1 OUTLIER -147.89 117.5 7.05 Favored 'General case' 0 N--CA 1.492 1.634 0 N-CA-C 109.206 -0.664 . . . . 0.0 109.206 178.639 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.593 ' OD1' ' HB1' ' A' ' 278' ' ' ALA . 1.0 OUTLIER -100.13 147.59 25.51 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 121.205 -0.934 . . . . 0.0 111.195 -178.663 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.782 ' CH2' HG23 ' A' ' 337' ' ' ILE . 32.9 p90 -130.14 18.61 5.46 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.541 -0.724 . . . . 0.0 109.864 179.398 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 87.19 -57.23 4.57 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.608 -1.397 . . . . 0.0 109.608 179.735 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -71.65 -14.91 62.19 Favored 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.224 -1.162 . . . . 0.0 110.264 -179.895 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.548 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . 179.6 175.08 46.14 Favored Glycine 0 N--CA 1.491 2.3 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.892 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.593 ' HB1' ' OD1' ' A' ' 273' ' ' ASP . . . -130.39 147.34 52.08 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.315 -1.109 . . . . 0.0 109.999 179.851 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.668 ' O ' HG13 ' A' ' 271' ' ' VAL . 5.8 mt-10 -103.12 147.64 26.74 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.264 -0.897 . . . . 0.0 110.519 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.684 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 84.2 m-85 -142.59 81.09 1.72 Allowed 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.556 -0.715 . . . . 0.0 110.625 -179.816 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.4 OUTLIER -62.63 153.97 30.61 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.384 -0.822 . . . . 0.0 109.825 179.335 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.75 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 3.7 t -147.62 86.77 0.14 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.571 -0.705 . . . . 0.0 109.982 -179.473 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.765 HG23 ' OG1' ' A' ' 333' ' ' THR . 24.9 m -86.21 118.72 25.84 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.092 -1.005 . . . . 0.0 109.387 179.656 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.079 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -106.04 147.24 29.12 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.196 -0.94 . . . . 0.0 110.374 -179.341 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.843 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -127.07 133.07 50.53 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.175 -0.953 . . . . 0.0 110.458 -179.432 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.843 HD23 ' O ' ' A' ' 285' ' ' ASN . 9.2 mt -142.1 158.54 43.63 Favored 'General case' 0 C--N 1.298 -1.671 0 O-C-N 120.896 -1.128 . . . . 0.0 108.992 179.332 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -91.66 35.56 0.96 Allowed 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.464 -0.894 . . . . 0.0 110.531 -179.588 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.546 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 158.21 -110.14 0.43 Allowed Glycine 0 N--CA 1.493 2.468 0 C-N-CA 118.758 -1.687 . . . . 0.0 110.982 179.779 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.505 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 0.2 OUTLIER -135.07 122.37 21.68 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.061 -1.258 . . . . 0.0 111.051 -178.594 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.665 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 8.6 m-85 -150.88 147.02 26.71 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.245 -0.91 . . . . 0.0 109.998 179.172 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.787 ' O ' HG23 ' A' ' 353' ' ' ILE . 18.8 m-20 -80.58 96.79 6.94 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.328 -0.858 . . . . 0.0 109.371 179.316 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.954 ' CE3' HD13 ' A' ' 284' ' ' LEU . 57.9 p-90 -96.82 115.64 27.78 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.365 -0.835 . . . . 0.0 110.424 -179.589 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 1.073 HG23 HG22 ' A' ' 322' ' ' THR . 3.3 m -109.31 113.72 26.79 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.465 -0.772 . . . . 0.0 109.753 179.927 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.76 HG21 ' HE2' ' A' ' 334' ' ' PHE . 2.5 t -97.07 113.06 30.45 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.613 0 O-C-N 121.287 -0.883 . . . . 0.0 110.339 -179.463 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.548 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 31.3 ttmt -94.55 135.58 35.84 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.283 -0.886 . . . . 0.0 109.598 179.362 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.875 HG11 ' CZ ' ' A' ' 336' ' ' PHE . 81.1 t -130.25 112.34 23.13 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.515 0 O-C-N 121.187 -0.946 . . . . 0.0 110.579 -179.548 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.524 ' O ' HG23 ' A' ' 346' ' ' VAL . 53.3 mmtt -70.32 136.08 49.46 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.063 -1.023 . . . . 0.0 109.472 179.421 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.991 HD13 ' HA ' ' A' ' 303' ' ' THR . 88.3 mt -90.49 163.12 14.75 Favored 'General case' 0 N--CA 1.493 1.683 0 O-C-N 121.296 -0.878 . . . . 0.0 111.838 -178.599 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.863 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -68.78 178.06 0.97 Allowed Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 121.82 -0.55 . . . . 0.0 109.846 179.583 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.863 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.2 77.39 0.87 Allowed 'Trans proline' 0 C--N 1.306 -1.684 0 O-C-N 123.757 1.398 . . . . 0.0 109.811 179.449 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 115.7 18.69 5.97 Favored Glycine 0 N--CA 1.488 2.115 0 N-CA-C 108.714 -1.755 . . . . 0.0 108.714 -179.275 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.855 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -105.04 141.68 36.18 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.417 -1.049 . . . . 0.0 109.677 -179.856 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.991 ' HA ' HD13 ' A' ' 298' ' ' LEU . 82.2 p -143.99 143.95 31.45 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.84 -1.162 . . . . 0.0 111.058 179.859 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.888 ' CG2' HG21 ' A' ' 319' ' ' VAL . 88.5 t -67.13 116.86 7.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.458 -0.776 . . . . 0.0 109.942 179.658 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -101.74 -31.6 5.39 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.341 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.465 ' O ' ' N ' ' A' ' 337' ' ' ILE . 0.3 OUTLIER -140.63 132.03 26.81 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 120.927 -1.337 . . . . 0.0 111.136 -179.414 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.576 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 16.4 p90 -146.42 168.93 19.94 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.411 -0.805 . . . . 0.0 109.496 179.287 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.51 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 0.9 OUTLIER -159.56 157.07 29.2 Favored 'General case' 0 N--CA 1.494 1.755 0 O-C-N 120.881 -1.137 . . . . 0.0 111.546 -179.558 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.549 ' HB3' ' CH2' ' A' ' 326' ' ' TRP . 0.4 OUTLIER 60.76 27.09 16.87 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.749 -0.595 . . . . 0.0 111.186 179.47 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.672 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.08 142.7 0.86 Allowed 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.265 -0.897 . . . . 0.0 110.102 179.627 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.738 HD22 HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -76.3 114.49 15.05 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.171 -0.956 . . . . 0.0 109.421 179.628 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.584 ' HA ' ' O ' ' A' ' 320' ' ' ILE . 1.1 ttpp -87.08 132.95 33.67 Favored 'General case' 0 N--CA 1.49 1.542 0 CA-C-O 121.76 0.79 . . . . 0.0 110.782 -179.579 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.577 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 0.0 OUTLIER -120.03 174.52 6.42 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 178.991 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 29.4 mt-10 -137.71 103.14 4.93 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 121.195 -0.94 . . . . 0.0 110.242 179.764 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.499 ' O ' ' CB ' ' A' ' 316' ' ' ASN . . . -90.44 30.44 6.03 Favored Glycine 0 N--CA 1.488 2.155 0 N-CA-C 109.411 -1.475 . . . . 0.0 109.411 179.893 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.499 ' CB ' ' O ' ' A' ' 315' ' ' GLY . 0.1 OUTLIER 69.89 89.03 0.1 Allowed 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.224 -1.162 . . . . 0.0 110.378 -179.992 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.632 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.55 1.32 71.54 Favored Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.787 -1.325 . . . . 0.0 109.787 179.861 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.805 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.2 m-85 -146.72 -168.6 3.07 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.463 -1.022 . . . . 0.0 108.921 179.396 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.888 HG21 ' CG2' ' A' ' 304' ' ' VAL . 6.4 t -162.18 158.15 1.99 Allowed 'Isoleucine or valine' 0 N--CA 1.496 1.826 0 O-C-N 120.973 -1.08 . . . . 0.0 110.123 179.116 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.584 ' O ' ' HA ' ' A' ' 312' ' ' LYS . 6.5 mm -122.41 152.38 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.911 0 O-C-N 120.896 -1.128 . . . . 0.0 110.747 -179.677 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 76.2 m-85 -132.54 115.12 15.07 Favored 'General case' 0 N--CA 1.496 1.861 0 O-C-N 121.167 -0.958 . . . . 0.0 110.026 179.224 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 1.073 HG22 HG23 ' A' ' 293' ' ' THR . 5.6 p -118.03 169.47 7.64 Favored Pre-proline 0 N--CA 1.494 1.743 0 O-C-N 120.65 -1.281 . . . . 0.0 109.676 179.456 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.571 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.7 Cg_endo -67.57 121.28 8.35 Favored 'Trans proline' 0 C--N 1.308 -1.582 0 O-C-N 123.619 1.326 . . . . 0.0 110.697 -179.554 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 1.057 HG22 ' HB2' ' A' ' 327' ' ' ASN . 2.7 m -75.75 -141.85 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.47 -0.769 . . . . 0.0 110.458 -179.563 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.786 ' N ' HG23 ' A' ' 324' ' ' VAL . 3.2 m -76.24 -37.25 57.9 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.3 -0.875 . . . . 0.0 110.775 -179.626 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.58 ' H ' HG23 ' A' ' 324' ' ' VAL . 42.0 p-90 -117.77 22.24 12.44 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.16 -0.962 . . . . 0.0 110.803 -179.57 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 1.057 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -122.73 32.62 5.68 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.096 -1.003 . . . . 0.0 110.897 -179.172 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.498 ' CB ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -120.64 9.86 10.9 Favored 'General case' 0 N--CA 1.496 1.83 0 O-C-N 121.085 -1.009 . . . . 0.0 110.061 179.785 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.436 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -72.05 -149.5 0.87 Allowed Glycine 0 N--CA 1.488 2.141 0 N-CA-C 109.109 -1.597 . . . . 0.0 109.109 179.895 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.556 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.3 Cg_endo -73.32 -52.46 0.14 Allowed 'Trans proline' 0 C--N 1.303 -1.868 0 O-C-N 123.934 1.492 . . . . 0.0 109.64 179.811 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.0 m -111.89 115.73 29.47 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.564 -0.71 . . . . 0.0 110.003 179.593 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -125.52 117.45 23.65 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.379 -0.825 . . . . 0.0 109.958 179.991 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.765 ' OG1' HG23 ' A' ' 283' ' ' THR . 53.2 m -107.6 142.87 36.86 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.287 -0.883 . . . . 0.0 110.32 -179.859 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.76 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.4 p90 -151.7 173.06 15.15 Favored 'General case' 0 N--CA 1.488 1.465 0 N-CA-C 108.757 -0.831 . . . . 0.0 108.757 179.766 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.525 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -153.89 153.73 25.02 Favored Glycine 0 N--CA 1.489 2.181 0 C-N-CA 119.021 -1.562 . . . . 0.0 110.1 -179.465 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.892 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.3 p90 -137.98 145.96 42.57 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.531 -0.982 . . . . 0.0 109.876 179.662 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.892 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.05 125.4 74.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.133 -0.979 . . . . 0.0 109.593 179.935 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.761 HG21 ' CD2' ' A' ' 298' ' ' LEU . 3.5 t -99.49 161.42 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.175 -0.953 . . . . 0.0 110.726 -179.371 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.48 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 1.9 m-80 -128.47 137.06 51.62 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.447 -0.783 . . . . 0.0 110.205 179.869 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.405 ' H ' ' HE3' ' A' ' 345' ' ' LYS . . . 172.9 -128.99 1.62 Allowed Glycine 0 N--CA 1.494 2.517 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.951 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.536 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 39.2 Cg_endo -65.53 -158.68 0.04 OUTLIER 'Trans proline' 0 C--N 1.307 -1.645 0 O-C-N 123.859 1.452 . . . . 0.0 110.223 179.467 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.564 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -125.22 130.25 51.71 Favored 'General case' 0 N--CA 1.494 1.752 0 O-C-N 121.028 -1.045 . . . . 0.0 111.342 -179.098 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 117.22 -75.33 0.28 Allowed Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.178 -1.569 . . . . 0.0 109.178 179.464 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 1.2 p-10 -130.14 133.65 46.78 Favored 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.533 -0.98 . . . . 0.0 108.776 179.149 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.686 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 0.0 OUTLIER -133.67 25.35 4.04 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.899 -1.126 . . . . 0.0 111.044 -179.35 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.632 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.9 p -138.44 119.18 16.06 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.249 -0.907 . . . . 0.0 110.064 179.062 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.413 ' N ' ' O ' ' A' ' 297' ' ' LYS . 4.2 mt-10 -54.34 -42.22 69.99 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.412 -0.805 . . . . 0.0 110.928 -179.152 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.4 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.6 OUTLIER -176.66 158.77 1.76 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 120.94 -1.1 . . . . 0.0 110.867 -179.666 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.725 HG12 HG13 ' A' ' 296' ' ' VAL . 14.6 mt -119.28 120.22 63.07 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.144 -0.973 . . . . 0.0 110.36 179.858 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -124.11 141.9 51.66 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.113 -0.992 . . . . 0.0 110.16 179.825 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.079 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -106.89 130.11 54.61 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.193 -0.942 . . . . 0.0 110.386 179.803 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 11.8 tt0 -139.47 116.62 11.11 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.239 -0.913 . . . . 0.0 109.582 179.642 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.787 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.6 mt -90.52 102.86 13.76 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 120.792 -1.193 . . . . 0.0 110.45 -179.704 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.465 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 1.0 OUTLIER 35.72 44.89 0.24 Allowed 'General case' 0 N--CA 1.491 1.607 0 CA-C-N 115.99 -0.55 . . . . 0.0 111.433 179.647 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 107.92 20.45 8.4 Favored Glycine 0 N--CA 1.492 2.382 0 C-N-CA 119.742 -1.218 . . . . 0.0 110.408 179.106 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.522 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 78.2 mm-40 -137.2 101.31 4.5 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.062 -1.258 . . . . 0.0 110.042 179.765 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.549 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.1 p -66.91 138.22 23.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.278 -0.889 . . . . 0.0 110.732 -179.672 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.549 HD13 ' O ' ' A' ' 357' ' ' VAL . 19.6 mm . . . . . 0 N--CA 1.491 1.617 0 CA-C-O 117.988 -1.006 . . . . 0.0 110.171 179.596 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.293 0 N-CA-C 109.434 -1.466 . . . . 0.0 109.434 . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.8 Cg_endo -73.6 -178.34 3.67 Favored 'Trans proline' 0 C--N 1.306 -1.685 0 O-C-N 124.002 1.528 . . . . 0.0 110.553 -179.951 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.401 ' O ' HG23 ' A' ' 258' ' ' THR . 5.8 t -66.27 135.37 54.33 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.358 -0.839 . . . . 0.0 110.159 179.826 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . 0.47 HG23 ' O ' ' A' ' 259' ' ' THR . 1.5 t -141.69 92.74 7.89 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.154 -0.966 . . . . 0.0 110.471 -179.981 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_endo -73.9 141.68 30.5 Favored 'Trans proline' 0 C--N 1.306 -1.708 0 O-C-N 123.853 1.449 . . . . 0.0 110.102 179.759 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.409 ' H ' HG12 ' A' ' 261' ' ' VAL . 2.4 p -102.65 138.04 19.51 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.116 -0.99 . . . . 0.0 110.554 -179.906 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.518 ' HB3' ' HA ' ' A' ' 358' ' ' ILE . 49.2 Cg_endo -75.29 158.1 41.24 Favored 'Trans proline' 0 C--N 1.305 -1.711 0 O-C-N 124.081 1.569 . . . . 0.0 110.626 179.916 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.752 HG12 ' O ' ' A' ' 263' ' ' VAL . 75.6 t -127.46 26.61 2.3 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.28 -0.888 . . . . 0.0 109.979 179.688 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.621 ' O ' HD12 ' A' ' 358' ' ' ILE . 1.4 t 169.87 143.49 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.277 -0.89 . . . . 0.0 110.45 179.929 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . 0.428 ' HA3' HD23 ' A' ' 286' ' ' LEU . . . 61.9 -169.89 11.8 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.966 -1.254 . . . . 0.0 109.966 179.621 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.572 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.39 162.82 34.11 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.371 -1.076 . . . . 0.0 109.736 179.762 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.983 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.4 tm? -155.23 131.39 10.22 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.048 -1.032 . . . . 0.0 110.565 -179.148 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.562 ' N ' HD13 ' A' ' 267' ' ' LEU . 18.0 mt-10 -133.28 124.02 26.56 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.542 -0.724 . . . . 0.0 109.285 179.455 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.675 HG23 HD11 ' A' ' 267' ' ' LEU . 32.0 t -115.54 139.08 43.73 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.625 0 O-C-N 120.924 -1.11 . . . . 0.0 111.809 -178.714 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.412 ' C ' HG23 ' A' ' 271' ' ' VAL . 7.6 mttt -123.21 156.65 34.72 Favored 'General case' 0 N--CA 1.49 1.574 0 N-CA-C 108.356 -0.979 . . . . 0.0 108.356 178.492 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.672 HG22 ' CD1' ' A' ' 280' ' ' TYR . 91.4 t -145.08 144.94 21.29 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 120.276 -1.515 . . . . 0.0 112.152 -179.275 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.549 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -139.27 109.05 6.27 Favored 'General case' 0 N--CA 1.487 1.396 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 179.175 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -94.62 146.17 24.32 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.208 -0.932 . . . . 0.0 111.36 -178.763 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.819 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.6 p90 -134.63 22.94 3.66 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.589 -0.694 . . . . 0.0 109.897 179.275 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 83.69 -66.81 3.84 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.739 -1.344 . . . . 0.0 109.739 179.827 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -60.41 -24.85 65.49 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.28 -1.129 . . . . 0.0 110.431 -179.668 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.535 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -171.92 -177.8 41.76 Favored Glycine 0 N--CA 1.491 2.318 0 C-N-CA 119.533 -1.318 . . . . 0.0 109.84 -179.999 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.584 ' HB2' ' HE3' ' A' ' 345' ' ' LYS . . . -136.5 144.8 44.5 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -1.1 . . . . 0.0 110.247 179.914 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.644 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.1 mt-10 -97.01 147.05 24.4 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.421 -0.8 . . . . 0.0 109.816 -179.629 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.7 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 99.6 m-85 -143.74 86.79 1.89 Allowed 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.204 -0.935 . . . . 0.0 110.894 -179.619 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.647 ' O ' HG13 ' A' ' 269' ' ' VAL . 4.6 t0 -71.06 151.58 44.39 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.405 -0.809 . . . . 0.0 109.641 179.11 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.735 HG21 ' CE1' ' A' ' 334' ' ' PHE . 3.4 t -143.52 91.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.67 0 O-C-N 121.46 -0.775 . . . . 0.0 109.717 -179.689 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.904 HG23 ' OG1' ' A' ' 333' ' ' THR . 5.6 m -85.82 123.14 30.85 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.18 -0.95 . . . . 0.0 109.104 179.66 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.076 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.5 OUTLIER -113.89 145.18 41.85 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.148 -0.97 . . . . 0.0 110.467 -179.034 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.904 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.6 OUTLIER -127.15 134.26 50.21 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.446 -0.784 . . . . 0.0 110.021 -179.642 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.904 HD23 ' O ' ' A' ' 285' ' ' ASN . 15.9 mt -142.94 148.66 37.24 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 120.808 -1.183 . . . . 0.0 109.83 179.638 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -85.68 38.7 0.76 Allowed 'General case' 0 C--N 1.297 -1.706 0 O-C-N 121.292 -0.88 . . . . 0.0 109.681 179.593 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.446 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 159.53 -136.42 4.61 Favored Glycine 0 N--CA 1.49 2.273 0 C-N-CA 119.301 -1.428 . . . . 0.0 109.752 -179.928 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.51 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 0.8 OUTLIER -117.82 94.25 4.45 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.192 -1.181 . . . . 0.0 110.815 -179.49 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.616 ' CD2' ' HB3' ' A' ' 286' ' ' LEU . 4.0 m-30 -116.05 137.14 52.38 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.192 -0.943 . . . . 0.0 109.918 179.311 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.782 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.1 m-20 -71.85 97.6 1.84 Allowed 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.104 -0.998 . . . . 0.0 109.287 179.248 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.967 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.9 p-90 -97.1 113.74 25.34 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.236 -0.915 . . . . 0.0 110.663 -179.376 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.898 HG23 ' CG2' ' A' ' 322' ' ' THR . 2.0 m -107.11 117.05 33.03 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.523 -0.735 . . . . 0.0 109.258 179.527 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.739 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.1 t -97.14 111.0 26.1 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.121 -0.987 . . . . 0.0 110.655 -179.247 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.687 ' HA ' HD13 ' A' ' 320' ' ' ILE . 18.7 ttpt -84.68 138.97 32.35 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.258 -0.901 . . . . 0.0 108.933 178.923 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.957 HG22 HG23 ' A' ' 349' ' ' ILE . 85.1 t -136.22 107.11 6.12 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.495 0 O-C-N 120.969 -1.082 . . . . 0.0 110.906 -179.116 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.59 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 8.2 mmtm -69.96 130.72 42.96 Favored 'General case' 0 C--N 1.306 -1.32 0 O-C-N 121.075 -1.016 . . . . 0.0 108.881 179.05 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.997 HD13 ' HA ' ' A' ' 303' ' ' THR . 66.2 mt -87.02 157.9 19.35 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.336 -0.853 . . . . 0.0 111.304 -178.816 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.9 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -59.14 177.89 0.24 Allowed Pre-proline 0 C--N 1.303 -1.438 0 O-C-N 121.764 -0.585 . . . . 0.0 109.803 179.503 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.839 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.3 Cg_endo -69.06 81.0 0.66 Allowed 'Trans proline' 0 C--N 1.305 -1.738 0 O-C-N 123.717 1.377 . . . . 0.0 109.449 179.294 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.05 21.98 6.1 Favored Glycine 0 N--CA 1.488 2.145 0 N-CA-C 108.81 -1.716 . . . . 0.0 108.81 -179.102 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.9 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -104.91 149.77 25.44 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.313 -1.11 . . . . 0.0 110.397 -179.661 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.997 ' HA ' HD13 ' A' ' 298' ' ' LEU . 4.7 p -148.9 145.63 27.53 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.294 -0.879 . . . . 0.0 110.424 179.729 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.786 HG21 HG11 ' A' ' 319' ' ' VAL . 55.5 t -71.64 117.66 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.247 -0.908 . . . . 0.0 110.044 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -97.38 -45.26 2.58 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 -179.97 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 68.1 m -126.15 148.76 49.33 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -1.161 . . . . 0.0 110.843 -179.77 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.513 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 54.0 p90 -162.95 160.03 24.29 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.462 -0.773 . . . . 0.0 109.479 179.473 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.498 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.0 OUTLIER -153.35 162.46 41.26 Favored 'General case' 0 N--CA 1.496 1.843 0 O-C-N 120.835 -1.166 . . . . 0.0 111.172 -179.268 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.513 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.3 OUTLIER 58.19 21.83 8.49 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.585 -0.697 . . . . 0.0 110.963 179.476 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.712 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -173.84 137.76 0.6 Allowed 'General case' 0 C--N 1.297 -1.677 0 O-C-N 121.426 -0.796 . . . . 0.0 110.057 179.622 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.697 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -77.31 124.96 28.57 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.117 -0.989 . . . . 0.0 109.538 179.861 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.757 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -92.2 139.83 30.23 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.719 0.771 . . . . 0.0 110.882 -179.25 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.636 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -122.61 170.5 9.96 Favored 'General case' 0 C--N 1.3 -1.545 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 179.135 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.579 ' HG2' HG22 ' A' ' 319' ' ' VAL . 46.3 mt-10 -141.55 100.98 3.89 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.137 -0.977 . . . . 0.0 110.518 -179.767 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -81.41 -76.68 1.05 Allowed Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.209 -1.557 . . . . 0.0 109.209 179.595 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.57 ' O ' ' CE2' ' A' ' 318' ' ' TYR . 2.8 m120 -163.85 86.79 0.5 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.423 -1.045 . . . . 0.0 109.001 179.553 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.622 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 86.63 14.4 65.6 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.402 -1.879 . . . . 0.0 108.402 -178.57 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.837 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.4 m-85 -146.79 -168.76 3.12 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.836 -0.803 . . . . 0.0 109.096 179.642 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.837 HG23 ' O ' ' A' ' 318' ' ' TYR . 3.8 t -163.85 161.59 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.247 -0.908 . . . . 0.0 109.32 179.177 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.687 HD13 ' HA ' ' A' ' 295' ' ' LYS . 40.6 mm -127.24 144.97 35.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.573 0 O-C-N 121.166 -0.959 . . . . 0.0 111.184 -179.854 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.646 ' CE2' ' CD2' ' A' ' 336' ' ' PHE . 49.2 m-85 -120.55 133.59 55.37 Favored 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.212 -0.93 . . . . 0.0 109.912 179.56 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.898 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.3 p -134.53 167.81 20.95 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 120.852 -1.155 . . . . 0.0 109.881 179.64 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.498 ' HB3' ' O ' ' A' ' 327' ' ' ASN . 42.2 Cg_endo -67.72 115.51 3.78 Favored 'Trans proline' 0 C--N 1.305 -1.737 0 O-C-N 123.858 1.451 . . . . 0.0 110.725 -179.384 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 1.061 HG22 ' HB2' ' A' ' 327' ' ' ASN . 23.0 m -61.18 -135.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.334 -0.854 . . . . 0.0 110.245 -179.88 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.525 ' N ' HG23 ' A' ' 324' ' ' VAL . 2.0 m -90.47 -18.68 24.92 Favored 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.059 -1.026 . . . . 0.0 110.763 -179.475 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.777 ' H ' HG23 ' A' ' 324' ' ' VAL . 27.7 p-90 -132.97 21.56 4.14 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.182 -0.949 . . . . 0.0 110.404 -179.742 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 1.061 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.7 m120 -120.25 38.25 4.02 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.073 -1.017 . . . . 0.0 110.614 -179.365 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.51 ' O ' ' HA ' ' A' ' 289' ' ' GLN . 0.0 OUTLIER -120.06 -4.95 10.04 Favored 'General case' 0 N--CA 1.495 1.775 0 O-C-N 121.184 -0.948 . . . . 0.0 109.889 179.565 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -56.99 -160.64 0.02 OUTLIER Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.719 -1.353 . . . . 0.0 109.719 -179.915 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.519 ' CB ' ' O ' ' A' ' 286' ' ' LEU . 48.1 Cg_endo -74.52 4.09 4.79 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.998 1.526 . . . . 0.0 110.72 -179.868 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.429 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 2.4 m -163.66 117.05 1.51 Allowed 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.19 -0.944 . . . . 0.0 110.048 -179.853 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.473 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -140.12 114.61 9.31 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.162 -0.961 . . . . 0.0 110.357 179.995 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.904 ' OG1' HG23 ' A' ' 283' ' ' THR . 21.7 m -105.15 139.17 40.22 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.23 -0.919 . . . . 0.0 110.022 179.793 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.739 ' HE2' HG21 ' A' ' 294' ' ' VAL . 8.5 p90 -141.57 174.5 10.51 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.349 -0.844 . . . . 0.0 109.019 179.891 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.513 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -151.23 156.33 26.61 Favored Glycine 0 N--CA 1.493 2.472 0 C-N-CA 119.162 -1.494 . . . . 0.0 110.015 -179.525 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.899 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -146.25 144.65 30.0 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.385 -1.068 . . . . 0.0 110.328 179.752 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.899 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -118.71 123.06 70.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.184 -0.948 . . . . 0.0 109.215 179.321 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.82 HG11 ' HB1' ' A' ' 302' ' ' ALA . 4.1 t -96.59 162.11 2.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.225 -0.922 . . . . 0.0 110.699 -179.144 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.507 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 0.7 OUTLIER -126.07 127.38 45.73 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.568 -0.707 . . . . 0.0 109.56 -179.967 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -178.52 -126.94 1.03 Allowed Glycine 0 N--CA 1.49 2.288 0 C-N-CA 119.494 -1.336 . . . . 0.0 110.042 179.977 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.509 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 43.5 Cg_endo -70.75 -174.79 1.18 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 O-C-N 123.921 1.484 . . . . 0.0 110.647 -179.676 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.475 ' NE2' ' C ' ' A' ' 341' ' ' PRO . 6.5 mp0 -104.65 135.34 46.24 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.237 -0.914 . . . . 0.0 110.655 -179.623 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.452 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 109.64 -88.94 0.53 Allowed Glycine 0 N--CA 1.491 2.329 0 N-CA-C 108.919 -1.672 . . . . 0.0 108.919 -179.728 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 85.4 m-20 -113.64 137.5 51.52 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.458 -1.025 . . . . 0.0 108.757 178.948 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.68 ' HA ' ' HB2' ' A' ' 299' ' ' ALA . 2.5 mtmt -129.32 14.43 6.12 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 120.834 -1.166 . . . . 0.0 110.492 -179.461 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.611 HG13 ' O ' ' A' ' 346' ' ' VAL . 11.8 p -136.85 118.35 18.72 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.545 0 O-C-N 121.415 -0.803 . . . . 0.0 110.026 179.272 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.466 ' N ' ' O ' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -50.96 -45.84 60.9 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.348 -0.845 . . . . 0.0 110.38 -179.513 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.436 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.0 pt-20 -176.61 157.84 1.65 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.272 -0.892 . . . . 0.0 110.426 -179.695 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.957 HG23 HG22 ' A' ' 296' ' ' VAL . 64.5 mt -120.59 106.54 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.157 -0.964 . . . . 0.0 110.232 179.644 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -105.82 130.91 53.7 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.497 -0.752 . . . . 0.0 110.286 -179.922 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.076 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -91.3 129.37 37.3 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.101 -0.999 . . . . 0.0 110.241 179.782 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.401 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 2.0 tt0 -138.83 112.69 8.46 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.183 -0.948 . . . . 0.0 109.934 179.81 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.782 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.9 mt -91.4 110.7 22.84 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.498 0 O-C-N 121.065 -1.022 . . . . 0.0 110.165 179.961 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.423 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 38.89 29.25 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.774 -0.578 . . . . 0.0 110.639 179.922 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.461 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 118.59 -21.68 9.7 Favored Glycine 0 N--CA 1.491 2.322 0 N-CA-C 110.135 -1.186 . . . . 0.0 110.135 179.63 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.41 ' O ' ' N ' ' A' ' 353' ' ' ILE . 1.2 mp0 -86.2 112.53 21.43 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.055 -1.262 . . . . 0.0 110.392 -179.755 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.843 ' O ' HD13 ' A' ' 358' ' ' ILE . 14.8 p -74.84 141.63 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.691 0 O-C-N 121.138 -0.976 . . . . 0.0 110.407 179.842 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.843 HD13 ' O ' ' A' ' 357' ' ' VAL . 30.8 mm . . . . . 0 N--CA 1.494 1.755 0 CA-C-O 117.971 -1.014 . . . . 0.0 110.309 179.837 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.304 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.0 Cg_endo -76.73 178.8 7.14 Favored 'Trans proline' 0 C--N 1.305 -1.749 0 O-C-N 123.995 1.523 . . . . 0.0 110.611 -179.931 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.469 HG23 ' O ' ' A' ' 258' ' ' THR . 4.3 t -60.73 128.91 38.87 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.291 -0.881 . . . . 0.0 109.938 179.798 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 25.0 m -61.55 137.24 94.78 Favored Pre-proline 0 N--CA 1.492 1.635 0 O-C-N 121.151 -0.968 . . . . 0.0 110.177 -179.853 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.61 142.0 35.43 Favored 'Trans proline' 0 C--N 1.305 -1.731 0 O-C-N 123.967 1.509 . . . . 0.0 110.365 -179.779 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.733 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.5 p -81.88 147.13 57.52 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.362 -0.836 . . . . 0.0 110.266 -179.883 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.733 ' HD2' HG23 ' A' ' 261' ' ' VAL . 44.7 Cg_endo -71.11 138.18 33.06 Favored 'Trans proline' 0 C--N 1.303 -1.824 0 O-C-N 124.061 1.559 . . . . 0.0 110.035 179.582 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.511 ' O ' ' CB ' ' A' ' 264' ' ' SER . 12.1 t -125.12 28.79 2.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.21 -0.931 . . . . 0.0 110.418 -179.696 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.511 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 3.0 t 169.13 64.64 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.273 -0.892 . . . . 0.0 110.638 179.866 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 136.86 171.25 12.15 Favored Glycine 0 N--CA 1.491 2.301 0 C-N-CA 119.607 -1.282 . . . . 0.0 110.245 179.442 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.581 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -128.52 165.94 19.76 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.617 -0.931 . . . . 0.0 109.664 179.665 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.748 ' HB2' HD12 ' A' ' 351' ' ' LEU . 0.0 OUTLIER -159.43 126.21 4.57 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 120.977 -1.077 . . . . 0.0 111.17 -179.555 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.52 ' N ' ' CD2' ' A' ' 267' ' ' LEU . 0.4 OUTLIER -123.78 118.05 26.3 Favored 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 108.627 -0.879 . . . . 0.0 108.627 178.681 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 281' ' ' ASP . 55.2 t -117.15 142.15 32.38 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 120.851 -1.156 . . . . 0.0 112.14 -178.428 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 7.9 tttm -128.5 157.28 41.59 Favored 'General case' 0 N--CA 1.494 1.727 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 178.969 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.625 HG13 ' O ' ' A' ' 279' ' ' GLU . 86.5 t -144.2 145.42 21.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.606 0 O-C-N 120.367 -1.458 . . . . 0.0 111.947 -179.445 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.527 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.65 113.23 7.71 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.483 179.534 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.514 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 3.6 p30 -95.86 145.76 25.11 Favored 'General case' 0 N--CA 1.494 1.729 0 O-C-N 121.151 -0.968 . . . . 0.0 110.942 -179.016 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.813 ' CH2' HG23 ' A' ' 337' ' ' ILE . 27.9 p90 -127.83 16.04 6.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.369 -0.832 . . . . 0.0 110.305 179.377 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 95.01 -56.11 1.82 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.8 -1.32 . . . . 0.0 109.8 179.483 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 3.6 m -78.53 -17.86 55.56 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.244 -1.151 . . . . 0.0 110.453 -179.678 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.53 ' C ' ' CZ2' ' A' ' 274' ' ' TRP . . . -174.1 177.71 46.24 Favored Glycine 0 N--CA 1.49 2.299 0 C-N-CA 119.35 -1.405 . . . . 0.0 109.922 -179.952 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.561 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -134.65 144.84 48.07 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.329 -1.1 . . . . 0.0 110.066 179.862 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.625 ' O ' HG13 ' A' ' 271' ' ' VAL . 4.2 mt-10 -96.88 147.48 23.91 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.365 -0.835 . . . . 0.0 109.878 -179.441 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD2' ' CE1' ' A' ' 336' ' ' PHE . 92.8 m-85 -139.38 86.43 2.12 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.302 -0.874 . . . . 0.0 110.69 -179.294 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.797 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.6 OUTLIER -69.77 145.65 52.04 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.431 -0.793 . . . . 0.0 109.809 179.317 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 294' ' ' VAL . 3.8 t -139.06 87.55 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.297 -1.704 0 O-C-N 121.577 -0.702 . . . . 0.0 109.452 -179.841 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.542 ' HA ' HG23 ' A' ' 333' ' ' THR . 19.2 m -86.12 117.12 24.75 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.102 -0.999 . . . . 0.0 109.645 -179.886 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.104 HD21 HD11 ' A' ' 351' ' ' LEU . 0.4 OUTLIER -103.05 150.43 23.6 Favored 'General case' 0 C--N 1.302 -1.5 0 O-C-N 121.109 -0.994 . . . . 0.0 110.769 -179.279 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.581 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.2 OUTLIER -133.62 106.63 7.51 Favored 'General case' 0 N--CA 1.494 1.74 0 O-C-N 121.576 -0.702 . . . . 0.0 110.098 -179.324 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.61 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 12.1 mt -113.98 157.16 22.83 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 120.824 -1.172 . . . . 0.0 109.987 179.772 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -88.47 35.16 0.76 Allowed 'General case' 0 C--N 1.298 -1.661 0 O-C-N 121.356 -0.84 . . . . 0.0 110.501 -179.432 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.491 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 159.15 -103.39 0.23 Allowed Glycine 0 N--CA 1.493 2.435 0 C-N-CA 118.878 -1.63 . . . . 0.0 110.423 179.855 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.443 ' HG3' ' O ' ' A' ' 328' ' ' LYS . 3.0 tt0 -149.95 111.06 4.37 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.053 -1.263 . . . . 0.0 110.705 -179.252 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.61 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 2.4 m-85 -140.14 138.54 35.31 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.405 -0.809 . . . . 0.0 109.866 179.542 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.694 ' O ' HG23 ' A' ' 353' ' ' ILE . 29.5 m-20 -64.92 97.09 0.21 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.102 -0.999 . . . . 0.0 109.294 179.349 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.884 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.5 p-90 -96.41 110.71 23.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.262 -0.899 . . . . 0.0 110.67 -179.502 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.669 HG22 ' CG2' ' A' ' 320' ' ' ILE . 5.5 m -102.81 114.94 29.62 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.518 -0.739 . . . . 0.0 109.314 179.459 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.805 HG11 HG11 ' A' ' 282' ' ' VAL . 4.5 t -96.18 113.08 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.102 -0.999 . . . . 0.0 110.007 -179.547 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.699 ' HA ' HD13 ' A' ' 320' ' ' ILE . 12.9 ttpt -89.73 149.47 22.73 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.527 -0.733 . . . . 0.0 109.184 179.657 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.793 HG13 HD13 ' A' ' 349' ' ' ILE . 77.4 t -148.16 109.33 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 O-C-N 121.005 -1.059 . . . . 0.0 110.763 -179.327 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.581 ' O ' HG23 ' A' ' 346' ' ' VAL . 9.0 mmtt -71.81 135.03 46.51 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.102 -0.999 . . . . 0.0 109.324 179.369 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.919 HD13 ' HA ' ' A' ' 303' ' ' THR . 89.6 mt -86.11 167.13 15.23 Favored 'General case' 0 N--CA 1.495 1.789 0 O-C-N 121.28 -0.888 . . . . 0.0 111.755 -178.75 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.787 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -72.18 176.17 2.56 Favored Pre-proline 0 N--CA 1.491 1.576 0 O-C-N 121.672 -0.643 . . . . 0.0 109.353 179.068 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.787 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 42.9 Cg_endo -69.3 80.3 0.76 Allowed 'Trans proline' 0 C--N 1.306 -1.709 0 O-C-N 123.554 1.291 . . . . 0.0 109.918 179.564 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.41 23.45 4.79 Favored Glycine 0 N--CA 1.488 2.163 0 N-CA-C 108.985 -1.646 . . . . 0.0 108.985 -179.446 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.913 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -111.7 150.4 30.26 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.373 -1.075 . . . . 0.0 110.401 -179.558 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.919 ' HA ' HD13 ' A' ' 298' ' ' LEU . 77.3 p -150.43 144.14 25.23 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 121.286 -0.884 . . . . 0.0 110.471 179.708 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.846 HG21 HG11 ' A' ' 319' ' ' VAL . 55.2 t -64.81 133.32 30.38 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.325 -0.859 . . . . 0.0 110.16 179.69 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.2 -37.6 1.48 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.831 -1.308 . . . . 0.0 109.831 -179.843 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -141.41 138.22 32.8 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.182 -1.187 . . . . 0.0 110.768 -179.681 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.529 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 48.1 p90 -147.11 163.78 35.2 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.326 -0.858 . . . . 0.0 109.776 179.486 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.464 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -155.47 158.2 38.17 Favored 'General case' 0 N--CA 1.496 1.859 0 O-C-N 120.941 -1.099 . . . . 0.0 111.554 -179.434 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.518 ' HB3' ' O ' ' A' ' 333' ' ' THR . 0.1 OUTLIER 62.52 21.6 12.74 Favored 'General case' 0 N--CA 1.495 1.824 0 O-C-N 121.719 -0.613 . . . . 0.0 110.818 179.479 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.638 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.7 143.6 0.78 Allowed 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.465 -0.772 . . . . 0.0 109.956 179.538 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.546 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -79.33 119.71 22.76 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.045 -1.035 . . . . 0.0 109.351 179.579 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.596 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.9 ttpt -86.2 140.33 30.25 Favored 'General case' 0 N--CA 1.49 1.554 0 CA-C-O 121.767 0.794 . . . . 0.0 110.59 -179.612 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.661 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -125.13 173.2 8.9 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 179.423 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 5.5 mt-10 -136.7 112.7 9.66 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.385 -0.822 . . . . 0.0 110.167 179.926 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . -102.73 43.56 1.66 Allowed Glycine 0 N--CA 1.491 2.328 0 N-CA-C 109.535 -1.426 . . . . 0.0 109.535 -179.87 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER 57.75 80.15 0.18 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.354 -1.086 . . . . 0.0 110.395 179.976 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.592 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 99.39 -1.02 57.12 Favored Glycine 0 N--CA 1.492 2.394 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 179.64 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.826 ' O ' HG23 ' A' ' 319' ' ' VAL . 2.1 m-85 -142.55 -170.1 3.13 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 121.377 -1.072 . . . . 0.0 109.472 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.846 HG11 HG21 ' A' ' 304' ' ' VAL . 3.9 t -162.81 156.12 2.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.755 0 O-C-N 121.177 -0.952 . . . . 0.0 109.922 179.2 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.699 HD13 ' HA ' ' A' ' 295' ' ' LYS . 37.2 mm -125.65 151.78 32.0 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.114 -0.991 . . . . 0.0 111.294 -179.462 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.636 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 78.5 m-85 -129.54 126.49 38.7 Favored 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.166 -0.959 . . . . 0.0 110.408 179.421 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.604 ' CG2' HG23 ' A' ' 293' ' ' THR . 6.4 p -126.5 167.56 16.91 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 120.919 -1.113 . . . . 0.0 109.579 179.195 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.504 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 39.4 Cg_endo -65.15 119.93 7.05 Favored 'Trans proline' 0 C--N 1.307 -1.621 0 O-C-N 123.76 1.4 . . . . 0.0 111.225 -179.164 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.723 HG22 ' HB2' ' A' ' 327' ' ' ASN . 12.4 m -63.74 -111.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.439 -0.788 . . . . 0.0 110.166 179.987 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.482 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.1 OUTLIER -111.67 -23.32 10.72 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.697 -1.252 . . . . 0.0 110.534 -179.811 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . . . . . . . . . 3.9 p-90 -125.73 1.49 7.47 Favored 'General case' 0 N--CA 1.495 1.785 0 O-C-N 121.162 -0.961 . . . . 0.0 110.539 -179.874 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.723 ' HB2' HG22 ' A' ' 324' ' ' VAL . 0.2 OUTLIER -99.91 40.97 1.19 Allowed 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.233 -0.917 . . . . 0.0 110.38 -179.69 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.458 ' O ' ' O ' ' A' ' 329' ' ' GLY . 0.0 OUTLIER -120.05 -8.4 9.77 Favored 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.25 -0.907 . . . . 0.0 109.532 179.736 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -57.89 -159.06 0.02 OUTLIER Glycine 0 N--CA 1.49 2.245 0 N-CA-C 109.439 -1.464 . . . . 0.0 109.439 179.939 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.525 ' O ' ' N ' ' A' ' 286' ' ' LEU . 46.1 Cg_endo -74.76 5.75 3.69 Favored 'Trans proline' 0 C--N 1.308 -1.6 0 O-C-N 123.978 1.515 . . . . 0.0 110.821 -179.899 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.428 ' OG1' ' C ' ' A' ' 330' ' ' PRO . 3.1 m -163.14 121.23 1.98 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.959 -1.088 . . . . 0.0 109.897 179.936 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.442 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -140.61 113.75 8.46 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.168 -0.957 . . . . 0.0 110.26 -179.776 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.542 HG23 ' HA ' ' A' ' 283' ' ' THR . 11.8 m -103.04 133.42 48.19 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.392 -0.817 . . . . 0.0 110.364 -179.739 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.8 ' HE2' HG21 ' A' ' 294' ' ' VAL . 15.0 p90 -141.77 164.6 29.75 Favored 'General case' 0 N--CA 1.49 1.562 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.379 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.529 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -144.24 158.27 27.41 Favored Glycine 0 N--CA 1.49 2.274 0 C-N-CA 118.843 -1.646 . . . . 0.0 110.32 -179.397 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.926 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.4 p90 -144.01 147.65 34.17 Favored 'General case' 0 C--N 1.304 -1.388 0 O-C-N 121.556 -0.967 . . . . 0.0 109.882 179.417 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.926 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.74 122.81 68.88 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 120.992 -1.068 . . . . 0.0 110.048 -179.969 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.913 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.9 t -97.07 157.28 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.286 -0.884 . . . . 0.0 109.999 179.712 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.498 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -125.85 131.32 52.42 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.355 -0.84 . . . . 0.0 110.396 -179.575 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . -179.84 -122.09 0.76 Allowed Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 179.851 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.547 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 41.2 Cg_endo -67.59 -158.28 0.04 OUTLIER 'Trans proline' 0 C--N 1.308 -1.57 0 O-C-N 123.864 1.455 . . . . 0.0 110.625 179.632 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.557 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -125.39 126.58 45.23 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.11 -0.994 . . . . 0.0 110.628 -179.467 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . . . . . . . . . . . 113.81 -71.61 0.23 Allowed Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.136 -1.586 . . . . 0.0 109.136 179.941 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 2.5 t0 -123.62 141.44 52.01 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.329 -1.101 . . . . 0.0 109.045 179.306 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.74 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.3 mtmt -141.68 10.25 2.02 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.83 -1.169 . . . . 0.0 111.234 -179.369 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.641 HG11 ' CE1' ' A' ' 280' ' ' TYR . 9.0 p -132.2 125.51 54.42 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 121.022 -1.049 . . . . 0.0 110.412 179.231 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.547 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 3.8 mt-10 -53.08 -45.74 68.29 Favored 'General case' 0 N--CA 1.487 1.415 0 O-C-N 121.313 -0.867 . . . . 0.0 110.149 -179.868 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.454 ' HG2' ' HB2' ' A' ' 297' ' ' LYS . 1.8 pt-20 -177.55 158.63 1.4 Allowed 'General case' 0 N--CA 1.493 1.724 0 C-N-CA 119.362 -0.935 . . . . 0.0 111.185 -179.704 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.793 HD13 HG13 ' A' ' 296' ' ' VAL . 3.5 mm -109.13 122.58 64.0 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.656 0 O-C-N 121.603 -0.686 . . . . 0.0 109.709 179.419 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -123.42 141.76 51.67 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 121.068 -1.02 . . . . 0.0 110.33 179.859 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.104 HD11 HD21 ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.68 126.84 52.62 Favored 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 109.952 179.633 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.457 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 11.5 tt0 -138.99 113.8 9.21 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.011 -1.056 . . . . 0.0 110.643 179.92 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.694 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -92.97 112.14 25.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.527 0 O-C-N 121.154 -0.966 . . . . 0.0 109.913 179.522 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.533 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 41.74 34.11 0.38 Allowed 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.492 -0.755 . . . . 0.0 110.113 -179.579 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 108.9 -25.12 19.89 Favored Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 -179.933 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.471 ' N ' ' CD ' ' A' ' 356' ' ' GLN . 3.2 mp0 -77.41 106.07 8.94 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.223 -1.163 . . . . 0.0 110.523 -179.834 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.622 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.5 p -70.92 120.93 19.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 121.259 -0.901 . . . . 0.0 110.184 179.719 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.514 ' HB ' HD13 ' A' ' 351' ' ' LEU . 35.5 mm . . . . . 0 N--CA 1.493 1.693 0 CA-C-O 118.069 -0.967 . . . . 0.0 110.009 179.777 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.426 0 N-CA-C 109.527 -1.429 . . . . 0.0 109.527 . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -72.87 -178.38 3.46 Favored 'Trans proline' 0 C--N 1.306 -1.696 0 O-C-N 123.879 1.463 . . . . 0.0 110.545 -179.981 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.437 HG23 ' O ' ' A' ' 258' ' ' THR . 5.1 t -68.26 131.85 46.09 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.426 -0.797 . . . . 0.0 110.61 -179.805 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 10.1 p -133.44 111.1 12.66 Favored Pre-proline 0 N--CA 1.491 1.618 0 O-C-N 121.223 -0.923 . . . . 0.0 110.141 179.813 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.8 Cg_endo -71.83 154.31 58.69 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.998 1.526 . . . . 0.0 110.254 179.672 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.563 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -89.7 141.59 28.59 Favored Pre-proline 0 N--CA 1.494 1.73 0 O-C-N 121.228 -0.92 . . . . 0.0 110.496 -179.833 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.563 ' HD2' HG23 ' A' ' 261' ' ' VAL . 48.7 Cg_endo -75.39 133.57 16.16 Favored 'Trans proline' 0 C--N 1.305 -1.759 0 O-C-N 124.094 1.576 . . . . 0.0 110.14 179.785 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . . . . . . . . . 2.8 t -115.64 29.06 2.57 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.108 -0.995 . . . . 0.0 110.222 -179.721 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -176.11 118.1 0.14 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.168 -0.958 . . . . 0.0 110.799 179.923 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 73.29 -173.42 48.86 Favored Glycine 0 N--CA 1.489 2.189 0 N-CA-C 110.198 -1.161 . . . . 0.0 110.198 179.365 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.54 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -139.79 169.35 17.87 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.585 -0.95 . . . . 0.0 109.33 179.909 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.904 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.38 134.49 6.34 Favored 'General case' 0 C--N 1.303 -1.444 0 C-N-CA 118.837 -1.145 . . . . 0.0 111.36 -179.993 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.777 ' N ' HD22 ' A' ' 267' ' ' LEU . 8.4 mm-40 -133.96 138.46 45.47 Favored 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 179.294 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.706 HG13 ' O ' ' A' ' 281' ' ' ASP . 59.4 t -131.35 142.0 44.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.492 0 O-C-N 120.858 -1.151 . . . . 0.0 111.753 -178.846 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -127.17 156.99 40.93 Favored 'General case' 0 N--CA 1.493 1.7 0 N-CA-C 108.572 -0.899 . . . . 0.0 108.572 178.771 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.641 HG13 ' O ' ' A' ' 279' ' ' GLU . 69.3 t -144.81 147.07 19.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 120.401 -1.437 . . . . 0.0 112.344 -179.258 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.514 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -143.18 113.91 7.57 Favored 'General case' 0 N--CA 1.489 1.477 0 N-CA-C 108.876 -0.787 . . . . 0.0 108.876 178.669 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.474 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 1.6 m-20 -100.07 142.87 30.96 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 120.872 -1.142 . . . . 0.0 111.205 -178.538 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.8 ' CH2' HG23 ' A' ' 337' ' ' ILE . 26.8 p90 -122.77 20.1 10.17 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 121.576 -0.703 . . . . 0.0 109.475 179.451 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.536 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 84.44 -58.32 5.0 Favored Glycine 0 N--CA 1.49 2.267 0 N-CA-C 109.294 -1.522 . . . . 0.0 109.294 -179.744 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.484 ' OG ' ' NE1' ' A' ' 274' ' ' TRP . 0.3 OUTLIER -66.87 -19.34 65.71 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.25 -1.147 . . . . 0.0 110.216 179.793 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.553 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -172.93 -172.69 38.79 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.915 -1.274 . . . . 0.0 109.915 179.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.597 ' O ' ' HA ' ' A' ' 337' ' ' ILE . . . -143.69 136.89 27.77 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.292 -1.122 . . . . 0.0 109.894 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.641 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.2 mt-10 -95.93 146.4 24.62 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.245 -0.909 . . . . 0.0 110.446 -179.447 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.662 ' CG ' ' CZ ' ' A' ' 336' ' ' PHE . 83.1 m-85 -140.01 86.36 2.08 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.378 -0.826 . . . . 0.0 110.766 -179.699 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.706 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.8 OUTLIER -66.54 143.64 56.93 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.305 -0.872 . . . . 0.0 109.428 179.155 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.811 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 5.4 t -138.35 89.36 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.574 0 O-C-N 121.191 -0.943 . . . . 0.0 110.014 -179.925 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.463 ' HA ' HG23 ' A' ' 333' ' ' THR . 87.4 m -86.76 126.96 34.94 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.181 -0.949 . . . . 0.0 109.568 179.799 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -114.81 147.08 40.31 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.291 -0.881 . . . . 0.0 110.77 -179.204 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.91 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.6 OUTLIER -125.3 135.21 52.25 Favored 'General case' 0 N--CA 1.495 1.814 0 O-C-N 121.35 -0.844 . . . . 0.0 110.467 -179.453 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.91 HD23 ' O ' ' A' ' 285' ' ' ASN . 10.3 mt -144.77 161.69 38.61 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.731 -1.23 . . . . 0.0 109.595 179.8 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -95.09 37.47 1.16 Allowed 'General case' 0 C--N 1.299 -1.625 0 O-C-N 121.255 -0.903 . . . . 0.0 109.776 179.733 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.473 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 148.55 -129.89 3.25 Favored Glycine 0 N--CA 1.491 2.366 0 C-N-CA 119.33 -1.414 . . . . 0.0 109.973 -179.68 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.546 ' C ' ' CD1' ' A' ' 290' ' ' TYR . 3.1 mm-40 -108.3 114.06 27.62 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.891 -1.358 . . . . 0.0 111.132 -179.326 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.721 ' HB2' HD13 ' A' ' 286' ' ' LEU . 6.3 m-85 -134.43 133.09 40.12 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.444 -0.785 . . . . 0.0 109.234 179.205 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.84 ' O ' HG23 ' A' ' 353' ' ' ILE . 1.1 m-20 -73.5 96.26 2.38 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 120.808 -1.183 . . . . 0.0 108.857 179.236 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.903 ' CE3' HD13 ' A' ' 284' ' ' LEU . 64.2 p-90 -98.98 117.47 33.56 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.272 -0.893 . . . . 0.0 110.996 -179.038 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 1.067 HG23 HG22 ' A' ' 322' ' ' THR . 17.3 m -112.68 113.98 26.37 Favored 'General case' 0 C--N 1.302 -1.485 0 N-CA-C 109.301 -0.629 . . . . 0.0 109.301 179.425 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.787 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.2 t -96.68 110.92 25.68 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.058 -1.026 . . . . 0.0 110.265 -179.43 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.537 ' HE2' ' CD1' ' A' ' 320' ' ' ILE . 17.6 ttmt -89.51 148.21 23.54 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.381 -0.825 . . . . 0.0 109.187 179.144 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.811 HG13 HG12 ' A' ' 349' ' ' ILE . 71.3 t -144.26 111.66 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.627 0 O-C-N 121.126 -0.984 . . . . 0.0 110.204 -179.666 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.507 ' O ' ' N ' ' A' ' 347' ' ' GLU . 72.6 mmtt -70.24 135.44 49.01 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.219 -0.926 . . . . 0.0 109.154 179.653 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 1.027 HD13 ' HA ' ' A' ' 303' ' ' THR . 93.9 mt -89.84 155.59 19.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.316 -0.865 . . . . 0.0 111.447 -178.851 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.781 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -59.4 173.86 0.46 Allowed Pre-proline 0 N--CA 1.487 1.378 0 O-C-N 121.493 -0.755 . . . . 0.0 109.086 179.134 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.695 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.7 Cg_endo -69.23 79.33 0.78 Allowed 'Trans proline' 0 C--N 1.302 -1.913 0 O-C-N 123.608 1.32 . . . . 0.0 109.874 179.747 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 116.93 20.15 4.99 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.918 -1.673 . . . . 0.0 108.918 -179.425 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.781 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -109.99 148.39 31.74 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.407 -1.055 . . . . 0.0 109.859 -179.884 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 1.027 ' HA ' HD13 ' A' ' 298' ' ' LEU . 19.8 p -147.52 146.15 29.36 Favored 'General case' 0 N--CA 1.497 1.896 0 O-C-N 120.953 -1.092 . . . . 0.0 111.247 -179.747 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.746 ' CG2' HG21 ' A' ' 319' ' ' VAL . 53.7 t -69.28 129.02 33.6 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.7 0 O-C-N 121.287 -0.883 . . . . 0.0 109.821 179.542 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -112.66 -40.22 1.13 Allowed Glycine 0 N--CA 1.491 2.338 0 C-N-CA 119.73 -1.224 . . . . 0.0 110.201 -179.466 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -126.96 129.65 48.55 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 120.998 -1.295 . . . . 0.0 110.686 -179.463 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.552 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.6 p90 -145.44 162.02 38.32 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.36 -0.837 . . . . 0.0 109.823 179.59 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.503 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -158.16 156.09 30.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 120.927 -1.108 . . . . 0.0 111.171 -179.579 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.538 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.6 OUTLIER 63.5 24.31 14.02 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.575 -0.703 . . . . 0.0 110.941 179.598 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.542 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.18 146.1 1.1 Allowed 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.248 -0.908 . . . . 0.0 110.497 179.474 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.496 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.0 m-80 -77.31 123.46 26.51 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.197 -0.939 . . . . 0.0 109.408 179.375 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.552 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 12.0 ttpt -93.03 121.94 34.88 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.5 -0.75 . . . . 0.0 111.025 -179.448 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.597 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 1.6 tt0 -109.86 175.13 5.56 Favored 'General case' 0 C--N 1.299 -1.624 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.324 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 24.2 mt-10 -138.17 101.99 4.55 Favored 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.347 -0.846 . . . . 0.0 110.12 179.773 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.451 ' O ' ' HB2' ' A' ' 316' ' ' ASN . . . -90.11 37.05 3.41 Favored Glycine 0 N--CA 1.493 2.45 0 N-CA-C 109.633 -1.387 . . . . 0.0 109.633 -179.868 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . 0.488 ' ND2' ' N ' ' A' ' 316' ' ' ASN . 2.2 m120 63.78 88.79 0.1 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.215 -1.168 . . . . 0.0 110.266 179.956 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.611 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 91.08 3.07 70.47 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.832 -1.307 . . . . 0.0 109.832 179.729 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.751 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.34 -169.38 3.25 Favored 'General case' 0 N--CA 1.494 1.728 0 O-C-N 121.376 -1.073 . . . . 0.0 109.338 179.491 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.751 HG23 ' O ' ' A' ' 318' ' ' TYR . 22.6 t -160.8 161.08 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 O-C-N 121.119 -0.988 . . . . 0.0 109.97 178.964 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.597 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 4.4 mm -126.55 152.33 34.08 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.968 0 O-C-N 121.133 -0.98 . . . . 0.0 110.93 -179.378 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.65 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 79.2 m-85 -131.76 112.48 12.55 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.232 -0.918 . . . . 0.0 109.888 178.791 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 1.067 HG22 HG23 ' A' ' 293' ' ' THR . 6.5 p -115.67 170.28 5.86 Favored Pre-proline 0 N--CA 1.494 1.758 0 O-C-N 120.725 -1.234 . . . . 0.0 109.529 179.561 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.577 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 41.0 Cg_endo -67.24 120.62 7.69 Favored 'Trans proline' 0 C--N 1.31 -1.476 0 O-C-N 123.495 1.261 . . . . 0.0 110.943 -179.199 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.727 HG22 ' HB2' ' A' ' 327' ' ' ASN . 30.7 m -68.24 -123.47 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.488 -0.757 . . . . 0.0 110.143 -179.922 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.481 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.0 OUTLIER -104.74 -18.1 14.39 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 120.776 -1.202 . . . . 0.0 110.67 -179.734 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.591 ' H ' HG23 ' A' ' 324' ' ' VAL . 19.7 p-90 -126.73 3.53 6.73 Favored 'General case' 0 N--CA 1.496 1.847 0 O-C-N 120.93 -1.106 . . . . 0.0 110.539 -179.994 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.727 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.6 t30 -110.92 34.76 3.83 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.141 -0.975 . . . . 0.0 110.646 -179.429 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.531 ' CG ' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -114.22 2.8 14.94 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.158 -0.964 . . . . 0.0 109.636 179.54 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.473 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -68.85 -153.4 0.58 Allowed Glycine 0 N--CA 1.487 2.075 0 N-CA-C 109.142 -1.583 . . . . 0.0 109.142 179.888 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.545 ' O ' ' N ' ' A' ' 286' ' ' LEU . 42.9 Cg_endo -69.24 -50.45 0.52 Allowed 'Trans proline' 0 C--N 1.305 -1.752 0 O-C-N 123.906 1.477 . . . . 0.0 109.863 179.974 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -110.56 116.66 31.75 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.358 -0.839 . . . . 0.0 110.34 179.779 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.475 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -130.34 113.62 14.6 Favored 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.271 -0.893 . . . . 0.0 109.98 179.947 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.463 HG23 ' HA ' ' A' ' 283' ' ' THR . 57.2 m -105.73 149.84 26.05 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.175 -0.953 . . . . 0.0 110.37 -179.966 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.811 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 8.3 p90 -154.73 170.74 20.88 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.408 -0.808 . . . . 0.0 108.905 179.67 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.542 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -150.71 149.73 21.62 Favored Glycine 0 N--CA 1.491 2.363 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.057 -179.3 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.92 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -136.15 147.98 47.98 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.496 -1.002 . . . . 0.0 110.019 179.573 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.92 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.6 mp -120.65 122.49 68.1 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 120.997 -1.065 . . . . 0.0 109.925 179.501 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.729 HG21 ' CD2' ' A' ' 298' ' ' LEU . 2.1 t -96.55 150.23 4.49 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.592 0 O-C-N 121.082 -1.011 . . . . 0.0 110.003 -179.968 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . . . . . . . . . 2.0 m-80 -119.1 132.36 56.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.437 -0.789 . . . . 0.0 109.946 -179.947 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.462 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . 178.57 -149.38 8.94 Favored Glycine 0 N--CA 1.489 2.177 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 -179.997 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.499 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 47.3 Cg_endo -76.52 116.77 4.38 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 124.071 1.564 . . . . 0.0 110.735 179.894 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.536 ' HB3' ' HA2' ' A' ' 275' ' ' GLY . 0.1 OUTLIER -37.41 158.49 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.502 -0.748 . . . . 0.0 110.99 -179.887 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.489 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 94.86 60.55 1.07 Allowed Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.179 -1.568 . . . . 0.0 109.179 -179.89 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.489 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 39.2 m-20 59.27 127.61 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.567 -0.961 . . . . 0.0 109.629 -179.406 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.691 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.5 OUTLIER -128.3 24.15 5.92 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.767 -1.208 . . . . 0.0 110.575 -179.681 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.628 HG21 ' CG1' ' A' ' 296' ' ' VAL . 14.5 p -130.02 126.74 62.57 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 O-C-N 121.386 -0.821 . . . . 0.0 109.667 179.106 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.507 ' N ' ' O ' ' A' ' 297' ' ' LYS . 2.1 mt-10 -62.85 -38.43 90.78 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.276 -0.89 . . . . 0.0 111.106 -179.072 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.457 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 4.7 pt-20 -176.86 158.9 1.68 Allowed 'General case' 0 N--CA 1.493 1.685 0 O-C-N 120.896 -1.127 . . . . 0.0 110.897 -179.479 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.811 HG12 HG13 ' A' ' 296' ' ' VAL . 14.7 mt -123.42 103.52 13.03 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.143 -0.973 . . . . 0.0 110.03 179.627 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -106.0 145.58 31.18 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.306 -0.871 . . . . 0.0 110.192 -179.787 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.0 OUTLIER -111.07 128.36 55.85 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.104 -0.997 . . . . 0.0 110.308 179.693 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.461 ' HA ' ' HA ' ' A' ' 357' ' ' VAL . 13.9 tt0 -138.61 120.86 15.85 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.168 -0.958 . . . . 0.0 109.875 179.689 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.84 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.0 OUTLIER -90.81 93.82 4.57 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.092 -1.005 . . . . 0.0 110.026 -179.99 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.553 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 46.34 26.38 0.47 Allowed 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.909 -0.495 . . . . 0.0 110.797 179.923 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 135.66 -29.66 2.85 Favored Glycine 0 N--CA 1.492 2.385 0 C-N-CA 119.658 -1.258 . . . . 0.0 110.658 179.398 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.485 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 58.7 mm-40 -89.06 110.18 20.93 Favored 'General case' 0 N--CA 1.494 1.746 0 O-C-N 120.911 -1.347 . . . . 0.0 110.65 -179.442 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.858 ' O ' HD13 ' A' ' 358' ' ' ILE . 13.9 p -74.13 140.36 17.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.626 0 O-C-N 121.255 -0.903 . . . . 0.0 109.917 179.408 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.858 HD13 ' O ' ' A' ' 357' ' ' VAL . 9.7 mm . . . . . 0 N--CA 1.491 1.621 0 O-C-N 121.114 -0.991 . . . . 0.0 110.234 -179.752 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 N-CA-C 109.66 -1.376 . . . . 0.0 109.66 . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -74.57 -178.42 4.02 Favored 'Trans proline' 0 C--N 1.306 -1.706 0 O-C-N 124.073 1.565 . . . . 0.0 110.48 179.993 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 11.9 t -60.04 142.03 54.7 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.394 -0.816 . . . . 0.0 110.309 179.836 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 96.6 m -121.99 133.29 24.26 Favored Pre-proline 0 N--CA 1.49 1.574 0 O-C-N 121.229 -0.919 . . . . 0.0 110.22 179.88 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -73.33 145.52 38.58 Favored 'Trans proline' 0 C--N 1.305 -1.734 0 O-C-N 123.968 1.51 . . . . 0.0 110.364 179.83 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.726 HG23 ' HD2' ' A' ' 262' ' ' PRO . 4.1 p -86.58 146.83 42.5 Favored Pre-proline 0 N--CA 1.49 1.57 0 O-C-N 121.279 -0.888 . . . . 0.0 110.125 -179.985 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.726 ' HD2' HG23 ' A' ' 261' ' ' VAL . 46.6 Cg_endo -73.57 150.23 45.32 Favored 'Trans proline' 0 C--N 1.303 -1.86 0 O-C-N 124.153 1.607 . . . . 0.0 110.065 179.681 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.714 HG12 ' O ' ' A' ' 263' ' ' VAL . 90.3 t -122.51 30.03 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.262 -0.899 . . . . 0.0 110.301 -179.863 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.411 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 0.4 OUTLIER 179.83 139.73 0.12 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.268 -0.895 . . . . 0.0 110.558 -179.99 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 59.9 -172.56 5.31 Favored Glycine 0 N--CA 1.491 2.363 0 N-CA-C 110.049 -1.22 . . . . 0.0 110.049 179.635 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.542 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.2 OUTLIER -139.43 164.69 29.19 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.402 -1.057 . . . . 0.0 109.841 179.933 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.858 HD22 ' N ' ' A' ' 268' ' ' GLU . 1.6 tm? -161.04 135.37 7.13 Favored 'General case' 0 N--CA 1.487 1.42 0 C-N-CA 119.152 -1.019 . . . . 0.0 111.124 -179.436 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.858 ' N ' HD22 ' A' ' 267' ' ' LEU . 1.4 mt-10 -132.31 144.25 50.44 Favored 'General case' 0 N--CA 1.49 1.575 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 179.175 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.795 HG13 ' O ' ' A' ' 281' ' ' ASP . 49.9 t -135.58 140.95 43.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 120.689 -1.257 . . . . 0.0 111.642 -179.205 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.47 156.7 41.72 Favored 'General case' 0 N--CA 1.496 1.828 0 N-CA-C 108.549 -0.908 . . . . 0.0 108.549 178.734 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.761 HG13 ' O ' ' A' ' 279' ' ' GLU . 94.4 t -143.31 146.93 20.86 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 120.391 -1.443 . . . . 0.0 112.162 -179.338 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.534 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.94 113.8 8.79 Favored 'General case' 0 N--CA 1.491 1.612 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 179.084 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.471 ' OD2' ' O ' ' A' ' 343' ' ' GLY . 2.3 m-20 -97.52 148.84 22.83 Favored 'General case' 0 N--CA 1.494 1.735 0 O-C-N 121.002 -1.061 . . . . 0.0 111.339 -178.818 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.814 ' CH2' HG23 ' A' ' 337' ' ' ILE . 34.1 p90 -133.74 17.68 3.9 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.487 -0.758 . . . . 0.0 109.942 179.417 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . . . . . . . . . . . 89.37 -57.04 3.9 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 179.711 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -72.78 -17.12 61.61 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.221 -1.164 . . . . 0.0 110.226 -179.827 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.543 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -178.14 -178.04 47.31 Favored Glycine 0 N--CA 1.489 2.215 0 C-N-CA 119.49 -1.338 . . . . 0.0 109.981 179.876 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.528 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -138.35 141.23 39.71 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.388 -1.066 . . . . 0.0 110.125 -179.898 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.761 ' O ' HG13 ' A' ' 271' ' ' VAL . 7.8 mt-10 -93.01 147.21 23.03 Favored 'General case' 0 N--CA 1.487 1.393 0 O-C-N 121.294 -0.879 . . . . 0.0 110.0 -179.838 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.693 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 92.6 m-85 -139.13 84.54 2.01 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.406 -0.809 . . . . 0.0 110.444 -179.581 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.795 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -66.26 150.68 48.44 Favored 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.525 -0.734 . . . . 0.0 109.736 179.419 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.767 HG11 HG11 ' A' ' 294' ' ' VAL . 3.2 t -146.47 89.37 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.502 0 O-C-N 121.392 -0.818 . . . . 0.0 110.019 -179.555 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.862 HG23 ' OG1' ' A' ' 333' ' ' THR . 26.2 m -86.04 126.15 33.95 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.265 -0.897 . . . . 0.0 109.342 179.601 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.097 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -113.12 152.18 29.93 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.119 -0.988 . . . . 0.0 110.929 -178.894 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.898 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.5 OUTLIER -131.39 134.73 46.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.524 -0.735 . . . . 0.0 109.958 -179.731 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.954 HD13 ' HB2' ' A' ' 290' ' ' TYR . 17.2 mt -142.72 162.04 36.51 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 120.871 -1.143 . . . . 0.0 110.332 -179.846 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -87.68 34.94 0.71 Allowed 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.29 -0.881 . . . . 0.0 109.984 179.731 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.45 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 144.98 -128.08 3.08 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.638 -1.385 . . . . 0.0 109.638 -179.825 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.48 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 2.6 mm-40 -106.25 108.0 19.28 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.033 -1.275 . . . . 0.0 110.969 -179.621 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.954 ' HB2' HD13 ' A' ' 286' ' ' LEU . 8.4 m-85 -127.02 134.76 50.26 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.336 -0.853 . . . . 0.0 109.493 179.523 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.864 ' O ' HG23 ' A' ' 353' ' ' ILE . 2.0 t70 -73.85 96.37 2.58 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 120.808 -1.183 . . . . 0.0 108.785 179.02 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.864 ' CE3' HD13 ' A' ' 284' ' ' LEU . 56.0 p-90 -98.66 109.26 22.04 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.186 -0.946 . . . . 0.0 111.36 -178.853 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.837 HG22 ' CG2' ' A' ' 320' ' ' ILE . 2.8 m -100.82 115.65 30.83 Favored 'General case' 0 N--CA 1.49 1.538 0 N-CA-C 108.959 -0.756 . . . . 0.0 108.959 178.769 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.874 HG21 ' HE2' ' A' ' 334' ' ' PHE . 6.6 t -96.59 111.01 25.79 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.579 0 O-C-N 121.132 -0.98 . . . . 0.0 110.83 -179.006 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.439 ' HB3' ' HE3' ' A' ' 295' ' ' LYS . 2.9 ttpp -87.87 145.32 26.12 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.459 -0.776 . . . . 0.0 109.346 179.118 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.829 HG13 HG12 ' A' ' 349' ' ' ILE . 84.6 t -145.4 107.94 0.86 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.153 -0.967 . . . . 0.0 110.452 -179.439 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.584 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 3.1 mmtt -70.33 133.06 46.58 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.194 -0.941 . . . . 0.0 109.773 179.806 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.947 HD13 ' HA ' ' A' ' 303' ' ' THR . 72.4 mt -87.43 157.83 19.13 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.441 -0.787 . . . . 0.0 111.731 -178.735 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.822 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -64.95 176.95 0.68 Allowed Pre-proline 0 N--CA 1.488 1.461 0 O-C-N 121.6 -0.688 . . . . 0.0 109.571 179.237 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.822 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 41.6 Cg_endo -68.1 82.47 0.48 Allowed 'Trans proline' 0 C--N 1.307 -1.657 0 O-C-N 123.62 1.327 . . . . 0.0 110.001 179.628 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.7 22.62 5.96 Favored Glycine 0 N--CA 1.487 2.095 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 -179.38 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.891 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -110.48 144.7 38.89 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 121.357 -1.084 . . . . 0.0 110.227 -179.747 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.947 ' HA ' HD13 ' A' ' 298' ' ' LEU . 17.5 p -147.57 146.12 29.29 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.315 -0.865 . . . . 0.0 110.391 179.977 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.731 HG21 HG11 ' A' ' 319' ' ' VAL . 77.8 t -73.11 125.73 32.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.374 -0.829 . . . . 0.0 110.101 179.896 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -118.63 -15.8 5.72 Favored Glycine 0 N--CA 1.488 2.128 0 N-CA-C 109.761 -1.336 . . . . 0.0 109.761 -179.875 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.44 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.3 OUTLIER -144.73 126.99 15.74 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.207 -1.173 . . . . 0.0 110.837 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.541 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 29.0 p90 -149.69 173.46 13.66 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.361 -0.837 . . . . 0.0 109.835 179.531 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.419 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -163.54 158.06 20.33 Favored 'General case' 0 N--CA 1.494 1.741 0 O-C-N 120.797 -1.189 . . . . 0.0 111.713 -179.761 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.495 ' HB2' ' HA ' ' A' ' 334' ' ' PHE . 1.2 m 58.87 26.32 14.73 Favored 'General case' 0 N--CA 1.496 1.853 0 CA-C-O 121.292 0.568 . . . . 0.0 111.052 179.575 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.618 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.87 141.47 0.61 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.301 -0.874 . . . . 0.0 110.089 179.405 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.519 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.2 m-80 -77.09 117.76 18.96 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.017 -1.052 . . . . 0.0 109.35 179.61 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.618 ' HG3' HG11 ' A' ' 304' ' ' VAL . 4.2 ttpt -86.21 133.16 33.86 Favored 'General case' 0 N--CA 1.491 1.622 0 CA-C-O 121.719 0.771 . . . . 0.0 110.877 -179.355 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.577 ' O ' HG22 ' A' ' 319' ' ' VAL . 0.0 OUTLIER -115.17 172.3 7.15 Favored 'General case' 0 C--N 1.298 -1.665 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 178.903 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 10.0 mt-10 -134.75 103.12 5.5 Favored 'General case' 0 C--N 1.299 -1.59 0 O-C-N 121.447 -0.783 . . . . 0.0 110.177 -179.868 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.496 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -91.21 49.82 3.01 Favored Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.517 -1.433 . . . . 0.0 109.517 -179.913 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER 47.92 80.85 0.05 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.146 -1.208 . . . . 0.0 109.971 -179.947 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.6 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 98.79 -1.26 58.05 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.635 -1.386 . . . . 0.0 109.635 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.6 ' CD1' ' O ' ' A' ' 317' ' ' GLY . 3.3 m-85 -141.71 179.48 6.81 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.464 -1.021 . . . . 0.0 109.256 179.502 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.731 HG11 HG21 ' A' ' 304' ' ' VAL . 5.2 t -154.22 153.8 7.96 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.208 -0.932 . . . . 0.0 109.286 178.721 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.837 ' CG2' HG22 ' A' ' 293' ' ' THR . 78.3 mt -132.19 138.69 51.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.996 -1.065 . . . . 0.0 111.337 -179.536 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.654 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 62.5 m-85 -113.42 133.61 55.09 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.084 -1.01 . . . . 0.0 111.066 -179.629 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.696 ' CG2' HG23 ' A' ' 293' ' ' THR . 1.3 p -127.74 169.19 12.99 Favored Pre-proline 0 C--N 1.3 -1.546 0 O-C-N 121.072 -1.017 . . . . 0.0 109.672 179.011 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.518 ' HB3' ' NE1' ' A' ' 292' ' ' TRP . 40.5 Cg_endo -66.34 117.23 4.54 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 123.812 1.428 . . . . 0.0 111.1 -179.22 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.599 HG22 ' HB2' ' A' ' 327' ' ' ASN . 13.3 m -62.12 -112.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 121.455 -0.778 . . . . 0.0 110.059 179.872 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.468 ' H ' HG23 ' A' ' 324' ' ' VAL . 0.3 OUTLIER -114.46 -19.38 11.21 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 120.732 -1.23 . . . . 0.0 110.124 179.873 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.46 ' H ' HG23 ' A' ' 324' ' ' VAL . 7.9 p-90 -122.48 -17.96 6.85 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.232 -0.917 . . . . 0.0 110.287 -179.904 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.734 ' CG ' ' HB1' ' A' ' 332' ' ' ALA . 4.5 t30 -83.9 46.47 1.19 Allowed 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.225 -0.922 . . . . 0.0 110.066 -179.885 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.5 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -123.61 -11.95 7.73 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.393 -0.817 . . . . 0.0 109.783 -179.933 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.462 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.49 -163.77 0.02 OUTLIER Glycine 0 N--CA 1.493 2.486 0 N-CA-C 109.828 -1.309 . . . . 0.0 109.828 -179.735 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_endo -73.13 2.24 5.75 Favored 'Trans proline' 0 C--N 1.307 -1.624 0 O-C-N 124.07 1.563 . . . . 0.0 110.625 179.9 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 2.8 m -159.61 114.98 2.43 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.35 -0.844 . . . . 0.0 109.619 179.785 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.734 ' HB1' ' CG ' ' A' ' 327' ' ' ASN . . . -137.76 128.23 26.49 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.136 -0.978 . . . . 0.0 110.13 -179.767 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.862 ' OG1' HG23 ' A' ' 283' ' ' THR . 87.0 m -117.27 148.9 41.26 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.151 -0.968 . . . . 0.0 110.496 -179.785 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.874 ' HE2' HG21 ' A' ' 294' ' ' VAL . 11.8 p90 -150.4 169.2 22.0 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.448 -0.782 . . . . 0.0 108.952 179.796 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.541 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -145.48 158.66 27.73 Favored Glycine 0 N--CA 1.489 2.21 0 C-N-CA 118.737 -1.697 . . . . 0.0 110.128 -179.704 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.95 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.1 p90 -145.03 148.18 33.43 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.521 -0.988 . . . . 0.0 109.876 179.397 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.95 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -121.48 120.19 61.16 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.163 -0.961 . . . . 0.0 109.839 -179.968 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.891 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 4.7 t -97.89 149.37 5.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.264 -0.897 . . . . 0.0 110.266 -179.749 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.514 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -118.96 131.36 56.02 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.398 -0.814 . . . . 0.0 110.396 -179.776 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.38 -124.33 0.92 Allowed Glycine 0 N--CA 1.492 2.388 0 N-CA-C 109.345 -1.502 . . . . 0.0 109.345 179.869 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.539 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 39.9 Cg_endo -65.71 -162.19 0.05 OUTLIER 'Trans proline' 0 C--N 1.308 -1.601 0 O-C-N 123.754 1.397 . . . . 0.0 110.448 179.702 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.589 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 0.0 OUTLIER -123.78 127.9 48.77 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.236 -0.915 . . . . 0.0 110.642 -179.199 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.471 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 111.35 -75.17 0.21 Allowed Glycine 0 N--CA 1.491 2.348 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.867 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -119.56 127.99 53.5 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.311 -1.111 . . . . 0.0 108.943 179.13 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.642 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.7 OUTLIER -129.22 9.67 5.7 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 120.821 -1.174 . . . . 0.0 110.757 -179.353 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.576 ' HA ' ' HA ' ' A' ' 298' ' ' LEU . 7.2 p -132.46 119.66 39.78 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.705 0 O-C-N 121.305 -0.872 . . . . 0.0 110.148 179.335 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.558 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.0 OUTLIER -49.87 -44.71 50.0 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.301 -0.874 . . . . 0.0 110.151 -179.793 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.447 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 0.0 OUTLIER -176.83 158.49 1.64 Allowed 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.287 -0.883 . . . . 0.0 110.524 -179.967 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.829 HG12 HG13 ' A' ' 296' ' ' VAL . 35.5 mt -118.89 104.85 16.58 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.198 -0.939 . . . . 0.0 110.04 179.521 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -108.03 138.76 43.74 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.304 -0.873 . . . . 0.0 110.325 -179.921 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.097 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -98.33 133.43 42.74 Favored 'General case' 0 N--CA 1.494 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.229 179.832 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.47 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 28.6 tt0 -139.24 108.83 6.2 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.192 -0.942 . . . . 0.0 110.262 179.985 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.864 HG23 ' O ' ' A' ' 291' ' ' ASP . 1.4 mt -91.64 108.62 20.21 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 120.932 -1.105 . . . . 0.0 109.816 179.447 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.527 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.7 OUTLIER 40.45 33.14 0.16 Allowed 'General case' 0 N--CA 1.492 1.648 0 O-C-N 121.688 -0.633 . . . . 0.0 110.474 -179.724 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 115.29 -22.33 12.25 Favored Glycine 0 N--CA 1.491 2.348 0 N-CA-C 109.813 -1.315 . . . . 0.0 109.813 179.842 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.47 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 0.1 OUTLIER -79.77 104.41 10.33 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.148 -1.207 . . . . 0.0 110.139 179.988 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.589 HG13 ' O ' ' A' ' 357' ' ' VAL . 5.2 p -74.5 109.9 7.97 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.279 -0.888 . . . . 0.0 110.358 -179.775 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.582 ' HB ' HD13 ' A' ' 351' ' ' LEU . 23.0 mm . . . . . 0 N--CA 1.492 1.63 0 CA-C-O 117.944 -1.027 . . . . 0.0 110.199 179.86 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 2.286 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 46.8 Cg_endo -74.57 -178.32 3.95 Favored 'Trans proline' 0 C--N 1.305 -1.74 0 O-C-N 124.078 1.567 . . . . 0.0 110.597 -179.833 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 14.1 t -58.83 145.41 40.96 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.473 -0.767 . . . . 0.0 110.33 179.977 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 1.9 m -102.39 125.14 37.12 Favored Pre-proline 0 N--CA 1.493 1.692 0 O-C-N 121.187 -0.946 . . . . 0.0 110.041 179.892 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.3 Cg_endo -72.57 150.37 51.09 Favored 'Trans proline' 0 C--N 1.307 -1.627 0 O-C-N 123.792 1.417 . . . . 0.0 110.408 -179.919 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.723 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.6 p -66.04 147.07 98.99 Favored Pre-proline 0 N--CA 1.491 1.578 0 O-C-N 121.238 -0.914 . . . . 0.0 110.081 -179.986 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.723 ' HD2' HG23 ' A' ' 261' ' ' VAL . 44.4 Cg_endo -71.45 157.2 56.99 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 123.996 1.524 . . . . 0.0 110.469 -179.994 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.51 ' O ' ' CB ' ' A' ' 264' ' ' SER . 15.5 t -119.03 22.75 5.43 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.285 -0.884 . . . . 0.0 110.45 -179.794 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.51 ' CB ' ' O ' ' A' ' 263' ' ' VAL . 0.5 OUTLIER 167.49 159.39 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.278 -0.889 . . . . 0.0 110.498 179.923 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 53.25 -177.94 0.15 Allowed Glycine 0 N--CA 1.49 2.298 0 N-CA-C 109.924 -1.271 . . . . 0.0 109.924 179.554 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.54 ' HB2' ' ND2' ' A' ' 285' ' ' ASN . 0.9 OUTLIER -138.76 164.86 28.49 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.373 -1.075 . . . . 0.0 110.234 179.958 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.88 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.7 tm? -160.59 133.9 6.7 Favored 'General case' 0 C--N 1.303 -1.422 0 C-N-CA 119.379 -0.928 . . . . 0.0 111.066 -179.703 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.84 ' N ' HD22 ' A' ' 267' ' ' LEU . 3.0 mp0 -131.35 146.72 52.4 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.175 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.824 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.2 t -139.99 145.66 26.08 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.587 -1.321 . . . . 0.0 111.551 -178.966 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -132.97 157.59 44.8 Favored 'General case' 0 N--CA 1.497 1.875 0 N-CA-C 108.827 -0.805 . . . . 0.0 108.827 179.203 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 279' ' ' GLU . 76.5 t -143.77 147.06 20.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.413 -1.429 . . . . 0.0 112.18 -179.175 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.541 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.1 OUTLIER -139.63 111.12 7.12 Favored 'General case' 0 N--CA 1.489 1.504 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.594 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.479 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 9.3 m-20 -96.29 147.87 23.34 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.982 -1.074 . . . . 0.0 111.179 -179.101 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.836 ' CH2' HG23 ' A' ' 337' ' ' ILE . 33.8 p90 -133.05 16.68 4.16 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.497 -0.752 . . . . 0.0 110.096 179.388 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.417 ' O ' ' OE1' ' A' ' 342' ' ' GLN . . . 92.0 -60.28 2.72 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.694 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.481 ' HB3' ' CD1' ' A' ' 274' ' ' TRP . 22.9 t -71.03 -17.73 62.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.198 -1.178 . . . . 0.0 110.293 -179.864 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.541 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -176.45 179.4 47.51 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.315 -1.422 . . . . 0.0 110.148 179.926 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.592 ' HB3' ' CE1' ' A' ' 280' ' ' TYR . . . -135.82 140.38 44.18 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.39 -1.065 . . . . 0.0 110.168 179.937 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.657 ' O ' HG13 ' A' ' 271' ' ' VAL . 9.5 mt-10 -93.11 147.06 23.18 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.365 -0.834 . . . . 0.0 109.734 -179.936 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.679 ' CD1' ' CE1' ' A' ' 336' ' ' PHE . 93.7 m-85 -140.64 87.77 2.15 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.202 -0.937 . . . . 0.0 110.383 -179.615 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.824 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.3 OUTLIER -70.16 150.05 46.91 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.436 -0.79 . . . . 0.0 109.854 179.573 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.748 HG11 HG11 ' A' ' 294' ' ' VAL . 3.6 t -143.21 90.35 0.42 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.651 0 O-C-N 121.409 -0.807 . . . . 0.0 109.87 -179.61 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.855 HG23 ' OG1' ' A' ' 333' ' ' THR . 10.6 m -86.49 122.45 30.44 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.109 -0.995 . . . . 0.0 109.6 179.745 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.095 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.22 149.95 29.39 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.205 -0.934 . . . . 0.0 110.801 -179.166 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.916 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -129.67 132.4 46.67 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.281 -0.887 . . . . 0.0 110.324 -179.557 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 1.039 HD13 ' HB2' ' A' ' 290' ' ' TYR . 16.4 mt -142.7 159.88 41.37 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 120.929 -1.107 . . . . 0.0 109.859 179.458 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 3.2 t0 -87.86 32.61 0.73 Allowed 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.253 -0.904 . . . . 0.0 110.154 -179.952 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.504 ' N ' ' HB3' ' A' ' 330' ' ' PRO . . . 150.97 -134.11 4.56 Favored Glycine 0 N--CA 1.49 2.266 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.475 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 8.7 mm-40 -101.52 106.95 18.11 Favored 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.253 -1.145 . . . . 0.0 110.476 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 1.039 ' HB2' HD13 ' A' ' 286' ' ' LEU . 7.2 m-85 -126.17 130.4 50.91 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.372 -0.83 . . . . 0.0 109.185 179.588 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.811 ' O ' HG23 ' A' ' 353' ' ' ILE . 24.7 m-20 -68.67 96.93 0.76 Allowed 'General case' 0 C--N 1.299 -1.592 0 O-C-N 120.718 -1.239 . . . . 0.0 109.291 179.576 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.949 ' CE3' HD13 ' A' ' 284' ' ' LEU . 60.7 p-90 -100.51 114.26 27.73 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.139 -0.976 . . . . 0.0 110.776 -179.424 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.718 HG23 ' CG2' ' A' ' 322' ' ' THR . 4.9 m -109.34 114.57 28.36 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.528 -0.732 . . . . 0.0 109.325 179.495 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.812 HG21 ' HE2' ' A' ' 334' ' ' PHE . 3.9 t -96.78 111.6 27.13 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.075 -1.016 . . . . 0.0 110.752 -179.198 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.634 ' HA ' HD13 ' A' ' 320' ' ' ILE . 32.7 ttpt -91.41 141.03 29.19 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.328 -0.857 . . . . 0.0 109.362 179.26 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.647 HG13 HG12 ' A' ' 349' ' ' ILE . 71.8 t -137.54 112.27 9.78 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.525 0 O-C-N 121.262 -0.899 . . . . 0.0 110.564 -179.311 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.6 ' HD3' ' CD1' ' A' ' 318' ' ' TYR . 10.4 mmtp -71.72 131.53 43.25 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.183 -0.948 . . . . 0.0 109.308 179.454 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.985 HD13 ' HA ' ' A' ' 303' ' ' THR . 91.1 mt -83.53 161.45 21.22 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 121.282 -0.886 . . . . 0.0 111.889 -178.658 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.908 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -66.16 176.99 0.84 Allowed Pre-proline 0 N--CA 1.489 1.525 0 O-C-N 121.686 -0.634 . . . . 0.0 109.77 179.354 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.807 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.9 Cg_endo -67.43 80.2 0.43 Allowed 'Trans proline' 0 C--N 1.306 -1.672 0 O-C-N 123.615 1.324 . . . . 0.0 109.79 179.288 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 112.2 19.88 6.95 Favored Glycine 0 N--CA 1.489 2.226 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 -179.377 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.908 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -101.33 156.37 17.49 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.365 -1.079 . . . . 0.0 110.351 -179.759 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.985 ' HA ' HD13 ' A' ' 298' ' ' LEU . 74.3 p -156.85 144.19 18.9 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.227 -0.92 . . . . 0.0 110.474 179.93 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.755 HG21 HG11 ' A' ' 319' ' ' VAL . 30.1 t -71.1 133.18 32.33 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.353 -0.842 . . . . 0.0 110.123 179.784 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -115.17 -42.11 0.78 Allowed Glycine 0 N--CA 1.489 2.2 0 N-CA-C 109.779 -1.328 . . . . 0.0 109.779 -179.706 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -132.61 136.41 46.51 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.108 -1.231 . . . . 0.0 110.998 -179.554 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.524 ' HA ' ' O ' ' A' ' 335' ' ' GLY . 23.9 p90 -149.08 174.99 11.73 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.413 -0.805 . . . . 0.0 109.693 179.469 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.499 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -163.57 159.29 21.71 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.041 -1.037 . . . . 0.0 111.136 -179.751 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.555 ' HA ' ' CZ2' ' A' ' 326' ' ' TRP . 0.3 OUTLIER 58.57 23.81 11.28 Favored 'General case' 0 N--CA 1.497 1.911 0 O-C-N 121.561 -0.712 . . . . 0.0 111.077 179.668 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.667 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.67 140.92 0.61 Allowed 'General case' 0 C--N 1.299 -1.616 0 O-C-N 121.284 -0.885 . . . . 0.0 110.262 179.494 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.637 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.1 m-80 -79.45 124.64 28.65 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.022 -1.049 . . . . 0.0 109.053 179.387 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.596 ' CD ' HG11 ' A' ' 304' ' ' VAL . 6.2 ttpt -91.85 133.18 35.88 Favored 'General case' 0 N--CA 1.49 1.555 0 CA-C-O 121.796 0.808 . . . . 0.0 111.199 -179.148 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.532 ' O ' ' HA ' ' A' ' 319' ' ' VAL . 0.0 OUTLIER -116.51 175.43 5.57 Favored 'General case' 0 C--N 1.299 -1.589 0 N-CA-C 108.593 -0.892 . . . . 0.0 108.593 178.61 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.453 ' HG2' HG22 ' A' ' 319' ' ' VAL . 1.2 mm-40 -135.77 103.6 5.47 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.251 -0.906 . . . . 0.0 110.286 -179.975 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.531 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -90.07 47.57 3.15 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 179.828 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 1.4 m120 51.9 82.62 0.06 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.343 -1.093 . . . . 0.0 110.416 179.874 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.607 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 96.29 1.43 60.91 Favored Glycine 0 N--CA 1.492 2.404 0 N-CA-C 109.722 -1.351 . . . . 0.0 109.722 179.985 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.797 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -143.32 -168.37 2.79 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.455 -1.027 . . . . 0.0 109.102 179.58 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.797 HG23 ' O ' ' A' ' 318' ' ' TYR . 6.8 t -162.52 158.21 1.89 Allowed 'Isoleucine or valine' 0 N--CA 1.495 1.798 0 O-C-N 121.325 -0.859 . . . . 0.0 109.832 178.964 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.634 HD13 ' HA ' ' A' ' 295' ' ' LYS . 21.6 mm -127.88 148.44 32.48 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.705 0 O-C-N 121.096 -1.003 . . . . 0.0 111.114 -179.717 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.632 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 84.8 m-85 -124.85 127.02 46.49 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.235 -0.916 . . . . 0.0 109.836 179.116 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.718 ' CG2' HG23 ' A' ' 293' ' ' THR . 3.2 p -126.76 168.77 13.56 Favored Pre-proline 0 C--N 1.301 -1.533 0 C-N-CA 119.068 -1.053 . . . . 0.0 110.307 179.984 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.537 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 40.8 Cg_endo -66.05 116.09 3.81 Favored 'Trans proline' 0 C--N 1.306 -1.701 0 O-C-N 123.84 1.442 . . . . 0.0 111.056 -179.448 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.637 HG12 ' ND2' ' A' ' 311' ' ' ASN . 16.0 m -63.18 -115.31 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.619 0 O-C-N 121.335 -0.853 . . . . 0.0 109.839 179.865 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.489 ' N ' HG23 ' A' ' 324' ' ' VAL . 73.6 m -118.18 -13.31 9.91 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.797 -1.189 . . . . 0.0 110.295 179.933 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.573 ' H ' HG23 ' A' ' 324' ' ' VAL . 18.6 p-90 -127.76 -3.36 5.93 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.206 -0.934 . . . . 0.0 110.411 -179.932 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.608 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.0 OUTLIER -104.99 41.59 1.32 Allowed 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.269 -0.894 . . . . 0.0 110.31 -179.72 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.492 ' HG2' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -115.91 -9.26 11.83 Favored 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.395 -0.816 . . . . 0.0 109.903 179.825 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.477 ' O ' ' O ' ' A' ' 328' ' ' LYS . . . -55.81 -161.73 0.02 OUTLIER Glycine 0 N--CA 1.491 2.364 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.607 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.504 ' HB3' ' N ' ' A' ' 288' ' ' GLY . 49.5 Cg_endo -74.37 4.77 4.12 Favored 'Trans proline' 0 C--N 1.307 -1.638 0 O-C-N 123.992 1.522 . . . . 0.0 111.097 -179.837 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 6.6 m -163.96 114.99 1.33 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.169 -0.957 . . . . 0.0 109.842 179.741 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.497 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.0 127.45 28.59 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.185 -0.947 . . . . 0.0 110.267 -179.774 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.855 ' OG1' HG23 ' A' ' 283' ' ' THR . 91.3 m -115.3 137.51 51.96 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.235 -0.915 . . . . 0.0 110.308 -179.95 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.812 ' HE2' HG21 ' A' ' 294' ' ' VAL . 14.9 p90 -138.87 174.95 9.98 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.303 -0.873 . . . . 0.0 109.014 179.568 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.524 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.31 156.87 26.94 Favored Glycine 0 N--CA 1.488 2.12 0 C-N-CA 119.034 -1.555 . . . . 0.0 109.946 -179.641 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.947 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.2 p90 -144.37 149.09 35.57 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.594 -0.945 . . . . 0.0 109.689 179.445 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.947 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -120.47 117.73 54.28 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.078 -1.014 . . . . 0.0 109.833 179.734 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.759 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.4 t -96.77 152.05 3.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.307 -0.871 . . . . 0.0 110.204 -179.598 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.491 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.0 m-80 -122.78 134.59 54.42 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.409 -0.807 . . . . 0.0 109.88 179.866 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 178.21 -122.72 0.83 Allowed Glycine 0 N--CA 1.493 2.453 0 N-CA-C 109.946 -1.261 . . . . 0.0 109.946 179.951 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.52 ' HD2' ' CG ' ' A' ' 345' ' ' LYS . 44.3 Cg_endo -69.74 -166.83 0.2 Allowed 'Trans proline' 0 C--N 1.308 -1.596 0 O-C-N 123.837 1.44 . . . . 0.0 110.477 -179.806 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.57 ' NE2' ' N ' ' A' ' 342' ' ' GLN . 1.8 mp0 -112.68 134.76 54.04 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.318 -0.864 . . . . 0.0 110.366 -179.696 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.43 ' O ' ' OD2' ' A' ' 273' ' ' ASP . . . 101.59 -88.66 0.72 Allowed Glycine 0 N--CA 1.49 2.264 0 N-CA-C 109.185 -1.566 . . . . 0.0 109.185 -179.92 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . . . . . . . . . 2.4 m-20 -104.28 132.79 50.15 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.319 -1.106 . . . . 0.0 109.308 179.376 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.817 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 1.0 OUTLIER -130.49 7.14 4.87 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 120.916 -1.115 . . . . 0.0 110.8 -179.558 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.595 HG11 ' CE2' ' A' ' 280' ' ' TYR . 3.9 p -132.55 116.94 29.38 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.562 0 O-C-N 121.231 -0.918 . . . . 0.0 109.938 179.561 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.529 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -45.3 -46.1 12.58 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.021 -1.049 . . . . 0.0 110.116 -179.604 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.418 ' HB3' ' O ' ' A' ' 347' ' ' GLU . 14.3 pt-20 -177.12 158.5 1.52 Allowed 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.294 -0.879 . . . . 0.0 110.473 179.979 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.647 HG12 HG13 ' A' ' 296' ' ' VAL . 27.3 mt -116.32 117.86 56.87 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.24 -0.912 . . . . 0.0 110.216 179.677 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -120.88 145.42 47.67 Favored 'General case' 0 N--CA 1.493 1.725 0 O-C-N 121.277 -0.889 . . . . 0.0 110.162 179.936 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.095 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -107.63 133.67 51.73 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.015 -1.053 . . . . 0.0 110.679 179.903 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -138.82 112.88 8.59 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.371 -0.83 . . . . 0.0 109.901 179.617 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.811 HG23 ' O ' ' A' ' 291' ' ' ASP . 0.9 OUTLIER -91.55 94.04 4.64 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.644 0 O-C-N 120.979 -1.075 . . . . 0.0 110.051 179.952 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.45 ' CG ' ' HB2' ' A' ' 291' ' ' ASP . 0.8 OUTLIER 50.68 31.23 5.6 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.699 -0.626 . . . . 0.0 110.704 179.981 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 122.65 -26.06 6.36 Favored Glycine 0 N--CA 1.493 2.487 0 C-N-CA 119.683 -1.246 . . . . 0.0 110.45 179.351 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.475 ' HB2' ' HB ' ' A' ' 353' ' ' ILE . 41.7 mm-40 -85.92 103.66 14.85 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.045 -1.267 . . . . 0.0 110.499 -179.576 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.67 HG13 ' O ' ' A' ' 357' ' ' VAL . 13.3 p -73.6 116.47 16.0 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.265 -0.897 . . . . 0.0 110.162 179.891 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.564 HG23 ' HB2' ' A' ' 262' ' ' PRO . 36.9 mm . . . . . 0 N--CA 1.491 1.601 0 CA-C-O 117.943 -1.027 . . . . 0.0 110.24 -179.992 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 2.334 0 N-CA-C 109.565 -1.414 . . . . 0.0 109.565 . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_endo -75.69 -178.16 4.11 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 123.978 1.514 . . . . 0.0 110.569 179.976 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . . . . . . . . . 2.1 t -78.17 146.38 35.07 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.406 -0.809 . . . . 0.0 110.279 179.989 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 2.4 m -134.77 93.84 17.45 Favored Pre-proline 0 N--CA 1.491 1.623 0 O-C-N 121.121 -0.987 . . . . 0.0 110.483 179.986 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 48.3 Cg_endo -74.85 161.18 39.58 Favored 'Trans proline' 0 C--N 1.304 -1.776 0 O-C-N 124.13 1.595 . . . . 0.0 110.111 179.787 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.597 HG23 ' HD2' ' A' ' 262' ' ' PRO . 3.0 p -106.8 143.53 27.25 Favored Pre-proline 0 N--CA 1.49 1.547 0 O-C-N 121.159 -0.963 . . . . 0.0 110.307 -179.985 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.597 ' HD2' HG23 ' A' ' 261' ' ' VAL . 45.8 Cg_endo -74.79 133.64 17.19 Favored 'Trans proline' 0 C--N 1.304 -1.777 0 O-C-N 124.106 1.582 . . . . 0.0 110.352 179.911 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.579 HG12 ' O ' ' A' ' 263' ' ' VAL . 41.5 t -120.11 29.35 2.71 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.258 -0.901 . . . . 0.0 110.201 179.899 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.437 ' HB2' ' O ' ' A' ' 263' ' ' VAL . 1.4 t -178.69 132.24 0.13 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.197 -0.939 . . . . 0.0 110.492 -179.975 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 64.19 179.0 6.0 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 109.916 -1.274 . . . . 0.0 109.916 179.807 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.554 ' HB3' ' ND2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -132.28 163.61 28.24 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.428 -1.042 . . . . 0.0 109.511 179.628 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.865 HD23 ' HG ' ' A' ' 284' ' ' LEU . 1.8 tm? -161.28 134.73 6.54 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 120.838 -1.164 . . . . 0.0 111.736 -179.611 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.832 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.0 mt-10 -130.38 149.61 51.99 Favored 'General case' 0 C--N 1.3 -1.552 0 N-CA-C 108.553 -0.906 . . . . 0.0 108.553 178.975 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.75 HG13 ' O ' ' A' ' 281' ' ' ASP . 58.6 t -141.3 141.23 30.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 120.628 -1.295 . . . . 0.0 111.684 -179.306 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . . . . . . . . . 19.7 tttt -126.81 157.99 37.78 Favored 'General case' 0 N--CA 1.495 1.798 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 178.908 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.658 HG13 ' O ' ' A' ' 279' ' ' GLU . 89.0 t -144.02 146.39 20.84 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 O-C-N 120.333 -1.479 . . . . 0.0 112.193 -179.325 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.517 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.0 OUTLIER -141.16 110.87 6.47 Favored 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.509 -0.923 . . . . 0.0 108.509 179.005 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.465 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 46.1 p30 -96.15 147.82 23.35 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.163 -0.961 . . . . 0.0 111.378 -178.493 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.809 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.4 p90 -134.95 23.65 3.58 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.586 -0.696 . . . . 0.0 109.884 179.42 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.476 ' HA2' ' HB3' ' A' ' 342' ' ' GLN . . . 82.97 -66.96 3.84 Favored Glycine 0 N--CA 1.49 2.287 0 N-CA-C 109.655 -1.378 . . . . 0.0 109.655 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . 0.54 ' HB2' ' CD1' ' A' ' 274' ' ' TRP . 9.2 m -59.85 -26.35 65.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.197 -1.178 . . . . 0.0 110.615 -179.881 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.562 ' N ' ' NE1' ' A' ' 274' ' ' TRP . . . -170.96 -177.8 41.1 Favored Glycine 0 N--CA 1.492 2.429 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 -179.972 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.554 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -137.22 144.07 42.63 Favored 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.244 -1.15 . . . . 0.0 110.18 179.965 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.658 ' O ' HG13 ' A' ' 271' ' ' VAL . 6.3 mt-10 -97.41 147.43 24.22 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.385 -0.822 . . . . 0.0 109.967 -179.523 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.745 ' CE2' HG11 ' A' ' 346' ' ' VAL . 91.1 m-85 -141.43 83.89 1.89 Allowed 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.341 -0.849 . . . . 0.0 110.787 -179.344 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.75 ' O ' HG13 ' A' ' 269' ' ' VAL . 1.8 t70 -64.52 146.98 53.74 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 121.434 -0.791 . . . . 0.0 109.623 179.144 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.739 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 6.7 t -142.58 89.08 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.626 0 O-C-N 121.366 -0.834 . . . . 0.0 109.79 -179.647 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.721 HG23 ' OG1' ' A' ' 333' ' ' THR . 97.8 m -86.46 123.5 31.74 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.203 -0.935 . . . . 0.0 109.756 -179.955 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.083 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -110.48 150.47 28.84 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.168 -0.957 . . . . 0.0 110.517 -179.525 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.931 ' O ' HD23 ' A' ' 286' ' ' LEU . 0.4 OUTLIER -129.12 135.77 49.32 Favored 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.416 -0.802 . . . . 0.0 109.958 -179.687 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.931 HD23 ' O ' ' A' ' 285' ' ' ASN . 11.6 mt -143.18 160.68 39.98 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.075 -1.016 . . . . 0.0 109.481 179.564 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -94.76 31.76 1.76 Allowed 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.178 -0.951 . . . . 0.0 110.528 -179.598 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.435 ' O ' ' C ' ' A' ' 329' ' ' GLY . . . 161.0 -94.6 0.13 Allowed Glycine 0 N--CA 1.491 2.312 0 C-N-CA 119.048 -1.548 . . . . 0.0 110.425 179.876 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.479 ' HA ' ' O ' ' A' ' 328' ' ' LYS . 1.5 tt0 -152.48 106.51 3.12 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.055 -1.262 . . . . 0.0 110.695 -179.322 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.644 ' CD1' ' N ' ' A' ' 290' ' ' TYR . 5.0 m-85 -128.38 134.85 48.92 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.335 -0.853 . . . . 0.0 109.649 179.585 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.579 ' CB ' ' ND2' ' A' ' 354' ' ' ASN . 96.7 m-20 -67.34 96.92 0.52 Allowed 'General case' 0 C--N 1.3 -1.573 0 O-C-N 120.846 -1.159 . . . . 0.0 108.754 178.859 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.931 ' CE3' HD13 ' A' ' 284' ' ' LEU . 59.5 p-90 -97.68 108.89 21.7 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 121.146 -0.971 . . . . 0.0 111.166 -178.862 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.756 HG22 ' CG2' ' A' ' 320' ' ' ILE . 8.6 m -102.18 114.85 29.36 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.643 -0.661 . . . . 0.0 109.233 179.312 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.752 HG21 ' HE2' ' A' ' 334' ' ' PHE . 5.5 t -96.71 111.88 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.1 -1.0 . . . . 0.0 111.076 -178.964 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . . . . . . . . . 6.3 ttpt -86.63 149.39 24.95 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.476 -0.765 . . . . 0.0 109.351 179.008 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.899 HG22 HG23 ' A' ' 349' ' ' ILE . 43.4 t -148.67 108.0 0.53 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.033 -1.042 . . . . 0.0 110.585 -179.597 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.561 ' HD2' ' CE1' ' A' ' 318' ' ' TYR . 9.1 mmtm -71.01 134.3 47.02 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.131 -0.981 . . . . 0.0 110.044 179.781 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 0.872 HD13 ' HA ' ' A' ' 303' ' ' THR . 74.9 mt -87.5 165.56 15.42 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.331 -0.855 . . . . 0.0 111.131 -179.37 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.708 ' HB1' ' HD2' ' A' ' 300' ' ' PRO . . . -79.73 173.98 6.85 Favored Pre-proline 0 C--N 1.303 -1.443 0 N-CA-C 108.934 -0.765 . . . . 0.0 108.934 178.883 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.708 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 39.4 Cg_endo -66.09 84.52 0.26 Allowed 'Trans proline' 0 C--N 1.306 -1.707 0 O-C-N 123.496 1.261 . . . . 0.0 110.125 179.816 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 114.11 24.15 4.62 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.62 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.938 ' HB1' ' CG1' ' A' ' 338' ' ' VAL . . . -115.73 149.29 38.68 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.283 -1.127 . . . . 0.0 110.202 -179.761 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 0.872 ' HA ' HD13 ' A' ' 298' ' ' LEU . 14.1 p -153.96 144.57 22.43 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.303 -0.873 . . . . 0.0 110.251 179.664 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.683 HG21 HG11 ' A' ' 319' ' ' VAL . 75.0 t -75.09 135.04 28.12 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.206 -0.934 . . . . 0.0 110.09 179.803 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -128.81 -31.33 0.65 Allowed Glycine 0 N--CA 1.489 2.217 0 N-CA-C 109.983 -1.247 . . . . 0.0 109.983 -179.707 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . . . . . . . . . 1.5 m -126.56 109.54 12.25 Favored 'General case' 0 N--CA 1.492 1.666 0 O-C-N 121.033 -1.275 . . . . 0.0 110.92 -179.555 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.581 ' CD1' ' HD3' ' A' ' 312' ' ' LYS . 55.4 p90 -133.44 156.54 47.53 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.249 -0.907 . . . . 0.0 109.631 179.213 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.491 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.2 p90 -149.32 158.42 44.16 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.966 -1.084 . . . . 0.0 111.201 -179.411 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.522 ' HA ' ' CH2' ' A' ' 326' ' ' TRP . 0.1 OUTLIER 65.46 21.12 11.82 Favored 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.741 -0.599 . . . . 0.0 111.279 179.55 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.637 ' HA ' HG13 ' A' ' 324' ' ' VAL . . . -174.97 150.49 1.23 Allowed 'General case' 0 C--N 1.298 -1.643 0 O-C-N 121.231 -0.918 . . . . 0.0 110.516 179.678 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.758 ' ND2' HG12 ' A' ' 324' ' ' VAL . 2.2 m-80 -83.62 119.25 24.52 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.148 -0.97 . . . . 0.0 108.979 179.134 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.581 ' HD3' ' CD1' ' A' ' 307' ' ' PHE . 6.7 ttpt -90.44 131.22 36.33 Favored 'General case' 0 C--N 1.299 -1.594 0 CA-C-O 121.916 0.865 . . . . 0.0 111.407 -178.891 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.622 ' O ' HG22 ' A' ' 319' ' ' VAL . 4.7 mt-30 -112.18 178.69 4.22 Favored 'General case' 0 C--N 1.299 -1.619 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 178.61 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . 0.561 ' HG2' HG22 ' A' ' 319' ' ' VAL . 7.5 mm-40 -143.78 108.13 4.8 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.458 -0.776 . . . . 0.0 110.183 179.843 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.44 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -96.53 50.65 1.59 Allowed Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.436 -1.466 . . . . 0.0 109.436 179.856 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 52.48 84.7 0.05 OUTLIER 'General case' 0 N--CA 1.492 1.63 0 O-C-N 121.315 -1.109 . . . . 0.0 110.003 -179.948 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.545 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 93.97 -2.28 68.98 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 109.488 -1.445 . . . . 0.0 109.488 -179.892 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.626 ' O ' HG23 ' A' ' 319' ' ' VAL . 3.2 m-85 -137.19 -179.59 5.81 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.315 -1.109 . . . . 0.0 109.683 179.665 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.683 HG11 HG21 ' A' ' 304' ' ' VAL . 3.8 t -157.63 155.69 4.73 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.444 -0.785 . . . . 0.0 109.421 178.771 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.756 ' CG2' HG22 ' A' ' 293' ' ' THR . 1.9 mt -131.99 140.31 48.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.062 -1.023 . . . . 0.0 111.674 -179.147 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 67.5 m-85 -115.74 130.17 56.75 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.985 -1.072 . . . . 0.0 110.384 179.548 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.621 ' CG2' HG23 ' A' ' 293' ' ' THR . 2.4 p -127.97 169.96 11.41 Favored Pre-proline 0 N--CA 1.49 1.56 0 O-C-N 120.963 -1.086 . . . . 0.0 109.57 179.657 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.525 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.9 Cg_endo -66.16 126.6 16.03 Favored 'Trans proline' 0 C--N 1.307 -1.652 0 O-C-N 123.594 1.313 . . . . 0.0 110.915 -179.301 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.885 HG22 ' HB2' ' A' ' 327' ' ' ASN . 35.4 m -77.79 -123.61 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.487 -0.758 . . . . 0.0 109.826 -179.985 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.583 ' N ' HG23 ' A' ' 324' ' ' VAL . 19.8 m -100.32 -12.98 19.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.766 -1.209 . . . . 0.0 110.586 -179.911 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.693 ' H ' HG23 ' A' ' 324' ' ' VAL . 15.3 p-90 -137.25 5.33 2.74 Favored 'General case' 0 N--CA 1.495 1.802 0 O-C-N 121.144 -0.972 . . . . 0.0 110.679 -179.887 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.885 ' HB2' HG22 ' A' ' 324' ' ' VAL . 1.4 t30 -107.09 43.14 1.2 Allowed 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.068 -1.02 . . . . 0.0 110.381 -179.639 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.495 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 1.2 pttt -126.82 -5.71 6.28 Favored 'General case' 0 N--CA 1.496 1.856 0 O-C-N 121.38 -0.825 . . . . 0.0 109.969 179.704 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.435 ' C ' ' O ' ' A' ' 288' ' ' GLY . . . -60.0 -156.13 0.03 OUTLIER Glycine 0 N--CA 1.49 2.293 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 -179.882 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.456 ' O ' ' OG1' ' A' ' 331' ' ' THR . 47.8 Cg_endo -72.23 2.5 4.91 Favored 'Trans proline' 0 C--N 1.307 -1.623 0 O-C-N 124.134 1.597 . . . . 0.0 110.964 -179.89 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . 0.456 ' OG1' ' O ' ' A' ' 330' ' ' PRO . 8.9 m -165.4 121.67 1.4 Allowed 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.257 -0.902 . . . . 0.0 109.946 179.972 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.454 ' CB ' ' O ' ' A' ' 327' ' ' ASN . . . -136.93 107.94 6.72 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.188 -0.945 . . . . 0.0 110.45 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.721 ' OG1' HG23 ' A' ' 283' ' ' THR . 25.6 m -98.41 142.04 30.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.192 -0.943 . . . . 0.0 109.96 179.631 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.752 ' HE2' HG21 ' A' ' 294' ' ' VAL . 7.2 p90 -149.14 169.82 19.83 Favored 'General case' 0 N--CA 1.489 1.518 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.771 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.553 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -148.45 151.68 23.84 Favored Glycine 0 N--CA 1.491 2.333 0 C-N-CA 118.854 -1.641 . . . . 0.0 110.141 -179.715 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.941 ' C ' HD12 ' A' ' 337' ' ' ILE . 1.0 OUTLIER -136.44 149.46 48.25 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.563 -0.963 . . . . 0.0 109.83 179.569 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.941 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.7 mp -122.86 119.34 57.67 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 121.144 -0.973 . . . . 0.0 109.529 179.356 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.938 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 3.4 t -95.95 143.74 11.52 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.077 -1.014 . . . . 0.0 109.239 179.702 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.429 ' O ' ' HA ' ' A' ' 302' ' ' ALA . 2.1 m-80 -120.07 140.48 50.97 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.176 -0.953 . . . . 0.0 110.86 -179.255 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . . . . . . . . . . . 175.78 -128.82 1.43 Allowed Glycine 0 N--CA 1.49 2.234 0 N-CA-C 108.6 -1.8 . . . . 0.0 108.6 179.817 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.528 ' HA ' ' NE2' ' A' ' 342' ' ' GLN . 44.3 Cg_endo -70.68 -153.42 0.04 OUTLIER 'Trans proline' 0 C--N 1.305 -1.754 0 O-C-N 123.739 1.389 . . . . 0.0 109.493 179.2 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.528 ' NE2' ' HA ' ' A' ' 341' ' ' PRO . 0.0 OUTLIER -130.27 143.67 50.92 Favored 'General case' 0 N--CA 1.496 1.853 0 O-C-N 120.759 -1.213 . . . . 0.0 110.021 179.357 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.461 ' O ' ' HB2' ' A' ' 344' ' ' ASP . . . 98.88 71.28 1.0 Allowed Glycine 0 N--CA 1.491 2.31 0 N-CA-C 108.632 -1.787 . . . . 0.0 108.632 -179.315 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.461 ' HB2' ' O ' ' A' ' 343' ' ' GLY . 3.3 m-20 65.76 127.97 0.02 OUTLIER 'General case' 0 N--CA 1.493 1.676 0 O-C-N 121.482 -1.011 . . . . 0.0 109.31 -178.99 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.582 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.1 OUTLIER -129.62 15.83 5.93 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.056 -1.027 . . . . 0.0 110.436 -179.61 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.745 HG11 ' CE2' ' A' ' 280' ' ' TYR . 6.2 p -127.61 120.18 53.8 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.572 0 O-C-N 121.168 -0.957 . . . . 0.0 110.133 179.614 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.551 ' HB2' ' CB ' ' A' ' 297' ' ' LYS . 0.8 OUTLIER -48.43 -46.38 37.53 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.074 -1.016 . . . . 0.0 109.717 -179.825 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.409 ' OE1' ' HB3' ' A' ' 347' ' ' GLU . 1.6 pt-20 -176.99 158.59 1.58 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.351 -0.843 . . . . 0.0 110.429 179.679 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.899 HG23 HG22 ' A' ' 296' ' ' VAL . 11.3 mt -117.07 103.53 15.15 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 121.282 -0.887 . . . . 0.0 109.793 179.675 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -104.61 146.45 28.9 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.292 -0.88 . . . . 0.0 110.306 -179.737 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.083 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -106.62 132.95 52.02 Favored 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.161 -0.962 . . . . 0.0 110.135 179.576 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.514 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 3.4 tt0 -138.53 112.69 8.62 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.298 -0.876 . . . . 0.0 109.948 179.86 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.532 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.7 mt -91.61 113.17 26.63 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.104 -0.997 . . . . 0.0 110.099 179.963 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.579 ' ND2' ' CB ' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.54 29.54 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.752 -0.592 . . . . 0.0 110.918 -179.809 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . 0.459 ' N ' ' O ' ' A' ' 353' ' ' ILE . . . 117.84 -13.85 12.91 Favored Glycine 0 N--CA 1.492 2.399 0 C-N-CA 119.774 -1.203 . . . . 0.0 110.523 179.23 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.514 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 72.7 mm-40 -93.8 113.98 26.14 Favored 'General case' 0 N--CA 1.494 1.743 0 O-C-N 120.885 -1.362 . . . . 0.0 110.368 -179.836 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.925 ' O ' HD13 ' A' ' 358' ' ' ILE . 2.2 p -74.23 138.35 21.33 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 121.258 -0.901 . . . . 0.0 110.183 179.998 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.925 HD13 ' O ' ' A' ' 357' ' ' VAL . 19.1 mm . . . . . 0 N--CA 1.493 1.702 0 CA-C-O 118.05 -0.976 . . . . 0.0 110.277 -179.909 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 256' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.492 2.373 0 N-CA-C 109.605 -1.398 . . . . 0.0 109.605 . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 257' ' ' PRO . . . . . . . . . . . . . 45.4 Cg_endo -73.23 -178.93 3.92 Favored 'Trans proline' 0 C--N 1.305 -1.736 0 O-C-N 124.051 1.553 . . . . 0.0 110.395 179.966 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 258' ' ' THR . . . . . 0.558 HG23 ' O ' ' A' ' 258' ' ' THR . 6.1 t -58.79 125.15 22.3 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.205 -0.935 . . . . 0.0 110.242 -179.849 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 259' ' ' THR . . . . . . . . . . . . . 57.6 m -124.68 112.15 27.45 Favored Pre-proline 0 N--CA 1.491 1.597 0 O-C-N 121.285 -0.884 . . . . 0.0 110.362 -179.882 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 260' ' ' PRO . . . . . . . . . . . . . 45.7 Cg_endo -72.67 155.41 54.31 Favored 'Trans proline' 0 C--N 1.306 -1.704 0 O-C-N 124.025 1.54 . . . . 0.0 110.339 179.781 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 261' ' ' VAL . . . . . 0.522 HG23 ' HD2' ' A' ' 262' ' ' PRO . 2.9 p -74.89 141.99 75.94 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.345 -0.847 . . . . 0.0 110.388 -179.806 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 262' ' ' PRO . . . . . 0.522 ' HD2' HG23 ' A' ' 261' ' ' VAL . 47.9 Cg_endo -75.97 152.75 36.71 Favored 'Trans proline' 0 C--N 1.305 -1.761 0 O-C-N 124.078 1.567 . . . . 0.0 110.131 179.705 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 263' ' ' VAL . . . . . 0.495 HG12 ' O ' ' A' ' 263' ' ' VAL . 18.0 t -147.4 30.39 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 121.194 -0.941 . . . . 0.0 110.288 179.955 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 264' ' ' SER . . . . . 0.454 ' HB3' HD11 ' A' ' 358' ' ' ILE . 45.3 t -174.29 89.32 0.06 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.209 -0.932 . . . . 0.0 110.637 -179.949 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 265' ' ' GLY . . . . . . . . . . . . . . . 98.88 -177.1 30.13 Favored Glycine 0 N--CA 1.49 2.29 0 N-CA-C 110.073 -1.211 . . . . 0.0 110.073 179.568 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 266' ' ' SER . . . . . 0.574 ' CB ' ' HB2' ' A' ' 285' ' ' ASN . 0.1 OUTLIER -134.62 165.95 24.04 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.532 -0.981 . . . . 0.0 109.69 179.866 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 267' ' ' LEU . . . . . 0.906 HD23 ' HG ' ' A' ' 284' ' ' LEU . 2.0 tm? -161.37 139.17 9.19 Favored 'General case' 0 N--CA 1.488 1.465 0 C-N-CA 118.984 -1.086 . . . . 0.0 111.193 179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 268' ' ' GLU . . . . . 0.749 ' N ' HD22 ' A' ' 267' ' ' LEU . 2.0 mp0 -138.02 130.38 29.16 Favored 'General case' 0 N--CA 1.49 1.568 0 N-CA-C 109.048 -0.723 . . . . 0.0 109.048 179.542 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 269' ' ' VAL . . . . . 0.788 HG13 ' O ' ' A' ' 281' ' ' ASP . 94.9 t -124.32 138.13 54.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 120.804 -1.185 . . . . 0.0 111.681 -178.854 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 270' ' ' LYS . . . . . 0.407 ' C ' HG23 ' A' ' 271' ' ' VAL . 20.1 tttt -121.19 157.64 29.78 Favored 'General case' 0 N--CA 1.496 1.841 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 179.131 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 271' ' ' VAL . . . . . 0.766 HG22 ' CD1' ' A' ' 280' ' ' TYR . 86.7 t -144.15 147.07 20.01 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 120.404 -1.435 . . . . 0.0 112.531 -179.049 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 272' ' ' ASN . . . . . 0.528 ' O ' ' CZ3' ' A' ' 274' ' ' TRP . 0.2 OUTLIER -141.35 109.98 6.04 Favored 'General case' 0 N--CA 1.49 1.53 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 178.864 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 273' ' ' ASP . . . . . 0.51 ' HA ' ' HA ' ' A' ' 278' ' ' ALA . 12.0 m-20 -94.82 146.71 24.01 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.114 -0.991 . . . . 0.0 111.535 -178.718 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 274' ' ' TRP . . . . . 0.807 ' CH2' HG23 ' A' ' 337' ' ' ILE . 39.0 p90 -134.67 23.52 3.66 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.616 -0.678 . . . . 0.0 109.667 179.062 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 275' ' ' GLY . . . . . 0.542 ' HA2' ' CB ' ' A' ' 342' ' ' GLN . . . 82.39 -65.33 4.11 Favored Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.756 -1.338 . . . . 0.0 109.756 179.932 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 276' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.0 -23.99 65.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.183 -1.186 . . . . 0.0 110.354 -179.929 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 277' ' ' GLY . . . . . 0.557 ' O ' ' CD2' ' A' ' 274' ' ' TRP . . . -176.57 176.43 47.87 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.855 -1.298 . . . . 0.0 109.855 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 278' ' ' ALA . . . . . 0.562 ' C ' ' CH2' ' A' ' 274' ' ' TRP . . . -131.36 148.55 52.68 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.359 -1.083 . . . . 0.0 110.259 -179.879 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 279' ' ' GLU . . . . . 0.666 ' O ' HG13 ' A' ' 271' ' ' VAL . 16.3 mt-10 -97.63 147.07 24.69 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.513 -0.742 . . . . 0.0 109.683 -179.81 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 280' ' ' TYR . . . . . 0.766 ' CD1' HG22 ' A' ' 271' ' ' VAL . 80.1 m-85 -141.7 85.98 1.97 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.362 -0.836 . . . . 0.0 111.045 -179.242 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 281' ' ' ASP . . . . . 0.788 ' O ' HG13 ' A' ' 269' ' ' VAL . 0.2 OUTLIER -69.22 150.22 47.7 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.389 -0.82 . . . . 0.0 109.54 179.115 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 282' ' ' VAL . . . . . 0.727 HG11 ' CZ ' ' A' ' 334' ' ' PHE . 4.9 t -143.86 87.4 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.548 0 O-C-N 121.353 -0.842 . . . . 0.0 109.872 -179.64 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 283' ' ' THR . . . . . 0.794 HG23 ' OG1' ' A' ' 333' ' ' THR . 98.0 m -86.68 123.44 31.86 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.093 -1.005 . . . . 0.0 109.885 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 284' ' ' LEU . . . . . 1.056 ' CD2' HD11 ' A' ' 351' ' ' LEU . 0.3 OUTLIER -108.4 148.25 30.41 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.201 -0.937 . . . . 0.0 110.062 -179.66 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 285' ' ' ASN . . . . . 0.574 ' HB2' ' CB ' ' A' ' 266' ' ' SER . 0.3 OUTLIER -129.6 111.98 13.25 Favored 'General case' 0 N--CA 1.497 1.876 0 O-C-N 121.221 -0.924 . . . . 0.0 111.134 -178.742 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 286' ' ' LEU . . . . . 0.642 ' HB3' ' CD1' ' A' ' 290' ' ' TYR . 10.2 mt -121.47 158.66 27.92 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.809 -1.182 . . . . 0.0 109.407 178.982 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 287' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -94.97 35.62 1.25 Allowed 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.201 -0.937 . . . . 0.0 110.38 -179.69 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 288' ' ' GLY . . . . . 0.532 ' O ' ' N ' ' A' ' 330' ' ' PRO . . . 163.79 -103.14 0.21 Allowed Glycine 0 N--CA 1.492 2.379 0 C-N-CA 118.879 -1.629 . . . . 0.0 110.561 179.983 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 289' ' ' GLN . . . . . 0.52 ' C ' ' CG ' ' A' ' 290' ' ' TYR . 1.7 mt-30 -148.27 120.45 8.33 Favored 'General case' 0 N--CA 1.493 1.711 0 O-C-N 121.276 -1.132 . . . . 0.0 110.411 -179.343 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 290' ' ' TYR . . . . . 0.642 ' CD1' ' HB3' ' A' ' 286' ' ' LEU . 3.3 m-85 -151.27 131.29 13.42 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.177 -0.952 . . . . 0.0 109.826 179.553 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 291' ' ' ASP . . . . . 0.822 ' O ' HG23 ' A' ' 353' ' ' ILE . 4.9 t70 -62.1 103.81 0.41 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.096 -1.002 . . . . 0.0 109.568 179.59 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 292' ' ' TRP . . . . . 0.912 ' CE3' HD13 ' A' ' 284' ' ' LEU . 53.9 p-90 -103.0 111.07 23.23 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.291 -0.881 . . . . 0.0 110.49 -179.758 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 293' ' ' THR . . . . . 0.703 HG23 ' CG2' ' A' ' 322' ' ' THR . 25.3 m -105.08 114.71 29.08 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.289 -0.882 . . . . 0.0 109.776 179.639 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 294' ' ' VAL . . . . . 0.783 HG22 ' CD2' ' A' ' 351' ' ' LEU . 3.1 t -97.07 110.86 25.8 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.211 -0.931 . . . . 0.0 110.077 -179.732 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 295' ' ' LYS . . . . . 0.439 ' HG3' HD13 ' A' ' 320' ' ' ILE . 21.2 ttmt -86.32 149.4 25.07 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.189 -0.945 . . . . 0.0 109.42 179.148 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 296' ' ' VAL . . . . . 0.734 HG13 HG12 ' A' ' 349' ' ' ILE . 86.3 t -145.6 107.04 0.78 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.586 0 O-C-N 121.275 -0.891 . . . . 0.0 110.749 -179.161 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 297' ' ' LYS . . . . . 0.598 ' HD2' ' CD1' ' A' ' 318' ' ' TYR . 4.4 mmtt -70.47 136.95 49.88 Favored 'General case' 0 C--N 1.304 -1.406 0 O-C-N 121.13 -0.981 . . . . 0.0 109.157 179.188 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 298' ' ' LEU . . . . . 1.011 HD13 ' HA ' ' A' ' 303' ' ' THR . 95.8 mt -90.47 157.43 17.57 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.23 -0.919 . . . . 0.0 111.673 -178.573 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 299' ' ' ALA . . . . . 0.804 ' HB3' ' HB2' ' A' ' 302' ' ' ALA . . . -65.02 175.43 1.01 Allowed Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.574 -0.704 . . . . 0.0 109.771 179.443 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 300' ' ' PRO . . . . . 0.764 ' HD2' ' HB1' ' A' ' 299' ' ' ALA . 40.4 Cg_endo -67.25 81.81 0.38 Allowed 'Trans proline' 0 C--N 1.306 -1.678 0 O-C-N 123.707 1.372 . . . . 0.0 110.049 179.55 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 301' ' ' GLY . . . . . . . . . . . . . . . 111.76 19.14 7.5 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 108.951 -1.66 . . . . 0.0 108.951 -179.54 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 302' ' ' ALA . . . . . 0.804 ' HB2' ' HB3' ' A' ' 299' ' ' ALA . . . -107.34 144.2 34.54 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.414 -1.051 . . . . 0.0 110.026 -179.812 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 303' ' ' THR . . . . . 1.011 ' HA ' HD13 ' A' ' 298' ' ' LEU . 18.4 p -145.09 145.04 31.26 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.137 -0.977 . . . . 0.0 110.886 -179.985 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 304' ' ' VAL . . . . . 0.801 ' CG2' HG21 ' A' ' 319' ' ' VAL . 75.4 t -70.39 142.41 15.8 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.697 0 O-C-N 121.46 -0.775 . . . . 0.0 109.96 179.697 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -132.65 -40.68 0.2 Allowed Glycine 0 N--CA 1.489 2.224 0 N-CA-C 110.009 -1.236 . . . . 0.0 110.009 -179.663 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 306' ' ' SER . . . . . 0.487 ' O ' ' HA ' ' A' ' 336' ' ' PHE . 0.1 OUTLIER -120.76 118.69 30.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.051 -1.264 . . . . 0.0 110.631 -179.599 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 307' ' ' PHE . . . . . 0.558 ' CD2' ' HB2' ' A' ' 312' ' ' LYS . 7.7 p90 -141.86 156.78 45.52 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.255 -0.903 . . . . 0.0 109.641 179.671 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 308' ' ' TRP . . . . . 0.485 ' O ' ' HB2' ' A' ' 334' ' ' PHE . 1.1 p90 -152.83 158.72 42.62 Favored 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.087 -1.008 . . . . 0.0 111.188 -179.206 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 309' ' ' SER . . . . . 0.489 ' HB2' ' O ' ' A' ' 333' ' ' THR . 0.5 OUTLIER 60.47 25.43 15.04 Favored 'General case' 0 N--CA 1.496 1.867 0 O-C-N 121.592 -0.692 . . . . 0.0 110.926 179.611 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 310' ' ' ALA . . . . . 0.61 ' HB2' ' CB ' ' A' ' 334' ' ' PHE . . . -174.61 142.24 0.71 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.183 -0.948 . . . . 0.0 110.282 179.679 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 311' ' ' ASN . . . . . 0.542 ' HB2' ' OG1' ' A' ' 322' ' ' THR . 2.1 m-80 -77.21 123.74 26.86 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.115 -0.991 . . . . 0.0 109.296 179.355 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 312' ' ' LYS . . . . . 0.558 ' HB2' ' CD2' ' A' ' 307' ' ' PHE . 1.7 ttpt -94.5 123.4 37.9 Favored 'General case' 0 N--CA 1.489 1.519 0 CA-C-O 121.555 0.693 . . . . 0.0 110.95 -179.341 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 313' ' ' GLN . . . . . 0.647 ' HB2' ' HB ' ' A' ' 320' ' ' ILE . 2.1 mt-30 -109.65 177.21 4.8 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 108.895 -0.78 . . . . 0.0 108.895 178.549 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 314' ' ' GLU . . . . . . . . . . . . . 33.5 mt-10 -136.28 99.69 4.18 Favored 'General case' 0 C--N 1.298 -1.65 0 O-C-N 121.468 -0.77 . . . . 0.0 110.129 179.939 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.556 ' O ' ' CD2' ' A' ' 318' ' ' TYR . . . -86.58 41.3 3.08 Favored Glycine 0 N--CA 1.49 2.27 0 N-CA-C 109.805 -1.318 . . . . 0.0 109.805 -179.777 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 316' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 58.31 83.98 0.11 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 121.155 -1.203 . . . . 0.0 110.158 179.981 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 317' ' ' GLY . . . . . 0.612 ' O ' ' CD1' ' A' ' 318' ' ' TYR . . . 94.14 3.99 63.22 Favored Glycine 0 N--CA 1.492 2.39 0 N-CA-C 109.648 -1.381 . . . . 0.0 109.648 -179.978 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 318' ' ' TYR . . . . . 0.786 ' O ' HG23 ' A' ' 319' ' ' VAL . 1.3 m-85 -146.47 -169.87 3.37 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.398 -1.06 . . . . 0.0 108.988 179.54 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 319' ' ' VAL . . . . . 0.801 HG21 ' CG2' ' A' ' 304' ' ' VAL . 12.8 t -161.44 149.98 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.192 -0.943 . . . . 0.0 109.843 179.147 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 320' ' ' ILE . . . . . 0.647 ' HB ' ' HB2' ' A' ' 313' ' ' GLN . 8.7 mm -114.76 151.72 16.47 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.927 0 O-C-N 120.937 -1.102 . . . . 0.0 110.836 -179.946 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 321' ' ' PHE . . . . . 0.653 ' CZ ' ' CB ' ' A' ' 336' ' ' PHE . 59.8 m-85 -130.06 115.68 17.45 Favored 'General case' 0 N--CA 1.493 1.704 0 O-C-N 121.166 -0.959 . . . . 0.0 109.963 178.977 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 322' ' ' THR . . . . . 0.703 ' CG2' HG23 ' A' ' 293' ' ' THR . 24.7 p -122.23 167.0 15.02 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 120.728 -1.232 . . . . 0.0 109.654 179.551 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 323' ' ' PRO . . . . . 0.526 ' HD2' ' HB ' ' A' ' 322' ' ' THR . 38.1 Cg_endo -64.81 120.05 7.22 Favored 'Trans proline' 0 C--N 1.307 -1.646 0 O-C-N 123.803 1.423 . . . . 0.0 110.893 -179.362 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 324' ' ' VAL . . . . . 0.658 HG22 ' HB2' ' A' ' 327' ' ' ASN . 28.9 m -63.31 -126.12 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.479 0 O-C-N 121.498 -0.751 . . . . 0.0 110.149 -179.873 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 325' ' ' SER . . . . . 0.496 ' N ' HG23 ' A' ' 324' ' ' VAL . 0.6 OUTLIER -101.09 -20.78 15.2 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.847 -1.158 . . . . 0.0 110.869 -179.585 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 326' ' ' TRP . . . . . 0.581 ' H ' HG23 ' A' ' 324' ' ' VAL . 23.9 p-90 -124.57 -1.68 7.99 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.998 -1.063 . . . . 0.0 110.699 -179.753 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 327' ' ' ASN . . . . . 0.658 ' HB2' HG22 ' A' ' 324' ' ' VAL . 2.7 t30 -104.7 44.52 1.02 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.107 -0.996 . . . . 0.0 110.614 -179.461 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 328' ' ' LYS . . . . . 0.447 ' HB3' ' HB2' ' A' ' 323' ' ' PRO . 0.0 OUTLIER -126.13 10.86 7.55 Favored 'General case' 0 N--CA 1.494 1.773 0 O-C-N 121.055 -1.028 . . . . 0.0 109.961 179.704 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 329' ' ' GLY . . . . . 0.452 ' HA2' ' HG2' ' A' ' 289' ' ' GLN . . . -73.89 -143.37 0.73 Allowed Glycine 0 N--CA 1.488 2.132 0 N-CA-C 108.873 -1.691 . . . . 0.0 108.873 179.615 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 330' ' ' PRO . . . . . 0.554 ' O ' ' N ' ' A' ' 286' ' ' LEU . 43.7 Cg_endo -72.75 -56.15 0.09 OUTLIER 'Trans proline' 0 C--N 1.303 -1.851 0 O-C-N 123.879 1.463 . . . . 0.0 109.756 179.602 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 331' ' ' THR . . . . . . . . . . . . . 7.2 m -107.94 126.43 52.69 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.177 -0.952 . . . . 0.0 110.204 179.76 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 332' ' ' ALA . . . . . 0.43 ' O ' ' HB2' ' A' ' 284' ' ' LEU . . . -138.66 109.48 6.7 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 121.379 -0.826 . . . . 0.0 109.945 179.902 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 333' ' ' THR . . . . . 0.794 ' OG1' HG23 ' A' ' 283' ' ' THR . 8.8 m -100.81 145.33 28.68 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 110.432 -179.715 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 334' ' ' PHE . . . . . 0.727 ' CZ ' HG11 ' A' ' 282' ' ' VAL . 10.1 p90 -151.54 174.92 12.85 Favored 'General case' 0 N--CA 1.49 1.561 0 N-CA-C 108.66 -0.867 . . . . 0.0 108.66 179.552 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 335' ' ' GLY . . . . . 0.502 ' O ' ' HA ' ' A' ' 307' ' ' PHE . . . -152.9 165.45 31.13 Favored Glycine 0 N--CA 1.49 2.281 0 C-N-CA 118.838 -1.648 . . . . 0.0 110.518 -179.319 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 336' ' ' PHE . . . . . 0.868 ' C ' HD12 ' A' ' 337' ' ' ILE . 0.8 OUTLIER -152.27 143.58 23.3 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.525 -0.986 . . . . 0.0 109.9 179.634 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 337' ' ' ILE . . . . . 0.868 HD12 ' C ' ' A' ' 336' ' ' PHE . 1.5 mp -117.76 125.27 74.01 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.778 0 O-C-N 121.064 -1.022 . . . . 0.0 109.886 179.971 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 338' ' ' VAL . . . . . 0.726 ' CG1' ' HB1' ' A' ' 302' ' ' ALA . 2.7 t -101.9 145.47 11.69 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.276 -0.89 . . . . 0.0 109.945 179.835 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 339' ' ' ASN . . . . . 0.496 ' HA ' ' HA2' ' A' ' 277' ' ' GLY . 1.9 m-80 -113.84 126.76 55.55 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.344 -0.847 . . . . 0.0 110.098 179.873 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 340' ' ' GLY . . . . . 0.423 ' C ' ' HD3' ' A' ' 345' ' ' LYS . . . -176.4 -147.37 6.45 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.729 -1.348 . . . . 0.0 109.729 179.994 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 341' ' ' PRO . . . . . 0.509 ' HD2' ' HG2' ' A' ' 345' ' ' LYS . 46.2 Cg_endo -71.33 118.38 5.64 Favored 'Trans proline' 0 C--N 1.306 -1.7 0 O-C-N 124.055 1.555 . . . . 0.0 110.658 -179.732 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 342' ' ' GLN . . . . . 0.542 ' CB ' ' HA2' ' A' ' 275' ' ' GLY . 0.0 OUTLIER -39.91 155.78 0.02 OUTLIER 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.389 -0.819 . . . . 0.0 110.851 -179.997 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 343' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 344' ' ' ASP . . . 92.32 63.17 1.14 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.475 -1.45 . . . . 0.0 109.475 179.665 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 344' ' ' ASP . . . . . 0.475 ' O ' ' O ' ' A' ' 343' ' ' GLY . 16.0 t0 60.97 134.41 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.333 -1.098 . . . . 0.0 109.566 -179.751 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 345' ' ' LYS . . . . . 0.661 ' C ' ' HB2' ' A' ' 299' ' ' ALA . 0.2 OUTLIER -135.05 28.92 3.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 120.996 -1.065 . . . . 0.0 110.809 -179.518 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 346' ' ' VAL . . . . . 0.639 HG13 ' O ' ' A' ' 346' ' ' VAL . 12.6 p -132.5 116.93 29.54 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.614 0 O-C-N 121.195 -0.941 . . . . 0.0 110.245 179.632 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 347' ' ' GLU . . . . . 0.483 ' HB3' ' HB2' ' A' ' 297' ' ' LYS . 0.1 OUTLIER -46.65 -45.39 19.19 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.895 . . . . 0.0 110.319 -179.937 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 348' ' ' GLU . . . . . 0.431 ' HG2' ' HB3' ' A' ' 347' ' ' GLU . 13.9 pt-20 -176.67 158.34 1.69 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.125 -0.984 . . . . 0.0 110.686 -179.781 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 349' ' ' ILE . . . . . 0.734 HG12 HG13 ' A' ' 296' ' ' VAL . 39.8 mt -122.31 105.94 17.03 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.763 0 O-C-N 121.121 -0.987 . . . . 0.0 109.918 179.516 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 350' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -107.78 143.92 35.66 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.085 -1.009 . . . . 0.0 110.283 -179.927 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 351' ' ' LEU . . . . . 1.056 HD11 ' CD2' ' A' ' 284' ' ' LEU . 0.1 OUTLIER -105.6 128.59 53.7 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.194 -0.941 . . . . 0.0 109.953 179.694 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 352' ' ' GLU . . . . . 0.504 ' HA ' ' O ' ' A' ' 356' ' ' GLN . 0.3 OUTLIER -138.62 119.26 14.01 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.142 -0.974 . . . . 0.0 110.123 179.814 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 353' ' ' ILE . . . . . 0.822 HG23 ' O ' ' A' ' 291' ' ' ASP . 2.0 mt -92.8 109.7 21.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.16 -0.963 . . . . 0.0 110.271 179.934 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 354' ' ' ASN . . . . . 0.526 ' ND2' ' HB3' ' A' ' 291' ' ' ASP . 0.6 OUTLIER 38.27 46.36 0.88 Allowed 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.753 -0.592 . . . . 0.0 111.202 -179.979 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 355' ' ' GLY . . . . . . . . . . . . . . . 110.37 -36.24 4.38 Favored Glycine 0 N--CA 1.492 2.426 0 C-N-CA 119.754 -1.212 . . . . 0.0 110.385 179.246 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 356' ' ' GLN . . . . . 0.504 ' O ' ' HA ' ' A' ' 352' ' ' GLU . 38.3 mm-40 -66.88 176.07 2.2 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.012 -1.287 . . . . 0.0 110.311 -179.587 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 357' ' ' VAL . . . . . 0.787 ' O ' HD13 ' A' ' 358' ' ' ILE . 5.6 p -140.65 129.82 25.9 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.305 -0.872 . . . . 0.0 109.969 -179.955 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 358' ' ' ILE . . . . . 0.787 HD13 ' O ' ' A' ' 357' ' ' VAL . 8.3 mm . . . . . 0 N--CA 1.494 1.726 0 CA-C-O 118.052 -0.975 . . . . 0.0 110.303 -179.795 . . . . . . . . 1 1 . 1 stop_ save_